

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12P 19/34	A1	(11) International Publication Number: WO 00/55350 (43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US00/05882 (22) International Filing Date: 8 March 2000 (08.03.00) (30) Priority Data: 60/124,270 12 March 1999 (12.03.99) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). (74) Agents: WALES, Michele, M. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMAN CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES (57) Abstract This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Human Cancer Associated Gene Sequences and Polypeptides

5 *Field of the Invention*

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such cancer antigens for detection, prevention and treatment of tissue specific diseases, particularly cancers. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to tissue specific diseases, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

20 *Background of the Invention*

Cell growth is a carefully regulated process which responds to specific needs of the body. Occasionally, the intricate, and highly regulated controls dictating the rules for cellular division break down. When this occurs, the cell begins to grow and divide independently of its homeostatic regulation resulting in a condition commonly referred to as cancer. In fact, cancer is the second leading cause of death among Americans aged 25-44.

Cancers or malignant tumors are characterized by continuous cell proliferation and cell death. Cancer cells have been shown to exhibit unique gene expression, and dozens of cancer-specific genetic markers, tumor antigens, have been identified. P35B, a tumor rejection antigen, was first identified in mouse. A point mutation in the P35B gene elicits a cytolytic T lymphocyte response but no detectable antibody response (Szikora, J. P. et al. (1990) EMBO J. 9:1041-1050). A human homolog of P35B, FX, is a homodimeric

NADP(H)-binding protein of 68 kDa. FX acts as a combined epimerase and NADPH-dependent reductase in converting GDP-4-keto-6-D-deoxymannose to GDP-L-fucose (Tonetti, M. et al. (1996) J. Biol. Chem. 271: 27274-27279). GDP-L-fucose is the substrate of several fucosyl-transferases involved in the biosynthesis of blood group ABH antigenic determinants. GDP-L-fucose is also utilized in synthesizing fucosylated glycoproteins and glycolipids which function in cell adhesion and recognition (Springer, T. A. and Lasky, L. A. (1991) Nature 329: 196-197; Brandley, B. K. et al. (1990) Cell 63: 861-863; and Feizi, T. and Childs, R. A. (1987) Biochem. J. 245: 1-11).

Thus, there is a need for the identification and characterization of novel tissue specific polynucleotides and polypeptides which modulate activation and differentiation of cells, both normally and in disease states. In particular, there is a need to isolate and characterize additional molecules that mediate apoptosis, DNA repair, tumor-mediated angiogenesis, genetic imprinting, immune responses to tumors and tumor antigens and, among other things, that can play a role in detecting, preventing, ameliorating or correcting dysfunctions or diseases.

Summary of the Invention

The present invention includes isolated nucleic acid molecules comprising, or alternatively, consisting of, a cancer associated polynucleotide sequence disclosed in the sequence listing (as SEQ ID NOs:1 to 842) and/or contained in a human cDNA clone described in Tables 1, 2 and 5 and deposited with the American Type Culture Collection ("ATCC"). Fragments, variant, and derivatives of these nucleic acid molecules are also encompassed by the invention. The present invention also includes isolated nucleic acid molecules comprising, or alternatively consisting of, a polynucleotide encoding a cancer polypeptide. The present invention further includes cancer polypeptides encoded by these polynucleotides. Further provided for are amino acid sequences comprising, or alternatively consisting of, cancer polypeptides as disclosed in the sequence listing (as SEQ ID Nos: 843 to 1684) and/or encoded by a human cDNA clone described in Tables 1, 2 and 5 and deposited with the ATCC. Antibodies that bind these polypeptides are also encompassed by the invention. Polypeptide fragments, variants, and derivatives of these amino acid sequences are also encompassed by the invention, as are polynucleotides encoding these polypeptides and antibodies that bind these polypeptides. Also provided are diagnostic methods for diagnosing

and treating, preventing, and/or prognosing disorders related to cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention.

5 *Detailed Description*

Tables

Table 1 summarizes some of the cancer antigens encompassed by the invention (including contig sequences (SEQ ID NO:X) and the cDNA clone related to the contig sequence) and further summarizes certain characteristics of the cancer polynucleotides and the polypeptides encoded thereby. The first column shows the "SEQ ID NO:" for each of the 842 cancer antigen polynucleotide sequences of the invention. The second column provides a unique "Sequence/Contig ID" identification for each cancer associated sequence. The third column, "Gene Name," and the fourth column, "Overlap," provide a putative identification of the gene based on the sequence similarity of its translation product to an amino acid sequence found in a publicly accessible gene database and the database accession no. for the database sequence having similarity, respectively. The fifth and sixth columns provide the location (nucleotide position nos. within the contig), "Start" and "End", in the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred ORF shown in the sequence listing as SEQ ID NO:Y. The seventh and eighth columns provide the "% Identity" (percent identity) and "% Similarity" (percent similarity), respectively, observed between the aligned sequence segments of the translation product of SEQ ID NO:X and the database sequence. The ninth column provides a unique "Clone ID" for a cDNA clone related to each contig sequence. The tenth column shows the tissue in which each SEQ ID NO:X is predominantly expressed.

Table 2 summarizes ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application.

Table 3 indicates public ESTs, of which at least one, two, three, four, five, ten, fifteen or more of any one or more of these public EST sequences are optionally excluded from certain embodiments of the invention.

Table 4 lists residues comprising antigenic epitopes of antigenic epitope-bearing fragments present in most of the cancer associated polynucleotides described in Table 1 as predicted by the inventors using the algorithm of Jameson and Wolf, (1988) Comp. Appl.

Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, WI). Cancer associated polypeptides (e.g., SEQ ID NO:Y, polypeptides encoded by SEQ ID NO:X, or polypeptides encoded by the cDNA in the referenced cDNA clone) may possess one or more antigenic epitopes comprising residues described in Table 4. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. The residues and locations shown in column two of Table 4 correspond to the amino acid sequences for most cancer associated polypeptide sequence shown in the Sequence Listing.

Table 5 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X (as described in column 1 of Table 1) or the related cDNA clone (as described in column 9 of Table 1 and contained within a library deposited with the ATCC). For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence.

Moreover, as used herein, a "polypeptide" refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

5 In the present invention, "SEQ ID NO:X" was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown in column 9 of Table 1, each clone is identified by a cDNA Clone ID. Each Clone ID is unique to an individual clone and the
10 Clone ID is all the information needed to retrieve a given clone from the HGS library. In addition to the individual cDNA clone deposits, most of the cDNA libraries from which the clones were derived were deposited at the American Type Culture Collection (hereinafter "ATCC"). Table 5 provides a list of the deposited cDNA libraries. One can use the Clone ID to determine the library source by reference to Tables 2 and 5. Table 5 lists the deposited
15 cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, "HTWE." The name of a cDNA clone ("Clone ID") isolated from that library begins with the same four characters, for example "HTWEP07". As mentioned below, Table 1 correlates the Clone ID names with SEQ ID NOs. Thus, starting with a SEQ ID NO, one can use Tables 1, 2 and 5 to determine the corresponding Clone ID,
20 from which library it came and in which ATCC deposit the library is contained. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for
25 the purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), and/or sequences contained in the
30 related cDNA clone within a library deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH

7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also included within "polynucleotides" of the present invention are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotides of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the

polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

"SEQ ID NO:X" refers to a tissue specific cancer antigen polynucleotide sequence described in Table 1. SEQ ID NO:X is identified by an integer specified in column 1 of Table 1. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. There are 842 cancer antigen polynucleotide sequences described in Table 1 and shown in the sequence listing (SEQ ID NO:1 through SEQ ID NO:842). Likewise there are 842 polypeptide sequences shown in the sequence listing, one polypeptide sequence for each of the polynucleotide sequences (SEQ ID NO:843 through SEQ ID NO:1684). The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEQ ID NO:1 is the first polypeptide sequence shown in the sequence listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:2, and so on. In other words, since there are 842 polynucleotide sequences, for any polynucleotide sequence SEQ ID NO:X, a corresponding polypeptide SEQ ID NO:Y can be determined by the formula $X + 842 = Y$. In addition, any of the unique "Sequence/Contig ID" defined in column 2 of Table 1, can be linked to the corresponding polypeptide SEQ ID NO:Y by reference to Table 4.

The polypeptides of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

The cancer polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The cancer polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.

By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

"A polypeptide having functional activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular assay, such as, for example, a biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

The functional activity of the cancer antigen polypeptides, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the present invention for binding to an antibody to the full length polypeptide antibody, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, physiological correlates polypeptide of the present invention binding to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants derivatives and analogs thereof to elicit polypeptide related biological activity (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

Cancer Associated Polynucleotides and Polypeptides of the Invention

It has been discovered herein that the polynucleotides described in Table 1 are expressed at significantly enhanced levels in human cancer tissues as shown in column 10 of

Table 1. Accordingly, such polynucleotides, polypeptides encoded by such polynucleotides, and antibodies specific for such polypeptides find use in the prediction, diagnosis, prevention and treatment of tissue specific disorders, including cancer as more fully described below.

5 Table 1 summarizes some of the polynucleotides encompassed by the invention (including contig sequences (SEQ ID NO:X) and the related cDNA clones) and further summarizes certain characteristics of these tissue specific cancer associated polynucleotides and the polypeptides encoded thereby.

Table 1

Seq ID Contig ID No.	Sequence/ Gene Name	Overlap	HGS Nucleotide		Clone ID	Tissue(s)
			Start	End		
1	507291 uvomorulin [Homo sapiens] >sp Q15855 Q15855 UVMOMORULIN PRECURSOR (E-CADHERIN) (ARC-1/UVMOMORULIN). >gi 930046 uvomorulin (140 AA) [Homo sapiens] {SUB 168-307; Length = 878	gi 340185	2	475	HCHAU23	Pancreas, Breast/Ovarian
2	508000 HLA-B-associated transcript 2 (BAT2) [Homo sapiens] >gi 179345 HLA-B-associated transcript 2 (BAT2) [Homo sapiens] >pir B35098 B35098 MHC class III histocompatibility antigen HLA-B- associated transcript 2 - human >sp P48634 BAT2_HUMAN LARGE PROLINE- RICH P	gi 179339	100	1902	HWAAK56	Lung, Breast/Ovarian
3	518325		110	310	HHFCP36	Lung, Pancreas, Colon, Breast/Ovarian
4	523111 Sm D2 [Homo sapiens] >pir 138861 138861 small nuclear ribonucleoprotein chain D2 - human Length = 118	gi 600748	233	670	HATAE67	Lung, Breast/Ovarian
5	526869 (AC002291) Similar ATP-dependent RNA Helicase [Arabidopsis thaliana] >sp O49289 O49289 SIMILAR ATP-DEPENDENT RNA HELICASE. Length = 845	gi 2829912	1	552	HT4FP57	Pancreas, Breast/Ovarian
6	532211 retinoic acid-binding protein [Bos taurus] Length = 138	gi 162906	2	481	HHGCV63	Lung, Breast/Ovarian

7	532247		160	384		HEBCC47	Pancreas, Breast/Ovarian Lung, Breast/Ovarian
8	537932	alcohol dehydrogenase [Homo sapiens] >gi 178134 alcohol dehydrogenase 3 [Homo sapiens] >pir JH0789 DEHUC2 alcohol dehydrogenase (EC 1.1.1.1) 5 - human >sp P11766 ADHX_HUMAN ALCOHOL DEHYDROGENASE CLASS III CHI CHAIN (EC 1.1.1.1) (GLUTATHIONE- DEPENDENT FOR	gi 178130	1	1149	92	HUISB86
9	540117		174	635		HRGBU25	Lung, Breast/Ovarian
10	547710	transketolase [Homo sapiens] Length = 623	gi 1297297	2	1189	92	HIMU/AZ27
11	551747	rtvp-1 [Homo sapiens] >pir JC5308 JC5308 testis- specific, vespid, and pathogenesis-related protein 1 - human >sp P48060 GLIP_HUMAN GLIOMA PATHOGENESIS-RELATED PROTEIN (RTVP-1 PROTEIN). Length = 266	gi 1030053	26	931	91	HTDAE10
12	552799	delta- aminolevulinate synthase (housekeeping) [Homo sapiens] >pir S13682 SYHUAL 5- aminolevulinate synthase (EC 2.3.1.37) 1 precursor - human >sp P13196 HEM1_HUMAN 5- AMINOLEVULINIC ACID SYNTHASE MITOCHONDRIAL PRECURSOR, NONSPECIFIC (EC 2.3.1.37) (DELTA-AM	gi 28583	104	814	100	HHECX90
							Lung, Pancreas, Breast/Ovarian

13	553243	RING7 [Homo sapiens] >gi 557702 HLA-DMB [Homo sapiens] >gi 512472 HLA-DMB [Homo sapiens] >gi 1054742 DMB [Homo sapiens] >pir I37533 I37533 MHC class II histocompatibility antigen HLA-DM beta chain precursor - human Length = 263	gi 313002	202	1017	93	93	HUKD144	Lung, Pancreas
14	553368	(AF053944) aortic carboxypeptidase-like protein ACLP [Homo sapiens] >sp G3288916 G3288916 AORTIC CARBOXYPEPTIDASE-LIKE PROTEIN ACLP. >gnl PID d1013781 AEBP1 [Homo sapiens] {SUB 314-1158} Length = 1158	gi 3288916	1	459	96	96	HADGE84	Lung, Pancreas
15	554349								
16	558491	immunoglobulin heavy chain [Homo sapiens] Length = 152	gi 567128	3	776	98	100	HUSGK19 HUFCN61	Lung, Pancreas Lung, Pancreas, Colon
17	558983	dJ68O2.2 [Homo sapiens] >sp P35579 MYSN_HUMAN MYOSIN HEAVY CHAIN, NONMUSCLE TYPE A (CELLULAR MYOSIN HEAVY CHAIN, TYPE A) (NMMHC-A). >gi 553596 cellular myosin heavy chain [Homo sapiens] {SUB 1-1337} Length = 1960	gnl PID c1294465	219	623	100	100	HOHBM82	Pancreas, Breast/Ovarian
18	572943			367	522			HBAMC47	Pancreas, Breast/Ovarian
19	585892	epithelial tumor antigen precursor, membrane-bound form - human Length = 515	pir SI10572 SI10572	3	965	89	89	HUKAL69	Lung, Pancreas, Colon, Breast/Ovarian

20	589390	C1 inhibitor [Homo sapiens] >gi29535 C1 inhibitor [Homo sapiens] >pirS15386[THUC1 complement C1 inhibitor precursor - human >spI05155[IC1_HUMAN PLASMA PROTEASE C1 INHIBITOR PRECURSOR (C1 INH). >gnlPID e3783 C1 inhibitor (AA 155-478) (1 is 2nd base i	gnlPID e222400	3	983	96	96	HSRAB10	Lung, Pancreas
21	596882			800	1057			HMCEP91	Lung, Pancreas, Colon
22	616289	nucleoporin p58 [Rattus norvegicus] >spIP70581P70581 NUCLEOPORIN P58. Length = 585	gi 1537068	1	390	67	70	HAJCB44	Lung, Pancreas
23	622140	selenophosphate synthetase 2 [Homo sapiens] >spIQ99611Q99611 SELENOPHOSPHATE SYNTHETASE 2. Length = 448	gi 1815622	92	325	97	97	HEONC67	Pancreas, Breast/Ovarian
24	623566	karyopherin alph 3 [Homo sapiens] >sp O00505 IMA3_HUMAN IMPORTIN ALPHA-3 SUBUNIT (KARYOPHERIN ALPHA-3 SUBUNIT). Length = 521	gnlPID d1021210	66	1652	99	99	HDPPP20	Lung, Breast/Ovarian
25	647714			1	711			HSS1129	Pancreas, Breast/Ovarian
26	647752	ubiquitin conjugating-protein [Oryctolagus cuniculus] >gi 184046 HHR6B (Human homologue of yeast RAD 6); putative [Homo sapiens] >gi 30954 E2 protein [Homo sapiens] >gi 207555 ubiquitin conjugating-protein [Rattus norvegicus] >gnlPID e233515 HR6B gene pr	gi 165780	3	590	100	100	HDTDH46	Lung, Colon

27	651774	P58 [Homo sapiens] >pir[S68363]S68363 protein disulfide-isomerase (EC 5.3.4.1) ER60 precursor - human >sp[P30101]ER60_HUMAN PROBABLE PROTEIN DISULFIDE ISOMERASE ER-60 PRECURSOR (EC 5.3.4.1) (ERP60) (58 KD MICROSOMAL PROTEIN) (P58) (GRP58) (ERP57). Length	gi 1147739	1	1632	96	96	HDPAA15	Lung, Pancreas, Breast/Ovarian
28	651995	collagen [Mus musculus] >pir[S23779]S23779 collagen alpha 1(VIII) chain - mouse >sp[Q00780]CA18_MOUSE COLLAGEN ALPHA 1(VIII) CHAIN PRECURSOR. >bbs[134935 alpha 1-VIII collagen [rats, mesangial cell, Peptide Partial, 172 aa] [Rattus sp.] {SUB 399-570} Leng	gnl PIDe245912	3	335	90	95	HBTAD44	Lung, Pancreas
29	652156	phospholipid hydroperoxide glutathione peroxidase [Homo sapiens] >sp[O43381]O43381 GSHH_HUMAN (EC 1.11.1.9) (GLUTATHIONE PEROXIDASE). >gi 3399677 (AC005390) GSSH_HUMAN, partial CDS [Homo sapiens] {SUB 149-197} Length = 197	gi 825667	262	633	94	94	HOEBK80	Lung, Breast/Ovarian
30	653010	von Willebrand factor [Homo sapiens]		79	183			HSRAA58	Lung, Pancreas
31	655904	>pir[A34480]VWHU von Willebrand factor precursor - human >gi 553810 von Willebrand factor [Homo sapiens] {SUB 990-1947} >gnl PIDe222518 von Willebrand factor [Homo sapiens] {SUB 1-178} >gi 340316 von Willebrand antigen	gi 340356	632	1891	96	96	HSEBB94	Lung, Breast/Ovarian
32	657852			70	522			HCHAL14	Colon, Breast/Ovarian
33	666414			1	285			HOSFG18	Lung, Pancreas

34	667847	ribosomal protein S9 [Rattus norvegicus] >pir JN0587 S21497 ribosomal protein S9 - rat Length = 194	gi 57143	1	714	98	98	HCF_LJ62	Lung, Pancreas, Breast/Ovarian
35	670188	G protein gamma-10 subunit [Homo sapiens] >pir J39158 J39158 GTP-binding regulatory protein gamma-10 chain - human >sp P50151 GBGA_HUMAN GUANINE NUCLEOTIDE-BINDING PROTEIN G(I)/G(S)/G(O) GAMMA-10 SUBUNIT. Length = 68	gi 995919	2	238	100	100	I1WADR30	Lung, Pancreas
36	670279	ribosomal protein S24 [Homo sapiens] >gi 517222 ribosomal protein S24 [Homo sapiens] >gi 49652 ribosomal protein S19 (AA 1 - 133) [Mesocricetus auratus] >gi 57858 ribosomal protein S24 [Rattus norvegicus] >gi 57722 ribosomal protein S24 (AA 1-133) [Rattus	gi 337506	96	503	87	87	HSAYG46	Lung, Pancreas, Breast/Ovarian
37	670729	acidic ribosomal phosphoprotein (P1) [Homo sapiens] >pir B27125 R6HUP1 acidic ribosomal protein P1 - human Length = 114	gi 190234	74	496	100	100	H2CBM17	Lung, Pancreas, Colon, Breast/Ovarian
38	674123			40	438			I1YACJ55	Lung, Pancreas
39	676496	collagen type VI, alpha 3 chain [Homo sapiens] >sp E1292418 E1292418 COLLAGEN TYPE VI, ALPHA 3 CHAIN. Length = 3176	gn PID e1292418	250	1029	98	98	HSLIC82	Lung, Pancreas
40	678162	TAXREB107 [Homo sapiens] >pir J51803 J51803 TAXREB107 - human Length = 288	gn PID d1005017	528	974	100	100	HBJJA02	Lung, Pancreas, Breast/Ovarian

41	678248	dolichol-phosphate-mannose synthase [Homo sapiens] >sp O60762 O60762 DOLICHOL-PHOSPHATE-MANNOSE SYNTHASE. >gnl PID d1026578 dolichol-phosphate-mannose synthase [Homo sapiens] {SUB 1-120; Length = 260	gnl PID d1026577	3	770	100	100	HMTAK71	Lung, Pancreas
42	683668	alpha 1 (I) chain propeptide [Homo sapiens] >gil180380 alpha-1 type I collagen [Homo sapiens] {SUB 64-201; Length = 1040	gil180392	566	1912	94	94	HWHGV07	Lung, Pancreas, Breast/Ovarian
43	693172	Q1Z 7F5 [Homo sapiens] >gil189266 may code for Wilms' tumor-related protein [Homo sapiens] >gil190814 Wilms' tumor-related protein [Homo sapiens] >gil1203971 QM gene product [Homo sapiens] >bbs135740 QM [human, nontumorigenic Wilms' microcell] hybrid c	gil184407	23	214	97	100	HNHIW05	Lung, Pancreas, Breast/Ovarian
44	694303			2824	3219			HOGAV47	Lung, Breast/Ovarian
45	695042	Description: KRAB zinc finger protein; this is a splicing variant that contains a stop codon and frame shift between the KRAB box and the zinc finger region; Method: conceptual translation supplied by author [Homo sapiens] >sp Q13359 Q13359 KRAB ZINC FING	gil1049295	471	680	74	91	IIISBX26	Pancreas, Breast/Ovarian
46	699799	lipocortin (AA 1-346) [Homo sapiens] >pir A03080 LUHU annexin I - human >sp P04083 ANX1_HUMAN ANNEXIN I (LIPOCORTIN I) (CALPACTIN II) (CHROMOBINDIN 9) (P35) (PHOSPHOLIPASE A2 INHIBITORY PROTEIN). {SUB 2-346; Length = 346	gil34388	3	1121	100	100	HNDAAS1	Lung, Breast/Ovarian

47	702216	dihydrodiol dehydrogenase [Homo sapiens] >gi 487135 hepatic dihydrodiol dehydrogenase [Homo sapiens] >gi 181549 dihydrodiol dehydrogenase [Homo sapiens] >pir A53436/A53436 3-alpha- hydroxysteroid/dihydrodiol dehydrogenase (EC 1.1.1.-) - human >sp Q04828 DB	gi 452484	41	1048	95	95	HNALC11	Lung, Pancreas
48	703015	latent transforming growth factor-beta-binding protein - human Length = 1820	pir A55494/A55494	3	587	100	100	HGCCX28	Lung, Pancreas
49	706391	vacuolar H+ ATPase proton channel subunit [Homo sapiens] >pir A39367/A39367 H+-transporting ATPase (EC 3.6.1.35) chain PKD1 - human Length = 155	gi 189676	29	622	85	85	HMA6L73	Lung, Breast/Ovarian
50	706892	copper transport protein HAH1 [Homo sapiens] >sp O00244 O00244 COPPER TRANSPORT PROTEIN HAH1. Length = 68	gi 1945365	3	287	82	82	HUFDS83	Lung, Breast/Ovarian
51	706924			2847	3215			HRAEB20	Lung, Breast/Ovarian
52	707642	ribosomal protein L8 [Homo sapiens] >gi 57704 ribosomal protein L8 [Rattus rattus] >gi 1527178 ribosomal protein L8 [Mus musculus] >pir J00177 R5RTL8 ribosomal protein L8, cytosolic - rat >pir JN0923 JN0923 ribosomal protein L8, cytosolic - human >gi 3851	gi 433899	1	516	94	94	HSRDJ44	Lung, Pancreas, Colon, Breast/Ovarian
53	710369			99	611			HSPA181	Lung, Pancreas, Breast/Ovarian
54	718826			581	877			HSIFK68	Lung, Breast/Ovarian

55	719790	lipocortin II [Homo sapiens] >pir A23942 LUHU36 annexin II - human >sp P07355 ANX2_HUMAN ANNEXIN II (LIPOCORTIN II) (CALPACTIN I HEAVY CHAIN) (CHROMOBINDIN 8) (P36) (PROTEIN I) (PLACENTAL ANTICOAGULANT PROTEIN IV) (PAP-IV). {SUB 2-339} >sp G545587 G545587	gnl PID d1000439	3	869	98	98	HKABK62	Lung, Pancreas
56	720222	homology with 16.7 KD putative viral protein YUB1_NPVAC [Caenorhabditis elegans] Length = 250	gnl PID c1346018	34	729	45	60	HSKLEP04	Lung, Pancreas, Breast/Ovarian
57	724033			1	654			HPJBV92	Lung, Pancreas, Breast/Ovarian
58	724767	epsilon isoform of 61kDa regulatory subunit of PP2A [Homo sapiens] >gil 478070 protein phosphatase B56-epsilon [Homo sapiens] >sp Q16537 Q16537 EPSILON ISOFORM OF 61KDA REGULATORY SUBUNIT OF PP2A. >gil 022892 protein phosphatase PP2A0 B' subunit delta is	gnl PID c220196	71	526	100	100	HKABH59	Lung, Breast/Ovarian
59	727065	ATPase [Homo sapiens] Length = 617	gil 291868	228	1010	99	99	HELGY15	Lung, Pancreas
60	727246	(AB009282) cytochrome b5 [Homo sapiens] >sp O43169 O43169 CYTOCHROME B5 (FRAGMENT). Length = 146	gnl PID d1024640	3	509	96	98	HCFMH52	Lung, Colon
61	727932			41	199			HLJDO53	Lung, Breast/Ovarian
62	731167	Sec23 protein [Homo sapiens] Length = 765	gnl PID c236013	1	987	99	99	HDTEM51	Lung, Pancreas

63	732514	lysophosphatidic acid acyltransferase-alpha [Homo sapiens] >gi 2253613 putative lysophospholipid acyltransferase [Homo sapiens] >gnl PIDe286645 l-acylglycerol-3-phosphate O-acyltransferase [Homo sapiens] >sp Q99943 PLCA_HUMAN l-ACYL-SN-GLYCEROL-3-PHOSPHA	gi 2155238	3	794	99	99	HLDBX26	Pancreas, Prostate
64	734080			1	567			HFIBK44	Lung, Breast/Ovarian
65	734288	cysteinyl-tRNA synthetase [Homo sapiens] Length = 595	gi 927229	154	2067	99	99	HKABU01	Lung, Pancreas
66	739448	Nascent polypeptide associated complex alpha subunit [Homo sapiens] >gi 4092060 (AF054187) alpha NAC [Homo sapiens] >pir S49326 S49326 Nascent polypeptide associated complex alpha chain - human >sp Q13765 Q13765 NASCENT POLYPEPTIDE ASSOCIATED COMPLEX ALPH	gi 556642	441	1184	82	82	HKGA131	Lung, Breast/Ovarian
67	739668			2	484			HAPTL07	Lung, Pancreas
68	740060	Dif33 gene product [Homo sapiens] >sp Q13530 Q13530 PLACENTAL PROTEIN DIF33. Length = 494	gi 1293563	76	1536	94	94	HMEGB82	Lung, Pancreas
69	741560			3	296			HCGM112	Lung, Colon
70	742543	human gamma-glutamyl hydrolase [Homo sapiens] >sp Q92820 Q92820 HUMAN GAMMA-GLUTAMYL HYDROLASE (EC 3.4.22.12). Length = 318	gi 2951931	187	804	99	100	HE2BG62	Lung, Colon, Breast/Ovarian
71	742831			25	297			HCDAL47	Pancreas, Colon

72	745327	channel-like integral membrane protein [Homo sapiens] >gi 1314304 channel-like integral membrane protein [Homo sapiens] >pir A41616/A41616 erythrocyte integral membrane protein 28K - human >sp P29972/AQP1_HUMAN AQUAPORIN-CHIP (WATER CHANNEL PROTEIN FOR RE	gi 180501	1	534	98	98	HWHPM73	Lung, Pancreas
73	745695	Mac-2 binding protein [Homo sapiens] >gi 483474 90K gene product [Homo sapiens] >pir A47161/A47161 Mac-2-binding glycoprotein precursor - human >sp Q08380/Q08380 MAC-2 BINDING PROTEIN PRECURSOR. Length = 585	gi 307153	886	2016	98	98	HOPBN02	Lung, Pancreas
74	750316	(AF029890) hepatitis B virus X interacting protein [Homo sapiens] >sp O43504/O43504 HEPATITIS B VIRUS X INTERACTING PROTEIN. Length = 91	gi 2745883	99	398	100	100	HKMLD65	Lung, Pancreas, Breast/Ovarian
75	750522			172	906			HUKF158	Lung, Pancreas, Colon, Breast/Ovarian
76	750583			58	189			IIBJJ366	Lung, Breast/Ovarian
77	751020			1	480			HEBAE80	Lung, Breast/Ovarian
78	752196			1	120			HL1AL67	Pancreas, Prostate
79	753084	UGTrel1 [Homo sapiens] >pir JC5024/JC5024 UDP-galactose transporter related isozyme 1 - human >sp P78383/P78383 UGTREL1. Length = 322	gi 1669560	53	1168	87	87	HDPKG74	Lung, Pancreas
80	754957	The ha1237 gene product is related to S.pombe rad21 gene product. [Homo sapiens] Length = 631	gnl PID d1008135	242	1330	94	94	HWBG01	Lung, Pancreas

81	756557	myosin I heavy chain [Rattus norvegicus] >pir A45439 A45439 myosin I heavy chain - rat >sp Q05096 Q05096 MYOSIN HEAVY CHAIN I. Length = 1136	gi 56733	1	888	94	94	HE8AF67	Lung, Pancreas, Colon, Breast/Ovarian
82	756712	5-lipoxygenase activating protein [Homo sapiens] >pir A39824 A39824 5-lipoxygenase-activating protein - human >sp P20292 FLAP_HUMAN 5- LIPPOXYGENASE ACTIVATING PROTEIN (FLAP) (MK-886-BINDING PROTEIN). Length = 161	gi 182658	1457	1729	477	99	HSYBW76 HCABA08	Lung, Pancreas Lung, Colon
84	757614	tetratricopeptide repeat protein [Homo sapiens] >sp Q99614 Q99614 TETRATRICPEPTIDE REPEAT PROTEIN. Length = 292	gi 1688074	83	991	100	100	HMEJS13	Lung, Pancreas, Breast/Ovarian
85	757815	(AF038604) contains similarity to Drosophila ovarian tumor locus protein (GB:X13693) [Caenorhabditis elegans] >sp O44438 O44438 B0546.2 PROTEIN. Length = 346	gi 2702370	2	988	58	81	HCHOL74	Lung, Breast/Ovarian
86	759878	nuclear pore complex protein NUP107 [Rattus norvegicus] >pir A54142 A54142 nucleoporin NUP107 - rat >sp P52590 N107_RAT NUCLEAR PORE COMPLEX PROTEIN NUP107 (NUCLEOPORIN NUP107) (107 KD NUCLEOPORIN) (P105). Length = 926	gi 510717	526	1833	86	88	HNTAP78	Lung, Breast/Ovarian
87	760227	(AC003040) putative nicotinate phosphoribosyltransferase [Arabidopsis thaliana] >sp O80459 O80459 PUTATIVE NICOTINATE PHOSPHORIBOSYLTRANSFERASE. Length = 574	gi 3242705	2	484	52	71	HCHMM71	Pancreas, Breast/Ovarian

88	760312	chondroitin sulfate proteoglycan versican V0 splice-variant precursor peptide [Homo sapiens] >sp P3611 PGCV_HUMAN VERSICAN CORE PROTEIN PRECURSOR (LARGE FIBROBLAST PROTEOGLYCAN) (CHONDROITIN SULFATE PROTEOGLYCAN CORE PROTEIN 2) (GLIAL HYALURONATE-BINDIN	gj 608515	993	3215	99	99	IIMVDD07	Lung, Pancreas
89	766051			1	627			HMAFA79	Lung, Breast/Ovarian
90	767593			327	497			HCECT76	Pancreas, Colon
91	768053	(AF039688) antigen NY-CO-3 [Homo sapiens] >sp O60525 O60525 ANTIGEN NY-CO-3 (FRAGMENT). Length = 192	gj 3170176	251	625	99		HTTPE171	Pancreas, Breast/Ovarian
92	768055	ATP synthase gamma-subunit [Homo sapiens] >gnl P1D d1004512 ATP synthase gamma-subunit [Homo sapiens] >pir A49108 A49108 H+-transporting ATP synthase (EC 3.6.1.34) gamma chain - human >sp P36542 ATPG_HUMAN ATP SYNTHASE GAMMA CHAIN, MITOCHONDRIAL PRECURSOR	gnl P1D d1004511	32	949	100		HAAQ70	Lung, Pancreas
93	769685	src-like tyrosine kinase (put.); putative [Homo sapiens] Length = 537	gj 338228	1005	1409	100		HRADN48	Lung, Pancreas, Colon, Breast/Ovarian
94	771920	F36D4.2 gene product [Caenorhabditis elegans] >sp Q20100 Q20100 COSMID F36D4. Length = 224	gj 1245686	711	1562	58	77	HAIDT44	Lung, Pancreas
95	772790	cell division inhibitor [Synechocystis sp.] >pir S77404 S77404 cell division inhibitor - Synechocystis sp. (PCC 6803) >sp P73467 P73467 CELL DIVISION INHIBITOR. Length = 339	gnl P1D d1018240	145	1158	35	54	HCEOT95	Lung, Breast/Ovarian

96	772916	similar to human ZFY protein. [Homo sapiens] >sp Q92610 Q92610 MYELOBLAST KIAA0211. Length = 1267	gnl PID d101389	3	965	99	99	HCT1126	Lung, Pancreas
97	773225			52	504			HCLBI78	Lung, Pancreas
98	773632	Hrs [Homo sapiens] >gi 2731383 HGF receptor substrate Hrs [Homo sapiens] >sp O14964 O14964 HRS, COMPLETE CDS. Length = 777	gnl PID d1024245	1	309	98	98	HCEVQ60	Pancreas, Prostate, Breast/Ovarian
99	774364	(AF080561) SYT interacting protein SIP [Homo sapiens] >sp O75932 O75932 SYT INTERACTING PROTEIN SIP. Length = 669	gi 3746787	1	408	100	100	HCHAR77	Pancreas, Breast/Ovarian
100	775355			1599	1781			HDTBY31	Lung, Pancreas
101	775844	rtp transforming protein [Homo sapiens] >pir A28101 TVHURF ret finger protein - human >gnl PID c308255 RFP [Homo sapiens] {SUB 250- 513} Length = 513	gi 337372	138	1877	92	92	HISCU10	Lung, Pancreas
102	777760	(AF015040) NUMB protein [Homo sapiens] >sp G4102705 G4102705 NUMB PROTEIN. >gi 4050088 (AF109907) S171 [Homo sapiens] {SUB 79-603} >gi 887362 ORF: putative [Homo sapiens] {SUB 469-603} Length = 603	gi 4102705	62	1372	88	88	HMSHK67	Pancreas, Breast/Ovarian
103	779837	tazarotene-induced gene 2 [Homo sapiens] >sp Q99969 Q99969 TAZAROTENE-INDUCED GENE 2. Length = 163	gi 1848264	88	567	97	98	HSWBV38	Lung, Pancreas
104	780769	(AF084259) bromodomain-containing protein BP75 [Mus musculus] >sp O88665 O88665 BROMODOMAIN-CONTAINING PROTEIN BP75. Length = 651	gi 3493162	100	762	35	58	HULBS08	Lung, Pancreas
105	781445			496	1443			HMVAF52	Pancreas, Breast/Ovarian

106	781531	lumican [Homo sapiens] Length = 338	gi 699577	1	486	100	100	HCIAF71	Pancreas, Breast/Ovarian
107	783018	ovary2 [Drosophila melanogaster] >sp Q27924 Q27924 OVARY2. >gi 1208729 ovary2 [Drosophila melanogaster] {SUB 386-545} Length = 545	gi 1208732	120	674	58	76	HTPCZ45	Pancreas, Breast/Ovarian
108	783097	myogenic repressor l-mf [Homo sapiens] >sp Q99750 Q99750 MYOGENIC REPRESSOR L- MF. Length = 246	gi 1763615	413	919	85	85	HMWGR19	Lung, Colon
109	784198	(A1005893) JM26 [Homo sapiens] >sp Q60828 Q60828 JM26 PROTEIN, COMPLETE CDS (CLONE LLOXNC01U138D3 (BAYLOR COLLEGE)). Length = 265	gnl PID e1289747	80	943	81	81	HNTNB85	Lung, Pancreas, Breast/Ovarian
110	784868	WW-domain binding protein 1 [Mus musculus] >sp P97764 P97764 WW-DOMAIN BINDING PROTEIN 1. Length = 305	gi 1777577	1	969	77	85	HNTNQ08	Lung, Pancreas, Breast/Ovarian
111	785428	translation initiation factor 5 [Homo sapiens] >sp P55010 P5_HUMAN EUKARYOTIC TRANSLATION INITIATION FACTOR 5 (EIF- 5). Length = 431	gi 1229140	308	1606	87	87	IIPMC114	Lung, Pancreas, Breast/Ovarian
112	785845			67	1350			HCGBE06	Lung, Colon, Breast/Ovarian
113	785854			3	509			HUSXJ65	Lung, Pancreas
114	786705			64	180			HBJB89	Lung, Pancreas, Breast/Ovarian
115	787186			319	975			HUKBB89	Lung, Pancreas
116	787279	proteasome subunit z [Homo sapiens] >sp Q99436 Q99436 PROTEASOME SUBUNIT Z. Length = 277	gnl PID d1007816	80	856	94	94	HKAJZ91	Lung, Breast/Ovarian
117	789002			178	402			HATBM56	Lung, Pancreas, Breast/Ovarian

118	789008	1.8 kb mRNA (AA 1-84) [Homo sapiens] >pir S03384 S03384 hypothetical protein (IGF-II 3' region) - human >sp P09365 IG2R_HUMAN PUTATIVE INSULIN-LIKE GROWTH FACTOR II ASSOCIATED PROTEIN. Length = 84	gj 33000	1354	1737	100	100	HISCN20	Lung, Pancreas
119	789555	(AL035247) hypothetical trp-asp repeat protein [Schizosaccharomyces pombe] Length = 760	gnl PID e 371207	124	1815	42	66	HTTCB23	Pancreas, Breast/Ovarian
120	789631			192	320			HLICN93	Lung, Pancreas, Colon
121	789779			1	396			HCHMS40	Colon, Breast/Ovarian
122	790387			3	527			HLMNA32	Colon, Breast/Ovarian
123	790461	(AF008445) phospholipid scramblase [Homo sapiens] >gnl PID d 1033532 (AB006746) hMmTRA1b [Homo sapiens] >gi 4092081 (AF098642) phospholipid scramblase; plasma membrane phospholipid scramblase [Homo sapiens] >sp O15162 O15162 PHOSPHOLIPID SCRAMBLASE. >sp G4	gj 2282601	105	1193	99	99	HTGAV10	Lung, Pancreas, Breast/Ovarian
124	790931			2	394			HBCAO30	Pancreas, Breast/Ovarian
125	791176	(AB002107) hPer [Homo sapiens] >gj 2435507 (AF022991) Rigui [Homo sapiens] >sp O15534 O15534 RIGUI. Length = 1290	dbj AB002107_1	3	1034	90	90	HNFC167	Lung, Pancreas
126	791983			637	837			HBJLE45	Lung, Pancreas, Colon, Breast/Ovarian

127	792539	(AF020833) eukaryotic translation initiation factor 3 subunit [Homo sapiens] >sp O14801 O14801 EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT. Length = 320	gi 2460200	94	1068	94	94	HDPPX89	Lung, Pancreas, Breast/Ovarian
128	792749	protein arginine N-methyltransferase [Rattus norvegicus] >sp Q63009 ANM1_RAT PROTEIN ARGININE N-METHYLTRANSFERASE 1 (EC 2.1.1.-). Length = 353	gi 1390025	34	1104	95	96	HDQEP64	Lung, Breast/Ovarian
129	792961	(AF036249) polymerase I-transcript release factor; PTRF [Mus musculus] >sp O54724 O54724 POLYMERASE I AND TRANSCRIPT RELEASE FACTOR (POLYMERASE I-TRANSCRIPT RELEASE FACTOR). Length = 392	gi 2674195	778	1305	85	86	HMEKG25	Lung, Breast/Ovarian
130	793206	dJ1409.2 (Melanoma-Associated Antigen MAGE LIKE) [Homo sapiens] >sp O76058 O76058 DJ1409.2 (MELANOMA-ASSOCIATED ANTIGEN MAGE LIKE). Length = 606	gnl PID c1311294	889	1365	99	99	HTWFN71	Lung, Pancreas
131	793249	proliferation associated gene (pag) gene product [Homo sapiens] >pir A46711 A46711 proliferation associated gene (pag) protein - human Length = 199	gi 287641	3	701	100	100	HJAAE81	Lung, Pancreas, Breast/Ovarian
132	793626	alpha mannosidase II isozyme [Homo sapiens] >sp P49641 MA2X_HUMAN ALPHA-MANNOSIDASE IIX (EC 3.2.1.114) (MANNOSYL-OLIGOSACCHARIDE 1,3-1,6-ALPHA-MANNOSIDASE) (MAN IIX). Length = 1139	gnl PID d1010153	119	640	99	99	HWABS13	Lung, Pancreas

133	794417	(AF047470) malate dehydrogenase precursor [Homo sapiens] >sp O43682 O43682 MALATE DEHYDROGENASE (EC 1.1.1.37) PRECURSOR (EC 1.1.1.37). Length = 338	gi 2906146	3	1142	99	99	HFPIBR03	Lung, Pancreas, Breast/Ovarian
134	795197			82	888			HDPFT26	Lung, Breast/Ovarian
135	795251	GAP SH3 binding protein [Homo sapiens] >sp Q13283 Q13283 GAP SH3 BINDING PROTEIN. Length = 466	gi 1051170	101	1531	91	91	HE8FJ92	Pancreas, Breast/Ovarian
136	795752			2	1018			HWBDR92	Lung, Pancreas
137	796261	ubiquitin carrier protein E2 - human >gi 181916 ubiquitin carrier protein [Homo sapiens] {SUB 23- 247} Length = 247	pir B42856 B42856	3	851	87	87	HCHPQ06	Colon, Breast/Ovarian
138	796933	lumican [Homo sapiens] Length = 338	gi 699577	49	1107	94	94	HPMSD56	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
139	799424			525	1553			HEONK47	Lung, Pancreas, Breast/Ovarian
140	799698			1	426			HCHAM08	Colon, Breast/Ovarian
141	800351	DNAJ homolog [Homo sapiens] >gi 1127833 heat shock protein hsp40 homolog [Homo sapiens] >pir G02272 G02272 heat shock protein hsp40 homolog - human >sp Q13431 Q13431 HEAT SHOCK PROTEIN HSP40 HOMOLOG. Length = 178	gi 1518918	282	860	83	84	HEMFP05	Pancreas, Breast/Ovarian

142	800573	26S protease subunit [Sus scrofa] >gi3193258 (AF069053) proteasome subunit SUG1 [Bos taurus] >gnl PID d1012606 proteasomal ATPase (rat SUG1) [Rattus norvegicus] >gnl PID d1023806 (AB000491) proteasome p45/SUG [Rattus norvegicus] >gnl PID e199326 mSUG1 pr	gnl PID e235521	178	1383	93	93	HCEVS28	Lung, Breast/Ovarian
143	805815			15	1055			HCHAP80	Lung, Colon, Breast/Ovarian
144	806445			711	1028			HTELC67	Lung, Pancreas
145	810309	(AF098482) transcriptional coactivator p52 [Homo sapiens] >sp G4050034 G4050034 TRANSCRIPTIONAL COACTIVATOR P52. Length = 333	gi 4050034	226	741	61	75	HNTDX22	Lung, Pancreas
146	811022			168	881			HISEA13	Lung, Pancreas
147	811023			13	234			HLWAW17	Lung, Pancreas, Colon, Breast/Ovarian
148	811143	cytokine inducible SH2-containing protein [Mus musculus] >pir S55551 S55551 cytokine-inducible protein CIS - mouse >sp Q62225 Q62225 CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN (SH2 DOMAIN CONTAINING PROTEIN INDUCED BY MULTIPLE CYTOKINES, SIC). Length = 257	gnl PID d1007285	3	887	90	92	IIDQPA25	Lung, Breast/Ovarian
149	811381	FIN14 gene product [Mus musculus] >sp Q61077 F114_MOUSE FIBROBLAST GROWTH FACTOR INDUCIBLE PROTEIN 14 (FIN14). Length = 61	gi 1353711	1338	1511	86	91	HLYEK93	Colon, Breast/Ovarian

150	811595	CIRP [Homo sapiens] >gi2924760 (AC004258) CIRP [Homo sapiens] >gi2541973 (AF021336) DNA damage-inducible RNA binding protein [Homo sapiens] >sp Q1401 Q1401.1 GLYCINE- RICH RNA BINDING PROTEIN CIRP. Length = 172	gi 1011874	1	609	100	100	HDTLA92	Pancreas, Breast/Ovarian
151	813000	Tera [Mus musculus] >sp P70361 P70361 TERA. Length = 277	gi 1575505	95	850	84	86	HDPVZ64	Pancreas, Breast/Ovarian
152	813288	fau gene product [Homo sapiens] >gi 31305 fau.1 gene product [Homo sapiens] >pir JC1278 JC1278 ubiquitin-like protein / ribosomal protein S30, cytosolic - human Length = 133	gi 31303	1	510	86	86	HC1IMQ63	Lung, Breast/Ovarian
153	813431	DAP-1 [Homo sapiens] >pir I37274 I37274 death- associated protein 1 - human >sp P51397 DAP1_HUMAN DEATH- ASSOCIATED PROTEIN 1 (DAP-1). Length = 102	gi 434845	3	470	89	89	HWHQ570	Lung, Pancreas
154	813450	PISSLRE gene product [Homo sapiens] >pir S49330 S49330 serine/threonine kinase (EC 2.7.1.-) pisslre - human >pir 38116 38116 gene PISSLRE protein - human >sp Q1513 Q1513 PISSLRE MRNA. Length = 360	gi 556651	1	651	100	100	HCEEJ73	Lung, Pancreas
155	813478	retinoblastoma-binding protein mRbAp48 [Mus musculus] >pir I49366 I49366 retinoblastoma- binding protein mRbAp48 - mouse Length = 461	gi 1016275	1	1398	99	100	HAJBH20	Lung, Pancreas, Breast/Ovarian
156	813505	ribosomal protein L23a [Homo sapiens] >gi 306549 homology to rat ribosomal protein L23 [Homo sapiens] {SUB 10-156} Length = 156	gi 404015	2	496	100	100	HDABK53	Lung, Pancreas

157	815552	(A1011497) Claudin-9 [Homo sapiens] >sp E1363658 E1363658 CLAUDIN-9. Length = 211	gnl PID e1363658	317	898	95	96	HUFEI129	Lung, Colon
158	815606	Ki-1/57 intracellular antigen [Homo sapiens] >sp O75804 O75804 Ki-1/57 INTRACELLULAR ANTIGEN (FRAGMENT). Length = 299	gi 3403154	218	1303	90	95	HDPRY63	Lung, Pancreas, Breast/Ovarian
159	816048	neutral protease alpha subunit [Homo sapiens] >gi 35328 protease small subunit (aa 1-268) [Homo sapiens] >gi 1905903 (AD001527) calcium-dependent protease, small (regulatory) subunit (calpain) (calcium-activated neutral proteinase) (CANP) [Homo sapiens] >	gi 179909	24	644	95	96	HTLCZ60	Lung, Breast/Ovarian
160	822978	(AF003130) similar to Achlya ambisexualis antheridiol steroid receptor (NID:gi166306) [Caenorhabditis elegans] >sp O01757 O01757 SIMILAR TO ACHLYA AMBISEXUALIS ANTHERIDIOL STEROID RECEPTOR. Length = 1043	gi 2088668	94 1449 992	156 1775 2617	60	78	HODEM46 HCEME79 HWHQH79	Lung, Pancreas Pancreas, Colon Lung, Breast/Ovarian
161	823616								
162	823981								
163	824364	drebrin E2 [Homo sapiens] >gnl PID d1005005 drebrin E [Homo sapiens] >pir JN0809 JN0809 drebrin E (clone gDhh13) - human >sp Q16643 DREB_HUMAN DREBRIN E. Length = 649	gi 392890	1	606	84	84	HCHPR34	Colon, Breast/Ovarian

164	824423	UDP-GalNAc:polypeptide N-acetylgalactosaminyl transferase [Homo sapiens] >pir JC4223 JC4223 polypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.41) - human >sp Q10472 PAGT_HUMAN POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE (EC 2.4.1.41) (PROTEIN- UDP	gij971459	61	1743	100	100	HPWDL83	Lung, Pancreas
165	825279			36	602			H6EDN61	Lung, Pancreas
166	825442			1	900			HTODA45	Colon, Breast/Ovarian
167	825548	ancient ubiquitous 46 kDa protein AUP46 precursor [Mus musculus] >sp P70295 P70295 ANCIENT UBIQUITOUS PROTEIN PRECURSOR (AUP1). Length = 410	gij1517822	473	1504	81	84	HLUDB77	Lung, Breast/Ovarian
168	825725	hNop56 [Homo sapiens] >sp Q00567 NO56_HUMAN NUCLEOLAR PROTEIN NOP56. Length = 602	gnl PID e1188703	25	723	99	99	HMWIV57	Lung, Pancreas
169	826639	H.sapiens mRNA for rat translocon-associated protein delta homolog [Homo sapiens] >gnl PID e212192 translocon-associated protein delta subunit precursor [Homo sapiens] >gnl PID e220312 translocon-associated protein delta subunit precursor [Homo sapiens] >	gij1071681	1	561	100	100	HPTVX93	Lung, Colon, Breast/Ovarian
170	827079	(AL009171) 62D9.a [Drosophila melanogaster] >sp E1198294 E1198294 62D9.A. Length = 1305	gnl PID e1198294	53	2176	71	85	HDAAD02	Lung, Breast/Ovarian

171	827153	pancreatitis-associated protein [Homo sapiens] >gi 312807 preprotein [Homo sapiens] >bbs 121222 PAP-H=pancreatitis-associated protein [human, pancreas, Peptide, 175 aa] [Homo sapiens] >gnl PID d1003233 PAP homologous protein [Homo sapiens] >pir A49616 A49	gi 482909	54	602	90	90	HLQBS95	Pancreas, Colon, Breast/Ovarian
172	827351			1	639			HSKJ135	Colon, Breast/Ovarian
173	827503	(AC004003) serine/threonine kinase RICK; match to protein AF027706 (PID: g3123887) and mRNA AF027706 (NID: g3123886) [Homo sapiens] >gi 3290172 (AF064824) CARD-containing ICE associated kinase [Homo sapiens] >gi 3342910 (AF078530) receptor interacting prote	gi 3264574	255	1886	98	98	HLAAB36	Lung, Breast/Ovarian
174	827563	rhophilin [Mus musculus] >sp Q61085 Q61085 GTP-RHO BINDING PROTEIN 1 (RHOPHILIN). Length = 643	gi 1176422	6	776	81	91	HIBGDH11	Colon, Breast/Ovarian
175	827565	serine protease [Homo sapiens] Length = 492	gi 2507613	1	744	55	68	HCHAK72	Lung, Pancreas, Colon, Breast/Ovarian
176	827893	homology with GTP binding protein; putative [Caenorhabditis elegans] >pir S44605 S44605 C02F5.3 protein - Caenorhabditis elegans Length = 573	gi 289610	165	836	62	75	HMSOT38	Lung, Pancreas
177	828072			1147	1305			HTECA53	Lung, Pancreas, Breast/Ovarian
178	828228			1105	1314			HWLA178	Prostate, Colon

179	828241	cathepsin O [Homo sapiens] >pir/A55090/A55090 cathepsin O (EC 3.4.-.-) precursor - human >sp P43234 CATO_HUMAN CATHEPSIN O PRECURSOR (EC 3.4.22.-). Length = 321	gi 574804	2	1012	93	93	HWBBP30	Lung, Pancreas, Prostate
180	828287	histone (H2A.Z) [Bos taurus] >gi 410 histone H2A.Z (AA 1-127) [Bos taurus] >gi 184060 histone (H2A.Z) [Homo sapiens] >gi 31975 histone H2A.Z (AA 1-127) [Homo sapiens] >gi 3649600 histone [Homo sapiens] >gi 204599 histone (H2A.Z) [Rattus norvegicus] >gi 57	gi 163150	171	572	100	100	HUSIS02	Lung, Pancreas, Prostate, Breast/Ovarian
181	828364			663	1340			HWHG117	Pancreas, Breast/Ovarian
182	828371	complement component C1s [Homo sapiens] >gi 179648 complement subcomponent C1s precursor [Homo sapiens] >gi 763110 complement protein C1s precursor [Homo sapiens] >pir/A40496 C1HUS complement subcomponent C1s (EC 3.4.21.42) precursor - human >sp P09871 C1	gi 179646	4	2283	97	97	HLQCQ12	Lung, Pancreas, Colon, Breast/Ovarian
183	828403	DNA-binding protein [Homo sapiens] >pir/A44478/A44478 probable cell growth or differentiation regulator (alternatively spliced type I transcript) - human >sp Q02833 Q02833 PUTATIVE TRANSCRIPTIONAL REGULATORY PROTEIN HRC1. Length = 373	gi 184390	1	648	98	98	HDTHL82	Lung, Pancreas, Colon
184	828501	(AF056302) eIF-2alpha kinase [Drosophila melanogaster] >sp O61651 O61651 EIF-2ALPHA KINASE. Length = 1589	gi 3046351	1	1812	36	58	IIBMDG73	Lung, Colon, Breast/Ovarian

185	828520	(A1010840) ATP-dependent RNA helicase [Homo sapiens] >sp E1321519 E1321519 ATP-DEPENDENT RNA HELICASE (FRAGMENT). Length = 420	gn PID c1321519	445	1821	91	91	HIRGBN47	Prostate, Breast/Ovarian
186	828527			723	926			HSKGQ05	Lung, Pancreas, Prostate, Breast/Ovarian
187	828538			332	976			HPWDF55	Lung, Prostate, Breast/Ovarian
188	828541	pre-pump-1 proteinase (AA -17 to 250) [Homo sapiens] >gi 35803 PUMP [Homo sapiens] >pir B28816 KCHUM matrilysin (EC 3.4.24.23) precursor - human >sp P09237 COG7_HUMAN MATRILYSIN PRECURSOR (EC 3.4.24.23) (PUMP-1 PROTEASE) (UTERINE METALLOPROTEINASE) (MATRI	gi 35799	43	933	100	100	HRACJ32	Pancreas, Prostate, Colon
189	828549	thrombospondin 2 [Homo sapiens] >pir A47379 TSHUP2 thrombospondin 2 precursor - human Length = 1172	gi 307506	26	1738	94	94	HF1AL22	Pancreas, Colon
190	828562			1	342			HPWBR24	Pancreas, Prostate
191	828576			3	731			HPTVU91	Pancreas, Prostate, Colon
192	828602			1050	1568			HPRAT58	Lung, Prostate
193	828628	tumor-associated antigen [Homo sapiens] >pir A36056 A36056 tumor-associated antigen CO-029 - human >sp P19075 CO02_HUMAN TUMOR-ASSOCIATED ANTIGEN CO-029. Length = 237	gi 180926	307	1029	94	94	HPRCM33	Pancreas, Prostate, Colon

194	828667	cytochrome c-1 [Homo sapiens] >sp P08574 CY1_HUMAN CYTOCHROME C1, HEME PROTEIN PRECURSOR. >gi 181238 cytochrome c1 [Homo sapiens] {SUB 99-325} length = 325	gi 181240	2	1006	85	85	HKA0B02	Pancreas, Breast/Ovarian
195	828684	p55CDC [Homo sapiens] >pir A56021 A56021 probable cell division control protein p55CDC - human >sp Q12834 Q12834 P55CDC. Length = 499	gi 468032	41	1573	92	92	HPJAE35	Pancreas, Prostate
196	828727	(AF044954) NADH:ubiquinone oxidoreductase PDSW subunit [Homo sapiens] >gi 4165091 (AF088991) NADH-ubiquinone oxidoreductase PDSW subunit [Homo sapiens] Length = 172	gi 4164442	3	629	93	93	HMCBB12	Lung, Prostate, Breast/Ovarian
197	828734	homologue of Drosophila Fat protein [Homo sapiens] >sp Q14517 Q14517 CADHERIN- RELATED TUMOR SUPPRESSOR HOMOLOG PRECURSOR (FAT PROTEIN HOMOLOG). >gnl PID d1022418 cadherin [Homo sapiens] {SUB 993-1132} Length = 4590	gi 1107687	1	657	99	99	HSRAB84	Pancreas, Colon, Breast/Ovarian
198	828750	(AF035940) similar to mago nashi [Homo sapiens] >gi 2330011 (AF007862) mm-Mago [Mus musculus] >gi 2909828 (AF035939) similar to mago nashi [Mus musculus] >sp O35169 O35169 MM-MAGO. >sp G2909830 G2909830 MAGOH. >sp P50606 MGH_HUMAN MAGO NASHI PROTEIN HOMOL	gi 2909830	13	546	100	100	HPIAC11	Pancreas, Prostate, Breast/Ovarian

199	828842	(AB007191) AMY-1 [Homo sapiens] >gnl PID d1009980 c-myc binding protein [Homo sapiens] >sp Q99417 Q99417 C-MYC BINDING PROTEIN. Length = 103	gnl PID d1023271	1	363	98	100	HOUGA12	Pancreas, Prostate, Breast/Ovarian
200	828843	p48 [Homo sapiens] >sp P50502 HIP_HUMAN HSC70-INTERACTING PROTEIN (PROGESTERONE RECEPTOR-ASSOCIATED P48 PROTEIN). >gi 1857033 SCN6 gene product [Homo sapiens] {SUB 99-369} Length = 369	gi 904032	3	761	99	100	HOVBK85	Lung, Pancreas, Prostate
201	828851	(AF054284) spliceosomal protein SAP 155 [Homo sapiens] >sp G4033735 G4033735 SPLICEOSOMAL PROTEIN SAP 155. >gi 3387899 (AF070540) putative nuclear protein [Homo sapiens] {SUB 1011-1304} Length = 1304	gi 4033735	1	1029	98	98	HOSGA73	Pancreas, Prostate
202	828856	thymidine kinase (EC 2.7.1.21) [Homo sapiens] >gi 339719 thymidine kinase [Homo sapiens] >pir A27318 KHUT thymidine kinase (EC 2.7.1.21), cytosolic - human >sp P04183 KITH_HUMAN THYMIDINE KINASE, CYTOSOLIC (EC 2.7.1.21). >gi 339713 thymidine kinase [Homo sapiens]	gi 339709	1	804	99	100	HOHEN75	Prostate, Breast/Ovarian
203	828862	tyrosine kinase receptor [Homo sapiens] >pir B41527 B41527 transforming protein (axl(-)) - human Length = 885	gi 292870	1	417	98	98	HOHB190	Prostate, Breast/Ovarian
204	828870	TRAM protein [Homo sapiens] >pir S30034 S30034 translocating chain-associating membrane protein - human >sp Q15629 Q15629 TRAM PROTEIN. Length = 374	gi 37265	32	1279	94	94	HOEKU65	Lung, Pancreas, Colon

205	828873	precursor polypeptide (AA -31 to 1139) [Homo sapiens] >gi 538354 thrombospondin [Homo sapiens] {SUB 1-397} >gi 339669 thrombospondin [Homo sapiens] {SUB 1028-1170} >gi 532689 thrombospondin-1p180 [Homo sapiens] {SUB 364-422} Length = 1170	gi 37465	1	1398	100	100	HOHCJ26	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
206	828892	keratin [Homo sapiens] >sp Q14533 Q14533 KERATIN (HAIR TYPE II BASIC KERATIN) (KERATIN LIKE). >gnl PID e118093 hair type II basic keratin [Homo sapiens] {SUB 81-505} >gi 951272 keratin like [Homo sapiens] {SUB 249-505} >bhs 161491 type II hair keratin {cl	gnl PID e321549	3	653	90	91	HOGAA83	Lung, Prostate, Breast/Ovarian
207	828893	ESX [Homo sapiens] >gi 1841523 ESE-1b [Homo sapiens] >gi 2338756 (AF017307) Ets-related transcription factor [Homo sapiens] >gi 2384740 (AF016295) Ets transcription factor [Homo sapiens] >gi 2459797 epithelial-specific ets protein [Homo sapiens] >sp P78545	gi 1754538	36	1253	86	86	HOGAS09	Pancreas, Prostate, Colon, Breast/Ovarian
208	828897	prostaticin [Homo sapiens] >gi 862305 prostaticin [Homo sapiens] >pir A57014 A57014 prostaticin (EC 3.4.21.-) precursor - human >sp G565130 G565130 PROSTASIN=SERINE PROTEINASE (N-TERMINAL). {SUB 45-64} Length = 343	gi 1143194	59	811	92	92	HBCAY53	Pancreas, Colon, Breast/Ovarian

209	828910	light chain 3 subunit of microtubule-associated proteins 1A and 1B [Rattus norvegicus] >pir A53624 A53624 microtubule-associated protein 1 light chain 3 - rat >sp Q62625 MPL3_RAT MICROTUBULE-ASSOCIATED PROTEINS 1A/1B LIGHT CHAIN 3 (MAP1A/MAP1B LC3). {SUB	gj 455109	28	540	96	98	HOHDY41	Prostate, Colon
210	828927	cytochrome c oxidase subunit Va [Homo sapiens] >pir JT0342 OTHU5A cytochrome-c oxidase (EC 1.9.3.1) chain Va precursor - human >sp P20674 COXA_HUMAN CYTOCHROME C OXIDASE POLYPEPTIDE VA PRECURSOR (EC 1.9.3.1). >gi 3859864 (AF067635) cytochrome c oxidase su	gj 695360	1	567	99	99	HHFJM88	Lung, Breast/Ovarian
211	828932	80K-H protein [Homo sapiens] >gi 1293640 protein kinase C substrate 80K-H [Homo sapiens] >pir A32469 A32469 80K protein H precursor - human >sp P14314 G19P_HUMAN PROTEIN KINASE C SUBSTRATE, 80 KD PROTEIN, HEAVY CHAIN (PKCSH) (80K-H PROTEIN). Length = 527	gj 182855	82	1026	83	83	HNTAC57	Lung, Pancreas, Prostate, Breast/Ovarian
212	828933	Csa-19 [Homo sapiens] Length = 217	gj 531171	439	852	97	98	HMEMA07	Lung, Pancreas, Breast/Ovarian
213	828941	ORF YJL115w [Saccharomyces cerevisiae] >gi 171091 ASF1 [Saccharomyces cerevisiae] >sp S30766 S30766 ASF1 protein - yeast (Saccharomyces cerevisiae) >sp P32447 ASF1_YEAST ANTI-SILENCING PROTEIN 1. Length = 279	gj 1008304	1	729	59	74	HMGIBJ25	Lung, Pancreas, Colon, Breast/Ovarian

214	828957	F31C3.5 [Caenorhabditis elegans] >sp O62193 O62193 F31C3.5 PROTEIN. Length = 180	gnl PID e1346411	3	635	37	68	HMWHG54	Prostate, Breast/Ovarian
215	828963	house-keeping protein [Mus musculus] >pir S27870 S27870 house-keeping protein - mouse >sp Q61669 Q61669 HOUSE-KEEPING PROTEIN 1. Length = 396	gil 193871	73	1293	55	77	HMWBH91	Lung, Prostate, Colon, Breast/Ovarian
216	828964			639	905			HMWFZ60	Pancreas, Prostate, Colon, Breast/Ovarian
217	828966	S-adenosylhomocysteine hydrolase [Homo sapiens] >pir A43629 A43629 adenosylhomocysteinease (EC 3.3.1.1) - human Length = 432	gil 178279	2	1372	98	98	HMWFV54	Lung, Pancreas, Prostate, Breast/Ovarian
218	828967	putative tRNA synthetase-like protein [Homo sapiens] >gil 4104935 (AF042347) putative phenylalanyl-tRNA synthetase alpha-subunit; PheHA [Homo sapiens] >sp E317305 E317305 PUTATIVE tRNA SYNTHETASE-LIKE PROTEIN. >sp G2102679 G2102679 PUTATIVE tRNA SYNTHETASE	gil 2102679	3	1535	98	98	HMUBT12	Pancreas, Prostate, Breast/Ovarian
219	828977	insulin-like growth factor binding protein 2 [Homo sapiens] >bbs 106618 insulin-like growth factor binding protein-2, IGFBP-2 [human, placenta, Peptide, 328 aa] [Homo sapiens] >pir A41927 A41927 insulin-like growth factor-binding protein 2 precursor - hum	gil 179477	2	685	100	100	HMVAW27	Lung, Pancreas, Prostate, Breast/Ovarian

220	828978	annexin IV (placental anticoagulant protein II) [Homo sapiens] >gnl PID d1011889 annexin IV (carbohydrate-binding protein p33/41) [Homo sapiens] >pir A42077 A42077 annexin IV - human >sp P09525 ANX4_HUMAN ANNEXIN IV (LIPOCORTIN IV) (ENDONEXIN I) (CHROMOBI	gi 178699	213	1184	100	100	100	HNTH78	Lung, Pancreas, Prostate
221	828979			16	1080				HMUBO53	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
222	829001			1621	1959				HMSJR30	Lung, Pancreas, Prostate, Breast/Ovarian
223	829003	plasma gelsolin [Homo sapiens] >pir A03011 FAHUP gelsolin precursor, plasma - human >sp P06396 GELS_HUMAN GELSOLIN PRECURSOR, PLASMA (ACTIN-DEPOLYMERIZING FACTOR) (ADF) (BREVIN) (AGEL). >gnl PID e20565 plasma gelsolin (AA 49-117) [Homo sapiens] {SUB 49-11	gi 736249	635	2536	99	99	99	HMSKA53	Lung, Pancreas, Prostate
224	829016	(AB006625) The human homolog of a mouse imprinted gene, Peg3. [Homo sapiens] >sp P78418 P78418 KIAA0287 (PEG3) (FRAGMENT). >gi 1899244 PEG3 [Homo sapiens] {SUB 518-1132} Length = 1132	dbj AB006625_1	409	759	87	87	87	HMIA173	Prostate, Breast/Ovarian
225	829027	ras-like protein [Homo sapiens] >pir D34788 TVHUC4 transforming protein ras (teratocarcinoma clone TC10) - human Length = 213	gi 190881	2	577	100	100	100	HMIBE59	Prostate, Colon

226	829028	RnudC gene product [Rattus norvegicus] >pir/A55897/A55897 prolactin-induced T cell protein c15 - rat >sp/Q63525/Q63525 C15 MRNA. Length = 332	gi 619907	31	1110	95	98	HMGIBQ56	Pancreas, Prostate, Breast/Ovarian
227	829031	protocadherin X [Mus musculus] >sp/G4099553/G4099553 PROTOCADHERIN X. Length = 928	gi 4099553	116	637	90	93	HMGIBI69	Lung, Pancreas, Prostate, Breast/Ovarian
228	829034			28	1362			HMEIY69	Pancreas, Prostate
229	829036	Similar to B.subtilis Poly(A) polymerase (SW:PAPS_BACSU) [Caenorhabditis elegans] >sp/Q93795/Q93795 F55B12.4 PROTEIN. Length = 440	gnl PID e1347205	114	1151	67	81	HMEI175	Pancreas, Prostate
230	829049	UDP-Gal:GlcNAc galactosyltransferase [Homo sapiens] >sp/O60910/O60910 UDP-GAL:GLCNAC GALACTOSYLTRANSFERASE. Length = 393	gnl PID e1283714	233	1444	94	94	HMEFQ33	Prostate, Colon
231	829073			193	843			HL YCD85	Pancreas, Prostate
232	829075			2	484			HMAAD66	Lung, Pancreas, Prostate, Breast/Ovarian
233	829076			3	665			HADDC41	Lung, Pancreas, Breast/Ovarian
234	829080			3	500			HMABG80	Prostate, Breast/Ovarian
235	829087	small GTP-binding protein [Oryctolagus cuniculus] >pir/A48500/A48500 small GTP-binding protein Rab25 - rabbit Length = 213	gi 436001	157	873	95	97	HL.WBY67	Pancreas, Prostate, Breast/Ovarian

236	829092	UDP-galactose translocator [Homo sapiens] >pir JC4903 JC4903 UDP-galactose transporter, splice form 1 - human Length = 393	gnl PID d1013353	1	513	85	85	HLWBC74	Pancreas, Prostate
237	829095			3	425			HLWBM89	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
238	829096	antiquitin=26g turgor protein homolog [human, kidney, Peptide, 511 aa] [Homo sapiens] >pir A54676 A54676 antiquitin - human >sp P49419 DHAX_HUMAN ANTIQUITIN (EC 1.2.1.-). Length = 511	bbs I38840	552	1628	97	97	HLWAO28	Prostate, Breast/Ovarian
239	829118	nuclear autoantigen fo 14 kDa [Homo sapiens] >sp O43805 O43805 NUCLEAR AUTOANTIGEN FO 14 KDA. Length = 119	gnl PID c322419	2	415	99	99	HLSDA35	Lung, Prostate
240	829152	unknown protein precursor [Homo sapiens] >pir JN0596 JN0596 fibrinogen-related protein HFERP-1 precursor - human >sp Q08830 Q08830 FIBRINOGEN-LIKE PROTEIN 1 PRECURSOR. Length = 312	gnl PID d1003846	215	1231	95	95	HLICU82	Lung, Pancreas, Prostate
241	829160	ubiquitin-conjugating enzyme UbcH6 [Homo sapiens] Length = 193	gil 1064914	2	769	83	83	HLFBF56	Lung, Pancreas, Prostate, Colon
242	829163			403	930			HSPBG80	Lung, Pancreas, Breast/Ovarian
243	829176	C4b-binding protein alpha chain [Homo sapiens] >gil 190502 C4b-binding protein alpha chain [Homo sapiens] >pir A33568 NBHUC4 C4b-binding protein alpha chain precursor - human >sp P04003 C4BP_HUMAN C4B-BINDING PROTEIN ALPHA CHAIN PRECURSOR (PROLINE-RICH PRO	gil 190500	3	662	100	100	HLQBR92	Lung, Pancreas
244	829204			515	913			HLISB22	Prostate, Breast/Ovarian

245	829207		111	977	HLISA66	Prostate, Breast/Ovarian
246	829228		1	2508	HKGBQ77	Lung, Prostate, Colon
247	829252		96	1322	HKAP121	Pancreas, Prostate
248	829254		1	483	HKFB196	Lung, Pancreas, Prostate, Breast/Ovarian
249	829269		121	474	HKAEE96	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
250	829277		3	596	HJPCG91	Lung, Prostate
251	829290		100	207	HJBDL52	Lung, Pancreas, Prostate, Breast/Ovarian
252	829294		3	1847	HISDU47	Pancreas, Prostate
253	829299		3	794	HISEC32	Lung, Pancreas, Prostate
254	829308	dJ1409.2 (Melanoma-Associated Antigen MAGE LIKE) [Homo sapiens] >sp O76058 O76058 DJ1409.2 (MELANOMA-ASSOCIATED ANTIGEN MAGE LIKE). Length = 606	207	938	HIIBC93	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
255	829349	ribosomal protein S15a [Rattus norvegicus] >pir JC2234 JC2234 ribosomal protein S15a - rat Length = 130	152	547	HICAF44	Lung, Pancreas, Prostate, Breast/Ovarian
256	829354	RAD4 gene product [Saccharomyces cerevisiae] Length = 730	1	1113	HAIBD51	Lung, Pancreas, Breast/Ovarian

257	829388	DNase protein [Homo sapiens] >gi 1620214 XIB [Homo sapiens] >pir JC4633 JC4633 DNase I-like endonuclease (EC 3.1.-.-) - human >sp P49184 DRNL_HUMAN MUSCLE-SPECIFIC DNASE I-LIKE PRECURSOR (EC 3.1.21.-) (DNASE X) (XIB). Length = 302	gi 929628	319	1281	94	94	HUVCJ22	Lung, Pancreas, Colon, Breast/Ovarian
258	829540			258	437			HAPOU28	Lung, Pancreas, Colon, Breast/Ovarian
259	829626	mannosyl-oligosaccharide 1,2-alpha-mannosidase (EC 3.2.1.113) - rabbit (fragment) >gi 474282 mannosyl-oligosaccharide alpha-1,2-mannosidase [Oryctolagus cuniculus] (SUB 12-480) Length = 480	pir B54408 B54408	3	764	75	88	HCEES14	Lung, Pancreas, Colon, Breast/Ovarian
260	829730	underexpressed in thyroid tissue after TSH stimulation [Canis familiaris] >sp Q28283 Q28283 C5FW PROTEIN. Length = 343	gnl PID e252512	455	1153	62	75	HAJBK53	Pancreas, Breast/Ovarian
261	829892	(AF053651) cellular apoptosis susceptibility protein [Homo sapiens] >sp O75432 O75432 CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN. Length = 971	gi 3598795	64	1053	85	85	HAMFJ43	Lung, Prostate
262	829933	(AF035606) calcium binding protein [Homo sapiens] >sp O75340 O75340 CALCIUM BINDING PROTEIN. Length = 191	gi 3342794	1	540	86	86	HAIC176	Pancreas, Prostate
263	829938	(AF067855) geminin [Homo sapiens] >sp O75496 O75496 GEMININ. Length = 209	gi 3249005	230	952	93	93	HAIBS55	Pancreas, Prostate
264	829969			551	814			HACCB64	Lung, Pancreas, Prostate, Breast/Ovarian

265	829982	(AF020352) NADH:ubiquinone oxidoreductase 15 kDa IP subunit [Homo sapiens] >gi 2911482 (AF047434) NADH-ubiquinone oxidoreductase 15kDa subunit; CI-15 protein [Homo sapiens] >sp O43920 NIPM_HUMAN NADH-UBIQUINONE OXIDOREDUCTASE 15 KD SUBUNIT (EC 1.6.5.3) (E	gi 2655055	28	399	100	100	11ABG1E25	Prostate, Breast/Ovarian
266	830007	catechol-O-methyltransferase [Homo sapiens] >gi 403304 catechol O-methyltransferase [Homo sapiens] >pir S37406 A38459 catechol O-methyltransferase (EC 2.1.1.6) - human >sp P21964 COMT_HUMAN CATECHOL O-METHYLTRANSFERASE, MEMBRANE-BOUND FORM (EC 2.1.1.6) (M	gi 180920	110	1006	99	99	H6EDW66	Lung, Prostate, Breast/Ovarian
267	830019	(AF030249) putative dienoyl-CoA isomerase [Homo sapiens] >gi 564065 peroxisomal enoyl-CoA hydratase-like protein [Homo sapiens] >pir 38882 38882 peroxisomal enoyl-CoA hydratase-like protein - human >sp Q1301 IECH1_HUMAN PROBABLE PEROXISOMAL ENOYL-COA HY	gi 2623168	77	976	94	96	112MAC92	Prostate, Breast/Ovarian
268	830073			1	690			HBWBK27	Lung, Pancreas, Breast/Ovarian
269	830130			1	177			H2LAD55	Lung, Prostate, Breast/Ovarian
270	830134			16	1290			H2CBP53	Lung, Pancreas, Prostate, Colon, Breast/Ovarian

271	830135	neutrophil gelatinase associated lipocalin [Homo sapiens] >sp P80188 NGAL_HUMAN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN PRECURSOR (NGAL) (P25) (25 KD ALPHA-2-MICROGLOBULIN-RELATED SUBUNIT OF MMP-9) (LIPOCALIN-2) (ONCOGENE 24P3). Length = 198	gi 929657	2	763	100	100	H2MAC06	Pancreas, Prostate, Breast/Ovarian
272	830148	snRNP polypeptide B [Homo sapiens] >sp Q15182 Q15182 SNRNP POLYPEPTIDE B. Length = 285	gi 190247	96	839	79	79	HAICK77	Lung, Prostate, Breast/Ovarian
273	830149	threonyl-tRNA synthetase [Homo sapiens] >pir A38867 YSHUT threonine--tRNA ligase (EC 6.1.1.3) - human Length = 712	gi 1464742	3	2333	95	95	H2CBC04	Lung, Pancreas, Prostate
274	830154	spectrin SH3 domain binding protein 1 [Homo sapiens] >sp O76049 O76049 SPECTRIN SH3 DOMAIN BINDING PROTEIN 1. Length = 508	gi 3165429	2	1081	100	100	HYAAC49	Lung, Pancreas
275	830183	heat shock protein 84 - mouse >pir B34461 B34461 heat shock protein 90 beta - rabbit (fragment) {SUB 1-25} >sp P30947 HS9B RABBIT HEAT SHOCK PROTEIN HSP 90-BETA (HSP 84) (FRAGMENT). {SUB 2-25} >pir S13268 S13268 heat shock protein, 90K - bovine (fragment)		92	358			HWLQF08	Pancreas, Breast/Ovarian
276	830194	heat shock protein 84 - mouse >pir B34461 B34461 heat shock protein 90 beta - rabbit (fragment) {SUB 1-25} >sp P30947 HS9B RABBIT HEAT SHOCK PROTEIN HSP 90-BETA (HSP 84) (FRAGMENT). {SUB 2-25} >pir S13268 S13268 heat shock protein, 90K - bovine (fragment)	pir A35569 HMS84	3	1043	100	100	HLDCP20	Lung, Pancreas, Breast/Ovarian
277	830207	(AF016437) contains similarity to a C2H2-type zinc finger [Caenorhabditis elegans] >sp O16350 O16350 F13H6.1 PROTEIN. Length = 631	gi 2315332	173	1051	45	63	HWLMF07	Pancreas, Colon
278	830242			85	654			HWLUF58	Lung, Pancreas

279	830328	putative cyclin G1 interacting protein [Homo sapiens] >sp O43257 O43257 PUTATIVE CYCLIN G1 INTERACTING PROTEIN. Length = 154	gj 2668505	304	954	81	81	HWLEL26	Lung, Colon, Breast/Ovarian
280	830340	putative cell surface antigen [Rattus norvegicus] >sp p97881 p97881 PUTATIVE CELL SURFACE ANTIGEN. Length = 547	gj 1890275	1	336	63	81	HWLEG68	Pancreas, Colon
281	830341	peroxisomal acyl-coenzyme A oxidase, AOX [human, liver, Peptide, 661 aa] [Homo sapiens] Length = 661	bbs 144907	1	648	100	100	HSIAI179	Lung, Pancreas
282	830351			3	656			HWHQT21	Colon, Breast/Ovarian
283	830358			456	716			HSUAE53	Lung, Colon, Breast/Ovarian
284	830390	platelet membrane glycoprotein IIIa beta subunit [Homo sapiens] >sp O15495 O15495 PLATELET MEMBRANE GLYCOPROTEIN IIIA BETA SUBUNIT. Length = 784	gj 2443452	2	523	90	90	HWGQA69	Pancreas, Colon
285	830400	phosphate carrier protein [Homo sapiens] >pir B53737 B53737 phosphate carrier protein, form B - human Length = 361	gj 38262	2	1078	99	100	HW11PY68	Lung, Pancreas, Breast/Ovarian
286	830437	IgG Fc receptor I [Homo sapiens] >gj 292169 Fc gamma receptor I [Homo sapiens] >pir A39878 A39878 Fc gamma (IgG) receptor I-A (high affinity) precursor - human >sp Q92663 Q92663 FC GAMMA RECEPTOR I. Length = 374	gj 180279	3	1199	91	91	HWABG32	Lung, Colon

287	830458	HBp15/L22 [Sus scrofa] >gnl P D d 1005074 HBp15/L22 [Mus musculus] >pir C 21 JC2121 heparin-binding protein 15 - pig >pir C2119 JC2119 heparin-binding protein 15 - mouse Length = 128	gnl P D d 1005075	1	441	70	70	HDQMF96	Lung, Pancreas
288	830466	tenascin X [Homo sapiens] >sp P78530 P78530		988	1260			HOEIZ61	Lung, Colon
289	830497	TENASCIN X (TENASCIN-X). >gi 2347137 (AF019413) tenascin X [Homo sapiens] {SUB 2593-4289} >pir A42175 A42175 tenascin homolog 3.9kF3-3 - human (fragment) {SUB 2793-2880} >pir B42175 B42175 tenascin homolog 3.9kF	gi 1841546	2	1331	99	99	HUFBX52	Lung, Breast/Ovarian
290	830511	carcinoembryonic antigen [Homo sapiens] >gi 178677 carcinoembryonic antigen precursor [Homo sapiens] >pir A36319 A36319 carcinoembryonic antigen precursor - human >sp P06731 CCEM_HUMAN CARCINOEMBRYONIC ANTIGEN PRECURSOR (CEA) (MECONIUM ANTIGEN 100) (CD66E	gi 180223	3	1292	99	99	HWLGV67	Pancreas, Colon
291	830512	carcinoembryonic antigen [Homo sapiens] >gi 178677 carcinoembryonic antigen precursor [Homo sapiens] >pir A36319 A36319 carcinoembryonic antigen precursor - human >sp P06731 CCEM_HUMAN CARCINOEMBRYONIC ANTIGEN PRECURSOR (CEA) (MECONIUM ANTIGEN 100) (CD66E	gi 180223	3	2213	87	89	HUFC129	Lung, Pancreas

292	830513		3	215		HPRTG72	Lung, Colon, Breast/Ovarian
293	830540	protein kinase MUK2 [Rattus norvegicus] >gi 2772514 serine/threonine protein kinase [Rattus norvegicus] >sp P35465 PAK1_RAT SERINE/THREONINE-PROTEIN KINASE PAK- ALPHA (EC 2.7.1.-) (P68-PAK) (P21- ACTIVATED KINASE) (ALPHA-PAK) (PROTEIN KINASE MUK2). Length	2	733	100	HTLHR67	Lung, Pancreas, Colon
294	830550	guanine nucleotide-binding regulatory protein-beta- 2 subunit [Homo sapiens] >gi 339935 transducin beta-2 subunit [Homo sapiens] >gi 3135310 (AF053356) GNB2 [Homo sapiens] >pir B26617 RGHUB2 GTP-binding regulatory protein beta-2 chain - human >sp P11016 GB	3	500	100	HTWJC08	Lung, Breast/Ovarian
295	830567		141	377		HTTBH33	Lung, Pancreas
296	830586	(2'-5')oligoadenylate synthetase [Homo sapiens] Length = 364	2	1192	98	HKACP86	Pancreas, Prostate, Breast/Ovarian
297	830632	P2 gene for c subunit of mitochondrial ATP synthase gene product [Homo sapiens] >gnl PID d1002921 ATP synthase subunit c precursor [Homo sapiens] >pir S34067 S34067 H+- transporting ATP synthase (EC 3.6.1.34) lipid- binding protein P2 precursor, mitochondri	264	803	85	HTPCV95	Lung, Breast/Ovarian

298	830645	propionyl CoA carboxylase beta subunit, beta PCC {EC 6.4.1.3} [human, liver, placenta, HL 1008. Peptide, 539 aa] [Homo sapiens] >pir/A53020/A53020 propionyl-CoA carboxylase (EC 6.4.1.3) beta chain precursor - human >gi 3036995 propionyl-CoA carboxylase B	bbs 140816	54	1505	99	99	HTDS58	Lung, Pancreas, Colon
299	830652	strong homology to human RING3 sequence [Homo sapiens] >sp O60885 O60885 HUNK1 MRNA. Length = 722	gnl PID e1290115	1	177	64	64	HUKFL74	Lung, Colon
300	830659	CDC42 GTP-binding protein [Canis familiaris] >gi 183490 GTP-binding protein G25K [Homo sapiens] >gi 293321 CDC42Mm [Mus musculus] >gi 1049309 CDC42 protein [Mus musculus] >pir/A39265/A39265 GTP-binding protein G25K, placental - human >pir S57563 S57563 CD	gi 887408	118	714	100	100	HKAOE74	Lung, Pancreas, Breast/Ovarian
301	830696			2	514			IISTBJ95	Lung, Breast/Ovarian
302	830706			2457	2909			HELPG05	Pancreas, Breast/Ovarian
303	830743	ATP SYNTHASE EPSILON CHAIN, MITOCHONDRIAL (EC 3.6.1.34). Length = 50	sp P56381 ATPE_HUMAN	53	262	100	100	HCBBA51	Lung, Colon
304	830770	p21-activated protein kinase [Homo sapiens] >pir S58682 S58682 protein kinase, p21-activated (EC 2.7.1.-) - human Length = 525	gi 780808	1	498	99	99	HEMCG27	Lung, Colon, Breast/Ovarian
305	830830	(AF002822) cyclin B2 [Homo sapiens] >sp G4101270 G4101270 CYCLIN B2. Length = 398	gi 4101270	99	1358	99	99	HIROCE57	Lung, Pancreas, Colon

306	830838		1	747		HS2AF59	Lung, Pancreas, Colon, Breast/Ovarian
307	830851		2	718		HTXLJ25	Pancreas, Colon
308	830853		2	1183		IIRDDS42	Pancreas, Colon
309	830856		542	874		HSAAX81	Colon, Breast/Ovarian
310	830862	ribosomal protein [Homo sapiens] >gi 453281 ribosomal protein S23 [Rattus norvegicus] >pir S41955 S41955 ribosomal protein S23, cytosolic - rat >pir S42105 S42105 ribosomal protein S23, cytosolic - human >pir 52292 52292 ribosomal protein S23 - rat >gnl	3	518	100	HL1CC05	Lung, Prostate, Breast/Ovarian
311	830879	(AJ002120) Zfx [Monodelphis domestica] >sp O19019 O19019 ZFX TYPE GENE (FRAGMENT). Length = 180	2	592	39	HVAAB82	Pancreas, Colon
312	830919		69	536		HOUHK65	Pancreas, Breast/Ovarian
313	830969	(AF005046) serine/threonine kinase [Homo sapiens] >gnl PID e1371371 (AJ011855) PAK4 protein [Homo sapiens] >sp G4101587 G4101587 SERINE/THREONINE KINASE. Length = 591	140	514	96	HOGAU20	Pancreas, Breast/Ovarian
314	830991	insulin-like growth factor-binding protein [Homo sapiens] >gi 386791 growth factor-binding protein-3 [Homo sapiens] >gi 398164 insulin-like growth factor binding protein 3 [Homo sapiens] >pir A36578 OHU3 insulin-like growth factor-binding protein 3 precu	2	607	86	HDLAE73	Pancreas, Breast/Ovarian

315	831002	cyclin [Homo sapiens] >gi387005 proliferating cell nuclear antigen (PCNA) [Homo sapiens] >pirA27445 WMHUET proliferating cell nuclear antigen - human >sp P12004 PCNA_HUMAN PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) (CYCLIN). Length = 261	gi 181272	168	974	100	100	HOEMJ36	Colon, Breast/Ovarian
316	831003	T-plastin - human >sp P13797 PLST_HUMAN T-PLASTIN. {SUB 4-630} >gi 190028 T-plastin polypeptide [Homo sapiens] {SUB 61-630} >gi339848 T-plastin [Homo sapiens] {SUB 1-143} >gi292832 T-plastin [Homo sapiens] {SUB 588-630} Length = 630	pir A34789 A34789	91	2007	94	95	HAIBD64	Lung, Pancreas
317	831021			474	662			HE8BN45	Pancreas, Colon, Breast/Ovarian
318	831036	(AJ006068) dTDP-D-glucose 4,6-dehydratase [Homo sapiens] >sp E1363774 E1363774 dTDP-D-GLUCOSE 4,6-DEHYDRATASE (EC 4.2.1.46). Length = 350	gnl PID e1363774	1	621	100	100	HNTSQ61	Pancreas, Colon
319	831071	Irp gene product [Homo sapiens] >pir S57723 S57723 Irp protein - human >sp Q14764 MVP_HUMAN MAJOR VAULT PROTEIN (MVP) (LUNG RESISTANCE-RELATED PROTEIN). Length = 896	gi 895840	67	2610	94	94	HWLEG93	Lung, Pancreas
320	831094			755	928			HNFEO67	Colon, Breast/Ovarian

321	831099	fibronectin receptor beta subunit precursor (AA -20 to 778) [Homo sapiens] >pir B27079 B27079 fibronectin receptor beta chain precursor - human >sp P05556 TB1_HUMAN FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BETA-1) (CD29) (INTEGRIN VLA-4 BETA	gi 31442	3	1697	99	100	HIA5AB03	Lung, Pancreas, Colon, Breast/Ovarian
322	831113	4E-binding protein 1 [Homo sapiens] >pir S0866 S0866 4E-BP1 protein - human >pir C5899 JC5899 initiation factor 4E-binding protein 1 - human >sp Q13541 Q13541 4E- BINDING PROTEIN 1. Length = 118	gi 561630	1	414	100	100	HMWHP74	Lung, Pancreas, Colon, Breast/Ovarian
323	831120			1	1221			HWLHV12	Pancreas, Colon
324	831172	Similarity to Human hnRNP F protein (PIR Acc. No. S43484); (AF042501) cytochrome b [Homo sapiens] >sp O78829 O78829 CYTOCHROME B (FRAGMENT). Length = 380	gnl PID e1349655	2	721	52	66	III.WBE22	Pancreas, Breast/Ovarian
325	831178		gi 3372365	512	829	69	70	HDLAG61	Lung, Colon
326	831184			770	1399			HWLGP91	Lung, Pancreas, Colon
327	831203			3	545			HMICQ42	Pancreas, Colon, Breast/Ovarian
328	831210	TGF-beta masking protein large subunit [Rattus norvegicus] >pir A38261 A38261 masking protein precursor - rat Length = 1712	gi 207286	1	498	86	91	HMFII62	Pancreas, Colon
329	831228			104	214			HMEAM30	Lung, Pancreas, Breast/Ovarian

330	831256	MLN 64 [Homo sapiens] >dbj D38255.1 CAB1 [Homo sapiens] >pir I38027 I38027 MLN 64 protein - human >sp Q14849 Q14849 MLN64 MRNA. Length = 445	gi 951279	658	1164	94	94	HMTBL29	Lung, Pancreas
331	831257	MLN 64 [Homo sapiens] >dbj D38255.1 CAB1 [Homo sapiens] >pir I38027 I38027 MLN 64 protein - human >sp Q14849 Q14849 MLN64 MRNA. Length = 445	gi 951279	323	862	91	91	HLWDQ05	Pancreas, Colon
332	831277	inter-alpha-trypsin inhibitor light chain [Homo sapiens] >gi 32047 HC polypeptide [Homo sapiens] >gi 24479 precursor polypeptide [Homo sapiens] >gi 825614 alpha I-microglobulin [Homo sapiens] >pir S13433 HCHU alpha-I-microglobulin/inter- alpha-trypsin inhib	gi 186600	193	1290	100	100	HLQAC21	Pancreas, Breast/Ovarian
333	831317			3	1310			HUTHD56	Lung, Pancreas, Colon
334	831339	(AB012276) ATFX [Mus musculus] >sp O70191 O70191 ATFX (FRAGMENT). >sp G246896 G246896 ATFX=ATF4 RELATED PROTEIN. {SUB 1-37} >sp G246899 G246899 ATFX=ATF4-RELATED PROTEIN. {SUB 38- 76} Length = 84	gn PID d1026241	631	1029	90	93	HLICC93	Lung, Colon, Breast/Ovarian
335	831363	acyl coenzyme A:cholesterol acyltransferase, carboxylesterase, ACAT {EC 2.3.1.26} [human, liver, Peptide, 568 aa] [Homo sapiens] >sp G415564 G415564 CARBOXYLESTERASE {EC 3.1.1.1}. {SUB 20-568} >gi 179930 carboxylesterase [Homo sapiens] {SUB 62-568} Length	bbs 156481	123	1871	98	98	HLDNR55	Lung, Colon

336	831367	D-dopachrome tautomerase [Homo sapiens] >gi 1864028 D-dopachrome tautomerase [Homo sapiens] >gi 3047378 (AF058293) D-dopachrome tautomerase [Homo sapiens] >gnl PIDc311354 phenylpyruvate tautomerase II [Homo sapiens] >gi 2352915 (AF012434) D-dopachrome ta	gi 1805303	325	618	100	100	HLDDR74	Lung, Colon
337	831379	cDNA from hypercalcemic tumour [Rattus norvegicus] >pir S28223 S28223 parathyroid hormone-like protein - rat >sp Q05310 L10K_RAT LEYDIG CELL TUMOR 10 KD PROTEIN. Length = 93	gi 57064	3	383	90	95	HKQAC03	Lung, Pancreas, Colon, Breast/Ovarian
338	831385			96	377			HKIMC75	Lung, Pancreas, Colon, Breast/Ovarian
339	831390	aldehyde reductase (EC 1.1.1.2) [Homo sapiens] >gi 2707824 (AF036683) aldehyde reductase [Homo sapiens] >pir A33851 A33851 alcohol dehydrogenase (NADP+) (EC 1.1.2) - human >sp G2707824 G2707824 ALDEHYDE REDUCTASE. >sp P14550 ALDX_HUMAN ALCOHOL DEHYDROGE	gi 178481	254	1312	94	94	HKGDF04	Lung, Pancreas

340	831391	islet regenerating protein [Homo sapiens] >pir A35197 RGHUIA regenerating islet lectin I- alpha precursor - human >sp P05451 LITA_HUMAN LITHOSTATHINE I ALPHA PRECURSOR (PANCREATIC STONE PROTEIN) (PSP) (PANCREATIC THREAD PROTEIN) (PTP) (ISLET OF LANGERHANS	gj 190979	71	592	100	100	HLDBE06	Pancreas, Colon
341	831405	factor H homologue [Homo sapiens] >pir I56100 I56100 factor H homologue - human >sp Q03591 CFH1_HUMAN COMPLEMENT FACTOR H-LIKE PROTEIN 1 PRECURSOR (H36). Length = 330	gj 183763	53	1078	94	94	HLDOB31	Lung, Pancreas, Colon, Breast/Ovarian
342	831442	PDGF associated protein [Homo sapiens] >sp Q13442 HP28_HUMAN 28 KD HEAT- AND ACID-STABLE PHOSPHOPROTEIN (HASPP28) (PDGF ASSOCIATED PROTEIN). Length = 181	gj 136584	2	595	60	60	HKAEB15	Lung, Pancreas, Colon, Breast/Ovarian
343	831476	dermatopontin [Homo sapiens] >pir A47220 A47220 dermatopontin precursor - human >sp Q07507 DERM_HUMAN DERMATOPONTIN PRECURSOR. >pir S34838 S34838 tyrosine-rich acidic matrix protein - pig (SUB 101-144) Length = 201	gj 311614	1	630	91	91	HJMBK21	Lung, Pancreas, Colon
344	831488	similar to Saccharomyces cerevisiae Spt4; protein has potential N-terminal zinc-finger [Homo sapiens] >gj 1401053 SUPT4H [Homo sapiens] >gj 1401055 SUPT4H [Homo sapiens] >gj 1401066 Supt4h [Mus musculus] >gj 3779194 chromatin structural protein homolog [M	gj 1209779	158	580	100	100	HJBCG39	Colon, Breast/Ovarian

345	831518		240	467		HA1CV09	Pancreas, Colon, Breast/Ovarian
346	831519	(AF062536) cullin 1 [Homo sapiens] >sp O60719 O60719 CULLIN 1. >gi 4153866 (AC005229) cullin 1 [Homo sapiens] {SUB 1-263} Length = 776	165	1712	100	H0EJC149	Pancreas, Breast/Ovarian
347	831521		3	863		HIBCE91	Colon, Breast/Ovarian
348	831550	mel-13a protein - mouse Length = 132	158	457	70	HCHNH46	Lung, Pancreas, Breast/Ovarian
349	831560		1474	1818		HCROA68	Pancreas, Breast/Ovarian
350	831562	fibromodulin [Homo sapiens] >sp Q06828 FMOD_HUMAN FIBROMODULIN PRECURSOR (FM) (COLLAGEN-BINDING 59 KD PROTEIN). Length = 376	28	1272	90	HEGAD80	Pancreas, Breast/Ovarian
351	831570	(AF042822) epithin [Mus musculus] >sp G4104970 G4104970 EPITHIN. Length = 902	2	1861	77	HLWCC68	Lung, Pancreas, Colon
352	831593		726	878		HHBFW28	Lung, Pancreas
353	831596	32 kd accessory protein [Bos taurus] >gi 190376 proton ATPase accessory subunit [Homo sapiens] {SUB 264-351} Length = 351	2	808	100	HHEDJ61	Colon, Breast/Ovarian
354	831627		1	903		HBJHI46	Lung, Pancreas
355	831649		1	738		HFTDD09	Lung, Colon
356	831664	transformation upregulated nuclear protein - human Length = 464	180	1574	94	HIFPCU40	Lung, Colon

357	831674	complement protein C8 beta subunit precursor [Homo sapiens] >pir A43071 C8HUB complement C8 beta chain precursor - human >sp P07358 CO8B_HUMAN COMPLEMENT COMPONENT C8 BETA CHAIN PRECURSOR. Length = 591	gi 179720	1	1338	96	96	HLD0X36	Pancreas, Colon
358	831684	(AF053630) monocyte/neutrophil elastase inhibitor [Homo sapiens] >pir S27383 S27383 elastase inhibitor - human >sp P30740 ILEU_HUMAN LEUKOCYTE ELASTASE INHIBITOR (LEI) (MONOCYTE/NEUTROPHIL ELASTASE INHIBITOR) (EI). >sp G2997692 G2997692 MONOCYTE/NEUTROPHIL	gi 2997692	1	1311	96	96	HFOX22	Pancreas, Colon
359	831687	Mpv17 [Mus musculus] >pir S29031 S29031 mpv17 protein - mouse >sp P19258 MPV1_MOUSE MPV17 PROTEIN. >gi 3252875 (AF038632) Mpv17 protein [Mus musculus] {SUB 155-176} Length = 176	gi 199790	60	305	89	93	IFFK11075	Pancreas, Colon
360	831726	rat ribosomal protein L36 [Rattus norvegicus] >pir JN0483 JN0483 ribosomal protein L36 - rat Length = 105	gi 312345	77	454	98	98	HAGDQ96	Lung, Breast/Ovarian
361	831736			95	484			HLWEQ18	Colon, Breast/Ovarian
362	831762	ear-2 gene product [Homo sapiens] >pir S02709 S02709 ear-2 protein - human >sp P10588 EAR2_HUMAN V-ERBA RELATED PROTEIN EAR-2. Length = 403	gi 31065	37	720	76	77	HEQB179	Pancreas, Colon
363	831801			3	812			HKAHB85	Lung, Pancreas, Breast/Ovarian

364	831848		2018	2284		HE8AF82	Lung, Colon, Breast/Ovarian
365	831861	(AF076786) serum amyloid A-activating factor SAF-8 [Oryctolagus cuniculus] >sp G3986442 G3986442 SERUM AMYLOID A- ACTIVATING FACTOR SAF-8 (FRAGMENT). Length = 214	341	775	77	HJPCX51	Lung, Pancreas, Breast/Ovarian
366	831866	(AF054174) histone macroH2A1.2 [Homo sapiens] >sp G3341992 G3341992 HISTONE MACROH2A1.2. Length = 371	53	1186	100	HE6FG90	Lung, Colon
367	831878		2	661		HDTLN67	Colon, Breast/Ovarian
368	831899		1	693		HDTBQ51	Colon, Breast/Ovarian
369	831913	nuclear antigen H731 [Homo sapiens] >pir JC5193 JC5193 nuclear protein H731 - human >sp Q99834 Q99834 NUCLEAR ANTIGEN H731. Length = 458	95	1132	96	HL YGA31	Lung, Colon
370	831972	p619 [Homo sapiens] >pir S71752 S71752 giant protein p619 - human >sp Q15751 Q15751 P619. Length = 4861	331	855	33	HDPKK57	Lung, Pancreas, Breast/Ovarian
371	831985		425	805		HDPFP36	Lung, Pancreas, Colon, Breast/Ovarian
372	831986		30	467		HCIC1168	Pancreas, Colon, Breast/Ovarian
373	832010	(AL021918) b3418.1 (Kruppel related Zinc Finger protein 184) [Homo sapiens] >sp O60792 O60792 B3418.1 (KRUPPEL RELATED ZINC FINGER PROTEIN 184). Length = 751	1	348	57	HDFUB44	Lung, Pancreas, Colon

374	832016	C protein (AA 1-159) [Homo sapiens] >pir S01387 S01387 U1 snRNP protein C - human Length = 159	gj 37543	2	604	100	100	100	HTTDC34	Lung, Breast/Ovarian
375	832041	metalloelastase HME (EC 3.4.24.-) - human >sp P39900 COGM_HUMAN MACROPHAGE METALLOELASTASE PRECURSOR (EC 3.4.24.65) (HME) (MATRIX METALLOPROTEINASE-12) (MMP-12). Length = 470	pir A49499 A49499	54	1472	100	100	100	HDPGC33	Lung, Pancreas, Colon
376	832044	5-aminimidazole-4-carboxamide-1-beta-D- ribofuranose ribonucleotide transformylase [Homo sapiens] >gn PID d1022617 5-aminimidazole-4- carboxamide ribonucleotide transformylase [Homo sapiens] >pir JC4642 JC4642 purH bifunctional enzyme - human >sp Q13856	gn PID d1012226	1	1794	99	99	99	HGCOL40	Lung, Pancreas, Colon, Breast/Ovarian
377	832049	proteasome subunit HsC10-II [Homo sapiens] >pir S55041 S55041 multicatalytic endopeptidase complex (EC 3.4.99.46) beta chain C10-II - human >sp P49720 PRCT_HUMAN PROTEASOME THIETA CHAIN (EC 3.4.99.46) (MACROPAIN THIETA CHAIN) (MULTICATALYTIC ENDOPEPTIDASE C	gn PID d1006190	84	710	100	99	100	HCFU68	Lung, Pancreas, Breast/Ovarian
378	832122			427	846				HCUDT18	Lung, Pancreas, Colon, Breast/Ovarian
379	832148			246	380				HFHN81	Colon, Breast/Ovarian
380	832197			433	642				HICQAI151	Pancreas, Breast/Ovarian
381	832237			290	553				HOCTE23	Lung, Colon
382	832246			66	959				HCM5D61	Lung, Pancreas

383	832256	ligand for eph-related receptor tyrosine kinases [Homo sapiens] >gi 1809292 putative EPH-related PTK receptor ligand LERK-8 [Homo sapiens] >sp Q15768 EFB3_HUMAN EPHRIN-B3 PRECURSOR (EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 8) (LERK-8) (EPH-RELATED RECE	gi 1469782	1	81	100	100	HBXAC19	Pancreas, Colon, Breast/Ovarian
384	832280	(AF071747) topoisomerase II alpha [Homo sapiens] >sp G38693 G38693 6 TOPOISOMERASE II ALPHA. Length = 1531	gi 38693 6	2	1141	79	79	INTSQ37	Lung, Colon, Breast/Ovarian
385	832285	CENP-B protein [Ovis aries] >sp P4945 CENB_SHEEP MAJOR CENTROMERE AUTOANTIGEN B (CENTROMERE PROTEIN B) (CENP-B) (FRAGMENT). Length = 239	gi 1016292	3	551	96	96	HLTBQ50	Lung, Prostate
386	832294							HBMC80	Lung, Colon
387	832326							HHPAT43	Lung, Colon, Breast/Ovarian
388	832333	CENP-B protein [Ovis aries] >sp P4945 CENB_SHEEP MAJOR CENTROMERE AUTOANTIGEN B (CENTROMERE PROTEIN B) (CENP-B) (FRAGMENT). Length = 239	gi 1016292	3	551	96	96	HCHMS55	Pancreas, Breast/Ovarian
389	832346							HBAGU45	Colon, Breast/Ovarian
390	832370							HFIEC83	Lung, Breast/Ovarian
391	832381	HER2 receptor [Homo sapiens] >gi 553282 c-erb-2 protein [Homo sapiens] {SUB 737-1031} >gi 553332 HER-2/neu [Homo sapiens] {SUB 1- 191} >gi 183989 HER2 receptor (AA at 3) [Homo sapiens] {SUB 740-910} >gi 182169 c-erb B2/neu protein [Homo sapiens] {SUB 1081-	gi 306840	2	406	83	83	HATAA19	Pancreas, Breast/Ovarian

392	832394	platelet-endothelial tetraspan antigen 3 [Homo sapiens] >sp P48509 C151_HUMAN PLATELET-ENDOTHELIAL TETRASPAN ANTIGEN 3 (PETA-3) (GP27) (MEMBRANE GLYCOPROTEIN SFA-1) (CD151 ANTIGEN). Length = 253	gi 541613	2	847	85	85	HFTD21	Lung, Pancreas
393	832454	precursor polypeptide [Homo sapiens] >pir A25971 C2HU complement C2 precursor - human >gi 187765 MHC complement component C2 [Homo sapiens] {SUB 21-46} Length = 752	gi 34628	160	357	100	100	HLQB44	Prostate, Breast/Ovarian
394	832465	X box binding protein-1 [Homo sapiens]		1	324			HBJC51	Lung, Pancreas
395	832475	>pir A36299 A36299 transcription factor hXBP-1 - human Length = 260	gi 306893	470	817	100	100	HTJM52	Pancreas, Breast/Ovarian
396	832495	EB1 [Homo sapiens] >pir 152726 152726 EB1 - human >sp Q15691 Q15691 EB1. Length = 268	gi 998357	1	933	100	100	HAHD85	Lung, Pancreas
397	832498	pyrroline-5-carboxylate synthase [Homo sapiens] >sp G4097816 G4097816 PYRROLINE-5-CARBOXYLATE SYNTHASE. Length = 793	gi 4097816	2	1036	95	95	HLTG24	Lung, Pancreas
398	832501	protein synthesis factor [Homo sapiens] >sp P47813 P1A_HUMAN EUKARYOTIC TRANSLATION INITIATION FACTOR 1A (EIF-1A) (EIF-4C). {SUB 2-144} Length = 144		736	996			HAGF57	Lung, Pancreas, Colon
399	832505	protein synthesis initiation factor 4A [Mus musculus] Length = 408	gi 673433	472	1125	93	93	HRABV57	Lung, Pancreas, Prostate
400	832539	protein synthesis initiation factor 4A [Mus musculus] Length = 408	gi 673433	472	1125	93	93	HRABO69	Lung, Breast/Ovarian
401	832554	HsGCN1 [Homo sapiens] >sp Q99736 Q99736 HSGCN1 (FRAGMENT). Length = 1928	gi 2282576	409	927	99	99	HIC10X71	Pancreas, Breast/Ovarian

402	832569	(A102377) rna binding protein	gnl PID e1295805	2	667		HFCAE43	Lung, Colon
403	832578	[Schizosaccharomyces pombe] >sp O74978 O74978 RNA BINDING PROTEIN. Length = 276		123	956	64	HBBD67	Pancreas, Colon, Breast/Ovarian
404	832615			630	992		H2CBK94	Lung, Colon
405	832620			190	297		H2CBG53	Colon, Breast/Ovarian
406	832632	(AC002388) 60S ribosomal protein L30 isolog [Arabidopsis thaliana] >sp O22165 O22165 60S RIBOSOMAL PROTEIN L30 ISOLOG. Length = 159	gil2344898	41	592	69	H2CBD94	Lung, Colon, Breast/Ovarian
407	832633	putative phospho-beta-glucosidase [Bacillus stearothermophilus] >pir D49898 D49898 cellobiose phosphotransferase system celC - Bacillus stearothermophilus >sp Q45401 Q45401 PUTATIVE PHOSPHO-BETA-GLUCOSIDASE. Length = 245	gil466475	3	566	64	HWACF51	Pancreas, Breast/Ovarian
408	833483			2	604		HCTCK33	Lung, Breast/Ovarian
409	834574	similar to S. cerevisiae longevity-assurance protein I (SP:P38703) [Caenorhabditis elegans] >sp Q17870 Q17870 SIMILAR TO S. CEREVISIAE LONGEVITY-ASSURANCE PROTEIN I. Length = 362	gil123105	634	1431	59	HHBF126	Lung, Pancreas, Colon, Breast/Ovarian
410	834859	acidic calponin [human, kidney, Peptide, 329 aa] [Homo sapiens] >pir C4501 C4501 acidic calponin - human >sp Q15417 Q15417 ACIDIC CALPONIN. Length = 329	bbs174416	53	541	100	HSTA170	Lung, Pancreas, Colon, Breast/Ovarian

411	834861	factor activating exoenzyme S [Bos taurus] >gi189953 phospholipase A2 [Homo sapiens] >gi899459 14-3-3 protein [Homo sapiens] >pirA38246PSHUAM 14-3-3 protein zeta - human >pirA47389/A47389 14-3-3 protein zeta - bovine >sp P29312 143Z_HUMAN 14-3-3 PROT	gi 163042	74	967	99	99	HBXFL41	Lung, Pancreas, Prostate, Breast/Ovarian
412	834890	TRANSCRIPTION FACTOR BTIF3 (RNA POLYMERASE B TRANSCRIPTION FACTOR 3). Length = 204	sp Q64152 BTIF3_M OUSE	70	588	90	91	H2C BT12	Lung, Pancreas, Prostate, Breast/Ovarian
413	835079			151	348			HOELH62	Lung, Pancreas, Breast/Ovarian
414	835554	homologue to sec61 [Rattus rattus] Length = 476	gi 206886	121	1287	98	98	HOHBH04	Lung, Pancreas
415	835560			2	574			HE9NK60	Lung, Pancreas
416	835723	immunoglobulin M heavy chain [Homo sapiens] >gi38408 immunoglobulin M heavy chain [Homo sapiens] >pir S37768 S37768 Ig mu chain C region - human Length = 453	gi 38406	48	1421	100	100	HL YFY90	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
417	835791	(AJ005890) JM1 [Homo sapiens] >sp O60826 O60826 JM1 PROTEIN, COMPLETE CDS (CLONE LLNLC110M011IQ7 (RZPD BERLIN)AND LLNLC110K2140Q7 (RZPD BERLIN)). Length = 627	gn PID e1289743	437	1177	87	87	HTXJH25	Pancreas, Breast/Ovarian
418	835817			1369	1554			HAAZ17	Lung, Breast/Ovarian
419	835840			2	730			HHEOI47	Lung, Pancreas
420	836048			2052	2276			HHDQDV21	Lung, Prostate

421	836898	human P5 [Homo sapiens] >pir C4369 C4369 P5 protein - human >sp Q15084 ERP5_HUMAN PROBABLE PROTEIN DISULFIDE ISOMERASE P5 PRECURSOR (EC 5.3.4.1). Length = 440	gnl PID d1009061	3	1427	90	90	HWIIPA75	Lung, Pancreas, Colon, Breast/Ovarian
422	836927	(AF027299) protein 4.1-G [Homo sapiens] >sp O43491 O43491 PROTEIN 4.1-G. Length = 1005	gi 2739096	3	1196	84	84	HDTKY58	Lung, Pancreas
423	837344	SIR [Cowpox virus] >sp O72763 O72763 SIR PROTEIN. Length = 210	gnl PID c1289272	38	658	48	58	HLDAG32	Lung, Prostate
424	837789	bikunin [Homo sapiens] >sp O00271 O00271 BIKUNIN. Length = 252	gi 2065529	365	1231	91	91	HDABR73	Colon, Breast/Ovarian
425	838549	(AL023828) Y17G7B.14 [Caenorhabditis elegans] >sp E1323274 E1323274 Y17G7B.14 PROTEIN. Length = 364	gnl PID c1323274	2	853	42	55	HDQDW56	Lung, Breast/Ovarian
426	838754			437	1198			HTEQK83	Lung, Pancreas, Breast/Ovarian
427	838768			570	770			HWBCW80	Lung, Pancreas, Breast/Ovarian
428	839486	fibronectin precursor [Homo sapiens] >gi 4096846 fibronectin [Homo sapiens] {SUB 76-454} >gi 4096848 fibronectin [Homo sapiens] {SUB 1892-2103} >gi 182706 fibronectin [Homo sapiens] {SUB 1921-2040} >gi 182684 fibronectin [Homo sapiens] {SUB 2233-2328} Len	gi 31397	2	493	98	98	HSLGC71	Lung, Breast/Ovarian
429	839561	p34 protein [Rattus sp.] >pir S36779 S36779 ribosome-binding protein p34 - rat >sp Q63742 Q63742 P34 PROTEIN. Length = 307	gnl PID d1003291	45	1133	86	88	HUVFB27	Lung, Pancreas, Prostate

430	839816	similar to plasmodium merozoite surface antigen precursor (SP:P04933) [Caenorhabditis elegans] >sp Q22585 Q22585 SIMILAR TO PLASMODIUM MEROZITE SURFACE ANTIGEN PRECURSOR. Length = 634	gi 1293808	1	432	46	61	HWADY11	Lung, Breast/Ovarian
431	840068	UMP-CMP kinase [Sus scrofa] >pir JC418 JC4181 cytidylate kinase (EC 2.7.4.14) - pig >sp Q29561 KCY_PIG UMP-CMP KINASE (EC 2.7.4.14) (CYTIDYLATE KINASE) (DEOXYCYTIDYLATE KINASE). Length = 196	gn PID d1006692	2	757	97	99	HE8EH64	Lung, Pancreas, Breast/Ovarian
432	840279	(AF062328) p120 catenin isoform 1AB [Homo sapiens] >sp O60715 O60715 P120 CATENIN ISOFORMS 1AB, 2AB, 3AB AND 4AB >gi 3152823 (AF062322) p120 catenin isoform 2AB [Homo sapiens] {SUB 55-962} >gi 3152855 (AF062338) p120 catenin isoform 3AB [Homo sapiens] {S	gi 3152835	219	1493	93	93	HSRB181	Lung, Pancreas
433	840489	connective tissue growth factor [Homo sapiens] >gi 474934 connective tissue growth factor [Homo sapiens] >pir A40551 A40551 connective tissue growth factor - human >sp P29279 CTGF_HUMAN CONNECTIVE TISSUE GROWTH FACTOR PRECURSOR. >gi 984956 connective tiss	gi 180924	1038	1370	100	100	HOEMS29	Lung, Pancreas

434	840538	glycyl tRNA synthetase [Homo sapiens] >pir A55314 A55314 glycine--tRNA ligase (EC 6.1.1.14) precursor - human >gil600727 glycyl-tRNA synthetase [Homo sapiens] {SUB 55-739} >gil3845409 (AC004976) glycyl tRNA synthetase [Homo sapiens] {SUB 348-739} Length =	gnl PID d1006904	1	2298	100	100	HYAAN81	Lung, Pancreas, Prostate, Breast/Ovarian
435	840545			145	1302			HMCFK75	Lung, Pancreas, Colon, Breast/Ovarian
436	840549			1	492			HWHGB33	Lung, Prostate
437	840551	IgG Fc binding protein [Homo sapiens] Length = 5405	gnl PID d1020288	3	1409	93	93	HWLKM77	Lung, Prostate, Colon
438	840557			346	1014			H6EDS19	Prostate, Colon
439	840561	putative [Mus musculus] >pir S15785 S15785 heat-stable antigen-related hypothetical protein HSA-C-mouse >sp Q61692 Q61692 HSA-C GENE CODING FOR HEAT STABLE ANTIGEN. Length = 141	gil51442	385	495	48	72	HLIBZ07	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
440	840562	(AB008549) type 1 procollagen C-proteinase enhancer protein [Homo sapiens] >gil3135316 (AF053356) PCOLCE [Homo sapiens] >sp O14550 O14550 TYPE 1 PROCOLLAGEN C-PROTEINASE ENHANCER PROTEIN. Length = 449	gil2589011	103	1476	96	96	HSSDI65	Lung, Pancreas, Prostate, Colon
441	840564	PQ-rich protein [Homo sapiens] >pir S58222 S58222 PQ-rich protein - human >sp Q15184 Q15184 PQ-RICH PROTEIN. Length = 400	gil929660	2	688	67	68	HPIDB01	Lung, Pancreas

442	840572	putative [Homo sapiens] >pir I54339 I54339 prot-oncogene - human >sp P35226 BM11_HUMAN DNA-BINDING PROTEIN BMI-1. Length = 326	gi 291873	3	1172	95	95	HTGAZ34	Prostate, Colon
443	840600			3	119			HYAB130	Prostate, Breast/Ovarian
444	840604	Similarity to Mouse A-RAF proto-oncogene serine/threonine-protein kinase (SW:KRAA_MOUSE);	gnl PID e1344589	1	1359	82	87	HWLHN58	Lung, Pancreas, Prostate, Breast/Ovarian
445	840608	olliactomedin [Rana catesbeiana] >pir A47442 A47442 olfactomedin precursor - bullfrog >sp Q07081 OLEM_RANCA OLFACTOMEDIN PRECURSOR (OLFACTORY MUCUS PROTEIN). Length = 464	gi 294502	200	1549	55	75	HWLFY46	Pancreas, Colon
446	840620	nicotinamide N-methyltransferase [Homo sapiens]		776	1267			HTXGB37	Lung, Prostate
447	840625	>gi 1063610 nicotinamide N-methyltransferase [Homo sapiens] >pir A54060 A54060 nicotinamide N-methyltransferase (EC 2.1.1.1) - human		138	257			HTXD774	Lung, Prostate
448	840626	>sp P40261 NNMT_HUMAN NICOTINAMIDE N-METHYLTRANSFERASE (EC 2.1.1.1). Length = 196	gi 494989	485	1282	100	100	HULAS90	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
449	840638			16	351			HTTDV02	Prostate, Breast/Ovarian
450	840649	BL34=B cell activation gene [human, Peptide, 196 aa] [Homo sapiens] >pir I56165 I56165 B cell activation protein BL34 - human Length = 196	bbs 129951	1	651	100	100	HTWCY84	Lung, Prostate
451	840651			2	706			HTTAD76	Pancreas, Prostate

452	840666	siah binding protein 1 [Homo sapiens] >sp Q99628 Q99628 SIAH BINDING PROTEIN 1 (FRAGMENT). Length = 541	gi 1809248	2	826	HTOAF86	Lung, Prostate
453	840681			157	2187	HTAER63	Lung, Prostate
454	840682			1	1734	HE9PW64	Lung, Breast/Ovarian
455	840684			3	539	HTGBT14	Pancreas, Prostate, Breast/Ovarian
456	840697			96	560	HTECA52	Lung, Prostate
457	840698	t-complex-type molecular chaperone TCP1 - human >gi 339211 t-complex 1 protein [Homo sapiens] {SUB 308-365} Length = 556	pir S10486 S10486	507	1853	HDABW50	Pancreas, Prostate
458	840708			1200	1487	HTLAF73	Lung, Prostate
459	840714	(AF053304) mitotic checkpoint component Bub3 [Homo sapiens] >gi 2921873 (AF047472) spleen mitotic checkpoint BUB3 [Homo sapiens] >gi 3639060 (AF081496) kinetochore protein BUB3 [Homo sapiens] >sp O43684 O43684 SPLEEN MITOTIC CHECKPOINT BUB3. Length = 328	gi 2981231	175	1170	HTEGU90	Lung, Pancreas, Prostate, Breast/Ovarian
460	840716	(AC005326) asparagine synthetase [Homo sapiens] >sp G3341715 G3341715 ASPARAGINE SYNTHETASE. >gi 703119 asparagine synthetase [Homo sapiens] {SUB 1-83} Length = 561	gi 3341715	166	1860	HSYAJ64	Lung, Prostate, Colon, Breast/Ovarian
461	840721			2	1324	HSUSE92	Lung, Pancreas, Prostate, Colon

462	840735	(AC002425) Gene product with similarity to Rat P8 [Homo sapiens] >gi 3202004 (AF069073) P8 protein [Homo sapiens] >gi 3202006 (AF069074) P8 protein [Homo sapiens] >sp O60356 O60356 GENE: PRODUCT WITH SIMILARITY TO RAT P8. Length = 82	gi 2947054	111	392	64	64	HSRDN44	Lung, Pancreas, Prostate, Breast/Ovarian
463	840738			985	1230			HTOJK11	Prostate, Colon
464	840745	52-kD SS-A/Ro autoantigen [Homo sapiens] Length = 475	gi 338490	2	694	46	63	HSSGC06	Lung, Prostate, Colon
465	840747	(AC004522) Zn-alpha2-glycoprotein [Homo sapiens] >sp O60386 O60386 ZN-ALPHA2-GLYCOPROTEIN. Length = 334	gi 3006228	368	877	95	95	HLDDL02	Lung, Pancreas, Breast/Ovarian
466	840756	(AB005624) rig-analog DNA-binding protein [Sus scrofa] >gi 306898 rig-analog protein (putative); putative [Homo sapiens] >gi 337416 human homologue of rat insulinoma gene (rig); putative [Homo sapiens] >gi 305361 Rig DNA-binding protein (putative); putati	gnl PID d1022359	148	480	97	97	HCHBQ33	Lung, Pancreas, Colon, Breast/Ovarian
467	840776	Notch3 [Homo sapiens] >sp G2668592 G2668592 NOTCH3. Length = 2321	gi 2668592	2	364	82	82	HSKJZ22	Lung, Breast/Ovarian
468	840784	aldehyde dehydrogenase 6 [Homo sapiens] >pir A55684 A55684 aldehyde dehydrogenase (NAD+) (EC 1.2.1.3) 6 precursor, salivary - human >sp P47895 DHA6_HUMAN ALDEHYDE DEHYDROGENASE 6 (EC 1.2.1.5). Length = 512	gi 544482	1	618	94	95	HSKAC75	Lung, Prostate, Colon, Breast/Ovarian

469	840788	P1 gene for c subunit of human mitochondrial ATP synthase gene product [Homo sapiens] >gnl PID d1002920 ATP synthase subunit c precursor [Homo sapiens] >pir S34066 S34066 H+-transporting ATP synthase (EC 3.6.1.34) lipid-binding protein P1 precursor, mitoc	gi 38430	59	484	85	85	HHFUM32	Lung, Prostate, Colon, Breast/Ovarian
470	840794			162	1646			HOHBT28	Lung, Pancreas, Prostate, Colon
471	840797	OSF-2p1 [Homo sapiens] >pir S36111 S36111 osteoblast-specific factor 2 - human >sp Q15064 Q15064 OSF-2P1. Length = 779	gnl PID d1003341	2	2371	93	93	HDTM52	Pancreas, Breast/Ovarian
472	840799			292	510			HWBCI48	Lung, Pancreas, Colon, Breast/Ovarian
473	840818	translational initiation factor eIF-2, alpha subunit [Homo sapiens] >sp P05198 P2A_HUMAN EUKARYOTIC TRANSLATION INITIATION FACTOR 2 ALPHA SUBUNIT (EIF-2-ALPHA); {SUB 2-315} Length = 315	gi 181995	3	806	100	100	HIIBHM68	Lung, Prostate
474	840822	fatty acid synthase [Homo sapiens] >pir G01880 G01880 fatty-acid synthase (EC 2.3.1.85) - human >sp Q16702 Q16702 FATTY ACID SYNTHASE (EC 2.3.1.85) (FATTY-ACID SYNTHASE) Length = 2509	gi 915392	1423	2367	93	93	HGIBHX28	Lung, Prostate, Colon, Breast/Ovarian
475	840830	diubiquitin [Homo sapiens] >sp O15205 O15205 DIUBIQUITIN. Length = 165	gnl PID e321293	1	573	99	99	HFXHP85	Pancreas, Prostate

476	840846	glutathione S-transferase Ha subunit 1 (EC 2.5.1.18) [Homo sapiens] >gi 306815 glutathione S-transferase (GST, EC 2.5.1.18) [Homo sapiens] >gi 306809 glutathione S-transferase [Homo sapiens] >bbs 76373 glutathione S-transferase Ha1 subunit [EC 2.5.1.18] {	gi 306810	144	833	95	95	HFVHP57	Prostate, Breast/Ovarian
477	840848	prohibitin [human, Peptide; 272 aa] [Homo sapiens] >pir 152690 152690 prohibitin - human >sp P35232 PHB_HUMAN PROHIBITIN. Length = 272	bbs 85658	81	917	93	93	IIIIIIIM75	Lung, Pancreas, Prostate, Breast/Ovarian
478	840860	NAP [Homo sapiens] >pir S40510 S40510 nucleosome assembly protein 1-like 1 - human >sp P55209 NPL1_HUMAN NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1 (NAP-1 RELATED PROTEIN). Length = 391	gi 189067	92	1309	80	80	HD1LJ39	Lung, Pancreas, Colon, Breast/Ovarian
479	840861	(AL021546) Cytochrome C Oxidase Polypeptide Vla-liver precursor (EC 1.9.3.1) [Homo sapiens] >sp O43714 O43714 CYTOCHROME C OXIDASE POLYPEPTIDE VIA-LIVER PRECURSOR (EC 1.9.3.1) (CYTOCHROME-C OXIDASE) (CYTOCHROME OXIDASE) (CYTOCHROME A(3)) (CYTOCHROME AA(3))	gnl PID e1248288	2	520	100	100	HFPBO29	Lung, Prostate, Breast/Ovarian
480	840871	DNA polymerase delta small subunit [Homo sapiens] >pir 138950 138950 DNA-directed DNA polymerase (EC 2.7.7.7) delta regulatory chain - human >sp P49005 DPD2_HUMAN DNA POLYMERASE DELTA SMALL SUBUNIT (EC 2.7.7.7). Length = 469	gi 1008458	2	628	99	99	HSDIX61	Pancreas, Colon, Breast/Ovarian

481	840874	secreted cyclophilin-like protein [Homo sapiens] >gi 181335 cyclophilin B [Homo sapiens] {SUB 9-216} >gi 181250 cyclophilin [Homo sapiens] {SUB 10-216} Length = 216	gj 337999	1	873	94	94	HFTDK64	Lung, Prostate
482	840878	unknown [Homo sapiens] >sp P41271 DAN_HUMAN ZINC FINGER PROTEIN DAN (N03). Length = 180	gn PID d1006216	227	676	99	100	H2MBT19	Lung, Pancreas, Colon, Breast/Ovarian
483	840880			153	320			HFIXK16	Prostate, Colon, Breast/Ovarian
484	840884	mutY homolog [Homo sapiens] >sp Q15830 Q15830 MUTY HOMOLOG. Length = 535	gj 1458228	108	1565	99	99	HIBC118	Lung, Prostate
485	840907			103	366			HETAD58	Pancreas, Prostate
486	840926			76	1347			HFEOM166	Lung, Pancreas, Prostate
487	840932	ATP synthase beta subunit precursor [Homo sapiens] >pir A33370 A33370 H+-transporting ATP synthase (EC 3.6.1.34) beta chain precursor, mitochondrial - human >sp P06576 ATPB_HUMAN ATP SYNTHASE BETA CHAIN, MITOCHONDRIAL PRECURSOR (EC 3.6.1.34). >gi 28931 be	gj 179281	2	1675	93	93	HFBIB89	Lung, Prostate
488	840940	carbonyl reductase [Sus scrofa] >pir JN0703 JN0703 carbonyl reductase (NADPH) (EC 1.1.1.184) - pig >sp Q29529 CBR2_PIG LUNG CARBONYL REDUCTASE [NADPH] (EC 1.1.1.184) (NADPH-DEPENDENT CARBONYL REDUCTASE) (LCR). Length = 244	gn PID d1004479	277	678	61	76	HCHNJ32	Pancreas, Breast/Ovarian

489	840947		2	565		HEG4N45	Lung, Pancreas, Prostate, Breast/Ovarian
490	840959	signal peptidase complex 25 kDa subunit [Canis familiaris] >pir/A55012/A55012 signal peptidase 25k chain - dog Length = 226	2	712	99	HEDAD53	Lung, Pancreas, Prostate, Breast/Ovarian
491	840964		177	344		HE8UK92	Prostate, Colon
492	840979	transcription factor-like protein 4 - human Length = 298	11	631	99	HE9HD45	Lung, Pancreas, Prostate, Colon
493	840984	p167 [Homo sapiens] >gnl PID d1010130 The KIAA0139 gene product is related to mouse centrosomin B. [Homo sapiens] >gij2501783 translation initiation factor 3 large subunit [Homo sapiens] >sp Q14152 Q14152 KIAA0139 PROTEIN. >gij1399801 p167 [Homo sapiens]	3	3017	91	HE8OC40	Lung, Pancreas, Prostate, Breast/Ovarian
494	840986		1	693		HE8TB60	Pancreas, Prostate, Colon
495	840988		1	465		HE8QQ04	Pancreas, Prostate, Breast/Ovarian
496	840990	(AB010415) dTDP-4-keto-L-rhamnose reductase [Actinobacillus actinomycetemcomitans] >sp O66251 O66251 DTDTP-4-KETO-L-RHAMNOSE REDUCTASE. Length = 294	157	1140	32	HE8AM92	Pancreas, Prostate
497	840992	nidogen gene product [Homo sapiens] Length = 1246	3	194	96	HE8BX38	Lung, Prostate, Colon, Breast/Ovarian
498	841009	sin3 associated polypeptide p18 [Homo sapiens] >sp O00422 O00422 SIN3 ASSOCIATED POLYPEPTIDE P18. Length = 153	59	523	92	HDYGP88	Lung, Pancreas, Prostate, Colon, Breast/Ovarian

499	841012	ribosomal protein L39 [Homo sapiens] >gnl PID d1012131 ribosomal protein L39 [Homo sapiens] >gi 575382 ribosomal protein L39 [Rattus norvegicus] >pir JC4229 R6RT39 ribosomal protein L39 - rat >pir G02654 G102654 ribosomal protein L39 - human Length = 51	gi 1373419	2	217	100	100	100	HSKXP01	Lung, Pancreas, Breast/Ovarian
500	841016	connexin 43 [Homo sapiens] >gi 29917 gap junction protein (AA 1-382) [Homo sapiens] >pir A35853 A35853 gap junction protein Cx43, cardiac - human >sp P17302 CXA1_HUMAN GAP JUNCTION ALPHA-1 PROTEIN (CONNEXIN 43) (CX43) (GAP JUNCTION 43 KD HEART PROTEIN). {	gi 181209	1	810	94	94	94	IIDYDIII3	Lung, Pancreas, Prostate, Colon
501	841017			402	683				HE2AY01	Lung, Prostate
502	841021			983	1357				HNAAE75	Lung, Pancreas, Colon, Breast/Ovarian
503	841032	(AB000910) ribosomal protein [Sus scrofa] >gi 1684917 L44-like ribosomal protein [Homo sapiens] >gi 1666702 ribosomal protein [Mus musculus] >gi 206732 ribosomal protein L36a [Rattus norvegicus] >pir A29820 R6RT36 ribosomal protein L36a - rat Length = 106	gnl PID d1019960	3	395	100	100	100	HDQAD36	Lung, Colon
504	841051			656	880				HDPPDC65	Lung, Pancreas
505	841064	small subunit ribonucleotide reductase [Homo sapiens] >pir S25854 S25854 ribonucleoside-diphosphate reductase (EC 1.17.4.1) small chain - human Length = 389	gi 36155	6	1244	96	96	96	HDPMF32	Prostate, Colon, Breast/Ovarian

506	841069		81	809		HDPMJ48	Prostate, Breast/Ovarian
507	841072	regulatory protein [Mus musculus] >gi452276 npdef-1 [Mus musculus] >pir44869148691 regulatory protein - mouse >spQ64322[NPD1_MOUSE NPDC-1 PROTEIN PRECURSOR. Length = 332	162	1139	91	95	Lung, Prostate, Colon, Breast/Ovarian
508	841078		521	706		HDPKD92	Pancreas, Prostate
509	841080	HCNGP gene product [Mus musculus] >pirS26660[S26660 HCNGP protein - mouse >spQ02614[HCNGP_MOUSE TRANSCRIPTIONAL REGULATOR PROTEIN HCNGP. Length = 308	1	936	88	88	Prostate, Breast/Ovarian
510	841088	quinone oxidoreductase [Homo sapiens] >gi516534 quinone oxidoreductase2 [Homo sapiens] >pirA32667[A32667 NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2) 2 - human Length = 231	320	1096	100	100	Lung, Pancreas, Prostate, Breast/Ovarian
511	841092		1187	1402		HJMBH15	Lung, Colon
512	841095	L protein (AA 1-558) [Homo sapiens] >pirA33616[A33616 heterogeneous ribonuclear particle protein L - human Length = 558	2	904	84	84	Lung, Pancreas, Colon, Breast/Ovarian
513	841096	(AB013357) 49 kDa zinc finger protein [Mus musculus] Length = 460	510	1907	80	80	Lung, Pancreas, Breast/Ovarian
514	841102		2	256		HDLAV12	Lung, Pancreas, Prostate, Breast/Ovarian
515	841104	zinc finger protein [Homo sapiens] >pirS35305[S35305 finger protein ZNF91 - human Length = 1191	712	2451	54	70	Pancreas, Prostate, Breast/Ovarian
516	841108	factor XIII a subunit [Homo sapiens] Length = 732	3	1838	99	99	Lung, Pancreas, Colon

517	841118			320	487		HDLAE34	Lung, Pancreas, Prostate
518	841119	C11 protein [Homo sapiens] >gi11890300 eukaryotic release factor 1 [Homo sapiens] >gnl P D e 118068 C11 protein [Mesocricetus auratus] >pir S50853 S50853 translation releasing factor eRF-1 - human >sp P46055 ERF1_HUMAN EUKARYOTIC PEPTIDE CHAIN RELEASE FACT	gnl P D e 118910	123	1367	100	HDPAE95	Lung, Pancreas, Prostate
519	841124	similar to deoxyribose-phosphate aldolase [Caenorhabditis elegans] >sp Q19264 DEOC_CAEEL PUTATIVE DEOXYRIBOSE-PHOSPHATE ALDOLASE (EC 4.1.2.4) (PHOSPHODEOXYRIBOALDOLASE) (DEOXYRIBOALDOLASE). Length = 303	gi 1019952	2	358	62	HDAAB17	Prostate, Colon
520	841137	(AF096285) serine-threonine kinase receptor- associated protein [Mus musculus] >sp G4063383 G4063383 SERINE-THREONINE KINASE RECEPTOR-ASSOCIATED PROTEIN. Length = 351	gi 4063383	3	848	98	HDAAP84	Lung, Pancreas, Prostate, Breast/Ovarian
521	841143	fibrillarin [Homo sapiens] >pir A38712 A38712 fibrillarin - human >gi 3399667 (AC005393) FBRL_HUMAN; 34 KD NUCLEOLAR SCLERODERMA ANTIGEN [Homo sapiens] {SUB 4-321} Length = 321	gi 31395	39	1040	100	HCRMJ87	Pancreas, Prostate, Breast/Ovarian
522	841148			2	1807		HCRNF38	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
523	841149			324	797		HCRBS04	Prostate, Breast/Ovarian

524	841151	keratin [Carassius auratus] Length = 455	gj212995	2	1399	45	64	HCRNY54	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
525	841155			103	561			HCHOF85	Prostate, Breast/Ovarian
526	841161	(AB014458) ubiquitin specific protease [Homo sapiens] >sp D1035685 D1035685 UBIQUITIN SPECIFIC PROTEASE. Length = 785	gn P1D d1035685	3	1199	95	95	HCLCA56	Lung, Prostate
527	841162	set [Homo sapiens] >pir/A57984/A45018 template activating factor-1, splice form beta - human Length = 277	gj338039	284	1063	99	100	HCWFR92	Prostate, Colon
528	841163	histone H2A [Mus musculus domesticus] >pir/S45110/S45110 histone H2A - mouse >sp Q64426 Q64426 HISTONE H2A (FRAGMENT). Length = 137	gj817939	201	665	100	100	HBMBF44	Pancreas, Breast/Ovarian
529	841169			21	440			HCFOF83	Lung, Prostate, Colon, Breast/Ovarian
530	841172	CLN3 protein [Homo sapiens] >gn P1D c283670 CLN3 protein [Homo sapiens] >gj2947055 (AC002425) CLN3 [Homo sapiens] >gj3337387 (AC002544) CLN [Homo sapiens] >gj4102729 (AF015593) CLN3 protein [Homo sapiens] >pir/A57219/A57219 Batten disease-related prot	gj1039423	291	740	100	100	HCHAG93	Prostate, Breast/Ovarian
531	841174	zinc finger protein 7 (ZFP7) [Homo sapiens] >pir/A34612/A34612 zinc finger protein ZNF7 - human Length = 686	gj340446	3	386	98	98	HCHAW34	Prostate, Breast/Ovarian

532	841179	(AF069517) RNA binding protein DEF-3 [Homo sapiens] >sp O75524 O75524 RNA BINDING PROTEIN DEF-3. Length = 1123	gj3212101	549	1742	85	85	HCHBU86	Lung, Pancreas, Prostate
533	841183	keratin 18 [Homo sapiens] >gj307081 keratin 18 precursor [Homo sapiens] >gj34037 cytokeratin 18 [Homo sapiens] >pir S05481 S05481 keratin 18, type I, cytoskeletal - human >sp P05783 K1CR_HUMAN KERATIN, TYPE I CYTOSKELETAL 18 (CYTOKERATIN 18) (K18) (CK 1	gj386844	1	501	80	92	HCHCE20	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
534	841186	(AJ006215) CMP-N-acetylneuraminic acid synthetase [Mus musculus] >sp O88719 O88719 CMP-N-ACETYLNEURAMINIC ACID SYNTHETASE (EC 2.7.7.43) (ACYLNEURAMINATE CYTIDYLTRANSFERASE) (CMP-SIALATE PYROPHOSPHORYLASE) (CMP-SIALATE SYNTHASE) Length = 432	gn PID e1314953	78	1421	95	97	HCFCQ26	Lung, Prostate
535	841204	similar to beta-mannosyltransferase [Caenorhabditis elegans] >sp Q22797 Q22797 SIMILAR TO BETA-MANNOSYLTRANSFERASE. Length = 487	gj470340	1	1407	51	72	HCEFFZ02	Lung, Pancreas, Prostate, Colon
536	841206	(AF062484) SDP8 [Mus musculus]		251	1192			HCEEM52	Lung, Prostate
537	841207	>sp O70493 O70493 SDP8. Length = 165 (AC004908) zinc finger protein from gene of uncertain exon structure; similar to Q99676 (PID:g3025333) [Homo sapiens] Length = 430	gj3126981	193	585	41	63	HMTAR23	Prostate, Colon
538	841211		gj4159888	110	766	47	62	HCEDM42	Prostate, Breast/Ovarian

539	841225	membrane protein [Homo sapiens] >gi 1048989 CD9 antigen [Homo sapiens] >gi 34769 MRP-1 (motility related protein) [Homo sapiens] >bbs 131345 CD9 antigen [human, leukocytes, Peptide, 228 aa] [Homo sapiens] >pir A46123/A40402 CD9 antigen - human >sp P21926	gi 508496	41	865	88	88	HCRB01	Lung, Pancreas, Prostate, Colon
540	841229	P1c47 [Homo sapiens] >pir S70583/S70583 CDC47 homolog - human >sp P33993/MCM7_HUMAN DNA REPLICATION LICENSING FACTOR MCM7 (CDC47 HOMOLOG) (P1.I-MCM3). >gnl PID d1006386 hMCM2 [Homo sapiens] {SUB 177-719; Length = 719	gnl PID d1010177	1	2298	98	98	HCE1D58	Lung, Pancreas, Prostate, Breast/Ovarian
541	841237	NAD(P)H:menadione oxidoreductase [Homo sapiens] >gi 189292 NAD(P)H:quinone oxidoreductase [Homo sapiens] >pir A41135/A30879 NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2) 1 - human >sp P15559/DHQU_HUMAN NAD(P)H DEHYDROGENASE (QUINONE) 1 (EC 1.6.99.2) (QUINON	gi 189246	141	1028	95	95	HBMTA19	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
542	841241	Thy-1 [Homo sapiens] >pir A02106/TDHU Thy-1 membrane glycoprotein precursor - human Length = 161	gi 339683	128	622	86	87	HBXFG67	Lung, Pancreas, Prostate, Breast/Ovarian
543	841259	(AD001528) spermidine aminopropyltransferase [Homo sapiens] >sp O00544/O00544 SPERMIDINE AMINOPROPYLTRANSFERASE. Length = 366	gi 2198557	3	1199	93	93	HCE1C53	Lung, Pancreas, Prostate, Breast/Ovarian

544	841260	FKBP51 [Homo sapiens] >pir JC5422 JC5422 FK506-binding protein, FKBP51 - human >sp Q13451 FKB5_HUMAN 51 KD FK506- BINDING PROTEIN (FKBP51) (PEPTIDYL- PROLYL CIS-TRANS ISOMERASE) (EC 5.2.1.8) (PIASE) (ROTAMASE) (54 KD PROGESTERONE RECEPTOR-ASSOCIATED IMMUNO	gi 1916641	3	863	88	91	HBODM14	Lung, Prostate
545	841264			1	618			HBHU33	Lung, Pancreas, Prostate
546	841275	Lutheran blood group glycoprotein [Homo sapiens] >sp I38000 I38000 Lutheran blood group glycoprotein precursor - human >sp P50895 LU_HUMAN LUTHERAN BLOOD GROUP GLYCOPROTEIN PRECURSOR (B- CAM CELL SURFACE GLYCOPROTEIN) (AUBERGER B ANTIGEN) (F8/G253 ANTIGEN	gi 603560	2	1183	89	89	HBGMO35	Prostate, Breast/Ovarian
547	841311	(AF019661) zeta proteasome chain; PSMA5 [Mus musculus] >sp G3805976 G3805976 ZETA PROTEASOME CHAIN. Length = 241	gi 3805976	45	836	100	100	HCFMY64	Lung, Pancreas, Prostate, Breast/Ovarian
548	841313	neuronal protein 15.6 [unidentified] >sp O09111 O09111 NEURONAL PROTEIN 15.6. Length = 133	gn PID e274746	11	544	75	82	HBGNM82	Lung, Prostate, Colon, Breast/Ovarian
549	841317			1155	1553			HAPSG63	Lung, Prostate
550	841322	unnamed protein product [unidentified] >gi 496609 basic transcription factor 2, 44 kD subunit [Homo sapiens] >sp Q13888 Q13888 BASIC TRANSCRIPTION FACTOR 2, 44 KD SUBUNIT (BASIC TRANSCRIPTION FACTOR 2 P44) (FRAGMENT). >gi 1737212 basic transcription factor	gn PID e306259	200	1402	95	95	HAMGE23	Pancreas, Prostate

551	841331			2	955		HHHJL19	Lung, Breast/Ovarian
552	841332	alpha-2-macroglobulin precursor [Homo sapiens] >pir A94033 MAHU alpha-2-macroglobulin precursor - human >sp P01023 A2MG_HUMAN ALPHA-2-MACROGLOBULIN PRECURSOR (ALPHA-2-M) >gi 825615 alpha2-macroglobulin [Homo sapiens] {SUB 672-746} Length = 1474	gi 177870	2	3856	98	HAPQO79	Lung, Prostate
553	841338			1139	1363		HABU58	Pancreas, Prostate
554	841345	yeast methionyl-tRNA synthetase homolog [Homo sapiens] >pir JC5224 JC5224 methionine--tRNA ligase (EC 6.1.1.10) - human >gi 804996 mitoxantrone-resistance associated gene [Homo sapiens] {SUB 423-900} Length = 900	gn PIDe218477	2	2761	94	HAAQ46	Lung, Pancreas, Prostate, Breast/Ovarian
555	841349			151	1578		HMWFM73	Lung, Pancreas, Prostate, Breast/Ovarian
556	841355	glucose regulated protein 94 (400 AA) [Mesocricetus auratus] >pir A26258 A26258 endoplasmic - hamster (fragment) >sp P08712 ENPL_MESAU ENDOPLASMIN (94 KD GLUCOSE-REGULATED PROTEIN) (GRP94) (FRAGMENT) Length = 400	gi 49628	2	562	99	HAA78	Prostate, Breast/Ovarian
557	841417	arginine-rich nuclear protein [Homo sapiens] >pir A40988 A40988 54K arginine-rich nuclear protein - human >sp Q05519 Q05519 ARGININE- RICH 54 KD NUCLEAR PROTEIN. Length = 484	gi 178997	708	1835	73	HN7CL10	Lung, Pancreas, Colon, Breast/Ovarian

558	841548		278	613		HBXDN79	Lung, Breast/Ovarian
559	841632	(AF073298) 4F5rel [Homo sapiens] >gj3641536 (AF073297) 4F5rel [Mus musculus] >sp O75918 O75918 4F5REL. >sp O88891 O88891 4F5REL. Length = 59	49	255	100	HTLGV25	Lung, Breast/Ovarian
560	841662	HYA22 protein - human Length = 338	2	532	78	HLQCP61	Prostate, Colon
561	841771		901	1146		HSYDN46	Lung, Pancreas
562	841827	RTP [Homo sapiens] >gj3046386 (AF004162) nickel-specific induction protein [Homo sapiens] >sp Q92597 Q92597 RTP, COMPLETE CDS. Length = 394	358	1110	97	HHFDJ26	Pancreas, Prostate
563	841835		1232	1612		HWLJT54	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
564	842259		2	691		HHFGF52	Lung, Pancreas, Prostate, Colon
565	842463		600	836		HETTY08	Lung, Pancreas
566	842595	ERp28 [Homo sapiens] >sp P30040 ER29_HUMAN ENDOPLASMIC RETICULUM PROTEIN ERP29 PRECURSOR (ERP31) (ERP28). >sp E1314951 E1314951 ERP28 PRECURSOR. Length = 261	50	916	92	HUFAB73	Lung, Breast/Ovarian
567	842722		2	1465		HYABB24	Lung, Pancreas, Prostate, Breast/Ovarian
568	842815		780	971		HPMSG47	Pancreas, Colon
569	842818	(AF038954) vacuolar H(+)-ATPase subunit [Homo sapiens] >sp O75348 O75348 VACUOLAR H(+)- ATPASE SUBUNIT. Length = 118	91	477	79	HSKJF03	Lung, Pancreas, Prostate, Breast/Ovarian

570	843251	(AF057297) ornithine decarboxylase antizyme 2 [Homo sapiens] >gi 3766170 (AF057297) ornithine decarboxylase antizyme 2 [Homo sapiens] >sp G3766170 G3766170 ORNITHINE DECARBOXYLASE ANTIZYME 2. >gnl PID d1020346 product is unknown; seizure- related gene [Mus]	gi 3766170	215	745	92	92	HTLIF83	Lung, Breast/Ovarian
571	843422			563	898			HIISW60	Lung, Pancreas, Colon, Breast/Ovarian
572	843784			1307	1864			HCECS78	Lung, Pancreas
573	844017			243	566			HKABG31	Lung, Colon
574	844138	Epithelin 1 & 2 [Homo sapiens] >gi 3005730 (AF055008) epithelin 1 and 2 [Homo sapiens] >pir JC1284 GYHU granulin precursor - human >sp G3005730 G3005730 EPTHELIN 1 AND 2. Length = 593	gi 31193	104	1966	100	100	HDPWW59	Lung, Breast/Ovarian
575	844166	(AF039689) antigen NY-CO-7 [Homo sapiens] >sp O60526 O60526 ANTIGEN NY-CO-7. Length = 303	gi 3170178	1	1020	94	94	HABAE22	Lung, Pancreas, Prostate, Breast/Ovarian
576	844194			3	707			HF8PB56	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
577	844394			378	635			HHEUP26	Lung, Pancreas, Breast/Ovarian
578	844450	weak similarity to rat TEGT protein (GI:456207) [Caenorhabditis elegans] >sp P91373 P91373 SIMILARITY TO RAT TEGT PROTEIN. Length = 342	gi 1825601	113	1165	61	78	HTXOX92	Lung, Pancreas
579	844534			2	244			HCE3165	Lung, Pancreas, Breast/Ovarian

580	844535	isocitrate dehydrogenase (NADP+) [Homo sapiens] >pir S57499 S57499 isocitrate dehydrogenase (NADP+) (EC 1.1.1.42) precursor, mitochondrial - human >sp P48735 IDHP_HUMAN ISOCITRATE DEHYDROGENASE [NADP]. MITOCHONDRIAL PRECURSOR (EC 1.1.1.42) (OXALOSUCCINATE	gi 872121	3	1454	96	96	HCWGLE38	Lung, Breast/Ovarian
581	844644	(AJ002308) synaptogyrin 2 [Homo sapiens] >sp O43760 O43760 SYNAPTOGYRIN 2. Length = 224	gn P D e 254905	1	720	91	91	HDPBQ51	Lung, Breast/Ovarian
582	844653	immunoglobulin lambda light chain gene product [Homo sapiens] >pir S25745 S25745 Ig lambda chain - human (fragment) Length = 226	gi 33718	1	732	89	91	HCRQC91	Lung, Pancreas, Colon
583	844659	cathepsin D [Homo sapiens] >gi 29678 precursor polypeptide (AA -20 to 392) [Homo sapiens] >gi 181180 preprocathepsin D [Homo sapiens] >pir A2577 KIHUUD cathepsin D (EC 3.4.23.5) precursor - human >sp P07339 CATD_HUMAN CATHEPSIN D PRECURSOR (EC 3.4.23.5).	gi 179948	21	539	94	94	HLDDQ71	Lung, Breast/Ovarian
584	844796			2	1054			HE6BS09	Colon, Breast/Ovarian
585	844812	(AF040642) contains similarity to transacylases [Caenorhabditis elegans] >sp O44793 O44793 C50D2.7 PROTEIN. Length = 895	gi 2746788	13	1542	33	59	HDPFV13	Lung, Pancreas
586	844894	E25B protein [Mus musculus] >sp O89051 O89051 E25B PROTEIN. Length = 266	gi 3746127	66	1013	96	99	HCLBO47	Lung, Pancreas, Colon

587	845361	phosphoglycerate kinase (EC 2.7.2.3) [Homo sapiens] >gi 387021 phosphoglycerate kinase [Homo sapiens] >gi 35435 coding sequence [Homo sapiens] >pir 59050 KIHUG phosphoglycerate kinase (EC 2.7.2.3) - human length = 417	gi 387020	39	1232	100	100	HHEUJ91	Pancreas, Colon
588	845620			508	1254			HWIIGQ46	Lung, Pancreas, Prostate, Breast/Ovarian
589	845639	leukocyte antigen F [Homo sapiens] >gi 3273731 (AF055066) MHC class I HLA-F [Homo sapiens] >pir A60384 A60384 MHC class I histocompatibility antigen HLA-F alpha chain Dew3 precursor - human >sp P30511 HLAF_HUMAN HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, F A	gi 312407	2	814	90	90	HCFNA68	Lung, Pancreas, Colon, Breast/Ovarian
590	845660	Cyr61 [Homo sapiens] >gnl P1D e311857 Gig1 protein [Homo sapiens] >gi 2196782 (AF003594) growth-factor inducible immediate early gene product CYR61 [Homo sapiens] >gnl P1D e1249319 hCYR61 protein [Homo sapiens] >sp O00622 CYR6_HUMAN CYR61 PROTEIN PRECURSOR	gi 2130527	1	1365	91	91	HKAJW79	Lung, Pancreas, Prostate, Breast/Ovarian
591	845720			1	261			HKDAF83	Lung, Breast/Ovarian
592	845785			180	509			HSODT09	Pancreas, Colon, Breast/Ovarian
593	845897			1369	1677			HADA1B09	Pancreas, Breast/Ovarian

594	845922	beta actin [Ovis aries] >gi 2661136 (AF035774) beta actin [Equus caballus] >gi 3320892 (AF076190) beta-actin [Trichosurus vulpecula] >gi 177968 cytoplasmic beta actin [Homo sapiens] >gnl PID d 1021082 (AB004047) beta-actin [Homo sapiens] >gi 28252 beta-act	gi 2182269	1	1239	100	100	100	HWLQQ65	Lung, Pancreas, Colon
595	846016	(AB005894) ecalectin [Homo sapiens] >sp O75028 O75028 ECALECTIN. Length = 323	gnl PID d 1032501	47	337	97	97	97	HDPIIT90	Lung, Pancreas
596	846040	0-44 protein [Rattus sp.] >pir 157612 157612 Rat brain 0-44 mRNA, segment 2 - rat >sp P38718 P044_RAT 0-44 PROTEIN. Length = 127	gi 203072	127	585	84	88	88	HLICQ57	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
597	846073	protein p68 (AA 1-614) [Homo sapiens] >gi 35220 p68 protein (AA 1-614) [Homo sapiens] >gi 2599360 (AF015812) RNA helicase p68 [Homo sapiens] >pir JC1087 JC1087 RNA helicase, ATP-dependent - human >sp P17844 DDX5_HUMAN PROBABLE RNA-DEPENDENT HELICASE P68	gi 38318	23	1051	91	92	92	HCWDW01	Lung, Pancreas
598	846257			286	651				HPWDE09	Lung, Prostate
599	HTXPN06R			65	286				HTXPN06	Lung, Breast/Ovarian
600	112LAQ12R			3	311	71	79	79	112LAQ12	Pancreas, Colon
601	HWAFU16R	(AB000911) ribosomal protein [Sus scrofa] >gnl PID e 1339008 (AL031228) d 1033B10.4 (40S ribosomal protein S18 (RPS18, KE-3)) [Homo sapiens] >gi 198580 ribosomal protein [Mus musculus] >gi 433447 ribosomal protein S18 [Rattus rattus] >gi 3811382 (AF100956)	gnl PID d 1019961	3	320	86	86	86	HWAFU16	Lung, Pancreas, Colon, Breast/Ovarian

602	HAEAM91R	(AB005218) L subunit of photosynthetic reaction center complex [Acidiphilium rubrum] >gnl PID d1026488 (AB005219) L subunit of photosynthetic reaction center complex [Acidiphilium angustum] >sp O70105 O70105 L SUBUNIT OF PHOTOSYNTHETIC REACTION CENTER COM	gnl PID d1026481	174	215	66	66	66	HAEAM91	Pancreas, Colon, Breast/Ovarian
603	HOEMT44R	(AB010959) natural killer cell enhancing factor [Cyprinus carpio] Length = 199	gnl PID d1033048	54	431	84	93	93	HOEMT44	Lung, Colon, Breast/Ovarian
604	HE2OW04R	(AF001631) glucose-regulated protein GRP94 [Oryctolagus cuniculus] >sp O18750 ENPL_RABIT ENDOPLASMIN (94 KD GLUCOSE-REGULATED PROTEIN) (GRP94) (FRAGMENT). Length = 716	gi 2581793	7	297	87	89	89	HE2OW04	Lung, Colon
605	HFCFG25R	(AF012422) ribosomal protein 46 [Drosophila melanogaster] Length = 51	gi 2307014	3	143	65	87	87	HFCFG25	Lung, Colon, Breast/Ovarian
606	HAPQP94R	(AF018432) dUTPase [Homo sapiens] >gi 144332 deoxyuridine nucleotidohydrolase [Homo sapiens] >gi 1421818 deoxyuridine triphosphatase [Homo sapiens] >pir G02777 G02777 dUTP pyrophosphatase (EC 3.6.1.23) - human >gi 292877 dUTP nucleotidohydrolase [Homo sa	gi 2443581	3	320	97	97	97	HAPQP94	Lung, Pancreas, Colon
607	H2CB137R	(AF042107) ribosomal protein S3a [Eimeria tenella] >gi 2792508 (AF042107) ribosomal protein S3a [Eimeria tenella] Length = 264	gi 2792508	3	182	64	64	64	H2CB137	Colon, Breast/Ovarian
608	HEOPQ13R	(AF042505) cytochrome b [Homo sapiens] >sp G3372377 G3372377 CYTOCHROME B (FRAGMENT). Length = 380	gi 3372377	82	216	80	82	82	HEOPQ13	Lung, Colon

609	HCRNC25R	(AF051894) 15 kDa selenoprotein [Homo sapiens] Length = 161	gj 3095111	61	162	100	100	100	HCRNC25	Lung, Pancreas, Colon
610	HTTF28R	(AF056218) superficial zone protein [Bos taurus] >sp O77765 O77765 SUPERFICIAL ZONE PROTEIN (FRAGMENT). Length = 401	gj 3676501	3	185	73	80	80	HTTF28	Pancreas, Colon
611	H2LAY26R			24	155				H2LAY26	Pancreas, Colon
612	HAPQA06R	40-kDa keratin protein [Homo sapiens] >pir A31370 KRHHU9 keratin 19, type I, cytoskeletal - human Length = 400	gj 386803	2	355	62	62	62	HAPQA06	Lung, Pancreas, Colon, Breast/Ovarian
613	HAQBM72R	40-kDa keratin protein [Homo sapiens] >pir A31370 KRHHU9 keratin 19, type I, cytoskeletal - human Length = 400	gj 386803	2	145	81	81	81	HAQBM72	Pancreas, Colon
614	HBGOK18R	40-kDa keratin protein [Homo sapiens] >pir A31370 KRHHU9 keratin 19, type I, cytoskeletal - human Length = 400	gj 386803	1	429	91	92	92	HBGOK18	Lung, Pancreas, Colon, Breast/Ovarian
615	H2MAC07R	acidic ribosomal phosphoprotein (P1) [Homo sapiens] >pir B27125 R6HUP1 acidic ribosomal protein P1 - human Length = 114	gj 190234	111	458	100	100	100	H2MAC07	Lung, Colon, Breast/Ovarian
616	HTWK26R	acidic ribosomal phosphoprotein (P2) [Homo sapiens] >pir C27125 R6HUP2 acidic ribosomal protein P2 - human Length = 115	gj 190236	1	345	95	96	96	HTWK26	Lung, Pancreas, Breast/Ovarian
617	HTAHR89R	ADP,ATP carrier protein T2 - human >sp P12236 ADT3_HUMAN ADP,ATP CARRIER PROTEIN, LIVER ISOFORM T2 (ADP/ATP TRANSLCLEASE 3) (ADENINE NUCLEOTIDE TRANSLCATOR 3) (ANT 3). Length = 298	pir S03894 S03894	13	408	96	96	96	HTAHR89	Lung, Pancreas

618	HOACE24R	alcohol dehydrogenase [Homo sapiens] >pir A3337 IDEHUE1 aldehyde dehydrogenase (NAD+) (EC 1.2.1.3) 1, cytosolic - human >sp P00352 DHAC_HUMAN ALDEHYDE DEHYDROGENASE, CYTOSOLIC (EC 1.2.1.3) (CLASS I) (ALHDII) (ALDH-E1). {SUB 2-501} Length = 501	gil178372	3	374	91	92	HOACE24	Pancreas, Colon
619	HOELC27R	aldolase A (EC 4.1.3.13) [Homo sapiens] >gil28597 aldolase A (AA 1-364) [Homo sapiens] >pir S14084 ADHUA fructose-bisphosphate aldolase (EC 4.1.2.13) A - human >sp P04075 ALFA_HUMAN FRUCTOSE- BISPHOSPHATE ALDOLASE A (EC 4.1.2.13) (MUSCLE-TYPE ALDOLASE). {S	gil178351	68	604	100	100	HOELC27	Lung, Pancreas, Breast/Ovarian
620	HWLBS25R	aldolase A [Gallus gallus] >gil409193 aldolase A [Gallus gallus] >bbs 167536 aldolase C=fructose- 1,6-bisphosphate aldolase {EC 4.1.2.13} [chickens, brain, Peptide Partial, 42 aa] [Gallus gallus] >pir 51291 51291 aldolase C - chicken (fragment) Length = 4	gil409191	3	95	90	93	HWLBS25	Lung, Pancreas, Colon, Breast/Ovarian
621	HWLVW62R	alpha-1 type III collagen [Homo sapiens] Length = 345	gil180414	1	213	97	97	HWLVW62	Lung, Colon, Breast/Ovarian
622	HALSE08R	ALPHA-1-ANTICHYMOTRYPSIN PRECURSOR sp P01011 AACT_H (ACT). >gil4165890 (AF089747) alpha-1- antichymotrypsin precursor [Homo sapiens] {SUB 17-423} >gil177933 alpha-1-antichymotrypsin precursor [Homo sapiens] {SUB 22-423} >gil28332 alpha 1 antichymotrypsin [Homo sapiens] {SU	sp P01011 AACT_H UMAN	3	233	95	97	HALSE08	Lung, Pancreas

623	HFKHD94R	alpha-2 chain precursor (AA -25 to 1018) (3416 is 2nd base in codon) [Homo sapiens] Length = 1043	gi 30076	2	316	97	97	HFKHD94	Pancreas, Breast/Ovarian
624	HCE2M86R	alpha-adaptin (A) (AA 1-977) [Mus musculus] >pir A30111 A30111 alpha-adaptin A - mouse >sp P17426 ADAA_MOUSE ALPHA-ADAPTIN A (CLATHRIN ASSEMBLY PROTEIN COMPLEX 2 ALPHA-A LARGE CHAIN) (100 KD COATED VESICLE PROTEIN A) (PLASMA MEMBRANE ADAPTOR HA2/AP2 ADAPT	gi 49878	58	165	75	80	HCE2M86	Lung, Colon, Breast/Ovarian
625	HFOFA89R	annexin IV (placental anticoagulant protein II) [Homo sapiens] >gnl PID d1011889 annexin IV (carbohydrate-binding protein p33/41) [Homo sapiens] >pir A42077 A42077 annexin IV - human >sp P09525 ANX4_HUMAN ANNEXIN IV (LIPOCORTIN IV) (ENDONEXIN I) (CHROMOB	gi 178699	154	399	94	94	HFOFA89	Pancreas, Colon, Breast/Ovarian
626	HBWCN69R	beta-1,2-N-acetylglucosaminyltransferase II [Homo sapiens] >pir S66256 S66256 alpha-1,6-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (EC 2.4.1.143) - human >sp Q10469 GNT2_HUMAN ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAM	gi 902745	60	308	88	90	HBWCN69	Pancreas, Colon
627	HLQGB43R	beta-2-microglobulin [Homo sapiens] Length = 119	gi 179318	1	78	100	100	HLQGB43	Lung, Pancreas, Colon
628	HCR0L58R			3	506			HCR0L58	Pancreas, Colon
629	HS2IF12R			83	475			HS2IF12	Pancreas, Colon
630	HWLWA01R			2	538			HWLWA01	Pancreas, Colon

631	HCHMV24R			12	185				HCHMV24	Pancreas, Colon, Breast/Ovarian Colon, Breast/Ovarian
632	HCHPT49R			94	303				HCHPT49	Pancreas, Colon, Breast/Ovarian
633	HCRMGI2R			2	187				HCRMGI2	Pancreas, Colon
634	HWLWE68R			2	241				HWLWE68	Pancreas, Colon
635	HCHPF59R			24	179				HCHPF59	Pancreas, Breast/Ovarian
636	HS2IA81R			90	551				HS2IA81	Pancreas, Colon
637	HCRNC17R			11	400				HCRNC17	Pancreas, Colon
638	HISDJ39R			14	406				HISDJ39	Pancreas, Colon
639	HWLEL43R			2	337				HWLEL43	Pancreas, Colon
640	HASCG71R			91	249				HASCG71	Lung, Colon, Breast/Ovarian
641	HOEMO43R			2	184				HOEMO43	Lung, Pancreas, Colon, Breast/Ovarian
642	HRDFT95R	c-erb-B-2 precursor [Homo sapiens] >pir/A24571/A24571 protein-tyrosine kinase (EC 2.7.1.112) erbB2 precursor - human >sp P04626 ERB2_HUMAN ERBB-2 RECEPTOR PROTEIN-TYROSINE KINASE PRECURSOR (EC 2.7.1.112) (P185ERBB2) (NEU PROTO- ONCOGENE) (C-ERBB-2). Length	gi 31198	151	231	76	82		HRDFT95	Pancreas, Colon
643	HAGEP27R	C10 protein [Bos taurus] >pir/A38464/A38464 33K laminin receptor homolog - bovine Length = 295	gi 163303	3	137	86	86		HAGEP27	Lung, Pancreas, Colon, Breast/Ovarian

644	HSYDG18R	calmodulin [Homo sapiens] >sp Q13942 Q13942 CALMODULIN. >pir A56785 A56785 calmodulin - pig (fragment) {SUB 80-130} >gi 3243222 (AF069912) calmodulin [Xiphias gladius] {SUB 80-114} >pir E44101 E44101 calmodulin, vasoactive intestinal peptide-binding prote	gi 825635	3	422	100	100	HSYDG18	Lung, Pancreas, Colon
645	HLJDZ15R	cathepsin C [Homo sapiens] >gi 1947071 prepro dipeptidyl peptidase I [Homo sapiens] >pir S66504 S66504 dipeptidyl-peptidase I (EC 3.4.14.1) precursor - human >sp P53634 CATC_HUMAN DIPEPTIDYL-PEPTIDASE I PRECURSOR (EC 3.4.14.1) (DPP-I) (CATHEPSIN C) (CATHE	gi 1006657	3	110	71	77	HLJDZ15	Lung, Colon
646	HAHDQ54R	cathepsin D [Homo sapiens] >gi 29678 precursor polypeptide (AA -20 to 392) [Homo sapiens] >gi 181180 preprocathepsin D [Homo sapiens] >pir A2577 KHHUD cathepsin D (EC 3.4.23.5) precursor - human >sp P07339 CATD_HUMAN CATHEPSIN D PRECURSOR (EC 3.4.23.5).	gi 179948	2	103	100	100	HAHDQ54	Lung, Pancreas
647	HTLHI18R	collagen alpha 2(VI) chain precursor, long splice form - human >gi 179711 alpha-2 collagen type VI-a' [Homo sapiens] {SUB 590-1018} >gi 291918 alpha-2 type VI collagen [Homo sapiens] {SUB 315-358} Length = 1018	pir S05378 CGHU2A	2	481	89	89	HTLHI18	Lung, Pancreas

648	HACAC47R	complement component C3 [Homo sapiens] >pir/A94065 C3HU complement C3 precursor - human >sp P01024 CO3_HUMAN COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]. >gi 181130 complement component C3 [Homo sapiens] {SUB 1-24} Length = 1663	gj 179665	1	315	79	80	HACAC47	Lung, Pancreas, Breast/Ovarian
649	III.QFY4IR	complement component C3 [Homo sapiens] >pir/A94065 C3HU complement C3 precursor - human >sp P01024 CO3_HUMAN COMPLEMENT C3 PRECURSOR [CONTAINS: C3A ANAPHYLATOXIN]. >gi 181130 complement component C3 [Homo sapiens] {SUB 1-24} Length = 1663	gj 179665	3	377	96	98	III.QFY4I	Lung, Pancreas, Colon, Breast/Ovarian
650	HOFMO83R	cyclin G [Homo sapiens] >gi 1236233 cyclin G1 [Homo sapiens] >gi 1236913 cyclin G1 [Homo sapiens] >pir G02401 G02401 cyclin G1 - human >sp P51959 CG2G_HUMAN G2/MITOTIC-SPECIFIC CYCLIN G1. >gn PID d1013694 cyclin G [Homo sapiens] {SUB 1-279} >gi 1486361 c	gn PID d1012016	2	205	87	93	HOFMO83	Pancreas, Breast/Ovarian
651	HFTDR22R	cytochrome b5, hepatic - brown howler monkey (fragment) Length = 87	pir S07959 S07959	136	357	100	100	HFTDR22	Pancreas, Colon, Breast/Ovarian
652	HPJCZ01R	cytochrome c oxidase II [Macaca fascicularis] >pir A27420 A27420 cytochrome-c oxidase (EC 1.9.3.1) chain II - crab-eating macaque mitochondrion (SGC1) >sp P11948 COX2_MACFA CYTOCHROME C OXIDASE POLYPEPTIDE II (EC 1.9.3.1). Length = 227	gi 342255	2	163	44	50	HPJCZ01	Lung, Pancreas, Colon

653	HOEKC39R	cytochrome oxidase 1 [Homo sapiens] >gi 506829 cytochrome oxidase subunit 1 [Homo sapiens] >pir A00463 ODHU1 cytochrome-c oxidase (EC 1.9.3.1) chain I - human mitochondrion (SGC1) >sp P00395 COX1_HUMAN CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1). Leng	gi 13006	54	167	91	95	HOEKC39	Lung, Pancreas, Colon
654	HOELI24R	cytochrome oxidase subunit 3 [Homo sapiens] Length = 260	gi 2052365	29	166	97	97	HOELI24	Lung, Pancreas, Colon
655	HODEI18R	cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 337187 cytochrome oxidase subunit II [gi 530069	1	180	69	72	HODEI18	Lung, Pancreas, Colon
656	HOSNR06R	cytochrome oxidase subunit II [Homo sapiens] >gi 530071 cytochrome oxidase subunit II [Homo sapiens] >gi 530073 cytochrome oxidase subunit II [Homo sapiens] >gi 530077 cytochrome oxidase subunit II [Homo sapiens] >gi 337187 cytochrome oxidase subunit II [gi 530069	269	403	93	95	HOSNR06	Lung, Pancreas
657	HCQDL20R	cytochrome P450 PCN3 [Homo sapiens] >pir A34101 A34101 cytochrome P450 3A5 - human >sp P20815 CP35_HUMAN CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYP11A5) (P450-PCN3). >gi 950342 cytochrome P450 [Homo sapiens] (SUB 1-24) Length = 502	gi 181346	39	245	98	98	HCQDL20	Pancreas, Colon

658	HTOHI64R	cytokeratin 15 (AA 1 - 456) [Homo sapiens] >pir[S01069]KRHU5 keratin 15, type I, cytoskeletal - human >sp P19012 K1CO_HUMAN KERATIN, TYPE I CYTOSKELETAL 15 (CYTOKERATIN 15) (K15) (CK 15). Length = 456	gj 34071	149	253	89	89	HTOHI64	Prostate, Breast/Ovarian
659	HCHBR11R	cytokeratin 8 [Homo sapiens] Length = 483	gj 181400	3	380	55	57	HCHBR11	Lung, Pancreas, Colon, Breast/Ovarian
660	HADBE77R	cytoplasmic chaperonin hTRiC5 [Homo sapiens] Length = 201	gj 609308	43	294	80	84	HADBE77	Lung, Pancreas, Colon, Breast/Ovarian
661	HFKHD49R	D-beta-hydroxybutyrate dehydrogenase [Rattus norvegicus] Length = 93	gj 930260	1	210	100	100	HFKHD49	Lung, Colon, Breast/Ovarian
662	HOEMI59R	decorin [Homo sapiens] >gj 609452 decorin [Homo sapiens] {SUB 1-70} Length = 347	gj 181519	3	128	72	75	HOEMI59	Lung, Colon
663	HTYNC43R	elongation factor 1-alpha 1 [Homo sapiens] >gj 927067 elongation factor 1-alpha 1 [Homo sapiens] >pir 59399 59399 oncogene PTL-1 - human >sp Q16577 Q16577 ONCOGENE. Length = 398	gj 927065	2	217	92	94	HTYNC43	Lung, Pancreas, Colon
664	H6EAQ15R	elongation factor 2 [Homo sapiens] >gj 31108 human elongation factor 2 [Homo sapiens] >pir S18294 EFHU2 translation elongation factor eEF-2 - human >sp P13639 EF2_HUMAN ELONGATION FACTOR 2 (EF-2) >gj 181969 elongation factor 2 [Homo sapiens] {SUB 501-858	gj 31106	2	70	100	100	H6EAQ15	Lung, Pancreas, Breast/Ovarian

665	HCFLM34R	elongation factor Tu [Mus musculus] >sp Q61511 Q61511 EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA 1 (EEF-TU GENE ENCODING ELONGATION FACTOR TU, 5' END) (FRAGMENT). Length = 108	gj 553907	48	308	94	95	HCFLM34	Lung, Breast/Ovarian
666	HTTID16R	ENA-78 prepeptide [Homo sapiens] >gi 607031 neutrophil-activating peptide 78 [Homo sapiens] >gi 471243 ENA-78 gene product [Homo sapiens] >pir JC2433 A55010 neutrophil-activating peptide ENA-78 - human >sp P42830 EN78 HUMAN NEUTROPHIL ACTIVATING PROTEIN E	gj 684922	2	331	85	85	HTTID16	Pancreas, Colon
667	HDPAI45R	endoglin [Homo sapiens] >pir S37628 S37628 endoglin - human Length = 625	gj 402207	2	181	65	65	HDPAI45	Pancreas, Colon
668	HKIXL19R	epoxide hydrolase [Homo sapiens] >gi 340390 epoxide hydrolase [Homo sapiens] >gi 34543 epoxide hydrolase (AA 1-455) [Homo sapiens] >gi 458701 epoxide hydrolase [Homo sapiens] >pir A29939 A29939 epoxide hydrolase (EC 3.3.2.3) 1, microsomal - human >sp P070	gj 450271	1	348	100	100	HKIXL19	Lung, Pancreas, Colon
669	H2LAY52R	EWS gene product [Mus musculus] >pir A55726 A55726 RNA-binding protein Ews - mouse >sp Q61545 EWS_MOUSE RNA-BINDING PROTEIN EWS. Length = 655	gj 488513	27	494	100	100	H2LAY52	Lung, Pancreas, Colon, Breast/Ovarian
670	HAJRB09R	FAST kinase [Homo sapiens] >pir J37386 J37386 FAST kinase - human >sp Q14296 Q14296 FAST KINASE. Length = 549	gj 1006659	19	324	77	77	HAJRB09	Pancreas, Colon

671	HAPNI86R	G9a [Homo sapiens] >pir[S30385]S30385 G9a protein - human >sp Q14349 Q14349 G9A PROTEIN CONTAINING ANKYRIN-LIKE REPEATS. Length = 1001	gi 287865	3	419	97	97	HAPNI86	Lung, Colon
672	HCEVB92R	glutamate dehydrogenase [Homo sapiens] >sp Q14400 Q14400 GLUTAMATE DEHYDROGENASE (FRAGMENT). Length = 258	gi 183056	2	217	78	81	HCEVB92	Pancreas, Colon
673	HAPRJ22R	glutamate--ammonia ligase [Homo sapiens] >pir S18455 AJHUQ glutamate--ammonia ligase (EC 6.3.1.2) - human Length = 373	gi 31831	168	431	100	100	HAPRJ22	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
674	HCRMZ32R	glutamine:fructose-6-phosphate amidotransferase [Homo sapiens] >pir A45055 A45055 glutamine--fructose-6-phosphate transaminase (isomerizing) (EC 2.6.1.16) - human >sp Q06210 GFAT_HUMAN GLUCOSAMINE--FRUCTOSE-6-PHOSPHATE AMINOTRANSFERASE [ISOMERIZING] (EC 2	gi 183082	2	316	91	91	HCRMZ32	Pancreas, Colon, Breast/Ovarian
675	HBMVM42R	guanine nucleotide regulatory protein [Homo sapiens] >gi 3041860 (AC004534) guanine nucleotide regulatory protein [Homo sapiens] >pir 38402 38402 guanine nucleotide regulatory protein - human >sp Q12774 Q12774 GUANINE NUCLEOTIDE REGULATORY PROTEIN. Leng	gi 484102	1	363	84	87	HBMVM42	Colon, Breast/Ovarian

676	HADGE45R	guanine nucleotide-binding protein G-s-alpha-4 [Homo sapiens] >gi31913 alpha-S1 (AA 1-380) [Homo sapiens] >pirC31927/RGHUA1 GTP-binding regulatory protein Gs alpha chain (adenylate cyclase-stimulating), splice form 4 - human Length = 380	gi386746	2	439	96	96	IIADGE45	Lung, Pancreas, Colon
677	HTXPN11R	heat shock-induced protein [Homo sapiens] >pirB45871/B45871 dnaK-type molecular chaperone HSP70-Hom - human >spP34931/H57H_HUMAN HEAT SHOCK 70 KD PROTEIN 1-HOM (HSP70-HOM). Length = 641	gi188492	3	413	94	98	HTXPN11	Lung, Pancreas, Colon
678	HCDBN37R	heterogeneous nuclear ribonucleoprotein C-like protein - human Length = 328	pirA44192/A44192	1	300	96	96	HCDBN37	Colon, Breast/Ovarian
679	HABGC02R	HLA-DR-beta-B [Homo sapiens] Length = 266	gi490048	3	389	89	94	HABGC02	Lung, Colon
680	HNTSA70R	HsMcm6 [Homo sapiens] >spQ14566/MCM6_HUMAN DNA REPLICATION LICENSING FACTOR MCM6 (P105MCM). Length = 821	gn PID d1013380	3	341	69	72	HNTSA70	Lung, Colon
681	HDTKP24R	hypothetical 18K protein (rRNA) - goldfish mitochondrion (SGC1) Length = 166	pirJC1348/JC1348	397	492	64	67	HDTKP24	Lung, Pancreas, Colon
682	HODEI14R	hypothetical 18K protein (rRNA) - goldfish mitochondrion (SGC1) Length = 166	pirJC1348/JC1348	164	247	62	68	HODEI14	Lung, Pancreas, Colon
683	HOELC42R	IGF-BP 4 [Homo sapiens] >gn PID e1227579 insulin-like growth factor binding protein 4 [Homo sapiens] >pirB37252/B37252 insulin-like growth factor-binding protein 4 precursor - human >spP22692/IBP4_HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 PREC	gi184816	13	288	83	83	HOELC42	Pancreas, Colon

684	HWAF44R	immunoglobulin heavy chain [Homo sapiens] >pir D36005 D36005 Ig heavy chain V region (M43) - human {SUB 38-156} Length = 156	gi 567121	2	463	83	90	HWAF44	Lung, Colon
685	HABGF46R	immunoglobulin light chain variable region [Homo sapiens] >gi 2970534 (AF049692) immunoglobulin kappa light chain [Homo sapiens] {SUB 3-106} Length = 143	gi 1136555	42	446	71	85	HABGF46	Lung, Pancreas, Colon, Breast/Ovarian
686	HOELC15R	insulin-like growth factor-binding protein [Homo sapiens] >gi 386791 growth factor-binding protein-3 [Homo sapiens] >gi 398164 insulin-like growth factor binding protein 3 [Homo sapiens] >pir A36578 IOHU3 insulin-like growth factor-binding protein 3 precu	gi 183116	8	424	96	96	HOELC15	Pancreas, Colon, Breast/Ovarian
687	H2LAR26R	keratin 18 [Homo sapiens] >gi 307081 keratin 18 precursor [Homo sapiens] >gi 34037 cytokeratin 18 [Homo sapiens] >pir S05481 S05481 keratin 18, type I, cytoskeletal - human >sp P05783 K1CR_HUMAN KERATIN, TYPE I CYTOSKELETAL, 18 (CYTOKERATIN 18) (K18) (CK 1	gi 386844	72	476	97	98	H2LAR26	Colon, Breast/Ovarian
688	H2LAV85R	Ku (p70/p80) subunit [Homo sapiens] >gi 307093 Ku antigen [Homo sapiens] >pir A35051 A32626 Ku antigen 80K chain - human >sp P13010 KU86_HUMAN ATP-DEPENDENT DNA HELICASE II, 86 KD SUBUNIT (LUPUS KU AUTOANTIGEN PROTEIN P86) (86 KD SUBUNIT OF KU ANTIGEN) (T	gi 307094	67	462	97	98	H2LAV85	Lung, Pancreas
689	HBSDC92R	l-caldesmon II [Homo sapiens] Length = 532	gn PID d1015132	56	337	64	76	HBSDC92	Lung, Breast/Ovarian

690	HUTHN01R	L6 [Homo sapiens] >pir A42926 A42926 L6 surface protein - human Length = 202	gj 186804	87	545	91	91	HUTHN01	Lung, Pancreas, Colon, Breast/Ovarian Lung, Pancreas
691	H2LAW03R	lactate dehydrogenase B [Homo sapiens] >gj 34329 lactate dehydrogenase B (AA 1 - 334) [Homo sapiens] >pir S02795 DEHULH L-lactate dehydrogenase (EC 1.1.1.27) chain H - human >sp P07195 LDHH_HUMAN L-LACTATE DEHYDROGENASE H CHAIN (EC 1.1.1.27) (LDH-B), {SUB	gn PID e223241	111	536	99	100	H2LAW03	Lung, Pancreas
692	HOE MO60R	lactate dehydrogenase-A [Homo sapiens] >gj 34313 lactate dehydrogenase-A [Homo sapiens] >pir A00347 DEHULM L-lactate dehydrogenase (EC 1.1.1.27) chain M - human >sp P00338 LDHM_HUMAN L-LACTATE DEHYDROGENASE M CHAIN (EC 1.1.1.27) (LDH-A), {SUB 2-332} Leng	gj 780261	1	201	59	59	HOE MO60	Pancreas, Breast/Ovarian
693	HKAHJ14R			1	216			HKAHJ14	Pancreas, Colon
694	HOHEA39R	latent transforming growth factor-beta-binding protein - human Length = 1820	pir A55494 A55494	1	240	85	86	HOHEA39	Pancreas, Breast/Ovarian
695	HOELF72R	lumican [Homo sapiens] Length = 338	gj 699577	58	468	97	97	HOELF72	Pancreas, Colon
696	HAPNX59R	M130 antigen [Homo sapiens] >pir I38003 S36077 M130 antigen - human >sp Q07898 Q07898 M130 ANTIGEN PRECURSOR. Length = 1116	gj 312142	1	432	85	88	HAPNX59	Lung, Colon
697	HIBJJS17R	methionine aminopeptidase [Homo sapiens] >gj 687243 eIF-2-associated p67 homolog [Homo sapiens] >pir S52112 DPHUM2 methionyl aminopeptidase (EC 3.4.11.18) 2 - human >sp P50579 AMP2_HUMAN METHIONINE AMINOPEPTIDASE 2 (EC 3.4.11.18) (METAP 2) (PEPTIDASE M 2)	gj 903982	1	255	100	100	HIBJJS17	Lung, Pancreas

698	HA1DU61R	midkine [Homo sapiens] >gi188571 retinoic acid inducible factor [Homo sapiens] >gi35087 neurite outgrowth-promoting protein [Homo sapiens] >gnlPIDd1001932 midkine [Homo sapiens] >pirJI0385JI0385 midkine precursor - human >spP21741MK_HUMAN MIDKINE	gi182651	1	108	67	67	HA1DU61	Pancreas, Colon
699	HCWHT65R	mitochondrial intermediate peptidase precursor [Homo sapiens] >spQ99797Q99797 MITOCHONDRIAL INTERMEDIATE PEPTIDASE PRECURSOR (EC 3.4.24.59). Length = 713	gil1763642	1	432	74	77	HCWHT65	Prostate, Colon
700	H2CBN02R	mitochondrial matrix protein [Homo sapiens] >pirA32800A32800 chaperonin GroEL precursor - human >spP10809P60_HUMAN MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR (P60 LYMPHOCYTE PROTEIN) (60 KD CHAPERONIN) (HEAT SHOCK PROTEIN 60) (HSP-60) (PROTEIN CPN60) (gil190127	1	435	99	99	H2CBN02	Pancreas, Colon
701	H2CBV68R	mitochondrial matrix protein [Homo sapiens] >pirA32800A32800 chaperonin GroEL precursor - human >spP10809P60_HUMAN MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR (P60 LYMPHOCYTE PROTEIN) (60 KD CHAPERONIN) (HEAT SHOCK PROTEIN 60) (HSP-60) (PROTEIN CPN60) (gil190127	2	406	100	100	H2CBV68	Colon, Breast/Ovarian

702	H6EDK07R	Mr 110,000 antigen [Homo sapiens] >pir I52703 I52703 42K membrane glycoprotein - human >sp Q16186 G100_HUMAN I10 KD CELL MEMBRANE GLYCOPROTEIN. Length = 407	gn PID d1011683	1	252	90	90	H6EDK07	Lung, Breast/Ovarian
703	HACAH10R	NADH dehydrogenase subunit 2, ND2 [human, brain, Peptide Mitochondrial Partial Mutant, 67 aa] [Homo sapiens] >sp Q36734 Q36734 NADH DEHYDROGENASE SUBUNIT 2 (FRAGMENT). Length = 67	bbs 75898	1	66	89	96	HACAH10	Lung, Pancreas, Colon
704	HCCMC56R	NADH-UBIQUINONE OXIDOREDUCTASE B18 SUBUNIT (EC 1.6.5.3) (COMPLEX I-B18) (CI-B18) (CELL ADHESION PROTEIN SQM1). Length = 134	sp P17568 NB8M_HUMAN	16	351	83	83	HCCMC56	Lung, Colon, Breast/Ovarian
705	H2CBN54R	NADH-ubiquinone oxidoreductase B22 subunit (C-terminal) [human, placenta, Peptide Mitochondrial Partial, 179 aa] [Homo sapiens] Length = 179	bbs 178894	2	427	99	99	H2CBN54	Pancreas, Colon
706	HMCGL12R	NMB gene product [Homo sapiens] >pir I38065 I38065 gene NMB protein - human >sp Q14956 NMB_HUMAN PUTATIVE TRANSMEMBRANE PROTEIN NMB PRECURSOR. Length = 560	gi 666043	96	389	76	80	HMCGL12	Lung, Pancreas
707	HWHPX50R	nucleolar protein [Mus musculus] >pir I52858 I52858 nucleolar protein - mouse >sp Q61937 NPM_MOUSE NUCLEOPHOSMIN (NPM) (NUCLEOLAR PHOSPHOPROTEIN B23) (NUMATRIN) (NUCLEOLAR PROTEIN NO38). Length = 292	gi 200011	1	414	87	87	HWHPX50	Lung, Pancreas, Colon, Breast/Ovarian

708	HAPQD84R		115	267		HAPQD84	Lung, Pancreas, Colon, Breast/Ovarian
709	HLIBN66R		1	219		HLIBN66	Lung, Pancreas
710	HE2BD84R	OSF-2p1 [Homo sapiens] >pir S36111 S36111 osteoblast-specific factor 2 - human >sp Q15064 Q15064 OSF-2P1. Length = 779	2	394	77	HE2BD84	Pancreas, Colon, Breast/Ovarian
711	HLQFY45R	pancreatitis-associated protein [Homo sapiens] >gi 312807 preprotein [Homo sapiens] >bbs 121222 PAP-H=pancreatitis-associated protein [human, pancreas, Peptide, 175 aa] [Homo sapiens] >gnl PID d1003233 PAP homologous protein [Homo sapiens] >pir A49616 A49	57	374	60	HLQFY45	Pancreas, Colon
712	HAMGQ78R	phosphate carrier isoform A (alternatively spliced, exon IIIA) - human >sp Q00325 MPCP_HUMAN MITOCHONDRIAL PHOSPHATE CARRIER PROTEIN PRECURSOR. Length = 362	2	352	82	HAMGQ78	Lung, Colon
713	HODEV64R	poly(A)-binding protein [Homo sapiens] >gi 1562511 poly(A)-binding protein [Homo sapiens] >sp P11940 PAB1_HUMAN POLYADENYLATE-BINDING PROTEIN 1 (POLY(A) BINDING PROTEIN 1) (PABP 1). Length = 636	1	492	97	HODEV64	Lung, Pancreas

714	H2C1BD48R	precursor polypeptide (AA -21 to 782) [Homo sapiens] >pir A35954 A35954 endoplasmin precursor - human >sp P14625 ENPL_HUMAN ENDOPLASMIN PRECURSOR (94 KD GLUCOSE-REGULATED PROTEIN) (GRP94) (GP96 HOMOLOG) (TUMOR REJECTION ANTIGEN 1). Length = 803	gj 37261	2	499	95	97	H2C1BD48	Pancreas, Colon
715	HCCMA82R	procarboxypeptidase B [Homo sapiens] >pir A42332 A42332 carboxypeptidase B (EC 3.4.17.2) precursor, pancreatic - human Length = 416	gj 189625	3	383	94	94	HCCMA82	Pancreas, Colon
716	HOEMK78R	prostaeyelin-stimulating factor, PG12-stimulating factor, PSF [human, cultured diploid fibroblast cells, Peptide, 282 aa] [Homo sapiens] >pir S5003 S50031 prostaeyelin-stimulating factor - human >sp Q16270 Q16270 PROSTACYCLIN-STIMULATING FACTOR. Length =	bbs 161346	3	329	95	95	HOEMK78	Lung, Pancreas
717	H2CBD13R	proteasome subunit C9 [Homo sapiens] >pir S15972 SNHUC9 multicatalytic endopeptidase complex (EC 3.4.99.46) chain C9 - human >sp P25789 PRC9_HUMAN PROTEASOME COMPONENT C9 (EC 3.4.99.46) (MACROPAIN SUBUNIT C9) (MULTICATALYTIC ENDOPEPTIDASE COMPLEX SUBUNIT	gnl PID d1001118	156	461	100	100	H2CBD13	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
718	HCFMU61R	protein-tyrosine kinase (EC 2.7.1.112) ZAP-70 - human Length = 619	pir A44266 A44266	1	477	98	98	HCFMU61	Pancreas, Colon

719	HIOSNE94R	proteoglycan core protein [Homo sapiens] >pir/A45016 NBHUC8 decorin precursor - human >sp P07585 PGS2_HUMAN BONE PROTEOGLYCAN II PRECURSOR (PG-S2) (DECORIN) (PG40). >gil1161226 decorin [Rattus norvegicus] {SUB 204-299} Length = 359	2	466	85	85	HIOSNE94	Lung, Pancreas
720	HCROZ08R	putative precursor (AA 1-304) [Homo sapiens] >gn PID e224276 uracil-DNA-glycosylase, UNG1 [Homo sapiens] >pir S05964 A60472 uracil-DNA glycosylase (EC 3.-.-) precursor - human >gn PID e1296296 MITOCHONDRIAL LOCALIZATION PEPTIDE [unidentified] {SUB 1-3	3	218	100	100	HCROZ08	Lung, Pancreas, Colon
721	HIIBEF47R	pyruvate dehydrogenase E1-alpha precursor [Homo sapiens] >pir/A60225 A60225 pyruvate dehydrogenase (lipoamide) (EC 1.2.4.1) alpha chain - bovine (fragment) {SUB 54-74} Length = 414	1	330	88	88	HIIBEF47	Colon, Breast/Ovarian
722	HTXPI31R	pyruvate kinase M2 [Sus scrofa] >sp Q29582 Q29582 PYRUVATE KINASE M2 (EC 2.7.1.40) (PHOSPHOENOLPYRUVATE KINASE) (PHOSPHOENOL TRANSPHOSPHORYLASE) (FRAGMENT). Length = 108	2	286	84	85	HTXPI31	Pancreas, Breast/Ovarian
723	HOEKC30R	rhoC coding region (AA 1-193) [Homo sapiens] >gil407699 GTPase [Homo sapiens] >pir S01029 TVHUURC GTP-binding protein rhoC - human Length = 193	2	151	94	94	HOEKC30	Lung, Pancreas, Breast/Ovarian
724	HOSNR67R	ribosomal protein small subunit [Homo sapiens] Length = 264	1	483	97	98	HOSNR67	Lung, Pancreas

725	H2LAV92R	ribosomal protein [Homo sapiens] >gi 57078 ribosomal protein L38 [Rattus rattus] >pir S15658 R5RT38 ribosomal protein L38 - rat >pir S38385 S38385 ribosomal protein L38 - human >gnl P11 d1026783 (AB007185) ribosomal protein L38 [Homo sapiens] {SUB 34-70}	gi 407423	13	351	72	72	H2LAV92	Lung, Pancreas, Prostate, Colon, Breast/Ovarian
726	H2LAO74R	ribosomal protein L10 [Homo sapiens] >sp D102677 D1026771 RIBOSOMAL PROTEIN L15 (FRAGMENT). {SUB 16-57} Length = 205	gi 414587	359	502	83	83	H2LAO74	Lung, Pancreas, Colon, Breast/Ovarian
727	HKMMF85R	ribosomal protein L18a [Homo sapiens] >gi 3702270 (AC005796) ribosomal protein L18a [Homo sapiens] >gnl PID d1029536 (AB007175) ribosomal protein L18a [Homo sapiens] {SUB 111- 176} Length = 176	gi 401845	1	360	96	96	HKMMF85	Lung, Breast/Ovarian
728	HCLBZ27R	ribosomal protein L19 [Homo sapiens] >bbs 127872 ribosomal protein L19 [human, breast cancer cell line, MCF-7, Peptide, 196 aa] [Homo sapiens] >gi 206726 ribosomal protein L19 [Rattus norvegicus] >gnl PID e218038 ribosomal protein L19 [Rattus norvegicus]	gi 36128	19	273	93	98	HCLBZ27	Lung, Pancreas, Colon
729	H2LAV11R	ribosomal protein L21 [Homo sapiens] >gi 984143 ribosomal protein L21 [Homo sapiens] >pir S55913 S55913 ribosomal protein L21, cytosolic - human >sp D1026774 D1026774 RIBOSOMAL PROTEIN L21 (FRAGMENT). {SUB 124-154} Length = 160	gi 550015	126	530	99	99	H2LAV11	Lung, Pancreas, Colon

730	HBAGP60R	ribosomal protein L27 [Homo sapiens] >gi3115335 ribosomal protein L27 [Homo sapiens] >gi57694 ribosomal protein L27 (AA 1 - 136) [Rattus norvegicus] >gi62981 ribosomal protein L27 [Gallus gallus] >pir[S0040]R5RT27 ribosomal protein L27, cytosolic - ra	gi388769	161	373	66	70	HBAGP60	Pancreas, Colon
731	HOEMJ56R	ribosomal protein L28 [Homo sapiens] >pir[S55915]S55915 ribosomal protein L28 - human Length = 137	gi550019	3	206	94	94	HOEMJ56	Lung, Colon, Breast/Ovarian
732	HA5AF77R	ribosomal protein L31 [Sus scrofa] >gi36130 ribosomal protein L31 (AA 1-125) [Homo sapiens] >gi57115 ribosomal protein L31 (AA 1-125) [Rattus norvegicus] >pir[S05576]R5HU31 ribosomal protein L31 - human >pir[A26417]R5RT31 ribosomal protein L31 - rat >gn	gn PID e276436	1	381	82	82	HA5AF77	Lung, Prostate, Colon, Breast/Ovarian
733	H2MAC95R	ribosomal protein L37 [Homo sapiens] >bbs172744 ribosomal protein L37 {C2-C2 zinc-finger-like} [human, HeLa cells, Peptide, 97 aa] [Homo sapiens] >gn PID d1005426 ribosomal protein L37 [Homo sapiens] >gi57121 ribosomal protein L37 [Rattus norvegicus] >	gi292441	67	411	79	79	H2MAC95	Lung, Colon, Breast/Ovarian
734	HDPLP40R	ribosomal protein L37 [Homo sapiens] >bbs172744 ribosomal protein L37 {C2-C2 zinc-finger-like} [human, HeLa cells, Peptide, 97 aa] [Homo sapiens] >gn PID d1005426 ribosomal protein L37 [Homo sapiens] >gi57121 ribosomal protein L37 [Rattus norvegicus] >	gi292441	1	363	100	100	HDPLP40	Lung, Pancreas, Breast/Ovarian

735	HOEMK92R	ribosomal protein L37a [Homo sapiens] >gi 36134 ribosomal protein L37a [Homo sapiens] >gi 57123 ribosomal protein L37a (AA 1 - 92) [Rattus rattus] >gi 312414 ribosomal protein L37a [Mus musculus] >pir S05014 R5RT37 ribosomal protein L37a - rat >pir S42109	gi 292439	3	185	96	96	HOEMK92	Lung, Pancreas, Breast/Ovarian
736	HABAD57R	ribosomal protein L4 [Homo sapiens] >pir S39803 S39803 ribosomal protein L4 - human Length = 425	gi 307385	210	431	80	90	HABAD57	Lung, Pancreas
737	HLXNA52R	ribosomal protein L4 [Rattus norvegicus] Length = 421	gnl PID e121603	3	296	86	86	HLXNA52	Lung, Pancreas
738	HWAFK82R	ribosomal protein L9 [Homo sapiens] >gnl PID d1003911 "human homologue of rat ribosomal protein L9" [Homo sapiens] Length = 192	gi 710366	139	354	77	78	HWAFK82	Lung, Colon, Breast/Ovarian
739	H2CBL68R	ribosomal protein S13 [Homo sapiens] >gi 488417 ribosomal protein S13 [Homo sapiens] >gnl PID d1014222 ribosomal protein S13 [Homo sapiens] >gi 57730 ribosomal protein S13 [Rattus rattus] >pir S34109 S34109 ribosomal protein S13, cytosolic - human >pir A3	gi 307391	3	461	100	100	H2CBL68	Lung, Pancreas
740	HINTNE17R	ribosomal protein S17 [Homo sapiens] >gi 337503 S17 ribosomal protein [Homo sapiens] >pir JT0405 R4HU17 ribosomal protein S17, cytosolic - human Length = 135	gi 337501	1	387	100	100	HINTNE17	Lung, Pancreas, Breast/Ovarian
741	HBJLR37R	ribosomal protein S26 [Homo sapiens] Length = 115	gi 296452	2	328	98	100	HBJLR37	Pancreas, Colon, Breast/Ovarian

742	HOSNG20R	ribosomal protein S4X isoform [Homo sapiens] >gi 2791861 (AF041428) ribosomal protein s4 X isoform [Homo sapiens] >gi 200864 ribosomal protein S4 [Mus musculus] >gi 57135 ribosomal protein S4 (AA 1 - 263) [Rattus rattus] >gnl P1D d1002335 ribosomal protei	gi 337510	1	357	97	98	HOSNG20	Lung, Pancreas, Colon, Breast/Ovarian
743	HCLBZ30R	ribosomal protein S5 [Mus musculus] Length = 204	gi 1685071	2	244	89	89	HCLBZ30	Lung, Pancreas, Colon, Breast/Ovarian
744	HBGNY11R	ribosomal protein S8 [Homo sapiens] >gi 57139 ribosomal protein S8 (AA 1-208) [Rattus norvegicus] >gi 313298 ribosomal protein S8 [Mus musculus] >pir S01609 R3RT8 ribosomal protein S8 - rat >pir S42110 S42110 ribosomal protein S8 - mouse >pir S25022 S2502	gi 36150	2	334	100	100	HBGNY11	Lung, Pancreas, Breast/Ovarian
745	HOEKC80R	S19 ribosomal protein [Homo sapiens] >pir 52692 52692 ribosomal protein S19, cytosolic - human Length = 145	gi 337733	2	376	98	98	HOEKC80	Lung, Pancreas, Colon, Breast/Ovarian
746	HCHBM70R	secretory protein [Homo sapiens] >gi 940946 intestinal trefoil factor [Homo sapiens] >pir A48284 A48284 intestinal trefoil factor 3 precursor - human >sp Q07654 TF_HUMAN INTESTINAL TREFOIL FACTOR PRECURSOR (HPI.B). Length = 80	gi 402483	1	114	57	57	HCHBM70	Colon, Breast/Ovarian
747	HFCES53R	semaphorin C [Mus musculus] >pir 148746 148746 semaphorin C - mouse (fragment) >sp Q62179 Q62179 SEMAPHORIN C (SEM C) (FRAGMENT). Length = 782	gi 854328	1	165	80	86	HFCES53	Colon, Breast/Ovarian

748	HCRQC92R	spermidine/spermine N1-acetyltransferase [Homo sapiens] >gi 338336 spermidine/spermine N1-acetyltransferase [Homo sapiens] >sp P21673 A_TDA_HUMAN DIAMINE ACETYLTRANSFERASE (EC 2.3.1.57) (SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE) (SSAT) (PUTRESCINE ACETYL	gi 338392	3	278	98	98	HCRQC92	Lung, Colon, Breast/Ovarian
749	HAOAG75R	TARBP-b gene product [Homo sapiens] Length = 277	gi 347964	2	418	100	100	HAOAG75	Lung, Colon
750	HWAFF36R	TEGT gene product [Homo sapiens] >pir 38334 38334 TEGT (testis enhanced gene transcript) - human Length = 237	gi 458545	2	127	100	100	HWAFF36	Pancreas, Colon
751	HBGOU57R	TIMP gene product [Homo sapiens] >gi 182483 prefibroblast collagenase inhibitor [Homo sapiens] >gi 189382 collagenase inhibitor [Homo sapiens] >gi 37183 precursor [Homo sapiens] >pir A93372 ZYHUEP metalloproteinase tissue inhibitor 1 precursor - human >gi	gi 490094	60	314	75	75	HBGOU57	Lung, Pancreas, Breast/Ovarian
752	HTXPF20R	TIMP gene product [Homo sapiens] >gi 182483 prefibroblast collagenase inhibitor [Homo sapiens] >gi 189382 collagenase inhibitor [Homo sapiens] >gi 37183 precursor [Homo sapiens] >pir A93372 ZYHUEP metalloproteinase tissue inhibitor 1 precursor - human >gi	gi 490094	1	549	84	84	HTXPF20	Lung, Pancreas, Colon, Breast/Ovarian
753	HCRMD09R	transforming growth factor-beta 1 binding protein precursor [Homo sapiens] >pir A35626 A35626 transforming growth factor beta-1-binding protein - human Length = 1394	gi 339548	2	460	86	87	HCRMD09	Lung, Pancreas, Colon

754	HAJRB47R	triose-phosphate isomerase [Pan troglodytes] >gi 37247 triosephosphate isomerase [Homo sapiens] >gi 1200507 triosephosphate isomerase [Homo sapiens] >gi 339841 triosephosphate isomerase (EC 5.3.1.1) [Homo sapiens] >pir S29743 ISHUT triose-phosphate isomer	gil176960	2	334	100	100	HJRB47	Lung, Pancreas, Breast/Ovarian
755	HABGB36R			6	251			HABGB36	Lung, Breast/Ovarian
756	HADBF86R			3	158			HADBF86	Lung, Colon
757	HADDP09R			2	97			HADDP09	Lung, Pancreas, Colon, Breast/Ovarian
758	HAGCY06R			2	58			HAGCY06	Pancreas, Breast/Ovarian
759	HAGDI75R			1	66			HAGDI75	Colon, Breast/Ovarian
760	HAHBD47R			118	429			HAHBD47	Lung, Pancreas
761	HAHCR61R			165	422			HAHCR61	Pancreas, Colon
762	HAJAU22R			101	202			HAJAU22	Pancreas, Colon
763	HAMGB62R			212	370			HAMGB62	Lung, Pancreas, Colon, Breast/Ovarian
764	HANGC52R			3	98			HANGC52	Lung, Pancreas, Colon
765	HAPCF30R			2	94			HAPCF30	Lung, Colon
766	HAPPV45R			216	536			HAPPV45	Lung, Pancreas
767	HAPQK19R			200	415			HAPQK19	Lung, Pancreas
768	HAPRL82R			3	233			HAPRL82	Lung, Pancreas
769	HAQBT45R			40	255			HAQBT45	Lung, Colon
770	HAUAL56R			127	315			HAUAL56	Pancreas, Breast/Ovarian

771	HAUBR22R	2	67	HAUBR22	Pancreas, Colon, Breast/Ovarian
772	HBAFN19R	3	257	HBAFN19	Lung, Colon, Breast/Ovarian
773	HBGOK25R	274	528	HBGOK25	Pancreas, Colon
774	HBCRA76R	2	88	HBCRA76	Pancreas, Colon
775	HBCRB47R	1	111	HBCRB47	Lung, Pancreas, Colon, Breast/Ovarian
776	HBJAS24R	1	66	HBJAS24	Colon, Breast/Ovarian
777	HBJKI05R	207	362	HBJKI05	Pancreas, Colon
778	HBJKEC86R	254	409	HBJKEC86	Pancreas, Colon
779	HBLGD42R	3	341	HBLGD42	Lung, Pancreas, Colon, Breast/Ovarian
780	HBPAP10R	3	65	HBPAP10	Lung, Pancreas
781	HCDBU02R	65	184	HCDBU02	Pancreas, Colon
782	HCDBU04R	64	348	HCDBU04	Lung, Pancreas, Colon
783	HCDDT61R	2	121	HCDDT61	Pancreas, Colon
784	HCEGY65R	2	79	HCEGY65	Pancreas, Colon
785	HCHAK80R	1	513	HCHAK80	Colon, Breast/Ovarian
786	HCHMW79R	73	432	HCHMW79	Pancreas, Breast/Ovarian
787	HCHOB92R	93	350	HCHOB92	Colon, Breast/Ovarian
788	HCLBO01R	45	149	HCLBO01	Lung, Colon
789	HCQAN60R	3	122	HCQAN60	Pancreas, Colon
790	HCRAK70R	3	293	HCRAK70	Colon, Breast/Ovarian
791	HCRPC63R	1	129	HCRPC63	Pancreas, Colon
792	HCUDC51R	2	265	HCUDC51	Lung, Colon

793	HDPF140R	139	453	HDPF140	Lung, Pancreas, Breast/Ovarian
794	HDPLP23R	1	141	HDPLP23	Pancreas, Colon, Breast/Ovarian
795	IIDPRZ54R	1	165	IIDPRZ54	Colon, Breast/Ovarian
796	HE9DP46R	2	166	HE9DP46	Lung, Pancreas, Colon
797	HEGAR19R	361	534	HEGAR19	Lung, Colon
798	HFAUO64R	27	137	HFAUO64	Colon, Breast/Ovarian
799	HFIAL90R	186	308	HFIAL90	Lung, Colon
800	HHBEQ12R	218	514	HHBEQ12	Lung, Pancreas
801	HHEUL94R	2	127	HHEUL94	Lung, Pancreas, Colon
802	HISCF76R	16	153	HISCF76	Pancreas, Colon
803	HJMAU64R	1	207	HJMAU64	Lung, Colon
804	IIPC125R	275	508	IIPC125	Lung, Pancreas, Colon
805	HKBAC48R	369	542	HKBAC48	Lung, Pancreas, Colon, Breast/Ovarian
806	HKBAD57R	165	341	HKBAD57	Lung, Pancreas
807	HKDBA91R	3	332	HKDBA91	Pancreas, Colon
808	HKGDB80R	3	224	HKGDB80	Lung, Colon
809	HLDNC95R	289	537	HLDNC95	Lung, Pancreas, Prostate, Colon
810	HMSNI52R	2	271	HMSNI52	Lung, Pancreas
811	HODAY16R	134	298	HODAY16	Colon, Breast/Ovarian
812	HODEA57R	289	471	HODEA57	Lung, Pancreas
813	HOEMO27R	1	60	HOEMO27	Colon, Breast/Ovarian

814	HOEMO62R	2	73	HOEMO62	Pancreas, Breast/Ovarian
815	HOEMS18R	1	102	HOEMS18	Lung, Pancreas, Colon,
816	HOENU53R	115	267	HOENU53	Breast/Ovarian
817	HOGAP33R	1	498	HOGAP33	Lung, Colon Pancreas, Prostate, Breast/Ovarian
818	HOSMV34R	124	327	HOSMV34	Lung, Pancreas, Breast/Ovarian
819	HOSNF25R	405	587	HOSNF25	Pancreas, Colon
820	HOUHO32R	230	391	HOUHO32	Lung, Colon
821	HPIAC23R	2	286	HPIAC23	Lung, Breast/Ovarian
822	HRAAD31R	115	414	HRAAD31	Lung, Colon
823	HRACR12R	2	100	HRACR12	Pancreas, Colon
824	HRADJ57R	2	142	HRADJ57	Lung, Colon
825	HROAX48R	184	285	HROAX48	Pancreas, Colon
826	HTAHR87R	369	491	HTAHR87	Lung, Pancreas
827	HTTIO45R	1	288	HTTIO45	Colon, Breast/Ovarian
828	HTWDH05R	1	420	HTWDH05	Lung, Pancreas, Colon, Breast/Ovarian
829	HUFDS13R	51	152	HUFDS13	Pancreas, Colon
830	HUSZE86R	2	340	HUSZE86	Pancreas, Colon
831	HUTHF75R	161	418	HUTHF75	Lung, Pancreas, Breast/Ovarian
832	HWAFW07R	3	170	HWAFW07	Lung, Pancreas, Colon
833	HWLIB82R	209	403	HWLIB82	Pancreas, Colon
834	HWLX91R	147	302	HWLX91	Lung, Colon
835	HWLMZ54R	1	120	HWLMZ54	Pancreas, Colon

836	HM1A178R		173	319		HM1A178	Pancreas, Colon, Breast/Ovarian
837	HBGFJ39R	unknown product specific to adipose tissue [Homo sapiens] >sp Q15847 Q15847 HYPOTHETICAL 7.9 KD PROTEIN. Length = 76	1	153	100	HBGFJ39	Pancreas, Colon
838	HAMHH32R		1	123		HAMHH32	Lung, Colon
839	HAQBQ95R		104	205		HAQBQ95	Colon, Breast/Ovarian
840	HAGHY58R	URF 1 (NADH dehydrogenase subunit) [Homo sapiens] >gi 337189 protein 1 [Homo sapiens] >pir A00407 DNHUN1 NADH dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 1 - human mitochondrion (SGC1) >sp P03886 NUIIM_HUMAN NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 1 (EC 1.6	157	411	95	HAGHY58	Lung, Colon
841	HOSNE37R	URF 2 (NADH dehydrogenase subunit) [Homo sapiens] >gi 2052363 protein 2 [Homo sapiens] >gi 2582057 (AF014882) NADH dehydrogenase subunit 2 [Homo sapiens] >gi 2582061 (AF014884) NADH dehydrogenase subunit 2 [Homo sapiens] >gi 2582063 (AF014885) NADH dehydr	73	231	59	HOSNE37	Lung, Pancreas, Colon
842	HWAFE41R	VDUP1=1,25-dihydroxyvitamin D-3 up-regulated [human, HL-60 promyelocytic leukemia cells, Peptide, 391 aa] [Homo sapiens] Length = 391	2	508	84	HWAFE41	Pancreas, Colon

The first column of Table 1 shows the "SEQ ID NO:" for each of the 842 cancer antigen polynucleotide sequences of the invention.

The second column in Table 1, provides a unique "Sequence/Contig ID" identification for each cancer associated sequence. The third column in Table 1, "Gene Name," provides a putative identification of the gene based on the sequence similarity of its translation product to an amino acid sequence found in a publicly accessible gene database, such as GenBank (NCBI). The great majority of the cDNA sequences reported in Table 1 are unrelated to any sequences previously described in the literature. The fourth column, in Table 1, "Overlap," provides the database accession no. for the database sequence having similarity. The fifth and sixth columns in Table 1 provide the location (nucleotide position nos. within the contig), "Start" and "End", in the polynucleotide sequence "SEQ ID NO:X" that delineate the preferred ORF shown in the sequence listing as SEQ ID NO:Y. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by the nucleotide position nos. "Start" and "End". Also provided are polynucleotides encoding such proteins and the complementary strand thereto. The seventh and eighth columns provide the "% Identity" (percent identity) and "% Similarity" (percent similarity) observed between the aligned sequence segments of the translation product of SEQ ID NO:X and the database sequence.

The ninth column of Table 1 provides a unique "Clone ID" for a clone related to each contig sequence. This clone ID references the cDNA clone which contains at least the 5' most sequence of the assembled contig and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone. The reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods described elsewhere herein.

The tenth column of Table 1, "Tissue," provides the tissue source where each unique SEQ ID NO:X was found to be predominantly expressed.

Table 3 indicates public ESTs, of which at least one, two, three, four, five, ten, or more of any one or more of these public ESTs are optionally excluded from the invention.

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing as SEQ ID NO:1 through SEQ ID NO:842) and the translated SEQ ID NO:Y

(where Y may be any of the polypeptide sequences disclosed in the sequence listing as SEQ ID NO:843 through SEQ ID NO:1684) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X has uses including, but not limited to, in designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the related cDNA clone contained in a library deposited with the ATCC. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y have uses that include, but are not limited to, generating antibodies which bind specifically to the cancer antigen polypeptides, or fragments thereof, and/or to the cancer antigen polypeptides encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing the related cDNA clone (deposited with the ATCC, as set forth in Table 1). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.

The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to vectors or plasmids which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC on:

5 **Table 2**

ATCC Deposits	Deposit Date	ATCC Designation Number
LP01, LP02, LP03, LP04, LP05, LP06, LP07, LP08, LP09, LP10, LP11,	May-20-97	209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069
LP12	Jan-12-98	209579
LP13	Jan-12-98	209578
LP14	Jul-16-98	203067
LP15	Jul-16-98	203068
LP16	Feb-1-99	203609
LP17	Feb-1-99	203610
LP20	Nov-17-98	203485
LP21	Jun-18-99	PTA-252
LP22	Jun-18-99	PTA-253
LP23	Dec-22-99	PTA-1081

each is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as shown in Table 5. These deposits are referred to as "the deposits" herein. The tissues from which the clones were derived are listed in Table 5, and the vector in which the cDNA is contained is also indicated in Table 5. The deposited material includes the cDNA clones which were partially sequenced and are related to the SEQ ID NO:X described in Table 1 (column 9). Thus, a clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Although the sequence listing lists only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to complete the sequence of the DNA included in a clone isolatable from the

ATCC Deposits by use of a sequence (or portion thereof) listed in Table 1 by procedures hereinafter further described, and others apparent to those skilled in the art.

Also provided in Table 5 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., *Nucleic Acids Res.* 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., *Nucleic Acids Res.* 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., *Strategies* 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into *E. coli* strain XL-1 Blue, also available from Stratagene.

Vectors pSport1, pCMVSPORT 1.0, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the cDNA contained in a deposited cDNA clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the cDNA contained in the related cDNA clone in the deposit, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the related cDNA clone (See, e.g., columns 1 and 9 of Table 1). The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in a deposited library. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by the the dDNA in the related cDNA clone contained in a deposited library, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the related cDNA clone contained in a deposited library.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would unduly burden the disclosure of this application. Accordingly, for each "Contig Id" listed in the first column of Table 3, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described in the second column of Table 3 by the general formula of a-b, each of which are uniquely defined for the SEQ ID NO:X corresponding to that Contig Id in Table 1. Additionally, specific embodiments are directed to polynucleotide sequences excluding at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. for each Contig Id which may be

included in column 3 of Table 3. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example.

Table 3.

Sequence/ Contig ID	General formula	Genbank Accession No.
507291	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 542 of SEQ ID NO:1, b is an integer of 15 to 556, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:1, and where b is greater than or equal to a + 14.	
508000	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2648 of SEQ ID NO:2, b is an integer of 15 to 2662, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:2, and where b is greater than or equal to a + 14.	T40333, T41194, T66286, T66339, T73997, T86453, T87207, R17614, R19835, R43336, R45934, R48920, R53521, R43336, R45934, R61813, R75928, R75937, H30115, H42959, H39114, H43825, AA028010, AA028107, AA028148, AA031964, AA032046, AA035668, AA190570, AA233781, AA461489, AA460726, AA460898
518325	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 324 of SEQ ID NO:3, b is an integer of 15 to 338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:3, and where b is greater than or equal to a + 14.	
523111	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 799 of SEQ ID NO:4, b is an integer of 15 to 813, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:4, and where b is greater than or equal to a + 14.	
526869	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 887 of SEQ ID NO:5, b is an integer of 15 to 901, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:5, and where b is greater than or equal to a + 14.	AA459771
532211	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 717 of SEQ ID NO:6, b is an integer of 15 to 731, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:6, and where b is greater than or equal to a + 14.	H30209, H92182, W95693, W95692, AA196967
532247	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	R14583, R93797, H52942, H75493, H78857, W17094, W38705, W81551, W90159, N90874, AA010244,

	where a is any integer between 1 to 2760 of SEQ ID NO:7, b is an integer of 15 to 2774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:7, and where b is greater than or equal to a + 14.	AA029093, AA126501, AA147066
537932	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2599 of SEQ ID NO:8, b is an integer of 15 to 2613, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:8, and where b is greater than or equal to a + 14.	T91131, T84801, T85952, R59198, R59256, H43456, H59480, H79111, N26560, N35676, N64506, N66078, N76033, N78705, W07594, W70111, W70169, N90844, AA026910, AA026911, AA057689, AA079631, AA079805, AA131257, AA136081, AA165115, AA210764, AA211886, AA232838, AA262352
540117	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1087 of SEQ ID NO:9, b is an integer of 15 to 1101, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:9, and where b is greater than or equal to a + 14.	T49371, T49372, T49850, T61568, T64892, N39534, W57682, AA031859
547710	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:10, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:10, and where b is greater than or equal to a + 14.	R11154, R11155, R61204, R61205, R82674, H06105, R88575, R88638, H89977, H97031, N20224, W01143, W39387, W90318, W90788, AA001027, AA045864, AA045839, AA070190, AA070357, AA070481, AA074270, AA099007, AA099084, AA100370, AA112324, AA113319, AA158425, AA161510, AA171909, AA172133, AA173087, AA181768, AA188815, AA188874, AA190370, AA226831, AA252143
551747	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3790 of SEQ ID NO:11, b is an integer of 15 to 3804, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.	
552799	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2143 of SEQ ID NO:12, b is an integer of 15 to 2157, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.	
553243	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1103 of SEQ ID NO:13, b is an integer of 15 to 1117, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is	H63183, W61352, AA151059

	greater than or equal to $a + 14$.	
553368	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 871 of SEQ ID NO:14, b is an integer of 15 to 885, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to $a + 14$.	
554349	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1010 of SEQ ID NO:15, b is an integer of 15 to 1024, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to $a + 14$.	
558491	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 531 of SEQ ID NO:16, b is an integer of 15 to 545, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to $a + 14$.	
558983	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 609 of SEQ ID NO:17, b is an integer of 15 to 623, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to $a + 14$.	
572943	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 545 of SEQ ID NO:18, b is an integer of 15 to 559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to $a + 14$.	
585892	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1341 of SEQ ID NO:19, b is an integer of 15 to 1355, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to $a + 14$.	
589390	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1266 of SEQ ID NO:20, b is an integer of 15 to 1280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to $a + 14$.	T47628, T49403, T49829, T49830, T50800, T50963, T51976, T55846, T55860, T55896, T55911, T58744, T58811, T58891, T59252, T59279, T59293, T59615, T59690, T59727, T59826, T60434, T60514, T60584, T61357, T40352, T62559, T62688, T62839, T63122, T64603, T64640.

		T67682, T67756, T68181, T68439, T68506, T68606, T68718, T68783, T68839, T68849, T68976, T69049, T71223, T71347, T71509, T71853, T71858, T71938, T72197, T72264, T72414, T72471, T72923, T73204, T73259, T73283, T73446, T73607, T73621, T73645, T73713, T73744, T73772, T73796, T74114, T74545, T74599, T87829, T90307, T90394, T91481, T92437, T92617, T81767, T82080, R27059, R27060, R31693, R31735, R50548, R50646, R64321, R64322, R75660, R75768, R75866, R76038, R79765, R79766, H22209, H24391, H25902, H27236, H28585, H29860, H29954, H41994, H42226, H42298, H43069, H43893, H43934, R83465, R84983, R94905, R94988, R96360, R96403, R97059, R98674, R98900, R99186, R99187, H50701, H50801, H57754, H62182, H63649, H63650, H64755, H64756, H69075, H70056, H70057, H70855, H70856, H71581, H75758, H75893, H80974, H80975, H83141, H83142, H83271, H85046, H84668, H91780, H92207, H92350, H94891, H94943, H94966, H95486, H99418, N52264, N58261, N74184, N77638, N81021, N92261, N99137, W04350, W07850, W16893, W39467, W45038, W47174, W47433, W52853, W63782, W67635, W67759, W67868, W67881, W93706, W94183, W96351, W96352, N89587, AA012898, AA019884, AA020863, AA025865, AA025866, AA056092, AA057434, AA070445, AA192155, AA192879, AA226741, AA227477
596882	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1177 of SEQ ID NO:21, b is an integer of 15 to 1191, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.	
616289	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 839 of SEQ ID NO:22, b is an integer of 15 to 853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.	
622140	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	W39497, W52751, AA099814, AA128882, AA173072, AA226739

	sequence described by the general formula of a-b, where a is any integer between 1 to 460 of SEQ ID NO:23, b is an integer of 15 to 474, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.	
623566	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2266 of SEQ ID NO:24, b is an integer of 15 to 2280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.	
647714	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1047 of SEQ ID NO:25, b is an integer of 15 to 1061, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.	
647752	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1558 of SEQ ID NO:26, b is an integer of 15 to 1572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.	
651774	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1991 of SEQ ID NO:27, b is an integer of 15 to 2005, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.	T69901, T69949, T70775, R20554, R33030, R33917, R48406, H58331, H58720, H67041, H68124, H93586, H94430, H94513, H97468, H99219, N23459, N26334, N35428, N49203, N50256, N64246, N93349, W19550, W19996, W25330, W73940, W77984, W93791, W94028, N90424, AA025537, AA025680, AA025371, AA026317, AA026318, AA084549, AA086048, AA086130, AA098995, AA099068, AA115309, AA136486, AA151843, AA149689, AA148825, AA150406, AA150425, AA173377
651995	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1394 of SEQ ID NO:28, b is an integer of 15 to 1408, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.	
652156	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 903 of SEQ ID NO:29, b is an integer of 15 to 917, where both a and	T40364, R22492, R49907, R49908, R62310, R62311, R65652, R67030, R81699, R81700, H18589, H20024, H20099, H20123, H20797, H22404, H22615, H25816, H27051, H42294,

	b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.	H44827, H49661, H51422, H51465, H56482, H56483, H70295, H86037, H93528, H93860, H96113, H96114, N22715, N31188, N33831, N54495, N70601, N70623, N76607, N78626, W04920, W05505, W07305, W15350, W39442, W60859, W60860, W72726, W76452, AA017463, AA024543, AA024544, AA026421, AA026498, AA027270, AA034429, AA046316, AA046142, AA053920, AA056230, AA063244, AA062885, AA085305, AA128171, AA126216, AA149890, AA150552, AA187825, AA188597, AA417004, AA417190
653010	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 563 of SEQ ID NO:30, b is an integer of 15 to 577, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.	
655904	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:31, b is an integer of 15 to 2059, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.	T61561, T90265, T90707, R09280, R17627, R43348, R54854, R54658, H20872, H27229, H64571, H64673, H64571, N47495, N54722, N75461, W73679, AA010711, AA010712, AA082107, AA130516, AA132052, AA132156, AA147852, AA147908, AA148276, AA148277, AA181933, AA187549, AA187845, AA186675, AA188310, AA193212
657852	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 535 of SEQ ID NO:32, b is an integer of 15 to 549, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.	
666414	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 827 of SEQ ID NO:33, b is an integer of 15 to 841, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.	
667847	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 849 of SEQ ID NO:34, b is an integer of 15 to 863, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.	T47009, T47010, T55133, T55301, T57663, T57702, T59664, T59797, T59800, T49370, T72020, T26631, R22343, R46325, R48879, R50151, R50204, R55208, R71485, R71535, R72144, R72362, R72553, R74062, H13587, H16167, H18121, H20172, H20361, H22514, H40774, H40775,

		H42435, H42865, H43100, H43164, H45140, H45441, H46013, H46083, H46159, R97084, R97131, H56498, H60260, H60567, H67238, H71802, H77325, H77338, H81556, H87775, H87825, H91889, H92057, H93187, H96056, H96420, H81556, H99575, N21484, N23829, N24221, N26831, N27079, N27278, N27582, N30213, N30255, N31642, N31989, N31996, N32655, N32790, N35515, N38983, N39859, N40012, N40488, N41792, N41978, N54988, N57097, N70071, N77176, N78930, N80037, N80573, N81058, N92768, N93810, W07000, W07659, W07868, W44961, W44962, W58175, W58263, W58182, AA001206, AA017579, AA026640, AA026706, AA057605, AA058758, AA082491, AA084088, AA086460, AA100968, AA112029, AA121337, AA121500, AA130704, AA130790, AA152420, AA156094, AA156123, AA181929, AA182575, AA182617, AA186931, AA195982, AA253952, AA283976, AA426098, AA425122, AA428823, AA429359
670188	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1216 of SEQ ID NO:35, b is an integer of 15 to 1230, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.	
670279	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 626 of SEQ ID NO:36, b is an integer of 15 to 640, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.	T50781, T51265, T55324, T56327
670729	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 583 of SEQ ID NO:37, b is an integer of 15 to 597, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.	
674123	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 610 of SEQ ID NO:38, b is an integer of 15 to 624, where both a and b correspond to the positions of nucleotide residues	

	shown in SEQ ID NO:38. and where b is greater than or equal to a + 14.	
676496	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1015 of SEQ ID NO:39, b is an integer of 15 to 1029, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.	
678162	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1093 of SEQ ID NO:40, b is an integer of 15 to 1107, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.	T40233, T40521, T41098, T47133, T47529, T49156, T49157, T51636, T55352, T55402, T55422, T57649, T59314, T62530, T62806, T62954, T72271, T73592, T89655, T78884, R19194, R89249, R93164, H57861, H93645, N22493, N26661, N32984, N63146, N66448, N67443, N69984, N72141, N77952, N78933, N81091, N95826, W02074, W24850, W24972, W38365, W44897, W57997, W58080, W65414, W65435, W74634, AA007562, AA009767, AA022918, AA022939, AA025169, AA029717, AA029656, AA032096, AA040581, AA046091, AA070493, AA070646, AA070707, AA071405, AA071414, AA074752, AA075706, AA075696, AA079282, AA085620, AA100126, AA126795, AA128838, AA136579, AA143069, AA143200, AA146637, AA147370, AA147705, AA156001, AA157342, AA161090, AA164798, AA179749, AA187235, AA188048, AA187029, AA188384, AA192271, AA196973, AA235468, AA243180, AA459416, AA459642
678248	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1037 of SEQ ID NO:41, b is an integer of 15 to 1051, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.	
683668	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2178 of SEQ ID NO:42, b is an integer of 15 to 2192, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.	T49549, T49550, T49700, T49912, T49937, T50912, T51558, T53285, T53375, T53376, T53721, T54314, T54840, T55217, T56413, T99069, T99669, R01522, R31653, R32820, R32921, R35743, R50997, R64077, R65723, R69349, R71009, R72798, R72824, R76854, R77142, R79240, R79511, R80194, R80295, R81155, H39823, H39824, R84909, R85592, R91193, H50793, H52341, H53594, H53916, H92997, N26572, N32090,

		N32406, N34179, N36271, N45401, N49216, N50267, N67233, N67568, N72254, N75478, N93355, N94504, W00543, W05288, W05816, W23954, W24625, W24650, W25354, W49666, W52302, AA121852, AA121851, AA128593, AA128712, AA136731, AA136688, AA167235, AA167584, AA173693, AA176648, AA176804, AA179999, AA181456, AA181457, AA256158, AA256215, AA256247, AA458729, AA458778, AA464936, AA464937
693172	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 339 of SEQ ID NO:43, b is an integer of 15 to 353, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.	T49005, T50129, T54766, T59468, T71241, T89633, R66699, R67578, H25853, H26090, H41256, H43182, H45273, N58288, N95319, AA054338, AA057604, AA084261
694303	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3476 of SEQ ID NO:44, b is an integer of 15 to 3490, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.	
695042	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 767 of SEQ ID NO:45, b is an integer of 15 to 781, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.	
699799	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1417 of SEQ ID NO:46, b is an integer of 15 to 1431, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.	T50599, R25615, R31078, R68513, R70896, R75848, R76864, R76865, H01087, H26949, H63077, H75713, H75642, H95014, H98885, N24938, N33815, N47174, N47897, N51152, N53997, N59590, N62387, N63017, N67836, N69948, N78655, N79355, N94343, N98329, W01767, W03440, W15144, W19292, W25534, W37911, W42857, W42912, W48630, W72791, W76438, W81113, W80546, W80525, W80526, W84575, W84645, AA010674, AA011261, AA026981, AA031662, AA039737, AA039810, AA040524, AA040523, AA046308, AA046396, AA099365, AA101915, AA129310, AA129354, AA131951, AA186409
702216	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	T64167, T64355, T68409, T68475, T73691, T73717, T97735, T97840,

	sequence described by the general formula of a-b, where a is any integer between 1 to 1899 of SEQ ID NO:47, b is an integer of 15 to 1913, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.	T98899, T99491, R00460, R01214, R01326, H45786, R93124, R96609, H61118, H61119, H61454, H62460, H64003, H64052, H91078, H91378, N58480, N64695, N65991, N74260, N78070, N79244, N91708, N95101, W03761, W04301, N90479, AA130077, AA130076, AA152275, AA150441
703015	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1747 of SEQ ID NO:48, b is an integer of 15 to 1761, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.	R72819, R73270, H43839, W47195, W52204, AA242894, AA424584, AA424629
706391	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 942 of SEQ ID NO:49, b is an integer of 15 to 956, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.	T48974, H26922, H30342, H44743, H45233, R88178, H81778, H92363, N29006, N44860, N46515, AA079547, AA158434, AA160590, AA428285
706892	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 549 of SEQ ID NO:50, b is an integer of 15 to 563, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.	
706924	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3201 of SEQ ID NO:51, b is an integer of 15 to 3215, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.	T68892, T68966, T75421, R15205, R16398, R41650, R42339, R52995, R52996, R41650, H12000, H16753, H16861, H27652, H27653, H27982, H28497, H29323, H29416, H85752, H98511, N22580, N24339, N28586, N42727, N50084, N75803, N78815, W07245, W21306, W23840, W57924, W58128, W72277, W76304, W86460, AA002243, AA002080, AA025565, AA025683, AA026606, AA026718, AA150696, AA150801
707642	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 612 of SEQ ID NO:52, b is an integer of 15 to 626, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.	
710369	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 906 of SEQ ID NO:53, b is an integer of 15 to 920, where both a and	T48815, T60685, T91108, T99835, AA150217, AA157340, AA157240, AA171947

	b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.	
718826	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1076 of SEQ ID NO:54, b is an integer of 15 to 1090, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.	
719790	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1450 of SEQ ID NO:55, b is an integer of 15 to 1464, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.	T47380, T47538, T47539, T53445, T53446, T54910, T55077, T59959, T60032, T62504, T62649, T63049, T63297, T63382, T65688, T71591, T71742, T93094, T93187, T94131, T94222, T91210, T84959, T99044, T99045, R26119, R26148, R33224, R35866, R36526, R53923, R53924, R69596, R69684, R76209, R76210, R79249, R79521, H03427, H03507, H12529, H13501, H19016, H19310, H21587, H21652, H21653, H30119, H39693, H42698, H46635, R93371, R98210, R99855, H54120, H54786, H54837, H58991, H65355, H65566, H67613, H72632, H74102, H95312, N48235, N58029, N64226, N66907, N70763, N78303, N93848, N94316, N95432, N98433, W01816, W02218, W05772, W21419, W24044, W24297, W30823, W32382, W37228, W37317, W40321, W42528, W46445, W49731, W51944, W53011, W53012, W60051, W60129, W60154, W68332, W68216, W72730, W74593, W92813, W93310, AA010985, AA011307, AA031435, AA035708, AA037040, AA053073, AA053374, AA055567, AA069724, AA069690, AA069682, AA069900, AA069951, AA070693, AA071421, AA074606, AA075555, AA075673, AA075544, AA081017, AA081251, AA081428, AA082119, AA082022, AA082213, AA082241, AA082247, AA082400, AA082365, AA082438, AA082679, AA083225, AA083266, AA083508, AA083411, AA083637, AA084202, AA099623, AA102015, AA099659, AA100102, AA100163, AA100429, AA100430, AA100455, AA100456, AA100711, AA100764, AA100906, AA100919, AA100963, AA101118, AA102494, AA101184, AA112123, AA122359, AA122360, AA126882, AA127103, AA128195, AA128674, AA128686, AA128741,

		AA128747, AA128785, AA133488, AA133489, AA130006, AA130007, AA134211, AA130492, AA130507, AA134345, AA134346, AA134457, AA134458, AA134461, AA134462, AA130907, AA131020, AA131973, AA132141, AA132493, AA132601, AA134904, AA135121, AA135182, AA135348, AA136318, AA143066, AA143256, AA143278, AA143386, AA146650, AA146835, AA146836, AA146860, AA146861, AA146870, AA146871, AA146918, AA147716, AA147707, AA147868, AA148130, AA148090, AA148091, AA152422, AA148435, AA148867, AA148492, AA148702, AA151453, AA151452, AA151828, AA155801, AA155886, AA156025, AA156044, AA156053, AA156155, AA156222, AA157080, AA157168, AA157325, AA157423, AA157434, AA157471, AA157605, AA157631, AA157546, AA157775, AA157826, AA158157, AA158273, AA158888, AA158887, AA159153, AA159250, AA160104, AA159856, AA161278, AA161301, AA160817, AA164741, AA165616, AA165606, AA173037, AA173038, AA176229, AA176317, AA179185, AA179190, AA179200, AA181043, AA181262, AA181342, AA181834, AA181989, AA182794, AA187247, AA187342, AA187379, AA187470, AA187528, AA187740, AA187911, AA188028, AA186378, AA186424, AA186441, AA186442, AA186568, AA186653, AA186661, AA186703, AA186910, AA187081, AA187087, AA187078, AA187135, AA188313, AA188330, AA188342, AA190473, AA193219
720222	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 971 of SEQ ID NO:56, b is an integer of 15 to 985, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.</p>	AA056718, AA428747
724033	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1232 of SEQ ID NO:57, b is an integer of 15 to 1246, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.</p>	N50855, AA076233, AA076232

724767	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1952 of SEQ ID NO:58, b is an integer of 15 to 1966, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.	
727065	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1597 of SEQ ID NO:59, b is an integer of 15 to 1611, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.	T26554, R31862, R31869, R67140, R70861, H00137, H23051, H23350, H60670, N28391, N28646, AA081571
727246	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1835 of SEQ ID NO:60, b is an integer of 15 to 1849, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.	
727932	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 219 of SEQ ID NO:61, b is an integer of 15 to 233, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.	
731167	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2319 of SEQ ID NO:62, b is an integer of 15 to 2333, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.	
732514	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1456 of SEQ ID NO:63, b is an integer of 15 to 1470, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.	
734080	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 925 of SEQ ID NO:64, b is an integer of 15 to 939, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.	
734288	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2054 of SEQ ID NO:65, b is an integer of 15 to 2068, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.	
739448	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1377 of SEQ ID NO:66, b is an integer of 15 to 1391, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.	T53676, T53677, T54741, T55855, T55906, T56935, T57622, T58975, T58979, T61059, T61143, T90498, T90594, T93775, R07734, R07735, R40067, R75954, R75978, R76790, R76809, R77290, R77315, R77348, R79433, R79434, R97814, H50168, H70091, H77406, H80889, H82088, H82195, N33576, N39028, N48219, N49421, N52598, N66328, N67208, N73788, N78932, N92856, N99411, W07071, W17213, W24422, W25582, W47407, W47574, W49651, W49725, W68140, W68467, AA025829, AA025972, AA074731, AA074835, AA075316, AA081368, AA081369, AA082652, AA082810, AA101054, AA102495, AA115718, AA115719, AA127079, AA127080, AA127200, AA127199, AA128645, AA128813, AA133732, AA130465, AA130466, AA132111, AA143233, AA143289, AA146780, AA147706, AA148134, AA151491, AA157062, AA157046, AA157630, AA165124, AA165123, AA164625, AA165420, AA165583, AA173407, AA173462, AA179910, AA179911, AA180198, AA181087, AA181556, AA182450, AA182951, AA186670, AA188289, AA192925, AA193075, AA464823
739668	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 645 of SEQ ID NO:67, b is an integer of 15 to 659, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.	
740060	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2967 of SEQ ID NO:68, b is an integer of 15 to 2981, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.	
741560	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	

	where a is any integer between 1 to 589 of SEQ ID NO:69, b is an integer of 15 to 603, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.	
742543	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1087 of SEQ ID NO:70, b is an integer of 15 to 1101, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.	
742831	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 700 of SEQ ID NO:71, b is an integer of 15 to 714, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.	
745327	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2876 of SEQ ID NO:72, b is an integer of 15 to 2890, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.	
745695	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2474 of SEQ ID NO:73, b is an integer of 15 to 2488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.	T56303, T58644, T58694, R48815, R48816, R68140, R74376, R78015, R81014, H00852, H01233, H17193, H17969, H25101, H27005, H30607, H41236, H42218, H42290, H42904, H42977, H45271, H45342, R83816, R98855, R98939, H53696, H62059, H82544, H83097, N40713, N92791, W19377, AA025571, AA053695, AA053675, AA069167, AA069166, AA076604, AA076603, AA079426, AA100088, AA099771, AA130265, AA158402, AA179641, AA235643, AA253454, AA250758, AA458951, AA458978, AA459194, AA419280, AA419329, AA425117, AA430664
750316	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 697 of SEQ ID NO:74, b is an integer of 15 to 711, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.	
750522	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID	

	NO:75, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.	
750583	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 257 of SEQ ID NO:76, b is an integer of 15 to 271, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.	
751020	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 659 of SEQ ID NO:77, b is an integer of 15 to 673, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.	N80268, N95387, W57806, W63590, AA182782, AA187759, AA199806, AA262640, AA262111, AA262106, AA460214
752196	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 353 of SEQ ID NO:78, b is an integer of 15 to 367, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.	R67541
753084	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1330 of SEQ ID NO:79, b is an integer of 15 to 1344, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.	T93791, T93840, R77826, R78199, R99272, H54274, H65600, H67128, H75533, H75532, H81433, N57836, N58786, N72699, N77475, W02480, W78743, W80625, W90276, AA007397, AA127528, AA127529, AA130419, AA147733, AA150095, AA195008, AA195060
754957	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3734 of SEQ ID NO:80, b is an integer of 15 to 3748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.	
756557	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1877 of SEQ ID NO:81, b is an integer of 15 to 1891, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.	
756712	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1940 of SEQ ID NO:82, b is an integer of 15 to 1954, where both a	

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.	
757414	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 922 of SEQ ID NO:83, b is an integer of 15 to 936, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.	T49651, T49652, T92946, T93013, H02307, H02419, N42072, AA169576
757614	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1499 of SEQ ID NO:84, b is an integer of 15 to 1513, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.	T93709, T96172, H00439, H00480, R85176, H51264, H51834, H53645, H57470, H57991, H73334, N33138, N42318, N94987, AA028955, AA081550, AA082013, AA113225, AA113810, AA133619, AA133522, AA132699, AA132810, AA151877, AA149662, AA157324, AA157422, AA159905, AA165014, AA165442, AA165443, AA167837, AA166621, AA166924, AA195339, AA195338, AA252790
757815	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1284 of SEQ ID NO:85, b is an integer of 15 to 1298, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.	
759878	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1995 of SEQ ID NO:86, b is an integer of 15 to 2009, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.	
760227	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 520 of SEQ ID NO:87, b is an integer of 15 to 534, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.	
760312	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4288 of SEQ ID NO:88, b is an integer of 15 to 4302, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.	
766051	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	T57753, T60650, R11036, R11084, R00826, R01482, H87221, N25112,

	sequence described by the general formula of a-b, where a is any integer between 1 to 2768 of SEQ ID NO:89, b is an integer of 15 to 2782, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.	N33451, N42424, N47338, N48186, N62628, N68902, N71490, N78399, N99533, W16943, W78948, W85915, W95743, N89568, AA039230, AA039231, AA047564, AA047582, AA047702, AA047752, AA120926, AA126453, AA135549, AA135529, AA429718
767593	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1023 of SEQ ID NO:90, b is an integer of 15 to 1037, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.	T51635, T57709, T61468, T63793, T63818, T92894, T92984, T94396, T75475, T75508, T87575, T79848, T85949, R25644, R27489, R70702, R78772, H44836, H44835, R84349, R86157, R89703, R99494, H48567, H48836, H57859, H83579, H86373, H86690, H88284, H97937, H98241, H99117, H99249, N24363, N24573, N26374, N27129, N31662, N36546, N40064, N45098, N45108, N53503, N59526, N63219, N64179, N64178, N66660, N70536, N72298, N98943, W02894, W19364, W60295, W60386, W72691, W77806, W93582, W93631, W92326, W92382, N90765, AA001997, AA013356, AA017023, AA017221, AA018780, AA026639, AA026705, AA029569, AA029496, AA029736, AA035387, AA035694, AA044958, AA055558, AA063564, AA100726, AA100744, AA134118, AA130301, AA151965, AA233192, AA253060, AA253117
768053	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:91, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.	
768055	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1220 of SEQ ID NO:92, b is an integer of 15 to 1234, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.	T68053, R09316, R09788, T84929, R24826, R66259, R68879, R80029, H00967, H89841, H96162, N39802, N44634, N68319, N70487, N71145, N72732, W01594, W52285, W73342, W85800, AA022906, AA022975, AA031962, AA032044, AA032163, AA037604, AA043694, AA043695, AA044134, AA074287, AA081041, AA081042, AA082218, AA082461, AA082475, AA083977, AA100460, AA155926, AA167365, AA171958, AA173534, AA187036, AA224429
769685	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1557 of SEQ ID	

	NO:93, b is an integer of 15 to 1571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.	
771920	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1858 of SEQ ID NO:94, b is an integer of 15 to 1872, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.	
772790	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1502 of SEQ ID NO:95, b is an integer of 15 to 1516, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.	
772916	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1756 of SEQ ID NO:96, b is an integer of 15 to 1770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.	
773225	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 924 of SEQ ID NO:97, b is an integer of 15 to 938, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.	
773632	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 297 of SEQ ID NO:98, b is an integer of 15 to 311, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.	
774364	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 606 of SEQ ID NO:99, b is an integer of 15 to 620, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.	W01405, AA172322
775355	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2497 of SEQ ID NO:100, b is an integer of 15 to 2511, where both a	T49285, T61774, T68350, T68396, T94414, T69842, T81078, R01216, R05674, R21522, R21626, R23745, R23797, R24081, R24137, R24753, R32662, R36359, R45484, R45484,

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.	R63380, R63433, R70942, R70995, R73973, R78964, H08973, H09543, H16712, H16713, H20846, H20896, R99241, H82276, H82382, H84715, H85367, H85516, H89615, H95047, H96450, H97881, N20953, N21537, N22201, N25769, N29477, N30442, N37087, N42334, N42354, N66424, N66864, N67873, N71242, N73740, N94555, N99903, W45394, W46993, W46961, W46960, W46881, W73247, W90778, AA026678, AA026215, AA043908, AA044414, AA042828, AA062957, AA076063, AA121145, AA121476, AA195131, AA234043, AA234044, AA426421
775844	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2967 of SEQ ID NO:101, b is an integer of 15 to 2981, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.	T73286, T66741, T66742, R12147, R15080, R19321, R39271, R42973, R44589, R44589, H06197, H08725, R94752, H71652, H71653, H79764, H79765, H79770, H79762, H79761, H79771, H92246, H96184, N45199, W93244, W93245, W93258, W93257, W94615, W94654, AA001180, AA039582, AA039689, AA082198, AA157370, AA157869, AA253368
777760	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2790 of SEQ ID NO:102, b is an integer of 15 to 2804, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.	
779837	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 708 of SEQ ID NO:103, b is an integer of 15 to 722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.	T67628, T72838, H59238, H84693, N80048, W07009, W37555, W39191, N90251, AA057629
780769	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1622 of SEQ ID NO:104, b is an integer of 15 to 1636, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.	T66609, T66610, T83560, R15983, R15984, R35702, R49338, R49338, H11613, R94244, H87098, H87745, W60710, W60772, W94034, AA258151, AA258913, AA425943
781445	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1547 of SEQ ID NO:105, b is an integer of 15 to 1561, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is	

	greater than or equal to $a + 14$.	
781531	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 472 of SEQ ID NO:106, b is an integer of 15 to 486, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to $a + 14$.	
783018	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 786 of SEQ ID NO:107, b is an integer of 15 to 800, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to $a + 14$.	R18976
783097	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1044 of SEQ ID NO:108, b is an integer of 15 to 1058, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to $a + 14$.	
784198	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1062 of SEQ ID NO:109, b is an integer of 15 to 1076, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:109, and where b is greater than or equal to $a + 14$.	
784868	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1185 of SEQ ID NO:110, b is an integer of 15 to 1199, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:110, and where b is greater than or equal to $a + 14$.	
785428	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3616 of SEQ ID NO:111, b is an integer of 15 to 3630, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:111, and where b is greater than or equal to $a + 14$.	T47751, T39348, T39359, T98137, T79193, T95760, R16653, R16654, R24052, R24245, R33230, R44846, R50794, R50912, R44846, R60930, R61049, R71116, R71620, R77888, R80860, H00109, H04333, H04688, H05041, H09555, H30257, H30320, H47931, R94218, R99062, R99260, H50702, H50803, H52629, H52628, H54000, H67115, H70269, H83460, H83572, H84911, H99358, N21482, N21632, N24626, N33762, N41609, N67949, N69593, N70188, N71452, N71818, N77888, N79031, N99501, W02150, W03072, W05781, W19647, W19972, W20125, W30896, W33043.

		W33197, W35407, W37262, W39072, W47654, W52846, W56143, W60064, W60074, W65501, W67522, W67591, W69745, W69926, W80811, W94093, W94156, N90996, AA039462, AA040857, AA043084, AA043810, AA053423, AA053042, AA064625, AA064709, AA115540, AA115051, AA120833, AA129500, AA129499, AA146736, AA148602, AA152314, AA150343, AA150620, AA150790, AA157282, AA160296, AA173937, AA173969, AA181340, AA188207, AA186354, AA188646, AA190484, AA199676, AA199677, AA243342, AA250981, AA459647, AA459773, AA460227
785845	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1512 of SEQ ID NO:112, b is an integer of 15 to 1526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:112, and where b is greater than or equal to a + 14.	
785854	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 571 of SEQ ID NO:113, b is an integer of 15 to 585, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:113, and where b is greater than or equal to a + 14.	T85881, W45204
786705	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 487 of SEQ ID NO:114, b is an integer of 15 to 501, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:114, and where b is greater than or equal to a + 14.	R09422
787186	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1951 of SEQ ID NO:115, b is an integer of 15 to 1965, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:115, and where b is greater than or equal to a + 14.	
787279	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1046 of SEQ ID NO:116, b is an integer of 15 to 1060, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:116, and where b is greater than or equal to a + 14.	T62081, T97170, R17585, R42923, R48789, R48896, R54561, R54562, R54721, R54722, R42923, R72984, R73595, H23901, H43508, H46275, H46348, H47255, H47254, R83475, R89352, R91048, R93150, R93669, R94520, R98839, H48417, H48899, H48900, H50560, H54157, H58936,

		H58983, H67630, H69455, H72554, H72955, H89822, N23388, N33070, N35168, N40256, N44641, N52556, N59706, N68387, N80806, N92514, W17007, W19578, W20217, W38835, W49822, W56061, W65416, W65285, N90575, AA002190, AA045344, AA045446, AA052950, AA053432, AA082245, AA083753, AA102071, AA099961, AA101574, AA112070, AA125782, AA125931, AA135139, AA135268, AA146635, AA151603, AA149484, AA149981, AA152120, AA171975, AA172123, AA181805, AA181821, AA188148, AA188225, AA186556, AA186917, AA460297, AA461585
789002	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 695 of SEQ ID NO:117, b is an integer of 15 to 709, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:117, and where b is greater than or equal to a + 14.	
789008	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2039 of SEQ ID NO:118, b is an integer of 15 to 2053, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:118, and where b is greater than or equal to a + 14.	T47492, T47493, T47900, T48303, T48445, T48456, T49007, T49079, T49080, T49218, T49310, T49311, T49913, T49914, T49941, T51256, T51337, T51371, T51423, T51604, T51757, T52271, T52400, T53326, T53327, T54148, T54244, T54295, T54330, T54402, T54407, T55485, T55733, T56237, T56379, T56414, T56565, T39384, T40546, T40551, T40552, T40824, T89603, T79470, T79561, R01378, R12635, R20536, R21209, R21238, R21239, R22062, R22119, R22190, R22241, R22534, R22535, R22823, R23625, R23881, R24090, R25741, R26431, R26587, R28327, R28328, R28330, R31619, R32132, R32349, R33134, R33286, R35454, R36658, R39739, R50498, R50581, R20536, R56656, R65717, R65777, R65870, R67856, R67857, R68076, R69399, R69531, R69752, R69920, R71289, R72350, R74061, R77148, R77149, R80495, R80640, R82550, H00862, H01301, H01472, H01571, H02637, H02893, H03072, H03073, H03443, H03525, H03812, H03836, H23457, H23458, H26513, H26583, H26584, R86226, R86227, R87053, R91130, R91174, R92513, R92642, R93418, R93468, R93700, R94462, R94463, R94793, R95110,

		R96330, R96329, R96675, R96943, R97000, R98195, R99857, H48277, H48366, H48451, H53119, H54247, H54246, H57144, H57217, H58791, H59276, H59324, H59614, H59654, H62873, H62997, H66302, H67109, H67468, H67594, H67634, H67646, H67685, H67891, H67935, H68007, H68476, H72996, H73208, H73882, H74057, H74076, H74196, H75522, H75366, H77704, H77705, H78593, H79262, H79373, H81287, H81343, H82036, H82218, H82313, H87010, H87011, H90552, H90551, H93198, H94403, N28269, N30773, N34862, N38975, N38989, N39317, N43935, N45164, N48122, N48136, N50666, N50756, N52570, N53559, N53589, N55006, N55026, N57654, N58258, N58340, N58627, N58738, N70218, N72552, N72649, N77216, N77511, N77635, N80637, W01074, W58701, W68231, W68232, W68700, W72561, W72580, W72399, W76223, W85725, W92304, W92318, W92144, W92354, AA004478, AA004551, AA009715, AA009825, AA024464, AA024465, AA025660, AA039523, AA039522, AA040081, AA040128, AA040033, AA040827, AA045744, AA053323, AA099152, AA099250
789555	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1810 of SEQ ID NO:119, b is an integer of 15 to 1824, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:119, and where b is greater than or equal to a + 14.	T85669, H62189, H62190, H73963, H73295, N74147, W04314, W23625, W35215, AA040573, AA040671
789631	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 592 of SEQ ID NO:120, b is an integer of 15 to 606, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:120, and where b is greater than or equal to a + 14.	
789779	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 824 of SEQ ID NO:121, b is an integer of 15 to 838, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:121, and where b is greater than or equal to a + 14.	N69694, AA151932
790387	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	H19654, H87102, H87749, N29354, N34298, N44187, N57052, W69612,

	sequence described by the general formula of a-b, where a is any integer between 1 to 642 of SEQ ID NO:122, b is an integer of 15 to 656, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:122, and where b is greater than or equal to a + 14.	W93844, W93865, AA027893, AA029638, AA058317, AA058495, AA179870, AA232827, AA233881, AA235809
790461	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1372 of SEQ ID NO:123, b is an integer of 15 to 1386, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:123, and where b is greater than or equal to a + 14.	R66275, R76171, R82537, AA054476, AA056199, AA127010, AA143025, AA151006, AA150976
790931	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 831 of SEQ ID NO:124, b is an integer of 15 to 845, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:124, and where b is greater than or equal to a + 14.	T92052, R10686, T84927, R21818, R22331, R22332, R22401, R23139, R23140, R23369, R32153, R32154, R63527, R63575, R68799, R68901, R80768, H12779, H12836, H56522, H56704, H94832, H96055, H96058, H96422, H96418, N26715, N27088, N31910, N32532, N33383, N34596, N42693, N42748, W32121, W37432, W44577, W44627, W51792, W61294, W65390, AA026773, AA026774
791176	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1642 of SEQ ID NO:125, b is an integer of 15 to 1656, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:125, and where b is greater than or equal to a + 14.	T51708, T51919, T69384, R50942, R73632, R73706, H28125, N22822, N78772
791983	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 823 of SEQ ID NO:126, b is an integer of 15 to 837, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:126, and where b is greater than or equal to a + 14.	
792539	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1203 of SEQ ID NO:127, b is an integer of 15 to 1217, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:127, and where b is greater than or equal to a + 14.	H53623, H53662, N23079, N69293, N89689, AA034518, AA035409, AA035410, AA046490, AA046762, AA085037, AA085105, AA134976, AA135078, AA459951, AA460040
792749	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1335 of SEQ ID NO:128, b is an integer of 15 to 1349, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:128, and where b is greater than or equal to a + 14.	R13058, R13951, R40011, R51765, R51766, R40011, R67629, R67630, H01808, H29310, H29403, R99196, H52742, H52788, H61636, H71767, H71768, N20919, N27779, N36030, N41741, N47900, N55480, N76967, W21551, W44410, W44331, W46458, W46528, W46810, W46928, W51766,

		W57869, W58140, W86456, N90422, AA029174, AA029253, AA031374, AA031375, AA062913, AA082549, AA133965, AA167773, AA166872, AA176295, AA176395, AA428235
792961	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2304 of SEQ ID NO:129, b is an integer of 15 to 2318, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:129, and where b is greater than or equal to a + 14.	
793206	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2135 of SEQ ID NO:130, b is an integer of 15 to 2149, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:130, and where b is greater than or equal to a + 14.	
793249	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1006 of SEQ ID NO:131, b is an integer of 15 to 1020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:131, and where b is greater than or equal to a + 14.	T48358, T48359, T71001, T71063, T72193, T72972, T67531, T69528, T86709, T86804, T89854, T90890, T91159, T85694, T85895, T95466, T95467, R00007, R00008, R12353, R23932, R23933, R37279, R63973, R64080, R73825, R73826, R76905, R77073, R77445, R77538, R79797, R79808, R79894, R79908, H11925, H11926, H15192, H16754, H16862, H19737, H20072, H21725, H22675, H24523, H26125, H26391, H39766, H41271, H41373, H41374, H43544, H43545, H44881, H45180, H45181, R92671, R94833, H57801, H58122, H58123, H62248, H62337, H69587, H69586, H80840, H80930, H85462, H85747, H86829, H86902, H96591, H96708, H97829, H99614, N25266, N26147, N27161, N29792, N33452, N33767, N33906, N36535, N38816, N39177, N40101, N42935, N42425, N44530, N45252, N45445, N57801, N59012, N78685, N79046, N91819, N98480, W02726, W04566, W15191, W15596, W17335, W24253, W25723, W30937, W31253, W31429, W31674, W39685, W44989, W46619, W46654, W57768, W57804, W57841, W57622, W67135, W67136, W73878, W73364, W73441, W77815, W80810, W80903, W92682, W92512, W92513, W96375, W96526, AA001447, AA001482, AA021374, AA021375, AA037268, AA037489, AA037569, AA039708, AA040262, AA040417, AA057011,

		AA074646, AA074679, AA075303, AA088467, AA098947, AA100987, AA126026, AA126122, AA126778, AA128010, AA128034, AA136619, AA136750, AA143234, AA143291, AA143564, AA143565, AA146915, AA151446, AA151447, AA156218, AA157383, AA159151, AA173294, AA179768, AA180442, AA181155, AA181156, AA181722, AA186611, AA188254, AA190686, AA191758, AA191547, AA195441, AA223540, AA223587
793626	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2305 of SEQ ID NO:132, b is an integer of 15 to 2319, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:132, and where b is greater than or equal to a + 14.	
794417	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:133, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:133, and where b is greater than or equal to a + 14.	
795197	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1643 of SEQ ID NO:134, b is an integer of 15 to 1657, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:134, and where b is greater than or equal to a + 14.	
795251	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2346 of SEQ ID NO:135, b is an integer of 15 to 2360, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:135, and where b is greater than or equal to a + 14.	T89826, T74514, T89080, R24028, H03686, H97493, N54611, W94797, W94798, AA129537, AA190765, AA191357, AA256363, AA425151, AA429405
795752	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1028 of SEQ ID NO:136, b is an integer of 15 to 1042, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:136, and where b is greater than or equal to a + 14.	
796261	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1023 of SEQ ID	

	NO:137. b is an integer of 15 to 1037, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:137, and where b is greater than or equal to a + 14.	
796933	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1476 of SEQ ID NO:138. b is an integer of 15 to 1490, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:138, and where b is greater than or equal to a + 14.	
799424	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1670 of SEQ ID NO:139. b is an integer of 15 to 1684, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:139, and where b is greater than or equal to a + 14.	
799698	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 413 of SEQ ID NO:140. b is an integer of 15 to 427, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:140, and where b is greater than or equal to a + 14.	
800351	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 875 of SEQ ID NO:141. b is an integer of 15 to 889, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:141, and where b is greater than or equal to a + 14.	
800573	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1491 of SEQ ID NO:142. b is an integer of 15 to 1505, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:142, and where b is greater than or equal to a + 14.	
805815	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1221 of SEQ ID NO:143. b is an integer of 15 to 1235, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:143, and where b is greater than or equal to a + 14.	
806445	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1406 of SEQ ID NO:144. b is an integer of 15 to 1420, where both a	

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:144, and where b is greater than or equal to $a + 14$.	
810309	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1905 of SEQ ID NO:145, b is an integer of 15 to 1919, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:145, and where b is greater than or equal to $a + 14$.	
811022	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1365 of SEQ ID NO:146, b is an integer of 15 to 1379, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:146, and where b is greater than or equal to $a + 14$.	
811023	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 500 of SEQ ID NO:147, b is an integer of 15 to 514, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:147, and where b is greater than or equal to $a + 14$.	
811143	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2044 of SEQ ID NO:148, b is an integer of 15 to 2058, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:148, and where b is greater than or equal to $a + 14$.	
811381	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1767 of SEQ ID NO:149, b is an integer of 15 to 1781, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:149, and where b is greater than or equal to $a + 14$.	
811595	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1695 of SEQ ID NO:150, b is an integer of 15 to 1709, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:150, and where b is greater than or equal to $a + 14$.	T51013, T51104, T54094, T54185, T68577, T68655, T90261, T90702, T92691, R34639, R49168, R51392, R49168, R84952, R84994, H84723, H84890, N29820, N42512, N64677, N67206, N73458, N80110, N92710, W02861, W20327, W23680, W76675, AA031294, AA062736, AA062781, AA070243, AA070244, AA084464, AA100714, AA100767, AA136726, AA136684, AA191613, AA223541, AA223589, AA252636
813000	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 908 of SEQ ID NO:151, b is an integer of 15 to 922, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:151, and where b is greater than or equal to a + 14.	
813288	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:152, b is an integer of 15 to 635, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:152, and where b is greater than or equal to a + 14.	
813431	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2314 of SEQ ID NO:153, b is an integer of 15 to 2328, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:153, and where b is greater than or equal to a + 14.	T94237, T89464, T89552, R09285, T78198, R14453, R15241, R15311, R21130, R33140, R33292, R40972, R46726, R42211, R40972, R46726, R66207, R67085, R73679, R73770, H12485, H19135, H22930, H24111, H26774, H26884, R89854, R89894, R92012, R92057, H53798, H61991, H61992, H64854, H65452, H73213, H74063, H79753, H79754, H80620, H80654, H81209, H81210, H84019, H84020, N35581, N68664, N73792, N91681, N92730, N99417, W20349, W46901, W52684, W60422, W61136, W61108, W61174, W68119, W73989, W79021, W79231, W80414, W80777, W80930, AA040315, AA045023, AA045024, AA045188, AA045352, AA181735, AA181799, AA223229, AA223428, AA464186, AA464780, AA428152, AA430305
813450	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1254 of SEQ ID NO:154, b is an integer of 15 to 1268, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:154, and where b is greater than or equal to a + 14.	T90954, T84401, T85262, R22109, R48652, R72000, R73453, H14261, H27403, H42017, H42018, H38149, H38150, H69302, H69397, N98775, AA148803, AA150212
813478	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4285 of SEQ ID NO:155, b is an integer of 15 to 4299, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:155, and where b is greater than or equal to a + 14.	
813505	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 992 of SEQ ID NO:156, b is an integer of 15 to 1006, where both a and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:156, and where b is greater than or equal to a + 14.	
815552	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1672 of SEQ ID NO:157, b is an integer of 15 to 1686, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:157, and where b is greater than or equal to a + 14.	
815606	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4133 of SEQ ID NO:158, b is an integer of 15 to 4147, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:158, and where b is greater than or equal to a + 14.	T69152, T69213, T80080, T80327, R19043, R27520, R38534, R38898, R44031, R44031, R67769, H11493, H11852, H13644, H22161, H28042, H39529, H42500, H43488, N32678, N50022, N51861, N54126, N54677, W16972, W32896, W35293, W38598, N89624, N90277, AA027830, AA027892, AA035739, AA055806, AA069223, AA078890, AA078891, AA099437, AA099478, AA101431, AA112543, AA121794, AA129629, AA136251, AA143110, AA150576, AA157125, AA158242, AA158709, AA159976, AA160357, AA159491, AA160534, AA160629, AA165150, AA165151, AA164643, AA166799, AA169647, AA169822, AA173082, AA187009, AA224150, AA224303, AA224514, AA224513, AA224488, AA226779, AA227396, AA227518, AA232104, AA232580, AA256938, AA255494, AA429442
816048	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1228 of SEQ ID NO:159, b is an integer of 15 to 1242, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:159, and where b is greater than or equal to a + 14.	T54940, T59322, R35627, R46514, R48419, R48536, R48537, R48569, R48582, R48668, R48683, R49781, R49827, R53111, R53210, R66870, R67958, R69435, R69517, R70414, R71907, R71948, R72113, R72818, R73269, R75924, R75959, R79565, R79566, R80393, H25645, H26211, H29817, H29904, H39626, H39738, H39881, H40715, H42210, H42281, H42354, H42710, H43124, R83615, R86066, R92103, R92104, R96726, R96727, H54075, H54232, H54233, H62253, H62342, H80441, H80442, H91114, H97541, H99927, N27357, N27665, N93636, W19226, W19703, W25418, W25514, W44404, W63554, W78078, N89960, AA027093, AA027132, AA045021, AA045022, AA045721, AA045720, AA046247, AA046280, AA058624, AA074786, AA074787, AA082394, AA085101, AA085282, AA100996, AA127562, AA127729, AA127784, AA128372,

		AA134954, AA143611, AA148145, AA150570, AA161257, AA182028, AA188387, AA232423, AA464270, AA464381, AA421219, AA425804, AA428372
822978	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2215 of SEQ ID NO:160, b is an integer of 15 to 2229, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:160, and where b is greater than or equal to a + 14.	R28400, R82355, R82411, H01338, H01388, N24952, N33829, AA043471, AA043472, AA125807, AA128280, AA129405, AA133871, AA129367, AA133179, AA133312, AA131385, AA428408
823616	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1906 of SEQ ID NO:161, b is an integer of 15 to 1920, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:161, and where b is greater than or equal to a + 14.	
823981	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2605 of SEQ ID NO:162, b is an integer of 15 to 2619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:162, and where b is greater than or equal to a + 14.	
824364	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1405 of SEQ ID NO:163, b is an integer of 15 to 1419, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:163, and where b is greater than or equal to a + 14.	R21933, H39733, N69879, AA027031, AA100964, AA157234, AA173338
824423	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3796 of SEQ ID NO:164, b is an integer of 15 to 3810, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:164, and where b is greater than or equal to a + 14.	
825279	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 803 of SEQ ID NO:165, b is an integer of 15 to 817, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:165, and where b is greater than or equal to a + 14.	R06729, R61520, R86829, H51131, N57993, W93696, AA423827
825442	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1564 of SEQ ID	

	NO:166, b is an integer of 15 to 1578, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:166, and where b is greater than or equal to a + 14.	
825548	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1680 of SEQ ID NO:167, b is an integer of 15 to 1694, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:167, and where b is greater than or equal to a + 14.	
825725	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1622 of SEQ ID NO:168, b is an integer of 15 to 1636, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:168, and where b is greater than or equal to a + 14.	
826639	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 653 of SEQ ID NO:169, b is an integer of 15 to 667, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:169, and where b is greater than or equal to a + 14.	
827079	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3584 of SEQ ID NO:170, b is an integer of 15 to 3598, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:170, and where b is greater than or equal to a + 14.	
827153	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 926 of SEQ ID NO:171, b is an integer of 15 to 940, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:171, and where b is greater than or equal to a + 14.	
827351	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1444 of SEQ ID NO:172, b is an integer of 15 to 1458, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:172, and where b is greater than or equal to a + 14.	R14710, H92769, H92882, AA195498, AA242878, AA242884, AA252152, AA251967, AA465181, AA465542, AA481105, AA481210, AA492206, AA732326
827503	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2695 of SEQ ID NO:173, b is an integer of 15 to 2709, where both a	

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:173, and where b is greater than or equal to a + 14.	
827563	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 999 of SEQ ID NO:174, b is an integer of 15 to 1013, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:174, and where b is greater than or equal to a + 14.	
827565	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1683 of SEQ ID NO:175, b is an integer of 15 to 1697, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:175, and where b is greater than or equal to a + 14.	
827893	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1395 of SEQ ID NO:176, b is an integer of 15 to 1409, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:176, and where b is greater than or equal to a + 14.	
828072	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1489 of SEQ ID NO:177, b is an integer of 15 to 1503, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:177, and where b is greater than or equal to a + 14.	R20502, R45322, R45322, H29062, H29165, N36388, N39601, AA043930, AA044003, AA115568, AA115087, AA232982, AA234020, AA251431, AA251432, AA459761, AA768137, AA830696, AA918618, AA977409
828228	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:178, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:178, and where b is greater than or equal to a + 14.	T76992, T83862, R37649, R68086, R68125, H05325, H05379, H11520, H60866, N27826, N59149, N71661, AA004459, AA004512, AA026983, AA031653, AA045803, AA045870, AA127220, AA126199, AA129772, AA133788, AA131742, AA166788, AA216416, AA229513, AA469120, AA469189, AA503687, AA516488, AA522741, AA542827, AA614664, AA847108, AA876618, AA886579, AA887825, AA888263, AA888262, AA934459, N31217, D79619, N55800, AA026982, AA031743
828241	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2237 of SEQ ID NO:179, b is an integer of 15 to 2251, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:179, and where b is greater than or equal to a + 14.	R09047, H71262, N28995, W07805, W89157, AA007537, AA203119

828287	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 986 of SEQ ID NO:180, b is an integer of 15 to 1000, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:180, and where b is greater than or equal to a + 14.</p>	R00158, R34699, R34806, R55812, R55897, H02931, H04234, H38596, H38841, H38877, R84345, R84762, R85507, H51401, N22910, N31298, N36027, N64463, N70710, N80820, N94519, N99846, W15234, W15579, W15620, W23968, W24669, W30920, W31655, W37399, W37400, W39182, W45512, W44342, W45653, W44569, W44608, W47630, W47631, W52183, W52421, W57603, W58189, W58466, W60614, W73715, W78044, W90451, W90258, W92042, W91902, AA012954, AA013060, AA013459, AA013460, AA018132, AA018050, AA021226, AA021359, AA021556, AA021640, AA033802, AA040580, AA040552, AA047883, AA054092, AA055181, AA055893, AA082252, AA082502, AA099128, AA099165, AA100988, AA131285, AA136296, AA136178, AA151469, AA151470, AA156144, AA158033, AA158325, AA164422, AA164402, AA167105, AA182609, AA182541, AA187289, AA187406, AA523678, AA582094, AA570257, AA573999, AA574305, AA579097, AA661683, AA662869, AA664665, AA736798, AA770689, AA865267, AA902336, AA923648, AA933570, AA939196, AA988468, AI000226, AI089764, D79059, N84733, W73650, N86290, N88454, C04677, C06015, AA033803, R29541, AA089664, AA089996, C17096, C17255, C19033, AA093458
828364	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1415 of SEQ ID NO:181, b is an integer of 15 to 1429, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:181, and where b is greater than or equal to a + 14.</p>	R55711, R55921, R68105, R68149, R72479, R72941, N70480, W72759
828371	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2711 of SEQ ID NO:182, b is an integer of 15 to 2725, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:182, and where b is greater than or equal to a + 14.</p>	T62048, T62112, T91683, T92364, T92416, T93284, N49690, N49793, N64329, N80813, W15549, W15404, W31643, W53039, W92220, W92342, AA055521, AA055520, AA149883, AA150063, AA148836, AA150436
828403	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1737 of SEQ ID NO:183, b is an integer of 15 to 1751, where both a</p>	AA485171, AA515218, AA603721, AA612760, AA838541, AA970526, C18512

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:183, and where b is greater than or equal to a + 14.	
828501	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2186 of SEQ ID NO:184, b is an integer of 15 to 2200, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:184, and where b is greater than or equal to a + 14.	H19145, N75547, AA044653, AA128979, AA159576, AA423963, AA523306, H62675, H97872, AA610503, AA010941, AA011327, AA043344
828520	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1973 of SEQ ID NO:185, b is an integer of 15 to 1987, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:185, and where b is greater than or equal to a + 14.	H70392, N30525, N30537, AA010769, AA463668, AA927343, AA091744
828527	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1723 of SEQ ID NO:186, b is an integer of 15 to 1737, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:186, and where b is greater than or equal to a + 14.	T39306, T40514, R08857, R08964, R00734, R00735, R13824, R20172, R37684, R44959, R44959, H05503, H17017, H17018, H54295, H54372, H54503, H67654, H67974, H87993, N33311, N37017, N44843, N55182, N75469, N75534, N77241, N93004, W05278, W05327, W45465, W88760, W88865, AA010623, AA010624, AA234956, AA235130, AA424457, AA282705, AA283023, AA283109, AA481529, AA481595, AA490727, AA491218, AA554176, AA614573, AA665370, AA687964, AA736921, AA765107, AA767430, AA809487, AA865595, N88052
828538	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1118 of SEQ ID NO:187, b is an integer of 15 to 1132, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:187, and where b is greater than or equal to a + 14.	
828541	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1253 of SEQ ID NO:188, b is an integer of 15 to 1267, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:188, and where b is greater than or equal to a + 14.	
828549	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3773 of SEQ ID NO:189, b is an integer of 15 to 3787, where both a and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:189, and where b is greater than or equal to $a + 14$.	
828562	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 540 of SEQ ID NO:190, b is an integer of 15 to 554, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:190, and where b is greater than or equal to $a + 14$.	
828576	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 860 of SEQ ID NO:191, b is an integer of 15 to 874, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:191, and where b is greater than or equal to $a + 14$.	
828602	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2089 of SEQ ID NO:192, b is an integer of 15 to 2103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:192, and where b is greater than or equal to $a + 14$.	
828628	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1303 of SEQ ID NO:193, b is an integer of 15 to 1317, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:193, and where b is greater than or equal to $a + 14$.	
828667	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1238 of SEQ ID NO:194, b is an integer of 15 to 1252, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:194, and where b is greater than or equal to $a + 14$.	
828684	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1674 of SEQ ID NO:195, b is an integer of 15 to 1688, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:195, and where b is greater than or equal to $a + 14$.	R11676, R12284, N68621, N71575, N99448, W02008, W58632, W74361, W76341, W78934, W85701, AA070898, AA070787, AA102636, AA102661, AA102678, AA190864, AA190957, AA197279, AA251577, AA464994, AA421724, AA470741, AA505341, AA506137, AA583780, AA579967, AA714136, AA743352, AA747903, AA814422, AA826755, AA836633, AA837944, AA936844, AI004160, C00265, AA641021
828727	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	R35925, R35954, R49443, R49468, R49443, R49468, N74960, AA083678, AA086366, AA100585, AA111863,

	where a is any integer between 1 to 742 of SEQ ID NO:196. b is an integer of 15 to 756. where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:196, and where b is greater than or equal to a + 14.	AA156573, AA159175, AA192611, AA195925, AA195976, AA418567, AA418582
828734	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1457 of SEQ ID NO:197. b is an integer of 15 to 1471, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:197, and where b is greater than or equal to a + 14.	
828750	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 678 of SEQ ID NO:198. b is an integer of 15 to 692, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:198, and where b is greater than or equal to a + 14.	
828842	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1559 of SEQ ID NO:199, b is an integer of 15 to 1573, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:199, and where b is greater than or equal to a + 14.	R31695, R31737, R86919, R86763, H66952, N30849, N41376, N95538, W03782, W24227, N90171, AA020001, AA046039, AA046149, AA099753, AA489705, AA552582, AA580818, AA584291, AA730113, AA910268
828843	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2728 of SEQ ID NO:200, b is an integer of 15 to 2742, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:200, and where b is greater than or equal to a + 14.	T57326, T57387, T94838, T94837, T94879, T94925, T74456, R11995, R15234, R19543, R21728, R36670, R39752, R39834, R40808, R40808, R43895, R70936, R70988, R74057, R74152, R79967, R80062, H02983, H04277, H08966, H09537, H25298, H25343, H25449, H25495, H29439, H29438, H29887, H29987, R86318, H65676, H87966, H88350, H97859, N20316, N26629, N27590, N39724, N52972, W39188, W45099, W45149, N90248, AA004834, AA033776, AA039900, AA039901, AA041524, AA044928, AA082729, AA085742, AA112974, AA128343, AA133157, AA171997, AA418609, AA418664, AA421626, AA430065, AA230107, AA230108, AA513630, AA521134, AA622056, AA635868, AA639882, AA714929, AA715480, AA715556, AA729814, AA731061, AA811597, AA830222, AA873240, AA886078, AA886270, AA907208, AA932201, AA977447, AA989000, D81476, N56281, C21262, AA089709
828851	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 1403 of SEQ ID NO:201, b is an integer of 15 to 1417, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:201, and where b is greater than or equal to a + 14.	
828856	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1498 of SEQ ID NO:202, b is an integer of 15 to 1512, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:202, and where b is greater than or equal to a + 14.	
828862	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 405 of SEQ ID NO:203, b is an integer of 15 to 419, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:203, and where b is greater than or equal to a + 14.	AA021223
828870	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2819 of SEQ ID NO:204, b is an integer of 15 to 2833, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:204, and where b is greater than or equal to a + 14.	
828873	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 5816 of SEQ ID NO:205, b is an integer of 15 to 5830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:205, and where b is greater than or equal to a + 14.	
828892	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 741 of SEQ ID NO:206, b is an integer of 15 to 755, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:206, and where b is greater than or equal to a + 14.	R54649, W46198
828893	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1982 of SEQ ID NO:207, b is an integer of 15 to 1996, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:207, and where b is greater than or equal to a + 14.	
828897	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	

	where a is any integer between 1 to 1654 of SEQ ID NO:208, b is an integer of 15 to 1668, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:208, and where b is greater than or equal to a + 14.	
828910	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2236 of SEQ ID NO:209, b is an integer of 15 to 2250, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:209, and where b is greater than or equal to a + 14.	T91595, T65436, T65518, T70584, T70847, T75377, R09159, R09261, R09950, T96365, T96446, R12590, R13068, R18120, R21193, R22430, R22480, R22810, R25025, R26742, R26976, R32026, R32079, R33017, R33904, R36588, R39200, R40499, R45972, R40499, R45972, R56330, R64494, R65591, R67446, R70974, R74477, R74579, R77932, R78301, R78497, R78547, R80142, R80143, H00643, H00729, H03024, H04306, H06614, H07124, H09643, H09677, H28706, H28835, H42802, H47310, R92010, H65658, H65657, H67068, H68151, H71685, H72248, H72786, H72785, H73342, H75583, H75514, H77433, H98557, N20087, N22979, N23822, N28617, N29593, N32509, N33262, N40705, N42724, N44752, N45195, N57760, N58105, N59101, N59726, N64423, N66868, N71993, N73995, N99375, W01801, W02025, W19280, W19667, W19930, W25451, W25645, W31475, W31938, W32153, W32005, W37711, W37710, W46758, W46905, W49818, W56089, W57771, W57844, W61375, W61376, W60415, W60416, W61142, W61190, W67942, W67941, W74649, W84332, W84393, W86146, W94323, AA016041, AA015933, AA022593, AA022594, AA030003, AA043309, AA069392, AA069393, AA069775, AA069812, AA102392, AA112674, AA112673, AA135337, AA135336, AA143448, AA152405, AA152459, AA149804, AA149829, AA149849, AA149856, AA156559, AA157731, AA159045, AA160734, AA173662, AA173661, AA235812, AA242974, AA243081, AA242998, AA252146, AA460003, AA460542, AA428205, AA429142, AA285041, AA283758, AA283993, AA480305, AA506566, AA524852, AA631324, AA575859, AA658502, AA766717, AA808234, AA837876, AA866075, AA877425, AA879058, AA886608, AA902179, AA904000, AA928667, AA937136, AA962263, AA995987, AI024986, W25995, W26229, W27231, W26246, W28106,

		W28807, W48809, C01974, AA640952, C14885, C15137
828927	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 824 of SEQ ID NO:210, b is an integer of 15 to 838, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:210, and where b is greater than or equal to a + 14.	
828932	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1199 of SEQ ID NO:211, b is an integer of 15 to 1213, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:211, and where b is greater than or equal to a + 14.	T50679, T51209, T78077, R42605, R48768, R42605, R91277, H61157, W38635, W44738, W46899, W80700, AA017684, AA017707, AA018069, AA019662, AA040254, AA053989, AA054041, AA070137, AA070138, AA074661, AA086354, AA158859, AA223111, AA224210, AA224315, AA232155, AA471047, AA588037, AA720832, AA872503
828933	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 955 of SEQ ID NO:212, b is an integer of 15 to 969, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:212, and where b is greater than or equal to a + 14.	
828941	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1680 of SEQ ID NO:213, b is an integer of 15 to 1694, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:213, and where b is greater than or equal to a + 14.	
828957	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1196 of SEQ ID NO:214, b is an integer of 15 to 1210, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:214, and where b is greater than or equal to a + 14.	R09987, R16645, R16734, R81727, H58067, H58066, H59815, H59816, H64860, H65458, N70923, W81647, W81187, AA052891, AA053046, AA251319, AA251723, AA262259, AA262870, AA463359, AA463865, AA417918, AA418169, AA480203, AA521273, AA836429, AA858135, AA888105, AA917914, AA937591, AA947712, AA961752, AA973797, A1085881
828963	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1762 of SEQ ID NO:215, b is an integer of 15 to 1776, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:215, and where b is greater than or equal to a + 14.	
828964	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 1404 of SEQ ID NO:216, b is an integer of 15 to 1418, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:216, and where b is greater than or equal to a + 14.	
828966	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2186 of SEQ ID NO:217, b is an integer of 15 to 2200, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:217, and where b is greater than or equal to a + 14.	T57322, T57383, R07432, R07433, R24183, R37889, R64196, R64212, H10798, H16281, H96182, N24864, N31801, N31897, N51466, N53607, N71323, N71374, N71696, N78973, N91801, N99595, N99806, W17338, W38617, W44695, W52815, W93325, W95029, AA027074, AA031625, AA031706, AA034522, AA101476, AA101477, AA156927, AA157179, AA173234, AA196758, AA506558, AA541561, AA552220, AA573198, AA687807, AA732065, AA769029, AA804914, AA858375, AA931935, AA995830, AI075078, AI075079, AA641307
828967	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1839 of SEQ ID NO:218, b is an integer of 15 to 1853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:218, and where b is greater than or equal to a + 14.	T86194, T99270, R00981, R21065, R28076, R28291, R46245, R46245, R61751, R61752, H20415, H41325, H46347, H46354, W01107, W96450, W96548, AA082920, AA192528, AA494252, AA507548, AA604189, AA604361, AA614008, AA622126, AA573865, AA578191, AA568157, AA780392, AA812241, AA830010, AA836096, AA876742, C21216
828977	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:219, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:219, and where b is greater than or equal to a + 14.	T54853, T55018, T61617, T61701, T71718, T71787, R43855, R43855, H79047, W23509, W78022, AA028959, AA028960, AA035641, AA035749, AA040562, AA042827, AA044641, AA150059, AA459301, AA459532, AA419054, AA532924, AA603462, AA573839, AA863332, AA877269, AI016670, AI083871, AI085531
828978	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2141 of SEQ ID NO:220, b is an integer of 15 to 2155, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:220, and where b is greater than or equal to a + 14.	
828979	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1250 of SEQ ID NO:221, b is an integer of 15 to 1264, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:221, and where b is greater than or equal to a + 14.	

829001	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2071 of SEQ ID NO:222, b is an integer of 15 to 2085, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:222, and where b is greater than or equal to a + 14.	
829003	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2907 of SEQ ID NO:223, b is an integer of 15 to 2921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:223, and where b is greater than or equal to a + 14.	T56900, T56901, T57894, T57976, T58709, T83854, T83994, T83995, T85283, T85493, T85938, T98545, T98546, R23866, R51491, R51492, R70815, H06524, H06579, H21400, H22212, H26306, H26465, H40800, H42803, H44004, H45104, H45577, R84544, R85933, R95902, R98186, R98187, R99129, H51499, H62734, H62818, H67266, H67280, H67971, H72027, H72028, H86532, H86617, H97834, N22060, N22322, N22927, N23444, N23843, N27358, N27627, N31797, N53099, N55505, N55527, N62760, N76278, N76994, N81072, N99969, W07363, W15385, W30908, W32209, W32266, W37612, W39341, W45721, W44369, W60688, W60728, W74331, W79764, W79508, AA010902, AA011007, AA013382, AA013383, AA017180, AA018376, AA021435, AA128552, AA128295, AA161229, AA160487, AA236095, AA259037, AA458538, AA428449, AA491943, AA492101, AA501898, AA505736, AA551906, AA552335, AA554636, AA564579, AA588897, AA593936, AA595710, AA610733, AA612690, AA569349, AA570259, AA570263, AA573856, AA579746, AA658849, AA721609, AA743280, AA743326, AA808972, AA831035, AA836900, AA887420, AA887859, AA970292, AA994943, AA994947, AI014465, F19724, N36447, D78889, N75198, W37467, W79607, C03008, C04753
829016	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4381 of SEQ ID NO:224, b is an integer of 15 to 4395, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:224, and where b is greater than or equal to a + 14.	
829027	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3021 of SEQ ID	

	NO:225, b is an integer of 15 to 3035, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:225, and where b is greater than or equal to a + 14.	
829028	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1497 of SEQ ID NO:226, b is an integer of 15 to 1511, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:226, and where b is greater than or equal to a + 14.	
829031	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2225 of SEQ ID NO:227, b is an integer of 15 to 2239, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:227, and where b is greater than or equal to a + 14.	T52373, T52446, T65540, T91789, R10959, T84998, R06717, R28502, R48288, R48390, R48442, R54616, R54879, R55311, R55316, R55413, R55418, R72602, R72669, R72946, H15595, H27333, H41543, H37781, R84976, R85050, R88513, R88514, H49052, H49116, H96219, H96754, H97979, N23664, N25056, N26150, N32997, N51857, N54122, W65281, W65277, W72409, W76488, W92510, N91031, AA045475, AA056943, AA057662, AA057806, AA126670, AA127032, AA136891, AA137001, AA158595, AA158989, AA279342, AA604130, AA604929, AA631863, C01812
829034	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2332 of SEQ ID NO:228, b is an integer of 15 to 2346, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:228, and where b is greater than or equal to a + 14.	
829036	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2232 of SEQ ID NO:229, b is an integer of 15 to 2246, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:229, and where b is greater than or equal to a + 14.	W19899, W56172, N91246, AA053015, AA258943, AA508101, AA557537, AA744258, C06034, AA053503
829049	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1988 of SEQ ID NO:230, b is an integer of 15 to 2002, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:230, and where b is greater than or equal to a + 14.	
829073	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 980 of SEQ ID	N71827, W07562, W79070, W94296, AA026190, AA215725, AA279902, AA832099

	NO:231, b is an integer of 15 to 994, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:231, and where b is greater than or equal to a + 14.	
829075	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 472 of SEQ ID NO:232, b is an integer of 15 to 486, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:232, and where b is greater than or equal to a + 14.	
829076	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2067 of SEQ ID NO:233, b is an integer of 15 to 2081, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:233, and where b is greater than or equal to a + 14.	
829080	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 502 of SEQ ID NO:234, b is an integer of 15 to 516, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:234, and where b is greater than or equal to a + 14.	
829087	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1115 of SEQ ID NO:235, b is an integer of 15 to 1129, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:235, and where b is greater than or equal to a + 14.	
829092	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1031 of SEQ ID NO:236, b is an integer of 15 to 1045, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:236, and where b is greater than or equal to a + 14.	
829095	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 676 of SEQ ID NO:237, b is an integer of 15 to 690, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:237, and where b is greater than or equal to a + 14.	T98739, T98740, R53404, R72484, H09731, H16600, H21795, H25680, N79773, N93472, AA812105, AA826523, AA954170, AI084914
829096	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1859 of SEQ ID NO:238, b is an integer of 15 to 1873, where both a	T40001, T40939, R53257, R62981, R62980, R63036, H15127, H15187, H24078, H24188, H81472, H88927, H88927, H99390, N32032, N47835, N66666, N98950, AA022842,

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:238, and where b is greater than or equal to a + 14.	AA022965, AA024917, AA024918, AA035721, AA062907, AA102646, AA101299, AA223395, AA419511, AA421963, AA421964, AA524699, AA532380, AA614315, AA570194, AA742712, AA865440, AA887301, AA987486, AA988144, AA091175
829118	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 891 of SEQ ID NO:239, b is an integer of 15 to 905, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:239, and where b is greater than or equal to a + 14.	
829152	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1470 of SEQ ID NO:240, b is an integer of 15 to 1484, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:240, and where b is greater than or equal to a + 14.	T72498, T73568, T74363, T86984, R10378, R10477, T85969, R05924, R06022, H58205, H65999, H66000, N68870, N92084, N92944, AA188651, AA188754, N72345
829160	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1507 of SEQ ID NO:241, b is an integer of 15 to 1521, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:241, and where b is greater than or equal to a + 14.	R19077, R24890, R70937, R70989, R75822, R75823, H13581, R88030, H97197, H97205, H97610, H97622, H97640, H99011, N22163, N22211, N25706, N31618, N31627, N34096, N35586, N57066, N57078, N57083, N63961, N71248, N71530, N79638, W23686, W25345, W80523, W80524, AA027117, AA044025, AA044347, AA056543, AA056646, AA082122, AA120870, AA120871, AA129173, AA129197, AA173547, AA173713, AA190689, AA252595, AA258865, AA259007, AA576323, AA768606, N55993, N84224
829163	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1130 of SEQ ID NO:242, b is an integer of 15 to 1144, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:242, and where b is greater than or equal to a + 14.	R27150, H50951, N39917, N41848, N41877
829176	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 920 of SEQ ID NO:243, b is an integer of 15 to 934, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:243, and where b is greater than or equal to a + 14.	T46875, T53785, T62036, T73807, R11065, R11122, T84299, T85183, R01714, R02656, R02737, R02738, H41134, H64904, H79712, H79713, N68598, N71315, N71366, N99798, W01984
829204	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	R50489, R50573, R74498, R74499, AA234014, AA535362, AA554207, AA847239

	where a is any integer between 1 to 901 of SEQ ID NO:244, b is an integer of 15 to 915, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:244, and where b is greater than or equal to a + 14.	
829207	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO:245, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:245, and where b is greater than or equal to a + 14.	
829228	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3352 of SEQ ID NO:246, b is an integer of 15 to 3366, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:246, and where b is greater than or equal to a + 14.	T40764, T49773, T49774, H05098, H49148, H51985, H52105, N36154, N51490, N52526, N53635, AA054314, AA074167, AA152473, AA152472, AA188950, AA278366, AA281330, AA468930, AA469004, AA482010, AA542938, AA554491, AA565215, AA579406, AA741363, AA807139, AA832066, AA836995, AA876036, AA995854
829252	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2134 of SEQ ID NO:247, b is an integer of 15 to 2148, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:247, and where b is greater than or equal to a + 14.	
829254	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2211 of SEQ ID NO:248, b is an integer of 15 to 2225, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:248, and where b is greater than or equal to a + 14.	
829269	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1190 of SEQ ID NO:249, b is an integer of 15 to 1204, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:249, and where b is greater than or equal to a + 14.	
829277	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1300 of SEQ ID NO:250, b is an integer of 15 to 1314, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:250, and where b is greater than or equal to a + 14.	
829290	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 1145 of SEQ ID NO:251, b is an integer of 15 to 1159, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:251, and where b is greater than or equal to a + 14.	
829294	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2474 of SEQ ID NO:252, b is an integer of 15 to 2488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:252, and where b is greater than or equal to a + 14.	
829299	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1540 of SEQ ID NO:253, b is an integer of 15 to 1554, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:253, and where b is greater than or equal to a + 14.	T82894, H25618, N48726, W52191, AA037331, AA223798, AA224330, AA635842, AA748884, AA826495, AA864458, AA903250, AA908466, AA931986, D81481, N56293, C02225
829308	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1492 of SEQ ID NO:254, b is an integer of 15 to 1506, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:254, and where b is greater than or equal to a + 14.	R13979, R17378, R40039, R42616, R42616, R40039, R56257, R56346, H05467, H07018, R86778, H99527, H99526, H99763, N24571, N25539, N25635, N28490, N30121, N34013, N34136, N34233, N35730, N49189, N50244, N92737, W20356, AA255602, AA262707, AA255576, AA262183, AA279758, AA570002, AA572777, AA721016, AA814424, AA864521, AA902860, AA948310, AI024777, AI056401
829349	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 640 of SEQ ID NO:255, b is an integer of 15 to 654, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:255, and where b is greater than or equal to a + 14.	T39288, T47082, T50451, T50586, T59000, T59073, T59535, T59586, T63704, T63861, T69920, T69974, T71240, T72474, T72943, T90268, T90710, T83786, T95048, R31368, R33435, R34369, R34489, R73911, R80467, R80667, R94351, R97310, R97345, H57329, H57376, H62783, H64845, H65444, H82981, H83214, H93955, H93956, N29780, N42940, N45379, N57200, N80805, W06876, W15396, W47162, W47283, W52164, W52024, W52758, W73045, W73275, W73604, W73643, W86783, W87274, AA009954, AA010849, AA011288, AA022621, AA022757, AA025805, AA025929, AA025968, AA046835, AA054475, AA058513, AA063327, AA075215, AA075451, AA088739, AA088740, AA099371, AA099457, AA112397, AA113053, AA121065, AA121066, AA132025, AA132147, AA132237, AA132357, AA146935,

		AA147721, AA147756, AA147602, AA148113, AA156063, AA157120, AA157223, AA157610, AA165107, AA164710, AA173741, AA173185, AA187331, AA187332, AA187293, AA187393, AA187741, AA188097, AA187033, AA188455, AA188457, AA188467, AA216356, AA228668, AA229001, AA228993, AA229108, AA397406, AA482922, AA483319, AA483431, AA491567, AA501502, AA507889, AA508445, AA513947, AA515053, AA522563, AA523140, AA525478, AA524922, AA526106, AA534088, AA535846, AA548219, AA552477, AA555012, AA558315, AA564882, AA565458, F16817, F16991, F17527, AA582793, AA587225, AA588487, AA595626, AA602055, AA602240, AA603392, AA631634, AA638971, AA639988, AA640535, AA576051, AA576894, AA566049, AA655021, AA659001, AA661609, AA662354, AA664631, AA664721, AA664980, AA665338, AA688035, AA714993, AA715012, AA720861, AA730373, AA730633, AA742678, AA742934, AA746812, AA747153, AA747192, AA747959, AA808437, AA836880, AA837645, AA838637, AA872341, AA876822, AA922665, AA961515, AA968734, AA970649, AA978219, AA988051, AA988404, AA991418, AA994111, AI002489, AI053409, AI053609, AI053760, AI082351, AI083631, N83854, N83948, N85971, N86260, N86628, N87758, AA641679, AA642097, AA642839, C20758, AA092159, AA092465, AA094493
829354	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1978 of SEQ ID NO:256, b is an integer of 15 to 1992, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:256, and where b is greater than or equal to a + 14.</p>	
829388	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2259 of SEQ ID NO:257, b is an integer of 15 to 2273, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:257, and where b is greater than or equal to a + 14.</p>	
829540	<p>Preferably excluded from the present invention are</p>	N26408, N28830, N28838, N31522,

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1490 of SEQ ID NO:258, b is an integer of 15 to 1504, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:258, and where b is greater than or equal to a + 14.	W15157, W81560, W81561, AA126749, AA126756, AA126772, AA187148
829626	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1778 of SEQ ID NO:259, b is an integer of 15 to 1792, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:259, and where b is greater than or equal to a + 14.	
829730	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2034 of SEQ ID NO:260, b is an integer of 15 to 2048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:260, and where b is greater than or equal to a + 14.	
829892	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1268 of SEQ ID NO:261, b is an integer of 15 to 1282, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:261, and where b is greater than or equal to a + 14.	R84306, N99830, N90467, AA113938, AA192541, AA243317, L44546, AA713588
829933	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 585 of SEQ ID NO:262, b is an integer of 15 to 599, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:262, and where b is greater than or equal to a + 14.	AA121059, AA429187
829938	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1247 of SEQ ID NO:263, b is an integer of 15 to 1261, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:263, and where b is greater than or equal to a + 14.	AA001837, AA142857, AA235114, AA235222, AA614412, AA687460, AA857702, AA857893, AA962131, AA962521
829969	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1006 of SEQ ID NO:264, b is an integer of 15 to 1020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:264, and where b is greater than or equal to a + 14.	R22931, R23036, H09755, H47088, N38971, N38985, N57545, AA075344, AA075597, AA136299, AA136180, AA279124, AA279243, AA279928, AA279929, AA909786, AI000293, N48117, N48131
829982	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	H40097, N80803, N93871, W07650, W15482, W40363, W42635, W45238,

	sequence described by the general formula of a-b, where a is any integer between 1 to 557 of SEQ ID NO:265, b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:265, and where b is greater than or equal to a + 14.	W67482, W67483, W70331, W72456, W73235, W73290, W76515, W78220, AA040927, AA040928, AA074829, AA075095, AA083686, AA166708, AA167049, AA228843, AA468686, AA469044, AA505509, AA548788, AA564157, AA595572, AA622149, AA633298, AA576799, AA746697, AA807946, AA873193, AA903706, AA919114, AA932502, AA938506, AA974058, AA977996, A1000750, N85073, N86741, N87037, N88197, N88746, AA090569
830007	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1336 of SEQ ID NO:266, b is an integer of 15 to 1350, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:266, and where b is greater than or equal to a + 14.	
830019	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1305 of SEQ ID NO:267, b is an integer of 15 to 1319, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:267, and where b is greater than or equal to a + 14.	T61424, T53868, T61391, T63785, R23153, R23154, R23905, R64468, R65575, R69390, R69523, R79153, R79154, H14532, H14533, H47318, H47402, H53647, H61347, H93017, H94242, N29789, N42932, W57927, W58148, W67701, W68160, W74342, W81702, W81703, W94692, W95218, W95440, W95785, AA043712, AA056570, AA114073, AA133633, AA133634, AA151774, AA149729, AA149782, AA149795, AA425861, AA425990, AA428095, AA428642, AA494401, AA515475, AA523534, AA548827, AA552032, AA564916, F16977, AA593645, AA613557, AA617694, AA618542, AA576565, AA576574, AA746168, AA766359, AA833956, AA837906, AA857421, AA857877, AA903383, AA903849, AA903888, AA916517, AA922889, AA962544, AA970534, AA974964, AA975402, AA976089, AA983583, AA992448, F18477, C04429, C17306
830073	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3680 of SEQ ID NO:268, b is an integer of 15 to 3694, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:268, and where b is greater than or equal to a + 14.	T93694, T96159, H04182, H04181, H15428, H48586, N74976, W05676, W44928, AA085826, AA085971, AA126446, AA425304, AA425408, AA280817, AA280995, AA287270, AA287417, AA668788, AA836455, AA977754
830130	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1228 of SEQ ID	

	NO:269, b is an integer of 15 to 1242, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:269, and where b is greater than or equal to a + 14.	
830134	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2043 of SEQ ID NO:270, b is an integer of 15 to 2057, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:270, and where b is greater than or equal to a + 14.	
830135	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 946 of SEQ ID NO:271, b is an integer of 15 to 960, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:271, and where b is greater than or equal to a + 14.	
830148	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1153 of SEQ ID NO:272, b is an integer of 15 to 1167, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:272, and where b is greater than or equal to a + 14.	R15244, R31943, R31992, H06853, H06894, H13355, H30882, R84410, R84411, R94120, H53381, H97695, H99925, N46996, N69023, N77897, W00690, W19694, W38937, W74721, W74795, N89822, N89950, AA009490, AA009904, AA031349, AA031350, AA035629, AA035719, AA046140, AA062845, AA062905, AA079564, AA079636, AA116062, AA116046, AA126968, AA148568, AA159591, AA160429, AA161272, AA161273, AA160576, AA179774, AA180491, AA179635, AA182631, AA182727, AA179634, AA192371, AA192282, AA199831, AA251312, AA256883, AA255477, AA430121, AA533720, AA551694, AA552307, AA552661, AA582138, AA586611, AA587906, AA594387, AA602977, AA605299, AA633388, AA573941, AA574038, AA579715, AA687647, AA741352, AA838339, AA857603, AA858082, AA866081, AA865003, AA875861, AA910672, AA927563, AI076918, W21962
830149	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2757 of SEQ ID NO:273, b is an integer of 15 to 2771, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:273, and where b is greater than or equal to a + 14.	R60249, R60762, R63751, R67526, H95029, H95095, N59347, N77158, W19778, AA047615, AA047555, AA047687, AA047738, AA056453, AA070880, AA112293, AA113105, AA112550, AA112614, AA158015, AA158228, AA160995, AA160996, AA190555, AA191131, AA224574, AA227422, AA255563, AA255586, AA418477, AA424689, AA470392, AA515485, AA515507, AA583475,

		AA588210, AA602533, AA573902, AA568354, AA746111, AA766146, AA804893, N83302
830154	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1875 of SEQ ID NO:274, b is an integer of 15 to 1889, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:274, and where b is greater than or equal to a + 14.	
830183	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 590 of SEQ ID NO:275, b is an integer of 15 to 604, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:275, and where b is greater than or equal to a + 14.	
830194	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1367 of SEQ ID NO:276, b is an integer of 15 to 1381, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:276, and where b is greater than or equal to a + 14.	T51023, T51115, T52795, T53595, T56300, T56767, T59691, T59827, T59904, T63354, T72200, T72269, T92900, T92990, R07165, R07217, R44334, R49609, R44334, R49609, H11106, H20800, H22618, H42472, H43453, H50320, H50321, H69947, N20118, N21306, N26128, N63140, N67225, N67232, W45407, W56419, W56420, W72419, W76279, W94626, W94710, AA029459, AA029524, AA034511, AA035053, AA035563, AA039819, AA041465, AA053002, AA055974, AA056002, AA070356, AA070320, AA074029, AA074039, AA074189, AA074336, AA075645, AA075646, AA076380, AA084435, AA084465, AA084453, AA085290, AA086454, AA099172, AA101922, AA101959, AA099618, AA102011, AA112794, AA126226, AA126304, AA128510, AA129955, AA133875, AA128443, AA133328, AA133403, AA134003, AA130990, AA131028, AA132940, AA135158, AA135628, AA143273, AA146730, AA151853, AA155641, AA155696, AA155726, AA157967, AA158903, AA158902, AA158943, AA158944, AA159293, AA159526, AA161206, AA160558, AA160739, AA160740, AA165357, AA167787, AA169218, AA169512, AA169691, AA176365, AA179272, AA179388, AA180903, AA181001, AA181325, AA181508, AA182781, AA173899, AA187757, AA188120, AA186725, AA187070, AA187152, AA190896, AA199819, AA223210,

		AA223254, AA227038, AA232399, AA233288, AA243192, AA252285, AA492525, AA420611, AA420688, AA492171, AA492254, AA503950, AA507398, AA513704, AA513757, AA515944, AA525799, AA558212, AA563863, AA565107, F17110, AA582829, AA586678, AA603895, AA604163, AA568617, AA617883, AA622814, AA635987, AA569079, AA570078, AA570258, AA570419, AA573205, AA573965, AA574048, AA566065, AA748781, AA834135, AA837022, AA838454, AA838636, AA838049, AA838058, AA856831, AA909853, AA910298, AA927706, AA932101, AA937900, AA953604, AA969555, AA973234, AA978074, AA985430, AA985432, AA988742, AA994207, A1002611, A1014411, N84537, N85082, W22113, W22114, W22431, W22639, W23207, W23271, W29046, N88675, AA640915, AA092777
830207	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1135 of SEQ ID NO:277, b is an integer of 15 to 1149, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:277, and where b is greater than or equal to a + 14.	R51744, R88177, W05323, AA746479, AA761644, AA826038, W27619, AA642452
830242	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 797 of SEQ ID NO:278, b is an integer of 15 to 811, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:278, and where b is greater than or equal to a + 14.	
830328	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1246 of SEQ ID NO:279, b is an integer of 15 to 1260, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:279, and where b is greater than or equal to a + 14.	
830340	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1654 of SEQ ID NO:280, b is an integer of 15 to 1668, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:280, and where b is greater than or equal to a + 14.	
830341	Preferably excluded from the present invention are	T62985, T63236, T71911, T66677,

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2314 of SEQ ID NO:281, b is an integer of 15 to 2328, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:281, and where b is greater than or equal to a + 14.	T66678, T80777, T81178, R16218, R16219, R67281, H15642, H15643, R96139, R96356, H61487, H61952, H62021, H62022, H62510, H62577, H62887, H63016, H65659, H65660, H72388, H72834, H80906, H97768, N30162, N35776, N52509, N66853, W44421, AA004323, AA004410, AA025214, AA026003, AA040205, AA040849, AA079158, AA079159, AA137066, AA137080, AA137137, AA136971, AA193479, AA532656, AA602312, AA828635, AA872751, AA934418, D80729, C15337
830351	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 942 of SEQ ID NO:282, b is an integer of 15 to 956, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:282, and where b is greater than or equal to a + 14.	
830358	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1388 of SEQ ID NO:283, b is an integer of 15 to 1402, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:283, and where b is greater than or equal to a + 14.	
830390	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 661 of SEQ ID NO:284, b is an integer of 15 to 675, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:284, and where b is greater than or equal to a + 14.	
830400	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1325 of SEQ ID NO:285, b is an integer of 15 to 1339, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:285, and where b is greater than or equal to a + 14.	T40239, T41103, T60782, T61153, T92326, T95403, R16530, R16587, R46049, R49231, R49231, R46049, H26122, H26387, H67872, H67872, H97917, N23194, N29748, N57652, N64158, N67587, N77509, N80178, W03502, W23838, W57929, W72584, AA011087, AA011088, AA070667, AA074878, AA075068, AA075019, AA076166, AA079857, AA082235, AA099016, AA099093, AA100754, AA113152, AA126886, AA128207, AA126932, AA128546, AA130882, AA136302, AA136408, AA143052, AA143693, AA148079, AA149931, AA151001, AA151091, AA155761, AA157290, AA160781, AA165535, AA173281, AA179903, AA180211, AA181162, AA181673, AA181986,

		AA187551, AA191657, AA192202, AA196746, AA196944, AA223166, AA224485, AA242866, AA397377, AA468734, AA514807, AA523669, AA534165, AA534195, AA565551, AA565552, H67199, AA581627, AA588734, AA588752, AA593857, AA595407, AA595555, AA603965, AA610486, AA614617, AA631563, AA635960, AA636057, AA576256, AA577470, AA580124, AA580480, AA714208, AA728790, AA729276, AA729361, AA744895, AA745002, AA746940, AA746948, AA747346, AA804602, AA810873, AA833970, AA836938, AA838563, AA858405, AA872330, AA922975, AA946823, AA954185, AA962678, AA978008, AA985504, AA987717, AI004904, AI017374, AI075264, F19611, AI089951, N83301, AA082282, AA091465, AA093298, AA094459
830437	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1384 of SEQ ID NO:286, b is an integer of 15 to 1398, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:286, and where b is greater than or equal to a + 14.</p>	
830458	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 912 of SEQ ID NO:287, b is an integer of 15 to 926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:287, and where b is greater than or equal to a + 14.</p>	T47583, T47584, T49761, T50148, T50203, T47161, R11382, R14878, H18220, H18258, R92715, N78687, W20222, W58210, W58319, W72115, W77801, W79332, W79431, W79487, W79631, W94437, N90582, AA043441, AA043442, AA148009, AA147947, AA150837, AA224863, AA225964, AA226110, AA259194, AA259193, AA420769, AA420829, AA470787, AA493672, AA501962, AA502082, AA506908, AA528607, AA588435, AA603500, AA603814, AA627229, AA627233, AA627240, AA632058, AA632689, AA639239, AA579023, AA580698, AA662633, AA661967, AA665215, AA729443, AA730546, AA737851, AA745424, AA745526, AA747036, AA878568, AA879157, AA886627, AA902180, AA922294, AA933050, AA962580, AA977360, AA985679, AA996058, AA996145, AI053546, AI085892, N83274, W15194, N88934, C04128, AA640839, AA091328, AA093116, AA094048, AA094287
830466	<p>Preferably excluded from the present invention are</p>	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3080 of SEQ ID NO:288, b is an integer of 15 to 3094, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:288, and where b is greater than or equal to a + 14.	
830497	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1969 of SEQ ID NO:289, b is an integer of 15 to 1983, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:289, and where b is greater than or equal to a + 14.	T47088, T47089, T58430, T58462, R00971, H42144, N77388, W51953, W52502, AA036671, AA114976, AA593693, AA575857, C01052
830511	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1284 of SEQ ID NO:290, b is an integer of 15 to 1298, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:290, and where b is greater than or equal to a + 14.	
830512	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2445 of SEQ ID NO:291, b is an integer of 15 to 2459, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:291, and where b is greater than or equal to a + 14.	
830513	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 556 of SEQ ID NO:292, b is an integer of 15 to 570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:292, and where b is greater than or equal to a + 14.	
830540	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2454 of SEQ ID NO:293, b is an integer of 15 to 2468, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:293, and where b is greater than or equal to a + 14.	T66458, T98908, R15832, R21916, R22565, H12306, R99043, H57499, H82961, AA046203, AA046283, AA055081, AA055141, AA173411, AA173467, AA173996, AA176693
830550	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1066 of SEQ ID NO:294, b is an integer of 15 to 1080, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:294, and where b is greater than or equal to a + 14.	R50040, R60172, R71512, H09125, H09475, H21789, R84538, R85928, R94762, R96633, R96680, R97580, H53135, H53241, H82960, H83191, N68166, N68684, N77903, N80174, N80625, N92442, N93242, N93314, N98261, W03498, W05839, W20000, W25100, W31279, W37087, W60751, W67554, W67583, W73877, W77814, W80412, W95868, W95954, N91343,

		AA026891, AA026892, AA033547, AA034170, AA069175, AA088435, AA151307, AA161037, AA237097, AA251326, AA251729, AA428848, AA429940, AA287366, AA287504, AA470593, AA470594, AA514493, AA564438, H67293, AA582501, AA583172, AA587111, AA602517, AA603483, AA569955, AA732412, AA737913, AA810504, AA832193, AA857743, AA915872, AA915896, AA915992, AA948498, AA983538, AA991546, AI052409, AI053921
830567	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2681 of SEQ ID NO:295, b is an integer of 15 to 2695, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:295, and where b is greater than or equal to a + 14.	R69708, R75813, R75814, N22294, N47088, N50300, N50983, N81194, N93236, AA074258, AA083867, AA083973, AA195801, AA196063, AA252500, AA252415, AA258014, AA287593, AA291332, AA492017, AA522597, AA617684, AA713960, AA740158, AA749386, AA808100, AA808680, AA814350, AA826203, AA831453, AA887306, AA918645, AA972761, N88184
830586	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1380 of SEQ ID NO:296, b is an integer of 15 to 1394, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:296, and where b is greater than or equal to a + 14.	R99131, H81094, W01508, AA045861, AA085947, AA102188, AA146772, AA148854, AA233843, AA424679, AA491204, AA514459, AA532818, AA809984, AA838521, AA954880, AI089939
830632	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 984 of SEQ ID NO:297, b is an integer of 15 to 998, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:297, and where b is greater than or equal to a + 14.	T47818, R21519, R21621, R22056, R22112, R31393, R32890, R48823, R48824, R66656, R67377, R71682, H25037, H25038, H25842, H26215, H26515, H26994, H28312, H28313, H29756, H30178, H41920, H41966, H42490, H43473, R83733, R85464, R88798, R89058, R93321, H52733, H59363, H60020, H73314, H73513, H80831, H80832, H82603, H86794, H86795, H86853, H86852, H92710, H96832, H98741, N23451, N23463, N26478, N26861, N31350, N31593, N35529, N39970, N42652, N62104, N74283, N76446, N78334, N92771, W04383, W19424, W20392, W24569, W35168, W60060, W60111, W84373, W84420, AA025658, AA029558, AA062705, AA062707, AA063390, AA062771, AA081934, AA126557, AA136019, AA151638, AA192245, AA194655, AA470430, AA493634, AA552261, AA552348, AA565278, AA565462, AA583788, AA593646, AA594277, AA604853, AA613755,

		AA632449, AA632505, AA657974, AA730677, AA730804, AA748100, AA765824, AA857805, AA954102, AA961763, AA962500, AA974525, AA983564, AA987422, AA987934, AA989423, A1000235, F19140, N84058, N84994, C03222, AA091370, AA091545
830645	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1652 of SEQ ID NO:298, b is an integer of 15 to 1666, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:298, and where b is greater than or equal to a + 14.	
830652	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2430 of SEQ ID NO:299, b is an integer of 15 to 2444, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:299, and where b is greater than or equal to a + 14.	
830659	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1012 of SEQ ID NO:300, b is an integer of 15 to 1026, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:300, and where b is greater than or equal to a + 14.	T65101, T66494, T66636, T84051, T86086, R05580, R13805, R15868, R16050, H05221, H05222, H13512, H16069, H18275, H21247, H44169, R83705, R92365, H48479, H48643, H54436, H54526, H73472, H73726, H97495, N29822, N30479, N31551, N32563, N39176, N39961, N45251, N68667, N91684, W07693, W32510, W32607, W38017, W74179, W79849, AA018138, AA028191, AA033572, AA033571, AA042915, AA043002, AA053878, AA054501, AA058344, AA099556, AA101993, AA134643, AA143525, AA176419, AA424269, AA555196, AA769107, AA987653, AI076212, N84624, N85006, AI084132, AI084154, AA094327
830696	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:301, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:301, and where b is greater than or equal to a + 14.	
830706	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3286 of SEQ ID NO:302, b is an integer of 15 to 3300, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:302, and where b is	

	greater than or equal to $a + 14$.	
830743	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 461 of SEQ ID NO:303, b is an integer of 15 to 475, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:303, and where b is greater than or equal to $a + 14$.	N30323, N56655, N69079, N69946, N80244, N98327, W07371, W42660, W45185, W55989, W56279, W68387, W68503, W72685, W74708, W74677, W77791, W80647, AA010723, AA011171, AA033537, AA034221, AA035773, AA056334, AA062820, AA132021, AA132124, AA135594, AA135681, AA151293, AA151292, AA181331, AA186392, AA187084, AA228662, AA228680, AA229819, AA468802, AA470869, AA483684, AA491891, AA514852, AA533423, AA548946, AA563674, AA564612, AA594511, AA600707, AA622053, AA635767, AA639353, AA662887, AA664589, AA729365, AA747035, AA747774, AA814124, AA873167, AA886626, AA903495, AA903981, AA922807, AA969768, AA973174, AA974282, AA976458, AA977143, AA983332, AI025140, AI066527, F19035, F19464, C03984, C13986, C14221, C14299, C14336, C14341, C14380, C14385, C14396, C14434, C14483, C14504, C14513, C15788
830770	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2888 of SEQ ID NO:304, b is an integer of 15 to 2902, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:304, and where b is greater than or equal to $a + 14$.	
830830	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1539 of SEQ ID NO:305, b is an integer of 15 to 1553, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:305, and where b is greater than or equal to $a + 14$.	
830838	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1973 of SEQ ID NO:306, b is an integer of 15 to 1987, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:306, and where b is greater than or equal to $a + 14$.	
830851	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 771 of SEQ ID NO:307, b is an integer of 15 to 785, where both a and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:307. and where b is greater than or equal to a + 14.	
830853	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2164 of SEQ ID NO:308, b is an integer of 15 to 2178, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:308, and where b is greater than or equal to a + 14.	
830856	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO:309, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:309, and where b is greater than or equal to a + 14.	
830862	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 742 of SEQ ID NO:310, b is an integer of 15 to 756, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:310, and where b is greater than or equal to a + 14.	T46908, T46909, T46921, T46922, T50921, T52918, T53038, T56001, T59028, T94115, T94204, R53898, R53908, H02747, H27523, H77792, H88026, H88248, H90255, H96065, H88248, N21994, N64072, N73723, N74262, N75815, N77939, W03894, W23887, AA081082, AA113423, AA115852, AA143290, AA143335, AA146868, AA157054, AA157208, AA179118, AA187792, AA188385, AA468513, AA468983, AA501970, AA523481, AA528461, AA533759, AA533618, AA535287, AA541570, AA558529, L44430, AA604961, AA568927, AA659814, AA661481, AA661996, AA731036, AA748135, AA847331, AA878667, AA885549, AA935403, AA938035, AI001062, F19242, N83489, N83646, N84328, N85002, N85167, N85223, N85325, N85833, N85949, N86287, N86329, N87923, N83150, AA642852, AA091775, AA093919
830879	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 837 of SEQ ID NO:311, b is an integer of 15 to 851, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:311, and where b is greater than or equal to a + 14.	T62074, T62130, T67747, T67857, R44816, R48904, R44816, H13822, H29311, W37451, N90567, AA128266, AA164552, AA235044, AA236012, AA746229, AA962194, AA987868, AA994828, AI000188, AI015557
830919	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1321 of SEQ ID NO:312, b is an integer of 15 to 1335, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:312, and where b is	

	greater than or equal to $a + 14$.	
830969	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 502 of SEQ ID NO:313, b is an integer of 15 to 516, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:313, and where b is greater than or equal to $a + 14$.	
830991	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1819 of SEQ ID NO:314, b is an integer of 15 to 1833, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:314, and where b is greater than or equal to $a + 14$.	
831002	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1340 of SEQ ID NO:315, b is an integer of 15 to 1354, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:315, and where b is greater than or equal to $a + 14$.	
831003	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2407 of SEQ ID NO:316, b is an integer of 15 to 2421, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:316, and where b is greater than or equal to $a + 14$.	T64373, N48387, W52748, W52754, W70187, AA029541, AA034463, AA058497, AA082001, AA082284, AA085967, AA088397, AA133444, AA133477, AA149568, AA187408, AA226818, AA226855
831021	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1078 of SEQ ID NO:317, b is an integer of 15 to 1092, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:317, and where b is greater than or equal to $a + 14$.	
831036	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1366 of SEQ ID NO:318, b is an integer of 15 to 1380, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:318, and where b is greater than or equal to $a + 14$.	
831071	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2598 of SEQ ID NO:319, b is an integer of 15 to 2612, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:319, and where b is greater than or equal to $a + 14$.	

831094	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 929 of SEQ ID NO:320, b is an integer of 15 to 943, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:320, and where b is greater than or equal to a + 14.	
831099	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2945 of SEQ ID NO:321, b is an integer of 15 to 2959, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:321, and where b is greater than or equal to a + 14.	T58120, T90056, T90158, T94290, T94639, R69200, R69590, R69678, R76031, H65424, H65425, N32273, N40465, N47619, N48504, N66482, N67212, N67243, N67881, N71915, N72302, N92538, N94512, W03004, W06930, W20370, W23962, W38380, W38525, W38716, W39486, W42582, W42594, W44824, W48665, W51898, W52474, W53040, W60142, N90075, N90423, AA025009, AA024962, AA029382, AA029726, AA031500, AA031546, AA037283, AA037749, AA039259, AA044145, AA044261, AA065061, AA070027, AA082386, AA083544, AA083757, AA088692, AA088829, AA099577, AA100236, AA100245, AA100517, AA112739, AA112091, AA116055, AA130509, AA130510, AA132145, AA135909, AA136308, AA136413, AA136528, AA136751, AA146853, AA146852, AA148049, AA156943, AA159808, AA165022, AA173867, AA181803, AA182563, AA182776, AA186553, AA186858, AA192463, AA194658, AA255837, AA261995, AA423999, AA493599, AA228337, AA228348, AA506755, AA506420, AA513968, AA514542, AA522900, AA524125, AA551485, AA553912, AA563900, AA594966, AA602651, AA610339, AA610361, AA614772, AA618333, AA576828, AA665045, AA714493, AA729997, AA738153, AA768641, AA804931, AA806122, AA827914, AA857664, AA876216, AA877173, AA877646, AA894385, AA922728, AA947835, AA977110, AA984009, AA988275, AA988567, N84005, N84600, N84939, N85553, A1084028, N86141, N88049, N89450, N89451, C02877, C02980, C03631, C05243, C05332, C05993, AA642453, AA090838, AA089614, AA091652, AA093130, AA093851
831113	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	AA122085, AA147371, A1005336

	where a is any integer between 1 to 788 of SEQ ID NO:322, b is an integer of 15 to 802, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:322, and where b is greater than or equal to $a + 14$.	
831120	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1710 of SEQ ID NO:323, b is an integer of 15 to 1724, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:323, and where b is greater than or equal to $a + 14$.	
831172	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2247 of SEQ ID NO:324, b is an integer of 15 to 2261, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:324, and where b is greater than or equal to $a + 14$.	
831178	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1199 of SEQ ID NO:325, b is an integer of 15 to 1213, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:325, and where b is greater than or equal to $a + 14$.	
831184	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2750 of SEQ ID NO:326, b is an integer of 15 to 2764, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:326, and where b is greater than or equal to $a + 14$.	
831203	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1750 of SEQ ID NO:327, b is an integer of 15 to 1764, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:327, and where b is greater than or equal to $a + 14$.	
831210	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 557 of SEQ ID NO:328, b is an integer of 15 to 571, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:328, and where b is greater than or equal to $a + 14$.	AA057014, AA059289
831228	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 459 of SEQ ID	

	NO:329, b is an integer of 15 to 473, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:329, and where b is greater than or equal to a + 14.	
831256	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1321 of SEQ ID NO:330, b is an integer of 15 to 1335, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:330, and where b is greater than or equal to a + 14.	R17500, R48877, H12160, R84358, H90367, N33987, AA161057
831257	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1032 of SEQ ID NO:331, b is an integer of 15 to 1046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:331, and where b is greater than or equal to a + 14.	T49922, T85470, R37545, H03610, AA005184, AA045346
831277	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1297 of SEQ ID NO:332, b is an integer of 15 to 1311, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:332, and where b is greater than or equal to a + 14.	
831317	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1430 of SEQ ID NO:333, b is an integer of 15 to 1444, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:333, and where b is greater than or equal to a + 14.	T39850, T47708, T47709, T47863, T51491, T52507, T53819, T53951, T55884, T60330, T60359, T60364, T60380, T60480, T60634, T61198, T61280, T61878, T62028, T67704, T67742, T67780, T67853, T67910, T68010, T68058, T68132, T68154, T68379, T68998, T68999, T69078, T69079, T69119, T69177, T69442, T70496, T71707, T72285, T72505, T72998, T73123, T73679, T73756, T73761, T73837, T74031, T74383, T74405, T74655, T74784, T74798, T74892, T85320, T85533, R83453, R88738, R90989, R90995, H58528, H59441, H60092, H60282, H60589, H67401, H67458, H72811, H79422, H80518, H80570, H91775, H91816, N57814, W60714, W60741, AA034367, AA040550, AA040667, AA242768, AA424551, AA424642, R29495, R29660, R29089, C21224
831339	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1016 of SEQ ID NO:334, b is an integer of 15 to 1030, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:334, and where b is	

	greater than or equal to $a + 14$.	
831363	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2113 of SEQ ID NO:335, b is an integer of 15 to 2127, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:335, and where b is greater than or equal to $a + 14$.	T58736, T58803, T61766, T64470, T64610, T67816, T68878, T68952, T72450, T72511, T72968, T73613, T73939, H41914, H41957, N75040, W05718, AA043436, AA043416, AA045231, AA058807, AA484773, AA502762, AA503811, AA527553, AA744171, AA902935, AA903099, A1002033
831367	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 833 of SEQ ID NO:336, b is an integer of 15 to 847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:336, and where b is greater than or equal to $a + 14$.	
831379	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 688 of SEQ ID NO:337, b is an integer of 15 to 702, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:337, and where b is greater than or equal to $a + 14$.	R26001, R26804, R82629, R82630, H21598, H27310, H27309, H38082, H38083, H44451, H44494, H47613, R83356, R83791, R96066, R96103, H72512, H72910, H80449, H80450, H90511, H90607, N71766, N94349, W16956, W23496, W24351, W46455, W46523, W48658, W70263, W73002, W76239, W92963, W92964, AA157329, AA157426, AA458665, AA229554, AA280810, AA280936, AA490898, AA491084, AA493730, AA527336, AA534762, AA535794, F17720, AA603439, AA568655, AA659071, AA826699, AA872867, AA876999, AA932403, AA953149, AA953343, A1000023, A1017353, A1094807, N95548, C02063, C04109
831385	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 861 of SEQ ID NO:338, b is an integer of 15 to 875, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:338, and where b is greater than or equal to $a + 14$.	
831390	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1434 of SEQ ID NO:339, b is an integer of 15 to 1448, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:339, and where b is greater than or equal to $a + 14$.	T53890, T54037, T81546, T81973, R20470, R21066, R45288, R46246, R45288, R46246, H13340, H17537, H30523, R85229, R85230, R94643, R94685, R94686, H52010, H52125, H71328, H71376, N25973, N28794, N30891, N36603, N41703, N62205, N63213, N76503, W45706, W44353, W52126, W74523, W79862, AA033566, AA034468, AA099015, AA099092, AA100315, AA129588, AA167137, AA194961, AA226935, AA226943, AA418898, AA428909,

		AA485083, AA485195, AA505107, AA506087, AA516109, AA525370, AA617946, AA627402, AA573848, AA574063, AA809830, AA834509, AA837985, AA862394, AA862989, AA974789, AA988779, AI000171, AI094917, W24010, N88026, C20972
831391	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 829 of SEQ ID NO:340, b is an integer of 15 to 843, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:340, and where b is greater than or equal to a + 14.	
831405	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1279 of SEQ ID NO:341, b is an integer of 15 to 1293, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:341, and where b is greater than or equal to a + 14.	T54632, T54714, T55384, T55812, T56220, T60613, T69578, R08164, R08219, T78003, T78164, R01577, R12676, R16414, H60551, N21984, N25878, N25887, N75352, W01648, W72541, W76166, W86984, W86811, W88909, W88788, AA022691, AA022784, AA193302, AA194256, AA235873, AA425660, AA573463, AA953249, R29055
831442	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1259 of SEQ ID NO:342, b is an integer of 15 to 1273, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:342, and where b is greater than or equal to a + 14.	
831476	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1779 of SEQ ID NO:343, b is an integer of 15 to 1793, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:343, and where b is greater than or equal to a + 14.	R48303, R48405, R73778, H30456, H81254, W02773, W24831, W73089, W73194, AA034015, AA151153, AA151154, AA418429, AA424672, AA593592, AA910532, AA987246, AI001017, C02335, C04320
831488	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1658 of SEQ ID NO:344, b is an integer of 15 to 1672, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:344, and where b is greater than or equal to a + 14.	
831518	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2095 of SEQ ID NO:345, b is an integer of 15 to 2109, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:345, and where b is greater than or equal to a + 14.	

831519	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1700 of SEQ ID NO:346, b is an integer of 15 to 1714, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:346, and where b is greater than or equal to a + 14.	
831521	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1658 of SEQ ID NO:347, b is an integer of 15 to 1672, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:347, and where b is greater than or equal to a + 14.	
831550	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1469 of SEQ ID NO:348, b is an integer of 15 to 1483, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:348, and where b is greater than or equal to a + 14.	
831560	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1828 of SEQ ID NO:349, b is an integer of 15 to 1842, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:349, and where b is greater than or equal to a + 14.	T56438, R22852, R46063, R52365, R81781, R81879, H02958, H04256, H05743, H05849, H23235, H23349, H43210, H43260, H87699, H91571, W00708, W56717, W56762, W70251, W70252, AA026841, AA027043, AA041261, AA041495, AA043451, AA043452, AA054505, AA054366, AA055050, AA055129, AA147629, AA147667
831562	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2994 of SEQ ID NO:350, b is an integer of 15 to 3008, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:350, and where b is greater than or equal to a + 14.	
831570	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2742 of SEQ ID NO:351, b is an integer of 15 to 2756, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:351, and where b is greater than or equal to a + 14.	
831593	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1631 of SEQ ID NO:352, b is an integer of 15 to 1645, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:352, and where b is	

	greater than or equal to $a + 14$.	
831596	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1623 of SEQ ID NO:353, b is an integer of 15 to 1637, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:353, and where b is greater than or equal to $a + 14$.	
831627	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1105 of SEQ ID NO:354, b is an integer of 15 to 1119, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:354, and where b is greater than or equal to $a + 14$.	AA147578, AA156449, AA588796, AA863066, D80116
831649	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 724 of SEQ ID NO:355, b is an integer of 15 to 738, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:355, and where b is greater than or equal to $a + 14$.	R21047
831664	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1952 of SEQ ID NO:356, b is an integer of 15 to 1966, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:356, and where b is greater than or equal to $a + 14$.	R35205, H13039, R84255, W24589, W93157, AA186436, AA188774, AA227246, AA658889, AA838204, W22056, W25833, W28198, W28494, AA090436, AA089530, AA089667
831674	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1548 of SEQ ID NO:357, b is an integer of 15 to 1562, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:357, and where b is greater than or equal to $a + 14$.	
831684	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1917 of SEQ ID NO:358, b is an integer of 15 to 1931, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:358, and where b is greater than or equal to $a + 14$.	T64083, R54664, R54665, W52888, W60096, W60162, AA009843, AA009870, AA236225, AA236291, AA459452, AA465675, AA554776, AA563899, AA583755, AA593849, AA596013, AA627978, AA573921, AA747840, AA828086, AA830260, AA837593, AA996154, C01662
831687	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 855 of SEQ ID NO:359, b is an integer of 15 to 869, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:359, and where b is greater than or equal to $a + 14$.	T49489, R05976, R55046, N21648, N31054, N48001, AA464953, AA426224, AA430556, AA600829, AA744708, AA747361, AA976473, AI097658

831726	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 547 of SEQ ID NO:360, b is an integer of 15 to 561, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:360, and where b is greater than or equal to a + 14.	
831736	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1666 of SEQ ID NO:361, b is an integer of 15 to 1680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:361, and where b is greater than or equal to a + 14.	T60384, T93026, T83297, R17403, R17423, R21319, H65765, N94506, W23956, W24344, W45068, W57786, W57860, W81343, AA058929, AA151788, AA151833
831762	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 726 of SEQ ID NO:362, b is an integer of 15 to 740, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:362, and where b is greater than or equal to a + 14.	
831801	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:363, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:363, and where b is greater than or equal to a + 14.	T39530, T64430, R36089, H12597, H12647, H19534, H20096, H26648, H26663, W15192, W45569, W45621, AA018144, AA018145, AA018470, AA039510, AA039529, AA047549, AA047837, AA057785, AA074201, AA075686, AA079138, AA135599, AA135658, AA147502, AA147931, AA156715, AA156811, AA188215, AA186362, AA425996, AA283917, AA514670, AA522463, AA714301, AA742700, AA872728, AA887841, AA971644, AI015637, AI053971, AI054233, AI074507, AI084901, W28363
831848	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2839 of SEQ ID NO:364, b is an integer of 15 to 2853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:364, and where b is greater than or equal to a + 14.	T77112, R13655, R19353, R19511, R24780, R35812, R36752, R38177, R43861, R44629, R45511, R43861, R45511, R44629, R71248, R71299, R82784, H00629, H01917, H04479, H45706, H45757, H94039, H94125, N30574, N57220, AA033684, AA114107, AA253260, AA461547, AA460619, AA715125, AI096588, C03714, AA092127
831861	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1823 of SEQ ID NO:365, b is an integer of 15 to 1837, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:365, and where b is greater than or equal to a + 14.	T57456, T58038, T58104, R08156, R27046, R28341, R28340, N32411, N56831, N78961, W16984, W16954, W17352, W74522, W79861, AA025882, AA025883, AA084109, AA100121, AA100060, AA132713

831866	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1809 of SEQ ID NO:366, b is an integer of 15 to 1823, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:366, and where b is greater than or equal to a + 14.	
831878	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 884 of SEQ ID NO:367, b is an integer of 15 to 898, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:367, and where b is greater than or equal to a + 14.	
831899	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1103 of SEQ ID NO:368, b is an integer of 15 to 1117, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:368, and where b is greater than or equal to a + 14.	AA159048, AA768390, AA806956
831913	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2212 of SEQ ID NO:369, b is an integer of 15 to 2226, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:369, and where b is greater than or equal to a + 14.	
831972	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3622 of SEQ ID NO:370, b is an integer of 15 to 3636, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:370, and where b is greater than or equal to a + 14.	
831985	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4025 of SEQ ID NO:371, b is an integer of 15 to 4039, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:371, and where b is greater than or equal to a + 14.	
831986	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1585 of SEQ ID NO:372, b is an integer of 15 to 1599, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:372, and where b is greater than or equal to a + 14.	
832010	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 450 of SEQ ID NO:373, b is an integer of 15 to 464, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:373, and where b is greater than or equal to a + 14.	
832016	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 876 of SEQ ID NO:374, b is an integer of 15 to 890, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:374, and where b is greater than or equal to a + 14.	
832041	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1860 of SEQ ID NO:375, b is an integer of 15 to 1874, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:375, and where b is greater than or equal to a + 14.	R63637, R92994, N30838, N30844, N41366, N41372, AA639771
832044	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2004 of SEQ ID NO:376, b is an integer of 15 to 2018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:376, and where b is greater than or equal to a + 14.	T56668, R09616, R20197, R44983, R52998, R52997, R44983, H06485, H06543, H09799, H09885, H24790, N57987, N62197, N76494, W02915, W78217, AA041290, AA041323, AA074236, AA075127, AA075212, AA075847, AA088708, AA088793, AA112359, AA121803, AA151677, AA166711, AA167069, AA181608, AA188478, AA194067, AA194182, AA221025, AA221037, AA228036, AA228145, AA557397, AA564567, AA582681, AA582151, AA601549, AA613841, AA832393, AA846987, AA865356, AA866164, AA872667, AA862962, AA911092, AA937359, AI000072, D83877
832049	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 804 of SEQ ID NO:377, b is an integer of 15 to 818, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:377, and where b is greater than or equal to a + 14.	
832122	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2551 of SEQ ID NO:378, b is an integer of 15 to 2565, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:378, and where b is greater than or equal to a + 14.	
832148	Preferably excluded from the present invention are	T78202, R37864, R62706, R78737,

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1666 of SEQ ID NO:379, b is an integer of 15 to 1680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:379, and where b is greater than or equal to a + 14.	R78736, H62109, N50394, N51659, N67973, N80394, W33108, W33107, AA016055, AA074831, AA075097, AA256793, AA256472, AA418825, AA418922, AA430755, AA280663, AA281049, AA467867, AA502148, H71558, AA721278, AA748880, AA809767, AA810852, AA832174, AA911263, AA938484, AA975282, D80672, D81573, D81746, A1096900, C02375
832197	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1253 of SEQ ID NO:380, b is an integer of 15 to 1267, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:380, and where b is greater than or equal to a + 14.	
832237	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1017 of SEQ ID NO:381, b is an integer of 15 to 1031, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:381, and where b is greater than or equal to a + 14.	R36943, R42259, R53230, R42259, H09607, AA150724, AA831055
832246	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1583 of SEQ ID NO:382, b is an integer of 15 to 1597, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:382, and where b is greater than or equal to a + 14.	H13698, H13750, R91283, R91322, H97506, N64810, N75659, W61290, W65386, H54890, AA568261, AA830860, AA863239, AA873329, AA938701, D82264, C18047
832256	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 161 of SEQ ID NO:383, b is an integer of 15 to 175, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:383, and where b is greater than or equal to a + 14.	
832280	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2157 of SEQ ID NO:384, b is an integer of 15 to 2171, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:384, and where b is greater than or equal to a + 14.	H09977, H09978, R89392, R94438, H93033, H93466, H93904, N29334, N53767, N57027, N71868, N71879, N73126, W24652, AA026682, AA047124, AA127259, AA224396, AA224473, AA227220, AA236734, AA236763, AA236910, AA236919
832285	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2350 of SEQ ID NO:385, b is an integer of 15 to 2364, where both a and b correspond to the positions of nucleotide	R12740, R14184, R15171, R26447, R28455, R34165, R35396, R39792, R40473, R49696, R41588, R40473, R49696, R70668, R70669, R79640, R79833, H02312, H08199, H08297, R99351, H84241, H84567, H85554,

	residues shown in SEQ ID NO:385. and where b is greater than or equal to a + 14.	N24354, N25230, N32462, N33863, N64676, N70374, N80109, W47526, W47527, W80678, W80934, W93668, AA082195, AA223758, AA243624, AA255527, AA256711, AA262387, AA281015, AA281094, AA281183, AA281203, AA287927, AA287991, AA505084, AA505086, AA525301, AA553559, AA564243, AA582189, AA737010, AA808271, AA872481, AA937541, A1015987, C01015, C20842
832294	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2850 of SEQ ID NO:386, b is an integer of 15 to 2864, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:386. and where b is greater than or equal to a + 14.	
832326	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2669 of SEQ ID NO:387, b is an integer of 15 to 2683, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:387, and where b is greater than or equal to a + 14.	
832333	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1432 of SEQ ID NO:388, b is an integer of 15 to 1446, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:388, and where b is greater than or equal to a + 14.	
832346	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 709 of SEQ ID NO:389, b is an integer of 15 to 723, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:389, and where b is greater than or equal to a + 14.	T88928, R12446, R37113, R42462, H15692, H18859, N34664, AA132220, AA224337, AA460720, AA492479
832370	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1032 of SEQ ID NO:390, b is an integer of 15 to 1046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:390, and where b is greater than or equal to a + 14.	
832381	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 685 of SEQ ID NO:391, b is an integer of 15 to 699, where both a	

	and b correspond to the positions of nucleotide residues shown in SEQ ID NO:391, and where b is greater than or equal to a + 14.	
832394	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1531 of SEQ ID NO:392, b is an integer of 15 to 1545, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:392, and where b is greater than or equal to a + 14.	
832454	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 735 of SEQ ID NO:393, b is an integer of 15 to 749, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:393, and where b is greater than or equal to a + 14.	T57094, T58711, T68990, T71879, R92183, H93778, N63977, N80768, AA034382, AA034383, AA057664, AA235744, AA425865, AA524693, AA551804, AA523604, AA614639, AA740316, AA872373, AA938571, AA947337, R28997, AA640968, C21135
832465	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 597 of SEQ ID NO:394, b is an integer of 15 to 611, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:394, and where b is greater than or equal to a + 14.	R36004, R36378, H71881, H96279, N50049, N63692, W74426, W79180, W87805, AA421015, AA527679, AA833773, AA987375, F19351, AA642491, C14893, C14937
832475	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1842 of SEQ ID NO:395, b is an integer of 15 to 1856, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:395, and where b is greater than or equal to a + 14.	
832495	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2637 of SEQ ID NO:396, b is an integer of 15 to 2651, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:396, and where b is greater than or equal to a + 14.	
832498	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2493 of SEQ ID NO:397, b is an integer of 15 to 2507, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:397, and where b is greater than or equal to a + 14.	T67126, T67127, R13516, R20638, H64071, N22361, N25516, N39506, N75609, N78204, W40313, W45344, AA074739, AA074803, AA143509, AA523999, AA552542, AA554032, N20483, AA588804, AA617733, AA577150, AA577309, AA579423, AA740813, AA835721, AA836640, AA909766, AA936979, AA947310, N26815, A1085484, D78707, W67520, W68152
832501	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	

	where a is any integer between 1 to 1259 of SEQ ID NO:398, b is an integer of 15 to 1273, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:398, and where b is greater than or equal to a + 14.	
832505	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3760 of SEQ ID NO:399, b is an integer of 15 to 3774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:399, and where b is greater than or equal to a + 14.	T50501, T50636, T92136, R52390, R59648, H06170, H28886, H28885, R96577, R96600, H84171, H94122, H98228, N36866, N36872, N46136, N46142, N63589, N66323, W48779, W49798, AA029033, AA054487, AA058524, AA084466, AA086177, AA098967, AA099485, AA100345, AA147008, AA147009, AA146910, AA146909, AA160346, AA159865, AA192832, AA203513, AA252521, AA252553, AA463513, AA463570, AA421250, AA425704, AA427774, AA278328, AA278999, AA280712, AA281733, AA281871, AA282407, AA282626, AA283639, AA542810, AA557893, AA568486, AA569759, AA577522, AA659517, AA659737, AA664537, AA713950, AA805488, AA835999, AA876619, AA931568, AA935758, AA946722, AI000603, D82640
832539	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1508 of SEQ ID NO:400, b is an integer of 15 to 1522, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:400, and where b is greater than or equal to a + 14.	H72563, AA160114, AA159654, AA161261, AA165097, AA223618, AA243203
832554	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1356 of SEQ ID NO:401, b is an integer of 15 to 1370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:401, and where b is greater than or equal to a + 14.	
832569	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1398 of SEQ ID NO:402, b is an integer of 15 to 1412, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:402, and where b is greater than or equal to a + 14.	
832578	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1736 of SEQ ID NO:403, b is an integer of 15 to 1750, where both a and b correspond to the positions of nucleotide	R09545, R09658, R09967, R11471, R16714, R16910, R16965, R19372, R80788, R80988, H28725, H63085, H63169, H75499, H75500, N33554, N41536, N52961, N52966, N74070, W01039, W57770, W57843, W60109,

	residues shown in SEQ ID NO:403, and where b is greater than or equal to a + 14.	W91978, W92107, AA001984, AA004653, AA027155, AA418427, AA281395, AA532870, AA564737, AA588889, AA631841, AA639548, AA765363, AA877896, AA887900, AA974026, AI057270, AI084214, AI094490, AI096750, AI097632, AI096745
832615	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1325 of SEQ ID NO:404, b is an integer of 15 to 1339, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:404, and where b is greater than or equal to a + 14.	
832620	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 468 of SEQ ID NO:405, b is an integer of 15 to 482, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:405, and where b is greater than or equal to a + 14.	
832632	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1399 of SEQ ID NO:406, b is an integer of 15 to 1413, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:406, and where b is greater than or equal to a + 14.	
832633	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1679 of SEQ ID NO:407, b is an integer of 15 to 1693, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:407, and where b is greater than or equal to a + 14.	R69173, AA053085, AA053597, AA427705, AA730380, AA865757, AA911497, AI083906
833483	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1328 of SEQ ID NO:408, b is an integer of 15 to 1342, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:408, and where b is greater than or equal to a + 14.	
834574	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2403 of SEQ ID NO:409, b is an integer of 15 to 2417, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:409, and where b is greater than or equal to a + 14.	
834859	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1387 of SEQ ID NO:410, b is an integer of 15 to 1401, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:410, and where b is greater than or equal to a + 14.	
834861	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3002 of SEQ ID NO:411, b is an integer of 15 to 3016, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:411, and where b is greater than or equal to a + 14.	
834890	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 944 of SEQ ID NO:412, b is an integer of 15 to 958, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:412, and where b is greater than or equal to a + 14.	T40255, T40256, T40770, T40778, T40803, T41118, T94280, T94627, R13201, R32388, R32389, R53769, H28669, H39502, H42532, H42533, R82957, R85205, R85206, R88749, R90730, R90754, R91006, R92221, H56130, H56210, H58500, H57659, H69479, H69882, N22547, N31579, N42592, N45537, N48687, N56654, N58050, N69059, N73728, N80748, N92927, N94545, W20471, W30838, W52039, W60171, W68292, W93085, W93140, N91563, AA010850, AA011289, AA054592, AA054780, AA081135, AA081214, AA081655, AA081936, AA082127, AA082262, AA088665, AA088804, AA102560, AA100239, AA114237, AA115714, AA115715, AA127304, AA127303, AA147789, AA148021, AA149821, AA152050, AA160878, AA169126, AA171659, AA172131, AA172285, AA194597, AA243129, AA419357, AA425135, AA426203, AA244212, AA505963, AA508221, AA527434, AA527878, AA565036, F17736, AA582605, AA582728, AA583851, AA586421, AA601920, AA570580, AA574367, AA577515, AA577538, AA565998, AA657417, AA659655, AA662658, AA665113, AA714991, AA770684, AA808865, AA826971, AA838507, AA876809, AA877842, AA878025, AA886042, AA886643, AA877950, AA937751, AA948428, AA947036, AA973473, AA983150, AA989361, A1082367, D78922, D82096, N83321, C04115, R29685, C17110, C18023, C18068, AA093539, AA094947, AA151399, AA654145, AA654136
835079	Preferably excluded from the present invention are	N25566, W00985, AA081340,

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 486 of SEQ ID NO:413, b is an integer of 15 to 500, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:413, and where b is greater than or equal to a + 14.	AA152231, AA164282, AA171619, AA187113, AI073932
835554	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3383 of SEQ ID NO:414, b is an integer of 15 to 3397, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:414, and where b is greater than or equal to a + 14.	
835560	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2866 of SEQ ID NO:415, b is an integer of 15 to 2880, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:415, and where b is greater than or equal to a + 14.	
835723	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1602 of SEQ ID NO:416, b is an integer of 15 to 1616, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:416, and where b is greater than or equal to a + 14.	T71562, R11480, R19383, R25309, R46659, R48802, R48913, R50038, R50376, R54963, R46659, R70030, R70077, R70161, R71380, R72303, R72352, R72772, R72773, R73386, R73387, H15775, H15776, H25239, H27204, H30499, H42026, H42613, H43207, H43254, H44314, H44936, H44975, R98394, R98395, R99071, R99271, H58902, H58903, H73590, H73436, H75566, H80599, N40440, N48475, N59703, AA515035, AA515043, AA515450, AA515650, AA515746, AA551788, AA551943, AA554602, AA557281, AA581549, AA581554, AA587399, AA593890, AA593997, AA593998, AA568878, AA568962, AA622458, AA714206, AA728962, AA737738, AA738036, AA738486, AA847538, AA865069, AA872029, AA886612, AA903381, AA916458, AA916464, AA922563, AA928617, AA928314, AA934581, AA973769, AA973767, AA983480, AA991199, AA994932, AA995182, AA999704, AI028371, AA643041
835791	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1801 of SEQ ID NO:417, b is an integer of 15 to 1815, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:417, and where b is greater than or equal to a + 14.	

835817	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1952 of SEQ ID NO:418, b is an integer of 15 to 1966, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:418, and where b is greater than or equal to a + 14.	
835840	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2838 of SEQ ID NO:419, b is an integer of 15 to 2852, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:419, and where b is greater than or equal to a + 14.	T66583, R15957, R22860, R62339, R62341, R62856, AA210836, AA214633, AA256340, AA732582, AA740735
836048	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2691 of SEQ ID NO:420, b is an integer of 15 to 2705, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:420, and where b is greater than or equal to a + 14.	
836898	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1887 of SEQ ID NO:421, b is an integer of 15 to 1901, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:421, and where b is greater than or equal to a + 14.	
836927	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2463 of SEQ ID NO:422, b is an integer of 15 to 2477, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:422, and where b is greater than or equal to a + 14.	
837344	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 763 of SEQ ID NO:423, b is an integer of 15 to 777, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:423, and where b is greater than or equal to a + 14.	
837789	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1635 of SEQ ID NO:424, b is an integer of 15 to 1649, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:424, and where b is greater than or equal to a + 14.	
838549	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1594 of SEQ ID NO:425, b is an integer of 15 to 1608, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:425, and where b is greater than or equal to a + 14.	
838754	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1780 of SEQ ID NO:426, b is an integer of 15 to 1794, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:426, and where b is greater than or equal to a + 14.	
838768	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:427, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:427, and where b is greater than or equal to a + 14.	
839486	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 498 of SEQ ID NO:428, b is an integer of 15 to 512, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:428, and where b is greater than or equal to a + 14.	
839561	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1456 of SEQ ID NO:429, b is an integer of 15 to 1470, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:429, and where b is greater than or equal to a + 14.	R61634, AA135004, AA159213
839816	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 420 of SEQ ID NO:430, b is an integer of 15 to 434, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:430, and where b is greater than or equal to a + 14.	
840068	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1809 of SEQ ID NO:431, b is an integer of 15 to 1823, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:431, and where b is greater than or equal to a + 14.	
840279	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 3377 of SEQ ID NO:432, b is an integer of 15 to 3391, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:432, and where b is greater than or equal to a + 14.	
840489	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2539 of SEQ ID NO:433, b is an integer of 15 to 2553, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:433, and where b is greater than or equal to a + 14.	
840538	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2518 of SEQ ID NO:434, b is an integer of 15 to 2532, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:434, and where b is greater than or equal to a + 14.	<p>T47551, T47552, T64522, T65947, R70190, H97064, N25641, N34240, N48063, N53261, N67904, N92702, N98774, W16899, W20316, W31028, W40137, W45371, W48722, W48577, W68670, W68773, W74242, AA033573, AA033574, AA063270, AA063271, AA065213, AA064894, AA082200, AA083707, AA085441, AA085694, AA088302, AA088303, AA099844, AA099984, AA102604, AA111894, AA112981, AA115039, AA115800, AA115799, AA122221, AA126905, AA126955, AA127109, AA127548, AA127549, AA128933, AA129152, AA129743, AA133290, AA135251, AA151963, AA156321, AA156382, AA160182, AA165104, AA164688, AA173757, AA180038, AA182644, AA190866, AA190959, AA191561, AA191637, AA197348, AA195895, AA258593, AA258622, AA262173, AA464978, AA465047, AA417938, AA418116, AA292727, AA523585, AA525020, AA548516, AA551816, AA554642, AA581720, AA568802, AA579801, AA738216, AA832441, AA903391, AA938688, AA977201, AA987552, AI095102, AI084149, W27768, C05889, C06263, AA089556, AA652586, AA213999, AA213977, AA219123, AA219290, AA435695, D12383, D12389, AA451677, AA453222, AA485641, AA485768, AA488670, AA485947, AA486053, AA486197, AA489511, AA489512, AA489558, AA491452, AA489876, AA600130, AA608644, AA620481, AA664307, AA629754, AA629909, AA677148, AA722910, AA772440, AA773550, AI038219, AI075755, AI081932, AI084706, T10852, T24678, F00208, F00897</p>

840545	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1808 of SEQ ID NO:435, b is an integer of 15 to 1822, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:435, and where b is greater than or equal to a + 14.	
840549	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1016 of SEQ ID NO:436, b is an integer of 15 to 1030, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:436, and where b is greater than or equal to a + 14.	R10733, T86298, R55182, R55183, H00476, H00530, H25856, H25909, H25910, N50923, W84600, W84452, AA227897, D78774, AA486440, AA629249
840551	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1618 of SEQ ID NO:437, b is an integer of 15 to 1632, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:437, and where b is greater than or equal to a + 14.	
840557	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1002 of SEQ ID NO:438, b is an integer of 15 to 1016, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:438, and where b is greater than or equal to a + 14.	
840561	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 580 of SEQ ID NO:439, b is an integer of 15 to 594, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:439, and where b is greater than or equal to a + 14.	
840562	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1566 of SEQ ID NO:440, b is an integer of 15 to 1580, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:440, and where b is greater than or equal to a + 14.	R08937, R09046, R14796, R18307, R31150, R42283, R51828, R54224, R42283, R72104, R72156, R73118, R73171, R73943, H25904, H27191, H27192, H30471, H72478, H72879, H88214, H98231, W45061, W45071, W49842, W67423, W67424, W93880, W94151, AA023007, AA022473, AA032224, AA032282, AA034411, AA035691, AA040428, AA046861, AA046994, AA046313, AA046139, AA053780, AA101657, AA101658, AA167298, AA227543, AA227684, AA458877, AA459067, AA463656, AA464047, AA464754, AA225370, AA225425, AA225400, AA558796, AA582089, AA565830, AA713907,

		AA864510, AA936117, C01002, N86320, C04277, AA652714, AA402391, AA402565, AA479073, AA621791, AA670200, AA456544, AA676732, AA707089, AI014599, AI022852, AI023739, AI091873, AI094288, Z39517, Z43438
840564	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1068 of SEQ ID NO:441, b is an integer of 15 to 1082, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:441, and where b is greater than or equal to a + 14.	
840572	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1227 of SEQ ID NO:442, b is an integer of 15 to 1241, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:442, and where b is greater than or equal to a + 14.	T87514, T87515, H84879, AA001503, AA506411, AA508167, AA715396, AA931268, AA292666, AA478036, AA478193, AA478194, AA707886, AA724969, AA725050, AA779127, AA843885
840600	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 954 of SEQ ID NO:443, b is an integer of 15 to 968, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:443, and where b is greater than or equal to a + 14.	R38172, AA226748, AA484320, AA831852
840604	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1346 of SEQ ID NO:444, b is an integer of 15 to 1360, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:444, and where b is greater than or equal to a + 14.	
840608	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1821 of SEQ ID NO:445, b is an integer of 15 to 1835, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:445, and where b is greater than or equal to a + 14.	
840620	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1341 of SEQ ID NO:446, b is an integer of 15 to 1355, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:446, and where b is greater than or equal to a + 14.	R17303, R41982, R41982, H43756, N62762, AA053677, AA053697, AA084224, AA084019, AA084952, AA419123, AA419160, AA426014, AA425077, AA427847, AA524035, AA565019, AA632254, AA745726, AA835832, AA931712, AA932520, AA937139, AA961716, AA995607, AA453838, AA455030, AA476981, AA479615, AA482659, AA455837,

		AA488554, AA620470, AA781416, AA844227, AI090902, T19161
840625	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 361 of SEQ ID NO:447, b is an integer of 15 to 375, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:447, and where b is greater than or equal to a + 14.	
840626	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1379 of SEQ ID NO:448, b is an integer of 15 to 1393, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:448, and where b is greater than or equal to a + 14.	
840638	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1649 of SEQ ID NO:449, b is an integer of 15 to 1663, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:449, and where b is greater than or equal to a + 14.	H01158, H01159, H05751, H05858, H83341, H83695, N47512, N47513, W39756, W79733, W90027, W90155, AA047691, AA047741, AA086374, AA100549, AA159315, AA159414, AA282525, AA282633, AA595381, AA688093, AA744757, AA865203, AA933811, AA969838, AA975917, F18424, D12197, D12219, AA478596, AA665540, AA909221, AA969720, AI049820
840649	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1366 of SEQ ID NO:450, b is an integer of 15 to 1380, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:450, and where b is greater than or equal to a + 14.	R00133, R22651, R44356, R44356, R56353, R93194, N47106, N50316, N50780, N55139, AA010596, AA010597, AA012940, AA012888, AA013216, AA013313, AA017544, AA017417, AA047814, AA047792, AA235545, AA262268, AA262879, AA563873, AA570239, AA573586, AA827412, AA862337, AA902472, AA962409, AA971292, AA973596, AI056509, AI080455, AA410833, T23822, T16761
840651	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 912 of SEQ ID NO:451, b is an integer of 15 to 926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:451, and where b is greater than or equal to a + 14.	
840666	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1628 of SEQ ID NO:452, b is an integer of 15 to 1642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:452, and where b is greater than or equal to a + 14.	N32778, N34353, N34537, N41780, N42818, N93337, W25190, AA035229, AA035230, AA044070, AA044162, AA195074, AA195174, AA419441, AA731906, AA761315, AA761330, AA766382, AA766593, AA769537, AA805515, AA806516, AA809893, AA814954, AA857917, N44554,

		AA393941, A1074651, T10618, Z35722
840681	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2240 of SEQ ID NO:453, b is an integer of 15 to 2254, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:453, and where b is greater than or equal to a + 14.	
840682	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1917 of SEQ ID NO:454, b is an integer of 15 to 1931, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:454, and where b is greater than or equal to a + 14.	
840684	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 757 of SEQ ID NO:455, b is an integer of 15 to 771, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:455, and where b is greater than or equal to a + 14.	
840697	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1155 of SEQ ID NO:456, b is an integer of 15 to 1169, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:456, and where b is greater than or equal to a + 14.	R00751, R02584, R02703, R69879, R69927, H13156, H29249, H29248, H41216, R83398, H54666, H54667, H73551, H73552, H90468, H91760, H97869, N31729, N31735, N51232, W32147, W32175, W44313, W45660, W57760, W57761, W68386, W68502, W68752, W68835, W72538, W76163, AA035740, AA043246, AA043585, AA044419, AA043053, AA047593, AA047601, AA088798, AA147253, AA155747, AA160105, AA165689, AA172386, AA173747, AA189005, AA189006, AA471066, AA507210, AA513086, AA516406, AA514685, AA635861, AA657400, AA668796, AA737126, AA768005, AA768358, AA887459, AA977176, D80509, D81008, D81471, D81800, D82666, N83795, AA643662, AA284937, AA290823, AA447984, AA448126, AA676807, AA709464, AA780333, AA843801, AA853391, AA868403, AA917460, T17166, T17177, T16671, T48481, T48507
840698	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3235 of SEQ ID NO:457, b is an integer of 15 to 3249, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:457, and where b is	

	greater than or equal to $a + 14$.	
840708	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1902 of SEQ ID NO:458, b is an integer of 15 to 1916, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:458, and where b is greater than or equal to $a + 14$.	R21272, R45362, R45362, H06049, H13385, AA082768, AA101114, AA131634, AA131718, AA152290, AA150232, AA418083, AA418230, AA422115, AA424919, AA426139, AA741277, AA749290, AA811505, AA836102, AA411231, AA453804, AA453890, AA758905, AA769817, AA770192, AA904708, AA905158, AA969156, A1093952, Z42470, Z41665, Z44053
840714	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2759 of SEQ ID NO:459, b is an integer of 15 to 2773, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:459, and where b is greater than or equal to $a + 14$.	
840716	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2017 of SEQ ID NO:460, b is an integer of 15 to 2031, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:460, and where b is greater than or equal to $a + 14$.	
840721	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1825 of SEQ ID NO:461, b is an integer of 15 to 1839, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:461, and where b is greater than or equal to $a + 14$.	
840735	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 765 of SEQ ID NO:462, b is an integer of 15 to 779, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:462, and where b is greater than or equal to $a + 14$.	T47277, T56085, T93319, T85388, H57620, H58465, N77902, N80219, N93978, W19715, W37380, W37643, W38508, W38722, W47048, W68079, W67976, W69349, W69350, AA025313, AA024560, AA063371, AA063370, AA463222, AA463223, AA424422, AA469264, AA480510, AA507733, AA524348, AA557233, AA602394, AA603318, AA631014, AA569554, AA575944, AA688112, AA911131, AA932225, AA937015, AA994856, A1077707, N92552, W00604, C00184, AA292823, AA401683, AA663906, AA664122, AA771943, AA779608, AA812529, A1028120, A1027559, A1032511, A1033880, A1034204, A1078458, A1041685, D31473, T64469
840738	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	

	sequence described by the general formula of a-b, where a is any integer between 1 to 1703 of SEQ ID NO:463, b is an integer of 15 to 1717, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:463, and where b is greater than or equal to a + 14.	
840745	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 814 of SEQ ID NO:464, b is an integer of 15 to 828, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:464, and where b is greater than or equal to a + 14.	
840747	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1159 of SEQ ID NO:465, b is an integer of 15 to 1173, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:465, and where b is greater than or equal to a + 14.	
840756	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 507 of SEQ ID NO:466, b is an integer of 15 to 521, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:466, and where b is greater than or equal to a + 14.	AA074254
840776	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1414 of SEQ ID NO:467, b is an integer of 15 to 1428, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:467, and where b is greater than or equal to a + 14.	T47069, T47068, T63511, T63587, T79637, T79722, R36141, R36419, R65831, R65934, R69612, R69701, H00464, H00514, H04572, H04575, H12602, H12652, H13166, H66218, H67195, H67868, H67868, N62959, W92249, W92250, W92609, W95234, AA007598, AA193373, AA195360, AA195359, AA425046, AA430627, AA428172, AA484871, AA557201, AA902998, AA927360, N79862, AA479674, AA477192, AA481418, AA481651, AA495983, AA496377, AA496655, AA912146, AA912181, AI049805, AA693485
840784	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3449 of SEQ ID NO:468, b is an integer of 15 to 3463, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:468, and where b is greater than or equal to a + 14.	
840788	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 607 of SEQ ID	

	NO:469, b is an integer of 15 to 621, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:469, and where b is greater than or equal to a + 14.	
840794	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1819 of SEQ ID NO:470, b is an integer of 15 to 1833, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:470, and where b is greater than or equal to a + 14.	
840797	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3188 of SEQ ID NO:471, b is an integer of 15 to 3202, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:471, and where b is greater than or equal to a + 14.	
840799	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 927 of SEQ ID NO:472, b is an integer of 15 to 941, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:472, and where b is greater than or equal to a + 14.	
840818	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1265 of SEQ ID NO:473, b is an integer of 15 to 1279, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:473, and where b is greater than or equal to a + 14.	
840822	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3195 of SEQ ID NO:474, b is an integer of 15 to 3209, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:474, and where b is greater than or equal to a + 14.	T47621, T77305, T83423, R18484, R51973, R51974, R73192, H06082, H12940, H27135, H45895, H45904, N72089, W00342, W52213, W96404, AA045488, AA058907, AA062768, AA069032, AA081439, AA082427, AA084417, AA101216, AA234022, AA534011, AA565390, AA588319, AA588430, AA568701, AA635907, AA579930, AA827039, AA857519, AA872490, AA904077, AA995057, A1073336, N95359, C15883, AA781445, AA906492, A1037943, A1039428
840830	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 819 of SEQ ID NO:475, b is an integer of 15 to 833, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:475, and where b is	N33920, N33932, N49642, N49629, AA508747, AA514767, AA583465, AA805203, AA878968, U37231, T24573

	greater than or equal to $a + 14$.	
840846	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1127 of SEQ ID NO:476, b is an integer of 15 to 1141, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:476, and where b is greater than or equal to $a + 14$.	T68706, T68719, T68771, T68784, T73424, T73431, T73486, T73492, T73499, T73535, T89865, R11465, T79345, T79774, T81799, T82119, T82855, T96198, T96454, T96686, T96802, T96920, T97027, T99996, T99997, R00156, R00157, R83404, R85816, R91357, R93314, R94713, R94794, R97348, R99024, R99798, H48280, H48369, H48754, H54738, H54739, H55985, H55984, H56050, H56244, H57662, H57872, H57873, H58502, H60170, H60211, H62933, H69203, H69228, H69229, H71630, H73011, H73012, H81193, H81194, H90826, H91385, N33963, N49672, N49822, N52577, N54836, N58435, N64440, N66934, N69249, N69373, N74062, N75759, N78025, N78145, N94249, N95116, W03303, W01169, W01912, N91401, AA025243, AA026028, AA193126, AA194255, AA236507, AA242995, AA622239, AA575858, AA575872, AA576026, AA576150, AA576597, AA864932, AA877934, AA969761, AA994970, AI017867, D82634, C21067, AA431221, AA779655, AA782374, AA812640, AA923315, AA962377, AA993251, AI018445, AI025584, AI092470, T79311
840848	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1088 of SEQ ID NO:477, b is an integer of 15 to 1102, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:477, and where b is greater than or equal to $a + 14$.	R10066, R10163, T26606, R61067, R72646, H08322, H47858, H47859, R86048, H68866, H68867, H69098, H82364, N58491, N78080, W52876, W60083, AA043086, AA045865, AA045866, AA055712, AA057298, AA058743, AA079887, AA079888, AA099233, AA099234, AA102153, AA113213, AA115932, AA121000, AA131067, AA143412, AA146598, AA155632, AA155688, AA160447, AA173257, AA173248, AA195987, AA196375, AA233537, AA463552, AA503072, AA551794, AA586410, AA594814, AA613123, AA573356, AA580449, AA731195, AA742856, AA827930, AA863440, AA865529, AA876847, AA953614, AA976924, N84278, N88762, C17112, AA219765, AA284503, AA293437, AA293046, AA669435, AA722103, AI027785, AI073617, AI092707, T17392, F08770, D12026
840860	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	T89645, T89919, T93704, R21871, R22387, R78094, R78181, R78515,

	sequence described by the general formula of a-b, where a is any integer between 1 to 4187 of SEQ ID NO:478, b is an integer of 15 to 4201, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:478, and where b is greater than or equal to a + 14.	R78560, H40124, H41731, N28359, N42893, N62851, N64787, N67463, N76199, N77065, N77758, W67341, W68381, AA034244, AA044935, AA045056, AA057392, AA057684, AA071214, AA071442, AA081937, AA082360, AA082229, AA082230, AA082708, AA083297, AA083188, AA127585, AA149575, AA151791, AA167113, AA173360, AA191227, AA195437, AA223329, AA223614, AA243268, AA261939, AA262815, AA262816, AA422160, AA426276, AA225924, AA504466, AA504634, AA522823, AA554566, AA632813, AA576873, AA662886, AA730326, AA748669, AA828942, AA837197, AA857065, AA857683, AA862276, AA864246, AA873317, AI083733, D82604, D82635, N81179, N85023, N85166, N85712, C00193, C00199, C02425, N87331, N88683, N88852, N89408, C02916, C05151, C06382, AA642209, C21319, AA091285, AA091688, AA094300, AA205974, AA206268, AA206598, AA205324, AA649340, AA247212, AA404505, AA421263, AA421361, D11545, AA441853, AA441826, AA463350, AA463858, AA487271, AA487388, AA496439, AA496488, AA634627, AA663685, AA665466, AA456144, AA722996, AA772136, AA772153, AA774179, AA992418, AI076734, T10506, Z30218, Z38961, T16262, T48571, D31110, D45597, F06042, F00682
840861	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 773 of SEQ ID NO:479, b is an integer of 15 to 787, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:479, and where b is greater than or equal to a + 14.	T52180, T52256, T57048, T60934, T60993, T94137, T94228, T91060, T85924, R23216, R23292, R31316, R31576, R62640, R62693, H03198, H18231, H18269, H22414, H26112, H26116, H26378, H40754, H38895, H47721, H48072, R89134, R89141, R91829, R91836, R98452, H65626, H65627, H69728, H71913, H71914, H78844, H80090, H83062, H84585, H87467, H87577, H93457, H93458, N23179, N30549, N32644, N39052, N40455, N48060, N48244, N53258, N53755, N63557, N94559, N94883, N94981, N95791, N42987, W19445, W19573, W23831, W24902, W30850, W32700, W32701, W37523, W56867, W60497, W60972, W61219, W69268, W69346, W80426, W80556, W94817, W95832, W95966, W96035, W96092,

		<p>N90310, AA010147, AA010148, AA025440, AA025757, AA027347, AA027822, AA027874, AA029650, AA029651, AA037779, AA039260, AA046801, AA046818, AA054707, AA058654, AA062684, AA063287, AA074876, AA074979, AA084381, AA085264, AA085328, AA085598, AA122190, AA120978, AA133892, AA129630, AA172403, AA172206, AA190489, AA190525, AA464455, AA464996, AA225769, AA259210, AA483109, AA483741, AA493542, AA502162, AA516183, AA522567, AA526813, AA557654, AA588882, AA593799, AA576216, AA659530, AA662308, AA688246, AA688254, AA687457, AA687516, AA689236, AA728852, AA729032, AA747479, AA747979, AA831447, AA887348, AA903105, AA916516, AA934714, AA953363, AA976759, AA991410, AA991434, AI002147, AI028033, N83338, C02469, R29174, AA090669, AA092066, AA648634, AA443968, AA444149, AA482243, AA482340, AA485406, AA598458, AA644566, AA664032, AA680199, AA676482, AA629708, AA630110, AA457100, AA431269, AA405296, AA405332, AA721997, AA724146, AA774657, AA781529, AA781641, AA781838, AA782849, AA813171, AA843229, AA846744, AA846814, AA854299, AA854765, AA789029, AA993047, AI023973, AI027725, AI031943, AI038463, AI041602, AI085085, AI086504, AI088189</p>
840871	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 717 of SEQ ID NO:480, b is an integer of 15 to 731, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:480, and where b is greater than or equal to a + 14.</p>	<p>H42821, AA028094, AA099211, AA160368, AA223572, AA232552, AA252811</p>
840874	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1105 of SEQ ID NO:481, b is an integer of 15 to 1119, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:481, and where b is greater than or equal to a + 14.</p>	
840878	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,</p>	<p>T40405, T41252, T47240, T47241, T50233, T52891, T57110, T58359, R19508, R43858, R43858, R75598,</p>

	where a is any integer between 1 to 2042 of SEQ ID NO:482, b is an integer of 15 to 2056, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:482, and where b is greater than or equal to a + 14.	R75665, H13192, H13193, N25264, N31900, N42683, N72995, N93388, W25360, W47628, W47629, AA009691, AA009410, AA045777, AA045910, AA063040, AA063076, AA130044, AA149205, AA149206, AA191678, AA252698, AA464304, AA225264, AA514845, AA526726, AA548411, AA548704, AA552050, AA552558, AA568675, AA827017, AA834447, AA838450, AA886357, AA886653, AA887879, AA916602, AA928685, AA968793, A1005016, W28859, AA134038, AA455118, AA496380, AA496656, AA598830, AA653270, AA725217, AA733068, A1004394, A1023815, A1026954, A1040891, Z25388, Z28470, AA702322
840880	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO:483, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:483, and where b is greater than or equal to a + 14.	H02306, H02418, N48196, N53344, AA059013, AA506159, AA613938, AA662759, AA976725, AA854631
840884	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1864 of SEQ ID NO:484, b is an integer of 15 to 1878, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:484, and where b is greater than or equal to a + 14.	
840907	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1552 of SEQ ID NO:485, b is an integer of 15 to 1566, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:485, and where b is greater than or equal to a + 14.	
840926	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3032 of SEQ ID NO:486, b is an integer of 15 to 3046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:486, and where b is greater than or equal to a + 14.	
840932	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1890 of SEQ ID NO:487, b is an integer of 15 to 1904, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:487, and where b is	

	greater than or equal to $a + 14$.	
840940	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 813 of SEQ ID NO:488, b is an integer of 15 to 827, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:488, and where b is greater than or equal to $a + 14$.	
840947	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1912 of SEQ ID NO:489, b is an integer of 15 to 1926, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:489, and where b is greater than or equal to $a + 14$.	
840959	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1447 of SEQ ID NO:490, b is an integer of 15 to 1461, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:490, and where b is greater than or equal to $a + 14$.	
840964	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 791 of SEQ ID NO:491, b is an integer of 15 to 805, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:491, and where b is greater than or equal to $a + 14$.	R79226, H12332, H51062, H83364, H89523, N27508, N30527, N40233, N52503, N53855, N94367, AA055215, AA055306, AA188169, AA468498, AA470473, AA563662, AA622643, AA579613, AA668790, AA748160, AA765447, AA873430, AA879079, AA903275, AA970424, N73354, AA402259, AA883758, AA890505, AA906005, AI023931
840979	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2255 of SEQ ID NO:492, b is an integer of 15 to 2269, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:492, and where b is greater than or equal to $a + 14$.	
840984	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4094 of SEQ ID NO:493, b is an integer of 15 to 4108, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:493, and where b is greater than or equal to $a + 14$.	
840986	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2195 of SEQ ID NO:494, b is an integer of 15 to 2209, where both a and b correspond to the positions of nucleotide	H25393, H25394, H25511, H25512, R95750, R95794, H64076, H64131, H68715, H80548, H80604, H94681, H95039, H99481, N28293, N30167, N35782, W47389, W47262, W61304, W65368, AA054346, AA054383,

	residues shown in SEQ ID NO:494, and where b is greater than or equal to a + 14.	AA058320, AA058448, AA512954, AA558416, AA588459, AA935690, AI097565, N87339, AA993027, AA993568, AA701454, AA702350
840988	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1663 of SEQ ID NO:495, b is an integer of 15 to 1677, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:495, and where b is greater than or equal to a + 14.	T87048, R24473, R43337, R43337, N75007, W05750, AA182467, AA227466, AA504464, AA504538, AA923479, AA648887, AA663889, AI027636, AI028506, AI026720, Z42717
840990	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1688 of SEQ ID NO:496, b is an integer of 15 to 1702, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:496, and where b is greater than or equal to a + 14.	
840992	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2362 of SEQ ID NO:497, b is an integer of 15 to 2376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:497, and where b is greater than or equal to a + 14.	
841009	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 826 of SEQ ID NO:498, b is an integer of 15 to 840, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:498, and where b is greater than or equal to a + 14.	T40334, T41195, T79150, T79231, T85615, T98895, T99485, R25796, H03311, H03312, H11314, H21245, R91754, R91755, R93025, R97834, R97886, R99577, R99583, R99683, R99689, H88057, H97799, H97870, N34019, N35363, N42786, N44738, N52502, N70158, N72884, N74746, N93542, N95357, N98354, W01181, W03108, W15165, W19587, W21350, W24700, W24805, W39226, W48682, W49637, W49739, W51977, W67546, W67528, W67665, W79731, W93828, W93829, AA025348, AA025356, AA024401, AA024402, AA029589, AA029588, AA099331, AA099865, AA121627, AA126717, AA126816, AA126817, AA133155, AA165162, AA165163, AA557332, AA640015, AA579505, AA665011, AA665221, AA738009, AA830748, AA918150, AA918992, AA947223, AA974955, AI083731, N56157, N89240, AA092060, AA094384, AA650291, AA292814, AA402491, F20671, F21115, D11655, D11564, D11605, D12048, AA634049, U54738, AA732766, AA782030, AA843638, AA860477, AA861482, AI018649,

		AI092171, Z28714, T23956, AA694568
841012	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 447 of SEQ ID NO:499, b is an integer of 15 to 461, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:499, and where b is greater than or equal to a + 14.	
841016	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2768 of SEQ ID NO:500, b is an integer of 15 to 2782, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:500, and where b is greater than or equal to a + 14.	R21854, R21868, R23349, R27518, R63726, R63775, R65731, R65957, R65958, R66192, R66977, R66978, R67072, R69600, R69690, H12415, H12416, N46541, N47260, N47778, N48572, N51984, N95008, W25613, W31713, W32142, W38029, W38650, W38655, AA034256, AA037658, AA037660, AA039268, AA042908, AA042921, AA063533, AA126558, AA130121, AA130157, AA137270, AA136020, AA232954, AA233044, AA429346, AA429872, AA565520, AA604780, AA610435, AA631349, AA631518, AA740206, AA770618, AA912228, AI079705, N84191, N85956, N92894, W38030, C00380, N83173, C03262, AA092010, U82782, AA247592, AA284977, AA283619, AA291890, AA293636, AA410312, AA410537, AA453566, AA487623, AA626442, AA628932, AA629190, AA629753, AA629916, AA719528, AA843073, AA844228, AA890492, AI024670, AI051881, AI061324, T11149
841017	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1235 of SEQ ID NO:501, b is an integer of 15 to 1249, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:501, and where b is greater than or equal to a + 14.	R21764, R21815, N71125, W17312, AA112660, AA179538, AA179507, AA902202, AA907419, AA913594, AA994481, AI049652
841021	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1344 of SEQ ID NO:502, b is an integer of 15 to 1358, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:502, and where b is greater than or equal to a + 14.	R23836, W38704, AA033686, AA176734, AA192268, AA525913, AA531505, AA532666, AA533781, AA533827, AA533949, AA554396, AA576754, AA906883, N24273, C14272, C14285, C14286, C18998
841032	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 487 of SEQ ID NO:503, b is an integer of 15 to 501, where both a and b correspond to the positions of nucleotide	T41136, T52990, T52991, T61494, T63001, T63145, T87321, T87328, T89480, T84361, R05264, N75935, W05120, W25352, AA191627, AA258512, AA418549, AA224774, AA225253, AA229538, AA229537,

	residues shown in SEQ ID NO:503, and where b is greater than or equal to a + 14.	AA229951, AA230318, AA468106, AA468170, AA482814, AA482855, AA482894, AA482906, AA483676, AA491563, AA491627, AA492175, AA501375, AA502205, AA505498, AA508058, AA508125, AA512979, AA513165, AA523347, AA528170, AA531497, AA542840, AA551430, AA553992, AA554420, AA582164, AA583205, AA593192, AA593362, AA602125, AA603378, AA603728, AA617691, AA622865, AA630937, AA631991, AA570802, AA569520, AA654990, AA664728, AA664864, AA665278, AA729616, AA729639, AA729652, AA730512, AA730705, AA730910, AA737300, AA737303, AA736808, AA736909, AA738098, AA740165, AA740553, AA742574, AA742885, AA746988, AA747057, AA747094, AA747099, AA747961, AA748108, AA804727, AA805835, AA834105, AA838466, AA864527, AA872303, AA875939, AA876612, AA876936, AA879219, AA885735, AA886033, AA888159, AA888528, AA888683, AA903652, AA935001, AA948734, AA947836, AA978250, AA994661, AI073926, AI085517, N83676, N86451, N87989, AA642538, AA090432, AA090481, AA092225, AA091643, AA094678, AA094818, AA095214, AA648652, AA649783, AA650377, AA401641, F21163, AA411822, AA442212, AA609798, AA679909, F22052, AA679265, AA722456, AI003421, AI028430, AI077884, AI086743, T89286, R05321, AA694044
841051	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1997 of SEQ ID NO:504, b is an integer of 15 to 2011, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:504, and where b is greater than or equal to a + 14.	AA427363
841064	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1975 of SEQ ID NO:505, b is an integer of 15 to 1989, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:505, and where b is greater than or equal to a + 14.	R95695, H49073, H61707, H61911, H68517, H89719, H89781, H89828, H90680, N76870, W88654, W88898, AA046748, AA053076, AA053592, AA127256, AA127257, AA187351, AA188218, H67307, AA602545, AA720701, AA742288, N87596, AA094084, AA204976, AA676787, AA703221, AA779414, AI038609, AI074626, AI088527, T17364,

		AA702787
841069	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1071 of SEQ ID NO:506, b is an integer of 15 to 1085, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:506, and where b is greater than or equal to a + 14.	
841072	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1471 of SEQ ID NO:507, b is an integer of 15 to 1485, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:507, and where b is greater than or equal to a + 14.	
841078	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1916 of SEQ ID NO:508, b is an integer of 15 to 1930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:508, and where b is greater than or equal to a + 14.	T39937, T68962, T84426, R20697, R36425, R45643, R45643, R68137, R70943, R70957, R70996, R71011, H02222, H05658, H05659, H25177, H29362, H54732, H54733, H60311, H60310, H77561, H77562, H78245, H78446, H82436, H82699, N20477, N57742, N59418, N59709, N76617, AA029237, AA055009, AA055434, AA236337, AA425703, AA427773, AA482193, AA482287, AA612777, AA729757, AA737276, AA744359, AA872776, AA972581, C06045, AA446583, AA449748, AA707197, AA757691, AA774691, AA992571, AI003756, AI027513, AI039704, AI042272, AI052652, AI077380, AI083949, AA774036
841080	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1120 of SEQ ID NO:509, b is an integer of 15 to 1134, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:509, and where b is greater than or equal to a + 14.	
841088	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1368 of SEQ ID NO:510, b is an integer of 15 to 1382, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:510, and where b is greater than or equal to a + 14.	R00895, R21561, R42090, R42090, H05080, N79589, N94381, W16578, W42724, W42813, W46346, W46347, W47346, W57707, W57783, AA070469, AA490938, AA586820, AA580196, AA745683, AA809239, AA931405, D11601, AA725448, AA992145, AI023735, AI025359, AI031575, AI033697, AI038145, AI093535, F00072
841092	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1727 of SEQ ID	

	NO:511, b is an integer of 15 to 1741, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:511, and where b is greater than or equal to a + 14.	
841095	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1516 of SEQ ID NO:512, b is an integer of 15 to 1530, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:512, and where b is greater than or equal to a + 14.	W20114, AA255840, AA568302, AA406006, AA434170
841096	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2985 of SEQ ID NO:513, b is an integer of 15 to 2999, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:513, and where b is greater than or equal to a + 14.	
841102	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2034 of SEQ ID NO:514, b is an integer of 15 to 2048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:514, and where b is greater than or equal to a + 14.	
841104	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3286 of SEQ ID NO:515, b is an integer of 15 to 3300, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:515, and where b is greater than or equal to a + 14.	T93851, R05295, R05354, R71097, R71445, R99396, N53129, W38359, W38417, W38418, W39384, W44785, W44786, W69719, W69847, W73703, AA134718, AA164646, AA164647, AA418958, AA420439, AA420440, AA548241, AA548224, AA558195, W73847, Z19840, AA707354, AA868898, AA917430, A1073454, F09131, F11469, AA700476
841108	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3411 of SEQ ID NO:516, b is an integer of 15 to 3425, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:516, and where b is greater than or equal to a + 14.	T89709, T89806, T91163, T93774, T93819, T95226, R06420, R06475, R23277, R23370, R32742, R32743, R52354, R52355, R64095, R64184, R65984, R65985, R70225, R70226, R76344, R76672, R80205, H00679, H00770, H04254, H24758, H24803, H40273, H38053, H38054, H47116, H47210, R92478, R94873, R94872, H57866, H57867, H59353, H61105, H63261, H63535, H63938, H67759, H67760, H77384, H77385, H82932, H87435, H87541, H88753, H88754, N59081, N59489, N63682, N63939, N66851, N70709, N92122, N99845, W32595, W88585, W90769, W90327, W93082, W93137, AA025425, AA041232, AA114914, AA114913, AA128525, AA235362, AA235944,

		AA235945, AA425197, AA636023, AA639557, AA729723, AA907495, AI056355, AI089809, AA448599, AA449742, AA476262, AA478567, AA478700, AA599706, AA634117, AA677126, AA716562, AA923333, AA948589, AI051569, AI073816, AI074666, AI080341, AI084428, AI090962, AI096407
841118	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1344 of SEQ ID NO:517, b is an integer of 15 to 1358, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:517, and where b is greater than or equal to a + 14.	R20815, R36529, R38448, R46586, R46586, R71122, R71625, R77658, R80438, R80643, H12595, H12644, H99733, N20132, N25939, N29738, N57157, N59874, N67154, N67834, W03438, W04625, W31524, AA044199, AA044996, AA135739, AA135782, AA146912, AA146911, AA173589, AA224431, AA232224, AA256600, AA256599, AA419270, AA419321, AA425195, AA484744, AA507823, AA513832, AA584296, AA600955, AA614813, AA807248, AA904059, AA937796, AA973678, AA983325, AA991604, W01284, C16969, AA476260, AA476318, AA476367, AA609550, AA678511, AA722726, AA904676, AA954468, AI001869, AI031538, Z41297
841119	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1354 of SEQ ID NO:518, b is an integer of 15 to 1368, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:518, and where b is greater than or equal to a + 14.	R18472, W39766, AA076303, AA985235
841124	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 919 of SEQ ID NO:519, b is an integer of 15 to 933, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:519, and where b is greater than or equal to a + 14.	
841137	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:520, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:520, and where b is greater than or equal to a + 14.	T65560, R52978, R59392, H24368, H25185, N33308, AA016160, AA019434, AA082036, AA099724, AA099725, AA101466, AA100553, AA100634, AA100635, AA143046, AA150250, AA151129, AA165491, AA172129, AA176104, AA176248, AA176272, AA197310, AA227454, AA232220, AA243156, AA261904, AA262541, AA458854, AA459044, AA481155, AA493247, AA514323, AA522820, AA558368, AA582973, AA604489, AA640528, AA569125,

		AA569824, AA737640, AA743846, AA808232, AA812222, AA847813, AA865060, AA872242, AA872353, AA922866, AA933823, AA988358, AI056397, AI085865, AI088865, AA205921, AA205923, AA205997, AA204887, AA205731, D11887, AA634040, AA703823, AA703893, Z20424, AA707344, AA707416, AA716243, AA683201, AA890456, AI003274, AI076618, AI090177, T10877, Z28746, T25145, Z40353, F11026, F09670, AA699695, AA701137
841143	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1155 of SEQ ID NO:521, b is an integer of 15 to 1169, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:521, and where b is greater than or equal to a + 14.	T52948, T57468, T59332, T91403, T84637, R69314, R69315, R77481, R77675, R77676, H30692, H70576, N24036, N24905, N26173, N35858, N36029, W39771, W45303, W80648, W80649, AA029895, AA029983, AA036639, AA036850, AA043430, AA043431, AA046109, AA046196, AA076106, AA076107, AA083131, AA083181, AA083285, AA083293, AA147761, AA147804, AA155831, AA155741, AA430082, AA581553, AA593886, AA594233, AA604399, AA576339, AA715836, AA730946, AA737298, AA768251, AA872423, AA888276, AA961744, AA962699, AA975874, AI000132, R29417, AA640954, AA094702, AA398483, AA402600, AA489817, AA489948, AA496290, AA663953, AA663986, AA725581, AA771972, AA781165, AA845829, AA772618, AA773208, AA907551, AI003883, AI004593, AI031669, AI052123, AI085380
841148	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2148 of SEQ ID NO:522, b is an integer of 15 to 2162, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:522, and where b is greater than or equal to a + 14.	
841149	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 785 of SEQ ID NO:523, b is an integer of 15 to 799, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:523, and where b is greater than or equal to a + 14.	AA812937
841151	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b,	

	where a is any integer between 1 to 1708 of SEQ ID NO:524, b is an integer of 15 to 1722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:524, and where b is greater than or equal to a + 14.	
841155	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 548 of SEQ ID NO:525, b is an integer of 15 to 562, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:525, and where b is greater than or equal to a + 14.	
841161	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2009 of SEQ ID NO:526, b is an integer of 15 to 2023, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:526, and where b is greater than or equal to a + 14.	H81836, AA015599, AA099033, AA099034, AA211818, AA741499, AA748367, AA768854, AA805297, AA804217, AI000120, AI090415, D79280, D79875, AA628397, AA628438, AA889584, Z36757
841162	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2833 of SEQ ID NO:527, b is an integer of 15 to 2847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:527, and where b is greater than or equal to a + 14.	T54529, T54568, T39916, T40885, T64421, T64740, T94433, T94519, T94763, T94764, T67443, T67536, T69533, R08782, R08783, T84049, T86084, R18023, R19657, R33054, R33948, R52119, R52216, R53248, R53249, R71311, H04393, H04418, H23196, H23309, H47118, R95161, H54791, H54843, H66487, H66488, H87522, H87523, H92220, H97204, H97637, H98041, N25008, N27036, N32850, N32940, N41677, N41803, N52911, N55243, N55603, N59425, N62367, N67146, N67527, N68040, N68109, N69439, N79136, W03264, W02511, W16533, W16511, W16949, W19590, W20032, W25683, W56022, W57870, W58141, W84752, W84757, W96458, W96558, N89892, N91494, AA035714, AA040577, AA040675, AA043889, AA052991, AA053277, AA053702, AA062923, AA063530, AA074314, AA074909, AA074744, AA076274, AA098982, AA099025, AA146894, AA146893, AA160127, AA160126, AA160195, AA160196, AA169764, AA169385, AA179301, AA223348, AA233558, AA235471, AA460676, AA420533, AA506563, AA523418, AA527621, AA528362, AA531060, AA532619, AA541282, AA552184, AA564466, AA564790, H98795, AA583450, AA613483, AA622733, AA627809, AA577550, AA578980, AA579413, AA714153, AA721494, AA721786, AA737104,

		AA738062, AA745852, AA746662, AA748113, AA814512, AA814515, AA848156, AA858182, AA877787, AA886219, AA886814, AA908510, AA919073, AA953828, AA971838, AA974669, AA974937, AA975070, AA978156, AA985412, AA985429, AA989103, AA989168, AA975750, AI053418, AI053736, AI053892, AI053967, AI053988, AI054073, AI054111, F18748, AI096767, W16689, F17979, W26593, W74635, R29761, AA090571, AA090284, AA092279, AA092676, AA174176, AA206002, AA206857, AA206939, AA204847, AA204862, AA205665, AA205777, C17805, AA215924, AA284942, AA285094, AA292514, AA293872, AA398296, AA401676, AA412021, AA450108, AA450173, AA477960, AA478675, AA479216, AA482218, AA608548, AA634838, AA634910, AA634951, AA644321, AA664196, AA665979, AA668238, AA668579, AA669764, AA669856, AA676279, AA630300, Z20366, AA716371, AA716380, Z19906, AA777040, AA778451, AA781061, AA845834, T25435, Z21568, AA772588, AA917780, AI003327, AI016140, AI024969, AI032559, AI056850, AI088269, AI090536, AI092597, AI093387, T15364, D29035, T27400, T27473, F02321, F06069, T69476, AA773898, AA694154
841163	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 802 of SEQ ID NO:528, b is an integer of 15 to 816, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:528, and where b is greater than or equal to a + 14.	T70512, W58177, W58266, AA027003, AA047260, AA057146, AA076110, AA150122, AA150030, AA424246, AA425670, AA523788, AA554661, AA582491, AA587000, AA633476, AA578397, AA662364, AA687611, AA729856, AA741041, AA806947, AA894899, AA922687, AA934486, AA946779, AA954606, AA962108, AA988276, AI054171, AA436000, AA436099, AA442324, AA451996, AA722958, AA780203, T25797, AI018410, AI024726, AI074321
841169	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 871 of SEQ ID NO:529, b is an integer of 15 to 885, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:529, and where b is greater than or equal to a + 14.	
841172	Preferably excluded from the present invention are	T47968, H14181, H26893, N40884,

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 728 of SEQ ID NO:530, b is an integer of 15 to 742, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:530, and where b is greater than or equal to a + 14.	Z42735
841174	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 511 of SEQ ID NO:531, b is an integer of 15 to 525, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:531, and where b is greater than or equal to a + 14.	
841179	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1911 of SEQ ID NO:532, b is an integer of 15 to 1925, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:532, and where b is greater than or equal to a + 14.	
841183	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 488 of SEQ ID NO:533, b is an integer of 15 to 502, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:533, and where b is greater than or equal to a + 14.	
841186	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1786 of SEQ ID NO:534, b is an integer of 15 to 1800, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:534, and where b is greater than or equal to a + 14.	
841204	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2483 of SEQ ID NO:535, b is an integer of 15 to 2497, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:535, and where b is greater than or equal to a + 14.	
841206	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4076 of SEQ ID NO:536, b is an integer of 15 to 4090, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:536, and where b is greater than or equal to a + 14.	
841207	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide	AA215286

	sequence described by the general formula of a-b, where a is any integer between 1 to 572 of SEQ ID NO:537, b is an integer of 15 to 586, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:537, and where b is greater than or equal to a + 14.	
841211	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1236 of SEQ ID NO:538, b is an integer of 15 to 1250, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:538, and where b is greater than or equal to a + 14.	
841225	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1336 of SEQ ID NO:539, b is an integer of 15 to 1350, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:539, and where b is greater than or equal to a + 14.	
841229	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2495 of SEQ ID NO:540, b is an integer of 15 to 2509, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:540, and where b is greater than or equal to a + 14.	
841237	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1729 of SEQ ID NO:541, b is an integer of 15 to 1743, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:541, and where b is greater than or equal to a + 14.	H39746, H38765, H53680, H84385, H84386, H95751, H96427, H96428, N22709, N24033, N27417, N27531, N31183, N34699, N35427, N40348, N46995, N47385, W47664, W52613, W58021, AA020909, AA032219, AA032277, AA036745, AA053732, AA055872, AA057318, AA062713, AA070398, AA134055, AA132315, AA132625, AA149601, AA149602, AA494458, AA516430, AA534386, AA582804, AA581987, AA588838, AA631158, AA635970, AA577392, AA577494, AA857008, AA894813, AA933084, AI000994, N47386, D11495, D11593, D12071, D11877, D11882, D11902, AA456436, AA683214, AA890528, AA983938, AI074406, AI084728
841241	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2196 of SEQ ID NO:542, b is an integer of 15 to 2210, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:542, and where b is greater than or equal to a + 14.	T64820, R18486, R48571, R48670, R51358, R51464, R70428, R71854, R77389, R77390, H18251, H18293, H18401, H18402, H19764, H19765, H21210, H21526, H24560, H25150, H26985, H28104, H30240, H30297, H30868, H30871, H40890, H41878, H41879, H43721, H43811, H43814,

		R84543, R85932, R87323, R93828, H49042, H49101, H51175, H51188, H68511, H75818, H80551, H80607, N41005, N45017, N56601, N70611, N74891, N93043, N93044, N94350, N98497, W04932, W21511, W21512, W24020, W31043, W47411, W47607, W47659, W47660, W48851, W48618, W52281, W56619, W56649, W68334, W68375, W70156, W70195, W84467, W84552, W90400, W94826, W96342, W96343, N91167, AA016293, AA017674, AA025151, AA025152, AA027955, AA031264, AA031395, AA031855, AA031854, AA035782, AA037318, AA040025, AA056359, AA069269, AA069418, AA069509, AA101608, AA114873, AA114837, AA115697, AA133516, AA220968, AA458530, AA460966, AA463596, AA419091, AA428836, AA507951, AA582836, AA640114, AA659114, AA836669, AA903136, AA903220, AA918099, AA928492, AA971856, AA973427, AA994099, AI016016, AI057267, AA069497, AA206877, AA218868, AA284783, AA284712, AA293434, AA293042, AA402851, AA454608, AA496283, AA609652, AA708123, AA757619, AA757695, AA774425, AA774630, AA775465, AA852435, AA852436, AA852604, AA852605, AA868271, AA884190, T03362, AI042345, AI042606, AI066399, AI086541, AI086967, AI091380, AI091725, AI092820, AI092945, T23722, F03416, F04814, F07127, F08608, F12341
841259	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1701 of SEQ ID NO:543, b is an integer of 15 to 1715, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:543, and where b is greater than or equal to a + 14.</p>	
841260	<p>Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3095 of SEQ ID NO:544, b is an integer of 15 to 3109, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:544, and where b is greater than or equal to a + 14.</p>	T93673, R01175, R01287, R72262, R72263, H53584, H53905, N57686, N59657, N63715, N98804, W86302, W86653, W87312, AA055614, AA058962, AA058961, AA149239, AA180323, AA460554, AA460555, AA492261, AA596073, AA604012, AA612811, AA617927, AA631804, AA767954, AA769298, AA804811, AA814647, AA833776, AA872768, AA873458, AA876551, AA886069,

		AA932445, AA976417, AA989268, AI055853, D80933, AI088938, AI096484, AA215901, AA393250, AA435612, AA449044, AA449758, AA653318, AA678103, AA678744, AA705036, AA854081, AA789188, AA813062, AA868902, AI023192, AI033456, AI090508, Z28555, T25877, D30980, D31048, D31377, F00724, AA682530, AA694353
841264	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1162 of SEQ ID NO:545, b is an integer of 15 to 1176, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:545, and where b is greater than or equal to a + 14.	
841275	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1721 of SEQ ID NO:546, b is an integer of 15 to 1735, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:546, and where b is greater than or equal to a + 14.	
841311	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:547, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:547, and where b is greater than or equal to a + 14.	
841313	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 722 of SEQ ID NO:548, b is an integer of 15 to 736, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:548, and where b is greater than or equal to a + 14.	
841317	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2217 of SEQ ID NO:549, b is an integer of 15 to 2231, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:549, and where b is greater than or equal to a + 14.	T78127, R31279, R31890, R38014, R68187, R68186, R68960, R81444, R81647, H03085, H42975, N22228, N35405, N40226, N52138, N66461, N66470, W48764, W49783, W58388, AA044222, AA044341, AA131687, AA131731, AA224224, AA224527, AA469092, AA580878, AA573581, AA863153, AA903745, AA971415, C03879, AA249392, AA448556, AA449703, F22605, AA723322, AA904943, Z18868, AA971554, AA991799, AI015846, AI037913, AI056007, AI082497, AI090170, AI095394

841322	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1802 of SEQ ID NO:550, b is an integer of 15 to 1816, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:550, and where b is greater than or equal to a + 14.	R21970, R83459, H65911, W76286, AA182592, AA281797, AA281874, AA291943, H65824, AA580660, AA748474, AA829390, AA293389, AA401755, AA910004, AA994494, AI005165, AI081877
841331	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2596 of SEQ ID NO:551, b is an integer of 15 to 2610, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:551, and where b is greater than or equal to a + 14.	
841332	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4007 of SEQ ID NO:552, b is an integer of 15 to 4021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:552, and where b is greater than or equal to a + 14.	
841338	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1766 of SEQ ID NO:553, b is an integer of 15 to 1780, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:553, and where b is greater than or equal to a + 14.	
841345	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3699 of SEQ ID NO:554, b is an integer of 15 to 3713, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:554, and where b is greater than or equal to a + 14.	
841349	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1983 of SEQ ID NO:555, b is an integer of 15 to 1997, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:555, and where b is greater than or equal to a + 14.	
841355	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:556, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:556, and where b is greater than or equal to a + 14.	
841417	Preferably excluded from the present invention are	

	one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3470 of SEQ ID NO:557, b is an integer of 15 to 3484, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:557, and where b is greater than or equal to a + 14.	
841548	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 776 of SEQ ID NO:558, b is an integer of 15 to 790, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:558, and where b is greater than or equal to a + 14.	AA223588
841632	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 544 of SEQ ID NO:559, b is an integer of 15 to 558, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:559, and where b is greater than or equal to a + 14.	
841662	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 520 of SEQ ID NO:560, b is an integer of 15 to 534, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:560, and where b is greater than or equal to a + 14.	H15850, H99706, N78646, W74702, W94916, AA809695
841771	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3029 of SEQ ID NO:561, b is an integer of 15 to 3043, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:561, and where b is greater than or equal to a + 14.	T50029, T67900, T74699, T74819, T88802, T81298, T84439, T95656, R06092, R06196, R14563, R14966, R14970, R16465, R38948, R40957, R40957, R63975, R64085, R66362, R66363, R67505, H17644, H17758, R92097, H48240, H48331, H49625, H49715, H61167, H62068, H69147, N25753, N36472, N69035, N71493, N92970, N98567, N99536, W00665, W24251, W40582, W45462, W45538, W45525, W45687, W44315, W57971, W57944, W70012, W70013, W86733, AA044684, AA071192, AA071199, AA190325, AA191520, AA533197, AA558210, AA581106, AA581161, AA577119, AA857551, AA878885, AA936839, AA975697, D78980, W28535, C02075, C17857
841827	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1372 of SEQ ID NO:562, b is an integer of 15 to 1386, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:562, and where b is	

	greater than or equal to $a + 14$.	
841835	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2624 of SEQ ID NO:563, b is an integer of 15 to 2638, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:563, and where b is greater than or equal to $a + 14$.	
842259	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 677 of SEQ ID NO:564, b is an integer of 15 to 691, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:564, and where b is greater than or equal to $a + 14$.	
842463	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1953 of SEQ ID NO:565, b is an integer of 15 to 1967, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:565, and where b is greater than or equal to $a + 14$.	
842595	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1320 of SEQ ID NO:566, b is an integer of 15 to 1334, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:566, and where b is greater than or equal to $a + 14$.	
842722	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1596 of SEQ ID NO:567, b is an integer of 15 to 1610, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:567, and where b is greater than or equal to $a + 14$.	
842815	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1398 of SEQ ID NO:568, b is an integer of 15 to 1412, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:568, and where b is greater than or equal to $a + 14$.	
842818	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1111 of SEQ ID NO:569, b is an integer of 15 to 1125, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:569, and where b is greater than or equal to $a + 14$.	

843251	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1902 of SEQ ID NO:570, b is an integer of 15 to 1916, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:570, and where b is greater than or equal to a + 14.	
843422	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1239 of SEQ ID NO:571, b is an integer of 15 to 1253, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:571, and where b is greater than or equal to a + 14.	
843784	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1999 of SEQ ID NO:572, b is an integer of 15 to 2013, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:572, and where b is greater than or equal to a + 14.	
844017	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 655 of SEQ ID NO:573, b is an integer of 15 to 669, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:573, and where b is greater than or equal to a + 14.	AA075932
844138	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2418 of SEQ ID NO:574, b is an integer of 15 to 2432, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:574, and where b is greater than or equal to a + 14.	T54096, T54187, T54360, T39143, T40432, T90493, T90589, T89428, T89794, T80000, R00221, R00327, R25952, R26450, R26761, R28459, R55293, R55390, R73233, H42630, H44454, H44498, R83525, R86282, H85785, N33586, N34419, N36244, N48653, N49430, W51915, AA055530, AA055939, AA069732, AA100817, AA122084, AA121407, AA126332, AA133329, AA134151, AA134152, AA134714, AA136470, AA136960, AA157850, AA157906, AA157976, AA159365, AA171854, AA187219, AA186342, AA250818, AA464565, AA464666, AA428826, AA429361, AA491863, AA505512, AA524490, AA558038, AA581979, AA588712, AA593885, AA601110, AA573930, AA577156, AA578735, AA689519, AA730155, AA768486, AA805061, AA826981, AA865985, AA931167, AA947324, AA953202, AA961105, AA962413, AA976440, AA977760, AI032134, AI053416, AI053575,

		A1054013, A1054146, A1054281, U46376, W22126, C00371, C05283, AA641416, AA643346, AA292261, AA421818, AA496452, AA496521, AA653437, AA664399, AA680123, AA431832, AA434143, AA678582, AA705952, AA679763, AA733019, AA781645, AA813232, AA833597, AA844624, A1024151, A1038232, A1042551, A1080152, A1086490, T24101, F03522, F07244
844166	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1358 of SEQ ID NO:575, b is an integer of 15 to 1372, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:575, and where b is greater than or equal to a + 14.	
844194	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2006 of SEQ ID NO:576, b is an integer of 15 to 2020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:576, and where b is greater than or equal to a + 14.	
844394	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3147 of SEQ ID NO:577, b is an integer of 15 to 3161, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:577, and where b is greater than or equal to a + 14.	
844450	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2032 of SEQ ID NO:578, b is an integer of 15 to 2046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:578, and where b is greater than or equal to a + 14.	
844534	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 288 of SEQ ID NO:579, b is an integer of 15 to 302, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:579, and where b is greater than or equal to a + 14.	
844535	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3053 of SEQ ID NO:580, b is an integer of 15 to 3067, where both a and b correspond to the positions of nucleotide	

	residues shown in SEQ ID NO:580, and where b is greater than or equal to $a + 14$.	
844644	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1560 of SEQ ID NO:581, b is an integer of 15 to 1574, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:581, and where b is greater than or equal to $a + 14$.	
844653	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 946 of SEQ ID NO:582, b is an integer of 15 to 960, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:582, and where b is greater than or equal to $a + 14$.	
844659	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 527 of SEQ ID NO:583, b is an integer of 15 to 541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:583, and where b is greater than or equal to $a + 14$.	
844796	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2954 of SEQ ID NO:584, b is an integer of 15 to 2968, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:584, and where b is greater than or equal to $a + 14$.	
844812	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2594 of SEQ ID NO:585, b is an integer of 15 to 2608, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:585, and where b is greater than or equal to $a + 14$.	
844894	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1879 of SEQ ID NO:586, b is an integer of 15 to 1893, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:586, and where b is greater than or equal to $a + 14$.	
845361	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2449 of SEQ ID NO:587, b is an integer of 15 to 2463, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:587, and where b is	T93072, T93161, T69748, T70732, R01200, R01312, R05457, R05477, R05584, R43190, R43190, R65942, R75719, R78234, H03875, H03876, H15845, H16155, H17787, H40269, H45881, R84787, R92493, R92931, H58301, H58912, H58913, H62257,

	greater than or equal to a + 14.	H67051, H68135, H81385, H83681, H91363, H96711, N20348, N22509, N27952, N28616, N31997, N32005, N36007, N39356, N40718, N70011, N70094, N92576, N99870, W00896, W00925, W04623, W25220, W31522, W37278, W37791, W38868, W52654, W51751, AA017158, AA019458, AA022914, AA022915, AA037370, AA037502, AA045696, AA045697, AA046013, AA054565, AA054625, AA069778, AA079736, AA081087, AA081144, AA100055, AA100504, AA100334, AA115581, AA115554, AA126149, AA126373, AA133101, AA130558, AA136439, AA151673, AA151821, AA151822, AA159031, AA165200, AA165201, AA176477, AA176498, AA176771, AA176830, AA182601, AA176736, AA187943, AA188578, AA188675, AA190342, AA190343, AA195091, AA213662, AA213715, AA232222, AA426516, AA424760, AA483564, AA490859, AA491042, AA505249, AA507988, AA508858, AA513433, AA514771, AA514785, AA514980, AA527545, AA534100, AA554008, AA557148, AA584946, AA586481, AA587849, AA588781, AA593916, AA605049, AA604893, AA617650, AA568567, AA621979, AA627588, AA578585, AA578744, AA661910, AA729355, AA729902, AA736994, AA738388, AA740375, AA741213, AA760943, AA830401, AA834201, AA834208, AA834250, AA864864, AA888527, AA906940, AA922073, AA927272, AA931625, AA933055, AA932772, AA936861, AA938504, AA975187, AA977857, AA975594, AI000724, AI014600, AI017381, AI066441, D82733, U47688, N83708, N83790, N85010, W22533, W23255, N86314, N87393, N88971, AA642249, AA642903, AA090403, AA091011, AA095990, AA205824, AA204931, AA643262, AA648446, AA216706, AA219615, AA249170, C75338, AA599187, AA668746, AA670340, AA405611, AA405150, AA708635, AA716044, AA722076, AA722829, AA725716, AA781064, AA844379, AI037987, AI039577, AI078722, AI077655, AI080306, AI084320, AI085219, AI093296, AI093479, AI095168, AI095267, D29018, F02782,
--	----------------------------------	---

		F06502, F00762, F00966
845620	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1931 of SEQ ID NO:588, b is an integer of 15 to 1945, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:588, and where b is greater than or equal to a + 14.	
845639	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 802 of SEQ ID NO:589, b is an integer of 15 to 816, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:589, and where b is greater than or equal to a + 14.	
845660	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2293 of SEQ ID NO:590, b is an integer of 15 to 2307, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:590, and where b is greater than or equal to a + 14.	
845720	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1424 of SEQ ID NO:591, b is an integer of 15 to 1438, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:591, and where b is greater than or equal to a + 14.	
845785	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1064 of SEQ ID NO:592, b is an integer of 15 to 1078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:592, and where b is greater than or equal to a + 14.	
845897	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2478 of SEQ ID NO:593, b is an integer of 15 to 2492, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:593, and where b is greater than or equal to a + 14.	
845922	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1890 of SEQ ID NO:594, b is an integer of 15 to 1904, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:594, and where b is greater than or equal to a + 14.	

846016	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 323 of SEQ ID NO:595, b is an integer of 15 to 337, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:595, and where b is greater than or equal to a + 14.	
846040	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:596, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:596, and where b is greater than or equal to a + 14.	
846073	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:597, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:597, and where b is greater than or equal to a + 14.	T83567, T83771, R51147, N26938, N32715, N36666, W57781, W74108, AA082091, AA425613
846257	Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2079 of SEQ ID NO:598, b is an integer of 15 to 2093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:598, and where b is greater than or equal to a + 14.	

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, and/or the cDNA sequence contained in a cDNA clone contained in the deposit.

5 The present invention also encompasses variants of the cancer polypeptide sequence disclosed in SEQ ID NO:Y, a polypeptide sequence encoded by the polynucleotide sequence in SEQ ID NO:X, and/or a polypeptide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

10 "Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

15 The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the related cDNA contained in a deposited library or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a nucleotide
20 sequence encoding the polypeptide encoded by the cDNA in the related cDNA contained in a deposited library, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polypeptides encoded by these nucleic acid molecules are also encompassed by the invention. In another embodiment, the invention encompasses nucleic acid molecules which comprise or alternatively consist of, a
25 polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under low stringency conditions, to the nucleotide coding sequence in SEQ ID NO:X, the nucleotide coding sequence of the related cDNA clone contained in a deposited library, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a
30 nucleotide sequence encoding the polypeptide encoded by the cDNA in the related cDNA clone contained in a deposited library, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which

hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the cDNA in the related cDNA clone contained in a deposited library, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these polypeptides under stringent hybridization conditions, or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be, for example, an entire sequence referred to in Table 1, an ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be

compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size
5 Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the
10 subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment.

This percentage is then subtracted from the percent identity, calculated by the above
15 FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of
20 manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and
25 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which
30 are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other

manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence in SEQ ID NO:Y or a fragment thereof, the amino acid sequence encoded by the nucleotide sequence in SEQ ID NO:X or a fragment thereof, or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library, or a fragment thereof, can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237- 245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences

truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is
5 matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the
10 query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the
15 subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent
20 identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject
25 sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce
30 silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which less than 50, less

than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, as discussed herein, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptide of the present invention without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, as discussed herein, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more

biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) of the polypeptide of the invention of which they are a variant. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.

The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein or fragments thereof, (e.g., including but not limited to fragments encoding a polypeptide having the amino acid sequence of an N and/or C terminal deletion), irrespective of whether they encode a polypeptide having functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having functional activity include, inter alia, (1) isolating a gene or allelic or splice variants thereof in a cDNA library; (2) in situ hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); and (3) Northern Blot analysis for detecting mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having a functional activity of a polypeptide of the invention.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to, for example, the nucleic acid sequence of the cDNA in the related cDNA clone contained in a

deposited library, the nucleic acid sequence referred to in Table 1 (SEQ ID NO:X), or fragments thereof, will encode polypeptides "having functional activity." In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, *Science* 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side

chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of a polypeptide having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of a polypeptide of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, and/or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library which contains, in order of ever-increasing preference, at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1

amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of SEQ ID NO:Y or fragments thereof (e.g., the mature form and/or other fragments described herein), an amino acid sequence encoded by SEQ ID NO:X or fragments thereof, and/or the amino acid sequence encoded by the cDNA in the related cDNA clone contained in a deposited library or fragments thereof, is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the cancer polynucleotides (nucleic acids) of the invention. In the present invention, a "polynucleotide fragment" refers, for example, to a polynucleotide having a nucleic acid sequence which: is a portion of the cDNA contained in a deposited cDNA clone; or is a portion of a polynucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited cDNA clone; or is a portion of the polynucleotide sequence in SEQ ID NO:X or the complementary strand thereto; or is a polynucleotide sequence encoding a portion of the polypeptide of SEQ ID NO:Y; or is a polynucleotide sequence encoding a portion of a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, at least about 100 nt, at least about 125 nt or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from, for example, the sequence contained in the cDNA in a related cDNA clone contained in a deposited library, the nucleotide sequence shown in SEQ ID NO:X or the complementary strand thereto. In this context "about" includes the particularly recited value or a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 150, 175, 200, 250, 500, 600, 1000, or 2000 nucleotides in length) are also encompassed by the invention.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900,

901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, and 3551 to the end of SEQ ID NO:X, or the complementary strand thereto. In this context “about” includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity) of the polypeptide encoded by the polynucleotide of which the sequence is a portion. More preferably, these fragments can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides or fragments.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, and 3551 to the end of the cDNA nucleotide sequence contained in the deposited cDNA clone, or the complementary strand thereto. In this context “about” includes the particularly recited range, or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity) of the polypeptide encoded by the cDNA

nucleotide sequence contained in the deposited cDNA clone. More preferably, these fragments can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these fragments under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides or fragments.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y, a portion of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:X, and/or encoded by the cDNA contained in the related cDNA clone contained in a deposited library. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, an amino acid sequence from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, and 1181 to the end of SEQ ID NO:Y. Moreover, polypeptide fragments of the invention may be at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, or ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either terminus or at both termini. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are

removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

Accordingly, polypeptide fragments of the invention include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

The present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, and/or a polypeptide encoded by the cDNA contained in the related cDNA clone contained in a deposited library). In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a polypeptide of the invention (e.g., the polypeptide disclosed in SEQ ID NO:Y), and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic

activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

5 Accordingly, the present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, and/or a polypeptide encoded by the cDNA contained in deposited cDNA clone referenced in Table 1). In particular, C-terminal deletions may be
10 described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where n corresponds to the position of an amino acid residue in a polypeptide of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, any of the above described N- or C-terminal deletions can be combined to
15 produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a polypeptide encoded by SEQ ID NO:X (e.g., including, but not limited to, the preferred polypeptide disclosed as SEQ ID NO:Y), and/or the cDNA in the related cDNA clone contained in a deposited library, where n
20 and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Any polypeptide sequence contained in the polypeptide of SEQ ID NO:Y, encoded by the polynucleotide sequences set forth as SEQ ID NO:X, or encoded by the cDNA in the related cDNA clone contained in a deposited library may be analyzed to determine certain
25 preferred regions of the polypeptide. For example, the amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X, or the cDNA in a deposited cDNA clone may be analyzed using the default parameters of the DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, WI 53715 USA; <http://www.dnastar.com/>).

Polypeptide regions that may be routinely obtained using the DNASTAR computer
30 algorithm include, but are not limited to, Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Eisenberg alpha- and

beta-amphipathic regions, Karplus-Schulz flexible regions, Emini surface-forming regions and Jameson-Wolf regions of high antigenic index. Among highly preferred polynucleotides of the invention in this regard are those that encode polypeptides comprising regions that combine several structural features, such as several (e.g., 1, 2, 3 or 4) of the features set out
5 above.

Additionally, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Emini surface-forming regions, and Jameson-Wolf regions of high antigenic index (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) can routinely be
10 used to determine polypeptide regions that exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from data by DNASTAR analysis by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

15 Preferred polypeptide fragments of the invention are fragments comprising, or alternatively consisting of, an amino acid sequence that displays a functional activity of the polypeptide sequence of which the amino acid sequence is a fragment.

By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length
20 (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

25 Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

In preferred embodiments, polypeptides of the invention comprise, or alternatively
30 consist of, one, two, three, four, five or more of the antigenic fragments of the polypeptide of SEQ ID NO:Y, or portions thereof. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Table 4.

Sequence/ Contig ID	Epitope
507291	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 843 as residues: Pro-12 to Pro-20, Lys-27 to Gly-34, Pro-67 to Arg-72, Asp-102 to Thr-111, Asp-136 to Gly-142, Ser-153 to Pro-158.
508000	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 844 as residues: Ala-16 to Trp-35.
518325	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 845 as residues: Glu-60 to Asp-67.
523111	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 846 as residues: Ser-1 to Gln-10.
532211	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 848 as residues: Cys-17 to Arg-22.
532247	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 849 as residues: Val-4 to His-10.
537932	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 850 as residues: Ser-62 to Gly-68.
540117	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 851 as residues: Pro-24 to Arg-30, Met-101 to Phe-106, Thr-138 to Asn-153.
547710	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 852 as residues: Asp-1 to Arg-7, Glu-25 to His-31, Ile-51 to Lys-56, Pro-61 to Pro-67, Gly-113 to Thr-119, Lys-125 to Asp-130, His-335 to Gly-340, Arg-364 to Pro-371.
551747	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 853 as residues: Lys-79 to Ala-88, Ser-109 to Leu-125, Asp-155 to Lys-163, Tyr-211 to Thr-219, Pro-221 to Ala-226.
552799	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 854 as residues: Gln-81 to Thr-114, Gln-200 to Arg-206.
553243	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 855 as residues: Ala-43 to Asp-48, Asp-64 to Lys-69, His-88 to Thr-94, Ala-107 to Phe-113, Leu-117 to Ser-125, Thr-132 to Glu-138, Ser-169 to Trp-181, Ser-194 to Thr-200.
553368	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 856 as residues: Ser-52 to Arg-57, Leu-76 to Gly-82, Ser-91 to Glu-96, Tyr-132 to Ala-147.
554349	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 857 as residues: Ala-31 to Gly-36, Ala-68 to Tyr-75, Gln-121 to Asp-127.
558491	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 858 as residues: Pro-1 to Arg-10.
558983	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 859 as residues: Pro-37 to Gly-42, Val-67 to Lys-84, Gln-122 to Gly-127.
589390	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 862 as residues: Glu-14 to Asn-19, Arg-68 to Ser-74, Ser-79 to Ala-84, Lys-95 to Ile-101, Lys-125 to Glu-138.
596882	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 863 as residues: Lys-15 to Lys-23, Pro-29 to Gly-34.
616289	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 864 as residues: Leu-1 to Pro-13, Thr-64 to Gly-70, Lys-119 to Arg-130.
622140	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 865 as residues: Ser-1 to Lys-6, Pro-16 to Ser-23, Arg-49 to Glu-58.
647714	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 867 as residues: Arg-1 to Gly-9, Glu-27 to Gly-36, Pro-72 to Phe-86, Pro-104 to Cys-111, Gln-145 to Lys-162, Arg-226 to Trp-233.
652156	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 871 as residues: Asn-30 to Ile-43, Ile-76 to Lys-81.
653010	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 872 as

	residues: Ser-1 to Ala-10.
655904	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 873 as residues: Ala-21 to Cys-27, Ser-76 to Gly-87, Ser-112 to Trp-121, Trp-128 to Asn-133, Glu-225 to Cys-231, Tyr-238 to Cys-248, Lys-269 to Asp-279, Phe-292 to Thr-298, Cys-357 to Ala-362, Pro-383 to Pro-388, Lys-412 to Lys-420.
657852	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 874 as residues: Arg-10 to Lys-22, Gln-48 to Glu-53, Arg-73 to Asn-86.
666414	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 875 as residues: Asn-9 to Lys-19, Arg-27 to Gly-32, Ser-58 to Thr-70, Ala-81 to Pro-86.
670188	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 877 as residues: Asn-68 to Ser-75.
670279	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 878 as residues: Lys-86 to Lys-91, Glu-101 to Val-120, Ala-130 to Glu-136.
670729	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 879 as residues: Ala-116 to Asp-134.
676496	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 881 as residues: Ile-1 to Arg-8.
678248	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 883 as residues: Ala-16 to Lys-22, Tyr-30 to Asn-35, Asp-61 to Val-70, Arg-129 to Asn-135, Thr-142 to Gly-148.
683668	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 884 as residues: Ser-3 to Gly-28, Gly-46 to Pro-56, Gly-70 to Ile-92, Gln-102 to Ser-117, Ala-123 to Pro-129, Pro-135 to Leu-140, Pro-150 to Asp-158, Pro-165 to Pro-177, Gln-188 to Asp-205, Ile-230 to Arg-245, His-251 to Trp-260, Asp-262 to Cys-267, Asn-296 to Arg-307, Glu-322 to Pro-330, Ile-351 to Asn-357, Asp-363 to Leu-369, Glu-386 to Phe-391, Lys-415 to Ser-420.
693172	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 885 as residues: Arg-11 to Arg-18, Pro-51 to Lys-58.
694303	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 886 as residues: Pro-12 to Ser-17, Leu-30 to Cys-39, Val-49 to Pro-54, Pro-67 to Leu-73, Pro-84 to Gln-90, His-99 to Leu-109.
695042	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 887 as residues: Ser-4 to Trp-28, Pro-51 to Leu-56, Asn-64 to His-70.
699799	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 888 as residues: Gln-17 to Phe-25, Glu-42 to Tyr-48, Val-52 to Gly-57, Pro-67 to Ser-73, Thr-97 to Gln-106, Gln-113 to Leu-123, Arg-171 to Asp-178, Arg-184 to Leu-191, Ile-195 to Phe-203, Lys-212 to Glu-217, Ala-236 to Asp-244, Arg-255 to Leu-260, Lys-266 to His-273, Glu-357 to Glu-363.
703015	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 890 as residues: Pro-27 to Asp-37, Gly-55 to Pro-61, His-96 to Ala-101, Glu-151 to Asn-156, Tyr-166 to Cys-178.
706391	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 891 as residues: Pro-22 to Ala-34, Pro-40 to Glu-52.
706924	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 893 as residues: Gly-1 to Gly-9, Gln-21 to Met-27.
707642	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 894 as residues: Glu-33 to Lys-40, Asn-55 to Lys-64, Tyr-104 to Cys-110, Ser-138 to Arg-148, Arg-157 to Gly-163, Lys-165 to Asn-172.
710369	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 895 as residues: Asn-1 to Thr-10.
718826	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 896 as residues: Ser-57 to Pro-63, Lys-93 to Ser-99.
719790	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 897 as residues: Phe-4 to Gln-23, Glu-47 to Ala-56, Asn-95 to Gln-102, Gln-109 to Glu-115, Arg-168 to Glu-175, Thr-196 to Arg-201, Lys-209 to Asp-215, Val-236 to Val-243.
720222	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 898 as

	residues: Glu-37 to Arg-43, Gly-62 to Pro-67, Gly-95 to Val-101, Gln-109 to Asp-114, Ala-137 to Phe-145, Asp-181 to Ser-188.
724033	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 899 as residues: Glu-55 to Glu-60, Asp-76 to Ser-85, Lys-106 to Asp-111, Gln-131 to Arg-137, Ala-172 to Gly-218.
724767	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 900 as residues: Leu-49 to Tyr-56, Tyr-114 to Glu-136, Arg-142 to Gly-148.
727065	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 901 as residues: Asn-41 to Gly-46, Lys-82 to His-88, Glu-107 to His-112, Leu-127 to Asp-132, Phe-163 to Phe-175, Thr-202 to Ile-209, Lys-229 to Gly-237, Ala-239 to Tyr-245.
727246	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 902 as residues: Pro-2 to Gly-10.
739448	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 908 as residues: His-2 to Leu-8, Gln-33 to Glu-40, Ala-44 to Glu-55, Gly-57 to Ser-67, Glu-70 to Ala-84, Glu-95 to Lys-111, Ile-186 to Asp-205, Leu-232 to Asp-238.
740060	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 910 as residues: Pro-44 to Thr-50, Arg-72 to Lys-80, Tyr-241 to Asn-251, Lys-273 to Gly-282, Ser-302 to Asn-312, Pro-337 to Ser-343, Ile-367 to Asp-376, Gly-395 to Tyr-417, Ser-442 to Gln-448.
741560	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 911 as residues: Gln-33 to Tyr-39, Pro-42 to Phe-47.
742543	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 912 as residues: Phe-10 to Tyr-15, Glu-139 to Asp-144, Glu-166 to Asn-171, Lys-175 to Glu-181.
742831	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 913 as residues: Val-64 to Glu-69.
745327	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 914 as residues: Arg-1 to Pro-13, Pro-54 to Ala-61.
745695	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 915 as residues: Trp-130 to Ser-135, Leu-199 to Thr-210, Ser-221 to Gln-229, Ala-249 to Tyr-255, Pro-257 to Pro-267, Ser-309 to Arg-314.
750316	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 916 as residues: Pro-18 to Asn-24, Thr-65 to Asp-70.
750522	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 917 as residues: Gln-10 to Lys-15.
750583	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 918 as residues: Lys-9 to Thr-15, Gln-32 to Gln-40.
751020	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 919 as residues: Arg-39 to Leu-47, Ser-107 to Ile-117, Pro-135 to Gln-144.
752196	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 920 as residues: Lys-20 to Lys-28.
753084	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 921 as residues: Lys-84 to Thr-98, Arg-128 to Ser-134, Arg-244 to Asn-252, Lys-365 to His-372.
754957	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 922 as residues: Pro-101 to Glu-106, Glu-116 to Asp-127, Ser-199 to Ile-210, Asp-217 to Asp-229, Ser-239 to Gly-244, Gln-262 to Asn-273, Pro-279 to Ser-284, Lys-318 to Arg-326, Lys-334 to Ile-341.
756557	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 923 as residues: Val-13 to Phe-21, Ile-55 to Pro-63, Ser-69 to Leu-74, Arg-82 to Leu-96, Asn-131 to Leu-139, Ile-156 to Thr-164, Thr-241 to Leu-249, Gly-273 to Ser-279, Thr-282 to Arg-289.
756712	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 924 as residues: Ile-4 to Thr-37, Gln-42 to Ser-48, Asn-56 to Lys-69, Ser-79 to Ser-85.
757414	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 925 as residues: Glu-14 to Thr-23, His-50 to Arg-62, Tyr-72 to Cys-78, Gly-121 to Pro-128.

757614	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 926 as residues: Gly-13 to Cys-19, Thr-32 to Glu-38, Val-44 to Gln-53, Lys-55 to Asp-60, Gln-65 to Glu-70, Lys-89 to Glu-105, Glu-112 to Asp-142, Glu-147 to Arg-152, Glu-211 to Leu-216, Leu-227 to Ser-232, Lys-245 to Lys-255, Glu-278 to Tyr-291, Gln-297 to Arg-303.
759878	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 928 as residues: Trp-16 to Glu-21, Trp-45 to Pro-54, Ile-154 to Phe-162, Gly-174 to Leu-181.
760227	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 929 as residues: Arg-99 to Asp-104.
766051	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 931 as residues: Asp-10 to Lys-19.
768053	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 933 as residues: Ile-1 to Tyr-7, Phe-52 to Cys-61, Val-118 to Ser-125.
768055	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 934 as residues: Asp-39 to Ser-46, Lys-92 to Lys-99, Val-165 to Phe-172, Lys-252 to Ala-261, Asn-268 to Ala-273.
769685	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 935 as residues: Pro-129 to Arg-135.
771920	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 936 as residues: Pro-47 to Val-53, Asp-85 to Phe-97, Val-136 to Gly-144, Pro-166 to Glu-172, Leu-190 to Ser-197.
772790	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 937 as residues: Leu-5 to Trp-13, Met-20 to Leu-39, Ile-50 to Pro-63, Glu-66 to Ser-72, Leu-112 to Gln-120, Ala-141 to Lys-146, Tyr-165 to Asp-173.
772916	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 938 as residues: Lys-16 to Arg-25.
773632	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 940 as residues: Arg-1 to His-33.
774364	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 941 as residues: Ser-97 to Asn-103.
775355	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 942 as residues: Ser-40 to Ala-46.
775844	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 943 as residues: Leu-20 to Ser-31, Thr-38 to Val-47.
777760	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 944 as residues: Thr-22 to Ser-28, Thr-35 to Glu-42, Met-47 to Thr-55.
779837	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 945 as residues: Thr-26 to Arg-31, Leu-75 to Lys-100.
780769	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 946 as residues: Gly-1 to Asp-7, Lys-25 to Lys-31, Tyr-65 to Gly-70, Thr-100 to Arg-106, Pro-118 to Glu-124, Lys-162 to Ser-172, Leu-176 to Leu-182.
781445	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 947 as residues: Asn-33 to Lys-38, Leu-67 to Met-73, Ser-111 to Lys-121, Lys-127 to Leu-134, Pro-153 to Trp-158, Lys-237 to Met-249, Pro-280 to Tyr-292.
781531	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 948 as residues: Ala-8 to Pro-23, Gln-56 to Cys-61, Asn-66 to Pro-72.
783018	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 949 as residues: Asn-4 to Leu-17, Gly-19 to Phe-26, Pro-37 to Glu-43, Val-58 to Ser-64, Gln-80 to Gly-85.
783097	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 950 as residues: Pro-1 to Asp-9, Pro-24 to Gly-40, Pro-47 to Thr-55, Gln-62 to Ser-76.
784198	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 951 as residues: Met-1 to Arg-15, Leu-43 to Glu-48, Asp-55 to Asp-62, Ser-111 to Lys-160.
784868	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 952 as residues: Trp-8 to Gly-17, Glu-20 to Arg-35, Gly-40 to Cys-45, Ser-59 to Ser-64, Ala-73 to Leu-78, Val-85 to Leu-91, Arg-130 to Lys-135, Leu-138 to Glu-146, Pro-188 to

	Pro-194. Ser-206 to Cys-212, Ser-232 to Ala-246, Asp-293 to Ser-298.
785428	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 953 as residues: Arg-9 to Met-20, Glu-28 to Gly-33, Asn-49 to Lys-57, Thr-67 to Arg-75, Ser-81 to Leu-87, Glu-103 to Thr-109, Pro-115 to Ile-120, Asn-146 to Ser-174, Ser-177 to His-195, Met-197 to Ile-221, Asp-232 to Glu-240, Glu-289 to Phe-302, Cys-306 to Arg-314, Ser-357 to Ser-366, Lys-385 to Glu-401, Val-419 to Asp-427.
785845	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 954 as residues: Arg-41 to Asp-52, Pro-82 to Arg-94, Pro-102 to Gln-107, Gln-170 to Tyr-181, Glu-248 to Lys-254, Asp-277 to Gly-287, Ala-302 to Arg-308, Thr-367 to Gly-374.
785854	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 955 as residues: Asp-1 to Asp-17, Cys-59 to Asp-65.
787279	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 958 as residues: Lys-13 to Lys-20.
789002	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 959 as residues: Met-20 to Glu-29.
789008	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 960 as residues: Ser-24 to Arg-33, Ile-44 to Gly-57, Arg-63 to Asn-72, Ile-76 to Pro-82.
789555	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 961 as residues: Trp-106 to Thr-117, Trp-156 to Gln-163, Gln-173 to Asp-178, Gln-227 to Glu-233, Gln-255 to Glu-261, Glu-297 to Tyr-306, Thr-339 to Val-345, Leu-378 to Ile-385, Asp-414 to Lys-420, Cys-437 to Ile-444, Thr-491 to Gln-497, Glu-509 to Ser-515, Lys-526 to Glu-538.
789631	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 962 as residues: Thr-10 to Gly-18.
789779	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 963 as residues: Glu-1 to Ala-13, Leu-103 to Ser-109.
790387	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 964 as residues: His-1 to Ala-12.
790461	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 965 as residues: Glu-14 to Gly-23, Asp-47 to Met-53, Ala-55 to Thr-60, Pro-67 to Thr-73, Pro-78 to Gly-86, Tyr-91 to Pro-101, Ala-133 to Asn-139, Glu-169 to Gln-182, Glu-189 to Thr-195, Asn-197 to Arg-203, Gln-265 to Asp-271.
790931	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 966 as residues: Val-3 to Glu-13, Pro-29 to Pro-35, Glu-116 to Arg-125.
791176	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 967 as residues: Pro-1 to Pro-10, Pro-17 to Phe-28, Ser-61 to Pro-67.
792539	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 969 as residues: Ser-12 to Trp-17, Gln-20 to Lys-29, Asp-45 to Glu-51, Tyr-75 to Lys-83, Arg-103 to Gly-119, Gln-145 to Lys-155, Lys-166 to Leu-180, Thr-195 to Gly-203, Gln-209 to Val-219, Ser-222 to Ala-244, Leu-251 to Leu-260, Lys-277 to Lys-285.
792749	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 970 as residues: Ala-22 to Asp-41, Thr-61 to Met-66, Asp-191 to Lys-198, Arg-280 to Phe-287, Thr-289 to Lys-299, Pro-325 to Asp-332, Ser-351 to Arg-357.
793206	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 972 as residues: Gly-1 to Arg-6, Gln-11 to Arg-22, Glu-86 to Asp-91.
793626	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 974 as residues: Ser-1 to Gly-13, Gly-17 to Asn-26.
794417	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 975 as residues: Ser-7 to Trp-16.
795197	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 976 as residues: Ser-67 to Glu-73, Arg-129 to Gly-136, Phe-154 to Ala-161, Tyr-198 to Tyr-203, Pro-206 to Asp-212, Glu-222 to Cys-231.
795251	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 977 as residues: Phe-44 to Ser-50, Asp-57 to Pro-62, Asn-80 to His-90, Ser-110 to Ala-115, Ile-141 to Val-148, Glu-155 to Thr-173, Val-202 to Pro-217, Ile-221 to Val-229, Thr-

	233 to Ser-243, Val-253 to Thr-259, Ala-290 to Asn-320, Pro-322 to Ile-330, Ala-333 to Met-344, Val-362 to Leu-367, Asp-397 to Val-402, Glu-422 to Gly-448, Met-453 to Gly-460.
795752	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 978 as residues: Pro-52 to Asn-63, Pro-70 to Ile-79, Arg-93 to Gln-111.
796261	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 979 as residues: His-1 to Val-6, Cys-10 to Ser-15, Gly-26 to Ser-34, Trp-36 to Pro-58, Pro-96 to Thr-102, Pro-111 to Tyr-116, Phe-131 to Gly-138, Pro-184 to Leu-190, Glu-237 to Gly-244, Pro-255 to Lys-267, Lys-271 to Leu-280.
796933	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 980 as residues: Arg-1 to Pro-14, Gln-47 to Cys-52, Asn-57 to Pro-63, Ser-277 to Lys-282.
799424	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 981 as residues: Tyr-18 to Leu-27, Met-50 to Met-60, Leu-169 to His-178, Ser-233 to Ser-241.
799698	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 982 as residues: Pro-16 to Pro-21, Ala-54 to Glu-61, Ala-96 to Gly-105.
800351	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 983 as residues: Gly-21 to Gln-34, His-39 to Lys-53, Ser-63 to Tyr-71.
800573	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 984 as residues: Asp-33 to Arg-39, Ala-43 to Leu-48, Glu-256 to Gln-266, Gly-305 to Ile-311, Pro-314 to Ala-320, Gln-388 to Asn-394.
805815	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 985 as residues: Arg-1 to Lys-22, Ser-34 to Arg-48, Thr-64 to Arg-70, Pro-81 to Phe-89, Arg-148 to Asn-154, Tyr-172 to Asp-185, Ser-205 to Asp-216, Tyr-278 to His-285, His-294 to Pro-299, Glu-326 to Gly-333, Gly-336 to Ser-345.
806445	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 986 as residues: Arg-15 to Gly-24, Lys-26 to Trp-32.
810309	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 987 as residues: Pro-33 to Phe-50, Ile-57 to Gly-62, Gln-72 to Asn-85, Ala-87 to Thr-172.
811022	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 988 as residues: Ala-1 to Met-11, Gln-62 to Trp-68, Ala-89 to Val-99.
811023	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 989 as residues: Tyr-54 to Lys-61, Met-64 to Thr-70.
811143	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 990 as residues: Ala-1 to Ser-7, Ser-19 to Gly-36, Arg-53 to Pro-58, Thr-87 to Glu-102, Arg-115 to Tyr-120, Thr-159 to Thr-164, Ala-171 to Ser-179, Ala-206 to Pro-217, Pro-224 to Ala-233, Arg-253 to Ser-259.
813000	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 993 as residues: Tyr-25 to Lys-30, Lys-36 to Ile-43, Lys-52 to Gln-69, Glu-76 to Asp-81, Arg-92 to Trp-104, Leu-120 to Lys-126, Ser-129 to Ser-135, Ser-139 to Thr-156, Pro-165 to Glu-178, Ser-181 to Thr-186, Tyr-196 to Lys-201, Cys-225 to Lys-230, Glu-234 to Ser-242.
813431	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 995 as residues: Leu-23 to His-29, Pro-38 to Leu-46, Ser-59 to Gly-68, Pro-85 to Lys-108, Arg-119 to Phe-124, Ser-139 to Lys-156.
813450	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 996 as residues: Asn-1 to Trp-10.
813478	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 997 as residues: Ala-8 to Arg-14, Ile-64 to Thr-69, Val-94 to Asp-101, His-112 to Gln-117, Tyr-139 to Glu-145, Tyr-195 to Cys-208, Gly-216 to Gly-223, Asp-297 to Ser-307, Gly-378 to Leu-383, Ile-391 to Pro-404, Asn-451 to Ser-466.
813505	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 998 as residues: Thr-1 to Ala-20, Pro-22 to Lys-27, His-44 to Thr-51, Pro-53 to Thr-60, Arg-62 to Lys-79, Lys-97 to Asn-103, Pro-139 to Lys-144.
815552	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 999 as residues: Pro-1 to Ser-6, Pro-25 to Cys-31, Arg-142 to Lys-150.

815606	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1000 as residues: Arg-1 to Ala-11.
816048	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1001 as residues: Ala-13 to Thr-24, Glu-30 to Gln-39, Arg-69 to Gly-77, Gln-119 to Gly-126, Tyr-156 to Asn-162, Ser-184 to Gly-191.
823981	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1004 as residues: Lys-1 to Cys-7, Ala-11 to Lys-17, Glu-90 to Ile-95, Asn-141 to Arg-148, Leu-158 to Ala-163, Ala-171 to Thr-177.
824364	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1005 as residues: Gln-43 to Gly-54.
824423	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1006 as residues: Cys-33 to Arg-42, Val-53 to Met-63, Lys-71 to Lys-78, Gly-107 to Pro-118, Ala-159 to Leu-165, Val-272 to Arg-284, Pro-422 to Pro-427, Arg-437 to Gln-443, Ala-474 to Asp-482, His-519 to Cys-525, Ala-529 to Gln-535, Arg-540 to Gln-548.
825279	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1007 as residues: Ser-8 to Arg-14, Asp-23 to Gly-28, Ser-30 to Pro-37, His-52 to Ala-57, Pro-65 to Ser-74, Pro-112 to Ser-118, Ala-181 to Pro-189.
825548	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1009 as residues: Pro-2 to Ser-9.
825725	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1010 as residues: Pro-1 to Gly-8, Leu-95 to Lys-100, Glu-118 to Thr-125, Ser-162 to Lys-167, Arg-201 to Tyr-206.
827079	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1012 as residues: Arg-9 to Ser-17.
827153	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1013 as residues: Val-32 to Ala-44, Pro-49 to Ser-57, Gln-77 to Gly-82, Asp-116 to Gly-127, Arg-165 to Asn-172.
827351	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1014 as residues: Gly-5 to Lys-11, Ser-59 to Lys-67, Glu-130 to Arg-136, Asn-176 to Leu-183.
827503	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1015 as residues: Asp-61 to Val-67, Arg-113 to Asp-119, Ser-180 to Gly-191, Pro-199 to Ser-211, Ser-228 to Asn-238, Gly-276 to Ser-286, His-343 to Gly-351, Gln-354 to Arg-366, Leu-368 to Gln-382, Pro-393 to Ser-400, Asp-412 to Cys-418, Gly-430 to Leu-435, Gln-445 to Asp-450, Lys-484 to Val-491, Leu-513 to Gly-520.
827563	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1016 as residues: Pro-69 to Ala-81, Pro-84 to Gly-91, Ala-106 to Leu-112, Arg-216 to Lys-224, Trp-239 to Gly-250.
827565	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1017 as residues: Ala-1 to Ser-8, Ser-88 to Gly-96, Asn-121 to Asp-128, Cys-191 to Gly-196, Met-242 to Thr-248.
827893	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1018 as residues: Ser-41 to Ala-50, Glu-72 to His-77, Ala-120 to Glu-125, Thr-144 to Ile-153.
828072	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1019 as residues: Lys-30 to Leu-35.
828241	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1021 as residues: Gly-35 to Phe-45, Pro-47 to Arg-55, Glu-62 to Leu-70, Arg-102 to Tyr-111, Phe-128 to Gln-134, Val-139 to Met-144, Ser-180 to Gly-188, Lys-214 to Leu-219, Ser-241 to Glu-246, Phe-292 to Thr-298.
828287	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1022 as residues: Ala-12 to Thr-21, Ala-23 to Gly-31, Leu-43 to Gly-51, Lys-127 to Val-134.
828371	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1024 as residues: Gln-1 to Ala-6, Lys-50 to Pro-71, Pro-98 to Ser-111, Asp-148 to His-164, Asp-185 to Arg-191, Asp-238 to Gly-244, Pro-262 to Cys-274.
828403	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1025 as residues: Gly-1 to Trp-15, Arg-73 to Leu-82.
828501	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1026 as

	residues: Arg-99 to Arg-105, Pro-171 to Ser-176, Lys-189 to Val-195, Lys-291 to Ala-296.
828527	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1028 as residues: Glu-58 to Cys-63.
828538	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1029 as residues: Pro-9 to Thr-24, Thr-46 to Gly-52, Ser-70 to Thr-76, Ser-142 to Thr-149, Pro-154 to Ser-171, Glu-189 to Ser-196.
828541	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1030 as residues: Arg-9 to Pro-23, Gln-64 to Leu-69, Asp-76 to Asn-83, Lys-88 to Gln-93, Pro-129 to Thr-135, Gly-194 to Gly-203, Asp-223 to Gly-231, Thr-265 to Ile-281, Leu-287 to Lys-297.
828549	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1031 as residues: Pro-22 to Asn-28.
828562	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1032 as residues: Arg-26 to Asp-33, Asp-42 to Pro-58, Thr-63 to Lys-70, Thr-103 to Asp-114.
828576	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1033 as residues: Arg-11 to Gly-17, Pro-26 to Gly-31, Ala-48 to His-58.
828602	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1034 as residues: Tyr-1 to Met-8, Leu-10 to Lys-26, Pro-47 to Pro-54, Lys-128 to Ser-133.
828628	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1035 as residues: Thr-124 to Thr-129, Gly-136 to Phe-142, Asp-164 to His-171, Asp-180 to Tyr-194.
828684	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1037 as residues: Ser-16 to Thr-22, Arg-39 to Ala-51, Arg-60 to Gly-65, Thr-67 to Arg-90, Lys-109 to Gln-125, Ser-146 to Arg-159, Gln-166 to Thr-176, Glu-192 to Tyr-197, Val-267 to His-279, Ala-351 to Gly-356, Phe-363 to Gly-368, Gly-387 to Arg-392, Asp-488 to Ala-498.
828727	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1038 as residues: Gly-14 to Val-21, Asp-40 to Gln-57, Gln-86 to Tyr-93, Gln-98 to Asp-104, Lys-124 to Asp-130, Gln-138 to Cys-156, Tyr-170 to Gln-175, Gln-196 to Ala-201.
828734	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1039 as residues: Asp-5 to Trp-19, Ile-37 to Pro-42, Asp-52 to Asp-72, Glu-85 to Ser-92, Ser-107 to Leu-117, Asp-128 to His-147.
828842	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1041 as residues: Ala-25 to Phe-32, Glu-54 to Ser-61, Thr-74 to Glu-79, Glu-99 to Lys-105, Glu-112 to Glu-121.
828843	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1042 as residues: Pro-3 to Asn-11, Gln-46 to Ala-51, Asn-62 to Lys-74, Val-108 to Gln-113, Arg-119 to Gly-163, Ala-223 to Lys-237.
828851	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1043 as residues: Thr-3 to Lys-8, Leu-63 to Val-70, Lys-141 to Val-149, Ile-326 to Thr-333.
828856	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1044 as residues: Leu-1 to Gly-10.
828862	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1045 as residues: Pro-1 to Pro-9, Arg-81 to Glu-87, Gln-114 to Glu-119.
828870	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1046 as residues: Ser-1 to Gly-18, Trp-25 to Gly-31, Arg-46 to Ser-52, Ala-103 to Ala-108, Ser-154 to Gly-165, Gln-228 to Pro-236, Ser-284 to Gly-291, Ala-321 to Asp-327, Lys-377 to Asn-394, Asp-406 to Ser-416.
828873	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1047 as residues: Tyr-15 to Gly-20, Asn-72 to Asp-80, Pro-105 to Pro-110, Gln-149 to Arg-154, Glu-161 to Gly-167, Ile-312 to Asp-318, Lys-353 to Leu-361, Arg-379 to Thr-385, Pro-423 to Trp-435, Pro-437 to Cys-444, Asn-450 to Met-466.
828892	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1048 as residues: Asp-19 to Asn-25, Gly-67 to Glu-79.
828893	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1049 as

	residues: Ser-55 to Thr-60, Glu-97 to Ser-103, Thr-164 to Glu-170, Gly-192 to Gly-197, Leu-204 to Ser-218, Ala-238 to Ser-250, Asp-265 to Tyr-292, Gly-298 to Gly-307, Gly-351 to Met-359, Phe-389 to Glu-400.
828897	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1050 as residues: Phe-28 to Arg-33.
828910	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1051 as residues: His-1 to Ile-13, Arg-20 to Glu-64, Arg-83 to Gln-89, Tyr-145 to Asp-152.
828927	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1052 as residues: Glu-10 to Pro-21, Thr-54 to Gly-60, Cys-79 to Glu-90, Lys-154 to Lys-159.
828932	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1053 as residues: Arg-1 to Arg-9, Phe-54 to Pro-60, Gln-74 to Gly-90, Asn-114 to Gly-119, Cys-124 to Ser-132, Thr-139 to Leu-151, Asp-171 to Lys-182, Ala-188 to Leu-193, Val-203 to Trp-222, Lys-230 to Glu-236, Glu-244 to Asp-250, Leu-258 to Gly-268, Gly-283 to Asp-288, Ser-291 to Trp-297, Gly-300 to Ala-308.
828933	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1054 as residues: Glu-21 to Ser-34, Thr-130 to Tyr-138.
828941	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1055 as residues: Gly-1 to Ala-6, Pro-15 to Gly-22, Asn-160 to Gln-177, Asn-193 to Asp-199, Glu-205 to Leu-211.
828963	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1057 as residues: Pro-48 to Gly-54, Ser-56 to Ser-76, Lys-102 to Pro-107, Ser-146 to Gly-153, Ser-208 to Arg-213, Tyr-285 to Leu-299, Pro-314 to Phe-319, Asn-322 to Asn-327.
828964	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1058 as residues: Thr-36 to Cys-47.
828966	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1059 as residues: Gly-1 to Ser-16, Met-26 to Pro-31, Lys-128 to Glu-134, His-165 to Gln-170, Asp-207 to Asn-216, Pro-348 to Arg-359, Lys-433 to Ala-439, Gly-448 to Tyr-457.
828967	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1060 as residues: Met-135 to Arg-141, Gly-149 to Lys-166, Ile-188 to Ser-196, Gly-203 to Tyr-213, Gln-267 to Asp-278, Arg-298 to Trp-317, Leu-319 to Leu-326, Gln-344 to Thr-349, Pro-410 to Ser-419, Ala-500 to Ala-510.
828977	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1061 as residues: Gly-32 to Tyr-42, Asn-52 to Glu-58, Ser-78 to Gly-87, Lys-97 to Gly-109, Glu-116 to Arg-127, Pro-147 to Pro-152, Pro-162 to Asn-171, Leu-179 to Glu-185, Ile-203 to Glu-208, Val-222 to Gln-228.
828978	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1062 as residues: Asp-24 to Lys-30, Arg-49 to Lys-62, Arg-121 to Thr-149, Gly-163 to Leu-171, Ala-186 to Glu-195, Glu-216 to Ser-221, Ile-229 to Ser-236, Lys-258 to Lys-264, Lys-305 to Arg-313.
829001	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1064 as residues: Thr-11 to Cys-24, Arg-48 to His-55, Arg-62 to Gly-70.
829003	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1065 as residues: Lys-14 to Gly-22, Ser-61 to Asp-66, Cys-80 to Lys-91, Lys-97 to Arg-107, Gly-135 to Asn-146, Lys-198 to Lys-208, Met-221 to Thr-227, Phe-244 to Gly-256, Asp-292 to Gln-300.
829016	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1066 as residues: Arg-1 to Asp-11, Ala-17 to Gln-25, Glu-30 to His-37, Cys-39 to Thr-44, Asn-86 to Phe-93.
829027	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1067 as residues: Pro-1 to Ser-7, Thr-45 to Leu-63, Arg-113 to Thr-118, Pro-172 to Gly-182.
829028	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1068 as residues: Ser-1 to Gln-19, Gly-32 to Phe-39, Ala-95 to Arg-116, Lys-122 to Glu-142, Ile-148 to Asn-156, Ser-168 to Asn-191, Ala-196 to Thr-204, Ser-289 to Lys-304, Leu-308 to Ser-314, Thr-332 to Ile-341.
829034	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1070 as residues: Ser-32 to Ala-43, Thr-62 to Glu-69, Phe-128 to Thr-156, Thr-179 to His-188,

	Gly-196 to Glu-203, Pro-205 to Ala-219, Gln-221 to Ile-230, Pro-246 to Thr-255, Thr-271 to His-276, Asn-324 to Thr-344, Pro-364 to Ala-370, Tyr-427 to Arg-434, Gly-440 to Pro-445.
829036	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1071 as residues: Leu-16 to Phe-21, Thr-69 to Lys-74, Asn-87 to His-92, Thr-126 to Leu-137, Phe-154 to Lys-164, Ala-171 to Asp-178, Ile-192 to Thr-203, Glu-261 to Ser-273.
829049	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1072 as residues: Gly-50 to Tyr-59.
829073	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1073 as residues: Asn-1 to Met-6, Asn-26 to Ser-35, Pro-43 to Ile-54.
829075	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1074 as residues: Gly-14 to Pro-30, Ser-64 to Ser-69, Asn-97 to Arg-109.
829076	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1075 as residues: Lys-84 to Gly-94, Asn-142 to Ile-147.
829080	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1076 as residues: Gly-13 to Trp-23, Pro-39 to Gly-44.
829087	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1077 as residues: Pro-13 to Arg-24.
829095	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1079 as residues: Pro-8 to Pro-13.
829118	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1081 as residues: Arg-7 to Val-12, Ile-52 to Thr-70, Ser-86 to Asp-91, Thr-126 to Ser-138.
829152	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1082 as residues: Asp-12 to Ser-19.
829160	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1083 as residues: Ala-7 to Arg-20.
829163	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1084 as residues: Ser-23 to Asp-32, Val-36 to Glu-59, Ser-65 to Asn-76, Cys-91 to Ser-102, Pro-108 to Leu-115, Thr-151 to Gln-164, Glu-167 to Lys-176.
829176	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1085 as residues: His-1 to Asn-8, Cys-22 to Arg-27, Gly-34 to Ser-44, Tyr-60 to Ser-65, Ser-118 to Gln-123, Ser-149 to Trp-154, Pro-159 to Gly-168, Gln-207 to Leu-220.
829204	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1086 as residues: Ala-11 to Ser-19, Thr-104 to Lys-133.
829207	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1087 as residues: Lys-5 to Ser-11, Pro-31 to Ser-37, Pro-87 to Asp-92, Asp-115 to Lys-123, Ser-149 to Arg-155, Thr-243 to Pro-253.
829228	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1088 as residues: Pro-1 to Trp-6, Leu-73 to Tyr-79, Glu-108 to Thr-117, Asp-136 to Asp-142, Ser-201 to Pro-207, Leu-224 to Pro-233, Val-242 to Ala-248, Ser-312 to Leu-319, Val-349 to Ser-359, Ala-362 to His-368, Thr-370 to Gly-376, Lys-403 to Tyr-409, Glu-426 to Arg-431, Lys-455 to Asp-460, Arg-499 to Thr-505, Asp-561 to Ser-570, Ser-665 to Ser-673.
829252	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1089 as residues: Thr-9 to Val-16.
829269	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1091 as residues: Ser-1 to Glu-7, Lys-76 to Gln-83.
829277	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1092 as residues: Lys-88 to Phe-97, Thr-106 to Leu-120, Thr-147 to Pro-152, Pro-173 to Met-179.
829290	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1093 as residues: Pro-1 to Pro-19, Pro-25 to Lys-30.
829308	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1096 as residues: Met-26 to Asn-37, Glu-42 to Gln-51, Thr-68 to Ser-95, Ala-97 to Lys-113, Asp-156 to Val-161, Val-208 to Asp-215, Pro-217 to Ala-228.
829349	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1097 as

	residues: Asn-18 to Lys-24, Asp-87 to Asn-94, Glu-116 to Gly-125.
829354	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1098 as residues: Ala-1 to Asn-16, Pro-36 to Arg-43.
829388	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1099 as residues: Glu-91 to Pro-100, Tyr-122 to Thr-127, Thr-168 to Val-173, Thr-210 to Asp-215, Leu-219 to Gly-224, Gly-232 to Val-237.
829626	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1101 as residues: Gly-145 to Ala-151.
829730	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1102 as residues: Pro-22 to His-27, Pro-87 to Asp-93, Arg-109 to Lys-115, Arg-172 to Glu-177, Glu-219 to Asp-226.
829892	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1103 as residues: Tyr-36 to Ala-46, Val-58 to Asn-63, Glu-73 to Asn-78, Asn-90 to Asn-95, Ser-125 to Leu-133, Glu-143 to Pro-150, Phe-186 to Leu-191, Leu-274 to Glu-281, Lys-303 to Phe-308, Thr-323 to Gly-330.
829938	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1105 as residues: Thr-1 to Pro-14, Ser-36 to Thr-57, Ser-81 to Thr-91, Glu-103 to Leu-110, Glu-124 to Tyr-130, Ala-135 to Lys-140, Leu-146 to Glu-162, Lys-167 to Glu-172, Glu-199 to Val-213.
829969	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1106 as residues: Arg-12 to His-21, Arg-77 to Ser-88.
829982	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1107 as residues: Arg-6 to His-14, Ser-40 to Met-47, Thr-68 to Cys-74, Ile-97 to His-115, Gly-118 to Pro-124.
830007	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1108 as residues: Ala-7 to Ala-16.
830019	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1109 as residues: Leu-21 to Pro-27.
830073	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1110 as residues: Gly-16 to Val-22, Pro-45 to Lys-50, Phe-58 to Arg-65, Ser-135 to Gly-141, Gly-153 to Ser-158, Pro-160 to Tyr-168.
830148	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1114 as residues: Asp-63 to Lys-81, Gly-101 to Gly-108, Pro-182 to Ala-200, Pro-210 to Met-216, Pro-235 to Gly-243.
830183	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1117 as residues: Pro-29 to Lys-37, Pro-40 to Val-47, Tyr-62 to His-67.
830194	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1118 as residues: Ala-43 to Lys-51, Glu-66 to Leu-74, His-81 to Glu-88, Arg-98 to Ser-105, Gly-111 to Gln-116, Leu-166 to Lys-182, Leu-261 to Ala-273, Glu-294 to Arg-302, Glu-335 to Asp-347.
830207	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1119 as residues: Pro-14 to Pro-48, Asp-55 to Gly-61, Lys-94 to Asn-99, Ala-107 to Ser-115, Ile-117 to Asn-124, Thr-133 to Cys-139, Thr-142 to Ile-147, Gly-163 to Ser-169.
830242	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1120 as residues: Glu-29 to Lys-34, Leu-151 to Gln-157, Arg-160 to Ser-171, Gln-177 to Pro-190.
830328	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1121 as residues: Pro-18 to Met-24, Glu-66 to Gln-78, Ala-85 to Arg-93, Glu-99 to His-108, Leu-114 to Asp-137, Pro-171 to Gln-176, Gly-205 to Leu-213.
830340	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1122 as residues: Gly-12 to Lys-18, Arg-46 to Glu-56, Leu-67 to Gly-73, Ala-91 to Tyr-112.
830341	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1123 as residues: Leu-14 to Gln-20, Asn-34 to Glu-41, Lys-193 to Asn-198.
830351	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1124 as residues: Pro-1 to Leu-13, Gly-42 to Pro-51, Arg-64 to Ala-69, Met-104 to Asp-109, Cys-125 to Trp-132, Asp-161 to Trp-175, Glu-206 to Glu-218.

830358	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1125 as residues: Cys-75 to Thr-81.
830400	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1127 as residues: Pro-1 to Gly-6, Arg-17 to Arg-33, Glu-151 to Trp-157, Ile-187 to Tyr-193, Lys-249 to Glu-258, Asn-289 to Ser-294, Pro-340 to Lys-353.
830437	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1128 as residues: Ala-87 to Ser-94, Asp-104 to Arg-112, Leu-114 to Asp-119, Ser-186 to Thr-202.
830466	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1130 as residues: Pro-14 to Ile-24, Thr-35 to Phe-42, Ser-45 to Asn-57, Pro-65 to Trp-89.
830497	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1131 as residues: Thr-1 to Leu-9, Ser-46 to Leu-56, Glu-117 to Lys-124, Pro-129 to Asp-135, Ala-144 to Gln-150, Gly-156 to Lys-162, Phe-182 to Pro-187, Pro-196 to Gln-201, Lys-217 to Asp-227.
830511	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1132 as residues: Lys-13 to Cys-44, Lys-101 to Arg-109, Gln-120 to Gly-129.
830540	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1135 as residues: Leu-31 to Lys-37, Arg-48 to Asn-54.
830550	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1136 as residues: Pro-8 to Cys-15, Val-80 to Cys-85.
830567	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1137 as residues: Lys-28 to Leu-33, Pro-60 to Ser-66.
830586	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1138 as residues: Pro-1 to Gln-15, Arg-33 to Leu-40, Arg-72 to Ser-78, Leu-98 to Asp-103, Phe-116 to Gly-124, Pro-152 to Arg-158, Thr-193 to Pro-200, Leu-213 to Phe-219, Asp-229 to Lys-237, Lys-246 to Lys-258, Arg-275 to Thr-280, Thr-306 to Lys-312, Leu-320 to Arg-328, Ala-335 to Asn-340, Gly-342 to Trp-349, Cys-364 to Pro-372.
830632	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1139 as residues: Ala-6 to Thr-14, Arg-143 to Lys-148.
830659	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1142 as residues: Thr-32 to Tyr-40, Ala-67 to Gln-82, Arg-128 to Thr-133, Leu-137 to Thr-146, Pro-187 to Ser-193.
830696	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1143 as residues: Glu-83 to Lys-91.
830743	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1145 as residues: Pro-11 to Phe-16, Thr-48 to Ser-60.
830770	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1146 as residues: Thr-36 to Thr-44.
830830	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1147 as residues: Lys-73 to Thr-78, Pro-84 to Pro-96, Lys-107 to Glu-124, Ile-142 to Cys-153, Asp-179 to Asn-184.
830838	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1148 as residues: Ser-17 to Arg-22, Gly-48 to Val-56, Asn-217 to Asp-223, Thr-238 to Asn-243.
830851	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1149 as residues: Arg-1 to Val-7, Ala-156 to Phe-162, Arg-216 to Lys-239.
830856	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1151 as residues: Trp-29 to Gly-35, Thr-41 to His-47, Val-95 to Lys-111.
830862	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1152 as residues: Arg-14 to Val-22, Ala-24 to Gly-35, Arg-37 to Lys-58, Ala-88 to Ala-94, Lys-164 to Ser-172.
830879	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1153 as residues: Cys-34 to Leu-44, Ser-60 to Gly-69, Asp-118 to Gly-123, Cys-148 to Gln-154.
830919	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1154 as residues: Pro-1 to Ser-41, Arg-53 to Pro-61, Arg-66 to Gln-132.

830969	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1155 as residues: His-17 to Pro-27, Phe-31 to Val-38, Gly-53 to Thr-62.
830991	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1156 as residues: Arg-1 to Pro-14, Ala-44 to Ser-56, His-69 to Lys-75, Gly-89 to Lys-98, Tyr-101 to Tyr-121, Pro-123 to Thr-131, Pro-149 to Gly-171, Tyr-186 to Glu-192.
831002	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1157 as residues: Glu-63 to Asn-73, Pro-114 to Tyr-122, Ser-194 to Glu-201, Ile-263 to Ser-269.
831003	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1158 as residues: Ile-9 to Leu-17, Asp-63 to Gly-70, Leu-112 to Ala-128.
831021	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1159 as residues: Asn-6 to Asp-12.
831036	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1160 as residues: Ser-6 to Ser-25, Tyr-37 to Lys-42, Arg-49 to Tyr-54, Pro-56 to Glu-61, Gln-72 to Cys-77, Lys-104 to Glu-110, Lys-134 to Met-142, Asp-147 to Arg-158, Arg-189 to Asn-194.
831071	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1161 as residues: Thr-41 to Arg-49, Glu-137 to Asp-142, Tyr-158 to Glu-163, Arg-184 to Thr-199, Arg-239 to Gly-253, Pro-297 to Gly-304, Pro-319 to Ile-327, Leu-347 to Val-356, Asn-435 to Leu-441, Asp-443 to Ser-452, Ala-457 to Thr-462, Asp-479 to Arg-484, Gly-510 to His-516, Glu-555 to Thr-565, Asp-597 to Ser-602, Thr-615 to Asp-622, Val-653 to Leu-661, Ala-684 to Arg-697, Ser-704 to Glu-712, Ala-731 to Ala-737, Lys-800 to Met-805.
831099	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1163 as residues: Leu-12 to Gly-18, Leu-93 to Ile-98, Lys-165 to Ser-183, Thr-198 to Lys-211, Glu-232 to Gly-237, Pro-239 to Gly-249, Arg-257 to Asp-278, Cys-292 to Glu-297, Arg-306 to Ser-316, Asp-323 to Asn-331, Glu-347 to Gly-354, Thr-365 to Asn-370, Pro-390 to Thr-396, Asn-420 to Ser-433, Val-440 to Gln-451, His-457 to Asp-465, Phe-533 to Met-538, Ala-540 to Tyr-550, Pro-560 to Lys-565.
831113	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1164 as residues: Ser-26 to Arg-33, Pro-51 to Thr-56, Cys-82 to Asp-94, Pro-104 to Gly-128.
831120	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1165 as residues: Ala-39 to Leu-47, Val-49 to Lys-55, Thr-66 to Asp-75, Thr-85 to Gly-104, Ala-114 to Gly-147, Pro-176 to Thr-199, Ser-205 to Ser-221, Glu-233 to Lys-240, Lys-246 to Asp-251, Glu-256 to Ser-267, Ser-291 to Leu-302, Thr-305 to Asp-324, Cys-336 to Val-345, Phe-367 to Cys-375.
831172	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1166 as residues: Pro-1 to Gly-7, His-119 to Gly-125, His-145 to Asp-151, Leu-173 to Leu-178.
831178	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1167 as residues: Glu-37 to Asn-42, Ser-48 to Thr-54, Pro-101 to Glu-106.
831184	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1168 as residues: Gln-1 to Pro-29.
831203	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1169 as residues: Thr-1 to Ser-6, Leu-10 to Asn-23, Gln-31 to Arg-36, Arg-43 to His-49, Ala-58 to Leu-63, Gln-81 to Asp-105, Glu-113 to Ile-122, Pro-132 to Lys-137, Ser-175 to Gln-181.
831257	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1173 as residues: Arg-87 to Leu-96, His-104 to Lys-112, Asp-144 to Pro-150.
831277	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1174 as residues: Arg-1 to Gly-13.
831317	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1175 as residues: Ser-97 to Lys-102, Thr-108 to Gly-119, Lys-151 to Gly-157, Pro-204 to Glu-210, Gln-224 to Gly-230, Val-238 to Cys-245, Met-279 to Asn-284, Gly-332 to Glu-349.
831339	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1176 as

	residues: Met-1 to His-19, Pro-21 to Pro-27, Ala-49 to Gly-59, Pro-82 to Ala-104.
831363	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1177 as residues: Thr-1 to Ser-14, Thr-82 to Pro-89, Met-102 to Ala-109, Phe-117 to Ile-124, Asp-142 to Arg-148, Thr-196 to Trp-205, Gln-304 to Leu-310, Gln-325 to Ser-331, Gly-387 to Thr-393, Ala-415 to Lys-430, Pro-469 to Pro-477, Gly-500 to Ile-506, Arg-521 to Gly-529, Pro-534 to Gly-541, Gln-553 to Lys-558, Ala-571 to Glu-579.
831385	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1180 as residues: Ser-1 to Thr-9, Ala-32 to Asn-37, Thr-40 to Tyr-49, Gln-71 to Thr-80.
831390	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1181 as residues: Trp-50 to Gly-55, Leu-109 to Val-119, Phe-146 to Asp-158, Ser-165 to Trp-172, Phe-192 to Ile-197, Leu-241 to Asp-252, Lys-268 to Pro-273, Ser-310 to Lys-315, Asp-334 to Ala-342, Pro-348 to Tyr-353.
831391	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1182 as residues: Ser-28 to Pro-38, Pro-45 to Cys-55, Leu-70 to Ser-77, Glu-98 to Phe-104, Asp-112 to Ser-122, Thr-152 to Lys-158.
831405	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1183 as residues: Asp-47 to Ser-55, Glu-86 to Cys-95, Glu-105 to Gly-113, Gln-133 to Asn-138, Arg-144 to Asp-156.
831476	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1185 as residues: Gln-28 to Gly-33, Asp-41 to Trp-47, Asn-51 to Ser-56, Ser-73 to Asn-83, Trp-111 to Asn-117, Leu-133 to Gln-138, Arg-143 to Tyr-150, Thr-156 to Glu-165.
831488	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1186 as residues: Glu-53 to Asn-59, Lys-97 to Phe-104, Lys-133 to Ala-138.
831519	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1188 as residues: Ser-17 to Gly-25, Thr-47 to Leu-59, His-71 to Arg-77, Pro-83 to Gln-90, Tyr-133 to Ser-143, Arg-160 to Gly-169, Pro-188 to Val-193, Glu-202 to Glu-208, Leu-283 to Arg-288, Glu-295 to Leu-301, Ala-327 to Leu-333, Ala-426 to Pro-433, Leu-444 to Leu-456, Asn-492 to Ala-498.
831550	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1190 as residues: Arg-1 to Gly-15, Ser-42 to Trp-51, Pro-59 to Arg-64.
831560	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1191 as residues: Arg-58 to Asp-64.
831570	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1193 as residues: Thr-61 to Cys-74, Gly-92 to Cys-104, Cys-128 to Ser-133, Asn-179 to Gly-186, Ser-198 to Cys-226, Asn-265 to Ser-274, Ser-280 to Ile-285, Ser-291 to Asp-297, Leu-305 to Gly-315, Phe-317 to Gly-333, Asp-336 to Leu-344, Phe-354 to Cys-361.
831596	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1195 as residues: Gln-80 to Gly-85.
831627	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1196 as residues: Arg-1 to Ser-12, Gly-94 to Thr-106, Ser-161 to Leu-169, Ser-183 to Val-188, Glu-199 to Cys-205, Ser-246 to Ile-251, Leu-271 to Thr-276.
831649	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1197 as residues: Tyr-32 to Lys-39.
831664	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1198 as residues: Lys-1 to Asp-42, Arg-71 to Ala-76, Gln-138 to Phe-145, Lys-170 to Thr-178, Cys-186 to Asp-192.
831684	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1200 as residues: Ile-135 to Ala-140, Tyr-151 to Asn-157, Ser-183 to Ile-190, Gly-196 to Lys-201, Lys-226 to Lys-232, Asn-246 to Thr-252, Asp-293 to Gly-300.
831687	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1201 as residues: Ala-56 to Tyr-63.
831726	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1202 as residues: Arg-3 to Arg-15, Lys-34 to Thr-39, Asn-41 to Lys-59, Ala-104 to Glu-110.
831762	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1204 as residues: Pro-83 to Leu-91, His-116 to Ala-122, Pro-141 to Ser-155.
831848	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1206 as

	residues: Gln-16 to Thr-23.
831861	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1207 as residues: Ala-20 to Lys-26, Pro-59 to Pro-67, Ser-104 to Thr-121, Gln-130 to Gln-136.
831866	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1208 as residues: Arg-11 to Ala-24, Ile-39 to Lys-45, Arg-76 to Pro-85, Lys-124 to Lys-130, Pro-139 to Ser-153, Ala-156 to Glu-170, Ser-179 to Thr-184, Asp-234 to Gly-244, Gly-321 to Lys-329.
831899	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1210 as residues: Asp-11 to Trp-16, Pro-37 to Thr-44, Pro-74 to Pro-82, Arg-112 to Gln-119, Cys-126 to Arg-138, Arg-199 to Thr-204.
831913	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1211 as residues: Pro-22 to Cys-27, Glu-54 to Glu-60, Asp-112 to Phe-117, Lys-183 to Asp-189, Gln-277 to Tyr-282, Pro-325 to Arg-331, Gly-336 to Tyr-346.
831985	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1213 as residues: Cys-7 to Asp-12, Pro-21 to Gly-26.
831986	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1214 as residues: Cys-1 to Ser-7, Ala-62 to Gly-72, Pro-83 to Ala-101.
832010	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1215 as residues: Leu-1 to Lys-21, Glu-39 to Cys-47, Lys-49 to Gln-61, His-64 to Gly-76, Thr-83 to Lys-90, His-92 to Ile-99.
832016	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1216 as residues: Phe-28 to Asn-33, Leu-55 to Tyr-80, Pro-126 to Gly-132, Pro-162 to Gly-169, Pro-194 to Arg-201.
832041	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1217 as residues: Lys-55 to Met-63, Arg-120 to Asp-132, Gly-266 to Glu-281, Val-313 to Thr-319, Leu-361 to Ser-370, Tyr-406 to Met-412, Leu-465 to Trp-470.
832049	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1219 as residues: Leu-80 to Lys-87, Lys-102 to Thr-109, Glu-195 to Thr-200, Thr-203 to Asp-209.
832122	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1220 as residues: Asn-29 to Phe-36, Asp-41 to Ser-50.
832197	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1222 as residues: Glu-61 to Leu-70.
832237	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1223 as residues: Lys-28 to Val-35, Arg-41 to Arg-55, Pro-76 to Thr-87.
832246	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1224 as residues: Arg-17 to Asn-23, Arg-90 to Gly-95, Leu-114 to Glu-121, Pro-153 to Asp-158.
832256	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1225 as residues: Gly-15 to Asn-22.
832280	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1226 as residues: Glu-1 to Trp-16, Ala-32 to Glu-38, Ala-49 to Gln-55, Pro-61 to Gln-66, Ala-78 to Asp-100, Leu-107 to Thr-127, Pro-133 to Phe-157, Pro-160 to Thr-171, Leu-179 to Asp-196, Asp-201 to Lys-222, Pro-249 to Ile-254, Val-258 to Val-263, Thr-268 to Ser-277, Thr-279 to Ala-295, Gly-299 to Phe-327, Val-335 to Asp-346, Lys-366 to Asp-378.
832285	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1227 as residues: Phe-18 to Leu-23.
832294	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1228 as residues: Pro-21 to Gln-28, Pro-56 to Leu-64, Glu-79 to Pro-95, Met-125 to Gly-138.
832326	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1229 as residues: Ser-30 to Trp-45, Gln-64 to Cys-72, Pro-74 to Pro-80, Ala-92 to Arg-98, Trp-104 to Ser-112, Ser-129 to Asp-135, Pro-145 to Gln-152, Arg-168 to Gly-173, Gln-176 to Pro-183.
832370	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1232 as residues: Ala-5 to Ala-11, Pro-23 to Pro-36, Glu-72 to Gly-82, Pro-85 to Pro-91, Asp-

	98 to Gly-119, Pro-121 to Glu-127.
832381	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1233 as residues: Arg-1 to Glu-6, Arg-52 to Ala-58, Phe-72 to Leu-79, Gly-88 to Glu-93, Tyr-124 to Arg-134.
832454	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1235 as residues: Ala-23 to Asp-41.
832465	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1236 as residues: Ala-1 to Gly-7, Ala-32 to Val-45, Ile-65 to Ser-75, Ser-93 to Ser-108.
832475	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1237 as residues: Arg-1 to Val-10, Thr-65 to Ser-71, Arg-83 to Tyr-96, Trp-104 to Trp-111.
832495	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1238 as residues: Arg-9 to Arg-14.
832498	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1239 as residues: Pro-26 to Asp-31, Thr-113 to Gly-125, Asn-158 to Glu-163, Asn-288 to Val-293.
832501	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1240 as residues: Ser-8 to Glu-13.
832505	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1241 as residues: Ala-27 to Arg-46, Pro-54 to Arg-76, Arg-134 to Lys-140, Asn-148 to Ser-154, Lys-166 to Thr-172, Pro-175 to Gln-182, Asp-185 to Asp-192.
832554	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1243 as residues: Arg-26 to Val-31, Asn-122 to Thr-128.
832569	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1244 as residues: Gln-6 to Met-16.
832578	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1245 as residues: Arg-15 to Leu-27, Ser-62 to Gly-72, Pro-107 to His-112, Pro-122 to Gln-142, Glu-147 to Arg-158, Lys-177 to Lys-191, Leu-195 to Val-202, Leu-206 to Pro-218, Glu-228 to Gln-233, Asp-239 to Asp-244, Glu-258 to Gln-278.
832615	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1246 as residues: Gln-41 to Ala-48.
832632	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1248 as residues: Asn-60 to Val-70, Glu-93 to Trp-107, Arg-116 to Gln-125, Leu-133 to Lys-141, Lys-162 to Glu-167.
832633	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1249 as residues: Gly-8 to Trp-13, Pro-36 to Gly-41, Pro-91 to Ala-96.
834859	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1252 as residues: Tyr-16 to Leu-22, Asp-24 to Asp-34, Gly-43 to Ala-48, Gly-57 to Thr-68, Gly-118 to Ser-127, Ile-129 to Tyr-134, Pro-139 to Asp-162.
834861	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1253 as residues: Glu-14 to Glu-50, Glu-67 to Asp-74, Leu-89 to Asn-95.
834890	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1254 as residues: Arg-8 to Lys-13, Gly-35 to Lys-42, Ala-48 to Lys-54, Ala-105 to Leu-110, Gly-150 to Val-157, Phe-164 to Asn-173.
835079	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1255 as residues: Ser-53 to Pro-60.
835554	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1256 as residues: Ile-31 to Ile-38, Asp-116 to Arg-121, Phe-246 to Leu-251, Lys-280 to Tyr-291, Met-363 to Arg-373, Gly-381 to Trp-386.
835723	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1258 as residues: Glu-20 to Thr-26, Trp-47 to Ser-57, Pro-98 to Asn-105, Pro-124 to Phe-129, Ala-173 to Val-183, Lys-190 to Ser-196, Asn-277 to Asn-284, Glu-297 to Phe-306, Thr-322 to Lys-327, Gln-372 to Val-383, Pro-387 to Gly-395, Ser-406 to Thr-415, Arg-432 to Thr-442.
835791	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1259 as residues: Ala-4 to Gly-10.
835817	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1260 as

	residues: Glu-37 to Leu-43.
835840	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1261 as residues: Gln-1 to Asn-6, Pro-18 to Ile-31.
836048	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1262 as residues: Lys-1 to Lys-11, Tyr-27 to Glu-35, Glu-61 to Gly-68.
836898	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1263 as residues: Gln-94 to Lys-102, Gly-140 to Thr-154, Arg-173 to Asp-196, Thr-201 to Asp-206, Glu-241 to Gly-248.
836927	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1264 as residues: His-1 to Arg-12.
837344	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1265 as residues: Pro-15 to Ile-24.
837789	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1266 as residues: Ser-1 to Trp-7, Asp-47 to Ile-52, Pro-70 to Ser-80, Cys-89 to Thr-98, Ala-131 to Ser-142, Phe-169 to Cys-176, Gly-183 to Ser-193, Phe-202 to Pro-209, Arg-243 to Ala-249, Ser-256 to Lys-265, Arg-277 to Asp-284.
838754	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1268 as residues: Phe-27 to Ser-37, Tyr-91 to Arg-96, Pro-156 to Gln-164, Cys-207 to Val-216, Met-242 to Tyr-251.
839561	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1271 as residues: Arg-2 to Gly-7, Arg-16 to Gln-22, Phe-41 to Gly-49, Ala-60 to Asn-74, Leu-125 to Gln-131, Asp-170 to Pro-175, Ala-209 to Arg-218, Glu-222 to Glu-258, Ala-265 to Ser-300.
839816	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1272 as residues: His-32 to Arg-37, Ser-42 to Ser-48, Glu-77 to Glu-88.
840068	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1273 as residues: Ala-1 to Gln-14.
840279	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1274 as residues: Ala-1 to Asp-15.
840538	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1276 as residues: Ala-8 to Pro-13, Pro-18 to Gln-26, Lys-107 to Pro-114, Ala-149 to Arg-157, Ile-294 to Leu-299, Ser-356 to Pro-363, Pro-384 to Phe-392, Ala-474 to Gly-481, Ala-489 to Tyr-494, Pro-512 to Lys-517, Arg-623 to Thr-630, Lys-673 to Ser-678, Thr-703 to His-709, Arg-714 to Arg-720, Gly-755 to Glu-766.
840549	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1278 as residues: Ala-5 to Lys-15, Pro-28 to Gln-34, Tyr-105 to His-111, Gln-150 to Cys-157.
840557	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1280 as residues: Gly-34 to Leu-40, Thr-125 to Gly-134, Ala-148 to Arg-156, Lys-196 to Lys-215.
840561	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1281 as residues: Ser-21 to Phe-30.
840562	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1282 as residues: Gln-33 to Arg-41, Tyr-66 to Glu-71, Thr-112 to Gly-118, Thr-141 to Gly-148, Thr-160 to Cys-168, Arg-171 to Gly-177, Thr-180 to Pro-191, Glu-217 to Asp-225, Asp-236 to Lys-243.
840564	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1283 as residues: Val-13 to Pro-19, Gln-34 to Gly-39.
840600	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1285 as residues: Leu-26 to Ile-39.
840620	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1288 as residues: Ser-17 to Ser-26, His-32 to Gly-42, Thr-78 to Gln-83, Asp-130 to Leu-136, Arg-158 to Pro-164.
840626	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1290 as residues: Phe-7 to Tyr-13, Pro-19 to Ala-35, Asp-87 to Leu-96, Lys-98 to Glu-105, Glu-120 to Leu-133.
840638	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1291 as

	residues: Gly-8 to Leu-13, Gly-21 to Ser-31, Arg-45 to Arg-54.
840649	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1292 as residues: Asn-30 to Thr-37, Asp-44 to Lys-52, Ser-71 to Asp-80, Glu-127 to Glu-133, Arg-162 to Ala-173, Glu-191 to Leu-199.
840651	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1293 as residues: Gly-14 to Glu-38, Asn-90 to Lys-100, Lys-150 to Val-158, Ser-166 to Gly-175.
840681	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1295 as residues: Thr-25 to Gly-31, Pro-86 to Trp-97, Ser-132 to Phe-138.
840682	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1296 as residues: Arg-12 to Lys-19, Asn-30 to Gly-36, Asp-50 to Gly-57, Glu-64 to Thr-69, Thr-79 to Lys-91, Gln-110 to Thr-115, Arg-223 to Gln-229, Asp-255 to Asp-260, Arg-278 to Gly-287, Glu-294 to Gln-300, Glu-433 to Glu-451, Leu-474 to Glu-479, Asp-490 to Leu-498, Gln-519 to Asp-527, Tyr-566 to Asp-575.
840684	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1297 as residues: Pro-1 to Ala-9, Val-56 to Val-63, Gly-86 to Glu-91.
840697	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1298 as residues: Pro-9 to Arg-15, Pro-36 to Ser-42, Ser-65 to Phe-72, Gly-99 to Ser-105, Ala-122 to Phe-129.
840698	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1299 as residues: Thr-75 to Pro-84, His-94 to Met-99, Asp-149 to Ile-168, Asn-370 to Asn-375, Ser-384 to Lys-392, His-427 to Tyr-438.
840708	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1300 as residues: Ala-27 to Ser-36.
840714	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1301 as residues: Gly-1 to Gly-20, Arg-54 to His-59, Asn-89 to Leu-95, Ser-119 to Lys-125, Trp-127 to Cys-133, Gln-175 to Gln-185, Asp-213 to Lys-222, Pro-267 to Gln-275, Asp-306 to Asp-313, Thr-321 to Cys-331.
840716	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1302 as residues: Asn-40 to Thr-45, His-210 to Pro-215, Glu-369 to Thr-375, Lys-383 to Leu-397, Pro-438 to Ile-447, Pro-510 to Tyr-520, Arg-528 to Arg-533, Thr-549 to Thr-555.
840721	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1303 as residues: Arg-1 to Arg-7, Pro-29 to Lys-56, Asp-103 to Arg-108, Tyr-122 to Ser-127, Gly-219 to Glu-227, Asp-250 to Glu-255, Glu-294 to Pro-301, Ala-321 to Tyr-327, Arg-367 to Pro-373, Glu-396 to Asn-405, Gly-411 to Arg-418, Asn-433 to Lys-441.
840735	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1304 as residues: Glu-1 to Gly-11, Thr-20 to Asp-40, Gly-51 to Glu-61, Ala-64 to Leu-78, Leu-82 to Arg-94.
840738	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1305 as residues: Gln-26 to Asn-34.
840745	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1306 as residues: Gln-7 to Gly-12, Leu-60 to Pro-65, Arg-85 to Lys-99, Ser-132 to Pro-145, Pro-150 to Asp-155, Pro-183 to Asn-193, Arg-200 to Tyr-206.
840747	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1307 as residues: Gln-1 to Asp-15, Ile-35 to Glu-41, Leu-66 to Asn-71, Leu-73 to Pro-79, Gln-87 to Lys-94, Val-117 to Arg-123, Pro-144 to Tyr-150.
840756	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1308 as residues: Arg-8 to Gln-19, Arg-25 to Lys-38.
840776	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1309 as residues: Val-2 to Pro-10, Ser-28 to Ala-33, Pro-39 to Tyr-44, Thr-46 to Trp-55, Ser-64 to Ser-72, Ala-103 to Pro-109, Pro-111 to Gln-118.
840784	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1310 as residues: Pro-9 to Gly-20, Asn-32 to Leu-42, Asn-60 to Lys-70, Pro-76 to Gln-81, Glu-86 to Val-93, Arg-106 to Arg-111, Lys-176 to Asn-183.
840788	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1311 as residues: Ser-1 to Gln-8, Val-40 to Ser-49, Arg-105 to Lys-110.

840794	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1312 as residues: Arg-1 to Gln-14, Arg-43 to Glu-54.
840797	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1313 as residues: Gly-1 to Arg-9, Asn-31 to Asp-37, Arg-44 to Asn-53, Gly-62 to Lys-77, Thr-123 to Ile-137, Gly-389 to Thr-394, Lys-486 to Asn-493, Glu-512 to Phe-520, Met-555 to Lys-560, Leu-618 to Ser-623, Ile-698 to Glu-706, Gly-723 to Leu-730, Ala-773 to Gln-790.
840818	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1315 as residues: Pro-1 to Ile-12, Asp-30 to Tyr-35, Leu-38 to Pro-45, Lys-54 to Thr-60, Thr-75 to Leu-80, Asp-92 to Tyr-100, Ile-133 to Thr-138, Thr-194 to Glu-199, Asp-233 to Leu-239, Met-243 to Ala-251, Asp-254 to Glu-261.
840822	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1316 as residues: Val-100 to Tyr-106, Ala-127 to His-135, Gln-153 to Lys-158, Gly-214 to Glu-219, Gln-236 to His-244, Lys-253 to Tyr-258.
840846	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1318 as residues: Ala-20 to Thr-27, Glu-47 to Tyr-57, Tyr-87 to Lys-95, Pro-121 to Ala-127, Pro-208 to Ala-224.
840848	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1319 as residues: Arg-77 to Asn-82, Glu-119 to Arg-124, Gln-156 to Thr-162, Lys-209 to Lys-215.
840860	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1320 as residues: Ile-27 to Asp-41, Glu-43 to Ala-58, Glu-149 to Glu-154, Lys-158 to Ile-165, Glu-167 to Gly-189, Glu-242 to Phe-247, Arg-259 to Phe-268, Ile-283 to Val-291, Thr-295 to Thr-307, Glu-328 to Asp-338, Asp-372 to Gly-387.
840871	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1322 as residues: Gly-31 to Tyr-38, Leu-40 to Leu-45, Pro-203 to Trp-208.
840874	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1323 as residues: Ala-23 to Gly-28.
840878	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1324 as residues: Thr-40 to Glu-46, Pro-69 to Arg-76, Glu-108 to Asp-150.
840880	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1325 as residues: Ser-5 to Lys-14, Phe-32 to Gln-37.
840884	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1326 as residues: Leu-4 to Ser-10.
840926	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1328 as residues: Met-6 to Thr-15, Ser-17 to Phe-37, Ser-148 to Lys-154, Lys-260 to Phe-276, Glu-285 to Ile-292, Lys-410 to Asp-424.
840932	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1329 as residues: Tyr-75 to Pro-83, Ile-181 to Gln-191, Glu-267 to Leu-275, Met-301 to Ala-307, Phe-322 to Gln-328, Met-371 to Gly-381, Gln-458 to Leu-463, Glu-474 to Lys-480, Lys-551 to Ser-558.
840940	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1330 as residues: Ser-26 to Thr-34, Thr-80 to Lys-88.
840947	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1331 as residues: Ile-1 to Arg-11, Pro-19 to Gln-46, Ala-55 to Pro-62, Cys-65 to Cys-82, Lys-93 to Pro-108.
840964	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1333 as residues: Ser-41 to Cys-46.
840979	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1334 as residues: Tyr-10 to His-27, Tyr-31 to Arg-41, Thr-44 to Leu-61, Cys-68 to Phe-73, Lys-98 to Glu-106, Gln-132 to Val-142, Glu-184 to Leu-191.
840984	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1335 as residues: Arg-38 to Gln-48, Met-137 to Asn-144, Gln-167 to Gln-172, Lys-182 to Gln-189, Gln-196 to Glu-206, Ile-210 to Glu-223, Gln-225 to Arg-246, Glu-250 to Thr-269, Gln-296 to Ile-318, Arg-323 to Glu-328, Tyr-337 to Lys-343, Glu-349 to Thr-357, Ser-393 to Glu-403, Arg-405 to Ile-427, Arg-431 to Glu-442, Leu-446 to Lys-473, Glu-475

	to Leu-486, Ile-488 to Asp-503, Ser-505 to Arg-623, Ala-625 to Asn-631, His-634 to Trp-792, Gly-799 to Gly-870, Arg-872 to Glu-929, Ser-931 to Pro-954, Ala-957 to Ala-977, Glu-982 to Trp-1000.
840986	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1336 as residues: Asp-41 to Tyr-51.
840988	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1337 as residues: Pro-17 to Leu-31, Ser-95 to Val-100, Lys-123 to Gly-129.
840990	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1338 as residues: Met-9 to Glu-16, Glu-41 to Trp-47, Arg-55 to Glu-62, Asp-135 to Ile-146, Gly-154 to Gly-160, Met-207 to Phe-214, Ser-245 to Lys-252, Gln-282 to Gln-288.
841009	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1340 as residues: Glu-12 to Thr-27, Met-45 to Asn-52, Tyr-79 to Thr-87, Asp-97 to Gly-102, Met-112 to Asp-120, Pro-141 to Tyr-155.
841012	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1341 as residues: Lys-36 to Ile-44, Arg-49 to Lys-69.
841016	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1342 as residues: Cys-75 to His-82, Asp-126 to Tyr-135, Pro-144 to Tyr-155, Gly-179 to Trp-198, Tyr-201 to Met-208, Pro-226 to Lys-234, Gln-249 to Asp-267.
841017	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1343 as residues: Gln-1 to Trp-19.
841021	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1344 as residues: Glu-58 to Gly-63, Leu-75 to Leu-82.
841032	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1345 as residues: Pro-1 to Gly-13, Pro-30 to Ser-57, Gln-61 to Thr-77, Arg-82 to Thr-88, Pro-100 to Lys-105, Gly-119 to Gly-126.
841051	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1346 as residues: Asn-1 to Lys-6, Thr-16 to Glu-21, Asn-45 to Ser-58, Asp-68 to Ser-75.
841064	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1347 as residues: Asp-53 to Pro-58, Glu-78 to Lys-85, Pro-95 to Arg-102, Ser-142 to Arg-148, Lys-209 to Arg-214, Lys-241 to Gly-246, Ser-287 to Leu-292, Lys-307 to Val-313, Arg-389 to Gln-394.
841069	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1348 as residues: Thr-1 to Trp-14, Lys-27 to Leu-44, Glu-59 to Arg-73, Lys-87 to Phe-95, Pro-160 to Asn-166, Leu-212 to Ile-220, Arg-236 to Asp-243.
841072	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1349 as residues: Pro-7 to Arg-12, Phe-71 to Gln-76, Arg-82 to Asp-98, Ala-108 to Glu-128.
841078	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1350 as residues: Arg-32 to Ala-39.
841080	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1351 as residues: Glu-1 to Gly-7, Glu-25 to Gly-33, Ala-54 to Phe-60, Gly-64 to Gln-108, Glu-116 to Ser-122, Pro-130 to Asn-138, Gln-141 to Lys-153, Arg-164 to Ser-172, Leu-186 to Met-194, Pro-197 to Tyr-205, Asp-218 to Lys-229, Thr-236 to Ser-246, Ala-259 to Trp-266, Pro-281 to Pro-287, Cys-291 to Gln-298.
841092	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1353 as residues: Glu-45 to Lys-50.
841095	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1354 as residues: Lys-1 to Ser-19, Gly-33 to Gly-63, Gly-77 to Pro-89, Ser-164 to Ser-180, Ser-233 to Lys-238, Lys-267 to Leu-286.
841096	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1355 as residues: Gly-5 to Leu-12, Tyr-18 to Asp-25, Ile-88 to Ala-125, Ser-129 to Tyr-141, Gln-191 to Gln-196, Thr-290 to Asn-296, Thr-301 to Thr-309, Leu-360 to Ala-365, Leu-367 to Gly-378, Pro-398 to Gly-418, Pro-443 to Gly-454.
841102	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1356 as residues: Ser-61 to Leu-71.
841108	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1358 as residues: Ala-8 to Leu-20, Lys-27 to Arg-33, Arg-40 to Ala-50, Asp-77 to Glu-84,

	Asn-99 to Gly-109.
841119	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1360 as residues: Lys-6 to Ala-14, Ile-68 to Asn-73, Val-84 to Leu-90, Glu-110 to Val-116, Leu-182 to Gly-190, Tyr-264 to Phe-270, Ile-300 to Lys-306, Pro-354 to Glu-367.
841124	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1361 as residues: Ser-21 to Thr-26.
841143	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1363 as residues: Thr-1 to Lys-9, Pro-20 to Gly-27, Gly-29 to Gly-52, Arg-54 to Gly-61, Gly-69 to Gly-75, Ser-79 to Gly-96, Val-130 to Arg-135, His-207 to Asp-212, Val-296 to Leu-310, Arg-327 to Asn-334.
841148	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1364 as residues: Pro-1 to Met-43, Pro-55 to Ala-66, Pro-118 to Glu-128, Arg-181 to Lys-192, Tyr-197 to Thr-207, Trp-278 to Cys-284, Arg-334 to Asp-349.
841155	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1367 as residues: Gly-9 to Arg-24, Glu-69 to Met-74, Leu-86 to Leu-92, Asp-95 to Arg-115.
841163	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1370 as residues: Gly-29 to Gly-35, Ala-37 to Ala-48, Arg-97 to Thr-102, Arg-114 to Leu-119, Lys-144 to Lys-155.
841169	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1371 as residues: Ala-31 to Thr-69, Pro-90 to Pro-95, Pro-117 to Trp-126, Pro-128 to Arg-136.
841172	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1372 as residues: Gly-17 to Arg-35, His-76 to Pro-90, Pro-92 to Cys-103.
841174	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1373 as residues: Arg-1 to Arg-8, Arg-14 to Phe-19.
841179	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1374 as residues: Leu-4 to Met-10, Leu-17 to Tyr-36, Arg-38 to Asp-63, Tyr-82 to Glu-90, Pro-97 to Gly-134, Arg-137 to Pro-148, Thr-160 to Lys-171, Tyr-183 to Asn-228, Gln-249 to Asn-258, Arg-263 to Glu-271, Arg-277 to Gln-296, Phe-298 to Asp-320, Glu-322 to Lys-329, Thr-337 to Thr-343, Glu-356 to Arg-363, Gly-371 to Asp-384.
841183	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1375 as residues: His-1 to Ser-27, Arg-60 to Arg-73, Arg-96 to Asp-124, Asp-131 to Gly-143, Lys-145 to Glu-150.
841186	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1376 as residues: Leu-7 to Val-18, Ser-27 to Pro-57, Arg-124 to Thr-135, Pro-212 to Ser-230, Gly-282 to Lys-287, Lys-441 to Lys-448.
841204	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1377 as residues: Lys-29 to Arg-35, Glu-81 to Arg-87, Ala-251 to Glu-261, Thr-266 to Gly-271, Thr-289 to Glu-295, Gly-328 to Tyr-334, Phe-432 to Lys-438, Asn-440 to Trp-458.
841206	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1378 as residues: Val-17 to Pro-25, Thr-55 to Asp-70, Lys-75 to Leu-81.
841207	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1379 as residues: Pro-9 to Glu-15, Arg-22 to Trp-32, Ser-54 to Glu-62, Asn-92 to Gly-103.
841211	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1380 as residues: Arg-7 to Gly-12, Met-42 to Ser-58, Gln-65 to Asn-73, Glu-91 to Ala-99, Pro-103 to Tyr-109, Arg-174 to Ala-179, His-189 to Gln-196, Asn-208 to Pro-219.
841225	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1381 as residues: Ala-32 to Ala-40, Glu-93 to Phe-103, Lys-173 to Thr-189.
841237	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1383 as residues: Arg-2 to Gln-12, Lys-76 to Ala-86, Tyr-155 to Lys-163, Glu-228 to Leu-234, Lys-263 to Lys-273, Ile-286 to Lys-296.
841241	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1384 as residues: Asp-41 to Ile-52, Thr-59 to Lys-64, Glu-75 to Asn-89, Thr-99 to Thr-105.
841259	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1385 as residues: His-1 to Cys-22, Pro-24 to Pro-30, Tyr-84 to Ser-90, Ser-108 to Glu-118, Val-126 to Arg-143, Asp-175 to Gln-181, Ser-217 to Gly-224, Cys-262 to Cys-270.

	Tyr-296 to Glu-302, Thr-317 to Thr-324, Gln-341 to Gln-348, Trp-394 to Pro-399.
841260	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1386 as residues: Ala-25 to Glu-32, Ala-48 to Phe-53, Ser-69 to Ser-76, Asp-80 to Glu-86, Ser-125 to Ser-132, Ser-168 to Glu-179, Asn-201 to Ala-206, Lys-216 to Ile-246, Met-259 to Asn-272, Tyr-277 to Gln-287.
841264	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1387 as residues: Met-34 to Gly-50, Asp-69 to Trp-90, Asp-99 to Lys-107, Val-164 to Thr-170.
841311	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1389 as residues: Arg-4 to Val-15.
841313	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1390 as residues: His-6 to Gly-16, Gly-60 to Pro-95, Pro-125 to Gly-131, Gly-138 to Ala-147, Gln-173 to Glu-178.
841322	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1392 as residues: Lys-6 to Arg-23, Ser-74 to Arg-86, Lys-116 to Lys-122, Ser-127 to His-133, Ser-269 to Pro-275, Glu-344 to Phe-350, Gly-356 to His-362.
841331	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1393 as residues: Ser-45 to Lys-67, Asp-155 to Asp-172, Gln-193 to Ile-199, Gln-271 to Glu-285.
841332	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1394 as residues: Glu-8 to Ser-13, Lys-20 to Glu-27, Arg-81 to Ser-94, Thr-147 to Ile-154, Asn-200 to Glu-212, Asn-235 to Gly-244, Leu-433 to Thr-439, Pro-444 to Asn-455, Ser-470 to Asp-476, Ser-492 to Met-499, Glu-535 to Pro-547, Glu-703 to Thr-709, Glu-719 to Thr-726, Asn-802 to Leu-807, Asn-820 to Arg-825, Lys-830 to Tyr-836, Thr-838 to Thr-850, Ser-882 to Ser-894, Lys-944 to Gly-952, Gly-969 to Val-977, Glu-984 to Asn-990, Arg-996 to Lys-1001, Pro-1032 to Leu-1039, Thr-1050 to Gly-1058, Val-1103 to Arg-1108, Pro-1160 to His-1169, Tyr-1180 to Ser-1187, Glu-1211 to Ser-1217, Pro-1277 to Leu-1282.
841338	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1395 as residues: Ser-13 to Ser-18, Phe-48 to Ser-54.
841345	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1396 as residues: Trp-83 to Thr-89, Ser-135 to Asn-140, Ser-185 to Cys-190, Tyr-209 to Glu-220, Val-224 to Glu-232, Leu-258 to Asn-263, Ser-306 to Asn-312, Thr-319 to Glu-327, Thr-365 to Ile-373, Gly-417 to Cys-429, Lys-439 to Val-445, Lys-464 to Leu-469, Leu-477 to Asn-485, Arg-546 to Val-554, Glu-598 to Gly-607, Pro-634 to Ser-639, Asn-730 to Ala-746, Lys-812 to Gln-817, Glu-819 to Lys-835, Leu-867 to Asn-875, Leu-902 to Arg-910.
841349	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1397 as residues: Asp-13 to Arg-18, Pro-36 to Arg-43, Gly-66 to Ser-74, Gly-87 to Lys-92, Asp-110 to Glu-115.
841417	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1399 as residues: Leu-102 to Ile-111, Pro-131 to Ile-337, Thr-339 to Asp-376.
841632	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1401 as residues: Arg-13 to Gly-40, Arg-46 to Glu-52, Gln-55 to Lys-69.
841771	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1403 as residues: Pro-22 to Gly-30, Asp-45 to Gln-56, Ser-67 to Ser-73.
841827	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1404 as residues: Thr-1 to Ser-20.
841835	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1405 as residues: Tyr-5 to Lys-13, Cys-52 to Arg-61, Cys-85 to Ala-91, Gly-122 to Asn-127.
842259	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1406 as residues: Pro-16 to Gly-23, Glu-37 to Pro-45, Gly-52 to Ser-57.
842463	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1407 as residues: Cys-74 to Tyr-79.
842595	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1408 as residues: Pro-93 to Ala-105, Ser-133 to Ser-142, Arg-150 to Glu-155, Lys-220 to Trp-

	226, Glu-257 to Lys-271, Gln-280 to Leu-289.
842722	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1409 as residues: Glu-9 to Arg-20, Ser-48 to Lys-56, Ile-69 to Glu-81, Pro-83 to Lys-89, Lys-94 to Ile-99, Pro-104 to Gly-110, Glu-116 to Asp-133, Ile-140 to Ser-154, Gln-206 to His-217, Pro-219 to Leu-231, Arg-237 to Lys-243, Gln-247 to Pro-256, Leu-271 to Thr-283, Lys-289 to Lys-294, Ser-338 to Lys-355, Gly-375 to Thr-381, Ser-428 to Pro-454, Gly-460 to Gln-467, Lys-480 to Lys-488.
842818	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1411 as residues: Ala-25 to Ala-30, Lys-32 to Ala-51, Gln-61 to Ala-68, Glu-83 to Lys-91, Phe-99 to Glu-105, Glu-123 to Gly-129.
843251	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1412 as residues: Pro-30 to Ser-40, Lys-47 to Thr-52, Val-59 to Pro-64, Lys-129 to Arg-134, Leu-169 to Asp-177.
843422	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1413 as residues: Thr-9 to Lys-20, Lys-25 to Cys-31, Pro-33 to Tyr-42, Asn-76 to Lys-84, Leu-102 to Trp-112.
843784	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1414 as residues: Leu-16 to Thr-24, Glu-41 to Gln-47, Lys-64 to Cys-72, Thr-87 to Ser-100, Pro-130 to Asn-143, Thr-163 to Asp-170.
844017	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1415 as residues: Leu-11 to Ile-17, Leu-30 to Met-45.
844138	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1416 as residues: Lys-19 to Thr-28, Arg-47 to Gln-52, Leu-73 to Leu-81, Asp-122 to Phe-131, Ala-135 to Ser-148, Pro-155 to Asp-163, Ser-184 to His-191, Leu-219 to Asn-225, Asp-238 to Thr-248, Pro-253 to Cys-259, Cys-356 to His-368, Ser-426 to Gly-435, Pro-467 to Cys-478, Glu-504 to Cys-509, His-553 to Gly-568, Ala-581 to Cys-586, Ala-595 to Cys-600, Arg-602 to Trp-608.
844194	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1418 as residues: Pro-23 to Arg-31, Gln-79 to Gln-85, Cys-93 to Cys-107, Pro-216 to Leu-222.
844394	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1419 as residues: Arg-1 to Phe-11.
844450	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1420 as residues: Ser-37 to Trp-43, Pro-47 to Thr-55, Arg-60 to Lys-69, Tyr-125 to His-131, Pro-187 to Lys-195, Gly-346 to Lys-351.
844535	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1422 as residues: Asp-8 to Ala-18, Ser-47 to Ala-52, Thr-62 to Arg-69, Pro-119 to Asp-126, Trp-164 to Thr-170, Ala-206 to Ala-213, Pro-230 to Gly-235, Lys-304 to Lys-314, Lys-341 to Val-347, Tyr-387 to Thr-398.
844644	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1423 as residues: Ala-9 to Asp-16, Asn-78 to Tyr-86.
844653	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1424 as residues: Arg-1 to Gly-8, Ala-30 to Gln-36.
844796	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1426 as residues: His-12 to His-22.
844812	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1427 as residues: Gly-281 to Arg-290, Ala-349 to Ser-355, Glu-378 to Asp-388.
844894	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1428 as residues: Pro-2 to Phe-8, Ser-13 to Ala-34, Pro-37 to Phe-43, Lys-63 to Gly-73, Cys-88 to Asp-93, Gly-98 to Trp-103, Cys-273 to Ile-287, Ile-290 to Ser-296.
845361	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1429 as residues: Met-10 to Ile-21, Glu-108 to Lys-122, Lys-272 to Gly-280, Gly-298 to Lys-304, Trp-364 to Lys-369.
845620	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1430 as residues: Thr-62 to Ala-67, Leu-96 to Glu-101, Cys-184 to Trp-190.
845639	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1431 as residues: Arg-41 to Arg-48, Met-72 to Val-79, Gln-81 to Trp-89, Ala-96 to Asp-101,

	Arg-110 to Gly-118, Asn-126 to Arg-135, Ala-144 to Asp-149, Leu-199 to Lys-213, Gln-245 to Glu-256, Arg-261 to Thr-267.
845660	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1432 as residues: Gly-5 to Leu-17, Arg-19 to Arg-29, Pro-36 to Arg-50, Arg-60 to Pro-67, Gln-133 to Leu-150, Gln-168 to Phe-187, Pro-189 to Gln-194, Asp-240 to Gly-251, Thr-308 to Cys-317, Val-325 to Glu-331, Leu-354 to Pro-369, Lys-381 to Cys-388, Arg-410 to Phe-417.
845720	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1433 as residues: Thr-1 to Glu-11, Arg-21 to Pro-27, Pro-44 to His-49, Glu-56 to Leu-69, Ala-74 to Gly-80, Phe-82 to Pro-87.
845897	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1435 as residues: Gly-1 to Ser-9, Gly-31 to Ser-38, Arg-52 to Val-68, Leu-71 to Glu-84.
845922	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1436 as residues: Asn-1 to Pro-6, Pro-29 to Gln-36, Glu-95 to Arg-100, Pro-150 to Met-157, Ser-272 to Tyr-278, Gly-289 to Arg-294, Lys-397 to Ser-403.
846040	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1438 as residues: Cys-6 to Ser-16, Glu-52 to Tyr-58, Asn-144 to Lys-153.
846073	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1439 as residues: Arg-6 to Thr-16, Ile-43 to Gln-48, Leu-131 to Gly-139, Gly-147 to Asp-155, Asp-191 to Asp-198, Gly-204 to Thr-214.
846257	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1440 as residues: Lys-24 to Phe-44, Arg-58 to Gly-64, Ser-69 to Val-75, Lys-83 to Leu-90, Lys-93 to Glu-106.
HTXPN06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1441 as residues: Gly-1 to His-8.
HWAFU16R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1443 as residues: Ile-29 to Lys-34.
HOEMT44R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1445 as residues: Asp-73 to Lys-79.
HE2OW04R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1446 as residues: Cys-1 to Asn-6, Met-41 to Thr-51, Lys-77 to Thr-82.
HFCFG25R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1447 as residues: Lys-29 to Ile-37, Arg-42 to Lys-47.
HAPQP94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1448 as residues: Pro-18 to Arg-23, Ala-43 to Ser-48.
H2CBI37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1449 as residues: Gly-5 to Lys-19, Phe-26 to Trp-31.
HCRNC25R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1451 as residues: Leu-2 to Asn-8.
H2LAY26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1453 as residues: Pro-20 to His-36.
HAPQA06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1454 as residues: Tyr-15 to Ala-22, Ser-68 to Gly-74.
HBGOK18R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1456 as residues: Gly-1 to Tyr-6, Asp-40 to Thr-47, Lys-91 to Glu-97.
HTWKF26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1458 as residues: Gly-31 to Gly-39.
HTAHR89R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1459 as residues: Asp-73 to Gly-78.
HOELC27R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1461 as residues: Asn-19 to Gln-25, Arg-33 to Ala-42, Pro-92 to Lys-99.
HWLVW62R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1463 as residues: Lys-6 to Phe-13, His-25 to Ser-30, Glu-35 to Ala-41, Pro-57 to Gly-62.
HFKHD94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1465 as residues: Leu-1 to Gly-6, Pro-29 to Gly-42, Lys-52 to Gly-62.
HOFOA89R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1467 as

	residues: Ala-20 to Lys-29, Arg-48 to Ile-56.
HCROL58R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1470 as residues: Lys-1 to Ser-16.
HCHMV24R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1473 as residues: Gly-4 to Lys-10, Gln-36 to Glu-41.
HCHPT49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1474 as residues: Gly-4 to Lys-10, Gln-36 to Glu-41, Arg-61 to Arg-70.
HCHPF59R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1477 as residues: Arg-10 to Lys-22.
HS2IA81R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1478 as residues: Gly-4 to Lys-10, Gln-36 to Glu-41, Arg-61 to Arg-76.
HCRNC17R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1479 as residues: Gly-4 to Lys-10, Gln-36 to Glu-41, Arg-61 to Arg-76, Lys-107 to Pro-112.
HISDJ39R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1480 as residues: Gly-4 to Lys-10, Gln-36 to Glu-41, Arg-61 to Arg-76.
HASCG71R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1482 as residues: Lys-6 to Ile-13.
HOEMO43R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1483 as residues: Lys-31 to Gln-43.
HSYDG18R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1486 as residues: Pro-1 to Glu-7, Asp-42 to Gly-47, Leu-61 to Glu-69, Lys-97 to Ile-107, Asp-115 to Gly-120.
HACAC47R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1490 as residues: Ala-18 to Asp-26.
HLQFY41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1491 as residues: Val-11 to Asp-16, Glu-46 to Arg-51, Pro-55 to Lys-61, Lys-82 to Val-87.
HOFMO83R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1492 as residues: Thr-31 to Asp-39, Thr-52 to Gly-60.
HFTDR22R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1493 as residues: Glu-1 to Trp-13.
HOEKC39R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1495 as residues: Tyr-25 to Phe-32.
HOSNR06R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1498 as residues: Thr-1 to Tyr-7.
HCQDL20R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1499 as residues: Ser-12 to His-21.
HFKHD49R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1503 as residues: Ala-42 to Glu-68.
H6EAQ15R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1506 as residues: Ala-1 to Leu-9.
HCFLM34R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1507 as residues: Lys-7 to Thr-13, Asp-24 to Thr-30, Gly-39 to Glu-52, Leu-70 to Ile-78.
HKIXL19R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1510 as residues: Thr-2 to Asn-12, Gly-14 to Arg-24.
HAJRB09R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1512 as residues: Pro-1 to Glu-8, Ala-10 to Gly-26.
HAPNI86R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1513 as residues: Glu-53 to Ser-59, His-121 to Gln-130.
HAPRJ22R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1515 as residues: Gly-49 to Glu-64, Phe-76 to Thr-81.
HADGE45R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1518 as residues: Arg-1 to Gln-26, Phe-59 to Lys-68.
HTXPN11R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1519 as residues: Asp-1 to Lys-8, Asp-35 to Glu-41.
HCDBN37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1520 as residues: Cys-1 to Leu-15.

HABGF46R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1527 as residues: Arg-11 to Arg-20, Asn-42 to Pro-57, Arg-64 to Ser-81.
HOELC15R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1528 as residues: His-8 to Gly-18, Gln-56 to Arg-61.
H2LAR26R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1529 as residues: Glu-11 to Asn-16, Lys-38 to Glu-43, Ala-62 to Asp-67, Asp-80 to Ser-101.
H2LAV85R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1530 as residues: Pro-14 to Thr-25, Asp-89 to Gln-102, Ile-121 to Thr-131.
HBSDC92R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1531 as residues: Arg-1 to Leu-11.
HUTHN01R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1532 as residues: Pro-34 to Ser-42, Cys-82 to Lys-89.
H2LAW03R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1533 as residues: Arg-120 to Arg-127.
HOEMO60R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1534 as residues: Pro-6 to Arg-11, Phe-18 to Asn-23, Leu-36 to Thr-41.
HOELF72R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1537 as residues: Arg-1 to Pro-14, Gln-47 to Cys-52.
HAPNX59R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1538 as residues: Cys-19 to Ser-25, Asp-28 to Trp-34, Lys-71 to Trp-76, Glu-112 to Lys-120.
HBJS17R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1539 as residues: His-14 to Glu-26.
H2CBN02R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1542 as residues: Ala-1 to Pro-9, Arg-20 to Val-25.
H2CBV68R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1543 as residues: Pro-41 to Asp-46, Leu-56 to Lys-61, Ala-72 to Thr-83, Lys-100 to Asn-106, Leu-125 to Thr-133.
H6EDK07R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1544 as residues: Glu-32 to Glu-40, Val-45 to Thr-51, Pro-61 to Arg-67.
H2CBN54R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1547 as residues: Cys-36 to Tyr-44, Glu-55 to Asp-61, Arg-79 to Pro-84, Asp-89 to Pro-105, Cys-108 to Ala-118, Lys-126 to Gly-142.
HWHPX50R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1549 as residues: Pro-35 to Tyr-41.
HAPQD84R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1550 as residues: Lys-32 to Glu-39.
HAMGQ78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1554 as residues: Arg-46 to Arg-60, Glu-69 to Gly-78.
HODEV64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1555 as residues: Glu-1 to Gly-27, Asn-34 to Phe-48, Gly-63 to Gly-68.
HOEMK78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1558 as residues: Asp-27 to Gly-34, Ser-41 to Glu-49, Val-55 to Gln-62.
H2CBD13R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1559 as residues: Ile-17 to His-22, Ser-24 to Arg-29.
HCFMU61R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1560 as residues: Ser-10 to Asp-20, Leu-22 to Pro-36, Ser-42 to Lys-57, Gln-102 to Glu-110.
HOSNE94R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1561 as residues: Arg-1 to Glu-6, Asp-74 to Ser-79, Asp-122 to Thr-127.
HHBEF47R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1563 as residues: Arg-25 to His-31, Ala-50 to Ala-55.
HOSNR67R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1566 as residues: Val-56 to Cys-61, Thr-108 to Gln-122, Gln-125 to Lys-131, Glu-140 to Leu-146.
H2LAV92R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1567 as residues: Leu-3 to Ala-10, Pro-12 to Gly-21, Pro-32 to Pro-38, Ala-58 to Lys-64, Lys-67 to Val-75, Asp-92 to Leu-103.

HCLBZ27R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1570 as residues: Asp-12 to Glu-18, Ala-22 to Ile-28, Ala-48 to Gly-60.
H2LAV11R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1571 as residues: Thr-5 to Thr-14, Arg-20 to His-25, Arg-35 to Gly-40, Lys-58 to Arg-66, His-101 to Ser-107, Arg-111 to Lys-125.
HOEMJ56R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1573 as residues: Lys-27 to Tyr-48.
HDPLP40R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1576 as residues: Gly-1 to Cys-24, Cys-27 to Gly-43, Ala-46 to Trp-54, Ala-56 to Arg-68, Phe-83 to Arg-93.
HABAD57R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1578 as residues: Gly-3 to Gln-16, Pro-36 to Ala-41.
H2CBL68R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1581 as residues: Pro-19 to Val-24, Thr-31 to Gln-38, His-103 to Lys-114, Arg-129 to Leu-137, Pro-139 to Ser-146.
HNTNE17R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1582 as residues: Val-8 to Lys-15, Tyr-25 to Asn-35, Lys-48 to Lys-53, Leu-77 to Asn-87, Asp-103 to Glu-108.
HBJLR37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1583 as residues: Asn-1 to His-11, Pro-82 to Glu-89, Pro-91 to Asp-96, Arg-103 to Met-109.
HOSNG20R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1584 as residues: Thr-50 to Lys-55.
HBGNY11R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1586 as residues: Thr-10 to Trp-15, Leu-24 to Ala-30, Leu-32 to Glu-38, Asn-41 to Ala-59, Arg-81 to Asp-89, Lys-104 to Lys-111.
HOEKC80R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1587 as residues: Pro-49 to Phe-55, Gly-82 to Gly-88.
HFCES53R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1589 as residues: Thr-12 to Leu-18.
HWAFE36R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1592 as residues: Glu-2 to Ile-9, Glu-34 to Lys-42.
HTXPF20R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1594 as residues: Gly-4 to Thr-13.
HCRMD09R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1595 as residues: Thr-2 to Asn-10, Glu-22 to Gln-30, Ser-58 to Gln-80, Gln-88 to Phe-96, Thr-99 to Tyr-104, Lys-110 to Asp-115.
HAJRB47R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1596 as residues: Trp-18 to Ser-26, Asp-91 to Trp-99.
HAHCR61R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1603 as residues: Ser-17 to Cys-25.
HAPQK19R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1609 as residues: Arg-1 to Lys-10, Ser-15 to Tyr-22, Gly-25 to Leu-31.
HBGOK25R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1615 as residues: Thr-38 to Trp-45, Pro-63 to Gln-70, Pro-78 to Gln-85.
HBJKI05R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1619 as residues: Pro-43 to Trp-50.
HBLGD42R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1621 as residues: Pro-17 to Pro-27, Pro-32 to Tyr-38, Ala-44 to Pro-49.
HCHAK80R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1627 as residues: Gln-3 to His-13, Gly-48 to Gly-55.
HCHMW79R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1628 as residues: Ser-16 to His-21, Ala-29 to Thr-35.
HCHOB92R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1629 as residues: Lys-20 to Lys-28, Ser-53 to Leu-60.
HCLBO01R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1630 as residues: Leu-1 to Leu-18.

HCRPC63R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1633 as residues: Glu-1 to Arg-28.
HCUDC51R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1634 as residues: Pro-22 to Gly-32, Trp-67 to Lys-81.
HDPFI40R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1635 as residues: Tyr-1 to Phe-6, Pro-9 to Asn-22, Arg-30 to Ala-38, Pro-47 to Lys-69.
HDPRZ54R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1637 as residues: Gly-1 to Ala-8.
HFAUO64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1640 as residues: Asn-7 to Lys-29.
HJMAU64R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1645 as residues: Leu-58 to Tyr-69.
HKBAC48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1647 as residues: Ser-16 to His-46, Arg-49 to Thr-58.
HKBAD57R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1648 as residues: Thr-23 to Ser-30.
HODAY16R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1653 as residues: Pro-15 to Thr-20.
HOEMO27R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1655 as residues: Ala-7 to Ser-12.
HOEMO62R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1656 as residues: Ile-3 to Lys-11.
HOENU53R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1658 as residues: Lys-37 to Asn-44.
HOGAP33R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1659 as residues: Gln-29 to Asp-35, Gln-43 to Thr-49.
HOSNF25R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1661 as residues: Pro-29 to Arg-36.
HPIAC23R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1663 as residues: Thr-62 to Thr-69.
HRAAD31R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1664 as residues: Val-1 to Thr-6, Arg-64 to Arg-69.
HRADJ57R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1666 as residues: Val-11 to Gln-16.
HROAX48R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1667 as residues: Gly-7 to Thr-20.
HTWDH05R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1670 as residues: Ala-5 to Lys-11, Arg-29 to Ser-36.
HUTHF75R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1673 as residues: Lys-40 to Gly-47.
HWAFW07R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1674 as residues: Phe-44 to Arg-49.
HWLLX91R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1676 as residues: Gly-29 to Asp-34.
HMIAI78R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1678 as residues: Lys-24 to Arg-29, Cys-34 to Ala-41.
HBGFJ39R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1679 as residues: Leu-21 to Asp-38.
HAMHH32R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1680 as residues: Ala-1 to Cys-10, Glu-15 to Gln-21.
HOSNE37R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1683 as residues: Lys-17 to Thr-23.
HWAFE41R	Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 1684 as residues: Ser-3 to Lys-8, Trp-92 to Leu-97.

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide sequence shown in SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by the cDNA in the related cDNA clone contained in a deposited library or encoded by a polynucleotide that hybridizes to the complement of an epitope encoding sequence of SEQ ID NO:X, or an epitope encoding sequence contained in the deposited cDNA clone under stringent hybridization conditions, or alternatively, under lower stringency hybridization conditions, as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to this complementary strand under stringent hybridization conditions or alternatively, under lower stringency hybridization conditions, as defined supra.

The term “epitopes,” as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An “immunogenic epitope,” as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term “antigenic epitope,” as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention, and immunogenic and/or antigenic epitope fragments thereof can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light

chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995).

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, may be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope

derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

5 Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., Proc. Natl. Acad. Sci. USA 10 88:8972- 897 (1991)). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing 15 buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to 20 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. 25 Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA 30 segments by homologous or site-specific recombination to generate variation in the

polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

As discussed herein, any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, polypeptides of the present invention which are shown to be secreted can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

In certain preferred embodiments, proteins of the invention comprise fusion proteins wherein the polypeptides are N and/or C- terminal deletion mutants. In preferred embodiments, the application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequences encoding polypeptides having the amino acid sequence of the specific N- and C-terminal deletions mutants. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell

or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

5

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral
10 vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced
15 in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac
20 promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a
25 translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin
30 resistance genes for culturing in E. coli and other bacteria. Representative examples

of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture
5 mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and
10 ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph,
15 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated
20 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

25 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most

preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether
5 directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition,
10 polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed
15 in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express polypeptides of the invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast
20 which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂.
25 Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast*

5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

10 In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

15 Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

20 In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

25 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and

which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

Non-naturally occurring variants may be produced using art-known mutagenesis techniques, which include, but are not limited to oligonucleotide mediated mutagenesis, alanine scanning, PCR mutagenesis, site directed mutagenesis (see, e.g., Carter et al., *Nucl. Acids Res.* 13:4331 (1986); and Zoller et al., *Nucl. Acids Res.* 10:6487 (1982)), cassette mutagenesis (see, e.g., Wells et al., *Gene* 34:315

(1985)), restriction selection mutagenesis (*see, e.g., Wells et al., Philos. Trans. R. Soc. London SerA 317:415 (1986)*).

The invention additionally, encompasses polypeptides of the present invention which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between

about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release
5 desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200; 500; 1000; 1500; 2000; 2500; 3000; 3500; 4000; 4500; 5000; 5500; 6000; 6500; 7000; 7500; 8000; 8500; 9000; 9500; 10,000;
10 10,500; 11,000; 11,500; 12,000; 12,500; 13,000; 13,500; 14,000; 14,500; 15,000; 15,500; 16,000; 16,500; 17,000; 17,500; 18,000; 18,500; 19,000; 19,500; 20,000; 25,000; 30,000; 35,000; 40,000; 50,000; 55,000; 60,000; 65,000; 70,000; 75,000; 80,000; 85,000; 90,000; 95,000; or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure.
15 Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

20 The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting
25 pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues;
30 those having a free carboxyl group may include aspartic acid residues glutamic acid

residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

5 As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine,
10 histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may
15 select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this
20 moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for
25 derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be
30 attached to the protein either directly or by an intervening linker. Linkerless systems

for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated
5 herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ($\text{ClSO}_2\text{CH}_2\text{CF}_3$). Upon reaction of protein with tresylated MPEG,
10 polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of
15 different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-
20 succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference.
25 Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,
30 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of

substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The cancer antigen polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or an amino acid sequence encoded by SEQ ID NO:X, and/or an amino acid sequence encoded by the cDNA in a related cDNA clone contained in a deposited library (including fragments, variants, splice variants, and fusion proteins, corresponding to any one of these as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to

the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

5 Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers
10 of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides
15 of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:Y, or contained in a polypeptide encoded by SEQ ID NO:X, and/or by the cDNA in the related cDNA clone contained in a deposited library). In one instance, the covalent associations are cross-linking between cysteine residues located within the
20 polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein. In one example, covalent associations are between the
25 heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from
30 another protein that is capable of forming covalently associated multimers, such as for

example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention

containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

5 The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).
10 Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely
15 modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the
20 polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

 Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained
25 in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the
30 invention to a sequence encoding a linker polypeptide and then further to a synthetic

polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as
15 determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id
20 antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass
25 of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and
30 fragments comprising either a VL or VH domain. Antigen-binding antibody

fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, or by size in contiguous amino acid residues. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog,

or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention
5 bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor
10 activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at
15 least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing
20 antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of
25 the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.
30 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.

58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups,

proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more
5 non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited
10 to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols,
15 polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display
20 technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by
25 reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire

or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999

(1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody

libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

5 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the
10 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous
15 deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.
20 Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG,
25 IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European
30 Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825;

5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or alternatively, under lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a

polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the
5 nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of
10 the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized
15 or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe
20 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the
25 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
30 and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley &

Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci.* 81:851-855 (1984); Neuberger et al., *Nature* 312:604-608 (1984); Takeda et al., *Nature* 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived

from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a

nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT
5 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an
10 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell
15 for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with
20 the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast
25 expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid)
30 containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,

BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*,
5 and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for
10 antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the
15 generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding
20 region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by
25 adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus
30 (AcNPV) is used as a vector to express foreign genes. The virus grows in

Spodoptera frugiperda cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

5 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo
10 recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the
15 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate
20 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,
25 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which
30 possess the cellular machinery for proper processing of the primary transcript,

glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell
5 line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by
10 appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection
15 and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

20 A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp^{rt}- or ap^{rt}- cells, respectively.
25 Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-
30 418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991);

Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in
5 the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in*
10 *Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA*
15 *cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

20 The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is
25 capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci. USA* 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452(1991), which are incorporated by reference in their entirety.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody

portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, 5 Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 10 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

15 As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody 20 portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having 25 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 30 232,262). Alternatively, deleting the Fc part after the fusion protein has been

expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to
5 identify antagonists of hIL-5. (See, Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the
10 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which
15 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as
20 part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron
25 emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics
30 according to the present invention. Examples of suitable enzymes include horseradish

peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine
5 fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{111}In or ^{99}Tc .

Further, an antibody or fragment thereof may be conjugated to a therapeutic
10 moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,
15 dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine,
20 thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic
25 agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include,
30 for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria

toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas
5 Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGF (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-
10 CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

15 Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson *et al.* (eds.), pp.
20 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*,
25 Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which
30 is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

5 ***Immunophenotyping***

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or
10 maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning"
15 with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to
20 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

25 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions,
30 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by
5 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1%
10 Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in
15 SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding
20 immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein
25 sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a
30 secondary antibody (which recognizes the primary antibody, e.g., an anti-human

antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by

scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., ^3H or ^{125}I) in the presence of increasing amounts of an unlabeled second antibody.

5

Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed
10 diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat,
15 inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is
20 not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the
25 present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes
30 without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

25 ***Gene Therapy***

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic

acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

5 For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art
10 of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences
15 encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment,
20 nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In
25 specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or
30 indirect, in which case, cells are first transformed with the nucleic acids in vitro, then

transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing
5 them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;
10 Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target
15 cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT
20 Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

25 In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding
30 the antibody to be used in gene therapy are cloned into one or more vectors, which

facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection

to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical

composition of the invention, preferably a polypeptide or antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after

surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J.Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,
5 Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a
10 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the
15 therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as
20 liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH
25 buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate,
30 sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation
5 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the
10 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the
15 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.
20 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

25 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the
30 formulation will also depend on the route of administration, and the seriousness of

the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body
5 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied
10 tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked
20 immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

25 One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which
30 specifically binds to the polypeptide of interest; b) waiting for a time interval

following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that
5 detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

10 It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc. The labeled antibody or antibody fragment will then preferentially
15 accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

20 Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5
25 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of

bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The cancer antigen polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome, thus each polynucleotide of the present invention can routinely be used as a chromosome marker using techniques known in the art.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably at least 15 bp (e.g., 15-25 bp) from the sequences shown in SEQ ID NO:X, or the complement thereto. Primers can optionally be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries, and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety).

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

Thus, the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table 3 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g. Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London
5 (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location,
10 the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).) Assuming 1 megabase mapping resolution and
15 one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in a polynucleotide of the invention and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as
20 deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required
25 to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using the polynucleotides of the invention. Any of these alterations (altered expression,

chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention provides a method of detecting increased or decreased expression levels of the cancer polynucleotides in affected individuals as compared to
5 unaffected individuals using polynucleotides of the present invention and techniques known in the art, including but not limited to the method described in Example 11. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis
10 of a tissue specific disorder, including cancer, involving measuring the expression level of cancer polynucleotides in tissues or other cells or body fluid from an individual and comparing the measured gene expression level with a standard cancer polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a tissue specific disorder.

15 In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the invention and a suitable container. In a specific embodiment,
20 the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the invention, where each probe has one strand containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a tissue specific disorder, including, for example,
25 diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed cancer polynucleotide expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of cancer polynucleotides" is intended qualitatively or quantitatively measuring or estimating the level of the cancer polypeptide or the level of the mRNA encoding the cancer polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the cancer polypeptide level or mRNA level in a second biological sample). Preferably, the cancer polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard cancer polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the tissue specific disorder or being determined by averaging levels from a population of individuals not having the tissue specific disorder. As will be appreciated in the art, once a standard cancer polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains a cancer polypeptide or the corresponding mRNA. As indicated, biological samples include body fluids (such as sputum, breast milk, vaginal pool, bile, semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the cancer polypeptide, and other tissue sources found to express the cancer polypeptide. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides of the invention are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with cancer antigen polynucleotides attached may be used to identify polymorphisms between the cancer antigen polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in

identifying disease loci for many disorders, such as for example, in neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. Such a method is described in
5 US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses cancer polynucleotides that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the
10 polynucleotides of the invention are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose
15 derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact,
20 PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong
25 binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the
30 analysis.

The present invention have uses which include, but are not limited to, detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative disorders are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., *supra*) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., *supra*) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., *supra*)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580). However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and

differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness is not limited to treatment of proliferative disorders of
5 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a cancer antigen polynucleotide can be used to control gene expression through triple helix formation or through antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56:
10 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these
15 techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as
20 Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. The oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of
25 polypeptide of the present invention antigens. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease, and in particular, for the treatment of proliferative diseases and/or conditions.

Polynucleotides of the present invention are also useful in gene therapy. One
30 goal of gene therapy is to insert a normal gene into an organism having a defective

gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

5 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for
10 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

 The polynucleotides of the present invention can also be used as an alternative
15 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once a unique ID database is established for an
20 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

 Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen,
25 synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are
30 digested with one or more restriction enzymes, yielding an identifying set of bands on

a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

5 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to cancer polynucleotides prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures
10 for contamination.

The polynucleotides of the present invention are also useful as hybridization probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential
15 identification of the tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In addition, for a number of disorders of the above tissues or cells, significantly higher or lower levels of gene expression of the polynucleotides/polypeptides of the present invention may be detected in certain tissues (e.g., tissues expressing polypeptides and/or polynucleotides of the present
20 invention, cancer tissues and/or cancerous and/or wounded tissues) or bodily fluids (e.g., semen, vaginal pool, breast milk, bile, lymph, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

25 Thus, the invention provides a diagnostic method of a disorder, which involves: (a) assaying gene expression level in cells or body fluid of an individual; (b) comparing the gene expression level with a standard gene expression level, whereby an increase or decrease in the assayed gene expression level compared to the standard expression level is indicative of a disorder.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making
5 oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

10 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

Polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays such as, for example, ABC
15 immunoperoxidase (Hsu et al., J. Histochem. Cytochem. 29:577-580 (1981)) or cell type(s) (e.g., immunocytochemistry assays).

Antibodies can be used to assay levels of polypeptides encoded by polynucleotides of the invention in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et
20 al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine
25 (^{131}I , ^{125}I , ^{123}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium ($^{115\text{m}}\text{In}$, $^{113\text{m}}\text{In}$, ^{112}In , ^{111}In), and technetium (^{99}Tc , $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F), ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , ^{97}Ru ; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and
30 rhodamine, and biotin.

In addition to assaying levels of polypeptide of the present invention in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$, (^{131}I , ^{125}I , ^{123}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium ($^{115\text{m}}\text{In}$, $^{113\text{m}}\text{In}$, ^{112}In , ^{111}In), and technetium (^{99}Tc , $^{99\text{m}}\text{Tc}$), thallium (^{201}Tl), gallium (^{68}Ga , ^{67}Ga), palladium (^{103}Pd), molybdenum (^{99}Mo), xenon (^{133}Xe), fluorine (^{18}F , ^{153}Sm , ^{177}Lu , ^{159}Gd , ^{149}Pm , ^{140}La , ^{175}Yb , ^{166}Ho , ^{90}Y , ^{47}Sc , ^{186}Re , ^{188}Re , ^{142}Pr , ^{105}Rh , ^{97}Ru), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for immune system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which express the polypeptide encoded by a polynucleotide of the invention. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or

antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate
5 episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

10 By "toxin" is meant one or more compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not
15 limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin.
20 "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi , or other radioisotopes such as, for example, ^{103}Pd , ^{133}Xe , ^{131}I , ^{68}Ge , ^{57}Co , ^{65}Zn , ^{85}Sr , ^{32}P , ^{35}S , ^{90}Y , ^{153}Sm , ^{153}Gd , ^{169}Yb , ^{51}Cr , ^{54}Mn , ^{75}Se , ^{113}Sn , $^{90}\text{Yttrium}$, ^{117}Tin , $^{186}\text{Rhenium}$, $^{166}\text{Holmium}$, and $^{188}\text{Rhenium}$; luminescent labels, such as luminol; and fluorescent
25 labels, such as fluorescein and rhodamine, and biotin.

Techniques known in the art may be applied to label polypeptides of the invention (including antibodies). Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Patent Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139;

5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety).

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression level of a cancer polypeptide of the present invention in cells or body fluid of an individual; and (b) comparing the assayed polypeptide expression level with a standard polypeptide expression level, whereby an increase or decrease in the assayed polypeptide expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, cancer antigen polypeptides of the present invention can be used to treat or prevent diseases or conditions such as, for example, neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease (as described supra, and elsewhere herein). For example,

administration of an antibody directed to a polypeptide of the present invention can bind, and/or neutralize the polypeptide, and/or reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

5 At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover,
10 the polypeptides of the present invention can be used to test the following biological activities.

Gene Therapy Methods

 Another aspect of the present invention is to gene therapy methods for treating
15 or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of the polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the present invention operatively linked to a promoter and any other genetic elements necessary
20 for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a
25 polynucleotide of the present invention ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide of the present invention. Such methods are well-known in the art. For example, see Belldegrün, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al.,
30 Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106

(1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J.-F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral

promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human
5 globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

Unlike other gene therapy techniques, one major advantage of introducing
10 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues
15 within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in
20 the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the
25 tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified

transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and

is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology* (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.

SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta* (1975) 394:483; Wilson et al., *Cell* (1979) 17:77); ether injection (Deamer, D. and Bangham, A., *Biochim. Biophys. Acta* (1976) 443:629; Ostro et al., *Biochem. Biophys. Res. Commun.* (1977) 76:836; Fraley et al., *Proc. Natl. Acad. Sci. USA* (1979) 76:3348); detergent dialysis (Enoch, H. and Strittmatter, P., *Proc. Natl. Acad. Sci. USA* (1979) 76:145); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.* (1980) 255:10431; Szoka, F. and Papahadjopoulos, D., *Proc. Natl. Acad. Sci.*

USA (1978) 75:145; Schaefer-Ridder et al., Science (1982) 215:166), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ratio will be from about 5:1 to about 1:5. More preferably, the
5 ratio will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469
10 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

15 In certain embodiments, cells are engineered, ex vivo or in vivo, using a retroviral particle containing RNA which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian
20 leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-
25 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral

plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding a polypeptide of the present invention. Such
5 retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express a polypeptide of the present invention.

In certain other embodiments, cells are engineered, ex vivo or in vivo, with polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated
10 such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years
15 with an excellent safety profile (Schwartz, A. R. et al. (1974) Am. Rev. Respir. Dis. 109:233-238). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld, M. A. et al. (1991) Science 252:431-434; Rosenfeld et al., (1992) Cell 68:143-155). Furthermore, extensive studies to attempt to establish
20 adenovirus as a causative agent in human cancer were uniformly negative (Green, M. et al. (1979) Proc. Natl. Acad. Sci. USA 76:6606).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel. 3:499-503 (1993); Rosenfeld et al., Cell 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.
25 4:759-769 (1993); Yang et al., Nature Genet. 7:362-369 (1994); Wilson et al., Nature 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the EI region of adenovirus and constitutively express Ela and Elb, which complement the defective adenoviruses by providing the

products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, ex vivo or in vivo, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., Curr. Topics in Microbiol. Immunol. 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the

polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding a polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can

be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

5 The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

Preferably, the polynucleotide encoding a polypeptide of the present invention contains a secretory signal sequence that facilitates secretion of the protein.
10 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

15 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available
20 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the
25 rat livers (Kaneda et al., Science 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting
30 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.
15 Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

5

Biological Activities

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or polypeptides, or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat the associated disease.

15

Immune Activity

A polypeptide or polynucleotide, or agonists or antagonists of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

25

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. Polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of

30

hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia
5 telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

10 Moreover, polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat blood coagulation disorders
15 (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of
20 heart attacks (infarction), strokes, or scarring.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response
25 leading to the destruction of the host tissue. Therefore, the administration of polynucleotides or polypeptides, or agonists or antagonists of the present invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or

systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

5

Hyperproliferative Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by Polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

5 One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

 Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the
10 present invention, wherein said polynucleotide represses said expression.

 Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA
15 construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is
20 hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic,
25 specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the
5 destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in
10 the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature
15 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating
20 and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for
25 polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The

polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of

the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering
5 a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or
10 hematopoietic growth factors, for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and
15 therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$,
20 $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere
25 herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may
30 also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,

Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous

polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic
5 and/or covalent interactions. Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the
10 expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the present
15 invention, may be used to treat cardiovascular disorders, including peripheral artery disease, such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects
20 include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion
25 defects, Lutembacher's Syndrome, trilogly of Fallot, ventricular heart septal defects.

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart
30 hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right

ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease,
5 ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-
10 type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia,
15 Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve
20 insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial
25 reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms,
30 angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease,

Klippel-Trenaunay-Weber Syndrome. Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, 5 thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

10 Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or 15 topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

20 **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound 25 healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. 30 A number of serious diseases are dominated by abnormal neovascularization

including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The polynucleotides encoding a polypeptide of the present invention may be administered along with other polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists

may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization;

telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however,

capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly

after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The

compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochel minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or antagonists may also be used in controlling menstruation or administered as either a

peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch
5 granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal
10 surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic
15 compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-
20 angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the
25 site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly

preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo

molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminimidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma,

lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

25

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound

30

healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avascular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentum graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of

epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the

production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

5 Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent
10 or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as
15 agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

 Polynucleotides or polypeptides, as well as agonists or antagonists of the
20 present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

25 In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate,
30 delay or prevent permanent manifestation of the disease. Also, polynucleotides or

polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

5 **Neurological Diseases**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to
10 stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

15 Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain
20 edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph
25 Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis, cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease, cerebral
30 amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and

thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, 5 vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache, migraine, dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis 10 which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular 15 leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, Hallervorden-Spatz Syndrome, hydrocephalus such as 20 Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia 25 Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, cerebral malaria, meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis. Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, 30 Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome,

Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie) cerebral toxoplasmosis, central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sclerolosis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele,

meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta, hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease

and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, Diabetic neuropathies such as diabetic foot, nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Infectious Disease

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific

embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more
5 other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or
10 antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi,
15 Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae,
20 Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B
25 Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme
30 Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning,

Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of
5 tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs
10 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists
15 of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome,
20 and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using
polynucleotides or polypeptides, as well as agonists or antagonists of the present
25 invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or
30 other medical therapies), localized neuropathies, and central nervous system diseases

(e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

5

Chemotaxis

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed
5 wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are
10 exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and
15 re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and
20 exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721,
25 5,834,252, and 5,837,458, and Patten, P. A., *et al.*, *Curr. Opinion Biotechnol.* 8:724-
30

33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and $^3\text{[H]}$

thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of $^3\text{[H]}$ thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of $^3\text{[H]}$ thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological

activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

5 In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

 As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or
10 prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic
15 protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

 In another embodiment, the invention provides a method for the specific
20 destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

 By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of
25 toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced
30 endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha

toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

10 **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a

complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained in the cDNA contained in the related cDNA clone identified in Table 1. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J.,

Neurochem. 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the

invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors
5 can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter
10 region (Bernoist and Chambon, *Nature* 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster, et al., *Nature* 296:39-42 (1982)), etc.

15 The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the
20 RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a
25 stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the
30 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the

3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre et al., 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,

5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are

commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy

endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic
5 cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular
10 cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

15 The antagonist/agonist may also be employed to treat the diseases described herein.

Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present
20 invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

Other Activities

25 A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of

the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

5 A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

10 A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone
15 grafts.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

20 A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

25 A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5 A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of
10 energy.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or
15 Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals,
20 cofactors or other nutritional components.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,
25 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in

the related cDNA clone contained in the deposit, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

5 Also preferred is a composition of matter comprising a DNA molecule which comprises a cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of the cDNA in the related cDNA clone
10 contained in the deposit.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

15 Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is an isolated nucleic acid molecule
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete
25 nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence
30 selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the

complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of
5 said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence
10 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

15 A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the
20 complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide
25 sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X; or the cDNA in the related cDNA clone identified in Table 1 which encodes a
30 protein, wherein the method comprises a step of detecting in a biological sample

obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide
5 sequence of the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for diagnosing a pathological condition which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous
10 nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a
15 sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is a composition of matter comprising isolated nucleic acid
20 molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or "chip" of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000 or 4000 nucleotide sequences, wherein at least one sequence in said DNA microarray or "chip" is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected
25 from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the cDNA clone referenced in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence
30 at least 90% identical to a sequence of at least about 10 contiguous amino acids in the

polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated polypeptide comprising an amino acid sequence
5 at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid
10 sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid
15 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid
20 sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino
acids is included in the amino acid sequence of a portion of said polypeptide encoded by the cDNA clone referenced in Table 1; a polypeptide encoded by SEQ ID NO:X;
25 and/or the polypeptide sequence of SEQ ID NO:Y.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

5 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a
10 sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is a method for detecting in a biological sample a
15 polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone
20 sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino
25 acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a
30 polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X;

and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence
5 selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said
10 polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

15 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

20 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from
25 the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an
30 increased level of a protein activity, which method comprises administering to such

an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

5 Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of
10 said protein activity in said individual.

 Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

*Examples**Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample*

5 Each deposited cDNA clone is contained in a plasmid vector. Table 5 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a
 10 particular clone is identified in Table 5 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
15	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
20	pCR [®] 2.1	pCR [®] 2.1
<p>Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 25 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3</p>		

primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 5, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited by reference to Table 2 and 5 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone referenced in Table 1.

TABLE 5

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKF HUKF HUKG	Human Uterine Cancer	Lambda ZAP II	LP01
HCNA HCNB	Human Colon	Lambda Zap II	LP01
HFFA	Human Fetal Brain, random primed	Lambda Zap II	LP01
HTWA	Resting T-Cell	Lambda ZAP II	LP01
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP01
HLMB HLMF HLMG HLMH HLMI HLMJ HLMN	breast lymph node CDNA library	Lambda ZAP II	LP01
HCQA HCQB	human colon cancer	Lambda ZAP II	LP01
HMEA HMEC HMED HMEE HMEF HMEG HMEI HMEJ HMEK HMEL	Human Microvascular Endothelial Cells, fract. A	Lambda ZAP II	LP01
HUSA HUSC	Human Umbilical Vein Endothelial Cells, fract. A	Lambda ZAP II	LP01
HLQA HLQB	Hepatocellular Tumor	Lambda ZAP II	LP01
HHGA HHGB HHGC HHGD	Hemangiopericytoma	Lambda ZAP II	LP01
HSDM	Human Striatum Depression, re-rescue	Lambda ZAP II	LP01
HUSH	H Umbilical Vein Endothelial Cells, frac A, re-excision	Lambda ZAP II	LP01
HSGS	Salivary gland, subtracted	Lambda ZAP II	LP01
HFXA HFXB HFXC HFXD HFXE HFXF HFXG HFXH	Brain frontal cortex	Lambda ZAP II	LP01
HPQA HPQB HPQC	PERM TF274	Lambda ZAP II	LP01
HFXJ HFXK	Brain Frontal Cortex, re-excision	Lambda ZAP II	LP01
HCWA HCWB HCWC HCWD HCWE HCWF HCWG HCWH HCWI HCWJ HCWK	CD34 positive cells (Cord Blood)	ZAP Express	LP02
HCUA HCUB HCUC	CD34 depleted Buffy Coat (Cord Blood)	ZAP Express	LP02
HRSM	A-14 cell line	ZAP Express	LP02
HRSA	A1-CELL LINE	ZAP Express	LP02
HCUD HCUE HCUF HCUG HCUH HCUI	CD34 depleted Buffy Coat (Cord Blood), re-excision	ZAP Express	LP02
HBXE HBXF HBXG	H. Whole Brain #2, re-excision	ZAP Express	LP02
HRLM	L8 cell line	ZAP Express	LP02
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP02
HUDA HUDB HUDC	Testes	ZAP Express	LP02
HHTM HHTN HHTO	H. hypothalamus, frac A; re-excision	ZAP Express	LP02
HHTL	H. hypothalamus, frac A	ZAP Express	LP02
HASA HASD	Human Adult Spleen	Uni-ZAP XR	LP03
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP03
HE8A HE8B HE8C HE8D HE8E HE8F HE8M HE8N	Human 8 Week Whole Embryo	Uni-ZAP XR	LP03
HGBA HGBD HGBE HGBF HGBG HGBH HGBI	Human Gall Bladder	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HLHA HLHB HLHC HLHD HLHE HLHF HLHG HLHH HLHQ	Human Fetal Lung III	Uni-ZAP XR	LP03
HPMA HPMB HPMC HPMD HPME HPMF HPMG HPMH	Human Placenta	Uni-ZAP XR	LP03
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP03
HSIA HSIC HSID HSIE	Human Adult Small Intestine	Uni-ZAP XR	LP03
HTEA HTEB HTEC HTED HTEE HTEF HTEG HTEH HTEI HTEJ HTEK	Human Testes	Uni-ZAP XR	LP03
HTPA HTPB HTPC HTPD HTPF	Human Pancreas Tumor	Uni-ZAP XR	LP03
HTTA HTTB HTTC HTTD HTTE HTTF	Human Testes Tumor	Uni-ZAP XR	LP03
HAPA HAPB HAPC HAPM	Human Adult Pulmonary	Uni-ZAP XR	LP03
HETA HETB HETC HETD HETE HETF HETG HETH HETI	Human Endometrial Tumor	Uni-ZAP XR	LP03
HHFB HHFC HHFD HHFE HHFF HHFG HHFH HHFI	Human Fetal Heart	Uni-ZAP XR	LP03
HHPB HHPD HHPF HHPG HHPH	Human Hippocampus	Uni-ZAP XR	LP03
HCE1 HCE2 HCE3 HCE4 HCE5 HCEB HCEC HCED HCEE HCEF HCEG	Human Cerebellum	Uni-ZAP XR	LP03
HUVB HUV C HUVD HUVE	Human Umbilical Vein, Endo. remake	Uni-ZAP XR	LP03
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP03
HTAA HTAB HTAC HTAD HTAE	Human Activated T-Cells	Uni-ZAP XR	LP03
HFEA HFEB HFEC	Human Fetal Epithelium (Skin)	Uni-ZAP XR	LP03
HJPA HJPB HJPC HJPD	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Uni-ZAP XR	LP03
HESA	Human epithelioid sarcoma	Uni-Zap XR	LP03
HLTA HLTB HLTC HLTD HLTE HLTF	Human T-Cell Lymphoma	Uni-ZAP XR	LP03
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP03
HRDA HRDB HRDC HRDD HRDE HRDF	Human Rhabdomyosarcoma	Uni-ZAP XR	LP03
HCAA HCAB HCAC	Cem cells cyclohexamide treated	Uni-ZAP XR	LP03
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HSUA HSUB HSUC HSUM	Supt Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HT4A HT4C HT4D	Activated T-Cells, 12 hrs.	Uni-ZAP XR	LP03
HE9A HE9B HE9C HE9D HE9E HE9F HE9G HE9H HE9M HE9N	Nine Week Old Early Stage Human	Uni-ZAP XR	LP03
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP03
HT5A	Activated T-Cells, 24 hrs.	Uni-ZAP XR	LP03
HFGA HFGM	Human Fetal Brain	Uni-ZAP XR	LP03
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP03
HBGB HBGD	Human Primary Breast Cancer	Uni-ZAP XR	LP03
HBNA HBNB	Human Normal Breast	Uni-ZAP XR	LP03
HCAS	Cem Cells, cyclohexamide treated, subtra	Uni-ZAP XR	LP03
HHPS	Human Hippocampus, subtracted	pBS	LP03
HKCS HKCU	Human Colon Cancer, subtracted	pBS	LP03
HRGS	Raji cells, cyclohexamide treated,	pBS	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
	subtracted		
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBS	LP03
HT4S	Activated T-Cells, 12 hrs, subtracted	Uni-ZAP XR	LP03
HCDA HCDB HCDC HCDD HCDE	Human Chondrosarcoma	Uni-ZAP XR	LP03
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP03
HTLA HTLB HTLC HTLD HTLE HTLF	Human adult testis, large inserts	Uni-ZAP XR	LP03
HLMA HLMC HLMD	Breast Lymph node cDNA library	Uni-ZAP XR	LP03
H6EA H6EB H6EC	HL-60, PMA 4H	Uni-ZAP XR	LP03
HTXA HTXB HTXC HTXD HTXE HTXF HTXG HTXH	Activated T-Cell (12hs)/Thiouridine labelledEco	Uni-ZAP XR	LP03
HNFA HNFH HNFC HNFD HNFE HNFF HNFG HNFH HNFJ	Human Neutrophil, Activated	Uni-ZAP XR	LP03
HTOB HTOC	HUMAN TONSILS, FRACTION 2	Uni-ZAP XR	LP03
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP03
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP03
HORB	Human OB HOS treated (10 nM E2) fraction I	Uni-ZAP XR	LP03
HSVA HSVB HSVC	Human Chronic Synovitis	Uni-ZAP XR	LP03
HROA	HUMAN STOMACH	Uni-ZAP XR	LP03
HBJA HBJB HBJC HBJD HBJE HBJF HBJG HBJH HBJI HBJJ HBJK	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP03
HCRA HCRB HCRC	human corpus colosum	Uni-ZAP XR	LP03
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP03
HDSA	Dermatofibrosarcoma Protuberance	Uni-ZAP XR	LP03
HMWA HMWB HMWC HMWD HMWE HMWF HMWG HMWH HMWI HMWJ	Bone Marrow Cell Line (RS4;11)	Uni-ZAP XR	LP03
HSOA	stomach cancer (human)	Uni-ZAP XR	LP03
HERA	SKIN	Uni-ZAP XR	LP03
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP03
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP03
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP03
HBCA HBCB	H. Lymph node breast Cancer	Uni-ZAP XR	LP03
HPWT	Human Prostate BPH, re-excision	Uni-ZAP XR	LP03
HFVG HFVH HFVI	Fetal Liver, subtraction II	pBS	LP03
HNFI	Human Neutrophils, Activated, re-excision	pBS	LP03
HBMB HBMC HBMD	Human Bone Marrow, re-excision	pBS	LP03
HKML HKMM HKMN	H. Kidney Medulla, re-excision	pBS	LP03
HKIX HKIY	H. Kidney Cortex, subtracted	pBS	LP03
HADT	H. Amygdala Depression, subtracted	pBS	LP03
H6AS	HL-60, untreated, subtracted	Uni-ZAP XR	LP03
H6ES	HL-60, PMA 4H, subtracted	Uni-ZAP XR	LP03
H6BS	HL-60, RA 4h, Subtracted	Uni-ZAP XR	LP03
H6CS	HL-60, PMA 1d, subtracted	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTXJ HTXK	Activated T-cell(12h)/Thiouridine-re-excision	Uni-ZAP XR	LP03
HMSA HMSB HMSC HMSD HMSE HMSF HMSG HMSH HMSI HMSJ HMSK	Monocyte activated	Uni-ZAP XR	LP03
HAGA HAGB HAGC HAGD HAGE HAGF	Human Amygdala	Uni-ZAP XR	LP03
HSRA HSRB HSRE	STROMAL -OSTEOCLASTOMA	Uni-ZAP XR	LP03
HSRD HSRF HSRG HSRH	Human Osteoclastoma Stromal Cells - unamplified	Uni-ZAP XR	LP03
HSQA HSQB HSQC HSQD HSQE HSQF HSQG	Stromal cell TF274	Uni-ZAP XR	LP03
HSKA HSKB HSKC HSKD HSKE HSKF HSKZ	Smooth muscle, serum treated	Uni-ZAP XR	LP03
HSLA HSLB HSLC HSLD HSLE HSLF HSLG	Smooth muscle.control	Uni-ZAP XR	LP03
HSDA HSDD HSDE HSDF HSDG HSDH	Spinal cord	Uni-ZAP XR	LP03
HPWS	Prostate-BPH subtracted II	pBS	LP03
HSKW HSKX HSKY	Smooth Muscle- HASTE normalized	pBS	LP03
HFPB HFPC HFPD	H. Frontal cortex.epileptic;re-excision	Uni-ZAP XR	LP03
HSDI HSDJ HSDK	Spinal Cord, re-excision	Uni-ZAP XR	LP03
HSKN HSKO	Smooth Muscle Serum Treated, Norm	pBS	LP03
HSKG HSKH HSKI	Smooth muscle, serum induced,re-exc	pBS	LP03
HFCA HFCB HFCC HFCD HFCE HFCF	Human Fetal Brain	Uni-ZAP XR	LP04
HPTA HPTB HPTD	Human Pituitary	Uni-ZAP XR	LP04
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP04
HE6B HE6C HE6D HE6E HE6F HE6G HE6S	Human Whole Six Week Old Embryo	Uni-ZAP XR	LP04
HSSA HSSB HSSC HSSD HSSE HSSF HSSG HSSH HSSI HSSJ HSSK	Human Synovial Sarcoma	Uni-ZAP XR	LP04
HE7T	7 Week Old Early Stage Human, subtracted	Uni-ZAP XR	LP04
HEPA HEPB HEPC	Human Epididymus	Uni-ZAP XR	LP04
HSNA HSNB HSNC HSNM HSNN	Human Synovium	Uni-ZAP XR	LP04
HPFB HPFC HPFD HPFE	Human Prostate Cancer, Stage C fraction	Uni-ZAP XR	LP04
HE2A HE2D HE2E HE2H HE2I HE2M HE2N HE2O	12 Week Old Early Stage Human	Uni-ZAP XR	LP04
HE2B HE2C HE2F HE2G HE2P HE2Q	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP04
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP04
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP04
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP04
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP04
HBSD	Bone Cancer, re-excision	Uni-ZAP XR	LP04
HSGB	Salivary gland, re-excision	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP04
HSXA HSXB HSXC HSXD	Human Substantia Nigra	Uni-ZAP XR	LP04
HSJA HSHB HSHC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HOUA HOUB HOUC HOUD HOUE	Adipocytes	Uni-ZAP XR	LP04
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP04
HELA HELB HELC HELD HELE HELF HELG HELH	Endothelial cells-control	Uni-ZAP XR	LP04
HEMA HEMB HEMC HEMD HEME HEMF HEMG HEMH	Endothelial-induced	Uni-ZAP XR	LP04
HBIA HBIB HBIC	Human Brain, Striatum	Uni-ZAP XR	LP04
HHSA HHSB HHSC HHSD HHSE	Human Hypothalamus.Schizophrenia	Uni-ZAP XR	LP04
HNGA HNGB HNGC HNGD HNGE HNGF HNGG HNGH HNGI HNGJ	neutrophils control	Uni-ZAP XR	LP04
HNHA HNHBB HNHC HNHD HNHE HNHF HNHG HNH HNNH HNNI HNNJ	Neutrophils IL-1 and LPS induced	Uni-ZAP XR	LP04
HSDB HSDC	STRIATUM DEPRESSION	Uni-ZAP XR	LP04
HHPT	Hypothalamus	Uni-ZAP XR	LP04
HSAT HSAU HSAV HSAW HSAX HSAY HSAZ	Anergic T-cell	Uni-ZAP XR	LP04
HBMS HBMT HBMU HBMV HBMW HBMX	Bone marrow	Uni-ZAP XR	LP04
HOEA HOEB HOEC HOED HOEE HOEF HOEJ	Osteoblasts	Uni-ZAP XR	LP04
HAIA HAIB HAIC HAID HAIE HAIF	Epithelial-TNF α and INF induced	Uni-ZAP XR	LP04
HTGA HTGB HTGC HTGD	Apoptotic T-cell	Uni-ZAP XR	LP04
HMCA HMCB HMCC HMCD HMCE	Macrophage-oxLDL	Uni-ZAP XR	LP04
HMAA HMAB HMAG HMAD HMAE HMAF HMAG	Macrophage (GM-CSF treated)	Uni-ZAP XR	LP04
HPHA	Normal Prostate	Uni-ZAP XR	LP04
HPIA HPIB HPIC	LNCAP prostate cell line	Uni-ZAP XR	LP04
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP04
HOSE HOSF HOSG	Human Osteoclastoma, re-excision	Uni-ZAP XR	LP04
HTGE HTGF	Apoptotic T-cell, re-excision	Uni-ZAP XR	LP04
HMAJ HMAK	H Macrophage (GM-CSF treated), re-excision	Uni-ZAP XR	LP04
HACB IIACC IIACD	Human Adipose Tissue, re-excision	Uni-ZAP XR	LP04
HFPA	H. Frontal Cortex, Epileptic	Uni-ZAP XR	LP04
HFAA HFAB HFAC HFAD HFAE	Alzheimers, spongy change	Uni-ZAP XR	LP04
HFAM	Frontal Lobe, Dementia	Uni-ZAP XR	LP04
HMIA HMIB HMIC	Human Manic Depression Tissue	Uni-ZAP XR	LP04
HTSA HTSE HTSF HTSG HTSH	Human Thymus	pBS	LP05
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBS	LP05
HSAA HSAB HSAC	HSA 172 Cells	pBS	LP05
HSBA HSBB HSBC HSBM	HSC172 cells	pBS	LP05
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBS	LP05
HJBA HJBB HJBC HJBD	Jurkat T-Cell, S phase	pBS	LP05
HAFA HAFB	Aorta endothelial cells + TNF-a	pBS	LP05
HAWA HAWB HAWC	Human White Adipose	pBS	LP05
HTNA HTNB	Human Thyroid	pBS	LP05
HONA	Normal Ovary, Premenopausal	pBS	LP05

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HARA HARB	Human Adult Retina	pBS	LP05
HLJA HLJB	Human Lung	pCMVSPORT 1	LP06
HOFM HOFN HOFO	H. Ovarian Tumor, II, OV5232	pCMVSPORT 2.0	LP07
HOGA HOGB HOGC	OV 10-3-95	pCMVSPORT 2.0	LP07
HCGL	CD34+cells, II	pCMVSPORT 2.0	LP07
HDLA	Hodgkin's Lymphoma I	pCMVSPORT 2.0	LP07
HDTA HDTB HDTC HDTD HDTE	Hodgkin's Lymphoma II	pCMVSPORT 2.0	LP07
HKAA HKAB HKAC HKAD HKAE HKAF HKAG HKAH	Keratinocyte	pCMVSPORT2.0	LP07
HCIM	CAPFINDER, Crohn's Disease, lib 2	pCMVSPORT 2.0	LP07
HKAL	Keratinocyte, lib 2	pCMVSPORT2.0	LP07
HKAT	Keratinocyte, lib 3	pCMVSPORT2.0	LP07
HNDA	Nasal polyps	pCMVSPORT2.0	LP07
HDRA	H. Primary Dendritic Cells, lib 3	pCMVSPORT2.0	LP07
HOHA HOHB HOHC	Human Osteoblasts II	pCMVSPORT2.0	LP07
HLDA HLDB HLDC	Liver, Hepatoma	pCMVSPORT3.0	LP08
HLDN HLDO HLDP	Human Liver, normal	pCMVSPORT3.0	LP08
HMTA	pBMC stimulated w/ poly I/C	pCMVSPORT3.0	LP08
HNTA	NTERA2, control	pCMVSPORT3.0	LP08
HDP A HDPB HDPC HDPD HDPF HDPG HDPH HDPI HDPJ HDPK HDP M HDPN HDPO HDPP	Primary Dendritic Cells, lib 1	pCMVSPORT3.0	LP08
	Primary Dendritic cells, frac 2	pCMVSPORT3.0	LP08
HMUA HMUB HMUC	Myeloid Progenitor Cell Line	pCMVSPORT3.0	LP08
HHEA HHEB HHEC HHED	T Cell helper I	pCMVSPORT3.0	LP08
HHEM HHEN HHEO HHEP	T cell helper II	pCMVSPORT3.0	LP08
HEQA HEQB HEQC	Human endometrial stromal cells	pCMVSPORT3.0	LP08
HJMA HJMB	Human endometrial stromal cells-treated with progesterone	pCMVSPORT3.0	LP08
HSWA HSWB HSWC	Human endometrial stromal cells-treated with estradiol	pCMVSPORT3.0	LP08
HSYA HSYB HSYC	Human Thymus Stromal Cells	pCMVSPORT3.0	LP08
HLWA HLWB HLWC	Human Placenta	pCMVSPORT3.0	LP08
HRAA HRAB HRAC	Rejected Kidney, lib 4	pCMVSPORT3.0	LP08
HMTM	PCR, pBMC I/C treated	PCR II	LP09
HMJA	H. Meningioma, M6	pSport 1	LP10
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSport 1	LP10
HUSG HUSI	Human umbilical vein endothelial cells, IL-4 induced	pSport 1	LP10
HUSX HUSY	Human Umbilical Vein Endothelial Cells, uninduced	pSport 1	LP10
HOFA	Ovarian Tumor I, OV5232	pSport 1	LP10
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport 1	LP10
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport 1	LP10
HADA HADC HADD HADE HADG	Human Adipose	pSport 1	LP10
HOVA HOVB HOVC	Human Ovary	pSport 1	LP10

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTWB HTWC HTWD HTWE HTWF	Resting T-Cell Library,II	pSport 1	LP10
HMMA	Spleen metastatic melanoma	pSport 1	LP10
HLYA HLYB HLYC HLYD HLYE	Spleen, Chronic lymphocytic leukemia	pSport 1	LP10
HCGA	CD34+ cell, I	pSport 1	LP10
HEOM HEON	Human Eosinophils	pSport 1	LP10
HTDA	Human Tonsil, Lib 3	pSport 1	LP10
HSPA	Salivary Gland, Lib 2	pSport 1	LP10
HCHA HCHB HCHC	Breast Cancer cell line, MDA 36	pSport 1	LP10
HCHM HCHN	Breast Cancer Cell line, angiogenic	pSport 1	LP10
HCIA	Crohn's Disease	pSport 1	LP10
HDAA HDAB HDAC	HEL cell line	pSport 1	LP10
HABA	Human Astrocyte	pSport 1	LP10
HUFA HUFB HUFC	Ulcerative Colitis	pSport 1	LP10
HNTM	NTERA2 + retinoic acid, 14 days	pSport 1	LP10
HDQA	Primary Dendritic cells,CapFinder2, frac 1	pSport 1	LP10
HDQM	Primary Dendritic Cells, CapFinder, frac 2	pSport 1	LP10
HLDX	Human Liver, normal,CapFinder	pSport 1	LP10
HULA HULB HULC	Human Dermal Endothelial Cells,untreated	pSport1	LP10
HUMA	Human Dermal Endothelial cells,treated	pSport1	LP10
HCJA	Human Stromal Endometrial fibroblasts, untreated	pSport1	LP10
HCJM	Human Stromal endometrial fibroblasts, treated w/ estradiol	pSport1	LP10
HEDA	Human Stromal endometrial fibroblasts, treated with progesterone	pSport1	LP10
HFNA	Human ovary tumor cell OV350721	pSport1	LP10
HKGA HKGB HKGC HKGD	Merkel Cells	pSport1	LP10
HISA HISB HISC	Pancreas Islet Cell Tumor	pSport1	LP10
HLSA	Skin, burned	pSport1	LP10
HBZA	Prostate,BPH, Lib 2	pSport 1	LP10
HBZS	Prostate BPH,Lib 2, subtracted	pSport 1	LP10
HFIA HFIB HFIC	Synovial Fibroblasts (control)	pSport 1	LP10
HFIH HFII HFIJ	Synovial hypoxia	pSport 1	LP10
HFIT HFIU HFIV	Synovial IL-1/TNF stimulated	pSport 1	LP10
HGCA	Messangial cell, frac 1	pSport1	LP10
HMVA HMVB HMVC	Bone Marrow Stromal Cell, untreated	pSport1	LP10
HFIX HFIY HFIZ	Synovial Fibroblasts (II1/TNF), subt	pSport1	LP10
HFOX HFOY HFOZ	Synovial hypoxia-RSF subtracted	pSport1	LP10
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP11
HLIA HLIB HLIC	Human Liver	pCMVSPORT 1	LP012
HHBA HHBB HHBC HHBD HHBE	Human Heart	pCMVSPORT 1	LP012
HBBA HBBB	Human Brain	pCMVSPORT 1	LP012
HLJA HLJB HLJC HLJD HLJE	Human Lung	pCMVSPORT 1	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HOGA HOGB HOGC	Ovarian Tumor	pCMVSPORT 2.0	LP012
HTJM	Human Tonsils, Lib 2	pCMVSPORT 2.0	LP012
HAMF HAMG	KMH2	pCMVSPORT 3.0	LP012
HAJA HAJB HAJC	L428	pCMVSPORT 3.0	LP012
HWBA HWBB HWBC HWBD HWBE	Dendritic cells, pooled	pCMVSPORT 3.0	LP012
HWAA HWAB HWAC HWAD HWAE	Human Bone Marrow, treated	pCMVSPORT 3.0	LP012
HYAA HYAB HYAC	B Cell lymphoma	pCMVSPORT 3.0	LP012
HWHG HWHH HWHI	Healing groin wound, 6.5 hours post incision	pCMVSPORT 3.0	LP012
HWHP HWHQ HWHR	Healing groin wound: 7.5 hours post incision	pCMVSPORT 3.0	LP012
HARM	Healing groin wound - zero hr post-incision (control)	pCMVSPORT 3.0	LP012
HBIM	Olfactory epithelium: nasalcavity	pCMVSPORT 3.0	LP012
HWDA	Healing Abdomen wound; 70&90 min post incision	pCMVSPORT 3.0	LP012
HWEA	Healing Abdomen Wound;15 days post incision	pCMVSPORT 3.0	LP012
HWJA	Healing Abdomen Wound;21&29 days	pCMVSPORT 3.0	LP012
HNAL	Human Tongue, frac 2	pSPORT1	LP012
HMJA	H. Meningioma, M6	pSPORT1	LP012
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSPORT1	LP012
HOFA	Ovarian Tumor I, OV5232	pSPORT1	LP012
HCFA HCFB HCFC HCFO	T-Cell PHA 16 hrs	pSPORT1	LP012
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSPORT1	LP012
HMMA HMMB HMMC	Spleen metastatic melanoma	pSPORT1	LP012
HTDA	Human Tonsil, Lib 3	pSPORT1	LP012
HDBA	Human Fetal Thymus	pSPORT1	LP012
HDUA	Pericardium	pSPORT1	LP012
HBZA	Prostate,BPH, Lib 2	pSPORT1	LP012
HWCA	Larynx tumor	pSPORT1	LP012
HWKA	Normal lung	pSPORT1	LP012
HSMB	Bone marrow stroma,treated	pSPORT1	LP012
HBHM	Normal trachea	pSPORT1	LP012
HLFC	Human Larynx	pSPORT1	LP012
HLRB	Siebben Polyposis	pSPORT1	LP012
HNIA	Mammary Gland	pSPORT1	LP012
HNJB	Palate carcinoma	pSPORT1	LP012
HNKA	Palate normal	pSPORT1	LP012
HMZA	Pharynx carcinoma	pSPORT1	LP012
HABG	Cheek Carcinoma	pSPORT1	LP012
HMZM	Pharynx Carcinoma	pSPORT1	LP012
HDRM	Larynx Carcinoma	pSPORT1	LP012
HVAA	Pancreas normal PCA4 No	pSPORT1	LP012
HICA	Tongue carcinoma	pSPORT1	LP012
HUKA HUKB HUKC HUKD HUKF	Human Uterine Cancer	Lambda ZAP II	LP013
HFFA	Human Fetal Brain, random primed	Lambda ZAP II	LP013
HTUA	Activated T-cell labeled with 4-thioluri	Lambda ZAP II	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP013
HMEB	Human microvascular Endothelial cells, fract. B	Lambda ZAP II	LP013
HUSH	Human Umbilical Vein Endothelial cells, fract. A, re-excision	Lambda ZAP II	LP013
HLQC HLQD	Hepatocellular tumor, re-excision	Lambda ZAP II	LP013
HTWJ HTWK HTWL	Resting T-cell, re-excision	Lambda ZAP II	LP013
HF6S	Human Whole 6 week Old Embryo (II), sublt	pBluescript	LP013
HHPS	Human Hippocampus, subtracted	pBluescript	LP013
HL1S	LNCAP, differential expression	pBluescript	LP013
HLHS HLHT	Early Stage Human Lung, Subtracted	pBluescript	LP013
HSUS	Supt cells, cyclohexamide treated, subtracted	pBluescript	LP013
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBluescript	LP013
HSDS	H. Striatum Depression, subtracted	pBluescript	LP013
HPTZ	Human Pituitary, Subtracted VII	pBluescript	LP013
HSDX	H. Striatum Depression, sublt II	pBluescript	LP013
HSDZ	H. Striatum Depression, sublt	pBluescript	LP013
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBluescript SK-	LP013
HRTA	Colorectal Tumor	pBluescript SK-	LP013
HSBA HSBB HSBC HSBM	HSC172 cells	pBluescript SK-	LP013
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBluescript SK-	LP013
HJBA HJBB HJBC HJBD	Jurkat T-cell, S1 phase	pBluescript SK-	LP013
HTNA HTNB	Human Thyroid	pBluescript SK-	LP013
HAHA HAHB	Human Adult Heart	Uni-ZAP XR	LP013
HE6A	Whole 6 week Old Embryo	Uni-ZAP XR	LP013
HFCA HFCB HFCC HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP013
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP013
HGBA HGBD HGBE HGBF HGBG	Human Gall Bladder	Uni-ZAP XR	LP013
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP013
HTEA HTEB HTEC HTED HTEE	Human Testes	Uni-ZAP XR	LP013
HTTA HTTB HTTC HTTD HTTE	Human Testes Tumor	Uni-ZAP XR	LP013
HYBA HYBB	Human Fetal Bone	Uni-ZAP XR	LP013
HFLA	Human Fetal Liver	Uni-ZAP XR	LP013
HHFB HHFC HHFD HHFE HHFF	Human Fetal Heart	Uni-ZAP XR	LP013
HUVB HUV C HUVD HUVE	Human Umbilical Vein, End. remake	Uni-ZAP XR	LP013
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP013
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP013
HTAA HTAB HTAC HTAD HTAE	Human Activated T-cells	Uni-ZAP XR	LP013
HFEA HFEB HFEC	Human Fetal Epithelium (skin)	Uni-ZAP XR	LP013
HJPA HJPB HJPC HJPD	Human Jurkat Membrane Bound Polysomes	Uni-ZAP XR	LP013
HESA	Human Epithelioid Sarcoma	Uni-ZAP XR	LP013
HALS	Human Adult Liver, Subtracted	Uni-ZAP XR	LP013
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP013
HCAA HCAB HCAC	Cern cells, cyclohexamide treated	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP013
HE9A HE9B HE9C HE9D HE9E	Nine Week Old Early Stage Human	Uni-ZAP XR	LP013
HSFA	Human Fibrosarcoma	Uni-ZAP XR	LP013
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP013
HTRA	Human Trachea Tumor	Uni-ZAP XR	LP013
HE2A HE2D HE2E HE2H HE2I	12 Week Old Early Stage Human	Uni-ZAP XR	LP013
HE2B HE2C HE2F HE2G HE2P	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP013
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP013
HBGA	Human Primary Breast Cancer	Uni-ZAP XR	LP013
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP013
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP013
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP013
HTOA HTOD HTOE HTOF HTOG	human tonsils	Uni-ZAP XR	LP013
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP013
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP013
HOQB	Human OB HOS treated (1 nM E2) fraction I	Uni-ZAP XR	LP013
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP013
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP013
HROA HROC	HUMAN STOMACH	Uni-ZAP XR	LP013
HBJA HBJB HBJC HBJD HBJE	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP013
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP013
HCPA	Corpus Callosum	Uni-ZAP XR	LP013
HSOA	stomach cancer (human)	Uni-ZAP XR	LP013
HERA	SKIN	Uni-ZAP XR	LP013
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP013
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP013
HWTA HWTB HWTC	wilm's tumor	Uni-ZAP XR	LP013
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP013
HAPN HAPO HAPR HAPQ HAPR	Human Adult Pulmonary;re-excision	Uni-ZAP XR	LP013
HLTG HLTH	Human T-cell lymphoma;re-excision	Uni-ZAP XR	LP013
HAHC HAHD HAHE	Human Adult Heart;re-excision	Uni-ZAP XR	LP013
HAGA HAGB HAGC HAGD HAGE	Human Amygdala	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP013
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP013
HPJA HPJB HPJC	LNCAP prostate cell line	Uni-ZAP XR	LP013
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP013
HBTA	Bone Marrow Stroma, TNF&LPS ind	Uni-ZAP XR	LP013
HMCF HMCB HMCH HMCI HMCJ	Macrophage-oxLDL; re-excision	Uni-ZAP XR	LP013
HAGG HAGH HAGI	Human Amygdala;re-excision	Uni-ZAP XR	LP013
HACA	H. Adipose Tissue	Uni-ZAP XR	LP013
HKFB	K562 + PMA (36 hrs);re-excision	ZAP Express	LP013
HCWT HCWU HCWV	CD34 positive cells (cord blood);re-ex	ZAP Express	LP013
HBWA	Whole brain	ZAP Express	LP013
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HAVM	Temporal cortex-Alzheimer	pT-Adv	LP014
HAVT	Hippocampus, Alzheimer Subtracted	pT-Adv	LP014
HHAS	CHME Cell Line	Uni-ZAP XR	LP014
HAJR	Larynx normal	pSport 1	LP014
HWLE HWLF HWLG HWLH	Colon Normal	pSport 1	LP014
HCRM HCRN HCRO	Colon Carcinoma	pSport 1	LP014
HWLI HWLJ HWLK	Colon Normal	pSport 1	LP014
HWLH HWLR HWLS HWLT	Colon Tumor	pSport 1	LP014
HBFM	Gastrocnemius Muscle	pSport 1	LP014
HBOD HBOE	Quadriceps Muscle	pSport 1	LP014
HBKD HBKE	Soleus Muscle	pSport 1	LP014
HCCM	Pancreatic Langerhans	pSport 1	LP014
HWGA	Larynx carcinoma	pSport 1	LP014
HWGM HWGN	Larynx carcinoma	pSport 1	LP014
HWLA HWLB HWLC	Normal colon	pSport 1	LP014
HWLM HWLN	Colon Tumor	pSport 1	LP014
HVAM HVAN HVAO	Pancreas Tumor	pSport 1	LP014
HWGQ	Larynx carcinoma	pSport 1	LP014
HAQM HAQN	Salivary Gland	pSport 1	LP014
HASM	Stomach; normal	pSport 1	LP014
HBCM	Uterus; normal	pSport 1	LP014
HCDM	Testis; normal	pSport 1	LP014
HDJM	Brain; normal	pSport 1	LP014
HEFM	Adrenal Gland,normal	pSport 1	LP014
HBAA	Rectum normal	pSport 1	LP014
HFDH	Rectum tumour	pSport 1	LP014
HGAM	Colon, normal	pSport 1	LP014
HHMM	Colon, tumour	pSport 1	LP014
HCLB HCLC	Human Lung Cancer	Lambda Zap II	LP015
HRLA	L1 Cell line	ZAP Express	LP015
HHAM	Hypothalamus, Alzheimer's	pCMVSPORT 3.0	LP015
HKBA	Ku 812F Basophils Line	pSport 1	LP015
HS2S	Saos2, Dexamethosone Treated	pSport 1	LP016
HA5A	Lung Carcinoma A549 TNFalpha activated	pSport 1	LP016
HTFM	TF-1 Cell Line GM-CSF Treated	pSport 1	LP016
HYAS	Thyroid Tumour	pSport 1	LP016
HUTS	Larynx Normal	pSport 1	LP016
HXOA	Larynx Tumor	pSport 1	LP016
HEAH	Ea.hy.926 cell line	pSport 1	LP016
HINA	Adenocarcinoma Human	pSport 1	LP016
HRMA	Lung Mesothelium	pSport 1	LP016
HLCL	Human Pre-Differentiated Adipocytes	Uni-Zap XR	LP017
HS2A	Saos2 Cells	pSport 1	LP020
HS2I	Saos2 Cells; Vitamin D3 Treated	pSport 1	LP020
HUCM	CHME Cell Line, untreated	pSport 1	LP020
HEPN	Aryepiglottis Normal	pSport 1	LP020

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPSN	Sinus Piniformis Tumour	pSport 1	LP020
HNSA	Stomach Normal	pSport 1	LP020
HNSM	Stomach Tumour	pSport 1	LP020
HNLA	Liver Normal Met5No	pSport 1	LP020
HUTA	Liver Tumour Met 5 Tu	pSport 1	LP020
HOCN	Colon Normal	pSport 1	LP020
HOCT	Colon Tumor	pSport 1	LP020
HTNT	Tongue Tumour	pSport 1	LP020
HLXN	Larynx Normal	pSport 1	LP020
HLXT	Larynx Tumour	pSport 1	LP020
HTYN	Thymus	pSport 1	LP020
HPLN	Placenta	pSport 1	LP020
HTNG	Tongue Normal	pSport 1	LP020
HZAA	Thyroid Normal (SDCA2 No)	pSport 1	LP020
HWES	Thyroid Thyroiditis	pSport 1	LP020
HFHD	Ficolled Human Stromal Cells, 5Fu treated	pTrip1Ex2	LP021
HFHM,HFHN	Ficolled Human Stromal Cells, Untreated	pTrip1Ex2	LP021
HPCI	Hep G2 Cells, lambda library	lambda Zap-CMV XR	LP021
HBCA,HBCB,HBCC	H. Lymph node breast Cancer	Uni-ZAP XR	LP021
HCOK	Chondrocytes	pSPORT1	LP022
HDCA, HDCB, HDCC	Dendritic Cells From CD34 Cells	pSPORT1	LP022
HDMA, HDMB	CD40 activated monocyte dendritic cells	pSPORT1	LP022
HDDM, HDDN, HDDO	LPS activated derived dendritic cells	pSPORT1	LP022
HPCR	Hep G2 Cells, PCR library	lambda Zap-CMV XR	LP022
HAAA, HAAB, HAAC	Lung, Cancer (4005313A3): Invasive Poorly Differentiated Lung Adenocarcinoma	pSPORT1	LP022
HIPA, HIPB, HIPC	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	pSPORT1	LP022
HOOH, HOOI	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	pSPORT1	LP022
HIDA	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HUJA,HUJB,HUJC,HUJD,HUJE	B-Cells	pCMVSPORT 3.0	LP022
HNOA,HNOB,HNOC,HNOD	Ovary, Normal: (9805C040R)	pSPORT1	LP022
HNLM	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HSCL	Stromal Cells	pSPORT1	LP022
HAAX	Lung, Cancer: (4005313 A3) Invasive Poorly-differentiated Metastatic lung adenocarcinoma	pSPORT1	LP022
HUUA,HUUB,HUUC,HUUD	B-cells (unstimulated)	pTrip1Ex2	LP022
HWWA,HWWB,HWWC,HWWD,HWE,HWWF,HWWG	B-cells (stimulated)	pSPORT1	LP022
HCCC	Colon, Cancer: (9808C064R)	pCMVSPORT 3.0	LP023
HPDO HPDP HPDQ HPDR HPD	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	pSport 1	LP023

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPCO HPCP HPCQ HPCT	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	pSport 1	LP023
HOCM HOCO HOCQ HOCQ	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	pSport 1	LP023
HCBM HCBN HCBO	Breast, Cancer: (4004943 A5)	pSport 1	LP023
HNBT HNBU HNBV	Breast, Normal: (4005522B2)	pSport 1	LP023
HBCP HBCQ	Breast, Cancer: (4005522 A2)	pSport 1	LP023
HBCJ	Breast, Cancer: (9806C012R)	pSport 1	LP023
HSAM HSAN	Stromal cells 3.88	pSport 1	LP023
HVCA HVCB HVCC HVCD	Ovary, Cancer: (4004332 A2)	pSport 1	LP023
HSCK HSEN HSEO	Stromal cells (HBM3.18)	pSport 1	LP023
HSCP HSCQ	stromal cell clone 2.5	pSport 1	LP023
HUXA	Breast Cancer: (4005385 A2)	pSport 1	LP023
HCOM HCON HCOO HCOP HCOQ	Ovary, Cancer (4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	pSport 1	LP023
HBNM	Breast, Cancer: (9802C020E)	pSport 1	LP023
HVVA HVVB HVVC HVVD HVVE	Human Bone Marrow, treated	pSport 1	LP023

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 5. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEQ ID NO:X.

5 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid
10 mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using
15 Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

 Alternatively, two primers of 17-20 nucleotides derived from both ends of the
20 nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of
25 Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA
30 product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not

limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

5 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full
10 length gene.

This above method starts with total RNA isolated from the desired source, although poly-A⁺ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the
15 RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis
20 using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

25 ***Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide***

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X, according to the method
30 described in Example 1. (See also, Sambrook.)

Example 3: Tissue specific expression analysis

The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs which show tissue specific expression are selected.

The original clone from which the specific EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured then transferred in 96 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.

Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed. The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65°C overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.

Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified and the full length sequence of these clones is generated.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute

cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR
5 fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using
10 PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial
15 expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is
20 ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is
25 isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto
30 pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction

sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

5 The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

10 The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell
15 paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then
20 mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is
25 discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous
30 stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 μm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commaassie blue stained 16% SDS-PAGE gel when 5 μg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the

polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc.*

Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μCi of ^{35}S -methionine and 5 μCi ^{35}S -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 5 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction 10 enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. 15 Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

20 The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

25 Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM 30 supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones

are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without

a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous
5 signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```

GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCCACCGTGCCCAG
CACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCC AAAACCCAAGGA
10 CACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTG GTGGTGGACGTAAGC
CACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAT
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAGCC
15 AAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGC
GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA ACTACAAGAC
CACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACC
GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
20 GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT
GAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1685)

```

Example 10: Production of an Antibody from a Polypeptide

25 a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide
30 of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide of the present invention are prepared using hybridoma technology. (Kohler et al., *Nature* 256:495 (1975); Kohler et al., *Eur. J. Immunol.* 6:511 (1976); Kohler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide of the present invention or, more preferably, with a secreted polypeptide of the present invention-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

Alternatively, additional antibodies capable of binding to polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide of the present invention-specific antibody can be blocked by polypeptide of the present invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized

antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed Against Polypeptide of the Present Invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations

(Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 μ m filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immuntubes (Nunc) are coated overnight in PBS with 4 ml of either 100 μ g/ml or 10 μ g/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 μ g/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 11: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X; and/or the nucleotide sequence of the related cDNA in the cDNA clone contained in a deposited library. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an

associated disease.

Example 12: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

5 A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

10 For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

15 The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

20 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

25 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 13: Formulation

30 The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed

herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

5 The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such
10 considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most
15 preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following
20 treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material
25 or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally,
30 rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler,

diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form

(solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the
5 Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such
10 carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate,
15 succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including
20 cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be
25 understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port,
30 for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example,

sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic
5 using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products,
10 which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention
15 include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include,
20 but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping
25 cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined
30 agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™

(didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™,

FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection.

- 5 In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an
- 10 opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

- In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the
- 15 Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

- In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases,
- 20 aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

- Conventional nonspecific immunosuppressive agents, that may be administered in
- 25 combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

- In specific embodiments, Therapeutics of the invention are administered in
- 30 combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin),

PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and

combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or
5 any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in
10 combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
15 IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived
20 Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International
25 Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial
30 Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as

disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 14: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or antagonist to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

Example 15: Method of Treating Increased Levels of the Polypeptide

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 13.

Example 16: Method of Treatment Using Gene Therapy-Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using

PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 17: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

Another method of gene therapy according to the present invention involves operably

associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5X10⁶ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a

10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 18: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that

allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to

arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology.

- 5 The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and
10 the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

- 15 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be
20 determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

25 *Example 19: Transgenic Animals*

- The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys,
30 and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campbell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of

the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 20: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and

preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 22: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity

of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to
5 determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of
10 ThB+, CD45R(B220)dull B cells over that which is observed in control mice. Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.

The studies described in this example tested activity of agonists or antagonists of the
15 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 23: T Cell Proliferation Assay

20 A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ^3H -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 μl /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 $\mu\text{g}/\text{ml}$ in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from
25 human peripheral blood and added to quadruplicate wells ($5 \times 10^4/\text{well}$) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200 μl). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μl of supernatant is removed and stored -20 degrees C for measurement of IL-2
30 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 μl of medium containing 0.5 μCi of ^3H -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of ^3H -thymidine used as a measure of proliferation.

Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of agonists or antagonists of the invention.

- 5 The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

10 *Example 24: Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells*

- Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

- FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

- Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of agonists or antagonists of the

invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

5

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

10

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

15

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

20

25

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha

30

dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e. g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRP) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H_2O_2 produced by the macrophages, a standard curve of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

5

Example 25: Biological Effects of Agonists or Antagonists of the Invention

Astrocyte and Neuronal Assays.

Agonists or antagonists of the invention, expressed in *Escherichia coli* and purified
10 as described above, can be tested for activity in promoting the survival, neurite outgrowth, or
phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial
fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for
the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures
and on the previously reported enhancement of cortical neuronal survival resulting from
15 FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an
agonist or antagonist of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on
cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival
and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of
20 dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci.*
USA 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However,
reports from experiments done on PC-12 cells suggest that these two responses are not
necessarily synonymous and may depend on not only which FGF is being tested but also on
which receptor(s) are expressed on the target cells. Using the primary cortical neuronal
25 culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite
outgrowth can be compared to the response achieved with FGF-2 using, for example, a
thymidine incorporation assay.

Fibroblast and endothelial cell assays.

30 Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained
in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from

Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 26: The Effect of Agonists or Antagonists of the Invention on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cell indicates that the compound of the invention inhibits vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 27: Rat Corneal Wound Healing Model

This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of an agonist or antagonist of the invention, within the pocket.
- e) Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of agonists or antagonists of the

invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 28: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

5

A. Diabetic db+/db+ Mouse Model.

To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and
10 reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II
15 diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and
20 suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*,
25 *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may
30 be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic

(db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

An agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and

obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

5

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome.

10 Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and
15 epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is
20 determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue
25 control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is
30 considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that an agonist or antagonist of the invention can accelerate the healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The

wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

5 Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

10 The agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for
15 histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

20 Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

25

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine
30 hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with an agonist or

antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

5 The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 29: Lymphadema Animal Model

10

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of an agonist or antagonist of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

15 Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

20 Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

30 Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal

and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

- 5 The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 30: Suppression of TNF alpha-induced adhesion molecule expression by a Agonist or Antagonist of the Invention

- 15 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

- 25 The potential of an agonist or antagonist of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

- 30 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well

plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca^{++} and Mg^{++}) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of agonists or antagonists of the

invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 31: Production Of Polypeptide of the Invention For High-Throughput Screening Assays

The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 33-42.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on

PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem 1 complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust

osmolarity to 327 mOsm) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

5 The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

10 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 33-40.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant.
15 Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 32: Construction of GAS Reporter Construct

20 One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

25 GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called
30 mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon

tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

5 The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g,
10 and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:1686)).

 Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is
15 encompassed in the Jaks-STATs signal transduction pathway.

 Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter
20 molecules, activators of the Jaks-STATs pathway can be identified.

509

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>			<u>STATs GAS(elements) or ISRE</u>	
			<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g (IRF1>Lys6>IFP)		+	+	-	1	GAS
	IL-10	+	?	?	-	1,3	
10	<u>gp130 family</u>						
	IL-6 (Pleiotrohic) (IRF1>Lys6>IFP)	+	+	+	?	1,3	GAS
	IL-11(Pleiotrohic)	?	+	?	?	1,3	
	OnM(Pleiotrohic)	?	+	+	?	1,3	
15	LIF(Pleiotrohic)	?	+	+	?	1,3	
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
	G-CSF(Pleiotrohic)	?	+	?	?	1,3	
	IL-12(Pleiotrohic)	+	-	+	+	1,3	
20	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid) >>Ly6)(IgH)	-	+	-	+	6	GAS (IRF1 = IFP
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
25	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
	<u>gp140 family</u>						
30	IL-3 (myeloid) (IRF1>IFP>>Ly6)	-	-	+	-	5	GAS
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS

Growth hormone family

	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
5	EPO	?	-	+	-	5	GAS(B-
	CAS>IRF1=IFP>>Ly6)						

Receptor Tyrosine Kinases

10	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 33-34, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5' : GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG : 3' (SEQ ID NO:1687)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5' : GCGGCAAGCTTTTGTCAAAGCCTAGGC : 3' (SEQ ID NO:1688)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5' : CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT : 3' (SEQ ID NO:1689)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and
5 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-
10 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding
15 as described in Examples 33-34.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 35 and 36. However, many other promoters can be substituted using the protocols described
20 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

Example 33: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention
30 proliferates and/or differentiates T-cells. T-cell activity is assessed using the

GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC
5 Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately
10 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells
15 containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

20 During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

25 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 31.

30 On the day of treatment with the supernatant, the cells should be washed and

resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

5 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
10 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul
15 samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 37. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.

20 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

 The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

25

Example 34: High-Throughput Screening Assay Identifying Myeloid Activity

 The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention
30 proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using

the GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

5 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 32, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml
10 penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37 degrees C for 45 min.

15 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

20 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example
25 31. Incubate at 37 degree C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 37.

30 *Example 35: High-Throughput Screening Assay Identifying Neuronal Activity.*

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO: 1690)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO: 1691)

Using the GAS:SEAP/Neo vector produced in Example 32, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter

sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 31. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 31, 37 degree C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 37.

Example 36: High-Throughput Screening Assay for T-cell Activity

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB
5 regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded,
10 causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants
15 produced in Example 31. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based
20 strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:1692), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
25 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:1693)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:1688)

PCR amplification is performed using the SV40 promoter template present in
30 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is

digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
 5 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
 ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
 CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
 TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
 GCTT:3' (SEQ ID NO:1694)

10 Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP
 15 cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are
 20 created and maintained according to the protocol described in Example 33. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 33. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25 *Example 37: Assay for SEAP Activity*

As a reporter molecule for the assays described in Examples 33-36, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution,
 30 Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- 5 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below).. Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it
- 10 takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

15 Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6

23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 38: High-Throughput Screening Assay Identifying Changes in Small

Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4 . The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 40: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine

kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately
5 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from
Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with
100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr
with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or
polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St.
10 Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or
calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is
assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of
cell number through use of alamarBlue as described by the manufacturer Alamar
Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from
15 Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen
Plates. Falcon Microtest III cell culture plates can also be used in some proliferation
experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of
Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium.
20 Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20
minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in
Example 31, the medium was removed and 100 ml of extraction buffer ((20 mM
HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM
Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from
25 Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is
shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a
vacuum transfer manifold and the extract filtered through the 0.45 mm membrane
bottoms of each well using house vacuum. Extracts are collected in a 96-well
catch/assay plate in the bottom of the vacuum manifold and immediately placed on
30 ice. To obtain extracts clarified by centrifugation, the content of each well, after

detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described
5 here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and
10 PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,
15 pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of
20 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul
25 of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the
30 absorbance of the sample at 405 nm by using ELISA reader. The level of bound

peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 41: High-Throughput Screening Assay Identifying Phosphorylation Activity

5

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 40, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

15 Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

25 A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 31 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

30 After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit)

antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by polypeptide of the present invention or a molecule induced by polypeptide of the present invention.

Example 42: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

10

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

30 Briefly, CD34+ cells are isolated using methods known in the art. The cells

are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10^5 cells/ml. During this time, 100 μ l of
5 sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l of the supernatants prepared in Example 31
10 (supernatants at 1:2 dilution = 50 μ l) and 20 μ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The
15 experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for
20 counting. The sealed plates is then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could
25 easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.
30 In contrast, potential agonists tested in this assay would be expected to enhance cell

proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are
5 useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the “Immune Activity” and “Infectious Disease” sections above, and elsewhere herein.

Example 43: Assay for Extracellular Matrix Enhanced Cell Response (EMECR)

10

The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

15

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is
20 dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should
25 be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2 \mu\text{g}/\text{cm}^2$. Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control,

conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 31), are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO₂, 7% O₂, and 88% N₂) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACSscan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 44: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

10

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF α stimulation, in order to check for costimulatory or inhibitory activity.

20

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 25 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μ g/ml hEGF, 5mg/ml insulin, 1 μ g/ml hFGF, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 5%FBS. After incubation at 37°C for at least 4-5 hours, culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for 30 AoSMC contains SM basal media, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B,

0.4% FBS. Incubate at 37°C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest
5 media. For inhibition experiments, TNF α is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides of the present invention and incubate at 37°C/5% CO₂ until day 5.

Transfer 60 μ l from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4°C until Day 6 (for IL6 ELISA). To the remaining 100 μ l in
10 the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10 μ l). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100
15 μ l/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 μ l/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash
20 buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 μ l/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker. Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin
25 1:1000 in Assay buffer, and add 100 μ l/well. Cover the plate and incubate 1 h at RT. Plates are again washed with wash buffer and blotted on paper towels. Add 100 μ l/well of Enhancement Solution and shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay are tabulated and averaged.

30 A positive result in this assay suggests AoSMC cell proliferation and that the

polypeptide of the present invention may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result.

5 For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing and dermal regeneration, as well as the promotion of vasculargenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, 10 for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign 15 tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; 20 rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; 25 hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the 30 activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or

antagonists and fragments and variants thereof.

Example 45: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

5

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 μ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 μ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 μ l of diluted ExtrAvidin-Alkaline

Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 46: Alamar Blue Endothelial Cells Proliferation Assay

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the

overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 47: Detection of Inhibition of a Mixed Lymphocyte Reaction

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides

since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2×10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 μ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 μ C of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or

antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Moreover, the hard copy of and the corresponding computer readable form of the Sequence Listing of Serial No. 60/124,270 are also incorporated herein by reference in their entireties.

539

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209059
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jon M. B. Sowell PCT/International Processing Div. (703) 305-6389</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209059**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209059

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

542

Applicant's or agent's file reference number	PA106PCT	International application number	UNASSIGNED
---	----------	----------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209060
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer PCT/US00/05882 Processing Div. (703) 305-3039</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209060**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2**ATCC Deposit No. 209060****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

545

Applicant's or agent's file reference number	PA106PCT	International application No.	UNASSIGNED
---	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209061
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer PCT/International Processing Div. (703) 305-3630</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 209061**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209061

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

548

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209062
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer: Jeryl McDowell PCT/Internat'l Appl Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 209062**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209062

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

551

Applicant's or agent's file reference number	PA106PCT	International application #	UNASSIGNED
---	----------	-----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209063</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer <u>PCT/Internat'l Appl Processing Div.</u> <u>(703) 305-3639</u>	Authorized officer

ATCC Deposit No. 209063**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209063

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

554

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209064
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer PCT/Internal Legal Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209064**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209064

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PA106PCT	557 International application	UNASSIGNED
---	----------	----------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209065
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 209065**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209065

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

560

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209066
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer PCT/International Application Processing Div. (703) 305-3639	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
--	---

ATCC Deposit No. 209066**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209066

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.


563

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209067
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer  International Application Processing Div. (703) 305-3339</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209067**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

566

Applicant's or agent's file reference number	PA106PCT	International application?	UNASSIGNED
--	----------	----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209068
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer: PCT/International Appl Processing Div. (703) 368-3339</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 209068**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

569

Applicant's or agent's file reference number	PA106PCT	International application?	UNASSIGNED
---	----------	----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209069</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p><u>Jerry McDowell</u> Authorized officer PCT/International Appl Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209069**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209069

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

572

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 12 January 1998	Accession Number 209579
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer Jon McDowell PCT/Int'l Appl Processing Div. (703) 305-3639

<input type="checkbox"/> For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer

ATCC Deposit No. 209579**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209579

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

575

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 12 January 1998	Accession Number 209578
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jeryl A. Cawell PCT/International Appl Processing Div. (703) 305-6880</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 209578**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209578

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

578

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 16 July 1998	Accession Number 203067
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer <u>Teryl McDowell</u> PCT/International Appl Processing Div. (703) 305-3333	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 203067**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

581

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 16 July 1998	Accession Number 203068
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jared McDowell PCT/Internat'l Appl Processing Div. (703) 305-3339</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 203068**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

584

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 1 February 1999	Accession Number 203609
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Jeryl McDowell Authorized officer PCT/International Appl Processing Div. (703) 305-3339</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 203609**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203609

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

587

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 1 February 1999	Accession Number 203610
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jeryl McCowell PCT/International Appl Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 203610**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203610

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

590

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 17 November 1998	Accession Number 203485
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jeryl McDevitt PCT/International Appl Processing Div. (703) 305-3839</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. 203485**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2**ATCC Deposit No. 203485****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

593

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 18 June 1999	Accession Number PTA-252
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer Jarryl McDowell PCT/International Appl Processing Div. (703) 305-3839</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. PTA-252**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. PTA-252

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

596

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 18 June 1999	Accession Number PTA-253
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p><u>Jerry McDowell</u> Authorized officer PCT/International Appl Processing Div. (703) 305-3639</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. PTA-253**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. PTA-253

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

599

Applicant's or agent's file reference number	PA106PCT	International application	UNASSIGNED
---	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>121</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>22 December 1999</u>	Accession Number <u>PTA-1081</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer <u>Jerry MacDonell</u> <u>PCT/International Appl Processing Div.</u> <u>(703) 305-3639</u></p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

ATCC Deposit No. PTA-1081**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2**ATCC Deposit No. PTA-1081****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 10 (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 20 (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X, having biological activity;
- (g) a polynucleotide which is a variant of SEQ ID NO:X;
- 25 (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide
- 30

sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.

5

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

10

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

15

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

30

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least
5 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (b) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity;
 - 10 (c) a polypeptide domain of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (d) a polypeptide epitope of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (e) a full length protein of SEQ ID NO:Y or of the sequence encoded by the
15 cDNA included in the related cDNA clone;
 - (f) a variant of SEQ ID NO:Y;
 - (g) an allelic variant of SEQ ID NO:Y; or
 - (h) a species homologue of the SEQ ID NO:Y.
- 20 12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide
25 of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
- 30 15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

5 16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

15 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

20 (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

25 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

30

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
22. A method of identifying an activity in a biological assay, wherein the method comprises:
- 5 (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.
- 10 23. The product produced by the method of claim 20.

SEQUENCE LISTING

<110> Craig Rosen,
Steve Ruben

<120> Human Cancer Associated Gene Sequences and Polypeptides

<130> PA106PCT

<140> Unassigned

<141> 2000-03-08

<150> 60/124,270

<151> 1999-03-12

<160> 1694

<170> PatentIn Ver. 2.0

<210> 1

<211> 556

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (546)

<223> n equals a,t,g, or c

<400> 1

```
gaagagagac tgggttattc ctcccatcag ctgcccagaa aatgaaaaag gcccatattcc 60
taaaaacctg gttcagatca aatccaacaa agacaaagaa ggcaagggtt tctacagcat 120
cactggccaa ggagctgaca caccacctgt tgggtgtcttt attattgaaa gagaaacagg 180
atggctgaag gtgacagagc ctctggatag agaacgcatt gccacataca ctctcttctc 240
tcacgctgtg tcatccaacg ggaatgcagt tgaggatcca atggagattt tgatcacggg 300
aaccgatcag aatgacaaca agcccgaatt caccaggag gtctttaagg ggtctgtcat 360
ggaagggtgct cttccaggaa cctctgtaat ggaggtcaca gccacagacg cggacgatgg 420
atgtggaaca cctacaatgc cgccatcgct tacaccatcc tcagcccaag atccctgagc 480
tccctgacaa aaatatgttc accattaaca ggaacacagg rgtcatcagt gttgtcacca 540
cttggnttgg ccgaga                                     556
```

<210> 2

<211> 2662

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2662)

<223> n equals a,t,g, or c

```

<400> 2
ggctgtggga actcctgggg gaggtggagg tggagccgta ccaggtatatt cagccatgtc 60
ccgcggwgat ctgwgccaga gagccaagga tttgagtaaa cggagcttct caagtcagcg 120
gccaggcatg gaacggcaga atcggcgccc tggcccaggg ggcaaggctg gcagcagtgg 180
cagcagcagt ggaggaggcg gtgggkgtcc tggaggaagg accgggccag gacgaggcga 240
caagaggagc tggccctctc ccaagaaccg aagtcgtcct ccagaggarc gtcccccggg 300
gcttccccctg cctccccccac ctcccagcag ttctgctgct tccgcctgga ccaagttatc 360
cacagcaacc ctgctggcat ccaacargct ctggcccagc ttagtarccg tcaarggagt 420
gtaactgcac caggggggtca tccaaggcac aagcctgggc ctcccccaagc ccctcagggc 480
ccctctccta ggcccccaac ccgatacgag cccagagggg tcaacagcgg cctcagttct 540
gacccccact ttraggagcc ggggccaatg gtgagagggg tgggtgggac tcctcgggac 600
tctgcggggg ttagtccctt tccccctaaa cgtcgggagc ggccctccag aaaaccagag 660
ctgctacag aggaatcttt gccacctcct catagctctg gattcttggg ctctaagcct 720
gagggcccag gccctcaggc agagtccaga gatacaggca cagaggccct gacccctcac 780
atctggaacc gtttacatac tgccactagc cgaaagagtt accggcccag ctccatggag 840
ccttggaatg agcccctgag tccttttgag gatgtggctg gcacagaaat gagtcaagtct 900
gacagtgggg tggacctgag tggggattct caggtgtcat caggtccctg cagccagcga 960
agttccccctg atggaggact caagggggca gcagaggggc cccccaagag gcctggaggc 1020
tcctcacccc tgaatgctgt tccttgtgag ggtccacctg gctctgaacc tcctaggaga 1080
ccaccacctg cccccacga tggggacaga aaggagctgc cccgggagca gcctctgccc 1140
cctggcccca ttggcacaga acgatcacag crtacagacc gaggcacaga gcctggcccc 1200
attcgcccat cccatcgacc tgggtcccca gtccagtttg gcactartga caaggactca 1260
gacttacgcc tagtggtagg agacagcttg aaagcagaga aggagctaac agcatcagtc 1320
actgaggcca ttcctgtatc acgagactgg gagctgcttc ccagtgtctg tgccctctgct 1380
gagccacaat ccaagaacct ggattctggg cactgtgtcc cggagcccag ctccctcaggc 1440
cagcgctgt atcctgaggt tttctatggc agtgctgggc cttccagttc tcagatctct 1500
gggggagcca tggactctca attacatcca aacagtggag gcttccgccc tgggacacccc 1560
tactgcacc cttacagatc acagccccta tacctacccc csggcccagc ccctccctca 1620
gcaactgctc ctggggtagc tctcaagggc cagtttctgg atttctccac aatgcaagct 1680
acagagctgg ggaagttgcc ggctggagga gttctctacc ctccaccttc ctctctctac 1740
tctccggctt tctgccccag tcctttgcct gacacatcgt tgcttcaggt acgccaggat 1800
ctgccatccc cttcggaattt ttattctact cctctgcagc ctggtggcca aagtggcttt 1860
ctcccttcag gggtcctgc cagcagatgc ttctacccat ggtagactca cagctgcctg 1920
tggtgaactt tggtccctg ccgccagcac cacctcctgc cccacctccc ctttctctgt 1980
tacctgtggg ccctgctctg cagcccccca gcctggctgt gcggccccca cctgctcctg 2040
ctactcgggt gctgccttca cctgccaggc ccttccccgc tagcttgggg cgagcagagc 2100
tgcattccagt ggaactaaag ccgttccagg attatcaaaa actgagcagc aaccttgggg 2160
gacctggatc atcacggact cccccaactg gaaggtcctt ctctggcctc aattcccgtc 2220
tcaaggccac gccttccacc tacagtggag tcttccgcac ccagcgcgtc gacctttacc 2280
agcaggcctc cccaccagat gccctgcgct ggatacctaa gccttgggar cggacagggc 2340
cgccacctcg agaagggccc tcccgacggg cagaggagcc tgggtcccga ggggacaagg 2400
agcctgggtt gccccacccc cgctgaggga gttcctcttg cccctacccc ccggggcttg 2460
tatatagatt ataaatatat aagggggaaa ggggtgggcg gggaggggtt gtggggctgg 2520
ggcctcactt cccctcctcc cccttcccct ggtcccctgt ccctggggct gtttgtaaaa 2580
aaagagtaat aaaaggattt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2640
aaaaaaaaaa aaaaaaaaaa tn 2662

```

<210> 3

<211> 338

<212> DNA

<213> Homo sapiens

```

<400> 3
gtgctttgtg ctttgtgcat gtggtaggca gaacactacc atatgtcccc acatacttac 60
actagacctt ggagcaagag caagaacagc aaaagcacag cgcttttgaa cccaaaagac 120
aagctccctt cttcctgctg tgtccctcca gctscctctg ctgaccagg ttagcatcat 180
gtgctctgta aaggaggaat tctggagagt ccagtccatt attacagagc tagtactgaa 240
gggtgagttt ggagttgaag aggcaatgaa attgataact ggacacagaag ccaaataataa 300
gagtattgac taaataatag ctaagtacaa gaacacag 338

```

```

<210> 4
<211> 813
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (784)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (787)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (793)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (807)
<223> n equals a,t,g, or c

```

```

<400> 4
aattcggcac gagccacctt gacctcctaa agtgctagga ttacaggcat gagccactgt 60
accatacccc tgggaggggt ttgaagagtg acatgttatg atttaggttt tagcacaacc 120
ccctcagacc actctgtgga gaacagactg tcagggaacg tgggtggagg cagagagacc 180
agaaagattc caggaggaca gatgtggtgg gacaaggttg ggagagacct gaagccaagg 240
ccctgatcac ccctcctcac agctccagcc tctcaactyc agcctctctc acttattggt 300
tccatgtttg tccatcatga gcctcctcaa caagcccaag agtgagatga cccagagga 360
gctgcagaag cgagaggagg aggaatttaa caccggtcca ctctctgtgc tcacacagtc 420
agtcaagaac aatacccaag tgctcatcaa ctgccgcaac aataagaaac tcctgggccc 480
cgtgaaggcc ttcgataggc actgcaacaa ggtgctggag aacgtgaagg agatgtggac 540
tgaggtaccc aagagtggca agggcaagaa gaagtccaag ccagtcaaca aagaccgcta 600
catctccaag atgttcctgc gcggggagtc agtcatcgtg gtccctgcgga acccgctcat 660
cgccggcaag tagggggccgc ctgtctgttg acagaactca ctctctgtgc ctatgaagac 720
cgctgccatt ggtgttgaga ataataaagc tctgtgtttt tttctaaaaa aaaaaaaaaa 780
aaanytncgg gcngaagctt tttcccntta ggg 813

```

```

<210> 5

```

<211> 901
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (838)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (846)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (870)
 <223> n equals a,t,g, or c

<400> 5
 gcccgaaatgg cggccgacaa gsgcccggcg gctggacctc ggtcgcgagc tgccatggcc 60
 cagtggagga agaagaaagg gctccggaag cgccgaggcg cggcctccca ggcccgcggc 120
 agcaactcgg aggacggcga gtttgagatc caggcggaag atgacgcccg ggcccggaag 180
 ctgggacctg gaagaccctt gccacacctc cccacctcgg aatgcacctc ggatgtggag 240
 ccggacaccc gggagatggg gcgtgcccag aacaagaaga agaagaagtc tggaggcttc 300
 cagtccatgg gcctgagcta cccggtgttc aaaggcatca tgaagaaggg gtacaagggtg 360
 ccaacaccca tccagaggaa gaccatcccg gtgatcttgg atggcaagga cgtggtggcc 420
 atggcccgga cgggcagtgg caagacagcc tgcttcctcc tcccaatgtt cgagcggtc 480
 aagaccacaca gtgcccagac cggggcccg cgcctcatcct ctgcgcgacc cgagarctgg 540
 ccctgcagac cctgaagtgc actaaggagc taggcaagtt cactggcctc aagactgccc 600
 tgatcctggg tggagacagg atggaagacc agtttgcagc cctgcacgaa aatcccagaca 660
 taattattgc cacgcccgga cggttggtgc atgtggctgt ggaaatragc ctgaagctgc 720
 agagtgtgga atacgtrgtg ttcgatgaag ctgaccggct ttttraaatg ggtttcgcag 780
 agcagctgca ggagatcatc gccggtctcc ccgggggcca ccagacggtg ctgttctncg 840
 ccacgntgcc caaactgctg gtggaatttn cccgggctgg cctcacggag cccgtgctca 900
 t 901

<210> 6
 <211> 731
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (106)
 <223> n equals a,t,g, or c

<400> 6
 ggcacgagcg agctcagagt gtgcccgtg cgcgcgcgt gtccgtacct gccgcgcgcg 60
 ccaccgccac catgcccaac ttgcgcggca cctggaagat gcgcacagcg agaatttcga 120
 cgagctgctg aaggcactgg gtgtgaacgc catgctgagg aaagtggccg tagcggctgc 180

```

gtccaagccg cacgtggaga tccgccagga cggggatcag ttctacatca agacatccac 240
cacggtgcmc accactgaga tcaacttcaa ggctcgagaa ggctttgagg aggagaccgt 300
ggacggacgc aagtgcagga gtttagccac ttgggagaat gagaacaaga tccactgcac 360
gcaaactctt cttgaagggg acggcccca aacctactgg acccgtgagc tggccaacga 420
tgaacttata ctgacgtttg gcgccgatga cgtgggtctgc accagaattt atgtccgaga 480
gtgaaggcag ctggcttgct cctactttca ggaagggatg caggctcccc tgaggaatat 540
gtcatagtgc tgagctgcca gtggaccgcc cttttccctt accaatatta ggtgatcccg 600
ttttcccat gacaatgttg tagtgtcccc caccaccacc cccaggcct tggcgctct 660
tgtatcccta gtgctccata gtttggcatt tgcacggtt cgaagtcatt aaactgggta 720
gacgtgtctc a 731

```

<210> 7

<211> 2774

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2652)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2698)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2714)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2756)

<223> n equals a,t,g, or c

<400> 7

```

ggcagagtca cctttgagta tttcagcctc ttcataaata tatctccctc tctttgattt 60
catgtaatat ctccttaaat atttctttgc atatgtgggc aagtgtacgt gtgtgtgtgt 120
catgtgtggc agaggggctt cctaaccctt gcctgatagg tgcagaacgt cggctatcag 180
agcaagcatt gtggagcggc tmcttatgcc aggcctgcat gtgagatgat ccaagaccaa 240
aacaaggccc tagactgcag taaaaccag aactcaagta gggcagaagg tggaggctc 300
atatggwtat aaggcccaaa gtataagaca gatgggttga gacttgagac ccgaggacta 360
agatggaaag cccatgttcc aagatagata gaagcctcag gcctgaaacc aacaaaagcc 420
tcaagagcca agaaaacaga ggggtggcctg aattggaccg aagcctgagt tggatggaag 480
tctcaaggct tgagttagaa gtcttaagac ctgggacagg acacatggaa ggcctaagaa 540
ctgagacttg tgacacaagg ccaacgacct aagattagcc caggggttga gctggaagac 600
ctacaaccca aggatggaag gccctgtcca caaagcctac ctagatggat agaggaccca 660
agcgaaaaag gtatctcaag actaacggcc ggaatctgga ggcccatgac ccagaaccca 720
ggaaggatag aagcttgaag acctggggaa atcccaagat gagaacccta aaccctacct 780
cttttctatt gtttacactt cttactctta gatattttca gttctcctgt ttatctttta 840

```

```

gcctgattct tttgagatgt actttttgat gttgccgggtt acctttagat tgacagtatt 900
atgcctgggc cagtcttgag ccagctttaa atcacagctt ttacctatatt gttaggctat 960
agtgttttgt aaacttctgt ttctattcac atcttctcca cttgagagag acaccaaatt 1020
ccagtcagta tctaattctgg cttttgttaa cttccctcag gagcagacat tcatataggt 1080
gatactgtat ttcagtcctt tcttttgacc ccagaagccc tagactgaga agataaaatg 1140
gtcagggtgt tgggraaaaa aaagtgccag gctctctaga gaaaaatgtg aagagatgct 1200
ccaggccaat gagaagaatt agacaagaaa tacacagatg tgccagactt ctgagaagca 1260
cctgccagca acagcttctt tctttgagct taggtgagca ggattctggg gtttgggatt 1320
tctagtgatg gttatggaaa ggggtgactgt gcctgggaca aagcgaggtc ccaaggggac 1380
agcctgaact ccctgctcat agtagtggcc aaataatttg gtggactgtg ccaacgctac 1440
tcctgggttt aatacccatc tctaggctta aagatgagag aacctgggac tgttgagcat 1500
gtttaatact ttcccttgatt tttttcttcc tgtttatgtg ggaagtgtat ttaaagtact 1560
gataatgtgt atgaaagcac tgtaaaacac aagagaaaaa ccaattagtg tattggcaat 1620
catgcagtta acatttgaaa gtgcagtgtg aattgtgaag cattatgtaa atcaggggtc 1680
cacagttttt ctgtaagggg tcaaatacata aatactttag actgtgggac atatggtttc 1740
tgttacatat ttgtttttta aacaacgttt ttataaggctc aaaatcattc ttagtttttg 1800
agccaattgg atttggcctg ctgttcatac cttaccaccc cctgatgtat tatttggtat 1860
tcagagaaaa tttctgaata ctactagttt ctttttctgt gcctgtccct gtgctaggca 1920
ctaaaaatgc aatgattatt gatattctagg tgacctgaaa aaaaatagtg aatgtgcttt 1980
gtaaaactgt aagcacttgt atttactgtg gataagcgtt gtggatacaa agaaaggagc 2040
aagcataaaa aagtgtctct tcaaaaggat atagtactat gcagacacaa ggaattgttt 2100
gataaatgaa taaattatat gtatatattga ggccaatttg tgtttgctgc tctggtaatt 2160
ttgagtaaaa atgcagtatt ccaggtatca gaaacgaaaa cacatggaaa ctgcttttaa 2220
actttaaaat atactgaaaa cataagggac taagcttggt gtggtcacct ataagtgtcc 2280
agataccatg ctgggtgcta gagctaccaa agggggaaaa gtattctcat agaacaaaaa 2340
atctcagaaa ggtgcatatt aaagtgtctt gtaaaactaa gcatgatata aatgtcaatg 2400
ggctacatat ttatgaatga atgaatggat gaatgaatat taagtgcctc ttacatacca 2460
gctatttttg gtactgtaaa atacaagatt aattctccta tgtaataaga ggaaagttaa 2520
tcctctatac tattcagatg taaggaatga tatattgctt aattttaaac aatcaagact 2580
ttactggatg ggtaagtta aattattact gatacatttt tcccaggtaa ccaggaagag 2640
ctagtatgag gnaatgaakt aatarcttar acccaagttc ccaagatcgg ccgaaccngg 2700
ccgcctccta gganggattc cccccgaagg gggccccaag ccttacgcgt ggccangggc 2760
gacggtccaa aggc 2774

```

<210> 8

<211> 2613

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (896)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1246)

<223> n equals a,t,g, or c

<400> 8

tcgaccacg cgtccgccca cgcgtccgtg gcgaacgagg ttatcaagtg caaggctgca 60

```

gttgcttggg aggctggaaa gcctctctcc atagaggaga tagaggtggc acccccaaag 120
gctcatgaag ttcgaatcaa gatcattgcc actgcggttt gccacaccga tgcctatacc 180
ctgagtggag ctgacctga gggttgtttt ccagtgatct tgggacatga aggtgctgga 240
attgtggaaa gtgttggtga gggagttaact aagctgaagg cgggtgacac tgtcatcca 300
ctttacatcc cacagtgtgg agaatgcaa ttttgtctaa atcctaaaac taacctttgc 360
cagaagataa gagtcaactca agggaaagga ttaatgccag atggtaccag cagatttact 420
tgcaaaggaa agacaatttt gcattacatg ggaaccagca cttttctga atacacagtt 480
gtggctgata tctctgttgc taaaatagat cctttagcac ctttgataa agtctgcctt 540
ctaggttgtg gcatttcaac cgttatggt gctgctgtga acactgccaa gttggagcct 600
ggctctgttt gtgccgtctt tggctcggga ggagtcggat tggcagttat catgggctgt 660
aaagtggctg gtgcttccc gacatttggt tgggacatca ataaagataa atttgcaagg 720
gccaaagagt ttggagccac tgaatgtatt aacctcagg attttagtaa acccatccag 780
gaagtgtcga ttgagatgac cgatggagga gtggactatt ctttgaatg tattggtaat 840
gtgaaggatca tgagagcagc acttgaggca tgtcacaagg gctggggcgt cagctnctgt 900
gttgagtaga ctgcttcagg tgaagaaatt gccactcgtc cattccagct ggtaacaggt 960
cgcacatgga aaggcactgc ctttgagga tggaagagt tagaaagtgt ccaaagtgt 1020
gtgtctgaat atatgtccaa aaagataaaa gttgatgaat ttgtgactca caatctgtct 1080
tttgatgaaa tcaacaaagc ctttgaactg atgcattctg gaaagagcat tcgaactgtt 1140
gtaaagattt aattcaaaa agaaaaataa tgtccatcct gtcgtgatgt gataggagca 1200
gcttaacagg cagggagaag cgctccaac ctacagcct cgtagnrctt cacagctact 1260
ccagaaaata gggttatgtg tgtcattcat gaatctctat aatcaaggac aaggataatt 1320
cagtcataaa cctgttttct ggatgtcctt ccacataaat aattgctagt ttattaagga 1380
atattttaac ataataaaag taatttctac atttgtgtgg aaattgtctt gttttatgct 1440
gtcatcattg tcacggtttg tctgccatt atcttcattc tgcaagggaa agggaaagga 1500
agcagggcag tgggtgggtgt ctgaaacctc agaaacataa cgttgaactt ttaagggctt 1560
cagtccccgt tgattaaaga acagatccta gccatcagtg acaaagttaa tcaggacca 1620
agtctgcttc tgtgatatta tctttaaggg aggtactgtg ccttgttcat acctgtacct 1680
caaattccta ggatggcatc tgcccttcag ggggactaa aatgtattat tgaaacagca 1740
ttctgggctt aaataggtgt atgtatgtgt tggttgtgac tgtactatct ctagtatagt 1800
gaactacata ctgaatatcc aagttctcag cacctacttt tgtcaaatct taacattttg 1860
ccacttcogag atcacattgc cattcctccc ctccagaggt aacaattatc cacaatttga 1920
tgtttatcat tcctgtgttg ttgtactttc actgtgtata acctaaacca tctactcttt 1980
agtactgttt tatatatatt taagcctcat acttgctcat tctacagctt ttttactca 2040
ttattgtata attatatctg aagctctcgt tcattaattt tagtcctgtg tagcagaatt 2100
caattacggg aactaccata atttatctgt tctccagttg aaggcatgaa gttgttgcca 2160
gtttctgtat tataacactg tagtggaaca ttctctgca ttgggctcwc tgcgtgttac 2220
ctaagacgta tcacagaata aacacattta gccttataga cattgccaaa ttgctcttca 2280
aagtaaatgt gagtttttgt gaattacatg agtatggaat ggtgttttat tatgacttta 2340
gtttgcattt tcctcaattc tcgttaaate cttcattcta atggacattt tattgtgaag 2400
aacctgttca tatcctgtgc tcaactttgt attgaattat ttttctctga ataattttta 2460
ggagttcttt tattctagac atcaatcatt tgtcagtttt atatgttgca aatatcttct 2520
agtctatctt gtgacttttc tttttacttt atggtatttt gttgaataaa gttttaatgt 2580
agtcacataa aaaaaaaaaa aaaaaaaaaa aaa 2613

```

<210> 9

<211> 1101

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (730)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (983)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1055)
 <223> n equals a,t,g, or c

<400> 9
 gtcggcacgc ccttcgggac gagctggagg cagagcgtga gtacaaagtg atcggcctcg 60
 gccgcacgca gtagccccc tactccccgg ccaagtcagg gcctccctct tcccgaggag 120
 tcgcaaccac gggtagctcg tgtaggtaac ggcaggtcca ggctccgca tgagcgaggg 180
 cccccgcgc gaccttgaat ggcccgggcg cgcgcggtcg tgtgggagtt gtagtcctcc 240
 gtccccgtcc gcgcgggactc cgtttcccggt ggtgccccgg gcggcccgct tccggcgag 300
 ttagttaoga gtcgggcgcac gcggcctcgg tccggttgac tttgcggacc atggaggggcg 360
 gcttcggctc cgatttcggg ggctccggca gcgggaagct ggaccaggg ctcataatgg 420
 agcaggtgaa agtgcagatc gccgtggcca acgcgcagga gctgctgcag aggatgacgg 480
 acaagtgttt ccggaagtgt atagggaac ctgggggctc cctggacaac tccgagcaga 540
 agtgcacgc catgtgcacg gaccgctaca tggacgcctg gaacaccgtg tctcgcgcct 600
 acaactcgcg gctgcagcgg gaacgagcca acatgtgacc ggcgagcgcg ggccacccca 660
 ccctgttcat ttccataaac gtgctttgag aggcggggctc cgcatgtacg tactgcctgc 720
 ccggggcttn aggagggtgg caccggtgct gggacacacg ggactgtgtc ctgccacccc 780
 cccgcctcgc cccctgccag ccagtgcagy ttggatctcg ggggtgtggg gccctgtgcc 840
 ttctgaagt gctggcagcc agtggcacct ccttcaggcm tttgggkat tcccctagt 900
 tgcccaagtc agcctcatat tctgggcgga cagcttgtct ggacttcgga gttgggggtg 960
 gtcagacacc acaggagctg tcnacctctg cggatgggca aataaattgg tggaggacgg 1020
 agaraaacct ctttatttcc ctctgaggg gtctntggga agaggtgacg cgtgtccctg 1080
 gaaccccgac tcggagggtc t 1101

<210> 10
 <211> 1373
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1364)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1373)
 <223> n equals a,t,g, or c

<400> 10
 ggattcccg gtcgaccac gcgtccgagc catcattgcc aagaccttca agggccgagg 60

```

gatcacgggg gtagaagata aggagtcttg gcatgggaag cccctcccca aaaacatggc 120
tgagcagatc atccaggaga tctacagcca gatccagagc aaaaagaaga tcctggcaac 180
ccctccacag gaggacgcac cctcagtgga cattgccaac atccgcatgc ccagcctgcc 240
cagctacaaa gttggggaca agatagccac ccgcaaggcc tacgggcagg cactggccaa 300
gctgggccat gccagtgacc gcatcatcgc cctggatggg gacacaaaaa attccacctt 360
ctcggagatc ttcaaaaagg agcaccggga ccgcttcacg gactgctaca ttgctgagca 420
gaacatggtg agcatcgcgg tgggctgtgc caccgcaac aggacggtgc cttctgcag 480
cacttttgca gccttcttca cgcgggcctt tgaccagatt cgcattggccg ccattctcga 540
gagcaacatc aacctctgcg gctcccactg cggcgcttcc atcggggaag acggggccctc 600
ccagatggcc ctagaagatc tggctatggt tcggtcagtc ccacatcaa ctgtctttta 660
cccaagtgat ggcgttgcta cagagaaggc agtggaacta gccgccaata caaaggggat 720
ctgcttcacg cggaccagcc gccagaaaa tgccatcatc tataacaaca atgaggactt 780
ccaggtcggg caagccaagg tggctcctgaa gagcaaggat gaccaggtga ccgttatcgg 840
ggctgggggtg accctgcacg aggccttggc cgctgccgaa ctgctgaaga aagaaaagat 900
caacatccgc gtgctggacc ccttcacat caagccctg gacagaaaac tcattctcga 960
cagcgctcgt gccaccaagg gcaggatcct caccgtggag gaccattatt atgaagggtg 1020
cattggtgag gctgtgtcca gtgcagtagt gggcgagcct ggcatcactg tcaccacct 1080
ggcagttaac cgggtacca gaagtgggaa gccggctgag ctgctgaaga tgtttggtat 1140
cgacagggat gccattgcac aagctgtgag gggcctcatc accaaggcct agggcggtta 1200
tgaagtgtgg ggcgggggtc tatacattcc tgagattctg ggaaagggtg tcaaagatgt 1260
actgagagga ggggtaaata tatgttttga gaaaaatgaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaanaaaaaa aan 1373

```

<210> 11

<211> 3804

<212> DNA

<213> Homo sapiens

<400> 11

```

tcgaccacag cgtccgcaaa gctgaagtcg gctaggtttg caaagctgtg ggctgagcac 60
tcaggcaatc aactctcag aaactgcggc ggctctggac tgcagcctcc caaggctcca 120
tgccagacaa agcatgcgtg tcacacttgc tacaatagcc tggatgggtt cttttgtctc 180
caattattca cacacagcaa atattttgcc agatatcgaa aatgaagatt tcatcaaaga 240
ctgcgttcga atccataaca agttccgac agaggtgaaa ccaacagcca gtgatatgct 300
atacatgact tgggaccag cactagccca aattgcaaaa gcatgggcca gcaattgcc 360
gttttcacat aatacacggc tgaagccacc ccacaagctg caccctaaact tcacttcaact 420
gggagagaac atctggactg ggtctgtgcc cattttttct gtgtcttccg ccattcaciaa 480
ctggtatgac gaaatccagg actatgactt caagactcgg atatgcaaaa aagtctgtgg 540
ccactacact cagggtgttt gggcagatag ttacaaagtt ggctgcgcag ttcaattttg 600
ccctaaagtt tctggctttg acgctctttc caatggagca cattttatat gcaactacgg 660
accaggaggg aattacccaa cttggccata taagagagga gccacckca gtgcctggcc 720
caataatgac aagtgttttg acaatctctg tgtaaccga cagcgagacc aagtcaaagc 780
ttactactct gttgtatata caggctggcc catatatcca cgtaacagat acacttctct 840
ctttctcatt gttaattcag taattctaata actgtctgtt ataattacca ttttggtaca 900
gcacaagtac cctaatttag ttcttttggc ctaatacaat tcaggaaaaga aaaaacccaa 960
aaaccaacct cattcacata tggctttttt tttaaccaat aacaattagg tgtacttcta 1020
ttttaaaaca tttcagaaaa aaatatatgt tatagcaata ctcttactca aaagaagaaa 1080
tttcttaact ctatcagata aactcatctt tagtataaat aagcattatt tgcagggttg 1140
cacagggtga ctttttagtaa gtaacctaac ccatgtttca gcttctaaat ctgcaaaatg 1200
agcarggtac agtagcacat ttttaggtga ttcttagtaa ctccagtagc cttcattagt 1260
taaaaacatt attatttttt gcatgctgct tcgactctaa atatctggtt ttccctgtct 1320

```

```

ttttggttta ctacttcccc agattcagaa cagaggagta actaggggat ctgatttttag 1380
aggccttaat tttctgttca tggactgtta aaagtaaaac caaactttca aaagggataa 1440
acctaaatat ttacttggtta tcattagaga gggaacatca aatgctggga catcattact 1500
aaccaatagc atcagacact ggatttaatg gataatcaca atggctcgtaa tgtatacaaa 1560
gacatatata ccackttcta gtataaaattt ttcaaaaaat acaataataa tataatttat 1620
aaagaacact cttctatgaa caaccaccac caccaaaaaa gaaaaagccc tcagaaaatt 1680
tctcaciaat aaggcaacta atgcctgata tctcaaaatc ctttacaaaa ggagatagtt 1740
ctagtcaagg agttttgggt atgttacttt tttttcttct ttttcttttc atctgcctcc 1800
atcttaagtg caatttcttc agctgtaaga gctcccagtt tcttattctt tgctttctta 1860
accttttctt tgatgctggc cacatcaatt ttagtttcag tagaagctag acaaattaaa 1920
agcacaacac atgtaatact ttagatttta ccaagtaaaa caaagaatat atgtttaaca 1980
agaatatata gttaaggca gttaacttca gattattctt ataattgaat aattgaaagr 2040
tgatcacagt ataaaatata aaaacacttg cctaaagcag ttagaaattt cttcagatta 2100
agataaaaac aatcataaaa tactttatat attagtacaa gtatacataa aaatggcmta 2160
aatggcataa ttgaaccaat tactggattc aactatatta agactatttc cttaaatcct 2220
acttcagact aaattatttt acctacattc ttttccatat tttggaactt ctgagtcatt 2280
attttccayc ttgcacatta aaataattta aaattacatg tatcccttct caataagttt 2340
aatcagctaa ccctaagcta gaggtcaaaa tctacttctt ctaatatcaa aacgaaaatt 2400
taaagttttc caaatattaa ttcaatatta attgaatatt caatgaattc atttaatggt 2460
agattaattc attgaatatt aattcratga atgactaatt aatagtattt taacaagatt 2520
ttggtatatt taacaacatt ttggtataaa agacaataat ttgagagtgt gtggaagtcc 2580
ccctaataka agccaactat ctaatcaatg ccaaaagtgt gaacaaaata gagaaaggaa 2640
gcagtgaaaa agaatgcaac tttttcttac cattcaaagt acaggatcac agcataaaag 2700
aatcataaga taaaacatca aactaccag caacctgaga agcacagagt gttaaagcct 2760
ccaccgtgtg gagaaactaa attagggtaa ctagctattg agtatattga gtaccttcaa 2820
agcactcaac tgacaggttt tacagactgg aaattataat acttatgaca tttctacctt 2880
ttatataacc aataatctac catagaatgt agtattytta aagctattaa caagcaatat 2940
attaaaataa taatgtatta tatctgtttc tgacccagtc tatgtacaat attgctggtg 3000
agccctctcc cttcagtgtg tctactgttg actttggagg gttacttttag gaagaggata 3060
agtgttacca caggggaaaa aaatgcagaa gaggatgcat cagaagaaat ggcatgacaa 3120
tgttttctct tagtgtcttt taaatactag gttagtgcga aagtgatttc tgccatttaa 3180
aaaccacaat cactttcgca ctaatagctc ctgaataaga cctgtcagca tccttttagtc 3240
taagggtgat agaaatccat gttaccgata tagaagccaa actctaagcc aagatcacat 3300
aaagagaaga aaaagtacaa cttctgataa ttctcttttg agaggcatga cagcagagct 3360
cagggatctt cttgcatttc tacagaagat gcactggctg ccctggggtt gtatctttca 3420
caacaaagag tcttttccaa gcacagacca gaggtcagga gaggactgtc aatccagttt 3480
gcactgaaat aggcattagc tgcctctaaa ttataaatta tctcagccat cccttgctct 3540
taggrttagt aattaatgaa atgctaagag aactgatgaa aagatacaac tgtttcttaa 3600
aaagattcag acaaatttat tatgggttta cttttcctaa ttaataaaga cttttacatc 3660
atagaaagca ttaccttctt taggtttcac aattggtttt tccttaggtg gaataaatgc 3720
tttgtttctt tcctcttgct tcttactgat ggcttctgct tgttttagcct acattaataa 3780
ataaaaaata tatcagttaa atgt 3804

```

<210> 12

<211> 2157

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (806)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (846)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1517)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2110)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2116)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2137)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2150)

<223> n equals a,t,g, or c

<400> 12

```

gcgcacgggt cactcccgct gtatatataag gcgcccggcga kcgcgggcctg aggctgctcc 60
cggacaaggg caacgagcgt ttcgtttgga cttctcgact tgagtggccg cctccttcgc 120
cgccgcctct gcagtcctca gcgcagtcct tccacaggag ccagcatact tcctgaacat 180
ggagagtgtt gttcgccgct gccatttctt atcccagagtc ccccaggcct ttctgcagaa 240
agcaggcaaa tctctgttgt tctatgcccc aaactgcccc aagatgatgg aagttggggc 300
caagccagcc cctcgggcat tgtccactgc agcagtacac taccaacaga tcaaagaaac 360
ccctccggcc agtgagaaaag acaaaaactgc taaggccaag gtccaacaga ctctgatgg 420
atcccagcag agtccagatg gcacacagct tccgtctgga ccccccttgc ctgccacaag 480
ccagggcact gcaagcaaat gccctttcct ggcagcacag atgaatcaga gaggcagcag 540
tgtcttctgc aaagccagtc ttgagcttca ggaggatgtg caggaaatga atgccgtgag 600
gaaagagggt gctgaaacct cagcaggccc cagtgtgggt agtgtgaaaa ccgatggagg 660
ggatcccagt ggactgctga agaacttcca ggacatyatg caaaagcaaa gaccagaaag 720
agtgctctcat cttcttcaag ataacttgcg aaaatctgtt tccacttttc agtatgatcg 780
tttctttgag aaaaaaattg atgagnaaaa agaattgacca cacctatcga gtttttaaaa 840
ctgtgnaacc ggcgagcaca catcttcccc atggcagatg actattcaga ctccctcatc 900
accaaaaagc aagtgtcagt ctggtgcagt aatgactacc taggaatgag tcgccaccca 960
cgggtgtgtg gggcagttat ggacactttg aaacaacatg gtgctggggc aggtggtact 1020
agaaatatat ctggaactag taaattccat gtggacttag agcgggagct ggcagacctc 1080

```

```

catgggaaag atgccgcact cttgttttcc tctgtctttg tggccaatga ctcaaccctc 1140
ttcaccttg ctaagatgat gccaggctgt gagatttact ctgattctgg gaaccatgcc 1200
tccatgatcc aagggattcg aaacagccga gtgccaaagt acatcttccg ccacaatgat 1260
gtcagccacc tcagagaact gctgcaaaga tctgaccctt cagtcccaa gattgtggca 1320
tttgaaactg tccattcaat ggatggggcg gtgtgcccac tggagagct gtgtgatgtg 1380
gcccattgag ttggagcaat caccttcgtg gatgaggtcc acgcaggggg ctttatgggg 1440
ctcgaggcgg agggattggg gatcgggatg gagtcatgcc aaaaatggac atcatttctg 1500
gaacacttg caaagccttt ggttgtkttg gaggtacat cgccagcacg agttctctga 1560
ttgacaccgt acggtcctat gctgctggct tcatcttcac cacctctctg ccacccatgc 1620
tgctggctgg agccctggag tctgtgcgga tctgaagag cgctgaggga cgggtgcttc 1680
gccgccagca ccagcgcaac gtcaaaactca tgagacagat gctaattgat gccggcctcc 1740
ctgttgtcca ctgccccagc cacatcatcc ctgtgcgggt tgcagatgct gctaaaaaca 1800
cagaagtctg tratgaacta atgagcagac ataacatcta cgtgcaagca atcaattacc 1860
ctacggtgcc ccggggagaa gagctcctac ggattgcccc caccctcac cacacacccc 1920
agatgatgaa ctacttcctt gagaatctgc tagtcacatg gaagcaagtg gggctgggaa 1980
ctgaagcctc attccttcag ctggagtggc aatttcttgc arggagggcc aytgcatttg 2040
aagtgatgag tgaaagagag aagtyctatt tttcttcagg gttttgaggc aagtttgggt 2100
attctggttn agggcntgag gcattggacc ttcattnttt ttcaatttan accccag 2157

```

<210> 13

<211> 1117

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1102)

<223> n equals a,t,g, or c

<400> 13

```

ggcagagcct ggactcccgt gagctggaag gaacagattt aatatctagg ggctgggtat 60
ccccacatca ctcatattgg ggtcaaggg acccgggcaa tatagtattc tgctcagtgt 120
ctggagatca tctaccagg ctggggcttc tgggacaggc gaggaccac ggaccctgga 180
agagctggtc caggggactg aactcccggc atctttacag agcagagcat gatcacattc 240
ctgccgctgc tgctggggct cagcctgggc tgcacaggag caggtggctt cgtggcccat 300
gtgaaagca cctgtctgtt ggatgatgct gggactccaa aggatttcac atactgcac 360
tccttcaaca aggatctgct gacctgctgg gatccagagg agaataagat ggccccttgc 420
gaatttgggg tgctgaatag cttggcgaat gtccctctcac agcacctcaa ccaaaaagac 480
accctgatgc agcgcttgcg caatgggctt cagaattgtg ccacacacac ccagcccttc 540
tggggatcac tgaccaacag gacacggcca ccatctgtgc aagtagccaa aaccactcct 600
tttaacacga gggagcctgt gatgctggcc tgctatgtgt ggggcttcta tccagcagaa 660
gtgactatca cgtggaggaa gaacgggaag cttgtcatgc ctacagcag tgcgcacaag 720
actgcccagc ccaatggaga ctggacatac cagaccctct cccatttagc cttaaccccc 780
tcttacgggg acacttacac ctgkttggtg gagcacattg gggctcctga gcccatcctt 840
cgggactgga cacctgggct gtccccatg cagaccctga aggtttctgt gtctgcagt 900
actctgggcc tgggcctcat catcttctct cttggtgtga tcagctggcg gagagctggc 960
cactctagtt acactcctct tcctgggtcc aattattcag aaggatggca catttcctag 1020
aggcagaatc tacaacttcc actccaagtg agaaggagrt tcaaactcaa tgrtgstacc 1080
awgcctctcc aacatcttca ancccctgac attatatt 1117

```

<210> 14

<211> 885
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (869)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (884)
 <223> n equals a,t,g, or c

<400> 14
 gtgggtggctc gtttcatccg catctaccca ctcacctgga atggcagcct gtgcatgcgc 60
 ctggagggtgc tgggggtgctc tgtggccctt gtctacagct actacgcaca gaatgagggtg 120
 gtggccaccg atgacctgga tttccggcac cacagctaca aggacatgcg ccagctcatg 180
 aaggtggtga acgaggagtg cccaccatc acccgactt acagcctggg caagagctca 240
 cgaggcctca agatctatgc catggagatc tcagacaacc ctggggagca tgaactgggg 300
 gagcccgagt tccgctacac tgctgggac ccatggcaac aggtgctggg ccgagagctg 360
 ttgctgctgc tcatgcagta cctgtgccga gactaccgc atgggaaccc acgtgtgcgc 420
 agctggtgca ggacacacgc atccacctgg tgccctcact gaaccctgat ggctacgagg 480
 tggcagcgca gatgggctca gagtttggga actgggcgct gggactgtgg actgaggagg 540
 gctttgacat ctttgaagat ttcccgatc tcaactctgt gctctgggga gctgaggaga 600
 ggaaatgggt cccctaccg gtccccaaca ataacttgcc catccctgaa cgctaccttt 660
 cgccagatgc cacggtatcc acggagggtcc gggccatcat tgcctggatg gagaagaacc 720
 ccttcgtgct gggagcaa atctgaacggcg gcgagcggct agtatcctac ccctacgata 780
 tggcccgcac gccttaccga ggagcagctg ctggccgcac catggcagca rcccgggggg 840
 aggatgagga cgaggtytcc raggcccgag agattccaga ccang 885

<210> 15
 <211> 1024
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (938)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1005)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1012)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1019)
 <223> n equals a,t,g, or c

<400> 15
 cttgcctttc ccagaaggct gtgcgtgctc ctgcgttyct ccgcggtcctt ccgagcgggc 60
 gcgtgaactg cttcctgcag gctggccatg gcgcttcacg ttcccaaggc tccgggcttt 120
 gccagatgct caaggaggga gcgaaacact tttcaggatt agaagaggct gtgtatagaa 180
 acatacaagc ttgcaaggag cttgcccaaa cactcgtac agcatatgga ccaaattggaa 240
 tgaacaaaat gggtatcaac cacttggaaga agttgtttgt gacaaacgat gcagcaacta 300
 ttttaagaga actagaagta cagcatcctg ctgcaaaaat gattgtaatg gcttctcata 360
 tgcaagagca agaagttgga gatggcacaa actttgttct ggtatttgct ggagctctcc 420
 tggaattagc tgaagaactt ctgaggattg gcctgtcagt ttcagaggtc atagaagggt 480
 atgaaatagc ctgcagaaaa gctcatgaga ttcttcctaa tttggtatgt tgttctgcaa 540
 aaaaccttcg agatattgat gaagtctcat ctctacttcg tacctccata atgagtaaac 600
 aatatggtaa tgaagtattt ctggccaagc ttattgctca ggcatgcgta tctatttttc 660
 ctgattccgg ccatttcaat gttgataaca tcagagtttg taaaattctg ggctctggta 720
 tcagttcctc ttcagttattg catggcatgg tttttaagaa ggaaaccgaa gtgatgtaac 780
 atctgtcaaa gatgcaaaaa tagcagtgtg ctcttgctcct tttgatggca tgataacaga 840
 aactaaggga acagtgttga taaagactgc tgaagrattg atgaatttta gtaagggagr 900
 agaaacctca tggrtgcaca agtcaaagct attgctgnta ctggtgcaat gtcgagtaca 960
 ggtggcaagt ggcagacatg gtctcatatg caataaatta attcntgtag gnggtaacnc 1020
 aaat 1024

<210> 16
 <211> 545
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (45)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (403)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (476)
 <223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (507)

<223> n equals a,t,g, or c

<400> 16

```

cccgaactcac tccccccccc ctccccccgc ctgccggccn ccggnccgga attccccgggt 60
cgacccacgc gtccggagag gagccccagc cttgggattc ccaagtgttt tcattcagtg 120
atcaggactg aacacagagg actcaccatg gagtttgggc tgagctggat ttcccttgct 180
gctattttta aaggtgtcca gtgtgaggtg cagctgggtg agtctggggg aggcttggtg 240
aagcctgggg ggtcccttag actctcctgt gcagcctctg gattcacttt cagtaacgcc 300
tggaatgagct ggggccgcca ggctccaggg aaggggctgg agtgggttg ccgtattaaa 360
agcaaaactg atggtgggac aacagactac gctgcacccg tgnaaaggca gattcaccat 420
ctcaagagat gattcaaaaa acacgytgta tytgcaaatg aacagcctga aaaccngagg 480
acacagccgt gtattactgt accacangac ccctaattac tatgatagta rtgcaaaaag 540
ctttt                                           545

```

<210> 17

<211> 623

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (613)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (616)

<223> n equals a,t,g, or c

<400> 17

```

cggattcgcg gccgntcgac gccgagctgg gtgcgggtgag gcgcgcagat caccgcgggt 60
cctgggcagg gcacggaagg ctaagcaagg ctgacctgct gcagctcccg cctcgtgcgc 120
tcgccccacc cggccgccgc ccgagcgctc gagaaagtcc tctcgggaga agcagcgcc 180
gttccccggg cagatccagg ttcaggtcct ggctataagt caccatggca cagcaagctg 240
ccgataagta tctctatgtg gataaaaact tcatcaacaa tccgctggcc caggccgact 300
gggctgccaa gaagctggta tgggtgcctt ccgacaagag tggctttgag ccagccagcc 360
tcaaggagga rgtgggcgaa gaggccatcg tggagctggt ggagaatggg aagaagggtg 420
aggtgaacaa ggatgacatc cagaagatga acccgcccaa gttctccaag gtggaggaca 480
tggcagagct cacgtgcctc aacgaagcct cggtgttgca caacctcaag gagcgttact 540
actcagggtc catctacgta agtggctgcc gtggcacccc gcaggctggg tctgagggtc 600
ccgaggtggg gngngnggcg ggt                                           623

```

<210> 18

<211> 559

<212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (371)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (531)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (544)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (547)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (556)
 <223> n equals a,t,g, or c

<400> 18
 cccacgcgctc cgcccacgcg tccggtgaga taggtaggca agtgtggaca aagataaaac 60
 tgaaaaaccca ctgcaaaggt tgaggtaaga caccataagc cgctgaacta agacaaagtc 120
 attagtaatt ttaaaatgag grtggaatt aactaacaga actgatagga agtggttaaca 180
 tacaacaggg gagtctaaga tggcttccaa ttttcaotta gaggggtaag ggtaccatta 240
 acttaagatc attaatacag raaaattaat cagatttgga gtttaccaag gtttgctttt 300
 gggttgtaaca atgatatatg ataaaattaa atgrataaat aagtgratgc actggtgaat 360
 taatgagctg ntctcattaa gaccagagta cttatttata acaaaagtaa cttttccctt 420
 tccttgggta catcaaactg tactccacag ataacagaca ccagtgagtt tttcatgggt 480
 aaaaaagccc caactttgac ctataaatgt ggaccaagaa attaaaataa nctggaacca 540
 gcgngcnacg gtattngga 559

<210> 19
 <211> 1355
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (55)
 <223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (1045)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1355)
 <223> n equals a,t,g, or c

<400> 19
 cagcccatgg tgtcacctcg gccccggaca acaggcccgc cttgggctcc accgnccctc 60
 cagtccacaa tgtcacctcg gcctcaggct ctgcatcagg ctcagcttct actctgggtgc 120
 acaacggcac ctctgccagg gctaccacaa ccccagccag caagagcact ccattctcaa 180
 ttcccagcca ccactctgat actcctacca cccttgccag ccatagcacc aagactgatg 240
 ccagtagcac tcaccatagc acggtacctc ctctcacctc ctccaatcac agcacttctc 300
 cccagttgtc tactgggggtc tctttctttt tcctgtcttt tcacatttca aacctccagt 360
 ttaattcctc tctggaagat cccagcaccg actactacca agagctgcag agagacattt 420
 ctgaaatgtt tttgcagatt tataaacaag ggggttttct gggcctctcc aatattaagt 480
 tcaggccagg atctgtgggtg gtacaattga ctctggcctt ccgagaaggt accatcaatg 540
 tccacgacgt ggagacacag ttcaatcagt ataaaacgga agcagcctct cgatataacc 600
 tgacgatctc agacgtcagc gtgagtgatg tgccatttcc tttctctgcc cagtctgggg 660
 ctgggggtgcc aggctggggc atcgcgctgc tgggtctggt ctgtgttctg gttgcgctgg 720
 ccattgtcta tctcattgcc ttggctgtct gtcagtgccg ccgaaagaac tacgggcagc 780
 tggacatctt tccagccccg gatacctacc atcctatgag cgagtacccc acctaccaca 840
 cccatgggag ctatgtgccc cctagcagta ccgatcgtag cccctatgag aagggttctg 900
 caggtaatgg tggcagcagc ctctcttaca caaaccagc agtggcagcc acttctgcca 960
 acttgtaggg gcacgtcgcc cgctgagctg agtggccagc cagtgccatt ccactccact 1020
 caggttcttc agggccagag ccctngcacc ctggttgggc tggtagagctg ggagttcagg 1080
 tgggctgctc acagctcctt cagaggcccc accaatttct cggacacttc tcagtgtgtg 1140
 gaagctcatg tgggcccctga ggctcatgcc tgggaagtgt tgtgggtgggg gctcccagga 1200
 ggactggccc agagagccct gagatagcgg ggatcctgaa ctggactgaa taaaacgtgg 1260
 tctcccactg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaan 1355

<210> 20
 <211> 1280
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1043)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1162)
 <223> n equals a,t,g, or c

<400> 20
 aattcggcac gagccttacc caggctctgc tcggggctgg ggagaacacc aaaacaaacc 60

```

tggagagcat cctctcttac cccaaggact tcacctgtgt ccaccaggcc ctgaagggct 120
tcacgaccaa aggtgtcacc tcagtctctc agatcttcca cagcccagac ctggccataa 180
gggacacctt tgtgaatgcc tctcggaccc tgtacagcag cagccccaga gtcctaagca 240
acaacagtga cgccaacttg gagctcatca acacctgggt ggccaagaac accaacaaca 300
agatcagccg gctgctagac agtctgccct ccgatacccc ccttgtctct ctcaatgcta 360
tctacctgag tgccaagtgg aagacaacat ttgatcccaa gaaaaccaga atggaaccct 420
ttcacttcaa aaactcagtt ataaaagtgc ccatgatgaa tagcaagaag taccctgtgg 480
cccatttcat tgaccaaact ttgaaagcca aggtggggca gctgcagctc tcccacaatc 540
tgagtttggg gatcctggta cccagaacc tgaaacatcg tcttgaagac atggaacagg 600
ctctcagccc ttctgttttc aaggccatca tggagaaact ggagatgtcc aagttccagc 660
ccactctcct aacactaccc cgcacaaag tgacgaccag ccaggatatg ctctcaatca 720
tggagaaatt ggaattcttc gatttttctt atgaccttaa cctgtgtggg ctgacagagg 780
accagatctt tcaggtttct gcgatgcagc accagacagt gctggaactg acagagactg 840
gggtggaggc gggtgcagcc tccgccatct ctgtggcccg caccctgctg gtctttgaag 900
tgacgagccc cttcctcttc rtgctctggg accagcagca caagttccct gtcttcatgg 960
ggcgagtata tgaccccagg gcctgagacc tgcaggatca ggtagggcg agcgctacct 1020
ctccagcctc agctctcagt ttnagccctg ctgctgcctg cctggacttg gccctgcca 1080
cctcctgcct caggtgtccg ctatccacca aaagggctcc ctgagggctt gggcaaggga 1140
cctgcttota ttagcccttc tnccatgccc tgccatgctc tccaaaccac tttttgcagc 1200
tttctctagt tcaagttcac cagactctat aaataaaacc tgacagacca tgaaaaaaaa 1260
aaaaaaaaac tcaagactag                                     1280

```

<210> 21

<211> 1191

<212> DNA

<213> Homo sapiens

<400> 21

```

gcaattcctt ctggcttcct gtgacctcac gcaagaaaag gttgtgtact aaatgaatct 60
gctttaactt gctctccttc ctcggggatc acaccttttt aagaaagcct gtcccttacc 120
ttgaagcaca aacatattct catTTTTtatt ctccaataac cttgaagggt ttcttctgca 180
catgtatttg tttgatctgc cttttgtgcg tgggggtggga gttaggtagg aatcttaaag 240
tgagagacca gtttcttccc aaattactga cctaaccat ccttaacccc cagttcaagg 300
ccacctttgt gatagtgaag cttccacatg ctactcagc cccttctgct ctctcttctt 360
ctctactgtg catgtcggct tgtacttttg ccagtttctc taaagacaca accagagtgg 420
gggtggctgtg tgtgcacaac ttcaacttta catgtggggc tgagtcccta tgttgatat 480
ccttgtgcaa aagcacataa tgtaattgc tatagctttt aaaaaaataa ttaatagttt 540
ttcataatca aattttcttg cttttttgtt ttttcaaaaa agcatacttt tattgaagaa 600
taaaccocct atatatgtac acttatttat aactatgaac gcctgaacta ggatagaaat 660
gcattgtgta tattacaaaa cataacaaaa ataatagggg tagggagggt cagatgttgg 720
tcaaaggata taaacctgca gttctatgat gaataagttc tggacatctg gaatacagca 780
tggtgactat acttagtaat actatattgt acacttgaag cttactgaaa gagtaaactt 840
caagtgttct caccacacaa acccaaaggt aactatgttc tcaccacaca aaccacaagg 900
gaactatgta ttaattagct tgattgtggg aaccatttca caatgtatac atttgccaaa 960
acattatgtt gtatacctgg aatatatac tttatttatc aattatacct caataaagct 1020
gaaagagggg attactaatt cccacaaaat acagatttaa caaaaacttt tattcaacaa 1080
acagtgtctat gaagttgtaa attggaaaca aaagaaataa aatttcatcc acagtcttct 1140
catcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaactcgtag g 1191

```

<210> 22

<211> 853

<212> DNA

<213> Homo sapiens

<400> 22

```

cttacacagc agcaacagcc tgctacaggg ccacagccat ctctgggagt tagttttgga 60
acgccattcg gctcaggtat tggcactggc ttgcaatcaa gtggccttagg ttcttcaaac 120
cttggaggat ttggaactag ctctgggttt ggatgcagca ccacaggggc ctccacattt 180
ggattttgga caacaaataa accctcagga agtcttagtg caggctttgg cagctcaagt 240
acatctgggt ttaacttcag caatcctggc atcacggcat cagctgggtt gacttttggg 300
gtgtccaatc ctgcctctgc aggttttgga acaggaggac aactccttca gttgaagaaa 360
cctccagctg graacaaaag aggaaaaaga taaacatggg ttgatgtgtt gagagaatcc 420
atagcagcac cgttcattct atgagtctat ttttctaata atgcagtaat taaattgcat 480
cccaggagat ttataaagtt ttgatatttt tccctactct ggratttgaa ctttcttcat 540
gtttgccata ctgaacawct ttttcttgtt ggaattttaa gtccagctgt gttttctttt 600
taatttgatt ctcagtgtaa gaaatgttct gattacatca ctgattggta atgggttaga 660
accattaacc taaaacttac tatttaacct agtgtttttg ttgatgaggt ttacattatg 720
tgaatacatg cacatttggt tcttatacag gtgggtgtgaa ctctagggcc tatactagaa 780
tcaatttggt ccttggttaa ggccttttga attatactgc agggcatctt gtgaatatgt 840
atgtaaatat ata 853

```

<210> 23

<211> 474

<212> DNA

<213> Homo sapiens

<400> 23

```

ggcacgagct cgtccggccc gtgggtctga cggcttgagt agcgctaggg agaatccctg 60
caggtaatat ttgacttttg cttcatatta atctgagtggt aaaataaaaag ggccctcttc 120
tcctctcgct tccctgccgg gcaggcgcca tggcggaagc tcggcgacgg gcgcctgcgg 180
agaggcgatg gcagcgggcg aaggctcctc gggcccggcg ggcttgactc tgggcccggag 240
cttctcgaac taccggccct tcgagcccca ggcgttgggc ctgagcccga gctggcggt 300
gacgggcttc tccggcatga agggctgagg ctgcaagggt ccgcagaggg gctgctcaa 360
ctcctggcgg gactgamcgg gccggacktk cggccccgct gggccggggc ctkgtkggk 420
gccargaara agcgtcccag gaagccggcc tgccggcaag agcggggccc agcc 474

```

<210> 24

<211> 2280

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<400> 24

```

ctctccccct ccnaccctc ccgctccaag attcgccgcc gccgcgcgcg cagccgcagg 60
agtagccgcc gccggagccg cgcgcarcca tggccgagaa cccagccttg gagaaccacc 120
gcatcaagag cttcaagaac aagggccgcg atgtggaaac aatgcgaaga catagaaatg 180
aagtgcaggt ggaactgcgg aagaacaaaa gagatgaaca cttattgaaa aagagaaatg 240
ttccccaaga agaaagtcta gaagattcag atgttgatgc tgatttttaa gcacaaaatg 300

```

```

taaccctaga agctatatattg cagaatgccca caagtgataa cccagtgggtc caattgagtg 360
ctgtccaggc agcaagaaaaa ctgttatcca gtgacagaaa tccaccgatt gatgacttaa 420
taaaatctgg gattttacca attctagtca aatgtctaga aagggatgat aatccttcat 480
tacagtttga agctgcttgg gcattaacta acatagcatc aggracttct gcacagactc 540
aagctgttgt gcagtctaata gcagtacctc tttttctgag acttcttcgt tcaccacatc 600
agaatgtttg tgaacaagca gtatgggctt tgggaaacat tataggtgat ggtcctcaat 660
gtagagatta tgtcatatca ctgggagttg tcaaacctct tctgtccttc atcagtcctt 720
ccatcccat cacttccctt cggaacgtca catgggtcat tgtcaatctc tgcaggaata 780
aggatcccc accgcctatg gagacagttc aggagatttt gccagcttta tgtgtcctca 840
tataccatac agatataaac attctttag acactgtttg ggctctgtca tacttgacag 900
atggaggtaa tgaacagata cagatggtta ttgattcagg agttgtgccc tttcttgtgc 960
cccttctgag ccatcaggaa gtcaaagttc aaacagcagc cctcagagca gttggcaaca 1020
tagtgactgg caccgacgag cagaccagg ttgttctcaa ttgtgatgtc ctgtcacact 1080
tccaaatct cttatcacac caaaagaga agataaataa ggaagcagtg tggttccttt 1140
ccaacataac agcaggcaac cagcaacaag ttcaagctgt aatagatgct ggattaattc 1200
ctatgataat tcatcagctt gctaaggggg actttggaac aaaaaagaa gctgcttggg 1260
caatcagcaa cttaacaata agtggcagaa aagatcaggt tgagtacctt gtacagcaga 1320
atgtaatacc accgttctgt aatttactgt cagtgaagaa ttctcaagtg gttcaggtgg 1380
ttctagatgg tctaaaaaac attctgataa tggccggtga tgaagcaagc acaatagctg 1440
aaataataga ggaatgtgga ggtttgaga aaattgaagt tttacagcaa catgaaaatg 1500
aagacatata taaattagca tttgaaatca tagatcagta tttctctggt gatgatattg 1560
atgaagatcc ctgcctcatt cctgaagcaa cacaaggagg tacctacaat tttratccaa 1620
cagccaacct tcaaacaaaa gaatttaatt tttaaattca gttgagtgtc gcatctttcc 1680
cacattcaat atgaagcacc accagatggc taccaaatga taagaacaac agcaacmaaa 1740
ggctccaaaa cacacatgcc tctttgtttt gatgcttcta aagcaagcca tgtctcagtc 1800
actttgcagt tgccaaaagt cactatcaca tggactgtaa atgcatatgc atgatttcct 1860
aaactgtttt agaactctcc ttaacaatct caactaccct atttttccct gttccctggt 1920
gccacaggct gacaactgca gtctccagtt tagaataaat attccatagt ggtgacatgt 1980
cagctgcccc ctgatactcc tttggaaaat ggtgcgctgt ggatcaagac actttggtat 2040
gatgcatata caagttggaa gactaaagag gtgcagtggt atctgagcct ccatcattgt 2100
cctccacaaa catattttca tattctttat gtggaagaat agatttttaa gtacaagcca 2160
aatgattttc attggtggaa ctgacacaaa aaaagtaact taaaaacaag aaacttggtt 2220
attgaataaa cagataagtt taaaaaaaaa aaaaactact tcatctacca gtaattgatg 2280

```

<210> 25

<211> 1061

<212> DNA

<213> Homo sapiens

<400> 25

```

cgacccggcc cagtgcgcag gcgcgggaaa gttgaactaa taaagtttgt acgagttcag 60
tgaggagagc cgcaagttga gtggaggagg cggcggtggg gccccggacc aggtgcctcc 120
atggcaggct ctgaagagct ggggctccgg gaagacacgc tgagggctct agctgccttc 180
cttaggcgtg gtgaggctgc cgggtctcct gttccaactc cacctagaag ccctgccccaa 240
gaagagccaa cagacttcct gagccgcctt cgaagatgtc ttccctgctc cctggggcga 300
ggagcagccc cctctgagtc ccctcggcct tgctctctgc ccatccgccc ctgctatggt 360
ttagagcctg gccagctac tccagacttc tatgcttttg tggcccagcg gctggaacag 420
ctggtccaag agcagctgaa atctccgccc agcccagaat tacagggtcc cccatcgaca 480
gagaaggaag ccatactgcg gaggtggtg gccctgctgg aggaggaggc agaagtcatt 540
aaccagaagc tggcctcgga ccccgccctg gcgacaagct ggtccgctg tcctccgact 600
ctttcgcccc cctggtggag ctgttctgta gccgggatga cagctctcgc ccaagccgag 660

```

```

catgccccgg gcccccgcct ccttccccgg agccccctggc ccgcctggcc ctagccatgg 720
agctgagccg gcgcgtggcc gggctggggg gcaccctggc cggactcagc gtggagcacg 780
tgcacagctt cacgccctgg atccaggcca cgggggctgg gagggcatcc tggctgtttc 840
acccgtggac ttgaacttgc cattggactg agctctttct cagaagctgc tacaagatga 900
cacctcatgt ccctgccctc ttctgtgtgt tttccaagtc ttctattcc actcagggt 960
gtggggtggg ggttgcccta cctgtttttg ccaaaaataa attgtttaa acttttctta 1020
ttaaaaacgt tacaaaaaaa aaaaaaaaam aggggggccg c 1061

```

<210> 26

<211> 1572

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (28)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1491)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1527)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1555)

<223> n equals a,t,g, or c

<400> 26

```

gtttgtcagt ctggcggnng gcggcggnng tggcgcgccg gccgatccac agtgattcgg 60
ccgccgcgcc ggggggtggg ggggctgcgc gggacttttt tttttttcag actgaccgcg 120
gggcagctgc ggacatgtcg accccggccc ggaggaggct catgcgggat ttcaagcggg 180
tacaagagga cccacctgtg ggtgtcagtg gcgcaccatc tgaaaacaac atcatgcagt 240
ggaatgcagt tatatttgga ccagaaggga cactttttga agatggtact tttaaactag 300
taatagaatt ttctgaagaa tatccaaata aaccaccaac tgtagggttt ttatccaaaa 360
tgtttcatcc aaatgtgtat gctgatggta gcataatggt agatatacct cagaatcgat 420
ggagtccaac atatgatgta tcttctatct taacatcaat tcagtctctg ctggatgaac 480
cgaatcctaa cagtccagcc aatagccagg cagcacagct ttatcaggaa aacaaacgag 540
aatatgagaa aagagtttcg gccattgttg aacaaagctg gaatgattca taatagacaa 600
ctgggtctgtt aatctttttc atcattgttg tgtataattt acctctcatt agaaaggcta 660
acaaatttta agtgccacag gttttaagga ttctgcagaa aaaaaagaaa aaagtccttc 720

```

```
agtttagaac ctacaaaagc ttgtgtatct tgattaatgt acttttttatt gcatggtgtg 780
aactaagtta ttgctgcata aatttgtaat atatcctggt tgtatttttt tccaagtgtg 840
taatgttggt gtggagtttt catgacagaa tatacacatt ttgtaaatct gtactttttt 900
caaattattga atgccttatt tttgaattct ttagattttt aaattggaga aaagcactta 960
aagtttttta tatatgaata ttacatgtaa agctgtttaa atacataact tcagtgcaag 1020
agactttgtc acttatttcc ttatgtgtgt aggaggggtt aataagtctc tagctctcca 1080
tctattgata gtttcattta caatttcaaa agaacattct tatattttat caaggaagtc 1140
ttcaaatttg attctaaata gcgattataa tctccaactt tattttgaat gtacctctat 1200
tagtttcaat tgagtaattc tagacataac tggtttgact ctgtccaact ctgtatttag 1260
gccatttggt acagtttctt catgcattac ttactgttaa aactgtacct tttgcgattt 1320
cacagttggc acttctgccg tgagcagaga actgatgcga cttgttttgc tgcttggtag 1380
cacttttaaaa aattttttga ttaatgaagg aaagtaaaac cataaacatt tgccaaaaat 1440
tcatgcccca gtattaggca atggaattag gttgcattgg gtttgaggaa ngggcacatt 1500
ggggggggga atcttggggt gttaacnttt aaattatttt gggaaaattt acccntttta 1560
tggccatggc ct 1572
```

<210> 27

<211> 2005

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1976)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1977)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1978)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1979)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1986)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1988)

<223> n equals a,t,g, or c

<400> 27

```

gcgagcgcggt gggcgcgccma cgcgygcgca agcagcggggt tagtggtcgc gcgccccgacc 60
tccgcagtgcc cagccgagcc gcgacccttc cggcccgctccc caccaccacct cgcccgccatg 120
cgccctccgcc gcctagcgct gttcccgggt gtggcgctgc ttcttgccgc ggcccgccctc 180
gccgctgcct ccgacgtgct agaactcacg gacgacaact tcgagagtcg catctccgac 240
acgggctctg cgggcctcat gctcgtcgag ttcttcgcyc cctgggtgtgg aacttgcaag 300
agacttgacac ctgagtatga agctgcagct accagattaa aaggaatagt cccattagca 360
aagggttgatt gcactgccaa cactaacacc tgtaataaat atggagtcag tggatatcca 420
accctgaaga tatttagaga tggatgaaga gcagggtgctt atgatggacc taggactgct 480
gatggaattg tcagccactt gaagaagcag gcaggaccag cttcagtgcc tctcaggact 540
gaggaagaat ttaagaaatt cattagtgtat aaagatgcct ctatagtagg ttttttcgat 600
gattcattca gtgaggctca ctccgagttc ctaaaagcag ccagcaactt gagggataac 660
taccgatttg cacatacgaa tggtgagtcg ctgggtgaacg agtatgatga taatggagag 720
ggtatcatct ttttctgctc ttccatcttc actaacaagt ttgaggacaa gactgtggca 780
tatacagagc aaaaaatgac cagtggcaaa attaaaaagt ttatccagga aaacattttt 840
ggtatctgcc ctccatgac agaagacaat aaagatttga tacagggcaa ggacttactt 900
attgcttact atgatgtgga ctatgaaaag aacgctaaaag gttccaacta ctggagaaac 960
agggtaatga tgggtggcaaa gaaattcctg gatgctgggc acaaactcaa ctttgctgta 1020
gctagccgca aaaccttttag ccatgaactt tctgattttg gcttgagag cactgctgga 1080
gagattcctg ttgttgctat cagaactgct aaaggagaga agtttgtcat gcaggaggag 1140
ttctcgctg atgggaaggc tctggagagg ttcctgcagg attactttga tggcaatctg 1200
aagagatacc tgaagtctga acctatocca gagagcaatg atgggcctgt gaaggtagtg 1260
gtagcagaga attttgatga aatagtgaat aatgaaaata aagatgtgct gattgaattt 1320
tatgcccctt ggtgtggtca ytgtaagaac ctggagccca agtataaaga acttgccgag 1380
aagctcagca aagacccaaa tatcgtcata gccaaagtgg atgccacagc caatgatgtg 1440
ccttctccat atgaagtcag aggttttctt accatatact tctctccagc caacaagaag 1500
ctaaatccaa agaaatatga aggtggccgt gaattaagtg attttattag ctatctacaa 1560
agagaagcta caaaccccc tgtaattcaa gaagaaaaac ccaagaagaa gaagaaggca 1620
caggaggatc tctaaagcag tagccaaaca ccactttgta aaaggactct tccatcagag 1680
atgggaaaac cattggggag gactaggacc catatgggaa ttattacctc tcagggccga 1740
gaggacagaa tggatataat ctgaatcctg ttaaattttc tctaaactgt ttcttagctg 1800
cactgtttat ggaaatacca ggaccagttt atgtttgtgg ttttgggaaa aattattttg 1860
gttgggggaa atgttggtgg ggtgggggtt agttgggggt attttctaata tttttttgta 1920
catttggaac agtgacaata aatgagaccc ctttaaaaaa aaaaaaaaaa aaaaannnnn 1980
gggggnccncc cagtcoccat cgccc
2005

```

<210> 28

<211> 1408

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (11)

<223> n equals a,t,g, or c

<400> 28

```

cccgcagaca ngcaattttc acctgtgagg tccctggtgt ctactacttt gsataccacg 60
ttcactgcaa ggggggcaac gtgtgggttg ctctattcaa gaacaacgag cccgtgatgt 120
acacgtacga cgagtacaaa aagggtcttc tggaccaggc atctgggagt gcagtgtcgc 180
tgctcaggcc cggagaccgg tgttcctcca gatgccctca gaacaggctg caggactgta 240

```

```

tgccgggcag tatgtccact cctccttttc aggatattta ttgtatccca tgtaaaaaaca 300
aaaaaacaaa aaacaaagaa aagaaagaga ttttatagaa gaaaatgaca caccacaaaaa 360
tccaaatgaa aaacataaatt gcttcaaaac acttacacag ttggaaagtt atatgtaagt 420
gaaaatttgg accattgtgt acaataaaaa actaagatgc atgtttaata ctccacacag 480
cagcctgtaa ttgcgaatga tgggatagag ttatgtatca agtactgaca ctgggttgta 540
cccactggaa tcatatttagc tgttttatgt tatatgcttc cacagtaacc tgcttattca 600
gatcagtcaa aatatatcag tatgaaagat catagctaata gaaaggcact cactcatatt 660
gtttacttta aaatatattat aaatatgcct taaagaaata caaatgataa caattacata 720
ccgtattttac ttgcttaatt tcctctgtat ttgtgtagat actttgacat ggaatatatg 780
gtggggagac ccgtagtggt accgccccag tgggaggggg ccctgggacc ctggtaatgc 840
tttagtcaaa gggatatctc tcctgtatca gaggtgtgtg cttttagtaa caggagtcc 900
cgtcagaatt gcgtgtctgt tgtctctaaa agaattgggtg aaccaatcgg cctttgtgaa 960
tttattcagt gccttctctg taccaagcac tgggtaaggc acttttgtgg agcattagac 1020
agtaaccctc aaggagctag agaaccggat gggagacatg agcggtaatt aactcacttg 1080
ttccccagag tttctatttg ttttgatttt ctttttctgt gacttatttt cctattttct 1140
ttcctccatg taattttcac tatggcccaa ctaatatata cacctgggaa attacaagga 1200
aaaaaaattc ttctctaat aactttccaa atttgtggaa tatttatttg taatagcagt 1260
tatcagttat gcttatatag cattaaaaat tctcctcctt tgactacaca cacaaccaca 1320
gtgtggttct aatcatggag atatcagtaa tttttagtaa ctgarttttg aggacatttc 1380
tctgttttagc atgtatgcaa actggata 1408

```

<210> 29

<211> 917

<212> DNA

<213> Homo sapiens

<400> 29

```

ggcacgagcg aggggaggag ccgctggctc ccagccccgc cgcgatgagc ctcggcgcgc 60
tttgccgcct actgaagccg gcgctgctct gtggggctct ggccgcgcct ggccctggccg 120
ggaccatgtg cgcgtcccg gacgactggc gctgtgcgct ccatgcacga kttttccgc 180
aaggacatcg acgggcacat ggttaacctg gacaagtacc ggggcttcgt gtgcacgtc 240
accaacgtgg cctcccagtg aggcaagacc gaagtaaaact aactcagct cgtcgacctg 300
cacgcccgat acgctgagtg tggtttgcg atcctggcct tcccggtgaa ccagttcggg 360
aagcaggagc caggagtaga cgaagagatc aaagagttcg ccgcgggcta caacgtcaaa 420
ttcgatatgt tcagcaagat ctgcgtgaac ggggacgacg cccacccgct gtggaagtgg 480
atgaagatcc aaccaaggga caaggcatc ctgggaaatg ccatcaagtg gaacttcacc 540
aagttcctca tcgacaagaa cggctgcgtg gtgaagcgct acggacccat ggaggagccc 600
ctgggtgatag agaaggacct gcccactat ttctagctcc acaagtgtgt ggccccgccc 660
gagcccctgc ccacgcccty ggagccttcc accggcactc atgacggcct gcctgcaaac 720
ctgctggtgg ggcagacccg aaaatccagc gtgcaccccg ccggaggaag gtcccatggc 780
ctgctgggct tggctcggcg cccccacccc tggctacctt gtgggaataa acagacaaat 840
tagcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900
aaaaaaaaa aaaaaaa 917

```

<210> 30

<211> 577

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (501)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (534)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (568)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (575)
 <223> n equals a,t,g, or c

<400> 30
 aattcggcac gaggtcatct ggtggaaaag gagactttaa gattgttttag ggctgggcgg 60
 ggtgactcac atctgtaatc ccagcacttt gggaggccaa ggcaggcaga acacttgaag 120
 gagttcaaga ccagcgtggc caacgtgggtg aacctgtct ctactaaaaa tacaaaaatt 180
 gtttagctct gtttttcata atagaaatag aaaaggtaaa attgcttttc ttctgaaaag 240
 aacaagtatt gttcatccaa gaagggtttt tgtgactgaa tcagcagtg ctagccctagt 300
 catagctgtg cttcagaaac ctcagcatga ttagtgttkg agcmmaacaa ggragcaaag 360
 caaatwcwgt ttttgaaatt ctatctgttg cttgaactat tttgtaataa ttaactttg 420
 gatgttgaga aatcacaaact ttattggtac acttcattgc aacttgaaat tccatgggtc 480
 ttaaagttag attggaattc naatgggcgg ccttttaaaa gtaattccca accnttaagg 540
 ttaaaaccca ggaaattggg gccaatcnaa aaccngg 577

<210> 31
 <211> 2059
 <212> DNA
 <213> Homo sapiens

<400> 31
 tgggagtaaa aatgtgtctt cagagactgt gaacatcacc atcactcaag gtttggcagt 60
 gtcaaccatc tcatcattct ttccacctgg gtaccaagtc tctttctgct tggatgatgt 120
 actccttttt gcagtggaac caggactata tttctctgtg aagacaaaca ttcgaagctc 180
 aacaagagac tggaaggacc ataaatttaa atggagaaa gacctcaag acaaagacc 240
 cccatcccat gggggtaata agagcagtag cagcagcatc tctgaacatt tctctggatt 300
 tgcaacccca tcatcctcag gcctctctac aagcagcagg aaacatagaa ctgagagcca 360
 gatcccttat ccaactctcg acttttccct ggtctccagt ggaagggaaa agcccatgat 420
 cttcaagcag ggaagcccca gtgagtagct gcattccctg aaattgaagt ttcagrgcta 480
 cacaaacamt tttctgtccc aaccgttccc tcacagcaaa gcaacaatac aggctaggga 540
 tgaaggagga gtgcaaaara gtgtccccac cctcctgccc cccgcaccgt ttgcccaccc 600
 ttcggaagac ccagtgctgt gatgagtatg agtgtgctg caactgtgtc aatccacagt 660
 gagctgtccc cttgggtact tggcctcaac cgccaccaat gactgtgggt gtaccacaac 720
 cacctgcctt cccgacaagg tgtgtgtcca ccgaagcacc atctaccctg tgggccagtt 780
 ctgggaggag ggtgctgatg tgtgcacctg caccgacatg gaggatgccg tgatgggcct 840
 ccgcgtggcc cagtgtctcc agaagccctg tgaggacagc tgtcggtcgg gcttactta 900

```

cgttctgcat gaaggcgagt gctgtggaag gtgcctgcc tctgcctgtg aggtggtgac 960
tggctcaccg cgggggggact cccagtcttc ctggaagagt gtcgggtccc agtgggcctc 1020
cccgagaaac ccctgcctca tcaatgagtg tgtccgagtg aaggaggagg tctttataca 1080
acaaaggaac gtctcctgcc cccagctgga ggtccctgtc tgccctcgg gctttcagct 1140
gagctgtaag acctcagcgt gctgcccagg ctgtcgtgtg gagcgcattg aggcctgcat 1200
gctcaatggc actgtcattg ggcccgggaa gactgtgatg atcgatgtgt gcacgacctg 1260
ccgctgcatg gtgcagggtg gggatcatctc tggattcaag ctggagtgca ggaagaccac 1320
ctgcaacccc tgccccctgg gttacaagga agaaaataac acaggtgaat gttgtgggag 1380
atgtttgcct acggcttgca ccattcagct aagaggagga cagatcatga cactgaagcg 1440
tgatgagacg ctccaggatg gctgtgatac tcacttctgc aaggtcaatg agagaggaga 1500
gtacttctgg gagaagaggg tcacaggctg cccacccttt gatgaacaca agtgtctggc 1560
tgaggagggt aaaattatga aaattccagg cacctgctgt gacacatgtg aggagcctga 1620
gtgcaacgac atcactgcca ggctgcagta tgtcaagggt ggaagctgta agtctgaagt 1680
agagggtgat atccactact gccagggcaa atgtgccagc aaagccatgt actccattga 1740
catcaacgat gtgcaggacc agtgctcctg ctgctctccg acacggacgg agcccatgca 1800
ggtggccctg cactgcacca atggctctgt tgtgtaccat gaggttctca atgccatgga 1860
gtgcaaatgc tccccagga agtgacagaa gtgaggctgc tgcagctgca tgggtgcctg 1920
ctgctgcctg ccttgccctga tggccaggcc agagtgtgc cagtcctctg catgttctgc 1980
tcttggtgcc ttctgagccc acaataaagg ctgagctctt atcttgcaaa aaaaaaaaaa 2040
aaaaaaaaa aaaaaaaaaa

```

<210> 32

<211> 549

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (337)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (378)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (497)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (537)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (546)

<223> n equals a,t,g, or c

```

<400> 32
gcagcgaggg agctgctctg ctacgtacga aaccccgacc cagaagcagg tcgtctacga 60
atggttttagc gccaggttcc ccacgaacgt gcggtgcgtg acgggcgagg gggcgccgc 120
tctagaggat ccaagcttac gtacgcgtgc atgcgacgtc atagctcttc tatagtgtca 180
cctaaattca attcactggc cgtcgtttta caacgtcgtg actgggaaaa ccctggcggtt 240
acccaactta atcgccttgc agcacatccc cctttcgcca gctggcgtaa tagcgaagag 300
gcccgcaccg attcgcctt tcccaacagt tgcgcancgt gaatggcgaa tggggacgcg 360
ccctgtatgg gcgcgttnaa gcgcggcggg tgtggtggtt acgcgcagt gacccgctac 420
acttgccagc gccctagcgc ccgctccttt cgctttcttc ccttcctttc tcgccacgtt 480
cgccggcttt ccccttnaag ctctaaatcg gtgggctccc tttagggtgc ctatttngtg 540
ctttanggt                                     549

```

<210> 33

<211> 841

<212> DNA

<213> Homo sapiens

```

<400> 33
gctttgaacc tcaacagcca gctgaacata ccaaagaca caagccaact gaagaaacat 60
atcaccttgc tctgcgatag attatccaaa ggtggccgtc tctgcctaag taccgatgca 120
gcagccccac agaccatggg catgccaggt ggttgacta caatcccaga gtcagacctt 180
gaagaaagat cagtagaaca agactctaca gaactgttta ccaaccacag acatctcact 240
gcagagacac ccaggcctgt ttcacccctc caaggagtct cggaataatt ccaagtagag 300
ttgtttggtt gagaggaaca tccccatctc aaggccgaac ctgtgtgaac ctcatgccaa 360
gcacagatat arggctggcg caggtgcttc cyaaagctya ccttcctgga gatgacatgc 420
atagaaagag gggttgggac tttttacttc actaggagaa cttgtaacac catggggaag 480
tcagctgaaa cttgtcttgt tttgccagga aaggaagtag ttgcctttgg tcatccatct 540
gctaatagtc acagaataca gtgaaatgac atagttttgg gttagatttt ataatgcaa 600
gattcagatc caaaataatt tcatacccca ttttttcaca gaattcttat atagtaaagt 660
tatcaagttt aataaagcat ctcatgttca aataatatct tggattttat ttataattag 720
agggatttat gagtgattgc tctacattat ttcttcaaag gaaaggaaag gaattgaaga 780
ctttgctact ctctggtaag acttgaatgt gattatttta taaataaaaag aaccactatg 840
a                                             841

```

<210> 34

<211> 863

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (58)

<223> n equals a,t,g, or c

<400> 34

```

accaaaaaag ctttggagnt ttccaaccnc cggtttgcgg ccnngttttt tagaactnag 60
tggaatcccc cgggggcttt caaggaattc ggcacgagtt tgcttaggcg cagacgggga 120
agcggagcca acatgccagt ggcccggagc tgggtttgtc gcaaaactta tgtgaccccg 180
cggagaccct tcgagaaatc tcgtctcgac caagagctga agctgacggy cgagtatggg 240
ctccggaaca aacgtgaggt ctggagggtc aaatttacct tggccaagat ccgcaaggcc 300
gcccgggaac tgctgacgct tgatgagaag gaccacggc gtctgttcga aggcaacgcc 360
ctgctgcggc ggctgggtccg cattggggtg ctggatgagg gcaagatgaa gctggattac 420
atcctgggcc tgaagataga ggatttctta gagagacgcc tgcagacca ggtcttcaag 480
ctgggcttgg ccaagtccat ccaccacgct cgcgtgctga tccgccagcg ccatatcagg 540
gtccgcaagc aggtgggtgaa catcccgctc ttcatgttgc gcctggattc ccagaagcac 600
atcgacttct ctctgcgctc tccctacggg ggtggccgcc cgggccgctg gaagaggaag 660
aatgccaaga agggccaggg tggggctggg gctggagacg acgaggagga ggattaagtc 720
cacctgtccc tcttgggctg ctggattgtc tcgttttctt gccaaataaa caggatcagc 780
gctttacaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa ttt                                     863

```

<210> 35

<211> 1230

<212> DNA

<213> Homo sapiens

<400> 35

```

tgcaggaatt cggcacgagc ccagcgccgc cgccatgtcc tccgggggcta gcgcgagcgc 60
cctgcagcgc ttggtagagc agctcaagtt ggaggctggc gtggagagga tcaaggtctc 120
tcaggcagct gcagagcttc aacagtactg tatgcagaat gcctgcaagg atgccctgct 180
ggtgggtggt ccagctggaa gtaacccctt ccgggagcct agatcctgtg ctttactctg 240
aagactctag gagagaagtt tgctgaggaa tgccttcaag cacaaagtga tgaatgactg 300
ccttcaagtc tcaagaaaac acttttccct aactttttaga gatatttcag ccctttcctg 360
tggcctggtc ctatagccaa aatcacagat attcatgagt ttctacttga gtgagaaaac 420
tgggtgaagg aatagaattt taaatagtaa taactgcttg ttttttttgt gcaagtactt 480
ttatacataa gataaataaa aaccttacca ccaaatacac caaaatgcac ctctttcata 540
agtgagttac taagatttct atacctggaa tatcatgtat gtttcattta ctggatgttt 600
acatttttagg aaggaaaata gtttgtttta tttaaacaac tgaatactta taaactgttg 660
ttcctggaag ttatttatcc cataaaaaat ttgttctttt ctcatgaatt tataattcct 720
aaatgaagac cagaaagtac aaattgctgg gaggaagaat aggctttatt aatcaactga 780
tgtcttgatt ttcttaaag ggaagattgc tttattttta acactaatta tgggagcaga 840
ttcttagcaa acttctttgg aaaagttaat gttatgatgt gcattaggct gccccatcgt 900
gtatataaat gaagcagatt tgatttttgt attcttacgt ttctctgctt tgtagtgtg 960
gctgtactta aagaaataca gaatttcata tatttaaaaa tgtttaaaat gtgaccaca 1020
gaacattgta aatgattaaa aactaacatg aaaatattac aacctaaaag aattcttaac 1080
ttcacaagtg ttttacttcg acgatgtgcc tttgatttta tttgggacac ttttttagaa 1140
ggatacatta ttcgtgtttg caacggtctt tgaagagctt ggaaataaaa tttctgctta 1200

```

attaatcatt tttctatgac agcaaaaaaa

1230

<210> 36

<211> 640

<212> DNA

<213> Homo sapiens

<400> 36

```
caaccctaat cgctcactat agggaaagct ggtcgcctgc aggtaccggt ccggaattcc 60
cgggtcgacc cagcggtcog gctgtctgaa gatagatcgc catcatgaac gacaccgtaa 120
ctatccgcac tagaaagttc atgaccaacc gactacttca gaggaacaa atggtcattg 180
atgtccttca ccccggaag ggcacagtgc ctaagacaga aattcgggaa aaactagcca 240
aaatgtacaa gaccacaccg gatgtcatct ttgtatttgg attcagaact cattttggtg 300
gtggcaagac aactggcttt ggcattgatt atgattccct ggattatgca aagaaaaatg 360
aaccctaaaca tagacttgca agacatggcc tgtatgagaa gaaaaagacc tcaagaaagc 420
aacgaaagga acgcaagaac agaatagaaga aagtcagggg gactgcaaag gccaatgttg 480
gtgctggcaa aaagccgaag gagtaaagg gctgcaatga tgtagctgt ggccactgtg 540
gatttttcgc aagaacatta ataaactaaa aacttcaaaa aaaaaaaaaa aaaaaaaaaa 600
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg
```

<210> 37

<211> 597

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (32)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (556)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (558)

<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (567)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (590)
 <223> n equals a,t,g, or c

<400> 37
 ggtgagaccn tctanaatat ggttccccgg gntgcccatt cgccaagggtg ctccggtcctt 60
 ccgaggaagc taaggctgcg ttgggggtgag gccctcactt catccggcga ctagcaccgc 120
 gtccggcagc gccagcccta cactcgcccg cgccatggcc tctgtctccg agctcgccctg 180
 catctactcg gccctcattc tgcacgacga tgagggtgaca gtcacggagg ataagatcaa 240
 tgccctcatt aaagcagccg gtgtaaatgt tgagccctttt tggcctggct tgtttgcaaa 300
 ggccctggcc aacgtcaaca ttgggagcct catctgcaat gtaggggccg gtggacctgc 360
 tccagcagct ggtgctgcac cagcaggagg tcctgcccc tccactgctg ctgctccagc 420
 tgaggagaag aaagtggaag caaagaaaga agaatccgag gagtctgatg atgacatggg 480
 ctttggtctt ttgactaaa cctcttttat aacatgttca ataaaaagct gaactttaaa 540
 aaaaaaaaaa aaaaancncg ggggggnccg ctttaagggtg tccaagttaa gtacggg 597

<210> 38
 <211> 624
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (79)
 <223> n equals a,t,g, or c

<400> 38
 ggaccccgctc gccctcctga tgctgctcgt ggacgctgat cagccggagc ccatgcgcac 60
 ggggcgcgcg agctcgcgnt ctccctgacc cccgacccctg gggccgaggc gaaggagggtg 120
 gaggagacca tcgagggcat gctcctcagg ctggaagagt tttgcagcct ggctgacctg 180
 atcaggagtg atacttcaca gatcctggag gaaaacatcc cagtccttaa ggccaaactg 240
 acagaaatgc gtggcatcta tgccaaagtg gaccggctag aggccttcgt caagatggtt 300
 ggacaccacg tcgccttcct ggaagcagac gtgcttcagg ctgagcggga ccatggggcc 360
 ttccctcagg ccctgcggag gtggtctggg tccgcaggct cccctccttc aggaacaagt 420
 camctgsacc kgtgcccgtg acgtacgagc tgcccacact gtataggacg gaggactatt 480
 ttctgttgga cgccgggkaa gcacagcamc amccccgcac ctgccctcgg cctttgtgag 540
 ctttgtggtc ttcccatcag gaacactgga aagtgcacatt gtgtacacgc tgcagcttg 600
 gggttttttc tttgtattgc tggtt 624

<210> 39
 <211> 1029
 <212> DNA
 <213> Homo sapiens

<400> 39
 ggccccctcga gggatcctct agagcggccg ccgactagtg agctcgtcga cccgggaatt 60

```

cgcgggccgcg tgcagcgtca gtcttccacc aaaggccgtt cagttctcct gggctccagc 120
ctcctgcaag gactgcaaga rttttcctcc gcagctctga rtctccactt ttttggtgga 180
gaaaggctgc aaaaagaaaa agagacgcag tgagtgggaa aagtatgcat cctattcaaa 240
cctaattgaa tcgargarcc caggacaca cgcttcagg tttgctcarg ggttcatatt 300
tggtgcttag acaaattcaa aatgaggaaa catcggcact tgcccttagt ggccgtcttt 360
tgctcttttc tctcaggctt tcctacaact catgcccagc agcagcaagc agtcattgaa 420
gtcaacaaga gagacatagt cttcctggtg gatggctcat ctgcaactggg actggccaac 480
ttcaatgcca tccgagactt cattgctaaa gtcattccaga ggctggaaat cggacaggat 540
cttatccagg tggcagtggc ccagtatgca gacactgtga ggctgaatt ttatttcaat 600
acccatccaa caaaaagggr agtcataacc gctgtgcgga aaatgaagcc cctggamggs 660
tcggccctgt acacgggctc tgctctagac tttgttcgta acaacctatt cagagttca 720
gccggctacc gggctgccga ggggattcct aagcttttgk tgctgatcac aggtggtaag 780
tccctagatg aaatcagcca gcctgccag gagctgaaga gaagcagcat aatggccttt 840
gccattggga acaagggtgc cgatcaggct gagctggaag agatcgcttt cgactcctcc 900
ctggtgttca tcccagctga gttccgagcc gcccattgc aaggcatgct gcctggcttg 960
ctggcacctc tcaggacctc ctctggaacc cctgaagttc actcaaaca aagggatatc 1020
atctttctg 1029

```

<210> 40

<211> 1107

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1098)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1106)

<223> n equals a,t,g, or c

<400> 40

```

tgaatggctt atttaaataa gttggatcta tggactctcc acagcctaga tattatccta 60
ctgaagatgt gcctcgaaaag ctgttgagcc acggcaaaaa acccttcagt cagcacgtga 120
gaaaactgcg agccagcatt acccccggga ccattctgat catcctcact ggacgccaca 180
ggggcaagggt gagagtacct gtgcttgggg cgcttcactg cagctgcctg ggggtgcctg 240
tggcaatgcg tttgcacgct aggtgtactt ttcttttatt tacctatgtt tggggcaagg 300
ggaaatgata tgcaagatac aacttagttg ttgcaataa gaagtgtaat ccatgggtgat 360
ttattagcca tttcctgctg ttgatwatgt tacacatgty catttactca aaaacgtgtt 420
tatgtctgga gtactacctt agtagcttgc tgtggttgct tccagaactg ccgagctgta 480
tacatataca tgtagaaatt tccttaccm aatttagatg cctgtgawtt tawgaatcag 540
aagycagttt taawtgcmga aaacyaatta ttytcttttt amcttacaag aggggtggtt 600
tcctgaagca gctggctagt ggcttattac ttgtgactgg acctctggtc ctcaatcgag 660
ttcctctacg aagaacacac cagaaatttg tcattgccac ttcaaccaa atcgatatca 720
gcaatgtaaa aatcccaaaa catcttactg atgcttactt caagaagaag aagctgcgga 780
agcccagaca ccaggaagggt gagatcttcg acacagaaaa agagaaatat gagattacgg 840
agcagcgcaa gattgatcag aaagctgtgg actcacaat tttaccaaaa atcaaagcta 900
ttcctcagct ccagggtctac ctgcgatctg tgtttgctct gacgaatgga atttatctc 960
acaaattgggt gttctaaatg tcttaagaac ctaattaaat agctgactac aaaaaaaaa 1020

```

```

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ccccgggggg 1080
gggcccggtt cccatttngc cctttng 1107

```

<210> 41

<211> 1051

<212> DNA

<213> Homo sapiens

<400> 41

```

cttggaagtc agtcgtagtc ctgcgagtc cggcgggagc tggaagtgc catccacgac 60
agaacaaata ttcggtgctt ttacctacct acaacgagcg cgagaacctg ccgctcatcg 120
tgtggctgct ggtgaaaagc ttctccgaga gtggaatcaa ctatgaaatt ataatacatg 180
atgatggaag ccagatgga acaagggatg ttgctgaaca gttggagaag atctatgggt 240
cagacagaat tcttctaaga ccacgagaga aaaagttggg actaggaact gcatatatatc 300
atggaatgaa acatgccaca ggaaactaca tcattattat ggatgctgat ctctcacacc 360
atccaaaatt tattcctgaa tttatttaga agcaaaagga gggtaatttt gatattgtct 420
ctggaactcg ctacaaagga aatggaggtg tataatggctg ggatttgaaa agaaaaataa 480
tcagccgtgg ggccaatttt ttaactcaga tcttgctgag accaggagca tctgatattaa 540
caggaagttt cagattatac cgaaaagaag ttctagagaa attaatagaa aaatgtgttt 600
ctaaaggcta cgtcttccag atggagatga ttgttcgggc aagacagttg aattataacta 660
ttggcgaggt tccaatatca tttgtggatc gtgtttatgg tgaatccaag ttggggaggaa 720
atgaaatagt atctttcttg aaaggattat tgactctttt tgctactaca taaaagaaag 780
atactcattt atagttacgt tcatttcagg ttaaactatga aagaagcctg gttactgatt 840
tgtataaaat gtactcttaa agtataaaat ataaggtaag gtaaatttca tgcactcttt 900
tatgaagacc acctatttta tatttcaaat taaataattt taaagtgtgct ggcctaataga 960
gcaatgttct caattttcgt tttcattttg ctgtattgag acctataaat aaatgtatat 1020
ttttttttgc ataaarwaaa aaaaaaaaac c 1051

```

<210> 42

<211> 2192

<212> DNA

<213> Homo sapiens

<400> 42

```

ggcgaacctg gtgatgctgg tgctaaaggc gatgctggtc cccctggccc tgccggaccc 60
gctggacccc ctggcccat tggtaatgtt ggtgctcctg gagccaaagg tgctcgcggc 120
aggctggtcc cctggtgct actggtttcc ctggtgctgc tggccgagtc ggtcctcctg 180
gcccctctgg aaatgctgga cccctggcc ctctggtcc tgctggcaaa gaaggcgga 240
aaggtccccc tggtagact ggccctgctg gacgtcctgg tgaagtgtgt cccctgggtc 300
cccctggccc tgctggcgag aaaggatccc ctggtgctga tggctcctgct ggtgctcctg 360
gtactcccg gctcaagggt attgctggac agcgtggtgt ggtcggcctg cctggtcaga 420
gaggagagag aggtctccct ggtcttccct gcccctctgg tgaacctggc aaacaagggtc 480
cctctggagc aagtgttgaa cgtggtcccc ctggtcccat gggccccctt ggattggctg 540
gacccccctg tgaatctgga cgtgaggggg ctccctggtg cgaagtccc ctggacgaga 600
cggttctcct ggcgccaagg gtgaccgtgg tgagaccggc cccgtggag cccctggtgc 660
tccgtgtgct cctggtgccc ctggccccgt tggccctgct ggcaagagt gtgatcgtgg 720
tgagactggt cctgctggtc ccgcccgtcc tgtcggccct gttggcgccc gtggccccgc 780
cggaccccaa ggccccctg gtgacaaggg tgagacaggc gaacagggcg acagaggcat 840
aaagggtcac cgtggcttct ctggcctcca gggctccccct ggccctcctg gctctcctgg 900
tgaacaagggt cctctggag cctctggtcc tgctggtccc cgaggtcccc ctggctctgc 960
tggtgctcct ggcaagatg gactcaacgg tctccctggc cccattgggc cccctggtcc 1020

```

```

tcgcggtcgc actggtgatg ctggtcctgt tgggtccccc ggccctcctg gacctcctgg 1080
tccccctggt cctcccagcg ctggtttcga cttcagcttc ctgccccagc cacctcaaga 1140
gaaggctcac gatggtggcc gctactaccg ggctgatgat gccaatgtgg ttcgtgaccg 1200
tgacctcgag gtggacacca ccctcaagag cctgagccag cagatcgaga acatccggag 1260
cccagagggc agccgcaaga accccgcccc cacctgccgt gacctcaaga tgtgccactc 1320
tgactggaag agtggagagt actggattga ccccaaccaa ggctgcaacc tggatgccat 1380
caaagtcttc tgcaacatgg agactggtga gacctgcgtg taccctactc agcccagtgt 1440
ggcccagaag aactggtaca tcagcaagaa cccaaggac aagaggcatg tytggttcgg 1500
cgagagcatg accgatggat tccagttcga gtatggcggc cagggtccg accctgccga 1560
tgtggccatc cagctgacct tccgtgcgct gatgtccacc gaggcctccc agaacatcac 1620
ctaccactgc aagaacagcg tggcctacat ggaccagcag actggcaacc tcaagaaggc 1680
cctgctcctc cagggctcca acgagatcga gatccgcgcc gagggcaaca gccgcttcac 1740
ctacagcgtc actgtcgatg gctgcacgag tcacaccgga gcctggggca agacagtgat 1800
tgaatacaaaa accaccaaga cctccgcct gccatcatc gatgtggccc ccttggaagt 1860
tgggtgcccc gaccaggaat tcggcttcga cgttggccct gtctgcttcc tgtaaaactcc 1920
ctccatccca acctggctcc ctcccaccca accaactttc cccccaaccc ggaaacagac 1980
aagcaaccca aactgaaccc cctcaaaaagc caaaaaatgg gagacaattt cacatggact 2040
ttggaaaata tttttttcct ttgcattcat ctctcaaaact tagtttttat ctttgaccaa 2100
ccgaacatga ccaaaaacca aaagtgcatt caaccttacc aaaaaaaaaa aaaaaaaaaa 2160
actcgggggg ggcccggtac caattggcct aa 2192

```

<210> 43

<211> 353

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (348)

<223> n equals a,t,g, or c

<400> 43

```

tctctaatac gactcactat agggaaagct ggttacnctg caggtagccg tccggaattc 60
ccgggtcgac ccacgcgtcc ggtggggctt caccaagttc aatgctgatg aatttgaaga 120
catggtggct gaaaagcggc tcattcccaga tggctgtggg gtcaagtaca tccccagtcg 180
tggccctctg gacaagtggc gggccctgca ctcatgaggg cttccaatgt gctgcccccc 240
tcttaatact caccaataaa ttctacttcc tgtccaaaaa aaaaaaaaaa aaaaaaaaaa 300
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaanaa aag 353

```

<210> 44

<211> 3490

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (782)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1311)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2298)
 <223> n equals a,t,g, or c

<400> 44
 acaaaaatttt tacgatacaa gtagcctgcc agtacgggtcc ggaaattccc gggctcgaccc 60
 acgcgtccgg tgaaaactgt tgcattattc ctccatccctg tctggaatac accagggtcaa 120
 caccagagat ctccagatcag aatcagagat ctccagagggg aataagttca tcctcatggg 180
 atgggtgaggg gcakgaaagc ggctgggctc ttggacacct gggtctcaga gaacctgtg 240
 atgatcacc cagccccagg ctgtcttagc ccctggagtt cagaagtcct ctctgtaaag 300
 cctgcctccc amtargtcaa gaggaactag agtacctttg gatttatcag gacctcatg 360
 tttaaatggg tatttcctt tgggaaaact tcagaaaact atgtatcaa tgaggccctg 420
 tgccctcgat ctatttcctt ctccctctg acctcctccc aggcactctt acttctagcc 480
 gaactcttag ctctgggcag atctccaagc gcctggagtg ctttttagca gagacacctc 540
 gttaagctcc gggatgacct ttagtagat ctgtctccct gtgcctggag agttacagcc 600
 agcaagggtgc ccccatctta gagtggtg tccaaacgtg aggtggcttc ctagttacat 660
 gaggatgtga tccaggaaat ccagtttggg ggcttgatgt ggggtttgac ctggcctcag 720
 ccttggggct gtttttctt gttgccccgc tctagacttt tagcagatct gcagcccaca 780
 gnkctttttt ggaaggagtg gcttccctga ggtgttccac ctgcyttcgg agcctgccac 840
 ccaggccctc agaactgagc cacagggtgc tctggccagg agagaaacag ctctgttggt 900
 ctgcattggg ggaggtacat tcctgcatct tctcaccccc tcaaccagga actggggatt 960
 tgggatgaga tatggtcaga cttgtagata accccaaaga tgtgaagatc gcttgtgaaa 1020
 ccattttgaa tgaatagatt ggtttctgt ggctccctcc aaacctggcc aagcccagct 1080
 tccgaagcag gaaccagcac tgtctctgt cctgactcac agcatatagg tcaggaaaga 1140
 atggagacgg cattcttggg ctccactggg gctgctggat tggatggga accttctgga 1200
 agaggcagat ggggggtcaa ccaactgcct ggccccagga aggggcatag gtaggtctga 1260
 acaactgccg caagaccact acatgactta gggaacttga aaccaactgg nctcatggag 1320
 aaaacaaatt tgacttggga aagggtattat gtaggaataa tgtttggact tgatttccc 1380
 acgtcataat gaagaatgga agtttggatc tgctcctcgt caggcgcagc atctctgaag 1440
 cttggaaagc tgtcttccag cagcctccgt ggctcgggt tcctaccggc ttctctgcat 1500
 ttggtctgct gatcatgtt ccataatgtg tatggaaagt gtacacattc ttactgggta 1560
 aagacgacta ccaggtatct aacttgttta acattgagtt tgtgtgtgtg tgtgtatgtt 1620
 tgtgtgtttt gtatattgtt tacattttga gaggtagcat tctgtttcaa atgctttttg 1680
 tttttctgac agtattgtt actgggtcat aacattttga gctgtggtt ggtggatttt 1740
 caattttttt ttttaaaggc cattcgctgt gctatcttca aaacctgag tttggcccc 1800
 aatttttggc attcaaatgt ttaaaagcta ttatcttgg tttatacaag tttcctttct 1860
 cttctttttg tcatgtatt ctatttggc tgccagtttg atgtagagaa agtggactga 1920
 tcccccaagc gttgtctgcc cccactctt cctccttggg tcccgcatt cttttactgg 1980
 gcagtcgagg gcattggagg ggaagtgact gccctcagcc tccctccctg gggccatgaa 2040
 gaaaagctaa acagtcctcat ggcatctcag aataatgttg ggtctcccaa gaagaaagg 2100
 gtaagaataa cgacatggct gattaggcga ggccaggata gggctaaggc caggattcct 2160
 ggctggcatc cagtcacccc ttctcccatc cttccccctc ttctccaca agtccgcagc 2220

```

cgagacactg tagtctccca gccacagtga tgagtgcctt ggagactcca ctgacctcta 2280
gatgaaggcc cctggccntg gttcctgtta attaacctct gggctcttga gtcccccagc 2340
acaaacttct ttcctgtacc ctgcggttg gggtcacagg gcatgccggg aagccacagc 2400
tgagggggcg agactgaagc agtgctccac ctctccttct ttagctcagg ggttgctggt 2460
ctgtggcagg cgccacgagt ggccccctgt gctgttctca gtggcagtct cttaagttcc 2520
caccacaggc agctctttat cccctctccc tacttsactc tttctcttgc ctgtgctttt 2580
ggcctcaaac aggcctgctg gtagcgctca gggcgtgagg ctacactcct gccctgcctt 2640
tcctgtcttc atggtctgcc agggcatacc ttggggaggt ggaccaaaga cccaggactt 2700
tttgacagtag ccagtcctac cccccagttg tctttttacc aattcagggt gggagagaaa 2760
actgcagcac cccagcatgt gagttactca ggtgttgggg gctagaaggg acagtgcgtt 2820
taaacaacac tcagagctct ggccttaaac ctgtggcccc ccaagtctag gacccctatc 2880
tcttctctgg agtcatgcgg gcaggaggtc ctgaaaggga aaacccattc agacaactgt 2940
tccccaatct accagccatc tgcaggggtc agtgaccgtg gccctctccc tctctagaa 3000
tgtgccactt atgaagagtg ccccatgggg aaaaggagac tcagctgtcc cttggcagct 3060
tgtgccagta tcccagggca gaagtttcca caggagcctc ttgcccttgc gcagagccac 3120
tgtgagaggc ggtgggagcc aacacccttg ggggaggggg cagtactgct cggcacatcc 3180
cagcatcagg tcagatcayt gaaattaaaa aatgtgaatt aagttcatat ccaccttttg 3240
gggaagcagg acaaaccacc accccaccaa gtgtgtgact tctccatata cactgcagt 3300
ttccatTTTT taaatgggaa ttttcaatcc cctgtgcttg tctaactctt gctttaaaaa 3360
gtttgagacc ctgttactgt ttgaaaatgc atgcatgtta cgatgaatct ccaacctgag 3420
gaaaaaaata aaactcaaaa agctttgtgt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3480
aaaaaacct                                     3490

```

<210> 45

<211> 781

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (750)

<223> n equals a,t,g, or c

<400> 45

```

gtcagatgtt ccttttccca aatcattatt cctttggcca gaagggttga cttgatacct 60
tccagcagcc tggagcctca tggccaaacc agtcctcag gcatcccagg atttccaggc 120
atcagatgga gggtaggggc tgcccagcaa atgtcagtgt gtgtcaacat ttactgcagg 180
ttcagagctc cctccagggt ccctgagtac atcatgtgct cctgagagtt ttaagggaaa 240
gccaaagtaa gacgtgatga tgttctaaac ccaagcaatt aataaaygcc acggaaatca 300
gtcattcact taccaagtat ttctctgctt tctgccatgt cacgggscca tgatcccctg 360
gagattgagg gaaataagat cacaggagct cccagtctga gtgagaaaag gcagctgctc 420
tgtggtactg tgcactggac ctgggaatgg cctaaggaga caagcattga gggctgagct 480
cagaagccag ggagaagagc tcagaacccc aggagaggag ctcagaaccc tgggagagga 540
gtcagaacc ctgggagggc ttggtaacct tcgaggatgt ggccgtggag ttcaccagg 600
aggagtgggc gttgctggac cctgccccaa ggacactgta cagggatgtg atgctggaga 660
actgcaggac ctggcctcac targgtgtcg tgtaataaa cccagtctga tatcccagtt 720
ggamcaagac aagaagktgg tgacagaggn aagaggaatc taccaagcac ctgtccagat 780
t

```

<210> 46

<211> 1431

<212> DNA

<213> Homo sapiens

<400> 46

```
gggtcgaccc acgcgtccgc ttcagagaag aatttctctt tagttctttg caagaaggta 60
gagataaaga cactttttca aaaatggcaa tggatcaga attcctcaag caggcctggt 120
ttattgaaaa tgaagagcag gaatatgttc aaactgtgaa gtcacccaaa ggtggtcccg 180
gatcagcggg gagcccctat cctaccttca atccatcctc ggatgtcgct gccttgcata 240
aggccataat gggttaaagg gtggatgaag caaccatcat tgacattcta actaagcgaa 300
acaatgcaca gcgtcaacag atcaaagcag catatctcca ggaaacagga aagcccctgg 360
atgaaacact gaagaaagcc cttacaggtc accttgagga ggttgtttta gctctgctaa 420
aaactccagc gcaatttgat gctgatgaac ttcgtgctgc catgaagggc cttggaactg 480
atgaagatac tctaattgag attttggcat caagaactaa caaagaaatc agagacatta 540
acaggggtcta cagagaggaa ctgaagagag atctggccaa agacataacc tcagacacat 600
ctggagattt tcggaacgct ttgctttctc ttgctaaggg tgaccgatct gaggactttg 660
gtgtgaatga agacttggtt gattcagatg ccagggcctt gtatgaagca ggagaaagga 720
gaaaggggac agacgtaaac gtgttcaata ccaccttac caccagaagc tatccacaac 780
ttcgcagagt gtttcagaaa tacaccaagt acagtaagca tgacatgaac aaagttctgg 840
acctggagtt gaaaggtgac attgagaaat gcctcacagc tatcgtgaag tgcgccacaa 900
gcaaaccagc tttctttgca gagaagcttc atcaagccat gaaagggtgtt ggaactcgcc 960
ataaggcatt gatcaggatt atgggttccc gttctgaaat tgacatgaat gatatcaaag 1020
cattctatca gaagatgtat ggtatctccc ttgccaagc catcctggat gaaaccaaag 1080
gagattatga gaaaatcctg gtggctcttt gtggaggaaa ctaaaccattc ccttgatggt 1140
ctcaagctat gatcagaaga ctttaattat atattttcat cctataagct taaataggaa 1200
agtttcttca acaggattac agtgtagcta cctacatgct gaaaaatata gccttttaat 1260
catttttata ttataactct gtataataga gataagtcca ttttttaaaa atgttttccc 1320
caaaccataa aaccctatac aagttgttct agtaacaata catgagaaag atgtctatgt 1380
agctgaaaat aaaatgacgt cacaagacaa aaaaaaaaaa aaaaaaaaaa a 1431
```

<210> 47

<211> 1913

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1878)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1896)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1905)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1907)

<223> n equals a,t,g, or c

<400> 47

```

cccacgcgtc cggccagctc attgctctta tagcctgtga ggnagraaga aacatttgcy 60
agccaggcta gtgacagaaa tggattcgaa ataycagtgt gtgaagctga atgatgggtca 120
cttcatgcct gtcctgggat ttggcaccta tgcgcctgca gaggttccta aaagtaaagc 180
tytagaggcc rycaaattgg caatwgaagc yggsttcrc catattgatt ctgcwcatkt 240
wtacaataat gaggagcagg ttggactggc catccgaagc aagattgcag atggcagtggt 300
gaagagagaa gacatattct acacttcaaa gctttggwgc aattcccatc gaccagagtt 360
ggtccgacca gccttggaag ggtcactgaa aaatcttcaa ttggattatg ttgacctcta 420
ycttattcat tttccagtgt ctgtaaagcc aggtgaggaa gtgatcccaa aagatgaaaa 480
tggaataata ctatttgaca cagtggatct ctgtgccacr tgggaggccg tggagaagtg 540
taaagatgca ggattggcca agtccatcgg ggtgtccaac ttcaaccrca ggcagctgga 600
gatgatcctc aacaagccag ggtcgaagta caagcctgtc tgcaaccagg tggaaatgtca 660
tccttacttc aaccagagaa aactgctgga tttctgcaag tcaaaagaca ttgttctggt 720
tgcttatagt gctctgggat ccaycgaga agaaccatgg gtggaccga actccccggt 780
gctcttgag gacccagtcc tttgtgcctt ggcaaaaaag cacaagcgaa cccagccct 840
gattgccctg cgctaccagc ttcagcgtgg ggttgtggtc ctggccaaga gctacaatga 900
gcagcgcctc agacagaacg tgcaggtgtt tgaattccag ttgacttcag aggagatgaa 960
agccatagat ggcctaaaca gaaatgtgcg atatttgacc cttgatattt ttgctggccc 1020
ccctaattat ccattttctg atgaatatta acatggaggg cattgcatga ggtctgccag 1080
aaggccctgc gtgtggatgg tgacacagag gatggctcta tgctggtgac tggacacatc 1140
gcctctggtt aaatctctcc tgcttgyga yttcagyaag ctacagcwaa gcccatyggc 1200
crgaaargaa agacaataat tttgtttttt cattttgaaa aaattaaatg ctctctccta 1260
aagattcttc acctactttc gtctccataa cttctatggt ttctttcctt ctgacacact 1320
agtcccccta aattgtgatt tgctatacgt tttagggccg ggggttgaag atgttaacaa 1380
ccatttaaga ttcattttctg cagtgggagt ggttggagt ttaccctctg ggaaaggggc 1440
aggtgacagg tatttatcag tcagtgcctc tctagctctt gtaggaagaa gcacacgcag 1500
gatggagtct agaggatgag cgatattgac tagcaattca tgggctccct ccagcagtcg 1560
gagggtcaga gtttctggag ccttgggagg aggcattccct gtgagggggg gttagggaga 1620
tgaggaggca ccaggaaaag tgattagaag tcaggatatgg gaaggctaaa taggacagag 1680
tcgagtacat ctctgcttgg aaaaacatat caacaccctt tttttttgaa cattatatct 1740
tgttcataaa agaaaacttt ccacattggt ttaacaaacc ccacagctgg agagttcagg 1800
cctggaatct ttggatgtgt gccagttca cagattggac cctattggtt tgtggtggg 1860
ccagggcatc caaagacntc attggactaa ttcacnttcc cccgnanagc ccc 1913

```

<210> 48

<211> 1761

<212> DNA

<213> Homo sapiens

<400> 48

```

cgaggagctc tgaggtctat gctcagctgt gcaacgtggc tcgcattgag gcagagcggg 60
aggccggggg ccacttccgg ccaggctatg agtatggccc cgggcccgat gacctgcact 120
acagcatcta tggcccagat ggggccccct tctacaacta cctgggcccc gaggacaccg 180

```

```

tccctgagcc tgccttcccc aacacagccg gtcactcagc ggaccgcaca cccatccttg 240
agtctccttt gcagccctca gaactccagc cccactacgt ggccagccat ccagagcccc 300
cagccggctt cgaagggtt cagggcgagg agtgcggcat cctgaacggc tgtgagaatg 360
gccgtgtgt gcgcgtgccc gagggctaca cctgtgactg ttttgagggc ttccagctgg 420
atgcggccca catggcctgc gtagatgtga atgagtgtga tgacttgaac gggcctgctg 480
tgctctgtgt ccatggttac tgcgagaaca cagagggctc ctaccgctgc cactgctccc 540
cgggatatgt ggctgaggca gggccccccc actgcactgc caaggagtag cagtcagggg 600
tcagtgtggc aactacctgg aaatggcctc cagtcacagg caggggcctt gaggatgatt 660
tcctagctgg gaagacaccg tgacatcagg ccagagggtt ccaatcagcc ttgcctgctt 720
tcctctctcc cagcttagcc tctggctgta agcttcggtc attgcctcca tgccttgct 780
tggctcaagc accaccaatc gctttaatgc ttcagccacc gcatgaggcc ctgtccacca 840
cctttcctgg ccttgctatg ggatgcttac caaaggatgg ccctcatcca cctcccaag 900
ctgtgcragc atgcaaggcc ccatggctca cactgcagac acccctttcc agccacaatc 960
caccatcatc ctgacgatcc cacaactggg acagaggcta catctgccct agggaggtcc 1020
ttcagaatct gtggagcaag aaaggatttg gggagccttg gggactgact ccagagcccc 1080
ctcctaagaa ccatcaccac cactcagcca atctgttctg ggccctgatt ttgccacacc 1140
tccatcctgt agccattct ctgaccccaa ggagtggcag aagatccctt cactcagaga 1200
agcaaggctg atattagctt gttgaatgta agagacacaa atgaagaaga acaaagagcc 1260
tgagaaagca gcaagaggac atgatgaaaa atacgtggag ttgatgagaa aggggagcca 1320
aggctttata cgtctaaaga aaatattcag tagctgaatc cgcccagtga tagcctgtgg 1380
gcaccagcag caagggctgc catgggatac agyaccatc tacaaagacc tctattacat 1440
aaactactgt tcttacagga aacaaacctc ttctgggatc tccttttgtg aaaaccagtt 1500
tgatgtgcta aaagtaaaaa gtctattttc cagtgtggtc ttgttcagaa gcagccagat 1560
ttccaatgtt gtttttcccc tccactcaga aaccctgcc ctttcccttc agaaaacgat 1620
ggcaggcatt cctctgagtt tacaagcaga gactcactcc aaccctaaact agctgggagt 1680
tcagaaccat ggtggaataa agaaatgtgc atctggtcaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa g                                     1761

```

<210> 49

<211> 956

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (352)

<223> n equals a,t,g, or c

<400> 49

```

tgcaggagtt cggcacgagg gtatttagag cgcaggngctg acggggccgga tgccttcgc 60
cgccgcccgc ccgcaaacct tcgtgcccg cccgtcctcg ccccgccctc cgccaccgcc 120
tcggcccgcga gagcttgccc cctccccacc cgcagacatg tccgagtcca agagcggccc 180
cgagtatgct tcgttttttcg ccgtcatggg cgctcggccc gccatggtct tcagcgcct 240
gggcgctgcc tatggcacag ccaagagcgg tacccgcatt gggccatgt ctgtcatgcg 300
gccggagcag atcatgaagt ccatcatccc agtggtcatg gctggcatca tngycatcta 360
cggcctggtg gtggcagtc tcatcgccaa ctccctgaat gacgacatca gcctctacaa 420

```

```

gagcttcctc cagctgggag ccggcctgag cgtgggcctg agcggcctgg cagccgggctt 480
tgccatcggc atcgtggggg acgctggcgt gcggggcaac gcccagcagc cccgactatt 540
cgtgggcatg atcctgattc tcattcttcgc cgagggtgctc ggccctctacg gtctcatcgt 600
cgccctcatc ctctccacaa agtagaccct ctccgagccc accagccaca gaatattatg 660
traagaccac cctcctcat cgccctcca ggccccggc gccccacccc cttagagtgt 720
ctgtgtatgc ggatgattta gaattgtcat ttctctttac tggatgttta ttataaaga 780
tctggcctgt tcctgcgtct gcggagcggc ccttgtctcc cagctatcta taaccttagc 840
tagagtgtcg ccttgtgggt tcctgttgct gagacttcct ggatggagcc gccctcaccg 900
wmcgkcccgt ggccctgcgc ggagctgtgt ccaataaagt tcttgatgt gaaaaa 956

```

<210> 50

<211> 563

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (510)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (519)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (530)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (558)

<223> n equals a,t,g, or c

<400> 50

```

cggacgcgtg ggcgcctcc gaatccagag aggcgtgtgt gacaccgccc ccacaccgcc 60
gccacaccgc cgtgcctca gtcatgccga agcacgagtt ctctgtggac atgacctgtg 120
gaggctgtgc tgaagctgtc tctcgggtcc tcaataagct tggaggagtt aagtatgaca 180
ttgacctgcc caacaagaag gtctgcattg aatctgagca cagcatggac actctgcttg 240
caaccctgaa gaaaacagga aagactgttt cctaccttgg ccttgagtag caggggcctg 300
gtccccacag cccacaggat ggaccaaagg gggcaggatg ctgacccccc cgctggcttc 360
cagacagacc tgggacttgg cagtcatgcc gggatgaggt gttcctgcgg agaccctcag 420
ttgtcctatt cttccttagc ttccctgcaa taaaatcaag ctgcttttgt tggaaaaaaa 480
aaaaaaaaaa gggggcgtct aaaaccaa ttatttcctn gatgaaatcn acctctttgt 540
tcccatcat ccggcctnaa aaa 563

```

<210> 51

<211> 3215

<212> DNA

<213> Homo sapiens

<220>
<221> misc feature
<222> (3196)
<223> n equals a,t,g, or c

<400> 51

```
gcctcgggtg ggggtgggagc ggggggggaca gtgccccggg aaccgcgggtg gtcacacaca 60
cgactgcgc ctgtcagtag tggacattgt aatccagtcg gcttgttctt gcagcattcc 120
cgctcccttc cctccatagc cacgctccaa accccagggt agccatggcc gggtaaagca 180
agggccattt agattaggaa ggtttttaag atccgcaatg tggagcagca gccactgcac 240
aggaggagggt gacaaacccat ttccaacagc aacacagcca ctaaaacaca aaaaggggga 300
ttgggcggaa agtgagagcc agcagcaaaa actacatttt gcaacttggt ggtgtggatc 360
tattggctga tctatgcctt tcaactagaa aattctaatg attggcaagt cacgttggtt 420
tcagggtccag agtagtttct ttctgtctgc tttaaatggr aacagactca taccacactt 480
acaattaagg tcaagcccag aaagtataa gtgcaggagg gaaaagtga agtccattat 540
gtaatagtga cagcaaagg accaggggag aggcattgcc ttctctgccc acagtctttc 600
cgtgtgattg tctttgaatc tgaatcagcc agtctcagat gcccacaaagt ttcggttcct 660
atgagcccgg ggcattgatc gatccccaa acatgtggag gggcagcctg tgcctgcctt 720
tgtgtcagaa aaaggaaacc acagtgcagc tgagagagac ggcgattttc gggctgagaa 780
ggcagtagtt ttcaaaacac atagttaaaa aagaaacaaa tgaaaaaat tttagaacag 840
tccagcaaat tgctagtcag ggtgaattgt gaaattgggt gaagagctta sgattctaata 900
ctcatgtttt ttccttttca catttttaaa agaacaatga caaacacca cttatttttc 960
aaggttttaa aacagtctac attgagcatt tgaaagggtg gctagaacaa ggtctcctga 1020
tccgtccgag gctgcttccc agaggagcag ctctcccag gcatttgcca agggaggcgg 1080
atttccctgg tagtgtagct gtgtggcttt ccttccgtga gagtccgtgg ttgccctaga 1140
acctaacacc ccctagcaaa actcacagag ctttccgttt ttttctttcc tgtaaagaaa 1200
catttccttt gaacttgatt gcctatggat caaagaaatt cagaacagcc tgcctgtccc 1260
cccgcacttt ttacatatat ttgtttcatt tctgcagatg gaaagttgac atgggtgggg 1320
tgtccccatc cagcgagaga gtttcaaaag caaaacatct ctgcagtttt tcccaagtrc 1380
cctgagatac ttcccaaagc ctttatgttt aatcagcgat gtatataagc cagttcactt 1440
agacaacttt acccttcttg tccaatgtac aggaagtagt tctaaaaaaa atgcatatta 1500
atcttctccc ccaaagccgg attcttaatt ctctgcaaca ctttgaggac atttatgatt 1560
gtccctctgg gccaatgctt ataccagtg aggatgctgc agtgaggctg taaagtggcc 1620
ccctgcggcc ctagcctgac ccggaggaaa ggatggtaga ttctgttaac tcttgaagac 1680
tccagtatga aaatcagcat gcccgcctag ttacctaccg gagagttaac ctgataaatt 1740
aacctctcac agttagtgat cctgtccttt taacaccttt tttgtgggtt tctctctgac 1800
ctttcatcgt aaagtgcctg ggaccttaag tgatttgcct gtaatttttg atgattaaaa 1860
aatgtgtata tatattagct aattagaaat attctacttc tctgttgtca aactgaaatt 1920
cagagcaagt tcctgagtcg gtggatctgg gtcttagttc tggttgattc actcaagagt 1980
tcagtgtcga tacgtatctg ctcattttga caaagtgcc catgcaaccg ggccctctct 2040
ctgcggcaga gtccttagtg gaggggttta cctggaacat tagtagttac cacagaatac 2100
ggaagagcag gtgactgtgc tgtgcagctc tctaaatggg aattctcagg taggaagcaa 2160
cagcttcaga aagagctcaa aataaattgg aaatgtgaat cgcagctgtg ggttttacca 2220
ccgtctgtct cagagtccca ggaccttgag tgtcattagt tactttattg aaggttttag 2280
acctatagca gctttgtctc tgtcacatca gcaatttcag aaccaaagg gaggtctct 2340
gtaggcacag agctgacta tcacgagcct ttgtttttct ccacaaagta tctaacaaaa 2400
ccaatgtgca gactgattgg cctggctcatt ggtctccgag agaggagggt tgcctgtgat 2460
ttcctaatta tcgctagggc caaggtggga tttgtaaagc tttacartaa tcattctgga 2520
tagagtcttg ggaggtcctt ggcagaactc agttaaatct ttgaagaata tttgtagtta 2580
tcttagaaga tagcatggga ggtgaggatt ccaaaaacat tttattttta aaatatcctg 2640
```

```

tgtaacactt ggctcttggt acctgtgggt tagcatcaag ttctccccag ggtagaattc 2700
aatcagagct ccagtttgca tttggatgtg taaattacag taatcccatt tcccaaacct 2760
aaaatctggt tttctcatca gactctgagt aactgggtgc tgtgtcataa cttcatagat 2820
gcaggaggct caggtgatct gtttgaggag agcaccctag gcagcctgca ggaataaca 2880
tactggccgt tctgacctgt tgccagcaga tacacaggac atggatgaaa ttcccgtttc 2940
ctctagtttc ttctgtagt actcctcttt tagatcctaa gtctcttaca aaagctttga 3000
atactgtgaa aatgttttac attccatttc atttgtgttg tttttttaac tgcattttac 3060
cagatgtttt gatgttatcg cttatgttaa tagtaattcc cgtacgtgtt cattttattt 3120
tcatgctttt tcagccatgt atcaatattc acttgactaa aatcactcaa ttaatcaawa 3180
aaaaaaaaaa aaaccncggg ggggggcccg gaacc 3215

```

<210> 52

<211> 626

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (571)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (572)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (573)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (618)

<223> n equals a,t,g, or c

<400> 52

```

cagtttgtgt attgcggcaa gaaggcccag ctcaacattg gcaatgtgct cctgtggggc 60
accatgcctg agggatacaat cgtgtgctgc ctggaggaga agcctggaga ccgtggcaag 120
ctggccccggg catcagggaa ctatgccacc gttatctccc acaaccctga gaccaagaag 180
accctgtgtga agctgccctc cggctccaag aaggttatct cctcagccaa cagagctgtg 240
gttggtgtgg tggctggagg tggccgaatt gacaaaccca tcttgaaggc tggccggggc 300
taccacaaat ataaggcaaa gaggaactgc tggccacgag tacgggggtg ggccatgaat 360
cctgtggagc atccttttgg aggtggcaac caccagcaca tcggcaagcc ctccaccatc 420
cgcagagatg cccctgctgg ccgcaaagtg ggtctcattg ctgcccggcg gactggacgt 480
ctccgggggaa ccaagactgt gcaggagaaa gagaactagt gctgagggcc tcaataaagt 540
ttgtgtttat gccaaaaaaa aaaaaaaaaa nnnngggggc cgctttarag rwtcctccaa 600
ggggccaact tacccttnca tgcaaa 626

```

<210> 53

<211> 920

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (617)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (621)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (725)
<223> n equals a,t,g, or c

<400> 53
atgagggctc ggctacagca agaagtagag gagcagctca aaaagaaatg tttcactctg 60
ctctgctact atgatcccaa ttcagatgct gacagtgaaa ccgtgaaggc agcaaagggtg 120
tggaaactcg cagagtcctg gtgggtgagc agcagcagtg ccasgatgcc aagagccagc 180
agaaggagca gatgttgctg ctggagaaka agagtgctgc ttactcccag gtgcttctcc 240
gctgcctcac tttgctgcag aggcttcttc aagaacaccg gctgaagact caatccgagc 300
tagaccgcat caatgcccag tacctggaag tcaagtgcgg tgctatgatc cttaagctga 360
ggatggagga gctaaagatt ttgtccgaca cttacactgt tgagaaagtg gaagttcatc 420
gtctgattag ggaccgtttg gagggagcca ttcacctaca ggagcaggac atggagaact 480
caagacagggt cctgaactcc tatgaggtcc ttggggagga gtttgacagg ctggtgaaag 540
agtacaccgt actcaagcag gcaacagaga acaagcgggtg ggccctccag gagttcagca 600
aggtctaccg ttgagcntcg ncagggccag gagacatggc ttctgcatag ctgctgcctc 660
ctaattcttc tgctagtggg accaccttca cctggggctg ccttcagtac aagggagtgt 720
ggaanatstt acgcttgaaa cactgcagtc atttaggcac tctcctgggt tctctttatt 780
ttttatgact gggcctcttc tggaaaatct agcaaggaga tttatataat ttttatgcat 840
agctgtgtgt cagtgtcagc cctgtattgt atttgattat ctcctgaata aagttatgat 900
attawaaaaa aaaaaaaaaa 920

<210> 54
<211> 1090
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1024)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1034)
<223> n equals a,t,g, or c

<400> 54

```

gagtaaccca gaaatgatgt tgcatttttt gctttacctg ataattgaaa ctttcaacaa 60
tctctggagt gactttttct cctcgaattg aaacaagtct atggcaaaag aagctgcatt 120
tttttcacaa aagggaagat ggtaacaatg gtcacttcaa acttttgggc taaattatat 180
gtacacagaa atgttcaaaa tcatagtttt aatgtgtttt gaaaaggcca cacaattata 240
ctttatcttt tcttaataat cctgcaaate tctgccctgg aatccgaaat ctgaaaatgt 300
actggcttga acaaaaatttg ttttgtgtgt tagagttata aatcattaat ctttatttcg 360
ggtggtttac gtttatgcca gttcctttat atttaaattt cttgttttat atattttgaa 420
tgtctttata gatttcttta aatttcctta tagaaccatt aatagaaaat cattacattt 480
aaaatatacc ttacagcaaa agcatccaaa taagtatagg gtttatgtcc ttatttttct 540
ttcagctgaa tacgaatgaa cacagtgggtg gaatttctga agggaagtga tgaaattata 600
tttatttcag tgggcacttt tccattttac cactgtacca ttatttggtt cctggagtta 660
tactactaatt ttcagtatat tactgttaaa ttaccaacac aaggcaattt atttgaaaga 720
ttccgtttat cctgccattg ctttgaaaag cagcaggaaa cgaaatcctt tgacttgtat 780
cagcttctgc agagcatctt tgttttcctt tgcctttgtt ttctacctt ttgaatcaga 840
ttccgtttta gtcaggaaga cttcttggga ccattcttag taacctgaaa tttctttttt 900
aattgcatga agtggaattg tcatgagcaa atgatgtgct tatttctccc tcaactgtga 960
atatctttga acttgctgtt ttcaatatgg gcagcacaaa ggtgagagat acatattaat 1020
agtngtatgt attnctctta tacattagat acctatattt aaatgaaagg gccaatattg 1080
aaacatatac                                     1090

```

<210> 55

<211> 1464

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (766)

<223> n equals a,t,g, or c

<400> 55

```

ccgctccgga attcccgggt cgaccacgc gtccgcccac gcgtcgccca cgcgtccggg 60
gacgtctca gctctcggcg caggcccgag cttccttcaa aatgtctact gttcacgaaa 120
tcctgtgcaa gctcagcttg gaggtgatc actctacacc cccaagtgca tatgggtctg 180
tcaaagccta tactaacttt gatgctgagc gggatgcttt gaacattgaa acagccatca 240
agaccaaaag tgtggatgag gtcaccattg tcaacatttt gaccaaccgc agcaatgcac 300
agagacagga tattgccttc gcctaccaga gaaggaccaa aaaggaaactt gcatcagcac 360
tgaagtcagc cttatctggc cacctggaga cggtgatttt gggcctattg aagacacctg 420
ctcagtatga cgcttctgag ctaaaagctt ccatgaaggg gctgggaacc gacgaggact 480
ctctcattga gatcatctgc tccagaacca accaggagct gcaggaaatt aacagagtct 540
acaaggaaat gtacaagact gatctggaga aggacattat ttcggacaca tctggtgact 600
tccgcaagct gatggttgcc ctggcaaggg gtagaagagc agaggatggc tctgtcattg 660
attatgaact gatggacca gatgctcggg atctctatga cgctggagtg aagaggaaag 720
gaactgatgt tcccaagtgg atcagcatca tgaccgagcg gagtgncccc acctccagaa 780
agtatttgat aggtacaaga gttacagccc ttatgacatg ttggaaagca tcaggaaaga 840
ggttaaaggga gacctgaaa atgctttcct gaacctggtt cagtgcattc agaacaagcc 900
cctgtatttt gctgatcggc tgtatgactc catgaagggc aaggggacgc gagataaggt 960
cctgatcaga atcatggtct cccgcagtga agtgacatg ttgaaaatta ggtctgaatt 1020
caagagaaaag tacggcaagt ccctgtacta ttatatccag caagacacta agggcgacta 1080
ccagaaaagcg ctgctgtacc tgtgtggtgg agatgactga agcccgacac ggccctgagcg 1140

```

```

tccagaaatg gtgctcacca tgcttcacgc taacaggtct agaaaaccag cttgcgaata 1200
acagtccccg tggccatccc tgtgaggggtg acgttagcat tcccccaac ctcatTTtag 1260
ttgcctaagc attgcctggc cttcctgtct agtctctcct gtaagccaaa gaaatgaaca 1320
ttccaaggag ttggaagtga agtctatgat gtgaaacact ttgcctcctg tgtactgtgt 1380
cataaacaga tgaataaaact gaatttgtag tttaraaaaa aaaaaaaaaa aactyrgggg 1440
ggggcccgka cccattggcc ttag                                     1464

```

<210> 56

<211> 985

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (647)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (875)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (962)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (973)

<223> n equals a,t,g, or c

<400> 56

```

agaagttgct agtgttcaat gcagctgggg tgaaacccca ggggcaaggt ggctggcttt 60
gatctggacg ggacgctcat caccacacgc tctgggaagg tctttccac tggccccagt 120
gactggagga tcttgtaccc agagattccc cgtaagctcc gagagctgga agccgagggc 180
tacaagctgg tgatcttcac caaccagatg agcatcgggc gcgggaagct gccagccgag 240
gagttcaagg ccaaggtgga ggctgtggtg gagaagctgg ggggtcccctt ccaggtgctg 300
gtggccacgc acgcaggctt gtaccggaag ccggtgacgg gcatgtggga ccactctgag 360
gagcaggcca acgacggcac gccatatcc atcggggaca gcatctttgt gggagacgca 420
gccggacgcc cggccaactg ggccccgggg cggaagaaga aagacttctc ctgcgccgat 480
cgctgttttg ccctcaacct tggcctgccc ttcgccacgc ctgaggagtt ctttctcaag 540
tggccagcag cgggcttcga gctcccagcc tttgatccga ggactgtctc ccgctcaggg 600
cctctctgcc tccccgagtc cagggccctc ctgagcgcca cccggangtg gttgtcgag 660
tgggattccc tggggccggg aagtccacct ttctcaagaa gcacctcgtg tcggccggat 720
atgtccacgt gaacaggga acgctaggct cctggcagcg ctgtgtgacc acgtgtgara 780
cagccctgaa gcaagggaaa cgggtcgcca tcgacaacac aaaccagac gccgcgagcc 840
gcgccaggta cgtccartgt gcccgagccg cggngtacc cctgccgctg cttcctcttc 900
accgccactc tggagcaggc gcgccacaac aaccgggtga gcccgttca gcccgggaca 960
cnccccgggg atngcacccc ctgga                                     985

```

<210> 57
<211> 1246
<212> DNA
<213> Homo sapiens

<400> 57
ctcagagtcg cgaggccgga cgcagcgcgc gccgcccac tcgcccagc cgccgccatg 60
aaggccgtgg tgcagcgcgt caccggggcc agcgtcacag ttggaggaga gcagattagt 120
gccattggaa ggggcatatg tgtgttgctg ggtatttccc ttgaggatac gcagaaggaa 180
ctggaacaca tgggtccgaaa gattctaaac ctgctgttat ttgaggatga gagtgggaag 240
cactgggtcg agagtgtgat ggacaaacag tacgagattc tgtgtgtcag ccagtttacc 300
ctccagtgtg tcctgaaggg aaacaagcct gatttccacc tagcaatgcc cacggagcag 360
gcagagggct tctacaacag cttcctggag cagctgcgta aaacatacag gccggagcct 420
atcaaagatg gcaagtttgg ggcctacatg caggtgcaca ttcagaatga tgggcctgtg 480
accatagagc tgggaatcgcc agctcccggc actgctacct ctgacccaaa gcagctgtca 540
aagctcgaaa aacagcagca gaggaagaa aagaccagag ctaagggacc ttctgaattc 600
aagcaaggaa agaaacactc cccgaaaaga agaccgcagt gccagcagcg gggctgaggg 660
cgacgtgtcc tctgaacggg agccgtagct caggaggcag aattcagtgt gttatcattg 720
ggcagaactg gatcctgaaa aattcaagat gctaagcacc tacactactt taagaatttg 780
gaactgaaac atgaagagga agacagaaat aagaatttgg gaacctgaat agctctgcaa 840
aaaacaccaa aggaccgttt tatcgttttc tgttgttgct gtggtggagt gatgcagtgg 900
gcactkccsg tgggcccagg ggcgggtgcg catgtggtag aagggtgtgcg ctctgtgcctc 960
ccccacagaa aggctttgtt ggtttctacc acatcttggc ttgcttttgg aacaggctgg 1020
ccccagcatc atttgtcatc aagtccactg ttggtgtattc tgcgtgtcca tggcgggggg 1080
tctccaayac actcacactg tccatgtttc ttttattgcc agggcccgtg ttgaagtgtc 1140
aagagagcaa tcatcaatga taatgtattg tgtgagacct ttgcatcttg taaattttct 1200
cttttttcta aaaataaata ataataaaat cctaaatctc aacaaa 1246

<210> 58
<211> 1966
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1926)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1942)
<223> n equals a,t,g, or c

<400> 58
gggagaaaga tccttcactc acagaaccag ttattagggg gttaatgaaa ttttggccta 60
aaacatgtag tcaaaaagag gtcatgttcc ttggggactg gaagaaatat tggatgtgat 120
tgaaccttca caatttgtaa aaatccaaga acctttgttt aaacaaatcg ccaagtgtgt 180
atctagcccc cattttcagg tggcagaaa agcactctat tattggaata atgaatacat 240
catgagtttg atagargaaa actotaacgt catccttccc atcatgtttt ccagccttta 300
taggatttca aaagaacatt ggaatccggc tattgtggcg ttggtgtaca atgtgttgaa 360
ggcatttatg gaaatgaaca gcaccatgtt tgacgagctg acagccacat acaagtcaga 420

```

tcgtcagcgt gagaaaaaga aagaaaagga gcgtgaagaa ttgtggaaaa aattggagga 480
tctggaggtta aagagaggtc ttagacgtga tggaataatt ccaacttaac aaaaacaatg 540
acaacaacat tactaacctg tggagtcaca cgtttatgta gtagaagatg gagcaacagt 600
tttctgtatt gtgcaacttt acagtagatt tcacctttgt ttcattatta cagcagcact 660
gtatatacct gtctctaagt aaaggaaaaa acaaaataag gacttcaatc caaagtttgg 720
acagtagatg gacttctcag aactttgcaa acataatcat tgttctcacc ctctttttaa 780
aaaaaaaatc ggtcttcaaa gatctgttga tgaaattgct atgttaaaat tccattatcg 840
ggagttcctt atttatcact agcagagagt atgatacaat tttcaaatgt gaacaatctt 900
aaatttagct tgtctttctg ctaagctgtt aaatgtattt atagttaaagg aagaaaaaaa 960
gactgtcatt tccttataag tttgtgtaac atcctcctct ggataacttg actgtaattt 1020
racatctttt tcttttgcac atcttcctga gttgaatgtc cacgtggaat ggggtcatga 1080
attataaaag tccctgataa aagttttgtt tactgggtg aacatctttc cagtaaccag 1140
gtagtcctgg tactccttta gttttaaaat taggagttaa gagagaagag gtgataaaca 1200
tagtagggaa gggaaatctg gattcatgca tcagtttatg gtgaatccaa atcaatgtct 1260
tgaatccttt gaaaacaggc actgggacat cacaggcttc agtacctgac cagtattagt 1320
tgcatatata attgaacaca cataccagag atgttttaga aatgtgagaa aaacatcctt 1380
ttggaccatt tgaaataaga aagacaaaca ctaaacaata caaccatgaa attgatcacc 1440
gggattgcaa atctaattgg gaaaagagtt gagcaaacag cttggactgt ttggagttgt 1500
tgccctactt tttaatatgt atttataaag tattccagca aaagaggatg tagcctctgg 1560
gaaaaaacia acatgttaca gtgttttttg tagattctcg ttctatatct catcacagcg 1620
ccagccctgt ttttagccgg aaaggattca ggataaacat tattatgcat tctgaattgg 1680
atgcatattc ctaactactg tatttgttac caaaagtggg tctacaaatg ctactgaaaa 1740
aaatctggaa attcctaatt tcctgagtat taataataaa gtttaaaaat gcttttatat 1800
caaaggtgca tcgtgaccaa attgttttaa aaaaaaaac aaaaaaaca aaatctaggg 1860
ctgtatttta tatatatata tatatatata tatatatata tatatatata tatatatgtc 1920
cttatnggac tctctgcttt gntattttaa taaaaaatct tacatc 1966

```

<210> 59

<211> 1611

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<400> 59

```

cgcgctcngtg cgaattcggc acgaggggac ttcccagagc tcacaatgga ggttgatggt 60
aaggtagagt caattatgaa gaggacagct ttggtagcca atacctccaa tatgcctgtt 120
gctgctagag aagccyctat ttatactgga atcacactgt cagagtactt ccgtgacatg 180
ggctatcatg tcagtatgat ggctgactct acctctagat gggctgaggc cttagagaaa 240
tctctggtcg tttagctgaa atgcctgcag atagtggata tccagcctat cttggtgcc 300
gtctggcctc gttttatgaa cgagcaggca gggtgaaatg tcttggaat cctgaaagag 360
aaggagtggt cagcattgta ggagcagttt ctccacctgg tgggtgatttt tctgatccag 420
ttacatctgc cactcttggt atcgttcagg tgttctgggg cttagataag aaactagctc 480
aacgtaagca tttccctct gtcaattggc tcatcagcta cagcaagtat atgcgtgcct 540
tggtatgaata ctatgacaaa cacttcacag agttcgttcc tctgaggacg aaagctaagg 600
aaattctgca ggaagaagaa gacctggcag aaattgtaca gcttggtggga aaggcttctt 660
tggcagaaac agataaaatc actctggagg tagcaaaact tatcaaagat gatttcctac 720
aacaaaatgg atatactcct tatgacaggt tctgccatt ctacaagaca gtagggatgc 780

```

```

tgtccaacat gattgcattt tatgatatgg ctctgtagagt gtttgaaacc actgcccaga 840
gtgacaataa aatcacatgg tccattattc gtgagcacat gggagacatc ctctataaac 900
tttcctccat gaaattcaag gatccactga aagatgggtga ggcaaagatc aaaagcgact 960
atgcacaact tcttgaagac atgcagaatg cattccgtag ccttgaagat tagaagcctt 1020
gaagattaca actgtgattt ccttttcctc agcaagctcc tatgtgtata ttttcctgaa 1080
tttctcatct caaacccctt gcttctttat tgtgcagctt tgagactagt gcctatgtgt 1140
gttatttgtt tccctgtttt tttggtaggt cttatataaa acaaacattc ctttgttcta 1200
gtgttgtgaa gggcctccct cttcctttat ctgaagtggg gaatatagta aatatacatt 1260
ctggttacac tactgtaaac ttgtatgtag ggtgatgacc ctctttgtcc taggtgtacc 1320
ctttcctcat ctctattaaa ttgtaaacag gactactgca tgtactctct ttgcagtga 1380
tttggaatgg aaggccaggt ttctataact tttgaacagg tactttgtga aatgactcaa 1440
tttctattgt ggtaagctca ttggcagctt agcattttgc aaaggaattg ctttgcagga 1500
aatatttaat ttcaaaaaac ataatgatta atgttccaat tatgcatcac ttccccagk 1560
ataaaycagg aatgkttgtg agaaaccatt gggaactata ctctttttta a 1611

```

<210> 60

<211> 1849

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (100)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (977)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1846)

<223> n equals a,t,g, or c

<400> 60

```

gattcccggg tcgaccacg cgtccgcgcg gaatctcagt tagcgggtgga gaggcagtat 60
gtccggttca atggcgactg cggaagctag cggcagcgan tgggaaaggg caggaagtcg 120
agacctcagt cacctattac cggttggagg aggtggcaaa gcgcaactcc ttgaaggaac 180
tgtggccttg gatccatggg cgagtctacg atgtcaccgg ctctctcaac gagcaccctg 240
gaggagaaga ggttctgctg gaacaagctg gtgtagatgc aagtgaagtc tttgaagatg 300
taggacactc ttctgatgcc agagaaatgc taaagcagta ctacattggg gatatccatc 360
cgagtgcctt taaacctgaa agtggtagca aggacccttc aaaaaatgat acatgcaaaa 420
gttgctgggg atattggatt ttacccatca taggcgctgt tctcttaggt ttctgtacc 480
gctactacac atcgaaaagc aaatcctcct gaggaggcct tgctgaagtt agaaagtgca 540
tccacttttg ggcgaaaact agagacttgc ttgggggctg cagaagtgcc ctctcctcga 600
atcctgccag ttgcattctt ccccttggga gccaaagcga ttggccagac atcacctcag 660
atctgagacc agcgtcttcc atctctcaga gccttactcc caaagtacct gctcactggt 720
ccgtgttgaa caattgccgg tgtttcctct cttcactggg ttccatgagt acccttatat 780
ttcacaactt tctgttcata agttatagtg acattgctct ttggtaaaaa tgccctgctt 840
ccaatacttt gattgcatat tagacattct taacaggggc gcagtctagt gttgaaagtt 900

```

```

ttattttttcc attttttcttt taagtaaatt ttttttaaaa aattctgatt tagggctagg 960
tgtggtggct caggccngta atcckggcac ttkgggrrgc caaggtggga agatcgsttg 1020
aggccaagag ttcaagacca gcctgggcaa catagcgaga cccctatctg tattaaaaaa 1080
aaatctgatt taattctttt atttatcata aggggtttta ttcttgaagt aaaggtttgc 1140
acctattaaa cttaaaactg ccaaattgatt tttgttcttt tatgtgcgtg ataaaaatac 1200
aaagaatggt gtggccacct cctccctttc aagctagggc agcaggtagc tcttcccagc 1260
ccctgagccc agccccttcc caagtgggtgc cggacaaaaa actacatggc cctttcgtgt 1320
cttgggggtg gaaagggagg gatgaattgg ggtgatagaa ccctggtgaa ttcagagtaa 1380
tctttcttta gaaaactggt gttttctaaa gaaacaggat aggagttag agaaggcacc 1440
aaagctttca ctttggtttg gcaccagttt ctaaccatct gttttttcta ccctagctat 1500
cttttattgg taaaatataa atgtataatt atgtttgtag agctttacca aggagtttcc 1560
ctcctttttt gtttgttgat tagcaaattt ttgattctcc attttccaaa agtaagagac 1620
tccagcatgg ccttctgttt gccccgcagt aaagtaactt ccatataaaa tggatattga 1680
aagtgagagt tcatgacaac agaccgtttt ccatttcata tgtattttat ctccgtgact 1740
ccaacttggt ggtttgttct gtttttccat gagaataaaa tactggcggg ttttttcaaa 1800
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaggngnga 1849

```

```

<210> 61
<211> 233
<212> DNA
<213> Homo sapiens

```

```

<400> 61
aagggtcggc ctctcaaagt gctgggatta caggcattag ccactgtgcc tggccaagaa 60
taaaaatttt ttaatcttga gaaraacat acagktcata catataaaaa gccttgaaaa 120
tattattccc ttgactcac taattacact gctggaatat aaagaaatga tcctaaatat 180
atatgtagtt ttatggtcct aaatatgtat aaagctttat gatcactcgt gcc 233

```

```

<210> 62
<211> 2333
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (14)

```

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2327)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2331)

<223> n equals a,t,g, or c

<400> 62

```

cgncgnnccg cgancccacg cgtccgggtgg aagatatgtg gacttagtcc cactacaacc 60
ttagccatat attttgaggt tgtcaatcag cataatgctc caattcytca aggagggcgt 120
ggtgcaatcc agtttgtgac tcagtatcag cattcaagtg ggcagagacg catccgagtg 180
accaccattg ctaggaactg ggcagatgct caaactcaaa tccaaaacat tgctgcatct 240
tttgaccagg aggcagctgc cattcttatg gcccggttag caatatatag agcagaaaca 300
gaagaaggtc cagatgtgct taggtggctg gacagacagc tcattcgact gtgtcagaaa 360
tttgagaaat atcataaaga tgacccaagt tccttcagat tttcagaaac tttctccctt 420
tatccacagt ttatgtttca tttaagaaga tcttctttcc tgcaagtttt taacaatagt 480
cctgatgaga gttcatatta tcgtcaccat tttatgcgtc aagatctgac ccagtctcta 540
attatgattc agcctatcct gtatgcgtat tcttttagtg gaccaccaga gccggttctt 600
cttgatagca gtagcattct tgcagatcgt attcttctca tggacacatt cttccagatt 660
ttgatttatc atggtgagac catagcacag tggcggaagt caggatacca ggatatgcct 720
gagtatgaaa atttccgccca ccttctgcaa gcccagtggt atgatgcaca ggaaattctt 780
cactccagat ttccaatgcc aagatacatt gacactgaac atggaggcag ccaggcccggt 840
ttcctccttt caaaaagtcaa cccttcacag actcataata atatgtatgc ctgggggcag 900
gagtctggag cacctattct tacagatgat gttagtttac aagtgtttat ggatcacttg 960
aagaaacttg ctgtgtccag tgctgcttga agtgctaata atgttaaaga cacttaagaa 1020
gatgaaaata tattcaaatt tcattttttc ctttttccat ttatctgtgg aaaccaacag 1080
atattgctct atattttttg tattagtatg gtttgagaca acatatggaa aatgttcaca 1140
tttgtagatt aagctggaat tataatgaga gcaataagaa caaatttatt ttgcttacca 1200
cagtgttata gctggttcta gaaatttgaa gtctttataa ctttaattatg tttaataaaa 1260
aatagagtct gcctcgact acagatgtaa ctcatgtgta tattgcagac agacccaaag 1320
tggcactgaa ttttcttgct caccctttta aaacttgctt ctttaatttta gccagaaagc 1380
aaaaaaacaa tagtaatgat aaatgtgaac atttttgctt attcattgaa tatttttctg 1440
taattttcag cacttatgta tacacttttt ctgtacttac taggttaagg cagattttatt 1500
tttatgattt gtttaggaat tatttgattt tataatggta attttcatga tgataatggt 1560
tttggttatt tggaaagata gtttagagat gaaagggttt tttgggtaac aatcccgcag 1620
ctgacaaaaa atgtgaaatt tccacaaaat atccaactta tgtgactaaa cgcagtagtt 1680
tttttaaaaag gggagataga aaataaatgg ttttgttgga gtgcatttta gtaagccttt 1740
gcagtaaaat gacggttgta actactaaac caaatttagt tttcacagca tggttttggt 1800
gttttccctt tgtttttcag aggtaaattt tgcattatat ccttcagtat tttaacacta 1860
ttttggcagt ttacacatta ctttttgttt ttccttcctt tttgtgaaat gtattaagtt 1920
gtggttctta ttgaaacagt attatataat gtttgcttaa ttatatcatg tgatgctcag 1980
ttctattttg atttattcat tagtattcac ttttacctt aaagtttact tgtagcaaat 2040
atgtttacat tgataaagcc agatatgttt tgacaatgaa atttacatat caagtactgc 2100
aaataaaaag tgggtgctatg atatatgctt aggaggacag ttttaaatgat tgtacttgca 2160
tgaacacaat catatgatgg taaagcagaa acttaagaaa aaattgttta tgtgttatat 2220
tcaattagct taaataagtt gctttgttat attttatttg aattgaacta cgctaggcct 2280

```

aaatgccaat aaaatataact tttcactggt aaaaaaaaaa aataaanacc nta 2333

<210> 63

<211> 1470

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1410)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1414)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1419)

<223> n equals a,t,g, or c

<400> 63

```

gcttcctgct gccaccctg tggttctgca gcccagtgcc caagtacttc ttcaagatgg 60
ccttctacaa tggtctggatc ctcttcctgg ctgtgctcgc catccctgtg tgtgccgtgc 120
gaggacgcaa cgctcgagaac atgamgatct tgcgtctaata gctgctccac atcaaatacc 180
tgtacgggat ccgagtggag gtgcgagggg ctccaccactt ccctccctcg cagccctatg 240
ttgtttgtctc caaccaccag agctctctcg atctgcttgg gatgatggag gtactgccag 300
gccgctgtgt gccattgcc aagcgcgagc tactgtgggc tggctctgcc gggctggcct 360
gctggctggc aggagtcac ttcatcgacc ggaagcgcac gggggatgcc atcagtgtca 420
tgtctgaggt cgcccagacc ctgctcacc aggacgtgag ggtctgggtg tttcctgagg 480
gaacgagaaa ccacaatggc tccatgctgc ccttcaaaacg tggcgccctc catcttgca 540
tgcaggccca ggttcccat gtcccatag tcatgtcctc ctaccaagac ttctactgca 600
agaaggagcg tcgcttcacc tcgggacaat gtcagggtgc ggtgctgcc ccagtgccca 660
cggaagggtc gacaccagat gacgtcccag ctctggctga cagagtcgg cactccatgc 720
tactgtttt ccgggaaatc tccactgatg gccgggggtg tggtgactat ctgaagaagc 780
ctggggggcg tgggtgaacc ctggctctga gctctcctc catctgtccc catcttcctc 840
cccacaccta cccaccagt gggccctgaa gcagggcmaa accctcttcc ttgtctcccc 900
tctccctact tattctcctc tttggaatct tcaactctg aagtgaatgt ggatacagcg 960
ccactcctgc cccctcttgg ccccatccat ggactcttgc ctccgtgcag tctccactct 1020
tgaccccccac ctctactgt cttgtctgtg ggacagttgc ctcccccctca tctccagtga 1080
ctcagcctac acaaggagg ggaacattcc atccccagtg gactctcttc ctatgtggtc 1140
ttctctaccc ctctaccca cattggccag tggactcacc cattctttgg aacaaatccc 1200
ccccactcca aagtccatgg attcaatgga ctcatccatt tgtgaggagg acttctcgcc 1260
ctctggctgg aagctgatac ctgaagcact cccaggctca tcmtgggagc tttcctcagc 1320
accttcacct tccctcccag tgtagcctcc tgctcagtggg ggctggacc ttctaattca 1380
gaggtctcat gcctgccctt gccagatgn ccangggtn tgcamtytyt ggggatacca 1440
gttcagctctc camatttytg ggttttytgt 1470

```

<210> 64

<211> 939

<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (3)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (11)
 <223> n equals a,t,g, or c

<400> 64
 agnntaccgg ntccggaatt cccgggtcgg acccacgcgt ccggtctcct cagaagtcgc 60
 ttagctcttc ggtggttgtc acacgtccgg aggcctagcc gtcgcgtacc taggatgccg 120
 cgtggaagcc gaagccgcac ctcccgcatg gcccctccgg ccagccgggc ccctcagatg 180
 agagctgcac ccaggccagc accagtcgct cagccaccag cagcggcacc cccatctgca 240
 gttggctctt ctgctgctgc gccccggcag ccagggtctga tggcccagat ggcaaccact 300
 gcagctggcg tggctgtggg ctctgctgtg gggcacacat tgggtcacgc cattactggg 360
 ggcttcagtg gaggaagtaa tgctgagcct gcgaggcctg acatcactta ccaggagcct 420
 cagggaaacc agccagcaca gcagcagcag ccttgccctct atgagatcaa acagtctctg 480
 gagtgtgccc agaaccaggg tgacatcaag ctctgtgagg gtttcaatga ggtgctgaaa 540
 cagtgccgac ttgcaaacgg attggcctaa tgaagaagtt caacctggag agatggaaaa 600
 tcagctctca taactaagtt aatttagtat aaaaatagaa ttgatatga gggataaaag 660
 tgtaaccatc agttaaacct ctctgtcat tcctagcttc cttgcttcag aattgaaatg 720
 gaagtggggg tgtccctact ctgtagaatc tgggactggg caaatgttt tgtggcctcc 780
 ttaaactagc tgttatgtta tgattttatt ctttgtgagt taattagaat aaagtcattt 840
 tctccaagg tatggttcat ttagtctata gtctctggtt atgaaattag catcctccca 900
 gatctgacag ctccctgagg ggttatataa ggagtagct 939

<210> 65
 <211> 2068
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (308)
 <223> n equals a,t,g, or c

<400> 65
 gtaggaagtg tctgtagccg cagctgcgsg tccgggattc ccagccatgg cagattcctc 60
 cgggcagcag gctcctgact acagggtccat tctgagcatt agtgacgarg cagccagggc 120
 acaagccctg aacgagcacc tcagcacgcg tagtatgtcc aggggtactc actgtccag 180
 gcagacgtgg acgcgttcag gcagctctcg gccccgcccg ctgaccccca gctcttccac 240

```

gtggctcggg ggttcaggca catagaagcg ctccctgggta rccctgtgg caaaggccag 300
ccctgcangc tyccaagcar gcaaaggccg gcgtgtgcag cccagtggt cccctcctgc 360
tgggaccas catgcagact ccacctttac aacagcctca ccaggaaca ggaagtgttc 420
atacctcaag atgggaaaaa ggtgacgtgg tattgctgtg ggccaaccgt ctatgacgca 480
tctcacatgg ggcacgccag gtcctacatc tcttttgata tcttgagaag agtggtgaag 540
gattacttca aatttgatgt cttttattgc atgaacatta cggatattga tgacaagatc 600
atcaagaggg cccggcagaa ccacctgttc gagcagtatc gggagaagag gcctgaagcg 660
gcacagctct tggaggatgt tcaggccgcc ctgaagccat tttcagtaaa attaaatgag 720
accacggatc ccgataaaaa gcagatgctc gaacggattc agcacgcagt gcagcttgcc 780
acagagccac ttgagaaagc tgtgcagtcc agactcacgg gagaggaagt caacagctgt 840
gtggaggtgt tgctggaaga agccaaggat ttgctctctg actggctgga ttctacactt 900
ggctgtgatg tcactgacaa ttccatcttc tccaagctgc ccaagtctct ggagggggac 960
ttccacagag acatggaagc tctgaatgtt ctccctccag atgtcttaac ccgggttagt 1020
gagtatgtgc cagaaattgt gaactttgtc cagaagattg tggacaacgg ttacggctat 1080
gtctccaatg ggtctgtcta ctttgataca gogaagtttg cttctagcga gaagcactcc 1140
tatgggaagc tgggtgcctga ggccgttgga gatcagaaag cccttcaaga aggggaaggt 1200
gacctgagca tctctgcaga ccgctgagt gagaagcgct ctccaacga ctttgcctta 1260
tggaaggcct ctaagcccgg agaaccgtcc tggccgtgcc cttggggaaa gggctcgtccg 1320
ggctggcata tcgagtgtc gcacatggca ggcaccctcc taggggcttc gatggacatt 1380
cacggaggtg gggtcgacct ccggttcccc caccatgaca atgagctggc acaktcggag 1440
gcctactttg aaaacgactg ctgggtcagg tacttcctgc acacaggcca cctgaccatt 1500
gcaggctgca aaatgtcaaa gtcactaaaa aacttcatca ccattaaaga tgccttgaaa 1560
aagcactcag cacggcagtt gcggctggcc ttcctcatgc actcgtggaa ggacaccctg 1620
gactactcca gcaacaccat ggagtcagcg cttcaatatg agaagttctt gaatgagttt 1680
ttcttaaatg tgaaagatat ccttcgcgct cctgttgaca tcaactgtca gtttgagaag 1740
tggggagaag aagaagcaga actgaataag aacttttatg acaagaagac agcaattcac 1800
aaagccctct gtgacaatgt tgacacccgc accgtcatgg aagagatgag ggccttggtc 1860
agtacgtgca acctctatat ggcagcccg aaagccgtga ggaagaggcc caaccaggct 1920
ctgctggaga acatcgccct gtacctcacc catatgctga agatctttgg ggcgtagaaa 1980
gaggacagct ccctgggatt cccggtcgga gggcctggaa ccagcctcag tctcgaggcc 2040
acagtcatgc cctaccttca ggtgttat 2068

```

<210> 66

<211> 1391

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (27)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1343)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1358)
 <223> n equals a,t,g, or c

<400> 66
 nccacgcgctc cgcggnacgn tgggngnttt taaaatgggt ttttttggtg ttgttgatgg 60
 ggggggagag ggtccagcat tttttaaatg ttttcacatc gtgtgttcca aaaataactg 120
 gttagcctaa gtcacttcca ccctccaatg ttgtgaatgc agtctctagc attcgctatt 180
 taatgtcttc ttcctgcact atttgagaaa tcgcgagggtc gacttaatac cgcagtcgcc 240
 acttcgcgga cggaggcgg agtctgctta gttctgagga ctgcgtgggt ccgcgcagag 300
 agtcctgct aggcctgcgc gtcccgttct aaattcttac ccttttagtyc ttgtcaccac 360
 ccccgccgtg ggaacggcct gacagtcact cgtcaaagga agtggtgcc gccagctctt 420
 gaccgggaat cggatcctag tcccaccccc tccgctccag gcttccttct gcaacaggcg 480
 tgggtcacgc tctcgctcgg tctttctgcc gccatcttgg ttccgcgttc cctgcacaaa 540
 atgcccggcg aagcacagaa accgtccctg ctacagagca ggagttgcc cagccccagg 600
 ctgagacagg gtctggaaca gaatctgaca gtgatgaatc agtaccagag cttgaagaac 660
 aggattccac ccaggcaacc acacaacaag cccagctggc ggcagcagct gaaatcgatg 720
 aagaaccagt cagtaaagca aaacagagtc ggagtgaana gaaggcacgg aaggctatgt 780
 ccaaactggg tcttcggcag gttacaggag ttactagagt cactatccgg aaatctaaga 840
 atatcctctt tgatcatcaca aaaccagatg tctacaagag ccctgcttca gatacttaca 900
 tagtTTTTTg ggaagccaag atcgaagatt tatcccagca agcacaacta gcagctgctg 960
 agaaattcaa agttcaaggt gaagctgtct caaacattca agaaaacaca cagactccaa 1020
 ctgtacaaga ggagagtga gaggaagagg tcgatgaaac aggtgtagaa gttgaagaca 1080
 tagaattggg catgtcaca gcaaatgtgt cgagagcaaa ggcagtcga gccctgaaga 1140
 acaacagtaa tgatattgta aatgcgatta tggaattaac aatgtaacca tatggaagca 1200
 actTTTTTt gtgtctcaaa ggagtaactg cagcttggtt tgaaatttgt actgtttcta 1260
 tcataaataa agttatggct tcttggtgga tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
 aaaaaaaaaa aaaaaaaaaa cngggccgca ggcttttncc ctttggtggg ggttattttt 1380
 ggcttgcccc t 1391

<210> 67
 <211> 659
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (139)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (475)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (585)
 <223> n equals a,t,g, or c

<400> 67
 gcaaggctgc tgctatgggg ccgggcggcg tgtggcgcggt ctgctcgccc cactaatgtg 60
 ggcgagggcg gtttcctcgg tggcggggtc cgcggttgga gccgagcccg ggcttcgggt 120
 gctggccgtg cagcgyttnc ccgtagagca gcgttctgcc gggcttgcca gaccccaaac 180
 tttgtccgcg gcctgcacag cgaagcctgg gctggaggag cgggaggagg ggacgggtcaa 240
 cgagggacgc ccagaatcgg acgcggcaga tcatactggg cccaagtttg acatcgatat 300
 gatggtttca cttctgaggc aagaaaatgc aagagacatt tgtgtgatcc argttcctcc 360
 agaaatgaga tatacagatt actttgtgat tgtagtgga acttctaccc gacacttaca 420
 tgccatggcy ttctacgttg tgaaaatgta caaacacctg aaatgtaaac gtganccctc 480
 atgttaagat agaagggaag gacactgatg actggctgtg cgtggatttt ggcagcatgg 540
 tggattcatt tgaatgcttc cagaaaacca gagaaatcta tgganttaga gaaattatgg 600
 accctacgtt cttatgaatg accagtttagc tcagatagca cctgaggaca gtacctgta 659

<210> 68
 <211> 2981
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (2858)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2948)
 <223> n equals a,t,g, or c

<400> 68
 ggcagagggt ttccggcctg agaaaccgtc atgtttcttg ggagtcacct cagctggcag 60
 ttaccaccgt gttagaaagc agcctcagga ccggccacct ccatcactgg cgtcaccatg 120
 ggggctgtgc tgggtgtctt ctccctcgcc agctgggttc catgcctctg cagcgggtgc 180
 tcatgtttgc tgtgtagttg ctgtcctaac agtaagaatt ccacgggtgac tcgcctcatt 240
 tatgctttca ttctcctcct gagcactgtc gtatcctata tcatgcagag aaaagagatg 300
 gaaacttact tgaagaagat tcctggattt tgtgaagggg gattttaaact ccatgagggt 360

```

gatataaatg cagataaaga ttgtgatgtg ctggttggtt ataaagctgt gtatcggatc 420
agctttgcc a tggccatctt tttctttgtc ttttctctgc tcatgttcaa agtaaaaaaca 480
agtaaagatc tccgagcggc agtacacaat gggttttggt tcttcaaaat tgctgccctt 540
attggaatca tggttggctc tttctacatc cctgggggct atttcagctc agtctggttt 600
gttgttggca tgataggggc cgccctcttc atcctcattc agctgggtgct gctggtagat 660
tttgctcatt cttggaatga atcatgggta aatcgaatgg aagaaggaaa cccaagggtt 720
tggtagctg ctttactgtc tttcacaagc gccttttata tctgtcaat catctgtgtc 780
gggctgctct atacatatta caccaaacca gatggctgca cagaaaacaa gttcttcac 840
agtattaacc tgatcctttg cggtgtggct tctattatat cgatccacc aaaaattcag 900
gaacaccagc ctgcgtccgg cctcttgag tctccctca tcaccctcta cactatgtac 960
ctcacctggt cagccatgtc caatgaacct gatcgcttct gcaatcccaa cctgatgagc 1020
tttattacac gcataactgc accaaccctg gctcctggaa attcaactgc tgtgggccct 1080
accctactc caccatcaaa gagtgggtct tttactggatt cagataat ttttggactg 1140
tttgtctttg ttctctgcct cttgtattct agcatccgca cttccactaa tagccaagta 1200
gacaagctga ccctgtcagg gagtgcagc gtcaccttg gtgatacaac taccagtgg 1260
gccagtgat aagaagatg acagcctcgg cgggctgtgg acaacgagaa agagggagt 1320
cagtatagct actccttatt ccacctcat ctctgcttg cttccttgta catcatgat 1380
accctgacca gctggtacag ccctgatgca aagtttcaga gcatgaccag caagtggcca 1440
gctgtgtggg tcaagatcag ctccagctgg gtctgcctcc tgccttacgt ctggaccctt 1500
gtggctccac ttgtcctcac cagtcgggac ttcagctgaa cctctgagt ccaaggacac 1560
cactggaact cacaagggtc tccttcaccg aaaaccata taccttttaa gtttgtttca 1620
actaaaatat taagtgaatg ctttgcaagt ttgactgtat gcaggtttat atcagaagg 1680
gagattgaat aatgcttgat gcagaatcga aacttctcat ttatctgtat attatgttta 1740
cttctaagga tatagcacia agggaacatt ttttgtttaa agtgaactac agctgtgctg 1800
tgaagagagt tctttataaa gcctgtaggt tcttttaact ttgggtttaaa atgtaagata 1860
ggaaaatggt ggatatttga ggccatgctt aatataattt tattgcagta tcctttaaaa 1920
gcaaaaaaaaa aaaaatgcat ttatattaca gttttcctct atgaaagtcc ttacttatat 1980
gatacaagca ctgtgttttg tgcttaaaact cttcagcggg gtagcatcaa agttcttggg 2040
gaaggatcgt atatgtgggt cccttcccta gaagaatggt tgctgatatg gctactgctt 2100
ctacatcttg agttttttta tttacttttt ttacactgta gcattgagac tgcttgattc 2160
aagtctggtg ctttgccaga tgtattaatt tccataaatg ctttgtgagt ttgggttaaaa 2220
tgaagattca cttgggaaaa cactgcagct ttagtctgtg ttactatctt gttatgagta 2280
tgtaaaagta aaatgcatgt gaatttatca tatttgcact atgaaggat ttgggttaaaa 2340
tacaaagact ttaagattt taaggccctt tcttccaaca gcttttatag ttagcagcca 2400
ttctttatct tctggatagc caggttttat cacgcttcta gtcaggatgc tcctattcct 2460
tctaaaaatt acggtctgac tagtgagcaa agtcttgaat ttattcaaaa gtcctaaata 2520
ccttctctag gtaagacact tggtagatga gagacggaag gcattgtcaa gaaccatttt 2580
catgagaggt ggtgtgcaaa aaggtagaat aaaagagttc tttcaamaaa gatttactgt 2640
ctawtctgta ctagaccctg taggttttg ggtacagtgt taaacatgat agaggctctg 2700
ccgtcttgga ctttaatagc ttagagaaga gagcaaatga gctgacaggt ggttataatg 2760
tgaattagtg ctgtggttta ggaattggag agaactcaaa ggagaggtat ttggtgtaat 2820
ggtaggcttt ctggagaaaa tgatatttaa gccaaagant cttagaagtt agctaagaga 2880
gagatgggaa aatgagacga cattgctgga gtagataaaa ctgcatgtta aaggcaggaa 2940
gatggggnaa aaaattccat aaaactggaa tggggaaatg t 2981

```

<210> 69

<211> 603

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (584)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (590)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (595)
 <223> n equals a,t,g, or c

<400> 69
 tcgacccacg cgtccggcac cgggggaaca aggtcgtgaa aaaaaaggtc ttggtgaggt 60
 gccgccattt catctgtcct cattctctgc gcctttcgca gagcttccag cagcgggatg 120
 ttggggccaga gcatccggag ttcacaacct ctgtgggtccg tagagccact atgaggaggg 180
 ccctgggaag aatttgccat tttcagtgkg taaggggcac ggcttcggtg ggggaggggg 240
 cgcttggtctg tgactcgcgc acctgcaagg ccgcctccgg gctgtggcgt gggagatgat 300
 agccagaaac caggctgaga cgcagactag cattccactt agcccaagga ccagtgagga 360
 agctgggcat cctagcgcgt accgctaaag gaatgggcag gtagatccgg aagccctgcc 420
 tccatcagcc acctgacgcc ccctcccccg ccccgagaa agccctgaga tggcyccggg 480
 aggccacggc tgtaggtgtg ttggttaaat ccgagctgga ggtcatcgga cccgaaatga 540
 aggtcattgg aaaatcatga ggaaatcagg gctctggtta tggnacaggn ttttnaaact 600
 agc 603

<210> 70
 <211> 1101
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (195)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1080)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1081)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1090)
 <223> n equals a,t,g, or c

<400> 70

```

aattcggcac gagcacagct catgttttcc agcctgtgtg ggagcttggt ctgaagagag 60
attaagtgat agcctactta tggatcctgg agaattcttc agaaatccat gtgtaactca 120
ggtgcctatt tggttatgac aaaagatatg gctaattttt attttgaaaa gtttgaataa 180
acttagtttt ctctntttcc acttgcaaag agttttgatg atggagacta ttttctgtg 240
tggggcacat gccttggatt tgaagagctt tcactgctga ttagtggaga gtgcttatta 300
actgccacag atactgttga cgtggcaatg ccgctgaact tcactggagg tcaattgcac 360
agcagaatgt tccagaatth tcctactgag ttgttgctgt cattagcagt agaacctctg 420
actgccaatt tccataagtg gagcctctcc gtgaagaatt ttacaatgaa tgaaaagtta 480
aagaagtttt tcaatgtctt aactacaaat acagatggca agattgagtt tatttcaaca 540
atggaaggat ataagtatcc agtatatggt gtccagtggc atccagagaa agcaccttat 600
gagtggaaaga atttggatgg catttcccat gcacctaatt ctgtgaaaaa cgcatthtat 660
ttagcagagt tttttgttaa tgaagctcgg aaaaaacaacc atcattttta atctgaatct 720
gaagaggaga aagcattgat ttatcagttc agtccaattt ataactggaaa tatttcttca 780
tttcagcaat gttacatatt tgattgaaag tcttcaattt gttaacagag caaatttgaa 840
taattccatg attaaactgt tagaataact tgctactcat ggcaagatta ggaagtcaca 900
gattcttttc tataatgtgc ctggctctga ttcttcattc tgtatgtgac tatttatata 960
acattagata attaaatagt gagacataaa tagagtgttt ttcatggaaa agccttctta 1020
tatctgaaga ttgaaaaaaa taaatttact gaaatacaaa aaaaaaaaaa aaaaaaatn 1080
nctcggtcgn caagggaatt c                                     1101

```

<210> 71

<211> 714

<212> DNA

<213> Homo sapiens

<400> 71

```

ggcagagaaa ctgtggcggg atagttttcg ggtccttgct cagtgaacac cctcggctgg 60
gaagtcagtt cgttctctcc tctcctctct tcttgtttga acatggtgcg gactaaagca 120
gacagtgttc caggcactta cagaaaagtg gtggctgctc gagccccag aaagggtgctt 180
ggttcttcca cctctgccac taattcgaca tcagtttcat cgaggaaaaga gcatgtcctt 240
tgcaacctga tcacacaaat gatgaaaaag aatagaactt tctcattcat ctttgaataa 300
cgtctccttg tttaccctgg tattctagaa tgtaaattha cataaatgtg tttgttccaa 360
ttagctttgt tgaacaggca ttttaattaaa aaatttaggt ttaaatttag atgttcaaaa 420
gtagttgtga aatttgagaa tttgtaagac taattatggt aacttagctt agtattcaat 480
ataatgcatt gtttggtttc ttttaccaaa ttaagtgtct agttcttgct aaaatcaagt 540
cattgcattg tgttctaatt acaagtatgt tgtatttgag atttgcttag attggtgtac 600
tgctgccatt tttattgggt tttgattatt ggaatggtgc catattgtca ctcttctac 660
ttgcttttaa aagcagagtt agatttttgc acattaaaaa attcagtatt aatt       714

```

<210> 72

<211> 2890

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (555)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2853)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2882)
 <223> n equals a,t,g, or c

<400> 72

```

aggggaattga gcaccccgga gcgggtctcag gccaaagcccc ctgccagcat ggccagcgag 60
ttcaagaaga agctcttctg gagggcagtg gtggccgagtg tcctggccac gacctctttt 120
gtcttcatca gcatcggttc tgccctgggc ttcaaatacc cgggtgggaa caaccagacg 180
gcgggtccagg acaacgtgaa ggtgtcgctg gccttcgggc tgagcatcgc cagctggcg 240
cagagtgtgg gccacatcag cggcgccac ctcaaccgg ctgtcacact ggggctgctg 300
ctcagctgcc agatcagcat cttcctgccc ctcagtaca tcatcgcca gtgctgggg 360
gccatcgctg ccaccgccat cctctcaggc atcamctcct ccctgactgg gaactcgctt 420
ggccgmaatg acctggctga wgtgtgaac ttccggccar ggccctgggca tcgagatcat 480
cgggaccctc cagctgggtg tatgctgct ggctactacc gaccggaggc gccgtgamct 540
tggtggctca gccgnccctt gccatcgccc tctctgtagc ccttgggaca cctcctggct 600
attgactaca ctggctgtgg gattaacct gctcggtcct ttggctccgc ggtgatcaca 660
cacaacttca gcaaccactg gattttctgg gtggggccat tcacggggg agccctggct 720
gtactcatct acgacttcat cctggcccca cgcagcagtg acctcacaga ccgctgaa 780
gtgtggacca gcggccaggt ggaggagtat gacctggatg ccgacgacat caactccagg 840
gtggagatga agcccaaata gaaggggtct ggcccgggca tccacgtakg gggcaggggc 900
agggcgggcg garggagggg aggggtgaaat ccatactgta gacactctga caagctggcc 960
aaagtcaactt cccaagatc tgccagacct gcatggtcaa gcctcttatg ggggtgtttc 1020
tatctctttc tttctctttc tgtttcctgg cctcagagct tcctggggac caagatttac 1080
caattcaccc actcccttga agttgtggag gaggtgaaag aaagggacct acctgctagt 1140
cgccctcag agcatgatgg gaggtgtgcc agaaagtccc ccctcgcccc aaagtgtctc 1200
accgactcac ctgcgcaagt gcctgggatt ctaccgtaat tgctttgtgc ctttgggac 1260
ggccctcctt cttttcctaa catgcacctt gctcccaatg gtgcttgag ggggaagaga 1320
tcccaggagg tgcagtggag ggggcaagct ttgctccttc agttctgctt gctcccaagc 1380
ccctgacctg ctcggactta ctgcctgacc ttggaatcgt ccctatatca gggcctsa 1440
gacctccttc tgcaaaagtg cagggaccgg cagagctcta caggcctgca gccctaagt 1500
gcaaacacag catgggtcca gaagacgtgg tctagaccag ggtgctctt tccacttgcc 1560
ctgtgttctt tccccagggg catgactgtc gccacacgcc tctgtgtaca tgtgtgcaga 1620
gcagacaggc taaaaagcag agatcgacag acagccaggt agttggaact ttctgttccc 1680
tatggagagg cttccctaca cagggcctgc tattgcagaa tgaagccatt tagagggtga 1740
aggagaaata cccatgttac ttctctgagt tttagtgggt ctttccatct atcactgcat 1800
tatcttgctc attcttctagt tctctactcc ctcttgctag tgtagacaca ggtcaccatt 1860
atgctggtgt atgtttatca aagagcactt gagctgtctg aagcccaaag cctgaggaca 1920
gaaagaccct gatgcaggtc agcccatgga ggcagatgcc cttgctgggc ctgggggttt 1980
tccaagccct cagctgggtc tgaccaggat ggagcaagct cttcccttgc tcatgagctc 2040
ctgatcagag gcatttgagc agctgaataa cctgcacagg cttgctgtat gacctctggc 2100
cacagccttc cctctgcatt gacctggagg ggagaggtca gccttgacct aatgaggtag 2160
ctatagttgc agcccaagga cagttcagag atcaggatca gctttgaagg ctggattcta 2220
tctacataag tcctttcaat tccaccaggg ccagagcagc tccaccactg tgcacttagc 2280
catgatggca acagaaacca agagacacaa ttacgcaggt atttagaagc agaggggaca 2340
ccagaaggcc cttaactatc accagtgcac cacatctgca cactctcttc tccattccct 2400

```

```

agcaggaact tctagctcat ttaacagata aagaaactga ggcccacggt ttcagctaga 2460
caatgatttg gccaggccta gtaaccaagg ccctgtctct ggctactccc tggaccacga 2520
ggctgattcc tctcatttcc agcttctcag tttctgcctg ggcaatgcca ggggccagga 2580
gtggggagag ttgtgatgga ggggagaggg gtcacacca cccctgcct ggttctagga 2640
tgctgcacac caaggccctg catctgtctg ctctgcatat atgtctcttt ggagttggaa 2700
tttcattata tgtaagaaa ataaaggaaa atgacttgta aggtcaaaaa aaaaaaaaaa 2760
aaaaaaaaaa aaaaagggcg gccgttctag gaggatccaa gcttacgtac ggggtgcatgg 2820
gacgtcatag ctcttcttta agtgtcaccc aanttcaatt cattgggcct cgtttttaca 2880
antcgtgact                                     2890

```

<210> 73

<211> 2488

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (277)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (446)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2382)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2412)

<223> n equals a,t,g, or c

<400> 73

```

ggcagagtga ccacgctcca tactgggaga ggcttctggg tcaaaggacc agtctgcaga 60
gggatcctgt ggctggaags gaggaggctc cacacggccg ttgcagctac cgcagccagt 120
agagacaggg ttctgccatc ttggccaggc tggctcctaaa ctctgacct ctggtgatcc 180
accgcctcg gcctcccaa gtgtaggat tacagggtg agccaccgca cccggccagg 240
gcacccctct ctctaacaca ggatctgggc atccagnac ggccatgacc cctccaaggc 300
tcttctgggt gtggctgctg gttgcaggaa cccaaggcgt gaacgatggt gacatgcggc 360
tggccgatgg gggcgccacc aaccagggcc gcgtggagat cttctacaga ggccagtggg 420
gcaactgtgt tgaacaacct gtgggnacct gactgatgcc agcgtcgtct gccgggccct 480
gggcttcgag aacgccaccc aggctctggg cagagctgcc ttcgggcaag gatcaggccc 540
catcatgctg gacgaggctc agtgcacggg aaccgaggcc tcaactggccg actgcaagtc 600
cctgggctgg ctgaagagca actgcaggca cgagagagac gctgggtgtg tctgcaccaa 660
tgaaaccagg agcaccaca ccctggacct ctccaggagg ctctcgagg cccttggcca 720
gatctttgac agccagcggg gctgcgacct gtccatcagc gtgaatgtgc agggcgagga 780
cgccctgggc ttctgtggcc acacggtcat cctgactgcc aacctggagg cccaggccct 840
gtggaaggag ccgggcagca atgtcacccat gagtgtggat gctgagtgtg tgcccatggt 900

```

```

cagggacttc tcaggtactt ctactcccga aggattgaca tcaccctgtc gtcagtcaag 960
tgcttccaca agctggcctc tgcctatggg gccaggcagc tgcagggcta ctgcgcaagc 1020
ctcttttgcca tctctctccc ccaggacccc tcgttccaga tgcccctgga cctgtatgcc 1080
tatgcagtgg ccacagggga cgccctgctg gagaagctct gcctacagtt cctggcctgg 1140
aacttcgagg ccttgacgca ggccgaggcc tggcccagtg tccccacaga cctgctccaa 1200
ctgctgctgc ccaggagcga cctggcggtg cccagcgagc tggccctact gaaggccgtg 1260
gacacctgga gctgggggga gcgtgcctcc catgaggagg tggagggctt ggtggagaag 1320
atccgcttcc ccatgatgct ccctgaggag ctctttgagc tgcagttcaa cctgtccctg 1380
tactggagcc acgaggccct gttccagaag aagactctgc aggccctgga attccacact 1440
gtgcccttcc agttgctggc ccggtacaaa ggctgaacc tcaccgagga tacctacaag 1500
ccccggattt acacctcgcc cacctggagt gcctttgtga cagacagttc ctggagtgca 1560
cggaagtcac aactggtcta tcagtccaga cgggggcctt tggtaaata ttcttctgat 1620
tacttccaa cccctctga ctacagatac taccctacc agtccttcca gactccaca 1680
caccacagct tctcttcca ggacaagagg gtgtcctggt ccctggtcta cctccccacc 1740
atccagagct gctggaacta cggcttctcc tgcctctcgg acgagctccc tgtcctgggc 1800
ctcaccaagt ctggcggtc agatcgcacc attgcctacg aaaacaaagc cctgatgctc 1860
tgcaagggc tcttcgtggc agacgtcacc gatttcgagg gctggaaggc tgcgattccc 1920
agtgcctgg acaccaacag ctggaaggm acctcctcct tcccctgccc ggcaggcact 1980
tcaacggctt ccgcacggtc atccgcccct tctacctgac caactcctca ggtgtggact 2040
agacggcgtg gcccaagggt ggtgagaacc ggagaacccc aggacgccct cactgcaggc 2100
tcccctcctc ggcttccctc ctctctgcaa tgaccttcaa caaccggcca ccagatgtcg 2160
ccctactcac ctgagcgctc agcttcaaga aattactgga aggcttccac tagggctccac 2220
caggagttct cccaccacct caccagtttc cagggtgtaa gcaccaggac gccctcgagg 2280
ttgctctggg atccccccac agcccctggt cagtctgccc ttgtcactgg tctgagggtca 2340
ttaaattac attgaggttc ctaaaaaaaaa aaaaaaaaaa anaaaaaaaa aaaaaaaagg 2400
gsggcgctc tngaggatcc ctcgaggggc ccaagcttac gcgtgcatgc gacgtcatag 2460
ctctctccct ataattgaat cgtattat 2488

```

<210> 74

<211> 711

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (696)

<223> n equals a,t,g, or c

<400> 74

```

ggcacgagcc ggagtggctg gtgggtggga tggaggcgac cttggagcag cacttggaa 60
acactatcta tgtaaaattc aaaactggaa aagtataaag ggtacagaga gacacctgcc 120
tcccaccgat gtccctcagc ttccacttac cctccaggag aatgaagaat ccctccattg 180
ttggagtcct gtgcacagat tcacaaggac ttaatctggg ttgccgcggg accctgtcag 240
atgagcatgc tggagtgata tctgttctag cccagcaagc agctaagcta acctctgacc 300
ccactgatat tcctgtggtg tgtctagaat cagataatgg gaacattatg atccagaaac 360
acgatggcat cacggtggca gtgcacaaaa tggcctcttg atgctcatat ctgttcttca 420
gcagcctgtc ataggaactg gatcctacct atgttaatta ccttatagaa ctactaaagt 480
tccagtagtt aggccattca tttaattgtc attaggcact tttctgttta tttaagagtc 540
aattgctttc taatgctcta tggaccgact atcaagatat tagtaagaaa ggatcatggt 600
ttgaagcagc aggtccaggt cactttgtat atagaatttt gctgtattca ataaatctgt 660
ttggaggaaa aaaaaaaaaa aaaaaattac tgccgnccga caagggaatt c 711

```

<210> 75
 <211> 906
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (362)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (889)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (894)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (897)
 <223> n equals a,t,g, or c

<400> 75
 nctncccata accatgttcc catgtgggtg gtcgatgggg ctgcagaagg ccgggaggag 60
 ccgctggggc agcctgggtg tccggcatag acgtgtgtgg gtggtcaagg caggctactc 120
 tgcccctctg agcctcagtc ttctgccagt gacgcaggga gacggcactg actgcctccc 180
 aggagcgtcg gtggcctgca gaagatgcgc aggaagctgg gmctcgtgca ggtggagctg 240
 gaggaagacg gggcgctgggt gtccaagctc ctggagacca tgcatactaac cggtgccgac 300
 ttsacaaaca ctttctactt gctgagctcc ttcccagtggt agctagagtc gccaggcctg 360
 gnsaattcc tggccagggt gatggagcag tgtgcctccc tggaggagct gaggtggcc 420
 ttccggcccm agatggatcc ccggcagcta tccatgatgc tgatgctggc gcagtcaaac 480
 ccgcagctgt tcgcgcttat gggcaccggt gcaggcatcg ccaggagct ggagcgtgtg 540
 gagcagcagt ctgcgctgga gcagctgagt gcggcagagc tgcagagcag gaaccagggc 600
 cactgggctg actggctaca ggcgtacaga gcccggtggg acaaggacct ggaaggcgct 660
 ggggacgctg ccgcctggca ggctkgagca cgtgcgcgtg atgcacgcca acaaccgaa 720
 gtacgtgctg aggaactaca ttgcgcgaga atgccattcg aggttgccga gcgcggggat 780
 ttttcagagg tgcggcgggt gttgaaatta tttgagacct tttaccattg cgaggcgggg 840

gccgccacaa gacggccgag gccacgggaa gccgacgggg gcggacggna aggnagnttt 900
 cttaca 906

<210> 76
 <211> 271
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (36)
 <223> n equals a,t,g, or c

<400> 76
 gaacactcta ctttatgcag gaatagcaga gatgantcat gggtgggaag acactagaat 60
 tcagccagga gaatatcatt aaaagaggga gaagggaata cagacttttt gtgtggtaca 120
 aaaacaaaac cctctgtatc attatgtgaa caacggtgca aaaaagagga gacacagttt 180
 acccatgggt agctaactat gatagtgaat gttgccttga accttgtttt agaaaaatgg 240
 caagtgtggg tctcactctt ctagttcctg a 271

<210> 77
 <211> 673
 <212> DNA
 <213> Homo sapiens

<400> 77
 ttgggcacga ggggtgaccag cggcggggtca cgtgacgcgg tgcctggcgc cgagcctccc 60
 aagatggcgg tgtgcatcgc ggtgattgcc aaggagaatt acccctccta cattcgcagc 120
 acccctacgg agaacgagct gaagttccac tacatggtgc acacatctct ggacgtggtg 180
 gatgagaaga tctccgcaat ggggaaggcc ctggctcgacc agagggagct gtacctgggc 240
 ctgctctacc ccacggagga ctacaaggta tacggctacg tcaccaactc caaggtgaag 300
 tttgtcatgg tggtagattc ctccaacaca gcccttcgag acaacgaaat tcgcagcatg 360
 ttccggaagc tacacaactc ctacacagac gtgatgtgca accccttcta caaccgggg 420
 gaccgcatcc agtccagggc ctttgataac atgggtgacgt cgatgatgat acaggtgtgc 480
 tgagtgaact gtgctgccag ccacgcgaga ggagcccgcg cagcactgtg gtggggccgt 540
 cgggtctgtt tggttgcttc ttctgaatg ggacgcctgg ggctttcagg gcaggcagct 600
 gtgcatgttc tctcaactaa aggtcttgtg agaggaaaaa aaaaaaaaaa aaaaaaactc 660
 gggggggggc cg 673

<210> 78
 <211> 367
 <212> DNA
 <213> Homo sapiens

<400> 78
 cttgctttct ttcttacctc tgaaggagaa aagaaagttg ctacttacat gtttgaaaaa 60
 cctctcaaat ctactcagtc aaaagatttt atgcttcaat ttggtcatat gtttaagagtt 120
 tagcttctaa actgatacct cagtagccca tagttttaaag gagtaaagag tacatggatg 180
 cttttggtac tactcagaag ctctgagttt ctggggccact gaaaccctga aaagtagcta 240
 aatacgttca cttgctatct taatccatca ctgtagatat gactcagtc ctttgttatt 300
 ttcccccaat ttgaaacaat ttaatgtgct gaaaagataa ctttctcctt ttttctttct 360

ttttctc

367

<210> 79

<211> 1344

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1319)

<223> n equals a,t,g, or c

<400> 79

```

gttctgagga gtttccccct tggcagccat gagccggcag ttctggtagt gactgctggg 60
ccctgctgga cagcggtcgc atgcagctcc tatgaggccc ctgccgccgg tcggcgatgt 120
ccggctggag ctgtcgctc cgccgccgct gctgccggtg ccggttgtga gcgggtctcc 180
agtcggctcc tctgggcgtc tcatggcctc tagcagctcc ctggtgccc accggctgcg 240
cctgccgctc tgcttcctgg gtgtctttgt ctgctatttt tactatggga tcctgcagga 300
aaagataaca agaggaaagt atggggaagg agccaagcag gagacgttca cctttgcctt 360
aactttggtc ttcatccaat gtgtgatcaa tgctgtgttt gccaagatct tgatccagtt 420
ttttgacact gccagggtgg atogtaccgc gagctggctc tatgctgcct gttctatctc 480
ctatctgggt gccatggtct ccagcaattc agcactacag tttgtcaact acccaactca 540
ggtccttggt aaatcctgca agccaatccc agtcatgctc cttgggggtga ccctcttgaa 600
gaagaagtac ccgttgcca agtacctgtg tgtgctgtta attgtggctg gagtggccct 660
tttcatgtac aaacccaaga aagttgttgg gatagaagaa cacacagtcg gctatggaga 720
gctactcttg ctattatcgc tgaccctgga tggactgact ggtgtttccc aggaccacat 780
gcgggctcat taccaaacag gctccaacca catgatgctg aacatcaacc tttggtcgac 840
attgctgctg ggaatgggaa tctgtttcac tggggagctc tgggagttct tgagctttgc 900
tgaaaggtac cctgccatca tctataacat cctgctcttt gggctgacca gtgccctggg 960
tcagagcttc atctttatga cggtttgtga ttttggctcc ctgacctgct ccatcatcac 1020
tacaactcga aagttcttca caattttggc ctctgtgatc ctcttcgcca atcccatcag 1080
ccccatgcag tgggtgggca ctgtgcttgt gttcctgggt cttggtcttg atgccaagtt 1140
tggaagagga gctaagaaga catccacta ggaagagaga gactacctc acatcaagaa 1200
tatttaagtt attatctcaa acagtgcac ctcttgggaa aatggactta ataggaatat 1260
gggactgagt tccagtcttt ttttaataaaa taaaatcaag caaaaaaaaa aaaaaaaanc 1320
ccgagggggg gcccggaacc caat                                     1344

```

<210> 80

<211> 3748

<212> DNA

<213> Homo sapiens

<400> 80

```

gccgatttga accgaggatt tgggcggcag gaagagccgc ggcgtaacgg cagccatctt 60
gtttgtttga gtgaatcgga aaggaggcgc cggctgtggc ggccggcgga gctgctcgga 120
agctacacct cgcaagggtt ccccccttc cccacccct ccccgacct ttttccccctc 180
cccgggccac ccagcccgcc caactccag cggagagcaa ggttttcttc tgttttcata 240
gccagccaga acaatgttct acgcacattt tgttctcagt aaaagagggc ctctggccaa 300
aatTTggcta gcggccatt gggataagaa gctaaccaaa gcccatgtgt tcgagtgtaa 360
tttagagagc agcgtggaga gtatcatctc accaaaggtg aaaatggcat tacggacatc 420
aggacatctc ttactgggag tagttcgaat ctatcacagg aaagccaaat accttcttgc 480

```

```

agactgtaat gaagcattca ttaagataaa gatggctttt cggccagggtg tggttgacct 540
gcctgaggaa aatcggaag cagcttataa tgccattact ttacctgaag aatttcatga 600
ctttgatcag ccactgcctg acttagatga catcgatgtg gccagcagc tcagcttgaa 660
tcagagtaga gtggaagaga taaccatgag agaagaagtt gggaacatca gtattttaca 720
agaaaatgat tttggtgatt ttggaatgga tgatcgtgag ataatgagag aaggcagtg 780
ttttgaggat gacgacatgt tagtaagcac tactacttct aacctcctat tagagtctga 840
acagagcacc agcaatctga atgagaaaaa taaccattta gaatatgaag atcaatataa 900
ggatgataat tttggagaag gaaatgatgg tggaatatta gatgacaaac ttattagtaa 960
taatgatggc ggtatctttg atgatcccc tgccctctct gaggcagggg tgatgttgcc 1020
agagcagcct gcacatgacg atatggatga ggatgataat gtatcaatgg gtgggcctga 1080
tagtcctgat tcagtggatc ccgttgaaac aatgccaaac atgactgatc aaacaacact 1140
tgttccaaat gaggaagaag catttgcat tggagcctatt gatataactg ttaagaaaac 1200
aaaagccaag aggaagagga agctaattgt tgacagtgtc aaagagttgg atagcaagac 1260
aattagagcc caacttagtg attattcaga tattgttact actttggatc tggcaccgcc 1320
accaagaaat tgatgatgtg gaaagagaca ggaggagtag aaaaactgtt ttctttacct 1380
gctcagcctt tgtggaataa cagactactg aagctcttta cacgctgtct tacaccgctt 1440
gtaccagaag accttagaaa aaggaggaaa ggaggagagg cagataat tt ggatgaattc 1500
ctcaaagaat ttgaaaatcc agagggttct agagaggacc agcaacagca gcatcagcag 1560
cgtgatgtta tcgatgagcc cattattgaa gagccaagcc gcctccagga gtcagtgatg 1620
gaggccagca gaacaaacat agatgagtca gctatgcctc caccaccacc tcagggagtt 1680
aagcgaaaaag ctggacaaat tgaccagag cctgtgatgc ctctcagca ggtagagcag 1740
atggaaaatc cacctgtaga gcttccccca gaagaacctc caaatatctg tcagctaata 1800
ccagagttag aacttctgcc agaaaaagag aaggagaaa agaggaaaa agaagatgat 1860
gaagaggaag aggatgaaga tgcacaggg ggcatcaag atcaggaaga aagaagatgg 1920
aacaaaagga ctcagcagat gcttcatggt cttcagcgtg ctcttgctaa aactggagct 1980
gaatctatca gtttgcttga gttatgtcga aatacgaaca gaaaacaagc tgccgcaaag 2040
ttctacagct tcttggttct taaaaagcag caagctattg agctgacaca ggaagaaccg 2100
tacagtgaac tcacgcaac acctggacca aggttccata ttatataagg agctagaagc 2160
attatagcta gtgtttgatt cactagtgtc tacaaattgc ccccatgtgt aggggacaca 2220
gaaccctttg agaaaactta gatttttgtc tgtacaaagt ctttgccctt ttcttcttc 2280
atttttttcc agtacattaa atttgtcaat ttcactcttg agggaaactg attagatggg 2340
ttgtgtttgt gttctgatgg agaaaacagc accccaagga ctcagaagat gattttaaca 2400
gttcagaaca gatgtgtgca atattggtgc atgtaataat gttgagtggc agtcaaaagt 2460
catgattttt atcttagttc ttcattactg cattgaaaag gaaaacctgt ctgagaaaat 2520
gcctgacagt ttaattttaa actatggtgt aagtccttga caagaaaaaa aaacaaacaa 2580
acacttcttt ccatcagtaa cactggcaat cttcctgtta accactctcc ttagggtgg 2640
tatctgaaac aacaatggtc acctccttga gattcgtttt aagtgtatt ccataatgag 2700
cagaggtgta cgcgaaattg tgttatgact gatagccttc agctacaaaa agataggact 2760
gacctggttt aaagtgttct attttgtaaa tcattccatt tgagtctttc tgatgaactt 2820
ggctatactg aaatctgtta ttttagtgag gctccaaaat gagcaaagct aggcctgatt 2880
agagtagagt gactattaaa aaacataact ttctaggagc tataaatcaa agttttaaaa 2940
agatgtttgg atatatttga gtattccgat catgaaaaca gaaattgccc tgcctactac 3000
aaggacagac tgatgggaaa ttatgcacct ggtcaactta gcttttaagc agacgatgct 3060
gtaaaaacta acggcttctc tgatatttat tgtaagtttt agtactgatc tccttttcca 3120
gtgctgcaca ctctgggtt ggaactttta tagcgttgca acgaaatcct atatccagtt 3180
tcctgtaatt taattgaaga aaaatacatc caaataaaga ctttattatt aacagaccag 3240
atagcatcag aaatcatgtg actgttatga ttatcagaat atgtcttaac tttttagggc 3300
aaagttaaca ctgaaagttc tagcttaagt gttgaaactt ttgtgggaaa aaaaaatcac 3360
ttttgaaact cagacttcag tgtataccca ataattttaa attatgtgaa atgtttttaa 3420
tttgtgaact cgtaattact gttttaatga ttcagtttct tcagagtggg aattgtataa 3480
aattgctatt gcagctttat attcaatatg atgtgcctgt aaaccaagga gttttccccg 3540

```

```

tttgtaaaaa gacattgtag ataattgaat gtttgatttt agaaagggtca ttagttttctt 3600
gttacacatt ttgttagtct ggtttttggt gcttatcggg tttaatattg ttcttgaaaa 3660
tagttgatgc tatgttatgt ataacttttc taataaaagt tgtgttataa gctgtaaaaa 3720
aaaaaaaaaa aaaaaaaaaa aaaaaacc                                     3748

```

<210> 81

<211> 1891

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1869)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1879)

<223> n equals a,t,g, or c

<400> 81

```

gttgctgtca tttgggctta ctggcttggg ctgaagggtac gtagagaata caggaaattc 60
ttcagagcca atgctggaaa gaaaatctat gagtttacgc ttcagagaat tgtgcaaaaa 120
tacttcttgg aaatgaaaaa taagatgcct tccttatctc caatagacaa gaattggccc 180
tcaagacctt acttattctt ggattctact cacaaggagc taaaaaggat tttccacttg 240
tgagggtgta aaaaatacac ggaccaattc acagaccagc agaaacttat ttatgaagag 300
aaactagaag ccagtgaact cttcaaagac aagaaggctt tatacccatc tagtggtggg 360
caaccattcc aaggggctta cctggaaatc aacaagaacc ccaagtataa gaaactcaaa 420
gatgccattg aagaaaagat catcattgct gaagtcgtga acaaaattaa ccgtgctaata 480
gggaagagta catctcggat ttctctctta acaacaata atctccttct tgctgaccaa 540
aagtctggac aaatcaagtc agaggttcca ytggtggatg tgaccaagggt atcaatgagc 600
tcacaaaatg atggcttctt cgccgtccac ctcaaagagg gctcagaagc agctagtaaa 660
ggagactttc tcttcagcag tgatcacctg attgaaatgg ccaccaagct ctatcgca 720
actctcagcc aaaccaaaca gaagctcaat attgagattt ccgatgagtt cctggtagag 780
ttcagacagg acaaagtatg tgtgaagttt attcagggaa accagaaaaa tgggagtgtc 840
ccaacatgta aacgaaaaaa caaccgtctc cttgaagttg ctgtccctta actggcgcct 900
cctctctact ttcattggact tgttcctttg taatagtga atttggtttt gttttatttg 960
gggttcattg tatgtttggg aatcaccaaa ggctttttaga gttctttggc aaaataaaaa 1020
tatttgacta atcaattttt attattggaa tagttttaac ctttcaaata catgttctgt 1080
cctggagcag gattgtagaa actaacagtg tctattttca tgtctgatgt gttcttcctt 1140
tagtcatcat gttaggctctg tgtaccctaa atcagcatat tactcataaa tcattaatta 1200
atataagcat aggaaatggg cttaaaagat actgcattca ttcattcagat atttattcca 1260
tgctactctt atgctaggca ctgtgctaga tggtagaaa acttattagg aacctttttg 1320
tttttgagac cattgcattc tggctggttt gtgctggttt aacgacatct aagaaggttt 1380
agaaatggtg agacaaaaac aataactgtt aatgatggac agcattatta ggaaccctgt 1440
agtatgatat ttaacaatat aggcttcaag aagggctggg cctaagaggg ggcagaaatg 1500
aatgaccagg ttaaatccct ctacatgttg tttctgtttg aaaaaaagaa aactgacatt 1560
tgaacaggac ttttaatttg tttaaaactc tggtaattac ttgtaacagt agaaaataga 1620
agtcattctt atttttagaaa aagtgcaga agcagtcag taagattata tgtttctgtt 1680
tctggtaaat accatatatg atcctcgaaa tgataatatc tccagaatat tgttttcacc 1740
caaatttgag tagatatattt aaacacctaa caaagtaaag ggctaaaagc cattcagata 1800

```

gcagtaaaac attctgtatg atgtgcaata aaacatccaa gatctttttt gaaagtgwka 1860
 tttccgttna agtcccccnt taggaccccc g 1891

<210> 82

<211> 1954

<212> DNA

<213> Homo sapiens

<400> 82

ttcagtgtct ggcacactga gacacctcca agaaggagat tgatgcatca ggttcagttt 60
 aacctggaat atctgactac ccctgaatcc acccagaaag ggggccaac acccttgtcc 120
 atttatgggt attttttttc gaagtattta agcatattoc tttccacga acctcttctg 180
 tactttgatt gtaataggtt ggctcttaca cccattccaa atgcagttta ttttttagacc 240
 cgattgcaaa tagtgatgta gttttaacca gtatggatta gttcagggat gaactgctcc 300
 ctccagcctt actggctctg atccacaggg ttttgttttg ttttgttttg tttttgttt 360
 aagtcgagat ataaaaactg aacacgataa cacttactct taaatcaagc atcaacactt 420
 tttccctgtt agaattcttt gcatttttgt gtttgtaaca gaaacgcctt aagacactat 480
 gtttggaat ataggaaact atgtgtgtcc caaggaaatc cctgtaaatt taactcacct 540
 acaaaaggct ttttccccgc ctttggttgt taacggcatt cctgaaagcc acatgtgttt 600
 attcattggg cttgttctta tcagcaaata ggttttctgg ttttatgact ttttgtctta 660
 ttttatkttt cctacatttc tttttttttt tttttccytt agaatgccck ggraatatat 720
 ttaagtggka atgraaaata gtaatcatag taaaacgcaa cargargraa accmacccaa 780
 accagtgaag ttttttagaa ccttttagaag ggtgggtctt attcaggttt tactgtaatg 840
 gtaaggattg actcaagaga cagtattagt aaatttattg tgtatggatc aaaagtgaat 900
 aatgtatgaa tgagagctgt aagaaggatt tttattttgt tataatttag ttaccatttt 960
 cagtgttatt tcaaaggctt tttgaagaat tttggggcag ggcacatgat tagagtttta 1020
 aaatttgagt attttgata tcagtgttcc tcatgaagat atacatggat attcaatttt 1080
 gatggcttcc agatttgtaa gattktatgt tgtatatacc attctattaa gaaacatgtc 1140
 cactgtgctt tcaaacatag ataaagcatg ataaagatta ttatttaaga tatacttgta 1200
 tttataacctc agatattctt ttgggttttg tacctcaagg cttttttctt cttattgtaa 1260
 atacacttta cgtgaatata gtctaagtga agaaaataaa taaaaggaag aggtttataa 1320
 cttgctctat atctgtacag attataatca ataagtgcac tattattaaa tgtttaaagt 1380
 aagggaag tctgggctgc ctctcctaat attgcatctc actcccacc ttaaaaccac 1440
 agattgcaaa gcatagcatt ttagcatcaa ctacaatcaa aagagcgatt tgctgaagga 1500
 aaaatcggac tgcaaatcat tccaaggcca aactgcaact gagccacca ctcccaaaca 1560
 ggaaaccctg gtgaagggtc aggaagcacg gagattctct ccaacaaagg tccagttagg 1620
 aaacgacgct gagaggatga cgacaacgtg caacagcaga aagatgcttg caagcagagt 1680
 cagggtcacc agtgaatgcc acaaaagtgc tctttccac tgtttaattt gacaagagaa 1740
 gaatttgaag gatatgaaca ttttcaagaa ctctgctgag gtcacttaga gcgccatcac 1800
 aacttatttg tgtgactaat tgcctagatt gtaagctctt tgagggcagg gcttgtctct 1860
 tacacatctt tataatcccc tgcagcggct ttcagtattt tgtacttgta ggcacctaat 1920
 aaatttatta tttgctatac tgaaaaaaaa aaaa 1954

<210> 83

<211> 936

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (895)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (930)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (936)

<223> n equals a,t,g, or c

<400> 83

```

aattcggcac gagctggagg cagagcagtc ctctctgggg agcctgaagc aaacatggat 60
caagaaactg taggcaatgt tgtcctgttg gccatcgtca ccctcatcag cgtgggtccag 120
aatggattct ttgcccataa agtggagcac gaaagcagga ccagaaatgg gaggagcttc 180
cagaggaccg gaacacttgc ctttgagcgg gtctacactg ccaaccagaa ctgtgtagat 240
gcgtacccca ctttcctcgc tgtgctctgg tctgcggggc tactttgcag ccaagttcct 300
gctgcgtttg ctggactgat gtacttgttt gtgaggcaaa agtactttgt cggttacctt 360
ggagagagaa cgcagagcac ccctggctac atatttgggg aaacgcacat tactcttcct 420
gttcctcatg tccgttgctg gcataattcaa ctattacctc atcttctttt tcggaagtga 480
ctttgaaaac tacataaaga cgatctccac caccatctcc cctctacttc tcattcccta 540
actctctgct gaatatgggg ttggtgttct catctaatac atacctacaa gtcatacata 600
ttcagctctt gagagcattc tgctcttctt tagatggctg taaatctatt ggccatctgg 660
gcttcacagc ttgagttaac cttgcttttc cggaacaaa atgatgtcat gtcagctccg 720
ccccttgaa atgaccgtgg ccccaaattt gctattccca tgcattttgt ttgtttcttc 780
acttatcctg ttctctgaag atgttttgtg accagggttg tgttttctta aaataaaatg 840
cagagacatg ttttaagctg aaaaaaaaaa aaaaaaaacc cggggggggg ccggnacca 900
ttcgcccaaa agggggcgat taaaatcccn ggccgn 936

```

<210> 84

<211> 1513

<212> DNA

<213> Homo sapiens

<400> 84

```

tctaaactag tggatccccg ggctgcagga attcggcaca ggctctcaga ggctaagaag 60
gtggagaccg gagaagctgt gaggttcttt agcgtcacct ccctcactgg gcagcatggg 120
ggagaagtca gagaactgtg gggttccaga ggatctgtta aatggtttga aggttacaga 180
tactcaggaa gccgagtgtg ctggccctcc agttcctgat cccaaaaatc agcattccca 240
gagtaagctg ctgagggatg atgaggccca tctccaggag gaccaggag aagaggagt 300
ttttcatgac tgcagtgcct catttgagga ggagccagga gcggacaagg ttgagaacaa 360
atctaataaa gatgtgaatt cctctgaact agatgaagaa tacctaataa aactggaaaa 420
aaacatgtcg gatgaagaga aacagaaaaa aagagaagag agcactagac taaaggagga 480
gggaaatgaa cagtttaaga aaggagatta tatagaagct gaaagtctct atagtcgagc 540
cctcgaaatg tgcccatcct gcttccaaaa ggagaggtcg attctatttt caaatagagc 600
tgcagcaagg atgaaacagg acaagaaaga aatggccatc aatgactgca gcaaagcaat 660
tcaattaaac ccagctata tcagggcaat attgaggaga gcagagttgt atgagaagac 720
ggacaagcta gatgaagccc tggaagacta taaatctata ttagaaaaag atccatcaat 780
acatcaagca agagaagctt gtatgagatt acctaagcaa attgaagaac gtaatgaaag 840
actaaaagaa gagatgttag gtaaatataa agatcttggg aacttggttc tccgaccttt 900

```

```

tgggctctcc acggaaaatt tccagatcaa acaggattcc tctaccggct cgtactccat 960
caatttcggt caaaatccaa ataataacag ataacaaaga taacaaaagc tttaacaagct 1020
gacttggaaat tgtgtgctgc ttgctgttag ctaggggaaa ggccctgccca atgtttaact 1080
tttaaaagca tcttatctaa aagaaaggct atccagtaga gccagtgct cccttgtccc 1140
tcttttatga tcagggtgaa atgtacttcc tgatgtaatg aacctaatgt gatttccatt 1200
ttaagggtgt gtctgtgcag ctggtgtccc cgattctggc tgtcctatgt ccaggaagaa 1260
gcccatgtgt tgaggctgac ctctctgac atacacacac acagcccagc aaaagcctct 1320
cctgaaccaa acaaacctgt tgggtgggag actgcccaga catgattgat gacgggttcc 1380
cgctgtgtgt cccctccctg atcacacagc taacgaggct gcctccagca tttcctgatt 1440
tcctctgtgt taataaaaagc tttctgtgct taaaaaaaaa aaaaaaaaaa aaacttcgag 1500
ggggggggccc ggt                                     1513

```

<210> 85

<211> 1298

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<400> 85

```

gtngggcggc tgctgctccg ggcctgggca cagcaagcgg cgacgtcaag ctccccgggt 60
tggcgcggtt ggcgggggca gtcccagcgc tgaggaggct ggcgaggct acaacagtga 120
ggacgagtat gaggcggctg cagcacgcat cgaggctatg gaccctgccca ctgtcgagca 180
gcaggagcat tggtttgaaa aggccctacg agacaagaag ggcttcatca tcaagcagat 240
gaaggaggat ggcgcctgtc tcttccgggc tgtagctgac cagggtgatg gagaccagga 300
catgcatgag gttgtgcgaa agcattgcat ggactatctg atgaagaatg ccgactactt 360
ctccaactat gtcacagagg actttaccac ctacattaac aggaagcggg aaaacaattg 420
ccatggcaac cacattgaga tgcaggccat ggcagagatg tacaaccgtc ctgtggagggt 480
gtaccagtac agcacagaac ccatcaacac attccatggg atacatcaaa acgaggacga 540
acccattcgt gttagctacc atcggaatat ccactataat tcagtgggtga atcctaacaa 600
ggccaccatt ggtgtggggc tgggcctgcc atcattcaaa ccagggtttg cagagcagtc 660
tctgatgaag aatgccataa aaacatcgga ggagtcattg attgaacagc agatgctaga 720
agacaagaaa cgggccacag actgggaggc caaaaatgaa gccatcgagg agcagggtggc 780
tcgggaatcc tacctgcagt ggttgcggga tcaggagaaa caggctcgcc aggtccgagg 840
ccccagccag ccccgaaaag ccagcgccac atgcagttcg gccacagcag cagcctccag 900
tggcctggag gagtggacta gccggtcccc gcggcaggag tttcagcctc gtcacctgag 960
caccctgagc tgcattgtga attgggcatg aagccccctt cccaggcac tgttttagct 1020
cttgccaaac ctctctcgcc ctgtgcgcca ggttacaagc agtcagttct cggcaggggc 1080
cgaccgggca acttcccccc ttgtgtccct ctaccctgct ttggagtkcc gggccctcat 1140
tcagcagatg tccccctctg ctttgggtct gaatgactgg gatgatgatg agatcctagc 1200
ttcgggtgct gcagtgtccc aacaggaata cctagacagt atgaagaaaa acaaagtgca 1260
cagagacccg cccccagaca agagttgatg gagaccca                                     1298

```

<210> 86

<211> 2009

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (1955)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1959)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2008)
 <223> n equals a,t,g, or c

<400> 86
 gtgttcgtcc gcttgctcact gaattggacc ctgatgctcc cataagacag aaaatgcccc 60
 ttgatgatct ggatagagaa gatgaagtta gattactcaa atatctcttt actctaattcc 120
 gtgctggaat gacagaagag gcacaacgac tctgtaaacg ctgtgggtcaa gcatggagag 180
 ctgcaacact tgaaggctgg aaactgtacc atgaccctaa tgttaattgga ggaacagaat 240
 tagaacctgt tgaagggaat ccatatagac gcatttggaa aataagttgc tggagaatgg 300
 cagaagatga gctttttaat agatacgaga gagcaattta tgcagcttta agtgggaatc 360
 ttaagcagct gcttcctgtc tgtgacacct gggaagacac agtttggggc tacttccggg 420
 tgatgggtgga cagtctggta gaacaggaga tccagacatc agtagcaact ctggatgaaa 480
 ctgaagaact ccctagagaa tatctgggag caaactggac gttagaaaag gtttttgagg 540
 aacttcaagc tactgacaaa aagagagttc tggaaagaga atcaagaaca ttatcatata 600
 gttcaaaaagt ttcttatcct gggagacatt gatgggttga tggatgagtt tagcaaatgg 660
 ctttccaaaa gcagaaacaa tctacctgga cacctgcttc gctttatgac tcaccttatt 720
 ttgtttttcc gtactctggg actacagacc aaggaggaag tttctattga agttttaaag 780
 acatacatac agcttttaat aagagagaaa catacaaatc ttatagcatt ttatacctgt 840
 catttgccctc aagaccatagc tgttgcccag tatgcattat ttttggaag tgttacagaa 900
 tttgaacagc gccaccattg cctggagttg gctaaagaag cagatttggga tgttgcaaca 960
 ataacaaaaa ctgtagttga gaatatcga aagaaagata atggtgaatt tagtcatcat 1020
 gacctggccc cagccctaga tactggcact actgaggagg atcgttttaa aattgatgta 1080
 attgactggt tggatattga cccagcgcag agggcagaag cactgaaaca aggcaatgca 1140
 attatgagaa aaytcttggc atcaaaaaag cacgragctg caaaagaagt atttgtgaaa 1200
 attcctcagg attctatagc agaaatctat aatcagtgcg aggaacaagg aatggaaagt 1260
 ccacttcctg ctgaagatga taatgctatc cgagaacatt tgtgcatcar agcttatttg 1320
 gaagcccatg aaacctttaa tgagtgggtt aagcatatga attcagttcc acaaaaacct 1380
 gctttgatac ctcaaccaac ttttactgag aaagtggctc atgaacacaa agaaaagaaa 1440
 tatgaaatgg attttggtat ttggaaaggg catttggtatg ccctaactgc tgatgtgaag 1500
 gagaaaatgt ataacgtctt gttgtttgtt gatggagggg ggatgggtgga tgttagagag 1560
 gatgccaaag aagaccatga aagaacacat caaatggtct tactgagaaa gctttgtctg 1620
 ccaatgttgt gttttctgct tcatacgata ttgcacagta ctgggtcagta tcaggaatgc 1680
 ctacagttag cagatatggt atcctctgag cgccacaaac tgtacctggt attttctaag 1740
 gaagagctaa ggaagttgct gcagaagctc agagagtcct ctctaattgct cctagaccag 1800
 ggacttgacc cattagggtta tgaaattcag ttatagttta atcttcgtaa tctcactaat 1860
 tttcatgata aatgaagttt ttaataaaaat atacttgtaa ttagtaaaaa aaaaaaaaaa 1920
 agggcgggcg ctctagagga tccctcgagg ggcencaant tacgcgtgca tgcgacgtca 1980
 tagctctctc cctatagtga gtcgtacng 2009

<210> 87
<211> 534
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (526)
<223> n equals a,t,g, or c

<400> 87
ggacgcccac gtgcagttcc tggcctcggg gctgccccca gacacggatc ctgcgttctt 60
cgagcacctt cgggccctcg actgctccga ggtgacgggt cgagccctgc ccgagggctc 120
cctgcgccttc cccggagtgc cgctcctgca ggtgtccggg ccgctcctgg tgggtgcagct 180
gctggagaca ccgctgctct gcctggtcag ctacgccagc ctggtggcca ccaacgcagc 240
gcggtctcgc ttgatcgagc ggccagagaa gcggctgcta gagatggggc tgagggcgggc 300
tcagggcccc gatggggggc tgacagcctc cacctacagc tacctggggc gcttcgacag 360
cagcagcaac gtgctagcgg gccagctgcy aggtgtgccg gtggccggga ccctggccca 420
ctccttcgtc acttcctttt caggcagcga ggtgcccctg acccgntgtt ggggcanaag 480
tttgtgaagg gccttggggtt gacctggggg caaagccaag ttttgnttga gcaa 534

<210> 88
<211> 4302
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1015)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (4270)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (4274)
<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4296)

<223> n equals a,t,g, or c

<400> 88

```

gtcagtaacc agcacaacat taatagaaat tttaagtgc actggagcag aaggacccac 60
ggtggcacct ctccctttct ccacggacat cggacatcct caaaatcaga ctgtcaggtg 120
ggcagaagaa atccagacta gtagaccaca aaccataact gaacaagact ctaacaagaa 180
ttcttcaaca gcagaaatta acgaaacaac aacctcatct actgattttc tggctagagc 240
ttatggtttt gaaatggcca aagaatttgt tacatcagca ccaaaacccat ctgacttgta 300
ttatgaacct tctggagaag gatctggaga agtggatatt gttgattcat ttcacacttc 360
tgcaactact caggcaacca gacaagaaag cagcaccaca tttgtttctg atgggtccct 420
ggaaaaacat cctgaggtgc caagcgctaa agctgttact gctgatggat tcccaacagt 480
ttcagtgatg ctgcctcttc attcagagca gaacaaaagc tcccctgatc caactagcac 540
actgtcaaat acagtgtcat atgagaggtc cacagacggt agtttccaag accgtttcag 600
ggaattcgag gattccacct taaaacctaa cagaaaaaaa cccactgaaa atattatcat 660
agacctggac aaagaggaca aggatttaat attgacaatt acagagagta ccaccttgga 720
aattctacct gagctgacat cggataaaaa tactatcata gatattgatc atactaaacc 780
tgtgtatgaa gacattcttg gaatgcaaac agatatagat acagaggtac catcagaacc 840
acatgacagt aatgatgaaa gtaatgatga cagcactcaa gttcaagaga tctatgaggc 900
agctgtcaac ctttctttta ctgaggaaac atttgagggc tctgctgatg ttctggctag 960
ctacactcag gcaacacatg atgaatcaat gacttatgaa gatagaagcc aactnagatc 1020
acatgggctt tcacttcaca actgggrtcc ctgctcctag cacagaaaca gaattagacg 1080
ttttacttcc cacggcaaca tccctgcca ttcctcgtaa gtctgccaca gttattccag 1140
agattgaagg aataaaagct gaagcaaaaag ccctggatga catgtttgaa tcaagcactt 1200
tgtctgatgg tcaagctatt gcagacaaaa gtgaaataat accaacattg ggccaatttg 1260
aaaggactca ggaggagtat gaagacaaaa aacatgctgg tccttctttt cagccagaat 1320
tctcttcagg agctgaggag gcattagtag accatactcc ctatctaagt attgctacta 1380
cccaccttat ggatcagagt gtaacagagg tgcctgatgt gatggaagga tccaatcccc 1440
catattacac tgatacaaca ttagcagttt caacatttgc gaagttgtct tctcagacac 1500
catcatctcc cctcactatc tactcaggca gtgaagcctc tggacacaca gagatcccc 1560
agcccagtg tctgccagga atagacgtcg gctcatctgt aatgtcccca caggattctt 1620
ttaaggaaat tcatgtaaat attgaagcga ctttcaaacc atcaagtga gaataccttc 1680
acataactga gcctccctct ttatctcctg acacaaaatt agaaccttca gaagatgatg 1740
gtaaacctga gttattagaa gaaatggaag cttctcccac agaacttatt gctgtggaag 1800
gaactgagat tctccaagat ttccaaaaca aaacckatgg tcaagtttct ggagaagcaa 1860
tcaagatgtt tcccaccatt aaaacacctg aggctggaac tgttattaca actgccgatg 1920
aaattgaatt agaaggtgct acacagtggc cacactctac ttctgcttct gccacctatg 1980
gggtcgaggc aggtgtggtg ccttggttaa gtccacagac ttctgagagg cccacgcttt 2040
cttcttctcc agaaataaac cctgaaactc aagcagcttt aatcagaggg caggattcca 2100
cgatagcagc atcagaacag caagtggcag cgagaattct tgattccaat gatcaggcaa 2160
cagtaaacc cgtggaattt aatactgagg ttgcaaacacc accattttcc cttctggaga 2220
cttctaataa aacagatttc ctgattggca ttaatgaaga gtcagtggaa ggcacggcaa 2280
tctattttacc aggacctgat cgctgcaaaa tgaacccgtg ccttaacgga ggcacctgtt 2340
atcctactga aacttcctac gtatgcacct gtgtgccagg atacagcgga gaccagtgtg 2400
aacttgattt tgatgaatgt cactctaata cctgtcgtaa tggagccact tgtgttgatg 2460
gttttaaacac attcaggtgc ctctgccttc caagttatgt tgggtgcactt tgtgagcaag 2520
ataccgagac atgtgactat ggctggcaca aattccaagg gcagtgttac aaatactttg 2580
cccatcgacg cacatgggat gcagctgaac gggaatgccg tctgcagggt gcccatctca 2640
caagcatcct gtctcacgaa gaacaaatgt ttgttaatcg tgtgggccaat gattatcagt 2700

```

```

ggataggcct caatgacaag atgtttgagc atgacttccg ttggactgat ggcagcacac 2760
tgcaatacga gaattggaga cccaaccagc cagacagctt cttttctgct ggagaagact 2820
gtgttgtaat catttggcat gagaatggcc agtggaatga tgttccctgc aattaccatc 2880
tcacctatac gtgcaagaaa ggaacagttg cttgcggcca gccccctggt gtagaaaatg 2940
ccaagacctt tggaagatg aaacctcggt atgaaatcaa ctccctgatt agataccact 3000
gcaaagatgg tttcattcaa cgtcaccttc caactatccg gtgcttagga aatggaagat 3060
gggctatacc taaaattacc tgcataaacc catctgcata ccaaaggact tattctatga 3120
aatactttaa aaattcctca tcagcaaagg acaattcaat aaatacatcc aaacatgatc 3180
atcgttggag cgggaggtgg caggagtcga ggcgctgatc cctaaaatgg cgaacatgtg 3240
ttttcatcat ttcagccaaa gtcctaactt cctgtgcctt tcctatcacc tcgagaagta 3300
attatcagtt ggtttggatt tttggaccac cgttcagtca ttttgggttg ccgtgctccc 3360
aaaacatttt aaatgaaagt attggcattc aaaaagacag cagacaaaat gaaagaaaat 3420
gagagcagaa agtaagcatt tccagcctat ctaatttctt tagttttcta tttgcctcca 3480
gtgcagtcca tttcctaatt tataccagcc tactgtacta tttaaaatgc tcaatttcag 3540
caccgatggc catgtaataa agatgattta atgttgattt taatcctgta tataaaataa 3600
aaagtcacaa tgagtttggg catattttaa gatgattatg gagccttaga ggtctttaat 3660
cattggttcg gctgctttta tgtagtttag gctggaaatg gtttcacttg ctctttgact 3720
gtcagcaaga ctgaagatgg cttttcctgg acagctagaa aacacaaaat cttgtaggtc 3780
attgcacctt tctcagccat aggtgcagtt tgcttctaca tgatgctaaa ggctgcgaat 3840
gggatcctga tggaactaag gactccaatg tcgaactcct ctttgctgca ttcccttttc 3900
ttcacttaca agaaaggcct gaatggagga cttttctgta accaggaaca ttttttaggg 3960
gtcaaagtgc taataattaa ctcaaccagg tctacttttt aatggctttc ataactacta 4020
ctcataaggt taccgatcaa tgcatttcac acggatatag acctagggct ctggagggtg 4080
ggggattggt aaaacacatg caaaaaaaaa aaaaaaaaaa aaattttgta tatataacca 4140
ttttaatcct ttataaagtt ttgaatgttc atgtatgaat gctgcagctg tgaagcatat 4200
ataataaat gaagtaagcc ataaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4260
aaaaaaaaan aanaaaaaaa aaaaaaaaaa aaaaangggg gg 4302

```

<210> 89

<211> 2782

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (82)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (743)

<223> n equals a,t,g, or c

<400> 89

```

ggaaaagcag gagaccagtt ggtgccagat aatctaaaag aaacagataa ggaaaagggc 60
aatgtggtgc tgaaaggaga antgagtgcc cggatgaaga ttccaagcaa tatgtgggta 120
gaagcctggg aaacagctaa gccaatcct gctagaaggc aaaggagact ctttgatgat 180
acacgggaag cagaaaaggt gctgcactat ctggcaatcc agaaacctgc agaccttgct 240
cggcacctgt taccttgtgt gattcatgca gctgtactca aggtaaagga agaagaaagt 300
ctcgaataca tttcttcagt taagaagatc ataaagcaga taatatccca ttccagtaaa 360
gttttgcact tccccaatcc agaagacaag aaattggaag aaatcattca ccagattact 420

```

```

aatgtggaag ctctcattgc cagagctcgg tcactaaaag ccaagtttgg aactgagaaa 480
tgtgaacagg aggaggaaaa ggaagatctt gaaaggtttg tgagttgcct gctggagcag 540
cctgaagtgt tagtcaccgg tgcaggaaga ggacatgctg gcaggatcat tcacaagctg 600
tttgtgaatg cccagagggtg ccagctatga ctccaccaga ggaggaattg aagagaattg 660
gctccccaga ggaaagaagg cagaactcgg tgtcagactt cccacccctt gctggccggg 720
aattcatttt gsgcamcact gtncgcgccc tgcctccctac tccaaagctc tgctcagcg 780
gatgtacagt gttctcacca aagaggactt tagacttgca ggtgcctttt catcagatac 840
ttccttcttc tgattcttct agcattactc gttgggtggc tcagagacag tgctgcctcc 900
tcctgagggg gggaagggtac cagggagaaac ctgggagggtc ctggagaggg ccctgtccag 960
ttgggtgatc aggaatcaaa ccagcatcgg aaagacttcc cagcaccaag cttgagctgt 1020
gtcgtttcgt ggaggggggca gcgaggatgg gcttgagctg ttgagagatt tctgccctag 1080
agatggcctt tgtatatggg ggggtggtgg ggggacacaa acacatcaga cactccgtcc 1140
tcacactggc aggacgggtg tcatcgcatc ctcttctgtg accagcctct aggctagcgg 1200
ctgcattcgt ggtctgtgca aacacttcgt ggttctatat atcagcagca agtgtgcaaa 1260
ataaaggacc tgttaactca gatttctgga tattttggtg gtagcttcta gtcccagaat 1320
ctgtgttttt aaaatactac atgacattct gtctattcaa tcacctggtg gtcattcttt 1380
ttgtactaat taactgttga tgagcatttt ggatattcta ggagaaagcc tataatttca 1440
catagtcttc ctttttcatg taactgtaac ctaaattgat tacttctgat aaaactatat 1500
atcaaattgtc actgcaaatt agttttatat ctgtcatgtg agatttgtct tacttatttt 1560
tcttttggtt gccatggaag ttatggccct gaaaatcgtc tccctcccct tctcttgctg 1620
tacagcatgc gttctctttt tgtggttgct ggctgggtac tgtatttaat gaagtagaga 1680
atagcacttg caaaaataca gtcttggtac cttagagactg tcatgcagat agtataattt 1740
ggtatatgtg ctaatgcatt gagtagagga ttattttaac acactatttt gcttttgat 1800
tttagttaa ataatcgatg gggatgtgta gccccccgt gtgaggatga catcaccaca 1860
tttctagttt catggagctc aagatgtctt gtgtctgtgt ggctagatgg cctctgcttg 1920
gtaatcttat ttttaggcct aaaattccca cttaaattcca aagtaaaaat ggttatactg 1980
aagcataaac ctgtcctgtg taatttttaa aaattaatag agctgtgcaa accctgttat 2040
ttttgtaaaa aaaaaaaaaa atacatatct atatataata tgttgtgtgtg tgtgacatat 2100
gcacacgtct ctgtgtatgt gaagtagggg aggccctggg ggatgacctc ccagccttta 2160
tgatgctttt ctctatgctg ctggacttca ttcttactgg tccacgcaga tgcaggcgcc 2220
tgaggccagt gctgtaccaa gtagaagacg gttcctaagg acagagtttg tctgttttct 2280
aacaagaaa aattctacaa aggagagggt gggcggttaca aaggcattgt gaatctaata 2340
aaaggaaagt gtcgctttct gtggcgtttt ctttcatttt ctcccgtgr ggcwtttcag 2400
tctaatttca tgtggktttg tgctgtctca gctctaattg ttgcagcctg ctgagcctaa 2460
caaggcagtg gtctcaagaa cattctttgt gcctttttta agtactccat tttattttta 2520
tgatagttat gtatttattt cacagatata ttaaagtacc cactttgtgt caggtagagt 2580
acaagcaatg aagataaaa acgaaaccaa acacactccc ttacagggaa aactgacacc 2640
acgttgccac aaaatgttga gtatagtcaa ctctgctgtg tggatcggag ggctgcatt 2700
tatoctacaa ataattgaat gtaatcctac attcatgtat tcattggcag tacggagtaa 2760
taaatgcagc aatgccataa aa

```

<210> 90

<211> 1037

<212> DNA

<213> Homo sapiens

<400> 90

```

aattcggcac gagctgtctg cgaagtggcc cttgattaca aaaagaagaa acacacctaa 60
acactttatc tccaagttac aaaagtttga ggtgcagagg gaaggccaga tttttttttt 120
aatgaaatta tatagattag atctcagtat ttaaactgtt cctcaatttt gtgaggctgt 180
gttggaata acccgctct agtgctgttg gtatgcaagg cagcggtgct taatcaatat 240

```

```

ttcctgtgct caccagagggc aaaatgtacc aatatcctga caccattctc tctccattta 300
cttctgggtg ttaccctgac tcttgactct tagaagtgcc cgagatgggg ctaaccttta 360
ttaaacagat cgcataattat gatcttgctg cagccacagt gcagctccac attactcta 420
cagaccaaac catttgatc tgccatcact tactaacaca cgacatgcgg cttttctgca 480
tcaactgcta tgacgggttaa gaatgtcagt atacaagaag gaatagaaaa ctgatactgt 540
tttaaataat ctgtaatttc aatttttttt tttttttgct gaaatacatt atattgtacg 600
tttgagataa ttctagtaca aagtataata aaactagatg tataataaac cctttaaatc 660
attggtaagt gtacaagtgg tggaaactgaa gcattttactg gacaaagtaa tgttactcta 720
atgggttactt gctcgtgcgt tgccacactg tggtataatt tgcttcattt ccttgctatt 780
tgatacatag tgtgcatttc tctgtcactg taactattgt aatgacaaat tttcatctta 840
ctgcacaatc aaaatgacat tgataggaat gaactccaga ggctgggcct gaacaggag 900
gtggctcgtc aggcctgggtg ctgagtcgta cgacctgtac ctctcaactt ttgccctatc 960
tgttaaatat atgctatgtc attaaatgct tttaaatcta aaaaaaaaaa aaaaaaaaaa 1020
aacggggggg ggcccg 1037

```

```

<210> 91
<211> 1052
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (76)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (962)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (965)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1044)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1048)
<223> n equals a,t,g, or c

```

```

<400> 91
gggcacgagt gcaggtggat gctgcactgc acccagcatc totgettatac aggaggtctt 60
ggagccacac cgcagnaagc acacgccctt ttgagccaga catgctgact ttctaataag 120
gatgtttctt ctccacagct gaaagatgaa aattctaagc tgagaagaaa gctgaatgag 180
gttcaragct tctytraagc wcawacagaa atgggtgagga cgcttgagcg gaagttagaa 240
gcaaaaatga atcaaggagg aaagcgacta ccacgacctg gagtcggtgg ttcagcaggt 300

```

```

ggagcagaac ctggagctga tgaccaaacg ggctgtaaag gcagaaaacc acgtcgtgaa 360
actaaaacag gaaatcagtt tgctccaggc gcaggctctcc aacttccagc gagagaatga 420
agccctgcgg tgccggccagg gtgccagcct gaccgtggtg aagcagaacg ccgacgtggc 480
cctgcagaac ctccgggtgg tcatgaacag tgcacaggct tccatcaagc aactgggttc 540
cggagctgag aactgaatc ttgttgccga aatcctaaa tctatagaca gaatttctga 600
agttaaagac gaggaggaag actcttgagg acccctgggt gttctcagca tgaagctccg 660
tgtataccct gaggtcacca ccgctcgatc taaatgtgca gttgtgtcct taaatatgca 720
gtcttcaccc agagtaaagt gttgatcgca agagtccagt gtcgtgccct cagccagttc 780
ttggccacca caatgggagc agccctggcc cgagttgtct ctgtgggttc tatgcagccc 840
ttcttgsga aattcctgcg atcttataga ttctaataag ctcttggaag acattgtcat 900
aaaagccagt gattttaara aaaaaaaaaa aaaaaggcg ggccggtttt aaaagatccc 960
tnganggggc ccaagcttac gcgtgcattc gacgtcataa cttttttccc tataagggag 1020
cgattataag cttaggcact tggncngng tt 1052

```

<210> 92

<211> 1234

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1115)

<223> n equals a,t,g, or c

<400> 92

```

cttcggcgca tgcgcgctga ggcctgcctg accgaccttc agcagggctg tggctaccat 60
gttctctcgc gcggtgtcgc ctgggctgtc ggctggacc ttgcagccgc aatggattca 120
agttcgaaat atggcaactt tgaaagatat caccaggaga ctaaagtcca tcaaaaacat 180
ccagaaaatt accaagtcta tgaaaatggt agcggcagca aaatatgccc gagctgagag 240
agagctgaaa ccagctcgaa tatatggatt gggatcttta gctctgtatg aaaaagctga 300
tatcaagggg cctgaagaca agaagaaaca cctccttatt ggtgtgtcct cagatcgagg 360
actgtgtggt gctattcatt cctccattgc taaacagatg aaaagcgagg ttgctacact 420
aacagcagct gggaaagaag ttatgcttgt tggaattggt gacaaaatca gaggcatact 480
ttataggact cattctgacc agtttctggt ggcattcaaa gaagtgggaa gaaagcccc 540
cacttttgga gatgcgtcag tcattgccct tgaattacta aattctggat atgaatttga 600
tgaaggctcc atcatcttta ataaattcag gtctgtcatc tctataaga cagaagaaaa 660
gcccattctt tcccttaata ccgttgcaag tgctgacagc atgagtatct atgacgatat 720
tgatgctgac gtgctgcaaa attaccaaga atacaatctg gccaacatca tctactactc 780
tctgaaggag tccaccacta gtgagcagag tgccaggatg acagccatgg acaatgccag 840
caagaatgct tctgagatga ttgacaaatt gacattgaca ttcaaccgta cccgccaagc 900
tgtcatcaca aaagagttga ttgaaattat ctctgggtgct gcagctctgt aaagaaggaa 960
aattcagcca gttgattttg tttttagctt actgctgcct ttgtccgaag aaactgttcc 1020
tccattatatt gaattactga agacagcaag atatttgtaa attatcttaa aataaacaac 1080
ttaaaataaa atcattgttt ttcttatata taagnacaat agatatagtt tttgaaatga 1140
gatgatacta aaacatttaa aaatattaat atgctactat taaaattttt tagtagaaga 1200
caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1234

```

<210> 93

<211> 1571

<212> DNA

<213> Homo sapiens

<220>
<221> misc feature
<222> (1497)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1516)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1530)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1546)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1571)
<223> n equals a,t,g, or c

<400> 93
gagcctgatt ccatcaaaaa gaaaggagta aaaagcaagt tacagcccag cagcacatct 60
gctttccctg ggtccggggg ctgccasgag ggascgggar gtctgtccac ctcacaaggc 120
aggctctgtc agcttttgtc actccctgat ttcttattct ttgttacctt ttttcgcctg 180
actgattttt acttggcatt taagtcccc ttagcactgc cagattctaa aaggttatat 240
tcttttttaa aaagaagaga aagaaagaag gaaagaagac aaagaaagaa taaaaacctc 300
cgagtgttaa ctacttttcc ctttcttctt ttttttataa agaatacatt ctttcacatc 360
ttgaatttct gtgaatttta gtttccattc tttctgcctt tgcaaaccag acacctaaat 420
tatacgtsga agctgttaaa aagttgtttt ttttttttta atggaaaata tccaagaagc 480
agcccaggag tatctgacat ggtggaatgg aatcagttag aaagcgaaga aatcactaaa 540
aaaagttact tctttttttc cccaccagtt ataatcttca accttactag tttataacag 600
tttaatgtcc tatagaagga tcctccacta aagttataat tttaagtata gtcatataga 660
gagatcccta atcccctggg taatctagat actaaagggt gggaagaaca gtcatataga 720
cattctttaa tccaaaacca ctgtttgaaa ttagtaagga tattttcagc attcccaaaa 780
acatgttatt agcacgttga gctgaaaacg ttttcttcc tcagttagta cagaaaccaa 840
agcagtcctgc gtgtatgtct atgtatagac tgtatcgtac ctgggctcat ggagtagtct 900
aaatttataa cgtcctctct tctacctcca atgaaaatgt ttccgtgtgt ggcgtctgat 960
cttccaccgt gtgtgtgggc gtctgctggt gtagcgtgt ttaaggagcg ctgtgtgctg 1020
ctagtgttcc acgatgtgtg tggctgtctg ctgggtgtagt agcactgttt gaggagcact 1080
gtgcgccgct agtgtgggtt tacacttatg agtgtgtgca ttacatgtgt tctgctcttc 1140
tctccctctc ctgcccctgc cctgctccat cagagagagc tgcaggctctc tgctgccgcc 1200
tagtagttcc ctgtcacaaa gggatgcaa ggcttaccga tctgtctgtc aaaaccaaag 1260
atgtctggga aatccctcga gaatccctgc agttgatcaa gagactggga aatgggcagt 1320
ttgggggaagt atggatgggt atgctgagac tcaattactc tcttatttagc tccccgttt 1380
ggaagatccc aaacaccaa gatggaaggt gaaaataaag actgcgtgac cgggaagaaa 1440

```

gtttgaatta ctaatagtgg ggaataataa tttcagtttt ggttttaaac atctggnatt 1500
cctaaaaaaaa aaaaanaaaa aaaaaaaacn cggggggggg cccggnaccc aattcccccc 1560
aaaggggggg n 1571

```

<210> 94

<211> 1872

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (51)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1271)

<223> n equals a,t,g, or c

<400> 94

```

gggnancccc cccggggggg aaaacggatg ggccccgggc cccccaaaaa ntacccccga 60
ggtttttttt tttttttttg atttaataaa gttttatttt tccaaatgta cagctgggtg 120
gacctattca tgcattctca ccagcagctg gagcatctcc acccttggtg tttctgggtg 180
aaattacttg agctctgtgc tttgaaacca gtttgataag tcctttacta aggagctcct 240
gaagggtgc cctggccagg gagcctcgaa tcttcagtct ctcagagacc acwkcttctt 300
tttggccttg cccccggatt tgttcaactg gtctttgtct ttcttgccg actttccagc 360
gtccttcttc ttcttgctgt ccttaggcgg cattgcgaag ctcggagaat agcagcagac 420
accgcagcct cgtcaagatg tcggacaaaa aggaagcgct gctcagaaac gkgcccaaaa 480
accaccgtcc gctgtgagta cttccggggc aagaggcgga gccaggcaga rgaagtccca 540
cggcgaagcg ctcgccctct agcctgaggc ggaagacagg aagyggattc tagttcccaa 600
gccgcaccgc ctaaatactg ccggagtctg cgctagtgtg gacgcagtac tatagcgtg 660
ttttcctgca ctgataaacg aaaagcaatc caccaggtct cggcagctaa ctttccggca 720
ctacttatgc ccgagcgtgt cgctcccagt gcgcaagtgc agcaggtggc tgcacggggg 780
gcgcggggag aggaggagga ggaggaggag gctgggggtg gccggcgggc aagtgtgtg 840
atgcggttcc ggggaggggc cgctcgggtg aggcgtgaata ccagtttccg agcggcaagg 900
cagcgatggc gatttttagt gtgtatgtgg tgaacaaagc tggcggcttg atttaccagt 960
tggaacagcta cgcgccacgg gctgaggctg agaaaacttt cagttatccg ctggatctgc 1020
tgctcaagct acacgatgag cgtgtgttg ttgctttcgg ccagcgggac ggcattccgag 1080
tggtcatgc agtgctggcc atcaatggca tggacgtgaa tggcaggtag acggccgacg 1140
ggaaagaggt gctggagtat ctgggtaacc ctgctaatta cccggtgtcc attcgatttg 1200
gccggccccg cctcacttct aatgagaagc ttatgctggc ctccatgttc cactcgctct 1260

```

```

ttgccatcgg ntcccagctg tctcctgaac agggaagctc aggcattgag atgctggaga 1320
cagacacatt caaattgcac tgctaccaga cactgacagg gatcaagttt gtggttctag 1380
cagatcctag gcaagctgga atagattctc ttctccgaaa gatttatgag atttactcag 1440
actttgccct caagaatcca ttctattcct tagaaatgcc tatcaggtgt gagctctttg 1500
accagaacct gaagctagct ctggagggtg cagagaaggc tggaactttt ggacctgggt 1560
cataggctga acctgttatg gacccccaaa ttctgagagt tcctgcaaca agaatactgc 1620
tgttgacact ccagtggaaa tcccagcagc cttgttagtg cacttgaaag tgggagaatg 1680
ctgacctga tgacttgtag tgattcctga gccttaacac tgtgctcttt ccttctgtat 1740
ataccatggg cttaactttcc aactctgtac agatttatat atggaggagc taggtccata 1800
aatgttgtaa taaatattcc tttgatcttg gtgtttgcaa aaaaaaaaaa aaaaaaaact 1860
cgagactagc gg                                     1872

```

<210> 95

<211> 1516

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1505)

<223> n equals a,t,g, or c

<400> 95

```

ggaggggcaga aaggaggagt gctgggaggg cttagtcgga gattgaggac tgggaatccg 60
cttccgggag ggcactgtct agtgcacagg caacctggcc ttsgcctcct agcccagaaa 120
gccgaatctc cctaattcct gtgacctgtg tcacctctgc atcgcgagga gggggataag 180
tgggggagaag tctggtgtca gatgggatgg cgccggaaga ggggtgccaca gcggggacgg 240
aaggcgcccc caccccaact ccacgggaat ataaacaatt tgtattttcc gatcaggtgg 300
cgggacaggc ttcattggga cagccctaac ccagctgctg aatgccagag gccacgaagt 360
acgttggtct cccgaaagcc cgggcccggc cggatcacgt gggatgagct cgctgcatcg 420
gggctgccga gctgcgatgc cgccgtcaac ctggccggag agaacatcct caaccctctc 480
cgaagatgga atgaaacctt caaaaaagag gttctcggca gccgcctaga gaccacccaa 540
ttgctggcta aagccatcac caaagcccca caacccccca aggcctgggt cttagtcaca 600
ggtgtagctt actaccagcc cagtctgact gcggagtatg atgaagacag ccaggagggg 660
gactttgact ttttctccaa cctcgttaac aaatgggaag ctgcagccag gcttcctgga 720
gattctacac gccagggtgg ggtgcgtca ggggttgtgc tgggccgtgg ggggtggtgc 780
atggggcaca tgctgctgcc ctttcgcctg ggccctgggg gccccatcgg ctcaggccac 840
caattcttcc cctggataca catcggggac ctggcaggaa tcctgaccca tgcccttgaa 900
gcaaaccacg tgcacggggg cctgaatgga gtggctccat cctccgccac taatgctgag 960
tttgcccaga ccttcgggtg tgccctgggc cgccgagcct tcacccctct cccagcgt 1020
gtggtgcaag ctgtctttgg gcgacagcgt gccatcatgc tgctggaggg ccagaagggtg 1080
atcccacggc gaacactggc cactggctac cagtattcct tcccagagct aggggctgcc 1140
ttaaaggaaa ttgtagccta agtaggtcat ggcaaggggc tgaggcctgt tcctcacagg 1200
cttcagggtt aggcactgtg aataggctca gctcctctag agagctgaag ccattctggt 1260
cttagattcc tctcccagtc ctctttccca ttgttctggt gctccacctt attgtctcaa 1320
ggccgtaatc tcatcagggt gggacattaa tcttttcaac tccttgtaag atttccgggt 1380
ttggtttctc tacatgtcct gcagctgcc cacttctcct ttacgctgtg tagagaatgc 1440
tctgcagttt aggcaataaa aataaattgt ctactataaa aaaaaaaaaa aaattggggg 1500
ggggncccg acccat                                     1516

```

<210> 96

<211> 1770

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (485)

<223> n equals a,t,g, or c

<400> 96

```
agtgccagga gtgggttcca gatcgggaga gctacgtgtc ccacatgaaa aagagccacg 60
gtcggacatt gaagcggtag ccatgccggc agwgtgaaca gtccttccac accccaaca 120
gcctgcgcaa acacatccgc aacaaccatg acacagtaaa gaagttctac acctgcgggt 180
actgcacaga ggacagcccc agctttcctc ggccctccct tctggagagc cacatcagcc 240
ttatgcatgg catcagaaac cctgatttga gccagacgtc caaagtgaaa cctccgggtg 300
gacattcccc tcaggtgaac catctgaaaa gaccagtcag tggagtgggg gacgctccag 360
gcaccagcaa tggcgcaact gtctcttcca ccaaaggca caagtcctt tttcagtgcg 420
cgaaatgtag ttttgccaca gactcggggc tcgagtttca gagccacata cctcagcacc 480
aggtnggaca gytccacagc ccaatgtctc ctctgtggtt tgtgctacac ctctgccagc 540
tccctcagcc gccacctctt cattgtccac aaggtgagag accaggagga ggaggaggaa 600
gaggaggcgg cggcacggag atggcagtg aggtggcaga gcagaggagg gctccgggga 660
rgargtgccc atggagacta gagagaatgg actggaagaa tgtgccggtg agccyttgtc 720
agctgacca gaggcgagga gattgctggg cccggcccct gaggacgatg gtggccacaa 780
tgatcacakt caaccacagg cytytcagga ccaggacagc cacacactgt cccctcaggt 840
gtgaccggag actttgcagt gtgcatggtc aggggtggtg ccgaagtgtc ttccacctgc 900
cctgcggacc gtggaaaata aaaggctctg ccccagtggt gagtgtgacc gggtgtaccc 960
tgagtagtg totgccctga gctgccagtg ctgggtatcc cccagcccca ggaaatgtgg 1020
ggtcggccag gaccctcaca gctctgaatt tgcttctgtt atttatggct tttcgytgct 1080
tcttggtgcc ccatctcttg tctgtgtcct tccaaccca agctgcttat gtggcccaac 1140
cccactgctg tcaactaggc ttgaaccca cagcggctgt gctcttctgg gaggttcccc 1200
cttgctgcct tcagccaggg cgctcctcag agctctatct tctgcagac accagctctc 1260
cttctgcct ttagatcctg agaaggaggg aaatgagggg tgctgacaca gtccctctgg 1320
gagagctctg cctagtctgg tttggcgagg gcccttgatc accttgcccc tcctccctgt 1380
cttctctgat tcttttccct caaaatagtc ctgagaacta attgtcacac tggctcatca 1440
tgtctctgtg ggtgggggtg gagaaacctc tgctgcacac ctctgtttgg aacctgggca 1500
gagcaggagg taaggcaaag gcaggcaggc accaagaacc agacccttg agaaggcgct 1560
gtgggtgggt ctttgttctg ctgttctgcc tttcctgaca ggtggggttg gggcacacag 1620
acattggaat atttgtactg ctctcgtgcc atttgagagg cttgctgccc caggcaggcc 1680
agcccctact cctcttggt acactcatgt tkctcagact atatttcaa taaaaaatct 1740
tctcaccatg caggtaggct cttgtattcc 1770
```

<210> 97

<211> 938

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (183)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (293)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (360)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (938)
 <223> n equals a,t,g, or c

<400> 97
 gcagaagagg ggagattggg ggagagatga cagctgcagg gatggttgtr agccgctagt 60
 ratggagagc agagggagag ggccaggctc caractccca cacgcccaca cagcacctct 120
 gccaggccta ggagaagaca ggtgcagctc ttgcagctct gcgggtgtgc ggccaaaggc 180
 aangcccacg ggctggatgt cacttccccg actgtctctt ggttggcttg tccttgtgca 240
 agaccacgcs tgtcacgaca garcctgggc acttcagagg aggagccagg ttngaattgt 300
 aaggggggaa ttgggggtcca ccatagtctt ctgctctggt cctccacggg tgggaccagn 360
 atggaagtct cctgcctaac ctactgcat tgcactggac ctgggatgcc tatccaccct 420
 ctggcagaag acactcacca ggttatctgt gaagagactc tgggatocca tcacctcaa 480
 gccagagggg ccccaagtca ccgctgagag cacttgagcc tcaaggatgt aagcctgacc 540
 ataggatctt gactccaaca gcggcaaccc ccacccccat tgtggtccgt ccttaaccca 600
 tccactcttc ttcgagggca actgagaaca cataaagcaa gcagctacct agcatcccc 660
 tcctaaagct ttagactcag agcccagggt cccccacaag cctcaaggta gcctcagggt 720
 totctaattt cctccactcc cagttcgaag caaacagctt actgcctagt ccccgccaat 780
 cccaagggcg ggctggctga tggcagcatg gtgggctggc ctgggtgtgg agtgaaagag 840
 tcaactgtgt gggggcgaga ggaggacttg ggagctggag gtgtgacacc ttcagttctg 900
 ttcctattaa aggaccttct gaagggcaaa aaaaaaan 938

<210> 98
 <211> 311
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (297)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (309)
 <223> n equals a,t,g, or c

<400> 98
 agatgcggct ggagcagcag aagcagacgg tccagatgcg cgcgcagatg cccgccttcc 60
 ccctgcccta cgcccaggca tgtgccatcc tcccgccacc cagaggtttg tgggctgagg 120

```

accaactctc accgctgtct ctttcgtccc cagctccagg ccatgcccgc agccggaggt 180
gtgctctacc agccctcggg accagccagy ttccccagca ctttcagccc ygccggctcg 240
gtggagggtc ccccaatgca cggcgtgtac atgagccagc cggtccttgc cgctggnccc 300
taccccagna t 311

```

<210> 99

<211> 620

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (368)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (570)

<223> n equals a,t,g, or c

<400> 99

```

actgccggtc gttcggacgt cttgcctgtc gctggaggag aggtccgggc tctccaggaa 60
ggtggctgcg gcgacaaaat gaagatattc gtgggcaacg tcgacggggc ggatacgact 120
ccggaggagc tggcagccct ctttgcgccc tacggcacgg tcatgagctg cgccgtcatg 180
aaacagttcg ctttcgtgca catgcgcgag aacgcggggc cgctgcgcgc catcgaagcc 240
ctgcacggcc acgagctgcg gccggggcgc gcgctcgtgg tggagatgtc gcgccaagg 300
cctcttaata cttggaagat ttctgtgggc aatgtgtcgg ctgcatgcac gagccaggaa 360
ctgcgcancct cttcgagcgc cgcggaacgc tcatcgagtg tgacgtggtg aaagactacg 420
cgtttgttca matggagaag gaagcagatg ccaaagccgc aatcgcgag ttcaacggca 480
aagaagtgaa gggcaagcgc atcaacgtgg aatctycacc aagggtcaga agaagggggc 540
tggcctggct gtccagtctt gggacaagan caagaaacca agggctgggg ataggccttc 600
cctggaatgg tggttttctg 620

```

<210> 100

<211> 2511

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (28)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2456)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2488)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2511)

<223> n equals a,t,g, or c

<400> 100

```

gtaccattcc cngaccgctt ggcctgtncg attaatccgc cccnatagga attggcccgg 60
gccagattcg gcogagcaag cggaacctct gggaaaagca atctgtggat aaggtcactt 120
ccccactaa ggtttgagac agttccagaa agaaccgaag ctcaagacgc aggacgagct 180
cagttgtaga gggctaattc gctctgtttt gtatttatgt tgatttacta aattgggttc 240
attatctttt atttttcaat atcccagtaa acccatgtat attatcacta tatttaataa 300
tcacagtcta gagatgttca tggtaaaagt actgcctttg cacaggagcc tgtttctaaa 360
gaaacccatg ctgtgaaata gagacttttc tactgatcat cataactctg tatctgagca 420
gtgataccaa ccacatctga agtcaacaga agatccaagt ttaaaattgc ctgcggaatg 480
tgtgcagtat ctagaaaaat gaaccgtagt ttttgttttt ttaaatacag aagtcatgtt 540
gtttctgcac ttataataa agcatggaag aaattatctt agtaggcaat tgtaacactt 600
tttgaaagta acccatttca gatttgaaat actgcaataa tggttgtctt taaaaaaaaa 660
aaagaaatgt actgttaagg tattactttt tttcatgctg atgattcata tctaaattac 720
attattatgt tagctgacag tggtagctat tttttagggt gggtgttttg tggatttctt 780
tagtagtgat agtagcctga accacatttt agataactca attatgtatg tatgtgcata 840
cacatatata aacacactaa tggtagaatg cttttttatg tgctagacta ttatatattag 900
tagtatgtca ttgtaactag ccaatatcac agcttttgaa aaattaaaaa atcacactat 960
attaatatat catatttgcc aacagaaaca tggcagatag gtatcaatat gttttcaatg 1020
cctgatgacc tataagaaga aagtattgaa aagaagagag attagaactg ttagaaggag 1080
ttgaaatttt ctaaaagaca tagtatttag ttataatta aatgcattct tgaagtccag 1140
tgtgaatttt attaatgcta tcatctcgac caagctcaaa gcctacttat tagaaacaat 1200
gaagttcaca ataggtcata aggtctcttc cttttctaaa attgaaagac aagaaattta 1260
gtgccaatat tgtacagaca gaaattccat gtatgagtct caacaaagac tacccttggc 1320
taaatgtcta gaagcagaga agtaaaagtga gcaaaatcca gtgttgagga gtcatgacag 1380
tactttgatc ttatatact ctgaagcatt tcttcaaact tttctacttt tatttgtcat 1440
tgatacctgt agtaagttga caatgtggtg aaatttcaaa attatatgta acttctacta 1500
gttttacttt ctcccccaag tcttttttaa ctcatgattt ttacacacac aatccagaac 1560
ttattatata gcctctaagt ctttattctt cacagtagat aatgaaagag tcctccagtg 1620
tcttgcaaaa atgttctagt atagctggat acatacagtg gagttctata aactcatacc 1680
tcagtggact taaccaaatt tgtgttagtc tcaattccta ccacactgag ggagcctccc 1740
aaataactat tttcttatct gcagtattcc tccagaagag ctaaccaggg cagggctggc 1800
atgagaagtg acatctgcgt tacaaagtct atcttctcca taagtctgta aagagcaatt 1860
gaatcttcta gcttttagcaa acctaagcca aaggaaggaa agccacgaag aatgcagaag 1920
tcaaaccctc atgacaaagt aggcacaagt ctacaataag ctaaatcaga atttacaaat 1980

```

```

acaagtgtcc caggtagcat tgactcccggt cattggagtg aaatggatca aagtttgaat 2040
taaggcctat ggtaaggtaa cattgctttg ttgtactttt gaacaagagc tcctcctgat 2100
cactattaca ttttttctta gaaaatctaa agttcagaag agaattgtatc actgctgact 2160
tttattccaa tatttggtatg gagtaagttt tagggtagaa ttttgttcag tttggattta 2220
atcttttgaa aagtaaattc cttgtttact ggtttgacta taattctctg ttatctttac 2280
gaggtaaaac tgcaagctga ctagcatggt ctgtgaatct gccattccta aaaattttat 2340
aaacacttga tacttttcac tgataatgga tcgctccaat aaacatatat tgtgaaaatg 2400
catccacaat aaatggaatt ccttcctgca aaaaaaaaaa aaaaaagggc ggccgntcta 2460
gaggatccag gcttacgtac gcgtgccngc gacgtccata gcccttcta n 2511

```

<210> 101

<211> 2981

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (293)

<223> n equals a,t,g, or c

<400> 101

```

cggacgcgtg ggcgccacg ttgtcttgcg cgctttgccc gcctggccct gggactctga 60
ccctcggcta ccctttcctg cccactagc gtggccgcga gcctcggta gccggccgta 120
ttcccgcctc cgcttagggg gcacaggcgc aggcacgcgc ccggccactc caagccttcg 180
gtgcgcgggc gcgtctggga tacgggcccg ggaggcgccg ccctccgtcc gcccggtgcc 240
tctcaggaac agcgaaccgg agagagcgcc ggagagttgg gctcagtgr ganctcggcg 300
ccggggccca tgcccgtgcg ccccgccagg ccggcgccat ggctccggg agtktgggcg 360
agtgcctgca gcaggagacc acctgccccg tgtgcctgca gtacttcgca gagcccatga 420
tgctcgactg cgcccataac atctgttgcg cgtgcctcgc ccgctgctgg ggcacggcag 480
agactaacgt gtcgtgcccg cagtgcggg agaccttccc gcagaggcac atgcggccca 540
accggcacct ggccaacgtg acccaactgg taaagcagct gcgcaccgag cggcgctcgg 600
ggccccggcg cgagatgggc gtgtgcgaga agcaccgcga gcccctgaag ctgtactgcg 660
aggaggacca gatgccatc tgcgtggtgt gcgaccgctc ccgcgagcac cggggccaca 720
gcgtgctgcc gctcgaggag gcggtggagg gcttcaagga gcaaatccag aaccagctcg 780
accatttaaa aagagtgaag gatttaaaag agagacgtcg ggcccagggg gaacaggcac 840
gagctgaact cttgagccta acccagatgg agaggagaaa gattgtttgg gaggttgagc 900
agctgtatca ctctttaaag gagcatgagt atcgctcctt ggcccgccct gaggagctag 960
acttggccat ctacaatagc atcaatggtg ccatcaccca gttctcttgc aacatctccc 1020
acctcagcag cctgacgct cagctagaag agaagcagca gcagcccacc agggagctcc 1080
tgcaggacat tggggacaca ttgagcagg ctgaaagaat caggattcct gaaccttgga 1140
tcacacctcc agatttgcaa gagaaaatcc acatttttgc ccaaaaatgt ctattcttga 1200
cggagagtct aaagcagttc acagaaaaaa tgcagtcaga tatggagaaa atccaagaat 1260
taagagaggc tcagttatac tcagtggacg tgactctgga ccagacacg gcctacccca 1320
gcctgatcct ctctgataat ctgcggcaag tgcggtacag ttacctcaa caggacctgc 1380
ctgacaaccc cgagaggttc aatctgtttc cctgtgtctt gggtctcca tgcttcatcg 1440
ccgggagaca ttattgggag gtagaggtgg gagataaagc caagtggacc atagggtgct 1500
gtgaagactc agtgtgcaga aaaggtggag taacctcagc ccccccagaat ggattctggg 1560
cagtgtcttt gtggtatggg aaagaatatt gggctcttac ctccccaatg actgccctac 1620
ccctgcggac ccgctccag cgggtgggga ttttcttgga ctatgatgct ggtgaggtct 1680
ccttctacaa cgtgacagag aggtgtcaca ccttcacttt ctctcatgct accttttgtg 1740
ggcctgtccg gccctacttc agtctgagtt actcgggagg gaaaagtgc gtcctctga 1800

```

```

tcatctgccc catgagtggg atagatgggt tttctggcca tgttggaat catggtcatt 1860
ccatggagac ctccccttga ggaggtgaat tcaggccaaa agggctgttg gctgtaatcc 1920
tacgccaggc acaaggcatc ttgttgccct gccacgtcct gtcacagctg ggtatccctta 1980
ccatgttcca cgcccttgca gtgggagaca ggatgtccat gttctctacc atccttttcc 2040
ttcccatgca gattgtgaaa tgtaatgaga tgtatcaaga tatcctagaa ataaaaacca 2100
gatgtccacc tccagtgttt catactttct ggttttacac atcgctggag ggataaagag 2160
tatggataat ctttggattt ggagagccgt tcaagatact tccagcttct tggctcagcc 2220
tggcttcctc tggttcagcc ccacataatg attatggcta tttgctgtca tttctgggct 2280
agggtcctt tctaacaacc tagactggaa taaggccctg tcagcatggc tccctttatc 2340
ccagttttcc gtctgggaac agtacctctg cccctgattc ccaatgtgcc atagttttat 2400
taactccatt aaagaagcct gtatgtgttt tggttagtta cagtattttt acaataatgg 2460
tgggtaatgg cccacctct gttatgagat aatgttctaa tcaatgtctc tgcctttgta 2520
tcttttctga gggctttgtc tgttctcttc attctaataa aagggtgtatt ctagtgtgtg 2580
gtgcatatca tccaggataa tattctgccc aactccatcc tctgttacta gatcccttac 2640
cagtcacatt tgtggaactg tggccagtcg tataccatcc ctggaaggat tctgggacaa 2700
tattccaggg attcattgac ttcttggctc cttttctcca tttcctttgg gggaaggggg 2760
aattgaccat gcttaagtgc atcctatcaa ggggcagctc cgtcccatg gccattggat 2820
catgagacac tctgaagtca gaaggctggg gcagatcact tcaagcaagc ccccatgatg 2880
gttctcagtc ctgcttctct gtgggtacgt gccctctgt ttaaaaataa actgaatatg 2940
gatgtttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa g 2981

```

<210> 102

<211> 2804

<212> DNA

<213> Homo sapiens

<400> 102

```

ccaaggacac aggtgaaagg ttgagccatg cagtaggctg tgcttttgca gcctgggttta 60
gagcgcaaca ggaagcggcg agaaggaatg tggagtgaat gctacttttg atgctagtcg 120
gaccactttt acaagagaag gatcattccg tgtcacaaca gccactgaac aagcagaaag 180
agaggagatc atgaaacaaa tgcaagatgc caagaaagct gaaacagata agatagtcgt 240
tggttcatca gttgcccctg gcaamactgc cccatcccca tctctctcca cctctcctac 300
ttctgatgcc acgacctctc tggagatgaa caatcctcat gccatccac gccggcatgc 360
tccaattgaa cagcttgctc gccaaagctc tttccgaggt tttcctgctc ttagccagaa 420
gatgtcacc tttaaacgcc aactatccct acgcatcaat gagttgcctt ccactatgca 480
gaggaagact gatttcccca ttaaaaatgc agtgccagaa gtagaagggg aggcagagag 540
catcagctcc ctgtgctsac agatcaccaa tgccttcagc acacctgagg accccttctc 600
atctgctccg atgaccaaac cagtgcagat ggtggcacca caatctccta ccttccaagg 660
gaccgagtgg ggtcaatctt ctggtgctgc ctctccaggt ctctccagc cgggtcatag 720
acgtactccc tctgaggccg accgatggtt agaagaggtg tctaagagcg tccgggctca 780
gcagccccag gcctcagctg ctctctgca gccagttctc cagcctcctc caccactgc 840
catctccag ccagcatcac ctttccaagg gaatgcattc ctacacctc agcctgtgcc 900
agtgggtgtg gtcccagccc tgcaaccagc ctttgtccct gccagtcct atcctgtggc 960
caatggaatg ccctatccag cccctaattg gcctgtggtg ggcatcacty cctcccagat 1020
ggtggccaac gtatttggca ctgcaggcca cctcaggct gccatcccc atcagtcacc 1080
cagcctggtc aggcagcaga cattccctca ctacgaggca agcagtgcta ccaccagtcc 1140
cttctttaag cctcctgctc agcacctcaa cggttctgca gctttcaatg gtgtagatga 1200
tggcaggttg gcctcagcag acaggcatac agaggttcct acaggcacct gccagtgga 1260
tccttttgaa gccagtgagg ctgcattaga aaataagtcc aagcagcgta ctaatccctc 1320
ccctaccaac ctttctcca gtgaattaca gaagacgttt gaaattgaac tttaagcaat 1380
cattatggct atgtatcttg tccataccag acagggagca gggggtagcg gtcaaaggag 1440

```

```

caaaacagac tttgtctcct gattagtact cttttcacta atcccaaagg tcccaaggaa 1500
caagtccagg cccagagtag tgtgaggggt gattttgaaa gacatgggaa aaagcattcc 1560
tagagaaaag ctgccttgca attaggctaa agaagtcagg gaaatgttgc tttctgtact 1620
ccctcttccc ttacccccctt acaaattctct ggcaacagag aggcaaagta tctgaacaag 1680
aatctatatt ccaagcacat ttactgaaat gtaaaacaca acaggaagca aagcaatctc 1740
cctttgtttt tcaggccatt cacctgcctc ctgtcagtag tggcctgtat tagagatcaa 1800
gaagagtggg ttgtgctcag gctggggaac agagaggcac gctatgctgc cagaattccc 1860
aggagggcat atcagcaact gccagcaga gctatatattt gggggagaag ttgagcttcc 1920
attttgagta acagaataaa tattatatat atcaaaagcc aaaatcttta tttttatgca 1980
tttagaatat tttaaatagt tctcagatat taagaagttg tatgagttgt aagtaatctt 2040
gccaaaggta aaggggctag ttgtaagaaa ttgtacataa gattgattta tcattgatgc 2100
ctactgaaat aaaaagagga aaggctggaa gctgcagaca ggatccctag cttgttttct 2160
gtcagtcatt cattgtaagt agcacattgc aacaacaatc atgcttatga ccaatacagt 2220
cactaggttg tagttttttt taaataaagg aaaagcagta ttgtcctggg tttaaacctt 2280
tgatggaatt ctaatgtcat tattttaatg gaatcaatcg aaatatgctc tatagagaat 2340
atatctttta tatattgctg cagtttcctt atgttaatcc tttaacacta aggtaacatg 2400
acataatcat accatagaag ggaacacagg ttaccatatt ggtttgtaat atgggtcttg 2460
gtgggttttg ttttatcctt taaattttgt tcccatgagt tttgtgggga tggggattct 2520
ggttttatta gctttgtgtg tgtcctcttc ccccaaacc ccttttggtg agaacatccc 2580
cttgacagtt gcagcctctt gacctcggat aacaataaga gagctcatct catttttact 2640
tttgaacggt ggccttacaa tcaaatgtaa gttatatata tttgtactga tgaaaattta 2700
taatctgctt taacaaaaat aaatgttcat ggtagaagct tttkcccatg aagggtctgt 2760
ctttcccctt tcctttatta gtaaatgaat ttatttttaa aaaa 2804

```

<210> 103

<211> 722

<212> DNA

<213> Homo sapiens

<400> 103

```

cgggaagagg cggacagcga ggccaagatt tcagctgcgg gacgggcagg ggagacctcc 60
aggcgagagg aaggacggcc aggggtgacac ggaagcatgc gacgggtgct gatccctctg 120
gccctgtggc tgggygcggg gggcgtgggc gtcgccgagc tcacggaagc ccagcgccgg 180
ggcctgcagg tggccctgga ggaatttcac aagcaccgcg ccgtgcagtg ggccttccag 240
gagaccagtg tggagagcgc cgtggacacg cccttcccag ctggaatatt tgtgaggctg 300
gaatttaagc tgcagcagac aagctgccgg aagagggact ggaagaaacc cgagtgcaaa 360
gtcaggccca atgggaggaa acggaatgc ctggcctgca tcaaactggg ctctgaggac 420
aaagttcttg gccggttggg camtgcccc atagagaccc aagttytgcg ggagaccag 480
tgccctcagg tgcagcgggc tggtagggac cccacagct tctacttccc tggacagttc 540
gccttctcca aggcctgcc ccgcagctaa gccagcactg agmtgcgtgg tgcctccagg 600
accgctgcgg gtggaacca gtggaagacc ccagcccca gggagaggaa cccgttctat 660
cccagccat gataataaag ctgctctccc agctgcctct caaaaaaaaa aaaaaaaaaa 720
aa 722

```

<210> 104

<211> 1636

<212> DNA

<213> Homo sapiens

<400> 104

```

tacggctgcg agaagacgac agaagggggg ctatctgaag aggacgggga cgggagcctg 60

```

```

ctctacagcg tgggtcaacac ggccgagcga cgctgatgag gaggagaccc acccggtgac 120
ttgagctcgc tctccagtaa gctactccca ggcttcacca cgctgggctt caaagacgag 180
agaagaaaca aagtcacctt tctctccagt gccactactg cgctttcgat gcagaataat 240
tcagtatttg gcgacttgaa gtcggacgag atggagctgc tctactcagc ctacggagat 300
gagacaggcg tgcagtgtgc gctgagcctg caggagtttg tgaaggatgc tgggagctac 360
agcaagaaaag tgggtggacga cctcctggac cagatcacag gcggagacca ctctaggacg 420
ctcttccagc tgaagcagag aagaaatgtt cccatgaagc ctccagatga agccaagggt 480
ggggacaccc taggagacag cagcagctct gttctggagt tcatgtcgat gaagtcctat 540
cccgacgttt ctgtggatat ctccatgctc agctctctgg ggaagggtgaa gaaggagctg 600
gaccctgacg acagccattt gaacttggat gacacgacga agctcctgca ggacctgcac 660
gaagcagcag cgagcgcggc ggctctcggc cktcgtccaa cctcagctcc ctgtccaacg 720
cctccgagag ggaccagcac cacctgggaa gcccttctcg cctgagtgtc ggggagcagc 780
cagacgtcac ccacgacccc tatgagtttc ttcagttctc agagcctgcg gcctctgcca 840
agacctaact ctagaccacc ttcagctctt ttattttatt tttttagttt tattttgcac 900
gtgtagagtt tttgtcatca gacaaggact ttgatcctgt cccctttggc atgcgggaag 960
cagccgcggc ggaggtaatg aattgtctgt ggtatcatgt cagcagagtc tccaagcccc 1020
acgaaccctg aggagtggag tcatacgca aggccatatg gcatcgtgtc agcagagaga 1080
gtctctgtac acagccccgt gaaccctgag gagtggagtc atacacgaag ggcgtgtggc 1140
catcgtgtca gcagagagag tctctgtaca cagccccgtg aaccctgagg agtggagtca 1200
tacgcgaagg gtgtgtggcc aggctgcaga gctgcgtgcc gtttgtgtcc gagcatcacg 1260
tgtggctcca gcccttgttt ctgccagtgt agacacctct gtctgccccca ctgtcctggg 1320
gtcgtctctg ggaggcacag gcatgggtgt gtctggcctc attctgtatc agtccagtgt 1380
gttcctgtca tagtttgtgt ctcccaggca ggccatggta ggggcctcgc agggggcatt 1440
ggggagcaca gggccaggct ggggtgagga gagctcccct gttttctgtt taattgatga 1500
gcctgggaaa ggagtgtgtt ctgcctgccc gttacagtgg agcgttccgt gtccataaaa 1560
cgttttctaa ctggraaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
aaaaaggggg gggggg 1636

```

<210> 105

<211> 1561

<212> DNA

<213> Homo sapiens

<400> 105

```

caggcgggaa catggccacc gagacccaaa tgtggtgcca ggtcctccca agccagcaaa 60
ggagaaacct cccaaaaaga aggccaggga caaaattctt agtaatgagt atgaggagaa 120
gtatgacctc agccggccta ctgcctctca gctggaggac gagctgcagg tggggaatgt 180
tccccttaaa aaagcaaagg agtctaaaaa gcatgaaaag cttgagaaac cagagaagga 240
gaagaaaaaa aagatgaaga atgagaacgc agacaagtta cttagagtg aaaagcaaat 300
gaagaagtct gagaaaaaga gcaagcaaga gaaagagaag agcaagaaga aaaaggagg 360
taaaacagaa caggatggct atcagaaacc caccaacaaa cacttcacgc agagtcccaa 420
gaagtcatgt gccgacctgc tggggctcct tgaaggcaaa cgaagactcc ttctgatcac 480
tgctcccaag gctgagaaca atatgtatgt gcacaacgtg atgaatatct ggaaagtctc 540
tgcaagatgg ctaccaggaa aatctctgtg atcacatct tcggccctgt caacaacagc 600
accatgaaaa tcgaccactt tcagctagat aatgagaagc ccatgcgagt ggtggatgat 660
gaagacttgg tagaccagcg tctcatcagc gagctgagga aagagtacgg aatgacctac 720
aatgacttct tcatggtgct aacagatgtg gatctgagag tcaagcaata ctatgaggta 780
ccaataacaa tgaagtctgt gtttgatctg atcgatactt tccagtcccg aatcaaagat 840
atggagaagc agaagaagga gggcattgtt tgcaaaagagg acaaaaagca gtccctggag 900
aacttcctat ccaggttccg gtggaggagg aggttgctgg tgatctctgc tcctaacgat 960
gaagactggg cctattcaca gcagctctct gccctcagtg gtcaggcgtg caattttggt 1020

```

```
<210> 106
<211> 486
<212> DNA
<213> Homo sapiens
```

<400>	106						
tcgacccacg	cgtccgccca	cgcgtccgga	aagcagtgtc	aagacagtaa	ggattcaaac	60	
catttgccaa	aaatgagtot	aagtgcattt	actctcttcc	tggcattgat	tgggtggtagc	120	
agtggccagt	actatgatta	tgattttccc	ctatcaattt	atgggcaatc	atcaccaaac	180	
tgtgcaccag	aatgtaactg	ccctgaaagc	tacccaagtg	ccatgtactg	tgatgagctg	240	
aaattgaaaa	gtgtaccaat	ggtgcctcct	ggaatcaagt	atctttacct	taggaataaac	300	
cagattgacc	atattgatga	aaaggccttt	gagaatgtaa	ctgatctgca	gtggctcatt	360	
ctagatcaca	accttctaga	aaactccaag	ataaaaagga	gagttttctc	taaattgaaa	420	
caactgaaga	agctgcatat	aaaccacaac	aacctgacag	agtctgtggg	cccacttccc	480	
aaatct						486	

```
<210> 107
<211> 800
<212> DNA
<213> Homo sapiens
```

<400>	107						
cttgtatctg	atcgtttctaa	aaaagagttg	tccccggttt	taaccagtg	agttcatagt	60	
gttcgtgcag	gacggcatct	tgctaccaa	ttgaatattt	tagtacagca	acattttgac	120	
ttggcttcaa	ctactattac	aaatattcca	atgaaggtga	ttcgcatcta	ggtggcggca	180	
gtcgagaagg	ctcgtttaaa	gaaacaataa	cattaaagtg	gtgtacacca	aggacaaata	240	
acattgaatt	acactattgt	actggagctt	atcggatttc	acctgtagat	gtaaatagta	300	
gaccttcctc	ctgccttact	aattttcttc	taaatggtcg	ttctgtttta	ttggaacaac	360	
cacgaaagtc	aggtttctaaa	gtcattagtc	atatgcttag	tagccatgga	ggagagattt	420	
ttttgcacgt	ccttagcagt	tctcgatcca	ttctagaagr	tccaccttca	attagtgaag	480	
gatgtggagg	aagrgttaca	gactaccgga	ttacagattt	tggtgaaattt	atgagggaaa	540	
acagattaac	tcctttttcta	gaccccagat	ataaaatcga	tggaagtctt	gagggtccctt	600	
tggaacgagc	aaaagatcag	ttagaaaaaac	atacccgtta	ctggcctatg	gatcatttca	660	
caaaccacca	tttttaacak	gcaagcggtg	gttccattag	ccagtgttat	tgtggaaaga	720	
tcyctggaca	gaggaagatg	tggttwaaac	ggtccaaaaa	acatwttcca	acttggttgg	780	
ataaggggaa	ggaaaaaagg					800	

<210>	108
<211>	1058
<212>	DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (895)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1019)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1054)

<223> n equals a,t,g, or c

<400> 108

```

ggcacgagcg tgactggcgc cgaaatggga gaaagcagcg agtgagaggg gaaggggagc 60
caggcgagca cccgggagcc agcgggacct gggcaggggc gcccggagca ggccgcatgg 120
cgggccccgc gcggggatcc ggctggaaga gagcgtacac ggctcgacag agtccggggc 180
cgatgtacca ggtgagcggc cagccccctc tggctgcgac gcgcccttat ggagcccca 240
gcgcamcccc ggcccagccc agaccytaty ccttccttcc tgggctggar gtaktaacag 300
gatccactca ccctgcgag gcagcaccag aggagggctc cctggaggag gcggcaacc 360
ccatgccccca aggcaatggc cctggcatcc cccagggcct ggacagcact gacctcgacg 420
tccccacaga agctgtgaca tgccagcctc aggggaaccc ttgggctgca cccacttct 480
gccgaatgac tctggccacc cctcagagct gggcggcacc agacgggagg ggaatggtgc 540
cctgggtggc cccaaggccc accggaagtt gcagacacac ccattctctc ccagccagg 600
cagcaagaag agtaagagca gcagcaaadc caccacctcc cagatcccccc tccaggcaca 660
ggaagactgc tgtgtccact gcacctgtgc ctgcctgttc tgcgagttcc tgacgctgtg 720
caacatcgtc ctggactgcg ccacctgtgg ctccctgcagc tcggaggact cgtgcctctg 780
ctgctgctgc tgtggctctg gcgagtgtgc cgaactgcgac ctgccctgcg acctggactg 840
cggcatcctg gatgcctgct gcgagtccgc ggactgcctg gaaatctgca tggantgctg 900
tgggctctgc ttctcctcct gacccctctg cgggggctaa gccagcctgg cggccctgca 960
gattccagca gggctcctct gagtggggcc aggccagga ctgtcacaca aggcttgana 1020
aagccccctc ccctggtcct ctctaccca cccntgtc 1058

```

<210> 109

<211> 1076

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (780)

<223> n equals a,t,g, or c

<400> 109

```

caggaggaag caggaagaaa caggaggagg aacctgagac agagccgctg aagtccttgc 60
tggaagcaga tgggattaaa tgagcgacga gactgggaga gtgccagaga gagacaccaa 120
gaggatgcag gtctgtctgc tatcagctat gccgctgccc gttgcgctgc agaccgctt 180

```

```

ggccaagaga ggcacccctca aacatctgga gcctgaacca gaggaagaga tcattgccga 240
ggactatgac gatgatcctg tggactacga ggccaccagg ttggagggcc taccaccaag 300
ctggtacaag gtgttcgacc ctccctgcgg gctcccttac tactggaatg cagacacaga 360
ccttgatacc tggctctccc cacatgaccc caactccgtg gttaccaaag cggccaagaa 420
gctcagaagc agtaatgcag atgctgaaga aaagttagac cggagccatg acaagtcgga 480
cagggggccat gacaagtcgg accgcagcca tgagaaacta gacagggggc acgacaagtc 540
agaccggggc cagcacaagt ytgacagggg tcgagagcgt ggctatgaca aggtagacag 600
agagagagag cgagacaggg aacgggagcg ggaccgcggg tatgacaagg cagaccggga 660
agagggcaaa gaacggcgcc accatcgccg ggaggagctg gctccctatc ccaagagcaa 720
gaaggcgagta agccgaaagg atgaagagtt agaccccatg gaccctagct catactcagn 780
acgcccccg ggcacgtggt caacaggact ccccaagcgg aatgaggcca agactggcgc 840
tgacaccaca gcagctgggc ccctcttcca gcagcgccg tatccatccc caggggctgt 900
gctccggggc aatgcagagg cctcccgaac caagcagcag gattgaagct tcggcctccc 960
tgggcctggg ttaaaataaa agctttctgg tgatcctgcc caccaaaaaa aaaaaaaaaa 1020
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa waaaaaaatt ttgggggggg cccccc 1076

```

<210> 110

<211> 1199

<212> DNA

<213> Homo sapiens

<400> 110

```

gttggtggag ttctgcccgg atggaagctc cggccgcgga gtgatggtgg cctcagcgaa 60
gatgggcccgg gcagggacca tggcggtggc agcagaggtg gcagggggcg ggcggtggc 120
ggtagaggag gctgtggtcc tcagggggct gtagggtgag gtatggctcg ggccagcagc 180
gggaacggca gcgaggaggc ctggggggca ctctgggcgc cgcaacagca gcttcgagag 240
ctgtgccag gagtgaacaa ccagccctac ctctgtgaga gtggtcactg ctgcggggag 300
actggctgct gcacctacta ctatgagctc tggtggttct ggctgctctg gactgtcctc 360
atcctcttta gctgctggtg cgccttcgcg caccgacgag cttaaactcag gctgcaacaa 420
cagcagcggc agcgtgaaat caacttggtg gcctatcatg gggcatgcca tggggctggt 480
cctttcccta ccggttcact gcttgacctc cgcttcctca gcacctcaa gccccagcc 540
tacgaggatg tggttcaccg cccaggcaca ccaccccccc cttatactgt ggccccaggc 600
cgccccctga ctgcttcacg tgaacaaacc tgctgttctt cctcatccag ctgcccctgc 660
cactttgaag gaacaaatgt ggaaggtgtt tcctcccacc agagtgcacc ccctcatcag 720
gaggggtgag ccggggcagg ggtgacctct gcctccacac cccctcctcg ccgctatcgc 780
cgtttaactg gcgactccgg tattgagctc tgcccttgct ctgcctccgg tgaggggtgag 840
ccagtcaagg aggtgagggt tagtgccacc ctgccagatc tggaggacta ctccccgtgt 900
gcactacccc cagagtctgt accgcagatc tttcccatgg ggctgtcttc cagtgaaggg 960
gacatcccat aagtagtttt gagagggtgg atgggttact tgcccaccag aaacagccct 1020
agtcccaact ccttgcgctt ctttggcccc tccttgccct cctagaatct gcctgaaagg 1080
gctggagagg ggcagtattg ggggactgtg ctagctttac ccccgagga catacacagg 1140
agcctttgat ctcattaaag agatgtgaac cagctaaaaa aaaaaaaaaa aaactcgag 1199

```

<210> 111

<211> 3630

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3606)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3608)

<223> n equals a,t,g, or c

<400> 111

```

cggcggttgtt cagtcagagc gagaacattc cagaggtcgc ccagctccgg cgctgacggg 60
tgtggaccgc ggacgtcgct gggacagccc ctccccgctg ctccggcggcg gcacctggcc 120
cggccgctcc tcgctgcgct tcgcctccgc ctccctcggac tcggactcgg gtttatatcg 180
cgcctcactt catcccagtc ccgggcgagc agcgttgggt ttatgtcttt atttgacgaa 240
aacgacagaa gataccaaaa agttgcaatc aaagatctct tcatcttatt gataaagcca 300
ctaataagcc aaaatgtctg tcaatgtcaa ccgcagcgtg tcagaccagt tctatcgcta 360
caagatgccc cgtctgattg ccaagggtga gggcaaaggc aatggaatca agacagttat 420
agtcaacatg gttgacgttg caaaggcgct taatcggcct ccaacgtatc ccaccaata 480
ttttggttgt gagctgggag cacagaccca gtttgatgtt aagaatgacc gttacattgt 540
caatggatct catgaggcga ataagctgca agacatgttg gatggattca ttaaaaaatt 600
tgttctctgt cctgaatgtg agaatcctga aacagatttg catgtcaatc caaagaagca 660
aacaataggt aattcttgta aagcctgtgg ctatcgaggc atgcttgaca cacatcataa 720
actctgcaca ttcattctca aaaacccacc tgagaatagt gacagtggta caggaaagaa 780
agaaaaagaa aagaaaaaca gaaagggcaa agacaaggaa aatggctccg tatccagcag 840
tgagacacca ccaccaccac caccaccaa tgaattaat cctcctccac atacaatgga 900
agaagaggag gatgatgact ggggagaaga tacaactgag gaagctcaa ggcgtcgaat 960
ggatgaaatc agtgaccatg caaaagtctt gacactcagt gatgatttgg aaagaacaat 1020
tgaggagagg gtcaatatcc tctttgattt tgtaagaaa aagaaagaag aggggtgtat 1080
tgattcatct gacaaagaaa tcgttgctga agcagaaaga ctggatgtaa aagccatggg 1140
ccctcttggt ctaactgaag ttctttttta tgagaagatt agagaacaga ttaagaaata 1200
caggcgccat ttcctacgat tttgtcacia caacaaaaaa gcccaacggg accttcttca 1260
tggtttgtag tgtgtggtag caatgcatca agctcagctt atctccaaga ttccacatat 1320
cttgaaggag atgtacgatg cagacctttt agaagaagag gtcacatca gctggtcggg 1380
aaaggcctct aagaaatatg tctccaaaga acttgccaaa gagattcgtg tcaaagcaga 1440
accatttata aaatggttga aggaggcaga ggaagaatct tctggtggcg aagaagaaga 1500
tgaagatgag aacattgagg tgggtgattc gaaggctgcc agtgtagcga aagttgagac 1560
tgtaaagtca gacaacaagg atgacgacat cgatattgat gccattttaa gggatggatg 1620
caacctagct taacagtata atgctgcaaa ttttcctcca ttatcagcca gaagtgaac 1680
atgtatgtgc aaaagctaaa atggcttaac atcatgctac actttacact aaaaatctat 1740
tactgtgagt ggtctgttat taagcccaat gagacatcta gggagtccat acacatcagt 1800
gagcagatgt agtttgctta tttatagcat gtttcttttt gaaaaactag tggtagacac 1860
atthggatca catthataca gttataaaaa taaagggttg atthtggtcg ttcttcagat 1920
gtthggctct gaatgactta agctgaagta actggctcct tactttaaat gttctgccat 1980
catttcacct gatgacatc cttggagcct gccagatatt gttaggtcct ggggtgcaa 2040
agaggtcctc aacaggatgt aaagcaact taattgtaat taatttattc agccattaa 2100
gaaagtacta aagtthttatc tctgtagttc ctcaaattgg catctggtaa tgtacattgt 2160
gaggtagact gataatgaaa tgacagtgca acatcttaac caagaagtaa atatgacctc 2220
agtgtcctat aaataatgta agagcaggat ttgaaacttg gagagctgtt ttctcatttc 2280
atgtacactt gcccacaaat gtctttgaag tcgtgtgcat tgcacgttgg atgagccagg 2340
gaaattatta cattaacaag catthttgtgt gtacgtagta gttactttgt actgagagaa 2400
cttgcttttg ggtgcaatta ataaactgat tttatttggg agaaacaagg aagggtgcac 2460
ttaactagca acctagcat gatttttcag cttttgccct taggggttaa attacaattc 2520
caaatgtta gacatactgt atthtttcgt tcagtgtggc ttaattttc ccctcttgca 2580

```

```

gtttgttctg taatgccttt tacatttgga cacatagttt atsccttttt ttgggtgtaag 2640
acttgggata ttttttactt cacattgaat atagccaggc acccaagaag tctgatggcc 2700
acctgagtgc aggtgacaag gacctgacag agcccatgca gggctttaga tttggacaca 2760
caagagttga taacttcctc atgaactcct tgcctgatct aaactcatat tatgggttct 2820
gactgtttga gtaatcatct tcaagggtta acctcctggc agttaccctt ttcacaaagt 2880
gcacagtggg aatcgagaat cgatagggtt aattttggag cagtggctta taccattcac 2940
ctctgttttt ttgtgattat ttcacagata atgagacctt aataacaaat aggcgtaaaa 3000
aaattttcac attgaaatga tagaaacatt tgatgtaata aaacttgggt ggcttgatat 3060
tttaaggaat tgaaacctag caatcttatt ggagagacaa gaattgggtc ccagctgcct 3120
ttgatcaaga ttcgggtgca agtggagcag gagccatata cctggaggga atgtgctttg 3180
tcacacccaaa gaggattttt ttttcttcaa acttgatatg tgcttaggtt tcaaattcct 3240
tgccgcaagg ctgatctgct ttcattaact ggaattctgt aggagatact ggtgacctaa 3300
gctaagttgc actcagcata ctacagtgtca agctaatag gttctattat aaagggttcta 3360
cttttaatat gagggaaaaac atgttcaggg cttctagaac actaaaaaat ttggcttaaa 3420
ccagtgttca gtctggtgcc aaacttcgaa tgggaatacaa attcacataa tctgaacttt 3480
gttcacaggt taccctaata gagtaattct tcactttgct ctattgaact gtcttaagga 3540
tttgtttaaa cagctaagtt acttgattaa aataatgata aaattgtaaa aaaaaaaaaa 3600
aaaaantnct gsggtccgct aagggaattc                                     3630

```

<210> 112

<211> 1526

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1496)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1511)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1512)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1515)

<223> n equals a,t,g, or c

<400> 112

```

tcgaccacag cgtccgcagc aggccctgcg cgcggaaca tggcggggtc cagggtggagg 60
tcttgaggct atcagatcgg tatggcattg gcgtccgggc ccgcaaggcg ggcgctagct 120
ggctccgggc agctcggcct tgggggcttc ggggccccga gacgcggggc gtatgagtgg 180
ggcgtgcgct ccacgcggaa gtcggagcct cctccccctg ataggggtgta cgagatccct 240
ggactggagc ccatcacctt tgcggggaag atgcacttcg tgccctggct ggcgcgggccg 300
atctttccgc cctgggaccg cggctacaag gacccaagg tctaccgctc gccccctctt 360

```

```

cacgagcatc cgctgtacaa agaccaggcc tgctatatct ttcaccaccg ttgccgcctt 420
ctcgaggggtg taaagcaggc cctctggctc accaagacca agttaataga aggccttccc 480
gagaaagtgc ttagccttgt tgatgatcca aggaaccaca tagagaacca agacgagtgc 540
gttctgaatg tgatctctca cgcccgtctc tggcagacca ctgaggaaat ccccaagaga 600
gagacctact gcccgggtcat cgtggacaac ctaatacagc tgtgtaaatc tcagattctc 660
aagcatcctt ctctggccag gaggatctgt gtccaaaact ccacgttttc tgctacctgg 720
aaccgagagt ctcttctcct tcaagtccgt ggttctgggt gagcccgact gagcactaag 780
gatcctctgc ccaccatcgc ctccagagag gagattgaag ctactaagaa tcatgttcta 840
gagaccttct accccatata acccatcatc gatcttcatg aatgcaatat ttatgatgtg 900
aaaaatgaca caggattcca ggaaggctat ccttaccctt atccccatac cctgtactta 960
ctggacaaaag ccaattttacg accacaccgc cttcaaccag atcagctgcg ggccaagatg 1020
atcctgtttg cttttggcag tgccctggct caggcccggc tcctctatgg gaatgatgcc 1080
aaggtcttgg agcagcccgt ggtggtgcag agcgtgggca cggatggacg tgtcttccat 1140
ttcctagtgt ttcaactgaa taccacagac ctggactcta acgaggggtg caagaatttg 1200
gcctgggtgg actcagacca gctcctctat cagcattttt ggtgtctccc agtgatcaaa 1260
aagagagtgg ttgtggaacc tgttggccca gttggtttca agccagagac attcagaaag 1320
tttttagctc tataatttgca tgggtgctgc tgagcggagg acccctctga atcctgaaac 1380
ccctcttgcc tctcttccac ggaagaggcc tgggccccgt ggagcctcag tgcccgtttg 1440
gcctgctgct ctcgctgaca ataaagagcc cttgcgttgc aaaaaaaaaa aaaaangggg 1500
ggccgctcaa nnggncccaa gttagt 1526

```

<210> 113

<211> 585

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (422)

<223> n equals a,t,g, or c

<400> 113

```

tcgacccacg cgtccgcca cgcgctccgc cacgcgtccg ggagcccggg gacaggatgt 60
tgggtgttgg attaggagat ctgcacatcc cacaccgggt caacagtttg ccagctaaat 120
tcaaaaaact cctggtgcca ggaaaaattc agcacattct ctgcacagga aacctttgca 180
ccaaagagag ttatgactat ctcaagactc tggctggtga tgttcatatt gtgagaggag 240
acttcgatga gaatctgaat tatccagaac agaaagttgt gactgttgga cagttcaaaa 300
ttggtctgat ccatggacat caagttattc catggggaga tatggccagc ttagccctgt 360
tgcagaggca atttgatgtg gacattctta tctygggaca cacacacaaa tttgaagcat 420
tngagcatga aaataaattc tacattaatc caggttctgc cactggggca tataatgcct 480
tggaacaaaa cattattyca tcattgtgtt gatggatatc caggcttcta cagtggkcac 540
ctatgtgtaa tcagctaatt ggagatgaag tgaaagtaga acgga 585

```

<210> 114

<211> 501

<212> DNA

<213> Homo sapiens

<400> 114

```

gatgaaaaga aggtttttgc tcttcaaatg ottaagtaaa ctaaaaggca gagctggaaa 60
taaagcccgt attgtggact ccaagtaatg ctctttctgc tacaccatac tttgtggtgt 120

```

```

ctgctcccat gtgcttcttc gctaaggctg atcaaaaaag ttagtaggtt gcttcagcta 180
taagaatttg atggtcttcc ttagtcatca tagtctgcag caatcatttt tggtcatcat 240
tgggatgtct gcttactcct gttgagtaaa tgtgatctat tcacccttgg ragctccttg 300
cacaccaaca gtattcttgg atagggacaa gtgtgtgcta agtcagtgc gatttcttta 360
gcataataaa aggctccatg taggatgcta atacttgagt gaaatatgct tcataagcag 420
ccttgttttg acagagttgg tgtaaagtga ggttatgtct tggcctgagc gtcttcaaag 480
catgtgccac tttgtgcac t 501

```

<210> 115

<211> 1965

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (338)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (343)

<223> n equals a,t,g, or c

<400> 115

```

agaggcggca ctggcggcaa gagcagacgc ccgaaccgag cgagaagagc ggcagagcct 60
tatccccctga agccggggccc cgcgtcccag mcctggccca aaggcaggag cagcagacaa 120
gagtgcagtg gtggctgccc ccgcaccagc ctcagtggca gatgacacac cccccccga 180
gcgtcggaac aagagcggta tcatcagtga gcccctcaac aagagcctgc gccgctcccg 240
cccgtctctc cactactctt cttttggcag cagtgggtgg agtggcggtg gcagcatgat 300
gggcgggagag tctgctgaca aggccactgc ggctgcanc c tgnccctccct gttggccaat 360
gggcatgacc tggcggcggc catggcgggt gacaaaagca accctacctc aaagcacaaa 420
agtgggtgctg tggccagcct gctgagcaag gcagagcggg ccacggagct ggcagccgag 480
ggacagctga cgctgcagca gtttgcgcag tccacagaga tgctgaagcg cgtgggtgcag 540
gagcatctcc cgctgatgag cgaggcgggt gctggcctgc ctgacatgga ggctgtggca 600
ggtgccgaag cctcaatgg ccagtcgcac ttcccctacc tgggcgcttt ccccatcaac 660
ccaggcctct tcattatgac cccggcaggt gtgttcctgg ccgagagcgc gctgcacatg 720
gcgggccttg ctgagtacc catgcaggga gagctggcct ctgccatcag ctccggcaag 780
aagaagcggg aacgctgcgg catgtgcgcg ccctgccggc ggcgcaccaa ctgcgagcag 840
tgcagcagtt gtaggaatcg aaagactggc catcagattt gcaaattcag aaaatgtgag 900
gaactcaaaa agaagccttc cgctgctctg gagaagggtg tgcttccgac gggagccgcc 960
ttccggtggt ttcagtgcag gcggcggaac ccaaagctgc cctctccgtg caatgtcact 1020
gctcgtgtgg tctccagcaa gggattcggg cgaagacaaa cggatgcacc cgtctttaga 1080
acaaaaaata ttctctcaca gatttcattc ctgtttttat atatataatt tttgttgtcg 1140
ttttaacatc tccacgtccc tagcataaaa agaaaaagaa aaaaatttaa actgcttttt 1200
cggaagaaca acaacaaaaa agaggtaaa acgaatctat aaagtaccga gacttccttg 1260
gcaaagaatg gacaatcagt ttcttccctg tgtcgatgtc gatgttgtct gtgcaggaga 1320
tgcagttttt gtgtagagaa tgtaaatttt ctgtaacctt ttgaaatcta gttactaata 1380
agcactactg taatttagca cagttaact ccaccctcat ttaaacttcc tttgattctt 1440
tccgaccatg aaatagtgc tagtttgcc ggagaatcca ctcacgttca taaagagaat 1500
gttgatggcg ccgtgtagaa gccgctctgt atccatccac gcgtgcagag ctgccagcag 1560
ggagctcaca gaaggggagg gagcaccagg ccagctgagc tgcaccaca gtcccagac 1620

```

```

tgggatcccc caccocaaca gtgatttttg aaaaaaaaaat gaaagtctctg ttcgtttatc 1680
cattgcgatac tggggagccc catctcgata tttccaatcc tggctacttt tcttagagaa 1740
aataagtcct ttttttctgg ccttgctaata ggcaacagaa gaaagggtt ctttgctgg 1800
tccccctgctg gtgggggttg tccccaggg cccctgctgc ctgggcccc ctsccacggc 1860
cagcttcctg ctgatgaaca tgctgtttgt attgttttag gaaaccaggc tgttttgtga 1920
ataaaacgaa tgcatgtttg tgtcacgaar maaaaaaaaa aaaaaa 1965

```

<210> 116

<211> 1060

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (299)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1060)

<223> n equals a,t,g, or c

<400> 116

```

gaaacacata cattggatat gggaagatgg cggctgtgtc ggtgtatgct ccaccagttg 60
gaggtctctc ttttgataac tgccgcagaa tgccgtcttg gaagccgatt ttgcaaagag 120
gggatacaag cttccaaagg yccgaaaaac tggcacgacc atcgctgggg tggctataaa 180
ggatggcata gttcttgagg cagatacaag agcaactgaa gggatgggtt ttgctgacaa 240
gaactgttca aaaatacact tcatatctcc taatatattat tgttgtggtg ctgggacanc 300
tgcagacaca gacatgacaa cccagctcat ttcttccaac ctggagctcc actccctctc 360
cactggccgt cttcccagag ttgtgacagc caatcggatg ctgaagcaga tgcttttcag 420
gtatcaaggt tacattggtg cagccctagt tttaggggga gtagatgtta ctggacctca 480
cctctacagc atctatcttc atggatcaac tgataagttg ccttatgtca ccatgggttc 540
tggtccttg gcagcaatgg ctgtatttga agataagttt aggccagaca tggaggagga 600
ggaagccaag aatctggtga gcgaagccat cgcagctggc atcttcaacg acctgggctc 660
cggaagcaac attgacctct gcgtcatcag caagaacaag ctggattttc tccgcccata 720
cacagtggcc aacaagaagg ggaccaggct tggccggtac aggtgtgaga aagggactac 780
tgcagtcctc actgagaaaa tcaactctct ggagattgag gtgctggaag aaacagtcca 840
aacaatggac acttctctgaa tggcatcagt ggggtggctgg ccgcggttct ggaaggtggt 900
gagcattgag gccagtaag acactcatgt ggctagtgtt tgccgaatga aactcaactc 960
aataaaaaac aaaaaccaa ttgggcagct gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1060

```

<210> 117

<211> 709

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (174)

<223> n equals a,t,g, or c

<400> 117

```

aattcggcac gagaacatcc attctaaagg gctactgtcc caaatcctgt gtgtcctttt 60
gacttgctctg atcacccaat ggaagtggat acttgtaaag tctacaccac tgtacttggc 120
gttaaattctt gctgaattcg tggtaagctg ttaccatgtc tacattttgt agantgattt 180
tgggtctgcag caaaattoga tttcacttct cataccctt tccttccact tgaaatgcaa 240
tttagacaga ggccctgtgg tgaaagtgtc aatattaagt ttmccttttag aagatcccyt 300
cctcaaacct cagaaccct agcagtgtta ccctwaaaca aaaatgagct cgagaaaaaa 360
gtagctcagt tacagagaag caaatcgagt tatttcccca cataaaaagt ttcccagat 420
tctaagaatt gcagtatcct gtaccctaaa atttttcaag gtgactcctg ttgtcgtctg 480
ttgataactt taataaaggc catttaagga cataagtttt taaagactcc caaagtgaaa 540
cttaaacatt ttcgggatta tcgattgcat atatcagttt atgctgtgtg ctgaattact 600
atgccatgtg ctatttttagt gtttggggaa aatgaaaaat aaaatttggt ctttagctta 660
ataaatatgt cttattttta aaaaaaaaaa aaaaaactcg agactagct 709

```

<210> 118

<211> 2053

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (813)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2049)

<223> n equals a,t,g, or c

<400> 118

```

ctccttggcg cctgtcccca cgcccccg agcgtgacca cgatgctccc catacccac 60
ccattcccga tacaccttac ttactgtgtg ttggcccagc cagagtgagg aaggagtgtg 120
gccacattgg agatggcggg actgagcaga catgccccca cgagtagcct gactccctgg 180
tgtgctcctg gaaggaagat cttggggacc cccccaccgg agcacacca rggatcatct 240
ttgccgtct cctggggacc cccaagaaa tgtggagtcc tcggggggcg tgcactgatg 300
cggggagtgt gggaagtctg gcggttggar ggggtgggtg ggggcagtgg gggctgggcg 360
gggggagttc tggggtagga agtgtcccg ggagattttg gatggaaaag tcaggaggat 420
tgacagcaga cttgcagaat tacatagaga aattaggaac ccccaaattt catgtcaatt 480
gatctattcc ccctctttgt ttcttggggc atttttcctt tttttttttt ttttgttttt 540
tttttaccce tccttagctt tatgcgctca gaaaccaa ataaaccccc ccccatgtaa 600
caggggggca gtgacaaaag caagaacgca cgaagccagc ctggagacca ccacgtcctg 660
cccccgcca tttatcgccc tgattggatt ttgtttttca tctgtccctg ttgcttgggt 720
tgagttgagg gtggagcctc ctggggggca ctggccactg agcccccttg gagaagtcag 780
aggggagtgg agaaggccac tgtccggcct ggnttctggg gacagtggct ggtccccaga 840
agtcctgagg gcggaggggg ggggtgggca ggggtctcctc aggtgtcagg aggggtgctc 900
gaggccacag gagggggctc ctggctggcc tgaggctggc cggaggggaa ggggctagca 960
ggtgtgtaaa cagagggttc catcaggctg gggcaggggtg gccgccttcc gcacacttga 1020
ggaaccctcc cctctccctc ggtgacatct tgcccggccc tcagcaccct gccttgtctc 1080
caggaggtcc gaagctctgt gggacctctt gggggcaagg tggggtgagg ccggggagta 1140
gggaggtcag gcgggtctga gcccacagag caggagagct gccaggtctg cccatcgacc 1200

```

```

aggttgcttg ggccccggag cccacgggtc tggatgatgcc atagcagcca ccaccgcggc 1260
gcctagggct gcggcagggg ctcggcctct gggaggttta cctcgcccc acttggtgcc 1320
ccagctcagc cccctgcac gcagcccgac tagcagtcta gaggcctgag gcttctgggt 1380
cctggtgacg gggctggcat gaccccgggg gtcgtccatg ccagtccgcc tcagtgcag 1440
agggctccctc ggcaagcgcc ctgtgagtgg gccattcgga acattggaca gaagcccaaa 1500
gagccaaatt gtcacaattg tggaaaccac attggcctga gatccaaaac gcttcgaggg 1560
accccaaat acctgcccac tcgtcaggac accacccac ccagtgttat attctgcctc 1620
gccggagtgg gtgttcccgg gggcacttgc cgaccagccc cttgcgtccc caggtttgca 1680
gctctccctt gggccactaa ccatcctggc ccgggtgcc tgtctgacct ccgtgcctag 1740
tcgtggctct ccatcttgtc tcctccccgt gtcccaatg tcttcagtgg ggggccccct 1800
cttgggtccc ctctctgcc atcacctgaa gacccccacg ccaaacactg aatgtcacct 1860
gtgcctgccg cctcggtcca cttggggccc gtgtttgact caactcagct cctttaacgc 1920
taatatattcc ggcaaaatcc catgcttggg tttgtcttt aacctgttaa cgcttgcaat 1980
cccaataaag cattaaaagt catraaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2040
ggggggggnc cgg 2053

```

<210> 119

<211> 1824

<212> DNA

<213> Homo sapiens

<400> 119

```

agttcctagc aagctgttca caagattgcc tgataagaat atggaagctg tatataaagt 60
caacatcttt agaaactcag gatgacgata acataagact gaaggaaaat acttttacca 120
tagaaaatga aaagtgttaa aatagcattt gctgttactc tggagacagt gctagccggg 180
catgaaaact gggtaaatgc agttcactgg caacctgtgt ttacaaaaga tgggtgtccta 240
cagcagccag tgagattatt atctgcttcc atggataaaa ccatgattct ctgggctcca 300
gatgaagagt caggagtttg gctagaacag gtcgagtag gtgaagtagg tgggaataact 360
ttgggatttt atgattgcca gttcaatgaa gatggctcca tgatcattgc tcatgctttc 420
cacggagcgt tgcacctttg gaaacagaat acagttaacc caagagagtg gactccagag 480
attgtcattt caggacactt tgatgggtgc caagacctag tctgggatcc agaaggagaa 540
tttattatca ctgttggtac tgatcagaca actagacttt ttgctccatg gaagagaaaa 600
gaccaatcac aggtgacttg gcatgaaatt gcaaggcctc agatacatgg gtatgacctg 660
aaatgttttg caatgattaa tcggtttcag tttgtatctg gagcagatga aaaagttctt 720
cgggtttttt ctgcacctcg gaattttgtg gaaaattttt gtgccattac aggacaatca 780
ctgaatcatg tgctctgtaa tcaagatagt gatcttccag aaggagccac tgtccctgca 840
ttgggattat caaataaagc tgtctttcag ggagatatag cttctcagcc ttctgatgaa 900
gaggagctgt taactagtac tggttttgag tatcagcagg tggcctttca gccctccata 960
cttactgagc ctcccactga ggatcatctt ctgcagaata ctttgtggcc tgaagttcaa 1020
aaactatatg ggcacggtta tgaaatattt tgtgttactt gtaacagttc aaagactctg 1080
cttgccctcag cttgtaaggc agctaagaaa gagcatgcag ctatcattct ttggaacact 1140
acatcttgga aacagggtgca gaatttagtt ttccacagtt tgacagtcac gcagatggcc 1200
ttctcaccta atgagaagtt cttactagct gtttccagag atcgaacctg gtcattgtgg 1260
aaaaagcagg atacaatctc acctgagtgc gagccagttt ttagtctttt tgccttcacc 1320
aacaaaatta cttctgtgca cagtagaatt atttgggtctt gtgattggag tcctgacagc 1380
aagtattttc tctactgggag tcgagacaaa aagggtgggtg tctgggggtga gtgtgactcc 1440
actgatgact gtattgagca caacattggc ccctgctcct cagtccctgga cgtgggtggg 1500
gctgtgacag ctgtcagcgt ctgccagtg ctccaccctt ctcaacgata cgtgggtgca 1560
gtaggattgg agtgtggaaa gatttgctta tatacctgga aaaagactga tcaagttcca 1620
gaaataaatg actggaccca ctgtgtagaa acaagtcaaa gccaaagtca tacactggct 1680
atcagaaaat tatgctggaa gaattgcagt ggaaaaactg aacagaagga agcagaaggt 1740

```

gctgagtggg tacactttgc aagctgtggg gaagatcaca ctgtgaagat acacagagtc 1800
 aataaatgtg cactgtaatg gaaa 1824

<210> 120

<211> 606

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (144)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (155)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (598)

<223> n equals a,t,g, or c

<400> 120

aggaagctgg gggaccattt tgcacccatga gtttgtgaaa aatctggatt aaaaaattac 60
 tcttccagtg tttttctcatg cmaaatttgc tyctarcatg tgataatgag taaactaaaa 120
 ctatttgcag cttttcctca attnacattt tggtngtata cttcagagtg atgttatcta 180
 agtttaagta gtttaagtat gttaaatgtg gatcttttac accacatcac agtgaacaca 240
 ctggggagat gtgctttttt ggaaaactca aagggtgctag ctccctgatt caaagaaata 300
 tttctcatgt ttgttcattc tagtttatat ttccatttaa aatccttttag gtttaagtta 360
 agctttttta aagtttagtta aaagaattga gacacaatac taatactgta ggaattgggtg 420
 aggccttgac ttaaaacttt ctttgtactg tgatttcctt ttgggtgtat tttgctaagt 480
 gaaacttggt aaattttttg ttaactaaat ttttttctta aaataaagac tttttcacia 540
 wraaaaaaaa aaaaaaaaaa actcgagggg gggcccgtac ccaatcgctt gtgatgtntc 600
 gtatac 606

<210> 121

<211> 838

<212> DNA

<213> Homo sapiens

<400> 121

gaatcccggg tcgaccacag cgtccgggaa agatcggcgc gcaccgcagg agcaacgggtt 60
 ggtcctgcgg ctgtgatgtc ggtgttgagg cccctggaca agctgcccgg cctgaacacg 120
 gccaccatct tgcgtggtgg cagcgaggat gctcttctgc agcagctggc ggactcgatg 180
 ctcaaagagg actgcgcctc cgagctgaag gtccacttgg caaagtccct ccctttgccc 240
 tccagtgtga atcgccccg aattgacctg atcgtgtttg tgggttaatc tcacagcaaa 300
 tacagyctcc agaacacaga ggagtccttg cgccatgtgg atgccagctt cttcttgggg 360
 aargtgtgtt tcctcgccac aggtggtggm rggttttagg gccaccatgg cgcacgcctt 420
 ggtgcgcgtg ctgcagatct gtgctggcca cgtgcccgtg gtctcagctc tgaacctgct 480
 gtccctgctg agaagctctg agggcccctc cctggaggac ctgtgagggt ggctkgcccc 540

```

tgggctgccc cttctcatgg cttcgtgctg actccataaa cattctctgt tgaggatgtc 600
cagtcagggc ttgacaggcc caggctcagc cccccgtggc tgggaagggt ccctgcagtg 660
ccagtgtctg agcagggaga gctgggcaga agcagcgagg gggcccagct ggcgagactg 720
tagccccctc cactccac actcactctt gcagagcctg tgtctttaag cagctggcgt 780
gttacatctc catttaaggt ttcccttgaa caaaagggtc gtggctaaaa aaagttta 838

```

<210> 122

<211> 656

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (41)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (218)

<223> n equals a,t,g, or c

<400> 122

```

ggcacgagcg ctcttgctgc gacgcacggt cggaagcggg ncaagggtcga ggccgggttg 60
gcgccggagc cggggccgct tggagctcgt gtgggggtctc cgggtccagg cgccggcatgg 120
gcgtcctggc cgcagcggcg cgtgcctgg tccgggggtgc ggaccgaatg agcaagtggg 180
cgagcaagcg gggcccgcgc agcttcagg gccgcaangg ccggggcgcc aagggcatcg 240
gcttcctcac ctcggttgagg aggttcgtgc agatcaagga gatgggtccc gagttcgtcg 300
tcccggtatc gaccggcttc aagctcaagc cctacgtgag ctacctcgcc cctgagagcg 360
aggagacgcc cctgacggcc gcgcagctct tcagcgaagc cgtggcgccct gccatcgaaa 420
aggacttcaa ggacggtacc ttcgaccctg acaacctgga aaagtacggc ttcgagccca 480
cacaggaggg aaagctcttc cagctctacc ccaggaaact cctgcgctag ctgggcgggg 540
gaggggcggc ctgccctcat ctcatctcta ttaaacgcct ttgccagcta aaaaaaaaaa 600
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggggggg gggcggaagc gtgggc 656

```

<210> 123

<211> 1386

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1283)

<223> n equals a,t,g, or c

<400> 123

```

aaccgggnaa aaggaaaccg tggtgtgtac gtaagattca ggaaacgaaa ccaggagccg 60

```

```

cgggtgttg  cgcaaagggtt  actcccagac  ccttttccgg  ctgacttctg  agaaggttgc  120
gcacagctgt  gcccggcagt  ctagaggcgc  agaagaggaa  gccatcgcc  ggccccggct  180
ctctggacct  tgtctcgctc  gggagcggaa  acagcggcag  ccagagaact  gttttaatca  240
tggacaaaca  aaactcacag  atgaatgctt  ctcacccgga  aacaaacttg  ccagttgggt  300
atcctcctca  gtatccaccg  acagcattcc  aaggacctcc  aggatatagt  ggctaccctg  360
ggccccaggt  cagctaccca  cccccaccag  cgggccattc  aggtcctggc  ccagctgggt  420
ttcctgtccc  aaatcagcca  gtgtataatc  agccagtata  taatcagcca  gttggagctg  480
caggggtacc  atggatgcca  gcgccacagc  ctccattaaa  ctgtccacct  ggattagaat  540
atttaagtca  gatagatcag  atactgattc  atcagcaaat  tgaacttctg  gaagttttaa  600
caggttttga  aactaataac  aaatatgaaa  ttaagaacag  ctttggacag  agggtttact  660
ttgcagcggg  agatactgat  tgctgtaccc  gaaattgctg  tgggccatct  agacctttta  720
ccttgaggat  tattgataat  atgggtcaag  aagtcataac  tctggagaga  ccactaagat  780
gtagcagctg  ttgttgctcc  tgctgccttc  aggagataga  aatccaagct  cctcctgggtg  840
taccaatagg  ttatgttatt  cagacttggc  acccatgtct  accaaagttt  acaattcaaa  900
atgagaaaag  agaggatgta  ctaaaaataa  gtggtccatg  tgttgtgtgc  agctgttgtg  960
gagatgttga  ttttgagatt  aaatctcttg  atgaacagtg  tgtggttggc  aaaatttcca  1020
agcactggac  tgggaattttg  agagaggcat  ttacagacgc  tgataacttt  ggaatccagt  1080
tccctttaga  ccttgatgtt  aaaatgaaag  ctgtaatgat  tgggtgcctgt  ttcctcattg  1140
actcatgtt  ttttgaaagc  actggcagcc  rggaacaaaa  atcaggagtg  tggtagtggr  1200
ttagtgaaaag  tctcctcagg  aaatctgaag  tctgtatatt  gattgagact  atctaaactc  1260
ataccygtat  grattaagcy  gtnaaggcct  gtagctctgg  ttgtatactt  ttgcytttcm  1320
aattawagtt  takcttctgt  ataactgatt  tataaagggt  tttgtacatt  ttttaatact  1380
cattgg  1386

```

<210> 124

<211> 845

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (823)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (825)

<223> n equals a,t,g, or c

<400> 124

```

ggcagagggt  cacacccgga  agcaggggcc  cgaggcggag  ccggccgcga  tgagcgggga  60
gccggggcag  acgtccgtag  cgccccctcc  cgaggagggtc  gagccgggca  gtgggggtccg  120
catcgtgggtg  gagtactgtg  aaccctgcgg  cttcgaggcg  acctacctgg  agctggccag  180
tgctgtgaag  gagcagtatc  cgggcacgca  gatcgagtcg  cgccctcgggg  gcacaggtgc  240
ctttgagata  gagataaatg  gacagctggt  gttctccaag  ctggagaatg  ggggctttcc  300
ctatgagaaa  gatctcattg  aggccatccg  aagagccagt  aatggagaaa  ccctagaaaa  360
gatcaccaac  agccgtcctc  cctgcgtcat  cctgtgactg  cacaggactc  tgggttcctg  420
ctctgttctg  ggggtccaaac  cttggtctcc  ctttggtcct  gctgggagct  cccctgcct  480
ctttccccta  cttagctcct  tagcaaagag  accctggcct  ccactttgcc  ctttgggtac  540
aaagaaggaa  tagaagattc  cgtggccttg  ggggcaggag  agagacactc  tccatgaaca  600
cttctccagc  cacctcatat  ccccttccca  gggtaagtgc  ccacgaaagc  ccagtccact  660

```

```

cttcgcctcg gtaatacctg tctgatgcc cagattttat ttattctccc ctaaccacag 720
gcaatgtcag ctattggcag taaagtggcg ctacaaacac taaaaaaaaa aaaaaaaaaa 780
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa atntnngggg gggggccccc 840
cccccc 845

```

<210> 125

<211> 1656

<212> DNA

<213> Homo sapiens

<400> 125

```

ctccactcc tgctcgcac tccccttoto catccttgcc cgccctcccc ccgagtcctc 60
ctcaccgccc ggactctcca ctgttcaact cgagatgcag ctctccactc cagctcaatc 120
tgctgcagct ggaggagctc ccccgctgctg agggggctgc tggtgcagga ggccctggga 180
gcagtgccgg gccccacact cccartgcgg aggctgctga gccagaggcc agactggcgg 240
aggctactga gtccctccaat caggacgcac tttccggctc cagtgcactg ctcgaacttc 300
tgctgcaaga rgactcgcgc tccggcacag gctccgcagc ctccggctcc ttgggctctg 360
gcttgggctc tgggtctggt tcaggctccc atgaaggggg cagcacctca gccagcatca 420
ctcgagcag ccagagcagc cacacaagca aatactttgg cagcatcgac tcttccgagg 480
ctgaggctgg ggctgctcgg ggcggggctg agcctgggga ccagggtgatt aagtacgtgc 540
tccaggatcc catttggtctg ctcatggcca atgctgacca gcgcgtcatg atgacctacc 600
agggtgccctc cagggacatg acctctgtgc tgaagcagga tcgggagcgg ctccgagcca 660
tgcaagaagca gcagcctcgg ttttctgagg accagcggcg ggaactgggt gctgtgcact 720
cctgggtccg gaagggccaa ctgcctcggg ctcttgatgt gatggcctgt gtggactgtg 780
ggagcagcac ccaagatcct ggtcaccctg atgacctact cttctcagag ctggatggac 840
tggggctgga gcccattgaa gaggtgagg gcgagcaggg cagcagcggg ggcggcagtg 900
gtgagggaga gggctgcrag gaggccaaag gcggggccaa ggcttcaagc tctcaggact 960
tggtatgga ggaggaggaa gaaggcagga gctcatccag tccagcctta cctacagcag 1020
gaaactgcac cagctagact ccattctggg accatctcca ggagtccatg agaggctttc 1080
ttctcctatg tcccattctc cagaactcag atgtggctag accaaccagt gggaaactgc 1140
cccagcttct cccaccatag ggggccggac ccccatgcac cagcctagga tccaggggct 1200
gcctctggcc tcttagggag cagagagcag aactccgcag cccagcccag aggagtgtca 1260
cctccacact ttggagagga atccttccct cccctggaca aagttgctga caagctgctg 1320
aagtggcctc tccatattcc agctgagcct gaatctgact cttgagggtt ggggctgcac 1380
ttatttattg cggggagaca gctctctctc ccacctcctc cccagatggg aggagagcct 1440
gaggcccaag caggaccggg gggttccagc ccctagctgc tctggagtgg gggagggttg 1500
tggaacctgg agtccctggt gctgccctc aggtgggacc caggcgctct cagctgtacc 1560
ctctgccgat ggcatttgtg tttttgatat ttgtgtctgt tactactttt ttaatacaaa 1620
aagataaaaa cgcccaaaaa aaaaaaaaaa aaaacc 1656

```

<210> 126

<211> 837

<212> DNA

<213> Homo sapiens

<400> 126

```

tggaagttgg ccctgtttgc tttttataaa ccaaactota tctgaaatcc caacaaaaaa 60
aatttaactc catatgtgtt cctcttgctc taatcttgct aaccagtgc aagtaccgac 120
aaaattccag ttattttattt ccaaaatggt tggaacagat ataattgac aaagaaaaat 180
gatacttctc tttttttgct gttccaccaa atacaattca aatgcttttt gttttatttt 240
tttaccaatt ccaatttcaa aatgtctcaa tggtgtctata ataaataaac ttcaactc 300

```

```
tttatgataa caacactgtg ttatatctct tgaatcctag cccatctgca gagcaatgac 360
tgtgctcacc agtaaaagat aacctttctt tctgaaatag tcaaatacga aattagaaaa 420
gccctcccta ttttaactac ctcaactggg cagaaacaca gattgtattc tatgagtccc 480
agaagatgaa aaaaatttta tacgttgata aaacttataa atttcattga ttaatctcct 540
ggaagattgg tttaaaaaga aaagtgtaat gcaagaattt aaagaaatat ttttaaagcc 600
acaattatth taatatggga tatcaactgc ttgtaaagggt gctcctcttt tttcttgtca 660
ttgctgggtca agattactaa tatttgaggaa ggctttaaaag acgcatgtta tgggtgcta 720
gtactttcac ttttaaactc tagatcagaa ttgttgactt gcattcagaa cataaatgca 780
caaaatctgt acatgtctcc catcagaaag attcattggc atgccacagg ggattct 837
```

<210> 127

<211> 1217

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1168)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1169)

<223> n equals a,t,g, or c

<400> 127

```
gatcgcggaagg gggggcacgg gaagcgggtg ggggtgctctg ggaagtatta tggggcctgg 60
gtacgccgag gctgcgggac cggrcctggc tgacttaatc ttcgttcccc acacatttgt 120
ttccgcagtt cgaagcccag ttgggcccag cagggtggagg aggaggggga ggacgacaaa 180
tgtgtcacca gcgagctcct caaggggatc cctctggcca cagggtgacac cagcccagag 240
ccagagctac tgccgggagc tccactgccg cctcccaagg aggtcatcaa cggaaacata 300
aagacagtga cagagtacaa gatagatgag gatggcaaga agttcaagat tgtccgcacc 360
ttcaggattg agaccgggaa ggcttcaaa gctgtcgcaa ggaggaagaa ctggaagaag 420
ttcgggaact cagagtttga ccccccgga cccaatgtgg ccaccaccac tgtcagtgc 480
gatgtctcta tgacgttcat caccagcaaa gaggacctga actgccagga ggaggaggac 540
cctatgaaca aactcaaggg ccagaagatc gtgtcctgcc gcactctgca gggcgaccac 600
tggaccaccc gctgccctta caaggatacg ctggggccca tgcagaagga gctggccgag 660
cagctggggc tgtctactgg cgagaaggag aagctgccgg gagagctaga gccggtgcag 720
gccacgcaga acaagacagg gaagtatgtg ccgccgagcc tgcgcgacgg ggccagccgc 780
cgcggggagt ccatgcagcc caaccgcaga gccgacgaca acgccaccat ccgtgtcacc 840
aacttgtcag aggacacgcg tgagaccgac ctgcaggagc tcttcgggcc tttcggctcc 900
atctcccgca tctacctggc taaggacaag accactggcc aatccaaggg ctttgccttc 960
atcagcttcc accgcgcgga ggatgctgcg cgtgccattg ccggggtgtc cggctttggc 1020
tacgaccacc tcatcctcaa cgtcgagtgg gccaaagccgt ccaccaacta agccagctgc 1080
cactgtgtac tcggtccggg acccttggcg acagaagaca gcctccgaga gcgcgggctc 1140
caagggcaat aaagcagctc cactctcnna aaaaaaaaaa aaaaaaaaaa ggcgccgct 1200
cgcgatctag aactagc 1217
```

<210> 128

<211> 1349

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (57)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1133)

<223> n equals a,t,g, or c

<400> 128

```

tggacgcgtg ggtggcggcc ggaggaggag taggtgcggg tgaagatggc ggcagcngag 60
gccgcgaact gcatcatgga ggtgtcctgt ggccaggcgg aaagcagtga gaagcccaac 120
gctgaggaca tgacatccaa agattactac tttgactcct acgcacactt tggcatccac 180
gaggagatgc tgaaggacga ggtgcgcacc ctcacttacc gcaactccat gtttcataac 240
cggcacctct tcaaggacaa ggtggtgctg gacgtcggct cgggcaccgg catcctctgc 300
atgtttgctg ccaaggccgg ggcccgaag gtcatcggga tcgagtgttc cagtatctct 360
gattatgcgg tgaagatcgt caaagccaac aagttagacc acgtggtgac catcatcaag 420
gggaagggtg aggaggtgga gctcccagtg gagaagggtg acatcatcat cagcgagtgg 480
atgggctact gcctcttcta cgagtccatg ctcaacaccg tgctctatgc ccgggacaag 540
tggctggcgc ccgatggcct catcttccca gaccgggcca cgctgtatgt gacggccatc 600
gaggaccggc agtacaaga ctacaagatc cactggtggg agaacgtgta tggcttcgac 660
atgtcttgca tcaaagatgt ggccattaag gagcccctag tggatgtcgt ggaccccaa 720
cagctggtca ccaacgcctg cctcataaag gaggtggaca tctataccgt caaggtggaa 780
gacctgacct tcacctcccc gttctgcctg caagtgaagc ggaatgacta cgtgcacgcc 840
ctggtggcct acttcaacat cgagttcaca cgctgccaca agaggaccgg cttctccacc 900
agccccgagt ccccgctacac gcactggaag cagacggtgt tctacatgga ggactacctg 960
accgtgaaga cgggcgagga gatcttcggc accatcggca tgcggcccaa cgccaagaac 1020
aaccgggacc tggacttcac catcgacctg gacttcaagg gccagctgtg cgagctgtcc 1080
tgctccaccg actaccgat gcgctgaggc ccggtctctc cgccctgcac ganccaggg 1140
gctgagcgtt cctaggcggg ttccggggctc ccccttctct tccctccctc ccgcagaagg 1200
gggttttagg ggccctgggct ggggggatgg ggagggcaca tcgtgactgt gtttttcata 1260
acttatgttt ttatatggtt gcatttacgc caataaatcc tgcagctggg aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1349

```

<210> 129

<211> 2318

<212> DNA

<213> Homo sapiens

<400> 129

```

tgcgcacgga cgtgctcgag tttcctctgc tctccgctct cgcccgctag ctctcctccc 60
ttccgctcct gcttctctcc ggttctcccg ctccagctcc agccccaccc ggccggtccc 120
gcacggctcc gggtagccat ggaggacccc acgctctata ttgtcgagcg gccgcttccc 180
gggtaccccc acgccgagga cccggagcct tcctccgctg gggtcaggc agcgaggagg 240
ccgtcggggg ccggctcaga agagctgatc aagtcggacc aggtgaacgg cgtgctggtg 300
ctgagcctcc tggacaaaat catcggggcc gtagaccaga tccagctgac tcaagcacag 360
ctggaggagc ggcaggcggg gatggagggc gcagtgcaga gcatccagg cgagctgagc 420
aagctgggca aggcgcacgc accacgagca atacggtgag caagctgctg gagaagggtg 480

```

```

gcaaggctcag cgtcaacgtg aagaccgtgc gcggcagcct ggagcgccag gcggggcaga 540
tcaagaagct ggaggtcaac gaggccgagc tgctkcggcg ccgcaacttt aaagtcatga 600
tctaccagga tgaagtgaag ctgccggcca aactgagcat cagcaaactg ctgaaagagt 660
cggaggcgct gccagagaag gagggcgagg agctgggcga gggcgagcgg cccaggagga 720
cgcagcggcg ctgsagcttt cgtcggacga ggcgggtggag gttgaggagg ttattgagga 780
gtcccgcgca gagcgtatca agcgcgrgcc ctgcggcgcg tggacgactt caagaaggcc 840
ttctccaagg agaagatgga gaagaccaag gtgcgtacyc gcgagaacct ggagaagacg 900
cgcctcaaga ccaaggaaaa cctggagaag acgcggcaca ccctggagaa gcgcatgaac 960
aagctgggca cgcgcctggt gcccgccgag cggcgcgaga aactgaagac gtcgcgggac 1020
aagttgcgca aatccttcac gcccgaccac gtggtgtacg cgcgctccaa gaccgcggtc 1080
tacaagggtgc cacccttcac cttccacgtc aagaagatcc gcgagggccca ggtggaagtg 1140
ctcaaggcca ccgagatggt ggaggtgggc gccgacgacg acgaggcgcg cgcggagcgc 1200
ggggaggccg gcgacctgcg gcgcgggagc agccccgacg tgcacgcgct gctggagatc 1260
accgaggagt cggacgccgt gctggtggac aagagcgaca gcrctgagc cgcccccgct 1320
gccacccacc ccattcctcg ctccctccga acttcctctt tcgcattctc tctcggtctg 1380
agctggctga gatttttcta aattgaaaac acgccccctt cccacacct ccaggaaactc 1440
cactcccagt cttagagctg ttaggacctg atggggaggc agcccccgca gtggacagcc 1500
ccgcttgga cacagtccga gtggaatggg aagggaatgg tcaatccctg tcctggttgt 1560
ccaagtcggg atctcagagg aaattgcagt gattccacgg ttaggcccc ctgggggggc 1620
tgccttcccc tcagcctctc cccacaccac ccaccagct gctgtcattc cgctcactga 1680
gctcttcttc attctcacc tgatccctgg gggactcaaa gccaaaactg cccaaagagg 1740
aaagattgaa tcctaaagg gatccttgcc cccatgggag gccccctact agaaggacgt 1800
gaaagcagct tttgggggaa actgaggcag tggggaagac agagcagaat gagccctcac 1860
cctggctggg gtccagcac aggctgtatc tgcagagggt cccagaggaa cgctggagcc 1920
aagagaagcc ctgggaagga ggggtgggga acgacatgca tgtgagggat ggcacactga 1980
tgtgtttatg cacctgtaca caggagcgca tggccatggc tttggaaagg agaatggaaa 2040
aatagaagaa gtcgggcccg gcttggtggc ttawgcctgt taaccccagc actttgggag 2100
gccgaggtgg gcggtwcacc tgaagtcagg agttcgggac cagcctggca aacaccccat 2160
ctctactaag cgaaaaccca tctctactaa aattacaaaa attagctggg catggttgcg 2220
catgcctgta aatcccagct actttgggag gctgaggtgg ggagaattgc ttgaacctgg 2280
ggaggtggga ggttgcagtt gagccaaggt tcgcgaca 2318

```

<210> 130

<211> 2149

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (787)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (819)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1518)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2116)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2147)
 <223> n equals a,t,g, or c

<400> 130

```

aactctaata gatcatacag gaaacggtag ctgcagtagc gtcggaattc ccgggtcgac 60
ccacgcgtcc ggagaaggca gacgcattccc gaactcgctg gaggacaagg ctcagctctt 120
gccaggccaa attgagacat gtctgacaca agcgagagtg gtgcaggtct aactcgcttc 180
caggctgaag cttcagaaaa ggacagtagc tcgatgatgc agactctgtt gacagtgacc 240
cagaatgtgg aggtcccaga gacaccgaag cctcaaaggc actggaggtc tcagaggatg 300
tgaaggtctc aaaagcctct ggggtctcaa aggccacaga ggtctcaaag accccagagg 360
ctcgggaggc acctgccacc caggcctcrt ctactactca gctgactgat acccaggttc 420
tggcagctga aaacaagagt ctagcagctg acaccaagaa acagaatgct gaccgcagc 480
ctgtgacaat gcctgccact gagacaaaaa aggtcagcca tgtggctgat acaaaggcca 540
atacaaggc tcaggagact gaggctgcac cctctcaggc cccagcagat gaacctgagc 600
ctgagagtgc agctgcccag tctcaggaga atcaggatac tcggcccaag gtcaaagcca 660
agaaagcccc aaaggtgaag catctggatg ggggaagagga tggcagcagt gatcagagtc 720
aggcttctgg aaccacaggt ggccgaaggt ctcaaaggcy ctaatggcct caatggcccc 780
cagcttncaa ggggtcccat agccttttgg gcccgacgna tcaaggactc gggtggctgc 840
ttggggcccc agagccttgc tctccctgag atcacctaaa gcccgtaggg caaggctcgc 900
cgtagagctg ccaagctcca gtcattccaa gagcctgaag caccaccacc tcgggatgtg 960
gcccttttgc aaggaggagg aaatgatttg gtgaagtacc ttttggctaa agaccagacg 1020
aagattccca tcaagcgctc ggacatgctg aaggacatca tcaaagaata cactgatgtg 1080
taccocgaaa tcattgaacg agcaggctat tcyttggaga aggtatttgg gattcaattg 1140
aaggaaattg ataagaatga ccacttgtac attcttctca gcaccttaga gcccactgat 1200
gcaggcatac tgggaacgac taaggactca cccaagctgg gtctgctcat ggtgcttctt 1260
agcatcatct tcatgaatgg aaatcggtcc agtgaggctg tcatctggga ggtgctgcgc 1320
aagttggggg tgcgcctggg atacatcatt cactctttgg ggacgtgaag aagctcatca 1380
ctgatgagtt tgtgaagcag aagtacctgg actatgccag agtccccaat agcaatcccc 1440
ctgaatatga gttcttctgg ggcctgcgct cttactatga gaccagcaag atgaaagtcc 1500
tcaagtttgc ctgcaagnta caaaagaagg atcccaagga atgggcagct cagtaccgag 1560
aggcgatgga agcrgatttg aaggctgcag ctgaggctgc agctgaagcc aaggctaggg 1620
ccgagattag agctcgaatg ggcattgggc tcggctcgga gaatgctgcc gggccctgca 1680
actgggacga agctgatatc ggaccctggg ccaaagcccc gatccaggcg ggagcagaag 1740
ctaaagccaa agcccaagag agtggcagtg ccagcactgg tgccagtacc agtaccaata 1800
acagtgccag tgccagtgcc agcaccagtg ttggcttcag tgctggtgcc agcctgaccg 1860
ccactctcac atttgggctc ttcgctggcc ttgggtggagc tgggtgccagc accagtggca 1920
gctctggtgc ctgtggtttc tcctacaagt gagattttag atattgttaa tcctgccagt 1980
ctttctcttc aagccagggt gcattcctcag aaacctactc aacacagcac tctaggcagc 2040
cactatcaat caattgaagt tgacactctg cattaaatct atttgccatt tcaaaaaaaaa 2100
aaaaaaaaaa actcnggggg gggcccggtg cccaattggc ccatagnngg 2149

```

<210> 131
 <211> 1020

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1019)

<223> n equals a,t,g, or c

<400> 131

```
ctcgtgcgta naaggcagcg ccccgagag ctcttgcgcg tcttggtctt gcctgggtgtc 60
gggtggttagt ttctgcgact tgtgttgga ctgctgatag gaagatgtct tcaggaaatg 120
ctaaaattgg gcaccctgcc cccaacttca aagccacagc tgttatgcca gatgggtcagt 180
ttaagatat cagcctgtct gactacaaag gaaaatatgt tgtgttcttc tttaccctc 240
tgacttcac ctttgtgtgc ccacggaga tcattgcttt cagtgatagg gcagaagaat 300
ttaagaaact caactgccaa gtgattggtg cttctgtgga ttctcacttc tgtcatctag 360
catgggtcaa tacacctaag aaacaaggag gactgggacc catgaacatt cctttggtat 420
cagacccgaa gcgcaccatt gctcaggatt atgggtctt aaaggctgat gaaggcatct 480
cggtcagggg cctttttatc attgatgata agggattctt tcggcagatc actgtaaagt 540
acctccctgt tggccgctct gtggatgaga ctttgagact agttcaggcc ttccagttca 600
ctgacaaaca tggggaagtg tgcccagctg gctggaaacc tggcagtgat accatcaagc 660
ctgatgtcca aaagagcaaa gaatatctt ccaagcagaa gtgagcgctg ggctgtttta 720
gtgccaggct gcggtgggca gccatgagaa caaacctct tctgtatctt tttttccat 780
tagtaaaaca caagacttca gattcagccg aattgtggtg tcttacaagg caggcctttc 840
ctacaggggg tggagagacc agcctttctt cctttggtag gaatggcctg agttggcggt 900
gtgggcaggc tactggtttg tatgatgtat tagtagagca acccataat cttttgtagt 960
ttgtattaaa cttgaactga gaaaaaaaaa aaaaaaaaaa aaaccccggt gggggcccng 1020
```

<210> 132

<211> 2319

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2246)

<223> n equals a,t,g, or c

<400> 132

```
acggctcggn attcccgggt cgacccacgc gtccgctacc tttgaaaggt cagtgcctgc 60
ttgggggtgg gggcgggcca gcactcactg tttgcttccc caggccagct ggaggtgatc 120
ttgggaccgg cggtgatgc aggatgacaa ccggggccta ggccaagggc tcaaggacaa 180
```

```

caagagaacc tgcaaccggt tccgcctcct gctagagcgg cgaaccrtgg gcagtgaagg 240
ccaagatagc cactctacca gctacccatc cctcctcagc cacctgacct ccatgtacct 300
gaacgccccg gcgctcgctc tgccctgtagc caggatgcag ctcccaggcc ctggctctgcg 360
ctcatttcat cctctggcct cctcactgcc ctgtgacttc cacctgctca acctacgtac 420
gctccaggct gaggaggaca cctaccctc ggcggagacc gcactcatct tacaccgcaa 480
ggttttgact gcggcctgga ggcaagaact tgggcttcaa ctgcaccaca agccaaggca 540
aggtagccct gggcagcctt ttccatggcc tggatgtggt attccttcag ccaacctcct 600
tgacgttact gtaccctctg gcctccccgt ccaacagcac tgacgtctat ttggagccca 660
tggagattgc taccttttgc ctccgcttgg gttagggtct cttgtggcct gaagagaaag 720
ttcattcaca gagactgcct cttaacatga agatcattgg acaagccaca cgggtatccc 780
atcccgatct gcctcccgaga actgtgacac actgggctct gccytcatth tctgtttatt 840
gctgctgctg tgttttcggc gcaaccaca aaccagtgta tgggtaaata gggcagacgc 900
catgagatca gggagagaag gcccttggtc agagtgggca gtgccaggct ctgctttggg 960
ttgtgagtgg acacccaact gggcacaggc tcaggcaccc atcctttttc caaacagggg 1020
tatagaagtg gtggaagcag acagaagagg taaggagggc taagtgggta acagcccagc 1080
atcagggtca ctgtggcaac agcaggctct aggggaatcc tgtggttatg tagagactcc 1140
atgtcctggt gtgatgagca ggatcagagt gactctggga ggacaggggt ggggacccag 1200
agttagcagt ggggatggag cagtagaagg aatcactgtt tctcctagga gtctgaaggc 1260
ctcgctgctt tctgtgatgg ctttgagta agtgccgcct ggctgcatg cattggctaa 1320
caggctgcag aatggcagga aggactcgct agagattgtc atggccagag atcataggtc 1380
acttcaggta gcaagacccc tggcaactg ggcacttggc ctatgtactg atttgtggga 1440
tgggtggcagg ggtgtggggg ccttcaccct gcctgaattc tctttggctt ctgtgctctg 1500
tatgtctgctg tccccaagrg ctctttctta ttatggcagg gagtggggat tggctcctact 1560
ttctttctct ggaaaggaaa gcctccaaga ctccatgtgc ttgggcagct tgagaaggcg 1620
ttcagcacca cgcctagcag gcagacctg aagcctcacc tttagtctat ctgcagaggt 1680
attcagttcc tggcacaggg gactaggggc atgtagagta tatgaggagg cagtatggct 1740
gtgcaggagc cttcatttca gcttcaatta ataggggaaga atttatgata gctctataga 1800
tgctgaaaag gtatttcgta agatttaaaa tccatccctt attaaaactc ttagtaaaatt 1860
aagtctggaa agaaacaccc taatctagat aaaggctctgt ttcagaaacc aacagtgatg 1920
gcattctaaa gagtcagacg ccacaggcat tcccatataa gtcagaaact agccaagggc 1980
aagctattat tcagcagtggt cccggcacta ctaacccttg caacaagcca gatgaggaac 2040
ataaggaaga attataattg tcattatttg tagacaataa aactgcctac ctgtaaaacc 2100
taagaatcaa ctgaagacct gttaagagta ttctgtaagt caacccaatg atacacatca 2160
tgttcctgtc cacatactgg ttttcccaa atcagctgat aaattcagtg taattccaat 2220
gagatgaaac tttggaattg acagtnctaa agtgcattgg gagagtgaat gtgtgagaac 2280
actaagacca ctctgaacga tgataatgag tttgggggt 2319

```

<210> 133

<211> 1373

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (403)

<223> n equals a,t,g, or c

<400> 133

```

cgcgaccgga agtccgtcac tctcgcgagg cccagagag caggcgctgg gcagtgtgga 60
ggtcgttgga gtcacttccg cgtcaccagc tctgtgcct gccagtcggg gccctccccg 120
ctccagccat gctctccgcc ctgcgccggc ctgccagcgc tgctctccgc cgcagettca 180

```

```

gcacctcggc ccagaacaat gctaaagtag ctgtgctagg ggcctctgga ggcacgcggc 240
agccactttc acttctcctg aagaacagcc ccttggtgag ccgcctgacc ctctatgata 300
tcgcgcacac acccgagtg gccgcagatc tgagccacat cgagaccaa gccgctgtga 360
aaggctacct cggacctgaa cagctgcctg actgcctgaa agnttgatgt gtggtagtta 420
ttccggctgg agtccccaga aagccaggca tgaccggga cgacctgttc aacaccaatg 480
ccacgattgt ggccaccctg accgctgcct gtgcccagca ctgcccggaa gccatgatct 540
gcgtcattgc caatccggtt aattccacca tccccatcac agcagaagtt ttcaagaagc 600
atggagtgtt caaccccaac aaaatcttcg gcgtgacgac cctggacatc gtcagaagcca 660
acacctttgt tgcagagctg aagggtttgg atccagctcg agtcaacgtc cctgtcattg 720
gtggccatgc tgggaagacc atcatcccc tgatctctca gtgcaccccc aaggtggact 780
ttccccagga ccagctgaca gcaactcact ggcggtatcca ggaggccggc acggaggtgg 840
tcaaggctaa agccggagca ggctctgcca cctctccat ggcgatgcc ggccccgct 900
ttgtcttctc ccttggtgat gcaatgaatg gaaaggaagg tgttggtgaa tgttccttcg 960
ttaagtcaca ggaaacggaa tgtacctact tctccacacc gctgctgctt gggaaaaagg 1020
gcacgcagaa gaacctgggc atcggcagg tctctctttt tgaggagaag atgatctcgg 1080
atgccatccc cgagctgaag gcctccatca agaaggggga agatttcgtg aagacctga 1140
agtgaagcgc tgtgacgggt ggccagtttc cttaatttat gaaggcatca tgtactgca 1200
aagccgttgc agataaactt tgtattttta tttgctttgg tgatgattac tgtattgaca 1260
tcacatgcc ttccaaattg tgggtggctc tgtggcgca tcaataaaaag ccgtccttga 1320
ttttattttt caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1373

```

<210> 134

<211> 1657

<212> DNA

<213> Homo sapiens

<400> 134

```

ggaacaagtg cctgtagtgt gtttggatct gtaccctacg actgattata cggatgaatgt 60
gacctgtctg agatctccta agcggcactc agtcaaataa caatagcaac tccccagca 120
gtaaaacaga ccatcagtaa catttcagga ttaaatgaaa cctgcttgag atggagaagc 180
atcaagacag ctgatatgga ggagatgtat ttattccaca tttggggcca gagatggtat 240
cagaaggaat ttgcccagga aatgaccttt aatatcagta gcagcagccg agatcccag 300
gtgtgcttgg acctacgtcc gggtagcaac tacaatgtca gtctccgggc tctgtcttcg 360
gaacttctctg tggatcatctc cctgacaacc cagataacag agcctcccct cccggaagta 420
gaatttttta cgggtgcacag aggacctcta ccacgcctca gactgaggaa agccaaggag 480
aaaaatggac caatcagttc atatcaggtg ttagtgcttc ccctggccct ccaaagcaca 540
ttttcttgtg attctgaagg cgcttctctc ttcttttagca acgcctctga tgcgtatgga 600
tacgtggctg cagaactact ggccaaagat gttccagatg atgcatgga gataacctata 660
ggagacaggc tgtactatgg ggaatattat aatgcaccct tgaaaagagg gactgattac 720
tgcatatatat tacgaatcac aagtgaatgg aataagggtg gaagacactc ctgtgcagtt 780
tgggctcagg tgaaagattc gtcactcatg ctgctgcaga tggcgggtgt tggactgggt 840
tccctggctg ttgtgatcat tctcacattc ctctccttct cagcgggtgt atggcagatg 900
gacactgagt ggggaggatg cactgctgct gggcaggtgt tctggcagct tctcaggtgc 960
ccgcacagag gctccgtgtg acttccgtcc agggagcatg tgggcctgca actttctcca 1020
ttcccagctg ggccccattc ctggattttaa gatggtggct atccctgagg agtcaccata 1080
aggagaaaac tcaggaattc tgagtcttcc ctgctacagg accagttctg tgcaatgaac 1140
ttgagactcc tgatgtacac tgtgatattg accgaagsta catacagatc tgtgaatctt 1200
ggctgggact tcctctgagt gatgcctgag ggtcagctcc tctagacatt gactgcaaga 1260
gaatctctgc aacctcctat ataaaagcat ttctgttaat tcattcagaa tccattcttt 1320
acaatatgca gtgagatggg cttaagtttg ggctagagtt tgactttatg aaggaggtca 1380
ttgaaaaaga gaacagtgc gtaggcaaat gtttcaagca ctttagaaac agtacttttc 1440

```

```

ctataattag ttgatatact aatgagaaaa tatactagcc tgccatgccataaagtgttcc 1500
tgctgtgtct gttaggcagc attgctttga tgcaatttct attgtcctat atattcaaaa 1560
gtaatgtcta cattccagta aaaatatccc gtaattaaaa aaaaaaaaaa aaaaaaaaaa 1620
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ggcggcc 1657

```

<210> 135

<211> 2360

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1517)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2330)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2353)

<223> n equals a,t,g, or c

<400> 135

```

ggcacgagcg cagttgcgtg aggggtttgt rctatcctcg gtgctgtggt gcagagctag 60
ttcctctcca gctcagccgc gtaggtttgg acatatttga ctcttttccc ccaggttga 120
attgacaaaa gcaatggtga tggagaagcc tagtcccctg ctggtcgggc gggaaattgt 180
gagacagtat tacacactgc tgaaccaggc ccagacatg ctgcatagat tttatggaaa 240
gaactcttct tatgtccatg ggggattgga ttcaaatgga aagccagcag atgcagtcta 300
cggacagaaa gaaatccaca ggaaagtgat gtcacaaaac ttcaccaact gccacaccaa 360
gattcgccat gttgatgctc atgccacgct aaatgatggt gtggtagtcc aggtgatggg 420
gcttctctct aacaacaacc aggcctttgag gagattcatg caaacgtttg tccttgctcc 480
tgagggtgct gttgcaaata aattctatgt tcacaatgat atcttcagat accaagatga 540
ggtcttttgt gggtttgtca ctgagcctca ggaggagtct gaagaagaag tagaggaacc 600
tgaagaaaga cagcaaacac ctgaggtggt acctgatgat tctggaactt tctatgatca 660
ggcagttgtc agtaatgaca tggaagaaca tttagaggag cctgttgctg aaccagagcc 720
tgatcctgaa ccagaaccag aacaagaacc tgtatctgaa atccaagagg aaaagcctga 780
gccagtatta gaagaaactg cccctgagga tgctcagaag agttcttctc cagcacctgc 840
agacatagct cagacagtac aggaagactt gaggacattt tcttgggcat ctgtgaccag 900
taagaatctt ccaccagtg gagctgttcc agttactggg ataccacctc atgttggttaa 960
agtaccagct tcacagcccc gtccagagtc taagcctgaa tctcagattc caccacaaag 1020
acctcagcgg gatcaaagag tgcgagaaca acgaataaat attcctcccc aaaggggacc 1080
cagaccaatc cgtgaggctg gtgagcaagg tgacattgaa ccccgaagaa tgggtgagaca 1140
ccctgacagt caccaactct tcattggcaa cctgcctcat gaagtggaca aatcagagct 1200
taaagatttc tttcaaagtt atggaaacgt ggtggagttg cgcattaaca gtggtgggaa 1260
attacccaat tttggttttg ttgtgtttga tgattctgag cctgttcaga aagtcttag 1320
caacaggccc atcatgttca gaggtgaggt ccgtctgaat gtogaagaga agaagactcg 1380
agctgccagg gaaggcgacc gacgagataa tcgccttcgg ggacctggag gccctcgagg 1440
tgggctgggt ggtggaatga gaggcctcc ccgtggaggg atggtgcaga aaccaggatt 1500

```

```

tggagtggga arggggnttg cgccacggca gtgaatcttc atggatcttc atgcagccat 1560
acaaaccctg gttccaacag aatgggtgaat ttctgacagc ctttggtatc ttggagtatg 1620
accccgagtct gttataaaact gcttaagttt gtataatttt actttttttg tgtgttaatg 1680
gtgtgtgctc cctctccctc tcttcccttt cctgaccttt agtctttcac ttccaatttt 1740
gtggaatgat attttaggaa taacggactt ttaaagaagc aaaaaaaaaa actgaatttc 1800
cttgcttact ttgcatatac agactggatt tttttttttt tttacagcca tttcccaaaa 1860
ggaatgtctt gcatattact gacatttggt atgtttcatt cattggaata tttcttattt 1920
tctacgtgtt tgaaaagcct gtaagaaata caggatttga taatatattt aaggcaggaa 1980
aaaccctaat tgtttcttct ttgagagtca tgactacctt ctggtgtgga gaaattgcca 2040
ttggaaaatt tgacaatttt gattctcact ggtatgttta aaaactgaat aaaaggaata 2100
gaattttttt ttgataaagg atcacaaaaa aattctaaaa cctaactgtt tttaccattg 2160
aaatttaaat tgtgataata ggttttaaat gtctagaatg caactgatag gcttttcttg 2220
aactgttagt ttttttgaag tagttttttc cakgtttaat ttgtatttgg ttaaaaaaac 2280
maaaaggcca aaaattcccc aaaaccccg gtaaccacca grgscaaacn gttgtggcct 2340
tcccaattaa ccntgggatt 2360

```

<210> 136

<211> 1042

<212> DNA

<213> Homo sapiens

<400> 136

```

gccggtggct gctgtctctg ggcggggcgt gggaggctcc cgaggtgggg gccggggcgg 60
gatggctgca gcggcgggcg gggccgggag cgggccctgg gcggcccagg agaagcagtt 120
cccgcgggcg ctgctgagtt tcttcatcta caaccgcgc tcggggccgc gcgaaggaca 180
ggaggaaaat aagattttat tttatcatcc aaatgaggta gaaaagaatg agaagattag 240
aaatgtcggg ttgtgtgaag ctattgtaca gtttacaagg acatttagcc catcaaaacc 300
tgcaaaatct ttacatacac agaagaacag acagttcttc aatgaaccag aagaaaattt 360
ctggatggtc atggttggtc ggartcctat aattgaaaaa cagagtaaag atggaaaacc 420
agtatttgaa tatcaagagg aggagttggt ggacaagggt tatagctcgg tgctgcggca 480
gtgctacagc atgtacaagc tttttaatgg tacatttctg aaagccatgg aagacggagg 540
cgtcaagctt ctgaaagaaa gattagagaa attcttccat cggtatattg aaacgctaca 600
tttgacgtca tgtgacctac ttgacatttt tggtggaatc agcttcttcc cgttgataa 660
aatgacttat ttgaaaatcc agtcctttat taatagaatg gaggaagcc tgaatatagt 720
caaatacact gcttttctct ataacgatca gctcatctgg agtgattag aacaagatga 780
catgagaatt ttatacaaat accttaccac ctccccttty ccaaggcaca tcgaacctga 840
gttagcagga agggattctc caataagagc agaaatgcca ggaaatcttc aacactatgg 900
aagatttctt accggaccct tgaacctcaa tgatccagat gcaaaatgca gattcccaaa 960
aatttttgta aatacagwtg acacttatga agagctccat ttaatcgktt ataaggyctg 1020
agaaagaacc ccagtttaag tt 1042

```

<210> 137

<211> 1037

<212> DNA

<213> Homo sapiens

<400> 137

```

ggcaccggga gcggcggggt ggtctacgct gtgcgcggcg gacgtcggag gcagcgggga 60
gcggagcggg gccgcggggg cctctccagg gccgcagcgg cagcagttgg gcccccgcc 120
ccggccggcg gaccgaagaa cgcaggaagg gggccggggg gacccgcccc cggccggccg 180
cagccatgaa ctccaacgtg gagaacctac ccccgcacat catccgctg gtgtacaagg 240

```

```
aggtgacgac actgaccgca gaccaccccg atggcatcaa ggtctttccc aacgaggagg 300
acctcaccga cctccaggtc accatcgagg gccctgaggg gaccccatat gctggaggtc 360
tggtccgcat gaaactcctg ctggggaagg acttccctgc ctccccaccc aagggtact 420
tcctgaccaa gatcttccac ccgaacgtgg gcgccaatgg cgagatctgc gtcaacgtgc 480
tcaagaggga ctggacggct gagctgggca tccgacacgt actgctgacc atcaagtgcc 540
tgctgatcca ccctaacccc gagtctgcac tcaacgagga ggcggggccgc ctgctcttgg 600
agaactacga ggagtatgcr gctcggggcc gtctgctcac agagatccac gggggcgccg 660
gcggggccag cggcagggcc gaagccggtc gggccctggc cagtggcact gaagcttcct 720
ccaccgaccc tggggcccca gggggcccg gaggggctga ggggtcccatg gccagaagc 780
atgctggcga gcgcgataag aagctggcgg ccaagaaaaa gacggacaag aagcgggcgc 840
tgcgggcggt gtagtgggct ctcttctcc ttccaccgtg accccaacct ctctgtccc 900
ctccctccaa ctctgtctct aagttattta aattatggct ggggtcgggg aggggtacagg 960
gggcaactgg acctggattt gtttttctaa ataaagtggg aaaagcaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaa 1037
```

<210> 138

<211> 1490

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1225)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1239)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1348)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1452)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1487)

<223> n equals a,t,g, or c

<400> 138

```
cggcacgagg tggattcttg tccatagtgc atctgcttta agaattaacg aaagcagtgt 60
caagacagta aggattcaaa ccatttgcca aaaatgagtc taagtgcatt tactctcttc 120
ctggcattga ttggtggtac cagtggccag tactatgatt atgattttcc cctatcaatt 180
tatgggcaat catcaccaaa ctgtgcacca gaatgtaact gccctgaaag ctacccaagt 240
gccatgtact gtgatgagct gaaattgaaa agtgtacca tggtgcctcc tggaatcaag 300
```

```

tattctttacc ttaggaataa ccagattgac catattgatg aaaaggcctt tgagaatgta 360
actgatctgc agtggctcat tctagatcac aaccttctag aaaactccaa gataaaaagg 420
agagttttct ctaaattgaa acaactgaag aagctgcata taaaccacaa caacctgaca 480
gagtcctggtg gccacttcc caaatctctg gaggatctgc agcttactca taacaagatc 540
acaaagctgg gctcttttga aggattggta aacctgacct tcatccatct ccagcacaat 600
cggctgaaaag aggatgctgt ttcagctgct tttaaaggct ttaaactact cgaatacctt 660
gacttgagct tcaatcagat agccagactg ccttctggtc tccctgtctc tcttctaact 720
ctctacttag acaacaataa gatcagcaac atccctgatg agtatttcaa gcgttttaat 780
gcattgcagt atctgcgttt atctcacaac gaactggctg atagtggaa acctggaaat 840
tctttcaatg tgtcatccct gggtgagctg gatctgtcct ataacaagct taaaaacata 900
ccaactgtca atgaaaacct tgaaaactat tacctggagg tcaatcaact tgagaagttt 960
gacataaaga gcttctgcaa gatcctgggg ccattatcct actccaagat caagcatttg 1020
cgtttggtg gcaatcgcac ctcaraaacc agtcttccac cggatatgta tgaatgtcta 1080
cgtgktgcta acgaagtcac tcttaattaa tatctgtatc ctggaacaat attttatggk 1140
tatgkttttc tgtgkgtcag ttttcatagt atccatawtt tawtactgkk tattacttcc 1200
atgaatttta aaatctgagg gaaangtttg taaacattna tttttttaa gaaaagagaa 1260
aggcaggcct attcatcaca agaacacaca catatwcacg aatagacatc aaactcatgc 1320
tttatttgta aatttagtgt ttttttantt ctacgtcaaa gatgtgcaaa acctttttacg 1380
gttgaggaa acagccagtt ttaaaatcct taaacttaag ttcctcaagc tggataaaac 1440
ataggagtac cncctgcacaa tatctgaaca tcaatgtcgg taaaatnggg 1490

```

<210> 139

<211> 1684

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (93)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (201)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1657)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1659)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1682)

<223> n equals a,t,g, or c

<400> 139

```
tcgaccacg cgtccggccg gctgagccac agcaggggtcg ccgcggggtc ccggggccgt 60
gctcccctgc ccctccggga gcgcgcgggg cgnngcgggg cggggcgga ccaggcgggc 120
gagctggggc ctgcgccctc cctcgggcgg tcacctgggc acgggcgctg caggtgtcgg 180
ggcctcaacc ttgcggaccg nacagccatc gatcctcggg tggcctcgag gtggtggcag 240
ggcgcggccc tgcagtccgg agacgaacgc acggaccggg cctccggagc argttcgggt 300
ggaargaamc gctctcgstt cgtcctacac ttgcgcaaatt gtctccgagc ttactcacat 360
agcatattgg tatatcaaaa tgaaatgcaa ggaacaaaaa ataacataat tgaaggcagt 420
aaaagtgaat ttaaataagg agatcatcag tcaaggaga cccactggag aggacagaaa 480
atgaagcagt gttttatcat gtgtatttca gcaggctctt ttgaaattta actaaaaata 540
tgactgctct ctcttcagag aactgctctt ttcagtacca gttacgtcaa acaaaccagc 600
ccctagatgt taactatctg ctattcttga tcatacttgg gaaaatatta ttaaataatcc 660
ttacactagg aatgagaaga aaaaacacct gtcaaaattt tatggaatat ttttgcatth 720
cactagcatt cgttgatctt ttaacttttg taaacatttc cattatattg tatttcaggg 780
atthttgtact ttttaagcatt aggttcaact aataccacat ctgcctattt actcaaatth 840
tttcttttac ttatggcttt ttgcattatc cagttttcct gacagcttgt atagattatt 900
gcctgaattt ctctaaaaa accaagcttt catttaagtg tcaaaaatta ttttatttct 960
ttacagtaat ttttaatttg atttcagtc ttgcttatgt tttgggagac ccagccatct 1020
accaaagcct gaaggcacag aatgcttatt ctgcgcactg tcctttctat gtcagcattc 1080
agagttactg gctgtcattt ttcattgtga tgattttatt ttagctttc ataacctgtt 1140
gggaagaagt tactactttg gtacaggcta tcaggataac ttctatatg aatgaaacta 1200
tcttatattt tcctttttca tcccaactca gttatactgt gagatctaaa aaaatattct 1260
tatccaagct cattgtctgt tttctcagta cctggttacc atttgtaacta ctccaggtaa 1320
tcattgtttt acttaaagtt cagattccag catatattga gatgaatatt ccctgggttat 1380
actttgtcaa tagttttctc attgctacag tgtattgggt taattgtcac aagcttaatt 1440
taaaagacat tggattacct ttggatccat ttgtcaactg gaagtgtctg tcattccac 1500
ttacaattcc taatcttgag caaattgaaa agcctatatc aataatgatt tgktaattatt 1560
attaattaaa agttacagct gtcataagat cataatttta tgaacagaaa gaactcagga 1620
catattaaaa aataaactgr actaaaacaa aaaaaancna aaaaaaaaaa aaaggggcgg 1680
cnac 1684
```

<210> 140

<211> 427

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (395)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (417)

<223> n equals a,t,g, or c

<400> 140

```
ggacttcctc ccagcacatt cctgcactct gccgtgtcca cactgcccc cagaccaggt 60
cctccaagcc tgctgccagc tccctgcaag cccctcaggt tgggccttgc cacggtgcca 120
gcaggcagcc ctgggctggg ggtaggggac tccctacagg cacgcagccc tgagacctca 180
gagggccacc ccttgagggt ggccaggccc ccagtggcca acctgagtgc tgctcttgc 240
```

```

accagccctg ctggcccctg gttccgctgg cccccagat gcctggctga gacacgccat 300
ggcccttcag ctggcccaca cytyttcccg gsccttgga kttggcaytg cagcagacag 360
ytccytgggc accagrcagy taacaggaca cagcngccag cccaaacagc agcgggnatg 420
ggggcag                                         427

```

<210> 141

<211> 889

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (60)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (698)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (889)

<223> n equals a,t,g, or c

<400> 141

```

ggcacgaggt tgacgtcctg tagcatttgc tgttctagaa agtacagaga cacgtagaan 60
agatgggagg atctagaagg aggctgtctc ctgtgtagtg tatatttatc tgtaagttag 120
ccgttgggga aggattgaat acagagacgc tgtctgcttg ctgccttaag acagctagct 180
gaattgctga ttaactttta aaataccag cttggtttat ttttcttaga atctgttgct 240
aagactgggg acgctgtttt cttttacaaa gggaaatcta agttaatttc aaggcattcg 300
aaatggggaa agactattat tgcatttttg gaattgagaa aggagcttca gatgaagata 360
ttaaaaaggc ttaccgaaaa caagccctca aatttcattc ggacaagaac aaatctcctc 420
aggcagagga aaaattttaa gaggtcgag aagcttatga agtattgagt gatcctaaaa 480
agagagaaat atatgrtcag tttggggagg aagggttgaa aggaggagca ggaggtactg 540
atggacaagg aggtaccttc cggtaacac ttcattggcg tcctcatgct acatttgctg 600
catttttcgg aggggtccaac ccctttgaaa ttttctttgg aagacgaatg ggtgggtgga 660
gagattctga agaaatggaa atagrtggtg atccttttag tgcctttggt ttcagcatga 720
atggatatcc aagagacagg aattctgtgg ggccatccc cctcaaacia gatcctccag 780
ttattcatga acttagagta tcacttgaag agatatatag tggttgtacc aaacgggatg 840
aaagatttct cgaaaaaggt taaaacgctg atggtaggag ttacagttn      889

```

<210> 142

<211> 1505

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1493)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1499)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1500)
 <223> n equals a,t,g, or c

<400> 142
 agtgagggaa gcgatgggag cggaatggc cggccacgg gtcgcaggag acgggacgcc 60
 agcttttggc tccgttccgc tggctccttc gtcagtactg acacctcggg cttgtagagc 120
 acttcacgca gcaaaagcgc ccccgctcta tatcatatcg cctctcgggc ctcctaaaag 180
 tcgtatgaga tggagctgga ggaggggaag gcaggcagcg gactccgcca atattatctg 240
 tccaagattg aagaactcca gctgattgtg aatgataaga gccaaaacct ccggaggctg 300
 caggcacaga ggaacgaact aaatgctaaa gttcgcctat tgcgggagga gctacagctg 360
 ctgcaggagc agggctccta tgtgggggaa gtagtccggg ccatggataa gaagaaagtg 420
 ttggtcaagg tacatcctga aggtaaattt gttgtagacg tggacaaaaa cattgacatc 480
 aatgatgtga caccgaattg ccgggtggct ctaaggaatg acagctacac tctgcacaag 540
 atcctgccc acaaggtaga cccattagtg tcaactgatga tggaggagaa agtaccagat 600
 tcaacttatg agatgattgg tggactggac aaacagatca aggagatcaa agaagtgatc 660
 gagctgcctg ttaagcatcc tgagctcttc gaagcactgg gcattgctca gccaagggga 720
 gtgctgctgt atggacctcc aggcaactgg aagacactgt tggcccgggc tgtggctcat 780
 catacggact gtacctttat tcgtgtctct ggctctgaat tggtagagaa attcataggg 840
 gaaggggcaa gaatggtgag ggagctgttt gtcattggcag gggaacatgc tccatctatc 900
 atcttcatgg acgaaatcga ctccatcggc tcctcgcggc tggagggggg ttctggaggg 960
 gacagtgaag tgcagcgcac gatgctggag ttgctcaacc agctygacgg ctttgaggcc 1020
 accaagaaca tcaagggttat catggctact aataggattg atatcctgga ctcggcactg 1080
 cttcgcccag ggcgcattga cagaaaaatt gaattcccac ccccaatga ggaggcccg 1140
 ctggacattt tgaagattca ttctcggaag atgaacctga cccgggggat caacctgaga 1200
 aaaattgctg agctcatgcc aggagcatca ggggctgaag tgaaggcgt gtgcacagaa 1260
 gctggcatgt atgcccctgc agaacggcga gtccatgtca ctcaggagga ctttgagatg 1320
 gcagttagcca aggtcatgca gaaggacagt gagaaaaaca tgtccatcaa gaaattatgg 1380
 aagtgaattg acagcctttg tgtgtatctc tccaataaag ctctgtgggc caagtcaaaa 1440
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aanggggggnn 1500
 ccccc 1505

<210> 143
 <211> 1235
 <212> DNA
 <213> Homo sapiens

<400> 143
 cggacggtgg gtagcggcgg cggcgctggc accccggccc cggcgggccc cggcggacgg 60
 cgggcaaagg tcccaggaag gtggcgctcag catctgcagc cgcgtcgacg ttgtcggagc 120
 ctccgaggag gaccaggag agccggacta ggaccagggc cctgggcctc cccacactcc 180
 ccatggagaa gctggcggcc tctacagagc cccaagggcc tcggccgggc ctgggcccgtg 240
 agagtgtcca ggtgcccgat gaccaagact ttcgcagctt ccggtcagag tgtgaggctg 300
 aggtgggctg gaacctgacc tatagcaggg ctggggtgtc tgtctgggtg caggctgtgg 360

```

agatggatcg gacgctgcac aagatcaagt gccggatgga gtgctgtgat gtgccagccg 420
agacactcta cgacgtccta cacgacattg agtaccgcaa gaaatgggac agcaacgtca 480
ttgagacttt tgacatcgcc cgcttgacag tcaacgctga cgtgggctat tactcctgga 540
ggtgtcccaa gcccctgaag aaccgtgatg tcatcacctt ccgctcctgg ctccccatgg 600
gcgctgatta catcattatg aactactcag tcaaacaatcc caaataacca cctcggaag 660
acttggtccg agctgtgtcc atccagacgg gctacatcat ccagagcaca gggccaaga 720
gctgcgtcat cacctacctg gccaggtgg accccaaagg ctccctacct aagtgggtgg 780
tgaataaata ttctcagttc ctggctccca aggccatgaa gaagatgtac aaggcgtgcc 840
tcaagtaccc cgagtggaaa cagaagcacc tgcctcactt caagcgtgg ctgcaccgg 900
agcagagccc gttgccgagc ctggcgctgt cggagctgtc ggtgcagcat gcggactcac 960
tggaagaacat cgacgagagc gcggtggccg agagcagaga ggagcggatg ggcggcgcg 1020
gcggcgaggg cagcgacgac gacacctcgc tcacctgagc gycgcaccgc ttcagggacg 1080
gagacaggac cgggcgagcc ctggggcgcc gcccgctcct gcaactttct cctccccca 1140
cccgccacct ggtggcaccg ggccaggccc aggcgggtgc tgcagcctgg ctggacagag 1200
ccccaataaa cgatcccaca gcctcaaaaa aaaaaa 1235

```

<210> 144

<211> 1420

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1385)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1396)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1400)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1410)

<223> n equals a,t,g, or c

<400> 144

```

gcaagaacgg agctgactga ggaaccaact ggagggtctt cactctctcc ttccccagtg 60
tacaaaacca gttttctgca acattcagga gccaaatgag gaaaaagaat caagaatctg 120
actcacagcc catctgatct gttcaaagct gtcttttcca cctgctgaaa ttcattaaat 180
cactggaggc atgcataatg aatggagaat gagtgaactt ccaatgcaac ttggattcac 240
aaaccattta tcatagccaa tatgcagatt ttaaacagca tttcacattt catttgacca 300
tgtcttcttt ttgcacatgc ctgctgcaga attccctact agaattgtgaa acaacgaaca 360
aaccacagaa cttagagtgt gctggttagt cacataactt agtagcagga ttgtgtatcc 420
aggcacaagg gtgtctttgc taatgtttct ttgtctacct ccctgcttca aacgctaaat 480
ggtatgggtc tttctttggt gccagccata ttctacaaat aagacttttc aatatagtta 540

```

```

tgagtaatat aattttatgt acatataatg ttagaatatt gtacagaatc ttggtttcta 600
cgatgcgctt ttcttgtttc aaaaagagga aaatgcttga tttttgttga tgatactttt 660
gttactgtcc ttaattttcc atagtttggt ttcttaattg tgctcactaa gcatcgatct 720
gtgctgatgc caagctatgg actatgtacg caagaccgag caatagacag aggtgcctag 780
gggtccaaaca cactgaacgc acgtggaccg cctggwtcag gagcctcatc agacccttct 840
ccatgcacat ccttcccaaa cagtcacaga ttccattgaa aggagcagat tctatcagtt 900
cttctgtgca gactttaaga gctgaacggt ctggttctgg aagccatgtg actgcgcaga 960
acaacctaag aaaccctttg tgtcctgagg ggtcgttgac ctctccttcc gggtcggagc 1020
agtcactctg agggcaaagc gtggtccact gtgtgtgatg ttttcaggat gctaggggtca 1080
aagaaagaaa ccaagtggta cataagccca gcttttctgc tgggctaagt gtaagtgtga 1140
gtaacatggt caagcccctc ttttttgggc tatgtaaagc ctttctctgc ttgcattaat 1200
gctatctccc tgtgtactgt ttctcttaaa tggagcagat agaaatctgc agtggtggca 1260
gataggtgga tgggagaggg atggataatt ttatcttctg ggccacagag ctggcagccc 1320
cagtttgtcc agagtccttt aaatggaaac ccccaaatcc atcccttctt ttccctaacc 1380
cccangggga tattcntagn attaagggcn cgggataagt 1420

```

<210> 145

<211> 1919

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1882)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1898)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1919)

<223> n equals a,t,g, or c

<400> 145

```

gcccacgcgt ccggccgctc gtccgcccgg cttgaggccc gcggggagcg cggcgcaatt 60
cgtcggcccc cgggggggcg gcctcccggc atcttcgctg cgaccaagga ctaccaggaa 120
ggggagcggc tgggatggcg cgtccggggc ccgskagtac aaagcgggag acctggtctt 180
cgccaagatg aagggtacc cgcactggcc ggcccggatt gatgaactcc cagaggcgct 240
gtgaagcctt cagcaaaca gtatcctatc ttcttttttg gcacccatga aactgcattt 300
ctagggtccca aagacctttt tccatataag gagtacaaaag acaagtttgg aaagtcaaac 360
aaacggaaag gatttaacga aggattgtgg gaaatagaaa ataaccagg agtaaagt 420
actggctacc aggcaattca gcaacagagc tcttcagaaa ctgagggaga agtggaat 480
actgcagatg caagcagtga ggaagaaggt gatagagtag aagaagatgg aaaaggcaaa 540
agaaagaatg aaaaagcagg ctcaaaacgg aaaaagtcac atacttcaaa gaaatcctct 600
aaacagtccc ggaaatctcc aggagatgaa gatgacaaag actgcaaaga agaggaaaac 660
aaaagcagct ctgaggggtg agatgcgggc aacgacacaa gaaacacaac ttcagacttg 720
cagaaaacca gtgaagggac ctaactacca taatgaatgc tgcatattaa gagaaccac 780
aagaaggtta tatgtttggt tgtctaatat tcttggattt gatatgaacc aacacatagt 840

```

```

ccttggtgtgc attgacagaa ccccgagtttg tatgtacatt attcatattc ctctctggtg 900
tgtttcgggg ggaaaagaca ttttagcctt ttttaaaagt tactgattta atttcatggt 960
atttggtgtgc atgaagttgc ccttaaccac taaggattat caagattttt gcgcagacct 1020
atacatgtct aggatccttt tatcaaggca gttatgatca tcgttttcct gccttgaccc 1080
caccatcatc aaacactcag ttaaataata attaacattt tttagatgac cactcaacat 1140
aatgcttaag aatggaattt cctctctgtg acagaaccca ggaattaatt cctaaataca 1200
taacggttgt atattgaaga cgaaattaaa attgtccttc agttttgagg ccatgtgtaa 1260
agtttaacca tattgtaaaa tatctattcc gtattagaaa tagctagttg acagcttata 1320
cttctcaaaa ttcataattgt tatgtacaca aactaagttt ctatatgtga agttagtga 1380
tctttttgtg ttactccaaa ataaaggcaa tgatttattt ttttcccagt gccaatata 1440
ttttgagcta agcactcaag gtggatactt tacattttta agctggaatc agcaacagcc 1500
ctatgggaaa ccagacaaaag cattgacttt taaatgtaga cttttaaaat aaactgtttt 1560
cttttggaac tacaattaga atagttaata ttcatacctta aaccattatt atgtgtacat 1620
tattgttgct attgtgataa tagagaattt tatttatttt tatgccagct tatattgtga 1680
gaacacattt agtcagtttg ggttttatca atcctgttaa tgcttgctct tggaacatct 1740
ttcgcggtatt cacggtttgt agttgaaaag tttactgtaa aaaaatcaaa aacaaaaaaa 1800
tgtattgttt ttacagaata aatttatttg aatgtgwact ggggagtaag atttgagggt 1860
gtaagcaaac taagttagtg tnaattggcc tccaatangt aacgtggagg cattaatgn 1919

```

<210> 146

<211> 1379

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (925)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1371)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1377)

<223> n equals a,t,g, or c

<400> 146

```

gccacgcgt ccgcccacgc gtccgcccac gcgtccgccc acgcgtccgg taagtttaga 60
tgactggtca atatcttaaa aatgtatatt agtaagaagt tcttcctgga attttcttt 120
cgattctggc agaataaaca ggtgttttta gtttccac tgctgagcc aagcaggacc 180
ctgtcccaga gcaagagatg tccccttcca tctctgacct ttgcctggga caagctttga 240
tgggggggccc cagcttcaag gctgtggtgg gaacagcacc cccaaatgcc agcctctcct 300
ttcttcccat ccaccagtat actgcggggc catttctggt ctttgtccaa caggaaaccc 360
atctctggtg ggatatgcct tccagtgcc cagggccact caccocatgc atctctgtcc 420
tgcccgtcag tgctgggacg gacagcaagg gcaagcccag tgtctggcrg atagggtgggt 480
gggaacagag aggggagaat gccgtcctaa gcttctgctt ggggatcccc cacacgacct 540
gggtactgcc tgggaaacct gtcctaagta aaactatgga cctcgcctcg cccaccggcc 600
tgcraagcca gcattctcgt gaaggtggat ggaagcgcct ttgtcctcay tttgagctgc 660

```

```

aagctggggtc agcgggctctg aagccctcga gtgactttct aacccaagac ccagcccctg 720
gcaggaggag ggtgggtgca gggctgggtg gacaaaaaga ggcctcagca ggcctggaag 780
acccttccag tacatccac agcgtgtcga gcagctggga gaacctgtgt caagctcgag 840
ccgtcatagg tccccatgag gtgtctgaag ccccttcttg gtgatgggag gcagaggtgc 900
tgacgttctg gagcatggac gtgantcytc aagctggctc cgcgtgggcc cttggagggg 960
gccaggtgtg tggtagacct ctggatgcct ttaacttcat ggctgcgtca ttcctgattt 1020
agaactttaa ccggagcttc atctagtgat tgcaaaactg gaccaatggg aggacggcgc 1080
gcagcccgtc cctccgtgg aatggagctc agctcttcgg aggcatacaa gcacctgtcg 1140
cctccgtggg cccoctgccc agggagtgcg gcctctgcaa ggttcggggg tggcttcgtt 1200
tgcttgaggt ggccggccct gcttggtcca tgtggatgtt tgtgagcctc ggtcctacag 1260
cactgtgtag gctgcatctg tttcgtgctg gtctgttga cttgtatgat atccacaaat 1320
aaatatatttc atggcaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggggg nccccnaa 1379

```

<210> 147

<211> 514

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (406)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (412)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (418)

<223> n equals a,t,g, or c

<400> 147

```

ttnggaaact gatcacttat caaggcttta tatattcttt acggatttag acatcaccat 60
accaagaagc ttactccatc tattccggtc tttgtaggac aggcttcatt tttcagccca 120
tgtttctgtaa gccacacagt atgcctgcag aagctgctta tcggagccaa atataattgt 180
cagtacaatt taaagaccac tatgtgtccc cggagaccaa cctgtttatt tccctgaaag 240
accgcaacac cccacacaac atgtttcaga catttggtacc ttgttagata agacacttgt 300
aggagaaaga gatttcttaa attaatgagc ttatatatccc ctagagaagg ccatacaaat 360
ctgcggacgc gtgggcggac gcgtgggggg accgtgggtc gaacgnaccc ancgctcncg 420
gacgcgtggg cggacgcgtg ggcggacgcg tgggcggacg cgtgggcgga cgcgtgggcg 480
gacgcgtggg cggacgcgtg ggcggacgcg tggg 514

```

<210> 148

<211> 2058

<212> DNA

<213> Homo sapiens

<400> 148

```

gtgcgcccgc gcgccccggg agcctaccca gcacgcgctc cgccccactg gttccctcca 60
gccgcgcgcg tccagccgag tccccactcc ggagtcgccg ctgccgcggg gacatgggcc 120
tctgcgttca gggacctcgt cctttgctgg ctgtggagcg gactgggcag cggcccctgt 180
gggccccgtc cctggaactg cccaagccag tcatgcagcc cttgcctgct ggggccttcc 240
tcgaggaggt ggcagagggt accccagccc agacagagag tgagccaaag gtgctggacc 300
cagaggagga tctgctgtgc atagccaaga ccttctccta ccttcgggaa tctggctggg 360
attggggttc cattacggcc agcgaggccc gacaacacct gcagaagatg ccagaaggca 420
cgttcttagt acgtgacagc acgcacccca gctacctgtt cacgctgtca gtgaaaacca 480
ctcgtggccc caccaatgta cgcattgagt atgccgactc cagcttccgt ctggactcca 540
actgcttgct caggccacgc atcctggcct ttccggatgt ggtcagcctt gtgcagcact 600
atgtggcctc ctgcaactgt gatacccgaa gcgacagccc cgatcctgct cccaccccg 660
ccctgcctat gcctaaggag gatgcgccta gtgaccagc actgcctgct cctccaccag 720
ccactgctgt acacctaata ctggtgcagc cctttgtacg cagaagcagt gccgcagcc 780
tgcaacacct gtgcgcgctt gtcaccaacc gtctggtggc cgacgtggac tgccctgccac 840
tgccccggcg catggccgac tacctccgac agtaccctt ccagctctga ctgtacgggg 900
caatctgccc accctcacc agtcgcaccc tggaggggac atcagcccca gctggacttg 960
ggccccact gtccctcctc caggcatcct ggtgcctgca tacctctggc agctggccca 1020
ggaagagcca gcaagagcaa ggcattggg aggggaggtg tcacacaact tggaggtaaa 1080
tgcccccagg ccgcatgtgg cttcattata ctgagccatg tgtcagagga tggggagaca 1140
ggcaggacct tgtctcacct gtgggctggg ccagacctc cactcgcttg cctgccctgg 1200
ccacctgaac tgtatgggca ctctcagccc tggtttttca atccccaggg tcgggtagga 1260
cccctactgg cagccagcct ctgtttctgg gaggatgaca tgcaagaggaa ctgagatcga 1320
cagtgcctag tgaccccttg ttgaggggta agccaggcta ggggactgca caattataca 1380
ctattttatt atttattctc cttggggttg gtgtcagggg cgagccaacc ccacctctat 1440
gccctgagcc ctggtagtcc agagacccca actctgccct ggcttctctg gttcttccct 1500
gtggaaagcc catcctgaga catcttgctg gaaccaaggc aatcctggat gtccctgtac 1560
tgaccacccc gtctgtgaat gtgtccactc tcttctgccc ccagccatat ttggggagga 1620
tggacaacta caataggtaa gaaaatgcag ccggagcctc agtccccagc agagcctgtg 1680
tctcaccccc tcacaggaca gagctgtatc tgcatagagc tgggtctcact gtggcgcagg 1740
ccccgggggg agtgccctgt ctgtcaggaa gagggggtgc tggtttgagg gccaccactg 1800
cagttctgct aggtctgctt cctgcccagg aaggtgcctg cacatgagag gagagaaata 1860
cacgtctgat aagacttcat gaaataataa ttatagcaaa gaacagtttg gtggtctttt 1920
ctcttccact gatttttctg taatgacatt atacctttat tacctcttta ttttattacc 1980
tctataataa aatgatacct ttcattgtaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2040
aaaaaaaaaa aaaaaaaag

```

<210> 149

<211> 1781

<212> DNA

<213> Homo sapiens

<400> 149

```

ggcaattact aaggaaggat tgtatttatg aggataactt cattatttct ctctcttttt 60
aaatctctca ttaggtgggt atggaggcct ttacaacagt gatggatatg gaggaaatta 120
taactcccag ggggttgact ggtggggtaa ctgagcctgc tttgcagtag gtcacctgc 180
caaacaagct aatatggaaa ccacatgtaa cttagccaga ctataccttg tgtagcttca 240
agaactcgca gtacattacc agctgtgatt ctccactgaa attttttttt taaggagact 300

```

```

caaggtcaca agaagaaatg aaaggaacaa tcagcagccc tggttcagaag gtggttttgaa 360
gacttcattg ctgtagtttg gattaactcc cctcccgct acccccatcc caaactgcat 420
ttataatttt gtgactgagg atcatttggt tgtaaatgta ctgtgccttt aacttttagac 480
aactttttat ttgatgtcc tgttggtca gtaatgctca agatatcaat tgttttgaca 540
aaataaattt actgaacttg ggctaaaatc aaaccttggc acacagggtg gatacaactt 600
aacaggaatc atcgattcat ccataaataa tataaggaaa aacttatgct gtagcctgca 660
ttagggcttt ttgatacttg cagattgggg gaaaacaaca aatgtcttga agcatattaa 720
tggaattagt ttctaattgt gcaaactgta ttaagttaaa gttctgattt gctcactcta 780
tcctggatag gtatttagaa cctgatagtc tttaagccat tccagtcatg atgagggtgat 840
gtatgaatac atgcatacat tcaaagcact gttttcaaag ttaatgcaag taaatacagc 900
aattcctctt tcaacgttta ggcagatcat taattatgag ctagccaaat gtgggcatac 960
tattacaggg aaagtttaaa ggtctgataa cttgaaatag gtttttagga gaattcatct 1020
acttagactt tttaaatgcc tgccataaat gaaattgaaa tggtagaatg gctgaccaca 1080
gcaatgacca gccctcatta gggccctgga tgatttttgg tctaataacg catgctagtg 1140
ttgatgtttt ttggtcaaga gggatgaac aggaagaatt aaatgcagca ggctttatatt 1200
taaatgccga ttcacattac tctgttcaag ctgcgttgag atgttaaact ggcttactat 1260
agacttcgta aaaatggctc cagaagagta acaaactgaa atctttgaga tcacacagggt 1320
tggaatatg tacataactg cacaagggtg caattctgct ctacagtgc gtttttagtca 1380
gttttagttg cataggtttc cattgtattt atagtctgtt tatgctaaat ctggccaaag 1440
atgagcattg tccaccacta aaatgcctct gccactttga attctgtgct aattttgtgg 1500
ccagaatgct gtgatcaaaa cgctccatct ttttacagt gcataggaag acggcaaaaa 1560
tttctaaaag tgcaatagat tttcaagtgt attgtgcctt gttctaaaac ttttattaag 1620
taggtgcact tgacagtatt gaggtcattt gttatgggtc tatttcaatt agtctagggt 1680
taggcccttg tacattttgc ccataacttt ttacaagtac ttcttttatc gcwcatataa 1740
agcggggggc ctaatcacta tgccggattg aggcgcagag g 1781

```

<210> 150

<211> 1709

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1612)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1660)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1678)

<223> n equals a,t,g, or c

<400> 150

```

gcccacgcgt cgcccacgcg tycggaggct cgggtcggtg tgggtgcgctg tcttcccgtc 60
tgcgctcaggg acctgcccga ctcagtggcc gccatggcat cagatgaagg caaacttttt 120
gttggagggc tgagttttga caccaatgag cagtcgctgg agcaggctct ctcaaagtac 180
ggacagatct ctgaagtggg ggttggtgaaa gacagggaga cccagagatc tcggggattt 240

```

```

gggtttgtca cctttgagaa cattgacgac gctaaggatg ccatgatggc catgaatggg 300
aagtctgtag atggacggca gatccgagta gaccaggcag gcaagtcgtc agacaaccga 360
tcccgtgggt accgtggtgg ctctgccggg ggccgggggt tcttcctggg gggccgagga 420
cggggccgtg ggttctctag aggaggaggg gaccgaggct atggggggaa ccggttcgag 480
tccaggagtg ggggctacgg aggtccaga gactactata gcagccggag tcagagtggg 540
ggctacagtg accggagctc gggcggtcc tacagagaca gttacgacag ttacgtaca 600
cacaacgagt aaaaaccctt cctgctcaag atcgtccttc caatggctgt gtgtttaaag 660
attgtgggag cttcgctgaa cgттаатgtg tagtaaатgc acctccttgt attcccactt 720
tcgtagtcат ttcggttctg atcttgtcaa accagcctg accgcttctg acgccgggat 780
ggcctcgтта ctagactttt ctttttaagg aagtgtgttt tttttttgag ggttttcaaa 840
acattttgaa aagcattttac ttttttgacc acgagccatg agttttcaaa aaaatcgggg 900
gttgtgtggg tttttggttt ttgttttagt ttttggttgc gttgcctttt ttttttagt 960
gggtttggcc ccatgaagtг ggtgccccac tcacttctct gagatcgaac ggactgtgaa 1020
tccgctcttt gtcggaagct gagcaagctg tggctttttt ccaactccgt gtgacgtttc 1080
tgagtgtagt gtggtaggac cccggcgggt gtggcagcaa ctgccctgga gccccagccc 1140
ctgcgtccat ctgtgctgtg cgtccacag tagacgtgca gacgtccctg agaggttctt 1200
gaagatgttt аттататтг tcttttttta ctggaagacg tacgcatact ccatcgatgt 1260
tgtatttgca gtggtgagg aattcttgta cgcagttttc tttggcttta cgaagccgat 1320
taaaagaccg tgtgaaatga accttgctct gacaattccc ttgcattgca ccacacactc 1380
cttgctgcgg gctcctgcag ccagacctga gcagagagag aaggtggaga agcagcgggt 1440
ctgcaagcct tccctggggc ctgcagagct agaaaggag gccagcaga ctggcgctgg 1500
tcagggtagg ggagccaggc gggggacggg agcgggcagc tcaggcctca gggcagccct 1560
ggggaggctt ctggcatggt ggccagaagg ctggactgtg cgggcaactt ancaaggaca 1620
tggaactgcac tgacgtgact ggatgctcat ctagagcagn caagacaaag cactggcncc 1680
caggggactt cagaaggcaa cggttacta 1709

```

<210> 151

<211> 922

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (906)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (915)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (922)

<223> n equals a,t,g, or c

<400> 151

```

gcggaatcta caccttcccg gccagcggta caactgcaga actgcaggag actatctttc 60
tagacaaggc agttgaggag gagggagcgc ttgaggggga ctggcctggc gtgcactccg 120
cacctcgggg acattattgc gcgtggaacg gctgcttttg gaagactatt gcccagaaga 180
aaagatgttt ggttttcaca agccaaagat gtaccgaagt atagagggct gctgtatttg 240

```

```

cagagctaag tcctccagtt ctcgattcac tgacagtaaa cgctatgaaa aggacttcca 300
gagctgtttt ggattgcatg agactcgttc aggagacatc tgcaatgcct gtgtcctgct 360
tgtgaaaaga tggaagaagt tgccagcagg atcaaaaaaa aactggaatc atgtggtaga 420
tgcaaggggct ggacccagtc taaagactac attgaaacca aagaaagtga aaactctatc 480
tgggaacagg ataaaaagca accagatcag taaactgcag aaggaattta aacgtcataa 540
ttctgatgct cacagtacca cctcaagtgc ctccccagct caatctcctt gttacagtaa 600
ccagtcagat gacggctcag atacagagat ggcttctggt tctaacagaa caccagtttt 660
ttccttttta gatctcactt actggaaaag acagaagata tgttgtggga tcatctataa 720
aggccgtttt ggggaagtcc tcattgacac acatctcttc aagccttgct gcagcaataa 780
gaaagcagct gctgagaagc cagaggagca gggccagagc ctctgcccac ctccactcag 840
gagtggtagc tgagggtttt atgtagaagg ggaacaaaaa aaaaaatata tgaattttga 900
aaaccncaaa ggtanaaaat gn 922

```

<210> 152

<211> 635

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (594)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (614)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (616)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (628)

<223> n equals a,t,g, or c

<400> 152

```

cggacgcgtg gngtgacac gcagcccacg gtctgtactg acgcgccctc gcttcttcct 60
ctttctcgac tccatcttcg cggtagctgg gaccgccgtt cagtcgccaa tatgcagctc 120
tttgctccgcg ccaggagct acacaccttc gaggtgaccg gccaggaaac ggtcgcccag 180
atcaaggctc atgtagcctc actggagggc attgccccgg aagatcaagt cgtgctcctg 240
gcaggcgcgc ccctggagga tgaggccact ctgggccagt gcggggtgga ggccctgact 300
accctggaag tagcaggccg catgcttgga ggtaaagtcc atggttccct ggcccgtgct 360
ggaaaagtga gaggtcagac tcctaaggtg gccaaacagg agaagaagaa gaagaagaca 420

```

```

ggtcgggcta agcggcggat gcagtacaac cggcgctttg tcaacgttgt gcccaccttt 480
ggcaagaaga agggcccca tgccaactct taagtctttt gtaattctgg ctttctctaa 540
taaaaaagcc acttagttca aaaaaaaaaa aaaaaamtgc gggggggccc gkancccaat 600
ttscctata gggngncgtt taaattcntt ggcgg                                     635

```

<210> 153

<211> 2328

<212> DNA

<213> Homo sapiens

<400> 153

```

acggcagtg cactcaccgc gctcgcgcgc cccggcgccc ccacgcgcgc gcgtcgttct 60
cccgcccgct cgctccccgc cgctcacacc tgagctcact cgcgcacgcc cgcccgggccc 120
gagaaccgcg ccgcgcgcct ggccccgcgg aagccccgcc gcgccatgtc ttgcctccc 180
gaaggaaact agagactaaa gctggacacc cgcccgccgt gaaagctggt ggaatgcgaa 240
ttgtgcagaa acaccacat acaggagaca ccaaagaaga gaaagacaag gatgaccagg 300
aatgggaaag cccagtgcca cctaaaccca ctgtgttcat ctctggggtc atcgccggg 360
gtgacaaaga tttccccccg gcggctgcgc aggtggtc caagaagccg catgcctcca 420
tggaacaagc tccttcccc aagaaccagc acatccagca gccacgcaag tragcctgga 480
gtccaccagc ctgccccatg gccccggctc tgctgcactt ggtatttccc tgacagagag 540
aaccagcagt ttgccccaaa tcctactctg ctgggaaatc taaggcaaaa ccaagtgtct 600
tgtcctttgc cttacatttc catattttaa actagaaaca gctccagccc aaacctgtgt 660
tatggggagt ctggttggtat gtcatttgag gatcattgtg cccctagagg tgccattagc 720
agaatttgcc aagatccgag aaaaatttta gctttagttc tatttcagca gtcacctgac 780
gtccttgtct atggtcttaa aaacaagaag gcacacattt gagaagatga gattaagggt 840
aggagaaaac ctcatgcatt gcatgctttt tagtatgggc caataaaatc tcaacacctg 900
tgggagagta agaactaagg gaatgagttt gggcgggccc tcataaagga ccttagaggc 960
agggaacagc aatgccaaat ttccctctct cgtgagatgg gggatcctgt gcaggctgat 1020
gaggcaccca tgagaaaagc cgaaaaagca tgcattctag aaatagcccc tcaattccag 1080
gagtcaacat gccaaagaat gaggctggag acaggtagct ccgagggagg acttctggca 1140
tgagatctcg gcacggcaag ccagcatcg cctcagccca gacaggctcc accaggagat 1200
caagcaaggg ctgcctttca ggagtcacct cctgagccac ttcagagttc tggaagtga 1260
cacggaccag ggtggaggaa tagacttcta gttcattctg ggacacttga gccagagagt 1320
tgaaagcttg gaaagaccag ataagaaacc tgccctttgt ctccctaggg acatgagaca 1380
ccacattcca tttgtgctag aaaaacctat ccactgatga gtctaactgt tccaaacgcc 1440
tcccacctgg tgtgcacagc tgctgggtc cattgtcact tgggtgcac aggttgtcct 1500
ccgattttta gatgagtttc ctgtctagag atgtcctagt ctgctcactg gctggtggca 1560
gtaggggtacc ctgcgtcctc gaaaagccag aggtttcacc tagtcagacg aaactccaga 1620
acagtgtttg tggagggcct gactgtcctg ctcaccaca gccgatctgc tgcaggtcag 1680
caactgtgtc gtgagcagct gccaaaccac agcctttctg gtgctgttct ccagttcacg 1740
tctgccagct ggtgagggca gaggcagacc tggtcagacc cagcgccct cctccctgag 1800
ggagcatggc acagcctcac acttgaaaga cggtgtttgg tttcccatct aatcaactta 1860
agggaagccg gcatgtaccc ttcaaggccc tgtcaccacc tatttctctga tcagttggta 1920
taaactgagg gtggttttta gagaccaga cttggttggc agcgctgcca tggaacacc 1980
cagcaagcac ctcccagcct gcctttcgga gcagcaccca ggaggggatg ccgcgctcca 2040
gcaacaccag gtcaggcctg tgcagacccc tgccctgccg ctgcagaaat ccagaagcat 2100
ccttaatgct tctcagtctt cagccagagg gagggctgtt atttccagag gtgcgctttt 2160
tatgtacttt tagctagatg tggcatgcat ctgtgagctt tagatcatta aatccaaaat 2220
gtttgcctaa atgagtttat cagttgttaa cttcaagaat attaaatgat ttataataaa 2280
gtcctgcat ttctctccaa aaaaaaaaaa aaaaaaaaaa aaaaaaat 2328

```

<210> 154
 <211> 1268
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (80)
 <223> n equals a,t,g, or c

<400> 154
 aattcggcag agcaggaggg gagccagtgg tccctgcctg tccttcacag tgtccctgac 60
 ccagcgtgcc tcacactggn cagggtcagc aaaggctctg ctgcagtcag gtccctctgtt 120
 cctcgcgctg gcgggggtcag cagacgtctg gccgcagtga ggtccactgt tctctgcagg 180
 gctgtgggct gcatactggc cgagctgctg gcgcacaggc ctcttctccc cggcacttcc 240
 gagatccacc agatcgactt gatcgtgcag ctgctgggca cggccagtga gaacatctgg 300
 ccgggctttt ccaagctgcc actggtcggc cagtacagcc tccggaagca gccctacaac 360
 aacctgaagc acaagttccc atggctgtcg gaggccgggc tgcgctgctg cacttcctgt 420
 tcatgtacga ccctaagaaa agggcgacgg ccggggactg cctggagagc tcctatttca 480
 aggagaagcc cctaccctgt gagccggagc tcatgccgac ctttccccac caccgcaaca 540
 agcggggccg cccagccacc tccgagggcc agagcaagcg ctgtaaaccc tgacgggtggg 600
 cctggcacac gcctgtattc ccacaccagg tcttcgac tcctcccgatc agtgggtgtct gtgaagggtg 660
 ccgcgagcca ggctgaccag gcgcccggga tccagctcat ccccttggct gggaacatcc 720
 tccactgact tcctcccaact gtctgccctg aacccactgc tgccccaga aaaaggccgg 780
 gtgacaccgg ggggctccca gcccgctgcac cctggaaggc caggtctggc ggctccatcc 840
 gtggctgcag gggctctcat tggctcctcct cgctatgttg gaaatgtgca accactgctt 900
 cttgggagga gtgggtgggt cagtcccccc gctgtctttg agttgtgggt gacgctggcc 960
 tgggatgaga gggcccagaa gaccttcgta tccccctcga gtcgcccggt gctgtcccgt 1020
 gcatgggttg gctgtgggga ccccaggtgg gcctggcagg actccagatg aggacaagag 1080
 ggacaaggta tggggtgagg gccacaattg aggatacccc gagactacca ggagagccct 1140
 gggctggagg ctgagctgca tccctgctcc ccacatggag gacccaacag gaggccgtgg 1200
 ctctgatgct gagcgaagct ataggctctt gttggataaa agctttttta asagaaaaaa 1260
 aaaaaaaa 1268

<210> 155
 <211> 4299
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (2813)
 <223> n equals a,t,g, or c

<400> 155
 gtcagccctc gcgctggggg cgcaggaaac aatagaggcc gcgcgcacag agcgagctct 60
 tgcagcctcc ccgcccctcc cgcaacgctc gacccagga ttccccggc tcgcctgccc 120
 gccatggccg acaaggaagc agccttcgac gacgcagtgg aagaacgagt gatcaacgag 180
 gaatacaaaa tatggaaaaa gaacaccctt tttctttatg atttggtgat gacccatgct 240
 ctggagtggc ccagcctaac tgcccagtgg cttccagatg taaccagacc agaagggaaa 300
 gatttcagca ttcacgact tgtcctgggg acacacacat cggatgaaca aaaccatctt 360

```

gttatagcca gtgtgcagct ccctaattgat gatgctcagt ttgatgcgtc acactacgac 420
agtgagaaag gagaattttgg aggtttttggt tcagtttagtg gaaaaattga aatagaaatc 480
aagatcaacc atgaaggaga agtaaacagg gcccgttata tgccccagaa cccttgatc 540
atcgcaacaa agactccttc cagtgatgtt cttgtctttg actatacaaa acatccttct 600
aaaccagatc cttctggaga gtgcaaccca gacttgcgtc tccgtggaca tcagaaggaa 660
ggctatgggc tttcttggaa cccaaatctc agtgggcact tacttagtgc ttcagatgac 720
cataccatct gcctgtggga catcagtgcc gttccaaagg agggaaaagt ggtagatgcg 780
aagaccatct ttacagggca tacggcagta gtagaagatg tttcctggca tctactccat 840
gagtctctgt ttgggtcagt tgctgatgat cagaaactta tgatttggga tactcgttca 900
aacaatactt ccaaaccaag ccactcagtt gatgctcaca ctgctgaagt gaactgcctt 960
tctttcaatc cttatagtga gttcattctt gccacaggat cagctgacaa gactgttgcc 1020
ttgtgggatac tgagaaatct gaaacttaag ttgcattcct ttgagtcaca taaggatgaa 1080
atattccagg ttcagtggtc acctcacaat gagactatct tagcttccag tggtagtgat 1140
cgcagactga atgtctggga tttaagtaaa attggagagg aacaatcccc agaagatgca 1200
gaagacgggc caccagagtt gttgtttatt catgggtggc atactgcaa gatattctgat 1260
ttctcctgga atcccaatga acctgggtg atttgttctg tatcagaaga caatatcatg 1320
caagtgtggc aaatggcaga gaacatttat aatgatgaag accctgaagg aagcgtggat 1380
ccagaaggac aagggtccta gatattgtct tacttgttgt gattttagac tccccctttt 1440
tcttctcaac cctgagagtg atttaacact ggttttgaga cagactttat tcagctatcc 1500
ctctatataa taggtaccac cgataatgct attagcccaa accgtgggtg ttttctaaat 1560
attaataggg gggcttgatt caacaaagcc acagacttaa cgttgaaatt ttcttcagga 1620
attttctagt aaccaggtc taaagtagct acagaaagg gaatattatg tgtgattatt 1680
tttctctta tgctatatcc ccaagttttt cagactcatt taagtaaagg ctagagttag 1740
taaggaatag agccaaatga ggtaggtgtc tgagccatga agtataaata ctgaaagatg 1800
tcacttttat tcaggaaata gggggagatt caagtcgtat agattcctac tcgaaaatct 1860
tgacacctga ctttccagga tgcacatttt catacgtaga ccagtttctt cttggtttct 1920
tcagttaagt caaaacaaca cgttcctctt tccccatata ttcatatatt tttgctcgtt 1980
agtgtatttc ttgagctgtt ttcattgtgt ttatttctctg tctgtgaaat ggtgtttttt 2040
tttttgttgt tggttttttt ttttttttt taacttggga ccaccaagtt gtaaagatgt 2100
atgtttttac ctgacagtta taccacaggt agactgtcaa gttgagaaga gtgaatcaat 2160
aacttgatatt tgttttaaaa attaaattaa tccttgataa gagttgcttt ttttttttag 2220
gagttagtc ttgaccacta gtttgatgcc atctccattt tgggtgacct gtttcaccag 2280
caggcctgtt actctccatg actaactgtg taagtgtcta aaatggaata aattgctttt 2340
ctacataacc ccatgctgat gggttttatt tagtataaaa catccatcaa acaccagtct 2400
ctggcttcta gaagagtcct tcagatgaca gttgtgtccc atggtctttg actatcaaga 2460
gcagaattaa atgtaatagt cccagagctg tagaaaagaa ctttactcct tcccagggaa 2520
agtgaaagac ataaaacact gaatcagagg tggcacagat tagtctttga taaggtaacg 2580
tttctttgaa gtctgtctgt agagaactac atggacttcc aagagtgtca aaggcagtgt 2640
ggtagagaga atttaaggca agatttaaat ttggaaaagg tgcttgaacc ttttctcaga 2700
ggtttttatt cccagtatg ttttttactg gggcctttac ttagggtaga aataataggc 2760
tttgaaggcc tctatcacca gatgcaataa ccagataaaa ttcctgtttt ttncccaatc 2820
gcttagtttt tkgtkgttgt tgttttttaa ctgagtagat cattctgacc cagaactact 2880
ttcatgaggt aagatctttg ggaaaatctg aatagcgtta accattagat tcaaatctca 2940
aatggtttct tttcaagtct agttgtttta gagtatagtg agaaatacct tgacacaatt 3000
ttaagagtaa actatatggg tcagcatatc cttgaacaaa aagtagactt tgtaaaagta 3060
ttcattttaa ttttaacact cgtggcacia aagaatggaa attgtaaacc catgtaatgg 3120
aaattggcta tctttttgac cccacatgtg cccctcaaaa atgttttttg tttgggtcaa 3180
cacaaggcaa gatacattct ttaaaatact cccagatgtg tccatacatt catcctttac 3240
tcagtgcata tgtgaggggt gttgctggaa gacaggaggc tcatctttcc tttccttggg 3300
gcattgagat cagtatcaac agcagatgaa atagaatcca gcaaagagtt gacatgttct 3360
gcctccggcc aactctagaa tctttttaag caggtcagcc agtatttgca acttccacag 3420

```

```

gatgaattgc ttgccaagtt tctggcactc ttgtctgggt ggaagagtac atccaaaggg 3480
tacttagtga tcctttgcta agaagttttt tgctgtttcc gggttacaga twtgggccata 3540
tattttctaaa cagcccttat aagtagagag ctcttcagca agactgagcc ttagctgttc 3600
catctctttg ttcttctgtt gctggagttg caccctattt mttactgcy tctgcgttct 3660
tccatttcct ccagctgttc ctgcatgaga tggccaagaa cttttctaata gagccaaaca 3720
ataaaaactc acattgtcca ctcttactta taaaacactt tttgttcat tgtttaatct 3780
tgatagcagt attgaggctg gtatttatat gatagggtat gaaacagggt caaagaagtt 3840
gtgtcttgga aaaaaagtga caatgctttt gaaaatgatg acgaaaaagg catcttgtct 3900
gttaaccaca gcttgcttta atagaatcct ggggagggtg attgggactt ttagtatta 3960
caaccttagt gtcattgagg aggatttttg tctagttagt gggctgagtt tcatatacct 4020
ctccctccat gtgcagggtt gttaagataa ttggtagttt ttaataatat aaaatactta 4080
agttgaaata caaaagtgtg gcamcaatta ttaaataattg gctagaattc taggagagtt 4140
acacaactag tggaagtcca tgtttagaaa ataaatggct tgtttaagga aaagtttttg 4200
tgtccaaagc tccttaaagt cagagagatt tctacctggt acttaacatc atatggaaat 4260
tgatgcttta gtgagggtgt tggctatcct attgtcaat 4299

```

<210> 156

<211> 1006

<212> DNA

<213> Homo sapiens

<400> 156

```

cacgcgtccg cccacgcgtc gaccacgcgc tccgccgaaa gcgaagaagg aagctcctgc 60
ccctcctaaa gctgaagcca aagcgaaggc tttaaaggcc aagaaggcag tgttgaaagg 120
tgtccacagc cacaaaaaga agaagatccg cactcaccac accttccggc ggccgaagac 180
actgcgactc cggagacagc ccaaatatcc tcggaagagc gctcccagga gaaacaagct 240
tgaccactat gctatcatca agtttccgct gaccactgag tctgccatga agaagataga 300
agacaacaac acacttggtg tcattgtgga tgttaaaggc aacaagcacc agattaaaca 360
ggctgtgaag aagctgtatg acattgatgt ggccaagggt aacaccctga ttcggcctga 420
tgagagagaag aaggcatatg ttcgactggc tcctgattac gatgcttttg atgttgccaa 480
caaaattggg atcatctaaa ctgagtccag ctgcctaatt ctgaatatat atatatatat 540
atcttttcac cataaaamat gcctgtctgt caatttcttg ttgggctggg aggccacaca 600
cacacactga catgacaggg cttgggcaag actcctgttc tacttatcct tttgaaatac 660
ctcaccctgc cactccacca tgtatgatca ttccagagat ctttgtgact agagtttagt 720
tcctaggaaa accagaactc agaacttgcc tccatggttg agtaacaagc tgtacaagaa 780
ccccttttat ccctggaaga ggctgtgtat gaaaccaatg cccagggttt gaagggtgtt 840
agcatccatt tcaggggagt gtggattggc tggctctctg gtagcatttt gtctcacac 900
acccatctac tatgtccaac cggctctgtc gcttccctca ccccttgccc aataaaggac 960
aaggacttca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1006

```

<210> 157

<211> 1686

<212> DNA

<213> Homo sapiens

<400> 157

```

gctggctcac ctccgagcca cctctgctgc gcaccgcagc ctccggacct cagcccagga 60
tactttggga cttgccggcg ctcaaaaacg cgcccagacg gcccctccac cttttgtttg 120
cctagggtcg ccgagagcgc ccggagggaa ccgcctggcc ttcggggacc accaattttg 180
tctggaacca cctccccggc gtatcctact ccctgtgccg cgaggccatc gcttacttg 240
aggggtcgat ttgtgtgtag tttggtgaca agatttgcat tcacctggcc caaacctttt 300

```

```

ttgtctcttt gggtgaccgg aaaactccac ctcaagtttt cttttgtggg gctgcccccc 360
aagtgtcgtt tgttttactg tagggctctc cggccggcgc cccagtggtt ttctgagggc 420
ggaaatggcc aattcggggc tgcagttgct gggcttctcc atggccctgc tgggctgggt 480
gggtctgggt gcctgcaccg ccaccccgca gtggcagatg agctcctatg cgggtgacaa 540
catcatcacg gcccaggcca tgtacaaggg gctgtggatg gactgcgtca cgcagagcac 600
ggggatgatg agctgcaaaa tgtacgactc ggtgctcgcc ctgtccgcgg ccttgccaggc 660
cactcgagcc ctaatgggtg tctccctggt gctgggcttc ctggccatgt ttgtggccac 720
gatgggcatg aagtgcacgc gctgtggggg agacgacaaa gtgaagaagg cccgtatagc 780
catgggtgga ggcataatth tcatcgtggc aggtcttgcc gccttggtag cttgctcctg 840
gtatggccat cagattgtca cagactttta taaccctttg atccctacca acattaagta 900
agtctgggaa ccctgcctcc taaggggaca ggtctggggg cctggaatag ggaggagggc 960
agaggcacgc cagggtttct aaccaccccc ttctyttcac aggtatgagt ttggccctgc 1020
catctttatt ggctgggcag ggtctgccct agtcacctg ggagggtcac tgctctcctg 1080
ttcctgtcct gggaatgaga gcaaggctgg gtaccgtgca ccccgctctt accctaagtc 1140
caactcttcc aaggagtatg tgtgacctgg gatctccttg ccccgacctg acaggctatg 1200
ggagtgtcta gatgcctgaa agggcctggg gctgagctca gcctgtgggc aggggtgccg 1260
acaaaggcct cctggctact ctgtccctgc actccatgta tagtcctctt ggggtggggg 1320
tggggggggt cggttgggtg gagagacaaa aagagggaga gtgtgctttt tgtacagtaa 1380
taaaaaataa gtattgggaa gcaggctttt ttcccttcag ggcctctgct ttccctccgt 1440
ccagatcctt gcaggagct tggaacctta gtgcacctac ttcagttcag aacacttagc 1500
acccactga ctccactgac aattgactaa aagatgcagg tgctcgtatc tcgacattca 1560
ttcccacccc cctcttattt aaatagctac caaagtactt cttttttaat aaaaaataa 1620
agatttttat taggtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680
aaaaaa 1686

```

<210> 158

<211> 4147

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (292)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4145)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4146)

<223> n equals a,t,g, or c

<400> 158

```

cggacgcgtg ggnccggcccc cctctctcgtg cccggccatc ttgtgggaag agctgaagca 60
ggcgctcttg gctcggcgcg gcccgtgca atccgtggag gaacgcgccg ccgagccacc 120
atcatgcctg ggcacttaca ggaaggcttc ggctgcgtgg tcaccaaccg attcgaccag 180
ttattttgacg acgaatcgga ccccttcgag gtgctgaagg cagcagagaa caagaaaaaa 240
gaagccggcg ggggcggcgt tgggggccct ggggccaaaga gcgcagctca gngccgcggc 300
ccagaccaac tccaacgcgg caggcaaaca gctgcgcaag gagtcccaga aagaccgcaa 360
gaacccgctg cccccagcg ttggcgtggt tgacaagaaa gaggagacgc agccgcccg 420
ggcgcttaag aaagaaggaa taagacgagt tggaagaaga cctgatcaac aacttcaggg 480
tgaagggaata ataattgata gaagaccaga aaggcgacca cctcgtgaac gaagattcga 540
aaagccactt gaagaaaagg gtgaaggagg cgaattttca gttgatagac cgattattga 600
ccgacctatt cgaggctcgt gtggtcttg aagaggtcga gggggccgtg gacgtggaat 660
gggcccagga gatggatttg attctcgtgg caaacgtgaa tttgataggc atagtggaa 720
tgatagatct tctttttcac attacagtgg cctgaagcac gaggacaaac gtggaggtag 780
cggatctcac aactggggaa ctgtcaaaga cgaattaact gacttggatc aatcaaatgt 840
gactgaggaa acacctgaag gtgaagaaca tcatccagtg gcagacactg aaaataagga 900
gaatgaagtt gaagaggtaa aagaggaggg tccaaaagag atgacttttg atgagtggaa 960
ggctattcaa aataaggacc gggcaaaagt agaattttaat atccgaaaac caaatgaagg 1020
tgctgatggg cagtggaaaga agggatttgt tcttcataaa tcaaagagtg aagaggctca 1080
tgctgaagat tcggttatgg accatcattt ccggaagcca gcaaatgata taacgtctca 1140
gctggagatc aattttggag accttggccg cccaggacgt ggcggcaggg gaggacgagg 1200
tgacgtggg cgtggtgggc gcccaaaccg tggcagcagg accgacaagt caagtgcctc 1260
tgctcctgat gtggatgacc cagaggcatt cccagctctg gcttaactgg atgccataag 1320
acaaccctgg ttccttttg aacccttctg ttcaaagctt ttgcatgctt aaggattcca 1380
aacgactaag aaattaaaaa aaaaaagact gtcattcata ccattcacac ctaaagactg 1440
aattttatct gttttaaaaa tgaacttctc ccgctacaca gaagtaacaa atatggtagt 1500
cagttttgta tttagaaatg tattggtagc agggatgttt tcataatttt cagagattat 1560
gcattcttca tgaatacttt tgtattgctg cttgcaaata tgcatttcca aacttgaaat 1620
ataggtgtga acagtgtgta ccagtttaaa gctttcactt catttgtgtt ttttaattaa 1680
ggatttagaa gttcccccaa ttacaaactg gttttaaata ttggacatac tggttttaat 1740
acctgctttg catattcaca catggtcaac tgggacatgt taaactttga tttgtcaaat 1800
tttatgctgt gtggaatact aactatatgt attttaactt agttttaata ttttcatttt 1860
tggggaaaaa tcttttttca cttctcatga tagctgttat atatatatgc taaatcttta 1920
tatacagaaa tatcagtact tgaacaaatt caaagcacat ttggtttatt aacccttgct 1980
ccttgcatgg ctcattaggt tcaaattata actgatttac attttcagct atatttactt 2040
tttaaagtgt tgagtttccc attttaaaat cttaaactaga catcttaatt ggtgaaagt 2100
gtttaaacta cttattgttg gtaggcacat cgtgtcaagt gaagtagttt tataggatat 2160
ggttttttct ccccttcac cagggtggtt ggaataagtt gatttggcca atgtgtaata 2220
tttaaactgt tctgtaaaat aagtgtctgg ccatttggtg tgatttctgt gtgtgaaagg 2280
tcccaaaatc aaaatggtac atccataatc agccaccatt taacccttcc ttgttctaaa 2340
acaaaaacca aagggcgctg gttggtaggg tgaggtgggg gagtatttta atttttgga 2400
tttggaagc agacagcttt actttgtaag gttggaacag cagcactata catgaaatat 2460
aaacaaaaaa cctttactgt ttctaaattt cctagattgc tattatttgg ttgtaagttg 2520
agtattccac agaaagtgg aattatctct tctctcttcc tccattagaa aattaggtaa 2580
ataatggatt cctataatgg gagcatcacc acttattaaa acacacatag aatgatgaat 2640
taaaaaagtt ttctaggatt gtcttttatt ctgccacatt tattgataaa cagtgaagga 2700
atttttaaaa aatttttaag aattgtttgt cacgtcattt ttagaaatgt tctacctgta 2760
tatggtaatg tccagtttta aaaatatttg acatcttcaa tcttaaacat ttctatttag 2820
ctgattggtt ctccatatata cttctaaaag aaacttttat gttataagag ttactttttg 2880
gataagattt ataatctca gttacctact attctgacat ttaggaagg aggttaattgt 2940
ttttaatgat ggataaactt gtgctggtgt tttggatctt atgatgctga gcatgttctg 3000
cactggtgct aatgtctaata ataattttat atttacacac atacgtgcta cccagagatt 3060

```

```

aatttagtcc atatgaacta ttgacccatt gttcattgag acagcaacat acgcactcct 3120
aaatcagtgt gtttagactt ttcaagtatc taactcattt ccaaacatgt accatgtttt 3180
ataaacctct tgatttccag caacatacta tagaaaacac ctgctactca aaacacaact 3240
tctcagtgtc atccattgct gtcgtgagag acaacatagc aatatctggt atgttgcaag 3300
ctttcaagat agcctgaact taaaaagttg gtgcattagt tgtatctgat ggatataaat 3360
ttgcctccta gttcactttg tgtcaagagc taaaactgtg aacctaaact tctcttattg 3420
gtgggtaata actgaaaata aagattttatt ttcatgctca cttcttaaaa gtcataaaaa 3480
caatcaaata ggatcatggt tattgtcatg tgtttcctgg kttctgacct gtgtgcacac 3540
ccctgtgtgt ttataatttt taaattgaat tttatatggg gtttttattt gctaaaaacc 3600
aggctgttga atcacatttg ggaagggtac ttatcttaat gactaatgac ttaattggga 3660
aagttgaatt cttgtaaaat acaaaatcca aggacttctt ggatttaatc taattgtcac 3720
ttcttagcag atcacttttt tgataatgaa agttaagcat actgaatgct acttttgatt 3780
gacaaactgg ctataatagt ctaggggaaa aatccctaaa cagataaaga ttcctaaagt 3840
aatggtggca gctgatgttt cagtgaactt ttatcttgat gcgtttaaat ggaagtaatg 3900
ccagacctga gattttttaag gcattttttac agcttgattt gaaatgattg gagacatggt 3960
ttctttatta gctattttga gacctgtgga gttaagcaag acttttataa attggcacca 4020
tatacatcta gttagtctct ttactcttat ttttttaaat aaaagtagta cacatcaaaa 4080
aaaaaaaaaa aaaaaaaaaa actcgagggg gggcccgkac ccaatcgccc tatgagtgat 4140
cgtanna 4147

```

<210> 159

<211> 1242

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1235)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1236)

<223> n equals a,t,g, or c

<400> 159

```

agcattttac ggcaagggct tgacttatga gtgtggctcag aggttttagc gaggcggctg 60
cgcagtacaa cccggagccc ccgccccac gcacacatta ctccaacatt gaggccaacg 120
agagtgagga ggtccggcag ttccggagac tctttgcca gctggctgga gatgacatgg 180
aggtcagcgc cacagaactc atgaacattc tcaataaggt tgtgacacga caccctgatc 240
tgaagactga tggttttggc attgacacat gtcgcagcat ggtggccgtg atggatagcg 300
acaccacagg caagctgggc tttgaggaat tcaagtactt gtggaacaac atcaaaaggt 360
ggcaggccat atacaaacag ttcgacactg accgatcagg gaccatttgc agtagtgaa 420
tcccagggtc ctttgaggca gcagggttcc acctgaatga gcatctctat aacatgatca 480
tccgacgcta ctcatatgaa agtggaaca tggattttga caacttcac agctgcttgg 540
tcaggctgga cgccatgttc cgtgccttca aatctcttga caaagatggc actggacaaa 600
tccaggtgaa catccaggag tggctgcagc tgactatgta ttcctgaact ggagccccag 660
acccgcccc tcaccgcctt gctataggag tcacctggag cctcggtctc tcccagggcc 720
gatcctgtct gcagtcacat ctttgtgggg cctgctgacc cacaagcttt tgttctctca 780
gtacttgtaa cccagcttct caacatccag ggcccaattt gccctgcctg gagttcccc 840
tggctctagg aactcctaac aagctctgtc cacgggtctc cccattccca ccaggccctg 900

```

```

cacacaccca ctccgtaacc tctccctgt acctgtgcca agcctagcac ttgtgatgcc 960
tccatgcccc gagggccctc tctcagttct gggaggatga ctccagtccc tgcacgccct 1020
ggcacaccct tcacggttgc taccagggcg gccaaagtcc agaccgtgcc agaccaggt 1080
gccccagtgc ctttgtctat attctgtcc cagcctgcca ggcccaggag gaaataaaca 1140
tgccccagtt gctgatctct aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaannngggg gg 1242

```

<210> 160

<211> 2229

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (55)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (59)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (128)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (301)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2226)

<223> n equals a,t,g, or c

<400> 160

```

tcaccttctt gggcccaagc catccttent gctttcacct tcntcagaag ctggnattnc 60
aggcatgcat gccatgcct ggctactttt taaatttttt gtgacacaag gtctcaccag 120
gttgccctnag gctggtttcg gattcctggg ctcaagtgat cttccacct aggtttccca 180

```

```

gagtgttgga attacaggcg tgagccatca catctggcctt gtttatgggtt agttaattca 240
ttccagactc tcagcctgaa amcactgaga atgtttgcat gctagttttc cacatcatat 300
ncaatattat taaaatactc atttggaata gaattccata tgggttaacc agagtactgt 360
tgggatgggtt gtggctatct gcacgtagca gatttcctgc ttttattcaa agmcaatatt 420
actggattttt aaaaatctgct tttamcatta tttttccttt tcactatmca taggtctatg 480
aaaattatcc tacttatgat ttaactgaaa gaaaagattt cataaaaaca actgtaaaag 540
agctaatttc ttgagataga ggacagagaa gatgactcgt tcccatagat ttgaagatct 600
gattttatacc attataccag caaagagaat gtatttcctt ttctaaatcc ttgttaagca 660
acgttagtag aacttactgc tgaccttttt atccttgagtg ttatgtgaat ttgagtttgc 720
tgtttttaaat tgcattttcta tgccattttt agtttaaaat cttgcatggc attaatgtgt 780
ccttgctttt atagttgtat tttgtacatt ttggattttc ttatataagg tcatagattc 840
ttgagctggt gtggttttta gtgcacttaa tattagcttg cttaaggcat acttttaatc 900
aagtagaaca aaaactatta tcaccaggat ttatacatat agagattgta gtatttagta 960
tatgaaatat tttgaatata catctctgtc agtgtgaaaa ttcagcggca gtgtgtccat 1020
catattaaaa atatacaagc tacagtgtgc cagatcactg aattggaact tttctcctgc 1080
atgtgtatat atgtcaaatt gtcagcatga caaaagtgc agatgttatt tttgtatttt 1140
taaaaaacaa ttggttgtat ataaagtgtt tttatttctt ttgtgcagat cactttttta 1200
actcacatag gtaggtatct ttatagttgt agactatgga atgtcagtgt tcagccaaac 1260
agtatgatgg aacagtgaat gtcaattcag tgatggcaac actgaaggaa cagttaccct 1320
gctttgcctc gaaagtgtca tcaatttgta atttttagtat taactctgta aaagtgtctg 1380
taggtacgtt ttatattata taaggacaga ccaaaaatca acctatcaa gcttcaaaaa 1440
ctttgggaaa ggggtgggatt aagtacaagc acatttggct tacagtaaata gaactgattt 1500
ttattaactg cttttgccca tataaaatgc tgataattac tggaaacctt gccagcttca 1560
cgattatgac taaagtacca gattataatg ccagaatata atgtgcaggc aatcgtggat 1620
gtctctgaca aagtgtgtct caaaaataat atacttttac attaaagaaa tttaatgttt 1680
ctctggagtt ggggctcctt gctttcagag tttgggttaat cagtgttgat tctagatgat 1740
caacataatg gaccactcct gaatgagact taattttgtc tttcaaattt actgtcttaa 1800
atcagtttat taaatctgaa ttttaaaaca tgctgtttat gacacaatga cacatttggt 1860
gcaccaatta agtgttgaaa aatatctttg catcatagaa cagaaatata taaaaatata 1920
tgttgaatgt taacaggtat tttcacaggt ttgtttcttg atagttactc agacactagg 1980
gaaaggtaaa tacaagtga caaaataagc aactaaatga gacctaatat ttggccttcg 2040
attttaaaata tttgttctta taaacctgt caataaaaaa aaatctaaat cactgggtgt 2100
ttaaaaaaaa aaaaaaaaaa aaaaaggcgg ccgctctaga ggatccctcg aggggcccaa 2160
gcttacgcgt gcatgcgacg tcatagctct ctccctatag tgagtcgtat taataggagt 2220
ccaaantgg                                     2229

```

<210> 161

<211> 1920

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (119)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1755)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1766)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1832)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1841)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1915)
 <223> n equals a,t,g, or c

<400> 161
 cagacgtcct gcaggcggct ggcgagtggt agcctgctgc gancccccctga agaggaggca 60
 gatgccgacc tggccgaggg gccccctccc tggacacctg cgctccccctc aagtgaggng 120
 accgtgaccg acatcacgc caactccatc accgtcacct tccgcgaggc ccaggcagct 180
 gagggcttct tccgagaccg cagtgggaag ttctgaatca ccgtttttac tcttcttaa 240
 ctgttttctt ttgggcttg ggtgggactt ccagagatag ggatgggttg ggggcgggt 300
 aattatttta tttaaaaaaa taccgagcag caaaagggga gaagatccca ctactctccc 360
 accacctgcc ctttctctga gggacgttta ccacgaggcc tcaggctggg gatggagaga 420
 gttgctctgg gagttgggt accaccccca gggcaggatg gggacaggat cacctgccc 480
 ggacaccacc attatcattc tcctctagt acgcagcagc tggttctgg agttaaagga 540
 gcattggaag gcccaaacc tctcccttga gtggccaccc cagcctggtt ggctggtttt 600
 ccccttttct cttgtttcaa ttgggtctt accttgaact ctctctctg gctttgcggt 660
 gggctgtgga ggctggtttt raccaaaagt gagtggggcg ggaggaagg gcaggaggaa 720
 gggttgaggt tacttggggc gagtccctc cccttcagag aggtctctat ccttcccagg 780
 gagggaggcg cgctgagacc cttctgctga gagctctgcc ctccccctat cacttgcct 840
 gtgcagaaac gctcatgcac acctggctgc acaggtgtgc acgcattacc cttcgcgtgt 900
 acgttcccat gtgccccgtg aaagcatgtg tggtgcaga cgtgtccaca tgggccttgc 960
 gaacctgggt tagaaaccct ggccaggcga catggggggtg attcacagca caaaagacct 1020
 caccaccaca cctgcactca cccaccttg catgcacctt gctacctgct tgcggcttct 1080
 agyggagggc aggggtcttg cacaggtgct atggcacccc atgctccagg catacagatg 1140
 tggtttctcg gctgcaccg gccaggctgc ggggtgtgcag gcgtctgcta agttgtgtga 1200
 tgtatcagca caggctttga gacgtctgga ccctgtcctt cctcccgtga ggggttcttg 1260
 ttctttctga ctcaggtgac ttttcagccc ttccaattcc cctctttttc tgsccctccc 1320
 tccaactcag ccaaccagg ygtgggcagt cagggaggga gggagtgtgc caccacgttc 1380
 tcagggcagc ccttgactcc taagcccctt cctccttcca ttctgcatcc cctccccatc 1440
 caacctaaat gccacagctg gggctragct gtattcctgt ggagggacct stgccgtgcc 1500

```

tctytgaggt caggctgtgc tgtgtgaatg ggcaggcttt gccccagccc acccctggca 1560
aggtgcactt gttttcttgt ttgtacaagg tgcctgggg gcccgtggct tccctgccag 1620
tgaggagtga cttctccctc tcttccagtc ctgtagggga gacaaaacca gattgggggg 1680
cccaagggga gcatggaaaa ggccggctcc cctgtctttc cttggctgtc agagtcaggg 1740
taacacacac caaantggag tgcggncarc aagtttgara cctgcccgcc ctctcgcag 1800
ctctgctctg tgtcctcagg aaattcacag antctactga ngcaagaaaa ggttgaatcc 1860
tttcccccaa ttccctcctt cccctggttt ccccaaaacc aaaaaaaagc ctgcnacccc 1920

```

<210> 162

<211> 2619

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2546)

<223> n equals a,t,g, or c

<400> 162

```

ctgagagggga cgcgtgccgc ggagccaggc ttactacgtg acccggacac caggcatacg 60
ctagggggcag tcagctgtgc cttctctttc ggagttgttc cgtgctccca cgtgcttccc 120
cttctccact ggctgggata ccccgggctc ggggcgcagt aataattttt caccatgcat 180
cggaaaaagg tggataaccg aatccggatt ctcatagaga atggagtagc tgagcggcaa 240
agatctctct ttgtttagt tggggatcga ggaaaagatc aggtggtaat acttcatcac 300
atgttatcca aagcaactgt gaaggctcgg ccttcagtgc tgtggtgtta taagaaagag 360
ctgggggttta gcagtcaccg gaagaaaaga atgcgacagc tgcagaagaa aataaagaat 420
ggaacactga acataaagca ggacgacccc tttgaactct tcatagcagc cacaacatt 480
cgctactgct actacaacga gaccacaaag atcctgggca atacctcgg catgtgtgtg 540
ctgcaggatt ttgaagcctt aactccaaac ttgctggcca ggactgtaga aacagtggaa 600
gtgggtgggct agtggtcata ctctacgga ccatgaactc actcaagcaa ttgtacacag 660
tgactatgga tgtgcattcc aggtacagaa ctgaggccca tcaggatgtg gtgggaagat 720
ttaatgaaag gtttattctg tctctggcct cttgtaagaa gtgtctcgtc attgatgacc 780
agctcaacat cctgcccata tcctcccacg ttgccaccat ggaggccctg cctcccaga 840
ctccggatga gagtcttggt ccttctgata tggagctgag ggagttgaag gagagcttgc 900
aggacaccca gcctgtgggt gtgttggtgg actgctgtaa gactctagac caggccaaag 960
ctgtcttgaa atttatcgag ggcattctctg aaaagaccct gaggagtact gttgcactcc 1020
agctgctcga ggacggggaa aatctgcagc cctgggattg gcgattgctg gggcgggtggc 1080
atltgggtac tccaatatct ttgttacctc cccaagccct gataacctcc atactctgtt 1140
tgaatttgta tttaaaggat ttgatgctct gcaatatcag gaacatctgg attatgagat 1200
tatccagtcct ctaaattcctg aatttaacaa agcagtgatc agagtgaatg tatttcgaga 1260
acacaggcag actattcagt atatacatcc tgcagatgct gtgaagctgg gccaggctga 1320
actagtgtgtg attgatgaag ctgccgccat cccctcccc ttggtgaaga gcctacttgg 1380
cccctacctt gttttcatgg catccaccat caatggctat gagggcactg gccggtcact 1440
gtccctcaag ctaattcagc agctccgtca acagagcgcc cagagccagg tcagcaccac 1500
tgctgagaat aagaccacga cgacagccag attggcatca gcgcggacac tgcatgaggt 1560
ttccctccag gagtcaatcc gatacgcccc tggggatgca gtggagaagt ggctgaatga 1620
cttgcctgtgc ctggattgcc tcaacatcac tcgtagatgc tcaggctgcc ccttgccctga 1680
agcttgtgaa ctgtactatg ttaatagaga taccctcttt tgctaccaca aggcctctga 1740
agttktcctc caacggctta tggccctcta cgtggcttct cactacaaga actctcccaa 1800
tgatctccag atgctctccg atgcacctgc tcaccatctc ttctgccttc tgccctctgt 1860
gccccccacc cagaatgcc ttccagaagt gcttgcctgt atccagggtg gccttgaagg 1920

```

```

ggagatttct cgccagtcca tcttgaacag tctgtctcga ggcaagaagg cttcagggga 1980
cctgattcca tggacagtgt cagaacagtt ccaagatcca gactttggtg gtctgtctgg 2040
tggaagggtc gttcgcattg ctgttcaccc agattatcaa gggatgggct atggcagccg 2100
tgctctgcag ctgctgcaga tgtactatga aggcagggtt ccttgtctgg aggaaaagg 2160
ccttgagaca ccacaggaaa ttcacaccgt aagcagcgag gctgtcagct tgttggaaga 2220
ggtcatcact ccccggaagg acctgcctcc tttactcctc aaattgaatg agaggcctgc 2280
cgaacgcctg gattacctgg gtgtttccta tggcttgacc ccaggctcc tcaagttctg 2340
gaaacgagct ggatttggtc ctgtttatct gagacagacc ccgaatgacc tgaccggaga 2400
gcactcgtgc atcatgctga agacgctcac tgatgaggat gaggctgacc agggaggctg 2460
gcttgacgcy ttctggaaag atttccgacg gcggttccta gccttgctct cctaccagtt 2520
cagtaccttc tctccttccc tggctntgaa catcattcag aacaggaaca tggggaagcc 2580
agcccagcct gccctgagcc gggaggagct ggaagcact 2619

```

<210> 163

<211> 1419

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (230)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (624)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (697)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1187)

<223> n equals a,t,g, or c

<400> 163

```

gatgcagctg acaccattga aactgacact gccactgctg acaccactgt tgccaacaac 60
gtaccccccg ccgccaccag cctcattgac ctatggcctg gcaacgggga aggggcctcc 120
acactccagg gtgagcccag ggccccacg ccaccctcgg gtactgaggt caccctggca 180
gaggtgcccc tgctggatga ggtggctccg gagccactgc tgccagcagn cgaaggctgt 240
gccacccttc tcaactttga tgagctgcct gagccgccag ccaccttctg tgaccagag 300
gaagtggaag gggagccccct ggctgcccc cagaccccaa ctytgccctc agcccttgag 360
gagctggagc aagagcagga gccggagccc cacctgctaa ccaatggcga gaccaccag 420
aaggagggga cccaggccag tgaggggtac ttcagtcaat cacaggagga ggagtttgcc 480
caatcggaag agctctgtgc caaggtccg cctcctgtgt tctacaacaa gcctccagag 540
atcgacatca catgctggga tgcagaccca gttccagaag aggaggaggg cttcgagggt 600
ggtgattagc ggtggcgcca gccntagget acccttgcca aggccgccca cctgcatcag 660
cctctggcca gacggcccg cgtgcctgca ttcgcancag ctccgcctgg caccactcc 720

```

```

ggattccggc cctggctggg gacttggccg cttccctacc cacagggcct gactttttaca 780
gcttttctct ttttttaaaa agttgatagg agacttgtac agttgactgg ctttcctctc 840
gttggtagtt gagacgctgt tgcaaattcc acccctcctt ccctggtcca gattgtagct 900
cttagtcctc cctgctcagc tggccgggtt ggaggcctca ccctgcttgg ggcttggcgt 960
ggggggagct ctggtgggaa aatgtccccc acctcttttc ctagttttat gtttcttggg 1020
aaaatatcac tttgtattct ctgtccaggg cttcagatat tttgcacgaa ttttaaaaca 1080
tggcaataaa tggctcgtgg gctctggctc cctgggaccc cctccccgcc cttcttttga 1140
ccccttcctg tctggcccaa aggaagtagc aggccagct ggggccnctc ggctaccccc 1200
cgtctcctgc cgggcagttc ccaggttgga ggccctaggc gcggttcagg tcagggtat 1260
ggatggggcc caggggcttt ggtggccct ccccaactcc ttctctttg cttgggttcc 1320
tttttcacgt ttagtaactg tttttttttt tttttgaaa gcacaaactt ctgtaacggg 1380
tcgtgctcat gtctgttaat aaagaaatcc agatccagg 1419

```

<210> 164

<211> 3810

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (189)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2523)

<223> n equals a,t,g, or c

<400> 164

```

aattttcatg atctttgtat atttatatat atatattttw aaattttgca ttttracttaa 60
agtgccatga gaaaatttgc atactgcaag gtggctcctag ccacctcctt gatttgggta 120
ctcttgata tgctcctgct gctttacttc agtgaatgca acaaatgtga tgaaaaaaag 180
gagagaggnc ttctgctgg agatgttcta gagccagtag aaaagcctca tgaaggctct 240
ggagaaatgg ggaaaccagt cgtcattcct aaagaggatc aagaaaagat gaaagagatg 300
tttaaaatca atcagttcaa tttaatggca agtgagatga ttgcaactca cagatcttta 360
ccagatgtta ggttagaagg gtgtaaaaca aagggtgtatc cagataatct tcctacaaca 420
agtgtggtga ttgttttcca caatgaggct tggagcacac ttctgcgaa tgccatagt 480
gtcattaatc gtcaccaag acacatgata gaagaaattg ttctagtaga tgatgccagt 540
gaaagagact ttttgaaaag gccttttagag agttatgtga aaaaactaaa agtaccagtt 600
catgtaattc gaatggaaca acgttctgga ttgatcagag ctagattaaa aggagctgct 660
gtgtctaaa gccaagtgat caccctcctg gatgccatt gtgagtgtac agtgggatgg 720
ctggagcctc tcttgccag gatcaaacat gacaggagaa cagtgggtgtg tcccatcatc 780
gatgtgatca gtgatgatac ttttgagtac atggcaggct ctgatatgac ctatggtggg 840
ttcaactgga agctcaattt tcgctggtat cctgttcccc aaagagaaat ggacagaagg 900
aaaggtgatc ggactcttcc tgtcaggaca octaccatgg caggaggcct tttttcaata 960
gacagagatt actttcagga aattggaaca tatgatgctg gaatggatat ttggggagga 1020
gaaaacctag aaatttcctt taggatttgg cagtgtggag gaactttgga aattgttaca 1080
tgctcacatg ttggacatgt gtttcggaaa gctacacctt acacgtttcc aggaggcaca 1140
gggcagatta tcaataaaaa taacagacga cttgcagaag tgtggatgga tgaattcaag 1200
aatttcttct atataatttc tccagggtgtt acaaaggtag attatggaga tatatcgtca 1260
agagttggct taagacacaa actacaatgc aaaccttttt cctggtacct agagaatata 1320

```

```

tattcctgatt ctcaaattcc acgtcactat ttctcattgg gagagatacg aaatgtggaa 1380
acgaatcagt gtctagataa catggctaga aaagagaatg aaaaagttgg aatttttaaat 1440
tgccatggta tggggggtaa tcagggttttc tcttatactg ccaacaaaga aattagaaca 1500
gatgaccttt gcttgatgt ttccaaactt aatggcccag ttacaatgct caaatgccac 1560
cacctaaaag gcaaccaact ctgggagtat gacccagtga aattaaccct gcagcatgtg 1620
aacagtaatc agtgcttga taaagccaca gaagaggata gccagggtgcc cagcattaga 1680
gactgcaatg gaagtcggtc ccagcagtgg cttcttcgaa acgtcaccct gccagaaata 1740
ttctgagacc aaattttaca aaaaacgaaa aaaaataagga ttgactgggc tacctcagca 1800
tacattttctg ccacattctt aagtagcaaa aaaggaaaag tgctttcctc ctctgcagga 1860
tgtaaggttt atcagccatt aaaacttaga cttctctagc ttttactag ctgtgaacca 1920
gccttcctgt ccatggacgt gaaactgcat agtaatgaga ctgtgcacac tgatgtttac 1980
aagattgaaa gagtctttct ccgaaaatca tggtaaagaa tactgagaca atgaaaaaaa 2040
atcaacaaaa tatgctttct ggagaactgt accttttatg gtttgcttgc acatcagtag 2100
tttctgctga acgtgctgtc ataatagaaga gatttccaag attttttttc ctgattagaa 2160
ctggtagcca gtatatataa tattgatata aaaataaaaag aactggaacc agattcagaa 2220
tcatgaaaac aacattttta caacaacaaa aaaactatat taaacagggt ttaaaggaaa 2280
ttaaaacaga actatgagaa gtacaatttg ttatagtata gtatcaaatt tctatataga 2340
ttttatacct cagtggggaa aaataactga ttccaatgac attcattttg ttttcatctg 2400
tgatagtcac ggatgctttt attttccttg ggggtgctgaa attgagctga aaaaaaagg 2460
ctctttgaat atagttttaa tttctctcta cagttttttt tgtttggtt gtgggctgtt 2520
ggnaattgta atttttaatt gccttctaaa aaatggaaat ttaacaatgt ctgatctcag 2580
ctgaacaaat tagatgtttc agttgctctt ggggtcaactg gcttacagat ttacatgtgc 2640
acacacacac aaatttctta tcacattttc gacttcttca cttgacctaa ctgattatgc 2700
gaaataccca agattcatgc tactgtacca cagatttggt ttcacagcaa taaatcttca 2760
gttctttgtt tatgattcca cttacaaaaa ggcctgcaga agtgatttat tatttggtta 2820
tttgagagata atacatttga tgggtttttg gaaaaccttt ttcactccat actcagatat 2880
gcttcattgt caaatgcata tttagattag attattgaat tgtaatgttt atctgctgct 2940
tttttttaaat aaaatttgac tgaaaatgtt taattggcat tttttaatga cttagccaaa 3000
gaagtgcagc tattattcca tattaatagg cttgcatttc ttttcctaaa tcttatttag 3060
gctaaatcag ttttattttt ctctgatttt ttttaatacc acagaatcac ctgagtgtca 3120
attgaaagtt gtcaattaaa aggtaacctt ttaatctcgt aggaggaatc tcattaagac 3180
atttttcctg atatgtagag cagtctgttg gcaaaaatgc atatattttc tttcatattt 3240
gtaaaattat atttaattga attcctttct ttgattatca aggactttca ctgcaggcag 3300
tgctatttct tgtgcctaag aatgtttcca aaagtcgcat cgctaagat atttgccaag 3360
ttgagtgtac acaaagtttc tcatactctg ttcaagttaa tcaacatcaa gcacrtgggg 3420
atgcttttag gtgagtctat agtacaaaat gcataaacca tgtccccagg aaatttgaaa 3480
ggaagcagggt gctgaatgga atttttttcc ttttccatga gctgtgttaa ttctatctcc 3540
agtaggccta atgcttgaat aagcaagatg tctaataaat aaattatttt catgctcaga 3600
atttcagggt tttgtactcc agcatagctt ggtcttattt cttactgtat gaaagcttaa 3660
cagcaatgtg atttaagggt ttgtttttaa tgggagatgt aagtgattta attcatgggt 3720
acttttagaa cctgatagat aatcccattg cctttatttt tctaattaaa gaattcctaa 3780
atactttgaa aatacaaaat attcctgaaa 3810

```

<210> 165

<211> 817

<212> DNA

<213> Homo sapiens

<400> 165

```

acagctgtga gccactgcgt ccagccctaa gatgattcat acctatcggg gaaaacagtg 60
ccactggaga gaacaggctg gcctctgcac tctggattgg tgacaggagt tatccaggcc 120

```

```

tgtctgaagg caatagcagg cctcccatcc ctggaccgcc ttatgtggcc tccccgacc 180
tctggtccca ctgggaagac tcagccctgc cccaccaag cctgaggcct gtgcagccca 240
cctgggaggg ctccctcagag gcaggcctgg actgggctgg ggccagcttc tccccaggga 300
ctccratgtg ggcggccttg gatgagcaga tgctgcagga gggcatccag gcmtocttc 360
ttgacggggc agcccaggaa cccagagcg caccatggct gtccaagtcc tctgtctcct 420
ctctgcggtc gcagcagctg gagcgcatgg gcttccctac ggagcaggcg gtggtggcac 480
tggcagccac aggcctgtg gagggtgccg tgtcactgtt ggttggagga caagtgggca 540
ctgagaccct ggtgacccat ggaaagggtg ggcctgcca ctccgagggt cctgggcctc 600
cctagcccag gcagagagtg gggcacaggc aggccttggt gtgctaagggt ctgggctgca 660
tgtgggtagc ccgagctcct actctgtcta aagagggcca cagtggggag caggggcacc 720
tctggaggca ggagaggccc ccagcatgc tgccctagta cgtgtttaga ataaaaacca 780
gtttgttttt caacctggac ctcttgtaa aaaaaaa 817

```

<210> 166

<211> 1578

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g,.or c

<220>

<221> misc feature

<222> (38)

<223> n equals a,t,g, or c

<400> 166

```

aggcagaagt cttctnttct ctggcctcac cccctcanto gccatagagc tgggcctggc 60
cttgcctggga atggaggcat ccttccaaac ctgggggagc ggggtggggg gtggtwgtgg 120
tgggagggaa accatgtctt gctaaacctg tttctggtgc ctcccatccc cagacccacc 180
agacaccaca cagcagacaa tacacaccca ctgcacaaag cttccatcca catgtgttgt 240
actttcagct ctaggcatgc agacaacccc acacggccac accaccacat gcccaagtgt 300
acacacacag agccacaccg tccctctggg cctgctggct cctcccttgg ctttcccttg 360
gcccacttcc agggcccagg tgctgcaact aaatgtgaaa gctcagtggc cgctccttct 420
ttcagcccat caaccagcat tggctccata gggaagcaca ggggactcac cctctttcat 480
atcccttgcc ctgcctgaa atggacaatc actttttggg ataggttgaa atttttaaag 540
agcctgcac attcggttcc ctcaaaggga agcccttgcc agtgggggtt tgaaagagaa 600
tttttgaac caacattcaa attctgcctc atctggaggg aaaccaaaat tgggaggggg 660
aagaggaccc ctgatgtttt gctgcttcca gagatattag aaactgactc acttgattgg 720
aaaatggaca aaagtgcctt gacgtggagg gtgggcacca gatggggacc agccttgcca 780
actgctgctg tggcctccag cttggctggt tttgcaggcc gccagcagga aggcgaagg 840
ggtagtacag caagaggcac tggcggggca gcaggcctgc aggagctgtt tttccattgc 900
taggcctgac ccctctctac ctgtgagcgt tcaggggggtc cctgagatag tttagatgcc 960
ccccatctt agacctcagc tcccacagtg ccttttaagg gggacctcac ctctgtgca 1020
cagccacccc actttcctct gcttccctgg cacascccag gcatagacga gctggcggtg 1080
gaccagttc tcccccttt tcagccccac agctgctgcc acaggggcca actagggcca 1140
ggtggaagg gagctgagaa gccaaacct agcccagggg tgctgtggga actgggatcc 1200
aattttagc ttcctgcctg gcttcagaga gccagcaac cttctaggcc tgctttccag 1260
acttctgaga tagcctggga tgagcaatcc tgttacagta catctggacc ttccctacct 1320

```

```

gggctctggg gaggctgtgg gcctggagag ggaaaaggag ggaggggggtg tctgcaccac 1380
ctgggaagat agcacaaggc ctaatgaggt caccctgact cccaccccca gcatttcatt 1440
cataccagat aatagctgca ttactgccaa ctgaccttat aaccctctgc accttcaaaa 1500
agattcatgg tttttaattg ctgcttttaa taacatttgt taaagttaaa aaaaaaaaaa 1560
aaatcttcgg gggggggg

```

<210> 167

<211> 1694

<212> DNA

<213> Homo sapiens

<400> 167

```

gccacgcgt ccgccacgc gtccgccac gcgssgggc ggcgcgcgcg acggccgggc 60
gctcctgaag cagcagttat ggagcttccc tcagggccgg ggccggagcg gctctttgac 120
tcgcaccggc ttccgggtga ctgcttccta ctgctcgtgc tgctgctcta cgcgccagtc 180
gggttctgcc tcctcgtcct gcgcctcttt ctcgggatcc acgtcttcct ggtcagctgc 240
gcgctgccag acagcgtcct tcgcagattc gtagtgcgga ccatgtgtgc ggtgctaggg 300
ctcgtggccc ggcaggagga ctccggactc cgggatcaca gtgtcagggt cctcatttcc 360
aaccatgtga cacctttcga ccacaacata gtcaatttgc ttaccacctg tagcaccgtg 420
agtgaagcgc aggccgarag cgccacgggg cggttccttg gggcccagct gaaggccccc 480
ctgtcccccac tcgcgttccs catggaggat actgagcctt acccctaacc ccgacccctc 540
acccaacatg tcagtttttt ttttcatttt cctcaatatt ttttctcttg ctttctcttc 600
tcctgggttc cagcctctac tcaatagtcc cccagcttt gtgtgctggc ctcggggctt 660
catggagatg aatgggcggg gggagttggg ggagtcactc aagagattct gtgcttcac 720
gaggttccc cccactcctc tgctgctatt ccctgaggaa gaggccacca atggccggga 780
ggggctcctg cgcttcagtt cctggccatt ttctatccaa gatgtggtac aacctcttac 840
cctgcaagtt cagagacccc tggctctctg gacgggtgtc gatgcctcct gggctctcaga 900
actgctgtgg tcacttttctg tccctttcac ggtgtatcaa gtaagggtggc ttgctcctgt 960
tcatcgccaa ctagggggaag cgaatgagga gtttgactc cgtgtacaac agctgggtggc 1020
caaggaattg ggccagacag ggacacggct cactccagct gacaaagcag agcacatgaa 1080
gcgacaaaaga cccccagat tgcgccccca gtcagcccag tcttcttttc ctccctcccc 1140
tggtccttct cctgatgtgc aactggcaac tctggctcag agagtcaagg aagttttgct 1200
ccatgtgccca ttgggtgtca tccagagaga cctggccaag actggctgtg tagacttgac 1260
tatcactaat ctgcttgagg gggccgtagc tttcatgcct gaagacatca ccaagggaac 1320
tcagtcccta cccacagcct ctgcctccaa gtttcccagc tctggcccgg tgacccctca 1380
gccaacagcc ctaacatttg ccaagtcttc ctggggccgg caggagagcc tgcaggagcg 1440
caagcaagca ctatatgaat acgcaagaag gagattcaca gagagacgag cccaggagggc 1500
tgactgagct caaaggaaca ggatggcacc cagagccgca ggacggagac tgggggcagc 1560
cctcacccaa ctcacaacag gctggatggg tgggtggtaa aaaggaagg atgaggctcc 1620
cccaatgtca cattaaattc atggttttca ttcaacaaaa aaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaact cgag

```

<210> 168

<211> 1636

<212> DNA

<213> Homo sapiens

<400> 168

```

ggcacgagcg ccggagcgcg ctagccgcat tgcgagccga acccgggagc tggcgccatg 60
gtgctgttgc acgtgctgtt tgagcacgcg gtcggctacg cgctgctggc gctgaaggaa 120
gtggaggaga tcagtctgct gcagccgagc gtggaggagt ccgtgctcaa cctgggcaaa 180

```

```

ttccacagca tcgttcgtct ggtggccttt tgtccctttg cctcatccca ggttgccttg 240
gaaaatgcc aacgccgtgtc tgaaggggtt gttcatgagg acctccgcct gctcttgag 300
accacactgc cgtccaaaaa gaagaaagta ctcttgggag ttggggatcc caagattggt 360
gccgcaatac aggaggagtt agggatcaac tgccagactg gaggagtcac agctgagatc 420
ctgcgaggag ttcgtctgca cttccacaat ctgggtgaagg gtctgaccga tctgtcagct 480
tgtaaaagcac agctggggct gggacacagc tattcccgctg ccaaagttaa gtttaattgtg 540
aaccgggttg acaatatgat catccagtcc attagcctcc tggaccagct ggataaggac 600
atcaatacct tctctatgct tgtcagggag tggtaggggt atcactttcc ggagctggtg 660
aagatcatca acgacaatgc cacatactgc cgtcttgccc agtttatttg aaaccgaagg 720
aactgaatga ggacaagctg gagaagctgg aggagctgac aatggatggg gccaaaggcta 780
aggctattct ggatgcctca cggtcctcca tgggcatgga catactctgc attgacttga 840
taaacatcga gagcttctcc agtcgtgtgg tgtctttatc tgaataccgc cagagcctac 900
acacttacct gcgctccaag atgagccaag tagcccccag cctgtcagcc ctaattgggg 960
aagcggtagg tgcacgtctc atcgcacatg ctggcagcct caccaacctg gccaaagtac 1020
cagcatccac agtgcagatc cttggggctg aaaaggccct gttcagagcc ctgaagacaa 1080
ggggtaacac cccaaaatat ggactcattt tccactccac cttcattggc cgagcagctg 1140
ccaagaacaa aggccgcac tcccgatacc tggcaaacaa atgcagtatt gcctcacgaa 1200
tcgattgctt ctctgaggtg cccacgagtg tattcgggga gaagcttcga gaacaagttg 1260
aagagcgact gtccttctat gagactggag agataccacg aaagaatctg gatgtcatga 1320
aggaagcaat ggttcaggca gaggaagcgg ctgctgagat tactaggaag ctggagaaac 1380
aggagaagaa acgcttaaaag aaggaaaaga aacggctggc tgcacttgcc ctgcgctctt 1440
cagaaaacag cagtagtact ccagaggagt gtgaggagay gagtgaacaa cccaaaaaga 1500
agaaaaagca aaagccccag gaggttcctc aggrgratgg aatggaagac ccatctatct 1560
ctttctccaa acccaagaaa aagaaatctt tttccaagga ggagttgatg agtagcgatc 1620
ttgaagagac cgctgg 1636

```

<210> 169

<211> 667

<212> DNA

<213> Homo sapiens

<400> 169

```

ggcacgagck mgttttcttt tcctctaggc agagaagagg cgatggcggc gatggcatct 60
ctcggcgccc tggcgctgct cctgctgtcc agcctctccc gctgctcagc cgaggcctgc 120
ctggagcccc agatcacccc ttctactac accacttctg acgctgtcat ttccactgag 180
accgtcttca ttgtggagat ctccctgaca tgcaagaaca ggggtccagaa catggctctc 240
tatgctgacg tcggtggaaa acaattccct gtcactcgag gccaggatgt ggggcgttat 300
caggtgtcct ggagcctgga ccacaagagc gccacgcag gcacctatga ggtagattc 360
ttcgacgagg agtcctacag cctcctcagg aaggctcaga ggaataacga ggacatttcc 420
atcatccgc ctctgtttac agtcagcgtg gaccatcggg gcacttgga cgggccctgg 480
gtgtccactg aggtgctggc tgcggcgatc ggccttgtga tctactactt ggccttcagt 540
gcgaagagcc acatccaggc ctgagggcgg caccacagcc ctgcccttgc ttcttcaat 600
aaacatcaca ggacctggga ctgcacagga aaaaaaaaaa aaactcgrg gggggcccg 660
tacccaa 667

```

<210> 170

<211> 3598

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (16)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (22)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (964)
 <223> n equals a,t,g, or c

<400> 170

```

ngcggtagccg tcgtgntgtg tngtgtttct gaaagctttg tggtttcggt gagctctcag 60
accgattttct agcgtccgtg ccggggacag gtgtcagagg tcgrctgctg cagacatggc 120
ggcctccacc gcggccggga agcagcggat tcccaaagtg gccaaaggta aaaacaaagc 180
cccggctgag gtacagataa ctgctgaaca actcttaaga gaggctaaag aaagagaact 240
tgagcttctt ccacctccac ctcaacagaa gatcacagat gaagaagaat taaatgatta 300
taaactaagg aaaaggaaga cttttgaaga taatataaga aaaaacagga ctgtgattag 360
taactggata aaatacgcac aatgggaaga aagcctaaag gagattcaaa gggctcgatc 420
catatacgag cgtgcttttag atgtagacta ccgaaatatt acactctggc tgaaatacgc 480
agaaatggaa atgaagaatc gccaaagtcam ccatgctcga aatatctggg accgggccat 540
aacaacgctg cctcgagtta atcagttctg gtacaagtac acgtacatgg aggaaatgtt 600
gggaaacggt gccgggtgcc ggcaggtgtt tgagcgtggt atggagtggc agcctgagga 660
gcaagcctgg cactcctaca tcaactttga gctgagatac aaagaggtgg atcggggccc 720
caccatttat gagcgakttg tcctcgtgca ccctgatgtt aagaactgga tcaagtatgc 780
ccgctttgaa gaaaaacatg cttattttgc ccatgcacgg aaagtgtatg agagagctgt 840
ggaattcttt ggagatgaac atatggatga gcacctttat gttgcctttg ccaagtttga 900
agaaaatcag aaagagtttg aaagggtacg agtgatttac aagtatgcc tggacagaat 960
ttcnaaaca gatgcccaag aactctttta aaattatacc atctttgaga agaagtttgg 1020
tgataggcgg ggtattgaag atatcattgt gagcaaacgg agattccagt acgargaaga 1080
agtgaaggcg aatccacaca attatgatgc atggtttgat tacttgcgct tggtagaaag 1140
tgacgcagaa gctgaagccg tgagagaagt ctatgaaagg gccattgcca atgtcccacc 1200
cattcaggag aagaggcact ggaagcgcta catttatctt tggatcaact atgcactcta 1260
tgaagaattg gaggcaaagg atcctgagag gacaagacag gtgtatcaag cctctttgga 1320
actaatcctt cacaaaaagt tcacatttgs caaatgtgg atactgtatg cacagtttga 1380
aatacgcagag aagaatctgt cattagccag aagagcattg ggaacttcca taggcaaattg 1440
tccaaagaac aaattattta aggtttacat agaattggag ctacagcttc gagaatttga 1500
cagatgccgg aagctttatg aaaagttcct ggaatttggga cctgaaaatt gtacctcatg 1560
gattaaattc gctgaattag agacaatcct tggatgattt gacagagcac gggcaatcta 1620
tgaattagcc atcagtcagc cacgtttaga catgccagag gtgctttgga aatcatatat 1680
tgattttgaa attgagcagg aagaaacaga aagaacacga aacctttacc ggcggttgct 1740
tcaacggacg cagcatgtca aggtatggat cagctttgct cagtttgagt tgtcttcagg 1800
aaaagaagga agtttgacta aatgcagaca aatttatgaa gaagctaaca aaaccatgcg 1860

```

```

aaactgtgaa gaaaaggaag agagacttat gctgctggaa tcttggcgaa gttttgaaga 1920
agaatttgga acagcttcag ataaggagag agtagacaaa ctcatgccag agaaagtcaa 1980
gaagagaaga aaggtccaga ctgatgatgg gtctgatgca ggctgggaag aatactttga 2040
ttacatcttt ccagaagatg ctgccacca acctaacctc aaactcctgg ccatggccaa 2100
actgtggaag aaacagcagc aggaaaagga ggatgctgag caccatccag atgaggacgt 2160
cgatgagagt gaatcctgat ctttttttca tagacaaatg ttttgttatt ttataaatt 2220
aattgtttgg aactcctgtg actcctggaa gttcttatat atttcaccag taagaaattg 2280
attggatatc ttgatggcta ctttttaagt ttttttttaa atgctcctgg gttagctagg 2340
ggtagggatt gcaagtaaag gactttttta actgctggat ttgtttttcc aacygagtc 2400
aaacttttct aatgtctgtc cacatcatgc attaggaaat gtaattaagg taacattcta 2460
cagttacttt tcatgtcata ccataaaga tagtttatgc attcatctga aatgtgtaac 2520
tttttcatgt cttcagagtc acagacttga gttcatttcc cagctactgc cactcatgat 2580
tatataactt aattttcatt ttctctattc aaaaaatggg ccaatagttt gacagctcat 2640
tttgaagatw acattataaa aggaatatac ctgggtgggtg catagtaagt gctcagtaaa 2700
ttgtttgttc taagccactt ttaaaaatgg tttcattcct tgtagaattg aatgcgagt 2760
gattaatwat ttaccttact ttcttactag tgtccagtta tattgttttt tagaacaaca 2820
cttggaatat aatttgcagt gattatatat ctgaacaagg ttcagaaaac attgtttact 2880
aagaatttag tctaataatt ycagttaggc gctcatcagt tctccagagt ggttgagt 2940
gtaatacctt gtttaaagaa taatggcttg ttcacgtgtg tgctatgaaa aatgatgtcc 3000
catgttcaca taaatttggg aaattctgga ctaagactta agtctcgtaa atcaaactc 3060
tttatagtta ggcttctgta cattatgtat ctccagtagc aatgttgcca tattatttat 3120
ttcccaaact tagtggaaca tggagtcatt tctacctaga gtaccagtaa acatctccca 3180
gtgtgctata gtagaaaatg tctactcctc actgctgaca tgttaaactt actcttggtt 3240
tagagcatgt gtagaaacac ctaaggtagc tctatgctaa ataatgaaga gtagcacaag 3300
aatgaatgta tttgctgata cgttgctcac attctcaagc aaaaattcaa ctgcattaac 3360
cgatctgaga gttttccttt aacctggact gtgtttctca agcacatttt ttctttgttc 3420
actgcccag gactagaact gtatttttaa gggtgttttc ccctaaaagg acctttagta 3480
agcaaattta ttattaaatg tgcacatctt attcacccaa gggaataaaa gctacttcgt 3540
aatgttgtaa ctaaatttta tcttgaaaat aaataacagt gtttgaggac araaaaaa 3598

```

<210> 171

<211> 940

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (919)

<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (935)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (938)
 <223> n equals a,t,g, or c

<400> 171
 gtgggggtntc tntgtgttct cccactgacc acgcttttctt tagtgactcc tgattgcctc 60
 ctcaagtcgc agacactatg ctgcctccca tggccctgcc cagtgtatct tggatgctgc 120
 tttcctgcct catgctgctg tctcaggttc aagggtgaaga accccagagg gaactgccct 180
 ctgcacggat ccgctgtccc aaaggctcca aggccatagg ctcccactgc tatgccttgt 240
 ttttgtcacc aaaatcctgg acagatgcag atctggcctg ccagaagcgg ccctctggaa 300
 acctggtgtc tgtgctcagt ggggctgagg gatccttcgt gtccctccctg gtgaagagca 360
 ttggtaacag ctactcatac gtctggattg ggctccatga cccacacag ggcaccgagc 420
 ccaatggaga aggttgggag tggagtagca gtgatgtgat gaattacttt gcatgggaga 480
 gaaatccctc caccatctca agccccggcc actgtgcgag cctgtcgaga agcacagcat 540
 ttctgagggtg gaaagattat aactgtaatg tgaggttacc ctatgtctgc aagttcactg 600
 actagtgcag gagggaagtc agcagcctgt gtttgggtgt caactcatca tgggcatgag 660
 accagtgtga ggactcacc tggaagagaa tattcgctta attcccccaa cctgaccacc 720
 tcattcttat ctttcttctg tttcttcctc cccgctgtca tttcagtcctc ttcattttgt 780
 catacggcct aaggctttaa agagcaataa aatttttagt ctgcaaaaaa aaaaaaaaaa 840
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaanaanaa 940

<210> 172
 <211> 1458
 <212> DNA
 <213> Homo sapiens

<400> 172
 gtaacagacg gcggcagtg gagaaagccg aagatggcgg tccccgcggc gctgataccta 60
 cgggagagcc ccagcatgaa gaaagcagtg tcaactgataa atgcaataga tacaggaaga 120
 tttccacggt tgetcactcg gattcttcaa aaacttcacc tgaaggctga gagcagtttc 180
 agtgaagaag aggaagaaaa acttcaagcg gcattttctc tagagaaaca agatcttcac 240
 ctagtctctg aaacaatatc atttatttta gaacaggcag tgtatcacaa tgtgaagcca 300
 gcagctttgc agcagcaatt agagaacatt catcttagac aagacaaagc tgaagcattt 360
 gtcaatackt ggtcttctat gggtaagaa acagttgaaa agttccggca gagaattctg 420
 gctccctgta agctagagac ygttggatgg cagcttaacc ttcagatggc tcaactctgt 480
 caagcaaaac taaaatctcc tcaagctgtg ttacaactcg gagtgaacaa tgaagattca 540
 aagagcctgg agaaagtctt tgtggaattc agtcacaagg agttgtttga tttctataac 600
 aagctagaga ctatacaagc acagctggat tcccttacat gatgttttcg aagactgttt 660
 ttttcatcac gctcctgcca cctcattatt ttgcattgaa gatacattgc caggtttgtgt 720
 tttctgaagg attcagtgac ttgctttctg taaattatat ggcttatcac ttcttagaca 780
 aataacaacc aatagagatc attgttaaga atactgaggt tctaataatac tttctttagt 840
 tctgtgagcc aacagtaatt attaagaaca ctttcccttt aaaggaaaca aaagtgaata 900
 ccatattgtt tttactgtca tagtgttgct ttottgcctg tcctgcttag tttttacttg 960
 ctggatgata ccataatgta tcaaggagcg tccatggata caagataaga tgtgtacctt 1020
 agtagaatac agagcttttg taattacatg aataaaatta agaaaatagc catatacaat 1080

```

caaatacact atggcatttt tatttgaata tgatgagtat attttgcttc ggaaataata 1140
taggaaggaa atgtaaaata gtgagtagta tggatcagat taattccagt ctgagcttct 1200
ctgtcaactt cagtttctct ctcagtttaa tgatttaata atagtccagg tttttgtgtg 1260
tttttcttta tactgcaaat taataatgat tcactttata gtttgggaga cagaatcagg 1320
tcttgaataa aataattgta atgagtgcta aatgggcacc attattcgaa tcagatacct 1380
tttatattct ctttcataa atacgttgat ttctgtcaat aaaatttttg tgtcttagga 1440
aaaaaaaaaa aaagtcga 1458

```

<210> 173

<211> 2709

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2595)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2622)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2659)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2670)

<223> n equals a,t,g, or c

<400> 173

```

ggggctgcga gagaggaagc tctttcgcgg cgctacggcg ttggcaccag tctctagaaa 60
agaagtcagc tctgggtcgg agaagcagcg gctggcgctgg gccatccggg gaatgggagc 120
cctcgtgacc tagtggttgcg gggcaaaaag ggtcttgccg gcctcgcctg tgcaggggag 180
tatctgggag cctgarcgag gcgtgggagc cttgggagcc gccgcagcag ggggcacacc 240
cggaaccggc ctgagcgccc gggaccatga acggggaggc catctgcagc gccctgcccc 300
ccattcccta ccacaaactc gccgacctgc gctacctgag ccgcggcgcc tctggcactg 360
tgtcgtccgc ccgccacgca gactggcgcg tccagggtggc cgtgaagcac ctgcacatcc 420
acactccgct gctcgacagt gaaagaaagg atgtcttaag agaagctgaa attttacaca 480
aagctagatt tagttacatt cttccaattt tgggaatttg caatgagcct gaatttttgg 540
gaatagttac tgaatacatg ccaaatggat cattaaatga actcctacat agggaaactg 600
aatatcctga tgttgcttgg ccattgagat ttgcgcatcct gcatgaaatt gcccttggtg 660
taaattacct gcacaatatg actcctcctt tacttcatca tgacttgaag actcagaata 720
tcttattgga caatgaattt catgttaaga ttgcagattt tgggtttatca aagtggcgca 780
tgatgtccct ctcacagtca cgaagtagca aatctgcacc agaaggaggg acaattatct 840
atatgccacc tgaaaactat gaacctggac aaaaatcaag ggccagtatc aagcacgata 900
tatatagcta tgcagttatc acatgggaag tggttatccag aaaacagcct tttgaagatg 960
tcaccaatcc tttgcagata atgtatagtg tgtcacaagg acatcgacct gttattaatg 1020

```

```

aagaaagttt gccatatgat atacctcacc gagcacgtat gatctctcta atagaaagtg 1080
gatgggcaca aaatccagat gaaagaccat ctttcttaaa atgtttaata gaacttgaac 1140
cagttttgag aacatttgaa gagataaactt ttcttgaagc tgttattcag ctaaagaaaa 1200
caaagttaca gagtgtttca agtgccattc acctatgtga caagaagaaa atggaattat 1260
ctctgaacat acctgtaaat catgggtccac aagaggaatc atgtggatcc tctcagctcc 1320
atgaaaatag tgggtctcct gaaacttcaa ggtccctgcc agctcctcaa gacaatgatt 1380
ttttatctag aaaagctcaa gactgttatt ttatgaagct gcatcactgt cctggaaatc 1440
acagttggga yagcaccatt tctggatctc aaagggtgc attctgtgat cacaagacca 1500
ctccatgctc ttcagcaata ataaatccac tctcaactgc aggaaactca gaacgtctgc 1560
agcctggtat agcccagcag tggatccaga gcaaaaggga agacattgtg aaccaaata 1620
cagaagcctg ccttaaccag tcgctagatg cccttctgtc cagggacttg atcatgaaag 1680
aggactatga acttgttagt accaagccta caaggacctc aaaagtcaga caattactag 1740
acactactga catccaagga gaagaatttg ccaaagttat agtacaaaaa ttgaaagata 1800
acaaacaaat ggggtcttcag ccttaccctg aaataactgt ggtttctaga tcaccatctt 1860
taaatttact tcaaaataaa agcatgtaag tgactgtttt tcaagaagaa atgtgtktca 1920
taaaaggata tttatatctc tgttgctttg acttttttta tataaaatcc gtgagtatta 1980
aagctttatt gaaggttctt tgggtaaata ttagtctccc tccatgacac tgcagtattt 2040
tttttaatta atacaagtaa aaagtttgaa ttttgctaca tagttcaatt tttatgtctc 2100
ttttgttaac agaaaccact tttaaaggat agtaattatt ctgtttata acagtgcctt 2160
aaggatgat gtatttctga tggaagccat ttccacattc atgttcttca tggattattt 2220
gttacttgkc taarawgcaa tttgatttta tgaagtatat accctttacc caccagagac 2280
agtacagaat ccctgcccta aaatcccagg cttaattgcc ctacaaaggg ttattaattt 2340
aaaactccat tattaggatt acatttttaa gttttattta tgaattccct ttaaaaatga 2400
tatttcaaag gtaaaacaat acaatataaa gaaaaaata aatatattaa taccggcttc 2460
ctgtccccat ttttaacctc agccttccct actgtcacca acaaccaagc taaataaagt 2520
caacagcctg atgtgtatct ttctgtccct ttcttctgc ttatatattg gaacatatgc 2580
tcatttgaga aaggntcttt ctgcatatta ttattataat tntacatcat actgcaacct 2640
gctttttgca tttaatagna caggcttccn ggtcaggat ggggtctaact taccctttta 2700
cttgggtggc 2709

```

<210> 174

<211> 1013

<212> DNA

<213> Homo sapiens

<400> 174

```

ggtgacatcc cagtgcctccg cgtgcaggca aggcacacct gaagcgtgcc atcctggggc 60
aggaggaggc gctgcggctg cacgccctgt gccgcgtcct gcgcgaggtg gacctgcttc 120
gggctgtgat ctccagacg ctgcagcgt cactggccaa gtatgcggag ctgcaccgtg 180
aggatgactt ctgtgaggct gccgaggccc cggacatcca gcctaagacc caccagaagc 240
cagaggccag gatgccacgc ctgtcccagg ggaagggggc tgacatcttc catcggtgg 300
ggcccctgtc tgtgttctca gccaaagacc ggtggcggct ggtggggccc gtccacctga 360
cccaggaga gggcggtttt ggcctcacgc ttccggggaga ctgcctgtc ctcatcgctg 420
ccgtcattcc agggagccag gccgcggcgg ctggcctgaa ggaggggcgc tacatttgtt 480
cagtgaatgg gcagccatgc aggtggtgga gacacgcgga ggtggtgacg gagctgaagg 540
ctgcgggaga ggcggggcgc agcctgcagg tgggtgcgct gctgcccagc tctagactgc 600
ccagcttggg ggaccgcccg cccgtcctgc tgggccccag ggggcttcta aggagccaga 660
gggagcatgg ttgcaagacc ccggcatcca cgtgggccag tccccgggccc ctctcaact 720
ggagccgaaa ggcccagcag ggcaagactg gaggetgccc cagccctgtg cccagtgaa 780
gccagctccg gcctcatcct tgaagcacc aggggtggccg tgagggccag gatccctgca 840
cgctcagcc ctggctccag ctggcagcaa gcaccgagca tgccctcccc acccagagga 900

```

```
cctccgggca atgcctgtcc cgcctcatgc tggaggctgc ctccggcacc tgcctgcccc 960
ttaaagactg gtcagacctg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1013
```

<210> 175

<211> 1697

<212> DNA

<213> Homo sapiens

<400> 175

```
gcgtccgata gaaggggcta cagctcacgc atcgtgggtg gaaacatgtc cttgctctcg 60
cagtggccct ggcaggccag ccttcagttc cagggctacc acctgtgcgg gggctctgtc 120
atcacgcccc tgtggatcat cactgctgca cactgtgttt atgacttgta cctccccaag 180
tcatggacca tccagggtggg tctagtttcc ctgttggaaca atccagcccc atcccacttg 240
gtggagaaga ttgtctacca cagcaagtac aagccaaaga ggctgggcaa tgacatcgcc 300
cttatgaagc tggccggggc actcacgttc aatgaaatga tccagcctgt gtgcctgccc 360
aactctgaag agaacttccc cgatggaaaa gtgtgctgga cgtcaggatg gggggccaca 420
gaggatggag caggtgacgc ctcccctgtc ctgaaccacg cgcccgctcc tttgatttcc 480
aacaagatct gcaaccacag ggacgtgtac ggtggcatca tctccccctc catgctctgc 540
gcgggctacc tgacgggttg cgtggacagc tgccaggggg acagcggggg gccctgggtg 600
tgtcaagaga ggaggctgtg gaagttagtg ggagcgacca gctttggcat cggctgcgca 660
gaggtgaaca agcctggggg gtacaccctg gtcacctcct tcctggactg gatccacgag 720
cagatggaga gagacctaaa aacctgaaga ggaaggggac aagtagccac ctgagttcct 780
gaggtgatga agacagcccc atcctccccct ggactcccgt gtaggaacct gcacacgagc 840
agacaccctt ggagctctga gttccggcac cagtagcagg cccgaaagag gcacccttcc 900
atctgattcc agcacaacct tcaagctgct ttttggtttt tgtttttttg agatggagtc 960
tcgtctgtgt gccaggtctg gagtgcagtg gcgaaatccc tgctcactgc agcctccgct 1020
tccctggttc aagcgattct cttgcctcag cttccccagt agctgggacc acaggtgccc 1080
gccaccacac ccaactaatt tttgtatttt tagtagagac agggtttcac catgttgccc 1140
aggctgctct caaacccctg acctcaaatg atgtgcctgc ttcagcctcc cacagtgtctg 1200
ggattacagg catgggccac cagcctagc ctcacgctcc tttctgatct tactaagaa 1260
caaaagaagc agcaacttgc aaggcgggcc tttcccactg gtccatcttg ttttctctcc 1320
aggggtcttg caaaattcct gacgagataa gcagttatgt gacctcacgt gcaaagccac 1380
caacagccac tcagaaaaga cgcaccagcc cagaagtgca gaactgcagt cactgcacgt 1440
tttcatctct agggaccaga accaaaccca ccctttctac ttccaagact tattttcaca 1500
tgtggggagg ttaatctagg aatgactcgt ttaaggccta ttttcatgat ttctttgtag 1560
catttggtgc ttgacgtatt attgtccttt gattccaaat aatatgtttc cttccctcat 1620
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaaa aaaaaaaa 1697
```

<210> 176

<211> 1409

<212> DNA

<213> Homo sapiens

<400> 176

```
acaattttaca caggaaacag ctatgaccat gattacgcca agctcgaaat taaccctcac 60
taaagggaac aaaagctgga gctccaccgc ggtggcggcc gctctagaac tagtggatcc 120
cccggtctgc aggaattccg ctgctggcct ggggttgttg ttgaggccgg gtctccgctc 180
ctgtgcccgg gaagatggtg ctagggtggt gcccggttag ttacttactt ctgtgcggcc 240
aggcggtttt gctgctgggg aatttacttc tgctgcattg tgtgtctcgg agccactcgc 300
aaatgcgcac cgctgagcct gagctcacat ccgctggcgc cgccagccg gagggccccg 360
```

```

ggggtgctgc gagctgggaa tatggcgacc cccactctcc ggtcatcctc tgctcttacc 420
tacctgatga atttatagaa tgtgaagacc cagtggatca tggtggaaat gcaactgcat 480
cccaggaact tggttatggg tgtctcaagt tcggcgggtca ggcttacagc gacgtggaac 540
acacttcagt ccagtgccat gccttagatg gaattgagtg tgccagtcct aggaccttct 600
tacgagaaaa taaaccttgt ataaagtata ccggacacta cttcataacc actttactct 660
actccttctt cctgggatgt tttggtgtgg atcgattctg tttgggacac actggcactg 720
cagtagggaa gctgttgacg cttggaggac ttgggatttg gtggtttgtt gaccttattt 780
tgctaattac tggagggctg atgccaagt atggcagcaa ctggtgcact gtttactaaa 840
aagagctgcc atcatggccc agggaggcgg gtgaaagctc cgtcttctga attcatctct 900
acaggctcaa aactcctctt tgatatcaga cctgatgtta ttttccttct tttggagggc 960
atgtgtttgg ttaagaaggc ttctttggac tttggaattt caaccagat tttaccttgc 1020
agacggaatg acaagcaaaa agtgttgtgg ggaatcaaat ttgttccttt cctcatgcac 1080
aaaacataaa ggatagtggc gagtttataa gctgtggatg ggtttcata gtcttccttt 1140
ctgtacattg ctatatcttc agtcctttgg agcaagtggg cctaacaagt tgagcaaaat 1200
gaatatattg atccatgttc ctcttgtgac cctgagtcct catgcaagga gatctgaagc 1260
tgaacaatga aaatcttcag cagaaataga aatggccgtg gattgtaata cacttgaaa 1320
ttctgacttt ctgaatttaa atgtagaata aattttacca acttgaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aaaaaaaaaa aaactcgag 1409

```

<210> 177

<211> 1503

<212> DNA

<213> Homo sapiens

<400> 177

```

tgccacatca ccgggggtttc ttatttttagt gttttgtttt caagtttggg tgctttattt 60
ccattctcta aaagtaagtt tcttgctctt acgagagtta gtgttccttt tgaaccagg 120
tgttccacct gacagtgttt gtctttcata gactttccag aatagacata gtcaagatca 180
gacacgtgag cttctctctc attttaatgt gaggaaaatc atctttcaga gacaaggcac 240
cgcttagaaa tgtatgtcca ggtatgaaag aaccttttta aaatggctgg ttgttcaga 300
tccagatttc tctgcacact ggacttcgta gagtaagtgt ggtagacaaa gagactacac 360
tgcacaacca ccagtgaata tcattgctaa gaagactttg ggtcgtgttt ctcagccact 420
ctcacagctt ttgtagactt atttgatttt gaaacaagca gtttagctaaa tctattttcc 480
ttttatgcat atatgttaat tggtcaact taatatgggtg ttcttacaga atatgagccc 540
atgtgaaata aggttttagg caattttgct gttggtctctg atttgtatat agcaaattta 600
aagttacaga gtgtttccta gatagaagat tagttcattt ggttcatttt gtctttgaag 660
caagccaagc tcatgagcca gttggttatt tgtcataaat gaacacccat cactatatgc 720
tatgttgagg ggaggcaagt ctgatcttcg aataattgat aaagttaa atctttgtag 780
ccaaaataca atttgcaaac cctaactcca gatgtgtcgt atgaatcttg acaaccagg 840
cttgagattt gttttactga ttgccaatca ggtatattat ttgtgatgtt cgtgggagca 900
tgcaaattag aagacagtgt tgtgggagtt cctcagtatt gaattacatg tgtgcactca 960
ggcctgccag tcaactgaatt ctgacttgta aagggtttta cctgctgttc caatcattga 1020
ggaccaattt gctttttgat aagattggaa aacatttatg gagactttcc cagttaaatc 1080
tatgacagtg tcccacttaa atagtgaat ttagtatatt ctcagataac tgcaacacaa 1140
aattgaaatg tgccagtatg tcatctttct acctggaaga tactgtatat ttggaaagt 1200
tatgcttctc tcaataaata catgttatta aataagccat atcacagttt aagaaattgt 1260
atatacttta tcatatgcc tttcagaaac caggatattt gcataatgatt gatttttagaa 1320
agattttgaa gctgggggtt gtccatgtta attaatgaca aagtatatat atatatatat 1380
atatgtgctg tatttgcaac tttcacattg taatttccta tacacttatt aaagtattgt 1440
tttgccatgt ggtttattaa ataaaaatgt acagtctctt aaaaaaaaaa aagaaaaaaa 1500
aaa 1503

```

<210> 178
<211> 1378
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (82)
<223> n equals a,t,g, or c

<400> 178
aanctgcccc gcctgcaggt accggtccgg aattcccggg tcgaccacg cgttcgccca 60
cgcgtccggg gaatgccata gntaattcac cagcagtaat cctttaataa ctggcagagc 120
actttattct tctggtgagc tccctgaata tttatttttc tgattataaa ttttctatat 180
tagtagcatt ttttaattat tacttcttca ctatagagca tttactttta gtctctagat 240
gtatattttg gaatgctrta cttggcataa catagattaa aatcataatg catgactaaa 300
aactccttgg atttatttcc cattttaaaa tttttagcgg taagttcaga tttataatct 360
ttctctagac ttccatgggc tgaatggtgc ctgctgaagt agcaaccctaa aaagtatccc 420
ctgcttatgc ttctccagtt ggccctccat gtccataggc ttcgcatctg tgattcagcc 480
cactgtgggt caaaaatatt tggggaaaaa aatggatggg tgcgcctttg ctgaacatgt 540
acaaaactttt ttttgtcatt aaacaatata gtataacaac tatttacaaa gcatttacat 600
tgtattagct attataggta atctagagat gattttaaagt gtatggtagg atgtgcacag 660
gttatatgca aatactacac cattttctat aagggacttg aacatcatgg acttttagtat 720
cctagggggg tcttggaacc catcacccat aggggcacca taggacaact atagtaccgt 780
gtttattttcc tattaattca ggttccggtt agagtctaaa actaaaacct aatcatttag 840
tcacagtgtg aaaacaaatg gaaataacag ctcaaactct caaaaatatta ctatagcatt 900
atgtttaaaa taatctacaa caaaaatgta ccattttcaa gcagtactac attaggagcc 960
cttttataga aaataatttc ttctttaccc ccgttccagt gtgaatctag tattctgtta 1020
acatttgtgt ggcatttgga gtttgtcatc ccatttgaag ggagagcctt ctcagacatg 1080
aagcaaggga aacatactga atagttttac acaaatttga tctggcttcc atttgtcccc 1140
ctcatttccc aaatgtttta atgtattgga tttggattct caatgtataa gttgccttat 1200
ctgttaaatg ctatcttctg tctctttaat tttgtatatc tgctgttttg cttttggata 1260
cattttctaa ttagaagtca catgataaat ataatcagta tagtaataat accataatgt 1320
gcacatactc aataaataaa tgactgcatt gttgtaaaaa aaaaaaaaaa aaaaaaaaaa 1378

<210> 179
<211> 2251
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2020)
<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2050)

<223> n equals a,t,g, or c

<400> 179

```

ccgaaagaga aaacaggccg cgcgggcggc agaggagccg ggcgccgcaa tggacgtgcg 60
ggcgctgccg tggctgccgt ggctgctgtg gctgctgtgc cggggcggcg gcgatgcgga 120
ctcccgcgcc cccttcaccc cgacctggcc gcggagccgc gagcgtgaag ccgccgcctt 180
ccgggaaagt cttaatagac atcgatactt gaattcttta tttcccagtg aaaactccac 240
cgcttcttat ggaataaatc agttttccta tttgtttcct gaagagttta aagccattta 300
tttaagaagc aaaccttcca agtttccag atactcagca gaagtacata tgtccatccc 360
caatgtgtct ttgccgttaa gatttgactg gagggacaag caggttgtga cacaagtga 420
aaaccagcag atgtgtggag gatgctgggc cttcagcgtg gtgggggcag tggaatctgc 480
ttatgcaata aaggggaagc ccctggaaga cctaagtgtc cagcagggtca ttgactgttc 540
gtataataat tatggctgca atggaggctc tactctcaat gctttgaact ggtaaaca 600
gatgcaagta aaactgggtga aagattcaga atatcctttt aaagcacaaa atggtctgtg 660
ccattacttt tctggttcac attctggatt ttcaatcaaa ggttattctg catatgactt 720
cagtgaacaa gaagatgaaa tggcaaaagc acttcttacc tttggccctt tggtagtcat 780
agtagatgca gtgagctggc aagattatct gggaggcatt atacagcatc actgctctag 840
tggagaagca aatcatgcag ttctcataac tgggtttgat aaaacaggaa gcaactccata 900
ttggattgtg cggaattcct ggggaagttc ttggggagta gatggttatg cccatgtcaa 960
aatgggaagt aatgtttgtg gtattgcaga ttccgtttct tctatatattg tgtgacatgt 1020
tgggcagatc aagagacagc taaaaaatg aaggttttca taatgcaatg taacatagta 1080
cttcaaagta ttattcaact tcaagtttca gcaactacct acaaaagatt ctaaggccta 1140
gtagtattta aactaagttt cagaatgttc ccttcttgta gagagatgga caaccaaagt 1200
cagtgggaca aactccagca cagaagcctg cgaggaaaggc tatggaatag tttcctgtcc 1260
tgagacgaaa ttcagattag gagatatttt aggccctgc aactggggaa ggctactgtt 1320
tgtttttggt tgcttattat ttatttgttt gtttattgtg agatatttca ggtgggatca 1380
aagaggatcat aagaatttat tttcttttgt ggggtgtaac tactagcttt agattacccc 1440
tatacacaag aatggccaac ctaaaattat gtgtgtcttg tacagttagt tatattagca 1500
gccctctgag atggcgatc tatcggaagg atttcaaaca ccaattgctt tacctgaaca 1560
aatggtgctt accctttgaa cagcagagt accaygtaga aggaaggaaa agggcaaaat 1620
cgcttcagtt aaactgaaat taaatgaaca ataaggcaac tatataagta acttctagta 1680
gcattgcctg agagacaaat tattgtttga taattttcat tgtgaatagg aatccaatag 1740
atcatattgc ttactttgtt ctttttatac tatagaataa tattttgttc tctagtatat 1800
caaaatacca aaatattatc tcatattttc tccctctttc tcttactctt taccaagttt 1860
tcctggtggc ttggcttccc tgactaaaga attaagtctc atttttactt tccatktcta 1920
ttttcttacc acttggttgg ctccctttgt ctctgtactt tacsacgata ggatscactc 1980
ttcttctcct taatcataac acactctatc aagccactcn tagctgggac taacactgtg 2040
gttcagactn gtcagttccg cagcttctgc tcaactgatgt cttggacctg cgtcctgacg 2100
actgacaggc actgagctat ggccaagggt tccggtgatct cgccgggttc tgaaagggtg 2160
ctcagaaaac tgtaggcatg agtcctttacc aatcgagaat tgggactaga ctagtagacc 2220
tagtcgcttt cggtgacctg tccgtacgtt t 2251

```

<210> 180

<211> 1000

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<400> 180

```

ctatagatca tagaggaatn gtagctgcag tacgggtccga attccccgggt cgacccacgc 60
gtccgggggaa ggcgggagac agcgagttt gaatcgcggt gcgacgaagg agtaggtggt 120
gggatctcac cgtgggtccg attagccttt tctctgcctt gcttgcttga gcttcagcgg 180
aattcgaaat ggctggcggt aaggctggaa aggactccgg aaaggccaag acaaaggcgg 240
tttcccgctc gcagagagcc ggcttgcaat tcccagtggg ccgtattcat cgacacctaa 300
aatctaggac gaccagtcac ggacgtgtgg gcgcgactgc cgctgtgtac agcgagacca 360
tcctggagta cctcaccgca gaggtacttg aactggcagg aaatgcatca aaagacttaa 420
aggtaaagcg tattaccctt cgtcacttgc aacttgctat tcgtggagat gaagaattgg 480
attctctcat caaggctaca attgctgggt gtggtgtcat tccacacatc cacaaatctc 540
tgattgggaa gaaaggacaa cagaagactg tctaaaggat gcctggattc cttgttatct 600
caggactcta aatactctaa cagctgtcca gtggtgggtga ttccagtggg ctgtatctct 660
gtgaaaaaca caattttgcc tttttgtaat tctatttgag caagttggaa gtttaattag 720
ctttccaacc aaccaaattt ctgcattcga gtcttaacca tatttaagtg ttactgtggc 780
ttcaaagaag ctattgattc tgaagtagtg ggttttgatt gagttgactg tttttaaaaa 840
actgtttgga ttttaattgt gatgcagaag ttatagtaac aaacatttgg ttttgtacag 900
acattatttc cactctggtg gataagttca ataaagggtca tatcccaaaa aaaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa maaaaaaggg gggggccccc 1000

```

<210> 181

<211> 1429

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (761)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1407)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1420)

<223> n equals a,t,g, or c

<400> 181

```

actgggactc ccagcagagc ccaccagcca gccctggccc acccccacgc ctccagagaa 60
gccccgcacg ggctgtctgg gtgtccgcca tccagggtct ggcagagcct ctgagatgat 120
gcatgatgcc ctcccctcag cgcaggctgc agagcccggc cccacctccc tgcgcccttg 180
agggggcccca gcgtctgcag ggtgacgcct garacagcac cactgctgag gagtgaggac 240
tgtcctccca cagacctgca gtgagggggc ctccatgcgc agatgagggg cactgacccc 300
acctgcgctt ctgctggagg aggggaagct gggcccaaaag gccmgsgrag gcagcgtggg 360
ctctgccaat gtgggctgcc cctcgcacac agggctcaca gggcaggcct tgctggggtc 420

```

```

cagggctgtt ggaggacccc gagggctgag gagcagcagg acccgccctgc tcccatcctc 480
accagatca ggaaccaggg cctccctgtt cacggtgaca caggtcaggg ctacagagtga 540
ccctcrctg tcacctgctc acagggatgc tgggtgctgg tgagaccccg cactgcasac 600
gggaatgcct aggtcccttc ccgaccagc cagctgcagg gcacggggac ctggatagtt 660
aagggctttt ccaaaccatgc atccatttac tgacacttcc tgtccttggt catggagagc 720
tgttcgctcc tccagatgg cttcggaggg ccgcaggscs nccttggacc ctggtgacct 780
cctgtmamtc actgaggcca tcagggccct gcccaggcc tggacggggc ctccctccct 840
cctgtgcccc agctgccagg yggccctggg gaggggtggt gtggtgttg gaaggggtcc 900
tgcaggggga ggaggacttg gaggtctgg gggcagctgt cctgaaccga ctgacctga 960
ggaggccgct tagtgctgct ttgcttttca tcaccgtccc gcacagtga cggagggtcc 1020
cgttgctgg tcagggtccc atggcttggt ctctggaacc tgactttaga tgttttggga 1080
tcaggagccc ccaacacagg caagtccacc ccataataac cctgccagt ccagggtggg 1140
ctggggactc tggcacagt atgccgggcg ccaggacagc agcactcccg ctgcacacag 1200
acggcctagg ggtggcgctc agaccccacc ctacgctcat ctctggaagg ggcagccctg 1260
agtgtcact ggtcagggca gtggccaagc ctgctgtgtc ctccctccac aaggtccccc 1320
caccgctcag tgtcagcggg tgacgtgtgt tcttttgagt ccttgtatga ataaaaggct 1380
ggaaacctaa aaaaaaaaaa aaaaaanggg ggcctctan aggttccaa 1429

```

<210> 182

<211> 2725

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2713)

<223> n equals a,t,g, or c

<400> 182

```

taacagggca aaaaaagggc tggaaacttc gctatcatgg agatccaatg ccctgcccta 60
aggaagacac tcccaattct gtttgggagc ctgcgaagggt gcttgtgttt gtcagacaaa 120
tacagccagg cctgccaccc cttaggctcc aaagtccgga ggtgcagaaa gccaggacca 180
agagacaggc agctcaccag ggtggacaaa tcgccagaga tgtggtgcat tgtcctgttt 240
tcacttttgg catgggttta tgctgagcct accatgtatg gggagatcct gtcccctaac 300
taccctcagg catatcccag tgaggtagag aaatcctggg acatagaagt tcctgaaggg 360
tatgggattc acctctactt caccatctg gacattgagc tgtcagagaa ctgtgcgtat 420
gactcagtg agataatctc aggagacact gaagaaggga ggctctgtgg acagaggagc 480
agtaacaatc ccactctcc aattgtggaa gagttccaag tccatacaa caaactccag 540
gtgatcttta agtcagactt ttccaatgaa gagcgtttta cgggggtttgc tgcatactat 600
gttgccacag acataaatga atgcacagat tttgtagatg tcccttgtag ccacttctgc 660
aacaatttca ttggtggtta cttctgctcc tgcccccccg aatatttcct ccatgatgac 720
atgaagaatt gcggagttaa ttgcagtggg gatgtattca ctgcactgat tggggagatt 780
gcaagtccca attatcccaa accatatcca gagaactcaa ggtgtgaata ccagatccgg 840
ttggagaaaag ggttccaagt ggtggtgacc ttgcggagag aagattttga tgtggaagca 900
gctgactcag cgggaaactg ccttgacagt ttagtttttg ttgcaggaga tcggcaattt 960
ggtccttact gtggtcatgg attccctggg scctctaaata ttgaaaccaa gagtaatgct 1020
cttgatatca tcttccaaac tgatctaaca gggcaaaaaa agggctggaa acttcgctat 1080
catggagatc caatgccctg ccctaaggaa gacactccca attctgtttg ggagcctgcg 1140
aaggcaaaat atgtctttag agatgtggtg cagataacct gtctggatgg gtttgaagtt 1200
gtggagggac gtgttggtgc aacatctttc tattcgactt gtcaaagcaa tggaaagtgg 1260
agtaattcca aactgaaatg tcaacctgtg gactgtggca ttctgaatc cattgagaat 1320

```

```

ggtaaagttg aagaccacaga gagcactttg tttggttctg tcatccgcta cacttgtgag 1380
gagccatatt actacatgga aaatggagga ggtggggagt atcactgtgc tggtaacggg 1440
agctgggtga atgaggtgct gggcccgag ctgccgaaat gtgttccagt ctgtggagtc 1500
cccagagaac cctttgaaga aaaacagagg ataattggag gatccgatgc agatattaaa 1560
aacttcccct ggcaagtctt ctttgacaac ccatgggctg gtggagcgct cattaatgag 1620
tactgggtgc tgacggctgc tcatgttggt gagggaaaca gggagccaac aatgtatgtt 1680
gggtccacct cagtgcagac ctacggctg gcaaaatcca agatgctcac tcctgagcat 1740
gtgtttattc atccgggatg gaagctgctg gaagtcccag aaggacgaac caattttgat 1800
aatgacattg cactggtgct gctgaaagac ccagtgaaaa tgggacccac cgtctctccc 1860
atctgcctac caggcacctc ttccgactac aacctcatgg atggggacct gggactgatc 1920
tcaggctggg gccgaacaga gaagagagt cgtgctgttc gcctcaaggc ggcaagggtta 1980
cctgtagctc ctttaagaaa atgcaaagaa gtgaaagtgg agaaaccac agcagatgca 2040
gaggcctatg ttttactcc taacatgatc tgtgctggag gagagaaggc catggatagc 2100
tgtaaagggg acagtgggtg ggcccttgct gtacaggatc ccaatgacaa gaccaaattc 2160
tacgcagctg gcctggtgtc ctggggggcc cagtgtggga cctatgggct ctacacacgg 2220
gtaaagaact atgttgactg gataatgaag actatgcagg aaaatagcac ccccgtagg 2280
gactaatcca gatacatccc accagcctct ccaaggggtg tgaccaatgc attaccttct 2340
gttccttatg atattctcat tatttcatca tgactgaaag aagacacgag cgaatgattt 2400
aaatagaact tgattgttga gacgccttgc tagaggtaga gtttgatcat agaattgtgc 2460
tggtcataca tttgtggtct gactccttgg ggtcctttcc ccggagtacc tattgtagat 2520
aacactatgg gtggggcact ctttcttgc actattccac agggatacct taattctttg 2580
tttctctttt acctgttcaa aattccattt acttgatcat tctcagtatc cactgtctat 2640
gtacaataaa ggatgtttat aagcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2700
aaaaaaaaaa aaaaaaaaaa aaaag 2725

```

<210> 183

<211> 1751

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (344)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (416)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1617)

<223> n equals a,t,g, or c

<400> 183

```

gggggcgga ggttgcggcg gcgccggagc ggttctccag gctggcgagc gccagggaca 60
ggcatgttgt tgggactggc ggccatggag ctgaagggtgt ggggtggatgg catccagcgt 120
gtggtctgtg gggctctcaga gcagaccacc tgccaggaag tggatcatgc actagcccaa 180
gcaataggcc agactggccg ctttgtgctt gtgcagcggc ttcgggagaa ggagcggcag 240
ttgctgccac aagagtgtcc agtgggcgcc caggccacct gcggacagtt tgccagcgat 300

```

```

gtccagtttg tcctgagggc cacagggccc agcctagctg ggangccctc ctcagacagc 360
tgtccacccc cggaacgctg cctaattcgt gccagcctcc ctgtaaagcc acgggntgcg 420
ctgggctgtg agccccgcaa aacactgacc cccgagccag cccccagcct ctcacgccct 480
gggcctgcgg cctgtgaaca cccacaccag gctgctgcac agacctgcgg ggcctggagc 540
tcaggggtgca gaggaatgct gaggagctgg gccatgaggc cttctgggag caagagctgc 600
gccgggagca ggcccgggag cgagagggac aggcacgcct gcaggcacta agtgcgcca 660
ctgctgagca tgccgcccgg ctgcaggccc tggacgtca ggcccgtgcc ctggaggctg 720
agctgcagct ggcagcggag gccctgggc cccctcacc tatggcatct gccactgagc 780
gcctgcacca ggacctggct gttcaggagc ggcagagtgc ggaggtgcag ggcagcctgg 840
ctctgggtgag ccgggcccctg gaggcagcag agcgagcctt gcaggctcag gctcaggagc 900
tggaggagct gaaccgagag ctccgtcagt gcaacctgca gcagttcatc cagcagaccg 960
gggctgcgct gccaccgccc ccacggcctg acaggggccc tcctggcact caggctggag 1020
tggttctggg gggaggctgg gaggtgagga cctggcccar cccactcca agctgacttc 1080
ccaaccacaca gggccctctg cctcagccag agaggagtcc ctccctggcg ctccctctga 1140
gtcccatgct ggtgcccagc ctaggccccg agggatatgtc tgtgcccac ctccccctgg 1200
ggcaccgggc cctcctgtgg ctgcagccac tgcagcctgt gtcctccgc agtggtcccc 1260
atgacgcaga actcctggag gtagcagcag ctccctgccc agagtgggtg cctctggcag 1320
cccagcccca ggctctgtga cagcctagtg agggctgcaa gaccatcctg cccggaccac 1380
agaaggagag ttggcggtca cagagggctc ctctgccagg cagtgggaag ccctgggttt 1440
ggcctcagga gctgggggtg cagtggggga ctgccctagt ccttgccagg tcgccagcac 1500
cctggagaag catggggcgt agccagctcg gaacttgcca ggcccaaaag gccacgactg 1560
cctgttgggg acaggagatg catggacagt gtgctcaagc tgtgggcatg tgcttgnctg 1620
cgggagaggt ccttctactgt gtgtacacag caagagcatg tgtgtgccac ttcccctacc 1680
ccaacgtgaa aacctcaata aactgcccga akyakaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa a 1751

```

<210> 184

<211> 2200

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2096)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2140)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2157)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2181)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2184)
 <223> n equals a,t,g, or c

<400> 184

```

ggcacgagca gcgacatact gaagggcaac ttctcaatcc gtacagccaa gatgcagcag 60
catgtgtgtg aaaccatcat ccgcattctt aaaagacatg gagctgttca gttgtgtact 120
ccactactgc ttccccgaaa cagacaaata tatgagcaca acgaagctgc cctattcatg 180
gaccacagcg ggatgctggg gatgcttcct tttagacctg ggatcccttt tgcaagatat 240
gtggcaagaa ataatatatt gaatttataa cgatactgca tagaacgtgt gttcaggccg 300
cgcaagttag atcgatttca tcccaaagaa cttctggagt gtgcatttga tattgtcact 360
tctaccacca acagctttct gccactgct gaaattatct acactatcta tgaaatcatc 420
caagagtttc cagcacttca ggaaagaaat tacagtattt atttgaacca taccatgtta 480
ttgaaagcaa tactcttaca ctgtgggac ccagaagata aactcagtca agtctacatt 540
attctgtatg atgctgtgac agagaagctg acgaggagag aagtggagc taaattttgt 600
aatctgtctt tgtcttctaa tagtctgtgt cgactctaca agtttattga acagaaggga 660
gatttgcaag atcttatgcc aacaataaat tcattaataa aacagaaaac aggtattgca 720
cagttggtga agtatggctt aaaagaccta gaggaggttg ttggactgtt gaagaaactc 780
ggcatcaagt tacaggtctt gatcaatttg ggcttggttt acaaggtgca gcagcacaat 840
ggaatcatct tccagtttgt ggctttcatc aaacgaaggc aaagggctgt acctgaaatc 900
ctgcagytg gaggcagata tgacctgctg attccccagt ttagagggcc acaagctctg 960
gggccagttc ccactgccat tggggtcagc atagctatag acaagatatc tgctgctgtc 1020
ctcaacatgg aggaatctgt tacaataagc tctgtgacc tcctggttgt aagtkttggg 1080
cagatgtcta tgtccagggc catcaaccta acccagaaac tctggacagc aggcatacaca 1140
gcagaaatca tgtacgactg gtcacagtcc caagaggaat tacaagagta ctgcagacat 1200
catgaaatca cctatgtggc cctgtgtctg gataaagaag gaagccatgt caagggttaag 1260
tctttcgaga aggaaaggca gacagagaag cgtgtgctgg agactgaact tgtggaccat 1320
gtactgcaga aactgaggac taaagtcact gatgaaagga atggcagaga agcttccgat 1380
aatcttgtag tgcaaaatct gaaggggtca ttttctaatt cttcagggtt gtttgaaatc 1440
catggagcaa cagtggttcc cattgtgagt gtgctagccc cggagaagct gtcagccagc 1500
actaggaggc gctatgaaac tcaggtagaa actcgacttc agacctccct tgccaactta 1560
catcagaaaa gcagtgaaat tgaaattctg gctgtggatc tacccaaaga aacaatatta 1620
cagtttttat cattagagtg ggatgctgat gaacaggcat ttaacacaac tgtgaagcag 1680
ctgctgtcac gcctgccaaa gcaaagatac ctcaaattag tctgtgatga aatttataac 1740
atcaaagtag aaaaaaagggt gtctgtgcta tttctgtaca gctatagaga tgactactac 1800
agaatcttat tttaacccta agaactgtc gttaacctca ttcaaacaga cagaggctta 1860
tactggaata atggaatgtt gtacattcat cataatttaa aattaaattc taagaagagg 1920
ctgggtgcag tggtcacac ctttaatccc agcactttgg gaagccaagg caggaagact 1980
gcttgaaacc aggagtttga gaccagcctg agcaacaaag caagaccca tctctataaa 2040
aactaaaaaa attagttggg catggtggca catgcctgta gtcccagcta ctccanaggc 2100
tgagatggat catctgagcc tcaggaggtt gacgctgcan tgactgtgac tgccgcncgt 2160
actccatctg gggcaacaga ncangaccct gcttaaatac 2200

```

<210> 185
 <211> 1987
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature

<222> (523)

<223> n equals a,t,g, or c

<400> 185

```

aactgtggcg cktttctggta aagatggacg tccacgatct ctttcgccgg ctccggcgcg 60
gggccaaatt cgacacgaga cgcttctcgg cagacgcagc tcgattccag ataggaaaaa 120
ggaaatatga ctttgattct tccggaggtgc ttcagggact ggactttttt ggaaacaaga 180
agtctgtccc aggtgtgtgt ggagcatcac aaacacatca gaagcccaa aatggagaga 240
aaaaagaaga gaggcctaact gaaaggaaga gggagcagag caagaaaaaa aggaagacga 300
tgacttcaga aattgcttcc caagaagaag gtgctactat acagtggatg tcatctgtag 360
aagcaaagat tgaagacaaa aaagttcaga gagaaagtaa actaacttcc ggaaagtgg 420
agaatctcag aaaagaaaag ataaacttct tgcggaataa acacaaaatt cacgtccaag 480
gaaccgatct tcctgaccca attgctacat ttcagcaact tgnaccagga atataaaatc 540
aattctcgac tacttcagaa cattctagat gcaggtttcc aaatgcctac gccaatccaa 600
atgcaagcca tcccagttat gctgcatggt cgggaacttc tggcttctgc tccaactgga 660
tctggaaaaa cattagcttt tagcattcct attttaatgc agctgaaaca acccgcaaat 720
aaaggcttca gagccctgat tatatcacca acacgagaac ttgccagcca gattcacaga 780
gagttaataa aaatttctga gggaacagga ttcagaatac acatgatcca caaagcagca 840
gtggcagcca agaaatttgg acctaaatca tctaaaaagt ttgatattct tgtgactact 900
ccaaatcgac taatctattt attaaagcaa gatccccccg gaatcgacct agcaagtgtt 960
gagtggcttg tagtagacga atcagataaa ctgtttgaag atggcaaaac tgggttcaga 1020
gaccagctgg ctccattttt cctggcctgc acatcccaca aggtccgaag agctatgttc 1080
agtgcaactt ttgcatatga tgttgaacag tgggtgcaaac tcaacctgga caatgtcatc 1140
agtgtgtcca ttggagcaag gaattctgca gtagaaactg tagaacaaga gcttctcttt 1200
gttgatctg agaccgaaa acttctggcc gtgagagaac ttgttaaaaa gggtttcaat 1260
ccacctgttc ttgtttttgt tcagtcatt gaaagggcta aagaactttt tcatgagctc 1320
atatatgaag gtattaatgt ggatgttatt catgcagaga gaacacaaca acagagagat 1380
aacacagtc acagtttcag agcaggaaaa atctgggttc tgatttgtac agccttgcta 1440
gcaagagggg ttgattttta aggtgtgaac ttggtgatca actatgactt tccaactagc 1500
tcagtggaa atatccacag gataggtcga actggaagag cagggaataa gggaaaagca 1560
attacatttt tcaactgagga tgataagcca ttattaagaa gcgttgctaa tgttatacag 1620
caggctgggt gtocctgtacc agaatacata aaaggttttc agaaactact aagcaaaaaa 1680
aagaaaaaga tgattaagaa accattggaa agggagagca ttagtacaac tccaaaatgt 1740
ttcttagaaa aagctaagga taaacagaaa aaggtcactg gtcagaacag caagaagaaa 1800
gtagctcttg aagacaaaag ttaaaaacag actttaaaaa tactgtccca gaaatgtaat 1860
tttatgatcc cagcatgaat gttattttca tggaaactt gaagtcttac agtcacctgt 1920
accaaacatt tgaaatcaac tacaagtaca tgggactggg gataaatgat cctaaactat 1980
caagtca
1987

```

<210> 186

<211> 1737

<212> DNA

<213> Homo sapiens

<400> 186

```

tcgagttttt tttttttttt ttttaaggta aaaaaaaaaa acaccttcag tttcctggtg 60
tgatcctggg taaaatggat gatttttcat tgaaagtttt gctgattaac aattaaagtg 120
ggatgatatg tgggcaaaat cacttatgaa agtagaagca agaatacagt ggtttgctac 180
cacataaagc catgctgttt ttggtcaaac tgtgtaaact ggaaaaatc acatcatttc 240
tgagtttaaa cacttttaga tatattcaca ttgttttggg gaatttgctg aattgaattg 300
tttttctttc tcaaactctg gatctctttt ctttatcctg tttctttgtt cctttcgttt 360

```

```
gctttcttat ttttcttttg ttccattcct ttcttacttt tttccctttt ccttttttgg 420
ggaggctggc tagtagtggt tgagaaaaga atagaagtga aatttgcata atgaatgtaa 480
aagggaata aaagtctttt gaaggtagct atactagcac ttttgatcat cttcagggcc 540
cacaaaaatg ttgtcaagat tttaaagggt tataattctg cttaagctct agtttggact 600
taggtatcct aactatgttg gaggtatttg cattgtttta agttaggata aaagcaagtt 660
cctcctgtga ctgcaacgtc ttactgattg ggacagttgc caggaggata ccaacttgat 720
agcagagggg gttttatgca aacgcactca cctccgcctt ggggaatgaa agggtcactt 780
ctgcatcatc actagctagt tttctagtgt tagagaggct tacaaatgtt tgccattctc 840
ataagtgttt tgaacttgat ctttgtgact tgtgcttttt tagcttctct cttgaatcag 900
agtatcattg tcttctcca aggagttaga atttccagt ttaaaacaaa aagggaatg 960
tcctaggttt tctttgtgct tctcattttt cctttgttga ttcaattcct gtgatttttg 1020
ttctcttccc tgaagtgtt tacagtgcac ggaatctcca tcattgttat ttaacgata 1080
gtaattcaca gtctcagaa gcctattttt aaagcagaag caaaaaagaa aaacaaaata 1140
acaaaaacaa cccttctct tttctctcat ctcacctctc tgtgttgatt actaatcatc 1200
ttagatatta ttgctagtgg atgtatggta gatgggttga agcttttctg ataattatta 1260
cacaatttaa aacaacatat atatttaaaa taaatatata cagtaaatat attgagccat 1320
gttaacctgc caatgagatc tgtgaaaaaa taatggcctc atttttctct ttttaatttc 1380
ttttaccctt ttgtgaagca gctatacgtg gcatacatgt atttaaagaa aaaaaaatag 1440
atgtagagtg ttttttttac acttttaact tagcatgtgg tgttgaagta ttactgtaga 1500
tcaagtttgt cttccgcaact aagatgtgag gaaattgtga tttgttctct ccaccacaaa 1560
tgaattacac atttattatc ttctatcatt ttgaaacact gcagtttacc atgggacact 1620
gtatatattt cttgccataa tggtaaagga ctgattgata tatttaagag ttaataaatt 1680
tgtgatttct gctgaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 1737
```

<210> 187

<211> 1132

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1131)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1132)

<223> n equals a,t,g, or c

<400> 187

```
ggcagagtgg acacctgcat caagaccaag tcgcagctga tgatgccagt ttcaaggccc 60
atgggcctgt ccccaacccc cagcccatcg acccagctag cctggaggag ttcaagagga 120
agatcctgga gtcccagagg cccctgcat gcattccctg agcccatcc agtggctgag 180
gaggctccag gcctgaggac caagggatgg ccgactcgg cggtttgagg aggatgcagg 240
gatatgctca cagcgcccga cacaaccccc tcccgccgcc cccaaccacc cagggccacc 300
atcagacaac tccctgcatg caaaccccta gtaccctctc acaccgcac ccgcgcctca 360
cgatccctca cccagagcac acggccgagg agatgacgtc acgcaagcaa cggcgctgac 420
gtcacatatc accgtggtga tggcgtcacg tggccatgta gacgtcacga agagatatag 480
cgatggcgtc gtgcagatgc agcacgtcgc acacagacat ggggaacttg gcatgacgtc 540
acaccgagat gcagcaacga cgtcacgggc catgtcgacg tcacacatat taatgtcaca 600
cagacgcggc gatggcatca cacagacggt gatgatgtca cacacagaca cagtgacaac 660
```

```
acacacccatg acaacgacac ctatagatat ggcaccaaca tcacatgcac gcatgccctt 720
tcacacacac tttctaccca attctcacct agtgtcacgt tccccgacc ctggcacacg 780
ggccaaggtta cccacaggat cccatcccc cccgcacagc cctgggcccc agcacctccc 840
ctcctccagc ttcctggcct cccagccact tcctcacccc cagtgcctgg acccggaggt 900
gagaacagga agccattcac ctccgctcct tgagcgtgag tgtttccagg accccctcgg 960
ggccctgagc cgggggtgag ggtcacctgt tgtcgggagg ggagccactc cttctcccc 1020
aactcccagc cctgcctgtg gcccgttgaa atgttggtgg cacttaataa atattagtaa 1080
atccttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa nn 1132
```

<210> 188

<211> 1267

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (25)

<223> n equals a,t,g, or c

<400> 188

```
ggggatggat gntctccttc agctnttttg gagacactat agaaggtacg cctgcaggta 60
ccggtccgga attcccgggt tgatccacgc gtccgcccac gcgtccgccc acgcgtccgc 120
tggaaggcag ctatgcgact caccgtgctg tgtgctgtgt gcctgctgcc tggcagcctg 180
gccctgccgc tgcctcagga ggccggaggc atgagtggagc tacagtggga acaggctcag 240
gactatctca agagatttta tctctatgac tcagaaacaa aaaatgccaa cagtttagaa 300
gccaaactca aggagatgca aaaattcttt ggccctaccta taactggaat gttaaactcc 360
cgcgctcatag aaataatgca gaagcccaga tgtggagtgc cagatgttgc agaatactca 420
ctatttccaa atagcccaaa atggacttcc aaagtgggtc cctacaggat cgtatcatat 480
actcgagact taccgcatat tacagtggat cgattagtgt caaaggcttt aaacatgtgg 540
ggcaaagaga tccccctgca ttccaggaaa gttgtatggg gaactgctga catcatgatt 600
ggctttgcgc gaggagctca tggggactcc taccatttg atgggccagg aaacacgctg 660
gctcatgcct ttgcgcctgg gacaggcttc ggaggagatg ctcacttcga tgaggatgaa 720
cgctggacgg atggttagcag tctagggatt aacttcctgt atgctgcaac tcatgaactt 780
ggccattctt tgggtatggg acattcctct gatcctaata cagtgatgta tccaacctat 840
ggaaatggag atccccaaa ttttaaaact tcccaggatg atattaaagg cattcagaaa 900
ctatatggaa agagaagtaa ttcaagaaag aaatagaaac ttcaggcaga acatccattc 960
attcatcatc tggattgtat atcattgttg cacaatcaga attgataagc actgttcctc 1020
cactccattt agcaattatg tcaccctttt ttattgcagt tggtttttga atgtctttca 1080
ctccttttaa ggaataaact ctttatgggt tgactgtgtc ttattcatct atacttgcag 1140
tgggtagatg tcaataaatg ttacatacac aaataaataa aatgtttatt ccatggtaaa 1200
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaata 1267
```

<210> 189

<211> 3787

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (155)

<223> n equals a,t,g, or c

<400> 189

```

agtccggaat tccccgggttt gntgacgcgt ccgcagcaag gtgcctcgct gtgtcaaacac 60
tcagcctggc ttccactgcc tgccctgccc gccccgatac agaggggaacc agcccgctcg 120
ggtcggcctg gaagcagcca agacggaaaa gcaantgtgt gagcccgaaa acccatgcaa 180
ggacaagaca cacaactgcc acaagcacgc ggagtgcac tacctgggtc acttcagcga 240
ccccatgtac aagtgcgagt gccagasagg ctacgcgggc gacgggctca tctgcgggga 300
ggactcggac ctggacggct ggcccaacct caatctggtc tgcgccacca acgccacct 360
ccactgcac aaggataact gcccccatct gccaaattct gggcaggaag actttgacaa 420
ggacgggatt ggcgatgcct gtgatgatga cgatgacaat gacggtgtga ccgatgagaa 480
ggacaactgc cagctcctct tcaatccccg ccaggctgac tatgacaagg atgaggttgg 540
ggaccgctgt gacaactgcc cttacgtgca caaccctgcc cagatcgaca cagacaacaa 600
tgagaggggt gacgcctgct ccgtggacat tgatggggac gatgtcttca atgaacgaga 660
caattgtccc tacgtctaca acactgacca gagggacacg gatggtgacg gtgtggggga 720
tactgtgac aactgcccc tggtgcacaa ccctgaccag accgacgtgg acaatgacct 780
tgttggggac cagtgtgaca acaacgagga catagatgac gacggccacc agaacaacca 840
ggacaactgc ccctacatct ccaacgcaa ccaggctgac catgacagag acggccaggg 900
cgacgcctgt gaccctgatg atgacaacga tggcgtcccc gatgacaggg acaactgccg 960
gcttgtgttc aaccagacc aggaggactt ggacggtgat ggacggggtg atatttgtaa 1020
agatgatttt gacaatgaca acatcccaga tattgatgat gtgtgtcctg aaaacaatgc 1080
catcagttag acagacttca ggaacttcca gatggtcccc ttggatccca aagggaccac 1140
ccaaattgat cccaactggg tcattcgcca tcaaggcaag gagctggttc agacagccaa 1200
ctcggacccc ggcatcgctg taggttttga cgagtttggg tctgtggact tcagtggcac 1260
attctacgta aacactgacc gggacgacga ctatgccggc ttcgtctttg gttaccagtc 1320
aagcagccgc ttctatgtgg tgatgtggaa gcagggtgac cagacctact gggaggacca 1380
gccacgcgg gcctatggct actccggcgt gtccctcaag gtggtgaact ccaccacggg 1440
gacgggcgag cacctgagga acgcgctgtg gcacasggg aacacgccgg ggcagggtgcg 1500
aaccttatgg cagacccca ggaacattgg ctggaaggac tacacggcct ataggtggca 1560
cctgactcac aggcccaaga ctggctacat cagagtctta gtgcatgaag gaaaacaggt 1620
catggcagac tcaggacct tctatgacca aacctacgct ggcgggcggc tgggtctatt 1680
tgtcttctct caagaaatgg tctatttctc agacctcaag tacgaatgca gagatattta 1740
aacaagattt gctgcatttc cggcaatgcc ctggtcatgc catggtccct agacacctca 1800
gttcattgtg gtctctgtgg ctctctctc tcagaacacc tctgtccct tgaccttaac 1860
tctgatgggt cttcacctcc tgccagcaac cccaaccca agtgccctca gaggataaat 1920
atcaatggaa ckcagagatg aacatctaac ccactagagg aaaccagttt ggtgatatat 1980
gagactttat gtggagtga aattgggcat gccattacat tgctttttct tgtttgttta 2040
aaaagaatga cgtttacata taaaatgtaa ttactttattg tattttatgtg tatatggagt 2100
tgaagggaat actgtgcata agccattatg ataaatgaag catgaaaaat attgctgaac 2160
tacttttggg gcttaaagtt gtcactattc ttgaattaga gttgctctac aatgacacac 2220
aatcccrtt aaataaatta taaacaaggg tcaattcaaa tttgaagtaa tgttttagta 2280

```

```

aggagagatt agaagacaac aggcatagca aatgacataa gctaccgatt aactaatcgg 2340
aacatgtaaa acagttacaa aaataaacga actctcctct tgcctacaa tgaaagccct 2400
catgtgcagt agagatgcag ttcatcaaa gaacaaacat ccttgcaaat ggggtgtgacg 2460
cgggtccaga tgtggtttg gcaaaacctc atttaagtaa aaggttagca gagcaaagtg 2520
cgggtgcttta gctgctgctt gtgocgctgt ggcgtcgggg aggcctcctgc ctgagcttcc 2580
ttccccagct ttgctgcctg agaggaacca gagcagacgc acaggccgga aaaggcgcgt 2640
ctaacgcgta tctaggcttt ggtaactgcg gacaagttgc tttacctga ttgatgata 2700
catttcatta aggttccagt tataaatatt ttgttaatat ttattaagtg actatagaat 2760
gcaactccat ttaccagtaa cttattttaa atatgcctag taacacatat gtagtataat 2820
ttctagaaac aaacatctaa taagtatata atcctgtgaa aatatgaggc ttgataatat 2880
taggttgtca cgatgaagca tgctagaagc tgtaacagaa tacatagaga ataatgagga 2940
gtttatgatg gaaccttaat atataatggt gccagcgatt ttagttcaat atttgttact 3000
gttatctatc tgctgtatat ggaattcttt taattcaaac gctgaaaacg aatcagcatt 3060
tagtcttgcc aggcacaccc aataatcagt catgtgtaat atgcacaagt ttgtttttgt 3120
ttttgttttt tttgttggtt ggtttgtttt tttgctttta gttgcatgat ctttctgcag 3180
gaaatagtca ctcacccac tccacataag gggtttagta agagaagtct gtctrctga 3240
tgatggatag ggggcaaatc tttttccctt ttctgttaat agtcacaca tttctatgcc 3300
aaacaggaac gatccataac tttagtctta atgtacacat tgcattttga taaaattaa 3360
tttgttggtt cctttgaggt tgatcggtgt gttgttggtt tgctgcactt tttacttttt 3420
tgctgtgga gctgtattcc cgagaccaac gaagcgttg gatacttcat taaatgtagc 3480
gactgtcaac agcgtgcagg tttctgttt ctgtgttggt gggcaaccg tacaatgggtg 3540
tgaggagtgc gatgatgtga atatttagaa tgtaccatat tttttgtaa ttatttatgt 3600
ttttctaaac aaatttatcg tataggttga tgaaacgtca tgtgttttgc caaagactgt 3660
aaatatttat ttatgtgttc acatgggtcaa aatttcacca ctgaaaccct gcacttagct 3720
agaacctcat ttttaaagat taacaacagg aaataaattg taaaaaagg tttctataaa 3780
aaaaaaa 3787

```

<210> 190

<211> 554

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (520)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (542)

<223> n equals a,t,g, or c

<400> 190

```

ggcagagggg cagcaacatt tccacagga cacgartttg tcggcccttg ccttggcaga 60
gctgaggcat tttggagatc aaagatgggt agaaaagatg ctgctactat aaaacttcct 120
gttgatcagt acagaaaaca aattggtaaa caggattata aaaaaactaa acctatttta 180
cgagcaacca aattaaaagc agaagcaaag aaaacagcaa taggcataaa ggaagttggc 240
cttgactttg cagctatatt ggcactacta ctggctttct atgctttctt ttatctcaga 300
ctcaccacgg atgttgaccc tgatctggac caagatgaag attagctaag caacaatcaa 360
tgcatgaaag agaaataact ttacgaaagc accttttggg accaaaaactt tcaatactga 420
aactgtaaca tctttaattm tttctgctaa tattttcagt ttgcagacat atgatttttg 480

```

atagttgcat aggatgtcag gaaaagaacc ttacctagen atgcagtata gtatgtgcta 540
 cngggatact tgta 554

<210> 191

<211> 874

<212> DNA

<213> Homo sapiens

<400> 191

ggcacagacg ggatgaggcg ctgcagtctc tgcgctttcg acgccgcccg ggggcccagg 60
 cggctgatgc gtgtgggcct cgcgctgacg ttggtgggccc acgtgaacct gctgctgggg 120
 gccgtgctgc atggcaccgt cctgcggcac gtggccaatc cccgcggcgc tgtcacgccg 180
 gagtacaccg tagccaatgt catctctgtc ggctcggggc tgcctgagcgt ttccgtggga 240
 ttgtggccct cctggcgtcc aggaamcttc ttgcacctcc actgcactgg gtccctgctgg 300
 camtagctct ggtgaacctg ctcttgctcg ttgcctgctc cctggggcctc cttcttgctg 360
 tgtcactcac tgtggccaac ggtggccgccc gccttattgc tgactgccac ccaggactgc 420
 tggatcctct ggtaccactg gatgaggggc cgggacatac tgactgcccc ttgacccca 480
 caagaatcta tgatacagcc ttggctctct ggatcccttc tttgctcatg tctgcagggg 540
 aggtgctctc atctggttac tgcctgtgtg ctgcactcac tctacgtgga gttgggcccct 600
 gcaggaagga cggacttcag gggcagctag aggaaatgac agagcttgaa tctcctaaat 660
 gtaaaaggca ggaaaatgag cagctactgg atcaaaatca agaaatccgg gcatcacaga 720
 gaagttgggt ttaggacagc aggtgctgtt ccgagactca gtcctaaagg gttttttttc 780
 ccactaagca aggggccctg acctcgggat gagataacaa attgtaataa agtaacttct 840
 cttttcttct aaaaaaaaaa aaaaaaaact cgag 874

<210> 192

<211> 2103

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (140)

<223> n equals a,t,g, or c

<400> 192

tagtagtaaa caggtgggga ctccattgcc agcttggtgc cttatctact gggcagtcga 60
 gttggtgtct tcatgggcag aaatagggtg taaagggtgg caactctcca ggtgagagag 120
 agttttgtag caggactttn ggttgtaaata cgactattac caacctactg gtgggtgaga 180
 gttcaagaaa cccatgaaaa aggacatagt ggaagatgaa gatgatgact ttctgaaagg 240
 cgaagtgcgc cagaatgata ccgtgattgg gatcacacca agctcctttg acacgcattt 300
 ccgaagtcct tcaagtagtg tgggctcccc acccggtgtg tacatgcaac ccagtcacct 360
 ctgacggcag aaatttgtga ctgagatgtg acatttggga ttccccatca cttgtcattg 420
 cctcagcacc cagcttgtgc cattgggcatt tgatggcatt gaactagagc gattgcctgc 480
 ctcggtctgt gcacttccag gttcgcactga atcaagcatc tgaagactgg gtttttttgt 540
 tgtttgtgtt ccccttacag acaaaatgaa gactatcatg tgcaatcttt tacagtgggg 600
 ttgatgatac atttggaagg atttgcttgt ttaatatgta ctttttttgt gttaacagct 660
 ttttgacaca attactgggt aattttcta ataggcagca gactgtttta cgggttgctg 720
 ttttaacatg ggtttttgtc agatccatgg tcttaggact tgactgatga gctttcagtg 780
 aagaatcctc taagataaaa cttctattta aagactttta ctagaaagtg tttatttttg 840
 ctacattgtt caccttctgc tgtattggta tttgtctgtt gggatttcaa gggagtgtag 900

```

agaagacaga aggaaagctg agagctggcc cgacatggtc tgggacacag agttggagct 960
ggcactgaag atctccaggg acttcagaga ccaataaaaag cccatagggg agagagagag 1020
gatatagggg aacagaatca gatgtgtaat atacttggca cagcgaaaaa atggatttaa 1080
aagacaaaaa tggaggtcca ggtagatgta attcacacag actgaaagtg agttcgggct 1140
tgtgtaaaaa acatgagatt ggatttgacc ccttggctct caagtgtccc cttagatcta 1200
gaactgctcc ttggtggcca ttagatcgag tcagttttga tctgcatcac ttagttattg 1260
ggaatttctt tgttggaac aggaaaattt ttttagatta tttggtgtac ggttttgctc 1320
acaacaatag gtggaagttg ctagtgcagt cttggtctga tggctgtgtg catcgacat 1380
tcggcttggg gaaatccttc tctaaagcct ctttttgat ttttataact aaacagagga 1440
agtcttcaga agacctcgct ttaaaacaaa tttgtgcaaa cactgctaga gtcattttga 1500
agctcaagca ttttcacttt gtttcttaca tgtgtacttt tttgtttact tgtgaaaatg 1560
gccatcttta agcatattta ttttctgcca ctttatttaa aggcaagcaa tattttcttg 1620
atcataaata ttttgtaatg aaatacttcc tcttttccag ggctttgtat gcacttgtat 1680
aattacattg atggcaatgt agagtttgaa tttcagttctg taaatacttt tttggaaaat 1740
agaaattttt attgctttta agttttggat atgggtgggt ttcttttccg ggtttgggtg 1800
aaagtaattt gagaacttta aggttgtctt ttaactgct ggcaaaatgt tgatttttta 1860
atattagata aaacgagtaa acgaaattcc ccagaaatta gtagtaagtg gggcttttgt 1920
gggttgggaa gtagttttta ttagaaaaga catttacata taagtctgtt taatttcaa 1980
ggagtttgtg aaaaaaaatc catggtgaaa atgaaacaat gacatggtta atctggaact 2040
tacgttctta taccaataaa aggtacctca atamaaaaaa aaaaaaaaaa accccggggg 2100
ggg 2103

```

<210> 193

<211> 1317

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1314)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1315)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1316)

<223> n equals a,t,g, or c

<400> 193

```

agcatagcct tcgtgtgaag gccagtgaac agcagctgag ctaattcatg aggtatttgc 60
ccttctgaag ttggaatctg taatgattta aaacatgaga ctggtccagt gggcttggtg 120
ctccagacct catgccttct gggacccaga catctctgca atctcgggaa ctggaatata 180
ccacttcttg tcaaggtact agcaagttgc cgtggataca gaaatctctg caggcaagtt 240
gctccagagc atattgcagg acaagcctgt aacgaatagt taaattcacg gcatctggat 300
tctaatacct tttccgaaat ggcaggtgtg agtgccctgta taaaatatcc tatgtttacc 360
ttcaacttct tgttctggct atgtggtatc ttgatccatg cattagcaat atgggtacga 420
gtaagcaatg actctcaagc aatttttggg tctgaagatg taggctctag ctctacgtt 480

```

```

gctgtggaca tattgattgc tgtaggtgcc atcatcatga ttctgggctt cctgggatgc 540
tgcggtgcta taaaagaaag tcgctgcatg cttctgttgt ttttcatagg cttgcttctg 600
atcctgctcc tgcaggtggc gacaggtatc ctaggagctg ttttcaaadc taagtctgat 660
cgcatgtgta atgaaactct ctatgaaaac acaaagcttt tgagcgccac aggggaaagt 720
gaaaaacaat tccaggaagc cataattgtg tttcaagaag agtttaaag ctgcggtttg 780
gtcaatggag ctgctgattg gggaaataat tttcaacact atcctgaatt atgtgcctgt 840
ctagataagc agagaccatg ccaaagctat aatggaaaac aagtttaca agagacctgt 900
atttctttca taaaagactt cttggcaaaa aatttgatta tagttattgg aatatcattt 960
ggactggcag ttattgagat actgggtttg gtgttttcta tggctctgta ttgccagatc 1020
gggaacaaat gaatctgttg atgcatcaac ctatcgtcag tcaaaccctt ttaaaatggt 1080
gctttggctt tgtaaattta aatatgtaag tgctatataa gtcaggagca gctgtctttt 1140
taaaatgtct cggctagcta gaccacagat atcttctaga catattgaac acatttaaga 1200
tttgagggat ataaggaaa atgatatgaa tgtgtatttt tactcaaat aaaagtaact 1260
gtttacgttg aaaaaaaaa aaaargkcg ccgytytara gayccarctt actnnnc 1317

```

<210> 194

<211> 1252

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1231)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1240)

<223> n equals a,t,g, or c

<400> 194

```

gcccacgmgc ggccgcgcgg aggaggccaa gatggcggca gctgcggctt cgcttcgcgg 60
ggtagtggtg ggcccgcggg gcgcggggct cccgggcgcg cgtgcccggg gtctgctgtg 120
cagcgcgcgg cccgggcagc tcccgcctac gacacctcag gcagtggcct tgctgctgaa 180
gtctggcctt tcccgaggcc ggaaagtgat gctgtcagcg ctgggcatgc tggcggcagg 240
gggtgcgggg ctggccgttg ctctgcattc ggctgtgagt gccagtgacc tggagctgca 300
cccccccagc tatccgtggt ctaccctggg cctcctctct tccttggacc acaccagcat 360
ccggaggggt ttccaggtat ataagcaggt gtgcgcctcc tgccacagca tggacttcgt 420
ggcctaccgc cacctgggtg gcgtgtgcta cacggaggat gaagctaagg agctggctgc 480
ggaggtggag gttcaagacg gcccacatga agatggggag atgttcatgc ggccagggaa 540
gctgttcgac tatttcccaa aaccataccc caacagttag gctgtctgag ctgccaacaa 600
cggagcattg cccctgacc tcagctacat cgtgcgagct aggcattggt gtgaggacta 660
cgtcttctcc ctgctcacgg gctactgcga gccacccacc ggggtgtcac tgcgggaagg 720
tctctacttc aaccctact ttcctggcca ggccattgcc atggcccctc ccatctacac 780
agatgtctta gagtttgacg atggcaccac agctaccatg tccagatag ccaaggatgt 840
gtgcaccttc ctgcgtggg catctgagcc agagcacgac catcgaaaac gcatggggct 900
caagatgttg atgatgatg ctctgctggt gccctgggtc tacaccataa agcggcacia 960
gtggtcagtc ctgaagagtc ggaagctggc atatcgggcc cccaagttag cctgtccagt 1020
gtctgcttgc catcctgcca gaacaggccc tcaagcccaa gagccatccc agcctgttca 1080
ggcctcagct aagcctctct tcatctggaa gaagaggcaa gggggcagga gaccaggctc 1140
tagctctggg ccctccttca gcccacatca tgggaataaa ttaattttct caatgtaaaa 1200

```

aaaaaaaaa aaaactcggg gggggcccg ncccaatttn cccttttggg gg 1252

<210> 195

<211> 1688

<212> DNA

<213> Homo sapiens

<400> 195

```

ggcacgagcg gaactgctcc ggagggcacg ggctccgtag caccaactgc aaggaccctt 60
ccccctgcgg gcgctcccat ggcacagtcc gcgttcgaga gtgacctgca ctcgctgctt 120
cagctggatg caccatcccc caatgcaccc cctgcgcgct ggcagcaaaa gccaagggaag 180
ccgcagcccg gccccctcac ccatgcgggc cgccaaccga toccacagcg ccggcaggac 240
tccgggccga actcctggca aatccagtcc caaggttcag accactccta gcaaacctgg 300
cggtgaccgc tatatccccc atcgcagtgc tgcccagatg gaggtggcca gcttcctcct 360
gagcaaggag aaccagcctg aaaacagcca gacgcccacc aagaaggaaac atcagaaaagc 420
ctgggctttg aacctgaacg gttttgatgt agaggaagcc aagatccttc ggctcagtgg 480
aaaaccacaa aatgcgccag agggttayca gaacagactg aaagtactct acagccaaaa 540
ggccactcct ggctccagcc ggaagacctg ccgttacatt ccttccctgc cagaccgtat 600
cctggatgcg cctgaaatcc gaaatgacta ttacctgaac cttgtggatt ggagttcttg 660
gaatgtactg gccgtggcac tggacaacag tgtgtacctg tggagtgcaa gctctggtga 720
catcctgcag cttttgcaaa tggagcagcc tggggaatat atatcctctg tggcctggat 780
caaagagggc aactacttgg ctgtgggcac cagcagtgtc gaggtgcagc tatgggatgt 840
gcagcagcag aaacggcttc gaaatatgac cagtcactct gcccgagtgg gctccctaag 900
ctggaacagc tatatcctgt ccagtgggtc acgttctggc cacatccacc accatgatgt 960
tcgggtagca gaacaccatg tggccacact gagtggccac agccaggaag tgtgtgggct 1020
gcgctgggcc ccagatggac gacatttggc cagtgggtgg aatgataact tggatcaatgt 1080
gtggcctagt gctcctggag aggggtggctg ggttcctctg cagacattca cccagcatca 1140
aggggctgtc aaggccgtag catggtgtcc ctggcagtc aatgtcctgg caacaggagg 1200
gggcaccagt gatcgacaca ttcgcatctg gaatgtgtgc tctggggcct gtctgagtgc 1260
cgtggatgcc cattcccagg tgtgtcccat cctctggtct cccattaca aggagctcat 1320
ctcaggccat ggctttgcac agaaccagct agttatttgg aagtaccaa ccatggccaa 1380
ggtggctgaa ctcaaaggct acacatcccg ggtcctgagt ctgacctga gccagatgg 1440
ggccacagtg gcatccgcag cagcagatga gaccctgagg ctatggcgct gttttgagtt 1500
ggaccctgcg cggcggcggg agcgggagaa ggccagtga gccaaaagca gcctcatcca 1560
ccaaggcatc cgctgaagac caacccatca cctcagttgt tttttatatt tctaataaaag 1620
tcatgtctcc cttcatgttt ttttttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaa 1688

```

<210> 196

<211> 756

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (756)

<223> n equals a,t,g, or c

<400> 196

```

ggcacgagcc gccctcggcg tcctctgtag cgggcgacct aggccgcggg acccggacgg 60
aggtagaggc cagggcagcg cgtccgggag cggagtccgc gcccgccgc gccatgccgg 120

```

```

acagctggga caaggatgtg taccctgagc ccccgcgccg cagcgccgtg cagcccaatc 180
ccatcgtcta catgatgaaa gcgttcgacc tcatcgtgga ccgacccgtg accctcgtga 240
gagaatztat agagcggcag cagcgaaga acaggtatta ctactaccac cggcagtacc 300
gccgcgtgcc agacatcact gagtgcagg aggaggacat catgtgcatg tatgaagccg 360
aaatgcagtg gaagagggac taaaaagtcg accaagaaat tatcaacatt atgcaggatc 420
ggctcaaagc ctgtcagcag agggaaggac agaactacca gcagaactgt atcaaggaag 480
tggagcagtt caccaggtg gccaaaggcct accaggaccg ctatcaggac ctgggggcct 540
acagttctgc caggaagtgc ctggccaaac agaggcagag gatgctgcaa gagagaaaag 600
ctgcaaaaga ggccgcccgt gccacctcct gaggcagctg tgggtgcccc tgctgtgtgg 660
ctctgtatga ctgttgctga aatataaagc cctgcaacct gaaaaaaaaa aaaaaaaaaa 720
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaattn 756

```

<210> 197

<211> 1471

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (458)

<223> n equals a,t,g, or c

<400> 197

```

ttggctgctc ctgacctcag caaaccaaga gggatcact gggatacatc agattggatg 60
ccaagcgttc ctctgccgga catacaagag ttccccaact atgaggtgat tgatgagcag 120
acaccctgt actcagcaga tccaaacgcc atcgatacgg actattacc cggaggctac 180
gacatcgaaa gtgattttcc tccaccccca gaagacttcc ccgcagctga tgagctacca 240
ccgttaccgc ccgaattcag caatcagttt gaatccatcc accctcctag agacatgcct 300
gccgcgggta gcttgggttc ttcatcaaga aaccggcaga ggttcaactt gaatcagtat 360
ttgcccaatt tttatcccct cgatatgtct gaacctcaa caaaaggcac tggtgagaat 420
agtacttgta gagaacccca tgccccttac ccgccagngt atcaaagaca cttcgaggcg 480
cccgtgtcg agagcatgcc catgtctgtg tacgcctcca ccgcctcctg ctctgacgtg 540
tcagcctgct gcgaagtgga gtccgaggtc atgatgagt actatgagag cggggacgac 600
ggccacttcg aagaggtgac gatcccgcgc ctggattccc agcagcacac ggaagtctga 660
ctctcaactc ccccaaagt gcctgacttt agtgaaccta gaggtgatgt gagtaatccg 720
cgctgttctt tgcagcagt cttccaagct ttttttggg agccgaatg gcatggctgc 780
gctggatcct gcgcctctgg acgtgctagc catttccagt gtcccaacta ctgtcatcgt 840
gaggttttca tcggctgtgc catttcccaa cgtcttttgg gatttacatc tgtctgtgtt 900
aaaataatca aacgaaaaat cagtccgtgt ttgtcagcat gattcatgta tttatataga 960
tttgattatt ttaattttcc tgtctctttt ttttgtaaat tttatgtaca gatttgattt 1020
ttcatagttt taactagatt tccaagatat tttgtgcatt tgtttcaact gaattttggg 1080
ggtggtagt ccattatcta gcaccctgat ttttttttt tactataacc agggtttcat 1140
tctgtctttt tccactgaag tgtgacattt tgtagtaca tttcagtgt gtcattcatt 1200
tctagctgta cataggatga aggagagatc agatacatga acatgtctta catgggttgc 1260
tgtatttaga attataaaca tttttcatta ttggaaagt taacggggac cttctgcata 1320
cctgttttag accaaaacca ccattgacaca gtttttatag tgtctgtata tttgtgatgc 1380
aatgggtctt taaaggtttt taatgaaaac taccattagc cagtctttct tactgacaat 1440
aaattattaa taaaaataaa aaaaaaaaaa a 1471

```

<210> 198

<211> 692

<212> DNA
 <213> Homo sapiens

 <220>
 <221> misc feature
 <222> (43)
 <223> n equals a,t,g, or c

<400> 198
 gtgaattggt aattcgacct cccctatagg gccgaatttg ggntaccggg cccccccctt 60
 agtgcggtct gctcttgga gttcaggctc gggtgtcttt tgggagccat ggagagtgc 120
 ttttatctgc gttactacgt ggggcacaag ggcaagtctg gccacgagtt cctggagttt 180
 gagtttcgac cggacgggaa gttaagatat gccaacaaca gcaattacaa gaatgatgtc 240
 atgatcagaa aagaggctta tgtacataaa agcgtgatgg aggaactgaa gagaataatt 300
 gacgacagtg aaattaccaa agaggatgat gcattgtggc ctccctcctga ccgagtgggc 360
 cggcaggagc ttgaaatcgt cattggagat gaacacattt cttttacaac atcaaaaatt 420
 ggttccctta ttgatgtcaa tcaatccaag gatccagaag gcttacgagt attttattat 480
 cttgtccagg acctgaagtg tttggtcttc agtcttattg gattacactt caagattaaa 540
 ccaatctaga ctgaatattg gtgtggacat ggggggtggg tgggagtaga aaattttgtg 600
 tatatcaggg cagtattttt ttatgaacta taaatgattg tctttaataa atatgtgata 660
 aaatccaatt tttattattt tataaagacc tg 692

<210> 199
 <211> 1573
 <212> DNA
 <213> Homo sapiens

<400> 199
 ctgctgccga attcggcacg agccggcgcc agctacgccg ctgccgctgt cactatggcc 60
 cattacaaag ccgccgactc gaagcgtgag cagttccgga ggtacttgga gaagtcgggg 120
 gtgctggaca cgctgaccaa ggtgttggtg gccttatatg aagaaccaga gaaacctaac 180
 agtgcttttg atttttttaa gcatcactta ggagctgcta ctccagaaaa tccagaaata 240
 gagctgcttc gcctagaact ggccgaaatg aaagagaagt atgaagctat tgtagaagaa 300
 aataaaaaac tgaaagcaaa gcttgctcag tatgaaccac ctccaggagga gaagcgtgct 360
 gaataggatt cttctcagtt tgaaagacaa tgaaaaatgg ttttgtatga cttgaatagt 420
 ttgtatagta tataatcttt tctgaacaga tgctatagaa ctctttttaa atgtttaatt 480
 cacctatcac actctgttaa aaacacatag aatcatcaat aaaaactcaa tataactttc 540
 tttgggtctt aaagcaggag aatccaaaagt aaatcctgaa caaaacctaa acacagccat 600
 ctaactcatt accttaaaag acattctgkt tattagtctg attaggaatg atggcactgg 660
 ttgtatttta gccaaagacag tttagcatgg agctattcct tgggtgcagtt caggatatga 720
 acacaggtac agtcattctt tgaaggtgac actgttctgt atattcccta taggcagctg 780
 gagagatctg tgtgacacaa gatgcttttg tacgggttcc catgaatctt ctgctcttgt 840
 ttgtgtgaca tggaacaaat aacttctttg ccaccacttt gccttagata actgtgtgtg 900
 tgtgtgccag tttgaactct gacaccacat tttccttcta tgcaatcatg cctgtctgat 960
 aatcttgcat tgctttcctc tgagcttttag tgggtcctag ttgcacactg gcctttctgt 1020
 gctgtttttc aatttgccca ataatagcag ttaccctgat tgtaatttat gtaactttta 1080
 acagatcac actgtacccc ctgcctgcct tatttgctta ctgagcacag gacagaggca 1140
 atatacaact ctgggttcac acacaagctg agatgagaag aggaatgagc catatattgg 1200
 ggaaaatcat agttttagtg tataattata tagtgctttt ctccctcaaa gtatttttct 1260
 agccttgaat tcattttatc ttcattatcc ctgtgaagta ggtgggacaa gtataagggg 1320
 aagaggggtg ctgaattttt aggccaaaaga ctgatattaa tacaatcac tcactaactg 1380

```

tagagccttg ggcattatca gtgaactact ctgagattta ctgtcttcat ctgtttaatg 1440
agtagaatgt ccgatgatgcc tacctcacag gggtgtgtgt aggggtcaaata gagaatgtat 1500
gtgaaagatt tgtaaatggt aaagcactat attcttgtta aaaaaaaaaa aaaaaaaaaa 1560
aaaaaaaaaa aaa 1573

```

<210> 200

<211> 2742

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (26)

<223> n equals a,t,g, or c

<400> 200

```

gggtcgaccc acgcgtccgc ccacgntccg tgaatgggtga actccagaaa gccattgact 60
tattcacaga tgccatcaag ctgaatcctc gcttggccat tttgtatgcc aagagggccca 120
gtgtcttcgt caaattacag aagccaaatg ctgccatccg agactgtgac agagccattg 180
aaataaatcc tgattcagct cagccttaca agtggcgggg gaaagcacac agacttctag 240
gccactggga agaagcagcc catgatcttg cccttgccctg taaattggat tatgatgaag 300
atgctagtgc aatgctgaaa gaagttcaac ctagggcaca gaaaattgca gaacatcgga 360
gaaagtatga gcgaaaacgt gaagagcgag agatcaaaga aagaatagaa cgagttaaga 420
aggctcgaga agagcatgag agagcccaga gggaggaaga agccagacga cagtcaggag 480
ctcagtatgg ctcttttcca ggtggctttc ctgggggaat gcctggtaat tttcccgag 540
gaatgcctgg aatgggaggg ggcatgcctg gaatggctgg aatgcctgga ctcaatgaaa 600
ttcttagtga tccagagggt cttgcagcca tgcaggatcc agaagttagt gtggctttcc 660
aggatgtggc tcagaaccca gcaaatatgt caaaatacca gagcaaccca aaggttatga 720
atctcatcag taaattgtca gccaaatttg gaggtcaagc gtaatgtcct tctgataaat 780
aaagcccttg ctgaaggaaa agcaacctag atcaccttat ggatgtcgca ataatacaaa 840
ccagtgtacc tctgaccttc tcatcaagag agctgggggtg ctttgaagat aatccctacc 900
cctctccccc aaatgcagct gaagcatttt acagtgggtt gccattaggg tattcattca 960
gataatgttt tcctactagg aattacaaac ttttaacact ttttaaatct tcaaaatatt 1020
taaaacaaat ttaaaggggc tgtaattctt tataattttt tttactaatc attttggatt 1080
tttttctttg aattattggc agggaaatata cttatgtatg gaagattact gctctgagt 1140
aaataaaaag tattagtgcg aggcaaacat aactcatttg aggataaagt ttgtgttgga 1200
tatgtggttc ctgatgcatt ttgacttgtc tttttaaatg ctttatcttt ttctttaaag 1260
atztatttca ataaaactaa ttgggaccac ccgtatttca gtaggacctg ggtagggatt 1320
ggaagtactt ggcagggcag cagcaatctt gctgtgtttg atataacatg catccttggg 1380
caggttgccc ttaaacttta cactgtggtg aagggatgtt tttttgttaa tgctgcagta 1440
gagttggagt acttagttct cttgttgtcc agtatatcta ataagtgtt ttcatattat 1500
ttccacgtaa gggaaataag gtagtacttt tcttttata tttctatgct taaaattctc 1560
tttcttagtc aaaaattgac caaatctgtg ttgtctttct gcttgctaca tttgtctccc 1620
ttacttttct tgagctaaag acaggctttt tccaccggca tcatcactgc tatcatatt 1680
aacagcgtaa ttatacaagc atatttaatg ctgagtttaa ttaatatgt aatacatatg 1740
gtaattgtag ggtaataccc acaacaactg tagtttctta cttggccaag agaattgctta 1800
tttaagtgtt agacttccat tctggcaaaa tcttgccctta tcagaagaca ttggaaagag 1860
ggattccctt tgggtgtttg tcttctactt agaaaaacct attgcagtta gtttatcttg 1920
tagtattcat ctttgtattc tgaagataag gtttgaatta aattgatata cacagagggg 1980
aaccgatttt ttttatccaa tgtgaattat aaatgagata atccacagtt attcattgtg 2040
gagttgttga gactatgaaa gactcattgt ctttgtattc agctcttaaa tagtgtaact 2100

```

```

atatccccac ctctgcttgc tttcttttccc tccccctccaa tgataaagaa aatgataaat 2160
tttctgtttgt gcatttcaatt cttatttttaa ataagactaa gtataggcat tgtacctgac 2220
attgctacgt ttctaccagt gtttcaattt aaagtgtctag tgtttaaaaa cattttcaag 2280
ggataaggcc ttctgtactt tgcttatttg aagaatcagt ggtaggagca gtgaagtaaa 2340
ttctatggag tacatttcta aaataccaca tttctgaaat cataaataag tttattcagg 2400
ttctaaccct ttgctgtaca caagcagaca gaaatgcatc tgttacataa atgagaaaaa 2460
gctattatgc tgatggagca tgcttttttaa atccttttaa aacactcacc atataaactt 2520
gcatttgagc ttgtgtgttc ttttgttaat gtgtagagtt ctcttttctc gaaattgcca 2580
gtgtgtactt ggcttaactc aagaacagtt tcttctggat tccttatttg atttatttaa 2640
cctaattata ttctaattatt gcaaatatta ccataagtgg gtaaaagtaa aattcctctt 2700
ctgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggggggg gg 2742

```

<210> 201

<211> 1417

<212> DNA

<213> Homo sapiens

<400> 201

```

atgaagactt gtcaagagga aaaattgatg ggacacttgg gtgttgattt gtatgagtat 60
ttgggtgaag agtaccctga agtattgggc agcattcttg gagcactgaa ggccattgta 120
aatgtcatag gtatgcataa gatgactcca ccaattaaag atctgctgcc tagactcacc 180
cccattctta agaacagaca tgaaaaagta caagagaatt gtattgatct tgttggtcgt 240
attgctgaca ggggagctga atatgtatct gcaagagagt ggatgaggat ttgctttgag 300
cttttagagc tcttaaaagc ccacaaaaag gctattcgta gagccacagt caacacattt 360
ggttatattg caaaggccat tggccctcat gatgtattgg ctacacttct gaacaacctc 420
aaagttcaag aaaggcagaa cagagtttgt accactgtag caatagctat tgttgcagaa 480
acatgttcac cctttacagt actccctgcc ttaatgaatg aatacagagt tcctgaactg 540
aatgttcaaa atggagtgtt aaaatcgctt tccttcttgg ttgaatatat tggtgaaatg 600
ggaaaagact acatttatgc cgtaacaccg ttacttgaag atgctttaat ggatagagac 660
cttgtagaca gacagacggc tagtgacgtg gtacagcaca tgtcacttgg ggtttatgga 720
tttggttggtg aagattcgct gaatcacttg ttgaaactatg tatggcccaa tgtrtttgag 780
acatctcctc atgtaattca ggcagttatg ggagccctag agggcctgag agttgctatt 840
ggaccatgta gaatgttgca atattgttta caggggtctgt ttcaaccagc ccggaaagtc 900
agagatgtat attggaaaat ttacaactcc atctacattg gttcccagga cgctctcata 960
gcacattacc caagaatcta caacgatgat aagaacacct atattcggtt tgaacttgac 1020
tatactctat aattttattg tttattttgt gtttaatgca cagctacttc acaccttaaa 1080
cttgctttga tttgggtgat taaactttta aacattgcag atcagtgtag aactggtcatt 1140
agaggaagag ctagaaatcc agtagcatga tttttaaata acctgtcttt gtttttgatg 1200
ttaaacagta aatgccagta gtgaccaaga acacagtgat tatatacact atactggagg 1260
gatttcattt ttaattcatc tttatgaaga tttagaactc attccttggtg tttaaaggga 1320
atgtttaatt gagaaataaa catttgtgta caaaatgcta aaaaaaaaaa aaaaaaaaaa 1380
ctcgaggggg gcccgtaccc aattcgccgt atagtga 1417

```

<210> 202

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (855)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1512)

<223> n equals a,t,g, or c

<400> 202

```

cttagaagac cctatgcaag gtacaacggc ttgtaccggt ccggaattcg cgggcgcgkc 60
aacttgagaga gtactcgggt tcgtgaactt cccggaggcg caatgagctg cattaacctg 120
cccactgtgc tgccyggctc cccagcaag acccgggggc agatccaggt gattctcggg 180
ccgatgttct caggaaaaag cacagagttg atgagacgcg tccgtcgctt ccagattgct 240
cagtacaagt gcctgggtgat caagtatgcc aaagacactc gctacagcag cagcttctgc 300
acacatgacc ggaacacccat ggaggcrtcg cccgcctgcc tgctccgaga cgtggcccag 360
gaggeccctgg gcgtggctgt cataggcatc gacgaggggc agtttttccc tgacatcgtg 420
gagttctgcg aggccatggc caacgccggg aagaccgtaa ttgtggctgc actggatggg 480
accttycaga ggaagccatt tggggccatc ctgaacctgg tgccgctggc cgagagcgtg 540
gtgaagctga cggcggtgtg catggagtgc ttccgggaag ccgcctatac caagaggctc 600
ggcacagaga aggaggtcga ggtgattggg ggagcagaca agtaccactc cgtgtgtcgg 660
ctctgctact tcaagaaggc ctcaggccag cctgccgggc cggacaacaa agagaactgc 720
ccagtgccag gaaagccagg ggaagccgtg gctgccagga agctctttgc cccacagcag 780
attctgcaat gcagccctgc caactgaggg acctgcgagg gccgcccgtt cccttccctgc 840
cactgccgcc tactnggacg ctgccctgca tgctgcccag ccactccagg aggaagtcgg 900
gaggcgtgga ggggtgaccac accttggcct tctgggaact ctcttttggt tggctgcccc 960
acctgccgca tgctccctcc tctcctacct actggtctgc ttaaagcttc cctctcagct 1020
gctgggacga tcgcccaggc tggagctggc cccgcttggg ggcttgggat ctggcacact 1080
ccctctcctt ggggtgaggg acagagcccc acgctgttga catcagcctg cttcttcccc 1140
tctgcggctt tcaactgctga gtttctgttc tccctgggaa gcctgtgcca gcaccttga 1200
gccttggccc aactgaggc ttaggcctct ctgcctggga tgggctccca ccctccccctg 1260
aggatggcct ggattcacgc cctcttgttt ccttttkggc tcaaagccct tcctacctct 1320
ggtgatggtt tccacaggaa caacagcatc ttccaccaag atgggtggca ccaaccttgc 1380
tgggacttgg atcccagggg cttatctctt caagtgtgga gagggcaggg tccacgcctc 1440
tgctgtagct tatgaaatta actaattgaa aattcaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaaaaaaa an 1512

```

<210> 203

<211> 419

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (384)

<223> n equals a,t,g, or c

<400> 203

```

cctgggcaga gccggtggca agggcctccc ctgccgctgt gccaggcagg cagtgccaaa 60
tccggggagc ctggagctgg ggggaaggcc ggggacagcc cggccctgcc ccctcccccg 120
ctgggagccc agcaacttct gaggaagtt tggcacccat ggcgtggcgg tgccccagga 180
tgggcagggg cccgctggcc tgggtgcttg cgctgtgcgg ctggggcgtg catggcccc 240
aggggcacgc argctgaaga aagtcccttc gtgggcaacc cagggaatat cacagtgctc 300

```

cggggactca cgggcaccct tcggtgtcag ctccaggttc agggagagcc ccccgaggta 360
cattggcttc gggatggaca gatnctggag ctccgggaca gcacccagac ccagggtgtt 419

<210> 204

<211> 2833

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2802)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2822)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2831)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2832)

<223> n equals a,t,g, or c

<400> 204

gctcgtgccg aattcggcac gagggaaagtg aagccccagc gagcggctgc agcggggccg 60
tgaggagcag ccagcgggag gcggcggcga gtcggtgagc agctgggaag agcagaaccg 120
gggcggagca cctgcaggcg cgggcggcgg cccaccatg gcgattcgca agaaaagcac 180
caagagcccc ccagtgtcga gccacgaatt cgctctgcag aatcacgcgg acatcgtctc 240
ctgtgtggcg atggtcttcc tgctggggct catgtttgag ataacggcaa aagcttctat 300
catttttgtt actcttcagt acaatgtcac cctcccagca acagaagaac aagctactga 360
atcagtgtcc ctttattact atggcatcaa agatttggct actgttttct tctacatgct 420
agtggcgata attattcatg ccgtaattca agagtatatg ttggataaaa ttaacaggcg 480
aatgcacttc tccaaaacaa aacacagcaa gtttaatgaa tctggtcagc ttagtgcgtt 540
ctaccttttt gcctgtgttt ggggcacatt cattctcatc tctgaaaact acatctcaga 600
cccaactatc ttatggaggg cttatcccca taacctgatg acatttcaaa tgaagttttt 660
ctacatatca cagctggctt actggcttca tgcttttctt gaactctact tccagaaaaa 720
caaaaaagaa gatattcctc gtcagcttgt ctacattggt ctttacctct tccacattgc 780
tgagagcttac cttttgaact tgaatcattt aggacttggt cttctggtgc tacattattt 840
tggtgaattt cttttccaca tttcccgccg gttttatttt agcaatgaaa agtatcagaa 900
aggattttct ctgtgggcag ttctttttgt tttgggaaga cttctgactt taattctttc 960
agtactgact gttggttttg gccttgcaag agcagaaaaa cagaagctgg atttcagtac 1020
tggaacttcc aatgtgttag ctgttagaat cgctgttctg gcatccattt gcgttactca 1080
ggcatttatg atgtggaagt tcattaattt tcagcttcga aggtggaggg aacattctgc 1140
ttttcaggca ccagctgtga agaagaaacc aacagtaact aaaggcagat cttctaaaaa 1200
aggaacagaa aatggtgtga atggaacatt aacttcaaat gtagcagact ctccccgaa 1260
taaaaaagag aaatcttcat aatgaattat aaactaattg attaatgtcc ccaaagaaat 1320

```

ctgctttcta ctatatcttt cagcattaga gatttttctg ttcttgaaaa tacagtctgt 1380
gctctttgat ttttgctatt gtacggtttc atgcattttt ttaaagggca tttgagggga 1440
ggattattgc tatgaatgaa aaaaatattt tagcttagac taagctacct gccttcaaaa 1500
tagtttaggg accaccacca tattttattt tgtttttatt tttgaacatt tttctaataga 1560
tttgagagaga aaactattta caaaaattcc acatatcagt gatacaattt cttgctgtca 1620
ccaatttttt ataatagcag agtggcctgt tctaagaagg ccatattttt taagttatct 1680
ttcagggtaa catggaaata ctataaagtt ggatgtcaaa ctttaatatg ttttcagtgt 1740
tctctaattt tttggaattt ttgtagactt tacacctgga aaaaaagatt tgtaaaatca 1800
ccggaacaat tgtgtgcttt attttatagg tagtggttat tagtattaca tccccatttt 1860
aaaaacaaaa acataataat ggttacaaca cgtggagttt tactaacata catattaaat 1920
caaagtatat tcttaaaagt acttgtgaag taaaatcttt cttgtgcatt ttcaatactt 1980
gtaaactgga aatcagaaaa tatttactat gaacaggaaa atctgacata tagccctttt 2040
tgatatgttt attaataatg attcttaatg gggctcataa taagtttaat atgcacagca 2100
tcttagaaaa gtttaacctg caaacacttt taaaacataa tgcctacttg atttatatct 2160
ataaaaagac tgacaggtaa ttatatgttg aaaaacattta atgcactaac tttaaagaaa 2220
ttgaaaattc aggtggataa atagtcttac aaaagacaat gtgctttatg ttataacctat 2280
agctttggtc ccatctttta ttgagaaaca tttatctgta taaaacatat ttttgataa 2340
atatatatat atatatgtt atcgctacag aaaggctcta aaaagcattt gaggaaaata 2400
tttggttccc ttttctataa tcatccttta agattcttat agctacattt ggtttattca 2460
tcatatttac agtatatata ttgttctttt cagtgttcac atcttgttcc ccatttctca 2520
cttgtgtcac cagctgtttg tgccattttt agtgtaaaag ttgcagacct attagatctg 2580
cagtttaagt tgccatgctg ctaggaaatt gtcctttttc tttctagctg ttaacctact 2640
tcttgaaaaa agtagtagct ctctgtagca ttatggagtt tcagtggaac caaatttttg 2700
ccattaaaaa ctggcattat actgaactat acattgagaa atcaatcaaa ataaaaattt 2760
ttactttcac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa anaaaaaaaa aaaaaaaaaa 2820
anaaaaaaaa nna 2833

```

<210> 205

<211> 5830

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5584)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (5585)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (5821)

<223> n equals a,t,g, or c

<400> 205

```

cctgcgagtt cagggctcct gccgctctcc aggagcaacc tctactccgg acgcacaggc 60
attccccgcg cccctccagc cctcgccgcc ctcgccaccg ctcccgcccg ccgcgctccg 120
gtacacacag gatccctgct gggcaccaac agctccacca tggggctggc ctggggacta 180

```

ggcgtcctgt	tcctgatgca	tgtgtgtggc	accaaccgca	ttccagagtc	tggcggagac	240
aacagcgtgt	ttgacatctt	tgaactcacc	ggggccgccc	gcaaggggtc	tgggcgccga	300
ctggtgaagg	gccccgaccc	ttccagccca	gctttccgca	tcgaggatgc	caacctgac	360
ccccctgtgc	ctgatgacaa	gttccaagac	ctggtggatg	ctgtgcgggc	agaaaaggtg	420
ttcctccttc	tggcatccct	gaggcagatg	aagaagaccc	ggggcacgct	gctggccctg	480
gagcggaaag	accactctgg	ccaggtcttc	agcgtggtgt	ccaatggcaa	ggcgggcacc	540
ctggacctca	gcctgaccgt	ccaaggaaa	cagcacgtgg	tgtctgtgga	agaagctctc	600
ctggcaaccg	gccagtggaa	gagcatcacc	ctgtttgtgc	aggaagacag	ggcccagctg	660
tacatcgact	gtgaaaagat	ggagaatgct	gagttggacg	tcccatcca	aagcgtcttc	720
accagagacc	tggccagcat	cgccagactc	cgcacgcgca	aggggggctg	caatgacaat	780
ttccaggggg	tgctgcagaa	tgtgaggttt	gtctttggaa	ccacaccaga	agacatcctc	840
aggaacaaag	gctgctccag	ctctaccagt	gtcctcctca	cccttgacaa	caacgtggtg	900
aatggttcca	gccctgccat	ccgcactaac	tacattggcc	acaagacaaa	ggacttgcaa	960
gccatctgcg	gcctctcctg	tgatgagctg	tccagcatgg	tcctggaact	caggggcctg	1020
cgcaccattg	tgaccacgct	gcaggacagc	atccgcaaag	tgactgaaga	gaacaaagag	1080
ttggccaatg	agctgaggcg	gcctcccta	tgtatcaca	acggagttca	gtacagaaat	1140
aacgaggaat	ggactgttga	tagctgcact	gagtgtcact	gtcagaactc	agttaccatc	1200
tgcaaaaagg	tgtcctgccc	catcatgccc	tgtccaatg	ccacagttcc	tgatggagaa	1260
tgtgtcctc	gctgttgccc	cagcgactct	gcggacgatg	gctgggtctc	atgggtccgag	1320
tggacctcct	gttctacgag	ctgtggcaat	ggaattcagc	agcgcggccg	ctcctgcgat	1380
agcgtcaac	aaccgatgtg	agggtcctc	ggtccagaca	cggacctgcc	acattcagga	1440
gtgtgacaag	agatttaaac	aggatggtgg	ctggagccac	tgggtcccgt	ggtcatcttg	1500
ttctgtgaca	tgtggtgatg	gtgtgatcac	aaggatccgg	ctctgcaact	ctcccagccc	1560
ccagatgaac	gggaaaccct	gtgaaggcga	acgcgggaga	ccaaagcctg	caagaaagac	1620
gcctgcccc	tcaatggagg	ctggggtcct	tggtcaccat	gggacatctg	ttctgtcacc	1680
tgtggaggag	gggtacagaa	acgtagtctg	ctctgcaaca	acccrcacc	ccagtttgga	1740
ggcaaggact	gcgttggtga	tgtaacagaa	aaccagatct	gcaacaagca	ggactgtcca	1800
attgatggat	gcctgtccaa	tccctgcttt	gccggcgctg	agtgtactag	ctaccctgat	1860
ggcagctgga	aatgtggtgc	ttgtccccct	ggttacagtg	gaaatggcat	ccagtgcaca	1920
gatgttgatg	agtgcaaaga	agtgcctgat	gcctgcttca	accacaatgg	agagcaccgg	1980
tgtgagaaca	cggaccccg	ctacaactgc	ctgccctgcc	ccccacgctt	caccggctca	2040
cagcccttcg	gccaggggtg	cgaacatgcc	acggccaaca	aacagggtgtg	caagccccgt	2100
aaccctgca	cggatgggac	ccacgactgc	aacaagaacg	ccaagtgcaa	ctacctgggc	2160
cactatagcg	accccatgta	ccgctgcgag	tgcaagcctg	gctacgctgg	caatggcatc	2220
atctgcgggg	aggacacaga	cctggatggc	tggcccaatg	agaacctggg	gtgcgtggcc	2280
aatgcgactt	accactgcaa	aaaggataat	tgcccccaacc	ttcccaactc	agggcaggaa	2340
gactatgaca	aggatggaat	tggatgatgc	tgtgatgatg	acgatgacaa	tgataaaatt	2400
ccagatgaca	gggacaactg	tccattccat	tacaacccag	ctcagtatga	ctatgacaga	2460
gatgatgtgg	gagaccgctg	tgacaactgt	ccctacaacc	acaaccagaa	tcaggcagac	2520
acagacaaca	atggggaagg	agacgcctgt	gctgcagaca	ttgatggaga	cggatcctc	2580
aatgaacggg	acaactgcca	gtacgtctac	aatgtggacc	agagagacac	tgatatggat	2640
ggggttgag	atcagtgtga	caattgcccc	ttggaacaca	atccggatca	gctggactct	2700
gagctgagac	taccttgaga	tacctgtgac	aacaatcagg	atattgatga	agatggccac	2760
cagaacaatc	tggacaactg	tccctatgtg	cccaatgcc	accaggctga	ccatgacaaa	2820
gatggcaagg	gagatgcctg	tgaccacgat	gatgacaacg	atggcattcc	tgatgacaag	2880
gacaactgca	gactcgtgcc	caatcccgac	cagaaggact	ctgacggcga	tggtcgaggt	2940
gatgcctgca	aagatgattt	tgaccatgac	agtgtgccag	acatcgatga	catctgtcct	3000
gagaatgttg	acatcagtga	gaccgatctc	cgcgattcc	agatgattcc	tctggacccc	3060
aaagggacat	cccaaaatga	ccctaactgg	gttgtagccc	atcagggtaa	agaactcgtc	3120
cagactgtca	actgtgatcc	tggactcgct	gtaggttatg	atgagtttaa	tgctgtggac	3180
ttcagtggca	ccttcttcat	caacaccgaa	agggacgatg	actatgctgg	atttgtcttt	3240

```

ggctaccagt ccagcagccg cttttatggt gtgatgtgga agcaagtcac ccagtcctac 3300
tgggacacca accccacgag ggctcaggga tactcgggcc tttctgtgaa agttgtaaac 3360
tccaccacag ggccctggcg gcacctgcgg aacgccctgt ggcacacagg aracacccct 3420
ggccaggtgc gcacctgtg gcatgacctt cgtcacatag gctggaaaga tttcaccgcc 3480
tacagatggc gtctcagcca caggccaaag acgggtttca ttagagtggg gatgtatgaa 3540
gggaagaaaa tcatggctga ctcaggacct atctatgata aaacctatgc tgggtggtaga 3600
ctagggttgt ttgtcttctc tcaagaaatg gtgttcttct ctgacctgaa atacgaatgt 3660
agagatccct aatcatcaaa ttgttgattg aaagactgat cataaaccaa tgctgggtatt 3720
gcaccttctg gaactatggg cttgagaaaa ccccaggat cacttctcct tggcttccct 3780
cttttctgtg cttgcatcag tgtggacctc tagaacgtgc gacctgcctc aagaaaaatgc 3840
agttttcaaa aacagactca gcattcagcc tccaatgaat aagacatctt ccaagcatat 3900
aaacaattgc tttggtttcc ttttgaaaaa gcatctactt gcttcagttg ggaaggtgcc 3960
cattccactc tgcctttgtc acagagcagg gtgctattgt gaggccatct ctgagcagtg 4020
gactcaaaaag cattttcagg catgtcagag aaggaggagc tactagaat tagcaaaaa 4080
aaccaccctg acatcctcct tcaggaacac ggggagcaga ggccaaagca ctaaggggag 4140
ggcgcatacc cgagacgatt gtatgaagaa aatatggagg aactgttaca tgttcggtac 4200
taagtcattt tcaggggatt gaaagactat tgctggattt catgatgctg actggcgtaa 4260
sctgattaac ccatgtaaat aggcacttaa atagaagcag gaaagggaga caaagactgg 4320
cttctggact tcctccctga tccccacct tactcatcac ctgcagtggc cagaattagg 4380
gaatcagaat caaacagtg taaggcagtg ctggtgcca ttgcctggtc acattgaaat 4440
tgggtggctt attctagatg tagcttgtgc agatgtagca ggaaaatagg aaaacctacc 4500
atctcagtg gcaccagctg cctcccaaag gaggggcagc cgtgcttata tttttatggt 4560
tacaatggca caaaattatt atcaacctaa ctaaaacatt ccttttctct tttttcctga 4620
attatcatgg agttttctaa ttctctcttt tggaatgtag atttttttta aatgctttac 4680
gatgtaaaaa atttattttt tacttattct ggaagatctg gctgaaggat tattcatgga 4740
acaggaagaa gcgtaaagac tatccatgtc atctttgttg agagtcttcg tgactgtaag 4800
attgtaaata cagattattt attaaactct ttctgcctgg aaatttaggc ttcatacgga 4860
aagtgtttga gagcaagtag ttgacattta tcagcaaata tcttgcaaga acagcacaag 4920
gaaaatcagt ctaataagct gctctgcccc ttgtgctcag agtggatgtt atgggattct 4980
ttttttctct gttttatctt ttcaagtggg attagtgttg tatccatttg caaatgtttt 5040
aaattgcaaa gaaagccatg aggtcttcaa tactgtttta ccccatccct tgtgcatatt 5100
tccagggaga aggaaagcat atacactttt ttctttcatt tttccaaaag agaaaaaaat 5160
gacaaaagg gaaacttaca taaaaatatt acctatttg ttgtgtgact gagtaaagaa 5220
tttttggtatc aagcggaag agtttaagt tctaacaac ttaaagctac tgtagtacct 5280
aaaaagtcag tgtgtacat agcataaaaa ctctgcagag aagtattccc aataaggaaa 5340
tagcattgaa atgttaaata caatttctga aagttatgtt ttttttctat catctggtat 5400
accattgctt tatttttata aattattttc tcattgccat tggaatagat atctcagatt 5460
gtgtagatat gctattttaa taatttatca ggaaatactg cctgtagagt tagtatttct 5520
atttttatat aatgtttgca cactgaattg aagaattgtt ggttttttct tttttttgtt 5580
ttgnnttttt tttttttttt ttttgctttt gacctcccat ttttactatt tgccaatacc 5640
tttttctagg aatgtgcttt tttttgtaca catttttatc catttttacat tctaaagcag 5700
tgtaagttgt atattactgt ttcttatgta caaggaacaa caataaatca tatggaaatt 5760
tatattttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaagg gggggccccc 5820
nagggggccc 5830

```

<210> 206

<211> 755

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (368)
 <223> n equals a,t,g, or c

<400> 206

```

tcgaccacg cgtccgccag tcgcacatct cagacacctc cgtggttgtc aaactggaca 60
acagccggga cctgaacatg gactgcatca ttgccgagat taaggcacag tatgacgaca 120
ttgtcaccgc cagccggggc gaggccgagt cctggtaccg cagcaagtgt gaggagatga 180
aggccacggt gatcaggcac ggggagaccc tgcgccgcac caaggaggag atcaacgagc 240
tgaaccgcat gatccagagg ctgacggccg aggtggagaa tgccaagtgc cagaactcca 300
agctggaggc cgcggtggcc cagtctgagc agcagggtga ggcggccctc agtcatgccc 360
gctgcaanct ggccgagctg gagggcgccc tgcagaaggc caagcaggac atggcctgcc 420
tgatcaggga gtaccaggag gtgatgaact ccaagctggg cctggacatc gagatcgcca 480
cctacaggcg cctgctggag ggcgaggagc agaggctatg tgaaggcatt ggggctgtga 540
atgtctgtgt cagcagctyc cggggcgggg tcgtgtgcgg ggacctctgc gtgtcaggct 600
yccggccagt gactgcagtg tctgcagcgc tycgtgcaac gggaacgtgg cggtagcac 660
cggcctgtgt gcgccctgcg gcaattgaca ccamctgcgg aggggggtct gcggcgtggg 720
ctyctgtggt atcaagytte cccccctttt gggggg 755

```

<210> 207

<211> 1996

<212> DNA

<213> Homo sapiens

<400> 207

```

gggtcgaccc acgcgtccga tttagagccg ggtaggggag cgcagcrgcc agatacctca 60
gcgctacctg gcggaactgg atttctctcc cgcctgccgg cctgcctgcc acagccggac 120
tccgccactc cggtagcctc atggctgcaa cctgtgagat tagcaacatt tttagcaact 180
acttcagtgc gatgtacagc tcggaggact ccaccctggc ctctgttccc cctgctgcca 240
cctttggggc cgatgacttg gtactgacct tgagcaaccc ccagatgtca ttggagggtta 300
cagagaaggc cagctggttg ggggaacagc ccagttcttg gtcgaagacg caggttcttg 360
actggatcag ctaccaagtg gagaagaaca agtacgacgc aagcgccatt gacttctcac 420
gatgtgacat ggatggcgcc accctctgca attgtgccct tgaggagctg cgtctggtct 480
ttgggcctct gggggaccaa ctccatgccc agctgcgaga cctcacttcc agctcttctg 540
atgagctcag ttggatcatt gagctgctgg agaaggatgg catggccttc caggaggccc 600
tagaccaggg gccctttgac cagggcagcc cctttgccc ggagctgctg gacgacggtc 660
agcaagccag cccctaccac cccggcagct gtggcgagc agccccctcc ccyggcagct 720
ctgacgtctc caccgcaggg actggtgctt ctcgagctc ccactcctca gactccgggtg 780
gaagtgacgt ggacctggat cccactgatg gcaagctctt cccagcgat ggttttctgt 840
actgcaagaa ggggatccc aagcacggga agcggaacg aggcggccc cgaaagctga 900
gcaaagagta ctgggactgt ctcgagggca agaagagcaa gcacgcgcc agaggcaccc 960
acctgtggga gttcatccgg gacatcctca tccaccggga gctcaacgag ggctcatga 1020
agtgggagaa tcggcatgaa ggcgtcttca agttcctgag ctccgaggct gtggcccaac 1080
tatggggcca aaagaaaaag aacagcaaca tgacctacga gaagctgagc cgggccatga 1140
ggtactacta caaacgggag atcctggaac ggggtggatgg ccggcgactc gtctacaagt 1200
ttggcaaaaa ctcaagcggc tggaaggagg aagagggtct ccagagtcgg aactgagggt 1260
tggaactata cccgggacca aactcacgga ccactcgagg cctgcaaacc ttctggggag 1320
gacaggcagg ccagatggcc cctccactgg ggaatgctcc cagctgtgct gtggagagaa 1380
gctgatgttt tgggtgtatt tcagccatcg tctgggact cggagactat ggctcgccct 1440
ccccaccctc ctcttggaaat tacaagccct ggggtttgaa gctgacttta tagctgcaag 1500
tgtatctcct tttatctggt gcctcctcaa acccagctct agacactaaa tgacagacaac 1560

```

```

accttcctcc tgcagacacc tggactgagc caaggaggcc tggggaggcc ctaggggagc 1620
accgtgatgg agaggacaga gcaggggctc cagcaccttc tttctggact ggcgttcacc 1680
tccttgctca gtgcttgggc tccacgggca ggggtcagag cactccctaa tttatgtgct 1740
atataaatat gtcagatgta catagagatc tattttttct aaaacattcc cctccccact 1800
cctctccac agagtgtggt actgttccag gccctccagt gggctgatgc tgggaccctt 1860
aggatggggc tcccagctcc tttctcctgt gaatggaggc agagacctcc aataaagtgc 1920
cttctgggct ttttctaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaaa ctcgag                                     1996

```

<210> 208

<211> 1668

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1505)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1565)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1598)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1620)

<223> n equals a,t,g, or c

<400> 208

```

cacactgctc gcttcggata ctccaggcgt ctcccgttgc ggccgctccc tgccttagag 60
gccagccttg gacacttgct gcccctttcc agcccggatt ctgggatacct tccctctgag 120
ccaacatctg ggtcctgcct tcgacaccac cccaaggctt cctaccttgc gtgcctggag 180
tctgccccag gggcccttgt cctggggccat ggccmagaag ggggtcctgg ggcctgggca 240
gctggggggt gtggccattc tgctctatct tggattactc cggtcgggga caggagcgga 300
aggggcagaa gctycctgcg gtgtggcccc ccaagcacgc atcacagggt gcagcagtgc 360
agtcgccgggt cagtggccct ggcaggtcag catcacctat gaaggcgtcc atgtgtgtgg 420
tggctctctc gtgtctgagc agtgggtgct gtcagctgct cactgcttcc ccagcgagca 480
ccacaaggaa gcctatgagg tcaagctggg ggcccaccag ctagactcct actccgagga 540
cgccaaggtc agcaccctga aggacatcat cccccacccc agctacctcc aggagggtc 600
ccagggcgac attgactcc tccaactcag cagacccatc acctctctcc gctacatccg 660
gcccctctgc ctccctgcag ccaacgcctc ctccccaac ggcctccact gcactgtcac 720
tggctgggggt catgtggccc cctcagtgag cctcctgacg cccaagccac tgcagcaact 780
cgagggtgct ctgatcagtc gtgagacgtg gtaactgcct gtacaacatc gacgccaagc 840
ctgaggagcc gcactttgtc caagaggaca tgggtgtgtg tggctatgtg gaggggggca 900
aggacgcctg ccagggtgac tctggggggc cactctcctg ccctgtggag ggtctctggt 960

```

```

acctgacggg cattgtgagc tggggagatg cctgtggggc ccgcaacagg cctgggtgtgt 1020
acactctggc ctccagctat gcctcctgga tccaaagcaa ggtgacagaa ctccagcctc 1080
gtgtgggtgcc ccaaaccagc gagtcccagc ccgacagcaa cctctgtggc agccacctgg 1140
ccttcagctc tgccccagcc cagggtctgc tgaggcccat ccttttctctg cctctggggc 1200
tggctctggg cctcctctcc ccatggctca gcgagcactg agctggccct acttccagga 1260
tggatgcac acactcaagg acaggagcct ggtccttccc tgatggcctt tggaccagga 1320
gocctgacttg agccactcct tccttcagga ctctgcggga ggctggggcc ccactctgat 1380
ctttgagccc attcttcttg gtgtgctttt tgggaccatc actgagagtc aggagtttta 1440
ctgcctgtag caatggccag agcctctggc ccctcamcca ccattggacca gccattggs 1500
cgagntcctg gggagtcctg ggacctgggy tatgaaaatg agccctgggt tcccacctgt 1560
ttctngaaga ctgcttcccg gccgccttc ccagactnga tgagcacatt ttttttgcen 1620
tttccctgtg tttttgggtt gggcaacttt ttggaagtgt gaggagaa 1668

```

<210> 209

<211> 2250

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (23)

<223> n equals a,t,g, or c

<400> 209

```

gctttaagca aaaaggtctt tangtgacac tatagaaggt acgcctgcag gtaccgggtcc 60
ggaattcgcg gccgcgtcga cattcgccgc cgcagcagcc gccgcccccg ggagccgccg 120
ggaccctcgc gtcgtcgccg ccgcccgcgc ccagatcccc gcacccatgcc gtcggagaag 180
accttcaagc agcgcgcgac cttcgaacaa agagtagaag atgtccgact tattcgagag 240
cagcatccaa ccaaaatccc ggtgataata gaacgataca aggggtgagaa gcagcttcc 300
gttctggata aaacaaagtt cctgtacct gaccatgtca acatgagtga gctcatcaag 360
ataattagaa ggcgcttaca gctcaatgct aatcaggcct tcttcctggt ggtgaacgga 420
cacagcatgg tcagcgtctc cacaccaatc tcagaggtgt atgagagtga gaaagatgaa 480
gatggattcc tgtacatggc ctatgcctcc caggagacgt tcgggatgaa attgtcagtg 540
taaaaccaga aaaaatgcat ctcttctaga attgtttaaa cccttaccaa ggaaaaaaaa 600
ggggtgttac caactgagat cgatcagttc atccaatcac agatcatgaa acagtagtgt 660
tcccacctag gagtgttagg aagttgtgtt tgtgtttcaa gcagaaaaac tgagctccaa 720
gtgagcacat tcagcttttg aaactatatt atttaattgta ggctagcttg ttttcaaatt 780
ttaaaagtgt aaaaataaaa tactttgcat tctaagttgc caataaaata gaccttcaag 840
ttattttaat gctcttttct cactaatagg aacttgtaat tccagcagta atttaaaggc 900
tttcagagag accctgagtc ttctcttcag gttcacagaa cccgcccgcct ttttgggtag 960
aagtttttcta ctacagtaga gagatctccc taagaggatc tttaggcctg agttgtgaag 1020
cgcaaccccc gcaaaacgca tttgccatca cagttggcac aaacgcaggg taaacgggct 1080
gtgtgagaaa acggccctga ctgtaaactg ctgaaggtcc ctgactccta agagaaccac 1140
acccaaagtc ctactcttg caggggtaga catttctggt ttggtttgtt ctctagatag 1200
ttcacacat aaagacacca ctcaaaagga aacttgaata atttataatt ttgatcgagt 1260
ttctttaaag accctggaga aagagtggca tttctctgtt ttcaggtttt gtctgagttc 1320
aaactagtc ctgtgttgtt acggaaagca gcagtgtacc agtgtcactc tggagtacag 1380
cgggagaaac acaaaatagt ataactgaaa acattaacat tcagacacac tcccttctgc 1440
cttccggctt aaagctgtgg atgatccacg tttttgtttt ttttaattgta aatgtgtaac 1500
tcagtattac tgaaaaggta cccacatttt gaatagtagt tatcactctt aggtcagaca 1560
gccatcagaa ttctcccaca ccaagtgcac gtcagttgtg gagaaaacat agcaaaaaga 1620

```

```

gccgtacgct ctttacagat actaatgtca agagttaaac ctccctcaggt tcaacctgtg 1680
ataaaagact agtgcttccc agtacttgca tgggggtcac tatttatagt tttcttgga 1740
gtatcacagg aaaatcacaa ttacaccact ttagacccta tgtgtagcag gtcacaactt 1800
acccttggtg gtttagatgt gtatgaaata cctgtatacg ttagtgaaag ctgtttactg 1860
taacggggaa aaccagattc tttgcatctg ggccctctac tgattgttaa aggagttcct 1920
gtcacctgct cccccaccc cgcgatgct ctgtccactt ggctaacttt taatatgtgt 1980
atttttacat tatgtatatt cttaactgga ctgtctcgtt tagactgtat acatcatatc 2040
tgacattatt gtaactaccg tgtgatcagt aagattcctg taagaaatac tgctttttaa 2100
gaaaaaaaaa aacatgctga ggggtgacct atatcccatg tgagtgggtca ctttatttat 2160
aggatcttta aaacattttt aatgaaactaa gttgaataaa ggcacaatta aaaactgtca 2220
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2250

```

<210> 210

<211> 838

<212> DNA

<213> Homo sapiens

<400> 210

```

ggcgggccta cgtgctccgc ccgctgtgag cctgtccggc ccccgccgcg tccggagcaa 60
cccgcgagct tacaccggct tctctctgtc ctcagccgcg gcgcccgcct cgcgctcatg 120
ctgggcgccc ctctccgccc ctgctgtgtg gccgcaacca cccgggcccga ccctcgaggc 180
ctcctgcact ccgcccggac ccccgccccg gcgctggcta tccagtcagt tcgctgctat 240
tcccatgggt cacaggagac agatgaggag tttgatgctc gctgggtaac atacttcaac 300
aagccagata tagatgcctg ggaattgcgt aaagggataa acacacttgt tacctatgat 360
atggttccag agcccaaaat cattgatgct gctttgcggg catgcagacg gttaaagtat 420
tttgctagta cagttcgtat cctagagggt gttaaggaca aagcaggacc tcataaggaa 480
atctaccctt atgtcatcca ggaacttaga ccaactttta atgaactggg aatctccact 540
ccggaggaac tgggccttga caaagtgtaa accgcatgga tgggcttccc caaggattta 600
ttgacattgc tacttgagtg tgaacagtta cctggaaata ctgatgataa catattacct 660
tatttgaaac agttttcctt tattgagtac caagccatgt aatggtaact tggactttta 720
taaaaggga atgagtttga actgaaaaaa aaaaaaaaaa aaactcatac agactgaagc 780
gcggtgatta aataatgaaa gagttcgacg cggccgggaa tttaggagggt aaatatcc 838

```

<210> 211

<211> 1213

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1206)

<223> n equals a,t,g, or c

<400> 211

```

gccacgcgt ccggcaggaa ccgcggtgc tggacaagag ggggtgcggtg gatactgacc 60
tttgctccgg cctcgtcgtg aagacacagc gcatctcccc gctgtaggct tcctcccaca 120
gaacccgttt cgggcctcag agcgtctggt gagatgctgt tgccgctgct gctgctgcta 180
cccatgtgct gggccgtgga ggtcaagagg ccccgggcg tctccctcac caatcatcac 240
ttctacgatg agtccaagcc ttacacctgc ctggacggtt cggccaccat cccatttgat 300
caggtaacg atgactattg cgaactgaaa gatggctctg acgagccagg cacggctgcc 360
tgtcctaata gcagcttcca ctgcaccaac actggctata agcccctgta tatcccctcc 420

```

```

aaccgggtca acgatggtgt ttgtgactgc tgcgatggaa cagacgagta caacagcggc 480
gtcatctgtg agaacacctg caaagagaag ggccgtaagg agagagagtc cctgcagcag 540
atggccgagg tcacccgcga agggttccgt ctgaagaaga tccttattga ggactggaag 600
aaggcacggg aggagaagca gaaaaagctc attgagctac aggctgggaa gaagtctctg 660
gaagaccagg tggagatgct gcggacagtg aaggaggaag ctgagaagcc agagagagag 720
gccaaagagc agcaccagaa gctgtgggaa gagcagctgg ctgctgcaa ggcccaacag 780
gagcaggagc tggcggctga tgccttcaag gagctggatg atgacatgga cgggacggtc 840
tcggtgactg agctgcagac tcacccggag ctggacacag atggggatgg ggcgttgtca 900
gaagcggaag ctcaggccct yctcagtggg gacacacaga cagacgccac ctctttctac 960
gaccgcgtct gggggcccagg cggggctggt ccacattccc agggcccaac agccttcaaa 1020
gatgggtaaa ggagcttgcc ctccctgggc ccccacctt ggtgactcgc cccaccacc 1080
ccagccctgt cctgccacc cctcctagtg gggactagt aatgacttga cctgtgacct 1140
caatacaata aatgtgatcc ccacccaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaa 1213

```

<210> 212

<211> 969

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (922)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (955)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (958)

<223> n equals a,t,g, or c

<400> 212

```

ccactgcttc ccatgggcag tcttgetcat atcctgggag ctctgttct ttcagaccca 60
aaggaaccca agcagaaatc tttgtatgta tatgtatgaa gaggttgtct gtttttagga 120
gttgtatgta aaagctaagg aaaccttttc ttttgaaga tcagtataaa catgctgctt 180
ttggtaaaat tcttttgagc cattttcatc taaatataac ttctgtttca ttttttttc 240
taaataatac tcagagtta atgagggctt ttcacatgga acaagctttt gagaggcct 300
gtgttgctga agttttcgcc cttggattgc tggggtgata ttggtgacaa actctgtagg 360
gaaggactgg gaacctgtca atcttttttc tttggttggg tggattgggc agggaatagc 420
tgacttgatt tgttataagt ttggaagggt atagtgttgg caccattctt attgatcaca 480
cttttaggga ttcttgaaga aaagggaagc aaaacataca cacacacccc cacccaatct 540
aacagcgtat tcaagcagat tccacgaatc ctgggccag gtttaaataa ggcaggaaag 600
ttcccttccc tgctcacaca caacgaaaaa atggtggcca aagtggatga ggtgaagtcc 660
acaatcaagt tccaaatgaa gaaggtgtta tgtctggctg tagctgttgg tcacgtgaag 720
atgacagacg atgagcttgt gtataacatt cacctggctg tcaacttctt ggtgtcattg 780
ctcaagaaaa actggcagaa tgtccgggcc ttatatatca agagcaccat gggcaagccc 840
cagcgcctat attaaggcac atttgaataa attctattac cagttaaaaa aaaaaaaaaa 900

```

aaaaaaaaa aaaaaaaaaa anaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaanccncg 960
 gggggggggg 969

<210> 213

<211> 1694

<212> DNA

<213> Homo sapiens

<400> 213

```

ggcacgagag aagaggcggg agtggacctg gtcagcccta cccactgac cccaccggac 60
ccaggcgcgg cctccgccac agccacagcc cctgcccctg ctgcggcgcg gcgaggcgag 120
gcgatggcca aggtgtcggg gctgaacgtg gcggtcctgg agaaccgag ccctttccac 180
agccccttcc gggtcggagat cagcttcgag tgcagtgaag ccctggcgga cgacctggag 240
tggaagatca tttatgttgg ctgggtgag agtgaggaat ttgatcagat cctagactcg 300
gtgctggtgg gccctgtgcc agcagggaga cacatgtttg tctttcaggc cgacgcccc 360
aaccatccc tcatccaga gactgatgcc gtgggtgtga ctgtggtcct catcacctgc 420
acctaccatg gacaggagt catccgagt ggctactacg tcaacaacga gtacctcaac 480
cctgagctgc gtgagaacct gccatgaag ccagatttct cccagctcca gcggaacatc 540
ttggcctcga acccccggtg gaccgcttc catatcaact gggacaacaa catggacagg 600
ctggaggcca tagagacca ggaccctcc ctgggtgag gcctccact caactgcact 660
cctatcaagg gcttggggct ccctggctgc atccctggcc tcctccctga gaactccatg 720
gactgcatct aactgcagga acccagagt tcccagcac ccgggagggg caaccaggcc 780
tcccagcgag tcctgcaggg cccatctaga ggaytttggg ggccatcagc ttgcaatcca 840
ggtctgtcaa actcagcccy taggaaagaa caggccttgg gtytycccta gtctggcca 900
gaaggatgat ctgccttttc ctctacaggc ctataagaag caggtaactc agttctaaat 960
tctgacttgt gttcttttctg tcttcataaa ttctaactaa ggccactgtg cactgtgca 1020
cccttgagta ccattgatcc aaagctttcc cacagacctc cctggcccac ctagaggctt 1080
tcttggtcag tgcctgtcaa ggytccagtc ctgctgagcc aaaggctttg tcattccttt 1140
ctcttctgtg acatctgagc agaccactc cagctttctg gtgtcacagg cgggaatggt 1200
agttagtagg tagacttaga tcccatttct gtctgtctcc caggaagatt cttaggctct 1260
cttcaatcca gcagcccctc ccagagggtg gatcagcagg atgctgagga accatggtgc 1320
ctttcctgtc aatcacagcc accttctgt tatctcctaa atggatctgg cttttcctgg 1380
aggctgccat ggttggaaga tggatcaga gggcctgcct gggcagctctg tctccgggcc 1440
agggtcaggg accctctkcc tctggcagcc ttaacctgtc ctctgctagg accagggtga 1500
tttcaagcca gggaagcaac tgggacctg aaaactgtcc ctcccagcc cgctccccct 1560
ctctgtgccc tgggtcccctt gctgccatgt ggatgctgtt gtgattgctg tttgtatatt 1620
atcaaaatgt ttttatatta aaaatgtttg gtctgaaaat taaaagcact tcatttgaaa 1680
aaaaaaaaaa aaaa 1694

```

<210> 214

<211> 1210

<212> DNA

<213> Homo sapiens

<400> 214

```

ggcacgagcc gggcgctctc ctccsggacg ctgaggggcc cgaggagacc gtgaggctct 60
ggcctgcagc tcgcgcgcc atggacgctg ccgaggctga attcctcgcc gagaaggagc 120
tggttaccat tatccccaac ttcagtctgg acaagatcta cctcatcgga ggggacctgg 180
ggccttttaa ccctggttta cccgtggaag tgcccctgtg gctggcgatt aacctgaaac 240
aaagacagaa atgtcgctg ctccctccag agtggatgga tgtagaaaag ttggagaaga 300
tgagggatca tgaacgaaag gaagaaactt ttaccccaat gccagccct tactacatgg 360

```

```

aacttacgaa gctcctgtta aatcatgctt cagacaacat cccgaaggca gacgaaatcc 420
ggaccctggt caaggatatg tgggacactc gtatagccaa actccgagtg tctgctgaca 480
gctttgtgag acagcaggag gcacatgcca agctggataa cttgaccttg atggagatca 540
acaccagcgg gactttcctc acacaagcgc tcaaccacat gtacaaactc cgcacgaacc 600
tccagcctct ggagagtact cagtctcagg acttctagag aaaggcctgg tgcaggcggc 660
ttgctggggg atgtgagcgc tcaggacgtg atgaggtact cgtggttctg gagctctaga 720
aacacttctg atgcatgaaa aatgtgtgat ggtgcaagga atggattcag gatgttgttg 780
gagaaacaag tttgtgatta gtccttaaaa cttagctccc tgggacattc ttcaattcca 840
catctgtttc tagaaaccag ccctttttcc cccactttt gagaaataaa aaagccttag 900
gtaaataagt cattctccct agcagagcca cttgggtctc ctgcatggaa gccatcacac 960
ttgggcaggt gttcagtgac tggtagtgt agatacagca ggagtggcca tgtggtccac 1020
ggctttttac cccttcttga tccctatttc ttgggctgaa tttagactct ctcacagagg 1080
tggctcacag agaaggatgg cagatggtgc agccaacaat gctgaccggg gcttatcctc 1140
taagccctga tccacaataa aaatggaccc aactcaaaaa aaagagagag agagagagag 1200
agagagagac                                     1210

```

<210> 215

<211> 1776

<212> DNA

<213> Homo sapiens

<400> 215

```

agctggcccc gacgccagaa aatgttccac gtgggatacc ctgcgtgggk ttcactgtag 60
tagctgcact aggtgattct tggagcgggc ctgagagaca aggacatgtg gatcccagtg 120
gtcgggcttc ctcggcggct gaggtctctc gccttggcgg gcgctggctg cttttgcatt 180
ttagggctctg aagcggcgac gcgaaagcat ttgccggcga ggaaccactg tgggctctct 240
gactcctctc cgcagctgtg gccgaaccg gatttcagga atccgccaa gaaggcgtct 300
aaggccagct tagactttta gcgttacgta accgatcgga gattggctga gaccctggcg 360
caaatctatt tgggaaaacc aagtagacct ccacacctac tgctggagtg caatccagg 420
cctggaatcc tgactcaggc attacttgaa gctggtgcca aagtggttgc gctcgaaagt 480
gacaaaactt ttattccaca tttggagtcc ttaggaaaaa atctggatgg aaaactacga 540
gtgattcact gtgacttctt taaactagat cctagaagtg gtggagtaat aaaaccacct 600
gctatgtctt ctcgagggct ctttaagaat ttgggaatag aagcagttcc ttggacagca 660
gacatccctt taaaagtagt tggaatgttc ccaagtagag gtgagaaaag ggcacttttg 720
aaactcgcat atgacttgta ttctgtact tctatatata aatttgagc aatagaagta 780
aatatgttta ttggtgaaaa agaattccag aaactaatgg cagatccygg aaatccagac 840
ttgtatcatg tattaagtgt tatctggcaa ttagcttgtg agattaaggt tctgcacatg 900
gagccttggt catcatttga tatatacacc cggaaagggc cgctggaaaa cccaaagcgt 960
aggaattat tagaccaatt acaacaaaag ctgtatctta ttcaaagat tcctcgtcaa 1020
aatttattta ccaagaactt aacacctatg aactataata tattttttca cttgttaaag 1080
cactgttthy ggaggcgag sgccactgta atagaccact tacgttcatt gactccactt 1140
gatgcgagag atatatgat gcaaatagga aaacaggagg atgagaaagt agttaacatg 1200
caccctcaag acttcaaaac actttttgaa actatagagc gttccaaaga ttgtgcttat 1260
aaatggctgt atgatgaaac cctggaagat aggtagcaac tagactgtcg tttttgggtg 1320
agcggttcat ttatttgaa actatgacat gaaaaccaaa tttgaaaact cacatccttt 1380
cagcagaagg taactgttct tgtcttgac aagccaggca gatcatttct cctaagctga 1440
tatcattggc ttattggatg aaacagtgct tgctatttta ttcacaattg aataaaatga 1500
aaacttcaat taatttgga tttgatcaga ttgaattcgt tttgtttcag attcctattt 1560
aaatattttca cttgtactgt tgctgatttt tgcatcttct tgaagagcaa gagtctgtac 1620
attattaagc ttagaaagta agcaaaactg atttactggg ttgcctttca gtttgttgaa 1680
atgtattgtc aagtactgta caatgaaatt gtttaaatat taatatgatt taagcttttt 1740

```

agaaattaaa atatttttaaa taagaaaaaa aaaaaa

1776

<210> 216

<211> 1418

<212> DNA

<213> Homo sapiens

<400> 216

```

agggtttcct ggataggcctt gctgaagatg aaggggacag tgagccagag gccgttggac 60
agtccagggg agaagacaga agaagtagag aggcagggcc tggtagacagt atcagtgagt 120
gccatacaga attgtgtatt caccagcatc atgaaacagt tgtggtcttt tgagttgac 180
ttggcagagt aaagggacgt gtcctggagc cattcctgaa tctccccttc tttgtgacag 240
ctcctcccac ccccccaaaa aataaaaaaa ccacaaaaaa caaaaaaaca aaactaaggc 300
acttcactta gagactggag tcctgcttat aatcatgcat ataaccttta ctttgatgga 360
tctggccaga ggggtgttgg agcccagccc acccacatac cagtcaagct cttaggggag 420
cagaagaaaa gcaggaagaa tttaaattgt taattttttt tttaaattga cttttctagt 480
tattaaaagt tgcttgtttc agcagtgata ttgtataaag aacatcttgt aagatactcc 540
tgacatcttg ctttagcaca tgtacagtac agtttctatg ataatgtgtt tgctctaact 600
tccttggtt ctccttcagc ccattccact tcctctagag cagttgggtt ggaggctcat 660
tgaggcaagc agcaacattg gagggggagc agggcagtcg tgtgtctgct gcctcccatg 720
cccgttctga cctcagcctt ggaactcctc aagaacctga agattccagt ggtcagtgct 780
ggtggggggt gggaggagag agcggcagag aagctctgag agccccttcc cccacaacaa 840
atctagctct agttgttata tttaggcaaa actttgtagt cttctttccc ttttatgatg 900
gattttgata aaagtacaaa acagggtttt tcttttttat cacctttgaa tttggaaatt 960
ttgagcacc cagctcttct gtacctattt aaagtccacc aaggggactg cagctcctag 1020
aacatgagaa tcaagcctct taatttttaa ctgcggaatg tggcctctgc ttctccgctc 1080
ctcctgcccc aggacgacga ggattgctcc agggctgctg gtagtttac cgtcccttct 1140
ataggcatgg agttggcact gacatcacag cttcataacc ccaccaccgc cagcttcccc 1200
tgctccttac atccagtctg ttcttgttca tagtgagaat cctgtgttcc cacttcagtg 1260
acacctgaat tgtttgttgt tgtttttttt ttttattgtc ttcaaagagg aagggcccca 1320
ttaaagggtg aacttgtaat aaattggaat ttcaaataaa cctcatgtac ttgtgtttat 1380
aaagaagaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1418

```

<210> 217

<211> 2200

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2188)

<223> n equals a,t,g, or c

<400> 217

```

gggcacgagg ccagttcct gttcccagac tgaggcccag ccccttcgc ccgtttccat 60
cacgagtgcc gccagcatgt ctgacaaact gccctacaaa gtgcgacaga tcggcctggc 120
tgcttgggga cgcaaggccc tggacattgc tgagaacgag atgccgggcc tgatgcgtat 180
gcgggagcgg tactcgccct ccaagccact gaaggcgcc cgcatcgctg gctgcctgca 240
catgaccgtg gagacggccg tcctcattga gacctcgtc accctgggtg ctgagggtgca 300
gtggtccagc tgcaacatct tctccacca ggaccatgcg gcggctgcca ttgccaggc 360
tggcattccg gtgtatgcct ggaagggcga aacggacgag gagtacctgt ggtgcattga 420

```

```

gcagaccctg tacttcaagg acggggccct caacatgatt ctggacgacg ggggagacct 480
caccaacctc atccacacca agtaccgcga gcttctgccg ggcatccgag gcatctctga 540
ggagaccacg actgggggtcc acaacctcta caagatgatg gccaatggga tcctcaagggt 600
gcctgccatc aatgtcaatg actccgtcac caagagcaag ttgacaacc tctatggctg 660
ccgggagtc ctcatagatg gcatcaagcg ggccacagat gtgatgattg ccggcaagggt 720
agcggtggtg gcaggctatg gtgatgtggg caagggtgtg gccaggccc tgcgggggtt 780
cggagcccgc gtcacatca ccgagattga ccccatcaac gactgcagg ctgccatgga 840
gggctatgag gtgaccacca tggatgaggc ctgtcaggag ggcaacatct ttgtcaccac 900
cacaggctgt attgacatca tccttggccg gcactttgag cagatgaagg atgatgccat 960
tgtgtgtaac attggacact ttgacgtgga gatcgatgtc aagtggctca acgagaacgc 1020
cgtggagaag gtgaacatca agccgcagggt ggaccgggat cgggtgaaga atgggcgccg 1080
catcatcctg ctggccgagg gtcggctggt caacctgggt tgtgccatgg gccacccag 1140
cttcgtgatg agtaactcct tcaccaacca ggtgatggcg cagatcgagc tgtggacca 1200
tccagacaag taccocgttg gggttcattt cctgcccagg aagctggatg aggcagtggc 1260
tgaagcccac ctgggcaagc tgaatgtgaa gttgaccaag ctaactgaga agcaagccc 1320
gtacctgggc atgtcctgtg atggcccctt caagccggat cactaccgct actgagagcc 1380
aggtctgcgt ttcacctcc agctgctgtc cttgcccagg cccacctct cctccctaag 1440
agctaattgg accaactttg tgattgggtt gtcagtgtcc cccatcgact ctctggggct 1500
gatcacttag tttttggcct ctgctgcagc cgtcactactg ttccaaatgt ggcagcggga 1560
acagagtacc ctcttcaagc cccggtcatg atggaggtcc cagccacagg gaaccatgag 1620
ctcagtggtc ttggaacagc tactaagtc agtccttcct tagcctggaa gtcagttagt 1680
gagtcacaaa gcccatgtgt tttgccatct aggccttcac ctggtctgtg gacttatacc 1740
tgtgtgcttg gtttacaggt ccagtgggtt ttcagcccat gacagatgag aaggggctat 1800
attgaagggc aaagaggaac tggtgtttga attttcctga gagcctggct tagtgctggg 1860
ccttctctta aacctatta caatgaggtt agtactttta gtccctgttt tacaggggtt 1920
agaatagact gttaaggggc aactgagaaa gaacagagaa gtgacagcta ggggttgaga 1980
ggggccagaa aaacatgaat gcaggcagat ttcgtgaaat ctgccaccac ttataacca 2040
gatggttcct ttcacaacc tgggtcaaaa agagaataat ttggcctata atgttaaaag 2100
aaagcaggaa ggtgggtaaa taaaaatcct ggtgcctgga aaaaaaaaaa aaaaaaaar 2160
aaaraaaaaa aaaaaaaaaa aaaaaanaa aaaaaaaaaa 2200

```

<210> 218

<211> 1853

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (890)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1794)

<223> n equals a,t,g, or c

<400> 218

```

gggaaggagt catggcggat ggtcaggtgg cggaactgct gctccggcgg ctggaggcgt 60
ctgatggcgg cctggacagc gccgagttgg cggctgagct gggcatggag caccaggcgg 120
tggtgggcgc cgtgaagagc cttcaggcgc tgggcgagggt catcgaggct gaacttcggt 180
ccaccaagca ctgggagctt actgcggagg gcgaggagat tgcccgagg ggcagccatg 240

```

```

aggcccgtgt gtttcgaagc attccccag agggcctggc ccagagcgag cttatgcgac 300
tgcccagtg gaaagtgggc ttcagcaagg ccatgtccaa caagtggatt cgggtggaca 360
agagtgcggc tgacggggcc cgggtgttcc gagtgggtga cagcatggag gatgaggtgc 420
agcggcggct ccagctggtc cgggggggac aggctgagaa gctgggggag aaggagagga 480
gagagctgag gaagaggaag ctgttggctg aagtgactct gaagacctac tgggtgagca 540
aaggcagtg ctttagtacc agcatctcca agcaagagac agagctgagc ccagagatga 600
tctccagtg ctcttggcgg gaccggccct tcaagcccta caacttcttg gcccacgggtg 660
tcctccccga cagcggccac cttcaccgc tgctcaaggt ccgctcccag ttccgacaga 720
tcttcctgga gatgggggtt accgagatgc cgactgataa cttcattgag agctccttct 780
ggaactttga cgccctcttc cagccccagc agcaccagc ccgtgaccag cagcacacct 840
tcttccttcg agatccagcg gaggccctgc agctcccaat ggactatgtn cagcgggtca 900
agcggaccca ctctcagggc ggctacggct cagacgggta caagtataac tggaagctgg 960
acgaggcccc gaaaaacctt ctgcgaacct acaccacatc agccagcgcc cgtgcgctct 1020
accgccttgc ccagaagaag cccttcactc cgggtcaagta cttctccatc gaccgcgtat 1080
tccggaatga gaccctggac gccacgcacc tggctgagtt ccaccagatc gagggcgagg 1140
tggcggatca tgggtctacc ttggggccacc tcatgggctg tctgcgggag ttcttyacca 1200
agctgggtat cagcgaactc cgcttcaagc cagcctacaa cccatacaca gagcccagca 1260
tgagagtggt cagctaccac caaggcctga agaagtgggt ggaggtcgga aactcggggg 1320
tcttcctgct agagatgctg ctgcccattg ggcttcccga gaacgtgtcg gtcattgcct 1380
ggggcctctc cctggagcgc ccaacgatga tcaaatatgg catcaacaat atccgggagc 1440
tggtgggcca caaggtgaac ctgcagatgg tgtatgacag tcccctgtgc cgctggatg 1500
ccgagccgag gccccctccc acacaggagg ctgcgtgaca tggggcactc taggacaggt 1560
catcctcccc gagtccctgc tgctgcgtc ctttgcatcc ctggccagtg acctgtatt 1620
tatgaggcct ctgtgaggcc agccccacc ttcctctttc ccacctgtcc caggaccaga 1680
atcccaggga cagaggactg ggtagcaggt tccttctgtt gtctgtgtg gtgtgtctac 1740
tgtgagggtg ggccctgagg agacctgtgg gccacctatt gtctaataaa gtgngcagtt 1800
gcccccaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1853

```

<210> 219

<211> 1093

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1090)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1091)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1092)

<223> n equals a,t,g, or c

<400> 219

```

gcgtgcggcg tctacacccc gcgtgcgcc aggggctgcg ctgtatcccc caccgggct 60
ccgagctgcc cctgcagcgc tggatcatgg cgagggcact tgtgagaagc gccgggacgc 120

```

```

cgagtatggc gccagccccg agcaggttgc agacaatggc gatgaccact cagaaggagg 180
cctggtggag aaccacgtgg acagcaccat gaacatgttg ggcgggggag gcagtgtctg 240
ccggaagccc ctcaagtcgg gtatgaagga gctggccgtg ttccgggaga aggtcactga 300
gcagcaccgg cagatgggca aggggtggca gcatcacctt ggcttgagg agcccaagaa 360
gctgcgacca ccccttgcca ggactccctg ccaacaggaa ctggaccagg tcctggagcg 420
gatctccacc atgcgccttc cggatgagcg gggccctctg gagcacctct actccctgca 480
catccccaac tgtgacaagc atggcctgta caacctcaaa cagtcaaga tgtctctgaa 540
cgggcagcgt ggggagtgct ggtgtgtgaa cccaacacc ggaagctga tccagggagc 600
ccccaccatc cgggggggacc ccgagtgtca tctcttctac aatgagcagc aggaggtctg 660
cggggtgcac acccagcgga tgcagtagac cgcagccagc cggtgccctg cgccccctgc 720
ccccgccccct ctccaaacac cggcagaaaa cggagagtgc ttgggtggtg ggtgctggag 780
gattttccag ttctgacaca cgtatttata tttgaaaaga gaccagcacc gagctcggca 840
cctccccggc ctctctcttc ccagctgcag atgccacacc tgctccttct tgctttcccc 900
gggggaggaa gggggtgtg gtcggggagc tggggtacag gtttggggag ggggaagaga 960
aatttttatt tttgaacccc tgtgtccctt ttgcataaga ttaaaggaag gaaaagtaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1080
aaaaaaaaan nna 1093

```

<210> 220

<211> 2155

<212> DNA

<213> Homo sapiens

<400> 220

```

accacgcgt ccgctagaga gggattttmc ggtctcgtgg gcagaggaac aaccaggaac 60
ttgggctcag tctccacccc acagtggggc ggatccgtcc cggataagac ccgctgtctg 120
gccctgagta ggggtgtgacc tccgcagccg cagaggagga gcgcascagg cctcgaagaa 180
cttctgcttg ggtggctgaa ctctgatctt gacctagagt catggccatg gcaaccaaa 240
gagggtactgt caaagctgct tcaggattca atgccatgga agatgcccag accctgagga 300
aggccatgaa agggctcggc accgatgaag acgccattat tagcgtcctt gcctaccgca 360
acaccgccc aacgcaggag atcaggacag cctacaagag caccatcggc agggacttga 420
tagacgacct gaagtcagaa ctgagtggca acttcgagca ggtgattgtg gggatgatga 480
cgcccacggt gctgtatgac gtgcaagagc tgcgaagggc catgaaggga gccggcactg 540
atgagggctg cctaattgag atcctggcct cccggacccc tgaggagatc cggcgcataa 600
gccaaaccta ccagcagcaa tatggacgga gccttgaaaga tgacattcgc tctgacacat 660
cgttcatggt ccagcagagt ctggtgtctc tgctcagctg tgggagggat gaaggaaatt 720
atctggacga tgctctcgtg agacaggatg cccaggacct gtatgaggct ggagagaaga 780
aatgggggac agatgaggtg aaatttctaa ctgttctctg ttcccggaac cgaaatcacc 840
tgttgcatgt gtttgatgaa taaaaagga tatcacagaa ggatattgaa cagagtatta 900
aatctgaaac atctggtagc tttgaagatg ctctgctggc tatagtaaag tgcatgagga 960
acaaatctgc atattttgct gaaaagctct ataaatcgat gaagggttg ggcaccgatg 1020
ataacaccct catcagagt atggtttctc gagcagaaat tgacatgttg gatatccggg 1080
cacacttcaa gagactctat ggaaagtctc tgtactcgtt catcaagggt gacacatctg 1140
gagactacag gaaagtactg cttgttctct gtggaggaga tgattaaaat aaaaatcccc 1200
gaaggacagg aggattctca acactttgaa tttttttaac ttcatttttc tacactgcta 1260
ttatcattat ctcaaatgc ttatttccaa ttaaaacgcc tacagctgcc tcctagaata 1320
tagactgtct gtattattat tcacctataa ttagtcatta tgatgcttta aagctgtact 1380
tgcatttcaa agcttataag atataaatgg agattttaaa gtagaaataa atatgtattc 1440
catgttttta aaagattact ttctactttg tgtttcacag acattgaata tattaaatta 1500
ttccatattt tcttttcagt gaaaaatttt ttaaatggaa gactgttcta aaatcacttt 1560
tttccctaata ccaattttta gagtggctag tagtttcttc atttgaaatt gtaagcatcc 1620

```

```

ggtcagtaag aatgcccato cagttttcta tatttcatag tcaaagcctt gaaagcatct 1680
acaaatctct ttttttaggt ttgtgccata gcatacagttg atccttacta agtttttcat 1740
gggagacttc cttcatcaca tcttatgttg aaatcacttt ctgtagtcaa agtatacca 1800
aaccaattta tctgaactaa attctaaagt atgggttatac aaaccatata catctgggta 1860
ccaaacataa atgctgaaca ttccatatta ttatagttaa tgtcttaatc cagcttgcaa 1920
gtgaatggaa aaaaaaataa gcttcaaact aggtattctg ggaatgatgt aatgctctga 1980
atttagtatg atataaagaa aacttttttg tgctaaaaat acttttttaa atcaattttg 2040
ttgattgtag taatttctat ttgcactgtg cctttcaact ccagaaacat tctgaagatg 2100
tacttggatt taattaaaaa gttcactttg taaaaaaaaa aaaawaaaaa aaaac 2155

```

<210> 221

<211> 1264

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (17)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (125)

<223> n equals a,t,g, or c

<400> 221

```

gtcnnngac agtgacngta cngtattccc gggtcgaccc acgcgtccgg taaaattctg 60
ggctctggta tcagttcctc ttcagtattg catggcatgg tttttaagaa ggaaaccgaa 120
gtgantgtaa catctgtcaa agatgcaaaa atagcagtggt actcttgtcc ttttgatggc 180
atgataacag aaactaaggg aacagtgttg ataaagactg ctgaagaatt gatgaatttt 240
agtaaggggag aagaaaacct catggatgca caagtcaaag ctattgctga tactgggtgca 300

```

```

aatgtcgtag taacaggtgg caaagtggca gacatggctc ttcattatgc aaataaatat 360
aatatcatgt tagtgaggct aaactcaaaa tgggatctcc gaagactttg taaaactggt 420
ggtgctacag ctcttcctag attgacacct cctgtccttg aagaaatggg acactgtgac 480
agtgtttacc tctcagaagt tggagatact caggtggtgg tttttaagca tgaaaaggaa 540
gatggcgcca tttctaccat agtacttcga ggctctacag acaatctgat ggatgacata 600
gaaagggcag tagacgatgg tgtaataact ttcaaagtgc ttacaaggga taaacgtctt 660
gtacccggag gtggagcaac agaaattgaa ttagccaaac agatcacatc atatggagag 720
acatgtcctg gacttgaaca gtatgctatt aagaagtttg ctgaggcatt tgaagctatt 780
ccccgcgcac tggcagaaaa ctctggagtt aaggccaatg aagtaatctc taaactttat 840
gcagtacatc aagaaggaaa taaaaacgtt ggattagata ttgaggctga agtccctgct 900
gtaaaggaca tgctggaagc tggatttcta gatacttacc tgggaaaata ttgggctatc 960
aaactcgcta ctaatgctgc agtcaactgta cttagagtgg atcagatcat catggcaaaa 1020
ccagctggtg ggcccaagcc tccaagtggg aagaaagact gggatgatga ccaaaatgat 1080
tgaaattggc ttaattttta ctgtagggtg aggctgtatt tgtagtagta ctcaagaatc 1140
acctgatgtt ttcttattct ccttaaatta agagtatttt tgtgtttgta ttcttggtctg 1200
gatgttataa taaacatatt gttactgtca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaa                                              1264

```

<210> 222

<211> 2085

<212> DNA

<213> Homo sapiens

<400> 222

```

ccttgggaga ggaggaacag gcccttgggc agatgcaggc attaccagca gggagcagac 60
ttacctccga agatggagac aggtgactga gagctgcagg cctcctctgc tcttccaaac 120
acgtagcatt tgcaccctc caaagccatc tttgtaaagg aaaacgtatt tgtaattgaa 180
tccagaagaa tttagttaca catagacata actcttcaac cttaactatg gcaatacatt 240
tgtgtcttaa ctgttacata gcagtatcac cacttaccag gatocaaatc gaaataataa 300
aagctgtctc catagtttaa aatcgaatag tgccatcatc acagtatatt agtcaaatag 360
aagcttcac cagaaatgtat cccacataga gttttaagac ttggattctc ttctgccctt 420
gttaatctcc aactaattac tacagattga cacgttttta attagctgtc ctttgtaaga 480
agtcaggaaa tctgatgctg tgtccaaaat tatgcactgt ttggtgaagt agaaccagaa 540
atcctgacct cctgttaaata gacatcagtt tccccctctg agcaacagac tgcttgtctt 600
gctaggagag gaggatgggg ggctgagcac tcaggctgtc cattgaaacc ccttgtccat 660
gaataggggc atactcctaa gactgatggg gtgttgatct tctaggacat cacttgttta 720
ttcagtgccc caaacacaga tttctcttct agcactttag agttgatcct tgaagtctct 780
cctggttcat tcaaatacaa gctgtgtgag tctggtggtt ttctgtgatt ggtctaattg 840
gagctctttg aacagacaga tctgacagtg aatgactctc cctgcttct gccataactg 900
ctttgcctct gtctagtgtc caagcatctt agctgttcaa gaggagaggg cagcataact 960
tcctgaccac cgggtgtcaga tatcagagca ttctggactc ctgagaggca gtggcctctt 1020
gagtgaacag gggaggccag tagatgcccc agatccagag ccgtggctgc aaatccagca 1080
ggaataagga gggacaacca cagcctcctc atccatgtgt catttccaag ggtttgcctt 1140
gtgtctcagc tcattctggg cagcacgttt gtcttctgtc cctagagatt tgaaggattt 1200
tggaactctt tgaatgggtg actggacttg gctttacaga gttgggtgct ttttctctc 1260
tgcaattacc tgtcatagca ttttgtgctc accacgaagg atggtctctg ccttctcttg 1320
tcggtgtatg ccactgaac ctaggaacac aaagtatatt ggcctcaaac ggagaccag 1380
ggttgccagt tttccgtggg ccttccccct ccttgaaatg tctttaatta cctccccctt 1440
atcgtcaggc cacgtgtgac ttctgttctt agcactgcca gggtcattga ctccatcta 1500
agcttgcac aggaagatgt tccttctgtg atcattggta ctgaagccag aaaagctctc 1560
attcaggaac tctgaagagc aaaaagggac aaacactaac tgctgagctg ggccatttga 1620

```

```

tctcctttca ccttgcattg ctgtcacagc accttgtatg atggcaggac aggctccagc 1680
agagagaact gcacagtgc cactgtatct ttcacgctct tccagggatc cctgtccccc 1740
gacattgaag agatctcatt caggccagag acacagagac cacatagccc agtgattaaa 1800
ccccggtttc actctggccc caggagtgga gcctggccac tctgttttg ttctcactgg 1860
gaggcccact ggccttggat catctcctca tgcacaccgc gagttttacc tgcttgcttg 1920
ctttcctgga ctgctgtttg caagaaagta actaaaacat gaaaagtaaa cctccagctt 1980
ccacagtata ttacctgccg ttgcatgcat ttgaaagtta rcctcctccc ttgccaccgt 2040
cttkgtggca gtagcggatg caagaatgga tgggagcttt ccgag 2085

```

<210> 223

<211> 2921

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1609)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2919)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2920)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2921)

<223> n equals a,t,g, or c

<400> 223

```

aaaaaaaaaa aaaaaaagaa aaaaagaaag aaagaaaaga aaggagcagg gaggtagagc 60
cctctgtacc ctccatcacc agaaaaagct gaagaggggc tgagtaggag ggacagatgc 120
tggccagggc acaggttttg aagcataaaa ctcttgccct gtttgctgac tcgttgagac 180
aggggtgcca gaaggggata gacttccctg gggcgtgggg agagcaggag gctcaagtga 240
gatgctcttg gtgctagaaa ccgccctccc tcatgcctgg ggtctctccc tgccaggacc 300
ctgmcccgcct taggctctgc cctgtctcat ccagcccaa cagcatgggt gtggaacacc 360
ccgagttcct caaggcaggg aaggagcctg gcctgcagat ctggcgtgtg gagaagttcg 420
atctggtgcc cgtgcccacc aacctttatg gagacttctt cacgggagac gcctacgtca 480
tcctgaagac agtgacagtg aggaacggaa atctgcagta tgacctccac tactggctgg 540
gcaatgagtg gaccagatg gagagcgggg cggccgccat ctttaccgtg cagctggatg 600
actacctgaa cggccggggc gtgcagcacc gtgagtccag ggcttcgagt cggccaccct 660
cctaggctac ttcaagtctg gcctgaagta caagaaagga ggtgtggcat caggattcaa 720
gcacgtggta cccaacgagg tgggtggtgca gagactcttc cagggtcaaag ggccggctgt 780
ggtccgtgcc accgaggtac ctgtgtctct ggagagcttc aacaatggcg actgcttcat 840
cctggacctg ggcaacaaca tccaccagtg gtgtggttcc aacagcaatc ggtatgaaag 900
actgaaggcc acacaggtgt ccaagggcac ccgggacaac gagcggagtg gccgggcccc 960

```

```

agtgcacgtg tctgaggagg gcactgagcc cgaggcgatg ctccaggtgc tgggccccaa 1020
gccggtctctg cctgcaggta ccgaggacac cgccaaggag gatgcggcca accgcaagct 1080
ggccaagctc tacaaggtct ccaatggtgc agggaccatg tccgtctccc tcgtggctga 1140
tgagaacccc ttcgcccagg gggccctgaa gtcagaggac tgcttcatcc tggaccacgg 1200
caaagatggg aaaatctttg tctggaaagg caagcaggca aacacggagg agaggaaggc 1260
tgccctcaaa acagcctctg acttcatcac caagatggac taccccaagc agactcaggt 1320
ctcggtcctt cctgagggcg gtgagacccc actgttcaag cagttcttca agaactggcg 1380
ggacccagac cagacagatg gcctgggctt gtctacctt tccagccata tcgccaacgt 1440
ggagcgggtg cccttcgacg ccgccaccct gcacacctcc actgccatgg ccgcccagca 1500
cggcatggat gacgatggca caggccagaa acagatctgg agaatcgaag gttccaacaa 1560
ggtgcccggtg gaccctggca catatggaca gttctatgga ggcgacagnt acatcattct 1620
gtacaactac cgccatggtg gccgccaggg gcagataatc tataactggc aggggtgcca 1680
gtctacccag gatgaggtcg ctgcatctgc catcctgact gctcagctgg atgaggagct 1740
gggaggtacc cctgtccaga gccgtgtggt ccaaggcaag gagcccggcc acctcatgag 1800
cctgtttggt gggaagccca tgatcatcta caaggcgggc acctcccgcg agggcgggca 1860
gacagccctt gccagcaccg gcctcttcca ggtccgcgcc aacagcgctg gagccacccg 1920
ggctgttgag gtattgccta aggctggtgc actgaactcc aacgatgcct ttgttctgaa 1980
aaccctctca gccgcctacc tgtgggtggg tacaggagcc agcgaggcag agaagacggg 2040
ggcccaggag ctgctcaggg tgetgcgggc ccaacctgtg caggtggcag aaggcagcga 2100
gccagatggc ttctgggagg ccctgggcgg gaaggctgcc taccgcacat cccacggct 2160
gaaggacaag aagatggatg cccatcctcc tcgcctcttt gcctgctcca acaagattgg 2220
acgttttgtg atcgaagagg ttctgtgtga gctcatgcag gaagacctgg caacggatga 2280
cgtcatgctt ctggacacct gggaccaggt ctttgtctgg gttggaaagg attctcaaga 2340
agaagaaaag acagaagcct tgacttctgc taagcggtag atcgagacgg acccagccaa 2400
tcgggatcgg cggacgcca tcaccgtggt gaagcaaggc tttgagcctc cctcctttgt 2460
gggctggttc cttggctggg atgatgatta ctggctctgtg gacctcttgg acagggccat 2520
ggctgagctg gctgcctgag gaggggcagg gccaccccat gtcaccggtc agtgcctttt 2580
ggaactgtcc ttccctcaaa gaggccttag agcgagcaga gcagctctgc tatgagtgtg 2640
tgtgtgtgtg tgtgttgttt cttttttttt tttttacagt atccaaaaat agccctgcaa 2700
aaattcagag tccttgcaaa attgtctaaa atgtcagtgt ttgggaaatt aaatccaata 2760
aaaacatttt gaagtgtgwa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2820
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2880
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaann n 2921

```

<210> 224

<211> 4395

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (325)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4382)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4391)

<223> n equals a,t,g, or c

<400> 224

```

ggtaagtcct ttattcatag cacagtcctc actaaacata aggagcttca tctggaagaa 60
gaagaagaag atgaagcagc agcagctgca gcagcagcag cccaggaagt tgaagccaat 120
gtccatgttc cacaagtagt tctgaggatt cagggcttaa acgtagaggc tgctgagcca 180
gaagtggagg ctgccgagcc agaagtggag gctgctgagc cagaagtgga ggctgctgag 240
ccaaacggag aggctgaagg gccagatgga gaggctgcag agccattgg agaggctgga 300
cagccaaatg gagaggccga gcagncaaat ggggatgctg atgagccaga tgggtgcagg 360
attgaagacc cagaagaaag agctgaagag ccagagggca aaagctgaag agccagaggg 420
agatgccgac ggagccctga cgggtgtggga attgaagcac ccaggaagaa ggtgaagtat 480
caagagattc aggtagaaga accatactat gactgccatg aatgcacaga aaccttcact 540
tccagcacag cattcagtga acacctgaaa actcatgccca gcatgatcat atttgagcct 600
gcaaatgcct ttggggagtg ctcaggctac atcgaacgtg ccagcaccag cacagggtgg 660
gccaatcaag ctgatgagaa gtacttcaaa tgtgacgtct gtgggcagct cttcaatgac 720
cgctgtccc tcgccagaca ccagaatacc cacactggct gagggcatgg ggtaaagggt 780
agaaaacctt cacctaggac ttgacctta ccaaaccaca gagaatccaa accaatccat 840
gataatgtca gtaggagact taaccttagt gtgttacaca cctgacttaa catctctaaa 900
ctcagattga aaagagaccg aatgtgcaga ttccacagtc ttaagctttc ccttcagat 960
gtcagtgtct gcatgtggga aagccatagc acacatctta cctttccaag taatcagatt 1020
gagaaaacct tatgagtatt ccagactaca gagtttgccc aaatcaactg taaatgacac 1080
ttgtgtaacg tatatatagt gtttcatgag gtgtatataa aatagcaa atgacagaa 1140
cagtgatcac atatatattg atttatatga tatacagtta cagtttactc tgcagaggta 1200
ccttacctgg tattctttga attttttttt tttttggagg aggaagagag caacaaattt 1260
gatttatatt ttaagtgtct tagatcctga gaaagattta ttgtgcatta tttgaacctt 1320
gtcaatatct ttttgagtaa ttgttttggt tcttaccctt aaatagtctt gtgaagctgt 1380
aggcatgata gataacatgg cttttactcc ttactgtttg aaaagataag tacttttagct 1440
tctttctgca gccatttcat ctgcrccaac actttggaac ctaatactgt gtaaggcttt 1500
acaatatacg gattggcttt ttgtgaccca gattgattgg ttgccacatg ttatgtttgt 1560
tgaagtgggt ctcatgcaaa aatattacac atttgtgttc tgggtttttt ttttttttta 1620
accaactcaa tatgtgtttg atgatagtga attgataaaa cccgaagctt ttccctgtaa 1680
atcttacatc tttgccttta aagaatgggt tacaaccatc actagatcac agtagtgcct 1740
aatgaagggt gagaaccgta ggagaggctc tcatgctgta aataatgttg caggctaata 1800
acctttcatc acttcctttg tgcgcttcct gccttaagtg acaagtagca acatggcttg 1860
ggccccctgt gcagcatcag cttatgctgc cacaagtcag tttkaccctt aggtgcccag 1920
gagctagtat ccttagatct ttctatcgct aacttaattc tcttcgttat ttatctgacc 1980
ctctaaactc atgtctaact tgcattaaaa aaaaaaaaaa tctttacagt caaccaagc 2040
ttaacatgga ctcaggttcc ccagcagcct taatttggtt tgtaacatc tgttccttct 2100
ttttcagctc tcctagagta tttctgagtg ttgtgttcct ctaatcttag tattctttta 2160
attacaaatt gacctcacag cttgaggttt cttgtgtcct attctgtgga ctacctgtgc 2220
tcctttgctt cccctccctt cgcataataa ctatattaag aaattttttt tggccttgag 2280
ttggctggaa aaaaaatata aaatttaaaa aatttaaaaa aaaagatttg caaatgtaa 2340
gtgtagatca tttgaacaag caaaattaaa gtaccactg ggggaaatgt gtctgaatct 2400
tactctcttg agattgcagg attagggctt ggaagtatgt caaagatgsa gggagtgtca 2460
aagtttagga agattgtaga gctgagagca agaagcagaa atgagtgagt caaagaagg 2520
agtctaata catcaccaga tctaggaggg gagaggagac agacagaaga aaacaccaga 2580
ggcaagaact gtagaaggcc aggtttctga gaatgaattg agcggggtgt cctgagcagt 2640
ttggaaaagg agtttttgat ggtatggtgt aggtgagggc tggctgcata ggaaggactg 2700
aggttggaac ggacatcggg aaagctgagg ggcagtgagg tttactacat gggaaaagga 2760
ctcttgaaac gagaatcagt gttgatgtcr ggggtgaactt tgtgggtaca ttacttggtg 2820

```

```

ttaacattgt tggcagtggt agcccccttt cagaaagcaa cttgctgtaa gtcaggggtgt 2880
ccgttccaac cttcagctag tgaaaaggta gtaacaaatg gtaacaaga gaatgattgt 2940
ttaaacctat ctgtggacac ttaatgcaac tgtttaaaaa tgataatcac gagttatgta 3000
gcaacgtgga aatatattta cagaacatta agtggagaaa gcaggacacg aaagtatatatt 3060
tatactacag ttataactca acagttcatt tataatgctgt tcatttaaca gttcatttaa 3120
acagttcatt ataactgttt aaaaatatat atgcttatag tcaaaagctg ttgtgggtgtt 3180
gttgtttag gcttatagtt gagcattatt ttcttaaatt tcttgaatgt tctttatgggt 3240
agtgttacta aaaagtttat gatcacattt tcattgtgaa cataatttga actcattatc 3300
acacacttgg aaaatacaga aaagtggagg aaaaaaaatc atatccccac catccaaaga 3360
catatactct cctcttatct tgttcattct tgtttctgtg cacaggttta tgattataac 3420
tgtgtcaaaa tgtatattca aaatagctgt tacattacct ttgtggratt atgggttaaat 3480
actttcactt taattttttc aaatgttccc tataataatg tcctgataac agtgtattat 3540
gtgtgtctcc attggtgtgc ataatacata ccagaggaa aaattagaaa ataaagtaaa 3600
ttattttaaa aaattacctt tattcccaac acctaacaac tactgctaac atcttgatct 3660
gtttcctcta tcttgtttca gtgcacacgc ttgtgataac agtgttaaat atgtgtgcat 3720
aaagtcttaa atgaaaagat gtgaaaata actaaaatag tgttgtcatt gtgggaattt 3780
ggttaaatat tttgtctcaa attccttaaa taatctttgg tgttttggtg ataaatttta 3840
tgtatgtatt ttccattaca aatataatac atactcatac aaaactttgg aaattcagta 3900
aagaaaattc acacatatcc ccaacaccca acaacaatta actgttaaca tcttgatctg 3960
tgcactagtc tgtgattatt aggggtgttag tgataagtat gcataaatgt caaagatggg 4020
aagaaagatg aaaaacaaga aatagttgtg tgggtgttgt gggattatgg ttattttgtt 4080
tcggtttcct tgaaaggtca tcattctagt gttttggtag tccaccttta ctacatatat 4140
ttccattata tatgaaatgt gttcattata gaaactttga agttacagaa atgtagaaga 4200
gaaactcacc catgttttca ccatccaaag agtgtggtta acatcttgat atattttctt 4260
catcttgttt ctgtgcacag gtttttggtt tgtaaatatg gttgtggtca ttctatctgt 4320
aatagtgtca acaataaaaa taaagttaaa aataaatatt aaaaaagaaa aaaaaaacc 4380
cngggggggg nccgg 4395

```

<210> 225

<211> 3035

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2911)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2959)

<223> n equals a,t,g, or c

<400> 225

```

cccggagcag cgcggcagca gcatggctca cgggcccggc gcgctgatgc tcaagtgcgt 60
gggtggtcggc gacggggcgg tgggcaagac gtgcctactc atgagctatg ccaacgacgc 120
cttcccggag agtacgtgcc caccgtcttc gaccactacg caggaagact atgaccgtct 180
gaggccttta tcttacccaa tgaccgatgt ctctcttata tgcttctcgg tggtaaattcc 240
agcctcattt caaaatgtka aagaggagtg ggtaccggaa cttaaggaat acgcaccaaa 300
tgtacccttt ttattaatag gaactcagat tgatctccga gatgaccca aaacttttagc 360
aagactgaat gatatgaaag aaaaacctat atgtgtggaa caaggacaga aactagcaaa 420

```

```

agagatagga gcatgctgct atgtggaatg ttcagcttta acccagaagg gattgaagac 480
tgtttttgat gaggctatca tagccatttt aactccaaaag aaacacactg taaaaaaaag 540
aataggatca agatgtataa actgtttgttt aattacgtga gaaacatctt cagtggccaa 600
ggaaactgtc cttttctctc agaaagcaaa tgaaatgcta cagctatacc cagacctttt 660
ataggtaatg aagcagttca aaacttgaaa gaaaacaaaa cctgtcctca gaattctata 720
aagtgtatta agaatgttcc ttaaaggttt aagaagcagt aagcagcatc tgaagccaca 780
atctattata aatactttat ttcaactaga aggtacaatc tctcaggggt ttcatagttt 840
aaaaagctac aatcacatca tgttgtaact acgtaaaaaa cagagctgta aatggaactg 900
cttggctttg accatacaca tttctgcccc gcccttacag aatctgcaca aagaaatata 960
tccctttgct ccagttaatt gttcttgtat gtaagttgct ttctattcca gtatatccag 1020
agtggtgaaa taacaaggcc agccacgtag ccaaagggtcg ctccaagcgt acaggagatg 1080
ggccatacct gaggagagaa tgtatgagat caaaaaagaa caaatgtttt attattactt 1140
gagcacaagt gtaacctaaa tatttctata ttaaagctta atgtgctttc ttaaagaatg 1200
ccaaaagtgt aataagggtca taactgcatt tatcatgaac actaaaaatg tacacatttt 1260
agttaatgtg cattaaactg taacaaggct tctggcaatt gtagatttag tttgacgctc 1320
cccaaagtgc atgagacaca tgctaaaatt acaaatataa attttgggtc agactttgcc 1380
ataatgatag actcaattta gctctctgaa ctagtgtgta attttttttt ttttaattccc 1440
actttggctg tgtacatcaa atgaaatgag aagtgtgtat gctgaccaa ccacaagaaa 1500
ctttctttta gttgtgttaa agaggaaaga cctagaatcc aagcgtgtta catgaaaatt 1560
gtaacagagc agctgcttcc acctttcaga tatagatgtt ggaaccacag cagaagttaa 1620
agagcgacaa cttatataca cacctagaat gtaagttaaa caaaataacc gcttccagag 1680
acctcttttc tccagccata ttacatcagg ctagaagtaa ttaatgttga tttatttcat 1740
ctacaagcag ttggtcccta agtgaaaggc tctgcttgaa aaaaaaaga aaaaaagtt 1800
ggaggaaaat tttcatgttc ttctgtgaag cttatttggg aactgggagc catttctaata 1860
ctttctctgg ggggaacagg ccacagaact gtgttagagg tgaaccatct taattactag 1920
ttctattacc taattcagct tccttgtttg gtctgctgtg gatctgcctt attgcatatg 1980
ccatgcatca gataatggat gcatcagata atgggtgttag acaaagcttc attgtgaaca 2040
acctaattgca ttttagagaa acaatctcat cacatttttt ctagcctttc ctacatttaa 2100
acttgctgtt gcccaaatta taatttttta aatgtctttg gtgggcttct gttaattcac 2160
atgacttgag cttatagcta tgttactgc acagattggg taatggaaca ctaaactttt 2220
atacttgaaa atgacagcct taaatgctca tatcagtcac aaatctagga tgtactgtct 2280
tgttgtatgt gagctttgta gagattttta aaaatataag catcaccttc ccattgaaga 2340
gtggagagag tctactggat gactggccag gaactttctc tctgaatcgg acatttggat 2400
gtcttctttc ttccaagaaa tgggtggttc cattaaagta tcatggcctt atgtatgctc 2460
aaatggaatc ttatgtaact ttcttattta attttgggtc gcttattttt agataaaaatt 2520
gaaaggaatt gtataaatca attaacatat tagctgagtt gtccaacaca tggatataaac 2580
gaattacaac agtaaaactat tacacatttc caacttgcct ttggggattt atgaggattt 2640
tttttgggtg ggggaggggg ctccaattca tatctctgaa acccttcaca cttgggtttac 2700
taattcaaak ttagaagtct agaatttgcc ctgccctaac agaaacagat taggaatttg 2760
tctacacaaa ctggtgtcac ctgtttcttg actgggattt ggtttcctca ttataaatat 2820
gggaggtaga acagagatct ccaacgtctc tcccatttat cacagtaatt ttcttattca 2880
cagtaatcat tgttggrrgt tactttttca ncttcacatt ctcaagatgg taaaaatcat 2940
gtatatagat tatcagaant ctaagcaaaag atgactgtca catctgaagc tgaggtgcct 3000
taggtacatc ggccgcgacc acggtaagcc gaatt 3035

```

<210> 226

<211> 1511

<212> DNA

<213> Homo sapiens

<400> 226

```

ccggctccgc tgcggaaggc ggacgactag agtcgttggg cccggcgcgga cccgcaggag 60
cgtagagagc gcgggactag agtgcagagc tccgggacgt ggatcggagc cggcgcgatg 120
ggcggagagc aggaggagga gcggttcgac ggcattgttg tggccatggc tcagcagcac 180
gagggcgggc tgcaggagct tgtgaacacc ttcttcagct tccttcgacg caaacagac 240
tttttcattg gaggagaaga agggatggca gagaagctta tcacacagac tttcagccac 300
cacaatcagc tggcacagaa gacccggcgg gagaagagag cccggcagga ggccgagcgg 360
cgggagaagg cggagcgggc ggccagactg gccaaggaag ccaagtcaga gacctcaggg 420
ccccagatca aggagctaac tgatgaagag gcagagaggc tgcagctaga gattgaccag 480
aaaaaggatg cagagaatca tgaggcccag ctcaagaacg gcagccttga ctccccaggg 540
aagcaggata ctgaggaaga tgaggcgaag gatgagaagg acaaaggaaa actgaagccc 600
aacctaggca acggggcaga cctgccaat taccgctgga cccagaccct gtcggagctg 660
gacctggcgg tccctttctg tgtgaacttc cggctgaaag ggaaggacat ggtggtggac 720
atccagcggc ggcacctccg ggtgggctc aaggggcagc cagcgatcat tgatggggag 780
ctctacaatg aagtgaaggt ggaggagagc tcgtggctca ttgaggacgg caaggtggtg 840
actgtgcatc tggagaagat caataagatg gagtgggtgga gccgcttggg gtccagtgc 900
cctgagatca acaccaagaa gattaaccct gagaattcca agctgtcaga cctggacagt 960
gagactcgca gcatggtgga aaagatgatg tatgaccagc gacagaagtc catggggctg 1020
ccaacttcag acgaacagaa gaaacaggag attctgaaga agttcatgga tcaacatccg 1080
gagatggatt tttccaaggc taaattcaac tagccctgt tttttcctcc ctgaactctt 1140
ggggctgagc tgcaaccacc caactttctt tccactctt ctctgggact tgtgggcctc 1200
agggcttggg gcaggcatgg gactggccca ggcacacagg tccgggggca tcaggagaaa 1260
ggctgggtct tgggaccttg tcctccccag ttggcctact gttacacatt aaaacgattt 1320
gccagctcc ttctgtgtcc tctcttgcc ctggcctttc tctggggcac aggcctctta 1380
cggctgctgc tgggaactgg gaktttggct tctagcccag attctgccat gtgacctagg 1440
gcacatcctt gccctctctt gggcctcagt ttctcattac ttaaagatta aaacaagctt 1500
tgccggtgtt a 1511

```

<210> 227

<211> 2239

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2238)

<223> n equals a,t,g, or c

<400> 227

```

ggcacgaggg gagctggggg ctgagtttcc ctgagtagag gctggcacag gagagaaggc 60
atcaccccca cctcgtccag gccagaagat gtccagcttc ttgaggctct cctaagtctg 120
gctctcctgg gaccaagaga aaatcccggg ccttgaccaa gaagctgctg atgggagctc 180
caccctggga gggggtgccg gcaccatggg attgagcgcc cgctacggac cccagttcac 240
cctgcagcac gtgcccgaact accgccagaw tgtctacatc ccaggcagca atgccacact 300
gaccaacgca gctggcaagc ggggatggca agggcccagc aggtggcaat ggcaacaaga 360
agaagtctgg caagaaggag aagaagtaac atggaggcca ggccaagagc cacaggcgcg 420
cctctcccca accagcccag cttctcctta cctgcaccca ggcctcagag tttcagggct 480
aacccccaga atactggtag gggccaaggc catgctcccc ttgggaaaca gaaacaagtg 540
cccagtcagc acctacccct tcccccccag gggkttgaat atgcaaaagc agttccgctg 600
ggaaccccca tccaatcaac tgcgtgtacc atgggggtag tggggttact gtagacacca 660
agaaccattt gccacacccc gtttagttac agctgaactc ctccatcttc caaatcaatc 720
aggcccatcc atcccatgcc tccctcctcc ccaccccact ccaacagttc ctctttcccg 780

```

```

agtaaggtgg ttgggggtgtt gaagtaccaa gtaacctaca agcctcctag ttctgaaaag 840
ttgsaagggc atcatgacct cttggcctct cctttgattc tcaatcttcc cccaaagcat 900
ggtttgggtgc cagcccccttc acctccttcc agagcccaag atcaatgctc aagttttgga 960
ggacatgatac accatcccca tggtagtgat gcttgctgga tttaggaggg gcattttgct 1020
accaagcctc ttcccaacgc cctggggacc aktcttctgt tttgttttcc attgtttgac 1080
gtttccactg catgccttga cttccccac ctctcctca aacaagagac tccactgcat 1140
gttccaagac agtatggggg ggtaagataa ggaagggaag tgtgtggatg tggatgggtg 1200
gggcatggac aaagcttgac acatcaagtt atcaaggcct tggaggaggc tctgtatgtc 1260
ctcaggggac tgacaacatc ctccagattc cagccataaa ccaataacta ggctggaccc 1320
ttccactac ataatagggc tcagcccagg cagccagctt tgggctgagc taacaggacc 1380
aatggattaa actggcattt cagtccaagg aagctcgaag caggtttagg accaggctcc 1440
cttgagagggt cagagggggc tctgtgggtg ctgggtactc cagaggtgcc actggtgga 1500
gggtcagcgg ascccagcag gaagggtggg ccagccaggc cattcttagt ccctgggttg 1560
gggaggcagg gagctagggc agggaccaaa tgaacagaaa gtctcagccc aggatggggc 1620
ttcttcaaca gggcccctgc cctcctgaag cctcagtcct tcaccttgcc aggtgccgtt 1680
tctcttccgt gaaggccact gccaggtcc ccagtgcgcc ccctagtggc catagcctgg 1740
ttaaagttcc ccagtgcctc cttgtgcata gaccttcttc tcccccccc ttctgcccct 1800
gggtccccgg ccattccagc gggctgccag agaaccccag acctgccctt acagtagtgt 1860
agcgcacctt cctcttttcg gctggtgtag aatagccagt agtgtagtgc ggtgtgcttt 1920
tacgtgatgg cgggtgggca gcgggcggcg ggctccgcgc agcctgtctg ccttgatctg 1980
cccgcggcgg ccggtgttgt gttttgtgct gtgtccacgc gctaaggcga cccctcccc 2040
cgtactgact tctcctataa gcgcttctct tcgcatagtc acgtagctcc cccccaccc 2100
tcttctgtg tctcacgcaa gttttatact ctaatattta tatggctttt tttcttcgac 2160
aaaaaataa taaaacgttt cttctgaaaa aaaaaaaaaa aaaaaaaaaa gggggggccc 2220
ggtccccaat cccccctnt 2239

```

<210> 228

<211> 2346

<212> DNA

<213> Homo sapiens

<400> 228

```

ggcacgagcc gaccggcgcg gcgctagcct cggggcttga cgggattgtg gcggtcctct 60
ctcccaattc ggaagctaca gctacctccg gacgctctca agatggcgac ctctctgggt 120
tccaacacct acaacaggca gaactgggag gatgcggact tccccattct gtgccagaca 180
tgtcttgag aaaacccata tatccgaatg accaaagaaa agtatgggaa ggaatgcaaa 240
atctgtgcc ggccattcac agtgtttcgc tggtgccctg gagtccgcat gcgtttcaag 300
aagactgaag tgtgccaaac ctgcagtaaa ttgaagaatg tctgtcagac ctgcctctta 360
gacctagagt atggcctgcc catccagggt cgtgacgcag gattgtcttt taaagatgac 420
atgccaaagt cagatgtcaa caaagagtac tatacacaga atatggagag agagatttct 480
aactctgatg gaacacggcc agttggcatg ctgggggaaag ccacatctac cagtgcacatg 540
ctgctcaaac tggcccggac cacaccctac taaaaagga atcgaccca catttgctcc 600
ttctgggtga aaggagagt taagagagga gaggaatgtc catacagaca tgagaagcct 660
acagatccag atgacccctt tgctgatcag aatataaag accgttatta cggaatcaat 720
gatcctgtag ctgacaagct tctaaagcgg gcttcaacaa tgccctgggt ggaccacca 780
gaggataaaa ctataccac actatatggt ggtggtctag gtgataccat tactgagaca 840
gatttaagaa atcatttcta ccagttcggg gagatccgga cgatcactgt tgtgcagaga 900
cagcagtgtg ctttcatcca gtttgccaca cggcaggctg cagaagtggc tgctgagaag 960
tcctttaata agttgattgt aaatggccgc agactgaatg tgaaatggg aagatccag 1020
gcagccagag gaaaagaaaa agagaaagat ggaactacag actctgggat caaactagaa 1080
cctgttccag gattgccagg agctcttctt cctcctcctg cagcagaaga agaagcctct 1140

```

```

gccaaactact tcaacttgcc cccaagtggc cctccagctg tggatgaacat tgctctgcca 1200
ccgccccctg gcattgctcc accccacccc ccagggtttg ggccacacat gttccaccca 1260
atgggaccac cccctccttt catgcggggt ccaggaccaa tccactatcc ttctcaggac 1320
cctcagagga tgggagctca tgctggaaaa cacagcagcc cctagcacct tgctaccact 1380
ctggggctct gtggaagaaa gggcacttaa aactcccagt aaatcttggg ataaatata 1440
ttttccttcc cttgtagttt ccatggtagc tgaatgtgct cagatgtgag cagtcagaga 1500
ctgacagcca tgctttccta tacttgttca aaggatcgat ggaccgtaaa taagctgcca 1560
ttaacacatc tggttactgc tgtaacatga ctaataaaac cgaacgcctg ttccccctac 1620
ccgtgtgggg gacacgcaga tgagtgaatt ggaatgtcca gcagagttac cctcccaatt 1680
atatgttcat tttgtatatt ttttggtcgg gggaaaaatt gacctgcagt aaaaaaacct 1740
ttgaccattt ttatgtccat tggatacttt cttttttatc atcttaaaaa aagataacta 1800
gtactaatca ttgtagtggc ctaagtgtga ttttaactct gaagtcacac cctccgaaag 1860
atgagtagaa accagacca gcacagccca gatcttctct ttcctctcct ttctctcatt 1920
tattcctaaa ggaatctgac cattttacgt ctctacggcc caaaaaaaga caaaaaataa 1980
aattcctttt tattcctgtc aactggatgg aaacacaaat ttcattggagc tgtgtaccat 2040
cgaagaaaacc tgggtgtctgg catgaaatta ctgtaaagaa cttcctgtaa aacacgttct 2100
ttaacaaact gaaatgaaaa gcattggagc gtctgaatga aagacgtgac ctctgtctgg 2160
gactctgatg gtcttcagca ttcacctcg tgtgtcttca gtgtctcatt gtcacccctg 2220
cttctgtttg gtcttagagt gtttgatat aactgaattg tagatggtaa aggaaatttg 2280
atgtgttttt tgtttttaaa taattaaaac gggatcaattt ttcaaaaaaa aaaaaaaaaa 2340
aaaaaa 2346

```

<210> 229

<211> 2246

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2235)

<223> n equals a,t,g, or c

<400> 229

```

ggcacagcgg cgggtggcggc tgcggcaaca gcggggccga tgtgtagttg gtgactgcct 60
ctccagatgc tgaggtgcct gtatcattgg cacaggccag tgctgaaccg tagtggagta 120
ggctgtgcct tctgaagcag tatctattca caatgaagtt gcagtctccc gaattccagt 180
cacttttcac agaaggactg aagagtctga cagaattatt tgtcaaagag aatcacgaat 240
taagaatagc aggaggagca gtgagggatt tattaatgg agtaaagcct caggatatag 300
atthttgccac cactgctacc cctactcaaa tgaaggagat gtttcagtcg gctgggattc 360
ggatgataaa caacagagga gaaaagcacg gaacaattac tgccaggcct catgaagaaa 420
atthttgagat tactacacta cggattgatg tcaccactga tggagacat gctgaggtag 480
aattttacaac tgactggcag aaagatgcgg aacgcagaga tctcactata aattctatgt 540
ttttaggttt tgatggcact ttatttgact actttaatgg ttatgaagat ttaaaaaata 600
agaaagttag atthttgtgga catgctaaac agagaatata agaggattat cttagaattt 660
taagatactt cagggttttat gggagaattg tagacaaacc tggtgaccat gatcctgaga 720
ctthttgaagc aattgcagaa aatgcaaaag gcttggtcgg aatatcagga gaaaggattt 780
gggtggaact gaaaaaaatt cttgttggt accatgtaaa tcatttgatt caccttatct 840
atgatcttga tgtggctcct tatataggtt tacctgctaa tgcaagttta gaagaatttg 900
acaaagtcag taaaaatgtt gatgggtttt caccaaagcc agtgactctt ttggcctcat 960
tattcaaagk acmagatgat gtcmaaaat tggawttgag gttgaagatc gcgaaagagg 1020
agaaaaacct tggcttattt atagttaaaa ataggaaaga ttttaattaaa gcaacagata 1080

```

```

gttcagaccc attgaaaccc tatcaagact tcattataga ttctagggaa cctgatgcac 1140
actcgtgtat gtgaactact gaagtaccaa ggagagcact gtctcctaaa ggaaatgcag 1200
cagtgggtcca ttcctccatt tcctgtaagt ggccatgaca tcagaaaagt gggcatttct 1260
tcaggaaaag aaattggggc tctattacaa cagttgagag aacagtggaa aaaaagtgg 1320
taccaaatgg aaaaagatga acttctgagt tacataaaga agacctaaaa ctgatggcta 1380
ctaaaaagca gagcatttct ggtaagacta aattttctcc cctccctctt aatgaggttt 1440
tagagactac accagaataa aagacagttt aggggacctc tgtagaacia caagggtctt 1500
atthttgtgaa ttatatattt caagaactaa acagagatcc acctttctgg atctgattta 1560
tatcactgaa atgtacagtt cttttggaat agtttcacct gagaaaacat agttggctat 1620
tatcwatctt aacctgttca ggcttttaaa aaaaactgtt tttgcatagg gtagtactaa 1680
gatcttaaaa agtggtaact gtcttgaaaga aaaaactgtt attgtttgtt tgcaattgaa 1740
ataacagggg taccttaaca atgactgtct atgatgtgtc agttcttctc tgaattccaa 1800
aataaacctg tgcttaaaaa agaaataatt gaccaagtaa gtttgcataa aatgtgaata 1860
ctaaatgtgt ccccgagttg tggcattcat atgtacagga tttgttctag caagctatgc 1920
ttcagtatgt ggttgatatt tttctgtcac aatgatttct ttatgcatgc agagcctggg 1980
aaagtcatgg gattaacttg agggcacta ttgagcctat taattaatta attattgttt 2040
taataaaaca aacattggta ttggaagata aatatgttta tgggttatct gacaatgtgt 2100
attaggtgtc atatacaatg gtaatatgcc tgtctttaa gtgttatttt attaatataa 2160
aggatatggc tattattata tattctctaa agatttatct tctaaagaaa gatttgagtc 2220
ctaaatgctt tcatncaggt aaataa 2246

```

<210> 230

<211> 2002

<212> DNA

<213> Homo sapiens

<400> 230

```

tctagactag tggatccccg ggctgcagga attcggcacg agatggcggc agcgatgcct 60
gcccggctgt tgggggtggcg gtgacgacag gcagcaaaag accagctggg cccagattcg 120
ctgctggagt gctggatgga gcctttctct gccctctgtg acatttccaa ttttagataa 180
tgccctcacat ctctgtcccc ccgggacccc ctggagcccc catgatccct aagaagacag 240
cttgaaacct gatctcacc ccaggatgtt gcggaggctg ctggagcggc cttgcacgct 300
ggccctgctt gtgggctccc agctggctgt catgatgtac ctgtcactgg ggggcttccg 360
aagtctcagt gccctatttg gccgagatca gggaccgaca tttgactatt ctcaccctcg 420
tgatgtctac agtaacctca gtcacctgcc tggggcccca rggggtcctc carctcctca 480
aggtctgccc tactgtccag aacgatctcc tctcttagtg ggtcctgtgt cgggtgtcctt 540
tagcccagtg ccatcactgg cagagattgt ggagcggaat ccccggttag aaccaggggg 600
ccggatccgc cctgcagggt gtgagccccg ctcccgaaca gccatcattg tgccctcatc 660
tgcccgggag caccacctgc gcctgtctgt ctaccacctg cacccttct tgcagcgcca 720
gcagcttgct tatggcatct atgtcatcca ccaggctgga aatggaacat ttaacagggc 780
aaaactgttg aacgttgggg tgcgagaggc cctgcgtgat gaagagtggg actgcctgtt 840
cttgccacgat gtggacctct tgccagaaaa tgaccacaat ctgtatgtgt gtgacccccg 900
gggacccccg catgttgccg ttgctatgaa caagtttgga tacagcctcc cgtacccccca 960
gtactctcga ggagtctcag cacttactcc tgaccagtac ctgaagatga atggcttccc 1020
caactgaatac tggggctggg gtgggtgagga tgacgacatt gctaccaggg tgcgctggc 1080
tgggatgaag atctctcggc ccccacatc ttagggacac tataagatgg tgaagcaccg 1140
aggagataag ggcaatgagg aaaatcccca cagatttgac ctctgggtcc gtacccagaa 1200
ttcctggacg caagatggga tgaactcact gacataccag ttgctggctc gagagctggg 1260
gcctctttat accaaccatc cagcagacat tgggactgac cctcgggggtc ctcggtctcc 1320
ttctgggcca cgttacccac ctggttcttc ccaagccttc cgtcaagaga tgctgcaacg 1380
ccggcccccga gccaggcctg ggctctctac tactgccaac cacacagccc tccgaggttc 1440

```

```

acactgactc ctccttcctg tctaccttaa tcatgaaacc gaattcatgg ggttgatttc 1500
tccccaccct cagctcctca ctgttctcag agggatgtga gggaactgaa ctctgggtgcc 1560
gtgctagggg gtaggggcct ctccctcact gctggactgg agctgggctc ctgtagacct 1620
gaggggtccc tctctctagg gtctcctgta gggcttatga ctgtgaatcc ttgatgtcat 1680
gattttatgt gacgattcct aggagtccct gcccttagag taggagcagg gctggacccc 1740
aagccccctc ctcttccatg gagagaagag tgatctggct tctcctcgga cctctgtgaa 1800
tatttattct atttatgggt cccgggaagt tgtttggtga aggaagcccc tccctgggca 1860
ttttctgcct atgctggaat agctccctct tctggctcctg gctcaggggg ctgggatttt 1920
gatatatattt ctaataaagg actttgtctc gcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaaa aaaaaaaaaa aa 2002

```

<210> 231

<211> 994

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (394)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (853)

<223> n equals a,t,g, or c

<400> 231

```

tcgaccacag cgtccgggtg gaggaggtcg gctggttatc gggagttgga gggctgaggt 60
cgggaggggtg gtgtgtacag agctctagga ctcacgcacc aggccagtcg cgggtttttg 120
gccgagggcct ggggttacaag cagcaagtgc gcggttgagg ccactgcgag gccgttttag 180
aaaactgttt aaaacaaaga gcaattgatg gataaatcag gaatagattc tcttgaccat 240
gtgacatctg atgctgtgga acttgcaaat cgaagtgata actcttctga tagcagctta 300
tttaaaactc agtgtatccc ttactcacct aaaggggaga aaagaaaccc cattcgaaaa 360
tttgttcgta cacctgaaag tggtcacgca agtnattcat caagtgactc atcttttgaa 420
ccaataccat tgactataaa agctattttt gaaagattca agaacaggaa aaagagatat 480
aaaaaaaaaga aaaagaggag gtaccagcca acaggaagac cacggggaag accagaagga 540
aggagaaatc ctatatactc actaatagat aagaagaaac aatttagaag cagaggatct 600
ggcttcccat ttttagaatc agagaatgaa aaaaacgcac cttggagaaa aattttaacg 660
tttgagcaag ctggtgcaag aggatttttt aactatattg aaaaactgaa gtatgaacac 720
cacctgaaag aatcattgaa gcaaatgaat gttggtgaag atttagaaaa tgaagatttt 780
gacagtcgta gatacaaatt tttggatgat gatggatcca tttctcctat tgaggagtca 840
acgtaagtgg aantcatatg aaatactttg gtaatagggt ataaattaaa tttctatggt 900
aattgcttca tattttgcct ttaatatagt tatacttaaa taatgaacaa agatacagag 960
tatgacaatt gggattatta cagttgagcc aagc 994

```

<210> 232

<211> 486

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (49)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (440)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (485)
 <223> n equals a,t,g, or c

<400> 232
 gactcactat agggc aaagc tggtagcct gccaggtacc gggtcggna attcccggt 60
 cgaccacgc gtccgggaac agccttctcc tgcctcctct gcacctggac aactcaactc 120
 ctgccaaagt gtctgccag cagaaccagc agcagtgcc acccccaccc aagtgtccct 180
 cacc aaagt tccccaaag agccagtagc agtgctgcc tccagcttcc tctggctgtg 240
 cccaagctc tgggggctgt ggcctagctc cgaggcggc tgcttctga accaccacag 300
 gcgccaccac cgatgccggc gccagaggy c aactcctgt gacagggcag tggtcagcaa 360
 ggcgrggggt ctggstgckg cayggttctg ggggtgctg ctgatccaga tctgatgct 420
 gagacaagcg atctttggan gaaacaagaa ttccaagag gccagaaca gcccctctg 480
 gaagnc 486

<210> 233
 <211> 2081
 <212> DNA
 <213> Homo sapiens

<400> 233
 gaagcagttc ttggcatgca cgatacacag tactgacct cctccagacc atgggtat 60
 ataacctctt tattttccta aacaatgaag atgcagttaa agatatcagg tggctgggta 120
 taagtctttt ggaggacgaa caactggagg ttccagaaat ggctgctact accttaagcg 180
 gtctgtctaca gtgtaacttt cttaccatgg acagtcctat gcagattcat tttgagcaac 240
 tttgcaaaac aaaactacct aagaaaagaa agcgagaccc tggttctgta ggagatacca 300
 ttccttctgc agagttggtc aaacgccatg ctgggggtgct aggacttggg gcatgtgttc 360
 tttctagtcc ttacgatgtt cccacctgga tgccccagct cctcatgaat ctcatgacac 420
 atctaaatga tcctcagcct attgagatga ctgtaaaaaa aaccttatcc aatttccgaa 480
 gactcaccat gacaactggc aggaacataa acagcaattc actgatgacc aactgcttgt 540
 tctcaccgat cttcttgtgt caccatgcta ttatgcatag aaagatgact agtcctcact 600
 tcaggctctt ttcatacaaaa attccacacc ctccaggtacc atctgtgggt gctctctgca 660
 agttttaaaa ctgcctctgc tgagctctca tcatcttggg ggtttctgtg ttagatctcg 720
 ttagtctgca ttccacagct tctcagttgc catttgattt cccaacttgt ccggaagtgt 780
 ttccagaata ctgatcactt ttttttttga ggcatctgac aaagtcacaa agtctcagac 840
 tagaaataat taccagtat gatcatggca tccaagacca gagtctcaga actcattaag 900
 aaacagttta cttggaatgg agaataccca tctgtaatac aggtcctgtc atttcattca 960
 tctcaaatat ttttgaattc ttcccaaatg gctgctggat ttaggtggta ataggggctg 1020
 tgggccataa atctgaagcc ttgagaacct tgggtctgga gagccatgaa gagggaagga 1080
 aaagagggca agtctgaac ctaaccaatg acctgatgga ttgctcgacc aagacacaga 1140
 agtgaagtct gtgtctgtgc acttcccaca gactggagtt tttgggtgctg aatagagcca 1200

```

gttgctaaaa aattgggggt ttggtgaaga aatctgattg ttgtgtgtat tcaatgtgtg 1260
attttaaaaa taaacagcaa caacaataaa aaccctgact ggctgttttt yccctgtatt 1320
ctttacaact attttttgac cctctgaaaa ttattatact tcacctaaat ggaagactgc 1380
tgtgtttgtg gaaattttgt aattttttwa tttatttwat tctctctccc tttttatttt 1440
gcctgcagaa tcgttgagag actaataagg cttaatatatt aattgatttg tttaatatgt 1500
tatataaatg taaaagagtg tataaactgt agagatagca ttggcaagac attgtacaga 1560
tgcaaccttt tacacaacat cattgtgtaa ttgttaaaga ttcacrtgta gttctttatt 1620
atagtgtatt tgggctttgt acccactgaa tgccattttt tgtgttttta aattattttc 1680
tttatcttgt tacaaaaact gagatgtggg gttttttttt ttcagttcac ttatcattag 1740
aatgtctgaa cttttatgta acatttttgt gtgcctctct caatgctaac accacatgtt 1800
tgccatgac aagtttatag agtgaaaggg tatcttctgg gttgaaataa ttcacaaatt 1860
gggtgaatgt atcttgcaac acaccctgta cagtcttcct taaaggaaca ctacagtata 1920
tttttagtat ctacatgctg aatgactgaa tacagaccta aagacagcag tgstcctggg 1980
acagtattta agtgtcggca tacacaggcg taatccctgt ataaagtagt gccaaactga 2040
tttcagttgt gtaactagtt taaaacccaa taaatggatt c 2081

```

<210> 234

<211> 516

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (490)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (498)

<223> n equals a,t,g, or c

<400> 234

```

cggcacgagg ggccaggggt cgggcctgcg cctccctcgg ctccctggcg gggcctcggg 60
gagaggggtg gaagatgtct atggatgtga cattcctggg gacgggtgca gcatacccat 120
ctccaacccg ggggtgcctct gctgtggtcc ttcggtgtga aggcgagts c tggctctttg 180
actgtgggga gggaaacacag acacagctta tgaaaagcca acttaaagca gggagaatta 240
ccaagatctt catcacacac cttcatggag accatttctt tggccttcct gggctcctct 300
gcacaatcag cctgcagagt ggctccatgg tgtccaaaca gcctattgaa atctatggcc 360
ctgtaggctt cgggacttta tctggcgaac catggaactc tctcamacgg gagctggctt 420
tccattatgt ggttcatgaa ctggttccta cagcagatca atgtcctgca gaaggaacta 480
aaagaatttn cgcattgtnaa tagagcagac agtcct 516

```

<210> 235

<211> 1129

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (807)

<223> n equals a,t,g, or c

<400> 235

```
cagctcgwcc tctgcttcct tacagcacc ccacctgcca gagctgatcc tccctaggcc 60
ctgcctaacc ttgagttggc ccccaatccc tctggctgca gaagtcccct taccaccaat 120
gagaggaggg gcaggaccag atcttttgag agctgagggt tgagggcatt gagccaacac 180
acagatttgt cgctctgtc cccgaagaca cctgcaccct ccatgcggas caagatgggg 240
aatggaactg aggaagatta taactttgtc ttcaagggtg tgctgatcgg cgaatcaggt 300
gtggggaaga ccaatctact ctcccgattc acgcgcaatg agttcagcca cgacagccgc 360
accaccatcg gggttgagtt ctccaccgc actgtgatgt tgggcaccgc tgctgtcaag 420
gctcagatct gggacacagc tggcctggag cggtagcgag ccatcacctc ggcgtactat 480
cgtggtgcag tggggggccct cctggtggtt gacctaacca agcaccagac ctatgctgtg 540
gtggagcgat ggctgaagga gctctatgac catgctgaag ccacgatcgt cgtcatgctc 600
gtgggtaaca aaagtgcct cagccaggcc cgggaagtgc cactgagga ggcccgaatg 660
ttcgctgaaa acaatggact gctcttcctg gagacctcag ccctggactc taccaatgtt 720
gagctagcct ttgagactgt cctgaaagaa atctttgcga aggtgtccaa gcagagacag 780
aacagcatcc ggaccaatgc catcacntct ggcagtgcc aggctggaca ggagcctggc 840
cctggggaga agagggcctg ttgcatcagc ctctgacctt ggccagcacc acctgcccc 900
actggctttt tgggtgcccct tgtccccact tcagccccag gacctttcct tgccctttgg 960
ttccagatat cagactgttc cctgttcaca gcacctcag ggtcttaagg tcttcatgcc 1020
ctatcacaaa tacctctttt atctgtccac ccctcacaga ctaggaccct caaataaagc 1080
tgttttatat caaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa 1129
```

<210> 236

<211> 1045

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (973)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1001)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1014)

<223> n equals a,t,g, or c

<400> 236

```
atcctcaaag gcagctcagg ctccgtgtgg ctgcgcaacc tgcaactggg cctcttcggc 60
acagcactgg gcctggtggg gctctggtgg gctgagggta ccgcctggc caccogtgg 120
ttcttttttg ggtacacacc tgctgtctgg ggcgtggtgc tcaaccaggc cttcggcggg 180
ctactggtgg ctgtggttgt caagtacgct gacaatatcc tcaagggtt tgccacctcc 240
ctgtccattg tgctgtccac tgttgccctc attcgctctt ttggcttcca cgtggacca 300
ttatttgccc ttggcgctgg actcgtcatt ggtgctgtct acctctacag ccttccccga 360
ggtgcagyca aagccatagc ctctgcctct gctccgcct ccgggcccctg cgttcaccag 420
cagcctcccg ggcagccacc accaccgcag ctgtcttccc accgtggaga cctcatcacg 480
```

```

gagccctttc tgccaaagtc agtgctggtg aagtragggc tggcagcaat ggggggacac 540
aaggaggagg gactgggggtg gaggggtgttg ggcactctgca ggacccaagt cgccaccctc 600
cggggcctgg ctcctctggg tttgggagat ggtcttttct ccaggtcac tgagacttct 660
ggaggggtgt gggactagag ctgggtgtca cgtgaaccct tcctggtagg gtgacccct 720
tcccctggag ggggtgtttag agctgccgcc tctgctccct ctaacctctt tggaggcagg 780
gttgggggta ttgtcattca aggccttttt tttgtctgct ccctccccga ccctgtgccc 840
tcttctggag gttctcgtct gggagagtcc ctccagcagt ccctcactca taaggcacac 900
tggacaaaac tccgagtctt aggaatgacg atgcctactg tggggtagtg ccatagttgg 960
gcttttctcc ttncacgttg atatgtatag tcgctttggg nctgccagtt cttntacttg 1020
aatgcttctg gagccaggaa aggca 1045

```

<210> 237

<211> 690

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (666)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (678)

<223> n equals a,t,g, or c

<400> 237

```

ggaggagggt ctgccacagc tctccgcacc tctcctctcc cagggcagcc tgtgagcagc 60
aagctgtggc tctgactctg caggaggaca gagcatccct gacgctttca ggggggccct 120
cggcactggc ctttgacctc tccaaggtag caggcccaga ggcagccccc aggetgyggg 180
cgctgacact gggcctggca aaacgcgtgt ggagcctgga gcggcgactg gcagctgcag 240
aagagacagc tgtcagcccg aggaagagcc cccggcctgc agggcctcag ctcttcttac 300
cagaccacaga tccccagaga ggtggccctg gacctggagt caggaggcgg tgtccaggag 360
agtcgctcat caaccccggt ttcaagagta agaaaccagc tgggtggcgtg gacttcgatg 420
agacctgaag gtgcagcaca agcgtggccc cgcggggagt ccgcctatga ggggagaggc 480
agtcttttag gcccccacat gagaccccc gccaccacct ccacctgcct gtcttgggcc 540
aggactaaca cggctcctca aattccttcc ctgtcaaata aacagctccc ttggttggaa 600
aaaaaaaaaa aaaaaaaaaa agtttttttt aattttaagg cgggccaaag ttttttttcc 660
tttttngttg aagggttnat tttttagttt 690

```

<210> 238

<211> 1873

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (568)

<223> n equals a,t,g, or c

<400> 238

```
cccggggtca gtatgtggcg ccttcctcgc gcgctgtgtg tgcacgctgc aaagaccagc 60
aagctctctg gaccttggag caggcctgcc gccttcatgt ccactctcct catcaatcag 120
ccccagtatg cgtggctgaa agagctgggg ctccgcgagg aaaacgaggg cgtgtataat 180
ggaagctggg gaggccgggg agaggttatt acgacctatt gccctgctaa caacgagcca 240
atagcaagag tccgacaggc cagtgtggca gactatgaag aaactgtaaa gaaagcaaga 300
gaagcatgga aaatctgggc agatattcct gctccaaaac gaggagaaat agtaagacag 360
attggcgatg ccttgcggga gaagatccaa gtactaggaa gcttgggtgc tttggagatg 420
gggaaaaatct tagtggaagg tgtgggtgaa gttcargagt atgtggatat ctgtgactat 480
gctgktggtt tatcaaggat gattggagga cctatcttgc cttctgaaag atctggccat 540
gcactgattg agcagtggaa tcccgtangc ctggttggaa tcatcacggc attcaatttc 600
cctgtggcag tgatgggttg gaacacgccca tcgccatgat ctgtggaaat gtctgcctct 660
ggaaaggagc tccaaccact tccctcatta gtgtggctgt cacaaagata atagccaagg 720
ttctggagga caacaagctg cctggtgcaa tttgttcctt gacttgtggt ggagcagata 780
ttggcacagc aatggccaaa gatgaacgag tgaacctgct gtccttcaact gggagcactc 840
aggtgggaaa acaggtgggc ctgatgggtgc aggagaggtt tgggagaagt ctgttggaaac 900
ttggaggaaa caatgccatt attgcctttg aagatgcaga cctcagctta gttgttccat 960
cagctctctt cgctgctgtg ggaacagctg gccagagggtg taccactgcg aggcgactgt 1020
ttatacatga aagcatccat gatgagggtt taaacagact taaaaaggcc tatgcacaga 1080
tccgagttgg gaacccatgg gaccctaatt ttctctatgg gccactccac accaagcagg 1140
cagtgaatcat gtttcttggg gcagtggaa agcaaagaa agaaggtggc acagtgggtc 1200
atgggggcaa gggtatggat cgccctggaa attatgtaga accgacaatt gtgacagggtc 1260
ttggccacga tgcgtccatt gcacacacag agacttttgc tccgattctc tatgtcttta 1320
aattcaagaa tgaagaagag gtctttgcat ggaataatga agtaaaacag ggactttcaa 1380
gtagcatctt taccaaagat ctgggcagaa tctttcgtg gcttggacct aaaggatcag 1440
actgtggcat tgtaaatgtc aacattccaa caagtggggc tgagattgga ggtgcctttg 1500
gaggagaaaa gcacactggg ggtggcagg agtctggcag tgatgcctgg aaacagtaca 1560
tgagaagggtc tacttggtact atcaactaca gtaaagacct tcctctggcc caaggaatca 1620
agtttccagta aagggtgttt agatgaacat cccttaattt gaggtgttcc agcagctgtt 1680
tttggagaag acaaagaaaa ttaaagtttt ccctgaataa atgcattatt atgactgtga 1740
cagtgactaa tccccctatg accccaaagc cctgattaaa tcaagagatt ccttttttaa 1800
aaatcaaaat aaaattgtta caacatagcc atagttacta aaagatgagt taggtggatt 1860
tttattatgg tca 1873
```

<210> 239

<211> 905

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (873)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (874)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (897)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (898)

<223> n equals a,t,g, or c

<400> 239

```
tgcggtcccc cttctaggtc gacccacgcg tccggtgggg ccccgggcgg cgttgaccat 60
gacccagcag ggcgcggcgc tgcagaacta caacaacgag ctggtcaagt gcatagagga 120
gctgtgccag aagcgggagg agctgtgccg gcagatccag gaggaggagg acgagaagca 180
gcggctgcag aatgaggtga ggcagctgac agagaagctg gcccggtca acgagaacct 240
ggcacgcaag attgcctctc gcaacgagtt cgaccggacc atcgcggaga cggaggccgc 300
ctacctcaag atcctggaga gctcccagac tttgctcagc gttctcaaga gggaagctgg 360
gaacctgacc aaggctacag cccagacca gaaaagtagc ggcggcaggg acagctgacc 420
agaccacggg cagggcctgc ctccgtgtgc ccctcagctc agccccagca agtgtgtgct 480
cagagcatct ttgttcttca cggcagcagc taccttccct cactgtctca ggtgccgaga 540
ggggcaggtg ccagcctcca ctggcatcag tgacaagccc agggcacagc ccacccgggg 600
gtcctcgctt catgctcaca caggctatgg ggatgggtgg ctccaggtca gctctgcaag 660
gggcttgtct ctgtggcacc cacactcctg ccctgccagg gaggtcttgg ttgtctgagc 720
accatggggg cccctcacc ttgtccctcc tcagccagca gaggcccagg gcaagggaca 780
ggaggacagg ggttctcctt caccacagaa cccaaacctc aggtctcacc cctgtggcct 840
gtgattatga ataaagatta tctttgtaaa gannaaaaaa aaaaaaaaaa aaaaccnngg 900
ggggg                                           905
```

<210> 240

<211> 1484

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1457)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1471)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1480)

<223> n equals a,t,g, or c

<400> 240

```
gtaacaaaac tcaghtaaca accattagct tttgcaagaa gtcaggttga ctagcaagga 60
gtctgcttct gctacttgga gaagagatgt agaattatgt atcttttgtt acagatatac 120
agatatacaa atatacagat atacaaataa gggatgaagat ggagggaatc tgataaagac 180
atcttataaa ttcaacagac acaaaagaat ttgatctccc ataagcaact gtgaaattac 240
aataacagat cctgggaagt tctacaattc taattcagtt ttttcaaggg ggaacatggc 300
```

```

aaaggtgttc agtttcatcc ttgttaccac cgctctgaya atgggacagg aaatttcggc 360
gctcgaggac tgtgcccagg agcagatgcg gctcagagcc cagggtgcgc tgcttgagac 420
ccgggtcaaa cagcaacagg tcaagatcaa gcagcttttg caggagaatg aagtccagtt 480
ccttgataaa ggagatgaga atactgtcgt tgatcttgga agcaagaggc agtatgcaga 540
ttgttcagag attttcaatg atgggtataa gctcagtggg ttttacaaaa tcaaacctct 600
ccagagccca gcagaatttt ctgtttattg tgacatgtcc gatggaggag gatggactgt 660
aattcagaga cgatctgatg gcagtgaata ctttaacaga ggatggaaag actatgaaaa 720
tggccttgga aattttgtcc aaaaacatgg tgaatattgg ctgggcaata aaaatcttca 780
cttcttgacc actcaagaag actacacttt aaaaatcgac cttgcagatt ttgaaaaaaa 840
tagccgttat gcacaatata agaatttcaa agttggagat gaaaagaatt tctacgagtt 900
gaatatggg gaatatcttg gaacagctgg agattccctt gcgggggaatt ttcactctga 960
ggtgcagtgg tgggctagtc accaaagaat gaaattcagc acgtgggaca gagatcatga 1020
caactatgaa ggggaactgcg cagaagaaga tcagtctggc tgggtggttta acagggtgtca 1080
ctctgcaaac ctgaatggtg tatactacag cgccccctac acggctaaaa cagacaatgg 1140
gattgtcttg tacacctggc atgggtgggt gtattctctg aaatctgtgg ttatgaaaat 1200
taggccaat gattttattc caaatgtaat ttaattgctg ctgttgggct ttcgtttctg 1260
caattcagct ttgtttaaag tgatttgaat aatactcatt ctgaacatat ccatgcgcaa 1320
tcatgataac tgttgtgagt agtgcttttc attctcttca cttgcctttg ttacttaatg 1380
tgctttcagt acagcagata tgcaatatc accaaataaa tgtagactgt gttaawaaaa 1440
aaacaacaaa tatgaanaaa aaaaaaaaaa nggggggctn tttt 1484

```

<210> 241

<211> 1521

<212> DNA

<213> Homo sapiens

<400> 241

```

caaaagcctt aatgggcctg cagactttga aaagcgagtg gagggcggtg ggcggccgcg 60
tgcgcccctg gtcaatgcc tcctgacagc acccgagttc cttattttaca ctggctgcat 120
ggtttgtgtg tttctgtttt gtttctctcc ccctgcaggg ctgtttkcg ggtggggtg 180
ggggttcgct atgtcggatg acgattcgag ggccagcacc agctcctcct catcttcgtc 240
ttccaaccag caaacggaga aagaaacaaa ccccccaag aagaaggaga gtaaagtcag 300
catgagcaaa aactccaaac tcctctccac cagcgccaag agaattcaga aggagctggc 360
ggacatcact ttagaccctc cacctaattg cagtgtgtgt cccaaaggcg ataacatcta 420
tgaatggaga tcaaccattc tagggcctcc aggatccgtg tatgaggggt gtgtattctt 480
tctcgatata acttttacac cagaatatcc cttcaagcct ccaaagggtta catttcggac 540
aagaatctat cattgtaata ttaacagtca aggtgttatt tgcttggaca tattgaaaga 600
taattggagt ccagcactaa ccattttctaa agtcctcctt tctatctgct cacttcttac 660
agactgtaat cctgccgacc ccttgggtgg aagtattgcc actcagtata tgaccaacag 720
agcagaacat gacagaatgg ccagacagtg gaccaagaga tacgctacat aaattggggg 780
ttcacaattc ttacattatt tgtctgtcac agaagagagc tgcttatgat tttgaagggg 840
tcagggaggg tgggagttgg taaagagtag ggtattttcta taacagatat tattcagctc 900
tatttcttaa gattttgttg taacttaagg tatcttgcta cagtagacag aattggtaat 960
agcaactttt aaaaattgtc ttagttctgc aatattagct gaaatgtagt acagaaaaa 1020
atgtacattt agacatttgg gtacagttgc ttgtagtctg taaattttaa acagcttaat 1080
ttggtacagg ttacacatat ggccatttat gtaaagtcct tctaagacta catactttt 1140
gtttaaaaca aaattggaat ttgttttccc ttcttgggag ggaacattga tatttaacag 1200
agttttttaga gattgtcatc tcatatatat aaaatggaca cgtggctata aaacaccata 1260
taagagatga gtagtgctt ttattttata tgccaatcta ctttgtttta aaaaggtctg 1320
aatcaggact tgtgaaaacc tgtagtgaat taccttaagc tgtaactaa ctgtaaggcg 1380
tggaatagga gttgctcagt ggattgggtc tatgttgtgg actacttaag tctgcatttg 1440

```

```

ttactgtgct aataaacaat attaaaaacc acctaataaaa cactgctgtg ttcatttact 1500
tttcttttgc cttttggttg c                                     1521

```

```

<210> 242
<211> 1144
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (1093)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1105)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1106)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1139)
<223> n equals a,t,g, or c

```

```

<400> 242
gcaaactgct acgaagaaat acagataaaa aaggcaagcc tgaaatagca tgtgaaaacc 60
cacattgtac agtagtacct ttgaagcagc ctactctaca cattgcagac aaagatccaa 120
tcccagagga gcaggaatta gaagcttatg tagatgatat agatattgat agtgatttca 180
gaaaggatga tttttattac ttgtctcaag aagacaaaga gagacagaag cgtgagcatg 240
aagaatccaa gaggggtgctc caagaattaa aatctgtgct gggattttaa gcttcagagg 300
cagaaaggca gaagtggaag caacttctat ttagtgatca tgtgtttctt catatagctt 360
taaaattatg ctattgacat tatgggaaag atttatcaat gagagaaatg tgtctctttt 420
tcagccgtgt tgaaatcctt gtctcctgta gaccagtggt aaccataag taattcagaa 480
ccatcaatga attcagatat gggaaaagtc agtaaaaatg atactgaaga ggaaagtaat 540
aaatccgcca caacagacaa tgaaataagt aggactgagt atttatgtga aaactctcta 600
gaaggtaaaa ataaagataa ttcttcaaat gaagtcttcc cccaaggagc agaagaaaga 660
atgtgttacc aatgtgagag tgaagatgaa ccacaagcag atggaagtgg tctgaccact 720
gcccctccaa ctcccaggga ctccattacag ccctccatta agcagaggct ggcacggcta 780
cagctgtcac cagattttac cttcactgct ggcccttgctg cagaagtggc tgctagatct 840
ctctccttta ccaccatgca ggaacagact tttggtgatg aggaggaaga acaaataata 900
gaagaaaata aaaatgagat agaagaaaag taagaaccaa gattcatatg aagtgatatt 960
agattgttcc ttttacaaaa gtgttttagct tcaagactgg aaagggataa tgagtgtgaa 1020
tttactatat ataaagctaa gatgtggatt tacaggaaga accctgggtt gaataactga 1080
tskgaaatta ggnaaaactt gtccnnggca tttcccgttg aaagttcccc cttaaaganc 1140
cccc                                              1144

```

```

<210> 243

```

<211> 934

<212> DNA

<213> Homo sapiens

<400> 243

```

aacacaggaa aagtcgtcct gccaatcact gtgtttatatt ctatggagat gagatttcat 60
tttcatgtca tgagaccagt aggttttcag ctatatgcc aaggatggc acgtggagtc 120
cccgaacacc atcatgtgga gacatttgca attttcctcc taaaattgcc catgggcatt 180
ataaacaatc tagttcatac agctttttca aagaagagat tatatatgaa tgtgataaag 240
gctacattct ggtcggacag gcgaaactct cctgcagtta ttcacactgg tcagctccag 300
cccctcaatg taaagctctg tgtcggaaac cagaattagt gaatggaagg ttgtctgtgg 360
ataaggatca gtatgttgag cctgaaaatg tcaccatcca atgtgattct ggctatgggtg 420
tggttggtcc ccaaagtatc acttgctctg ggaacagaac ctggtaccca gaggtgcca 480
agtgtgagtg ggagaccccc gaaggctgtg aacaagtgtc cacaggcaaa agactcatgc 540
agtgtctccc aaaccagag gatgtgaaaa tggccctgga ggtatataag ctgtctctgg 600
aaattgaaca actggaacta cagagagaca gcgcaagaca atccactttg gataaagaac 660
tataattttt ctcaaaagaa ggaggaaaag gtgtcttgct ggcttgctc ttgcaattca 720
atacagatca gtttagcaaa tctactgtca atttggcagt gatattcatc ataataaata 780
tctagaaatg ataatttgct aaagtttagt gctttgagat tgtgaaatta ttaatcatcc 840
tctgtgtggc tcatgttttt gcttttcaac acacaaagca caaatttttt ttcgattaaa 900
aatgtatgta taaaaaaaaa aaaaaaaaaa tcga 934

```

<210> 244

<211> 915

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (210)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (243)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<400> 244

```

gcgaccgcg gggcgctgca gaacatcacg gcaggcgacc gagtgggcgg ggggtgctgag 60
ccgcctgccc tggagcagga gcgtattctg aacccctgc tagaccgtgt caggaccgcc 120
gaccaccacc agctgcgctc actgactggc ctcatccgaa acctgtctcg gaacgctagg 180
aacaaggacg agatgtccac gaaggtggtg gagccacctg atcgagaagc tgccrggcas 240
gtnnnggtga gaagtygccc ccagccgagg tgctgggtcaa catcatagct gtgctcaaca 300
acctgggtgt ggccagcccc atcgctgccc gagacctgct gtattttgac ggactccgaa 360
agctcatctt catcaagaag aagcgggaca gccccgacag tgagaagtcc tcccgggcag 420
catccagcct cctggccaac ctgtggcagt acaacaagct ccaccgtgac ttcggggcga 480

```

```

aggctatcgg aaggaggact tcctgggccc ataggtgaag ccttctggag gagaagggtga 540
cgtggcccag cgtccaaggg acagactcag ctccaggctg cttggcagcc cagcctggag 600
gagaaggcta atgacggagg ggcccctcgc tggggcccct gtgtgcatct ttgagggtcc 660
tggggcacca ggaggggagc ggtcttatag ctggggactt ggcttccgca gggcaggggg 720
tggggcaggg ctcaaggctg ctctgggtga tgggggtggtg acccagtcac attggcagag 780
gtggggggtt gctgtggcct ggcagtatct tgggtagacc agcactggga ataaagatgg 840
ccatgaacag tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900
aaaaaaaaaa aaac 915

```

<210> 245

<211> 1276

<212> DNA

<213> Homo sapiens

<400> 245

```

gaattcggca gagccccaag gaagaccagc ctgcctctgg tcggttcctg gcgctctgcg 60
tttcgtgacc ttgtccagta gaaggctatt taattttcac aactgcttga attttgacat 120
acaagatgaa gcaagatgcc tcaagaaatg ctgcctacac tgtggattgt gaagattatg 180
tgcattgtgt agaatttaat ccctttgaga atggggattc aggaaacctt attgcatatg 240
gtggcaataa ttatgtggtc attggcacgt gtacgtttca ggaagaagaa gcagacgttg 300
aaggcattca gtataaaaca cttcgaacat ttcaccatgg agtcaggggt gatggcatag 360
cttggagccc agagactaga cttgattcat tgcctccagt aatcaaattt tgtacttcag 420
ctgctgatat gaaaattaga ttatttactt cagatcttca ggataaaaaat gaatataagg 480
tttttagagg ccataccgat ttcattaatg gtttggtggt tgatcccaa gaaggccaag 540
aaattgcaag tgtgagtga gatcacacct gcaggatttg gaacttgga ggagtgcaga 600
cagctcattt tgttcttcat tctcctggca tgagtgtgtg ctggcatcct gaggagactt 660
ttaagcta at ggttgagag aagaatggaa caatccggtt ttatgatctt ttggcccaac 720
aggctatttt atctcttgaa tcagaacaag tgccattaat gtcagcacac tgggtgcttaa 780
aaaacacctt caaagttgga gccgttgag gaaatgattg gttaatttg gatattactc 840
ggtccagtta tcctcaaaat aagagacctg ttcacatgga tcgagcctgc ttattcaggt 900
ggtccacaat tagtgaaaat ctgtttgcaa ccaactggta tcctggcaaa atgcaagcca 960
gtttcaaatt catcatttag gacacctca gcccatcctc atgggttctg tagccgttgg 1020
atctggactg tcctggcatc gaactctccc tctgtgtgta attggaggag accacaagct 1080
gttgttttgg gtgactgaag tataaagtgt tttctgtacc ttagattcac aaactttgta 1140
tttttagtac atattttgaa gaatttctat agtacatatt ttgaagaatt tttatatcaa 1200
atataccgta tacttttaga aatgtctcag ttgcttttat taaataaaat gttgatggtt 1260
tgaaaaatta aaaaaa 1276

```

<210> 246

<211> 3366

<212> DNA

<213> Homo sapiens

<400> 246

```

cccacgcgtc cgaactggac agggatgacc aacctgctgg atatcccagg acttagctca 60
ctctctgaca ccatgatcat ggactccatt gctgccttcc tcgtgttgcc caaccgatta 120
ctgggtgccc ttgtgcctga ccttcaagat gtggctcagt tgcgttcccc tctgccagg 180
ggcattattc gaattcacct gctggctgct cgagggtga gttccaagga caaatatgtg 240
aagggcctga ttgagggcaa gtcagaccca tatgcacttg tgcgtttggg taccagaca 300
ttctgcagtc gtgtcattga tgaagaactc aaccacaggt ggggagagac ttatgaggtg 360
atggtacacg aggtcccagg gcaggagatt gaagtggagg tgttcgacaa ggatccagat 420

```

```

aaagatgact ttctgggcag aatgaagctg gatgtagga aggtgttaca ggctagcgtt 480
ctggatgatt ggttccctct acaaggtggg caaggccaag ttcacttgag gctagaatgg 540
ctgtcacttt tgtcagatgc agagaaactg gagcaggttc tacagtggaa ttggggagtc 600
tcctctcgac cagatcccc gtcagctgcc atcttagttg tctacctgga tcggggccag 660
gatcttcttc tgaagaagg gaacaaggaa cccaacccta tggtaacct gtcaattcag 720
gatgtgactc aggagagcaa ggctgtctac agtaccaact gccagtggtg ggaggaagcg 780
ttcoggttct tcctacaaga ccctcaaagc caggagctcg atgtgcaagt gaaggatgat 840
tccagggccc tgactttagg agcactgacg ctgcctctgg ccgcctgct gactgcccc 900
gaactcatcc tggaccagtg gttccagctc agcagctctg gtccaaactc cagactctat 960
atgaaactag tcatgaggat cctgtacttg gattcatcag aaatatgctt cccacgggtg 1020
cctggttgct ctggtgcttg ggacgtggac agtgagaatc cccagagagg cagcagtggtg 1080
gatgccccac ctgcaccctg tcacacgact cctgatagcc agtttgggac tgagcatgtg 1140
cttcggatcc atgtattaga ggcccaggac ctgattgcca aagaccgttt cttgggggga 1200
ctggtgaagg gcaagtcaga cccctatgtc aaactaaagt tggcaggacg aagcttccgg 1260
agccatgttg ttcgggaaga tctcaatccc cgctggaatg aggtttttga ggtgatcgtc 1320
acatcagttc caggccaaga gctagaggtt gaagtctttg acaaggactt ggacaaggat 1380
gattttcttg gcaggtgtaa agtgctctc accacagtct taaacagtgg cttccttgat 1440
gagtggctga ccctggagga tgtcccatct ggccgcctgc acttgccgct ggagcgtctc 1500
accccccgct ccactgctgc tgagttagag gaggtgctgc aggtgaatag tttgatccag 1560
actcagaaga gtgcggagct ggctgcggcc ctgctatcca tctatatgga gcgggcagag 1620
gacctcccg tgcgaaaagg caccaagcac ctcagccctt atgctactct cactgtggga 1680
gatagttctc ataaaaccaa gactatttcg caaacttcag cccctgtctg ggatgagagt 1740
gcctcctttc tcatcaggaa accacacact gagagcctag agttgcagg tccgggtgag 1800
ggcactggcg tgcgtgggctc attatccctg cccctctcag agctcctcgt ggctgaccag 1860
ctctgcttgg accgctggtt tactctcagc agtggtcagg ggcagggtgct actgagagca 1920
cagctagga tcctggtgtc ccagcactcg ggagtggaa ctcatagcca cagctacagc 1980
cacagctcct catcgctgag tgaagaacca gagctctcgg ggggaccccy tcacatcacc 2040
tcctcagccc cagagctccg gcagcgccca acacatgttg acagtcccct tgaggctcca 2100
gcsgggcctc tgggccaggt gaaactgact ctgtggtact acagtgaaga acgaaagctg 2160
gtcagcattg ttcattggtg ccggtccctt cgacagaatg gacgtgatcc tcctgatccc 2220
tatgtgtcac tgttgctact gccagacaag aaccgaggca ccaagaggag gacctcacag 2280
aagaagagga ccctgagtc tgaatttaat gaacggtttg agtggaact cccctggat 2340
gaggcccaga gacgaaagct ggatgtctct gtcaagtcta attcctcctt catgtcaaga 2400
gagcgtgagc tgcgtgggaa ggtgcagctg gacctagctg agacagacct ttcccagggt 2460
gtagcccggt ggtatgacct gatggacaac aaggacaagg gcagctccta ggagctggcg 2520
agtcccagcc tgactgctct gtcttcctgc cttcgtctcg ctccatcacc gcctcaatgt 2580
gatgagccta aagctagggt ccaagggcag agcctgtgcc cttcagccct ttcacctaac 2640
aggcccatat tcgggccttt gcctgaccaa agagaagaac cgtatgttcc ctttactgca 2700
cggcctttat ccttctgggc ccctggggcg gggacctgag ctggctgttt cctgctttgc 2760
ctgcacattg ttctcccttc ctcccaactc ctcagggcct tctgtatctg tgcctggcca 2820
gtggcagcac tagcagtgtt attagcttat gccaaatata gctttggaag gatctttttt 2880
tctttaacta gatgtcacc ttcttcccta ccacacatgg gtgggaagg ggacaggcta 2940
acctctccag ctgtgagcct cttagactac tgcatgtagc aaatgttcag cagctcaggc 3000
ccccatgtcc agttctgtcc ccactgtcct caaccctgtc ctgaaaattc tactgctttg 3060
atggctgggg ccagtctctt gtcacttttg aaactgagga cgcgtggatt ctactcaagc 3120
ctccaagtag tggcatatca gtcttgagc tcctagctgg tgatacggag agggcttttg 3180
aggacttggt acagcagggc caattttttt gcccaagtgc ctaggctgct aactcactga 3240
ctagaactta atctggtact ttacagtttt gcaccaactc tgccaagcca ctggatctta 3300
cattaaacat cataactcaa aaaaaaaaaa aaaaaaaatt cggggggggg cccgttacct 3360
atttgg

```

<210> 247
<211> 2148
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1259)
<223> n equals a,t,g, or c

<400> 247
gcggccgccca agcgatccct gctccgcgcg acactgcgtg cccgcgcacg cagagaggcg 60
gtgacgcact ttacggcggc agcgtaagtg cgtgacgctc gtcagtggct tcagttcaca 120
cgtggcgcca gcggaggcag gttgmtgtgt ttgtgcttcc ttctacagcc aatatgaaaa 180
ggcctaagtt aaagaaagca agtaaacgca tgacctgccca taagcgggtat aaaatccaaa 240
aaaaggttcg agaacatcat cgaaaattaa gaaaggaggc taaaaagcrg ggtcacaaga 300
agcctaggaa agaccagga gttccaaaca gtgctccctt taaggaggct cttcttaggg 360
aagctgagct aaggaaacag aggcttgaag aactaaaaca gcagcagaaa cttgacaggc 420
agaaggaaact agaaaagaaa agaaaacttg aaactaatcc tgatattaag ccatcaaagt 480
tggaacctat ggaaaaggag tttgggcttt gcaaaactga gaacaaagcc aagtcgggca 540
aacagaattc aaagaagctg tactgccaa gacttaaaaaa ggtgattgaa gcctccgatg 600
ttgtcctaga ggtgttgat gccagagatc ctcttggttg cagatgtcct caggtagaag 660
aggccattgt ccagagtga cagaaaaagc tgggtacttat attaaataaa tcagatctgg 720
taccaaagga gaatttgag agctggctaa attatgtgaa gaaagaattg ccaacagtgg 780
tgttcagagc ctcaacaaaa ccaaaggata aagggaagat aaccaagcgt gtgaaggcaa 840
agaagaatgc tgctccattc agaagtgaag tctgctttgg gaaagagggc ctttggaac 900
ttcttgaggg ttttcaggaa acttgagca aagccattcg ggttgaggta attgggttcc 960
caaatgtggg gaaaagcagc attatcaata gcttaaaaaa agaacagatg tgtaattgtg 1020
gtgtatccat ggggcttaca aggagcatgc aagttgtccc cttggacaaa cagatcacia 1080
tcatagatag tccgagcttc atcgtatctc cacttaattc ctctctctgc cttgctctgc 1140
gaagtccagc aagtattgaa gtagtaaaac cgatggaggc tgccagtgcc atcctttccc 1200
aggctgatgc tcgacaggta gtactgaaat atactgtccc aggctacagg aattctctng 1260
gaatttttta ctrtgcttgc tcagagaaga ggtatgcacc aaaaagggtg ratcccaaat 1320
gttgaagggt ctgccaact gctgtggtct gagtgacag ggtaagcttt cttttctgtt 1380
ggcatttttg tgaccactag aataaacctt cttttgacac atcttatttt taatatcagt 1440
gcctcattag ctactattg ccctccctt acatcttggg ctctctctcc atattttaat 1500
gagagtattg tggtagacat gaaaagcggc ttcaatctgg aagaactgga aaagaacaat 1560
gcacagagca taagagccat caagggccct catttgggca atagcatcct tttccagtct 1620
tccggtctga caaatggaat aatagaagaa aaggacatac atgaagaatt gccaaaacgg 1680
aaagaaagga agcaggagga gagggaggat gacaaagaca gtgaccagga aactgttgat 1740
gaagaagttg atgaaaacag ctgaggcatg tttgctgcag aagagacagg ggaggcactg 1800
tctgaggaga ctacagcagg tgaacagtct acaaggctct ttatcttgga taaaatcatt 1860
gaagaggatg atgcttatga cttcagtaca gattatgtgt aacagaacaa tggcttttta 1920
tgattttttt tttaacattt taagcagact gctaaactgt tctctgtata agttatggta 1980
tgcagtagct gtgtaaattt tgtgaatatg tattatatta aaaccaggca acttggaatc 2040
cctaaattct gtaaaaagac aattcatctc attgtgagtg gaagtagtta tctggaataa 2100
aaaaagaaga tacctattaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2148

<210> 248
<211> 2225
<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<400> 248

```
ccaaagaatt gggncacagc acgtgctgac caccatgcct cgatgaactg ggtcccctgc 60
ggccactctt attttgwgc cacacttaat agcttcatcc acgtcctcat gtactcttac 120
tatggtttgt cgtcagtccc ttccatgcgt ccatacctct ggtggkaaga agtacatcac 180
tcaggggcag ctgcttcagt ttgtgctgac aatcatccag accagctgcg gggtcactctg 240
gccgtgcaca ttccctcttg gttggttgta tttccagatt ggatacatga tttccctgat 300
tgctctcttc acaaacttct acattcagac ctacaacaag aaaggggcct cccgaaggaa 360
agaccacctg aaggaccacc agaatgggtc catggctgct gtgaatggac acaccaacag 420
cttttccacc ctggaaaaca atgtgaagcc aaggaagctg cggaaggatt gaagtcaaag 480
aattgaaacc ctccaaacca cgtcactctga ttgtaagcac aatatgagtt gtgccccaat 540
gctcgttaac agctgctgta actagtctgg cctacaatag tgtgattcat gtaggacttc 600
tttcatcaat tcaaaacccc tagaaaacgt atacagatta tataagtagg gataagattt 660
ctaacatttc tgggctctct gaccctgcg ctagactgtg gaaagggagt attattatag 720
tatacaacac tgctgttgcc ttattagtta taacatgata ggtgctgaat tgtgattcac 780
aatttaaaaa cactgtaatc caaacttttt tttttaactg tagatcatgc atgtgattgt 840
aaatgtaaat ttgtacaatg ttgttatggt agagaaacac acatgcctta aaatttaaaa 900
agcagggccc aaagcttatt agtttaaat agggtatgtt tcaagtttgt attaatgtgt 960
aatagctctg tttagaaaaa atcaaagacc atgatttatg aaactaatgt gacataattt 1020
ccagtgcact gttgatgtga aatcagacac ggcaccttca gttttgtact attggctttg 1080
aatcaagcag gctcaaactc agtggaacag tcagtttaac tttttaacag atcttatttt 1140
tttattttga gtgccactat taatgtaaaa aggggggggc tctacagcag tcgtgatgaa 1200
acttaaatat atattctttg tcctcgagat tttaggaagg gtgtaggggtg agtaggccat 1260
ttttaatttc tgaagtgtca agtgttttta tacagcaaac aaaaagtcaa ttttgctttc 1320
caccagtgcg agagaggatg tatacttttc aagagagatg attgcctatt taccgtttga 1380
cagagtcccg tagatgagca atggggaact ggttgccagg gtctaaattt ggattgattt 1440
atgcaactgt atctgttttg acacagattt ccttgtaaaa tgtgcctagt ttacccaaat 1500
taacaaaggg ggggaaagga ccttagaact ttttaaggta aaatcaaata tagctacagc 1560
ataagagaat cgagaaattt gatagaggta acttgtttaa tgtaaatcta atagtacttg 1620
taatttcttt ctgcttagaa tctaaagatg tgtttagaac ctcttgttta aaaataatag 1680
actgcttata ataaaatcac atctcacaca tttgaggcag tggtaacaac ggtaaagcct 1740
atgatgtgtg tcatttttaa gtgtcggaat ttagcctctg aataccttct ccattggggg 1800
aaagatatcc ttggaaccac tcatgacata tcttagaagg tcattgacaa tgtataaact 1860
aattgttggt ttgatattta tgtaaatatc agtttaccat gctttaattt tgcacattcg 1920
tactataggg agcctatttg ttctctatta gtcttggtgg ttttctgttt gaaaaggagt 1980
catggcatct gtttacattt accttatcaa acctagaatg tgtatattta taaatgtatg 2040
tcttcattgc taggtactaa tttgcagatg tctttacata tttcaataca gaaactataa 2100
cattcaatag tgtgctgtca aagtgtgctt agctcacctg gatataccta cattgttaaa 2160
tgtctaaaca gtaatcatta aaacattttt gattaaaaaa aaaaaaaaaa aaaaaaaaaa 2220
aaaaa 2225
```

<210> 249

<211> 1204

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (1197)
 <223> n equals a,t,g, or c

<400> 249

```

tcgccgctgg ctccgtctgt tggggggcga acacgccgcg gtcctcgtcg tggtgagcgc 60
ascactcagg ctggtcctgg ggggtggggct gtaggggaaa gtgctaaagc cgctgagtga 120
agtaagaact ctgctagaga ggaaatggct gcttcatcat catcctcctc agctgggtggg 180
gtcagtgga gttctgtcac tggatctgggt ttcagtgtct cagacctgcg cccaccacgg 240
aaagcccttt tcacctaccc caaaggagct ggagagatgt tagaagatgg ctctgagaga 300
ttcctctgcg aatctgtttt tagctatcaa gtggcatcca cgcttaaaca ggtgaaacat 360
gatcagcaag ttgctcggat ggaaaaacta gctggtttgg tagaagagct ggaggctgac 420
gagtggcggt ttaagcccat cgagcagctg ctgggattca cccctcttcc aggttgatac 480
tgccctggatg gtcacctctg gtgcgcagca agtgcaaagc cagtggggga ctttctcaca 540
gcttacatag ccatccagag atccacagct acgtcactga attgttaatg cacatttgta 600
cttggtttct ctgtatctat tcacaggcaa caaatactta tatgtgtgat ctttcaggga 660
atgttttggt tatttggttt taaaagtatt gggaaatcaga ttaagacaat cagtttcaga 720
gaaccaggag gtttggggtt aagagatact caaaaatttt cacaagccaa gtagggcata 780
tatcagatgt ggccaactga atggcgtctg tcctgtcatc catatgggtg ctggaaatat 840
ttaccagtca aggtcaaggt cagcatctgt ggttaaaaa atagcattct gacctaaaaa 900
agttattttg cagatgaatg tgttttcaac tcaggacctt tccaaatgag gaatttttaa 960
atattctttt ttttttctta tttttagaca tcaattctat agattctgac tttttctaac 1020
ctcttataga catgccaaat gctggcaaaa agaagtgtt tttggatatg gcagcacttg 1080
taaaaaataa gcagtaagca aaatcctttt aaacacagaa atcctgagtt cttctcattg 1140
gtggactcaa gcaattctgt agcaaataaa tcctttgaaa gagctccaaa aaaaaanaaa 1200
aaaa                                              1204

```

<210> 250
 <211> 1314
 <212> DNA
 <213> Homo sapiens

<400> 250

```

gcgctccttt cctggcagca ggggtttcaa tgggaggaat gctgcttota aattacttgg 60
gcaaaattgg gtccaaaacg cctttgatgg cagctgcaac tttttccgtt ggttggaaca 120
ccttcgcttg ctcagagtca ttggaaaaac cactgaactg gctacttttt aattactatt 180
tgacaacctg ctttcagtct tcagttaata agcaccgaca tatgtttgta aaacaagttg 240
atatggatca tgtcatgaag gctaaatcca tcagagagtt tgataagcga ttcacttcag 300
tcatgttttg ataccaaaca attgatgatt attatactga tgccagtcgg agtcctagac 360
tgaagtcaag aggaattcca gtattgtgtc taaattctgt ggatgatgtt ttctcaccga 420
gtcatgctat tccaatagaa actgctaagc aaaatcctaa tgttgctttg gtccttactt 480
cttatggagg ccatattggg tttctggagg gaatctggcc aagacagtcg acttacatgg 540
atcgtgtcct caagcaattt gtgcaagcca tgggtgagca tggacatgaa ctctcttaac 600
atgtagtctt ttgggtgcat tttgtctgaa ccacaattgt gaaggcagct cagcttagtg 660
cacaaatttt aacttttgta tataaagcaa ataagccagc agatgggtga agaggtccag 720
aatgatatgc aaaaactact ttttagagaa acaaaacaac tttgtagcaa caaattaaat 780
atagtattag attgttactt acgtagatgt tatttttact atgccttacc aagtacatcc 840
ttaaacaaag tagtatgtac atgaaattgc acttaaccaa aactattgtg taaaacaaat 900
tttaattcct cagggtttta atttaaaacta gtattttttt agattatttg ttttaggtga 960

```

```

tttaatggta ctttaataac tactaagaaa tattggctat ttcaatgtaa gttataaggt 1020
ggtacattcc taaggggtatt tatagttgat gataacatga aaactgaaat aagataaaat 1080
acaacgtgct aaatctttta tgtattctaa ctttaaaaga caagtgcaac aaagtttagac 1140
tgacttctat atgtgctctt ttactctgat aatattaaat taggactaac ttatgtttta 1200
taatgattat aatttacatg cttattttta aaatagtata tgtggacaca tatatatcat 1260
tatattaaaa taaattctac cattttaaat tggaaaaaaa aaaaaaaaaa aaaa 1314

```

<210> 251

<211> 1159

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1132)

<223> n equals a,t,g, or c

<400> 251

```

cctgcctcag cctcctcagt agctgggact acaagtgcct gccaccacgc ctgggttatt 60
ttttatatatt ttagtagaga cggggtttca ctgtgttagc caggatggtc tcgatctcca 120
ggatgggtctc gatctccagg atggtctcga tctcctgacg tcgtgatcca cccgcctcgg 180
cctcccaaaa tgctgggatt acaggtgtga gccactgtgc ccggccaaaa gaacagaaat 240
tatttttatcc tgaagtaagc tgtttatatt tgggattata ctgaacctat ttgtccaata 300
acctgagttt tcaaataaatt ttagttctat aagtactata attatataaa tattaatgaa 360
ttcagattag ctgaaaggaa aaaaagtaga agcctgacta cttggtgcta actactaaag 420
atthttggcag aatcaatggt ggatttggct ttctgtgcc ttcccatgc cagcccccca 480
gagtgttctg ccttgtgctg cctcccttca cckggagtgc cacaccctc tctctgccag 540
ttcagctctt cattcttcaa ggctgacct tgtctgacct ttgtgcctct aaaccctggtg 600
gccccacctc tcttgggttcc tatgtcaggt gatgtttgtg tttttggtta tgcccatctc 660
catagccaga ccaagcactc tgggaagccag gggtgggtgc ttattttatct gtttgccatg 720
cagaaaaatat cttgcacaaa attacctctg ttaaggaatc tgaagctgaa tttagtttgg 780
ctgagtcagg gttgggtttt ttttaagggg ctgtgggggtg aaatgttgac tgggaagccac 840
ccacaaacac acacctgctg gtttaggaacc cggctgtggg tggttctgag ctgtttggct 900
tcattgacag tttctgattg ccctgagcac cagggtctcat cttgcatctc atcctggcct 960
ggagaacatt cagtttcctt ccaacccttc ccacctttcc cccactccct tggaggaact 1020
gaagttgggg ttgaggagag ccagatggct ggagtgggta tttgaaggkc tttctgtcac 1080
ctgttcagtg tggcttgccc caccctgtct gacmaagact gactgaaatg tnaaataata 1140
cagaccatct caactcaga 1159

```

<210> 252

<211> 2488

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (64)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2334)

<223> n equals a,t,g, or c

<400> 252

```

tgtatgncca gctggtactc ctgcaggtac cgggtccggat tcccgggtcg acccacgcgt 60
ccngngacgc gtgggttgct cggcagcttg caaagcctga caacaccttg tttgtaaaca 120
gaacactttt tgatcaggtc cttgaattcc tttgtagtcc tgacgatgac tcccgacact 180
ctgaaagaca gcaggtcctt ttagaattgc tgcaggctgg aggcatagtt caatttgaag 240
agagtcgact catccggatg gcagaaaaag ctgagttcta tcaaatttgt gaatttatgt 300
atgaaagaga acaccaatat gacaaaatta ttgattgcyt cttacgtgac cctctgcgag 360
aggaagaagt ctttaattac attcacaata tcttayccat tcccggacac agtgcagagg 420
agaagcagtc tgtatggcag aaagcaatgg atcatattga ggaacycgkg kccctgaagc 480
cttgtaaagc tgcggagctg gttgccaccc acttttcttg acatattgaa acggtcatta 540
aaaaacttca gaaccagggt ttgcttttca aatttttgag gagtcttctt gacccaaggg 600
aaggatttca tgtaaataca gaattactgc aaatatctcc ttgtatcaca gaggcattca 660
ttgagctggt gtgtcagttc aacccaaccc aagttataga gactctgcaa gtccttgagt 720
gctaccgtct ggaagaaact attcagatta ctcagaagta tcaacttcat gaagtcaccg 780
cttatctatt ggaaaagaaa ggagatattc atggtgcctt cctaataatg ttagagagac 840
tacaaagcaa acttcaagag gtaacacatc aaggtgaaaa taccaaagag gatccctcat 900
tgaaggatgt tgaagatact atggtggaga ccattgctct ttgccagaga aattcacata 960
atgtgaacca gcagcaacgt gaggcccttt ggtttccgtt attggaggca atgatggccc 1020
ctcagaagct gtccagttca gccattcctc atctacactc tgaagctctg aagtctttga 1080
ccatgcaagt tttaaatagc atggcagcat ttattgccct tccatcaatc ttgcaaagaa 1140
tcttacagga tccagtttat ggaaaaggaa aacttgagaa aatccaggga cttatcttgg 1200
gaatgttaga tacctttaac tatgaacaaa ccctgctgga aacaacaacc agccttytaa 1260
accaagatct ccattgggtc ttgtgtaacc tgagagcttc ggtaaccaga ggactgaatc 1320
ccaaacaaga ttactgctct atatgtttgc agcagtacaa gagacgcaa gaaatggctg 1380
atgaaataat tgtcttttagc tgtggccatt tgtatcactc attctgccta caaaacaaag 1440
aatgcactgt ggaatttgag ggccaaacaa gatggacatg ctacaaatgc agttcaagta 1500
acaaagtagg aaaactcagt gaaaattcat ctgaaattaa aaagggaagg ataaccccat 1560
cacaggtaaa aatgtctcca tcgtatcatc agtccaaagg ggatccact gctaaaaagg 1620
gaacctcaga acctgttctg gatccacagc aaatccaagc atttgatcag ctttgccgtc 1680
tctaccgagg aagctccagg ctggctctcc tcacggaact ctcccagaat cgcagcagcg 1740
agagctatag gccattcagt ggctcgcaga gtgctcctgc tttcaacagc atcttcaga 1800
atgagaactt ccagctgcag ctcatcctc cacctgtgac tgaggattga tgactccatg 1860
gagcctggcc caggagaacc agagatgatc ccgaggcagc tggggagagg ccccgctct 1920
ggtgggcttg gcctccacca cctcccatgc ttctgagaag aggttccaaa ttgggctcct 1980
gtgccagag cgtccacagc accattccca gtgtagactc ccagtcttct ccacattgct 2040
gtcatggcgt cagttcacca gactcattga ttttggtttg cttgttaagc aaaggaatgt 2100
cacatacctc tgtccagctt tttaggaaat acatttcgcc tattgcgact ttttccattt 2160
accctgaagc ctagaaagta ggtggaactc acacaaatgg cattccagag tctgccatac 2220
tccgtctcct ccagctgctg gataatacag aggaacttca acttctacag ggaacagtgg 2280
ttggccaggc tgcagtataa ctgaagcatg ccttgagag agcagacact gtgngggcca 2340
gggccatctc cttttaatgt gttcatgtta aaacctatct gagtgtgaaga cttgcccttt 2400
ctaacaataa atgctctgtg tttaagttct gcagggtctc tggctggctg gctggctctc 2460
agtctgtcaa gtcattggag acatttctg

```

<210> 253
 <211> 1554
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (6)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (81)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1496)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1523)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1535)
 <223> n equals a,t,g, or c

<400> 253
 actggnaatc cactactatt tggaaagctg gtccgcctgc aggtaccggt ccggaattcc 60
 cgggtcgacc cagcgctccg nggacgcgtg ggttctggtt ttgctctagt gtttggggtt 120
 ctctcgcggt gctcaagatg aaccgactct tcgggaaagc gaaacccaag gctccgccgc 180
 ccagcctgac tgactgcatt ggcacggtgg acagtagagc agaatccatt gacaagaaga 240
 tttctcgatt ggatgctgag ctagtgaagt ataaggatca gatcaagaag atgagagagg 300
 gtcttgcaaa gaatatggtc aagcagaaaag ccttgcgagt tttaaagcaa aagaggatgt 360
 atgagcagca gcgggacaat cttgccaac agtcattcaa catggaacaa gccaattata 420
 ccattccagtc tttgaaggac accaagacca cggttgatgc tatgaaactg ggagtaaagg 480
 aaatgaagaa ggcatacaag caagtgaaga tcgaccagat tgaggattta caagaccagc 540
 tagaggatat gatggaagat gcaaatgaaa tccaagaagc actgagtcgc agttatggca 600
 ccccagaact ggatgaagat gatttagaag cagagttgga tgcactagggt gatgagcttc 660
 tggtctgatga agacagttct tatttgatg aggcagcatc tgcacctgca attccagaag 720
 gtgttccac tgatacaaaa aacaaggatg gagttctggt ggatgaattt ggattgccac 780
 agatccctgc ttcataagatt tgcatcattc aagcatatct tgtaaaacaa acacatatta 840
 tgggactagg aaatatattt ctttccaaat ttgccataac agatttaggt ttctttcctt 900
 tctttgaagg aaagtttaac tacattgctc ttttatTTTT tccattaaga gactcattgc 960
 ttgggaaatg ctttcttcgt actaaaattt gattcctttt tttcttatga aaaacgaact 1020
 cagtttaaaa gtatttttag ctcgatatgac ttgttttcat tcattaataa taatttgaaa 1080
 taaaactaag gaaatggaat cttaaaagtc tatgacagtg taactctaca gtctcaaaat 1140

```

gacctgataa attgataaga caaagatgag attattgggg ctgttcatat tatgattcag 1200
aatcatTTTT tattgtggta ttatagggtg gttaaagtga tggcctTTTT gatgggTTTT 1260
gttggtgtcct gtgaacaagt cgttactgtg tccattattg gaatggaatt atcactactg 1320
tatcatgagt gggatTTTT attctatggt tccctcagta ttacatcttg acttgtaatc 1380
aattatgaat atttcttgat atttaatgta taggacattt atttatactc aataaatatt 1440
tttcaaaagg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggggCGG cccgcncTag 1500
aggatcccc gaggggggCC cangcttacg cgtgncatgc gacgtccaaa gccc 1554

```

<210> 254

<211> 1506

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1492)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1501)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1506)

<223> n equals a,t,g, or c

<400> 254

```

ctggaagaat tcgcgtggca ggagaggcgg ggcaattttg ctnagctttc tcgcgggctt 60
gcagctgcgg caagtgctgg cggcggctgc tcgcgcaagt cagctggcgt gggaactacc 120
ctttgtagct gagaacggct tgtttattgc tacaaagact ctattgacat tggtagcttc 180
agcggcagca gcttcttacg gtataaagct gttgcttcct gaagaggcta caagcatcct 240
tccctaggac tgctgtaagc tttgagcctc tagcaggaga catgcctcgg ggacgaaaga 300
gtcggcgccg ccgtaatgCG agagccgCag aagagaaccg caacaatcgc aaaatccagg 360
cctcagaggc ctccgagacc cctatggccg cctctgtggt agcagcacc cccgaagacg 420
acctgagcgg ccccagggaa gaccgagca ctccagagga ggcctctacc acccctgaag 480
aagcctcgag cactgccccaa gcacaaaagc cttcagtGCC cggagcaat tttcagggca 540
ccaagaaaag tctcctgatg tctatattag cgctcatctt catcatgggc aacagcgcca 600
aggaagctct ggtctggaaa gtgctgggga agttaaggaat gcagcctgga cgtcagcaca 660
gcactctttg agatccgaag aagatcgtca cagaagagtt tgtgcgcaga gggtagctga 720
tttataaacc ggtgccccgt agcagtcCG tggagtatga gttcttctgg gggccccgag 780
cacacgtgga atcgagcaaa ctgaaagtca tgcattttgt ggcaagggtt cgtaaccgat 840
gctctaaaga ctggccttgt aattatgact gggattcGga cgatgatgca gaggttgagg 900
ctatcctcaa ttcagggtgct aggggttatt cgcgccctta agtagatctg aggcagacc 960
ttgggggtgt aaaagagagt cacagggtacc ccaaggagta gatgccaggg tcctaagttg 1020

```

```

aaaatgatgt cgattggggg cgggggacac tgtatttgat atttgtgac agtgatcatt 1080
gttcaactgc gaaatagagt gtttgctttt gataatggaa aattgtattc gttttaaaat 1140
tccgtttgtt gagaataaca atatgtttta aaatataatt gaacaaattt ttttctttgt 1200
ttcctgtcat tgacatttag tataacagtt ttgctaactg tctaaaatga agtcgttcca 1260
tcataatcta tgatcttgta cagcacttat agaaataagc tgttcttttg aagttgaaat 1320
acccagtaaa atgttgaaga aggatggagg atttcttcat atctgacgtt tctgaaacc 1380
tttgtgtctg ctggtgtgtg aagattgaca tttaccatga ttttcttag ttactgcaga 1440
acatagagaa aaataaaagc ctaacgaata gtataaaaaa aaaaaaaccc tngggggggg 1500
ncccg      1506

```

<210> 255

<211> 654

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (632)

<223> n equals a,t,g, or c

<400> 255

```

actcacnta ttggaaaagc tggtagcct gcaggccccg gtccggaatt cccgggtcga 60
cccacgcgtc cgatctttcc gcgccggtga gtagcactct ctgagagctc caatttcac 120
cgtctgccat cggcgccatc ctgcaatcta agccacaatg gtgcgcatga atgtcctggc 180
agatgctctc aagagtatca acaatgccga aaagagaggc aaacgccagg tgcttattag 240
gccgtgctcc aaagtcatcg tccggtttct cactgtgatg atgaagcatg gttacattgg 300
cgaatttgaa atcattgatg accacagagc tgggaaaatt gttgtgaacc tcacaggcag 360
gctaaacaag tgtgggggtga tcagccccag atttgacgtg caactcaaag acctgaaaa 420
atggcagaat aatctgcttc catcccgcc gtttggtttc attgtactga caacctcagc 480
tggcatcatg gaccatgaag aagcaagacg aaaacacaca ggagggaata tcctgggatt 540
ctttttctag ggatgtaata catatattta caaataaaat gcctcatgga caaaaaaaaa 600
aaaaaaaaaa aaaaaagggg gsgsggtctag anggtccaag cttacgtacg cgtg      654

```

<210> 256

<211> 1992

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (558)

<223> n equals a,t,g, or c

<400> 256

```

gctcgccata cacctgcgca acgccatgac caccgcgaag aaggaaacat accagtctgt 60
gtacaactgg cagtatgtgc actgcctctt cctgtggtgc cgggtcctga gcaactgcgg 120

```

```

ccccagcgaa sctccagcc cttggtctac ccccttgccc aagtcatcat tggctgtatc 180
aagctcatcc ccaactgccc cttctacccg ctgcgaatgc actgcatccg tgccctgacg 240
ctgctctcgg ggagctcggg ggccttcac cgggtgctgc ctttcatcct ggagatgttc 300
cagcaggtcg acttcaacag gaagccaggg cgcagtagct ccaagcccat caacttctcc 360
gtgatcctga agctgtccaa tgtcaacctg caggagaagg cgtaccggga cggcctggtg 420
gagcagctgt acgacctcac cctggagtac ctgcacagcc aggcacactg catcggttc 480
ccggagctgg tgctgcctgt ggtcctgcag ctgaagtcgt tcctccggga gtgcaagggtg 540
gccaaactact gccggcangt gcagcagctg cttgggaagg ttcaggagaa ctccggcatac 600
atctgcagcc gccgccagag ggtttccttc ggcgtctctg agcagcaggc agtggaagcc 660
tgggagaagc tgacccggga agaggggaca cccytgacct tgtactacag ccactggcgc 720
aagctgcgtg accggggagt ccagctggag atcagtggca aagagcggct ggaagacctg 780
aacttccctg agatcaaacg aaggaagatg gctgacagga aggatgagga caggaagcaa 840
tttaaagacc tctttgacct gaacagctct gaagaggacg acaccgaggg attctcggag 900
agaggggatac tgaggcccct gagcactcgg catgggggtg aagacgatga agaggacgag 960
gaggagggcg aggaggacag cagcaactcg gagggtgaat ggtcttggga tggagaccca 1020
gacgcagagg cggggctggc ccctggggag ctgcagcagc tggcccaggg gccggaggac 1080
gagctggagg atctgcagct ctgagggac gactgaggca gcccactctg ggggcctgta 1140
ggggctgccg ggctgggtggc cagtgtttcc acctccctgg cagtcaggcc tagaggctgg 1200
cgtctgtgca gttgggggag gcagtagaca cgggacaggc tttattatit atttttcagc 1260
atgaaagacc aaacgtatcg agagctgggc tgggtggtggc tgggtgtggc gctgaagccc 1320
cacagctgtg ggctgctgaa gtcagctccg cgggggagct gaccctgacg tcagcagacc 1380
gagaccagtc ccagttccag ggggaggcct gcagcccctg gccmmtcca ccacctctgc 1440
cctccgtctg cagacctcgt ccatctgcac cmggctctgc yttactccc ccaagtcttt 1500
ggaaatttgt tcttttcctt tgaagtcaca ttttctttta aaattttttg ttttgcatac 1560
gaaaccgaaa gaaataaagc ggtgggaggc agggccattg tgttgagtgg tgggaagggt 1620
gccgtcctgg ctgcaggacg cctctcggaa agagatgttc acgtcccagt ggggtgtggac 1680
tcttctcttc atgatacgga tgtgcggacc atcctcctgc ttcaagcctg ccgccgccac 1740
aggtggggcc actcccgctg ctgtcaccat cgctggcaga gaagctggga gttcgctcct 1800
tcttcagggt ccggggcgga ggcaggcgca ctgtcctctt gtctgccagc cgcaccgggt 1860
caccggggag gatattcggc agcccgggca gtcgcagatc ggaggatgca cctgcaggat 1920
ccccttggac ataagcgtct tcagactttt ccctccgag cggaggggag ggcccgcgag 1980
ccccaaagcg tg
1992

```

<210> 257

<211> 2273

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2271)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2273)

<223> n equals a,t,g, or c

<400> 257

```

ggcacgagct ggcggggaag gagaggtcag gcgctccggg ctgcgccgct aggtcggggc 60
cgcggcgtcc cccaccctaa gtcccacctc cgcccgggca tgggtacccg ggcgggcctg 120

```

```

gctcggcctg ggcccactca ctggtccaga agcagctgta ggtgcccacc aagcccatga 180
cgacgctgct ggccagggtc cagccctatt caggcaggag ctgctcttct ggggtatcgc 240
gatccactta aggatgagggc agacttggtg acaagctggt ctgagcagcg cttccagagc 300
cagaactgag ccagtgaga gcgcaccctg gggcagcctg gattcctggg gtgtccccgg 360
cagccacaca cagccatgca ctacccaact gcactcctct tcctcatcct ggccaatggg 420
gcccaggcct ttcgcatctg cgccttcaat gcccagcggc tgacactggc caaggtggcc 480
agggagcagg tgatggacac cttagttcgg atactggctc gctgtgacat catggtgctg 540
caggaggtgg tggactcttc cggcagcgcc atcccgtctc tgcttcgaga actcaatcga 600
tttgatggct ctggggcccta cagcaccctg agcagcccc agctggggcg cagcacctac 660
atggagacgt atgtgtactt ctatcgttca cacaaaacac aggtcctgag ttcctacgtg 720
tacaacgatg aggatgacgt ctttgcccgg gagccatttg tggcccagtt ctctttgccc 780
agcaatgtcc ttcccagcct ggtgttggtc ccgctgcaca ccactcctaa ggccgtagag 840
aaggagctga acgcccctcta cgatgtgttt ctggaggctc cccagcactg gcagagcaag 900
gacgtgatcc tgcttgggga cttcaatgct gactgcgctt cactgaccaa aaagcgctg 960
gacaagctgg agctgcggac tgagccaggc ttccactggg tgattgccga tggggaggac 1020
accacagtgc gggccagcac ccactgcacc tatgaccgag tcgtgctgca cggggagcgc 1080
tgccggagtc tgctgcacac tgcggtgcc tttgacttcc ccacgagctt ccagctcacc 1140
gaggaggagg ccctcaacat cagtgaccac taccctgtgg aggtggagct gaagctgagc 1200
caggcgcaca gcgtccagcc tctcagcctc actgttctgt tgctgctatc actcctgtcc 1260
cctcagctgt gccctgctgc ctgagcgtcc ccctaccccc ccagggcctg ctgccttttg 1320
ggacttaaac cccagcctcc cccgtccatc cagccctggg gctggggggc ttcaactata 1380
gttgccctgt gactgtagtc caccctgtcc tgccttgttt gatttggtc ttgttctttg 1440
gttgggcttg tgcctagatt aggagaggaa gccaggggcc ctgcactcat gccacctgcc 1500
aggtagtgtg gtatcaggag tggagacaaa gtgggctctg ggttggggta ggggaaggga 1560
gggttcagaa agaggaatga agatgttgta tgacaagaag gaaagttact gagaacaaaa 1620
accagattg gtgagatagg acacttgtgc agcagatatg ccaatggggc atgtttattg 1680
tggattggta agaatcacca ggaaaccatt aagccccaat agctacaagg aggggtggtta 1740
atctgctata tcaaactcct tccctgaaac cagcaaacac cgggaaacat tttggctcat 1800
tataatccgg tgaacaatgc agtcaggcct gttataaccg ctgagcagcc acactcgac 1860
ctcctgggtg ctgtagtctg tgttggtaca ggcttctgca tgcctggtaa agtccagcca 1920
aggctggtca aggcaacatc tccacacaga aaatctgcac cagttatgta agctaaaaag 1980
ctgtgtgaac ccagggtgtc cggaaagggg ctgcaggaca cagcaaaatg ccagcagcrt 2040
gccggacccc tcccttccat cctcctctcc aaagaasaga ggtcaggaaa aacactggct 2100
gggacgctag aagggtcatg tgtaaactat aatcacatct atggtttgga accatcacc 2160
caaggtaaaa aaaaaataaa aggtattccc aggtatgttt ggcaaaataa aataaaggta 2220
attaaaaacc taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaattttgcg ncn 2273

```

<210> 258

<211> 1504

<212> DNA

<213> Homo sapiens

<400> 258

```

ctgtactctg ccctagattg ttttagcttc tgttctgtaa tcatgagttt ggttggagat 60
attctccata gatgatcttc tactgaaatg cctaaagaag tcacaggctg gcttctgttt 120
tattcaggga ttttttttaa aagtcaatca gaaaagggat actggagctt cttcatgtat 180
gtaacagcat attaaactgg agacagtgat gaatcagcta caaaggtaat attgtattaa 240
aatcatgttt aagatagctg cttttatgtg tattttatat tgcatgcttt tgtaaaaaca 300
tgctgggtga tgaaagatta gttttagaga gaaaatgttc atctgtgcag aggatgcatt 360
ttcttccatt aattctggaa aaaacgttca cagttatata tatggtatct tgcaaaagga 420
ctattaatag aaccttttga gatgaattaa tgtaagaata ttttttaa ataggcttactg 480

```

```

tcaaattgca actttttttt tagatacaga gtggaaaaca gtgctaagtc atttggcacc 540
tccttacaaa tatttttcat ggtcacattt attaaatgtt actacatttc tgaatttttg 600
aaaaatgtat tttatcatta aatggcatta ttttaaaggg tgaaaaactg acacagtcaa 660
ttcagaaaat ggactgaagt ctgaataagg tcattgcatt taaaaagcat ataactgtac 720
ttgactgatg agggaggtgt tactttcatt gtatataggt cttatttcat aaacagatat 780
cctgtatcaa ataaaagtat ttgttatata tttgaagtta tgcattggaaa ggagtgtgtt 840
taaattgtta caacaataa tgcgtcatta aaggccatgc tgatcttgca taactataag 900
tactatgaat gaatttggtt ggttttggtg ttgtacagct cacatgttta cactcagt 960
gccctaattt cccctgaggg aatcgctttt taagtgatcc ttacagtggg gttttatgtt 1020
actttattac agagctcctt ggttttttac ttctgcactt aaattttttt aaataacatg 1080
atgatggtag attttcctct attgtctagc taagggcttt cgggtccacca gtaaataaga 1140
tcaaattgctc ttaaattgtt ctgttaccat cctaattgtaa atactggatt tttctgtcat 1200
ttagcaccat gctgcttctg tctgtcttaa tgctggcatt aagatcatga gccctttttc 1260
tcagtagta caggctttga aaactacttc tattaagtta ttgatgcaat ttgatatttt 1320
ttcataatct atatttaaac aaaattacat cattgcatca tcttttctaa attcatctcc 1380
attaaaactt gccttaagct accagattgc ttttgccacc attggccata ctgtgtgttt 1440
gtttgtttta tttactttca caataaactt ctgtgtagta aaaaaaaaaa aaaaaaaaaa 1500
aaaa                                              1504

```

<210> 259

<211> 1792

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (107)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (487)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1306)

<223> n equals a,t,g, or c

<400> 259

```

aattcggcac gagctacatc gggggactcc tctcagcctt ctacctgaca ggagaagagg 60
tgttccgaat aaaggccatc aggtgaggag agaagctcct gccggcnttc aacaccccca 120
cggaatccc aaaggcgctg gtgagcttca aaagtgggaa ctggggctgg gccacagccg 180
gcagcagcag catcttggcg gagtttgat ccctgcactt ggaattctta cacctcactg 240
aactctctgg caaccaggtc ttcgctgaaa aggtcaggaa catccgcaag gtcctcagga 300
agatcgaaaa gccctttggc ctctaccca acttcctcag cccagttagt gggaactggg 360
tgcaacacca tgtctcagtt ggaggactcg gggacagttt ttatgaatat ttgatcaaat 420
cctggttgat gtcgggcaag acagatatgg aggctaaaaa tatgtactac gaagccttgg 480
aggcgantag agacctactt gctgaatgty tctcccgggg ggctgacctt cattgccgag 540
tggcgagggg ggattctgga ccacaagatg gggcacctgg cctgtttctc cgggggcatg 600
atcgcccttg gcccgaggat gccaaaggaag aaaagagggc ccactaccga gagctcgag 660

```

```

cccagatcac caagacgtgt cacgagtcac acgcccgcctc agacacccaaa cttgggcctg 720
aggcttcttg ttttaactccg gcagagagggc cgtggccacc cagctgagcg agagytacta 780
catcctccgg ccagaggttg tggagagcta catgtacctg tggcgacaga cccacaaccc 840
catctacagg gagtggggct gggaggtggt gctggccttg gagaaatact gtcggacaga 900
agccggtttc tctgggatcc aagacgtgta cagtagcacc cccaaccacg acaacaagca 960
gcagagcttc tttctagcgg agacactaaa gtatctctat cttctgttct ctgaagatga 1020
cttgctctcc ctggaagact ggggtgtcaa caccgaggcc caccactcc cggatgaacca 1080
ctcagacagc tccggcagag ctggggcaga cactgacccc atctcctgcc gccgcccctgg 1140
ggcgcgcgca ggatgccttg ccttttcagg atttgagact gttctcaaag ggattgggaa 1200
cgaaggcccc atctcgggca gaccccagc agatgtgtcg gacaagcaac ttcttttctt 1260
ctgtgaggag acaagacttg gagactcagc gatgtcaggc cagggncatg gccacactgg 1320
cccacacatt cctttctaca gagaatttct atgaagccca ctcacttgcc attccagggc 1380
caaaggaccg gaggtttgca tatccgcccc ttgtatttga tttgcttcct tttggtttct 1440
tggtttttgt ttttgcttga ttttgctctt tctctacagt ttagttttgt cacaattaca 1500
catatagttt tcaaaatcat gcactttcta aaatggtgtc atcctgaaaa acaaaaccca 1560
gtgtttgcac acacacaaaa tcttgacccc gttatctata ttttaaagtc tttttgcca 1620
acactgaccc tatgttcaac tttgtgtcat ttaccttata atttgaggag gggtttccct 1680
ttgggcctca gtgttacaaa ttactagtgc tattttcatt attattgtaa tggaaaaatc 1740
tgtggactag aataaaagag tttattgaat aagaaaaaaa aaaaaaaaaa aa 1792

```

<210> 260

<211> 2048

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (66)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (67)

<223> n equals a,t,g, or c

<400> 260

```

atcccttttg atccgggcct gggctgagtg ctccccccgg gcttcagggtg acgcgcccc 60
gcgganntgg ggtcgcccga gttgggctgg ggaagccagg gacggagggtg tccggccgctc 120
acccttagag gagggcgtgc ggggtctgt tttgcatgcg agccaccct ctggctgctc 180
ctgcgggttc cctgtccagg aagaagcggg tggagttgga tgacaactta gataccgagc 240
gtcccgtcca gaaacgagct cgaagtgggc ccagcccag actgcccccc tgcctgttgc 300
ccctgagccc gaggaggcg ggcgggccta ccaggcctgc actgccctac aggactgag 360
tatacctgca agtgtacccc gtccaggaaag ccctggccgt gctggagccc taygcgcggc 420
tgcccccgca caagcatgtg gctcggccca ctgaggtcct ggctggtagc cagctcctct 480
acgccttttt cactcggacc catggggaca tgcacagcct ggtgcgaagc gccaccgtat 540
ccctgagcct gaggtgccc tgctcttcgg ccagatggcc accgccctgg cgcactgtca 600
ccagcacggg ctggtcctgc gtgatctcaa gctgtgtgcg tttgtcttcg ctgaccgtga 660
gaggaagaag ctggtgctgg agaacctgga ggactcctgc gtgctgactg ggccagatga 720
ttccctgtgg gacaagcacg cgtgccacgc ctacgtggga cctgagatac tcagctcamg 780
ggcctcatat tcgggcaagg cagccgatgt ctggagcctg ggcgtggcgc tcttcaccat 840
gctggccggc cactaccct tccaggactc ggagcctgtc ctgctcttcg gcaagatccg 900

```

```

ccgcggggcc tacgccttgc ctgcaggcct ctcggcccct gcccgctgtc tggttcgctg 960
cctccttcgt cgggagccag ctgaacggct cacagccaca ggcatcctcc tgcacccttg 1020
gctgcgacag gacccgatgc ccttagcycc aaccgatcc catctctggg aggctgcccc 1080
ggtggtccct gatggactgg ggctggacga agccaggga gagggaggag acagagaagt 1140
ggttctgtat ggctaggacc accctactac acgctcagct gccaacagtg gattgagttt 1200
gggggtagct ccaagccttc tctgcctct gaactgagcc aaaccttcag tgccttcag 1260
aaggagaaaa ggagaagcc tgtgtggagt gtgctgtgta cacatctgct ttgttcaca 1320
cacatgcagt tcctgcttgg gtgcttatca ggtgccaaag cctgttctcg gtgctgggag 1380
tacagcagt agcaaaggag acaatattcc ctgctcacag agatgacaaa ctggcatcct 1440
tgagctgaca acacttttcc atgaccatag gtcactgtct acactgggta cactttgtac 1500
cagtgtcggc ctccactgat gctggtgctc aggcacctct gtccaaggac aatccctttc 1560
acaaacaaac cagctgcctt tgtatcttgt accttttcag agaaaggagg gtatccctgt 1620
gccaaaggct ccaggcctct cccctgcaac tcaggaccca agcccagctc actctgggaa 1680
ctgtrttccc agcatctctg tctctttgat taagagattc tccttcagg cctaagcctg 1740
ggatttgggc cagagataag aatccaaact atgaggctag ttcttgtcta actcaagact 1800
gttctggaat gaggggtccag gcctgtcaac catggggctt ctgacctgag caccaagggt 1860
gagggacagg attaggcagg gtctgtcctg tggccacctg gaaagtccca ggtgggactc 1920
ttctggggac acttggggtc cacaatccca ggtccatact ctaggttttg gataccatga 1980
gtatgtatgt ttacctgtgc ctaataaagg agaattatga aataaaaaaa aaaaaaaaaa 2040
aactcgac                                     2048

```

<210> 261

<211> 1282

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1244)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1261)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1265)

<223> n equals a,t,g, or c

<400> 261

```

ctcgtgtcgc cgccattttg ccgggggtttg aatgtgaggc ggagcggcgg caggagcggg 60
tagtgccagc tacgggtccgc ggctgggggtt ccctcctccg tttctgtatc cccacgagat 120
cctatagcaa tggaactcag cgatgcaaat ctgcaaacac taacagaata tttaaagaaa 180
acacttgatc ctgatcctgc catccgacgt ccagctgaga aatttcttga atctgttgaa 240
ggaaaatcaga attatccact gttgcttttg acattactgg agaagtccca ggataatgtt 300
atcaaagtat gtgcttcagt aacattcaaa aactatatta aaaggaaactg gagaattgtt 360
gaagatgaac caaacaataa ttgtgaagcc gatcgagtgg ccattaaaag caacatagtg 420
cacttgatgc ttagcgagccc agagcaaatt cagaagcagt taagtgatgc aattagcatt 480
attggcagag aagatttttc acagaaatgg cctgacttgc tgacagaaat ggtgaatcgc 540

```

```

tttcagagtg gagatttcca tgttattaat ggagtcctcc gtacagcaca ttcattatTT 600
aaaagatacc gtcatgaatt taagtcaaac gagttatgga ctgaaattaa gcttgttctg 660
gatgcctttg ctttgccttt gactaatctt tttaaggcca ctattgaact ctgcagtacc 720
catgcaaatg atgcctctgc cctgaggatt ctgttttctt ccctsatcct gatctcaaaa 780
ttgttctata gtttaaactt tcaggatctc cctgaatttt ttgaagataa tatggaaact 840
tggatgaata attttcatac tctcttaaca ttggataata agcttttaca aactgatgat 900
gaagaggaag ccggcttatt ggagctctta aaatcccaga tttgtgataa tgccgcactc 960
tatgcacaaa agtacgatga agaattccag cgatacctgc ctcgttttgt tacagccatc 1020
tgggaattta ctagttacaa cgggtcaaga ggttaaataat gatttggttg taagtaatgc 1080
aattcaatTT ctggcttcag tttgtgagag acctcattat aagaatctat ttgaggacca 1140
gaacacgctg acaagtatct gtggaaaagg ttattgtgcc taacatggga tttagagctg 1200
ctgatggaag aagcattgaa gtaattctga ggggttacag agngagatt tggaagggtc 1260
nggtnttggg actagacgca gg                                     1282

```

<210> 262

<211> 599

<212> DNA

<213> Homo sapiens

<400> 262

```

ggcacgagcc ccggcagagg cggargcgga gtcggcctga gaggtctctc gtcgctgcag 60
gogcctcagc ccagccgcgt gccttggccc atggccgcct actcttaccg ccccgccct 120
ggggccggcc ctgggcctgc tgcaggcgcg gcgctgccgg accagagctt cctgtggaac 180
gttttccaga gggctgataa agacaggagt ggagtgatat cagacaccga gcttcagcaa 240
gctctctcca acggcacgtg gactccctt aatccagtga ctgtcaggtc gatcatatcc 300
atgtttgacc gtgagaacaa ggccggcgtg aacttcagcg agttcacggg tgtgtggaag 360
tacatcacgg actggcagaa cgtcttccgc acgtacgacc gggacaactc cgggatgatc 420
gataagaacg agctgaagca ggccctctma gtttcggcta ccggctctct kaccagttcc 480
acgacatcct cattcgaaag kttgacaggc argggacggg gcaratcgsc ttcgacgast 540
taatccaagg ctggcatggc ctgcagaggt ttacggatat attcaaagg ttcggcacg 599

```

<210> 263

<211> 1261

<212> DNA

<213> Homo sapiens

<400> 263

```

ggcacgaggt tgttcggagc gggcgagcgg agttagcagg gctttactgc agagcgcgcc 60
gggcaactcca gcgaccgtgg ggatcagcgt aggtgagctg tggccttttg cgaggtgctg 120
cagccatagc tacgtgcgtt cgctacgagg attgagcgtc tccaccaggt aagtgggcaa 180
gaggcggcag gaagtgggta cgcagggcg caaggcgcac agcctctaga cgactcgctt 240
tccctccggc caacctctga agccgcgtcc tactttgaca gctgcagggc cgcggcctgg 300
tcttctgtgc ttcaccatct acataatgaa tccagtatg aagcagaaac aagaagaaat 360
caaagagaat ataaagaata gttctgtccc aagaagaact ctgaagatga ttcagccttc 420
tgcactctga tctcttggtg gaagagaaaa tgagctgtcc gcaggcttgt ccaaaaggaa 480
acatcggaat gaccacttaa catctacaac ttccagccct ggggttattg tcccagaatc 540
tagtgaanaa aaaaatcttg gaggagtcac ccaggagtca tttgatotta tgattaaaga 600
aaatccatcc tctcagtatt ggaagggaag ggcagaaaaa cggagaaagg cgctgtatga 660
agcacttaag gaaaatgaga aacttcataa agaaattgaa caaaaggaca atgaaattgc 720
ccgcctgaaa aaggagaata aagaactggc agaagtagca gaacatgtac agtatatggc 780
agagctaata gagagactga atggtgaacc tctggataat tttgaatcac tggataatca 840

```

```

ggaatttgat tctgaagaag aaactgttga ggattctcta gtggaagact cagaaattgg 900
cacgtgtgct gaaggaactg tatcttcctc tacggatgca aagccatgta tatgaaatgc 960
attaatatatt gactgttgag aattttactg ccgaagttaa cctccactag ttctttgtag 1020
cagagtacat aactacataa tgccaactct ggaatcaaat ttccttggtt gaatcctggg 1080
accctattgc attaaagtac aaatactatg tatttttaat ctatgatggt ttatgtgaat 1140
aggattttct cagttgtcag ccatgactta tgtttattac taaataaact tcaaaactcct 1200
gttgaacatt gtgtataact tagaataatg aaatataagg agtatgtgta gaaaaaaaaa 1260
a 1261

```

<210> 264

<211> 1020

<212> DNA

<213> Homo sapiens

<400> 264

```

ctgctcctgg ccaacatcca gtattttatc ttgactgtcc taaccttacc ttagatgcta 60
acagaagggg cctgctcaaa taacactggg tgctatatgt atgggtaaat gtgtacatcc 120
tattccttcc tctttatctc acaatttttg tctccactaa gcaagaagta aactaacact 180
tcgtcactct aaagaaataa cttatgtaaa actcttagta accctgtttg tcttcaaagt 240
agtaaataga ccaaagtggg gggacaattt tctagtcttg tagagggaaa aacatctgag 300
tcaacatttt gaaatgcaga gggatttggt acatgacgac atggaaaagg gcacttttaa 360
acacagctta ctcttcctca agtacagaga gtatatagtg aatcaaaact aactacagcc 420
attcttttta aagcccaagg gatggagcaa aggtgtaagg atgttacctg tttgttttaa 480
tcagagagca aaaagaagtc acaatagttt gggagaaaaa gtagtatggt gagtaagggt 540
atgcgtataa tttcatactg aatttattac tatttgggat gtacgtcart gttctaaca 600
acactgccaa cacgtcaatt ttttaaaaag cgtgggccac attgctaaga atttgttaaa 660
gcataactgt attttttggt ttagggcctt attgatgttt tgccgttcca atgtatgcat 720
ttttttactc aataaacttg tcttaatttt agaactgtct gatgatttcg tactggaaa 780
aactactcaa agacggcagt gtaaaagcaa gtcttaggaa agtcccattt tatttgtgtc 840
taacaaacat acaggaactg aaatatTTTT gttaaactct gggatgcacc gaagtaactt 900
aaaacaaacc gttcaacagg ttcccccaac cgcccacgcc acataaagaa cagacatatc 960
tacacttgaa aaagctcata cctgtctcag ttctgaaagt cccttaagga ttgcttgctg 1020

```

<210> 265

<211> 571

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (557)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (565)

<223> n equals a,t,g, or c

<400> 265

```

ctttacggca sgmgtccgcg tcgctageta gtcgttctga agcggcggcc agagaagagt 60
caagggcacg agcatcgggc catgcctttc ttggacatcc agaaaagggt cggccttaac 120

```

221

```

atagatcgat ggttgacaat ccagagtggg gaacagccct acaagatggc tggtcgatgc 180
catgcttttg aaaaagaatg gatagaatgt gcacatggaa tcggttatac tcgggcagag 240
aaagagtgcg agatagaata tgatgatttc gtagagtgtt tgcttcggca gaaaacgatg 300
agacgtgcag gtaccatcag gaagcagcgg gataagctga taaaggaagg aaagtacacc 360
cctccacctc accacattgg caagggggag cctcggccct gaacagagca gctgctgatg 420
tctggaggct gattttcctg ttctctgttc tccactggaa aggttgttta cgacaaacct 480
ccttgtcaaa gtgtgtaaaa ataaaggatt gctccatcct aaaaaaaaaa aaaaaaaaaa 540
aaaatttggg ggggggnccc cgtancccat t 571

```

<210> 266

<211> 1350

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (204)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1313)

<223> n equals a,t,g, or c

<400> 266

```

tgccgccatc gtcgtggggc ttctggggca gctagggctg cccgccgcgc tgcctgcgcc 60
ggaccggggc ggggtccagtc ccgggcgggc cgtcgcggga gagaaataac atctgctttg 120
ctgccgagct cagaggagac ccagacccc tcccgagcc agagggctgg agcctgctca 180
gaggtgcttt gaagatgccg gagncccgcc tctgctgttg gcagctgtgt tgcctggccct 240
ggtgctgctg gtggtgctgc tgctgcttct gaggcactgg ggctggggcc tgtgccttat 300
cggctggaac gagttcatcc tgcagcccat ccacaacctg ctcatgggtg acaccaagga 360
gcagcgcacg ctgaaccayg tgctgcagca tgcggagccc gggaacgcac agagcgtgct 420
ggaggccatt gacacctact gcgagcagaa ggagtgggcc atgaacgtgg gcgacaagaa 480
aggcaagatc gtggacgccg tgattcagga gcaccagccc tccgtgctgc tggagctggg 540
ggcctactgt ggctactcag ctgtgcgcat ggcccgccctg ctgtcaccag gggcgaggct 600
catcaccatc gagatcaacc ccgactgtgc cgccatcacc cagcggatgg tggatttcgc 660
tggcrtgaag gacaaggtca cccttgtggt tggagcgtcc caggacatca tccccagct 720
gaagaagaag tatgatgtgg acacactgga catggtcttc ctgcaccact ggaaggaccg 780
gtacctgccg gacacgcttc tcttgagga atgtggcctg ctgcggaagg ggacagtgtc 840
actggctgac aacgtgatct gccaggtgc gccagacttc ctagcacacg tgcgcgggag 900
cagctgcttt gagtgcacac actaccaatc gttcctggaa tacagggagg tggtgacgg 960
cctggagaag gccatctaca agggcccagg cagcgaagca gggccctgac tgccccccc 1020
ggccccctc tcgggctctc tcaccagcc tggtagaa ggtgccagac gtgctcctgc 1080
tgaccttctg cggctccggg ctgtgtccta aatgcaaagc acacctcgcc gagcctgcgc 1140
cctgacctgc taacctctc gaactgcaac actggtattgt tcttttttaa gactcaatca 1200
tgacttcttt actaacactg gctagctata ttatcttata tactaatatc atgttttaaa 1260
aatataaaat agaaattaag aatctaaawa aaawaaaaaa acggggggcg ctntaaaggg 1320
tccaagctta acgtaagcgt gcatgggaag 1350

```

<210> 267

<211> 1319

<212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (7)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (61)
 <223> n equals a,t,g, or c

<400> 267
 gcaaganaga aattaaccct cactaaaggg aacaaaagct ggagctccac cgcgggtggcg 60
 nccgctctag aactagtggg tccccgggc tgcaggaatt cggcacgaga gactccgcga 120
 cctactgacc cggcgactga caggctccaa ctacccggga ctacgtatta gccttcgcct 180
 cactggctcc tctgcacaag aggmggcttc cggagtagcc ctcggtgaag ccccagacca 240
 cagctatgag tcccttcgtg tgacgtctgc gcagaaacat gttctgcatg tccagctcaa 300
 ccggcccaac aagaggaatg ccatgaacaa ggtcttctgg agagagatgg tagagtgttt 360
 caacaagatt tcgagagacg ctgactgtcg ggcggtgggtg atctctgggtg caggaaaaat 420
 gttcactgca ggtattgacc tgatggacat ggcttcggac atcctgcagc ccaaaggaga 480
 tgatgtggcc cggatcagct ggtacctccg tgacatcatc actcgatacc aggagacctt 540
 caacgtcatc gagaggtgcc ccaagcccgt gattgctgcc gtccatgggg gctgcattgg 600
 cggaggtgtg gaccttgtca ccgcctgtga catccggtac tgtgcccagg atgctttctt 660
 ccaggtgaag gaggtggacg tgggtttggc tgccgatgta ggaacactgc agcgccctgcc 720
 caaggtcatc ggggaaccaga gcctgggtcaa cgagctggcc ttcaccgccc gcaagatgat 780
 ggctgacgag gccctgggca gtgggctggt cagccgggtg tccccagaca aagaggtcat 840
 gctggatgct gccttagcgc tggcgccga gatttccagc aagagccccg tggcgtgcag 900
 agcaccaagg tcaacctgct gtattcccgc gaccttcgg tggccgagag cctcaactac 960
 gtggcgctct ggaacatgag catgctgcag acccaagacc tcgtgaagtc ggtccaggcc 1020
 acgactgaga acaaggaact gaaaaccgtc accttctcca agctctgaga gccctcgcgt 1080
 cccaggcccc agccaggggg ccggccttgt cccgcctcat ccacagaaaag ggaggtggg 1140
 cgatgacagt tgtttctatg ctttctgacc cagtttccca gttttataact ttatgacaat 1200
 gagttttctca agcccaaggc cttatcttca cccacaaaac aataaagcaa agtaaagaaa 1260
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa gggggggggc 1319

<210> 268
 <211> 3694
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (746)
 <223> n equals a,t,g, or c

<400> 268
 cggagctgcg ccctgggtgtg caagcactgg taccgctgcc tgcacggcga tgagaacagc 60
 gaggtgtggc ggagcctgtg cgccgcagc ctggcagaag aggcctctgcg caggacatc 120
 ctgtgcaacc tgcccagcta caaggccaag atacgtgctt ttcaacatgc cttcagcact 180

```

aatgactgct ccaggaatgt ctacattaag aagaatggct ttactttaca tcgaaacccc 240
attgctcaga gcaactgatgg tgcaaggacc aagattgggt tcagtggagg ccgccatgca 300
tggaagtgt ggtgggaggg cccctctgggc actgtggcag tgattggaat tgccacaaaa 360
cgggccccca tgcagtgcc aagttatgtg gcattgctgg gcagtgatga ccagagctgg 420
ggctggaatc tgggtggaca taatctacta cataatggag aagtcaatgg cagttttcca 480
cagtgcaca acgcaccaa atatcagata ggagaaagaa ttcgagtcac cttggacatg 540
gaagataaga ctttagcttt tgaacgtgga tatgagttcc tgggggttgc ttttagagga 600
cttccaaagg tctgcttata cccagcagtt tctgctgtat atggcaacac agaagtgact 660
ttggttttacc ttggaacc tttggacgga tgacagtggc tttcttgtga tgacmgacas 720
aatggaggag agatctgctt atgggnaakt asaaccatga agtgactgtc acacatgcat 780
gtccaagaaa catcctgaaa acacatgaag tcgtaaaactg gagaagcagc tctacagcag 840
agattatctc gtgtttcctc tttctactgg gccagaaaaa tctcagggt tgcagttgg 900
tgagtgggca gttgacatat gcatgttgca cccgatgttg tctctaagtt agcaatgtgt 960
tatttccagc tttaaagggt agattgtaga gatgctgtca aagggataag gaaatagcaa 1020
gatttttaag tagtgtgttt gtgaagactg atcccatttt acaactgcct gttctttctc 1080
cagtcctttt ttttccagcc agcttgacta ttagaaaagt atgaaactgg ttgggtttta 1140
tttaatatatt ttaatatatt gagaagcatg gtctgcctgg actgcacttc tctaaaagt 1200
agatataaaa ttgtgcagct attttaaaag ttgtatataa tatgtgtgta aaaaaaaaaa 1260
actgtaaaaa agaaaggaca aacaggttgt tttgttctag ttctaatttc ttaaaaacca 1320
ctacatgggt acaaaattgg aataacattt tggggggaca actgggttaa ctacaaagaa 1380
gaggatttwa agaggagatg tgttgwattg acycatttkg watwattttw ggcttacagt 1440
tcccatagct gttagagtct ggtttgtttt tgtttttact ctcaaatca tagtaaagat 1500
ctctcagtc cctggctaaa gattgaagga aggcaaactc atttctaatt atacatatat 1560
cagtaaggat gatctcaaca taatagtaat gtgtatcttt tggatatccag ttttattttt 1620
ggccttctaa gaaagtgtct cataacacag aacattgcca tttgctcttg taggcctcaa 1680
atatgaaagc tattagtcac agagcctagg aaaaaaagaa ttgattaatg gtccttttat 1740
tttgtaacct tataaatgct gtagatatta tcaaaaaaat ttaatttca tattgtttac 1800
atcatgcaac taatctaagc ctcaaactcg ttattggggc tataaagaaa acgtttactt 1860
accagctga aacaggttaa gaatattcct aatctcatta tagataattg ccccatggg 1920
acttgaaata caacaccttg tgctgaaaac ttcagggttg gcaatatatt aaggtttcgt 1980
tgtaraagag tttaacatta actcctatth tgacttacaa atcttgtttc tcatcactaa 2040
aatgcttttg aattaataat ccaaccaca tgagctgaga gtttttcttt tgtagaaaa 2100
gaaacagaca tctttctgta tgaaagtata aattgtatgg ttttagatac ataagaattg 2160
acaaaagcga gcgaaatctt tgtacttctg agttcttgct gtatgtatgt tttgttttaa 2220
atctgattag ggacaccag cagctggcgg ggattcttgg attgctcctt gggagttaag 2280
attgtcaata ctctgtgaa gcaagggatt tcagccatag aacaaagatt tattgttgcc 2340
acctgaaaag tttacaagta tttattgtgt atttgatata ttgcttgaaa agatgaaatc 2400
tgtaaagat tcttttcgat gtccaggtta agargaaacc tcttgattt gagtgaacta 2460
tatgttaaat gtattagaga atgtagggtg tatagaaatt gatttttctt ggtgtagaac 2520
aactcagttc ggcaaagttt aaaatttgat taacaagag aagtggttca ggtgaagat 2580
ggacttgtaa ggaagtgatc aagtccttta agtacttggt tctttttcag gttgtgatgt 2640
ggccattccg aattttgttg agagtttggt ttataattgt ctcttttgtc ttgttagtaa 2700
acattcattt gcaacagttt tgaagggtgct gagtgaaaaa ccgaaacaca tggttattgc 2760
gtattggacc tagaatgaaa taattgcctc aatatttaac aacaagccat tcttatctca 2820
aagatttaaa tcccgaatg tccattcgc aaatcatatg caattgaagt gagcagcatg 2880
agcatctggg tcatgagggc cttcatttac gtaaatttgt cactaaaacc cagtagtagc 2940
tctacaaaat cttaaactgc tgcagtgtct aaggagatgg aatatctttg tcattgggtgc 3000
tgaggagagc atttcggtag aagacagttg gcctgaaga ttgagtgtaa atcattcaaa 3060
ccagtggttc tcaagtgttg ctgtatacac tttgtagtca ctttggaatg ttggaagaca 3120
catcgatgct tgggttccgt atgccaaagt tctgatgttg gtctggaata tgagctggtc 3180
ataaggattt ttaaaaactt tctggtcatt tcaatatgct gccaaaggtg agaaccactg 3240

```

```

ttgtaaaaatt caccttgagt tttctcatct gcaaaataga aaaaaaaaaat ccttgctccc 3300
tcccttcact acctcacaag gatattgagg gtaaaggaga aaataatggg aaagtgcttg 3360
tgccgtggat gaaaagtgtt attaaaagtc aaaggagtgt tctgtttcaa ttcatagtat 3420
gatcagggaa agtgaactg agtatacttt gttgacttgg gaaacctgga gcactttctt 3480
tggttggtta acgaagcatg cagatgtgga agcagacgtt actattatcc ctactatggt 3540
cttctgtcat actgagacag gctgttttaa ttacctggtt ttacatagga aagaagaaat 3600
attaaggctt aaagtgtgta atgatcaatg gctcataatt cattaaatct tttcatacaa 3660
ggaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 3694

```

<210> 269

<211> 1242

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (460)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1233)

<223> n equals a,t,g, or c

<400> 269

```

ccanccctca ctaaagggaa caaaagctgg ngctccaccg cggtgncgac cgctctagaa 60
ctagtggatc cccggggctg caggaattcg gcaccgcaaa aaaattttaa aaatacagtg 120
ttttgtattg atatatgtac tgtgtgtgtc tgtgtgtgtg agatcaagat caggttttga 180
ttgggtgatg actattactg ttgtccttgg tcagggacac agaggatgtt tggggtttgg 240
tggtgagaca ttatctaaca cgtgctgtgt ccttttttggg tttgagcccc acaccagtga 300
gaagcatcag caccgtgaac ttgtctgaga atagcagtggt tgatcatccc ccacccgact 360
acttggaatg cttatccatg ggggcagytg ccgacaggag agcagattcg gccaggacga 420
catccacott taaggcccca gcgtccaagc ccgagaccgn ggctcctaac gatgccaacg 480
ggactgcaaa gccgcctttt ctacgcggag aaaacccctt tgccactgtg aaactccgcc 540
cgactgtgac gaatgatcgc tcggcaccca tcattcgatg agaggacagc caaggactct 600
cccgggcctc tccggttctc ccttgcgga tgaatgggcgc atcctgtctg ccacgtgctg 660

```

```

acggtcggga agcttcagtg gagaggccta actctaattgt cgcttgccta agcaaatacat 720
gcttctctgt ttcacgtagt tgggttgaca agtttctgcc ttttaagataa atgagtaata 780
gtctaatacag cagctcagcc atttaaaata ttttcttcct attctgttca agaaacagta 840
aacttggttt caatctttac tgtatttttt aaatgaattt tttccttaat aacagccaga 900
ataagggata gtctatgctt tcaggactgg ctttctgcac ctgatatgaa tgagaccagt 960
tttattttat aaagcatgtg ctcttaatac cattatgtct aaagaagata tcacgtaagt 1020
ttgcatctta gcatgcaaata cataatttta agcaatataa attatgaaaa tactatataa 1080
atgtaatttta acttaaaatg ttttaagtga gagcttccag agrtgggagg aaacccccac 1140
cctccctcca accacgccag agsctgtagg agtgctaagg acgstttgcc tggcccttta 1200
tcacagccac acgtaggcac ytcgacggga atnctccctt cc 1242

```

<210> 270

<211> 2057

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2053)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2054)

<223> n equals a,t,g, or c

<400> 270

```

cggagcgggt tgtaatgtat tnctggattt tattttgctg tattagctcc tcaagagtta 60
ctgatctatg aaatggcaga gaatggaaaa aattgtgacc agagacgtgt agcaatgaac 120
aaggaacatc ataatggaaa tttcacagac ccctcttcag tgaatgaaaa gaagaggagg 180
gagcgggaag aaaggcagaa tattgtcctg tggagacagc cgctcattac cttgcagtat 240
ttttctctgg aaatccttgt aatcttgaag gaatggayct caaaattatg gcatcgtcaa 300
agcattgtgg tgtctttttt actgctgctt gctgtgctta tagctacgta ttatgttgaa 360
ggagtgcac aacagtatgt gcaacgtata gagaaacagt ttcttttgta tgcctactgg 420
ataggcttag gaattttgtc ttctgttggg cttggaacag ggctgcacac ctttctgctt 480
tatctggggt cacatatagc ctcagttaca ttagctgctt atgaatgcaa ttcagttaat 540
tttcccgaac caccctatcc tgatcagatt atttgtccag atgaagaggg cactgaagga 600
accatttctt tctggagtat catctcaaaa gttaggattg aagcctgcat gtggggatc 660
ggtacagcaa tcggagagct gcctccatat ttcatggyca gagcagctcg cctctcaggt 720
gctgaaccag atgatgaaga gtatcaggaa tttgaagaga tgctggaaca tgcaagtct 780
gcacaagact ttgcctcccg ggccaaactg gcagttcaaa aactagtaca gaaagtggga 840
tttttttgaa ttttggcctg tgcttcaatt ccaaatacctt tatttgatct ggctggaata 900
acgtgtggac actttctggt accttttttg accttctttg gtgcaaccct aattggaaaa 960
gcaataataa aaatgcatat ccagaaaaat tttgttataa taacattcag caagcacata 1020
gtggagcaaa tgggtggctt cattggtgct gtccccggca taggtccatc tctgcagaag 1080
ccatttcagg agtacctgga ggctcaacgg cagaagcttc accacaaaag cgaaatgggc 1140

```

```

acaccacagg gagaaaactg gttgtcctgg atgtttgaaa agttggctcgt tgtcatggtg 1200
tgttactttca tcctatctat cattaactcc atggcacaaa gttatgccaa acgaatccag 1260
cagcggttga actcagagga gaaaactaaa taagtagaga aagttttaaa ctgcagaaat 1320
tggagtggat gggttctgcc ttaaattggg aggactccaa gccgggaagg aaaattccct 1380
ttccaacct gtatcaattt ttacaacttt tttcctgaaa gcagtttagt ccatactttg 1440
cactgacata ctttttcctt ctgtgctaag gtaaggatc caccctcgat gcaatccacc 1500
ttgtgttttc ttagggtgga atgtgatgtt cagcagcaaa cttgcaacag actggccttc 1560
tgttgtttac tttcaaaagg cccacatgat acaattagag aattcccacc gcacaaaaaa 1620
agttcctaag tatgttaa atgtcaagct ttttaggctt gtcacaaatg attgctttgt 1680
tttcctaagt catcaaaatg tatataaatt atctagattg gataacagtc ttgcatgttt 1740
atcatgttac aatttaatat tccatcctgc ccaacccttc ctctcccatc ctcaaaaaag 1800
ggccatttta tgatgcattg cacaccctct ggggaaattg atctttaaat tttgagacag 1860
tataaggaaa atctggttgg tgtcttacia gtgagctgac accatttttt attctgtgta 1920
tttagaatga agtcttgaaa aaaactttat aaagacatct ttaatcattc caaaaaaaaa 1980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaggaaaa 2040
aaaaaaaaaa aannaaa 2057

```

<210> 271

<211> 960

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (951)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (956)

<223> n equals a,t,g, or c

<400> 271

```

aagnatagaa attaaccctc acgtaaaggg nacaaaagct ggagctccac cgcggtgcgg 60
ccgctctaga actagtggat cccccgggct gcaggaaattc ggcacgagct cttccacccc 120
tgccaggccc agcagccacc acagcgctg cttcctcggc cctgaaatca tgcccctagg 180
tctcctgtgg ctgggcctag ccctgttggg ggctctgcat gcccaggccc aggactccac 240
ctcagacctg atcccagccc cacctctgag caaggtccct ctgcagcaga acttccagga 300
caaccaatct caggggaagt ggtatgtggt aggcctggca gggaatgcaa ttctcagaga 360
agacaaagac ccgcaaaaga tgtatgccac catctatgag ctgaaagaag acaagagcta 420
caatgtcacc tccgtcctgt ttaggaaaaa gaagtgtgac tactggatca ggacttttgt 480

```

```

tccaggttgc cagccccggcg agttcacgct gggcaacatt aagagttacc ctggattaac 540
gagttacctc gtccgagtgg tgagcaccaa ctacaaccag catgctatgg tgttcttcaa 600
gaaagtttct caaaacaggg agtacttcaa gatcacccctc tacgggagaa ccaaggagct 660
gacttcggaa cttaaaggaga acttcatccg cttctccaaa tctctgggce tccctgaaaa 720
ccacatcgtc ttccctgtcc caatcgacca gtgtatcgac ggctgagtgc acaggtgccg 780
ccagctgccg caccagcccc aacaccattg agggagctgg gagaccctcc ccacagtgcc 840
acccatgcag ctgctcccca ggccaccccc ctgatggagc cccaccttgt ctgctaaata 900
aacatgtgcc ctcaggaaaa aaaaaaaaaa aaaaaaaaaa aagggggggg ncccgntccc 960

```

<210> 272

<211> 1167

<212> DNA

<213> Homo sapiens

<400> 272

```

ggcacgaggg aagtaggttt ctacccgacc gcatttttac tgggtgctgca tttccggtag 60
cggcgggcgg aaatcggttg tgggagagag gctaggcctc tgaggaggcg aatccggcgg 120
gtatcagagc catcagaacc gccaccatga cggtgggcaa gagcagcaag atgctgcagc 180
atattgatta caggatgagg tgcacctgac aggacggccg gatcttcatt ggcaccttca 240
aggcttttga caagcacatg aatttgatcc tctgtgactg tgatgagttc agaaagatca 300
agccaaagaa ctccaaacaa gcagaaaggg aagagaagcg agtcctcggc ctgggtgctgc 360
tgcgagggga gaatctggtc tcaatgacag tagagggacc tcctcccaa gatactggta 420
ttgctcgagt tccacttgct ggagctgccg ggggcccagg gatcggcagg gctgctggca 480
gaggaatccc agctgggggt cccatgcccc aggcctcctg aggaacttgc gggccagtcc 540
gtgggggttg cgggccatcc caacaggtga tgacccca ca aggaagaggt actgttgca 600
ccgctgcagc tgctgccaca gccagtattg ccggggctcc aaccagtac ccacctggcc 660
gtgggggtcc tccccacat atgggccgag gagcaccccc tccaggcatg atggggccac 720
ctcctggtat gagacctcct atgggtcccc caatggggat cccccctgga agagggactc 780
caatgggcat gccccctccg ggaatgcggc ctccctcccc tgggatgcga ggccttcttt 840
gacccttgcc cacagagtat ggaagtagct ccgcagaggc gtgggctcga ttcctcaggg 900
ccacgttacc acagacctgt ttgtttctta tgctgttggt cgtggagtct catgggattg 960
tctggtttcc cttacagggc cccctccccc gggaatgcgc ccaccaaggc cctagactca 1020
tcttgccct cctcagctcc ctgcctgttt cccgtaaggc tgtacatagt ctttttatct 1080
ccttggtgcc tatgaaactg gtttataata aactcttaag agaacattaa aaaaaaaaaa 1140
aaaaactyrr gggggggccc ggtccca 1167

```

<210> 273

<211> 2771

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (42)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (64)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2715)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2717)
 <223> n equals a,t,g, or c

<400> 273
 tcctcactaa agggancaaa agctggngct ccaccgcggt gncgaccgct ctagaactag 60
 tggntccccc gggctgcagg aattcggcac gagccsaccc gcctcttggc tcctctcctc 120
 taggcgctcg ctttcgggtt ctctcatcgc ttcgtcgttc gccaatgttt gaggagaagg 180
 ccagcagtcct ttcagggaag atgggaggcg aggagaagcc gattggtgct ggtgaagaga 240
 agcaaaaagga aggaggcaaa aagaagaaca aagaaggatc tggagatgga ggtcgcagctg 300
 agttgaatcc ttggcctgaa tatatttaca cacgtcttga gatgtataat atactaaaag 360
 cagaacatga ttccattctg gcagaaaagg cagaaaaaga tagcaagcca attaaagtca 420
 ctttgccctga tggtaaacag gttgatgcgg aatcttggaa aactacacca tatcaaattg 480
 cctgtggaat tagtcaaggc ctggccgaca acaccgttat tgctaaagta aataatgttg 540
 tgtgggacct ggaccgccct ctggaagaag attgtacctt ggagcttctc aagtttgagg 600
 atgaggaagc tcaggcagtg tattggcact ctagtgtctc cataatgggt gaagccatgg 660
 aaagagtcta tgggtgatgt ttatgctacg gtccgccaat agaaaatgga ttctattatg 720
 acatgtacct cgaagaaggg ggtgtgtcta gcaatgattt ctcttctctg gaggtttgt 780
 gtaagaaaat cattaaagaa aaacaagctt ttgaaagact ggaagttaag aaagaaactt 840
 tactggcaat gtttaagtac aacaagttca aatgccgat attgaatgaa aaggtgaata 900
 ctccaactac cacagtctat agatgtggcc ctttgataga tctctgccgg ggtcctcatg 960
 ttagacacac gggcaaaaatt aaggctttta aaatacaca aaattcctcc acgtactggg 1020
 aaggcaaaagc agatatggag actctccaga gaatttatgg catttcattc ccagatccta 1080
 aaatgttgaa agagtgggag aagttccaag aggaagctaa aaaccgagat cataggaaaa 1140
 ttggcaggga ccaagaacta tatttctttc atgaactcag ccctggaagt tgcttttttc 1200
 tgccaaaagg agcctacatt tataatgcac ttattgaatt cattaggagc gaatatagga 1260
 aaagaggatt ccaggaggta gtcaccccaa acatcttcaa cagccgactc tggatgacct 1320
 cgggccactg gcagcactac agcgagaaca tgttctcctt tgagggtggag aaggagctgt 1380
 ttgccctgaa acccatgaac tgcccaggac actgccttat gtttgatcat cggccaagggt 1440
 cctggcgaga actgcctctg cggctagctg attttggggg acttcatagg aacgagctgt 1500
 ctggagcact cacaggactc acccggttac gaagattcca acaggatgat gctcacatat 1560
 tctgtgccat ggagcagatt gaagatgaaa taaaagggtt tttggatttt ctacgtacgg 1620
 tatatagcgt atttggattt tcttttaaac taaacctttc tactcgcccg gaaaaattcc 1680
 ttggagatat cgaagtatgg gatcaagctg agaaacaact tgaaaacagt ctgaatgaat 1740
 ttggtgaaaa gtgggagtta aactctggag atggagcttt ctatggccca aagattgaca 1800

```

tacagattaa agatgcgatt gggcgggtacc accagtgtgc aaccatccag ctggatttcc 1860
agttgcccac cagatttaac cttacttatg taagccatga tggatgatgat aagaaaaggc 1920
cagtgtattgt tcatcgagcc atcttgggat cagtggaaag aatgattgct atcctcacag 1980
aaaactatgg gggcaaatgg cccttttggc tgtcccctcg ccaggtaatg gtagttccag 2040
tgggaccaac ctgtgatgaa tatgcccaca aggtacgaca acaattccac gatgccaaat 2100
tcatggcaga cattgatctg gatccaggct gtacattgaa taaaaagatt cgaaatgcac 2160
agttagcaca gtataacttc attttagttg ttggtgaaaa agagaaaatc agtggcactg 2220
ttaatatccg cacaagagac aataagggtc acggggaacg caccatttct gaaactatcg 2280
agcggctaca gcagctcaaa gagttccgca gcaaacaggc agaagaagaa ttttaatgaa 2340
aaaattaccc agattggctc catggaaaag gaggaacagc gtttccgtaa aattgacttt 2400
gtactctgaa aacgtcaatt tatattgaac ttggaggagt ttggcaaagt ctgaataggc 2460
caacctgcag gcgtaactat ttttgaccta gtcagttttt aaacaatgtg catttgaagg 2520
agttaattaa aagagagcca ataaaatgat tttactcatt cagtatctga gtactggaag 2580
tgaaacatga ggaatgcttt agtgtaatgt gggagaactt ttttgtaa ataatgcaat 2640
tgaaaaagtt ttcaaattca attagataa ctagaattgg attatggtgt aaaaataaaa 2700
aaaaaattta ttcananana aaaaaaaaaa aaaaaaaagc tacctcggcc gcgaccacgc 2760
taagccgaat t 2771

```

<210> 274

<211> 1889

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (57)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (87)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (113)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1676)

<223> n equals a,t,g, or c

<400> 274

```

cacgacgtcc gcggnacggt gggacggaac gcgtgggcgg acgcgtgggc ggacgcntgg 60
gttcggaaac ctatcgatta cacagtnctg gatgatgtgg gccatggtgt cangcatgga 120

```

```

aatagaccag cctgcaggaa ctggcacact gtcgagaaca aatcctccta ctcagaaacc 180
gccaaagtcc cccatgtcag gccggggaac actgggacgg aatactcctt ataaaaccct 240
ggaacctgtt aaacccccaa cagttcctaa tgactatatg accagtcctg ctaggcttgg 300
aagtcagcat agtccaggca ggacagcatc tttaaatcag agaccaagga cacacagtgg 360
aagtagtgga ggaagtggaa gtcgagaaaa cagtggtagc agtagtattg gcattcccat 420
tgctgtgcct acaccttcgc caccactat tgaccagca gcccgggct cagctcctgg 480
ttcccagtat ggcacaatga ccaggcagat atctcgacac aactctacta cttcttcgac 540
atcttctggt ggatacagac gaactccctc tgtgactgct caattttctg ctcagcctca 600
tgттаатгга ggtccacttt attctcaaaa ttcaatttct attgctccac cccctccccc 660
tatgcctcag ttgactccac agatacctct cacaggcttc gtggccaggg tgcagggaaa 720
cattgctgat agtccaactc caccgccacc acctccacca gatgacattc ccatgtttga 780
tgactctcca cctccccac caccaccacc agtggtattat gaagatgagg aggctgcagt 840
agttcagtat aatgatccat atgcagatgg ggtcctgct tgggccccca agaattatat 900
tgagaaagtt gttgcaatat atgattatac aaaagacaag gatgatgagc tgtcatttat 960
ggagggtgca atcattttatg ttataaagaa gaatgatgat ggctgggtatg aaggagtctg 1020
caatcgagtg actgggtctgt tccctgggaa ctatgttgaa tcaatcatgc actatactga 1080
ttaatttttt tttttctttt gaagtagatt cttattactc agtcatactg tgggactatt 1140
atggttaaca gaactgtctt aatatgtttt aaaatgtgcc catattttca gaacatgctg 1200
ttttattggt aaattgaatg tctacctgta agcataaaatc tttgaggcag tttatgtatt 1260
gctgaatagc aattttataca agaagctgtc cataactgat tatgcttatg tacttactta 1320
cacattttta actttatgac cagcctaaat attctggggg aagtggggta taatatttaa 1380
cgaatcatga ttcagattgt accattacat gtttcagtgc agcatgggta ctaacgctat 1440
gtcagactaa tattaaaatc agaaaattta aatgctgggtg ctggtcagac tttttttgtt 1500
agattctctc atttaaaaaa aatactgttt gtttaaagca tgcataaaaa tttatgtatt 1560
gaaatatact taaaaattca agatgcttcc catttggtga atatttacct ggaggactcg 1620
tacttaggtg tcttaacgtg aattgagtct ccaaggtctc catgtgaaac aaaagnagca 1680
aaaagagaat tatctgtaat gttgtaattt gtacctaaagt tttttaatga gtgaaatttg 1740
cattataaac tttttccatt cataaataca taagtgaacc aaagggtttt gtcttttcc 1800
tcactgattt gctttaaaaa aaataaaaaga taatgattta ttgcagaaaa aaaaaaaaaa 1860
aaaaaaaaaa aaaaaataaa aaaaaataaa 1889

```

<210> 275

<211> 604

<212> DNA

<213> Homo sapiens

<400> 275

```

ttttccgggc cacctgggtc ctcagccagt gcctttgaaa catttctgcc tgtaatgtca 60
gggccaaatt gcgttactga gcatgttctg accggcccgt ttgggcatca cctgccattc 120
tctgcccac ctcacaacag ctctgtgggg tgggtcctcc ccataacctg atgcaccgac 180
cacacagtgg aaagtgacaa agccagcgcc ttgccccagg ccccgagggg tggagcccgt 240
ctgctcaggg ttgcaggccc agattctcca ctgctaccga gatcgccgc atgaggtgct 300
gtgtgtctcg gacctggtca aggcatacca gcgctgcgtg agcgccsccc acaagggtct 360
aggagcagac atcattccct gccctggcag tgactggag ccctgaagaa gggaccaatc 420
atggggaccac agccactgtg ccctgccgtt tctgtctggg cccctgcata tgcccctgag 480
cctggggctg ccacgtgttt aggaaacaaa gtatgcgcta ctgtctgaaa acaaataaag 540
cagatgcctt tgttttcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 600
aaag 604

```

<210> 276

<211> 1381

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1348)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1349)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1350)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1358)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1359)
<223> n equals a,t,g, or c

<400> 276
tccgtggtgt ggttgactct gaggatctgc ccctgaacat ctcccgagaa atgctccagc 60
agagcaaaat cttgaaagtc attcgcaaaa acattgttaa gaagtgcctt gagctcttct 120
ctgagctggc agaagacaag gagaattaca agaaattcta tgaggcattc tctaaaaatc 180
tcaagcttgg aatccacgaa gactccacta accgccgccg cctgtctgag ctgctgcgct 240
atcatacctc ccagtctgga gatgagatga catctctgtc agagtatgtt tctcgcatga 300
aggagacaca gaagtccatc tattacatca ctggtgagag caaagagcag gtggccaact 360
cagcttttgt ggagcagagt cggaacggg gcttcgaggt ggtatatatg accgagccca 420
ttgacgagta ctgtgtgcag cagctcaagg aatttgatgg gaagagcctg gtctcagtta 480
ccaaggaggg tctggagctg cctgaggatg aggaggagaa gaagaagatg gaagagagca 540
aggcaaagtt tgagaacctc tgcaagctca tgaaagaaat cttagataag aaggttgaga 600
aggtgacaat ctccaataga cttgtgtctt caccttgctg cattgtgacc agcacctacg 660
gctggacagc caatatggag cggatcatga aagcccaggc acttcgggac aactccacca 720
tgggctatat gatggccaaa aagcacctgg agatcaaccc tgaccacccc attgtggaga 780
cgctgcggca gaaggctgag gccgacaaga atgataaggc agttaaggac ctgggtggtgc 840
tgctgtttga aaccgccctg ctatcttctg gcttttccct tgaggatccc cagaccact 900
ccaaccgcat ctatcgcatg atcaagctag gtctaggtat tgatgaagat gaagtggcag 960
cagaggaacc caatctgca gttcctgatg agatccccc tctcgagggc gatgaggatg 1020
cgtctcgcat ggaagaagtc gattaggtta ggagttcata gttggaaaac ttgtgccctt 1080
gtatagtgtc cccatgggct cccactgcag cctcgagtg cctgtccca cctggctccc 1140
cctgctggtg tctagtgtt ttttccctct cctgtccttg tgttgaaggc agtaaaactaa 1200
gggtgtcaag cccattccc tctctactct tgacagcagg attggatgtt gtgtattgtg 1260
gtttatttta ttttcttcat tttgttctga aattaaagta tgcaaaataa agaatatgcc 1320

gttttttatac aaaaaaaaaa aaaaaaannn ggggggggng ccccggtccc matttcccc 1380
c 1381

<210> 277

<211> 1149

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (680)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1088)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1098)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1140)

<223> n equals a,t,g, or c

<400> 277

```

tcccgggggg gatttttttt tttttttttt tttttttttt tgcttaaaaa aaagccatga 60
cggtctctccc acaattcatc ttccctgcgc catctttgta ttattttctaa tttatttttg 120
atgtcaaaaag gcaactgatga agatattttc tctggagtct ccttctttct aaccgggctc 180
tcccgatgtg aaccgagccg tcgtccgccc gccgccgccg ccgccgccgc cgccgcccgc 240
cccgagcccc accatgtctc gccgcaagca aggcaaacc cagcaactta gcaaacggga 300
attctcgccc gagcctcttg aagccattct tacagatgat gaaccagacc acggcccgtt 360
gggagctcca gaaggggatc atgacctcct cacctgtggg cagtgccaga tgaacttccc 420
attgggggac attcttattt ttatcgagca caaacggaaa caatgcaatg gcagcctctg 480
cttagaaaaa gctgtggata agccaccttc cccttcacca atcgagatga aaaaagcatc 540
caatcccgtg gaggttggca tccaggtcac gccagaggat gacgattgtt tatcaacgtc 600
atctagagga atttgcccca aacaggaaca catagcagat aaacttctgc actggagggg 660
cctctcctcc cctcgttctn gcacatggag ctctaattccc cacgcctggg atgagtgcag 720
aatatgcccc gcaggtattt gtaaagatga gccagcagc tacacatgta caacttgcaa 780
acagccattc accagtgcac ggtttctctt gcaacacgca cagaacactc atggattaag 840
aatctactta gaaagcgaac acggaagtcc cctgaccccg cggttggtta tcccttcagg 900
actaggtgca gaatgtcctt cccagccacc tctccatggg attcatattg cagacaataa 960
cccctttaac ctgctaagaa taccaggatc agtatcgaga gaggcttccg gcctgggcag 1020
aagggcgctt tccaccact cccccctgt ttagtccacc accgagacat cattgggacc 1080
cccaccgnat agagcgcntg gggggcggtg aggagatggg cctggggcaa acccttcaan 1140
ccgagttgc 1149

```

<210> 278

<211> 811

<212> DNA

<213> Homo sapiens

<400> 278

```

ggagaccaga gtgggaggaa ggcggggagt ccagggttccg ccccgaggcc gacttcctcc 60
tggtcggcggt ctgcagcggg gtgagcggcg gcagcggccg gggatcctgg agccatgggg 120
cgcgcgcgcg acgccatcct ggatgcgctg gagaacctga ccgccgagga gctcaagaag 180
ttcaagctga agctgctgtc ggtgccgctg cgcgaggggct acgggcgcat cccgcggggc 240
gcgctgctgt ccatggacgc cttggacctc accgacaagc tggtcagctt ctacctggag 300
acctacggcg ccgagctcac cgctaactgt ctgcgcgaca tgggcctgca ggagatggcc 360
gggcagctgc aggcggccac gcaccaggcg tctggagccg cgccagctgg gatccaggcc 420
cctcctcagt cggcagccaa gccaggcctg cactttatag accagcaccg ggctgcgctt 480
atcgcgaggg tcacaaacgt tgagtggctg ctggatgctc tgtacgggaa ggtcctgacg 540
gatgagcagt accaggcagt gcggccgagc ccaccaaccc aagcaagatg cggaagctct 600
tcagtttcac accagcctgg aactggacct gcaaggactt gctcctccag gccctaaggg 660
agtcccagtc ctacctggtg gaggacctgg agcgagctga ggctccttcc cagcaacact 720
ccggtcasc cttggcaatcc caccaaatca tcctgaatct gatcttttta tacacaatat 780
acgaaaagcc agcttgaaaa aaaaaaaaaa a 811

```

<210> 279

<211> 1260

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1249)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1252)

<223> n equals a,t,g, or c

<400> 279

```

ggtcggcgac agggaggagg gaagcctag agtccgcgcg gggacggagg cctgggggaa 60
ctgggagttc agctttctgc agagggccac taggaacctc ggattgcca cggaagccag 120
ccacttttyt tgacagtcca gccacacctc tcttctgccc ggagaagctc caggggytgc 180
ctttktgatc acagcatctt cacaaggacc aaaggaaaat aagatttcty gtaagaacac 240
cgtgaccaca tctttaaaat gacctatttc gtggctycca caagatttac acctycacac 300
tgaggccgga agtggttttg cccctataaa acatggcgaa aagctttctt gtctccaagg 360
aaacgccacg taatgagtca aagctgtggc gcacgcgcag aagtacaagc taccggaagt 420
gatggcgccc ctactaaagc cttgggggta gtacgcgtcg cagcagtctc ttccgacagt 480
tgtgttgtgc caatggtgga gaagaaaact tcggttcgct cccaggaccc cgggcagcgg 540
cgggtgctgg accgggctgc ccggcagcgt cgcatcaacc ggcagctgga ggccctggag 600
aatgacaact tccaggatga cccccacgcg ggactccctc agctcggcaa gagactgcct 660
cagtttgatg acgatgcgga cactggaaa gaaaaagaaga aaaccgagg tgatcatttt 720
aaacttcgct tccgaaaaaa ctttcaggcc ctgttgagg agcagaactt gagtgtggcc 780
gagggcccta actacctgac ggctgtgctg ggaccccat cgcgcccca gcgcccttc 840
tgtgctgtct gtggcttccc atccccctac acctgtgtca gctgcgggtgc ccggtactgc 900

```

```

actgtgctgct gtctggggac ccaccaggag accagggtgtc tgaagtggac tgtgtgagcc 960
tgggcattcc cagagaggaa gggccgctgt gcaactgccc gccttcagaa agacagaatt 1020
tcatacacca atgcaggggg agctcttccct ggaccaaggg aggagccgct cattcaccca 1080
acaaaactgt gtcttatctg ccaggaaaaga ccagcctcac tcctgggaac tgtctggcag 1140
gtaggctggg cccccagtg ctgttagaat aaaaagcctc gtgccgaaa aaaaaaara 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaant tngggggggg 1260

```

<210> 280

<211> 1668

<212> DNA

<213> Homo sapiens

<400> 280

```

gggaactgcc aaaagtgtgc atttggctac agtggactcg actgtaagga caaatttcag 60
ctgatcctca ctattgtggg caccatcgct ggcattgtca ttctcagcat gataattgca 120
ttgattgtsa cagcaagatc aaataacaaa acgaagcata ttgaagaaga gaacttgatt 180
gacgaagact ttcaaaatct aaaactgcgg tcgacaggct tcaccaatct tggagcagaa 240
gggagcgtct ttctaaggt caggataacg gcctccagag acagccagat gcaaaatccc 300
tattcaagcc acagcagcat gccccgccct gactattaga atcataagaa tgtggaaccc 360
gccatggccc ccaaccaatg tacaagctat tatttagagt gtttagaaag actgatggag 420
aagtgagcac cagtaaagat ctggcctccg gggtttttct tccatctgac atctgccagc 480
ctctctgaat ggaagtgtg aatgtttgca acgaatccag ctcaactgct aaataagaat 540
ctatgacatt aaatgtagta gatgctatta gcgcttgctca gagagggtgt tttcttcaat 600
cagtacaaag tactgagaca atgggtaggg ttgttttctt aattcttttc ctggtagggc 660
aacaagaacc atttccaatc tagaggaaag ctcccagca ttgcttgctc ctgggcaaac 720
attgctcttg agttaagtga cctaattccc ctgggagaca tacgcatcaa ctgtggagggt 780
ccgaggggat gagaagggat acccaccacc tttcaagggt cacaagctca ctctctgaca 840
agtcagaata gggacactgc ttctatccct ccaatggaga gattctggca acctttgaac 900
agcccagagc ttgcaaccta gcctcaccca agaagactgg aaagagacat atctctcagc 960
tttttcagga ggcgtgcctg ggaatccagg aactttttga tgctaattag aaggcctgga 1020
ctaaaaatgt ccactatggg gtgcactcta cagtttttga aatgctagga ggcagaaggg 1080
gcagagagta aaaaacatga cctggtagaa ggaagagagg caaaggaaac tgggtgggga 1140
ggatcaatta gagaggaggc acctgggatc caccttcttc cttaggtccc ctccctccatc 1200
agcaaaggag cacttctcta atcatgccct cccgaagact ggctgggaga aggtttaaaa 1260
acaaaaaatc caggagtaag agccttaggt cagtttgaaa ttggagacaa actgtctggc 1320
aaagggtgcg agagggagct tgtgtctcagg agtccagccg tccagcctcg ggggttaggt 1380
ttctgagggt tgccattggg gcctcagcct tctctgggtg cagaggctca gctgtggcca 1440
ccaacacaca accacacaca cacaaccaca cacacaaatg ggggcaacca catccagtac 1500
aagcttttac aaatgttatt agtgtccttt tttatttcta atgccttgct ctcttaaaag 1560
ttattttatt tgttattatt atttgttctt gactgttaat tgtgaatggt aatgcaataa 1620
agtgcctttg ttagatggaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1668

```

<210> 281

<211> 2328

<212> DNA

<213> Homo sapiens

<400> 281

```

ggaaaagtgg tgtgtggcat ggtgtcctat ttgaacgacc tgcccagtca gcgcattccag 60
ccacagcagg tagcagtctg gccaacctat gtggatatca acagccccga aagcctaacc 120
gaagcatata aactccgtgc agccagatta gtagaaattg ctgcaaaaaa ccttcaaaaa 180

```

```

gaagtgattc acagaaaaag caaggaggta gcttggaaacc taacttctgt tgaccttggt 240
cgagcaagtg aggcacattg ccactatgtg gtagttaagc tcttttcaga aaaactcctc 300
aaaattcaag ataaagccat tcaagctgtc ttaaggagtt tatgtctgct gtattctctg 360
tatggaatca gtcagaacgc gggggatttc cttcagggga gcatcatgac agagcctcag 420
attacacaag taaaccagcg tgtaaaggag ttactcactc tgattcgctc agatgctggt 480
gcttttggtg atgcatttga ttttcaggat gtgacacttg gctctgtgct tggccgctat 540
gatgggaatg tgtatgaaaa cttgtttgag tgggctaaga actccccact gaacaaagca 600
gaggtccacg aatcttacia gcacctgaag tcaactgcagt ccaagctctg aagtgtcaca 660
aggacaagtt taatctgctt cagaaagcgc ctgtgtgcaa ctcaaatttt gtggaatctt 720
tttcgaattc aaatagctat agagcaaattg ataaattgac ccctttttat aaatggaggg 780
aaaaaatgaa cagatttcag agattaaattg aaaaaagca gatgttttaa gtgcaattaa 840
cactgaaaga gacctgttaa accattcaga aaaagcttaa gaaatgcgat atgacttctc 900
tttgtaatgc tgctgatccc agtagactat gacttttgat aattagcaga atttaactac 960
tgagtagttg attattttca cattttaatt gctaactact ggctatataa gtgtttttaa 1020
gcaaagggtat ttttgaaagt gtgtagaacc cttccaagct ttcttgctca gtgttctacc 1080
agacttacct tggggcctgg cttaaaagca ggattgaaga aaagggactg ggggaaggaa 1140
acttattgga aaacttgatg cgaatgagtt tctgcttggc acagtctctg cctgcttgct 1200
ctcctttgct gatggattgc atttatcaaa ctattcatgc tagcattttt ccaacgaggg 1260
aaactattcc gcacgggcct actgtaggac cattgtctcg tgtaattagg aattttccat 1320
ttgaaggaty gctaaattgt cacagtagta ggaagtatag ggaaacctct cagctgtggc 1380
actgtttagt ctttgaggag cagagtgtaa ctctgggaca atcagatttc acatattctg 1440
tcatcttggc ataagccatt aaaagcttgg agattactgt atttggcatt aaaaaaaaaat 1500
gtcacttagg tcagcactcc cagacgtagc acagaaaaac cctttgacac aaacctgtg 1560
ttctgatttt tgggttcagaa aatattgaaa ctgtgagttg tttttttttt aacaactggg 1620
aaaaaacaaa acaaaaaaac tatagttaga aaaatggaag ttccataggt tctatttctt 1680
actctatgta tggctttgtt ttcagtctat ttctaggagc tttctctgaa tcgctaattg 1740
tcctttcagt tgaaatctaa tttatacaat cattctatac ttaaagggtta aatacatctt 1800
aattaatttt ttcttaaagt caatgtaagt cactttgttt tgtttttttt taatctacgc 1860
catatgcctc atgaaaccag ctgttctaga atcagtcctg agaatatggc ttaattccat 1920
ggaaacataa ctcctatctt gggacctgac ataatatcta tctatcctgg ggaactggta 1980
atatgagact tataggttac agcagaaatg ctacatgttg acaaaagcct taatcgttcc 2040
actgggagaa ctaattgata attgtgttaa gattgaagat taacctgtg ttaatctcac 2100
ttgagtctat cctgacagta gttcagattc tggaaaatga taaactgacc tgctagatgt 2160
agaattgttt caaaattagt gttgaaatac cttgttcaca gatgaatatc tgggcaggat 2220
ctgaggggtg ttggaatgac acccccctat ccagttgcat agatgggatg tctttgcagg 2280
tttgaggaga tcatcgacct gcagagcccc ctttgaccca gtacctca 2328

```

<210> 282

<211> 956

<212> DNA

<213> Homo sapiens

<400> 282

```

ggccgagccc ggcggcccca gaccccgaga gctcgcagct ccggcccgcc ggcgatggcg 60
cggagctgcy cgtgctggtg gacatggagc gcgtcctggc cgacttcgag gccggcctcc 120
tgccgggctt ccgcgcgcgc ttccctgagc agccgcacgt gccgctggag carcgccgcg 180
gcttcctggc ccgcgagcag taccgcgccc tgcggcccca cctggcggat aaagtggcca 240
gtgtgtacga agccccgggc tttttcctgg acctggagcc catcccggga gccttgagcg 300
ctgtgcggga gatgaacgac ctaccggaca cgcaggctct catctgcacc agccccctgc 360
tgaagtacca ccactgtgtg ggtgagaagt accgctgggt ggagcagcac ctggggcccc 420
agttcgtaga acgaattatc ctgacaaggg acaagacggg ggtcttgggg gacctgctca 480

```

ttgatgacaa ggacacagtt cgaggccagg aggagacccc aagctgggag cacatcttgt 540
tcacctgctg ccacaatcgg cacctgggtcc tgcccccgac aaggagacgg ctgctctcct 600
ggagtgacaa ctggagggag atcttagata gcaagcgcgg agctgcgcag cgggaatgag 660
cggggatgcc gcgggcagca gctggagcta aaggaagggc agggccacag gggccaccgc 720
agagccgagt cggggcggca tcgtgctggt gcctctggcc ccgtggagtg gagcaggcag 780
ataccgttaa gcgctgtgct accggcccca ggcccagcca cccggtacct cccgagaggc 840
tgtccctgga ccctggctgg catggaaata cagtgggaaa accagtcggg acctttaata 900
aaagaccttg gcttttctaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaat 956

<210> 283

<211> 1402

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (26)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (97)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (131)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1344)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1355)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1394)

<223> n equals a,t,g, or c

<400> 283

ccccccgccc cccgcacccc cgaaanccag tgaaggtgaa gactccgcgg cccgcgggcg 60

```

tgccaggaga gcggactgtt tgatgtgntg ccgggggnccg tgcaggggag agtgggtttcg 120
ggcggggggg nagaaaaagat ttttttcttc tcttaatcgg aatcgtgatg gtgttggtt 180
atttcaatgg tgggggttaat atagcatgtt atcctgtcta tcttttaaag atttctgtat 240
aagactgttg agcagttttt aaaatagtgt aggataatat aaaaagcaga tagatggcgc 300
tatgtttgat tctacaacg aaattatcac cagctttttt tcattcttaa ctctttaaag 360
gattcaaacg caactcaaat ctgtgctgga ctttaaaaaa acaattcagg accaaatttt 420
ttctcagtgt gtgtgtttat tccttatagg tgtaaatgag aagacgtgtt ttttcccttc 480
accgatgctc catcctcgta tttctttttc cttgtaaatg taatcagatg ccattttata 540
tgtggacgta ttataactgg ccaaacatat ttttctttt gtcccttttt ttctttcctt 600
tctttttact tcctttatct ctttattcct tccttttcct ttttttcttt ttttttctt 660
ttttttttgg tagttgttgt taccacgccc attttacgtc tccttcactg aagggtctaga 720
gttttaactt ttaatttttt atattttaat gtagactttt gacactttta aaaaacaaaa 780
aaagacaaga gagatgaaaa cgtttgatta ttttctcagt gtatttttgt aaaaaatata 840
taaagggggg gttaatcggg gtaaatcgct gtttggtatt cctgatttta taacagggcg 900
gctggttaat atctcacaca gtttaaaaaa tcagccccta atttctccat gtttacactt 960
caatctgcag gcttctttaa gtgacagtat cccttaacct gccaccagtg tccacctctc 1020
ggcccccgtc ttgtaaaaag gggaggagaa ttagccaaac actgtaagct tttaagaaaa 1080
acaaagtttt aaacgaaata ctgctctgtc cagaggcttt aaaactggtg caattacagc 1140
aaaaagggat tctgtagctt taacttgtaa accacatctt ttttgcactt tttttataag 1200
caaaaacgtg ccgttttaac cactggatct atctaaatgc cgatttgagt tcgcgacact 1260
atgtactgcg tttttcattc ttgkatttga ctatttaatc ctttctactt gtcgctaaat 1320
ataaatgggt taaggcctaa tggntgsatg atagncataw ggkgtcagggt ttataacttt 1380
gggttaaaaa ttgnaaaagg gg                                     1402

```

<210> 284

<211> 675

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (520)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (560)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (618)

<223> n equals a,t,g, or c

<400> 284

accccccttta ggaaaaaagn tggagctcca ccgcggtggc ggccgctcta gactcgagga 60

```

attccagatg cgagcgcggc cgcggccccc gccgctctgg gcgactgtgc tggcgtggg 120
ggcgtggcg ggcgttgccg taggagggcc caacatctgt accacgcgag gtgtgagctc 180
ctgccagcag tgcctggctg tgagcccat gtgtgcctgg tgctctgatg aggccctgcc 240
tctgggetca cctcgtctgt acctgaagga gaatctgctg aaggataact gtgccccaga 300
atccatcgag ttcccagtga gtgaggcccc agtactagag gacaggcccc tcagcgacaa 360
gggctctgga gacagctccc aggtcactca agtcagtccc cagaggattg cactccggct 420
ccggccagat gattcgaaga atttctccat ccaagtgcgg caggtggarg attaccctgt 480
ggacatctac tacttgatgg acctgtctta ctccatgaan ggatgatctg tggarcaccc 540
agaacctggg taccaagctn ggccacccar atgcgaaagc tcaccartaa cctgcggatt 600
ggcttcsggg catttgtnng acaagcctgt gtcaccatac atgtacctcg tgcgaatttt 660
ggctcagggc aaatt 675

```

<210> 285

<211> 1339

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1330)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1331)

<223> n equals a,t,g, or c

<400> 285

```

gccgcaacct ttccaaggga gtggttgtgt gatcgccatc ttagggaaaa gatgttctcg 60
tccgtggcgc acctggcgcg ggcgaacccc ttcaacacgc cacatctgca gctggtgcac 120
gatggtctcg gggacctccg ccgccgtgga agagtacagt tgtgaatttg gctccgcgaa 180
gtattatgca ctgtgtggct ttgggtgggt cttaagttgt ggtctgacac acactgctgt 240
ggtccccctg gatttagtga aatgccgtat gcagggtggac ccccaaaagt acaagggcat 300
atttaacgga ttctcagtta cacttaaaga ggatgggtgtt cgtggtttgg ctaaaggatg 360
ggctccgact ttccttgget actccatgca gggactctgc aagtttggct tttatgaagt 420
ctttaaagtc ttgtatagca atatgcttgg agaggagaat acttatctct ggcgcacatc 480
actatatattg gctgcctctg ccagtgtgta attctttgct gacattgccc tggctcctat 540
ggaagctgct aaggttcgaa ttcaaaccga gccagggttat gccaacactt tgagggatgc 600
agctcccaaa atgtataagg aagaaggcct aaaagcattc tacaaggggg ttgctcctct 660
ctggatgaga cagataccat acaccatgat gaagttcgcc tgctttgaac gtactgttga 720
agcactgtac aagtttgttg ttccaaagcc ccgcagtga ttttcaaagc cagagcagct 780
ggttgtaaca tttgtagcag gttacatagc tggagtcctt tgtgcaattg tttctcacc 840
tgctgattct gtggtatctg tgttgaataa agaaaaaggt agcagtgcct ctctggctct 900
caagagactt ggatttaaag gtgtatggaa gggactgttt gcccgatatc tcatgattgg 960
taccctgact gcactacagt ggtttatcta tgactccgtg aaggtctact tcagacttcc 1020
tcgccctcct ccacccgaga tgccagagtc tctgaagaag aagcttgggt taactcagta 1080
gttagatcaa agcaaagtgt gactgaatct gcttggtgat cagtgttgaa gaaagtgcaa 1140
aaggaaacttt tatatatattg acagtgtagg aaattgtcta ttctgatata aattactgta 1200
gtactcttgc ttaaggcaag agtttcagat ttactgttga aataaaacca actcttcatg 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaan naaaaaaaaa 1339

```

<210> 286
<211> 1398
<212> DNA
<213> Homo sapiens

<400> 286
ctctggagcc accagcagaa cctcttcaat atcttgcatg ttacagattt cactgctccc 60
accagcttgg agacaacatg tggttcttga caactctgct cctttgggtt ccagttgatg 120
ggcaagtggg caccacaaag gcagtgatca ctttgcagcc tccatgggtc agcgtgttcc 180
aagaggaaac cgtaaccttg cactgtgagg tgctccatct gcctgggagc agctcyacac 240
agtggtttct caatggcaca gccactcaga cctcgacccc cagctacaga atcacctctg 300
ccagtgtcaa tgacagtggg gaatacaggt gccagagagg tctctcaggg cgaagtgacc 360
ccatacagct ggaaatccac agaggctggc tactactgca ggtctccagc agagtcttca 420
cggaaggaga acctctggcc ttgaggtgtc atgcgtggaa ggataagctg gtgtacaatg 480
tgctttacta tcgaaatggc aaagccttta agtttttcca ctggaattct aacctcacca 540
ttctgaaaac caacataagt cacaatggca cctaccattg ctcaggcatg ggaaagcatc 600
gctacacatc agcaggaata tcwrtactg tgaaagagct atttccagct ccagtgtctga 660
atgcatctgt gacatcccca ctcttgagg ggaatctggg caccctgagc tgtgaaacaa 720
agttgctctt gcagaggcct ggtttgcagc tttacttctc cttctacatg ggcagcaaga 780
ccctgcgagg caggaacaca tctctgaat accaaatact aactgctaga agagaagact 840
ctgggttata ctggtgagag gctgccacag aggatggaaa tgccttaag cgcagccctg 900
agttggagct tcaagtgtt ggctccagt taccaactcc tgtctggtt catgtccttt 960
tctatctggc agtgggaata atgtttttag tgaacactgt tctctgggtg acaatacgtg 1020
aagaactgaa aagaaagaaa aagtggrratt tagaaatctc tttggattct ggtcatgaga 1080
agaaggtaat ttccagcctt caagaagaca gacatttaga agaagagctg aaatgtcagg 1140
aacaaaaaga agaacagctg caggaagggg tgcaccgga ggagccccag ggggccacgt 1200
agcagcggct cagtgggtgg ccatcgatct ggaccgtccc ctgcccactt gctccccgtg 1260
agcactgcgt acaaacatcc aaaagttcaa caacaccaga actgtgtgtc tcatgggtatg 1320
taactcttaa agcaataaaa tgaactgact tcaactgaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aaaaaaaaaa 1398

<210> 287
<211> 926
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (896)
<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (917)
 <223> n equals a,t,g, or c

<400> 287
 gaaatccttt ttatctttcn tntttttttt aagggccttt ctaactccgc tgccgccatg 60
 gctcctgtga aaaagcctgt ggtgaagggg ggcaaaaaaa agaagcaagt tctgaagttc 120
 actcttgatt gcaccacccc tgtagaagat ggaatcatgg atgctgcca ttttgagcag 180
 tttttgcaag aaaggatcaa agtgaacgga aaagctggga accttgggtg aggggtggtg 240
 accatcgaaa ggagcaagag caagatcacc gtgacatccg aggtgccttt ctccaaaagg 300
 tatttgaaat atctcaccaa aaaatatttg aagaagaata atctacgtga ctggttgccg 360
 gtagttgcta acagcaaaga gagttacgaa ttacgttact tccagattaa ccaggacgaa 420
 gaagaggagg aagacgagga ttaaatttca tttatctgga aaattttgta tgagttcttg 480
 aataaaactt gggaaccaa atggtggttt atccttgat ctctgcagtg tggattgaac 540
 agaaaattgg aaatcatagt caaagggctt cccttggttc gccactcatt tatttgtaac 600
 ttgacttctt tttttttctg cttaaaaatt tcaattctcg tggtaatacc agagtagaag 660
 gagagggtga ctttaccgaa ctgacagcca ttggggaggc agatgcgggt gtggagggtg 720
 gggctgaagg tagtgactgt ttgattttaa aaagtgtgac tgtcagttgt atctgttgct 780
 tttctcaatg attcagggat acaaatgggc ttctctcatt cattaaaaga aaacgcgaca 840
 tctttctaag attctctgtg ggaaaatgac tgtcaataaa atgcggggtt ctgggncaaa 900
 aaaaaaaaaa aaaaccncgg ggagtc 926

<210> 288
 <211> 3094
 <212> DNA
 <213> Homo sapiens

<400> 288
 agagagctca gatggccctt ttaagggggc tccaagaacc aacatcactg ctctttttaga 60
 taaacctctg ccctccactc cttgcttgag tgggttaaag gaactaacag ttgtcccttt 120
 aggaggacaa aatgggggtca agaggacaca gaagagttgt atagcaccag attggttcca 180
 aatagttaat ggatgtgtgc acattttctg ttcagggtatt aagaccagaa tatcagtggg 240
 tttgttttcc ccaccaagtg gcctcttaga ctagtcatta acttatgatt agctctaaag 300
 atttcaaata gtggcagaca gtgtctctg aatgtaagtt ttgagaaata cgagtcgtgc 360
 agagcggcca taagccataa agagtcaatc tottaattat atttttcatc atgtaaacaa 420
 gtttccatt tccctttctt agattgcacc agtgaaggag atgttttgca aagattcaga 480
 gaactaattt ttcactggat aagacctgag taaccagac cccccaccgt ggttcttttc 540
 acagccctcg actttgcact taaaaaggga tattgtaaat gaaaggctgc agtgccagtt 600
 ttaagaaaga atttctgtga agtgtgagga ctctggagtc tagctcacat aaagagagtg 660
 ttatataaaa atccgacagc tgaactaggt tgctcttttt tggcaggagag tggggtagag 720
 atttgacacc aatatgggca aaattagata accttttggg taatataaat gattttgatt 780
 tggaggccta atttgtagat tgtgaaagca gcttttagtt taacttattc acagaccct 840
 tataattacc atgttttttt tttcttccta aatctcttgg ttcagcttgt gaactttacg 900
 tgcccgtaaa gttgggatgt tgaattggct cttctttggt ctggcagtga gtcaagtgtc 960
 cagcattttt tcataagtgt tttttaaaat tgttctocag catttttatg ctccctccctc 1020
 ccatgtcctc agaccagca aaagcgtaga ggcagaatta gaggcctctc caggccagct 1080
 cctctgcccc catgtcatac aaggtgtgaa tttgagcaca gtccagaaat ggagacatcc 1140
 cccccccagt tgaataatgg cccattcatg ccaaccttgc caacacggag agggcagaga 1200
 tgcactagaa gaccttcac cttcccttcc tctgccccaa gtcactacag ttggttctat 1260

```

tgaagccagt ctttaagaaa cctgggttaa agacaccagc acttctgctt gctgggctgg 1320
ctggacctgt gaagcmatgg gcaggtagtg cctcttgaga gtcattttat ttggccacct 1380
tcaggtagaga ctatccatag acacatgcta ggataggccc cgctgggagg gcagttacag 1440
gagagagtag gtggtggtga cgtgagggtc gtgaaggatc cagagacaag acttagatgt 1500
ttcgttcatt cactcactca ttcagttact cctaagactt ttcagtttca taaggaagag 1560
tggtgcctga ggccctaggg aatattgggg aatagaaggg attgaggaaa cattaataat 1620
agttattcaa aagacccaaa tgcttatact tctctctccc ttcttctctc tctgacacac 1680
acacacacac acacacacac acacacacac gtgcacattc ctcccttaca tgctcatttg 1740
tgccctaaat gtgccttata ggtaaatacca ggatgactga ggaatccctc gtcactggga 1800
gattttgtat atattctttt attattagat tgagttgggt gtgggaaaaa attttttctc 1860
gaaggctcaa aagtgggttc ctaaaagtga gccactatca gatttgcaca tcaggagaaa 1920
agaaataggg ttacgtccat taggaaaaatc ccagtttgca ggagtgcaat cacatcaaaa 1980
aaacaaccag ccaggattaa aggtattata aatcctcata gcggaacatt tctcagggca 2040
aaggaacctg gctcatttga agattaatgt tccatgcctt tgtggtcaaa sggtcagcac 2100
ttaacacagg aaaaaactag gtgttggttt gttttgttat tttggacaac ataaaaattca 2160
ggaatgtttt atttagcctt ggtttctaga aggaaggga ataatatttc ttgagcattt 2220
actagggtgt tgctgtctgt gctaagtaaa ttttaagtct ttcagtttta tagatacgga 2280
aaacaagggt gactctttac cacaggatga ataaagaact aagtaatatg ggaaatgcag 2340
caattttctg actagctgag ccgattcctt cctgtgagca cactgtaagc tttcaagttc 2400
tctgggcagg aattacagca cctgtccctt gcaatggccc tgctgtgtga tgctcatcgc 2460
ttcccttcgt gctggagcag tccccagggt gtccatctcc tatctttttg ttccaatctt 2520
ctgtgagttc cagctagcag gctttacatc tggggaaagg aaaaccaggg gttttagctc 2580
tgttctctgc tcccatcctt cgctcaccag ctgagtgaga acatgaactt tttgcaccat 2640
gtacccatgg cttacactac ttagaaaaatc accttttcag ataaaacagt ttatgagttc 2700
atagagaaca ccagcactct ttgacaaaac tgtgagtga ccttttttaa caatgctgag 2760
caggccctga gctataatca acggtgagct ttaatgtcta tgctgacagt taggttttgc 2820
tctcttttgt aacagggttac gtagaccagc agtggtttaa tctaaatacg ttgtgagtct 2880
gttatctgtc ctatcgctt ttttaaatga ctttttattc tttatcatag ctaagtaaat 2940
acaaaaaaaa aaaaaaagct ttgtaggaca cttgtactta gtttgggaaa aaaaaataaa 3000
ttgaaattgt tatgcttttg tatttccatt tcttgcaaat aaatattttt tcttaaatag 3060
taagatgttg ccagtcctt ataatcttgg tact 3094

```

<210> 289

<211> 1983

<212> DNA

<213> Homo sapiens

<400> 289

```

gacctcagag gagtcaaggc cccgcctgtc ccagctgtct gtgactgacg tgaccaccag 60
ttcactgagg ctcaactggg aggcccccac gggggccttc gactccttcc tgctccgctt 120
tggggttcca tcaccaagca ctctggagcc gcatccgcgt cactgctgc agcgcgagct 180
gatggtgccg gggacgcggc actcggccgt gctccgggac ctgcgttccg ggactctgta 240
cagcctgaca ctgtatgggc tgcgaggacc ccacaaggcc gacagcatcc agggaaaccgc 300
ccgcaccctc agcccagttc tggagagccc ccgtgacctc caattcagtg aaatcaggga 360
gacctcagcc aaggtaact ggatgcccc accatcccgg gcggacagct tcaaagctctc 420
ctaccagctg cggagcggag gggagcctca gagtgtgcag gtggatggcc agggccggac 480
ccagaaactc caggggctga tcccaggcca tcgctatgag gtgaccgtgg tctcgttccg 540
aggctttgag gagagtgagc ctctcacagg cttcctcacc acggttctctg acggtccac 600
acagttgcgt gactgaact tgaccgaggg attcgccgtg ctgcactgga agcccccca 660
gaatcctgtr gacacctatg acrtccaggt cacagcccct ggggccccgc ctctgcaggc 720
ggagacccca ggcagcgcgg tggactaccc cctgcatgac cttgtcctcc acaccaacta 780

```

```
caccgccaca gtgcgtggcc tgcggggccc caacctcact tccccagcca gcatcacctt 840
caccacaggg ctagaggccc ctccgggactt ggaggccaag gaagtgacct cccgcaccgc 900
cctgctcact tggactgagc ccccagtcgg gcccgcaggc tacctgctca gcttccacac 960
ccctggtgga cagacccagg agatcctgct cccaggaggg atcacatctc accagctcct 1020
tggcctcttt ccctccacct cctacaatgc acggytccag gccatgtggg gccagagcct 1080
cctgcccgcc gktkccacct ctttcaccac ggggtgggctg cggatccccct tccccaggga 1140
ctgcggggag gagatgcaga acggagccgg tgcctccagg accagcacca tcttcctcaa 1200
cggcaaccgc gagcggcccc tgaacgkkt ttgcgacatg gagactgatg ggggcggctg 1260
gctggtgttc cagcgycgca tggatggaca gacagacttc tggagggact gggaggacta 1320
tgcccatggt tttggaaca tctctggaga gttctggctg ggcaatgagg ccctgcacag 1380
cctgacacag gcagggtgact actccatgcg cgtggacctg cgggctgggg acgaggctgt 1440
gttgccccag tacgactcct tccacgtaga ctcggctgcg gactactacc gcctccactt 1500
ggagggctac cacggcaccg cagggactcc atgagctacc acagcggcag tgtcttctct 1560
gcccgtgata gggacccccaa cagcttgctc atctcctgcg ctgtctccta ccgagggggc 1620
tggtggtaca ggaactgcc aactgccaac ctcaacgggc tctacgggag cacagtggac 1680
catcagggag tgagctggta ccaactggaag ggcttcgagt tctcgggtgc cttcacggaa 1740
atgaagctga gaccaagaaa ctttcgctcc ccagcggggg gaggtgagc tgctgcccac 1800
ctctctcgca ccccagtatg actgccgagc actgaggggt cggcccgaga gaagagccag 1860
ggtccttcac caccagccg ctggaggaag ccttctctgc cagcgatctc gcagcactgt 1920
gtttacaggg gggaggggag gggttcgtac gggagcaata aaggagaaac tgaggtaacc 1980
gga 1983
```

<210> 290

<211> 1298

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1224)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1231)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1242)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1262)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1285)

<223> n equals a,t,g, or c

<400> 290

```
gaaggacagc agaccagaca gtcacagcag ccttgacaaa acgttcctgg aactcaagct 60
cttctccaca gaggaggaca gagcagacag cagagaccat ggagtctccc tcggccccctc 120
cccacagatg gtgcatcccc tggcagaggc tcctgctcac agcctcactt ctaaccttct 180
ggaacccgcc caccactgcc aagctcacta ttgaatccac gccgttcaat gtcgcagagg 240
ggaaggaggt gcttctactt gtccacaatc tgccccagca tctttttggc tacagctggt 300
acaaaggtga aagagtggat ggcaaccgtc aaattatagg atatgtaata ggaactcaac 360
aagctacccc agggcccgca tacagtggtc gagagataat ataccccaat gcatccctgc 420
tgatccagaa catcatccag aatgacacag gattctacac cctacacgtc ataaagtcag 480
atcttgtgaa tgaagaagca actggccagt tccgggtata ccgggagctg cccaagccct 540
ccatctycag caacaactcc aaacccgtgg aggacaagga tgctgtggcc ttcacctgtg 600
aacctgagac tcaggacgca acctacctgt ggtgggtaaa caatcagarc ctcccggtca 660
gtcccaggct gcagctgtcc aatggcaaca ggaccctcac tctattcaat gtcacaagaa 720
atgacacagc aagctacaaa tgtgaaaccc agaaccacgt gagtgccagg cgcagtgatt 780
cagtcactct gaatgtcctc tatggcccggt atgcccccac catttccctt ctaaacacat 840
cttacagatc aggggaaaaat ctgaacctct cctgccacgc agcctctaac ccacctgcac 900
agtactcttg gtttgtcaat gggactttcc agcaatccac ccaagagctc tttatcccca 960
acatcactgt gaataatagt ggatcctata cgtgccaaag ccataactca gacactggcc 1020
tcaataggac cacagtcacg acgatcacag tctatgcaga gccacccaaa cccttcatca 1080
ccagcaacaa ctccaacccc gtggaggatg aggatgctgt agccttaacc tgtgaacctg 1140
agattcagaa cacaacctac ctgtgggtgg taaataatca gagccttccg gtcagtccca 1200
ggctgcactt gccaatgaca acangaccct nactctactc antggcacia ggaatgatgt 1260
angaccctat gaatgtggaa tccanaacaa attaagtg 1298
```

<210> 291

<211> 2459

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1604)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1605)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2374)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2392)

<223> n equals a,t,g, or c

<400> 291

```

cgnnccacgc gtcgcgagca rggccaacag tcacagcagc cctgaccaga gcattcctgg 60
agctcaagct ctctacaaag aggtggacag agaagacagc agagaccatg ggacccccct 120
cagccccctc ctgcagattg catgtcccct ggaaggagggt cctgctcaca gcctcacttc 180
taaccttctg gaaccacccc accactgcc agetcactat tgaatccacg ccrttcaatg 240
tcgcagaggg gaaggagggt cttctactcg cccacaacct gccccagaat cgtattgggt 300
acagctggta caaaggcgaa agagtggatg gcaacagtct aattgtagga tatgtaatag 360
gaactcaaca agctacccca gggcccgcat acagtggctg agagacaata taccccaatg 420
yatccctgct gatccagaac gtcaccacaga atgacacagg attctatacc ctacaagtca 480
taaagtcaga tcttgtgaat gaagaagcaa ccggacagtt ccatgtatac ccggagctgc 540
ccaagccctc catctccarc aacaactcca accccgtgga ggrcaaggat gctgtrgcct 600
tcacctgtga acctgagggt cagaacacaa cctacctgtg gtgggtaa at ggtagagcc 660
tcccggctcag tcccaggctg cagctgtcca atggcaacat gacctcact ctactcagcg 720
tcaaaaggaa cgatgcagga tcctatgaat gtgaaatata gaaccacagc agtgccaacc 780
gcagtgacct agtcaccctg aatgtcctct atggcccaga tggccccacc atttccccct 840
caaaggccaa ttaccgtcca ggggaaaatc tgaacctctc ctgccacgca gcctctaacc 900
cacctgcaca gtactcttgg tttrtcaatg ggackttcca gcaatccacm caagagctct 960
ttatccccaa catcactgtg aataatagtg gatcctatac gtgccaagcc cataactcag 1020
acactggcct caataggacc acagtacaga cgatcacagt ctatgcagag ccacccaaac 1080
ccttcacac cagcaacaac tccaaccccg tggaggatga ggatgctgta gccttaacct 1140
gtgaacctga gattcagaac acaacctacc tgtgggtgggt aaataatcag agcctcccg 1200
tcagtccag gctgcagctg tccaatgaca acaggacct cactctactc agtgtcacia 1260
ggaatgatgt aggacctat gagtgtggaa tcagaaacga attaagtgtt gaccacagcg 1320
accagtcac cctgaatgtc ctctatggcc cagacgaccc caccatttcc ccctcataca 1380
cctattaccg tccaggggtg aacctcagcc tctcctgcca tgcagcctct aaccacctg 1440
cacagtattc ttggctgatt gatgggaaca tcagcaaca cacacaagag ctctttatct 1500
ccaacatcac tgagaagaac agcggactct atacctgcca ggccaataac tcagccagtg 1560
gccacagcag gactacagtc aagacaatca cagtctctgc gganntgccc aagccctcca 1620
tctccagcaa caactccaaa cccgtggagg acaaggatgc tgtggccttc acctgtgaac 1680
ctgaggctca gaacacaacc tacctgtgggt gggtaaatgg tcagagcctc ccagtcaatc 1740
ccaggctgca gctgtccaat ggcaacagga cctcactct attcaatgtc acaagaaatg 1800
acgcaagagc ctatgtatgt ggaatccaga actcagttag tgcaaaccgc agtgaccag 1860
tcaccctgga tgtctctat gggccggaca ccccatcat tccccccca gactcgtctt 1920
acctttcggg agcgaacctc aacctctcct gccactcggc ctctaaccce tccccgcagt 1980
attcttggcg tatcaatggg ataccgcagc aacacacaca agttctcttt atcgccaaaa 2040
tcacgccaaa taataacggg acctatgcct gttttgtctc taacttggct actggccgca 2100
ataattccat agtcaagagc atcacagtct ctgcatctgg aacttctcct ggtctctcag 2160
ctggggccac tgtcggcatc atgattggag tgcgtggttg ggttgctctg atatagcagc 2220
cctggtgtag tttcttcatt tcaggaagac tgacagttgt tttgcttctt ccttaaagca 2280
tttgcaacag ctacagtcta aaattgcttc tttaccaagg atattttacag aaaagactct 2340
gaccagagaa tcgagaacca tcctagccaa catngtgaaa accccatctg tnactaaaaa 2400
tacaaaaatg agctgggctt tgtggcgcg cactgttagt ccccgtaaat ttggggagg 2459

```

<210> 292
 <211> 570
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (567)
 <223> n equals a,t,g, or c

<400> 292
 aattcggcac gmgccggagt gtggtacttc tcctagttag agtcaggcct catacgctat 60
 tgtcctgccc gttagagcag ccagcgggta cagaatggat tttggaagag ggagtcacca 120
 ctggacctcc aaggaagcca cgtgcagaca tctacaacct tcgatctcct gacgagttaa 180
 ttgttggcca aaaccaggct ttgattgaac caggatgaat gcgggtgttg gaagtagaat 240
 atatatatac atataaaatt ggttgggagc cacgtgtacc agtgtgtgtt gatcttggct 300
 tgattcagtc tgccttgtaa cagaaactgg cgatggaata tgagaggagc cctctggaaa 360
 gaaaaggaca gacctgtgc ttcatgaaa gtgaagatct ggctgaacca gttccacaag 420
 gttactgtat acatagcctg agtttaaaag gctgtgcca cttcaagaat gtcattgtta 480
 gactttgaaa tttctaactg cctacctgca taaagaaaat aaaatctttt aaatcaaaaa 540
 aaaaaaaaaa raagggggcc gctctanagg 570

<210> 293
 <211> 2468
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (2076)
 <223> n equals a,t,g, or c

<400> 293
 gggtttgaga agattggaca gtgcttcagg caccgtgtac acagcaatgg atgtggccac 60
 aggacaggag gtggccatta agcagatgaa tcttcagcag cagccaaga aagagctgat 120
 tattaatgag atcctggta tgagggaaaa caagaacca aacattgtga attacttgga 180
 cagttacctc gtgggagatg agctgtgggt tgttatggaa tacttggctg gaggctcctt 240
 gacagatgtg gtgacagaaa ctgtcatgga tgaaggccaa attgcagctg tgtgccgtga 300
 gktctgcag gctctggagt tcttgcatc gaaccagata acccagagc agagcaaacg 360
 gagcaccatg gtaggaacct cactatggat ggcaccagag gttgtgacac gaaaggccta 420
 tggggccaaag gttgacatct ggtccctggg catcatggcc atcgaaatga ttgaagggga 480
 gccctccatac ctcaatgaaa accctctgag agccttgtac ctcatgcca ccaatgggag 540
 cccgaacctt cagaacctc agagctgttc agctatcttc cgggactttc tgaaccgctg 600
 tctcgagatg gatgtggaga agagagggtt agctaaagag ctgctacagc atcaattcct 660
 gaagattgcc aagccccctc ccagcctcac tccactgatt gctgcagcta aggaggcaac 720
 aaagaacaat cactaaaacc aactcacc cagcctcatt gtgccaagcc ttctgtgaga 780
 taaatgcaca ttctcagaaat tccaactcct gatgccctct tctccttgcc ttgcttctcc 840
 catttctga tctagcactc ctcaagactt tgatccttgg aaaccgtgtg tccagcattg 900
 aagagaactg caactgaatg actaatcaga tgatggccat ttctaaataa ggaatttctc 960
 cccaattcat ggatatgagg gtggtttatg attaagggtt tatataaata aatgtttcta 1020

```

gtcttccgtg tgtcaaaatc ctcacctcct tcataaccat ctcccacaat taattcttga 1080
ctatataaat ttatggtttg ataataattat caatttgtaa tcaattgaga tttcttttagt 1140
gcttgctttt ctgtgactca actgcccaga cacctcattg tacttgaaaa ctggaacagc 1200
ttgggaatgc catgggggtt gataatctgc caggggacatg aagaggctca gcttcctgga 1260
ccatgacttt ggctcagctg atcctgacat gggagaacaa ccacattttt ctttgtgtgt 1320
gcttctagca gctgttcggg aggaccttga cccaayagtg ttcccatgct gtttcttgtg 1380
aaatgctctc ggctatgtag cagcttttga ttccctgcat accctaggct gctgccccta 1440
tctgtccct tgtttataac attgagaggt tttctagggc acatactgag tgagagcagt 1500
gttgagaagt cggggaaaat ggtgactact tttagagcaa ggctgggcat cagcacctgt 1560
ccagctctac ttgtgtgatg tttcaggaac tcagcccctt tttctgccta ggataaggag 1620
ctgaaagatt aacttggatc ttctaattgg ccaaatcttt tggtcacaat aaagagtctc 1680
caaattagag actgcatgtt agttctggat ggatttggtg gcctgacatg ataccctgcc 1740
agctgtgagg ggaccccggt tttaagatgc atggccaagc tctctgcaaa tggaaatgct 1800
tacactgggt gttggggatg tttgctacct cctgctattt ttgtggtttt ggttctccca 1860
ctatggtagg acccctggcc agcattgtgg ctgtcatgt cagccccatt gactaccttc 1920
tcatgctctg aggtactact gcctctgcag cacaaatttc tatttctgtc aataaaagga 1980
gatgaaaata ttctatttga gtatgccttt cttttttctc ttcgtttttt ctttcctttt 2040
ctaatttttt atatgaaata atgagtaagt ttcttntctg accatttgag agtggttaagt 2100
tgcagataga atgccccctt accactatat acctgaatgt gtattctttc yttttaaacac 2160
ttttatttta aatataaatt aagagaaatg ggccaaaacc atttgtattg tttaaagaat 2220
aattataaac acacttgtat ccaccaaadc aagaaaakgga aactgacag taagaacctt 2280
ctctatcttg tccttccttt ctcatatag ccccccaccta agaggtaacc acctcttga 2340
cttttattta aataactttc ttgcttttct gtatactttc atcacattca ggtgtgttcc 2400
aatacaagta gatttttagt cggccagttt ttgaacttta aataaacata tcataataga 2460
taaaaaaa 2468

```

<210> 294

<211> 1080

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1038)

<223> n equals a,t,g, or c

<400> 294

```

ctcgtgccga attcggcacg agcccacggg cccggcgcca tgagtgttgc cgcttcctgg 60
atgacaacca aatcatcacc agctctgggg ataccacctg tgccctgtgg gacattgaga 120
caggccagca gacagtgggt ttgtctggac acagtgggga tgtgatgtcc ctgtccctgg 180
ccccgatgg ccgcacgttt gtgtcaggcg cctgtgatgc ctctatcaag ctgtgggacg 240
tgcgggattc catgtgccga cagacctca tcggccatga atccgacatc aatgcagtgg 300
ctttcttccc caacggctac gccttcacca ccggctctga cgacgccacg tgccgcctct 360
tcgacctgcg ggccgatcag gagctcctca tgtactccca tgacaacatc atctgtggca 420
tcacctctgt tgccttctcg cgcagcgacg gctgctgctc gctggctacg acgacttcaa 480
ctgcaaacat tgggatgcc tgaaggcgga ccgtgcagga gtccctcgctg gccacgacaa 540
ccgcgtgagc tgccctcggg tcaccgacga tggcatggct gtggccaagg gctcctggga 600
ctccttcctc aagatctgga actaatggcc ccacccccac tggggccagg ccaggagggg 660
ccctgcccat gccacacta caggccaggg ctgcgggggt ggcgcaatcc cagccccctt 720
ccccgggcca cggggccttg ggtccctgcc ctcccaccca ggtttggttc ctccgggggc 780
cccactgtg gagataagaa ggggatggaa tgggggaaga ggaggagcag gaggccctca 840

```

```

tccttctgct gccctgggggt tggggcctca cccctctgga gggccggagg caggaggtgg 900
aaaccccagg ggctggcttt tttaaaactg gttttatttt aatttttatt atattttcag 960
tttttccata aaggagccaa ttccaactct gwaaaaaaaa aaaaaaaaaa acttcgrggg 1020
ggggcccgtg cccaattngc ctttaggggg gggtttaaat taatggcggg gttttaaaaa 1080

```

<210> 295

<211> 2695

<212> DNA

<213> Homo sapiens

<400> 295

```

tcatgattcc aagctaaagg aaattaaaaa tgtaatttaa taatttccta tttttagggt 60
tgtaattttt tttctacaaa aaaaccttga aatttttagat atcccaatgt gaatctaatt 120
tccatatata cagaaattag acaataata agtctttagt tcaacttaag catatctcaa 180
atgacttctc taaattttaa gttgatcatg ataggatcat aaaagacaga aaagacttaa 240
gtaatcttgt aatgacaatt atttccattt ttgctgaact aaaaatattt aacttcataa 300
atatgttact acagcttcca gatttaaaga aaaaaagttt cccccactct caattaaaag 360
ttagaaccct ccacttttaa aattatacaa atatttcttt ttacattac acagaagcct 420
tctgtaccat tttacgaatt tctgtcttca taatataagt gaaaatactg tcatttcaat 480
tttctgcttt aaattgtttt taataagcat yccaaagtga tacagactta agcttttaaat 540
caatcagtca ttcagttgat agacaaagtt agcgatgctt tatgctagga aacttgttga 600
cagtaacctg tgcgacttta tgcagaagac aaatgctagt aattattatg cacagaggaa 660
aaatcatttt aagtatgtgg taaagcagct tcacttttca aaattgattt gctctggttt 720
ttcttttagtc cattagattc cagaatgtcc ttttactggg aatttagtta tgtattaaga 780
taacctgttt tcagttcttt ttgaaaagaa gacattattt atattgaacc acctattttt 840
aaaattttta actttttatat accacttgtg tgattccagt gtcatgtctt gggtttgatg 900
tcgttggaca gaaaagtgtg tcaattattt taaatgaatt tttcccatg tttgaggctt 960
agtctgtaaa tgtgttgctg taacagaaaa tacttgggta tgcattactt gaatacttga 1020
aaactgaaat taataagatg tattacataa tgaattagat ttctctgaac agtttttaca 1080
ctgaaaatct tcatttctgg attgcagttt gaaatggaat gaagacctga attatttggg 1140
tagaaaaaat tatgatagtg cttataagaa ctgtaaactg ttttaaacta ttttgtgttt 1200
gacgcatcaa acttcaagtt ttttgtaagt ttctctcctg aaattttctt tctcttctat 1260
actttatgca cttactatac tactgatgta ataaaagagc agggttaaaa atattgtatc 1320
tgtattcatt gtgaatcctg tagcttttct agttaacaaa aaatcgcttt ctaaaatact 1380
cttaatccca ttgttttggt taacatctta cccatttggt gtatttcaaa tgccattaat 1440
catttttagta caacacctat gtttataaaa atttgaaaac attacatatt gtatttataa 1500
ctaattagtg aagagtaaga aaaaaactag ccaacagaat tgtaggtgat gcattagtta 1560
aatttcacaaa ctcataataa aggaactttc agagattggg tgaaaccagc tggtatccct 1620
gtaaattagc tcctgtgact ggaaaagacc ccaaaaaggc agtagaggag attagtgttt 1680
acttgctgtg gttgtgggtg gctgctactt aattataggt agtgacacac tgaaattctt 1740
atltgtccaa taatctgaag tagtttccta tatttatctg tactaaattg actataaatt 1800
gagctgcaa agaggaaact ttttgactgt actgtattta ggagcctttg tacagcttgg 1860
tcaaatttcc atgatatgaa gtatttgagt tttaaaatat actgttatta aaaggaaaaa 1920
gacatggcca ttattccatg tgcttaaatg ataatttcct tattcagttt cagaagaaaa 1980
agaatgaaat tgggtaactg tcattgcgtt agytttatgt tgaattggga aattgtggca 2040
taaagcttaa attcgtgttt atcaaagtgt aaccatagta gtataatgct gctttgtata 2100
taatgtaagt gtcacaaata gtctcagcag tgaanaatgta ttgataacct ttaaatgaat 2160
gcaacttttg atgtagggtg tttgctatgc ctcagaaaaat atctgtctga gaatttgta 2220
atctgtttga taatgaagat acttcctggt ttctgttttc atattttcat gttcaaaatt 2280
taagttttac atttttacta ctgttaattt aaataaaatt tgttctgtgg ataaaatgag 2340
gttggcagtg aagaaaatta aaaacagcct cattcatgta actggtttaag taaaaatata 2400

```

```

ttttcactat gtgttcataa actttttaatg aagctgtttg tctttcagtt caaatataag 2460
tgatgttttag gctttatttc tgtaataaag gctttttacc attgattaaa tgaaggaatg 2520
tatctttttg aagagattta tattctgtaa ataaaaattc gttgtaacaa taaagttgag 2580
ttctaactac aaaaaaaaaa aagtcgacac cgccgggaat ttaggtgtag tagtcccccg 2640
ggaaattcgg accggttact gaaggcgatc cagttttccc aaagttgggc gtatt 2695

```

<210> 296

<211> 1394

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1238)

<223> n equals a,t,g, or c

<400> 296

```

gccacgcgt ccgagctcag tcagcagaag agataaaagc aaacaggtct gggaggcagt 60
tctgttgcca ctctctctcc tgtcaatgat ggatctcaga aataccccag ccaaattctct 120
ggacaagttc attgaagact atctcttgcc agacacgtgt ttccgcatgc aaatcaacca 180
tgccattgac atcatctgtg ggttcctgaa ggaaaggtgc ttccgaggta gctcctaccc 240
tgtgtgtgtg tccaaggtgg taaaggggtg ctctcaggc aagggcacca cctcagagg 300
ccgatctgac gctgacctgg ttgtcttctc cagtcctctc accacttttc aggatcagtt 360
aaatcgccgg ggagagttca tccaggaaat taggagacag ctggaagcct gtcaaagaga 420
gagagcattt tccgtgaagt ttgaggtcca ggctccacgc tggggcaacc cccgtgcgct 480
cagcttcgta ctgagttcgc tccagctcgg ggagggggtk gaggtcgatg tgctgcctgc 540
ctttgatgcc ctggattttg cccgwacagg tcaattgact ggcggctata aacctaaccc 600
ccaaatctat gtcaagctca tcgaggagtg caccgacctg cagaaagagg gcgagttctc 660
cacctgcttc acagaactac agagagactt cctgaagcag cgtccaccac agctcaagag 720
cctcatccgc ctagtcaagc actggtacca aaattgtaag aagaagcttg ggaagctgcc 780
acctcagtat gccctggagc tcctgacggt ctatgcttgg gagcgaggga gcatgaaaac 840
acatttcaac acagcccagg gatttcggac ggtcttgga ttagtcataa actaccagca 900
actctgcata tactggacaa agtattatga ctttaaaaac cccattattg aaaagtacct 960
gagaaggcag ctacgaaaac ccaggcctgt gatcctggac ccggcggaac ctacaggaaa 1020
cttgggtggt ggagacccaa agggttggag gcagctggca caagargctg aggcctggct 1080
gaattaccca tgctttaaga attgggatgg gtccccagt agctcctgga ttctgctggt 1140
gagacctcct gcttctctcc tgccattcat cctgccccct ctccatgaag cttgagacat 1200
atagctggag accattcttt ccaaagaact tacctctntc gcaaaggcca tttatattca 1260
tatagtgaca ggctgtgctc catattttac agtcattttg gtcacaatcg agggtttctg 1320
gaattttcac atcccttgtc cagaattcat tcccctaaga gtaataataa ataattctta 1380
acaccaaaaa aaaa 1394

```

<210> 297

<211> 998

<212> DNA

<213> Homo sapiens

<400> 297

```

ggcacgagggt gaaataacgg gcccatataa atccctctgc cgcccgctg caagatggat 60
tgccgcgatt gaaattcctc cgcragataa ttaaactcgg ggctcatcc gggcaaaatt 120
acattccttg tgacgactgc gcatgctcgg aaaggggacg caatcragat cccaaacgcy 180

```

```

gtacagacca aaccgcagtc cacgttacgg atcggccttac tccgcggagt tggcctcatt 240
tctgcagtcg gcgctccctg tagtttctcc tctcgaacgc caggtggagc aaccggccgg 300
ataccgccac agccctggca ggcggcgctg tgatgcctga gctgatcctc tctcctgcc 360
cagctcctca cccctgaaa atgttcgcct gctccaagtt tgtctccact cctccttgg 420
tcaagagcac ctacagctg ctgagccgtc cgctatctgc agtgggtgctg aaacgaccgg 480
agatactgac agatgagagc ctacagcagct tggcagtcctc atgtccctt acctcacttg 540
tctctagccg cagcttccaa accagcgcca tttcaaggga catcgacaca gcagccaagt 600
tcattggagc tggggctgcc acagtggggg tggctgggtc tggggctggg attggaactg 660
tgtttgggag cctcatcatt ggttatgcc aagacccttc tctgaagcaa cagctcttct 720
cctacgccat tctgggcttt gccctctcgg aggccatggg gctcttttgt ctgatggtag 780
cctttctcat cctctttgcc atgtgaagg aagcgtctcca cctcccatag ttctcccgcg 840
tctggttgcc cccgtgtgtt ccttttctta tacctcccca ggcagcctgg ggaacgtggg 900
tggtcaggg tttgacagag aaaagacaaa taaatactgt attaataaga aaaaaaaaaa 960
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 998

```

<210> 298

<211> 1666

<212> DNA

<213> Homo sapiens

<400> 298

```

atccttctact aagcctgctt tagtttccac cacctgcttc tgcattcttt taatggctcc 60
ttaggtctcc aggaagcta acagccagg agaggatcag tctcttgctg gaccctggca 120
gctttkttga gagcgacatg tttgtggaac acagatgtgc agattttgga atggctgctg 180
ataagaataa gtttcctgga gacagcgtgg tcaactggac aggccgaatc aatggaagat 240
tggtttatgt ctacagtcag gattttacag tttttggagg cagtctgtca ggagcacatg 300
ccaaaagat ctgcaaaatc atggaccagg ccataacggg gggggctcca gtgattgggc 360
tgaatgactc tgggggagca cggatccaag aaggagtggg gtctttgggt ggctatgcag 420
acatctttct gaggaatgtt acggcatccg gagtcatccc tcagatttct ctgatcatgg 480
gcccattgtc tgggtggggc gtctactccc cagccctaac agacttcacg ttcatggtaa 540
aggacacctc ctacctgttc atcactggcc ctgatgttgt gaagtctgtc accaatgagg 600
atgttaccca ggaggagctc ggtggtgcca agaccacac caccatgtca ggtgtggccc 660
acagagcttt tgaaaatgat gttgatgcct tgtgtaatct cgggatttc ttcaactacc 720
tgcccttgag cagtcaggac ccggtcccg tccgtgagt ccacgatccc agtgaccgtc 780
tggttcctga gcttgacaca attgtccct tgggaatcaac caaagcctac aacatggttg 840
acatcataca ctctgttgtt gatgagcgtg aattttttga gatcatgcc aattatgcca 900
agaacatcat tgttggtttt gcaagaatga atgggaggac tgttggaatt gttggcaacc 960
aacctaaggt ggcctcagga tgcttgata ttaattcatc tgtgaaagg gctcgttttg 1020
tcagattctg tgatgcattc aatattccac tcatcacttt tgttgatgtc cctggctttc 1080
tacctggcac agcacaggaa tacgggggca tcatccggca tggtgccaag cttctctacg 1140
catttgctga ggcaactgta cccaaagtca cagtcacac caggaaggcc tatggaggtg 1200
cctatgatgt catgagctct aagcaccttt gtggtgatac caactatgcc tggcccaccg 1260
cagagattgc agtcattgga gcaaagggcg ctgtggagat catcttcaa gggcatgaga 1320
atgtggaagc tgctcaggca gagtacatcg agaagtgtgc caaccctttc cctgcagcag 1380
tgcgagggtt tgtggatgac atcatccaac cttcttccac acgtgcccga atctgctgtg 1440
acctggatgt cttggccagc aagaaggtag aacgtccttg gagaaaacat gcaaattatc 1500
cattgtaaac aaatcaaagg aaaagaaacc aagaactgaa ttactgtctg cccattcaca 1560
tcccattcct gccttttgca atcatgaaac ctgggaatcc aaatagtttg ataacttaga 1620
ataactaagt ttattaaatt ctagaaagat aaaaaaaaaa aaaaaa 1666

```

<210> 299

<211> 2444
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (4)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (402)
 <223> n equals a,t,g, or c

<400> 299

```

ctgngtgagc tggagcgcta tgtcacctcc tgtttgcgga agaaaaggaa acctcaagct 60
gagaaagttg atgtgattgc cggctcctcc aagatgaagg gcttctcgtc ctcagagtcg 120
gagagctcca gtgagtccag ctctctgac agcgaagmcw ccgaaacagg tcctgcctaa 180
tcattggaca cggactctta ataaaacggt cttcagttcc agattccttc ccagcaagct 240
atagcttaag tccattttct tccgtgaaag ggacaggact ccatcaagtt atggaattcc 300
tcagagccct gggcctgtcc cccgggtggg attagtcatg tccagcagca cagcctagt 360
ccgccttcg ggaaggctgc ctgcctggcc agccgccag gnetctctgt gtaaagactg 420
cctggctgtc ctgcccagcc ttctgtgttc tctgggtgct tctgggtggg tggcatctcc 480
tggagggtga tgacaatccc caacacatgc attcatgtgg tgctactctg tgtgcaaagc 540
cagaccccaa gtatgttttc tctctttgtc ccatccctct tttctctgga ctttggacct 600
taactacttc cctcctgaac cttgcagtga catcagtcga ggagagctct cgttcagtgt 660
gcggaagaac actctgacct cttagagctgt cctagataag gagtgggagc tttagaggca 720
aggcctctag accctggaag gctcagttag gctcttccca cagcatgctt ctactggtg 780
ccctgtaagg ctcgagccac cgctgactct gagccttttg gagtctttcc tccttcgtct 840
ccattgttcc cgtgcatttc caaaagctta agttgcctgg tgggcatttc cccagtttct 900
ttggcctccg tcttctcaag tcacataggg aaagtacctc ctggaaccag gctgcagtat 960
gcaggamctg ccaggcagsc actggtgaag ggccctgggc ctatcatccc cccaacccca 1020
cctcacccca cccgcctcct ctagtggggt gagtctgggc tgggtggacca gaggagggtg 1080
tcacagacct tcagggactg ccccatggac acctctgact ggtgttaaca gtgtgaacat 1140
tttccccgtc ttcagtcctt tagaatgacg acagcccctg ggggtggggc aggcgagtg 1200
ggccacatca tccaagccct cccagagaca caaataggct tttttgctct aaaaataaat 1260
accagccctt ttttggtcac aaatccagca tctcagcaga aaactgcctg acatgaaaag 1320
tcccctgagg aactgcatct gcgtttcagg ggcttttcat tttttctcct tttttaaaag 1380
gtagattgtg ggtgcttcct agaggcctgc cttcttcttg aactggaagt gggctatcac 1440
catgggcaag cccttgggtg caggctcccc acctgcctgg gaactctggc agctctcctc 1500
agctccttgg gcttgagcag ctgcaactgc cccagatttg ctgtggaagc aggggctagc 1560
cctggcctca ccagggccty ccggggccct gcattgatgc tcaggagtgc ctgggctgct 1620
cttgatcctt tctgggcctc cagcttccag ttaagctctg tttgccaaac aaactattct 1680
cagctgccct ttggcctgcy cctgatgtgt tctgttgca gtccgcctg cctgagacag 1740
gagcaggcag gagagccttc atgcccagat tcccacagga caattgggga gctgctggca 1800
ttgtctttct gggaagattc tgctttcttg gaccaaattg cagcctgatt accagtgtcg 1860
ggcctgcatg ctgccccga cacacgcacg cagcgcaca cacgtgtgca catgggccat 1920
agccacaagc cagctctcct ccagggtcct ttcaacctcg ctgtccaggg acctgtcct 1980
tcttgccctg ggggcttcca tctggcagag aacgttcagg gcttggtgaa cttgaaagct 2040
cattagactt aagctgtcac ctgtgcttgg tgccccagga acagccagag aggacagtgc 2100
ccactcactt cttgttggca gcctcctgtg cagggaagtgc cagccggggc tcgacgcacc 2160

```

251

```

agctggctgt gggctcctgag gagggggcggg aggcggccgc tcagtgcaga tggggactcc 2220
tctcctctgc cctgacctta ccctccatta cctccttcac tggagtgggg ctgggggggtg 2280
ggtggaatca gtgtttttaat cggattttta aaaaacattt tatttctttg tacaattacc 2340
atcctatgta aagatgaaat ttgtgttgag ttgaagattg tcatggaata aagatcacac 2400
cgtacttgag gccatcttca tgtaaaaaaaa aaaaaaaaaa aaaa 2444

```

<210> 300

<211> 1026

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1026)

<223> n equals a,t,g, or c

<400> 300

```

gctcctgcgc gctgacgtca ggtgcgtgcc cctgtccggc agccgaggag accccgcgca 60
gtgctgccaa cgccccgggtg gagaagctga ggtcatcatc agatttgaaa tatttaaagt 120
ggatacaaaa ctatttcagc aatgcagaca attaagtgtg ttgttggtgg cgatgggtgct 180
gttggttaaaa catgtctcct gatatcctac acaacaaaca aatttccatc ggaatatgta 240
ccgactgttt ttgacaacta tgcagtcaca gttatgattg gtggagaacc atatactctt 300
ggactttttg atactgcagg gcaagaggat tatgacagat tacgaccgct gagttatcca 360
caaacagatg tatttctagt ctgtttttca gtggtctctc catcttcatt tgaaaacgtg 420
aaagaaaagt ggggtgcctga gataactcac cactgtccaa agactccttt cttgcttggt 480
gggactcaaa ttgatctcag agatgacccc tctactattg agaaacttgc caagaacaaa 540
cagaagccta tcaactccaga gactgctgaa aagctggccc gtgacctgaa ggctgtcaag 600
tatgtggagt gttctgcact tacacagaaa ggcctaaaga atgtatttga cgaagcaata 660
ttggctgccc tggagcctcc agaaccgaag aagagccgca ggtgtgtgct gctatgaaca 720
tctctccaga gccctttctg cacagctggt gtcggcatca tactaaaagc aatgttttaa 780
tcaaaactaaa gattaaaaat taaaattcgt ttttgcaata atgacaaatg ccctgcacct 840
accacatgc actcgtgtga gacaaggccc ataggatagg cccccccctt cccctccca 900
gtactagtta attttgagta attgtattgt cagaaaagtg attagtacta tttttttttg 960
ttgtttcaaa aaaaaaattt ttgtgtgtgt gttttttttt tttttttttt tttgggggtt 1020
aaaaan 1026

```

<210> 301

<211> 830

<212> DNA

<213> Homo sapiens

<400> 301

```

tggtgatctg gactgtcccg actgggtcct ggcagaaatc agcacgctgg ccaagatgta 60
tgaraagatc ctgaagctca cggctgacgc caagtttgag tcaggcgatg tgaaggccac 120
agtggcagtg ctgagtttca tcctctccag tgcggccaag cacagtgtcg atggcgaatc 180
cttgtccagt gaactgcagc agctggggct gcccaaagag cacgcggcca gcctgtgccg 240
ctgttatgag gagaagcaaa gcccttgca gaagcacttg cgggtctgca gcctacgcat 300
gaatagggtg gcaggtgtgg gctggcgggt ggactacacc ctgagctcca gcctgctgca 360
atccgtggaa gagcccatgg tgcacctgcy gctggagggt gcagctgccc cagggacccc 420
agcccagcct gttgccatgt ccctctcagc agacaagttc cagggtcctcc tggcagaact 480
gaagcaggcc cagaccctga tgagctccct gggctgagga gaagggtgtt ccaggcctgt 540

```

```

gtggagccgc cctgcccgtg tggagtcacg ccctctgaac tgctcttcgg gaggcagccc 600
tggttctagg atgctgaggc cctggcccgg actctggcct cccagatccc cagctgcctc 660
acttctctct tgagaacttg gctcagggct cctgaggacc tttcccagca ttaccttccc 720
ttcccttgaa aggcaattgt tggctgtttt cataagcagg aaaaataaac agaagtataa 780
aggaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 830

```

<210> 302

<211> 3300

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1158)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3232)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3280)

<223> n equals a,t,g, or c

<400> 302

```

cagccgcgac agtctcaagg gcggcggcgc gctggagaag gagagccatc gccgctcgta 60
cccgc tcaac gccgccagcc taaacggcgc ccccaagggg ggcaagtacg acgacgtcac 120
cctgatgggc gcggaggtag ccagcggcgc ctgcatgaag accggactct ggaagagcga 180
aactaccgtc taaggtgggg cgggcgacgc ggtagacggg ctggccacgc ggctcgttcc 240
cccgc tccctc ggggccctcc aaggtgtctc cgtagtcagc aggttggagg cagaggagcc 300
gatggctgga ggaagcccac aggcggatgt tccccacttg cctagagggc atccctctgg 360
ggtagcgaca gacaatccca gaaacacgca taatacattt ccgtccagcc cggggcagtc 420
tgactgtcgg tgccctccca ggaacgggga aggcctccgt ctgtgtgaaa gggcacagca 480
catcccaggt gcaccctccc caagtactcc caccctccct actgtccatg cggcctcact 540
gggggccatc agcctcacca gcaaagcaga gatgagagcg tgggaactgt gttctttcct 600
ccctgcccct tactgatttc agcccagccc ctgcctagat cctaggtccc ttttccctcc 660
gagtttggct ggcacgagag ctagcccagc acatgaagca ggtgatgtta agtcacaagg 720
tgctgctttt cagatccact atgcaagagg ggagggtggg gccacgtgra aaggcagctc 780
tagacatcaa ccagtcctgg gggaggggag tgggaaccgg gcacaactag gaacaatgcc 840
accattccca caggagtggg acttaaacca gacagcaggg ttcagagggtg gcacacsagg 900
acaaagctga ggccctgcac ctcaacagct gactgccagg tgccctgtggg tgaactgagg 960
ggagtagagg gagagggcag gtggaactgg ggcagaatct agtcatgccc taaagctagt 1020
cctgtaaaca atggtgcccc agaaagctgc aggtggtgtt tggagaagca gttacttttc 1080
agttacaaga cccatctccc tagtctcagc cttacaacac cacgggacta aggaagagca 1140
cttcccttgc tccgtaangc cagaggaaga accatcccaa tcatttgatc tccagctcca 1200
cagtagagag aaacctacaa aatgtcaaac cagcttcccg actcccagga gctcaagcca 1260
agcccagagg cagtggctgg ggtccctgca ggtcatgagg ggccatagcc tttactcctt 1320
ttaaacacca gcaccctgtc tttcccacac ctaaaaccaa ccaccagcat ttcactacag 1380
gaccaaatgg aaaccgaggg aaccctgggt cttgggaaga acaacaggaa accaaggtct 1440

```

```
gacctaggggt tccctcccag tcttcacatc actctggcct catcaccaag gtgacagagg 1500
acacagggga gggggaaaac ccacacacac tccttggaat gggtcctggt atttatgctt 1560
gctgcacaga catattagaa gaaaaaaaaa agctttgtat tattcttcca catatgctgg 1620
ctgctgttta cacaccctgc caatgcctta gcactggaga gctttttgca atatgctggg 1680
gaaaggggag ggaggggaatg aaagtgccaa agaaaacatg tttttaagaa ctcggtttt 1740
atacaataga atgttttcta gcagatgcct ctgtttttaa tatattaaaa ttttgcaaag 1800
ccctttgagc tactgcctta gtctaccac tgctcttttg ttatgaggta gaggatctca 1860
tgacaccata cacacaaacc catcattgcc tgtgaatgca cgtagggcca gaattcccca 1920
gttcccgtc ctctgagggt tgatactgct gggaatgcca accactccac aagcagagg 1980
aagccccctc aggcctgcag gaggagccgc agcagtgtgt ccaattcaaa ccagcagcaa 2040
agagcctgac attttcccat ccatctatga ggaaagccat ctacagaaac atggacatag 2100
gcaacttgct ctccacacc aagggatggg aatctctcct acctatagtc atccctgcac 2160
tcctgacttt actccaggac ccagggtcca actaatggca gagccccctc tggttccttc 2220
aaacaagaaa agcaatacct acggactggg gtacacttcc atccttggtt ataacaggaa 2280
tgttatcaag ctgtcagaac aggatgaagt gctcccagtg gatatccatc agggagggtt 2340
agggacactc gtggcagcct gtctagcagc ctgggctctc tgaaagtccc taacttcttg 2400
aggggtacgc aaatactgtt ctattttact atcagaaatg ttctcatctc cagtgcagct 2460
ggagacaggg ggtacagggc agatccgctt cggggacttc aacatgcagg gtggcaagar 2520
aagggcagga ctggccggcc gcttcccctg gggtaaacct aaggaattrk ttcmcacctc 2580
cccttctcct tgcccctgtc cccactccgg tggctccttc tctcgggtct ccacttctgc 2640
tgtcccatcc cgaaaggcag agcggaccag tgactggcgg tgctggagaa ggtcaccgat 2700
gtgcttcacc acagaccgtt tgtcaagtct cagaactcgt aaccaggcca gctgctcagc 2760
catccgcagc agcacagcca gcagctcctg caggcgggag gacgccgggt agggcaggctc 2820
cacatttgcc aatttcaaaa atcgggcaag ggaacatgaa agccgatctg caggctgcag 2880
cgactgcaa gccaggaaaag tcgcagcagt gatgacgggc aagggatgcc tcccggtcac 2940
cagccacgtc tcatttgcca gctccacca ctgcattgtt cgagacagca tcttctcttt 3000
gtcttccacg tatttggtg gcacagaagg tgaagcttg aacagtttga agctgaaata 3060
acaaaaatga ggggttgatc ttaatgatat aggggctgct ctccacagc gaggaaagac 3120
agcccactca agatggggaa gctattctgc cctcaggaat actcaagctc actgggcagc 3180
aagttaataa aggtagttag agaaaacagg gcgtcttccg cttgttaggg gnagggtggaa 3240
ggatggagga gaaccacgaa catttattgg gccgctcccn atccacatta ttctgagtgc 3300
```

<210> 303

<211> 475

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (444)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (451)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (454)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (470)

<223> n equals a,t,g, or c

<400> 303

```

caaagaattc ggcacgaggt ctgatcttcc tgcggctgaa ccgcccggct gagccgacat 60
tgccggcgtc ttggcgattc ggcccgcacga gctccgcttt cgctacagca tgggtggccta 120
ctggagacag gctggactca gctacatccg atactcccag atctgtgcaa aagcagtgag 180
agatgcactg aagacagaat tcaaagcaaa tgctgagaag acttctggca gcaacgtaaa 240
aattgtgaaa gtaaagaagg aataatctac cctgactaaa gcttgaaatg ctacatttcc 300
aaggtgaaga tgtgtgggca catgttatgg cagattgaaa aggatctcat tccatgggaa 360
aaaaaaaaat cctgtcttgt tcataaattg acaatgtcaa taaattgaaa tatggttcac 420
tgttaaaaaa aaaaaaaaaa aaangggggg nccnttttaa agaatccaan ttctac 475

```

<210> 304

<211> 2902

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2888)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2891)

<223> n equals a,t,g, or c

<400> 304

```

ttacatgcta atcaagtgat ccacagagac atcaaaagtg acaatgtact tttgggaatg 60
gaaggatctg ttaagctcac tgacttttgg ttctgtgccc agatcacccc tgagcagagc 120
aaacgcagta ccatggtcgg aacgccatac tggatggcac cagagktggt tacacggaaa 180
gcttatggcc cttaaagtca catatggtct ctgggtatca tggctattga gatggtagaa 240
ggagagcctc catacctcaa tgaaaatccc ttgagggcct tgtacctaat agcaactaat 300
ggaaccccag aacttcagaa tccagagaaa ctttcccaa tatttcggga tttcttaaat 360
cgatgttttg aaatggatgt ggaaaaaagg ggttcagcca aagaattatt acagcatcct 420
ttcctgaaac tggccaaacc gttatctagc ttgacaccac tgatcatggc agctaaagaa 480
gcaatgaaga gtaaccgtta acatcactgc tgtggcctca tactcttttt tccattttct 540
acaagaagcc ttttagtata tgaaaattat tactcttttt ggggttttaa gaaatggtct 600
gcataacctg aatgaaagaa gcaaatgact attctctgaa gacaaccaag agaaaattgc 660
aaaaagacaa gtatgacttt tatatgaacc cttcttttag ggtccagaag gaattgtgga 720
ctgaatcact agccttaggt ctttcagcaa acagcctatc agggccattt atcatgtgtg 780
agatttgcat tttactttgc tgactttggt gtaatagatc ccattcattg tcccctttgg 840
ggtatttcca atacttgaat ggcagattgg agtttttcag agtatgtgtt tcatctgcta 900
gtctttctct cttcatagc ttttcttttc ctggacttgc tccttttgag ttgcttttgc 960
gtttctcatg cctaggcaag tgtaatagaa attatgtagc tccttatgtt ggcaaaggag 1020
ctctatatag tttcactttg tataaaagtt aggaccagct gttgtttacat gtaatatatt 1080
agttcagaac ttgacctgaa ggaagggaag aaaagtatgt gattttttacc ttttttaaca 1140

```

```

aatgtgaaaa agtcagtttt agaaatttcg tggtagtaag ttcggcattt gttacatgta 1200
tagagagaag actaataatc tctattttata actaaatcat tgagatagaa aaagattccc 1260
attgactgta gacttcttcc cattttgtct tcccttctgc ctgtttcccc ttcaggcttg 1320
gctctaggaa ccaaagtgat ttgttggtgt tccaacctgg gctttgtgac tttggttagt 1380
gccactacct tcttccctcc tttccccctt caatttgga ataaatttct gtatatgttg 1440
caatttttagg tttaggtttg ttctttttct ttttcattaa tcctctctca cctcacagat 1500
acccccctcc atggcaaata atataataac cagtgaattt tcaggaattt aaaaatttagc 1560
ttttttccac tttaaaggaga aaaatatttg ggactagcag cagaggcagt aagagatgtg 1620
aaccttggtg agctctgata cagtgagaag agattatact catgaaagag aatgttagt 1680
ttacagagaa gcagccgata gcaaatcrac tgtagagact tggcggcggt ggcattgccc 1740
caggctgtca gcagtgtggt attatctatg agaacttgag cgacagagta tttcttgatg 1800
aatttataga tcatttgaga tgttgagtta ctttagttta gttttgtttt gttttttcaa 1860
ataagtagag actattgtaa aaaacgagaa aggaaaatga aatgtgcgtg ttgatagcaa 1920
taatttgttt cttttaaaga ttctaaaagg tctgagacct gtagcattaa ttatttgagt 1980
gccccctctt cccccctccc ctcccttttc tcttctcttt tttcctctcc tctycttctc 2040
ctttattcat tgttttgctt ttggagtrgg tgttgttcaa gtatctgtgg tttggttctg 2100
gcattttggt cccaccatcc ccttccccca ttaacttccc ccctgcttgc catcctgcag 2160
tagtataaat catgaataaa aaataatttt gctgttgtag tatacattgg agaaactggc 2220
aggttttatt tccattattt tatttccact atatctatga taagatgcaa ttataaggag 2280
agaagtgact gttttttatt gataaggcaa gattttcaga aaaatgagta aaataattaa 2340
tgaaacatat ttagagcact taatggctct tgttttcaat ataattcttg atttcatttt 2400
tctctggaat atattggcct tctacagcta ttactgaatt atagaaactg gtttatttct 2460
ggcagaaagc tgcagtgcc cctgagttcc aaattttacc attctttgta aacagttgga 2520
tggattatga taaagaagat gctaccaatg aaatagaaaa ccaacgagat gagaagactg 2580
tgatcctcat gtactcagag gcacttccct cctaagtcaa agaccatcct cactgactat 2640
gtgccaacgc ctcgtttcag gcttgtagct caacaaaggg cttttccatt gatagaagca 2700
gtttgggatt tgtagttgcg acttcttcga tagttacctg cacgtccatt gctggcaact 2760
gacttgatcat taaaacctgg ctctttggtt aagggagcta cgctgtggtt tattcttaag 2820
ttacgtggat aaactaacct ctaacagaaa tatacttttg ttaattttga aaaaaaaaaa 2880
aaaaaacncg ngggggggcc cg 2902

```

<210> 305

<211> 1553

<212> DNA

<213> Homo sapiens

<400> 305

```

ggcgacgcgg tatttgaatc ctggaacaar gctacagcgt cgaagatccc cagcgctgcg 60
ggctcggaga gcagtcctaa cggcgccctg tacgctagtg tccctccctt tcagtcgcg 120
tccctccctg ggccgggctg gcactcttgc ctcccccgtc cctcatggcg ctgctccgac 180
gccgacgggt gtccagtgat ttggagaata ttgacacagg agttaattct aaagttaaga 240
gtcatgtgac tattaggcga actgttttag aagaaattgg aaatagagtt acaaccagag 300
cagcacaagt agctaagaaa gctcagaaca ccaaagttcc agttcaaccc accaaaacaa 360
caaatgtcaa caaacaactg aaacctactg cttctgtcaa accagtacag atggaaaagt 420
tggctccaaa gggctccttct cccacacctg aggatgtctc catgaaggaa gagaatctct 480
gccaaagctt ttctgatgcc ttgctctgca aaatcgagga cattgataac gaagattggg 540
agaacctca gctctgcagt gactacgtta aggatatcta tcagtatctc aggcagctgg 600
aggttttgca gtccataaac ccacatttct tagatggaag agatataaat ggacgcatgc 660
gtgccatcct agtggtattg ctggtacaag tccactccaa gtttargctt ctgcaggaga 720
ctctgtacat gtgcgttggc attatggatc gattttttaca ggttcagcca gtttcccggg 780
agaagcttca attagttggg attactgctc tgctcttggc ttccaagtat gaggagatgt 840

```

```

tttctccaaa tattgaagac tttgtttaca tcacagacaa tgcttatacc agttcccaaa 900
tccgagaaat ggaaactcta attttgaaag aattgaaatt tgagttgggt cgacccttgc 960
cactacactt cttaaggcga gcatcaaaaag ccggggaggt tgatgttgaa cagcacactt 1020
tagccaagta tttgatggag ctgactctca tcgactatga tatggtgcat tatcatcctt 1080
ctaaggtagc agcagctgct tcctgcttgt ctcaagaagg tctaggacaa ggaaaatgga 1140
acttaaagca gcagtattac acaggataca cagagaatga agtattggaa gtcatgcagc 1200
acatggccaa gaatgtggtg aaagtaaatg aaaacttaac taaattcatc gccatcaaga 1260
ataagtatgc aagcagcaaa ctctgaaga tcagcatgat ccctcagctg aactcaaaaag 1320
ccgtcaaaga ccttgccctc ccactgatag gaaggctccta ggctgccgtg gcccctgggg 1380
atgtgtgctt cattgtgcc ttttcttat tggtttagaa ctcttgattt tgtacatagt 1440
cctctggtct atctcatgaa acctcttctc agaccagttt tctaaacata tattgaggaa 1500
aaataaagcg attggttttt cttaaggtaa aaaaaaaaaa aaaaaaactc gag 1553

```

<210> 306

<211> 1987

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (731)

<223> n equals a,t,g, or c

<400> 306

```

cagtcaaatg cagtctggct tcttggacat ctctcatctat ctactctatc ctcaagtcaa 60
agtagagcct ctgttcctac tgactatagc tacttgccctg aaagcagttt tattggagca 120
gctattggct tcttcattac aggaggaaaa aaaggctcctg aatctgtgcc tccttccctt 180
cttaaagtag tgatgaaacc catagcaact gttggagaaa gctaccaata tcctcctgtg 240
aactgggctg cacttctctc tccacttatg aggctaaatt ttggtgaaga gatccagcaa 300
ctgtgccttg aaattatggg gaccagggca cagtcatccc agaatgcagc tgcactattg 360
ggcttgtggg tgacaccacc actgatccac agtctgagtc tgaataccaa gagatatctc 420
ctgatatctg cacctctgtg gataaaacac atctctgatg aacagatcct gggttttgtt 480
gaaaatttaa tgggtggcagt ttttaaagca gcttccccac ttggaagtcc tgagctatgc 540
ccaagtgctt tacacggtct gagccaggcc atgaaactgc ccagccctgc ccaccacctc 600
tggagtctgc tctctgaagc tactgggaaa atttttgacc tcctgccaaa taagattcgg 660
agaaaggatc tagagctgta tatcagcata gcaaaatgcc tcttagaaat gacagatgat 720
gatgccaatc nggatcgccc aggttactaa gagcaacata gaaaaagctg ctttgtcaa 780
actgtactta gtctctcaag gacgattccc ctgggtgaac ctgaaccgat atgctgagcg 840
ttgctgtgca gcaccgtgag aaagaggtgt tggcctggat gattctgcac agcttatacc 900
aggcacggat tgtgagccat gccaatacgg gcgttttgaa gagaatggag tggctcttgg 960
aactgatggg ttatattaga aatgttgctt accagtcac atcctttcac aatacggctc 1020
ttgacgaggg tttggaactt ttcttgctga tatttgcaac cgcagtgggt gcatgggctg 1080
accacactgc ccttctctc ctccggctca gtgccagttg gttgccatgg catcaggaga 1140
atggcccggc tgggccagta ccaagcttcc ttggcaggag tccaatgcac agggctactc 1200
tgcaggaggt tctcactctc cttccaata gcatggctct gctgctgcag aaagagccat 1260
ggaaggaaca gaccagaag ttcattgact ggctattcag catcatggaa agccctaaag 1320
aagccctctc agcacagtcc agggatcttt tgaaagccac cctgctgtcc ttgagagttc 1380
tcccagagtt taagaagaaa gctgtatgga ccagagcata tggttggtga acagttttgc 1440
agtaaccagc agcattctca gctggatgag gaaaaccata taagtgaag aagtttttca 1500
gaattcatgc ctggtattgc tgagacatga tgcagagagt taagggtcat gaaaagatgg 1560
ccacatcact gacagcttga cacatgcctc ctaagagagg agtgcattgc tttagtacc 1620

```

```

gggccagttg agactgaaac aggaacttgg attttcttta tttggcttga gttcaatgtg 1680
gagattttct ttgtgaaagc ttgaagatat tatcttctcc ctgctaaatt ccagtaaaat 1740
aatgttgtca attttgtgcg tgtgactttt gttttaaggc atgggggaag gtgccagaac 1800
cacttggtga caatggcatt atgatctatt ttccatgaat ctccatgagg atattcattg 1860
actcagtga ttagacaaat ttccttattg ataaaacact ctcttggaac tgctatacac 1920
atttaaataa taagcataac attgaatatt agctaaatca gattcattaa tgggtgtctat 1980
catttcc 1987

```

<210> 307

<211> 785

<212> DNA

<213> Homo sapiens

<400> 307

```

gcgcgacccg ccccgctccg tccagtctgg cctgggcgcc gcgggaacgc tgcctgggt 60
gccgccaccc gaacagcctg tcctgggtgcc cgggctccct gcccgcgcc cagtcatgac 120
cctgcgcccc tcactcctcc cgctccatct gctgctgctg ctgctgctca gtgcggcggt 180
gtgccggggt gaggtctggc tcgaaaccga aagtcctcgc cggaccctcc aagtggagac 240
cctggtggag ccccccagaac catgtgccga gcccgctgct tttggagaca cgcttcacat 300
acactacacg ggaagcttgg tagatggacg tattattgac acctccctga ccagagaccc 360
tctggttata gaacttggcc aaaagcaggt gattccaggt ctggagcaga gtcttctcga 420
catgtgtgtg ggagagaagc gaagggaat cattccttct cacttggcct atggaaaacg 480
gggatttcca ccactctgtc cagcggatgc agtgggtgcag tatgacgtgg agctgattgc 540
actaatccga gccaaactact ggctaaagct ggtgaagggc attttgcctc tggtagggat 600
ggccatggtg ccagccctcc tgggcctcat tgggtatcac ctatacagaa aggccaatag 660
acccaaagtc tccaaaaaga agctcaagga agagaaacga aacaagagca aaaagaaata 720
ataaataata aatttttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780
aaaaa 785

```

<210> 308

<211> 2178

<212> DNA

<213> Homo sapiens

<400> 308

```

ggcagaggrc gggaagaccg agtggctctt tggcatggat gagggccgga aacagctggc 60
ggccagtgtt ggcttcagga ggttgattac agtggccctt caccgaggtc agcagtatga 120
aagcatggac cacatccaag ctgagctgtc rgctagagtc atggagctgg cccagctgg 180
gatgcccacc cagcagcagg tcccctttct gtctgtgggt ggggacattg gggctccggac 240
cgttcagcac caagactgca gcccttgag cggtgactat gtcattgagg atgtgcaagg 300
ggatgacaag cgatacttcc gtcgactgat cttcctcagc aacaggaatg tgggtgcagtc 360
cgaagccagg ttgctgaagg atgtgtctca caaagcccag aagaagcggg aaaaggacag 420
gaagaagcag cggcctgtgt atgcggagga cctccctgca gccccggggc agtccattga 480
taagaggtac ctgtgttgtg aacaccacaa agccatgacg gctggccttg ccctgctgag 540
aaaccagag ctactcctag agatcccact ggcatgtgtg gtggtaggcc tgggcggggg 600
cagcctcccc ctctttgtcc acgatcattt tccaaagtcc tgcatgtgat ctgtggagat 660
cgatccctcc atgttgggaag tggccaccca gtggtttggc ttctcccaga gtgaccgaat 720
gaaggtccac attgcagatg gcctggacta tatcgccagc ttggcaggag gaggagaagc 780
acggccttgc tacgatgtca taatgtttga tgttgacagt aaggacccaa cactgggaat 840
gagttgtccg ccccccagcat ttgtggagca atcttttcta cagaaggtta aaagcatctt 900
gactcctgaa ggtgttttta ttctcaacct tgtgtgccga gacttggggc taaaagactc 960

```

```

agtgtctggct gggctcaagg cagtgttccc cctcctatat gtccggcgaa ttgaggggtga 1020
agtgaatgag atcctgttct gtcagctgca ccctgagcaa aaacttgcca caccagagct 1080
cctagaaaaca gcccaggctt tggagcggac cctgaggaag cctgggaggg gttgggatga 1140
cacgtatgtc ttgtcagata tgctcaagac ggtgaaaatt gtgtgactgc ttaggccaaag 1200
cagccctcct gcctagactg accttggaact cccagcctgc cagagaatga agaaatacaa 1260
cgcacagtac ttttgaagct tcgtattttt cttggtttca cactcagcta catgtgacct 1320
ccagcttggg gaggttgccct gaagattagg gaaaataaaa atgtccttcc catcttgtcc 1380
tcttcagtac cacttgggtt gggttgtcct tgcttcctac accacgtcct tgagtggagt 1440
tccctgctga agcccctagc acacactgca tgccttaaca agtgtgtgca agcccctcag 1500
aactcaagac atccaaattt tattgcgtct ctacttatac tgggttgctt ttgattttatt 1560
cctctatttag ttctatagga gtgatctcaa gtgagatagc agagcaagat gccaaaagac 1620
cataaataga gtaagggtttc tatagatgtg agacagattt gagagagcat ttactctgtc 1680
tccctgtgga tgaaactgct gctgaaatgg ttccaatttt taggaatctg cttaccact 1740
tcattatttg acagctttcc ttggtgacct aaaccttgta gcctaagcca tttgtctttt 1800
tctcagtgga gggagtgtat ggacctggcc ccatggcttt gcatgttaga gacctggcag 1860
actaaagtct ctagtgtttg tttgctcaca tttgtgtagt gacagctatg tgccagactg 1920
cataaagggg ggtggcagaa gtgaaaatgt ttaagaatga ccaaaaacat tagtaatgaa 1980
agttaatgtg ttccaggcat tcttctaagt ggtttacatg cactgtctca tttaatctga 2040
gataaaggat acttaagccc aaactatatc taaacccaaa tctcacttgg ctggaaacat 2100
caatcttaac catttattca gaaccattaa accaatgatt ccaaaaaaaaa aaaaaaaaaa 2160
aaaaaaaaaa aactcgta 2178

```

<210> 309

<211> 875

<212> DNA

<213> Homo sapiens

<400> 309

```

caagctcctg tggccacctg tgtcccagca gcagtgagtg gagctgctca ggggtgccctc 60
tcctgcggac cagtctctga atgttcaaag atgagggcct ggcttccgtg ctctggcttt 120
gtaacttata tggaagggaag agcacatgcc ttcacgggca gggatatgtt cttttcttct 180
cggggtgttg acttgcatte ctgtgtgaac tgttccctct gccatgttta ccgtgtgatg 240
ttctgtagtt gaaaatgtta gttgtctgct ggcacagaat ttatctcgtt cttttctctc 300
ccttctctcc tccaaatcag tctcttccct tctccactag ataactgtaa aaccttttcc 360
tggggtacat acattcggtt aytcttgggc agtggtgagc acgagatgac tttctgcagc 420
gtttatcact gttgggtgga gtcacgtccc ttccctccac cgaagtcata aaccagatag 480
ggaagggaaa gatgaggccc agaaaacgag ttcaaactct aggtcttgta cacgtatgta 540
agtaaatgtc aataacccaa gcctttgtca tagcagtcac ttggttgact taggatctgg 600
gtctgttgaa ttttgtgctt gggaatggag ctggagggag tggggcctgt gtacagcagc 660
tacctctccc aggtcctctc acttgcctgc cccgcgtcct ggttgcatgg ccgcacctgt 720
gtgtgtgcag aggtctgtgt cccatcctct gcacctcct tccggggggc tggggagccc 780
cacgtgttgc caagatcttg gtgcaataaa atactccgtt tttgtgaaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 875

```

<210> 310

<211> 756

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (613)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (638)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (684)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (756)
 <223> n equals a,t,g, or c

<400> 310
 atttagggtga cackatagaa ggtcgccctgc aggtaccggt ccggaattcc cgggtcgacc 60
 cacgcgtccg ggcccgtggc gccgacagga tgggcaagtgc tcgtggactt cgtactgcta 120
 ggaagctccg tagtcaccga cgagaccaga agtggcatga taaacagtat aagaaagctc 180
 atttgggcac agccctaaag gccaacccctt ttggagggtgc ttctcatgca aaaggaatcg 240
 tgctggaaaa agtaggagtt gaagccaaac agccaaattc tgccattagg aagtgtgtaa 300
 ggggtccagct gatcaagaat ggcaagaaaa tcacagcctt tgtacccaat gacggttgct 360
 tgaactttat tgaggaaaat gatgaagttc tgggttgctgg atttgggtcgc aaaggtcatg 420
 ctggttggtga tattcctgga gtccgcttta aggttggtcaa agtagccaat gtttctcttt 480
 tggccctata caaaggcaag aaggaaagac caagatcata aatattaatg gtgaaaacac 540
 tgtagtaata aattttcata tgccaaaaaa aaaaaaaaaa aaaaaaaagg gsgggcscyc 600
 taaaagatcc tcnaagggcc aagcttacgc tgcatgcnac tctactctct cctatatgaa 660
 tctattataa ctagcctggc ctcnttacac tctgatggaa ttctactgga ttttaagact 720
 atcttggttat atgacactct caaataacca gtattn 756

<210> 311
 <211> 851
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (834)
 <223> n equals a,t,g, or c

<400> 311
 ctattggtgt gaacagtgtg atgtacaatt ctccctcaagc agtgaactct acctacattt 60
 ccaggagcac agctgtgatg aacagtactt gtgtcagttc tgtgaacatg aaactaatga 120
 tccagaagac ttgcatagcc atgtggtaaa tgagcatgca tgtaaattaa tagagttaag 180
 tgataagtat aacaatgggtg aacatggaca gtatagcctc ttaagcaaaa ttacctttga 240
 caaatgtaaa aacttctttg tatgtcaagt atgtggtttt cggagtagac ttcacacaaa 300
 tgtaaacagg catgttgcta ttgaacatac aaaaattttt cctcatgttt gtgatgactg 360
 tgggaaaggc ttttcaagta tgctagaata ttgcaagcat ttaaattcac atttatctga 420

```

agggatttat ttatgtcaat attgtgaata ttcaacagga caaattgaag atcttaaaat 480
tcacttagat ttcaagcatt cagctgactt gcctcataaa tgtagtgact gcttgatgag 540
gtttggaaat gaaagggaat taataagtca ccttccagtc catgagacaa cttgattatt 600
ctctttaact tacagaatgt tagtttaaaa taataaattc atcctttttt tggagatgat 660
taaattggatg attgtaaaca caacttatga aatctgcctt taacaagtaa ctttttttaa 720
ttataaaaatt ttattggcat tgctccattt tctgtatata aatataatctt taatgtggta 780
ttttcaaaaa aaaaaaaaaa aaaaaaatcc acgcggccgc gaattcccgc gtznaacaag 840
ctcactaatc c 851

```

<210> 312

<211> 1335

<212> DNA

<213> Homo sapiens

<400> 312

```

cagaaccgca ccagcagcca accttgccag caggattcct gcagcctctg cggcagccat 60
gaacctagcc agcaaaggag cggcggagtt cctcctcgtc gtcgtcgtcc tctagctcct 120
cctcctcttc atcatcgctg tcgtcgtcct cctcctcctc tggctccagt tctagtact 180
cagagggctc tagccttcct gtgcaacctg aggtggcact gaagagggtc cccagcccca 240
ccccagcccc aaaggaggct gttcgagagg gacgtcctcc ggagccaacc ccagccaaac 300
ggaagaggcg ctctagcagt tccagttcca gctcctcctc ttcactctcc tcctcctcct 360
cctcctcctc ttcttctctc tcctcttctc cttcttcttc ttcctcctca tcttctcct 420
cctcgtcgtc ttcctccctc tcccctgcta agcctggccc tcaggcttgc ccaaacctgc 480
aagccccaag aagccacccc ctggcgagcg gaggtcccgc agcccccgga agccaataga 540
ctccctcagg gactctcggg cctcagcta ctgcctgtg gagcgtcgcc gtccctcgcc 600
ccagccctca ccacgggacc agcagagcag cagcagtgag cgggggtccc ggagaggcca 660
gcgtggggac agccgctccc ccagccacaa gcgcaggagg gagacaccta gccctcggcc 720
catgagacac cgctcctcca ggtctccata aattgtcttt gggggattcc accacaccca 780
atgctctgga gccacaagga gtgtcccttc tccccagca gagccgtggg agggtccttg 840
tctgctctcc tttgaacctt ggcagccctt ggatggaggg ctccctttcc ctcccttttt 900
ttttttcttt gttcctgtga aatgttaatc tccgtgagtt cttcctggtt catgtgttct 960
gggggggttg ggttgggagg gaatgcagat gggagtggg ggaggggagg atacagttca 1020
ggatacccca gcctggagtc agggccaggg aggcattggc ccacttgat ccagaagttc 1080
ccaggggtga ttgtgatggt ggttgggact ggaggttgta taaggtgttc ttggaaggaa 1140
ggggcaggag ttggaattag ttggtcccta ctgtcccca tgaggttggt aaccctccc 1200
cccaactttt catgtttctt aaaggcattt tggtttttta aaatctgtac agcaagagca 1260
actttttctg tcaataaaaa atgagaaatg caggaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaa 1335

```

<210> 313

<211> 516

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (505)

<223> n equals a,t,g, or c

<400> 313

```

tcgaccacg cgtccgaaca tggcggcggg agtgtccgcg gtggtggcgg tgcaagagag 60

```

```

ctgagggagg cgcgagggcg cggagttcca ggtcgagcag ttaggccgcg agcgactgcg 120
gcgcccagcc gatgagtaac ccgaagcccc tagaggagtg gtcacctgcc tgagggcact 180
tctgtcccac cagcatcaga ccaggccgca ccgagtcccc ggcaccatgt ttgggaagag 240
gaagaagcgg gtggagatct ccgcgccgtc caacttcgag caccgcgtgc acacgggctt 300
cgaccagcac gagcagaagt tcacgggggt gccccgccag tggcagagcc tgatcgasga 360
gtcggctcgc cggcccaagc ccctcgtcga ccccgccctgc atcacctcca tccagcccgg 420
ggcccccaag accatcgtgc ggggcagcaa argtgccaaa gatggggccc tcacgctgct 480
gctggacgag tttgagaaca tgttngtgac acgctt 516

```

<210> 314

<211> 1833

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (625)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1761)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1766)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1792)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1806)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1827)

<223> n equals a,t,g, or c

<400> 314

```

tcgacccacg cgtccgcagc cgtcgcccca cgaggcgcga ccgctgcagg cgctgctgga 60
cggccgcggg ctctgcgtca acgctagtgc cgtcagccgc ctgcgcgcct acctgctgcc 120
agcgccgcca gctccaggaa atgctagtga gtcggaggaa gaccgcagcg ccggcagtgt 180
ggagagcccc tccgtctcca gcacgcaccg ggtgtctgat cccaagtcc accccctcca 240
ttcaaagata atcatcatca agaaagggca tgctaaagac agccagcgct acaaagttga 300
ctacgagtct cagagcacag ataccagaa cttctcctcc gagtccaagc gggagacaga 360

```

```

atatggtccc  tgccgtagag  aaatggaaga  cacactgaat  cacctgaagt  tcctcaatgt  420
gctgagtcctc  aggggtgtac  acattcccaa  ctgtgacaag  aagggatttt  ataagaaaa  480
gcagtgtcgc  ccttccaaag  gcaggaagcg  gggcttctgc  tgggtgtgtg  ataagtatgg  540
gcagcctctc  ccaggctaca  ccaccaaggg  gaaggaggac  gtgcaactgc  acagcatgca  600
gagcaagtag  acgcctgccc  caagnttaat  gtggagctca  aatatgcctt  attttgaca  660
aaagactgcc  aaggacatga  ccagcagctg  gctacagcct  cgatttatat  ttctgtttgt  720
ggtgaactga  ttttttttaa  accaaagtgt  agaaagaggt  ttttgaaatg  cctatgggtt  780
ctttgaatgg  taaacttgag  catcttttca  cttccagta  gtcagcaaag  agcagtttga  840
atcttcttgt  cgcttcctat  caaaatatct  agagactcga  gcacagcacc  cagacttcat  900
gcgcccgtgg  aatgctcacc  acatgttggt  cgaagcggcc  gaccactgac  tttgtgactt  960
aggcggctgt  gttgcctatg  tagagaacac  gcttcacccc  cactccccgt  acagtgcgca  1020
caggctttat  cgagaatagg  aaaaccttta  aaccccggtc  atccggacat  cccaacgcat  1080
gctcctggag  ctacagcct  tctgtggtgt  catttctgaa  acaaggcgt  ggatccctca  1140
accaagaaga  atgtttatgt  cttcaagtga  cctgtactgc  ttggggacta  ttggagaaaa  1200
taagggtggag  tcctacttgt  ttaaaaaata  tgtatctaag  aatgttctag  ggactctgg  1260
gaacctataa  aggcaggtat  ttcgggccct  cctcttcagg  aatcttctg  aagacatggc  1320
ccagtcgaag  gcccaggatg  gcttttgctg  cgccccctg  gggtaggagg  gacagagaga  1380
caggagaggt  cagcctccac  attcagaggc  atcacaagta  atggcacaat  tcttcggatg  1440
actgcagaaa  atagtgtttt  gtagttcaac  aactcaagac  gaagcttatt  tctgaggata  1500
agctctttta  aggcaaagct  ttattttcat  ctctcatctt  ttgtcctcct  tagcacaatg  1560
taaaaaagaa  tagtaatatc  agaacaggaa  ggaggaatgg  cttgctgggg  agcccatcca  1620
ggacactggg  agcacataga  gattcaccca  tgtttgttga  acttagagtc  attctcatgc  1680
ttttctttat  aattcacaca  tatatgcaga  gaagatatgt  tcttgttaac  attgtatata  1740
acatagcccc  aaatatagta  ngrtcntata  ctagrtwaty  cctgggtgga  angtttgga  1800
ggtgcntttt  tggataccac  tttgggncc  gga  1833

```

<210> 315

<211> 1354

<212> DNA

<213> Homo sapiens

<400> 315

```

ggtgagagcg  cgcgcttgcg  gacgcgsgg  cattaaacgg  ttgcaggcgt  agcagagtgg  60
tcgttgtctt  tctaggtctc  agccggtcgt  cgcgacgttc  gcccgctcgc  tctgaggtc  120
ctgaagccga  aaccagctag  actttcctcc  ttcccgctg  cctgtagcgg  cgttgttgcc  180
actccgccac  catgttcgag  gcgcgcctgg  tccagggtc  catcctcaag  aaggtgttgg  240
aggcactcaa  ggacctcatc  aacgaggcct  gctgggatat  tagctccagc  ggtgtaaacc  300
tgcagagcat  ggactcgtcc  cacgtctctt  tgggtgcagct  caccctgcgg  tctgagggct  360
tcgacaccta  ccgctgcgac  cgcaacctgg  ccattggcgt  gaacctcacc  agtatgtcca  420
aaatactaaa  atgcgccggc  aatgaagata  tcattacact  aagggccgaa  gataacgcgg  480
ataccttgcc  gctagtattt  gaagcaccaa  accaggagaa  agtttcagac  tatgaaatga  540
agttgatgga  tttagatgtt  gaacaacttg  gaattccaga  acaggagtac  agctgtgtag  600
taaagatgcc  ttctggtgaa  ttgacagta  tatgccgaga  tctcagccat  attggagatg  660
ctgttgtaat  ttcctgtgca  aaagacggag  tgaaattttc  tgcaagtgga  gaacttgaa  720
atggaaacat  taaattgtca  cagacaagta  atgtcgataa  agaggaggaa  gctgttacca  780
tagagatgaa  tgaaccagtt  caactaactt  ttgcaactgag  gtacctgaac  ttctttacaa  840
aagccactcc  actctcttca  acggtgacac  tcagtatgtc  tgcagatgta  ccccttggtg  900
tagagtataa  aattgcggat  atgggacact  taaaatacta  cttggctccc  aagatcgagg  960
atgaagaagg  atcttaggca  ttcttaaaat  tcaagaaaat  aaaactaagc  tctttgagaa  1020
ctgcttctaa  gatgccagca  tatactgaag  tcttttctgt  caccaaattt  gtacctctaa  1080
gtacatatgt  agatattgtt  ttctgtaaat  aacctatttt  tttctctatt  ctctgcaatt  1140

```

```

tggttaaaga ataaagtcca aagtcagatc tgggtctagtt aacctagaag tattttttgtc 1200
tcttagaaat acttgtgatt ttataatac aaaaggggtct tgactctaaa tgcagtttta 1260
agaattgttt ttgaatttaa ataaagttac ttgaatttca aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1354

```

<210> 316

<211> 2421

<212> DNA

<213> Homo sapiens

<400> 316

```

ggcacgagct cttctgggcg tgggagaag tttctgtctat cagtgtctgag agaaaggaaa 60
gaaacaagtt tgctctcagc ggatctttta atggatgaga tggctaccac tcagattttcc 120
aaagatgagc ttgatgaact caaagaggcc tttgcaaaag ttgatctcaa cagcaacgga 180
ttcattttgtg actatgaact tcatgagctc ttcaagggaag ctaatatgcc attaccagga 240
tataaagtga gagaaattat tcagaaactc atgctggatg gtgacaggaa taaagatggg 300
aaaataagtt ttgacgaatt tgtttatatt tttcaagagg taaaaagtag tgatattgcc 360
aagaccttcc gcaaagcaat caacaggaaa gaaggatttt gtgctctggg tggaaacttca 420
gagttgtcca gcgaagggaac acagcattct tactcagagg aagaaaaata tgctkttgtt 480
aactggataa acaaagcttt ggaaaatgat cctgattgta gacatgttat accaatgrac 540
cctaaccacc atgacctgtt caaagctgtt ggtgatggaa ttgtgctttg taaaatgatt 600
aacctttcag ttcttgatac cattgatgaa agagcaatca acaagaagaa acttacaccc 660
ttcatcattc aggaaaactt gaacttggca ctgaactctg cttctgccat tgggtgtcat 720
gttgtgaaca ttggtgcaga agatttgagg gctgggaaac ctcatctggg tttgggactg 780
ctttggcaga tcattaagat cggtttggtc gctgacattg aattaagcag gaatgaagcc 840
ttggctgctt tactccgaga tggtgagact ttggaggaac ttatgaaatt gtctccagaa 900
gagcttctgc ttagatgggc aaactttcat ttggaaaact cgggctggca aaaaattaac 960
aacttttagtg ctgacatcaa gcttattgac ttcagtaatt cagtgaagga ttccaaagcc 1020
tattttccatc ttctcaatca aatcgacca aaaggacaaa aggaaggtga accacggata 1080
gatattaaca tgtcagggtt caatgaaaca gatgatttga agagagctga gagtatgctt 1140
caacaagcag ataaattagg ttgcagacag tttgttacct ctgctgatgt tgtcagtgga 1200
aaccccaaac tcaacttagc tttcgtggct aacctgttta ataaataccc agcactaact 1260
aagccagaga accaggatat tgactggact ctattagaag gagaaactcg tgaagaaaga 1320
accttccgta actggatgaa ctctcttggt gtcaatcctc acgtaaacca tctctatgct 1380
gacctgcaag atgccctggg aatcttacag ttatatgaac gaattaaagt tctgttgac 1440
tggagtaagg ttaataaacc tccataccc aaactgggag ccaacatgaa aaagctagaa 1500
aactgcaact atgctgttga attaggaag catcctgcta aattctccct ggttggcatt 1560
ggagggcaag acctgaatga tgggaaccaa accctgactt tagctttagt ctggcagctg 1620
atgagaagat ataccctcaa tgcctggaa gatcttggag atggtcagaa agccaatgac 1680
gacatcattg tgaactgggt gaacagaacg ttgagtgaag ctggaaaatc aacttccatt 1740
cagagtttta aggacaagac gatcagctcc agtttggcag ttgtggattt aattgatgcc 1800
atccagccag gctgtataaa ctatgacctt gtgaagagtg gcaatctaac agaagatgac 1860
aagcacata atgccaagta tgcagtgtca atggctagaa gaatcggagc cagagtgtat 1920
gctctccctg aagaccttgt ggaagtaaa cccaagatgg tcatgactgt gtttgcatgt 1980
ttgatgggca ggggaatgaa gagagtgtaa aataaccaat ctgaataaaa cagccatgct 2040
cccagggtgca tgattcgagc gtcagctatt tccaggtgaa gtgcttatgg cttaaggaaac 2100
tcttggccat tcaaaggact tttcattttg attaacagga ctagcttatc atgagagccc 2160
tcaggggaaa gggtttaaga aaaacaactc ctctttccca tagtcagagt tgaatttgtc 2220
aggcacgcct gaaatgtgct catagccaaa acattttact ctctcctcct agaatgctgc 2280
ccttgacatt tcccattgct gtatgttatt tcttgctctg ktawcytttg ccctcttaga 2340
atgtccctct cttgggactt gcttagatga tgggatatga atattattag acagtaattt 2400

```

tgctttccat ccagtatgct a

2421

<210> 317

<211> 1092

<212> DNA

<213> Homo sapiens

<400> 317

```

aattcggcac agattgatat tgtgtactat aatagagact ctttaaggag aatcttaaaa 60
aaaaaaaaaac gtttctcact gtcttaaata gaatttttaa atagtatata ttcagtggca 120
ttttggagaa caaagtgaat ttacttcgac ttcttaaatt tttgtaaaag actataagtt 180
tagacatctt tctcattcaa atttaaagat atctttctcc tcttgatcaa tctatcaata 240
ttgatagaag tcacactagt atataccatt taatacattt acactttctt atttaagaag 300
atattgaatg caaaataatt gacatataga actttacaaa catatgtcca aggactctaa 360
attgagactc ttccacatgt acaatctcat catcctgaag cctataatga agaaaaagat 420
ctagaaactg agttgtggag ctgactctaa tcaaagtga tgattggaat tagaccattt 480
ggcctttgaa ctttcatagg aaaaatgacc caacatttct tagcatgagc tacctcatct 540
ctagaagctg ggatggactt actattcttg tttatatatt agatactgaa aggtgctatg 600
cttctgttat tattccaaga ctggagatag gcagggctaa aaaggtatta ttatttttcc 660
tttaatgatg gtgctaaaat tcttcctata aaattcctta aaaataaaga tggtttaatc 720
actaccattg tgaaaacata actgttagac ttcccgtttc tgaaagaaag agcatcgttc 780
caatgcttgt tcaactgttc tctgtcatac tgtatctgga atgctttgta atacttgcac 840
gcttcttaga ccagaacatg taggtcccct tgtgtctcaa tacttttttt ttcttaattg 900
catttgttgg ctctatttta atttttttct tttaaaataa acagctggga ccatcccaaa 960
agacaagcca tgcatacaac tttggtcatg tatctctgca aagcatcaaa ttaaatgcac 1020
gcttttgtca tgtcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1080
aaaaaaaaaa ac 1092

```

<210> 318

<211> 1380

<212> DNA

<213> Homo sapiens

<400> 318

```

gaagtatatg gtggcagtc t gataaggaa tttgatgaat cttcacccaa acaacctaca 60
aatccttatg catcatctaa agcagctgct gaatgttttg tacagtctta ctgggaacaa 120
tataagtttc cagttgtcat cacaagaagc agtaatgttt atggaccaca tcaatatcca 180
gaaaaggtta ttccaaaatt tatatctttg ctacagcaca acaggaaatg ttgcattcat 240
gggtcagggc ttcaaacaaag aaacttcctt tatgtactg atgtttaga agcatttctc 300
actgtcctca aaaaagggaa accaggtgaa atttataaca tcggaaccaa ttttgaaatg 360
tcagttgtcc agcttgccaa agaactaata caactgatca aagagaccaa ttcagagtct 420
gaaatggaaa attgggttga ttatgttaat gatagacca ccaatgacat gagataccca 480
atgaagtcag aaaaaataca tggcttagga tggagaccta aagtgccttg gaaagaagga 540
ataaagaaaa caattgaatg gtacagagag aattttcaca actggaagaa tgtggaaaag 600
gcattagaac cctttccggt ataatcacca tttatatagt cgagacagtt gtcaaagaag 660
aaagtatatc tacctcgcca agtggtaga aattaagtga ccaaataaag tgcaactctt 720
tcttttgtaa ttagattcat gactttctgt ataaaattca aatgcagaat gcctcaatct 780
ttgggagagt ttcagtactg gcatagaatt taaatgtcaa aattctttct gaaacccttt 840
ctcctagaaa ctaggaaata ataggtgtag aagactctcc ctaagggtag ccaggaagaa 900
gtctcctgat tcggacaacc atgaggggta gtgggtgctag ggagaaggca accttactg 960
gttttgaact cagtgcctaa gaaagtctct gaaatgttcg tttttaggca atataggatg 1020

```

```

tcttaggccc taattcacca tttctttttt aagatctgat atgctatcat tgccttaata 1080
atggaacaaa atagaagcat atctaacact ttttaaattg ataattttgt aaaattgatt 1140
acgttgaatg ctttttaaga gaagtgtgta aagtttttat attttcacia ttaacgtatg 1200
taaaaccttg tatcagaaat ttatcatgtt tactgtttta atgattgta tttataaaat 1260
tgtcaatatc ttaatgtatt taatgtagaa tattgctttt taaaataatg tttttatttt 1320
gctgtagaaa aataaaaaaa aatttgatta taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380

```

<210> 319

<211> 2612

<212> DNA

<213> Homo sapiens

<400> 319

```

cacgcgtccg ccccatctga ggcgtttgtt gcagctacct gcacttctag attcatcttc 60
ttgtgagccc tgggcttagg agtcaccatg gcaactgaag agttcatcat ccgcatcccc 120
ccataccact atatccatgt gctggaccag aacagcaacg tgtcccggtg ggaggtcggg 180
ccaaagacct acatccggca ggacaatgag aggggtactgt ttgcccccat gcgcatgggtg 240
accgtccccc cacgtcacta ctgcacagtg gccaaccttg tgtctcggga tgcccagggc 300
ttggtgctgt ttgatgtcac agggcaagtt cggcttcgcc acgctgacct cgagatccgg 360
ctggcccagg accccttccc cctgtaccca ggggaggtgc tggaaaagga catcacaccc 420
ctgcaggtgg ttctgccccaa cactgccctc catctaaagg cgctgcttga ttttgaggat 480
aaagatggag acaaggtggg ggcaggagat gagtggcttt tcgagggacc tggcacgtac 540
atcccccgga aggaagtggg ggtcgtggag atcattcagg ccaccatcat caggcagaac 600
caggctctgc ggctcagggc ccgcaaggag tgctgggacc gggacggcaa ggagaggggtg 660
acaggggaag aatggctggg caccacagta ggggcgtacc tyccagcggg gtttgaggag 720
gttctggatt tgggtggacg cgtcatcctt acggaaaaga cagccctgca cctccgggct 780
cggcggaact tccgggactt caggggagtg tcccgccgca ctggggagga gtggctggta 840
acagtgcagg acacagaggc ccacgtgccg gatgtccacg aggaggtgct gggggttgtg 900
cccatcacca ccctgggccc ccacaactac tgcggtgattc tcgaccctgt cggaccggat 960
ggcaagaatc agctggggca gaagcgcgtg gtcaaggagg agaagtcttt tttcctccag 1020
ccaggagagc agctggaaca aggcattccag gatgtgtatg tgctgtcggg gcagcagggg 1080
ctgctgctga gggccctgca gcccctggag gagggggagg atgaggagaa ggtctcacac 1140
caggctgggg accactggct catccgcgga cccctggagt atgtgccatc tgccaaagtg 1200
gaggtggtgg aggagcgcca ggccatccct ctagacgaga acgagggcat ctatgtgcag 1260
gatgtcaaga ccggaaggtg gcgcgctgtg attggaagca cctacatgct gaccacggac 1320
gaagtcctgt gggagaaaga gctgcctccc ggggtggagg agctgctgaa caaggggcag 1380
gaccctctgg cagacagggg tgagaaggac acagctaaga gcctccagcc cttggcgccc 1440
cggaacaaga cccgtgtggg cagctaccgc gtgccccaca acgctgcggg gcaggtgtac 1500
gactaccgag agaagcgagc ccgcgtgggc ttcgggcctg agctggtgtc gctgggtcct 1560
gaggagcagt tcacagtgtt gtccctctca gctgggcggc ccaagcgtcc catgcccgc 1620
cgtgcgctct gcctgctgct ggggcctgac ttcttcacag acgtcatcac catcgaacg 1680
gcggatcatg ccaggctgca actgcagctg gcctacaact ggcactttga ggtgaatgac 1740
cggaaggacc cccaagagac ggccaagctc ttttcagtgc cagactttgt aggtgatgcc 1800
tgcaaagcca tcgcattccc ggtgcggggg gccgtggcct ctgtcacttt cgatgacttc 1860
cataagaact cagcccgcac cattcgcaact gctgtctttg gctttgagac ctcggaagcg 1920
aagggccccg atggcatggc cctgcccagg ccccgggacc aggtgtctt ccccaaaac 1980
gggctggtgg tcagcagtgt ggacgtgcag tcagtgagc ctgtggatca gaggaccggg 2040
gacgccctgc aacgcagcgt ccagctggcc atcgagatca ccaccaactc ccaggaagcg 2100
gcggccaagc atgaggtcga gagactggag caggaagccc gcggccggct tgagcggcag 2160
aagatcctgg accagtcaga agccgagaaa gctcgcaagg aacttttgga gctggaggct 2220
ctgagcatgg ccgtggagag caccgggact gccaaaggcg aggcagagtc ccgtgcggag 2280

```

```

gcagcccgga ttgagggaga aggggtccgtg ctgcaggcca agctaaaagc acaggccttg 2340
gccattgaaa cggagggtga gctccagagg gtccagaagg tccgagagct ggaactgggc 2400
tatgcccggg cccagctgga gctggagggtg agcaaggctc agcagctggc tgagggtggag 2460
gtgaagaagt tcaagcagat gacagaggcc ataggcccca gcaccatcar ggaccttgct 2520
gtggctgggc ctgagatgca ggtaaaactg ctccagtcctc tgggcctgaa atcaaccctc 2580
atcaccgatg gcttcamttc catcaacttc tt 2612

```

<210> 320

<211> 943

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (52)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (54)

<223> n equals a,t,g, or c

<400> 320

```

gcaccacagc gctccagcct ggctcgacaga gtgagactcc atctcaagaa anantaaaaa 60
taaagtgtgt ctctgaagag caaatgtctc attccagtaa tgacccactc agcaggaata 120
tggtggagtt cagtccaatt cagggtcagcc atatccaaaa gaccacaagt cattactaag 180
ttgagcaaaa gagttttttat ctattagcag aaagggcctc tctggcagca gagattaaaa 240
actggcccaa cttcattttcc atacttcagg gaacagcaaa ttgaggattt acttatctag 300
gacttgaatt ctttcttttg gaccaagtta ataaaagacc aagaaactcc tgattaaact 360
ggataatgaa ggattctgta gacagggctg cacgtatcgg ctttgtttga cttctctttt 420
ctcagttaac atctcagagc tagaacattc cacattcccc agcagcgtgt gggggctgac 480
taaagtttac aattccaact aaaaatcacc ctgcttcttg cttatctgaa tcccttacct 540
acccaccccc accaccctac tcctattttat tcagcaccac actaccagag aaatacacta 600
gcaaatgtgt caatggaata aaatccacac tttagattct tgcaactgta tcatatgtaa 660
tagtatcact ttttctacat tttggtcaaa taaataggag taggggtggtg ggggtggggtg 720
ggtaagggat tcagataagc cagaagcagg gtgattttwa gttggaattg taaacttttag 780
tcagccccc cagcgtgctg gggaatgtgg atgttctagc tctgagatgt taactgrgaa 840
aagagaagtc aaacaaagcc gatacgtgca gccctgtcta cagaatcctt cattatccag 900
tttaataagg agtttcttg tcttttatta acttgggtcg acc 943

```

<210> 321

<211> 2959

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2948)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2956)

<223> n equals a,t,g, or c

<400> 321

```

ccattcccgg gtcgacccac gcgtccgctg gaaattttgga ttctccagaa ggtgggtttcg 60
atgccatcat gcaagttgca gtttgtggat cactgattgg ctggagggaat gttacacggc 120
tgctgggtgtt ttccacagat gccgggtttc actttgctgg agatgggaaa cttgggtggca 180
ttgtttttacc aaatgatgga caatgtcacc tggaaaaataa tatgtacaca atgagccatt 240
attatgatta tccttctatt gctcaccttg tccagaaaact gagtgaaaat aatattcaga 300
caattttttgc agttactgaa gaatttcagc ctgtttacaa ggagctgaaa aacttgatcc 360
ctaagtcagc agtaggaaca ttatctgcma attctagcaa tgtaattcag ttgatcattg 420
atgcatacaa ttccctttcc tcagaagtca ttttggaaaa cggcaaattg tcagaaggmg 480
taacaataag ttacaaatct tactgcaaga acggggtgaa tggaacaggg gaaaatggaa 540
gaaaatgttc caatattttcc attggagatg aggttcaatt tgaaattagc ataacttcaa 600
ataagtgtcc aaaaaaggat tctgacagct ttaaaattag gcctctgggc tttacggagg 660
aagtagaggt tattcttcag tacatctgtg aatgtgaatg ccaaagcgaa ggcattccctg 720
aaagtcccaa gtgtcatgaa ggaaatggga catttgagtg tggcgcgctgc aggtgcaatg 780
aaggcgctgt tggtagacat tgtgaatgca gcacagatga agttaacagt gaagacatgg 840
atgcttactg caggaaagaa aacagttcag aaatctgcag taacaatgga gagtgcgtct 900
gcggacagtg tgtttgtagg aagagggata atacaaatga aatttattct ggcaaattct 960
gcgagtgtga taatttcaac tgtgatagat ccaatggctt aatttgtgga ggaaatggtg 1020
tttgcaagtg tcgtgtgtgt gagtgcaacc ccaactacac tggcagtgca tgtgactgtt 1080
ctttggatac tagtacttgt gaagccagca acggacagat ctgcaatggc cggggcatct 1140
gcgagtgtgg tgtctgtaag tgtacagatc cgaagtttca agggcaaacg tgtgagatgt 1200
gtcagacctg ccttggtgtc tgtgctgagc ataaagaatg tgttcagtg agagccttca 1260
ataaaggaga aaagaaagac acatgcacac aggaatgttc ctattttaac attaccaagg 1320
tagaaagtcg ggacaaatta cccagccgg tccaaacctga tcctgtgtcc cattgtaagg 1380
agaaggatgt tgacgactgt tggttctatt ttacgtattc agtgaatggg aacaacgagg 1440
tcatggttca tgttgtggag aatccagagt gtcccactgg tccagacatc attccaattg 1500
tagctggtgt ggttgcctgga attgttctta ttggccttgc attactgctg atatggaagc 1560
ttttaatgat aattcatgac agaaggaggt ttgctaaatt tgaaaaggag aaaatgaatg 1620
ccaaatggga cacgggtgaa aatcctatth ataagagtgc cgtaacaact gtggtcaatc 1680
cgaagtatga gggaaaatga gtactgcccg tgcaaatccc acaacactga atgcaaagta 1740
gcaatttcca tagtcacagt taggtagctt tagggcaata ttgccatggt tttactcatg 1800
tgcaggtttt gaaaatgtac aatatgtata atttttaaaa tgttttatta ttttgaaaat 1860
aatgttgtaa ttcatgccag ggactgacaa aagacttgag acaggatggt tattcttgtc 1920
agctaaggtc acattgtgcc tttttgacct tttcttccctg gactattgaa atcaagctta 1980
ttggattaag tgatatttct atagcgattg aaagggcaat agttaagta atgagcatga 2040
tgagagtttc tgtaatcat gtattaaaac tgatttttag ctttacaat atgtcagttt 2100
gcagttatgc agaatccaaa gtaaatgtcc tgctagctag ttaaggattg ttttaaatct 2160
gttattttgc tatttgcctg ttagacatga ctgatgacat atctgaaaga caagtatgtt 2220
gagagttgct ggtgtaaaat acgtttgaaa tagttgatct acaaaggcca tgggaaaaat 2280
tcagagagtt aggaaggaaa aaccaatagc tttaaaacct gtgtgccatt ttaagagtta 2340
cttaatgttt ggtaactttt atgccttcac tttacaaatt caagccttag ataaaaaac 2400
cgagcaattt tctgctaaaa agtccttgat ttagcactat ttacatacag gccatacttt 2460
acaaagtatt tgctgaatgg ggaccttttg agttgaattt attttattat ttttattttg 2520
tttaatgtct ggtgctttct atcacctctt ctaatctttt aatgtatttg tttgcaattt 2580
tggggtaaga ctttttttat gagtactttt tctttgaagt tttagcggtc aatttgcctt 2640
tttaatgaac atgtgaagtt atactgtggc tatgcaacag ctctcaccta cgcgagtctt 2700
actttgagtt agtgccataa cagaccactg tatgtttact tctcaccatt tgagttgccc 2760

```

```

atcttgtttc acactagtca cattcttggt ttaagtgcct ttagttttaa cagttcactt 2820
tttacagtgc tatttactga agttatttat taaatatgcc taaaatactt aaatcggatg 2880
tcttgactct gatgtatttt awcagggtgt gtgcatgaaa tttttataga taaagragtt 2940
gaggaaanaa aaaaanaaa                               2959

```

<210> 322

<211> 802

<212> DNA

<213> Homo sapiens

<400> 322

```

ggcacagctg gaggcgcggg agggcagcga gaggttcgcg ggtgcagcgc acaggagacc 60
atgtccgggg gcagcagctg cagccagacc ccaagccggg ccatccccgc cactcgccgg 120
gtggtgctcg gcgacggcgt gcagctcccc cccggggact acagcacgac ccccgccggc 180
acgctcttca gcaccacccc gggaggtacc aggatcatct atgaccggaa attcctgatg 240
gagtgtcgga actcacctgt gacaaaaaca cccccaaggg atctgccac cattccgggg 300
gtcaccagcc cttccagtga tgagccccc atggaagcca gccagagcca cctgcgcaat 360
agcccagaag ataagcgggc gggcggtgaa gagtcacagt ttgagatgga catttaaagc 420
accagccatc gtgtggagca ctaccaaggg gccctcagg gccttcctgg gaggagtccc 480
accagccagg ccttatgaaa gtgatcatc tgggcaggcg ttggcgtggg gtcggacacc 540
ccagcccttt ctccctcact cagggcacct gccccctcct cttcgtgaac accagcagat 600
acctccttgt gcctccactg atgcaggagc tgccaccca aggggagtga cccctgccag 660
cacaccctcg cwgcyggggg sgcaaccacc ccttccttag gttgatgtgc ttgggaaagc 720
tccctcccc tccttcccc aagagagaaa taaaagccmc cttcgcccta gggccaaraa 780
aaaaaaaaaa aaaaaaaaaa aa                               802

```

<210> 323

<211> 1724

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1590)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1650)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1701)

<223> n equals a,t,g, or c

<400> 323

```

gcagcctgcc agccgcgctg ctgctgctcc tcctgctgtg ggaccgctga ccgcgcggct 60
gtcccgctct ccccgctcca agcgccgctc tgggcacccg ccaccagcat ggacgctcgc 120
cgcgtgccgc agaaagatct cagagtaaag aagaacttaa agaaattcag atatgtgaag 180
ttgatttcca tggaacctc gtcctcctct gatgacagtt gtgacagctt tgcttctgat 240

```

```

aattttgcaa acacgaggct gcagtcagtt cgggaaggct gtaggaccg cagccagtgc 300
aggcactctg gacctctcag ggtggcgatg aagtttccag cgcggagtag caggggagca 360
accaacaaaa aagcagagtc ccgccagccc tcagagaatt ctgtgactga ttccaactcc 420
gattcagaag atgaaagtgg aatgaatttt ttggagaaaa gggctttaaa tataaagcaa 480
aacaaagcaa tgcttgcaaa actcatgtct gaattagaaa gcttccctgg ctggttccgt 540
ggaagacatc ccctcccagg ctccgactca caatcaagga gaccgcgaag gcgtacattc 600
ccgggtgttg cttccaggag aaaccctgaa cggagagctc gtctctttac cagggtcaagg 660
tcccggatcc tcgggtccct tgacgctcta cccatggagg aggaggagga agaggataag 720
tacatgttgg tgagaaagag gaagaccgtg gatggctaca tgaatgaaga tgacctgccc 780
agaagccgtc gctccagatc atccgtgacc cttccgcata taattcgccc agtggagaa 840
attacagagg aggagtgtga gaacgtctgc agcaattctc gagagaagat atataaccgt 900
tactgtggct ctacttgtca tcaatgccgt cagaagacta ttgataccaa aacaaactgc 960
agaaacccag actgctgggg cgttcgaggc cagttctgtg gcccctgcct tcgaaaccgt 1020
tatggtgaag aggtcaggga tgctctgttg gatccgaact ggcattgccc gccttgtcga 1080
ggaatctgca actgcagttt ctgccggcag cgagatggac ggtgtgcgac tggggtcctt 1140
gtgtatttag ccaaatatca tggctttggg aatgtgcatg cctacttgaa aagcctgaaa 1200
caggaatttg aaatgcaagc ataatatctg gaaaatttgc tgcctgcctt ctacttctca 1260
aatctttctt gtaaaagttt ccaatttttt cactgaaacc tgagttaaaa atcttgatga 1320
tcagcctgtt tcataagaaa ctccaatcaa gttaatctta gcagacatgt gtttctggag 1380
catcacagaa ggtatatgtc tagttacact ttgccctcct gcagtttctt ctctgctccc 1440
aacccccatc tcatagcatc cccctctatt tccaatgctc ctctccaacc gcttagtttc 1500
tgaatttctt ttaaattaca gttttatgaa agcatatttt atttacttgg tgttgaaata 1560
gccctyataa aacctaaagc cttggaaaacn caataatagt attaaactaac tagatctatt 1620
gaatttcaga gaagagccta aatagcaaan ttacacaaa aacgagtatg atttagcact 1680
catactagtt gaggggttgg ngccgatagc gactgctaata gaac 1724

```

<210> 324

<211> 2261

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1098)

<223> n equals a,t,g, or c

<400> 324

```

cccagatggg aggccaaacag gggacgcttt tgtcctcttt gcctgtgagg aatatgcaca 60
gaatgcgttg aggaagcata aagacttggt gggtaaaaga tacattgaac tcttcaggag 120
cacagcagct gaagttcagc aggtgctgaa tcgattctcc tcggcccctc tcattccact 180
tccaacccct cccattattc cagtactacc tcagcaattt gtgccccta caaatgttag 240
agactgtata cgccttcgag gtcttcctta tgcagccaca attgaggaca tcctggattt 300
cctgggggag ttccgccacag atattcgtac tcatggggtt cacatggttt tgaatcacca 360
gggccgccc aacaggagatg cttttatcca gatgaagtct gcggacagag catttatggc 420
tgcacagaag tgcataaaaa aaaacatgaa ggacagatat gttgaagtct ttcagtgttc 480
agctgaggag atgaactttg tgtaaatggg gggcacttta aatcgaaatg gcttatcccc 540
accgccatgc ctgtctcttc cctctacac atttccagct cctgctgcar ttattcctac 600
araarctgcc atttaccagc cctctgtgat tttgaatcca cgagcactgc agccctycac 660
agcgtactac ccagcaggca ctcagctctt catgaactac acagcgtact atcccagtgt 720
ttgaaagatg tatggtgatc ttgaaacctc cagacacaa aaaacttcta gcaaattcag 780
gggaagtttg tctacactca ggctgcagta ttttcagcaa acttgatttg acaaacgggc 840

```

```

ctgtgcctta tcttttggtg gagtgaaaaa atttgagcta gtgaagccaa atcgtaactt 900
acagcaagca gcatgcagca tacctggctc tttgctgatt gcaaataaggc atttaaaatg 960
tgaatttgga atcagatgtc tccattactt ccagttaaag tggcatcata ggtgtttcct 1020
aagttttaag tcttgataa aaactccacc agtgtctacc atctccacca tgaactctgt 1080
taaggaagct tcattttngt atattcccgc tcttttctct tcattttccct gtcttctgca 1140
taatcatgcc ttcttgctaa gtaattcaag cataagatct tggaataata aaatcacaat 1200
cttaggagaa agaataaaat tgttattttc ccagtctctt ggccatgatg atatcttatg 1260
attaaaaaca aattaaatth taaaacacct gaagatawat tagaagaaat tgtgcaccct 1320
ccacaaaaca tacaaagttt aaaagtttgg atctttttct cagcaggtat cagttgtaaa 1380
taatgaatta gggggcaaaa tgcaaaacga aaaatgaagc agctacatgt agttagtaat 1440
ttctagtttg aactgtaatt gaattattgtg gcttcatatg tattatttta tattgtactt 1500
ttttcattat tgatggtttg gactttaata agagaaattc catagttttt aatatcccag 1560
aagtgaagaca atttgaacag tgtattctag aaaacaatac actaactgaa cagaagtga 1620
tgcttatata tattatgata gccttaaacc tttttcctct aatgccttaa ctgtcaaata 1680
attataacct tttaaagcat aggactatag tcagcatgct agactgagag gtaaactactg 1740
atgcaattag aacagggtact gatgctgtca gtgtttaaca ctatgtttag ctgtgtttat 1800
gctataaaag tgcaatatta gacactagct agtactgctg cctcatgtaa ctccaaagaa 1860
aacaggattt cattaagtgc attgaatgtg gmtatttctc taagttactc atattgtcct 1920
ttgcttgaat gcaatgccgt gcagatttat gwggctgcta tttttatttt ctgtgcatta 1980
ctttaacacc ttaaagggag aagcaaacat ttccttcttc agctgactgg caatggccct 2040
ttaactgcaa taggaagaaa aaaaaaaagg tttgtgtgaa aattggatgat aactggcact 2100
taagatcgaa aagaaatthc tgtatacttg atgccttaag atgcccagag ctgcccagag 2160
ctctgaaaga ctttaagata ggcagtaatg cttactacaa tactactgag tttttgtaga 2220
gttaacattt gataataaaa cttgcctgtt taatctcaaa a 2261

```

<210> 325

<211> 1213

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1213)

<223> n equals a,t,g, or c

<400> 325

```

tggacgcgtg ggtcgaccca cgcgctccggt caaaaytaac cccctaataa aattaattaa 60
ccactcattc atcgacctcc ccaccccatc caacatctcc gcatgatgaa acttcggctc 120
actccttggc gcttgctga tccctccaaat caccacagga ctattcctag ccatgcacta 180
ctcaccagac gcctcaaccg ccttttcac aatcgcccac atcactcgag acgtaaatta 240
tggtgaatc atccgctacc ttcacgcaa tggcgcctca atattcttta tctgcctctt 300
cctacacatc gggcgaggcc tatattacgg atcatttctc tactcagaaa cctgaaacat 360
cggcattatc ctcctgcttg caactatagc aacagccttc ataggctatg tccctccgtg 420
aggccaaata tcattctgag gggccacagt aatacaaac ttactatccg ccatcccata 480
cattgggaca gacctagtthc aatgaatctg aggaggctac tcagtagaca gtcccacct 540
cacacgattc tttacctthc acttcactct gcccttcatt attgcagccc tagcagcact 600
ccacctccta ttcttgacg aaacgggatc aaacaacccc ctaggaatca cctcccattc 660
cgataaaatc acctccacc cttactacac aatcaaagac gccctcggct tacttctctt 720
ccttctctcc ttaatgacat taacactatt ctcaaccagac ctccataggcg acccagacaa 780
ttatacccta gccaacccct taaacacccc tccccacatc aagcccgaat gatatttctt 840
attgccttac acaattctcc gatccgtccc taacaaacta ggaggcgctc ttgccctatt 900

```

```

actatccatc ctcatcctag caataatccc catcctccat atatccaaac aacaaagcat 960
aatatttcgc ccaactaagcc aatcacttta ttgactccta gccgcagacc tcctcattct 1020
aacctgaatc ggaggacaac cagtaagcta cccttttacc atcattggac aagtagcatc 1080
cgtactatac ttcacaacaa tcctaatacct aataccaact atctccctaa tkgaaaacaa 1140
aatactcaaa tgggcctaaa aaaaaaaaaa aaaaacycgg gggggggccg ggtwcccaat 1200
ttcccccta ggn 1213

```

<210> 326

<211> 2764

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (372)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2128)

<223> n equals a,t,g, or c

<400> 326

```

gccggagcaa ggctgagctg ctccgcagca tcgccaagag gaaggagcgc ctggccatcc 60
tggaacagtc ggctgggcag atccgggctc aggccgkca rgartcagaa cgcctggccc 120
gggacaagaa tgcctcctta cagctgctgc aaaaggagaa ggagaagctg actgtgctgg 180
aaaggagata ccactcactc acagggggca ggcctttccc gaagaccaca tcgaccctca 240
aagaggttta ccgctccaag atggatggcg aggccaccag cccccttccc cggaccgcga 300
gcggccctc cctcctcct ctggctcttc ctccctctcc tcccagctca gcgtggctac 360
cctggggcgt ancycckccc caaagagcgc tctactcacc cagaatggca cgggcagcct 420
tcctcgcaac ctggcagcca cactgcagga catcgagacc aagcgccaac tagctctgca 480
gcagaagggg caacaagtga ttgaagagca gcggcggcga ctggctgagc tgaagcagaa 540
agcggcagtg aggcacagtg ccagtgggat gcccttcacg gggcagcacc cttcccagcg 600
ggcccctcgg gcttcccccc tctcatgcac cactctatcc tacaccacct gcctgcgggg 660
cgggagcgtg gggaggaggg tgagcacgcc tatgatacgc tgagtctgga gagctctgac 720
agcatggaga ccagcatctc caccgggggc aactcggtg ctcccctgac aacatgtcca 780
gcgcgagtg tctggacatg gggaagatcg aggagatgga gaagatgctg aaagaggctc 840
atgcagagaa gaaccggctc atggagtcga gggagcggga gatggagctg cggcggcagg 900
ccctggagga ggagcggcgg aggcgkaca ggtagaacgg aggctgcaga gtgagagtgc 960
ccggaggcag cagctggctg agaaggaggt caagatgcgg gagaaacaat tttcccaggc 1020
acgacccctg acccgctacc tgccaatccg gaaggaggac tttgacctga agacacatat 1080
tgagtcmtcg ggccatggtg ttgatacctg cctgcacgtg gtgctcagca gcaaggctctg 1140
ccgtggctac ttggtcaaga tgggcggcaa gattaaatca tggaagaarc gctggtttgt 1200
cttcgacccg ctcaagcgca ccctttccta ttatgtggac aagcatgaga cgaagctgaa 1260
aggagtcac tatttccarg ccattgaagg aagtgtacta cgaccacctg cgccagtgc 1320
gccaaagaaga ggtttttccg cttccactat ggtgactgag aagcccgaac ccagccctca 1380
ccttctgcgt aaagacccat gaccggctgt aytacatggt ggccccatct gcagaggcca 1440
tgcgatatct gatggatgtc attgtcacag gggctgaggg ctacactcag ttcattgaact 1500
aactgcctg ggcctcctg cagagcacia ctggggcttt tgtataagaa gactttaata 1560
ttctgtaagg agcttggctc tgtgagtttc tgggctctgg cctcctgaag aaccagccag 1620
aagaagaaaa gtagagggtg ctttgctgcc tcctgggagc ccagaacttg cagtaaccct 1680

```

```

ttaggtcctg cccagggccc agccagggct gaggagctgt cacagagagg gcctcagctc 1740
tgacctgaca cctgctctcc ccagcctggt ttctcttttc taaaagacaa attatggtac 1800
cataagctgc caaagatccc ctctgcctc agacccttt gccaggggct ttgggggctg 1860
agcagagcca catccagagt ggggtaatag ctcaggcggc ccgcttccca tttctcaaac 1920
cccgtctgctg ccattgttc tcctttccct tatacttttt attaccttgc tcaagggcca 1980
gagatctcaa gtgtcaacct tgagggtccca gctccatccc ctagtgtgag actcatcacc 2040
atgggtacca tagtgactgc ttcattgccca tgggtacata ctaattgctg cagctctgtg 2100
gcccagccca ctgcttcagc tgtgggcnat ctgagggtac gtgccatcat ctctccagcc 2160
caggccctctg ggcatctcat gctgggggga agggactgaa tacctttttc cttccccctg 2220
cctgtgtctt cagccctgat gcacaggctg ccagccccc agtccagccc tctcccttcc 2280
actggtgcct tgcttagagc cagaagggat gaagccgggg gatctatgga acagaggagg 2340
agcgatgcag ttgggagagg aagctagaag ggttatggtt ggagttctgt acagtgttga 2400
gtttccgaca gggaaagagg attcctccaa tgctcctaga gagaaagcct gagcaggaga 2460
tgatgcagca gaggggaagg gccctgtggt gccgccgccc ttccttcagc ctccgaaggg 2520
tgatggaaat ggagagtgga ggaccaggcc tccagctgtc tggcctcgcc cttcacgcct 2580
taacactaag cccacctccc ctgctctcct tcccagcatt gagcccttgg ttgcctgggc 2640
ccaggctggg ggttttcagt atttgtaagc atttcagcag aacaataaag cttttggact 2700
acgraaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagggag 2760
gggc

```

<210> 327

<211> 1764

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1398)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1758)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1759)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1762)

<223> n equals a,t,g, or c

<400> 327

```

ggacatcaaa gatgaggagc ctggagactt tgggccgacc gaagcctgaa tgtgagggtt 60
acgaccccaa cgccctgtat tgcatttgcc gccagcctca caacaacagg tttatgattt 120
gctgtgaccg ctgtgaagaa tggtttcagt gcgatttgtt gggcatttct gaggctcgag 180
ggaggctttt ggaaaggaat ggggaagact atatctgccc aaactgcacc attctgcaag 240
tgcaggatga gactcattca gaaacggcag atcagcagga agctaaatgg agacctggag 300

```

```

atgctgatgg caccgattgt acaagtatag gaacaataga gcagaagtct agcgaagacc 360
aagggataaa gggtagaatt gagaaagctg caaatccaag tggcaagaag aaactcaaga 420
tcttccagcc tgtgatagag gcgcctgggt cctcaaaatg tattggcccc ggggtgctgtc 480
acgtggcgca cccgactcgg tgtactgcag taatgactgt atcctcaaac acgccgcagc 540
gacaatgaag tttctaagct caggtaaaga acagaagcca aagcctaaag aaaagatgaa 600
gatgaagcca gagaagccca gtcttccgaa atgcggtgct caggcaggta ttaaaatctc 660
ttctgtgcac aagagaccag ctccagaaaa aaaagagacc acagtgaaga aggcagtggg 720
ggtccttgcg cggagtgaag cactcgggaa ggaagcagct tgtgagagca gcacgccgtc 780
gtgggcgagc gatcacaatt acaatgcagt aaagccagaa aagactgctg ctccctcgcc 840
gtcactgttg tataaatgta tgtatcacct aggggttggc ctctgggacc cctcccgttc 900
tttctggata gccatcccct gggcctgtcc aggactggga gttgcagctt tgtgttaagc 960
tgatcacaga caccggctgc accatcagcg ggaagcagag cccatgtcca ggatgcctcc 1020
tgctgccctg tgtccatccc tagtctgtca ggacttcctg tctactgtttt ccaaagctgt 1080
aaacctcact ggtgaacgtt caccttaatg attgattctt taatctctgt tttcactctc 1140
aggtcttggg aagtattcgt attctcttca tcccagtctg attgcatagc cacactgccc 1200
ggcacgccac atccaccctt gtctgcacat gagttgttct gacaacagcg ctgtatacgc 1260
ttcagttttt ccacattgtc cacggccagc acatgaaagc atcacttctt ttttatgttg 1320
tggaatctt tgcaagttag tgttgcatct gattttcagg tgtacattta tttttgactg 1380
ggcagatagg ggattttntt ttttccatgt ccgattcaca cgctacacac ccacatgaac 1440
acattcgaac ttcgaaggcc acacactcct gcttcatagg cccacaggta agtgagtcca 1500
cacctagaac actgtcctga ccgcaggacg cgtgccttgg acttggtatt ctacatgtga 1560
ctggctttct tgccctcgtc tcttgaatgt ttagactctt aagatcatat cctgccccaa 1620
atttcaaatt aatgaaatga agatatttca aacagatctt tgaaacctca gattctgtgg 1680
tgcaatttta atgttttctt gtttctcagt tttctgctat aaaactatth tcaattcagt 1740
ctttaaaaaa aaaaaaannt cnaa 1764

```

<210> 328

<211> 571

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (535)

<223> n equals a,t,g, or c

<400> 328

```

goccaantac tttccagccc agtaaggggt atttcaggag agcagtcocac tkaagggttct 60
ttcccttttaa gatatgtgca ggatcaagtt gcggcacctt ttcagctgag taaccacact 120
ggccgcatca aggtggtctt tactccgagc atctgttaaag tgacctgcac caagggcagc 180
tgtcagaaca gctgtgagaa ggggaacacc accactctca ttagtgagaa tggtcatgct 240
gccgacaccc tgacggccac gaacttccga gtggtaattt gccatcttcc atgtatgaat 300
gggtggccagt gcagttcaag ggacaaatgt cagtgccttc caaatttcac agggaaaactt 360
tgtcagatcc cagtccatgg tgccagcgtg cstaaacttt atcagcatte ccagcagcca 420
ggcaaggcat tggggacgca tgtcatccat tcaacacata ccttgccctc gaccgtgact 480
agccagcagg agtcaaagtg aaatttcctc cttaacatag tcaatatcca tgtgnaacat 540

```

cctcctgaag cttccgtcca gatacatcag g

571

<210> 329

<211> 473

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (449)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (467)

<223> n equals a,t,g, or c

<400> 329

cacgtagtaa	tcttttaaata	taaatagcca	cgtgtgnact	actatcatat	gggacagaac	60
agttccagac	cacattattg	ataagatgtg	ttaaaataaa	taagatcttt	ctgtgaactt	120
ttgggaacca	aatggttttg	ggcatgattt	cccagctcat	tatatattga	cacagaattt	180
tttcagaatg	gcatttacta	gtaccccaga	aatttagcaa	agtatagtta	ggtacttatt	240
gtaaaatata	ttgcatattt	gatttaaggt	ttgttatgaa	cacactaatc	tgatatttta	300
tattttaaacc	attttcaatk	ctgtaagact	cagtaagagc	tatttaatta	tactgwaaca	360
aagaaaatct	ataaataaat	agcacaaata	ggcacatgcg	ggtgtataat	actgaagtgg	420
tagtttttaa	tttccgaaga	gaataagcnt	ttcaggccca	ttagaancac	aga	473

<210> 330

<211> 1335

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (865)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1004)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1156)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1301)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1328)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1333)
 <223> n equals a,t,g, or c

<400> 330
 ggcgctactg aggcgcgga ccggactgcg gttggggcgg gaagagccgg ggccgtggct 60
 gacatggagc agccctgctg ctgaggccgc gccctccccg ccctgagggtg ggggcccacc 120
 aggatgagca agctgcccag ggagctgacc cgagacttgg agcgcagctg cctgccgtgg 180
 cctccctggg ctctcactg tcccacagcc agagcctctc ctgcacctc ctccgcgcgc 240
 ctgagaagcg aagggccatc tctgatgtcc gccgcacctt ctgtctcttc gtcaccttcg 300
 acctgctctt catctccctg ctctggatca tcgaactgaa taccaacaca ggcattccgt 360
 agaacttgga gcaggagatc atccagtaca actttaaaac ttccttcttc gacatctttg 420
 tcctggccctt ctccgccttc tctggactgc tcctaggcta tgcgtgctgc rgctccggca 480
 ctggtgggtg attgcggtca cgacgctggt gtccagtgc ttcctcattg tcaaggatcat 540
 cctctctgag ctgctcagca aaggggcatt tggctacctg ctcccatcg tctcttttgt 600
 cctcgcctgg ttggagacct gggttcctga cttcaaagtc ctacccagc aagctgaaga 660
 ggagcgtatg tatcttgccg cccaggttgc tgttgcccgt ggaccctgc tgttctccgg 720
 tgstctgtcc gagggacatt ctattcacc ccagaatcct ttgcagggtc tgacaatgaa 780
 tcagatgaag aagttgctgg gaagaaaagt ttctctgctc aggagcggga gtacatccgc 840
 caggggaagg aggcacggc agtgntggac cagatcttgg ccaggaaga gaactggaag 900
 tttgagaaga ataataata tggggacacc gtgtacacca ttgaagttcc ctttcacggc 960
 aagacgttta tcctgaagac ctctctgccc tgcctgctgc astncgtgta ccaggaggtg 1020
 atcctgcagc ccgagaggat ggtgctgtgg aacaagacag tgactgcctg ccagatcctg 1080
 cagcgagtgg aagacaacac cctcatctcc tatgacgtgt ctgcaagggg ctgcgggcgg 1140
 cgtkgtcttc cccaangac ttcgtgaatg tccggcgcac tgarcggcgc agggaccgat 1200
 acttgttcat cagggatcgc caccttcaca cagtgccaa ccccgacgc acaaatatgt 1260
 tccggggaga gaatggcctg ggggtttcat cgtggttcaa ntcggccatt aacccctgt 1320
 tttgcacntt gtntg 1335

<210> 331
 <211> 1046
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (982)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (997)
 <223> n equals a,t,g, or c

<400> 331
 ggtaaaacag agagcaacat gccccagtc ctctctcttg ccagttcttg tggcagcccc 60
 attggccttg agacatgggt ttttgtgggt gcagctgcag ctgtccccc gtcttttaac 120
 tcgacatcaa aagcctctct cctgccagt ccatagggtt gttagagcta ctgttttgta 180
 acagctgctc aggtgtcccc aaactcctgg agttttccac cctgagctgt taaaaacctg 240
 ccctgcctgt caccatttc tgtgccacca gcccacccc tgccctccact ctctccctg 300
 ccaccttctg tccctgccat aggaatatgg ggacaccgtg tacaccattg aagttccctt 360
 tcacggcaag acgtttatcc tgaagacctt cctgccctgt cctgcggagc tcgtgtacca 420
 ggaggtgatc ctgcagcccg agaggatggt gctgtggaac aagacagtga ctgcctgcca 480
 gatcctgcag cgagtggaa acaacacct catctcctat gacgtgtctg caggggctgc 540
 gggcggcgtg gtctcccaa gggacttcgt gaatgtccgg cgcatgagc ggcgcaggga 600
 ccgatacttg tcatcaggga tcgccacct acacagtgc aagccccga cgcacaaata 660
 tgtccgggga gagaatggcc ctgggggctt catcgtgctc aagtcggcca gtaacccccg 720
 tgtttgcacc tttgtctgga ttcttaatac agatctcaag ggccgcctgc cccggtacct 780
 catccaccag agcctcgcgg ccaccatgtt tgaatttgcc ttccacctgc gacascgcat 840
 cagcgagctg ggggcccggg cgtgactgtg cccctccca ccctgcgggc cagggctctg 900
 tcgccaccac ttccagagcc agaaagggtg ccagttgggc tcgcactgcc cacatgggac 960
 ctggccccag gcwgtmamcc tncamcgagc cacgcantcc tgggagttga tgaagtgaaca 1020
 gstttgggtg gacattggat tcgggg 1046

<210> 332
 <211> 1311
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1280)
 <223> n equals a,t,g, or c

<400> 332
 ggcggcacca ggcggcggcg tctgtgtgga gaagcagggg cwgtgctgc cgctgctgct 60
 gcacgaatcg ccgcagcccc cagccttgcg cgtcgtcgt acctcctcgg acaggtgaga 120
 agcagcccag aaattttatg aataagcatc agaagccagt gctaacaggc cagcggttca 180
 aaactcggaa aagggatgaa aaagagaaat tcgaaccac agtcttcagg gatacattg 240
 tccaggggct taatgaggct ggtgatgacc ttgaagctgt agccaaattt ctggactcta 300
 caggctcaag attagattat cgtcgtatg cagacacact ctccgatatc ctgggtggctg 360
 gcagtatgct tgcccctgga ggaacgcgca tagatgatgg tgacaagacc aagatgacca 420
 accactgtgt gttttcagca aatgaagatc atgaaaccat ccgaaactat gctcaggctc 480
 tcaataaact catcaggaga tataagtatt tggagaaggc atttgaagat gaaatgaaaa 540
 agcttctcct ctctcttaaa gccttttcgg aaacagagca gacaaagttg gcgatgctgt 600
 cggggattct gctgggcaat ggcacctgc ccgccaccat cctcaccagt ctcttcaccg 660
 acagcttagt caaagaaggc attgcggcct catttgctgt caagcttttc aaagcatgga 720
 tggcagaaaa agatgccaac tctgttacct cgtctttgag aaaagccaac ttagacaaga 780
 ggctgcttga actctttcca gttaacagac agagtgtgga tcattttgct aaatacttca 840
 ctgacgcagg tcttaaggag ctttccgact tcctccgagt ccagcagtc ctagggcacca 900

```

ggaaggaact gcagaaggag ctccaggagc gtctttctca ggaatgcccg atcaaggagg 960
tggtgcttta tgtcaaagaa gaaatgaaga ggaatgatct tccagaaaca gcagtgattg 1020
gtcttctgtg gacatgtata atgaacgctg ttgagtggaa caagaaggaa gaacttggtg 1080
cagagcaggc tctgaagcac ctgaagcaat atgctcccct gctggccgtg ttcagctccc 1140
aaggccagtc agagctgata ctctccaga aggttcagga atactgctac gacaacatcc 1200
atttcatgaa agcctttcag aagattgtgc ttccttatac catttcagta ttgcttcttc 1260
gctcagaaca tcagctttan tcgtgccgat tcggcacgag cggcacgagc c 1311

```

<210> 333

<211> 1444

<212> DNA

<213> Homo sapiens

<400> 333

```

ggcagagccc ggccctcttg tactgctgac cccagccagg ctacagggat cgattggagc 60
tgtccttggg gctgtaattg gcccagctg agcagggcaa aactgaggt caactacaag 120
ccacaggccc cttcccagc ctgagttcac agctgccctg ttgcaggag gcggtggccc 180
ttctgttgct agaccgagcc tgtgggatat accaaggcag aggagcccat agccatgagg 240
agcctcgggg ccctgctctt gctgctgagc gcctgcctgg cggtgagcgc tggccctgtg 300
ccaacgccgc ccgacaacat ccaagtgcag gaaaacttca atatctctcg gatctatggg 360
aagtggatca acctggccat cggttccacc tgcccctggc tgaagaagat catggacagg 420
atgacagtga gcacgctggg gctgggagag ggcgtacag aggcggagat cagcatgacc 480
agcactcgtt ggcggaaagg tgtctgtgag gagacgtctg gagcttatga gaaaacagat 540
actgatggga agtttctcta tcacaaatcc aaatggaaca taaccatgga gtcctatgtg 600
gtccacacca actatgatga gtatgccatt ttcctgacca agaaattcag ccgccatcat 660
ggacccacca ttactgccaa gctctacggg cgggcgcgcg agctgaggga aactctcctg 720
caggacttca gagtgggtgc ccagggtgtg ggcacccctg aggactccat cttcaccatg 780
gctgaccgag gtgaatgtgt ccctggggag cagggaaccag agcccatctt aatcccgaga 840
gtccggaggg ctgtgctacc ccaagaagag gaaggatcag ggggtgggca actggtaact 900
gaagtcacca agaaagaaga ttcctgccag ctgggctact cggccgggtc ctgcatggga 960
atgaccagca ggtatttcta taatggtaca tccatggcct gtgagacttt ccagtacggc 1020
ggctgcatgg gcaacggtaa caacttcgtc acagaaaagg agtgtctgca gacctgccga 1080
actgtggcgg cctgcaatct ccccatagtc cggggccctt gccagacctt catccagctc 1140
tgggcatttg atgctgtcaa ggggaagtgc gtccctcttc cctacggggg ctgccagggc 1200
aacgggaaca agttctactc agagaaggag tgacagagag actgcggtgt ccctgggtgat 1260
ggtgatgagg agctgctgag cttctccaac tgacaactgg ccggtctgca agtcagagga 1320
tggccagtgt ctgtcccggg gtccctgtggc aggcagcgc aagcaacctg ggtccaaata 1380
aaaactaaat tgtaaacctc tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440
aagg 1444

```

<210> 334

<211> 1030

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (59)

<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (989)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1006)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1023)
 <223> n equals a,t,g, or c

<400> 334
 tagaattcgg agaagctgaa gcttagtggt ctaaacgggt gttgggaagg gggaaggang 60
 acctcatgga cgtgcctggg ggtgtggctt ggcttccctt gatatttgcc ggtggatgac 120
 gctgtcctga ccacacccac tccttgcctgc agccrtgkag tcttccactt tcgccttggt 180
 gcctgtcttc gccacactga gcacccctca gagcctcgtg ccagctgctg gtgcagcctc 240
 tcctgttgcc atcagtggcc agcacctgtg ctacagccat gtcactcctg gcgacccctg 300
 ggctggagct ggacagggcc ctgctcccag ctagtgggct gggatggctc gtagactatg 360
 ggaaactccc ccgggcccct gccccctgg ctccctatga ggtccttggg ggagccctgg 420
 agggcgggct tccagtgggg ggagagcccc tggcaggtga tggcttctct gactggatga 480
 ctgagcgagt tgatttcaca gctctcctcc ctctggagcc tcccytacct ccggcaccc 540
 tcccccaacc tcccccaacc ccacctgacc tggaagctat ggccctccctc ctcaagaagg 600
 agctggaaca gatggaagac ttcttcctag atgccccgct cctccaccca ccctccccgc 660
 cgccactacc accaccacca ctaccaccag cccctccct cccctgtcc ctccctcct 720
 ttgacctccc ccagccccct gtcttgata ctctggactt gctggccatc tactgccgca 780
 acgaggccgg gcaggaggaa gtggggatgc cgctctgcc cccgccacag cagccccctc 840
 ctcttctcc acctcaacct tctcgctgg gccccctacc cacatcctgc caccaccga 900
 ggggaccgca agcaaaagaa gagagaccag aacaagtcgg cggtytgag gtaccgccag 960
 cggaaggggg caggaggggt tgagggcynk gggaagggga agttgncagg gggttgggaa 1020
 ggnaagggaa 1030

<210> 335
 <211> 2127
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (72)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2098)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature

<222> (2114)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2117)

<223> n equals a,t,g, or c

<400> 335

```

ggatctgagg aaagggaggg cttttctgat ctctcccaat tagaggatta ggcaattggc 60
agcgcagtg gntaactctg ggcggggctg ggctccaggg ctggacagca cagtccctct 120
gaactgcaca gagacctcgc agccccgaga actgtcgccc ttccacgatg tggctccgtg 180
cctttatcct ggccactctc tctgcttccg cggcttgggc agggcatccg tcctcgccac 240
ctgtggtgga caccgtgcat ggcaaagtgc tggggaagtt cgtcagctta gaaggatttg 300
cacagcctgt ggccattttc ctgggaatcc cttttgccaa gccgcctctt ggacccttga 360
ggtttactcc accgcagcct gcagaacctat ggagctttgt gaagaatgcc acctcgtacc 420
ctcctatgtg cacccaagat cccaaggcgg ggcagttact ctacagagcta tttacaaacc 480
gaaaggagaa cattcctctc aagctttctg aagactgtct ttacctcaat atttactc 540
ctgctgactt gaccaagaaa aacaggctgc cggatgatgt gtggatccac ggaggggggc 600
tgatggtggg tgcggcatca acctatgatg ggctggccct tgcctgcccac gaaaacgtgg 660
tggtggtgac cattcaatat cgcctgggca tctggggatt cttcagcaca ggggatgaac 720
acagccgggg gaactggggg cacctggacc aggtggctgc cctgcgctgg gtccaggaca 780
acattgccag ctttgagggg aaccaggct ctgtgacct ctttgagag tcagcgggag 840
gagaaagtgt ctctgttctt gttttgtctc cattggccaa gaacctctc caccgggcca 900
tttctgagag tggcgtggcc ctacttctg ttctggtgaa gaaaggtgat gtcaagccct 960
tggtctgagc aattgctatc actgctgggt gcaaaaccac cacctctgct gtcatgggtc 1020
actgcctgcg acagaagacg gaagaggagc tcttgagagac gacattgaaa atgaaattct 1080
tatctctgga cttacaggga gacccagag agagtcaacc ctttctgggc actgtgattg 1140
atgggatgct gctgctgaaa acacctgaag agcttcaagc tgaaaggaaat ttccacactg 1200
tcccctacat ggtcggaatt aacaagcagg agtttggtct gttgattcca atgcagttga 1260
tgagctatcc actctccgaa gggcaactgg accagaagac agccatgtca ctctgtgga 1320
agtccatcc ccttgtttgc attgctaagg aactgattcc agaagccact gagaaatact 1380
taggaggaac agacgaca ctgtcaaaaaga aagacctgtt cctggacttg atagcagatg 1440
tgatgtttgg tgtcccatct gtgattgtgg ccggaacca cagagatgct ggagcacca 1500
cctacatgta tgagtttcag taccgtccaa gcttctcctc agacatgaaa cccaagacgg 1560
tgataggaga ccacggggat gagctcttct ccgtcttttg ggccccattt ttaaaagagg 1620
gtgcctcaga agaggagatc agacttagca agatggtgat gaaattcttg gccactttg 1680
ctcgcaatgg aaaccccaat ggggaagggc tgccccactg gccagagtac aaccagaagg 1740
aagggtatct gcagattggt gccaacaccc aggcggccca gaagctgaag gacaaagaag 1800
tagctttctg gaccaacctc ttgccaaga aggcagtgga gaagccaccc cagacagaac 1860
acatagagct gtgaatgaag atccagccgg ccttgggagc ctggaggagc aaagactggg 1920
gtcttttgcg aaagggattg caggttcaga aggcattcta ccatggcttg ggaattgtct 1980
ggtggtgggg ggcaggggag agaggccatg aaggagcaag ttttgtattt gtgacctcag 2040
ctttgggaat aaaggatctt ttgaaggcca aaaaaaaaaa aaaagggcgc ccttttangg 2100
gttcccaatt tacnaanggg tgcttgg 2127

```

<210> 336

<211> 847

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (291)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (334)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (829)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (847)
 <223> n equals a,t,g, or c

<400> 336
 ccgccatgcc gttcctggag ctggacacga atttgccgc caaccgagt cccgcggggc 60
 tggagaaacg actctgcgcc gccgctgcct ccctcctggg caaacctgcg gacggaccac 120
 tccccactcc tttcctcacg ccaagctctg actttccgtg ctccacgac cccgcggctcc 180
 ccctccgcac gtctttccct tgcgcgccct cccagtcattg acccggggcgt gaccttcagg 240
 gaccgcggcc cgtatcggga tccctgcccc gcgaacactg cgcgtttcgg ntttcgcgcg 300
 ctggggtccc gtccccagag gtagcccgcc cggntccaac ttcggggcaa attttcattgt 360
 cccctgcgg accgcgtgaa cgtgacggta cggccggggc tggccatggc gctgagcggg 420
 tccaccgagc cctgcgcgca gctgtccatc tcctccatcg gcgtagtggg caccgcgcag 480
 gacaaccgca gccacagcgc ccacttcttt gaggttctca ccaaggagct agccctgggc 540
 caggaccgga tacttatccg ctttttcccc ttggagtcct ggcagattgg caagataggg 600
 acgggtcatga cttttttatg attgggcacg gagggatcca gggcatctgt gaactggctg 660
 cttcttccag agagatctct tggcagagt agggcctgga gataaccagc tttggattat 720
 cccgcattga acattcctgt gatcacataa tcctctctct catcctcata tgaaataaat 780
 gaagagagct tcctcattca aaaaaaaaaa aaaaaaaccc cgggggggnc cggtaaccca 840
 ttggccn 847

<210> 337
 <211> 702
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (21)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (150)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (669)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (679)
 <223> n equals a,t,g, or c

<400> 337
 ttttccgccc cgctgtatcc natgggttccc tgtgccttcc ggctagaact gctcacagtc 60
 ccgcctcttc cgctgcgtgc cggaccatgg cgcaggggca gcgcaagttt caggcgcaca 120
 aaccgcgaaa gagtaagacg gcagcggcan cctctgaaaa gaatcggggc ccaagaaaag 180
 gcggtcgtgt tatcgctccc argaaggcgc gcgtcgtgca gcagcaaaag ctcaagaaga 240
 acctagaagt cggaatccgg aagaagatcg aacatgacgt ggtgatgaaa gccagcagca 300
 gcctgcccga gaagctggca ctgctgaagg ccccagccaa gaagaaaggg gcagctgccg 360
 ccacctcttc caagacacct tcctgaggac gctggcccca gtgcaggcca acatcccacc 420
 ccctaccttc atatgggacc ttgcaagtca tcccacaggc tgcaactgtca ggaagaggac 480
 cctgtccccc agcactgggc ttcacctaga acttcagtgg gggccaaggg tgctgagaac 540
 ccagcaatga ccaggaagat acagtcacta acttcactctg tccccgtgcc ccttcccagg 600
 tcctgccttc acaggtttta cccagaacaa taaacctggc tttgtcaama aaaaaaaaaa 660
 agggccggnc gtttttagang atccagctta cgtaccgtgc tt 702

<210> 338
 <211> 875
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (791)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (813)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (830)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (861)
 <223> n equals a,t,g, or c

<400> 338

```

taagatagca aaccagttcg ttttaagtaa gctaacttgt tcattagtat ctgtggctta 60
aaatggcaaa aaagaaaata tccttgagtt tgtaatctag ttacagaagt aaggcataca 120
cacacacaaa gataacagta cctagagaga gagtgtgtgt gagtgtgctg gtctctgtgt 180
gtgcacgtgc acgctcatgg ccaaatgtgc gcactctaca taaaggaggc aggagttcct 240
ataggctatt taatgtaaga gaaactattt ttctcctggt ccagctgtat cagatactcg 300
ttccgcaaca cagaaatgac tcagaatctc agacaaaatg tattatttgt tcaattttaa 360
ttttgctact acattcataa ctcttaaatt gttaggctgt ttcatTTtaca tcaaagttat 420
ctcacaaaag agaaggcagg aaacgttttg tgagtgccta ttctatgtca aacactgtgt 480
tggcaccata ttttacaagt ttttttcctc ttctcacagt gatcttgtga gttagttact 540
tatattttta ttagaactca ttattctggg taccctccaa tgagaattag agaggttaaa 600
taccttttcc tagattccca cagcaggaag gtgggcatag ctgttttgtc tgacaccaga 660
accatctca ccacactgct ttacagtctt cctgaaggga cattttgagg tggggggggg 720
ccttcaaagc tcagaggact gggtttkgaa tgggtttaat ttttgcaagg gatccatgtc 780
catgccaggg ngtttacaat tctttaactt cntcccaaa ttcgtgtgtn ccattagga 840
catttggtt acatccgggc nggggagggg caggg 875

```

<210> 339

<211> 1448

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1427)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1432)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1440)

<223> n equals a,t,g, or c

<400> 339

```

cagcgccact agcctcattg tgcccaggag ttctccaaac ccgcgctgcg gagtgagtga 60
ccaagttccg gccagttcga cctcgaggat ccagaggtgg agacggtact acctcccagc 120
tctgttttcc atccccttca ggtccttcct cgggaggcgg cgaaggcggg ccaccctgcg 180
cgtgatcctt yatgcccggc ccctgcccct ccctccgggt ggaacttccc cctcaccgcc 240
agacttaagc tgaggatcgt tggatctctg gcgggggtgca gaactgagcc caggccacag 300
taccctattc acgctctgtg cttgtgccaa ggggggcaatg gcggcttcct gtgttctact 360
gcacactggg cagaagatgc ctctgattgg ctctgggtacc tggaagagtg agcctggtca 420
ggtaaaagca gctgttaagt atgcccttag cgtaggctac cgccacattg attgtgctgc 480
tatctacggc aatgagcctg agattgggga ggccctgaag gaggacgtgg gaccaggcaa 540
ggcgggtgct cgggaggagc tgtttgtgac atccaagctg tggaacacca agcaccaccc 600
cgaggatgtg gagcctgccc tccggaagac tctggctgac ctccagctgg agtatctgga 660
cctgtacctg atgcaactggc cttatgcctt tgagcgggga gacaaccctt tccccaaaga 720
tgctgatggg actatatgct acgactccac ccaactacaag gagacttgga aggctctgga 780
ggcactggtg gctaaggggc tgggtgcaggc gctgggcctg tccaacttca acagtcggca 840

```

```

gattgatgac atactcagtg tggcctccgt gcgtccagct gtcttgcagg tggaatgcca 900
cccatacttg gctcaaaatg agctaattgc ccactgccaa gcacgtggcc tggaggtaac 960
tgcttatagc cctttgggct cctctgatcg tgcatggcgt gatcctgatg agcctgtcct 1020
gctggaggaa ccagtagtcc tggcattggc tgaaaagtat ggccgatctc cagctcagat 1080
cttgctcagg tggcagggtcc agcggaaagt gatctgcatc cccaaaagta tcaactccttc 1140
tcgaatcctt cagaacatca aggtgtttga cttcaccttt agcccagaag agatgaagca 1200
gctaaatgcc ctgaacaaaa attggagata tattgtgcct atgcttacgg tggatgggaa 1260
gagagtccca agggatgcag ggcacacctt aatgaccttt actgagacca 1320
cagcttcttg gcctcccttc cagctctgca gctaattgagg tcctgccaca acggaaagag 1380
ggagttaata aagccattgg agcatccaaa aaaaaaaaaa aaaaaanayc tngsggccgn 1440
caagggaa 1448

```

<210> 340

<211> 843

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (812)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (822)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (829)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (838)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (841)

<223> n equals a,t,g, or c

<400> 340

```

aattcggcac gagctggcct gagaagccaa ctcagactca gccaacagag attgttgatt 60
tgccctcttaa gcaagagatt cattgcagct cagcatggct cagaccagct cataacttcat 120
gtgatctccc tgccctgatgt ttctgtctca gagccaaggc caagaggccc agacagagtt 180
gccccaggcc cggatcagct gcccagaagg caccaatgcc tatcgctcct actgctacta 240
ctttaatgaa gaccgtgaga cctgggttga tgcagatctc tattgccaga acatgaattc 300
gggcaacctg gtgtctgtgc tcaccaggc cgagggtgcc tttgtggcct cactgattaa 360
ggagagtggc actgatgact tcaatgtctg gattggcctc catgacccca aaaagaaccg 420
ccgctggcac tggagcagtg ggtccctggt ctctacaag tcctggggca ttggagcccc 480

```

```

aagcagtgtt aatcctggct actgtgtgag cctgacctca agcacaggat tccagaaatg 540
gaaggatgtg ccttgtgaag acaagttctc ctttgtctgc aagttcaaaa actagaggca 600
gctggaaaaa acatgtctag aactgatcca gcaattacaa cggagtcaaa aattaaaccg 660
gaccatctct ccaactcaac tcaacctgga cactctcttc tctgctgagt ttgccttgtt 720
aatcttcaat agttttacct accccagtc tttggaaccyt aaataataaa aataaacatg 780
tttccactaa aaaaaaaaaa aaaaaaaamt cncagggggg gnccggtanc caattcgnc 840
naa 843

```

<210> 341

<211> 1293

<212> DNA

<213> Homo sapiens

<400> 341

```

gtgctcataa ctgttaatga aagcagattc aaagcaacac caccaccact gaagtatttt 60
tagttatata agattggaac taccaagcat gtggctcctg gtcagtgtaa ttctaattctc 120
acggatatcc tctgttgggg gagaagcaac attttgtgat tttccaaaaa taaaccatgg 180
aattctatat gatgaagaaa aatataagcc attttcccag gttcctacag gggaagtatt 240
ctattactcc tgtgaatata attttgtgtc tccttcaaaa tcattttgga ctgcataaac 300
atgcacagaa gaaggatggt caccaacacc aaagtgtctc agactgtgtt tctttccttt 360
tgtggaaaat ggtcattctg aatcttcagg acaaacacat ctggaagggtg atactgtgca 420
aattatttgc aacacaggat acagacttca aaacaatgag aacaacattt catgtgtaga 480
acggggctgg tccaccctc ccaaatgcag gtccactgac acttcctgtg tgaatccgcc 540
cacagtacaa aatgctyata tastgtcgag acagatgagt aaatatccat ctgggtgagag 600
agtacgttat saatgtagga gcccttatga aatgtttggg gatgaagaag tgatgtgttt 660
aaatggaaac tggacrgaac cacctcaatg caaagattct acrggaaaat gtggggcccc 720
tccacctatt gacaatggg acattacttc attcccgttg tcagtatatg ctccagcttc 780
atcagttgag taccaatgcc agaacttgta tcaacttgag ggtaacaagc gaataacatg 840
tagaaatgga caatggtcag aaccaccaa atgcttacat ccgtgtgtaa tatcccgaga 900
aattatggaa aattataaca tagcattaag gtggacagcc aaacagaagc tttattygag 960
aacaggtgaa tcagytgaat ttgtgtgtaa acggggatat cgtctttcat cacgttctca 1020
cacattgcga acaacatgtt gggatgggaa actggagtat ccaacttgtg caaaaagata 1080
gaatcaatca taaartgcac acctttattc agaactttag tattaaatca gttctyaatt 1140
tcatttttwa tgtattgttt tactcctttt tattcatacg taaaattttg gattaatttg 1200
tgaaaatgta attataagct gagaccggtg gctctcttct taaaagcacc atattaaatc 1260
ctggaaaact aaaaaaaaaa aaaaaaaact cgc 1293

```

<210> 342

<211> 1273

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (483)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1247)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1262)
 <223> n equals a,t,g, or c

<400> 342
 gccangcgg ccgcgaggcg ccgccgccgc cgccgcagcc gccggagccg caatgcctaa 60
 aggaggaaga aagggaggcc acaaaggccg ggccgaggcag tatacaagcc ctgaggagat 120
 cgacgcgcag ctgcaggctg agaagcagaa ggccaggga gaagaggagc aaaaagaagg 180
 tggagatggg gctgcagggtg accccaaaaa ggagaagaaa tctctagact cagatgagag 240
 tgaggatgaa gaagatgact accagcaaaa gcgcaaaggc gttgaagggc tcatcgacat 300
 cgagaacccc aaccgggttg cacagacaac caaaaaggtc acacaactgg atctggacgg 360
 gccaaaggag ctttcgagga gagaacgaga agagattgag aagcagaagg caaaagagcg 420
 ttacatgaaa atgcacttgg ccgggaagac agagcaagcc aaggctgacc tggcccggct 480
 ggncatcatc cggaacacgc gggaggaggc tgcccggag aaggaagagg aaaggaaagc 540
 aaaagacgat gccacattgt caggaaaacg aatgcagtca ctctccctga ataagtaact 600
 gcgacccgtg ggaggagatg ccggggacct gggccgcgct gccaggacct ctgctgtgtc 660
 tcgcccaccc tgtgccctgg cgccgctgca acagcccctc atggccagga gccccccatg 720
 gcctggggcc tcctcttcat cttggcacag aaattgtttg ggggatgggg ggggggactg 780
 gggggaggggt agctgctatc tttgagacag aaagrkggag aagagctttc atttgtctgg 840
 tagatagata gcatgtaagg ggggtggtgt cccaggaggc agctgctgac aggtttgcta 900
 cacacagccc cgactgtgtg tgcctgggtg ctcatcaga gaggggctat catctgggag 960
 cctgtgcccc tgggtcctcg agggatcatg cttgtccctg gtcagtcctg tctgactgac 1020
 ctgaggccct cacctctctg cccttccctg cccgggtcct actcacctgg ctagggccag 1080
 tgcccatttt cagccctacc cattgatcat ttcaagaaac ctctgtttac tgtgtggcac 1140
 ccaggcaaaa catgctccac aaattcaact tgtatatattg gcagattaaa cttgacatta 1200
 tcgtaaaaaa aaaaaaaaaa atttgggggg gggcccggta cccattnggg cccttagggg 1260
 gnggtttaaa tta 1273

<210> 343
 <211> 1793
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1251)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1267)
 <223> n equals a,t,g, or c

<400> 343

```

gcccacgcgt cgcgccacgc gtccggcatg gacctcagtc ttctctgggt acttctgccc 60
ctagtcacca tggcctgggg ccagtatggc gattatggat acccatacca gcagtatcat 120
gactacagcg atgatgggtg ggtgaatttg aaccggcaag gcttcagcta ccagtgtccc 180
caggggcagg tgatagtggc cgtgaggagc atcttcagca agaaggaagg ttctgacaga 240
caatggaact acgcctgcat gccacacca cagagcctcg gggaaccac ggagtgtctg 300
tgggaggaga tcaacagggc tggcatggaa tggtagcaga cgtgctccaa caatgggctg 360
gtggcaggat tccagagccg ctacttcgag tcagtgtctg atcgggagtg gcagttttac 420
tgttgtcgct acagcaagag gtgcccata tctgtctggc taacaacaga atatccaggt 480
cactatgggt aggaaatgga catgatttcc tacaattatg attactatat ccgaggagca 540
acaaccactt tctctgcagt ggaaagggat cgccagtggg agttcataat gtgccggatg 600
actgaatacg actgtgaatt tgcaaatgtt tagatttgcc acataccaaa tctgggtgaa 660
aggaaagggg ccaggggaca ggagggtgtc cacatatgtt aacatcagtt ggatctccta 720
tagaagtttc tgctgtcttc ttctctcttc cctgagctgg taactgcaat gccacttcc 780
tgggcctttc tgactagtat cacacttcta ataaaatcca caattaaacc atgtttctca 840
cttttcacat gtttcatagc aactgcttta tatgactgat gatggottcc ttgcacacca 900
catatacagt gcgcatgctt acagccgggc ttctggagca ccagctgcag cctggctact 960
gctttttact gcagaatgaa ctgcaagttc agcatagtgg aggggagagg cagaactgga 1020
ggagaggtgc agtgaaggtt ctctacagct aagcctgttt gaatgatacg taggttcccc 1080
acaaaaagca ggctttctgc cctgagggac atcttcccac tcccctgctc cacatgagcc 1140
atgcatgctt agcaatccaa gtgcagagct ctttgctcca ggagttagga gactgggagg 1200
tgaaatgggg aaatggaagg gtttgagggc agagctgaaa acagggttgg naagggattt 1260
cctgaantta raagacaaac gttagcatac ccagtaagga aaatgagtgc aggggccagg 1320
ggaacccgtg aggatcactc tcaaatgaga ttaaaaacaa ggaagcagag aatggtcaga 1380
gaatgggatt cagattggga acttgtgggg atgagagtga ccaggttgaa ctgggaagtg 1440
gaaaaaggag tttgagtcac tggcacctag aagcctgccc acgattccta ggaaggctgg 1500
cagacaccct ggaaccctgg ggagctactg gcaaacctct ctggattggg cctgattttt 1560
ttggtgggaa aggctgccct ggggatcaac ttctctctct tgtgtggctc aggagttctt 1620
ctgcagagat ggcgctatct ttctctctcc tgtgatgtcc tgctcccaac catttgtact 1680
cttcattaca aaagaaataa aaatattaac gttcamwawg ctgaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1793

```

<210> 344

<211> 1672

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (95)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1667)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1668)

<223> n equals a,t,g, or c

<400> 344

```

ctgcgacgcg ctccggccca ggtggcgggc ggccgcccag cctccccgcc tgctggcggg 60
agaaaccatc tcctctggcg ggggtagggg cggantggcg tccgaccaca ccggaagagg 120
aagtctaagc gccggaagtg gtgggcattc tgggtaacga gctatctact tcctgcgggg 180
gcacaggctg tggtcgtcta tctccctggt gttcttccca tcggcgaaga tggccctgga 240
gacggtgccg aaggacctgc ggcatctgcg ggccgtgttg ctgtgttcgc tggccaagac 300
tatagaccag tttgaatatg atggttgtga caattgtgat gcatactac aaatgaaggg 360
taaccgagag atggtatatg actgcactag ctcttccttt gatggaatca ttgcgatgat 420
gagtccagag gacagctggg tctccaagtg gcagcgagtc agtaacttta agccaggtgt 480
atatgcggtg tcagtcactg gtcgcctgcc ccaaggaaatc gtgcgggagc tgaaaagtcg 540
aggatgggcc tacaaatcca gagacagcgc tataaagacc tagcaagatg caaggctgcc 600
agcatctttg ctctccacct cctgcctctg cttatttctt gttctggaac taaatgaaca 660
gaacttcaaa tacttcctac cctccaattc agactcagct gactgttgag agagcagcac 720
atcattttat cattttatct tctttggact acagggtggg tgggagggat ttgggttggg 780
ggattaacag atggaattga ggagagagta ggatgctgat tttcctaccc gtggcccagg 840
tctgtgcctt ccccatgcca aggactctag gtcaaatgtc aataaatatg aacctcgaga 900
aagttctgaa ggccatgaca cctgccttgc ctccctcttc cattctctta ggcacagtaa 960
tagcttattt gccctataag aaccttccca gacgagcaga ggcccttcta ctccctcttg 1020
actgtctcag cctctgggat tgcagccttt gtagtgtgct tccttgcttc ctatcagagg 1080
gtgctgatcc agaggctcag taaccccatc aacttggtgg ccctgggtgc tcacacttgt 1140
atccttctgc cctcgagacc tggcacagca gtatcccttg aagaaatcct gaggctttgt 1200
agagtgtccc ttgacctagt ttaataattc ttccctcccc tgcttgtcta ttttcttctc 1260
ttcacggctc ttctataacc ttaggccagt ctcaagcact cactggagac ccttgggcct 1320
tgggcgacca ttgagtccta gtctcccttg tttgtgcccc tgtaggaggt aggtcctttt 1380
ctctccggcc tagtagggga ccttgggtaa catcccattt ttcggccaag gtgagttgtt 1440
ttaggataaa aaaatttacc acaaattctc atttaaat tccacagaaat cctgttcgta 1500
tccccatttt gatttcctta agttccttgt tctccctcta aaaagagaat gattgcaccc 1560
tgccctgttta cctcaggatt gttgtgattg tagaaacgaa gctatgtgaa aattatataa 1620
gtattataaa ggtgaaatac ttttgctctc aaaaaaaaaa aaaaaanntt aa 1672

```

<210> 345

<211> 2109

<212> DNA

<213> Homo sapiens

<400> 345

```

agcactagct ttgacatcca cggtagagctg caggggaagca tcacacacca gccagcatgt 60
gagcagaggg aggcagttgg ggttgaactt cggaactagg ccgggtctyc tgacagatca 120
caagacaccc cagaggatct tcagcagtc tacttcccat tctctataga gctttgaagc 180
ttggaaccct tcagggttaa acattttctc ttgtgctgct yaggacatyt ggggcctagc 240
tcctgggttc ctgtctccaa gaagcaatga ccttaaaactc tgagccatac tctgtcctca 300
ccagcggctc ccatgttttt ctgtgtcagg ttattaagta cctagtccct gttttctgtc 360
tctstcctaa gctactctctc tgggtccaca gaagacttgg tagtatagtg agaatggcta 420
tacgtgagta caaacrtgga ttttccaagg gcttgggaam tgattcttga gccagaaga 480
gccamgcctg ctttgaggtc ttttgagtg gagatgcagc cctgggaaat ttggggagtc 540
agcaggccag tgtgaagcwa ttggtccctag gagtatatga gcttgctgtt tctttgatgg 600
aaaatacatg cttctcttgt atactcagaa gtgactaagg gcaataactc attaatagcc 660
atctatccaa cttctttact gagtgatgta ttccatgggg ttaccttttt cagattattg 720
agttgctctg taagcactaa aactttttta tcatttttta gaaacttttt agattgtatt 780
acaaatttgc cttaacagta attagatgtt gaataataat ttaacatttt attaatgact 840
tgggtcatca gttaatacca gtactaaaac catacgaatt attggtttat tccagaaaat 900

```

```

acagtatttg ttctatTTTT aggtagacaa tcatttggga tcagagtaca ttagcatagt 960
aatgctcagt cagacctgtt caagtagtag agcttggaga atgccatgaa atacttatat 1020
aattaatttg attgcatgaa ctaagcaatt ttactaatga aaaggttgta tatgtgcaag 1080
tcactTTTTT aaaaaccaag aaaaaacttt aatagaggaa atcttattca ttaatttatt 1140
tttctgagta aaaaaacgaa acccaaattct cattttattt caactgttaa acattttgat 1200
ctgttgaccc ataggatcag gatttgggaa ccactttact aggaaagagc agatcagtac 1260
catttgatata aaaccggcct cattatgtaa gaaagaaaat gttacgtgtt ttcttcttta 1320
gcttggttgt gggcacttct acagcaagga ccatatcata ttcactcttg catccctggc 1380
acatgcatga gacataagta ctttaataaat gcagttgaat ggataatgat tagtggtatt 1440
tatggattag aaaaagcatg ttctatTTTA agtaagctgt aaaaagtatt attgaatatt 1500
tactgtaaat atatgttcac ataaaaaaat aacttggagg gtctttgtgt ccctggcata 1560
ttatcatctt catggaaaga atccactgtg gtttctgtag agtgattgga aaaatggatt 1620
atTTTtgagga ttgaagaaag tgTtcttTct gcgttgtcac tttgttcaac agtaaaactt 1680
tattctcagt gttcctactc tgcattgttt acatttttga cagttttttt tratcaccta 1740
caatctgtaa agaatgtata tattcttttc agcatctcag tttgaaaaga catgcagtta 1800
aacttgacct tttgataatc gctcttacag gtcattgtct gttctaacag caaattgtaa 1860
acatgtgctt catagatat tgggctctca gtcactactt tgcctatgg tatttattga 1920
atgttcacat actaatggtg cacagggtgt ttttctata aatcttctga ctgtcctgta 1980
attcattctt aagctTTaac ttgaaggat cgtaattgcc ggcatttgat gtttagcaat 2040
aaaagaataa atgtgtacca gcattttatg tttaaaaaaa aaaaaaaaaa actcgagact 2100
agtctctct 2109

```

<210> 346

<211> 1714

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (21)

<223> n equals a,t,g, or c

<400> 346

```

caggcggagg cgtcgcggga nctttggggc accacagaga tgcgggtttg cctgcaatga 60
gatttcattc tctacattta aaggacatcc tttctgagct gctgtgaata aatttggaa 120
ggtactgtat attttcatct aatggagaac tagctgtact ttgaataagg attgctgcac 180
tggaagcact tagaacatcc ctcacaatgt cgtcaacccg gagccagaac cccacgggc 240
tgaagcagat tggcctggac cagatctggg acgacctcag agccggcatc cagcagggtg 300
acacacggca gagcatggcc aagtccagat atatggagct ctacactcat gtttataact 360
actgtactag tgttcaccag tcaaaccaag cacgaggagc tggagttcct ccttctaagt 420
cgaaaaaggg gcagacacct ggaggagctc agtttgttgg cctggaatta tataaacgac 480
ttaaggaatt tttgaagaat tacttgacaa atcttcttaa ggaaggagaa gatttgatgg 540
atgagagtgt actgaaatcc tactactaac aatgggaaga ttatcgattt tcaagcaaa 600
tgctgaatgg aatttgtgcc tacctcaata gacattgggt tcgccgtgaa tgtgacgaag 660
gacgaaaagg aatatatgaa atctattcgc ttgcattggg gacttggaga gactgtctgt 720
tcaggccact gaataaacag gtaacaaatg ctgtttttaa gctgattgaa aaggaaagga 780
atgggtgaaac catcaatata agattgatta gtggagtgtg acagtcttac gtggaattgg 840
ggctgaatga agatgatgca tttgcaaagg gccctacgtt aacagtgtat aaagaatcct 900
ttgaatctca atttttggct gacacagaga gattttatac cagagagagt actgaattct 960
tgcagcagaa cccagttact gaatatatga aaaaggcaga ggctcgtctg cttgaggaac 1020
aacgaagagt tcaggttttac cttcatgaaa gcacacaaga tgaattagca aggaaatgtg 1080

```

```

aacaagtcct cattgaaaaa cacttggaag ttttccacac agaatttcag aattttattgg 1140
atgctgacaa aaatgaagat ttgggacgca tgtataatct tgtatctaga atccaggatg 1200
gcctaggaga attgaaaaaa ctgttgagga cacacattca taatcagggt cttgcagcca 1260
ttgaaaagtg tggagaagct gctttaaatg accccaaaat gtatgtacag acagtgccttg 1320
atgttcataa aaaatacaat gccctggtaa tgtctgcatt caacaatgac gctggccttg 1380
tggctgctct tgataaggct tgtggtcgct tcataaacia caacgcggtt accaagatgg 1440
cccaatcatc cagtaaatcc cctgagttgc tggctcgata ctgtgactcc ttgttgaaga 1500
aaagtcccaa gaaccagag gaggcagaac tagaagacac actcaatcaa gtgatgggtg 1560
tcttcaagta catagaagac aaagacgtat ttcagaagtt ctatgcgaag atgctcgcca 1620
agaggctcgt ccaccagaac agtgcaagtg acgatgccga agccagcatg atctccaagt 1680
taaagcaagc ttgcgggttc gagtacacct ctaa 1714

```

<210> 347

<211> 1672

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1667)

<223> n equals a,t,g, or c

<400> 347

```

cgatgtctta ttgtgatgag tctcgactgt caaatcttct tcggaggatc acccggggaar 60
acgacmgaga cygaagattg gyyactgtaa agcagttgaa agaatttatt cagcaaccag 120
aaaataagct ggtactagtt aaacaattgg atatcttggc tgctgyacat gatgtgctta 180
atgaaagtag caaatlgctt caggagttga gacaggaggg agcttgctgt ctyggccttc 240
tttgtgcttc tctgagctat gaggctgaga agatcttcaa gtggattttt agcaaattta 300
gctcatctgc aaaagatgaa gttaaactcc tctacttatg tgccacctac aaagcactag 360
agactgtagg agaaaagaaa gccttttcat ctgtaatgca gcttgtaatg accagcctgc 420
agtcaattct tgaatatgtg gatacaccag aattgctttg caaatgtgtt aagtgcattc 480
ttttgggtggc tcgatgttac cctcatatth tcagcrctaa ttttagggat acagttgata 540
tattagttgg atggcataga gatcatactc agaaaccttc gctcacgcag caggatatctg 600
ggtggttgca gagtttgagg ccattttggg tagctgatct tgcattttct acgactcttc 660
ttggtcagtt tctagaagac atggaagcat atgctgagga cctcagccat gtggcctctg 720
gggaatcagt ggatgaagac gtccctcctc catcagtgct atyaccaaag ctggctgcgc 780
ttctccgggt atttagtact gtggtgagga gcaytgggga amgcytcagc ccaattcggg 840
ycctccaatt actgagcat acgtaacaga tgttctgtac agagtaatga gatgtgtgac 900
ggctgcaaac cagggtgttt tttctgaggc tgtgttgaca gctgctaatt agygtgttgg 960
tgttttgctc ggcagcttgg atcctagcat gactatacat tgtgacatgg tcattacata 1020
tggattagac caactggaga attgccagac ttgtggtacc gattatatca tctcagctct 1080
gaatttactc acgctgattg ttgaacagat aaatacgaaa ctgccatcat catttgtaga 1140
aaaactgttt ataccatcat ctaaaactact attcttgctg tatcataaag aaaaagagg 1200
tgttgctgta gcccatgctg tttatcaagc aatgctcagc ttgaagaata ttctgtttt 1260
ggagactgcc tataagttaa tattgggaga aatgacttgt gccctaaaca acctcctgca 1320
cagtctgcaa cttcctgagg cctgttctga aataaaacat gaggctttta agaatcatgt 1380
gttcaatgta gacaatgcaa aatttgtagt taaatttgac ctgagtgcct tgactacaay 1440
tggaatgcc aaaaactcga gtctttaatt gtaatgactt tgttttatcc acagttaagc 1500
ctttttctcat tacatattha tgtatttcac tgtcatgtca acatgtctgc agaatactg 1560
tatgtaacaa acagccatat ttaagacatg cctggataaa taaaattggg aggaatgttt 1620
tcttgccatt ataaaaaaaa aaaaaaaaaa aaaaaaaagg gggggcncct tt 1672

```

<210> 348
 <211> 1483
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (19)
 <223> n equals a,t,g, or c

<400> 348
 ccgcggggcgc ggcgcggggna ggcgaccatg cgcggcgcgcg gggcgatcct gcggccggcg 60
 gcgcgtgggtg cccggggacct gaaccgcgcg cgggacatct cctcctggct ggcccagtg 120
 ttccctagaa cccagccag gtccgtgggtg gccctgaaga ccccatcaa ggtggagctg 180
 gtggcagga aaacctacag gtgggtgtgtg tgtggccgca gcaagaagca gcccttctgt 240
 gacggctccc acttcttcca acgcactggc ctatctccac tcaagttcaa ggcccaagag 300
 acccgcatgg tggcactctg tacctgcaag gccactcaga ggccccgta ctgcgatggc 360
 acccacagga gtgagcgcg gtgagaaggca gaagtgggct cccactctg agggggctgc 420
 tgctgtccag ccacaggtgg ccttggtcc aggcctctga caggcaccct cttctgtggg 480
 aaaggaaaca ggtgctgagc ccaagagact ctggtacca ctgctggctc atgaaggaag 540
 aattattcct tataacctaa aagtctccag tctggggcag gcgggagtg gccctgggtc 600
 aatgtttgct gatggggaag atggcaaaaa caagcctgcc caaccagact ggtagtcctg 660
 cagtcactgc tatgaggccc atgtgctgcc tcctgctcca gattttaacc tctctgtggg 720
 ctggggggcac ctgaccagcc acaggagagg gcagttcaga ttcattctgt atgggggtccc 780
 caagccaggc taaaccaga gatgagagg acccttccct tcttccctcc accccaaaga 840
 actacaggct ccagaaagta tgcagcattt attacaaagc caagagatac agatgtccca 900
 gggcaaagga ggggtacagtc acaggacctc agacacagga caaggtgcaa acacagacaa 960
 gcccatcagg gggctcccaa cccacacac ctacgctatg atggaatctc gagtctcgac 1020
 tcccgactcc tctcagatct atgcacactt gaggaatct cggtgggcag cgacctgcc 1080
 ggtctgtcc ctaaggagg gtccgctga cctctcaagg ggtgggggtg ggtcagagc 1140
 ttacaggttt ctgtcttctt gtgcttttag atgcagttgc tctgtcctga ccaggtgacc 1200
 gggcctcagc tgggggtgga ggggcaattg gaaggtgtt tgccctctggc aaagtctggg 1260
 atctgtgctt gtgtgaggtt aaccacccc cacttccact ctaggcccca ggtgagactc 1320
 caccaccagt cctgctagtg agggttcccc ggtgagggtg aggttggtg ggtgcagcg 1380
 cttcacaatg ctaaagcctt agccctctc caagagctga gacctctcag ggcctgaatc 1440
 ttcttttcca caagataaat gatgcaaagg ccacacacac agg 1483

<210> 349
 <211> 1842
 <212> DNA
 <213> Homo sapiens

<400> 349
 aatatwtgta ttttttgatc ctwtgaacct gaaaagggtc agaaggatgc ccagacatca 60
 gcctccttct ttcacccctt accccaaaga gaaagagttt gaaactcgag accataaaga 120
 tattcttttag tggaggctgg atgtgcatta gcctggatcc tcagttctca aatgtgtgtg 180
 gcagccagga tgactagatc ctgggtttcc atccttgaga ttctgaagta tgaagtctga 240
 gggaaaccag agtctgtatt tttctaaact ccctggctgt tctgatcggc cagttttcgg 300
 aaacactgac ttaggtttca ggaagttgcc atgggaaaca aataatttga actttggaac 360
 agggttggaa ttcaaccag caggaagcct actatttaaa tccttggtt caggttagtg 420

```

acatttaatg ccatctagct agcaattgcg accttaattt aactttccag tcttagctga 480
ggctgagaaa gctaaagttt ggttttgaca ggttttccaa aagtaaagat gctacttccc 540
actgtatggg ggagattgaa ctttccccgt ctcccgctct ctgcctcca ctccataccc 600
cgccaaggaa aggcattgtac aaaaattatg caattcagtg ttccaagtct ctgtgtaacc 660
agctcagtgt tttggtggaa aaaacatttt aagttttact gataatttga ggtagatgg 720
gaggatgaat tgtcacatct atccacactg tcaaacaggt tgggtgtggg tcattggcat 780
tctttgcaat actgcttaat tgctgatacc atatgaatga aacatgggct gtgattactg 840
caatcactgt gctatcggca gatgatgctt tggaagatgc agaagcaata ataaagtact 900
tgactacctt ctggtgtaat ctcaatgcaa gcccacactt tcttatccaa ctttttcata 960
gtaagtgcga agactgagcc agattggcca attaaaaacg aaaacctgac taggttctgt 1020
agagccaatt agacttgaaa tacgtttgtg tttctagaat cacagctcaa gcattctgtt 1080
tatcgctcac tctcccttgt acagccttat tttgttggtg ctttgcattt tgatattgct 1140
gtgagccttg catgacatca tgaggccgga tgaaacttct cagtccagca gtttccagtc 1200
ctaacaaatg ctcccacctg aatttgtata tgactgcatt tgtgggtgtg tgtgtgtttt 1260
cagcaaatc cagatttgtt tccttttggc ctcttgcaaa gtctccagaa gaaaatttgc 1320
caatctttcc tactttctat ttttatgatg acaatcaaag ccggcctgag aaacactatt 1380
tgtgactttt taaacgatta gtgatgtcct taaaatgtgg tctgccaatc tgtacaaaat 1440
ggctctattt ttgtgaagag ggacataaga taaaatgatg ttatacatca atatgtatat 1500
atgtatttct atatagactt ggagaatact gccaaaacat ttatgacaag ctgtatcact 1560
gccttcgttt atattttttt aactgtgata atccccacag gcacattaac tgttgcaact 1620
ttgaatgtcc aaaatttata ttttagaaat aataaaaaaga aagatactta catgttccca 1680
aaacaatggg gtgggtgaatg tgtgagaaaa actaacttga tagggctctac caatacaaaa 1740
tgtattacga atgcccctgt tcatgttttt gttttaaaac gtgtaaatga agatctttat 1800
atttcaataa atgatatata atttaaagtt aaaaaaaaaa ga 1842

```

<210> 350

<211> 3008

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (59)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (65)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1307)

<223> n equals a,t,g, or c

<400> 350

```

acagcatcnt taggaaacct aaggtagaga atccccccag agagcctggc aagggaatnt 60
cgagncacga agagttttct caacccaagg aggccagaca gagggacgtg gtcactctct 120
gaaaagttca acttgagaga caaaatgcag tggacctccc tcctgctgct ggcagggtct 180
ttctccctct cccaggccca gtatgaagat gacctcatt ggtggttcca ctacctccgc 240
agccagcagt ccacctacta cgatccctat gaccttacc cgtatgagac ctacgagcct 300
tacccttatg ggggtgatga agggccagcc tacacctacg gctctccatc cctccagat 360
ccccgcgact gccccagga atgcgactgc ccacccaact tccccacggc catgtactgt 420
gacaatcgca acctcaagta cctgcccttc gttccctccc gcatgaagta tgtgtacttc 480
cagaacaacc agatcacctc catccaggaa ggctcttttg acaatgccac agggctgctc 540
tggattgctc tccacggcaa ccagatcacc agtgataagg tgggcaggaa ggtcttctcc 600
aagctgaggc acctggagag gctgtacctg gaccacaaca acctgacctg gatgccggt 660
cccctgcctc gatccctgag agagctccat ctcgaccaca accagatctc acgggtcccc 720
aacaatgctc tggaggggct ggagaacctc acggccttgt acctccaaca caatgagatc 780
caggaagtgg gcagttccat gaggggcctc cggctactga tcttgctgga cctgagttat 840
aaccaccttc ggaagggtgc tgatgggctg cctcagctc ttgagcagct gtacatggag 900
cacaacaatg tctacaccgt cccgatagc tacttccggg gggcgcccaa gctgctgtat 960
gtgcggctgt cccacaacag tctaaccaac aatggcctgg cctccaacac cttcaattcc 1020
agcagcctcc ttgagctaga cctctcctac aaccagctgc agaagatccc cccagtcaac 1080
accaacctgg agaacctcta cctccaaggc aataggatca atgagttctc catcagcagc 1140
ttctgcaccg tgggtggactg cgtgaacttc tccaagctgc aggtgctgcg cctggacggg 1200
aacgagatca agcgcagcgc catgcctgcc gacgcgcccc tctgcctgcg ccttgccagc 1260
ctcatcgaga tctgagcagc cctggcaccg ggtactgggc ggaaranccc ccgtggcatt 1320
tggcttgatg gtttggtttg gcttttgctg gaaggtccag gatggaccat gtgacagaag 1380
tccacgggca cctctgttag tcttctttcc tgtaggtggg gttagggggg gcgatcaggg 1440
acaggcagcc ttctgctgag gacataggca gaagctcact cttttccagg gacagaagtg 1500
gtggtagatg gaaggatccc tggatgttcc aaccccataa atctcacggc tcttaagttc 1560
ttcccaatga tctgaggtca tggaaactta aaagtggcat gggcaatagt atataacat 1620
acttttctaa caatccctgg ctgtctgtga gcagcacttg acagctctcc ctctgtgctg 1680
ggctggctgt gcagttactc tgggctccca tttgttgctt ctcaaaatat acctcttgcc 1740
cagctgcctc ttctgaaatc cacttcaccc actccacttt cctccacaga tgccctctct 1800
gtgccttaag cagagtcagg agaccccaag gcatgtgagc atctgcccag caacctgtgg 1860
agacaaccca cactgtgtct gagggtgaaa ggacaccagg agtcaactct atacctccct 1920
aacctcacc ctagaaagcc accagattgg aggtcaccag catgatgata atattcatga 1980
cctgatgtgg gaggagacag ccaacctcag gcttagatca atgtatagg ctatattttg 2040
gcagctgggt agctctttga aggtggataa gacttcagaa gaggaaggc cagactttgc 2100
ttaccatcag catctgcaat gggccaaaca cacctcaaat tggctgagtt gagaaagcag 2160
ccccagtagt tcattctttg cccagcactt tctgcattcc aaacagcatc ctacctgggt 2220
ttttatccac aaaggtagcg gccacatggt ttttaaagta tgagaaacac agtttgtcct 2280
ctccttttat ccaagcagga agattctata tcctgatggt agagacagac tccaggcagc 2340
cctggacttg ctagcccaa gaaggaggat gtggttaatc tgtttcacct ggtttgtcct 2400
aaggccatag ttaaaaagta ccagctctgg ctgggggtccg tgaagcccag gccaggcagc 2460
caaatcttgc ctgtgctggg catacaaccc tctgctttca catctctgag ctatatcctc 2520
attagtgaag gtggcttttg ctttatagtt tggctgggga gcacttaatt cttccatttt 2580
caaaaggtaa tgttgccctg ggcttaaccc acctgccctt tgggcaagg tgggacaaag 2640
ccatctgggc agtcaggggc aaggactgtt ggaggagagt tagcccaagt atagctctgc 2700
ccagatgcca tcacatccct gatactgtgt atgctttgaa gcaccttccc tgagaaggga 2760
agaggggatc tttggactas gttcttggt ccagacctgg aatccacaaa agccaaacca 2820
gctcatttca acaaaggagc tccgatgtga gggcaaggct gccccctgcc ccagggtctc 2880
tcagaaagca tctgcatgtg aacaccatca tgcctttata aaggatcctt attacaggaa 2940
aagcatgagt ggtggctaac ctgaccaata aagttatttt atgattgcaw mwaaaaaaaa 3000
aaaaaaaaa 3008

```

<210> 351
 <211> 2756
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1597)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2540)
 <223> n equals a,t,g, or c

<400> 351
 gtcggctgtg acggccttca gcgagggcag cgtcatcgcc tactactggt ctgagttcag 60
 catcccgcag cacctgggtg aggaggccga gcgcgtcatg gccgaggagc gcgtagtcat 120
 gctgcccccg cgggcgcgct ccctgaagtc ctttgtggtc acctcagtgg tggctttccc 180
 cacggactcc aaaacagtac agaggacca ggacaacagc tgcagctttg gcctgcacgc 240
 ccgcggtgtg gagctgatgc gcttcaccac gcccggttc cctgacagcc cctaccccg 300
 tcatgccccg tgccagtggg ccctgcgggg ggacgcccag tcagtgtctga gcctcacctt 360
 ccgcagcttt gaccttgctt cctgcgacga gcgcggcagc gacctggtga cgggtgtaca 420
 caccctgagc cccatggagc cccacgccct ggtgcagttg tgtggcacct accctccctc 480
 ctacaacctg accttccact cctcccagaa cgtcctgctc atcacactga taaccaacac 540
 tgagcggcgg catcccggct ttgaggccac cttcttccag ctgcctagga tgagcagctg 600
 tggaggccgc ttacgtaaag cccaggggac attcaacagc ccctactacc caggccacta 660
 cccacccaac attgaytgca catggaacat tgaggtgccc aacaaccagc atgtgaaggt 720
 gcgcttcaaa ttcttctacc tgctggagcc cggcgtgcct gcgggcacct gcccgaagga 780
 ctacgtggag atcaayggg agaaatactg cggagagagg tcccagttcg tcgtcaccag 840
 caacagcaac aagatcacag ttcgcttcca ctcagatcag tcctacaccg acaccggctt 900
 cttagctgaa tacctctcct acgactccag tgacccatgc ccggggcagt tcacgtgccg 960
 cacggggcgg tgtatccgga aggagctgcg ctgtgatggc tgggcccact gcaccgacca 1020
 cagcgatgag ctcaactgca gttgcgacgc cggccaccag ttcacgtgca agaacaagtt 1080
 ctgcaagccc ctcttctggg tctgcgacag tgtgaacgac tgcrgagaca acagcgacga 1140
 gcaggggtgc agttgtccgg cccagacctt caggtgttcc aatgggaagt gcctctcgaa 1200
 aagccagcag tgcaatggga aggacgactg tggggacggg tccgacgagg cctcctgcc 1260
 caaggtgaac gtcgtcactt gtaccaaaca cacctaccgc tgccctaatg ggctctgctt 1320
 gagcaagggc aaccctgagt gtgacgggaa ggaggactgt agcgacggct cagatgagaa 1380
 ggactgcgac tgtgggctgc ggtcattcac gagacaggct cgtgttggtg ggggcacgga 1440
 tgcggatgag ggcgagtggc cctggcaggt aagcctgcat gctctgggccc agggcacatc 1500
 tkcggtgct tccctcatct ctcccaactg gctggtctct gccgcacact gctacatcga 1560
 tgacagagga ttcaggtact cagacccac gcagtgnaag gccttcctgg gcttgcacga 1620
 ccagagccag cgcagccycc tggggtgcag gagcgcaggc tcaagcgcac catctccac 1680
 cccttcttca atgacttcac cttcgactat gacatcgcg tgctggagct ggagaaaccg 1740
 gcagagtaca gctccatggt gcggcccac tgccctgccg acgcctccca tgtcttccct 1800
 gccggcaagg ccatctgggt cacgggctgg ggacacaccc agtatggagg cactggcgcg 1860
 ctgatcctgc aaaaggggtga gatccgcgtc atcaaccaga ccacctgcga gaacctcctg 1920
 ccgcagcaga tcacgccgcg catgatgtgc gtgggcttcc tcagcggcgg cgtggactcc 1980
 tgccagggtg attccggggg acccctgtcc agcgtggagg cggatggggc gatcttccag 2040

```

gccggtgtgg  tgagctgggg  agacggctgc  gctcagagga  acaagccagg  cgtgtacaca  2100
aggctccctc  tgtttcggga  ctggatcaaa  gagaacactg  gggatatagg  gccggggcca  2160
cccaaagtgt  tacacctgcg  gggccacca  tcgtccacc  cagtgtgcac  gcctgcaggc  2220
tgagactgg  accgctgact  gcaccagcgc  cccagaaca  tacactgtga  actcaatctc  2280
cagggctcca  aatctgccta  gaaaacctct  cgcttcctca  gcctccaaag  tggagctggg  2340
aggtagaagg  ggaggacact  ggtggttcta  ctgacccaac  tgggggcaaa  ggtttgaaga  2400
cacagcctcc  cccgccagcc  ccaagctggg  ccgaggcgcg  tttgtgyata  tctgcctccc  2460
ctgtctstaa  ggagcagcgc  gaacggagct  tcggrgcctc  ctcaagtgaag  gtgggtgggg  2520
tgccggatct  gggctgtggn  gcccttgggc  cacgctcttg  aggaagccca  ggctcggagg  2580
accctggaaa  acagacgggt  ctgagactga  aattgtttta  ccagctccca  ggggtggactt  2640
cagtgtgtgt  atttgtgtaa  atgagtaaaa  cattttattt  ctttttaaaa  aaaaaaaaaa  2700
aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaa      2756

```

<210> 352

<211> 1645

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (97)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1574)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1596)

<223> n equals a,t,g, or c

<400> 352

```

cgcgctccgcc  cacgcgtccg  cccacgcgtc  cggaaaaata  ttctttgaat  aaccttgcat  60
tactatatttt  caatttcttt  ataaatttaa  gtgcatntta  actcataatt  gtacactata  120
atataagcct  aagtttttat  tcataagttt  tattgaagtt  ctgatcggtc  cccttcagaa  180
atTTTTTTtat  attattcttc  aagttacttt  cttatttata  ttgtatgtgc  attttatcca  240
ttaatgtttc  atactttctg  agagtataat  acccttttaa  aagatatttg  gtataccaat  300
acttttcctg  gattgaaaac  tttttttaa  ctttttaaaa  tttgggccac  tctgtatgca  360
tatgtttggt  cttgttaaag  aggaagaaag  gatgtgtgtt  atactgtacc  tgtgaatgtt  420
gatacagtta  caatttat  gacaagggtt  taattctaga  atatgcttaa  taaaatgaaa  480
actggccatg  actacagcca  gaactgttat  gagattaaca  tttctattga  gaagcttttg  540
agtaaagtac  tgtatttg  catgaagatg  actgagatgg  taacacttcg  tgtagcttaa  600
ggaaatgggc  agaatttcgt  aaatgctgtt  gtgcagatgt  gttttccctg  aatgctttcg  660
tattagtggc  gaccagt  tcacagaatt  gtgaagcctg  aaggccaaga  ggaagtcact  720
gttaaaggac  tctgtgccat  cttacaacct  tggatgaatt  atcctgccaa  cgtgaaaacc  780
tcatgttcaa  agaacacttc  ccttttagccg  atgtaactgc  tggttttgtt  tttcatatgt  840
gtttttctta  cactcatttg  aatgctttca  agcatttgta  aacttaaaaa  atgtataaag  900
ggcaaaaagt  ctgaaccctt  gttttctgaa  atctaatacag  ttatgtatgg  tttctgaagg  960
gtaattttat  tttggaatag  gtaaaggaaa  cctgttttgt  ttgtttttcc  tgagggctag  1020

```

```

atgcattttt tttctcacac tcttaatgac ttttaacatt tatactgagc atccatagat 1080
atattcctag aagtatgaga agaattattc ttattgacca ttaatgtcat gttcatttta 1140
atgtaataata attgagatga aatgttctct gggtggaaca gatactctct ttttttctt 1200
gcaatcttta agaatacata gatctaaaat tcattagctt gacccctcaa agtaactttt 1260
aagtaaagat taaagctttt cttctcagtg aatataatctg ctagaaggaa atagctggga 1320
agaatttaat gatcagggaa attcattatt tctatatgtg gaaacttttt gcttcgaata 1380
ttgtatcttt ttaaactctaa atgttcatat ttttcctgaa gaaaccactg tgtaaaaatc 1440
aaattttaat ttggaatgga ataatttcaa agaactatga agatgatttg aagctctaata 1500
ttatatagtc acctataaaa tgttctttat atgtgttcat aagtaaatat tatattgatt 1560
aagttaaact tttngaattg gatttgagga gcagtnaaaa tgaaagctat atctattctr 1620
aaaccttrtt taagaccatt tgggg 1645

```

<210> 353

<211> 1637

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (738)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (771)

<223> n equals a,t,g, or c

<400> 353

```

gcccgtgag gacgcagcgt cactgacctg gggagtcgcg attcgtgccg gccggtcctg 60
gttctccggt cccgccgctc ccgcagcagc catgtcgttc ttcccggagc tttactttaa 120
cgtggacaat ggctacttgg agggactggt gcgcggcctg aaggccgggg tgctcagcca 180
ggccgactac ctcaacctgg tgcagtgcga gacgctagag gacttgaaac tgcactctga 240
gagcactgat tatggtaact tcctggccaa cgaggcatca cctctgacgg tgctcagcat 300
cgatgaccgg ctcaaggaga agatggtggt ggagttccgc cacatgagga accatgccta 360
tgagccactc gccagcttcc tagacttcat tacttacagt tacatgatcg acaacgtgat 420
cctgctcatc acaggcacgc tgcaccagcg ctccatcgct gagctcgtgc ccaagtgcga 480
cccactaggc agcttcgagc agatggaggc cgtgaacatt gctcagacac ctgctgagct 540
ctacaatgcc attctggtgg acacgcctct tgcggctttt ttccaggact gcatttcaga 600
gcaggacctt gacgagatga acatcgagat catccgcaac accctctaca aggcctacct 660
ggagtccctt tacaagttct gcaccctact gggcgggact acggctgatg ccatgtgcc 720
catcctggag ttttscaangc agaccgtgcc aagctctttc cacactgtgg ncggctctac 780
cctgagggcc tggcgcastg gctcgggctg acgactatga acaggtcaag aacgtggccg 840
attactaccc ggagtacaag ctgctcttcg aggggtgcagg tagcaaccct ggagacaaga 900
cgctggagga ccgattcttt gagcacgagg taaagctgaa caagttggcc ttctgaacc 960
agttccactt tgggtgtctt tatgccttcg tgaagctcaa ggagcaggag tgtcgcaaca 1020
tcgtgtggat cgctgaatgt atcgcccagc gccaccgcgc caaaatcgac aactacatcc 1080
ctatcttcta gcgtccctggc ccaaggctct caattgcact ctttgtgtgt gtgtgtgtgt 1140
gtgtgcgcgt gtgtgtgcgt gtgtgtgtat gtggtctgtg acaagcctgt ggctcacctg 1200
cctgtccggg gtgtagtacg ctgtcctagc ggctgcccag ttctcctgac cctcttagag 1260
actgttctta ggctgaaaaa ggggctgggc accccccccc accaaggatg gacgaagacc 1320
ccctccagag caaggaggcc ccctcagccc tgtggttaca gccgctgatg tatctaagaa 1380

```

```

gcatgtcact ttcattgttcc tccctaactc cctgacctga gaaccctggg gcctgggggc 1440
agtttgagcc tcctctccct tctgtgggtc gctcccagag ccatggccca tgggaaggac 1500
agagtgtgtg tgtccttggg gcctgggggg atgttgctcc tcagctccct ccctcagccc 1560
tgcccctctg agacaataaa actgcctctc ctaaggccaa aaaaaaaaaa aaaaaaaaaa 1620
aaaaaaaaaa aaaaaaa                                     1637

```

<210> 354

<211> 1119

<212> DNA

<213> Homo sapiens

<400> 354

```

cggcacgagc cgcgcgcccc cgaggctccg gggctctcggg cttccgcctt cttgctgccc 60
tcgttcttgc crgggcgcgc gttagtccct gctggccacc cactgcgac catgttcgtt 120
ccctgcgggg agtcggcccc cgaccttgcc ggcttcaccc tcctaattgcc agcagtatct 180
gttggaatg ttggccagct tgcaatggat ctgattatct ctacactgaa tatgtctaag 240
attggttact tctataccga ttgtcttgtg ccaatgggtg gaaacaatcc atatgcgacc 300
acagaaggaa attcaacaga acttagcata aatgctgaag tgtattcatt gccttcaaga 360
aagctggtgg ctctacagtt aagatccatt tttattaagt ataaatcaaa gccattctgt 420
gaaaaactgc tttcctgggt gaaaagcagt ggctgtgcca gagtcattgt tctttcragc 480
agtcattcat atcagcgtaa tgatctgcag cttcgtagta ctcccttcgc gtacctactt 540
acaccttcca tgcaaaaaag tgttcaaaat aaaataaaga gccttaactg ggaagaaatg 600
gaaaaaagcc ggtgcattcc tgaaatagat gattccgagt tttgtatccg cattccggga 660
ggagggtatca caaaaacact ctatgatgaa agctgttcta aagaaatcca aatggcagtt 720
ctgctgaaat ttgtttcaga aggggacaac atcccagatg cattaggtct tgttgagtat 780
cttaatgagt ggcttcagat actcaaacca cttagcgatg accccacagt atctgcctca 840
cgggtgaaaaa taccaagttc ttggagatta ctctttggca gtggtcttcc ccctgcactt 900
ttctgatcta atttctgttt tataccttat acccaaaaca cttactacca acacagctgt 960
taaacattct atacaaaaaa attgtatgat ctggtattag gaaattactt tcacagtaaa 1020
tatcaaagaa aaaagattaa rggtctcttt gccatgcttt tcatcatatg caccaaattg 1080
aaattttgta cctcggccgc gaccacgcta agccgaatt                                     1119

```

<210> 355

<211> 738

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (654)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (689)

<223> n equals a,t,g, or c

<400> 355

```

ggcacgaggg acttgctgct ggctgcccgc gccgccactg gaaagctgaa atccttcgcc 60
cggaaattca tcaatttgaa tgaattcaca acctatggca gcgargaaag caccaaaccg 120
gcctccgtcc gggccctgct gtttgamatc tccttctca tgctgtgcca tgtggcccag 180

```

```

acctatggtt caraggtgat tctgtccgag tcgcgcacag gagctgaggt gcccttcttc 240
gagacctgga tgcagacctg catgcctgag gagggcaaga tcctgaacct tgaccacccc 300
tgcttccgcc ccgactccac caaagtggag tccctgggtg ccctgctcaa caactcctcg 360
gagatgaagc tagtgcagat gaagtggcat gaggcctgtc tcagcatctc agccgccatc 420
ttggaaatcc tcaatgcctg ggagaatggg gtcctggcct tcgagtccat ccagaaaatc 480
actgataaca tcaaagggaa ggtatgcagt ctggcggtgt gtgctgtggc ttggcttgtg 540
gcccacgtcc ggatgctggg gctggatgag cgtgagaagt cgctgcagat gatccgccag 600
ctggcagggc cactgttttag ygagaacacc ctgcagttct acaatgagag ggtngtgatc 660
atgaactcga tcctgggagc gcatgtgtnc cgacgtgctg cagcagacag ccacgcagga 720
ttcaagtttc cctccaac 738

```

<210> 356

<211> 1966

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (56)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (788)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1753)

<223> n equals a,t,g, or c

<400> 356

```

gaactagtct cgagtttttt ctgtctagct ccgaccggct gaggcggcgc ggcagnngag 60
ggacggcagc ctcgcrcggc tactgcagca ctgggggtgtc agttgttggc cgcaccaga 120
acgcttcagt tctgtctctg aagatatat aataactgat tgggtgtgcc gtttaataaa 180
agaatatgga aactgaacag ccagaagaaa ccttccctaa cactgaaacc aatggtgaat 240
ttggtaaacc ccctgcagaa gatattggaag aggaacaagc atttaaaaga tctagaaaca 300
ctgatgagat gggtgaatta cgcattctgc ttcagagcaa gaatgctggg gcagtgattg 360
gaaaaggagg caagaatatt aaggctctcc gtacagacta caatgccagt gtttcagtcc 420
cagacagcag tggccccgag cgcattattga gtatcagtgc tgatattgaa acaattggag 480
aaattctgaa gaaaatcatc cctaccttgg aagagggcct gcagttgcc tccccactg 540
caaccagcca gctcccgtc gaatctgatg ctgtggaatg cttaaattac caacactata 600
aaggaagtga ctttgactgc gagttgagc tggtgattca tcagagtcta gcaggaggaa 660
ttattggggc caaagggtgct aaaatcaaag aacttcgaga gaacactcaa accaccatca 720
agctttttcca ggaatgctgt cctcattcca ctgacagagt tggtcttatt ggaggaaaac 780
ccgatagngt ttagagtgat ataaagatca tccttgatct tatacttgag tctcccatca 840
aaggacgtgc acagccttat gatcccaatt tttacgatga aacctatgat tatggtgggt 900
ttacaatgat gtttgatgac cgtcgcggac gccagtgagg atttcccatg cggggaagag 960
gtgggttttg cagaatgcct cctgggtcggg gtgggcgtcc catgcctcca tctagaagag 1020
attatgatga tatgagccct cgtcgaggac cacctcccc tcctcccgga cgaggcggc 1080
ggggtggtag cagagctcgg aatcttcctc ttctccacc accaccacct agagggggag 1140

```

```

acctcatggc ctatgacaga agagggagac ctggagaccg ttacgacggc atggttgggt 1200
tcagtgctga tgaaacttgg gactctgcaa tagatacatg gagcccatca gaatggcaga 1260
tggcttatga accacagggg ggctccggat atgattattc ctatgcaggg ggctgtgggt 1320
catatggtga tcttgggtga cctattatta ctacacaagt aactattccc aaagatttgg 1380
ctggatctat tattggcaaa ggtggtcagc ggattaaaca aatccgtcat gagtcgggag 1440
cttcgatcaa aattgatgag cctttagaag gatccgaaga tcggatcatt accattacag 1500
gaacacagga ccagatacag aatgcacagt atttgctgca gaacagtgtg agcagwtma 1560
gwttagcttt gtgttagctt atacatacta aaacctttaa aaagcttttc ttctcaattg 1620
atTTTTTtct tttagaagcc atggtgtctc aaccttttgg ggacctaaact tctaaacatt 1680
ctaatagttt gccttaattt ttcttctgct ttcttactaa aaacgargac attcaatact 1740
aatcttgctt ggnaggaagc cttgaaccaa gcaaacttct gcatttctct ggtgaaaact 1800
gctgccaaaa ccacttgcta aaaattgtac agagcctgta ggaaaatata gaaggttcca 1860
ttgggatgtt ggcttagttc tgtgtgggaa gacttagtgg attttgtttg tttttagata 1920
actaaatcgg ccaacaaatc accgttctgg cctatgggac cgggcc 1966

```

<210> 357

<211> 1562

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (18)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (260)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (262)

<223> n equals a,t,g, or c

<400> 357

```

taccgcgcgc cctgcngnac cggtcgggaa ttcccggtgc gaccacgcgc tccgcatgaa 60
atggaccaat actggggaat tggcagtcctg gccagtgagg taaatttggt cacaacagct 120
tttgagggcc cagttcttga tcacaggtat tatgcagggt gatgctcccc gcattacatc 180
ctgaacacga ggtttaggaa gccctacaat gtggaaagct acacgccaca gaccacaggc 240
aaatacgaat tcatattaan anagtatgaa tcatactcag attttgaacg caatgtcaca 300
gagaaaaatg caagcaagtc tggtttcagt tttggtttta aaatacctgg aatatttgaa 360
cttggcatca gtagtcaaag tgatcgaggc aaacactata ttaggagaac caaacgattc 420
tctcatacta aaagcgtatt tctgcatgca cgctctgacc ttgaagtagc acattacaag 480
ctgaaaccca gaagcctcat gctccattac gagttccttc agagagttaa gcggctgccc 540
ctggagtaca gctacgggga atacagagat ctcttccgtg attttgggac ccactacatc 600

```

```

acagaggctg tgcttggggg catttatgaa tacaccctcg ttatgaacaa agaggccatg 660
gagagaggag attatactct taacaacgtc catgcctgtg ccaaaaatga ttttaaaatt 720
ggtggtgcc a ttgaagaggt ctacgtcagt ctgggtgtgt ctgtaggcaa atgcagaggt 780
attctgaatg aaataaaaaga cagaaacaag agggacacca tggtaggaga cttggtgggtc 840
ctggtacgag gaggggcaag tgagcacatc accaccctgg cataccagga gctgccgacg 900
gaggacctga tgcaggagt gggagacgct gtgcagtaca acccagccat catcaaagtt 960
aagggtggagc ctctgtatga actagtgaca gccacagatt ttgcctattc cagcacagtg 1020
aggcagaaca tgaagcaggc actggaggag ttccagaagg aagttagtct ctgccactgt 1080
gctccctgcc aaggaaatgg agtccctgtc ctgaaaggat cacgctgtga ctgcatctgt 1140
cctgttggtat cccaaggcct agcctgtgag gtctcctatc ggaagaatac cccattgat 1200
gggaagtgg a attgctggtc aaattggtct tcatgctctg gaagacgtaa gacaagacaa 1260
aggcagtgt a acaatccacc tcctcaaaat gggggtagcc cctgttcagg ccctgcttca 1320
gaaacacttg actgctccta gcagatgata cagcagtggg ctacatacaa tgagagccct 1380
gagccctcaa gaactcaygc cagctcagcc ctacaccagt ttccacctgg agttcatgca 1440
agggcaaaa g gcagtgccat gcaagctgtt taaaataaag atgttacctt gtaaaatgca 1500
agttgattta aataaatact gagttaaagg ctttaaaaaa aaaaaaaaaa aaaggggggg 1560
cg 1562

```

<210> 358

<211> 1931

<212> DNA

<213> Homo sapiens

<400> 358

```

ctcgggagct cggactccta cgcatacccg ggaagggccg ccgccccgcc cgcggctgct 60
ggcccgggtg aacttccgc ctgtataaag agcagcggcc ctcggtgcct ccttcctgac 120
ctcgaccca gctcggagcc cggagcgtgc ctcgggggcc tgcgggtttt caccatggag 180
cagctgagct cagcaaacac ccgcttcgcc ttggacctgt tcctggcggt gagtgagaac 240
aatccggctg gaaacatctt catctctccc ttcagcattt catctgctat ggccatggtt 300
tttctgggga ccagaggtaa cacggcagca cagctgtcca agactttcca tttcaacacg 360
gttgaagagg ttcatccaag attccagagt ctgaatgctg atatcaacaa acgtggagcg 420
tcttatattc tgaacttgc taatagatta tatggagaga aaacttaciaa tttccttcct 480
gagttcttgg tttcgactca gaaaacatat ggtgctgacc tggccagtgt ggattttcag 540
catgcctctg aagatgcaag gaagaccata aaccagtggg tcaaaggaca gacagaagga 600
aaaattccgg aactgttggc ttcgggcatg gttgataaca tgaccaaaact tgtgctagta 660
aatgccatct atttcaaggg aaactggaag gataaattca tgaaagaagc cacgacgaat 720
gcaccattca gattgaataa gaaagacaga aaaactgtga aaatgatgta tcagaagaaa 780
aaatttgc atggctacat cgaggacctt aagtgccgtg tgctggaact gccttaccac 840
ggcgaggagc tcagcatggt catcctgctg ccggatgaca ttgaggacga gtccacgggc 900
ctgaagaaga ttgaggaaca gttgactttg gaaaagttgc atgagtggac taaacctgag 960
aatctcgatt tcattgaagt taatgtcagc ttgccagggt tcaaactgga agagagttac 1020
actctcaact ccgacctgc ccgcctagggt gtgcaggatc tctttaacag tagcaaggct 1080
gatctgtctg gcatgtcagg agccagagat atttttatat caaaaattgt ccacaagtca 1140
tttgtggaag tgaatgaaga gggaacagag gggcagctg ccacagcagg catcgcaact 1200
ttctgcatgt tgatgccga agaaaatttc actgccgacc atccattcct tttctttatt 1260
cggcataatt cctcaggtag catcctattc ttggggagat tttcttcccc ttagaagaaa 1320
gagactgtag caatacaaaa atcaagctta gtgctttatt acctgagttt ttaatagagc 1380
caatatgtct tatactttta ccaataaaac cactgtccag aaacaagtct ttcattttct 1440
ttgtaagttt ggctctgttg gctgtttaca cccatgaatt ttggcatggg tatctatttt 1500
ycttttttac attgaaaaaa atccagtggg tgcttttgaa tgcatcaagt aaagaagaag 1560
aaaagaatac atccgatgag tagattcttg accatgtagt aatctataaa attgctatat 1620

```

300

```

cctcctgata gccatgggaa aacatgataa gatggtcatt tattttgcag ttagaatttt 1680
ggaagccaca aaatagacag acaccctgac tggtgaaggg aggttttaaaa acagatattc 1740
aattgaaatg taagagagca cccaattga gagcccagggt tacgaagaca agcttgccctc 1800
gcctgacttt tctgtccctt gttctgcagg attagtattc tgttacagac ctctagtttt 1860
tagactcttc aattaaaggg ccaatgggta taacctgcaa aaaaaaaaaa aaaaaaaaaa 1920
aaaaaaaaaa a                                     1931

```

<210> 359

<211> 869

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (869)

<223> n equals a,t,g, or c

<400> 359

```

gctctggcgg gcataccagc gggccctggc cgctcaccgg tggaaagtac aggttyctgac 60
agctggggccc tgtggttaga ggctggtaca aggttttgga tcggttcatc cctggcacca 120
ccaaagtggg tgcactgaag aagatgttgt tggatcaggg gggctttgcc ccgtgttttc 180
taggctgctt tctcccactg gtaggggcac ttaatggact gtcagcccag gacaactggc 240
caaactacag cgggattatc ctgatgccct tatcaccacac tactatctat ggcctgctgt 300
gcakttagcc aacttctacc tgggtccccc tcatcacagg ttggccggtt tccaatgtgt 360
tgctgtttatc tggaaactcct acctgtccctg gaaggcacat cggctctaag cctgcctcac 420
tccatcgttt ccaccttgca gtgatgcagc ttgacctggg aacggtcaga caacctcctc 480
aaagtgggca taccagtttc cacgggggtt gggtgcccgg cagagcttaa gaggactagc 540
accctgcaat gcccctcttc actctaaaat gtacactgac tgcttttagag cccttgataa 600
tagtcttatt cccaccacat actaggcact ccataaatat ctggttgaacc ttcattgacct 660
tatcaacttt acaccatata cccagcaaat gccactcatc cccactcttc atagacacat 720
ttgttactct aacctgcctt aggtctcttg tagctccagc tcttttagaga ctcccggaaac 780
cctttatatg gtgcctcagt aaatatgtta ttaaatatgt aatccggaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa                                     869

```

<210> 360

<211> 561

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (521)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (525)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (560)

<223> n equals a,t,g, or c

<400> 360

```
ggcacgagag actccagccg ccaggggagc gcgtgccgtt cttgcctctc tggcctgcgc 60
ctcctgagcc gagtagatat cccggagttc cgcgcggcgc cagcccttcc gccacggccg 120
tctctggaga gcagcagcca tggccctacg ctaccctatg gccgtgggcc tcaacaaggg 180
ccacaaagtg accaagaacg tgagcaagcc caggcacagc cgacgccgcg ggcgtctgac 240
caaacacacc aagttcgtgc gggacatgat tcgggaggtg tgtggctttg ccccgtagca 300
gcggcgcgcc atggagttac tgaaggcttc caaggacaaa cgggccctca aatttatcaa 360
gaaaaggtg gggacgcaca tccgcgccaa gaggaagcgg gaggagctga gcaacgtact 420
ggccgccatg aggaaagctg ctgccaagaa agactgagcc cctcccctgc cctctccctg 480
aaataaagaa cagcttgaca gaaaaaaaaa aaaaaaaaaa ntcgnggggg ggcccgtac 540
ccattcgccc tawagggggg g 561
```

<210> 361

<211> 1680

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (33)

<223> n equals a,t,g, or c

<400> 361

```
gagtttacac tgaccatggt ggaatgttaa ggngaacccc accccttctt acagatgggtg 60
accagagcc tgctcttggg aacagccaga gtaagattgg aaccagact tgcaagccag 120
cgctgtttgc attaaaaggg tgggtgagtc aggaccctg gctcargac cgyctctcct 180
aaaagagggg ttcaaggcca aatgggtttg tcaacgggtg tgtctccctt tcttgagat 240
gctcattagc ttatcaaaga ctgagaagtc ccgctgttac agaaataatt tagtttgctg 300
tattaactgc tcctgggcct ggagcagtat tcccacctta agattcccag catccctgtg 360
ctgtcccggc tctcattcat gccgaaggcc caaccattg gctgtgttct gtttgaagat 420
ttggggggcg ccttctcttt cttcccagg gaattctcta gcagaggag gggacccacc 480
ccagttagga agtagattgc tgcccttagc cagagacctg aactggggaa tttgaacatt 540
cctttacatt gttggagaaa tgaagccaaa gttattcaga tggttttccc aggctaaagg 600
aaagtcacct gcaagagatc ccggcactga tctggagcag ctgacagggt gggctctccct 660
taccaaagag aagaaccact ctctggcgct ggggtgacct gctggctggg cctgtaagg 720
ttccatgttg ctgaggccat ggagattccc agagctggtc acaccgaccg ctctcagggc 780
ccgctgccct gggctggcaa caccattctg gccttggcct gcagaagctt tcagagtctt 840
cactggcagt agggggagat ggggagagga atgatctctg cccagcccct tcctttccaa 900
accatgcaat ggaagagccc agatgggtga agattgattt tgccttaact caagagaatt 960
cctgttctcc ttgtgctatg atttgacac aagattctgg atacctggaa cttagctgtg 1020
tactcctgta ccctaaacag tggatttgag ttccagcgtt tattcttttt tccttttttc 1080
agatcaccat ctaagttaca tctttagctc aggtccatcc ttctcaagat ctcttcttta 1140
gccccccagc ccctggtgct gtctgtggtc aggtgacctt actcaggagc agatatctcc 1200
cttctagatg tgccttcccg cttggcttcc agcggtctgt gctcactctg tctgccagg 1320
atgagaagaa cacgtaagac cgccaccaca ctaccctcc ctcaaggccc tgtgccatag 1380
gggtggccac ccgacctgcc cccagaactt ttggatactg gaggcagttg cataggtctc 1440
cctctctggg caccaggact cagtccagcc caagactact ctgggcagct cccatcccag 1500
```

```
tctggggcca tttgcagact caggaaagga tttctacagt gttctataaa agccaaaaga 1560
gagagtgggt ttgggaagag tgaggggtgt tggggagagg ggaccgatgt gcctcattgt 1620
ttagtgtga ttacaaatat gcttttctgg ataaagtgtg gttgtttgct cttggaaaaa 1680
```

<210> 362

<211> 740

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (591)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (709)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (718)

<223> n equals a,t,g, or c

<400> 362

```
cagaaacaaa caaaaaggca gctgggttgt cactgatggg cagcatttga gcctgccaca 60
ctggcctgga agtttccctt ccagtctgga ttttgtctgc tccttccttc cccctcaccc 120
cgttacctct tcacctccca tctcatttca ctgtgtagct cagtctctcc cacgcacata 180
attggggaca gtggggggctc tcttaccagc ctcctcagca acgcacgtcc atcaggcctg 240
gcctcagtggt ccagccacat tgatgtcaca ctggaattgt taccacagag agggcggaaga 300
gataggctat ctccccacct cccaccctac tccccactat attcccgttt tgaccacctc 360
agccccctcag ctgccccctc tcactttggc caatcccagg caccaatcag acttcctcct 420
ccacctggag cccctagcat ttccttgtcc cctcttcccc aaaacctctg taaagggtag 480
gagagggacc ccctgccgag ccgcccgcga ctcagggcag tccgatctaa gaagcagaag 540
ctggttggag gctggctggg cctctgtcca gtccccagat gggataaaact ngccttttct 600
camatccccct cttgggtgcc tkgatctttc tytgcccccg gggccaggac ccactgtgct 660
gttttcttgt tcagttttgt ggggaaagga accaaggttt ttgccaagna accagtttct 720
tgaaaagggt tagggaaggg                                     740
```

<210> 363

<211> 1324

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (385)

<223> n equals a,t,g, or c

<400> 363

```
cgctgcctgg tgccgtggcc gcctcctcgg gcagccccc gggctcggcg ctggcggcag 60
```

```

tggcgagcgg cggagacctc ttcccggggc agccgggtgtc cgaactgata gcgcagctgc 120
tgcgcgctga gccctaccct gcggcgggcg gacgcttcgg cgcagggggc ggcgcgggcg 180
gcgcgggtgt gggcatcgac aacgtgtgcg agctggcggc gcggtgctc ttacgaccg 240
tggagtgggc gcgccacgcg cccttcttcc ccgagctgcc ggtggccgac caggtggcgc 300
tgctgcgcct gagctggagc gagctcttcg tgctgaacgc ggcgcaggcg gcgctgcccc 360
tgcacacggc gccgctactg gccgncgccg gcctccacgc cgcgcctatg gccgccgagc 420
gcgccgtggc tttcatggac caggtgcgcg ccttccagga gcaggaggac aagctgggac 480
gcctgcaggt cgactcggcc gagtatggct gcctcaaggc catcgcgctc ttcacgcccg 540
acgcctgtgg cctctcagac ccggcccacg ttgagagcct gcaggagaag gcgcaggtgg 600
ccctcaccga gtatgtgcgg gcgcagtagc cgtcccagcc ccagcgcttc gggcgccctg 660
tgctgcggct ccccgccctg cgcgcggtcc ctgcctccct catctcccag ctgttcttca 720
tgcgccgtgt ggggaagacg ccatttgaga cactgatcag agacatgctg ctgtcgggga 780
gtaccttcaa ctggccctac ggctcgggac agtgaccatg acggggccac gtgtgctgtg 840
gccaggcctg cagacagacc tcaagggaca gggaatgctg aggcctcgag gggcctcccg 900
ggggccagga ctctggcttc tctcctcaga cttctatctt ttaaagactg tgaaatgttt 960
gtcttttctg ttttttaaat gatcatgaaa ccaaaaagag actgatcatc caggcctcag 1020
cctcatcttc ccaggaccc ctgtccagga tggagggtcc aatcctagga cagccttggt 1080
cctcagcacc cctagcatga acttgaggga tgggtggggt ggcttccctg gcctgatgga 1140
caaaggcctg gcgtcggcca gaggggctgc tccagtgggc aggggtagct agcgtgtgcc 1200
aggcagatcc tctggacacg taacctatgt cagacactac atgatgactc aaggccaata 1260
ataaagacat ttcctacctg caaaaaaaaa aaaaaagggt ggccgctcgc gatctagaac 1320
tagt 1324

```

<210> 364

<211> 2853

<212> DNA

<213> Homo sapiens

<400> 364

```

cacctcgtct atggtgtatt tttgaaagac aatTTTTTaa aggtagattt gggaaaaaaaa 60
tagaattgaa gatgggaaat tttgttttat taaaaagggt ctagaagatg tttcaaagac 120
aatattctta ttttaatacg ctgtagaagg taggtgtgga acctccatgc taccatgtgc 180
acaaacctaa ttatgctttg ggtcacttgt cagttcagta aatctgcctt cctcttctcc 240
caaatcatgt catcttttag ttgttcacct gcagctgctt taaatgaatt agtatcttcc 300
agatagataa ccttacaagg agaattgttg ttttgagcag ctgacccaaa atatatcaaa 360
caggattatg gccaaaaagt cactcaaat tctagagatt cttttaaag atgtatgttg 420
atgaaattgc ccctttataa gaaaaacaac agcaagtctt ttagtagaaa tttgaaagaa 480
gtgtttgcta ccattttgac ccattattcc cttacctatc agatgaattt gccattcact 540
ggatagaaac cattcttgga tttggttaaga ggtgagcaag acaaatcttg taccatactc 600
ttatgtacca gcacttctga tggagaagca gtgaagttca gaacgktctt cacatagtcc 660
agatactgkt tagagtcagg caaatcagca aagcctttgg tatggagatg mccccatgatg 720
gctgcagttg taagtgggca tacatgttct atcattttga aggagaaaga aaaccgttct 780
cacatgtcgc aaatatgtga atcatactat attcccttaa agtaaaacca gtgacttagt 840
ggtttttgrt ttatttagaa gttggtttag acccttatga aacattattt acgagttggc 900
cttatcctta agggaaaagt tctaaatttt taaatttatt ttttaattccc tagtctgagg 960
gaaatgtctt tattgtccat tacataaaaa tgttgactcc agtaatttat ttttctctat 1020
tttttccctc atgtatttac tccatttttc tctatttttt ccttccctga tggatttgca 1080
gaaatgttaa ccaattagct caacttttct ctacctttgt tgagtcttaa tcttttagaa 1140
gataggctta ccgtatattt atgaagcata atatatataa agaaaacaaa tctaggatgc 1200
ttgcatgaca taaagtattt gcctgcagtt ttcattaaaa actgcaagaa tatcatgctt 1260
gtctgcttct tagtaaatgt taagtctgra atggaagtga ggatgtaact ctactgaata 1320

```

```

atcaaagatc atcttagatt tggcttgatc tgtgtttatt gcttctatta atgtaaatca 1380
actctgtgcc aaatcctcct ccacaaacca tttattgtct tagttctagt ggtatcaatg 1440
aagatagtta cagtatatga attctaagtc ctgaggaaga aattttatgg ggtttgttaa 1500
gtttcacatt cgtgaaagag gaaattagta gagtattcag actttgatat ttggctgtta 1560
atgggatgca tatcaaattt ttaaaagaag gcttggccta aggagtttat tggtagaggt 1620
gcagatgatt ttaaggcatt aaaggattat agagttatgt catttagact gtttctaata 1680
actgagacca tctaacattt ttcttttgga gtctcatttt tatttgtgca atattttcag 1740
gcataataggc tactgttcat tgtatttata tataatattag aatttactaa gtactttaac 1800
aagtaaaaat ctgaatatga aagaaaatat cagatttgca ctttaaatga gcttaattgc 1860
ttgaagttgt gcctgaaata tcgaattgcc tcctattggg tgtggctttg ttgaaataaa 1920
tttgtaattg ttgctgtttg aagatattcag tacagctgtt cacagaaata tattccagc 1980
atgtcacttt tccattaaag cactaagttt tccttgaatg ttccattgtt ccgataagta 2040
ttttactttt ttctcagtac atcagagaga gcgtgatccc cctacagctg tcacttccaa 2100
atgttcctgt agcataaatg gtgttacaga cactgaggtg cactcttggt ttctgagcag 2160
agttgtcata ctggtttcct ggtctctagg gcactgggga tgtactttga aatcacccgaa 2220
caggcttgca attaagatca ataaggctgc agcaccattt caatttactt tccatcttac 2280
ccagtagttt ttgtgttttt aaattcgttt ggggtggttat gtttgcatgc ttaagcacac 2340
at ttgaaaat taattatagc tgtactaccg gatgtttttc cttggggatg atggccttgt 2400
tcctttttta attctgatgc ttgaattcta ttttctagtg atttttcaca tctcccttta 2460
agtttttgct gcagcaattt gagagagtac ttttgattaa atgattctga tgggtgggcac 2520
caatctacaa ctatgtcatt aactgaagat acatgtttta atcttggttg gaataagctt 2580
accactttc tccttggtta agcgtttact taacaaaata ataccgaga atgtaaggtc 2640
tctaagtcac tactaacaaa gagcaaaaat aatatctgca gtattgtttt tccattgat 2700
tttaagtcag ttttagagtac aaactgtata ttagaatttg cctgtaaaat gaattctaaa 2760
aagcagatgt aaagtctctc ctgaaaatgt tggcatagta aataaaaata aagttcataa 2820
ttataaaaaa aaaaaaaaaa aaaaaaatta ctg 2853

```

<210> 365

<211> 1837

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (136)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (749)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1816)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1829)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1832)
 <223> n equals a,t,g, or c

<400> 365
 nnnntttttt tttttcacgt gtgtggtcaa gatgctrvag ctcggettatt atttcggacc 60
 acatgaagggt gcacagccag ggtcctcacc atgtctgtga gctctgcaac aaaggtacat 120
 gccgagggtt gccggnaggg ccaggggcag aggggtgggcg cctggccaga cgccttgcca 180
 cggatacggg ttaaggggtgc ttagaccaag agctcgtggc gtctagattc ctacaagagg 240
 tcaagggagc agcgggggga cacctgaatg aacatcatta gactctaaga agtcctgggt 300
 ggaagagatg atctgccaga gaggttgaac ctccctggtaa tgtgtgggga aagcgggagt 360
 ggaacttggc tgctctgggg aaggagtagt caagaaagcc agttccaggg gtcacaaggc 420
 aaggtttccg ctgcgcagcc acaaggctct gtctccagct cctggggcag gtggagtaca 480
 cgggccgggc tttaccagca cgcaccctgc gcatccacgc ggtgaaggac cacgggctcc 540
 agggccccgc gctgaccgca tcctgtgcaa gctgtgcagc gtgcactgca agaccctgc 600
 ccagctggcc ggccacatgc agaccatct gggggggggc gccccctgt cccgggagac 660
 gccccccagc cacagcccac ctgctgaggg ggacccccgc acccaccagg tactgggtgag 720
 gtttgtccaa tggcgggcgc agcggcagng gcggcagcgg cagcagcggc agcagtagca 780
 gcccctccca cagctgtggg ctccctctcg ggggcggagg ggggtgcctgt gagctctcag 840
 ccaacttccct cccaaccctg gtgagctcca agttggttgc ggggggagagg ggagaatgga 900
 gtagagtccc ttggtacaag ctccctctccc cctcttttcc ccaccaactc ctatttccct 960
 accaaccaag gagcctccag aaggaaagga ggaagaaatg ttttcttagg ggaattcgct 1020
 aggttttaac gatttgtttc tcctgtcctt cttctatcag acctgacccc acacaaacct 1080
 gtccccctcg ttgtgttgaa gtccccctga cagtgggcag ggggtggcaga ggacacgagc 1140
 agccaactgcc cgtacccccct ctccctctctg taagcccatg ccctgtcttc ccagggaactt 1200
 gtgagcctct tcctctgacg gtccctctct ctccctccag tcctctcccc ctgctgtctg 1260
 cagccccctc ccgggggagtt ggtgctttct tttccttttt ttttttttcc aggggggaggg 1320
 aggagaggaa ggagggggat cagagctgtc ccaaagaggg aaagcgggtga ggtttgagga 1380
 ggggcagaag cagggccggc aaaggttgta ccttcataag gtggtatggg ggggtggggg 1440
 caggccctga acatcgtcct acttgagaat ctgtcagggg aaaaagtcaa ggggagcagg 1500
 aggaagagcc agggaggcca gaggcagaga agagatggag tcttaggggc cagggtgagc 1560
 gaggggtcca gggcctagag gtgcttcctg ggggcggggg aatgcagcca gtgtccccct 1620
 cccctcttcc accccagctc cagccctggt cttgtctttt catccctctt cccacgaca 1680
 gaagaagttg tggccctggc catgtcatcg tgttcctgtg tccccctgat gtaccccacc 1740

ctccacccct tccttttgcg cggaccccat tacaataaat tttaaataaa atcctgaaaa 1800
aaaaaaaaaa aaaacncgag ggggggcccng gnaccca 1837

<210> 366

<211> 1823

<212> DNA

<213> Homo sapiens

<400> 366

ggcacgaggc aggrcggggy ccaysgaagy cggaatccgc tgtgctcact gatccgcctc 60
cagggccacc gccatgtcga gccgcggtgg gaagaagaag tccaccaaga cgtccagggtc 120
tgccaaagca ggagtcacat ttcccgtggg gcggtacatg cggtagatca agaaaggcca 180
ccccaaagtac aggattggag tggggggcacc cgtgtacatg gccgccgtcc tggaaatcct 240
gacagcggag attctggagc tggctggcaa tgcagcgaga gacaacaaga agggacgggt 300
cacaccccg caccatcctgc tggctgtggc caatgatgaa gagctgaatc agctgctaaa 360
aggagtcacc atagccagtg ggggtgtgtt acccaacatc caccgccagt tgctagcgaa 420
gaagcgggga tccaaaggaa agttggaagc catcatcaca ccaccccgag ccaaaaaggc 480
caagtctcca tcccagaaga agcctgtatc taaaaaagca ggaggcaaga aaggggccccg 540
gaaatccaag aagcaggggtg aagtcagtaa ggcagccagc gccgacagca caaccgaggg 600
cacacctgcc gacggcttca cagtcctctc caccaagagc ctcttccttg gccagaagct 660
gaaccttatt cacagtgaat tcagtaattt agccggcttt gaggtggagg ccataatcaa 720
tcctaccaat gctgacattg acctaaaga tgacctagga aacacgctgg agaagaaagg 780
tggcaaggag tttgtggaag ctgtcctgga actccgaaa aagaacgggc ccttggaagt 840
agctggagct gctgtcagcg caggccatgg cctgcctgcc aagtttgtga tccactgtaa 900
tagtccagtt tggggtgcag acaagtgtga agaacttctg gaaaagacag tgaaaaactg 960
cttgggcctg gctgatgata agaagctgaa atccattgca tttccatcca tcggcagcgg 1020
caggaacggt tttccaaagc agacagcagc tcagctgatt ctgaaggcca tctccagtta 1080
cttcgtgtct acaatgtcct cttccatcaa aacgggtgtac ttcgtgcttt ttgacagcga 1140
gagtataggc atctatgtgc aggaatggc caagctggac gccaaactagg ctgagcaatg 1200
acagaaccag ctgcaccatg taccacacct tcagtttaaa agaaaaaaaa aatccccttc 1260
actcctactg ggaggtggga cccctttcat tttcagtttt gctcatctag ggaaaataag 1320
gctttggttt ccagtttaat tgtttttgac cttctaaaat gtttttatgt tagcactgat 1380
agttggcatt actgttggtt agcactgtgt tccagaccgt gtctgactta gtgtaacctt 1440
ggagatttta tagttttatt ttaatgaaac cctgattgac gcacagcagt ggggagaaca 1500
gcgtctttta cctgtcaccg aagccaggaa gccccgtttg taagcgtgtg ttgtgggtgt 1560
ttattgtaca tcctccagtg gcgttctttt tactctaatag ttcttttggg tttccccctc 1620
agaagaatca tgaatttgca acagacctaa tttttgggtt ctttttgtct tattgatgga 1680
tttgaatatg aaagatttaa taaggcaaag cagaatctgt tgtccttaat tatatttgca 1740
atttggaatt tgtgtgagtt gatttagtaa aatgttaaac cgtaaaaaaa aaaaaaaaaa 1800
aaaaactcga gactagttct ctc 1823

<210> 367

<211> 898

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (17)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c

<400> 367
 aagggggggg aaaattngag acacnttttn aaggtacgcc cgcaggtacc ggtccggaat 60
 tcccgggtcg acccacgcgt scgctcctgg ggccatgagg ctgtcactgc cactgctgct 120
 gctgctgctg ggagcctggg ccatcccagg gggcctcggg gacagggcgc cactcacagc 180
 cacagcccca caactggatg atgaggagat gtactcagcc cacatgcccg ctcacctgcg 240
 ctgtgatgcc tgcagagctg tggcttacca gatgtggcaa aatctggcaa aggagagac 300
 caaacttcat acctcaaact ctggggggcg gcgggagctg agcgagttgg tctacacgga 360
 tgtcctggac cggagctgct cccggaactg gcaggactac ggagttcgag aagtggacca 420
 agtgaacgt ctcacaggcc caggacttag cgaggggcca gagccaagca tcagcgtgat 480
 ggtcacaggg gggccctggc ctaccaggct ctccaggaca tgtttgcaact acttggggga 540
 gtttgaggaa gaccagatct atgaagccca ccaacaaggc cgaggggctc tggaggcatt 600
 gctatgtggg ggaccccagg gggcctgctc agagaagggtg tcagccacaa gagaagagct 660
 ctagtctctg actctaccct cctctgaaag aagctggggc ttgctctgac ggtctccact 720
 cccgtctgca ggcagccagg agggcaggaa gcccttgctc tgtgctgcca tctgcctcc 780
 ctctccagc ctcagggcac tcgggcctgg gtgggagtca acgccttccc ctctggactc 840
 aaataaaacc cagtgcacct aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaactcga 898

<210> 368
 <211> 1117
 <212> DNA
 <213> Homo sapiens

<400> 368
 gccctgagcc ccgccatggt ggtgccggag gaccagctga cccgctggca cccgcgcttc 60
 aacgtggatg aagtaccgca catcgagccg gccgcgctgc cccagccacc cgccacggag 120
 aagctcacca ctgctcagga ggtgctggcc cgggcccgcga acctgatctc acccaggatg 180
 gagaaggcct tgagtcaatt ggccctgcgy tctgctgcgc ccagcagccc cgggtctccc 240
 aggccagcac tgccggctac cccaccagcc accccgcctg cagcctctcc cagtgtctctg 300
 aagggggtgt cccaggatct gctggagcgg atccgagcca aggaggcaca gaagcagctg 360
 gcacagatga cgcggtgccc ggagcaggag cagcggctgc agcgcttaga acggctgcct 420
 gagyttggcc gcgtgctgcg gacgctcttt gtgtccgaac gcaagcctgc gctcagcatg 480
 gaggtggcct gtgccaggat ggtgggcagc tgttgtacta tcatgagccc tggggaaatg 540
 gagaagcacc tgctgctcct ctccgagctg ctgccggact ggctcagcct ccaccgcctc 600
 cgcaccgaca cctacgtcaa gctggacaag gccgcggacc tsgccacat cactgcacgc 660
 ctggcccacc agacacgtgc tgaggagggg ctgtgagcct gggggccact gtggacagac 720
 gtgggcttca gaagctcgct ggcctggggc caccagcatt ttcttttatg aacatgatac 780
 actttggyct tcctttcccc agcgcccctg agggccagag gcagatgtgg gctgcaggct 840
 gcacagcccg agggctctctg gctgcggcgc tctggccccct tcatggggct cacctggtgg 900
 attcacatta aaccggtttc tgtgggcacc tctgtccttg ctgctgggtg ggaagggaag 960
 ccagatccag caccctctgg ggggccatcg ggagtgtggc tggrrgtgaa gggggctctg 1020
 tggcaatatg gggttgggta gtgtgggtgg caaggccatc ccctctaatac ttggaacctc 1080

tgaatatggg accttccaca gcaaaggggtg actttttg 1117

<210> 369

<211> 2226

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (24)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (35)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (36)

<223> n equals a,t,g, or c

<400> 369

tataggagaa agctggtagc ccnccaggt accgnntccg gaattcccgg gtcgaccac 60
 gcgtccgggg gattattaac cacttagaat ataaaattgt acaacaattt cacttgttta 120
 ttgcatttt gttttttata actcttactc ctttttcccc tcaaaggaga actgtgttta 180
 tgaaactgta gttttgcctt tggatgaaag ggcatttgag aagactttaa caccaatcat 240
 acaggaatat tttagagcat gagatactaa tgaagttgag gaaatgttaa gagatttaaa 300
 tcttggtgaa atgaaaagtg gagtaccagt gttggcagta tccttagcat tggaggggaa 360
 ggctagtcac agagagatga catctaagct tctttctgac ctttgtggga cagtaatgag 420
 cacaactgat gtggaaaaat catttgataa attgttgaaa gatctacctg aattagcact 480
 ggatactcct agagcaccac agttgggtgg ccagtttatt gctagagctg ttggagatgg 540
 aattttatgt aatacctata ttgatagtta caaaggaact gtagattgtg tgcaggctag 600
 agctgctctg gataaggcta ccgtgcttct gagtatgtct aaaggtggaa agcgtaaaga 660
 tagtgtgtgg ggctctggag gtgggcagca atctgtcaat caccttgtaa aagagattga 720
 tatgctgctg aaagaatatt tactctctgg agacatatct gaagctgaac attgccttaa 780
 ggaactggaa gtacctcatt ttcacatga gcttgatat gaagctatta taatgggttt 840
 agagtcaact ggagaaagta catttaagat gattttggat ttattaaagt ccctttggaa 900
 gtcttctacc attactgtag accaaatgaa aagaggttat gagagaattt acaatgaaat 960
 tccggacatt aatctggatg tcccacattc atactctgtg ctggagcggg ttgtagaaga 1020
 atgttttcag gctggaataa tttccaaaca actcagagat ctttgtcctt caagggggcag 1080
 aaagcgtttt gtaagcgaag gagatggagg tcgtcttaaa ccagagagct actgaatata 1140
 agaactcttg cagtcttaga tgttataaaa atatatactt gaattgtaag agttgttagc 1200
 acaagttttt tttttttttt ttttaagcac ttgttttggg tacaaggcat ttctgacatt 1260
 ttataaacct acatttaagg ggaattttta aaggaaatgt tttttctttt ttttttgttt 1320
 ttcgaggggg caaggaggga cagaaaagta acctcttctt aagtggaaata ttctaataag 1380
 ctaccttttg taagtgccat gtttattatc taatcattcc aagttttgca ttgatgtctg 1440
 actgccactc ctttcttttc aggacagtgt tttttgtagt aaaatcactg gtttatacaa 1500
 agctttatatt agggggtaaa gtttaagctgc taaaacccca tgttggctgc tgctgttgag 1560
 atactgtgct ttgggagtaa aaaaagaaag tttttctttt gtcttaaaaga atttttaaaa 1620
 aattagtcac gagacttatt catctttcca ggaacatac tgattgggtc taaaagacta 1680

```

gacagttaag taaaagggtgg ctggaacatc tatttttcta caaaactgga aaaatgaacc 1740
tggttctaga agaattgtaca ccaaaataaa acatgtgaag cagtattgat tctttattgg 1800
gagtacattt ttttaggtct cttaaacttt aatttcacac agtaaatttt gaatctcata 1860
aggaagcata tttgaaccta gtcaatttaa tcttagtggt cccttgaaaa ctttttttcc 1920
ctacaaaatt ttaagtgaat aatacaatag taaattaaga ttacactggg gaaaaaatg 1980
caggtatcac tttactccat tggtatctga cctagagctt aattaagttt tagaaatatg 2040
taataccttc catcattcca tcctccttaa attctgttac caaataatgg ctaatgttac 2100
aaaaagttat actccagaga cccaaagctt gacatttacc taatgtatga gaaaatatta 2160
ccaattaaca ataaagaatg atcatatttt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220
aaaaaa 2226

```

<210> 370

<211> 3636

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1937)

<223> n equals a,t,g, or c

<400> 370

```

caccaaggag cgcgtcaaac ttgaagggtc aaagtgcaaa gggcagcttt tgatttttgg 60
ggcaaccaac tgggacttga ttggtcgaaa agaagtgcct aaacagcaag ctgcttaccg 120
caatctcggg cagaatttgt gggggcccca cagatatggg tgccctggcg gggtccgggt 180
gcggacagtg gtctcgggct cgtgtgctgc acacagcctc ctcatcacca cggaaggga 240
gctgtggagc tggggtcgaa awgagaaggg gcagctggga catggtgaca ccaagagagt 300
agaagcccct agactcatcg agggctcttag ccacgaagka ttgtgtctgc agcatgtggg 360
cggaaccaca ccttggcctt gacggaacg ggctccgtgt ttgcgtttgg ggaaaacaag 420
atggggcagc tgggccttgg caaccagaca gacgctgttc ccagccccgc gcagataatg 480
tacaacggcc agccaattac caaaatggcc tgtgggstg aattcagtat gataatggac 540
tgcaaaggaa acctctattc ctttgggtgc cctgaatatg gtcagctggg acacaactca 600
gatgggaagt tcctcgcccg ggcacagcgg atagagtacg actgtgaact agttccccgg 660
cgagtggcca tcttcattga gaagacgaaa gatggacaga ttctgcctgt accaaacgtg 720
gttgtagcag acgtggcctg tggcgctaac cacacgctgg tcctggactc ccagaagcga 780
gtcttctcct ggggcttttg tggctatggc cggctgggca cgagagcag aaggatgaga 840
tggtcccccg cctgggtgaag ctgtttgact tccctgggcg tggggcttcc cagatctatg 900
ctggttacac ctgctccttt gctgtcagtg aagtgggtgg tctgtttttc tggggggcca 960
ccaacacctc ccgtgaatct accatgtacc caaaagcagt gcaggacctc tgcggctgga 1020
gaatccggar cctggcttgt gggaagagca gcatcattgt ggccgccgat gagagcacca 1080
tcagctgggg tccgtcaccg acctttgggg aactgggcta cggggaccac aagcccaagt 1140
cttccactgc agcccaggag gtaaagactc tggatggcat tttctcagag caggctcgcca 1200
tgggctactc aactccttg gtgatagcaa gagatgaaag tgagactgag aaagagaaga 1260
tcaagaaact gccagaatac aacccccgaa cctctgatg ctcccggaga ctectccgac 1320
tccacacctc tcgcggcagc tgtcatttcc atgtgactg ggacgggaag tcaaacgagg 1380
aatttaaaaa agcaaaaagt gaccgaagtg catttttgtt tagactccct gaggttccgt 1440
tttacacatg atccaacgtt aactaccttt ttttctgtat gctttccaaa gtcttttttt 1500
tcccttaatg ttgaattaaa atacttgctc atagttgatt taccattcct acaaaagagg 1560
cagaaacttt gagcaatcta ggtttttttt ttttttaagt tttttctttc ttcccttcc 1620
gaatacactc cccaaaacac ccctttccag ttacaattag catcgtgatc caagcagatg 1680
ccacatggaa gaggaatcgc catttactca gaaaaaatgt cccttacagg aaccggcagc 1740

```

```

agctaggcag tcaccggccc gcctccatcc aaaatcacgc tcgctgtgctt cggaagcatc 1800
cgggtcactc cttctccgct ttttcttgca gatgggccta ggccggtgtc ggttctgttt 1860
ctcccccttg ctgcctgtac gccacagcc ttctggctgc gacattatag aatcggccgt 1920
gtcccccttg gtggggnatt ggggatctgt gtttagccat ttatatctac ttagctgtt 1980
aaagagggtcc aaatgaaaat cagggtgatt tggaaacatg gggacttggg ggtggggcag 2040
aggtgggaac atttgtatca gttgagtcag cttggtggct ccctgtggag cagggtgag 2100
ccttgtcacg cgcactcgcc aattaagaga tggaccagcc agcagtcaag tgcattctcc 2160
agtccttgca agaaggatca gccctttctg tgccagcctc gatcgccctg tgccttggtc 2220
tctttttctc cccccgcct ggatcctgcc tcgcgcgggc cgtcctgttg ctgagactcg 2280
gggtaccgtt ctgctgacct agctcccttt agtcacgttt gcttggtctt ggtaccaa 2340
agttgggatt accgaagagt ccccttcctt gcgtgtcagc acggatgctg tgactgccac 2400
ctgcgtcctc gtcaagtgcc cgagctcgcc gccgtgtgtg ctgcgtgag tgagttatga 2460
ggtgcctttc ccggaaccct cctctcgcc ggaccaaga gaggcgacag ctgtggctgg 2520
ggctcttggt ttccagaggg tctggactgg tttgggtgct ttaaaataga tatttagttc 2580
agtgggtgct atgggggaga tgggactaga acttaagtgt gagacttggg tggatgggaa 2640
agttaaatat tggctctctc aagttttttt tttcttttgc tttgttacca cttgtcactg 2700
tctccatggt aaaatgccaa aaatgatgta gttgtgtgtg cttttttccc tattttccac 2760
cccagtcgct ccttaccgtg actcctgccc ttggagggca tgtagcagtg tctgtcctgc 2820
cagtcccaag gccctgtggg aggagactgg cctgcatctc tctaagactt agtctgacgc 2880
cacgcgcata tcttgttctg tgttcaatca gtagtcagg ggagaagctt ctgctacttc 2940
agagctttgc taaactaacc taatttgtcc aaatcacccc aaaaccacca tctctgacgt 3000
aagcttccat gcgacagcct gatccgtttc cctggacagg tctctttcct ggaatgcagc 3060
ccaggcacct gtgctcctgg cacccttgag gtctctcctt tgagccgtgg tcaccgagag 3120
ggttgaggac gcagcacccg aggtcccagc ctttgcaagg gcctccctgg gcttagctgg 3180
acttagatct tcggtggcct catgtaaacg tggcagccag cctcttctag aaccctagcc 3240
cagggactgg agcaggaaaag ggacctcaa agtgaagact gccttgtccc gcagctcctt 3300
ctggcttaga ttgaaamatg ggcttcctaa tgggttaaat cctttaaaac aaggagtgtg 3360
gggggaaggg tgtcgtgcac tcctagagaa aggtacacag ttgcccggtt gggaatgtgc 3420
ttggcgctga ctgcgggcat ctgactggtc ttccagctca ggaaaaagaa tttgaaagag 3480
gcttagcggt aaggggaatc aaagaggagg ttgtgatttg gtcgaagggt cctgggttag 3540
tgctgtaatt gtcttattat tttttttata tataattttc ttggagtaaa cattttaaat 3600
aaacaacatt gtctactgtc aaaaaaaaaa aaaaaa 3636

```

<210> 371

<211> 4039

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1085)

<223> n equals a,t,g, or c

<400> 371

```

aattcggaac gaggggtgaag cacaaggatt aagttggaaa agctgtaaat tgcattgtga 60
tatttgtcta ttttttctat aagttttatt gcaagaggta aagaagaaaa ctatatatat 120
atatcttatt tagataatct cagtaccttt tctggcattt ttgccctgta taggttgact 180
tggcaattcg gccttttttag aggcattaac tactcctcgt aagtgttgca tttacatggc 240
tgtttagaaa actgctgccc aaattttatt tatatttttg tacagattct gcagtttatg 300
atatgttttt ctaaaaacaa atgctgttta tacatatgag atagctattt tgataggatt 360
tgctcacata gttcctgcaa acttcagatg tacaagttgc acttgactt ttatagagtt 420

```

```

gtaatgtttt atatgtgtat ggtgcaagag aaaattggat caaatcaayc tgcagttgat 480
gtcccccacac gcaaacacag gcacacacat gcacacaccc ataaacacac acacagtgcac 540
tttaaraaag ggccaggtga tatcacacccc aaatttcaca agcactgacc ccctggcacc 600
aacacccgcc agtactgtga cttccaaagc cagagccaca tgtgctcatc aaacttgcac 660
taagcagttg gcgggagatg gctgtggagc tgggggttta agtgatgggt ctcttttgct 720
ccctcttytg agggtaaagc tactgtcttt cttaagagtg tatttatgcc aagtttgcc 780
ttttaattgt ttttattttg twttttaatg aaaaccaga tctttccttt ttggcataat 840
ttttatgatg acctgaaatt ttacatccga acaaaatttt acatccgaaa agcaaccaac 900
ttcttcatgg aactcagccc tgttgcaatg cttagggccc ttaaagaaga aaatctcccc 960
agaaggcatc catcatgttg cttaattgtc ttctgcagct tcctttccct agagctttcc 1020
ctgtgttgct aagagctgra aatggcatct tcgtgatcac cacagtgagc ttggctcgcc 1080
tcggncggcc cggggatgca ctcttacaac atgtgtgact cttgaacctg gagttcatca 1140
cattacgtca cagcttccca tctggttgct ttcttgagtc agctacttca cacttgtcaa 1200
ggctgtttta cccaaaact cagacaggac ttctatgca tgttttcct cctccccca 1260
attccccccc catcacctta tctcccagga cacacttgag aagtagcttt ttattcttag 1320
tggtgtacat ttaattttaa aaaggttgca atgtatcatg cttgttgccg aaactgttta 1380
tggccttctt gtttcagttt tttcttttct tccaatggta ctttagctgt tgagtgcagg 1440
ttacaaccta tattgttatg cagatggctt ctttaggaat aacttttata tttatttaaa 1500
aatttttaaa ttatgggatg tttgttgtt gttgttgtct ttgttgttg tcatgtgtca 1560
atattcagtc accaattctg ctacttctt gccatggata aaattgggtc tttctggcta 1620
attaaaaaag acaactttat aaaatggcac tttaagcaag ccatagttag ttttattttt 1680
gtaatgcaca tggcaaagca aagacgtttg tgatgaagga actgctcatc taagcaaaag 1740
atgtgagtat gatatgataa aggttttcta cattctaatt tactttttcc cccacttga 1800
atgtgtttta aaggctaatt atcagctcag tagagcagtg agaaactgat caaattgcac 1860
ttgttctcct acaagcaacc tccacgcaga cacctcgtac tgctacaggt gtgtcatttc 1920
ctttaatagg accagggacc atgtaactga ggtgagggtt gtagtaratg cttccagtgt 1980
cagtatgcct gttaatttta agagcttccc tttcttgagc agaacaagtc tgcccagatt 2040
ccatgctttc tataactgga ggacctggca aacctgccgc atgctgcaca catctacct 2100
cgtacacata tacaatagta ttgatgatc tgaacaataa cagggtaaaa cagttggttt 2160
gccattgtta aaaactgatt tacagtaact tacaacaact gtacttttgt tggattagca 2220
aatcatgtgt ttaaacaaat cccatatgtt gggcaacagt tcaaataagc acggagaagt 2280
gttgcccaa cttggttctc tgactcttat gtatttgtaa ggctgggctt caaaatcaa 2340
acaaaacccc caaaaacagc aggc aaatgc tttttaactc tgacaccgtt gccataaatc 2400
cctgatactc aaagtctaac aagaaagaca tggaaaatta gcagcccatt ttcagaaaga 2460
tcaaaatgat ctagggttct aattgctttt gcacctatt cttacaaagt gatgtcccaa 2520
cagggaacag taggagctgg agtgggatct ccaagtccca gtttgagtgt gggatgtgct 2580
tccagcagtg ccttcccttt atgaaagaca tcacatggca tccagggcca ggcaggcagc 2640
ttgaggtgcc tttacgagaa aaccgagctg gggctgggag aggacagtta ttgacactga 2700
tgtgcaatga agtgacaaga tgagagcaga atcgtaagag ctttgaattt gaagtgaagt 2760
ttttcccccc ataagttatt ttttctttt ttctgtgtaa atataattat tttactgtgg 2820
agcgctaaca tctggatcgt aacatgtgca gaatgtatgg taggaatgta ttctcttgta 2880
ggaatgtaaa tctgtattaa aaggggttcc aagccaggcc cccaggctct ctcatgtat 2940
gcacagtcgg cattcatttt tactcttctc taatatgggt ctatttgaaa tatgcaaaag 3000
gtatgaggaa tgttttaata cttccaaatt ttttaaaaa gcacaaagg gttgatattt 3060
tttaaagttt ttttagtagc actttctctg gatgacagaa ggggcaacca catgggcacc 3120
cttgttcata ccaaagggtg agcagtggcc agagcctcct ctgcacctct cgagtgtctt 3180
taccaattga gctttttatc gccatagccc cttggagtgc cccagctgcc ctgagggtcaa 3240
tcaaggaaaa tttcttaatg aaataagctc caaagagcca aagtatcaac ttacagatcg 3300
tttttaagc ttaaatatt gaaccactt tgtggttaaac aatgaattat gaataccgca 3360
gggcagcctt cttaaatgac aaatgtaaaa aaaaaaaa aaaaactcta cttcgtgcag 3420
caattgctac tctatacgaa ttgtcttaat ttgaaaacct tgctgttaca aattggacct 3480

```

```

ttatacattt tctgaaaaca atgaaaagag tatatttaac cttttctggc tgtaaatggt 3540
taccttcctg taactgcccc gcacctggag gcatggagtt gtgtgcatcc tgcttatgta 3600
caattgtttt cagtgtttct aagaatgagt ctgaatgggt cttgaaaatt agccaggatc 3660
aaatgctatt gcagacaaaag ccaataaaaaa gttggacttc ttttggggat aacaagtttt 3720
ggaagagaaa tgcaggccat atgtgcgcat gaccgagatt ttgaaaaaag atgtacatag 3780
tgacatgttt ggtgcatggt ttttgaggag ggcttttgtc aaaaaggagg tataaccttt 3840
ccccacaga cctgagagct gtgccttttc tatgcaatat tacagacgtt acatcggaac 3900
ccagatggct gtattcacat gtaggttttg gctgtaatct aaacaattgg acagattaaa 3960
tgtacatgga aatgagcagt cttacttttg tagttttata ttatacaata aacagttaaa 4020
agatgaaaaa aaaaaaaaaa 4039

```

<210> 372

<211> 1599

<212> DNA

<213> Homo sapiens

<400> 372

```

ccatccagct ggggatgcag agcacctgat gcacctggaa cagggtgctct gcatccccag 60
ctggatggca aaattctttt cttggacact tgaaccatc ttctcttctt cagaaccac 120
cagcgaacag aattgggatg ggagccacgc tggacatcca gagacagcag agaatggagc 180
tgctggaccg gcagctgatg ttctctcagt ttgcacaagg gaggcgacag agacagcagc 240
agggaggaat gatcaattgg aatcgtcttt ttctctcttt acgtcagcga caaaacgtaa 300
actatcaggg cggtcggcag tctgagccag cagcgccccc tctagaagtt tctgaggaac 360
aggtcgcccc gctcatggag atgggatttt ccagagggtga tgctttggaa gccctgagag 420
cttcaaacia tgacctcaat gtcgccacca acttcttgct gcagcactga tagtcccagg 480
ccaacactgg gaccggaccg gcagccgagt gacagtgcgt ggtccccacc atcagatcag 540
cccggggacc gagcatctct ggtgctgatg ttcttgtggg aagagggagg ttccaccgca 600
cccctgccct caaccgcaag actggtgccg ttttagtgtg gagataagtt tgccattaca 660
ttagcatgta ttttctatct atatttttta ttgggcattt tccctagggt ggagagtcag 720
cactcgtttt gaatgtgttt aaaatgcatt aaaatggaag atttctgcag gcagttgaat 780
ggcactccag atggggaatt gctgtaaccc tcttactgta acatgtcatc tcctgcgtcg 840
tgatggggag agggtaatgt tacttcacaa aggacatgtc agatccttct tcatggactt 900
ttttagttac tgttttttct ctcaaacttg ttttcgaatc tcctgggagt gagggagaaa 960
cagggagctg aatcctcccc caagctgttc caggccagag gactctgcag taccttctcc 1020
tacatctagt aacaaagaat ggtgataacc atgcactggg tcaaggttct ggagttctcc 1080
atgaaacttg ggtaattttt gctcagagta tccagagtta gccactaggc tgcgggtgaa 1140
atgggatgga gaagaacaac agcaggcttc ctggagccac atgggctgac tagggcactc 1200
tgtggctggc ctggcatggg ctgagcccag gaagaggaga aacgatccct tgcctgcccc 1260
tccctgtggc agggctaact gcctggccct cctggctcgc agccagccag cccctggcca 1320
gcaggttctc ctgagggtt gggtcttcaa cctgtggcga caggaggcag ggcagactgt 1380
ggaggacagg atgcagggtc gggagagggg aggcaggggt ggaccgccat gagcatgaaa 1440
agaccggaag caagttgact cttgcaatgt gcaactgtta tgttctgcaa aatgagcaac 1500
gatgtatcaa attgatgcaa atttagatgt tgatacttac aataaagttt ttaatgtgtt 1560
ttaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agggcggcc 1599

```

<210> 373

<211> 464

<212> DNA

<213> Homo sapiens

<400> 373

```

ctcaaaaatc accagaaaac tcatactagt gaaaaatcct ataaatgtaa tgaatgtaga 60
aaggccttta gttactgctc tggctcttatt caatgtcagg tcattcatac tatagaaaaa 120
ccttatgaat acggtaaatg tggcaaaagcc ttttaggcaga ggacagacct taaaaaacat 180
cagaaaatgc ataccgarga gaaaccctat gaatgtaatg aatgtgggaa agccttttagc 240
cagagcacat atcttacaaa acaccaaaaa attcatagtg aagagaaaatc aaatatacat 300
actgagtgtg gggaaaccwt twgrcaaaac tcttcttttt tacaacaata aaaacctcac 360
actggagaga ttctctgaat gccttaagaa tttggttaat atggagaccc ttcccagggg 420
aaccagaagg aggatcgtga aaacctgttg actacttaga tgat 464

```

<210> 374

<211> 890

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (886)

<223> n equals a,t,g, or c

<400> 374

```

ggctgctgga ggcgagggct tcggaagtct tcatgctagt ctctggtgggt tccgcggtgt 60
cgctcgctggc tgtgcgcgtc atttccgggc gtcacgtaac ggagtggcca acggcctgca 120
gagcaacatg cccaagtttt attgtgacta ctgcgataca tacctcacc atgactctcc 180
atctgtgaga aagacacact gcagtggag gaaacacaaa gagaatgtga aagactatta 240
tcagaaatgg atggaagagc aggtcagag cctgattgac aaaacaacgg ctgcatttca 300
acaaggaaa atacctccta ctccattctc tgcctcctc cctgcagggg cgatgatacc 360
acctcccccc agccttccgg gtccctcctc ccctgggatg atgccagcac cccatatggg 420
gggccctccc atgatgcaa tgatggggcc tcctcctcct gggatgatgc cagtggggacc 480
tgctcctgga atgaggccgc ccattggagg ccataatgcca atgatgcctg ggcccccaat 540
gatgagacct cctgcccgtc ccattgatgt gccactcgg ccggaatga ctcgaccaga 600
cagataagga tagaggggag gccttattgt atcggtttta tattacctgt tctgcttcac 660
caggagatca tgctgctgtg atactgagtt ttctaacacag cataaggaag acttgctccc 720
ctgtcctatg aaagagaata gttttggagg ggagaagtgg gacaaaaaag atgcagtttt 780
cctttgtatt gggaaatgtg aaaataaaat tgtcaactct ttcagttaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaanaaaa 890

```

<210> 375

<211> 1874

<212> DNA

<213> Homo sapiens

<400> 375

```

gttcaggaac ttaggctaga aaggaacaca gtaaactgaa ttgatccgtt tagaagttta 60
caatgaagtt tcttctaata ctgctcctgc aggccactgc ttctggagct cttccccctga 120
acagctctac aagcctggaa aaaaataatg tgctatttgg tgaaagatac ttagaaaaat 180
tttatggcct tgagataaac aaacttccag tgacaaaaat gaaatatagt ggaaacttaa 240
tgaaggaaaa aatccaagaa atgcagcact tcttgggtct gaaagtgacc gggcaactgg 300
acacatctac cctggagatg atgcacgcac ctcgatgtgg agtccccgat gtccatcatt 360
tcagggaatc gccagggggg cccgtatgga ggaaacatta tatcacctac agaatacaata 420
attacacacc tgacatgaac cgtgaggatg ttgactacgc aatccggaag gctttccaag 480
tatggagtaa tgtaaccccc ttgaaattca gcaagattaa cacaggcatg gctgacattt 540

```

```

tggtgggtttt tgcccggtgga gctcatggag acttccatgc ttttgatggc aaaggtggaa 600
tcctagcccca tgctttttgga cctggatctg gcattggagg ggatgcacat ttcgatgagg 660
acgaattctg gactacacat tcaggaggca caaacttggt cctcactgct gtccacgaga 720
ttggccattc cttagggtctt ggccatttcta gtgatccaaa ggccgtaatg tccccacct 780
acaaatatgt tgacatcaac acatttcgcc tctctgctga tgacatacgt ggcattcagt 840
ccctgtatgg agacccaaaa gagaaccaac gcttgccaaa tcctgacaat tcagaaccag 900
ctctctgtga ccccaatttg agttttgatg ctgtcactac cgtgggaaat aagatctttt 960
tcttcaaaga caggttcttc tggctgaagg tttctgagag accaaagacc agtgттаatt 1020
taattttcttc cttatggcca accttgccat ctggcattga agctgcttat gaaattgaag 1080
ccagaaatca agtttttctt tttaaagatg acaaatactg gttaattagc aatttaagac 1140
cagagccaaa ttatcccaag agcatacatt cttttgggtt tcctaacttt gtgaaaaaaaa 1200
ttgatgcagc tgtttttaac ccacgttttt ataggaccta cttctttgta gataaccagt 1260
attggaggta tgatgaaagg agacagatga tggaccctgg ttatcccaaa ctgattacca 1320
agaacttcca aggaatcggg cctaaaattg atgcagtctt ctactctaaa aacaaatact 1380
actatttctt ccaaggatct aaccaatttg aatatgactt cctactccaa cgtatcacca 1440
aaacactgaa aagcaatagc tggtttggtt gttagaaatg gtgtaattaa tggtttttgt 1500
tagttcactt cagcttaata agtatttatt gcataattgc tatgtcctca gtgtaccact 1560
acttagagat atgtatcata aaaataaaat ctgtaaacca taggtaatga ttatataaaa 1620
tacataatat ttttcaattt tgaaaactct aattgtccat tcttgcttga ctctactatt 1680
aagtttgaaa atagttacct tcaaaggcca agagaattct atttgaagca tgctctgtaa 1740
gttgcttcct aacatccttg gactgagaaa ttatacttac ttctggcata actaaaatta 1800
agtatatata ttttggtctc aataaaattg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaaaaaaaaa aagc 1874

```

<210> 376

<211> 2018

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1997)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2012)

<223> n equals a,t,g, or c

<400> 376

```

gccacatccc ggcagccctc ctacckgcgc acgtgggtgcc gccgctgctg cctcccgctc 60
gccctgaacc cagtgcctgc agccatggct cccggccagc tcgccttatt tagtgtctct 120
gacaaaaccg gccttggtga atttgcaaga aacctgaccg ctcttggttt gaatctggct 180
gcttcgggag ggactgcaaa agctctcagg gatgctggtc tggcagtcag agatgtctct 240
gagttgacgg gatttcctga aatgttgagg ggacgtgtga aaactttgca tcctgcagtc 300
catgctggaa tcctagctcg taatattcca gaagataatg ctgacatggc cagacttgat 360
ttcaatctta taagagttgt tgcttgcaat ctctatccct ttgtaaagac agtggcttct 420
ccaggtgtaa stgttgagga ggctgtggag caaattgaca ttggtggagt aaccttactg 480
agagctgcag ccaaaaacca cgctcgagtg acagtgggtg gtgaaccaga ggactatgtg 540
gtggtgtcca cggagatgca gagctccgag agtaaggaca cctccttgga gactagacgc 600
cagttagcct tgaaggcatt cactcatagc gcacaatatg atgaagcaat ttcagattat 660

```

```

ttcaggaaac agtacagcaa aggcgtatct cagatgccct tgagatatgg aatgaaccca 720
catcagaccc ctgcccagct gtacacactg cagcccaagc ttcccatcac agttctaaat 780
ggagcccctg gattttataaa cttgtgcatg gctttgaacg cctggcagct ggtgaaggaa 840
ctcaaggagg ctttaggtat tccagccgct gcctctttca aacatgtcag cccagcaggt 900
gctgctgttg gaattccact cagtgaagat gaggccaaag tctgcatggg ttatgatctc 960
tataaaaccc tcacacccat ctcagcggca tatgcaagag caagaggggc tgataggatg 1020
tcttcatttg gtgattttgt tgcattgtcc gatgtttgtg atgtaccaac tgcaaaaatt 1080
atttccagag aagtatctga tgggtataatt gccccaggat atgaagaaga agccttgaca 1140
atactttcca aaaagaaaaa tggaaactat tgtgtccttc agatggacca atcttacaaa 1200
ccagatgaaa atgaagtctg aactctcttt ggtcttcatt taagccagaa gagaaataat 1260
ggtgtcgtcg acaagtcatt atttagcaat gttgttacca aaaataaaga tttgccagag 1320
tctgccctcc gagacctcat cgtagccacc attgctgtca agtacactca gtctaactct 1380
gtgtgctacg ccaagaacgg gcaggttatc ggcatggag caggacagca gtctcgtata 1440
cactgcactc gccttgacag agataaggca aactattggg ggcttagaca ccatccacaa 1500
gtgctttcga tgaagtttaa aacaggagtg aagagagcag aaatctcaa tgccatcgat 1560
caatatgtga ctggaacctt tggcgaggat gaagatttga taaagtggaa ggcactgttt 1620
gaggaagtcc ctgagttact cactgaggca gagaagaagg aatgggttga gaaactgact 1680
gaagtttcta tcagctctga tgccttcttc cctttccgag ataacgtaga cagagctaaa 1740
aggagtgggtg tggcgctacat tgcggctcct ccggttctgc tgctgacaaa gttgtgattg 1800
aggcctgcga cgaactggga atcatcctcg ctcatacgaa cttcggctct tccaccactg 1860
attttaccac acactgtttt ttggcttgct tatgtgtagg tgaacagtca cgcctgaaac 1920
tttgaggata acttttttaa aaaataaaac agtatctctt aatcactgga aaaaaaaaaa 1980
aaaaaaaaaa aaaaccncgg ggggggcccc gnacccca 2018

```

<210> 377

<211> 818

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (818)

<223> n equals a,t,g, or c

<400> 377

```

atcgacccac gcgtccggag cggttgcgca gtgaaggcta gacccgggtt actggaattg 60
ctctggcgat cgaggggtcc tagtacaccg caatcatgtc tattatgtcc tataacggag 120
gggcccgtcat ggccatgaag gggaagaact gtgtggccat cgctgcagac aggcgcttcg 180
ggatccaggc ccagatggtg accacggact tccagaagat ctttcccatg ggtgaccggc 240
tgtacatcgg tctggccggg ctgcacctg acgtccagac agttgccagc cgcctcaagt 300
tccggtgtaa cctgtatgag ttgaaggaag gtcggcagat caaaccttat accctcatga 360
gcatgggtgg caacctcttg tatgagaaac ggtttggccc ttactacact gagccagtca 420
ttgcccgggt ggacccgaag acctttaagc cttcatttg ctctctagac ctcatcggct 480
gccccatggt gactgatgac tttgtggtca gtggcacctg cgccgaacaa atgtacggaa 540
tgtgtgagtc cctctgggag cccaacatgg atccggatca cctgtttgaa accatctccc 600
aagccatgct gaatgctgtg gaccgggatg cagtgtcagg catgggagtc attgtccaca 660
tcatcgagaa ggacaaaatc accaccagga cactgaaggc ccgaatggac taacctgttt 720
cccagagccc actttttttt ctttttttga aataaaatag cctgtctttc aaaaaaaaaa 780
aaaaaaaaaa accccggggg gggcccgga ccaatttn 818

```

<210> 378

<211> 2565
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1508)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2565)
 <223> n equals a,t,g, or c

<400> 378
 ggcacgagct cgtgccgggg ccatagctgt tactgaagga agtagcctac gtccacgcct 60
 acaactgaag tctcttgaca aacacctcac ccctgcctcc gggatgaaag ggggtaacct 120
 agacctgaat gggcttgacc atctcacaac tgctcgcgtg acgaccgcat tcgtggcagg 180
 taagaagatt gctgtatcaa ctcaagaaag cagtaacttc actgtctttg tattttgaat 240
 tgcaacaaca actttgatata caacaatgaa gcaatgatata ctaagaacma aagartattt 300
 gccaacagtc atcataatat caagtgattg tataagcaga aacaagctgt cacagacctg 360
 tgcgtcagct aatatatgga gaatgcttct tctgatacta ttacttaga ggcagtttta 420
 atataaatca tttcaattat atctacatca aataaaataa aaatgagtga agccccaga 480
 ttcttcggtg gaccagaaga tacagaaata aatcctggaa attatcgaca tttctttcac 540
 catgcagatg aagacgatga ggaggaagat gattctycac cagaaaggca gattgtggtt 600
 ggaatatggt ccatggmaaa gaaatccaaa tccaaaccaa tgaaggaaat tcttgracgg 660
 atctccttat ttaaataatat cacagtagta gtatttgaag aggaggttat tttgaatgaa 720
 ccagtggaaa actggccttt atgtgattgt cttatttctt tccattctaa aggatttcca 780
 ctggacaaaag cggttgccta tgcaaaactc aggaatccat ttgtaatcaa tgacttgaat 840
 atgcagtagc tcttgaaagc agctttgagt tagaagtatg tgtgttacac cctcacatta 900
 gtgtgctgtg tggggcagtt caacacaaat gtaacaatgt atttttgtga atgagagttg 960
 gcatgtcaaa tgcatcctct agaaaaataa ttagtggtat agtcttaaga tttgttttct 1020
 aaagttgata ctgtgggtta tttttgtgaa cagcctgatg tttgggacct tttttcctca 1080
 aaataaaca gtccttatta aaccaggaat ttggagaaaa aaaaaaccct ggttttttat 1140
 ttttgatatt tattattggt tacttcaaac tttgttttac agcgtcctcc acaaaacctc 1200
 tagaatgcac tagatatatt tttcttgagg tcataatcat gatgcatacc aacacaacac 1260
 tactcaaatt atatttcatt gagatgcag ttgcattgag gagtcaactt gacatagagt 1320
 ggagactttt tcaaaatggc ttttacatcc taatgaaagt ttgggaagta tatcctctct 1380
 gccttttcat cagtgccttg tggccagct ggcacccttt ctgaggtttg tgttttgtgc 1440
 taaatggttt tgtccttaaa taggagaggc tcaaaaacat caagatttca ggaaaatggc 1500
 gacastgnca taatggaacc ccctgcttc tattttgttc ttttaattac tatttatagc 1560
 cccagttacc ttctgaattc tgaagtgtat atacctccat gttcctgaaa acaagaaaac 1620
 tottacttcc tgatawtcca tagactgcct tcccagggtga ttgagaacat agagaatggt 1680
 acacatttat tttactctaa atgatctttt acccctgtta gctaactctt gtgttttctt 1740
 caactttatt aattacagt attgcatttt tagcatccag ttgtaagatg aatatattaa 1800
 acagctacca gtgttggtga tacctcatcc ttgaaaggct tagttcattt gtgttttata 1860
 cttcagtttt tccagcatag cagaaaatgc cgcttataat ttttgtgcac acaaaccttg 1920
 gattcccttg taaagttgct attgtttcat agcatgcggc actggccttt tttcatccta 1980
 ctcattacag gcaaaactca tgtcttattt atgaggattt tatagatcat tttctgtaac 2040
 aggtgacaaa agcagaaaaag aatgaagagg ctgaaagtatg aactaccctt ggagcccata 2100
 tacatgatata aggcaatttc ttttgatagt taattcrgtc aaaaatacta ccacttgat 2160

```

gttttctaatt ctgatgtgag ctcatgttac acagactttt agtaagtaac ccgtgactag 2220
aaaataaaact ggatgcttag gagagagtgt cagatgtata agatgctaatt aaaacctgtt 2280
taatattattt gtttagctgta agtttttggg aaatactgaa caaatttagtc cacaatcaag 2340
tgtctactttt tcccttccact gtagggcctc tccctgcaca gagcagtcctg ttttagctgtg 2400
aacaccacaa tctgcagatg ttcaagtccc ttacataaaa tggcatagta tttatatgta 2460
acctatgcat attctcctgt atatttttaa tcatctctac attaaaatac ctgataaaat 2520
gtaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaggg ggggn 2565

```

<210> 379

<211> 1680

<212> DNA

<213> Homo sapiens

<400> 379

```

ccaaagtgcg ggaattccag gcatgagcca ctgcgccag tctacacact aattcttgtt 60
agcccaacag ctgttctgtt ctatctaccc ctcatttcac gctcaaggag tcatacctag 120
aatagttaca cacaagaggg aaactggaag ccaaacactg tacagtattg tgtagaaagt 180
cacctcccta ctcccttttat ttacatgag tgctgatgtg ttttggcaga tgagctttca 240
gctgaggcct gatggaaatt gagataacct gcaaagacat aacagtattt atgagttata 300
tcttagttct tgaaattgtg gaatgcatga ttgacaatat atttttaatt tttatttttt 360
caagtaatac cagtactgtt taactatagc cagaactggc taaaattttt atattttcag 420
agttgaagtt ggtgaagaca ttcattgatt aaacaccaga tcctgaaagg ggttaaatct 480
actttgaaat gaactctgaa tcagtatttc aaagcttttc tggtaatttt agtgatctta 540
tttgattaga ctttttcaga agtactaaat aaggaatttt aacaggtttt tattaatgca 600
cagataaata gaagtacagt gaggtctata gccattttat taaaatagct taaaagtgtg 660
taaaaaaatg aatctttgta attacttaat atgttagtta agaaccctgc aagcttatat 720
ttgctagact tacaaattat tttaaatgca tttatctttt ttgacactat tcagtggaa 780
gtgtaagcta gctaattctt gttttctgat ttaaagcact tttaaatctt atcctgcccc 840
ctaaaaacaa aagggttttg tacaagggg aaatttaaga ttgttaacct tgtttttcag 900
aagggtact gttaattgca cataaacatg aaatgtgttt tcccctgtgt actaacacat 960
tctaggcaaa attcaaactt atagtggtaa agaaacaggt tgttcacttg ctgagggtgca 1020
aaaattctta agacttctgt ttgaaattgc tcaatgacta ggaaaagatg tagtagttta 1080
ctaaaattgt ttttctacca tatcaaatta acaattcat gcctttatag ggtcaggcct 1140
acaatgaata ggtatggtgg ttccacagaa ttttaaaata gagttaaagg gaagtgatgt 1200
acatttcggg ggcattaggg tagggagatg aatcaaaaaa tacccttagt aatgctttat 1260
attttaatac tgcaaaagct ttacaaatgg aaacatgca attacctgcc ttagttcttt 1320
tgtcataaaa acaatcactt gggtggtgt attgtagcta ttacttatac agcaacattt 1380
cttcaattag cagtctagac attttataaa cagaaatctt ggaccaattg ataataattt 1440
tgactgtatt aatatttttag tgctataaaa tactatgtga atctcttaaa aatctgacat 1500
tttacagtct gtattagaca tactgttttt ataatgtttt acttctgcct taagatttag 1560
gtttttttaa tgtatttttg ccctgaatta agtggttaatt tgatggaaac tctgctttta 1620
aatcatcat ttactgggtt ctaataaatt aaaaatttaa cttgaaaaaa aaaaaaacga 1680

```

<210> 380

<211> 1267

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (214)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1165)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1255)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1262)

<223> n equals a,t,g, or c

<400> 380

```

aagnaagaaa accacaacta aaactggaaa tgtatatattt gtatatattga gaaaacaggg 60
aatacattgt attaataacca aagtgtttgg tcattttaag aatctggaat gcttgctgta 120
atgtatatgg ctttactcaa gcaratctca tctcatgaca ggcagccacg tctcaacatg 180
ggtaaggggt ggggggtggag gggaatgtgt gcancgtttt tacctaggca ccatcattta 240
atgtgacagt gttcartaaa caaatcagtt ggcaggcacc agaagaagaa tggattgtat 300
gtcaagattt tacttggcat tgagtagttt ttttcaatag taggtaattc cttagagata 360
cagtatacct ggcaattcac aaatagccat tgaacaaatg tgtgggtttt taaaaattat 420
atacatatat gagttgccta tatttgctat tcaaaatttt gtaaatatgc aaatcagctt 480
tataggttta ttacaagttt tttaggattc ttttggggaa gagtcataat tcttttgaaa 540
ataacatga atacacttac agttaggatt tgtggtaagg tacctctcaa cattaccaa 600
atcatttctt tagaggggaag gaataatcat tcaaataaac tttaaaaaag caaatttcat 660
gcaactgatta aaataggatt attttaarta caaaaggcat tttatatgaa ttataaactg 720
aagagcttaa agatagttac aaaatacaaa agttcaacct cttacaataa gctaaacgca 780
atgtcatttt taaaaagaag gacttaggggt gtcgttttca catatgacaa tgttgcat 840
atgatgcagt ttcaagtacc aaaacgttga attgatgatg cagttttcat atatcgagat 900
gttcgctcgt gcagtactgt tggttaaatg acaatttatg tggattttgc atgtaataca 960
cagtgaagaca cagtaatttt atctaaatta cagtgcagtt tagttaatct attaatactg 1020
actcagtgtc tgccctttaa tataaatgak atgttgaaaa cttaaggaag caaatgctac 1080
atatatgcaa tataaaatag taatgtgatg ctgatgctgt taaccrragg gcagaataaa 1140
taagcaaaat gccaaaagggt gtctnaattg aartgaaaat gtaattttgt ttttaaaata 1200
ttgtttatct tttatttagg gggggtgggt aattattagt taagtttttt ttaanaaaaa 1260
anaaatt
1267

```

<210> 381

<211> 1031

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1015)

<223> n equals a,t,g, or c

<400> 381

```

ggtccaggat tctagcagtc ctggggcact gacctttgcc agctacctgg gggagggcctt 60
gccactggaa aacctttcag gccgccccca tcagtgggct ccaaagtaaa tggctgaaaa 120
caaaaatggt tcaacttccta acagttttcc tttttccact gtgtgactga aagctcctat 180
atcattttat atttctgaat ctataaaaca aaacaaacaa gcctgamagt gtctggarga 240
rccaaagggt gcctccctgt ccccaaatat attggctata tgagagtaat tttaccctc 300
tacgtacctt aaggcaccca gttcactagt ctgtggggtc ctggagcctg tctcttcttt 360
ctggagggtc aaactgaata gcaataatta cgttacccaa agcatgtgga ggaaaagtga 420
aaccagccac ggagacgctg gccacgggc tcggcctgcg gtgtggcctg ctttgctcac 480
cagcgtcagc cgctcatttc cttctcatga agtcccatct ggcatgggg acgagggccg 540
ggagggcacc gggtagcctt ttcacacttg gggattaggg gagtgagaaa agatttgggc 600
catgcatgca aagtcaaagt ttaaaatttt atccttttca aatagatgat ataataacc 660
tatacatgat ataatatgtg tatatatgaa atctctctat atttgtttaw tttgagccat 720
tcaatctaaa ccaatgtaca ggtgtacaat gaaaaattta aatgcttagt tatttttccc 780
aacacagtgt aaagtcaccc tcctctgaga gtgggatgtg cagagttttg atgttgacgc 840
tttgctcact tcctggcaag ggcaggctat gcctcaattt gtaatgggag tctggggtaa 900
gggtgggggt tgaaagttgt tatctttaa tacatgtaca aatcgttgtc aaaagtaacg 960
ttattaaaat agatttatta tccctgaaaa aaaaaaaaaa aaaaaaaaaa aaancccg 1020
ggggggggccc c 1031

```

<210> 382

<211> 1597

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1577)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1579)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1597)

<223> n equals a,t,g, or c

<400> 382

```

atcacgtgga cgctactcgc tatccccggc ctgttggtt cttccgcgct ggagtatcca 60
gataggcgac acgccgrcgg gcggctgagg cggaatggc tgctgtactg cagcgcgtcg 120
agcggctgtc caactcagtc gtgcgtgtgt tgggctgtaa cccgggtccc atgacctcc 180
aaggcaccaa cacctaccta gtggggaccg gccccaggag aatcctcatt gacactggag 240
aaccagcaat tccagaatac atcagctgtt taaagcaggc tctaactgaa tttaacacag 300

```

```

caatccagga aattgtagtg actcactggc accgagatca ttctggaggc ataggagata 360
tttgtaaaaag catcaataat gacactacct attgcattaa aaaactccca cggaatcctc 420
agagagaaga aattatagga aatggagagc aacaatatgt ttatctgaaa gatggagatg 480
tgattaagac tgaggggagcc actctaagag ttctatatac ccctggccac actgatgatc 540
acatggctct actccttagaa gaggaaaatg ctatcttttc tggagattgc atcctagggg 600
aaggaacaac ggtatttgaa gacctctatg attatatgaa ctctttaaaa gagttattga 660
aaatcaaagc tgatattata tatccaggac atggcccagt aattcataat gctgaagcta 720
aaattcaaca atacatttct cacagaaata ttcgagagca gcaaattctt acattatttc 780
gtgagaactt tgagaaatca ttacagtaa tggagcttgt aaaaattatt tacaagaata 840
ctcctgagaa ttacatgaa atggctaaac ataatctctt acttcatttg aaaaaactar 900
aaaaagaagg aaaaatattt agcaacacag atcctgacaa gaaatggaaa gctcatcttt 960
agtttcagat taaagaaagc ttgtttttat ttgtctttsa gagaatggta tgttttctta 1020
actataggtt attttataga gaatataaaa gtataaaaca ttaaaaaataa ccctagatat 1080
actttaaaat aatgttatat ttatgctaaa atatgtaaat tacactatac aaccatatga 1140
taggttatatt ctctaacctt gtcttctaac gttttaccaa aaattcataa tctaatagtt 1200
tatcagtttt caatagatta aataaaatga ttactttaaa aataataaaa ttatctaata 1260
ttaaagttga tattattttt ggccgttagt tatctattac tagtgatcag ttatactgtt 1320
ttctatagct actttattta acagcacaga ttctatgca cttttactct ttctcaacc 1380
cttgtctcta tctgtacata attgctttgt cttgatgttt ctatcaacta tatcakgact 1440
atctattggg tccataactc tgtatcatgt gtattttctt attctggtat accacaaatg 1500
attcatgcaa atgaattttt ggtgattgaa aaatattaaa ttccaattt aaagtaaaaa 1560
aaaaaaaaaa aaaaaangnc cccggggggg ggccggn 1597

```

<210> 383

<211> 175

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (95)

<223> n equals a,t,g, or c

<400> 383

```

gtgagtgggtg actatgggca tcctgtgtat atcgtgcagg atggggcccc ccagagccct 60
ccaaacatct actacaagggt atgagggctc ctctnacgtg gctatcctga atccagccct 120
tcttgggggtg ctctccaggt ttaaattcct ggtttraggg acamctstaa catct 175

```

<210> 384

<211> 2171

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2166)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2170)

<223> n equals a,t,g, or c

<400> 384

```

agaacaagag ctggacacat taaaaagaaa gagtccatca gatttgtgga aagaagactt 60
ggctacatatt attgaagaat tggaggctgt tgaagccaag gaaaaacaag atgaacaagt 120
cggacttcctt gggaaagtgg ggaaggccaa ggggaaaaaa acacaaatgg ctgaagtttt 180
gccttctccg cgtggtcaaa gagtcattcc acgaataacc atagaaatga aagcagaggc 240
agaaaaagaaa aataaaaaaga aaattaagaa tgaaaatact gaaggaagcc ctcaagaaga 300
tggtgtggaa ctagaaggcc taaaacaaag attagaaaag aaacagaaaa gagaaccagg 360
tacaaagaca aagaaacaaa ctacattggc atttaagcca atcaaaaaag gaaagaagag 420
aaatccctgg tctgattcag aatcagatag gagcagtgc gaaagtaatt ttgatgtccc 480
tccacgagaa acagagccac ggagagcagc aacaaaaaca aaattcaca tggatttggg 540
ttcagatgaa gatttctcag attttgcag aaaaactgat gatgaagatt ttgtcccatc 600
agatgctagt ccacctaaga ccaaaacttc cccaaaactt agtaacaaag aactgaaacc 660
acagaaaagt gtcgtgtcag accttgaagc tgatgatgtt aagggcagtg taccactgtc 720
ttcaagccct cctgctacac atttcccaga tgaaactgaa attacaaacc cagttcctaa 780
aaagaatgtg acagtgaaga agacagcagc aaaaagtcag tcttcacct ccactaccgg 840
tgccaaaaaaa agggctgccc caaaaggaac taaaagggat ccagctttga attctggtgt 900
ctctcaaaaag cctgatcctg ccaaaaccaa gaatcgccgc aaaagggaagc catccacttc 960
tgatgattct gactctaatt ttgagaaaat tgtttcgaaa gcagtcacaa gcaagaaatc 1020
caaggggggag agtgatgact tccatattga ctttgactca gctgtggctc ctcgggcaaa 1080
atctgtacgg gcaaagaaac ctataaagta cctggaagag tcagatgaag atgatctgtt 1140
ttaaaatgtg aggcgattat tttaagtaat tatcttacca agcccaagac tggtttttaa 1200
gttacctgaa gctottaact tcctcccctc tgaatttagt ttgggggaag tgtttttagt 1260
acaagacatc aaagtgaagt aaagcccaag tgttctttag ctttttataa tactgtctaa 1320
atagtaccca tctcatgggc attgttttct tctctgcttt gtctgtgttt tgagtctgct 1380
ttcttttgtc tttaaaacct gattttwaag ttcttctgaa ctgtagaat agctatctga 1440
tcacttcagc gtaaagcagt gtgtttatta accatccact aagctaaaac tagagcagtt 1500
tgatttataa gtgtcactct tcctcctttt ctactttcag tagatatgag atagagcata 1560
attatctgtt ttatcttagt tttatacata atttaccatc agatagaact ttatggttct 1620
agtacagata ctctactaca ctcagcctct tatgtgcaa gtttttcttt aagcaatgag 1680
aaattgctca tgttcttcat cttctcaaat catcagaggc cgaagaaaaa cactttggct 1740
gtgtctataa cttgacacag tcaatagaat gaagaaaatt agagtagtta tgtgattatt 1800
tcagctcttg acctgtcccc tctggctgcc tctgagtctg aatctcccaa agagagaaac 1860
caatttctaa gaggactgga ttgcagaaga ctcggggaca acatttgatc caagatctta 1920
aatgttatat tgataacat gctcagcaat gagctattag attcattttg ggaaatctcc 1980
ataatttcaa tttgtaaaact ttgttaagac ctgtctacat tgttatatgt gtgtgacttg 2040
agtaatgtta tcaacgtttt tgtaaatatt tactatgttt ttctattagc taaattccaa 2100
caattttgta ctttaataaa atgttctaaa cattgcaaaa aaaaaaaaaa aaaccccggg 2160
gggggncccn g 2171

```

<210> 385

<211> 2364

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<400> 385

```

ggttttcacc  ctgttgccna  aggctggctc  ccgaactcck  tgacctcarg  tgattcacc  60
accgttggcc  tcataaacct  gttttgcaga  actcatttat  tcagcaaata  tttattgagt  120
gcctaccaga  tgccagtcac  cgcacaaggc  actgggtata  tggatatccc  aaacaagaga  180
cataatcccc  gtccttaggt  agtgctagt  tggctctgta  tatcttacta  aggcccttgg  240
tatacgaccc  agagataaca  cgatgcgtat  tttagttttg  caaagaaggg  gtttggctct  300
tgtgccagct  ctataattgt  tttgctacga  ttccactgaa  actcttcgat  caagctactt  360
tatgtaaatc  acttcattgt  tttaaaggaa  taaacttgat  tatattgttt  ttttatttgg  420
cataactgtg  attcttttgg  gacaattact  gtacacatta  aggtgtatgt  cagatattca  480
tattgaccca  aatgtgtaat  attccagttt  tctctgcata  agtaattaaa  atatacttaa  540
aaattaatag  ttttatctgg  gtacaaataa  acagggtgct  gaactagttc  acagacaagg  600
aaacttctat  gtaaaaaatc  ctatgatttc  tgaattgcta  tgtgaaacta  cagatctttg  660
gaacactggt  taggtagggt  gtttaagact  acacagtacc  tcgtttctac  acagagaaag  720
aaatggccat  acttcaggaa  ctgcagtgt  tatgagggga  tatttaggcc  tcttgaattt  780
ttgatgtaga  tgggcatttt  ttttaaggtag  tggtaattac  ctttatgtga  actttgaatg  840
gtttaacaaa  agatttggtt  ttgtagagat  tttaaagggg  gagaattcta  gaaataaatg  900
ttacctaat  attacagcct  taaagataaa  aatccttggt  gaagtttttt  aaaaaaagc  960
taaattacat  agacttaggc  attaacatgt  ttgtggaaga  atatagcaga  cgtatattgt  1020
atcatttgag  tgaatgttcc  caagtaggca  ttctaggctc  tatttaactg  agtcacactg  1080
cataggaatt  tagaacctaa  cttttatagg  ttatcaaaac  tgttgtcacc  attgcacaat  1140
tttgtcctaa  tatatacata  gaaactttgt  ggggcatgtt  aagttacagt  ttgcacaagt  1200
tcatctcatt  tgtattccat  tgattttttt  tttcttctaa  acattttttc  ttcaaacagt  1260
atataacttt  ttttagggga  ttttttttta  gacagcaaaa  actatctgam  gatttccatt  1320
tgtcaaaaag  taatgrtttc  ttgataattg  tgtagtaatg  ttttttagaa  cccagcagtt  1380
accttaaagc  tgaatttata  tttagtaact  tctgtgttaa  tactggatag  catgaattct  1440
gcattgagaa  cctgaatagc  tgtcataaaa  tgaaactttc  tttctaaaga  aagataactca  1500
catgagttct  tgaagaatag  tcataactag  attaagatct  gtgttttagt  ttaatagttt  1560
gaagtgcctg  tttgggataa  tgataggtaa  tttagatgaa  tttaggggaa  aaaagttatc  1620
tgcagawatg  ttgagggcc  atctctcccc  ccacaccccc  acagagctaa  ctgggttaca  1680
gtgtttttat  cgaaagtttc  caattccact  gtcttggtgt  ttcatgttga  aaatactttt  1740
gcatttttcc  tttgagtgcc  aatttcttac  tagtactatt  tcttaatgta  acatgtttac  1800
ctggaatgta  ttttaactat  ttttgtatag  tgtaaaactg  aacatgcaca  ttttgtacat  1860
tgtgctttct  tttgtgggac  atatgcagt  tgatccagtt  gttttccatc  atttgggtgc  1920
gctgacctag  gaatgttgg  catatcaaac  attaaaaatg  accactcttt  taattgaaat  1980
taacttttaa  atgtttatag  gagtatgtgc  tgtgaagtga  tctaaaattt  gtaatatatt  2040
tgtcatgaac  tgtactactc  ctaattattg  taatgtaata  aaaatagtta  cagtgactat  2100
gagtgtgtat  ttattccatg  aaatttgaac  tgtttgcccc  gaaatggata  tggaaacttt  2160
tataagccat  agacactata  gtataccagt  gaatctttta  tgcagcttgt  tagaagtatc  2220
ctttattttc  aaaaggtgct  gtggatatta  tgtaaaggcg  tgtttgctta  aacttaaaac  2280
catatttaga  agtagatgca  aaacaaatct  gccttttatg  caaaaaata  ggataacatt  2340
atttatttat  ttccttttat  caaa  2364

```

<210> 386

<211> 2864

<212> DNA

<213> Homo sapiens

<400> 386

```

gctaatagaga  aagtggctct  gcagaaagct  ctgttatatt  atgaaagcat  tcatggacgg  60
ccggttaacaa  agaacgaacg  gcagggtgat  aagccactat  acgacaggta  ccggctggct  120
aaacagatcc  tctcccagc  taacaccata  cccatcattg  gttccccctc  cagcaagcgg  180

```

```

agaagccctt tgctgcagcc aattatcgag ggcgaaactg cttccttctt caaggagata 240
aaggaagaag aggaggggtc agaagacgat agcaatgtga agccagactt catggtcact 300
ctgaaaaccg atttcagtgac acgatgcttt ctggaycaat tcgaagatga cgctgatgga 360
tttatttccc caatggatga taaaatacca tcaaaatgca gccaggacac agggctttca 420
aatmtccatg ctgcctcaat acctgaactc ctggaacacc tccaggaaat gagagaagaa 480
aagaaaagga ttcgaaagaa acttcgggat tttgaagaca actttttcag acagaatgga 540
agaaatgtcc agaaggaaga ccgcactcct atggctgaag aatacagtga atataagcac 600
ataaaggcga aactgaggct cctggagggtg ctcacagca agagagacac tgattccaaag 660
tccatgtgag gggcatggcc aagcacaggg ggcyyggcagc tgcggtgaga gtttactgtc 720
cccagagaaa gtgcagctct ggaaggcagc cttgggggtg gccctgcaaa gcatgcagcc 780
cttctgcctc tagaccattt ggcacgggt cctgtttcca ttgcctgcct tagaaactgg 840
ctggaagaag acaatgtgac ctgacttagg cattttgtaa ttggaagtc aagactgcag 900
tatgtgcaca tgcgcacgcg catgcacgca cacacacaca cagtagtgga gctttcctaa 960
cactagcaga gattaatcac tacattagac aacactcacc tacagagaat atacactggt 1020
cttcctgga taactgagaa acaagagacc attctctgtc taactgtgat aaaaacaagc 1080
tcaggacttt attctataga gcaaaacttg tgtggagggc catgctctcc ttggacccag 1140
ttaactgcaa acgtgcattg gagccctatt tgcctgcgct gccattctag tgacctttcc 1200
acagagctgc gccttcctca cgtgtgtgaa aggttttccc cttcagccct caggtagatg 1260
gaagctgcat ctgcccacga tggcagtgca gtcacatctc tcaggatgtt tcttcaggac 1320
ttcctcagct gacaaggaat tttggtccct gcctaggacc gggcatctg cagaggacag 1380
agagatggta agcagctgta tgaatgctga ttttaaaacc aggtcatggg agaagagcct 1440
ggagattctt tcctgaacac tgactgcact taccagtctg attttatcgt caaacaccaa 1500
gccaggctag catgctcatg gcaatctgtt tggggctgtt ttgttgtggc actagccaaa 1560
cataaagggg cttaagtcag cctgcataca gaggatcggg gagagaaggg gcctgtgttc 1620
tcagcctcct gagtacttac cagagttaa tttttttaa aaaaatctgc actaaaatcc 1680
ccaaactgac aggtaaatgt agccctcaga gctcagccca aggcagaatc taaatcacac 1740
tattttcgag atcatgtata aaaagaaaaa aaagaagtca tgctgtgtgg ccaattataa 1800
tttttttcaa agactttgtc acaaaactgt ctatattaga cattttggag ggaccaggaa 1860
atgtaagaca ccaaactcct catctcttca gtgtgcctga tgtcacctca tgatttgctg 1920
ttactttttt aactcctgcg ccaaggacag tgggttctgt gtccaccttt gtgctttgcg 1980
aggccgagcc caggcatctg ctgcctgcc acggctgacc agagaagggt cttcaggagc 2040
tctgccttag acgacgtgtt acagtatgaa cacacagcag aggcaccctc gtatgttttg 2100
aaagtgcct tctgaaaggg cacagtttta aggaaaagaa aaagaatgta aaactatact 2160
gaccggttt cagttttaa gggtcgtgag aaactggctg gtccaatggg atttacagca 2220
acattttcca ttgctgaagt gaggtagcag ctctcttctg tcagctgaat gttaaggatg 2280
gggaaaaaga atgcctttaa gtttgctctt aatcgtatgg aagcttgagc tatgtgttg 2340
aagtgccctg gttttaatcc atacacaaag acggtacata atcctacagg tttaaatgta 2400
cataaaaaata tagtttgga ttctttgtc tactgtttac attgcagatt gctataat 2460
caaggagtga gattataaat aaaatgatgc actttaggat gtttcctatt tttgaaatct 2520
gaacatgaat cattcacatg accaaaaatt gtgttttttt aaaaatacat gtctagtctg 2580
tcctttaata gctctcttaa ataagctatg atattaatca gatcattacc agtttagctt 2640
taaagcacat ttgtttaaga ctatgttttt ggaaaaatac gctacagaat ttttttttaa 2700
gctacaaaata aatgagatgc tactaattgt tttggaatct gttgtttctg ccaaaggtaa 2760
attaactaaa gatttattca ggaatcccca tttgaatttg tatgattcaa taaaagaaaa 2820
caccaagtaa gttatataaa ataaaaaaaa aaaaaaaaaa tcga 2864

```

<210> 387

<211> 2683

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2649)
 <223> n equals a,t,g, or c

<400> 387
 acgccttccc cgaggtgtac gacaagatct gcaaggccgn cagactgags ctggagccccg 60
 cctggagaga cagacacgtg tgagtgggtca ggcatcttcc cttcactcaa gcttgggtgc 120
 ttctctagat ccacactttc aaagagaaac ccctccagaa ctcccacccct gacagcccaa 180
 caccaccttc ctcttggtt ccagggggca gccagtgga atggaaagaa tgtgggattt 240
 ggagtcagac aagcctgagt ccagttcccc gtttagaact cattagctgt gtgactctgg 300
 gtgagtcocct taaccctctc gagcccggt ctcttcatta gttgaaagg atagtaatac 360
 ctacttgcag gtygttgtca tctgagttga gcaactgtca cattgaagg gctgggtaag 420
 tggtagctct tgttgcttcc cgttcagcgt cacatctgca gtggagcctg aaaaggctcc 480
 acattaggtc acctgtgcac agccatggct ggaatgatga aggggatacg ctggagttgc 540
 cctgccatcg cctccatcag ccagacgagg tcctcacagg agaaggacag ctcttcccca 600
 ccctgggata tcaggagggc agccacggag ggggaggccc cagatgcgct gtgccaaagc 660
 caggtccgag gccaaagttc tccctgcat ccttggtgcc gtcctgcccc ttcctccttc 720
 atgcctgggc ctgcaggcac cccagccacc actgagtcca ctcgagtgcc cctgtgttcc 780
 tggagaaggc attccagggt tgaatcttgt cccagcctca gcctgggaca cctaggtgga 840
 gagagtggtc tccgctctga attggatcca ggggacctgg gctcattctt cttggctcac 900
 caaccctgca ggcctcatct ttccaaaac ccactttgtc ttggtgggag tgggtccgag 960
 ctgctctgca gcaggcggct ggggagtgga cagcatcagg tgggaaagt gagtccacc 1020
 tcatgtttct gtaggattct caccgtgggg ctggaagaaa agagcatcga cttgatttct 1080
 ccaaccactc atccctcttt ttctttcttc caccactccc caccocagct gtagttaatt 1140
 tcagtgcctt acaaatccta agctcagaga aagttccatt tccgttccag aggggaaggga 1200
 acctccctag gtccttccct ggcttggtat aacgcaaagc ttggttggtt atgcaactct 1260
 atcttaagaa ctgcccagcc tcagctgaaa acccgaatct gagaagggaat tgcgtcatgt 1320
 aagggagct ggaattaagg gagctgagcc agtcatgggt gtggcggtg agtcaggaga 1380
 cctaggtttc agcccctctc tactgtcagc gagctgtgca acgtgggcaa gtcattgtcc 1440
 tctgagctgc agtttcctca tctgtcacat cgctacagac aagacctccc tggaaccctt 1500
 ctgattgtct tagacactgt ggttgcaaaa cccacggaaa gcctcatttg tgtggaaagt 1560
 cagaggaaaa atgatccagt ggacacttgg ggattatctg tcattcaaga tccttccttc 1620
 aacccaagg ycagctccca tctcatttcc agaaaggctc atacctggct tgcagggaag 1680
 catctgtctt gtcattccag gtgccagaat cctctcagag tcattgaagg gtgttcacc 1740
 atcccaccca aggcttggca cactgccagt gtcttagcag ggtcttgtga gggctggggg 1800
 catccaggca ctcagaaggc aaaggaacca ccctacccat ttggcctctg gagggggcag 1860
 aagaaagaaa gaaacctcat cctatatattt acaaagcatg tgaattcttg cattagctct 1920
 cataggagac ccatgtgctt ccttgctcag tgcaaaaactg atgattctac ttgctgtaga 1980
 tgaatggtta acacgagcta gttaaacagt gccattgttt tgccagtga gcctccaacc 2040
 ctaagccact gggacgggtg ccagagatgc cagcagcctc tgtcgccctt agtcatataa 2100
 ccaaaatcca gacctatcc acaaccggg gcttggaag gaaggatatt tggaatcaca 2160
 ccctccggtt atgttgctcc agtaaaatct tgccctggaa gaggcagtct tcttagcatg 2220
 gtgagctgag ttcattggct tttttttag ccagtcctgt ccctggccat ccattgtgat 2280
 gttttggatg gagttaaact tgatgccagt gggcagtgca tgtggaaagt atcagagtaa 2340
 gsctctcccc tccagagccc tgagtttctt ggctgcatga aggttttctt tagaatcaga 2400

```

attgtagcca gtttcttttg ccagaaggat gaatacttgg atattactga aagggagggg 2460
tggagatggg tgtggcagtg tatggtgtgt gatttttatt ttcttctttg gtcattggggg 2520
ccaaggagaa aggcattgaat cttccctgtc aggcctcttac ascacaggca ctgtgtctac 2580
tgtctggaag acatgtcccc gtggctgtgg ggcgcgtgct tctgtttaaa taaaagtggc 2640
ctggaarmna aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 2683

```

<210> 388

<211> 1446

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (35)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (57)

<223> n equals a,t,g, or c

<400> 388

```

aagaactaaa acgactcact atagggaaaa actananacg cctgacagga aaccgggccg 60
gaattcccg gtcgaccac gcgtccgaar argaggtgga ggargagggt gatgttgata 120
gtgatgaaga agaggaggaa gatgaggaga gctcctcgga gggcttgagg gctgaggact 180
gggcccagg agtagtgagg gccggtggca gcttcggggc ttatgggtgcc caggagggaag 240
cccagtgcc tactctgcat ttcttggaag gtggggagga ctctgattca gacagtgagg 300
aagaggacga tgaggaagag gatgatgaag atgaagacga cgatgatgat gaggaggatg 360
gtgatgagg gtctgtaccc agctttgggg aggccatggc ttactttgcc atgggtcaaga 420
ggtacctgac ctcttcccc attgatgacc gcgtgcagag ccacatcctc cacttggaac 480
acgatctggt tcatgtgacc aggaagaacc acgccaggca ggccggagtt cgagggtctt 540
gacatcaaa ctgagtcact ggacctagct gtgcccccaa cctagattgg cagcaccacc 600
ccagggcaga ggactctctg ggcaccgct gtgcatggag ccagagtgc gagccccaga 660
tccttttagta atgcttcccc tggctctgca acaggccccg tcacctcggc cgggccccggg 720
gctgagggtca gcctcactgc ctgcttattg cctctttctc agaatcctct ttcttcccca 780
tttggccctg ggctcagggg accaggtggg gcgggtgggg agctgtccgg tgctaccaca 840
ccgtgccctc agtggaactaa ccacagcagc agccagggat gggccctgga ggttccccggc 900
cggagagtgc ctctccctc tgccatccac gtcagggtctt tgggtggggg accccaaagc 960
cattctggga agggctccag aagaagggtc agcctaggcc ccctgcaagg ctggcagccc 1020
ccacccccac cccccaggcc gccttgagaa gcacagtta actcactgcg ggctcctgag 1080
cctgcttctg cctgctttcc acctccccag tccctttctc tggccctgtc catgtgactt 1140
tggcccttgg ttttctttcc agattggagg ttccaagag gccccccacc gtggaagtaa 1200
ccaagggcgc ttcttctgtg gcagctgcag gccccatgcc tctcctccct ctctggcagg 1260
gccccatcct gggcagaggg gcctgggggt gggccagag tccagccgtc cagctgctcc 1320
tttcccagtt tgatttcaat aaatctgtcc actccccctt tgtgggggtg aacgttttaa 1380
cagccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440

```

aaaaaa

1446

<210> 389

<211> 723

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (705)

<223> n equals a,t,g, or c

<400> 389

```
gggcaagacc tcatgcctaa aaaataaaga gaaagcagag taaaactgga ctctgagata 60
ygactaaagt tctgtgtgat acgtgtgcct tatttagctc aagacattcc tggagcacct 120
ataaaaaactg acttgtaatc caggctatgt ctcttttttag cttcgtaatc tttggcaagg 180
ccattggatt cttcagctgt acaattagga gactcgatca ggtgattgcc tttctcagct 240
gtcagttctc taatttcagg cttggtagct tgtaggaact gaaattgcaa ttaaaacctt 300
tataaactca aactaaatca tgaattacag aaaaagtcca ttcttccaaa acttgatgtt 360
accacactta caagtttaaa atatgaagtc gactgtttta aggattctgc atatatctta 420
gtgtgcacat tcagaaacat ttttcttgga aaaagtaccc aacatttttt ataactgcac 480
atattaattt attgccagaa taaattgcat tgcattgctaa ataaagtcag ataattcaaa 540
tccattttgct tttatgtagt ttttcttcta aatgtcaaca ttttggaatt aaaatgttta 600
tggtttttata tgagggtagg aaatcttaac tgctttgggg ggtattgttt ataggctttt 660
tgttatgggg ccggtagttt tttaataggg ggattgccca tttcnaccgt ttggggggccc 720
ggg 723
```

<210> 390

<211> 1046

<212> DNA

<213> Homo sapiens

<400> 390

```
cggggtcgacc cgcgcgtccg gtccaccaca ggcaccgcag ctcatctacc aggaatatgt 60
gaaccagcca gatgttcggc cccagccccc ttcgccccga gagggccctc tgcctgctgc 120
ccgacctgct ggtgccactc tggaaagggc caagactctc tccccaggga agaattgggt 180
cgtcaaaagac gttttttgcct ttgggggtgc cgtggagaac cccgagtact tgacacccca 240
gggaggagct gccccctcagc cccaccctcc tcctgccttc agcccagcct tcgacaacct 300
ctattactgg gaccaggacc caccagagcg gggggctcca cccagcacct tcaaagggac 360
acctacggca gagaacccag agtacctggg tctggacgtg ccagtgtgaa ccagaaggcc 420
aagtccgcag aagccctgat gtgtcctcag ggagcaggga aggcctgact tctgctggca 480
tcaagagggtg ggagggccct ccgaccactt ccaggggaac ctgccatgcc aggaacctgt 540
cctaaggaac ctctcttctt gcttgagttc ccagatggct ggaaggggtc cagcctcgtt 600
ggaagaggaa cagcactggg gagtctttgt ggattctgag gccctgcca atgagactct 660
aggggtccagt ggatgccaca gccagcttg gcccttctc tccagatcct ggggtactgaa 720
agccttaggg aagctggcct gagaggggaa gcggccctaa gggagtgtct aagaacaaaa 780
gcgacccatt cagagactgt ccctgaaacc tagtactgcc ccccatgagg aaggaacagc 840
aatgggtgtca gtatccaggc tttgtacaga gtgcttttct gtttagtttt tacttttttt 900
gtttttgttt tttaaagatg aaataaagac ccagggggag aatgggtgtt gtatggggag 960
gcaagtgttg ggggtccttc tccacaccca ctttgtccat ttgcaaatat attttggaaa 1020
acaaaaaaaa aaaaaaaaaa aaaaaa 1046
```

<210> 391
 <211> 699
 <212> DNA
 <213> Homo sapiens

<400> 391
 cg gat ggggc gtaggtgggc ggtgygccca cagctacctg ggtaaggccc aagatggctg 60
 tcttgcctt agtactcgtg tgaagttggc ggggacggtt cctgtcatct tcttgggctt 120
 atttggtgtg ctgttgaagg ggggagacta gagaaatggc agggaaacctc ttatccgggg 180
 caggtaggcg cctgtgggac tgggtgcctc tggcgtgcag aagcttctct cttgggtgtg 240
 ctagattgat cgggtataagg ctcaactctcc cgcccccaa agtgggttgat cgttggaacg 300
 agaaaagggc catgttcgga gtgtatgaca acatcgggat cctgggaaac tttgaaaagc 360
 accccaaaga actgatcagg gggcccatat ggcttcgagg ttggaaaggg aatgaattgc 420
 aacgttgtat ccgaaagagg aaaatggttg gaagtagaat gtctgctgat gacctgcaca 480
 accttaataa acgcatccgc tatctctaca aacactttaa ccgacatggg aagtttcgat 540
 agaagagaaa gctgagaact tcggaaaagg ctcatctgtc accctggaga agggaaactg 600
 tacttttccc tgtgaggaaa cggctttgta ttttctctgt aataaaatgg ggcttctttg 660
 gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aagtcgacc 699

<210> 392
 <211> 1545
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (24)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (25)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (54)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (58)
 <223> n equals a,t,g, or c

<400> 392
 taccggtcgg gaattcccg gtcnnccac gcgtccgcgc actgccgccg ccgnttcngc 60
 ccggactcgg acgctgtgta gccccaggat ggggtgagttc aacgagaaga agacaacatg 120
 tggcaccggtt tgccctcaagt acctgctgtt tacctacaat tgctgcttct ggctggctgg 180
 cctggctgtc atggcagtg gcatctggac gctggccctc aagagtgact acatcagcct 240
 gctggcctca ggcacctacc tggccacagc ctacatcctg gtgggtggcgg gcactgtcgt 300

```
catggtgact ggggtcttgg gctgctgcgc caccttcaag gagcgtcggg acctgctgcg 360
cctgtacttc atcctgctcc tcacatctt tctgctggag atcatcgctg gtatcctcgc 420
ctacgcctac taccagcagc tgaacacgga gctcaaggag aacctgaagg acaccatgac 480
caagcgctac caccagccgg gccatgaggc tgtgaccagc gctgtggacc agctgcagca 540
ggagttccac tgcgtgtggc gcaacaactc acaggactgg cgagacagtg agtggatccg 600
ctcacaggag gccggtggcc gtgtggtccc agacagctgc tgcaagacgg tgggtggctct 660
ttgtggacag cgagaccatg cctccaacat ctacaagggt gagggcggct gcatcaccaa 720
gttgagagacc ttcacccagg agcacctgag ggtcattggg gctgtgggga tcggcattgc 780
ctgtgtgcag gtctttggca tgatcttcac gtgctgcctg tacaggagtc tcaagctgga 840
gcactactga ccctgccttg ggcttgctg ctgctgcacc caactactga gctgagacca 900
ctgagtacca ggggctgggc tccctgatga caccaccct gtgcatcac cataacctct 960
ggggacccca acctcagagg cagcttcaag tgccttttgc tgcgcaccaa tgcccagcag 1020
gggaggtgag gggggctggc ggggcgaagt ttggggggtg ttttgtggg ctcgccggac 1080
atactctctg cctggtggtc agatgcaggt tggaaggggc cttgctgagt ggcgcaaggc 1140
cgagcgcttc cagcaggggg agaaaccctt cacaccccag gcccttcagg aactggggct 1200
ttgccttgca gccacatggc cccatcccag ttggggaagc cagggtgagct ctgacccttg 1260
ggcctgggcc tctgcccctc ccaaccacgc cgtcgtctcc ctgcacagcg cccctgctgt 1320
cttccccacc gcagtcacca ccaccgaaa tgccacgtgg tcaactgtga ctgccctgtt 1380
catgtgcctc tgcggggcag ggccttcctg gttttgtaca ctgctgtacc cagatgccta 1440
caaccatccc tgccacatac aggtgctcaa taaacacttg tagagcagaa aaaaaaaaaa 1500
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1545
```

<210> 393

<211> 749

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (490)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (748)

<223> n equals a,t,g, or c

<400> 393

```
gcttgagccc aggagttctg ggctgttagt gcgctatgcc gatcgggtgt ccgcactaag 60
ttyggcatca atatggtgac ctcccgggag cggrggacca ccaggttgcc taaggagggg 120
tgaaccggyg caggtcggaa acggagcagt ttcccttgag cgagattca ggtttttcag 180
gtgggtcttg tgagctgggg tctttacaac ccctgccttg gctctgctga caaaaactcc 240
cgcaaaaggg cccctcgtag caaggtccc cgcacacgag actttcacat caatctcttc 300
cgcatgcagc cctggctgag gcagcacctg ggggatgtcc tgaatttttt acccctctag 360
ccatggccac tgagccctct gctgccctgc cagaatctgc cgccctoca tcttctacct 420
ctgaatggcc acccttagac cctgtgatcc atcctctctc ctactgtgag aaatccgggt 480
ctctaggatn ccagaggcag cgacacaaag ctgggaaatc ctacgggctc ctaccagcag 540
gactgcctcg ctgccccacc tcccgctcct tggcctgtcc ccagattcct tccctgggtg 600
acttgactca tgcttgtttc actttcacat ggaatttccc agttatgaaa ttaataaaaa 660
tcaatggttt ccacaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 720
aaaaaaaaaa aaaaaaaaaa aaaaaaana 749
```

<210> 394
 <211> 611
 <212> DNA
 <213> Homo sapiens

<400> 394
 gcgcggcggc ggccggggtgg ctggggccggc ggccggcggcg gtacgaggcg cgcgctcggg 60
 gtcccggtcg cgaggaggag gaggatgtgg cgcgcggagg ggaaatggct gccgaaaaca 120
 agccggaaga gcgtttccca aagtgtattc tgcggaacta gcacctactg tgttctcaac 180
 accgtgccac ctatagaaga tgatcatggg aacagcaata gtagtcatgt aaaaatcttt 240
 ttaccgaaaa agctgcttga atgtctgccg aaatgttcaa gtttaccaaa agagaggcac 300
 cgctggaaca ctaatgagag atcatgatgc agccgtcctt ttggatttct ttttaataat 360
 gtgtgaccct tcacctttga tccctgacc tgcattacct tggtaaccat ttcatTTTTT 420
 aattttaattt catttttttaa ttttggtgta caagctgtaa catttcatct ttcaaagtgt 480
 aacacgtgta tttcctcaaa tagagatacc cctttgagtg ataaatttgc aaaatgctgt 540
 cttcatTTTt tgtattaaaa ttcatTTcag ttttaaaata aagtgtaatc tgtgtTTTca 600
 tccttttaaa a 611

<210> 395
 <211> 1856
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1851)
 <223> n equals a,t,g, or c

<400> 395
 gttggcgcg cgtgcgcggt gcgtagtctg gagctatggt ggtggtggca gccgcgccga 60
 acccgccga cgggacccct aaagtTctgc ttctgtcggg gcagcccgcc tccgcccgccg 120
 gagccccggc cggccaggcc ctgccgctca tgggtgccagc ccagagaggg gccagcccg 180
 aggcagcgag cgggggggctg cccagggcgc gcaagcgaca gcgcctcacg cacctgagcc 240
 ccgaggagaa ggcgctgagg aggaaactga aaaacagagt agcagctcag actgccagag 300
 atcgaaaaga ggctcgaaatg agtgagctgg aacagcaagt ggtagattta gaagaagaga 360
 accaaaaact tttgctagaa aatcagcttt tacgagagaa aactcatggc cttgtagtgtg 420
 agaaccagga gttaagacag cgcttgggga tggatgccct ggttgctgaa gaggaggcgg 480
 aagcaagggg aatgaagtga ggccagtggc cgggtctgct gagtccgcag cactcagact 540
 acgtgcacct ctgcagcagg tgcaggccca gttgtcacc cccagaaca tctcccatg 600
 gattctggcg gtattgactc ttcagattca gactctgata tcctgttggg cattctggac 660
 aacttgagcc cagtcattgt cttcaaatgc cttcccccag agcctgccag cctggaggag 720
 ctcccagagg tctaccaga aggaccagc tccttaccag cctccctttc tctgtcagtg 780
 gggacgtcat cagccaagct ggaagccatt aatgaactaa ttcgttttga ccacatatat 840
 accaagcccc tagtcttaga gataccctct gagacagaga gccaagctaa tgtggtagt 900
 aaaatcgagg aagcacctct cagccctca gagaatgat accctgaatt cattgtctca 960
 gtgaaggag aacctgtaga agatgacctc gttccggagc tgggtatctc aaatctgctt 1020
 tcatccagcc actgccc aaa gcatcttcc tgcctactgg atgcttacag tgactgtgga 1080
 tacgggggtt ccttttcccc attcagtgac atgtcctctc tgcttgggtg aaaccattct 1140
 tgggaggaca cttttgccaa tgaactcttt cccagctga ttagtgtcta aggaatgatc 1200
 caatactgtt gcccttttcc ttgactatta cactgcctgg aggatagcag agaagcctgt 1260

```

ctgtacttca ttcaaaaagc caaaatagag agtatacagt cctagagaat tcctctatatt 1320
gttcagatct catagatgac ccccaggtat tgtcttttga catccagcag tccaagggtat 1380
tgagacatat tactggaagt aagaaatatt actataattg agaactacag cttttaagat 1440
tgtactttta tcttaaaagg gtggtagttt tccctaaaat acttattatg taagggtcat 1500
tagacaaatg tcttgaagta gacatggaat ttatgaatgg ttctttatca tttctcttcc 1560
ccctttttgg catcctggct tgcctccagt tttaggtcct ttagtttgct tctgtaagca 1620
acgggaacac ctgctgaggg ggctctttcc ctcagtataa cttcaagtaa gatcaagaat 1680
cttttgtgaa attatagaaa tttactatgt aaatgcttga tggaattttt tcctgctagt 1740
gtagcttctg aaaggtgctt tctccattta tttaaaacta cccatgcaat taaaagggtac 1800
aatgcaaaaa aaaaaaaaaa aaaaaaaacc ggggggsgcc ccggaacca nttccc 1856

```

<210> 396

<211> 2651

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2642)

<223> n equals a,t,g, or c

<400> 396

```

gtcacgagcg aggggggtgcg tgtgaggtca tcgcgcgggc gggcntncgg ggtctggcgg 60
tttgaacgag acgaagacgg aaccggagcc ggttgcgggc agtggacgcg gttctgccga 120
gagccgaaga tggcagtgaa cgtatactca acgtcagtgga ccagtgataa cctaagtcga 180
catgacatgc tggcctggat caatgagtct ctgcagttga atctgacaaa gatcgaacag 240
ttgtgctcag gggctgcgta ttgtcagttt atggacatgc tgttccctgg ctccattgcc 300
ttgaagaaaag tgaaattcca agctaagcta gaacacgagt acatccagaa cttcaaaata 360
ctacaagcag gttttaagag aatgggtggt gacaaaataa ttcctgtgga caaattagta 420
aaaggaaaag ttcaggacaa ttttgaattc gttcagtggt tcaagaagtt tttcgatgca 480
aactatgatg gaaaagacta tgaccctgtg gctgccagac aaggtaaga aactgcagtg 540
gtccttccc ttgttgctcc agctctgaat aaaccgaaga aacctctcac ttctagcagt 600
gcagctcccc agaggcccat ctcaacacag agaaccgctg cggctcctaa ggctggccct 660
ggtgtggtgc gaaagaaccc tgggtgaggc aacggagacg acgaggcagc tgagttgatg 720
cagcaggtca acgtattgaa acttactgtt gaagacttgg agaaagagag ggatttctac 780
ttcggaaaagc tacggaacat tgaattgatt tgccaggaga acgaggggga aaacgacct 840
gtattgcaga ggattgtaga cattctgtat gccacagatg aaggctttgt gatacctgat 900
gaagggggcc cacaggagga gcaagaagag tattaacagc ctggaccagc agagcaacat 960
cggaattctt cactccaaat catgtgctta actgtaaaat actccctttt gttatcctta 1020
gaggactcac tggtttcttt tcataagcaa aaagtacctc ttcttaaaag gcactttgca 1080
gacgtttcac tccttttcca ataagtttga gttaggagct tttaccttgt agcagagcag 1140

```

```

tattaacayc tagttgggtc acctggaaaa cagagaggct gaccgtgggg ctcaccatgc 1200
ggatgcgggt cacactgaat gctggagaga tgttatgtaa tatgctgagg tggcgacctc 1260
agtggagaaa tgtaaagact gaattgaatt ttaagctaata gtgaaatcag agaattgtgt 1320
aataagtaaa tgccttaaga gtatttaaaa tatgcttcca catttcaaaa tataaaatgt 1380
aacatgacaa gagattttgc gtttgacatt gtgtctggga aggaagggcc agaccttgga 1440
acctttggaa cctgctgtca acaggtctta cagggtgtct tgaaccctca taggcctagg 1500
ctttgggtcta aaaggaacat ttaaaaagtt gccctgtaaa gttatttggg gtcattgacc 1560
aattgcatcc cagctaaaaa gcaagaggca tcgttgccctg gataatagag gatgtgtttc 1620
agccctgaga tgttacagtt gaagagcttg gttttcattg agcatttctc tatttttcca 1680
gttatccccg aaatttctat gtattatatt ttttggggaa gtgaggtgtg cccagttttt 1740
taacttaaca actacttttg gggacttgcc cacatctctg ggatttgaat ggggattgta 1800
tcccatttta ctgtctttta ggtttacatt taccacgttt ctcttctctg ctccccttgc 1860
ccactgggga ctccctcttg gctccttgaa gtttgctgct tagagttgga agtgcagcag 1920
gcaggtgatc atgctgcaag ttctttcttg acctctggca aaggagtggt tcagtgaagg 1980
ccatcggttac cttgggatct gccaggctgg ggtgttttcg gtatctgctg ttcacagctc 2040
tccactgtaa tccgaatact ttgccagtgc actaatctct ttggagataa aattcattag 2100
tgtgttacta aatgttaatt ttcttttgcg gaaaatacag taccgtgtct gaattaatta 2160
ttaatattta aaataacttca ttccttaact ctccctcatt tgctttgccc acagcctatt 2220
cagttccttt gtttggcagg attctgcaaa atgtgtctca cccactactg agattgttca 2280
gcccctgatg tatttgtatt gatttgtttc tgggtgtagc ttgtcctgaa atgtgtgtag 2340
aaagcaagta ttttatgata aaaatgttgt gtagtgcatt ctctgtgtgg aattcagagg 2400
aaaaccagaa ttcagtgatt aacaatgcc aaaaatgcaa gtaactagcc attgttcaaa 2460
tgacagtggg gctatttctc ttttgtggcc ttttagactt ttgttgccct aaaattccat 2520
tttattggga acccattttc cacctggtct ttcttgacag gggttttttc tacttttaaac 2580
agtttctaaa taaaattctg tatttcaaga gtaaaaaaaa aaaaaaaggg gggccsccca 2640
angggaccca a 2651

```

<210> 397

<211> 2507

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2489)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2496)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2504)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2505)

<223> n equals a,t,g, or c

<400> 397

```

ggctgcccga ctggctgtgg aaatgaaaac tgatctcttg attgttcttt cagatgtaga 60
aggccttttt gacagccccc caggttcaga tgatgcaaag cttattgata tattttatcc 120
cggagatcag cagtctgtga catttggaac caagtctaga gtkggaatgg gtggcatgga 180
agccaaggtg aaagcagccc tctgggcttt gcaaggtggc acttctgtwg twattgcca 240
tggaaccac ccaaaggtgt ctgggcacgt catcacagac attgtggagg ggaagaaagt 300
tggtaccttc ttttcagaag taaagcctgc aggcctact gttgagcagc agggagaaat 360
ggcgcgatct ggaggaagga tgttgccac cttggaacct gagcagagag cagaaattat 420
ccatcatctg gctgatctgt tgacggacca gcgtgatgag atcctgttag ccaacaaaaa 480
agacttggag gaggcagagg ggagacttgc agctcctctg ctgaaacgtt taagcctctc 540
cacatccaaa ttgaacagcc tggccatcgg tctgcgacag atcgcagcct cctcccagga 600
cagcgtggga cgtgttttgc gccgcaccg aatcgccaaa aacttggaa tggacaagt 660
gactgtccca attggagtgc tgctgggtgat ctttgaatct cgtcctgact gtctacccca 720
ggtggcagct ttggctatcg caagtggcaa tggcttgtaa ctcaaaggag ggaaggaggc 780
tgcacacagc aaccggattc tccacctcct gaccaggag gctctctcaa tccatggagt 840
caaggaggcc gtgcaactgg tgaataccag agaagaagt gaagatcttt gccgcctaga 900
caaatgata gatctgatca ttccacgtgg ctcttcccag ctggtcagag acatccagaa 960
agctgctaag gggattccag tgatggggca cagcgaagg atctgtgcac atgtatgtgg 1020
attccgaggc cagtgttgat aaggtcacca ggctagtcag agactctaaa tgtgaatata 1080
cagctgcctg taatgctttg gagactttgt taatccaccg ggatctgctc aggacaccat 1140
tatttgacca gatcattgat atgctgagag tggaaacaggt aaaaattcat gcaggcccca 1200
aatttgcctc ctatctgacc ttacagccct ccgaagtga gtcactccga actgagtatg 1260
gggacctgga attatgcatt gaagtagtgg acaacgttca ggatgccatt gaccacatcc 1320
acaagtatgg cagctccac acggatgtca tcgtcacaga ggacgaaaac acagcggagt 1380
tcttcctgca gcacgtagac agtgctgtg tgttctggaa tgccagcact cgcttttctg 1440
atggttaccg ctttggactg ggagctgaag tgggaatcag tacatcgaga atccacgccc 1500
ggggaccagt aggacttgag ggactgctta ctactaagt gctgctgcga gggaaggacc 1560
acgtggtctc agattttctc gagcatggaa gtttaaaata tcttcatgag aacctcccta 1620
ttcctcagag aaacaccaac tgaaaagagc caggaaaacc cggaatttt ccaaaaggtc 1680
ttcacgttaa acttgtctta tctcaggaga gagcccgctc ttgtctccca gttcctggta 1740
gggtctgcct gttggaaagt gtacctggat gcttctgggc tccgtttggc aatagcartc 1800
ttggctgatg tgcacagtct ggctcccagc tcaccctttt tttttaagt aagaaaatag 1860
ttgctaccga tagggacttt gccaaagtcca attatcttct aggattgaaa ggtgcatttt 1920
ccccataaaa aaggcgagga aaacccatgg ctgctttgtg tcacctcagt gacttacagt 1980
cccccttggc atttagttgg tactagagcc agtcactcct aacaaatctt ttcacatttt 2040
atttctttca catgtagtca tcttcaaaaa ggaaagattt ggaatttttag aaaaggggca 2100
actcttcttt ttagcattct catcagaaag tcacaaaaat cgatggaatc atttccactg 2160
ggaagattga ccttttgtat ttatttgtgg ggtaaattaa taagcattcc agatgcttgc 2220
agcttctgc atccaggaga tgctgtgttc cccgtgatgc agctggaacc caagctgcag 2280
caggagatgc aagtttcagg atgttcccca ctgagctgga ggaatatcta cagcagtgat 2340
gcttgaaatt tttgtatgaa ttatttgtgc gtcctaccct tttcctccaa aacaaaaatt 2400
agaggattat ttttaatactt tggattcttc cccctttttt gagaaataaa gttttttatg 2460
aaaagccaaa aaaaaaaaaa aaaaagggng ggcggnctag aggnncc 2507

```

<210> 398

<211> 1273

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (1227)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1229)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1252)
 <223> n equals a,t,g, or c

<400> 398
 ggcacgagtg gagtagctgg gattacagat ttccagaagc tgttctgtca ataacaaagt 60
 ctcaragaaa accacaaaac caccaacact aagatcattc ttgagtccaa tttgaaaaac 120
 taggggtcaag ttctgcagag gcattgaaag gacaagaaac caccctgata cccatcgtgt 180
 gagggaaaaat gctctattca ccattcctca gcttctgctt ctggtttcag agttctctct 240
 atattggagg gtgtttttaa gctagagtgg tctttatcca cttttattaa cacatctgaa 300
 tgtgaagggtc aagagaggaa agtgatatgt cctaagtcag agtagagtca acaagaaaat 360
 aagacaaaaca gcgactgagc ccctgggtgta tactgggcat tggccagcta ctggggatat 420
 ggagatgaag aaaacataac ctttcttcaa ggagcccaac ctaccaaggt agacagacat 480
 atagacaaat agatacttgc atagaaaaaa agaggaaaag gggatcagtg tgacctgtgt 540
 aactaagtac cctataaacc ctctgcaac agatcatatt gccctttata gtggggatgg 600
 taatcccac tgaattccac aggtactttg cagtcatacc acacccatgt gtctgtcggg 660
 cctgactgta ccatttataa acagcttcac tttcagcagt tctcagccct ctttagctag 720
 ggtcattgtc agtagggata ctgcttcata agcaccagca gaacaccaa ggagaccata 780
 tgggtgaaag caaccagcac tgccctggcg cttcataggt tcttagagtt tttatctttt 840
 actttcagtc taacacagca ctgcctgctt tttgtttttg ttgcttggtt tgtttttttc 900
 ttaccgtgtt caccaaactt gtgtccaaat agctttgggc tgatgcaaaa atatctatgt 960
 ggaagagaag agttgttctc atggagggcc ttcagatgag tgctatagac tctctaggca 1020
 actccaagag gcttctcaag caggggtggc agtgagagct gctatggaat caatggacaa 1080
 actgacaggg actgctttga aagacagtac tcagttgagt atatatattc tctcttaagg 1140
 gctaaaagtt tataatcatc ccttaaacac tctgtgatgg gatcttcagg atcatctttt 1200
 gaagtaaact atattttaca atgtganana aaaaaaaaaa aaaaaaaaaa tntgcgggtc 1260
 cgcaaggga ttc 1273

<210> 399
 <211> 3774
 <212> DNA
 <213> Homo sapiens

<400> 399
 gacgcaaaga gtcgcggcgc catttgctgc cgccgagcgt ggacgcaggc ggatctctga 60
 agagctgggt cgccagcctc tcccgcgac gttgcctggc ctccagcacc tacttggtcc 120
 cgcgcgctcc ctctgtcgc ccctcggagc agcagccgcc gcggtcgcgc ctaccggaa 180
 agaagtcaga gacgccgca ggtcgcgcc accgccatgc ccaagaataa aggtaaagga 240
 ggtaaaaaca gacgcagggg taagaatgag aatgaatctg aaaaaagaga actggtattc 300
 aaagaggatg gtcaggagta tgctcaggta atcaaaatgt tgggaaatgg acggctagaa 360
 gcaatgtgtt tcgatggtgt aaagaggtta tgctcacatca gaggaaatt gagaaaaag 420

```

gtttggataa atacctcggga cattatthttg gttgggtctcc gagactacca ggataacaaa 480
gctgatgtaa ttttaaaata caatgcagac gaagctagaa gtctgaaggc atacggcgag 540
cttcagagc atgctaaaat caatgaaact gatacattht gtcctggaga tgatgatgaa 600
attcagthttg atgacatthg agatgatgat gaagatattg atgacatcta aattgaactc 660
aacatthttac attccatctt ttctgaagat tgcctacaa tttggattht gatcatgaca 720
aagaagatta aaatthtcatt agcatgaatg caatthtgta aagcagactg atthgtthct 780
aagatathtt tggtthttttt aaaactgata ataatgctga attatcttaa gtgagatgth 840
aagcccactt tgthctthtt atgtaatgga gctthtcccta ccacttccag taagaaaatg 900
tacaaaaaaa aaaaaaaacc atgcattgct gctthtcccta ccacttccag taagaaaatg 960
gggtgthttga agaaatcatt tgccttgctc tcacggaaatc tgattaagcc ctggcctctt 1020
gattgtatag agtcattgtg tatattccag ttacctagat attcccttga gattthtgata 1080
caatthtgagg gaggcagaag tctgcakttg aagaaaaaaa ataagtctgt ttgtcatatt 1140
taagtagcct gtggctatth ttatactgat tthgatataca tgttctthttc atagtctgat 1200
thtgccaccg taaacataaaa aaaaaaaaaa aagatthtoca aaatgccgtt ttcagaacct 1260
gggtthttaat agcagtattg aatthtgtaag cttagtagth gcagaaattg aacactaggt 1320
ggcactcagt tatcttaaca ggggaagtac tgatacaatt gttgacttht cthttactat 1380
gtgtaagaaa taccocaaac atgaaaagat tgtthtgatc atatgcatgt atgtagaata 1440
thtttgacaga gcagaaagat tatgttagaa gtgtgattth tathttcaga agtcataata 1500
atgtaagcta caatthtgag tgctthataa acacttaaga tatatatata aatthttaatt 1560
tcatagcaac thgtaaaaaa taaaatactt gttgaaaagc cthtttcaac atatccctaa 1620
gctaagggaa gaggaaggaa taacaactca gtgaaaagat ggtctccagt ttctgaatga 1680
aaaagctaca gctgagaaat aaaataaaat gtcatgctgc agaataatgt atacccttat 1740
thtggtgthaa ggataattht tattatgtga atggthttgt thttgtthttt tgtthttgtt 1800
thttgctthg attgggaatt agctthactg gtaacttcc taththagtht ttagtggtca 1860
actctaataa aatgaaacta gggctgagct agthtagcct cactagccaa actgaaactc 1920
tatgcaacat taaaagaaga gatccatcat gtagcttgth acactthttat thtattagtc 1980
accggggaac thttcagthg tgaaaataca cagggttaata aaccttcaca tggcttcaaa 2040
aggaaaacaa gcaaatcttc tctaacttac tcttactata atthcctaag tgtacaccaa 2100
actctggatt taaaaatctg aagtactata gaacattaag ttgaagaatg gaaattaaga 2160
gtacgtatth atggtthtata thtcttatth tatggagthc gtgaacacat ctaggtggaa 2220
tgcatctgag actaagggtt ggtthttaat cctcataaga aaccagcctt gaagaattaa 2280
caatthctctt cattggtatt ctaaacctcc taagatatht aggtctctgt acataaaagt 2340
gtthtttgcta aatthtacagt atatatagat cthttcataat taththtacta agaathgtth 2400
aactthgcat atthgatata gthcctggta ggaatagcac agtcaaaca ttagthttthc 2460
tacttacctc ctctaacacg tggtthgtct ggagagthtc taaaaattca gctataacct 2520
cagthcatgt atthactggt gattgtthct gctgaggtag taacagccca atcttgggt 2580
gttaaatcct aggaaatctc gaatcatagt gattaaaata gttggggtaa agthgtagct 2640
tatatgcaat actacttgga ggaatthctt tactaaththg taththaatgt ggaaattgta 2700
tagththcatt gaththaatca taaataatgg aaatggtctc caagaagtht taththtcat 2760
thttthtgct atacactctg atthcctataa tacagtgcta taagctatgc acagaaaaa 2820
aaatgththg aatccaagaa taatggttht tactgctaag agggagtaat agthtact 2880
aatgaththg atgggtthg atththgtth caatgthtat tccacttgca gthtagaat 2940
gaatagthth tatcactagt tgggttaaat aaccaaact tthgtgtaaaa aaaaaaaa 3000
gccaaagath cattgththt tgaatathth ttaagcatct ggcccctaaa gagaccgtt 3060
cttaccagc ctgtaaaact tgcagatgg aaatctthgt atthththta ggaatggctg 3120
thgtththt caccacatct tgggaatcat ggctataaat gthtgcttac aaactctthg 3180
tgactthgta thtaacttaa tctcatctaa tgtaaatath agathatgat gthcagtaac 3240
atcttccata ggtataaact gctgtcatta thgaththcag agtaactctg agtaatcaaa 3300
taggtaaaag catgthththg gtaaaaatagc tagaththata cththactthg atacagact 3360
aacaacaacc ggtaththgact ggaththgacag ctaaaagtatc agaathgaaag caaggtthth 3420
thgatgthac ctgactgtca taaagatgaa ratgaththg atkggtatga matgcttatc 3480

```

```

tttatctack tcgtaagggt arggtaatta acgctgtgac tccacgaact tgccactgca 3540
tggtgttttg ttccctacat caccctttac ttcgctttct ctatctgaaa gcgaaggaaac 3600
gcagcctccg taatgcagca attggaggat ggggtcgcct taccagctc cagggggtgg 3660
gacattggcg agatgtgggt cccgttgccg ccggcaggac tgttctgcac tagggacacc 3720
catgggattt aatggccaca gaaagctcct tggagaacgg accgggcccg tttt 3774

```

<210> 400

<211> 1522

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (479)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1471)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1481)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1487)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1501)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1508)

<223> n equals a,t,g, or c

<400> 400

```

gcgcccgtgt cttttcagtc sgcgctgagt ggtttttcgg atcatgtctg gtggctccgc 60
ggattataac agagaacatg gcggcccaga gggaatggac cccgatggtg tcatcgagag 120
caactggaat gagattgttg ataactttga tgatatgaat ttaaaggagt ctctccttcg 180
tggcatctat gcttacggtt ttgagaagcc ttccgctatt cagcagagag ctattattcc 240
ctgtattaaa gatccaaaag gtaattctgg cacttgagga ctatatggga gccacttgtc 300
atgcctgcat tgggtggaaca aatgttcgaa atgaaatgca aaaactgcag gctgaagcac 360
cacatattgt tgttggtaca cccgggagag tgtttgatat gttaaacaga agataccttt 420
ctccaaaatg gatcaaaatg tttgttttgg atgaagcaga tgaaatgttg agccgtggnt 480
tttaaggatc maatctatga gattttccaa aaactaaaca caagtattca ggttgtgttg 540

```

```

ctttctgcca caatgccaac tgatgtgttg gaagtgacca aaaaattcat gagagatcca 600
attcgaattc tggtgaaaaa ggaagaattg acccttgaag gaatcaaaca gttttatatt 660
aatgttgaga gagaggaatg gaagttggat acactttgtg acttgtaga gacactgacc 720
attacacagg ctgttatatt tctcaatacg aggcgcaagg tggactggct gactgagaag 780
atgcatgcca gagacttcac agtttctgct ctgcatgggtg acatggacca gaaggagaga 840
gatgttatca tgagggaatt ccggtcaggg tcaagtcgtg ttctgacac tactgacttg 900
ttggctcgcg ggattgatgt gcaacaagtg tctttgggta taaattatga tctacctacc 960
aatcgtgaaa actatatcca cagaattggc agaggggggc gatttgggag gaaagggtgtg 1020
gctataaaact ttgttactga agaagacaag aggattcttc gtgacattga gactttctac 1080
aatactacag tggaggagat gcccatgaat gtggctgacc ttatttaatt cctgggatga 1140
gagttttgga tgcagtgtc gctgttgctg aataggcgat cacaacgtgc attgtgcttc 1200
tttctttggg aatatttgaa tcttgtctca atgctcataa cggatcagaa atacagattt 1260
tgatagcaaa gcgacgttag tctgtagctc ttgtgaggaa agtcattggc tttatcctct 1320
ttagagttag actgttgggg tgggtataaa agatgggggc tgtaaaatct tyytttctta 1380
gaaattttatt tcctagtctt gtagaaatgg ttgtattaga tgttctctat catttaataa 1440
tatacttgtg gactaaaaga tataagtgtc ntataaaatc nggcccatt atgtttaaat 1500
ntcagatnac ccttaatcaa at 1522

```

<210> 401

<211> 1370

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1223)

<223> n equals a,t,g, or c

<400> 401

```

agcccttcct gcccagctg cagaccactt tcaccaaagc cctgcaggac tccaaccggg 60
gggtgcgctt gaaggcgag atgctctggg gaagctcatt tccatccaca ttaagggtgga 120
ccccctcttc acagagctgc tcaatggcat ccgcgccatg gaggaccag gtgtcagggg 180
cacattgctg caggccctga ggtttgtgat tcaggagca ggggccaaag tggatgccgt 240
catccggaaa aacatcgtct cactcctgct gagcatgctg ggacacgatg aggacaacac 300
tcgcatctcc tcagccgggt gcctagggga actgtgtgcc tttttgactg aagaggagct 360
tagtgccgtt ctacagcagt gcttgtggc ggacgtgtcc ggcattgact ggatggttcg 420
gcacgggagg agctggcact ttccgtggct gtgaatgtgg ctccctggcag actttgtgcc 480
ggcagatata gcagtgatgt tcaggaaatg atcctgagca gtgccacggc ggacaggatc 540
cccattgcgg tgagcggggg ccggggcatg ggctttctca tgagacacca catcgagaca 600
ggcggagggc agttgccggc caaactttcc agcctgttcg ttaagtgtct gcagaaccca 660
tccagcgaca tcaggctggg ggctgagaag atgatctggg gggcaaataa ggacccactg 720
cctccccctg acccccaggc catcaagccc atcctgaagg ctcttcttga caacaccaag 780
gataagaaca ccgtggtcag ggcctacagc gaccaggcaa ttgtcaacct cctcaagatg 840
cggcaggggtg aagagggtgt tcagtccttc tccaagatcc tggatgtggc cagtttggag 900
gtgctgaacg aggttaaccg aagtcctga agaagctggc cagccaggcc gactccacgg 960
agcagggtgga cgacaccatc ctgacatgag aggcctgggc cagcagcagc attgccgctc 1020
cacatctttg ctcaatgttt tcatttttga aaatacattt gttccaatgg ggagcttgga 1080
agatggcggt cccagaaagt attttaatat caatagacca cagccaaagc cttaaataca 1140
acccacacac aactgaaaat tgcctcctcc atctctcacc ttttcctgtg gagaagagaa 1200
ggaaaagcac acgcgatgcg ctnacgcaaa tggcagccca ggagctgttt gtccakttta 1260
ggcatggcta ggtctgggaa ctattaatag gcagggtcag aytktggggt tcctcttctc 1320

```

ctgtgcttga gctctgggtt gagagctggc gctaccaacc tttttcctat

1370

<210> 402

<211> 1412

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (51)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1406)

<223> n equals a,t,g, or c

<400> 402

```

ttatataaag atctatcaag gtgaagaatt accacatccc aaatccatgt nacaggccac 60
agcagaagct aacaatttag cagccgtggc aactgccaaag gacacataca acaaaaaaat 120
ggaagagatt tgtggtgggtg acaaacatt tctggcccca aatgacttgc agaccaaaca 180
cctgcaactt aaggaagaat ctgtgaagct attccraggg gtgaagaaga tgggtgggga 240
agaatttagc cggcgttacc tgcagcagtt ggagagtga atagatgaac tttacatcca 300
atatatcaag cacaatgata gcaaaaatat cttccatgca gctcgtaccc cagccacact 360
gtttgtagtc atctttatca catatgtgat tgctgggtgt actggattca ttggtttgga 420
catcatagct agcctatgca atatgataat gggactgacc cttatcacc tgtgcacttg 480
ggcatatatc cgggtactctg gagaataccg agagctggga gctgtaatag accaggtggc 540
tgcagctctg tgggaccagg ctttgtacaa gctttacagt gcagcagcaa cccacagaca 600
tctgtatcat caagctttcc ctacaccaa gtcggaatct actgaacaat cagaaaagaa 660
aaaaatgtaa tgcaaat tttt aagaaataga ggtgcatgac caattgtcaa ttaaataattc 720
agttttatgt ctccatgcaa acattcaaag tgcttccatc agaacggagt aaaatactaa 780
acacctctga agactgcaaa ctggattagt tcttttactt cagtgtttaa taagcagatg 840
tatgtatgca tgggtatact attttgttaa catgtacaat ttcttgattt ttcttcaaaa 900
atgctgttat aaagtatttg tctatttatg ataacagtac acgtgttctg cttgaattta 960
ctaaattcta ctactgggtt ataattaaat catgtgatat tccacgtttg gatatgctca 1020
tttaatttct acagaaaaaa ttttaaatta tttcacatta gccatttggt aaaacacagc 1080
atcataactc agcaggctgg atttaattctg tatcatctta tatatatcac aatcttattt 1140
ttaagcacat ttttagagttc cttagttgct ttatcaaaaa ccagatattg cttttacatg 1200
gtttaataga atataaacct cttgataaaa aatgcacaaa aaatcacttt gtatatgtga 1260
gtttcactgc attgtatatt ttttcatttg gtacacaaa aatgtattct tcataggttt 1320
attcttttaa tatgtgaact attattaaag tttactctgg ttcctaagat taaaaamaaa 1380
aaaaaaaaaa aaaaaaaaaa aaaaanaaaa aa 1412

```

<210> 403

<211> 1750

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (40)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (70)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (107)

<223> n equals a,t,g, or c

<400> 403

```

tngtgctcca cgcggtgga ggaccgctcc tagcaactan tggntcccc gggcctgtca 60
ggaattcggc cagtgggcat ggcgactttt tctggcccg cgtggcnaat cctgtcgctt 120
aatccgcaga agatgtcgag tttcaaaagg aggtggcgca ggttcgcaag cgcataaccc 180
agcgaaaaaa acaagaacaa cttactcctg gagtagtcta tgtgcgccac ctacctaac 240
tacttgacga aaccagatc tttcatatt tctccagtt tggcactgtg acacggttca 300
ggctgtccag aagtaaaagg actggaaata gcaaaggcta tgcatttgtg gagtttgagt 360
ctgaggatgt tgccaaaata gttgctgaaa caatgaacaa ctacctgttt ggtgaaagac 420
tcttgagagt tcattttatg ccacctgaaa aagtacataa agaactcttt aaagactgga 480
atattccatt taagcagcca tcatatccat cagtgaacg gtataatcgg aatcggacac 540
taacacaaaa gctacggatg gaggagcgat ttaaaaagaa agaaagatta ctcaggaaga 600
aattagctaa aaaaggaatt gactatgatt ttcccttctt gattttacag aaaacggaaa 660
gtattttcaa aactaatcgt cagacgtcta caaaaggcca ggttttacgt aagaagaaga 720
aaaaagtttc aggtactctt gacactcctg agaagactgt ggatagccag ggccccacac 780
cagtttgtac accaacattt ttggagaggc gaaaatctca agtggctgaa ctgaatgatg 840
atgataaaga tgatgaaata gttttcaaac agcccatatc ctgtgtaaaa gaagaaatac 900
aagagactca aacacctaca cattcacgga aaaaaagacg aagaagcagc aatcagtgat 960
tttcaatgta ttatatttct tttgaaaaat ataataattt tatgagagtg gactttgtat 1020
ttcactaggt acaatggaat acaacctttg acaagatttt cagaggaaaa atacactgtt 1080
tgggtcaagtt aaggaaagca gtgtgtaatt ttggattgcc tgcccttggc tgaaatacag 1140
gggtgcatac cagcttgacg tggcttggtc gacattgcct ctttgtcctg gcctctagtt 1200
ttcttttgat atttcatagc tctccttagt ttactctgcc tggatagaaa gttgaccact 1260
aactgcaggt ttaagtacta aaytcagcc ttttctgtcg ccagcaatta aagaccacca 1320
atcttgtttg tccatctaca tggtttgtcg gggacattta actcatggag gtgctttaga 1380
tttcaacatc agatggttga agctggaagt ttaattatat gtagagttag aaggcagttc 1440
cagtttttagc acagatttgt ttatgtgttc agattttaat agagattcaa aaatgactca 1500
ttttttacca taatgttaaa ttagttttgg ttgtgctagc atgaattaat aaccaccatt 1560
ttataccagt atcatcagtg aagaattgta tttcaagatt caaacaataa ccagcaatta 1620
aacttttttc tacaatgtat ttgtttgcga gtaggacttg ggagtcattg ggaaaaaaa 1680

```

339

ataataaaatt ttccccttca ttaacgaatt cagactcatt aaaaacattg ccatcagaaa 1740
aaaaataaaaa 1750

<210> 404

<211> 1339

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (150)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1330)

<223> n equals a,t,g, or c

<400> 404

atttcaggga aatgaagatg gaatttgaag gtcactttta aaattaagtc attgatgctg 60
ctgttacaga gtgtgacaga ggatccatgt ctgtgacaca ggacggtggg aagcctgaga 120
gagagtgaat ttatgtgata cactgaaatn acttttgttt ttcttctaac tcatacaaaa 180
ctggtttgga aagtctttgc tttggaagcg tcagacatta gaacaggcca aactggactg 240
tctgttcata gcgtgcctga ataagaaggc ctcttaggga gccagaggga gcagagtggg 300
cgtgtcctgc gtgctcttca cctctgggg cgccctgct gcggctggca ggtgcagaca 360
gcctttgctg gtcccagca cgtccagggt ggggtgctccc ttgcccagca gaaccatccc 420
cactgtgagg ctgtgagaga tttgtggcag gaactgttta tgaggctcta gttgttgctg 480
ttgtggcggg aaagttaaga aacatagccc ttaaggaaac cacctttatg tattttctta 540
aagcacgcct ttaaataagc aaaaacttta aaaggcagga aagagaattc ttaggcaaat 600
tcagagaaat aagtgtcagt taatactaac cacctcctcc tctgtctctc atcctccttt 660
ctcccatcaa agcaaaatat ggcctcacca ccagcccaa atcagtgtct agaccctctc 720
tgtgtctgtg tgccctcctg ggagtcagtc agcgtcagg ccaggactgt gcagggccag 780
ccagcccatg cgctagtcag gagcacaggc aaggggtgct tgtggcagtg gccgggcacc 840
tgagccccag ctggttggtta aacgtgctga cggcaagggg caatggagtg agtttcccaa 900
ctaagaaacc actattatat atttttyccc ttcagtcaca tagacttcag acaactctcc 960
tattttttat ggatttttca gtcattttca gatgaaggaa ctaagtcatt gtgaactgtc 1020
tcttgagatc taaaaacaag atgacttttc ctggcacata ttccaaagca aagactttgt 1080
tgctgtctgc ttattgtcta atttacaggg atatttaatt ttgtcaggtc tatgtatatt 1140
tatccagcta tacttacttg cacagtggat tggagagaaa ggattctcca gtgtgcacac 1200
tcacgggtac tctttctgca tttccctcgt gctgtgtccc gctcgggttc caatggacag 1260
tatcagggtc tgtttgactt aggtctttca gttttccttt cggttccctt ttaaaaatgt 1320
gattgttaan ctgcctctt 1339

<210> 405

<211> 482

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (440)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (469)

<223> n equals a,t,g, or c

<400> 405

```

cttgggtatc ggctattgcc tgagtgtgct agagtcctcg aagagtaact gctgacctta 60
ttcactggct gtgggcctta tggcacagtc agtcaccagg ttagagacat gcttcacatt 120
cacctaccca caaactagtg gatgataaat tttggctatt cagaagacgt ttattatagg 180
agtatgtaga ttttccatag agtgctgtta tgtgacttga attttagtct cggccctgcc 240
tctgacattg tcggtgggtt atcctgggtc caggaaataa gactagcctt ttcctcatga 300
tagtctttgg tggtttttaa aacagttggt taagtcaaca gatgtatcat atgcctgaca 360
ctgctctaca ccagtgaata atttacactc taataggggg tggttaactat aaagatgata 420
aacatagcat cttaattggn gtgtgtatga aggtggttgt tacctcttnc tagccaccca 480
gg                                                                 482

```

<210> 406

<211> 1413

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (24)

<223> n equals a,t,g, or c

<400> 406

```

ctgggtgctnc accgcggtgt cggnccgctc tagcaactag tggatcccc gggcctgcag 60
ggaattcggc acgagggttg gtggggttac acgcgggttc aacatgcgta tcgaaaagtg 120
ttattttctgt tcggggccca tctatcctgg acacggcatg atgttcgtcc gcaacgattg 180
caagggtgttc agattttgca aatctaaatg tcataaaaaac tttaaaaaga agcgcaatcc 240
tcgcaaagtt aggtggacca aagcattccg gaaagcagct ggtaaagagc ttacagtggg 300
taattcattt gaatttgaaa aacgtagaaa tgaacctatc aaataccagc gagagctatg 360
gaataaaaact attgatgcga tgaagagagt tgaagaaatc aaacagaagc gccaaagctaa 420
at ttataatg aacagattga agaaaaataa agagctacag aaagttcagg atatcaaaga 480
agtcaagcaa aacatccatc ttatccgagc cctctttgca ggcaaaggga aacagttgga 540
agagaaaatg gtacagcagt tacaagagga tgtggacatg gaagatgctc cttaaaaaatc 600
tctgtaacca tttcttttat gtacatttga aaatgccctt tggatacttg gaactgctaa 660
attatttttat tttttacata aggtcactta aatgaaaagc gattaaaaga catctttcct 720
gcattgccat ctacataata tcagatatta cggatgttag attgcatctc agtggttaaat 780
ctttactgat agatgtactt aagtaaatca tgaaaattct acttgtaact atagaagtga 840
attgtggacg taaaatgggt gtgctatttg gataaaggca ctaggcagca tttgtatagt 900
aactaatggc aaaaattcat ggctagtgat gtataaaata aaatattctt tgcagtaaaa 960
tattcccttt gttaatgtta tagaaggggg gatacaaaaa ggaactaaca atttgtatgg 1020

```

```

cagtgtcaga tatttttatt ttagtatttc ctgttttggt ttatttgcac cttagaagag 1080
cataatgaca ttgtttgatg aagcctaatt atgctggact gttttgacct ggtttaaccc 1140
ttctgatagg tagttgtgga tgctggggat gagaactgaa taatctttgc ctggagtgc 1200
actacactct agaatttcca ctttgagaa tactcagttc caacttgtga ttctgatag 1260
aacagacttt acttttctag cccagcattg atctagaagc agaggaatcc cagcgccctt 1320
taaaagttgt tatgtggttt tcttttaaaa agtcctgttt tttggaaagt agaatttatg 1380
ggtacctcgg ccgcgaccac gctaagccga att 1413

```

<210> 407

<211> 1693

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1548)

<223> n equals a,t,g, or c

<400> 407

```

tgggctgtcc ggcccactcc cctgggagcg cgaagcgktg gacccaggcg gccatgtccc 60
gccctcgcac gcgcctgggtg gtcaccgagg acgactttgg ttactgcccc cgacgcgatg 120
agggtatcgt ggaggcccttt ctggccgggg ctgtgaccag cgtgtccctg ctgggtcaacg 180
gtgcggccac ggagagcgcg gcggagctgg cccgcaggca cagcatcccc acgggcctcc 240
acgccaacct gtccgagggc cgccccgtgg gtccggcccc cctgtggcgcc tcacgcgtgc 300
tcggccccga argcttcttc cttggcaaga tgggattccg ggaggcggtg gcggccggag 360
acgtggattt gcctcaggtg cggagccgca gctacaggag gatgctcgcg aggaccccc 420
gagctccgcc cggaggtagt gtgaggccgt tagagctggc ggtggatgac ttccgcattc 480
aaacactgga gccatcacac ggaagcacga ggagggtatc ctccggcagc actcccggtc 540
gctcaagggtg tctctcgcgc gccctctagg tgccgggagga gctcgaggcc caactaagct 600
gcttccggga gctgctgggc aggcycaccac gcacgcggac gggcaccagc actgcacgtr 660
ckcycagggtg cgtgggttagt gatcccagtt tggagggcgt tactcccagg cggggctggg 720
ggagtakggg aagttcgcag cccccagggt aaaggacgtg ctccctccctg acccgctccg 780
cccgagggcg tgtgccagggt gttcgccgag gcgctgcagg cctatgggggt gcgctttacg 840
cgactgccgc tggagcgcgg tgtgggtggc tgcacttggc tggaggcccc cgcgcggtgc 900
ttcgccctgc cgtggagcg cgacgcccgg gccgcccgtg gccccttctc ccgccacggc 960
ctgcggtgga cagacgcctt cgtgggcctg agcacttgcg gccggcacat gtccgctcac 1020
cgcggtgtcc gggccctggc gcgggtcctg gaagtaccct agcggggccac accctgacag 1080
ccgagctgat ggcgcacccc ggctacccca gtgtgcctcc caccggcggc tgcggtgaag 1140
gccccgacgc tttctcttgc tcttgggagc ggctgcatga gctgcgcgtc ctacccgcgc 1200
ccacgctgcg gggccagctt gccaggatg gcgtgcagct ttgcgccctc gacgacctgg 1260
actccaagag gccaggggag gaggtccctt gtgagcccac tctggaaccc ttcttgaac 1320
cctccctact ctgacccctt acagacaacc aagcactaat ccccttagta ccaagaaagg 1380
ggagccagga tttagtctct gccagccca gagctgggac ctggagcacg atctgttgac 1440
ttccctgggt aggacactgc cacctctggg ctcaggtcct catgcctcca aatggcatct 1500
agagtttgag cagccttctt ggctgcaggc aggcctagcc tgtggcancg ggctagggcc 1560
cgcagagcat ttggtgcccc tccatgttgc aatgcaaaca ccttcaccac tggggcagtg 1620
gggagagatg gctatatata taaaataacg tgtgtctttc aaaaaaaaaa aaaaaaac 1680
tcgagacagt tct 1693

```

<210> 408

<211> 1342

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1332)
<223> n equals a,t,g, or c

<400> 408
caggaaaaat ctggagattt acgaggctgt gacgtccccc cagggccccc ccatgacctg 60
gagcatgttt gctgtgggct ggatggagct gaaggacgca tgcgggncgc ggggcctcct 120
ggacaggagc tttgccaaaca tggctgaacc cttcaagggtg tggacggaga atgcagacgg 180
gtcaggcgct gtgaacttcc tgacaggcat ggggggcttc ctgcaggcgg tggctctcgg 240
gtgcacgggg ttcagrtsa gcgtctccgg catcttctac caggggmacr agctcaactt 300
ctstttttcc gaggactccg tgaccgtgga ggtcacagct cgagcagggc cctgggctcc 360
tcacctggag gctgagctgt ggccatccca gtcccggtc tccctgttgc caggacacaa 420
ggtctccttt ccccgctcgg ctggccggat acaaagtca cccccgaagc tgcctggaag 480
ttccagctcc gagttccctg ggaggacttt ttcagatgtt agggaccgc tccagagccc 540
cctctgggtc accctgggtt cctccagccc caccgagtca ctactgttg accctgcctc 600
tgaataatca ggaacgggtg cttcagagac gtctcttggg ccttccctct ggccacgtct 660
gcaccacccc ctctgggca ccctcctagc ctgccatccc tcacctgcag ccaggctctc 720
agggaaggtc catgctgctt ggcctgagtt caaggctttc tgcctgtagc ctggactccc 780
gtggaccccc gtgggcagggt ggcttccccg tggcatctcc acaccgcctc tgcctgcccc 840
tgtggactga tgctatcgcg caccgtccca cgacccacc ccgagctcct gaagccgggg 900
tctgagcctg catcacctct ggcctctcat cccccactct cctgagagca gtgggtcacag 960
cggccggccg ctctgctgag aaggcagaga ggcaggctca ggcctcagcg tggacagcag 1020
ggataagggg cacgaaggac ggggactcgg ccccttcaga attcctcagg actctcagg 1080
gcagctttgc caaaaaggaa cttttcatgt catgcagttg aggggactta gtctcaatcc 1140
caggctcctc ttgactctgg gcagcyttrt cttgggcagc tcwgccccag gggtcgggtc 1200
tcagcagttt cccaagaaca agatgtgatg gcactctgtg ctgaaaccct gatgaggacc 1260
aggccccctg caccgctgtc agcctgagga attaaagctt tgggtgctggg aaaaaaaaaa 1320
aaaaaaaaaa anaaaaaaaa ca 1342

<210> 409
<211> 2417
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (680)

<223> n equals a,t,g, or c

<400> 409

```

aaaaaaaaa aaaaaaacca aacacaaaga gagcaatttt gggccaacag ttaccattca 60
agcctggccc tttaggccag cccagtcac gggctctgag tgtggangct gcgtagcacc 120
aggaagcggc tctgctgagg ttcaaggggc cccagcacag tgtggcatcc gttcagcttt 180
tggttggtcc aggatggtgg ggagccaggc ctcggggcct cggagcaacc acccgagcag 240
acggagtaca cggagcagcg gccccggccc cgccaacgct gccgccggga tgctccagac 300
cttgatgat tacttctggt gggaacgtct gtggctgcct gtgaacttga cctgggccga 360
tctagaagac cgagatggac gtgtctacgc caaagcctca gatctctata tcacgtgcc 420
cctggccttg ctcttctca tcgttcgata cttctttgag ctgtacgtgg ctacaccact 480
ggctgcccctc ttgaacataa aggagaaaac tcggctgcgg gcacctcca acgccacctt 540
gggaacattt ctacctgacc agtggcaagc agcccaagca ggtggaagta garcttttgt 600
cccggcagar cgggcttytc tggccgccag taragcgttg gttccgtcgc cgccgcaacc 660
aggaccggcc cagtctcctn caagaagttc cgagaagcca gctggagatt cacattttac 720
ctgattgcct tcattgccgg catggcgcctc attgtggata aaccctggtt ctatgacatg 780
aagaaagtgtt gggaggggata tcccatacag agcactatcc cttcccagta ttggtactac 840
atgattgaac tttccttcta ctggctccctg ctcttcagca ttgcctctga tgtcaagcga 900
aaggatttca aggaacagat catccaccat gtggccacca tcattctcat cagcttttcc 960
tggtttgcca attacatccg agctgggact ctaatcatgg ctctgcatga ctcttccgat 1020
tacctgctgg agtcagccaa gatgtttaac tacgcgggat ggaagaacac ctgcaacaac 1080
atcttcatcg tcttcgccat tgtttttatc atcaccgcac tggtcacctt gcccttcttg 1140
atcctgcatt gcacctggt gtaccactg gagctctatc ctgccttctt tggctattac 1200
ttcttcaatt ccatgatggg agttctacag ctgctgcata tcttctgggc ctacctcatt 1260
ttgcgcatgg ccacaagtt cataactgga aagctggtag aagatgaacg cagtgaccgg 1320
gaagaaacag agagctcaga gggggaggag gctgcagctg ggggaggagc aaagagccgg 1380
cccctagcca atggccaccc catcctcaat aacaaccatc gtaagaatga ctgaaccatt 1440
attccagctg cctcccagat taatgcataa agccaaggaa ctaccctgct cctgcgcta 1500
tagggtcact ttaagctctg gggaaaaagg agaaagttag aggagagttc tctgcatcct 1560
ccctccttgc ttgtcaccca gttgccttta aaccaaattc taaccagcct atccccaggt 1620
agggggacgt tggttatatt ctgttagagg gggacggtcg tattttcctc cctaccgcc 1680
aagtcatcct ttctactgct tttgaggccc tccctcagct ctctgtgggt aggggttaca 1740
attcacattc cttattctga gaatttgcc ccagctgttt gcctttgact ccctgacctc 1800
cagagccagg gttgtgcctt attgtcccat ctgtgggcct cattctgcca aagctggacc 1860
aaggctaacc tttctaagct ccctaacttg ggcagaaac caaagctgag cttttaactt 1920
tctccctcta tgacacaaat gaattgaggg taggaggagg gtgcacataa cccttaccct 1980
acctctgcca aaaagtggg gctgtactgg ggactgctcg gatgatcttt cttagtgcta 2040
cttctttcag ctgtccctgt agcgacaggt ctaagatctg actgcctcct cctttctctg 2100
gcctcttccc ccttccctct tctcttcagc taggctagct gggttgaggt agaattggaa 2160
ctaattctaa tttttattta ttaaataattt ggggttttg ttttaaagcc agaattacgg 2220
ctagcaccta gcatttcagc agaggacca ttttagacca aaatgtactg ttaatgggtt 2280
tttttttaaa attaaaagat taaataaaaa atattaaata aaacatggca ataagtgtca 2340
gactattagg aattgagaag ggggatcaac taaataaacg aagagagtct ttcttaaaaa 2400
aaaaaaaaa aaaaaaa

```

2417

<210> 410

<211> 1401

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1394)

<223> n equals a,t,g, or c

<400> 410

```

ttgtgtatat tgttgacatc tgataatttg tgcaatttta tttttaactt aaaagatggg 60
aaccaacaaa tgtgccagcc aggcaggtat gacagcttac gggactagga ggcattctta 120
tgatcccaaa atgcaaactg acaaaccctt tgaccagacc acaattagtc tgcagatggg 180
cactaataaa ggagccagcc aggcagggat gttagcacca ggtaccagaa gagacatcta 240
tgatcagaag ctaacattac agccgggtga caactcgaca atttccttac agatgggtac 300
caacaaaagt gcttcccaga aaggaatgag tgtgtatggg cttgggcggc aagtatatga 360
tccc aaatac tgtgtctgtc ctacagaacc tgtcattcac aacggaagcc aaggaacagg 420
aaca aatggt tcggaaatca gtgatagtga ttaccaggca gaataccctg atgagtatca 480
tggcgagtac caggatgact ccccagaga ttaccaatat agcgaccaag gcattgatta 540
ttagatccac acagaaggag ctcagtattt agtcctttgt ttttattcag tgagaaccaa 600
gctagccttg agtaattttt atcttgtctt cctaaaacac tattaagctt attgtacttt 660
taagaaaaat tgccttacgt acattccttt ttcctttttc tgccctcttc ctcaatagtt 720
gccttttagt gctgtaatag ttaa atccta cagcataatc aataactcgc atatgaagta 780
aaaaggaata ctgtgaaagg ggagtactct tgtacagcca gttcctttat gcaaaaatct 840
atgcattttt acaatcttat attaaactgg tattttcaaa caataggaaa cttttttttt 900
ttttttttta cagtttagtg tatctgggtt ctacatggaa gactaaactc atgcttattg 960
ctaaatgtgg tctttgccaa ctaaatttta gatgcagcat tttagaaatt tacatatcaa 1020
tgtttctaca gtattgtttg ctaattttta aataaagtca tgatcagtg gcatttgtga 1080
ttatatgtgt actcattctc ttacctagcg aacaagatct tttcagagtg gtgtttctaa 1140
aagagcatgt acaaaagtgg cctgtggaca tttaggcctg ggtgatgcat ttgctcttcc 1200
tgtttgtgcc aatgtatcaa tgtagagttg ctctgttttc ttcaactgta tttattgctg 1260
catttctcag cataaactta tccattgta ttttttataa ataaatattt tttttgaact 1320
ttmaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaaaaaaaa gggnggccgt t                                     1401

```

<210> 411

<211> 3016

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (399)

<223> n equals a,t,g, or c

<400> 411

```

cggaccgctt ccccgagcc agcagcgctt gacgtcatcg tgcgtgtggt gcccctgctg 60
ccggggctgg tgattggagg aaaccccggt tctgcggacg gctgtagcct gtgagcagcg 120
agatccaggg acagagtctc agcctcgccg ctgctgcccg cggcgccgcc cagagactgc 180
tgagcccgtc cgtccgccgc caccacccac tccggacaca gaacatccag tcatggataa 240
aaatgagctg gttcagaagg ccaaactggc cgagcaggct gagcgatatg atgacatggc 300
agcctgcatg aagtctgtaa ctgagcaagg agctgaatta tccaatgagg agaggaatct 360
tctctcagtt ccttataaaa atgttgtagg agcccgtag tcatcttggg gggctgtctc 420
aagtattgaa caaaagacgg aaggtgctga gaaaaaacag cagatggctc gagaatacag 480
agagaaaaat gagacggagc taagagatat ctgcaatgat gtactgtctc ttttgaaaaa 540
gttcttgatc cccaatgctt cacaagcaga gagcaaagtc ttctatttga aaatgaaagg 600

```

```

agattactac cgttacttgg ctgaggttgc cgctggtgat gacaagaaag ggattgtcga 660
tcagtcacaa caagcatacc aagaagcttt tgaaatcagc aaaaaggaaa tgcaaccaac 720
acatcctatc agactgggtc tggcccttaa ctctctgtgt ttctattatg agattctgaa 780
ctccccagag aaagcctgct ctcttgcaaa gacagctttt gatgaagcca ttgctgaact 840
tgatacatta agtgaagagt catacaaaga cagcacgcta ataatgcaat tactgagaga 900
caacttgaca ttgtggacat cggataccca aggagacgaa gctgaagcag gagaaggagg 960
ggaaaattaa ccggccttcc aacttttgtc tgccctcattc taaaatttac acagtagacc 1020
at ttgtgcac catgctgtcc cacaatatgt tttttgttta cgatttatga caggtttatg 1080
ttactttctat ttgaatttct atatttccca tgtggttttt atgtttaata ttaggggagt 1140
agagccagtt aacatttagg gagttatctg tttctatctt gaggtggcca atatggggat 1200
gtggaatttt tatacaagtt ataagtgttt ggcatagtac ttttggtaga ttgtggcttc 1260
aaaaggggcca gtgtaaaact gcttccatgt ctaagcaaag aaaactgcct acatactggt 1320
ttgtcctggc ggggaataaa agggatcatt ggttccagtc acaggtgtag taattgtggg 1380
tactttaagg tttggagcac ttacaaggct gtggtagaat cataccocat ggataccaca 1440
tattaaacca tgtatatctg tggaaactc aatgtgtaca cctttgacta cagctgcaga 1500
agtgttcctt tagacaaagt tgtgacccat tttactctgg ataagggcag aaacggttca 1560
cattccatta tttgtaaagt tacctgctgt tagctttcat tttttttgct acactcattt 1620
tatttgtatt taaatgtttt aggcaaccta agaacaaatg taaaagtaaa gatgcaggaa 1680
aaatgaattg cttggtattc attacttcat gtatatcaag cacagcagta aaacaaaaaac 1740
ccatgtattt aacttttttt taggattttt gcttttgtga tttttttttt ttttttgata 1800
cttgccctaac atgcatgtgc tgtaaaaata gttaacaggg aaataaactg agatgatggc 1860
tagctttgtt taatgtctta tgaaattttc atgaacaatc caagcataat tgттаагаас 1920
acgtgtatta aattcatgta agtggaataa aagttttatg aatggacttt tcaactactt 1980
tctctacagc ttttcatgta aattagtctt ggttctgaaa cttctctaaa ggaaattgta 2040
cattttttga aatttattcc ttattccctc ttggcagcta atgggctctt accaagttta 2100
aacacaaaat ttatcataac aaaaatacta ctaatataac tactgtttcc atgtcccatg 2160
atccccctct ttcctcccca ccctgaaaaa aatgagttcc ttttttttct gggggggggg 2220
gggggggggg gggggggggg gggggggggg gggggggggg gggggggggg gggggggggg 2280
ggggaaaaat atttatttat aaaaaataca atgggataag tttatgctga gaaatgcagc 2340
aataaatata gttgaagaaa acagagcaac tctacattga tacattggca caaacaggaa 2400
gagcaaatgc atcacccagg cctaaatgtc cacaggccac ttttgtacat gctcttttag 2460
aaacaccact ctgaaaagat cttgttcgct aggtaaagaga atgagtacac atataatcac 2520
aaatgcacac tgatcatgac tttattttaa aattagcaaa caatactgta gaaacattga 2580
tatgtaaatt tctaaaatgc tgcattctaa atttagttgg caaagaccac atttagcaat 2640
aagcatgagt ttagtcttcc atgtagaaac cagatacact aaactgtaaa aaaaaaaaaa 2700
aaaaaagttt cctattgttt gaaaatacca gtttaatata agattgtaaa aatgcataga 2760
tttttgcata aaagaactgg ctgtacaaga gtactccctt ttcacagtat tcctttttac 2820
ttcatatgcy agttattgat tatgctgtag gatttaacta ttacagcact aaaaggcaac 2880
tattgaggga agaggcagaa aaaggaaaaa ggaatgtacg taaggcaatt tttcttaaaa 2940
gtacaataag cttaatatgt ttttaggaag acaagataaa aaaaactcga gactagttct 3000
ctctcgtgcc gaattc 3016

```

<210> 412

<211> 958

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (930)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (934)
 <223> n equals a,t,g, or c

<400> 412
 cttgctgccc cgcgtgtgtg cgcctaattct caggttgtcc acccgagacc ccttgagcac 60
 caaccctagt ccccgcgcg gccccttatt cgctccgaca agatgaaaga aacaatcatg 120
 aaccaggaaa aactcgccaa actgcaggca caagtgcgca ttggtgggaa aggaactgct 180
 cgcagaaaaga agaaggtggt tcatagaaca gccacagcag atgacaaaaa acttcagttc 240
 tccttaaaaga agttaggggt aaacaatatc tctggtattg aagaggtgaa tatgtttaca 300
 aaccaaggaa cagtgatcca ctttaacaac cctaaagtgc aggcattctct ggcagcgaac 360
 actttcacca ttacaggcca tgctgagaca aagcagctga cagaaatgct acccagcatc 420
 ttaaacaccagc ttggtgcgga tagtctgact agtttaagga gactggccga agctctgccc 480
 aaacaatctg tggatggaaa agcaccactt gctactggag aggatgatga tgatgaagtt 540
 ccagatcttg tggagaatth tgatgaggct tccaagaatg aggcacactg aattgagtca 600
 acttctgaag ataaaacctg aagaagttac tgggagctgc tattttatat tatgactgct 660
 ttttaagaaa tttttgttta tggatctgat aaaatctaga tctctaatat ttttaagccc 720
 aagccccttg gacactgcag ctcttttcag tttttgctta tacacaattc attctttgca 780
 gctaattaag ccgaagaagc ctgggaatca agtttgaaac aaagattaat aaagttcttt 840
 gcctagtaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa gggnggccgt tttaaaggaa ccaggttt 958

<210> 413
 <211> 500
 <212> DNA
 <213> Homo sapiens

<400> 413
 cgattgaaca ggagaagcaa gcaggcgaat cgtaatgagg cgtgcgccgc caatatgcac 60
 tgtacattcc acaagcattg ccttcttatt ttacttcttt tagctgttta actttgtaag 120
 atgcaaagag gttggatcaa gtttaaatga ctgtgctgcc cctttcacat caaagaacta 180
 ctgacaacga aggcgcgccc tgcctttccc atctgtctat ctatctggct ggcagggaag 240
 gaaagaactt gcatgttggg gaaggaagaa gtgggggtgga agaagtggg tgggacgaca 300
 gtgaaatcta gagtaaaacc aagctggccc aaggtgtcct gcaggctgta atgcagttta 360
 atcagagtgc cttttttttt tttgttcaaa tgattttaat tattggaatg cacaattttt 420
 ttaatatgca aataaaaagt ttaaaaactt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 480
 gcggccgctc gaattaagcc 500

<210> 414
 <211> 3397
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (15)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (24)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (3081)
 <223> n equals a,t,g, or c

<400> 414
 nggattcgcg gccgntccga ctgnccgcgg ggctagcact gacgtgtctc tcggcggagc 60
 tgctgtgcag tggaacgcgc tgggccgcgg gcagcgtcgc ctacgcgga gcagagctga 120
 gctgaagcgg gaccgcggagc ccgagcagcc gccgccatgg caatcaaatt tctggaagtc 180
 atcaagccct tctgtgtcat cctgccggaa attcagaagc cagagaggaa gattcagttt 240
 aaggagaaaag tgctgtggac cgctatcacc ctctttatct tcttagtgtg ctgccagatt 300
 cccctgtttg ggatcatgtc ttcagattca gctgaccctt tctattggat gagagtgatt 360
 ctagcctcta acagaggcac attgatggag ctagggatct ctcctattgt cagctctggc 420
 cttataatgc aactcttggc tggcgccaag ataattgaag ttggtgacac cccaaaagac 480
 cgagctctct tcaacggagc ccaaaagtta tttggcatga tcattactat cggccagtct 540
 atcgtgtatg tgatgaccgg gatgtatggg gacccttctg aaatgggtgc tggaaatttg 600
 ctgctaataca ccattcagct ctttgttgct ggcttaattg tcctactttt ggatgaactc 660
 ctgcaaaaag gatattggcct tggctctggt atttctctct tcattgcaac taacatctgt 720
 gaaaccatcg tatggaaggc attcagcccc actactgtca aactggccg aggaatggaa 780
 tttgaagggtg ctatcatcgc acttttccat ctgctggcca cagcacaga caaggtccga 840
 gcccttcggg aggcgttcta ccgccagaat cttcccaacc tcatgaatct catcgccacc 900
 atctttgtct ttgcagtggc catctatttc cagggcttcc gagtggacct gccaatcaag 960
 tcggccccgct accgtggcca gtacaacacc tatcccatca agctcttcta tacgtccaac 1020
 atccccatca tcctgcagtc tgccctggtg tccaaccttt atgtcatctc ccaaatgtct 1080
 tcagctcgct tcagtggcaa cttgctggtc agcctgctgg gcacctggtc ggacacgtct 1140
 tctggggggc cagcacgtgc ttatccagtk ggtggccttt gctattacct gtccccctca 1200
 tgggtccatga actcaaccgg tacatcccca cagccgcggc ctttgggtgg ctgtgcatcg 1260
 gggccctctc ggtcctggct gacttcctag gcgccattgg gtctggaacc gggatcctgc 1320
 tcgcagtcac aatcatctac cagtactttg agatcttctg taaggagcaa agcgaggttg 1380
 gcagcatggg ggccctgctc ttctgagccc gtctcccga caggttgagg aagctgctcc 1440
 agaagcgctt cggaagggga gctctcatca tggcgcgctg tgctgcggca tatggacttt 1500
 taataatggt tttgaatttc gtattctttc attccactgt gtaaagtgtc agacattttc 1560
 caatttaaaa ttttgctttt tatcctggca ctggcaaaaa gaactgtgaa agtgaaattt 1620
 tattcagccg actgccagag aagtgggaat ggtataggat tgtccccaag tgtccatgta 1680
 acttttgttt taacctttgc acctctcag tgctgtatgc ggctgcagcc gtctcacctg 1740
 tttccccaca aagggaaatt ctcactctgg ttggaagcac aaacactgaa atgtctacgt 1800
 ttcattttgg cagtagggtg tgaagctggg agcagatcat gtatttcccg gagacgtggg 1860
 accttgctgg catgtctcct tcacaatcag gcgtgggaat atctggctta ggactgtttc 1920
 tctctaagac accattgttt tcccttattt taaaagtgat ttttttaagg acagaacttc 1980
 ttccaaaaga gagggatggc tttcccagaa gacactcctg gccatctgtg gatttgtctg 2040
 tgcacctatt ggctcttcta gctgactctt ctggttgggc ttagagtctg cctgtttctg 2100
 ctagctccgt gtttagtcca cttgggtcat cagctctgcc aagctgagcc tggccaagct 2160

```

aggtggacag acccttgacg tgatgtccgt ttgtccagat tctgccagtc atcactggac 2220
acgtctcctc gcagctgccc tagcaagggg agacattgtg gtagctatca gacatggaca 2280
gaaactgact tagtgctcac aagcccctac accttctggg ctgaagatca cccagctgtg 2340
ttcagaatth tcttactgtg cttaggactg cacgcaagtg agcagacacc accgacttcc 2400
tttctgcgtc accagtgtcg tcagcagaga gaggacagca caggctcaag gttggtagtg 2460
aagtcagggt cggggtgcat gggctgtggt ggtgktgatc agttgctcca gtgtttgaaa 2520
taagaagact catgtttatg tctggaataa gttctgtttg tgctgacagg tggcctaggt 2580
cctggagatg agcaccctct ctctggcctt tagggagtcc cctcttagga caggcactgc 2640
ccagcagcaa gggcagcaga gttgggtgct aagatcctga ggagctcgag gtttcgagct 2700
ggcttttagac attggtggga ccaaggatgt tttgcaggat gccctgatcc taagaagggg 2760
gcctgggggt gcgtgcagcc tgtcggggag accycactgc tgrcagtgtc agccaggaaa 2820
cagagtgacc aagggaacaag aagggacttg cctaaagcca cccagcaact cagcagcaga 2880
accaagatgg gccccaggct cctccatag gcccagggtc taccacccta tcacacgtgg 2940
ccttgtctag acccagtcct gagcagggga gaggctcttg agacctgatg ccctcctacc 3000
cacatggttc tcccactgcc ctgtctgctc tgctgttaca gaggggagag gcctcccca 3060
gccacgctt aggaatgctt ngcctctggc aggcaggcag ctgtacccaa gctggtgggc 3120
agggggctgg aaggcaccag gcctcaggag gagccccata gtcccgctg cagcctgtaa 3180
ccatcggtcg gccctgcaag gccacactc acgccctgtg ggtgatggtc acggtgggtg 3240
ggtgggggct gacccagct tccaggggac tgtcactgtg gacgccaaaa tggcataact 3300
gagataagggt gaataagtga caaataaagc cagtttttta caaggtaaaa aaaaaaaaaa 3360
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3397

```

<210> 415

<211> 2880

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<400> 415

```

tggnaccct tcaagctctc gtgctcattc ccccatgata gccgtaggaa gtgatgacag 60
tagccccaac gcaatggcca aggttcagat ttttgaatat aatgaaaaca ccaggaaata 120
tgcaaaagct gaaactctta tgacagtcac tgatcctgtt catgatattg cattcgctcc 180
aaatthggga agatctttcc atattctagc aatagcgacc aaagatgtga gaatthttac 240
attaaagcct gtgaggaaaag aactgacttc ctctgggtggg ccaacaaagt ttgaaatcca 300
tatagtggct cagttcgata atcataattc tcagggtctgg cgagtgaagt ggaatataac 360
aggaacgggt ctagcatctt caggagatga tgggtgtgta agattgtgga aagctaatta 420
tatggacaat tggaagtgtg ctggtattht gaaaggtaat gggagcccag tcaatgggag 480
ttctcagcag ggaacctcaa atccttcctt aggttcaaat attccaagtc ttcagaattc 540
attaaatgga tcttctgctg gcagaaagca cagctgagta caagctaact ggagtaactt 600
tgctgttht ctgcttggtg catgcacaca ggaatggaaa gcgagctcct thtccccttc 660
cccagcgccg thtgacctct cccaagatac accagcagcc tgcttactac taaacgcaat 720
ccaaaaggcc thtaaaaata cagtgtatat thtttgtact agtcagttta ttgacatat 780
ttgaaaatth tgaaatataa acggagaggc thtctgttga gacattgtca ccaaaacaat 840
thtttgaaat gttcctgaaa ctaatttggg thtaagatt aaaagggttg ttaccattct 900
tatctgagta gttgggagga ggggaatacc actthtagttc atthggaaaa tatagacata 960
thtctthtgc thtctthaaa cagctthaaa tgatgaactt ttataattht aatthgaaga 1020
ttgaataaat atththttata aagattgtth tgagtgtgta thtgtthact thtgtagat 1080

```

```

ttgctttatc catgatattc agtacaactc tgtcatttct ttgtaatat taaaaaatat 1140
tagtaaagga gtgaattaat aaagtagtaa tagtaaaatg aaaggaactt gactgtacag 1200
tttgtagcca ggttaagcat ttggtattgt ttcathttaca atttgggact aagatggaaa 1260
cacttttttt ataagttttt aattcatagt cactaaagag ataaatgttt cttatataca 1320
tttgtrtatt tttatgggtg tatttattcc atggotttagc ttcccttcaa tcaaaatttg 1380
gacacacact attaagagaa gccattaaaa ttttactaaa attgtgcatg taaattaatt 1440
gtcagcattc catgtctcaa gattttctta atttagttcg ctgtttaaat taattcatgt 1500
cctgtaaagt tctgaccttg ataacaaagc tataaatatt taagtttgct aatatgcgta 1560
agtattatcg gtaagttaca agatggaaga agaataacag tagggcacag tcattctgtg 1620
aatcccttta cttatcaaaa tttggtagct attctaaggc ttttgcagaa aaataagtgt 1680
tcaatgtttg tagttcttca aaagcatgtt gcagtagcca gccatactat gtgtattccc 1740
agtatcatgt acgcactaaa aaaaatgtgt gcttgctgct gctgtgagtg aaccattgct 1800
taagataaaa aacttaacta gatctgtaaa tgtacagaat agcatcagat gtttctgaga 1860
gattagaaaa tgttttgaat ttataaaaat aatgttttct tttgtaacat ttatatatat 1920
tтыttaacat tttaagttta acagattgta ttcccttcaa gtttctatac ttgcttaagc 1980
aatcttgatt tgagtaaggg tcttgatttg tgctattatg ttctgttagt tttggcatga 2040
atatactaaa gctttttttt tttttywag catgtgttty ctccctcttg gttctcttg 2100
tatttactac ttttctcttt ttcttggtt ttttttttcc tgtttttggt ttgtttggtg 2160
ttttgttctt gtcttcattg ttccaggtat ttctttaccc ctctggattc cccacgggct 2220
ggatcgagat ggtccagtta tgcccagctc ctccctcctc ctccctcctc tctggtagag 2280
cactcttgcg atgctgacac tgccaacctc cagtatcctc accctcgag acgatatctc 2340
tctcggcctc ttaatccctt acctgagaat gaagggattt aaaacactga tttaacattg 2400
aaaggcctta ttcaagtgtc tgtaaatgct ttcathttctg gctgcttttt gtttttcatt 2460
ttctttcaga agatttttct aacttagggg ctgtcttgca tgtattacaa ccagaatata 2520
gtgtttggaa cctaaatctg tttgtgctgc tgcacaaaag gaacatttgc ttactgggt 2580
gataaccttt gatgaaatga gatatgtcca agtaacgtta actgtgaagt tacacacagt 2640
agctgacttc aaagtgcctg ttctgtaaat tttattttta actgttacca tagtcttaag 2700
ttgtttatgc tttatcagac tggctaagt gaaagcataa tattatgaag tttattctgc 2760
cttatgagac cttaaaaaat ggatttcatt ttacaggcta atgttgtaac tgactagtat 2820
gtaaaataaa tcattcctgt gtataaagca gcaaaaccta aaaaaaaaaa aaaaaaaat 2880

```

<210> 416

<211> 1616

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1610)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1611)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1616)

<223> n equals a,t,g, or c

<400> 416

```
cggacgctgg tngattccat gccaaagctt tgcaaggctc gcagtgacca ggcgcccgcg 60
atgggagtg atccgcccc acccttttcc ccctcgtctc ctgtgagaat tccccgtcgg 120
atacgagcag cgtggccggt ggctgcctcg cacaggactt ccttcccgcg tccatcactt 180
tctcctggaa atacaagaac aactctgaca tcagcagcac ccggggcttc ccatcagtc 240
tgagaggggg caagtacgca gccacctcac aggtgctgct gccttccaag gacgtcatgc 300
agggcacaga cgaacacgtg gtgtgcaaag tccagcacc caacggcaac aaagaaaaga 360
acgtgcctct tccagtatt gcygagctgc ctcccaaagt gacgtcttc gtcccacccc 420
gcgacggctt cttcggcaac ccccgcaagt ccaagctcat ctgccaggcc acgggtttca 480
gtccccggca gattcagggt tcctggctgc gcgaggggaa gcagggtggg tctggcgta 540
ccacggacca ggtgcaggct gaggccaaag agtctgggcc cacgacctac aaggtagaca 600
gcacactgac catcaaagag agcgactggc tcagccagag catgttcacc tgccgcgtgg 660
atcacagggg cctgaccttc cagcagaatg cgtcctccat gtgtgtcccc gatcaagaca 720
cagccatccg ggtcttcgcc atccccccat cctttgccag catcttctc accaagtcca 780
ccaagttgac ctgcctggtc acagacctga ccacctatga cagcgtgacc atctcctgga 840
cccgccagaa tggcgaagct gtgaaaaccc acaccaacat ctccgagagc caccccaatg 900
ccactttcag cgccgtgggt gaggccagca tctgcgagga tgactggaat tccggggaga 960
ggttcacgtg caccgtgacc cacacagacc tgccctcgcc actgaagcag accatctccc 1020
ggcccaaggg ggtggccctg cacaggcccg atgtctactt gctgccacca gcccgggagc 1080
agctgaacct gcgggagtcg gccaccatca cgtgcctggt gacgggcttc tctccgcgg 1140
acgtcttcgt gcagtggatg cagagggggc agcccttgct cccggagaag tatgtgacca 1200
gcgccccaat gcctgagccc caggccccag gccggtactt cggccacagc atcctgaccg 1260
tgtccgaaga ggaatggaac acgggggaga cctacacctg cgtggtggcc catgaggccc 1320
tgcccaacag ggtcaccgag aggaccgtgg acaagtccac cggtaaacc accctgtaca 1380
acgtgtccct ggtcatgtcc gacacagctg gcacctgcta ctgacctgc tggcctgccc 1440
acaggctcgg ggcggctggc cgctctgtgt gtgcattgcaa actaacctg tcaacgggg 1500
gagatgttgc atcttataaa attagaaata aaaagatcca ttcaaaaara aaaaaaaaaa 1560
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggggggn nccccn 1616
```

<210> 417

<211> 1815

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (270)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1184)

<223> n equals a,t,g, or c

<400> 417

```
cagggtcagg agatttctcc acgagcaagc actctggccc gaggttgacg atgggtgcctt 60
```

```

taccacacata gtcacagtct ggccaccatc ggtgcttcag tgggcatgca tgccgcactg 120
ggggcagttc tcaggggagg ctgaggctgg gccacgtgag gaagggcctt ccctggcagc 180
caggatgcc ctcgtcactc cccttaggag cccagggccc agggcactca ggtgtcagat 240
gtgccagcca cctcccggcg gcctgaacan gtcacgtggg cagctcagga acaggagctc 300
gagtccttc gggagcagct ggaaggagt gaaaggcagca ttgaggaggt tgaggccgac 360
atgaagacc tgggcgtcac tttgtgcagg cagagtctga gtgccggcac agcaagctca 420
gtacagcaga gcgtgagcag gccctgccc gaaagagccg cgcgggtggag ctgctgccc 480
atgggactgc caaccttgcc aagctgcags tgtggtggag aatagtgcc agcgggtcat 540
ccacttggcg ggtcagtggg agaagcaccg ggtcccactc ctgctgagt accgccacct 600
ccgaaagctg caggattgca gagagctgga atcttctcga cggctggcag agatccaaga 660
actgcaccag agtgctccgg cggctgctga agaggcccgc aggaaggagg aggtctataa 720
gcagctgatg tcagagctgg agactctgcc cagagatgtg tcccggctgg cctacaccca 780
gcgcacctc gagatcgtgg gcaacatccg gaagcagaag gaagagatca ccaagatctt 840
gtctgatacg aaggagcttc agaaggaaat caactcccta tctgggaagc tggaccggac 900
gtttgcggtg actgatgagc ttgtgttcaa ggatgccaa aaggacgatg ctgttcggaa 960
ggcctataag tatctagctg ctctgcacga gaactgcagc cagctcatcc agaccatcga 1020
ggacacagcg accatcatgc gggagggtcg agacctcgag gagcagatcg agacagagct 1080
gggcaagaag accctcagca acctggagaa gatccgggag gactaccgag ccctccgcca 1140
ggagaacgct ggcctcctag gccgggtccg ggaggcctga gganccgccg gcagagggtc 1200
ctccccagcc tcaggcaggg atttggggtg ctggaggcag tggccaagca catgccctag 1260
ctacttcctc cgctgtccag ttctcctgc tgcggccttg gaccagacc cctgcccact 1320
gaccgcaacc cttatatggg gtgatagtcc agcatgtggg gagctcggct gcagtttatt 1380
ggggacggta ctgtgggttg ggggccttg atcccaata aatgagtagt tcctctgcag 1440
tctaagctga ggcattgagc agggctcagg gaatgggagt gaggtgagt gcaggggaga 1500
cacggggtat ttttggaag gcagtgtgtg tggctgtgtg tgtctgcacg ggactcaaga 1560
gaccactgg ggggctgtgc gtgtgcata gcgtgagata cacagggtga ttctaacagg 1620
ccgtgtgtgt gagcgagcac gtgttgggac ctcatcct gagggtagt acgctgcttc 1680
tgtgtaggcc tctgggcaca ccctgtgtt gacagtccc ctgtggggcc tgaggctggc 1740
tgtgggtgcg tgccttgggg tgtgtgggtt gtcagggctg tgcttgtgtg tgattgtgtg 1800
atgatgcagc tttga 1815

```

<210> 418

<211> 1966

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<400> 418

```

agaaaaccag tttanggtga cacgtagaga acgcacgccg tgcaggtagc ggtccggaat 60
tcccagggtc gaccacgcg tccggcttga gtaggcaaaa tttgaagtt aagttttcca 120
ataatgtgac ttcttaaaa ttttattaaa ggggaggggc aaatattggc aattagttgg 180
cagtggcctg ttacggttgg gattggtggg gtgggtttag gtaattgttt agtttatgat 240
tgcagataaa ctcatgccag agaacttaaa gtcttagaat ggaaaaagta aagaaatatc 300
aacttccaag ttggcaagta actcccaatg atttagtttt tttccccca gtttgaattg 360
ggaagctggg ggaagttaaa tatgagccac tgggtgtacc agtgcattaa tttgggcaag 420
gaaagtgtca taatttgata ctgtatctgt tttccttcaa agtatagagc ttttggggaa 480
ggaaagtatt gaactggggg ttggtctggc ctactgggct gacattaact acaattatgg 540

```

```

gaaatgcaaa agttgttttg atatggtagt gtgtgggttct cttttggaat ttttttcagg 600
tgattttaata ataattttaa actactatag aaactgcaga gcaaaggaag tggcttaatg 660
atcctgaagg gatttcttct gatggtagct tttgtattat caagtaagat tctattttca 720
gttggtgtga agcaagtttt tttttagtgt aggagaaata cttttccatt gtttaactgc 780
aaaacaagat gttaaggatg gcttcaaaaa ttttgtaaat tgtttatatt aaacttatct 840
gtttgtaaat tgtaactgat taagaattgt gatagtgcag cttgaatgtc tcttagaggg 900
tggtgttttg ttgatgaggg aggggaaact tttttttttt ctatagactt ttttcagata 960
acatcttctg agtcataacc agcctggcag tatgatggcc tagatgcaga gaaaacagct 1020
ccttggtgaa ttgataagta aaggcagaaa agattatatg tcataacctc attggggaat 1080
aagcataacc ctgagattct tactactgat gagaacatta tctgcatatg ccaaaaaatt 1140
ttaagcaaat gaaagctacc aatttaaagt tacggaatct accattttta agttaattgc 1200
ttgtcaagct ataaccacaa aaataatgaa ttgatgagaa atacaatgaa gaggcaatgt 1260
ccatctcaaa atactgcttt tacaaaagca gaataaaagc gaaaagaaat gaaaatgtta 1320
cactacatta atcctggaat aaaagaagcc gaaataaatg agagatgagt tgggatcaag 1380
tggattgagg aggtgtgct gtgtgccaat gtttcgtttg cctcagacag gtatctcttc 1440
gttatcagaa gagttgcttc atttcactct ggagcagaaa acagcaggca gctgttaaca 1500
gataagttta acttgcactc gcagtattgc atgttaggga taagtgttta tttttaagag 1560
ctgtggagtt cttaaataatc aaccatggca ctttctcttg accccttccc taggggattt 1620
caggattgag aaatttttcc atcgagcctt tttaaaattg taggacttgt tcctgtgggc 1680
ttcagtgatg ggatagtaca cttcactcag aggcatattg atctttaaat aatttcttaa 1740
aagcctctaa agtgatcagt gccttgatgc caactaagga aatttgttta gcattgaatc 1800
tctgaaggct ctatgaaagg aatagcatga tgtgctgtta gaatcagatg ttactgctaa 1860
aatttacatg ttgtgatgta aattgtgtag aaaaccatta aatcattcaa aataataaac 1920
tatttttatt agagaatgta waaaaaaaaa aaaaaaaaaa ctcgta 1966

```

<210> 419

<211> 2852

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2838)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2843)

<223> n equals a,t,g, or c

<400> 419

```

tcaagagcgg cctgggaatt tctacgtttc ctcagagagc atcaggaaaag ggccgcccgt 60
cagaccatgg agggacaggc cccagtcaag tatatatgac ctttttgagg gaatgaaaac 120
gccaggccag cggcagctta tcacctcca ggagcagggt aagctgggca ttgtcaacgt 180
ggatgaggct gtgctccact tcaaagagtg gcagctcaac cagaagarac gatcggagtc 240
ctttcgtttc cagcaggaaa atcttaaacy gctaagagac agcatcacc gaagacagag 300
agagaagcaa aaatcaggaa agcagacaga cttggagatc acggtcccaa ttcggcactc 360
acagcacctg cctgcaaaaag tggagtttgg agtctatgag agtggcccca ggaaaagtgt 420
cattccccct aggacggagc tgagacgagg agactggaaa acagacagca cctccagcac 480
agcaagtagc acaagtaacc gctccagcac ccggagcctc ctcagtgtga gcagcgggat 540
ggaaggggac aacgaggata atgaagtccc tgagggttacc agaagtcgca gtccaggccc 600

```

```

cccacaagtg gatgggacac ccaccatgty cctcgagaga ccccccaggg tgcctccgag 660
agotgcctca cagaggmctc cgaccagga gaccttccat cctcctccac ctgttccacc 720
cagaggacgc tgattccacc tcctaaaacc tgcctacttc aggacttta gactcacagt 780
cttcagcctg ttaatgatgt cttcatgttg agttttatag catgactgtt gaccttaaga 840
tccatttctca ttgctgataa tgctgcagcc ctgctgggtt gggcttgcc cgaagatttt 900
attaaggcac gaagaagtga aaaactaagg gcttcattca ccatcaccaa gtatatcgaa 960
ccatatactt gtttgccaaa aggatgaaga cttaatcgaa atacttacct ctaatttgcc 1020
atatcagaag cctaaaaaga atgatcataa atgtacttca ccagtgattt tactgaaatg 1080
cacttatatt agtctttatg tatttgctag ttcagcctga tttctagaag aggttatagt 1140
gtgagacttg tagtattcaa gtaagataag tgacctaat ttaaaataat tcttctactt 1200
ttctgtatat tcagcagggt atttaagtgc tagggctggt cacacacaac caactgaaaa 1260
agactagagg gattagtaca aactcctctt atacagaagg caaatctgag gttccacaga 1320
agtctggaac caagactatt cagttggtta aataaagagg ttagtctaga ctgggcctgc 1380
tcattctagg tcaccacatt ttccatctcc aaatagccag gccctctctc cctcaagaaa 1440
tgcccagatg tagaaattca tcagtgccta ttggtcttcc agaattttcc atcttccgta 1500
tctcccaggc atgagactac caagtgtgtt tgttttcttt ccaatttggg aattttatact 1560
tcagtatggt ttcaacgcag ttatgtttcc agagaacatc tagaagtggc tggaaaccag 1620
aagctgggga ttccaggac ccacttagt gctctatttc ctttataggt tttatttctg 1680
gtcatagaga gagraggacc tttgactttt tcttcgttga ggcttctgag gaggaaaaac 1740
aaacctaaaa tagaaataca gtcagccttt caaatccatg ggttctgtgt ccgtggattc 1800
aaccaacctt ggatcaaaaa tatttgaaaa aaaatctaca aagtttcaaa aagcaaaact 1860
tgaatttgct gcatgccaag aagtatgttg aattcatgta aatgaagtga tgtgtaggca 1920
ttgtattaga tattataaga aatctagaaa tgattttaa catacaggag gatgtgcata 1980
ggttatatgc aaatactatg ctattttata tatgggactt gagcatttgt ggattttgat 2040
actgggggat cctggaacca atcccccatg gataccaaag tacgactgta gttatctatt 2100
ttttacatac ttattattac caccatgctc agtaagtcca tttttgcatg gaatatggag 2160
ccttaaaaca tgtcatgaat ttggagtccc tggcacataa atctaccttc aaatcagagg 2220
tccttaatga tgcctaaaca tacagtaaaa ttagaatcag aamtacttct ttaaaaaata 2280
ttcaaaatgt gtttggttcc catgggatta ttctctatcc cacacgaatg taaaaaaatc 2340
cacattaatg atccatttaa gtatagtttt attgggtcct tttctaata ttaaaggttc 2400
tttctcaatt tcattcctca gtctgcaag taaggactca tactgaagag tactgaaaca 2460
aggacttctt gtcagaaaca gcttctggaa tcttgggttt tgtttttgtt ttttgacaaa 2520
atacactatt ggccatgtcc atcacgagag tgtttgtagt aattaattac cttgtacagg 2580
acctggcact tagtagcatt cttcaaatgt tccctcagtg atccttttac tctccttgtc 2640
acttattttg gagaaatagg ggcacrtgag ataagaagaa gaataatttt gatgttggt 2700
tgcttgccct gttacttata gacagtcttt gtcataggca aacttgaatt tgatttaaaa 2760
tagggctggg aaaaatattc aataactgta agccccctt taaatcaaat tcaagtttgc 2820
ccggcacgag gcctcgtnaa aanttcttgg cc 2852

```

<210> 420

<211> 2705

<212> DNA

<213> Homo sapiens

<400> 420

```

tgagactgca ttcgtatctg agcaggtttt ctatgcctac tgatgtcagt atgtttatac 60
taaccttcat gcttttttcc cagaatccct catctgccag aaaacttgaa aagttttattg 120
cttgtagagt tgtactgctt tgatttttga agttggggta gtagttagaa ctagatttaa 180
ctagtctata atgaacatga aggcttttat atatgaagtt gtataccttt ttgtgttttag 240
agaattatgg gaaacctggg aagcaaaaact ttccctccag ataattgctt ccaaattcga 300
agagtttagtc accaagagag ccatatgtat gaaagcgtat ctgtgaaagg taggaaactt 360

```

```

accccccccta agtgtaaatgt tgcttttaggc aactccttgta aatagtgaga cttgtttggt 420
ctctttacatg tagagatttg agtgcagttg gtacagtact ttggtgtctc caccactgtc 480
ccttctcccc gcttcaaaat aagtgtaatc cacggtagca gccacacttc ctttagaagg 540
aactgttata atttatttaa aagttgaaaa accacccaag atgactacca actttcactt 600
ttttcttctg ccatccaccc tcatttttcc ttttagcaaga tttttatata taactttcct 660
tcctccatt gagtacgtgc tttgagaaaa catttcttaa aacagtgtgt gccacctaag 720
gctggatggg aaagtgcagt cttgttggtc atataaaaaac acacttctta ttagtttacc 780
acttgccctt ttctattggt aatgttctga atttcctttt cttggcttgt ttctacttca 840
ttttaccctg ggtcacttgc tgccagcagt ttgtgaatgg tgtctttcaa ataacttagt 900
tcctatggct tcacttaaaag actgtctcaa aaatactttg ctctcttctt ctttttttgt 960
catgggacat ggtacctaag caaataggag ttgggtttgg tttttctcct aaaataatgc 1020
tcaatactta cctaatacaa tggcatccat ttgaataaaa tgacaataac taaagctagt 1080
taatgtcagt gacattaaac taactccagg attcaggagt ttaaatgtta gaatttagat 1140
ttaacagata gagtgtggct tcatttgcct atggtagccc atctctccta agaccttttc 1200
tagtctgtct tcctgccttc gaacttgatg acagtataaac cctgtttagt attctcttgt 1260
gcatttggtt tgttggttag ccgactgtct tgaaaactatt cattttgctt ctagttttat 1320
tttacagagg tagcattggg gggttttttt tttttctctg tctctgtgtt tgaagtttca 1380
gtttctgttt tctaggtaag gcttattttt gattagcagt caatggcaaa gaaaaagtaa 1440
atcaaagatg acttcttttc aaaatgtatt gtttagcact taactcagat gaatttataa 1500
attattaatc ttgatactaa ggatttggtt cttttttgca tattaggtta atttttacct 1560
tacatgtgag agtcttacca ctaagccatt ctgtctctgt actgttgga agttttggaa 1620
acccctgcca gtgatctggg gatgatctga tgatttattt aaagagccgt tgatgcctcc 1680
aggaaactta agtattttat taatatatat ataggaaattt ttttttattt tgctttgtct 1740
ttctctccct tcttttatcc tcatgttcat tcttcaaacc agtgttttgg aagtatgcat 1800
gcaggcctat aaatgaaaaa cacaattctt tatgtgtata gcatgtgtat taatgtctaa 1860
ctacatacgc aaaaacttcc ttacagagg ttccgactaa catttcacat gcacatttca 1920
aaacaagatg tgtcatgaaa acagcccctt tacctgccaa gacaagcagg gctatatttc 1980
agtgcagct gatatttggt ttgaaagtga atctcataat atatatatgt attacacatt 2040
attatgacta gaagtatgta agaaatgatc agaacaaaag aaaatttcta ttttcatgca 2100
aatatttttc atcagtcatc actctcaa ataaattaaa atataacact cctgaatgcc 2160
tgaggcacga tctggatttt aaatgtgtgg tattcattga aaagaagctc tccaccact 2220
tggtatttca agaaaattta aaacgatccc aaggaaaagat gatttgatg ttaaagtgc 2280
tgcacaagta aaagtccaat gttgtgtgca tgaaaaggat tccttggtta tgtgcagga 2340
atcatctcac atgctgtttt tcctatttgg tttgagaaac aggtgacac tattctctt 2400
gattagaaaa taaactcata aaactcataa tgttgatata atcaagatgt aaccactata 2460
aatatgtaga agaggaagtt ttaaaagacc ttaagctggc attgtgaagg aacaccatgg 2520
tagactcttt ttgtaaatgt attttgtatt taatgaaatg cagtataaag gttggtgaag 2580
tgtaataataa ttgtgtaaac aaatcctgtt aatagagaga tgtacagaat cgttttgtac 2640
tgtatcttga aacttgtgaa ataaagattc cacctctggg taaaaaaaaa aaaaaaaaaa 2700
aaaaa 2705

```

<210> 421

<211> 1901

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1828)

<223> n equals a,t,g, or c

<400> 421

```

accggactgg cctggggcgg gacgtgggcg cgggggcgcg gcgtgcggca cgctgcaggg 60
ctgaagcggc ggcggcgggtg gggactgcac gtagcccgcc gctcggcatg gctctcctgg 120
tgctcggctc ggtgagctgt accttctttc tggcagtgaa tggctctgtat tcctctagt 180
atgatgtgat cgaattaact ccatacraatt tcaaccgaga agttattcag agtgatagtt 240
tgtggcttgt agaattctat gctccatggt gtggtcactg tcaaagatta acaccagaat 300
ggaagaaagc agcaactgca ttaaaagatg ttgtcaaagt tgggtgcagtt gatgcagata 360
agcatcattc cctaggagggt cagtatgggt ttcagggtt tcctaccatt aagatttttg 420
gatccaacaa aaacagacca gaagattacc aagggtggcag aactggtgaa gccattgtag 480
atgctgcgct gagtgtctct cgccagctcg tgaaggatcg cctcggggga cgaagcggag 540
gatacagttc tggaaaacaa ggcagaagtg atagttcaag taagaaggat gtgattgagc 600
tgacagacga cagctttgat aagaatgttc tggacagtga agatgtttgg atggttgagt 660
tctatgtctc ttggtgtgga cactgcaaaa acctagagcc agagtgggct gccgcagctt 720
cagaagataa agagcagacg aaaggaarag tgaactggc agctgtggat gctacagtca 780
atcaggttct ggccctccga tacgggatta gaggatttcc tacaatcaag atatttcaga 840
aaggcgagtc tcctgtggat tatgacggtg ggcggacaag atccgacatc gtgtcccggg 900
cccttgattt gttttctgat aacgccccac ctctgagct gcttgagatt atcaacgagg 960
acattgccaa gaggacgtgt gaggagcacc agctctgtgt tgtggctgtg ctgcccata 1020
tccttgatac tggagctgca ggcagaaatt cttatctgga agttctctg aagttggcag 1080
acaaatacaa aaagaaaatg tgggggtggc tgtggacaga agctggagcc cagtctgaac 1140
ttgagaccgc gttggggatt ggagggtttg ggtaccccgcc catggccgcc atcaatgcac 1200
gcaagatgaa atttgtctct ctaaaaggct ccttcagtga gcaaggcatc aacgagtttc 1260
tcagggagct ctcttttggg cgtggctcca cggcacctgt aggaggcggg gctttcccta 1320
ccatcgttga gagagagcct tgggacggca gggatggcga gcttcccgtg gaggatgaca 1380
ttgacctcag tgatgtggag cttgatgact tagggaaaga tgagttgtga gagccacaac 1440
agaggcttca gaccattttc ttttcttggg agccagtggg tttttccagc agtgaaggga 1500
cattctctac actcagatga ctctaccagt ggccttttaa ccaagaagta gtacttgatt 1560
ggtcatttga aaacactgca acagtgaact tttgcatctc aagaaaacat tgaaaaattc 1620
tatgaattgt tgtagccggt gaattgagtc gtattctgtc acataatatt ttgaagaaaa 1680
cttggctgtc gaaacatttt tctctctgac tgctgtctga atgttcttg aggctgtttc 1740
ttatgtatgg gtttttttta atgtgatccc ttcatttgaa tattaatggc tttttccatt 1800
aaagaataaa atatttttga caatgccnaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
cycsaggggg ggcccggtcc caattcgccc tatagtgagt c 1901

```

<210> 422

<211> 2477

<212> DNA

<213> Homo sapiens

<400> 422

```

cacactttga gcgcacttct agtaaacggg tctccaggag tctagatgga gctccgattg 60
gtgtcatgga ccaaagtctt atgarggatt ttcctggcgc tgctggggag atttcagcct 120
atggacctgg acttgtcagc attgccgtgg tacaagatgg ggacggcagg aggggaagtga 180
gaagcccaac taaagcccca catttgacg c cattgaagg aaagagttca catgagactc 240
tgaatatagt ggaggagaag aagcgggcag aggttgggaa agacgaaaga gtaatcacag 300
aagaaatgaa tggtaaaag atatacctg ggagtgttcc tggggagatt cgtaagggtg 360
agcctgtgac acaaaaagac tccacctccc tgtcttctga gagcagcagc agcagcagtg 420
agagtggagg ggaagacgtg ggagagtacc gtccccacca ccgagtgacc gagggacca 480
tcaggaggga acaggagtat gaagaagagg tggagggaaga accccgcccg gcagccaagg 540
tagtagagag ggaggaagca gtgccgaag ccagcccagt cacacaagca ggtgccagtg 600
taatcacagt agaaacagt atccaggaaa atgtaggtgc ccaaaagata cccggagaga 660

```

```

agagtgtaca cgaaggcgct cttaagcaag acatgggaga agaagcagag gaagagccac 720
agaaagttaa cggagagggtg tcccatgttg acattgatgt tttgccacaa attatttggt 780
gttcagagcc accagtggta aaaacagaga tggttaacaat ttctgatgcc tcacaaagga 840
cagaaatctc caccaaggaa gtccccattg tccaaactga gaccaaacc atcacatatg 900
agtctccaca gattgatggc ggggctgggtg gtgattcggg cacgttactg accgcacaaa 960
ccatcacatc tgagtccgtg tcaacaacga caaccacaca catcaccaag actgtaaaaag 1020
gtggaatttc tgaaacaaga attgagaaac gcattgtgat cacaggagat ggagatattg 1080
atcatgacca ggcactggct caggcgatca ggggaagccag agagcagcac cctgacatgt 1140
cggtcacaag agtgggtgta cacaaagaaa cagagttggc tgaggaaggg gaagattaag 1200
taagaaagtc attttttaaa caacactcaa ctttgtgaac ccctgaagat ttttgaccg 1260
ttccaagtct taatgccaca ccactattcc agcgaattta tgctacaact ggtaacaatg 1320
accagaagcc tgaagaatta aaatgccaac accaaacctt tccttaccag ctctggtcta 1380
tattgctccc atgcatttaa tatattattt tgttttataa ccacttctaa atattctcag 1440
ttctttcttt ttggtgttgt taattaaggg gttttgggtt tgttttctgt ttactttgtg 1500
tgcaactacc tgcttttaat gactcacttt gatcaaatga cagtgaacaa agccagcca 1560
agctgktaag gtgctgttca cttgaacagg tgctgttgcg cagaaaggaa actctgtgac 1620
taatttagat agtggctttc cttcttctgg attcttttca ttgaattctc acagtaaata 1680
tttacggagt tttcaaattg cagcaaatat actgtatgag aaaatattaa tacagattaa 1740
aagcctttct tacatcttga aaattttcta atatttgaga atttcacagg gatgtttttt 1800
atattggacc cttttgactt tccagtcctg tgactttcta cttttagtag agagtcagaa 1860
tctctggact ggagaataat gaagaagttc actgactgtg cactgtgctt agagaccctg 1920
ccgcaccaca gtgccaatgc ttgtcagaca catgcccttc ggcagcattc cagaacagga 1980
gggaagagaa agagaaaact ttcttccctt ctactaaaag attcaggcag cttaaaacct 2040
tagtgctttc tttcttaaca taccctaaat tcaattcttt ccattatttg aacacttggg 2100
tagaactctt gctttgtatt aaacctcttt gtctacacat gtaaaactta ccttttggtta 2160
ttgagcaggc ctatctcttt cagatagttt tatgattcac acaggtttga ggatgctggg 2220
gagaggggga gggggctgtg gtggtgttct gttggttaca agaaagtat accatttaaa 2280
gctggcacca gagaccgat agggacttat taactatatt gaacattttt tcctttgcct 2340
ttgaccctat gtatagttac gatgccagat tagatttata gcagcctcaa gttgtattaa 2400
atgatatttt gcttcctgta atactattat aaaataaagt ttgtttattc tctaaaaaaa 2460
aaaaaaaaaa actcgag 2477

```

<210> 423

<211> 777

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (759)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (764)

<223> n equals a,t,g, or c

<400> 423

```

ttcctcgcg aagtggggag gaggcggttg cggttagtgg accgggaccg gtaggggtgc 60
tgttgccatc atggctgacc ccgacccccg gtaccctcgc tcctcgatcg aggacgactt 120
caactatggc agcagcgtgg cctccgccac cgtgcacatc cgaatggcct ttctgagaaa 180

```

```

agtctacagc attctttctc tgcaggttct cttactaca gtgacttcaa cagttttttt 240
atactttgag tctgtacgga catttgtaca tgagagtcct gccttaattt tgctgtttgc 300
cctcggatct ctgggtttga tttttgcgtt gaytttaaac agacataagt atccccctaa 360
cctgtaccta ctttttgat ttacgctgtt ggaagctctg actgtggcag ttgttggtac 420
tttctatgat gtatatatta ttctgcaagc ttccatactg actactacag tatttttttg 480
tttgactgtg tatactctac aatctaagaa ggatttcagc aaatttggag cagggctgtt 540
tgctcttttg tggatattgt gcctgtcagg attcttgaag tttttttttt atagtgagat 600
aatggagttg gtcttagccg ctgcaggagc ccttcttttc tgggggattc atcatctatg 660
acacacacta ctgatgcata aactgtcacc tgaagagtac gtattagctg gcatcaagcc 720
tctacttgga tatcatcaat ctattcctgg acctgtacng gtnnttggga acaagtt 777

```

<210> 424

<211> 1649

<212> DNA

<213> Homo sapiens

<400> 424

```

ggcccttttg gcctgcgccc agctcgccct gcctagccag gagcgccccg cccctgcct 60
gcccgccac cttcgggagc cgcttccaat aggcgttcgc cattggctct ggcgacctcc 120
gcgcgttgagg aggtgtagcg cggctctgaa cgcgctgagg gccgttgagt gtcgcaggcg 180
gcgagggcgc gaggtaggag cagaccagc catcgcgcgc cgagaaggcc gggcgctccc 240
aactgaagg tccggaaagg cgacttccgg gggctttggc acctggcgga cctcccggga 300
gcgtcggcac ctgaacgcga ggcgtccat tgcgctgcgc cgttgagggg cttcccgcac 360
ctgatcgcga gaccccaacg gctggtggcg tcgcctgcgc gtctcgctg agctggccat 420
ggcgagctg tgcgggctga ggcggagccg ggcgtttctc gccctgctgg gatcgctgct 480
cctctctggg gtccctggcg cgcaccgaga acgcagcatc cagacttct gcctgggtgtc 540
gaagtggtg ggcagatgcc gggcctccat gcctaggtgg tggtaacaatg tcaactgacgg 600
atcctgccag ctgtttgtgt atgggggctg tgacggaaac agcaataatt acctgaccac 660
ggaggagtgc ctcaagaaat gtgccactgt cacagagaat gccacgggtg acctggccac 720
cagcaggaat gcagcggatt cctctgtccc aagtgtccc agaaggcagg attctgaaga 780
ccactccagc gatattgttca actatgaaga atactgcacc gccaacgcag tcaactgggc 840
ttgccgtgca tccttcccac gctggtactt tgacgtggag aggaactcct gcaataactt 900
catctatgga ggctgccggg gcaataagaa cagctaccgc tctgaggagg cctgcatgct 960
ccgctgcttc cgccagcagg agaatcctcc cctgcccctt ggctcaaagg tgggtggtct 1020
ggcggggctg ttcgtgatgg tgttgatcct cttcctggga gcctccatgg tctacctgat 1080
ccgggtggca cggaggaacc aggagcgtgc cctgcgcacc gtctggagct ccggagatga 1140
caaggagcag ctggtgaaga acacatatgt cctgtgccgc cctgtcgcca agaggactgg 1200
ggaagggagg ggagacatgt gtgacttttt ttaaataagag ggattgactc ggatttgagt 1260
gatcattagg gctgaggtct gtttctctgg gaggtaggac ggctgcttcc tggctctggca 1320
gggatgggtt tgctttggaa atcctctagg aggcctctcc tcgcatggcc tgcagtctgg 1380
cagcagcccc gagttgtttc ctgcgtgatc gatttcttcc ccaggtaga gttttctttg 1440
cttatgttga atccattgcc tcttttctca tcacagaagt gatgttgaa tcgtttcttt 1500
tgtttgtctg atttatggtt tttttaagta taaacaaaag ttttttatta gcattctgaa 1560
agaaggaaag taaatgtaca agtttaataa aaggggcctt cccctttakt aaaaaaaaa 1620
aaaaaaaaa aaaaaaaaa aaaaaaaaa 1649

```

<210> 425

<211> 1608

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (1598)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1600)
 <223> n equals a,t,g, or c

<400> 425
 gcgcggggcg cggrcgrggg cgtcgctgcg cggctggccg gtgaggcgcg gcatggggcg 60
 agtgcagctc ttcgagatca gcctgagcca cggccgcgctc gtctacagcc ccggggagcc 120
 gttggctggg accgtgcgcg tgcgcctggg ggcaccgctg ccgttccgag ccatccgggt 180
 gacctgcata gggtcctgcg gggctctcaa caaggctaata gacacagcgt gggtagtgga 240
 ggaggggttac ttcaacagtt ccctgtcgct ggcagacaag gggagcctgc ccgctggaga 300
 gcacagcttc cccttccagt tctgtcttcc tgccactgca cccacgtcct ttgaggggtcc 360
 tttcgggaag atcgtgcacc aggtgagggc cgccatccac acgccacggg tttccaagga 420
 tcacaagtgc agcctcgtgt tctatatctt gagccccttg aacctgaaca gcatcccaga 480
 cattgagcaa cccaacgtgg cctctgccac caagaagtgc tcctacaagc tgggtgaagac 540
 gggcagcgtg gtcctcacag ccagcactga tctccgcggc tatgtgggtg ggcaggcact 600
 gcagctgcat gccgacgttg agaaccagtc aggcaaggac accagccctg tgggtggccag 660
 tctgtgcag aaagtgtcct ataaggccaa gcgctggatc cagcagctac ggaccattgc 720
 ggaggtggag ggtgcggggc tcaaggcctg gcggcgggcg cagtggcacg agcagatcct 780
 ggtgcctgcc ttgccccagt cggccctgcc ggctgcagcc tcatccacat cgactactac 840
 ttacaggtct ctctgaaggc gccggaagct actgtraccc tcccgggtctt cattgggaat 900
 attgctgtga accatgcccc agtgagcccc cggccaggcc tggggctgcc tcctggggcc 960
 ccacccctgg tgtgccttcc gcaccacccc aggaggaggc tgaggctgag gctgcggctg 1020
 gcggccccca cttcttgga cccgtcttcc tctccaccaa gagccattcg cagcggcagc 1080
 ccctgctggc caccttgagt tctgtgcctg gtgcgcggga gccctgccct caggatggca 1140
 gccctgcctc acaccgcgtg caccctccct tgtgcatttc aacaggtgcc actgtcccct 1200
 actttgcaga gggtccggg gggccagtgc ccactaccag caccttgatt ctctctccag 1260
 agtacagttc ttggggctac ccctatgagg cccacccgtc ttatgagcag agctgcggcg 1320
 gcgtggaacc cagcctgacc cctgagagct gaccccgctg tgccctctcc aggcaggcct 1380
 ggccctctgcc ctgggactgg ggcgcccagg gcctcgtgcc ttctctcttg gcctagcctg 1440
 gcccaactcag gacctgcca gcctctgcca gctcctctgc atccgccctc ttctccctgg 1500
 ggctgggggtg ggggtggcag ggagctggga cctggagaga caactcctgt aaataaaaca 1560
 ctttatttgt agaaaaaaaa aaaaaaaaaa aaaaaaantn gggggggg 1608

<210> 426
 <211> 1794
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1789)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature

<222> (1790)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1793)
<223> n equals a,t,g, or c

<400> 426
gtctctctct ctctctctct ctctcccttg tgcccgccttt ctgccatccg cgctgtctcg 60
tgtctccctt tttccattaa atgcctcttt tcttgcggtt ctcatstcgg gaatagtgcg 120
ctacggggac atacctatcc ccaactatcc tagggccgag aaccagccct tgccttcgag 180
taacaggcgg agactcgctg aggcgagttg cacttctaata tgggcgtgag gtcttgtcaa 240
tccccaggtt cttccaatca gaagtccggt ccatccagcc ttccgctccc cattggcctg 300
tgtggaggaa gaggggtggg taagccgaag tcgctgcgct cagtgcgcag gcgcgaagaa 360
gctggcaggg gcacgagccg ggggcgggtt tgaagacgag tcgttggtt ttggaggccg 420
tgaaacagcc gtttgagttt ggctgcgggt ggagaacgtt tgtcaggggc ccggccaaga 480
aggaggcccg cctgttacga tgggtgccat gagtttcaag cggaaccgca gtgaccggtt 540
ctacagcacc cgggtgctgcg gctgttgcca tgtccgcacc gggacgatca tcctggggac 600
ctggtacatg gtagtaaac tattgatggc aattttgctg actgtggaag tgactcatcc 660
aaactccatg ccagctgtca acattcagta tgaagtcac ggtaattact attcgtctga 720
gagaatggct gataatgcct gtgttctttt tgccgtctct gttcttatgt ttataatcag 780
ttcaatgctg gtttatggag caatttctta tcaagtgggt tggctgattc cattcttctg 840
ttaccgactt tttagacttcg tcctcagttg cctgggtgct attagttctc tcacctattt 900
gccagaatc aaagaatatc tggatcaact acctgatttt ccctacaaag atgacctcct 960
ggccttgagc tccagctgcc tcctgttcat tgttcttggt ttctttgcct tattcatcat 1020
ttttaaggct tatctaatta actgtgtttg gaactgctat aaatacatca acaaccgaaa 1080
cgtgccggag attgctgtgt accctgcctt tgaagcacct cctcagtagc ttttgccaac 1140
ctatgaaatg gccgtgaaaa tgcctgaaaa agaaccacca cctccttact tacctgcctg 1200
aagaaattct gcctttgaca ataaatccta taccagcttt ttgtttgttt atgttacaga 1260
atgctgcaat tcagggtctt tcaaacttgt ttgatataaa atatgttgct ttttgtttaa 1320
gcattttatt tcaaacacta aggagctttt tgacatctgt taaacgtctt tttgtttttt 1380
tgttaagtct ttacattttt aatagttttt gaagacaatc taggttaagc aagagcaaag 1440
tgccattgtt tgcctttaat tgggggtggg gaagggaaag agggtagctt ccacatagtt 1500
tcctttttta ctgcactttc tttatataat cgtttgcat ttgttacttg ctaccctgag 1560
tactttcagg aagactgact taaatattcg gggtagtaaa gtagttgggt ataagatctg 1620
aacttttcat ctgcagaggc aagaaaaata tttgacattg tgacttgact gtggaagatg 1680
atggttgcat gtttctagtt tgtatatgtt tccatctttg tgataagatg atttaataaa 1740
tctcttttaa tactaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaann aana 1794

<210> 427
<211> 770
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (14)
<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (40)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (97)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (618)
 <223> n equals a,t,g, or c

<400> 427
 ccaggcccta taancccggc accttgggga ggctgaggcn ggaagcacca cggagcccca 60
 ggagttgggg acccggtgg gccaccatag ccagggnccc tgtctatttt tttaaaaaag 120
 taaaaaatag aaattatctc actacttaaa tcccattttt ttcacttcat atgaaagaac 180
 atattgatag tatattctat attatttcat agatctgtct gaaagagatt gggaacaaaa 240
 atatctaatt gagatattct ttaatttttt acatagcagc tttatttttt ttattctgta 300
 gtatcagcga aatcagtcac gtttatacct tgaatataaa tatcaggaat catgcaatta 360
 tttctactat gtatttagta gtatcttata tttgtataac attattacat tttgcaaatt 420
 agtatcacia ctgctaagta gatgtttctg agtattagaa aaatcagtggt tattacctgc 480
 aggatattaa aaaacatttg aaaaagagaa aaagaaaaat cagtgttttag aaatgttgat 540
 agttattgaa tctttgaatt gaatttttaa aatccattct agtaatcaga gtatactttt 600
 tttatagaac aaggtggnca ggtggggagc cctttaccct tctgggtgaag ttaaaccata 660
 ggaagtttac aatttgcctt tcacaaacat tagcagtcctg gggcatgggt gctgragcct 720
 gtgratyccc agcatgttg ggaggcccga gttggggagg gttgcctgag 770

<210> 428
 <211> 512
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (18)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (30)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (38)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature

<222> (484)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (491)

<223> n equals a,t,g, or c

<400> 428

```
tg gatcccc gggactgnca gaattccggn cacgaggnaa gagacttgct ttgacaagta 60
cactgggaac acttaccgag tgggtgacac ttatgagcgt cctaaagact ccatgatctg 120
ggactgtacc tgcacgggg ctgggcgagg gagaataagc tgtaccatcg caaacgctg 180
ccatgaaggg ggtcagtcct acaagattgg tgacacctgg aggagaccac atgagactgg 240
tggttacatg ttagagtgtg tgtgtcttgg taatggaaaa ggagaatgga cctgcaagcc 300
catagctgag aagtgttttg atcatgctgc tgggacttcc tatgtggtcg gagaaacgtg 360
ggagaagccc taccaaggct ggatgatggt agattgtact tgcctgggag aargcagcgg 420
acgcatacact tgcacttcta gaaatagatg caacgwtcag gacacaagga catctataga 480
attngagaca ncttgagcaa gaaggataat cg 512
```

<210> 429

<211> 1470

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1346)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1347)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1357)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1387)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1415)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1454)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1462)

<223> n equals a,t,g, or c

<400> 429

```

gtggacacgg aagtggtcgt cgtcgcggca ccggtgggag ctaggcgcga ggctcggagt 60
gcggccagcg ggcggaggcg gtctcgcacg ggcggcgacg gagggctcag gcgtcgtcgt 120
ttgggtgggg ggccgctgaa ctgacaagcg acatttcagc tcctttcacc cgccggaacc 180
ccggagccgg ggcccgcctca gccggcggtta ccatgaccaa ggccggtagc aagggcggga 240
acctccgcga caagctggac ggcaacgaac tggacctgag cctcagcgac ctgaatgagg 300
tcccgggtgaa ggagctggct gcccttccaa aggccaccat cctggatctg tcttgtaata 360
aactgactac tctaccgtcg gatttctgtg gcctcacaca cctgggtgaag ctgacctga 420
gtaagaacaa gctgcagcag ctgccagcag actttggccg tctgggtcaac ctccagcacc 480
tggatctcct caacaacaag ctgggtcacct tgccgtgcag ctttgctcag ctcaagaacc 540
tgaagtgggt ggacctgaag gataaccccc tggatcctgt cctggccaag gtggcagggtg 600
actgcttgga tgagaagcag tgtaagcagt gtgcaaacaa ggtgttacag cacatgaagg 660
ccgtgcaggc agatcaggag cgggagaggc agcggcggct ggaagtagaa cgtgaggcag 720
agaagaagcg tgaggctaag cagcgagcta aggaagctca ggagcgggaa ctgcggaagc 780
gggagaaggc ggaagagaag gagcgccgga gaaaggagta tgatgccctc aaagcagcca 840
agcgggagca ggagaagaaa cctaagaagg aagcaaatac ggccccgaaa tctaagtctg 900
gctcccgtcc ccgcaagcca ccaccccgga agcacactcg ttcctgggct gtgctgaagc 960
tgctgctgct gctgctgcta tttgggtgtg cgggagggct ggttgcttgt cgggtgacag 1020
agctgcagca gcagcccctc tgcaccagcg tgaacaccat ctatgacaat gcgggtccagg 1080
gtctacgccg ccatgagatc ctccagtggg tcctccagac cgactctcag cagtgaagctt 1140
gtccccagca cctgctgcct ccagccttg gagtttggtat tcctatggaa ttgggttctg 1200
ctggacacaa cctcttttta gcatcagacc tacctgccat catcaaatgg ctgcagattg 1260
gtacatgaga ccttctcttt gtaggacttc ttcattcctt agtcagggtt ccctgaagga 1320
atgaggagaa atgggagggtg gccggnnggg ccgtggnngc aagttacctg catgcctaaa 1380
ggagtangct tgggggtggg agagagaaaa catanctttt tagtgtatat aagttgggaa 1440
aggcaagggtt ggtntactaa anggcagttg 1470

```

<210> 430

<211> 434

<212> DNA

<213> Homo sapiens

<400> 430

```

ggccttggtta tggtccttat tgcttggttg ctgccagcct tctcctcggc ccagaggcc 60
atgcaccctgt gggagctctt tgtaaagtac taccatgcta agaacggccg tgcttatgtg 120
gaatccccag cccggaagct ctcccagtc ttcgcccttc ctgttacggg aggcactgtt 180
gtcaccacca aacagagcct actgacagcc atccacatgg tgctgacaga gcatgaccct 240
tttaagcgca tcctcagactc agaattgaag gccttggtgt gcatggcact gaatgagcca 300
gcgtctggtg tcctgggtga acctcatctg caaktccggg tcaactsatcg agcctacta 360
ccagccctgg rctcatatgg cacacacagg cttttgaaaa ttgcctcaac ctgctcagtc 420
gcctcaacaa cctc 434

```

<210> 431

<211> 1823
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1804)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1805)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1815)
<223> n equals a,t,g, or c

<400> 431
ggcacgagcc ccgccccgcc cgcgccgcgc cggccgctgt cagctccctc agcgtccggc 60
cgaggcgagg tgtatgctga gccgctgccg cagcsggctg ctccacgtcc tgggccttag 120
cttcctgctg cagaccgccg gcccgattct cctctgctct ccacgtctca tgaagccgct 180
ggtcgtgttc gtcctcgggc gccccggcgc cggcaagggg acccagtgcg cccgcctcgt 240
cgagaaatat ggctacacac acctttctgc aggagagctg cttcgtgatg aaaggaagaa 300
cccagattca cagtatgggt aacttattga aaagtacatt aaagaaggaa agattgtacc 360
agttgagata accatcagtt tattaagag ggaaatggat cagacaatgg ctgccaatgc 420
tcagaagaat aaattcttga ttgatgggtt tccaagaaat caagacaacc ttcaaggatg 480
gaacaagacc atggatggga aggcagatgt atctttcgtt ctcttttttg actgtaataa 540
tgagatttgt attgaacgat gtcttgagag gggaaagagt agtggttaga gtgatgacaa 600
cagagagagc ttggaaaaga gaattcagac ctacctcag tcaacaaagc caattattga 660
cttatatgaa gaaatgggga aagtcaagaa aatagatgct tctaaatctg ttgatgaagt 720
ttttgatgaa gttgtgcaga tttttgacaa ggaaggctaa ttctaaacct gaaagcatcc 780
ttgaaatcat gcttgaatat tgctttgata gctgctatca tgaccctttt ttaaggcaat 840
tctaactctt cataactaca tctcaattag tggctggaaa gtacatggta aaacaaagta 900
aattttttta tgttcttttt tttggtcaca ggagtagaca gtgaattcag gtttaacttc 960
accttagtta tgggtgctcac caaacgaagg gtatcagcta ttttttttta aattcaaaaa 1020
gaatatccct tttatagttt gtgccttctg tgagcaaaac ttttttagtac gcgtatatat 1080
ccctctagta atcacaacat tttaggattt agggataccc gcttcctctt tttcttgcaa 1140
gttttaaatt tccaacctta agtgaatttg tggacaaat ttc aaaggaa ctttttgtgt 1200
agtcagttct tgcacaatgt gtttggtaaa caaactcaa atggattctt aggagcattt 1260
tagtgtttat taaataactg accatttgct gtagaaagat gagaaaactt aagctttgtt 1320
ttactacaac ttgtacaaag ttgtatgaca gggcatattc tttgcttcca agatttggtt 1380
tgggggcact aggggttcag agcctggcag aattgtcagc tttagtctga cataatctaa 1440
gggtatgggg caaggatcac atctaagtct tgtgttcctt atactctatt atatagtgtt 1500
attcatgatt cagctgatct taacaaaatt cgtagcagtg gaaccttgaa atgcattgtg 1560
ctagatttat gctaaaaatga ttctcagtta gcatttttagt aacacttcaa aggttttttt 1620
ttgtttgttt tctagactta ataaaagctt aggattaatt agaagaagca atctagttaa 1680
atttcccatt tgtattttat tttcttgaat acttttttca tagttatttg tttaaaaaga 1740
tttaaaaaatc attgcacttt ggtcagaaaa ataataaata tatcttataa gggggggccc 1800
ggannccaat tcggnctgga gga 1823

<210> 432
 <211> 3391
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (33)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (68)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (99)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (114)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (3293)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (3391)
 <223> n equals a,t,g, or c

<400> 432
 nccccctttg ccctcaaatc caaaaatggg aanaattgtg gaaccattg ccacttgcac 60
 tgcccttnga ccaggattga aattgatcca ttcccctcna ttcttggtt ggnaaccgg 120
 ggaaacccta attgaaagac ttgtaaagcc cagcgcatt atttaagtgg gaaatcgggt 180
 gcctccaccc aacacagctg gctgccttag gaatgtaagc ctcagagagg agtgaagctc 240
 gccggaaact tcgggaatgt gatggtttag ttgatgccct ctttttcatt gttcaggctg 300
 agattgggca gaaggattca racagcaagc ttgtagagaa ctgtgtttgc cttcttcgga 360
 acttatcata tcaagttcac cgggagatcc cacaggcaga gcgttaccaa gaggcagctc 420
 ccaatgttgc caacaatact gggccacatg ctgccagttg ctttggggcc aagaagggca 480
 aagggaacaaa acctatagag gatccagcaa acgatacagt ggatttcctt aaaagaacga 540

```

gtccagctcg aggctatgag ctcttatttc agccagaggt ggttcggata tacatctcac 600
ttcttaagga gagcaagact cctgccatcc tagaagcctc agctggagct atccagaact 660
tgtgtgctgg gcgctggacg tatggtcgat acatccgctc tgctctgcgt caagagaagg 720
ctctttctgc catagctgac ctccctgacta atgaacatga acgggtggtg aaagctgcat 780
ctggagcact gagaaacctg gctgtggatg ctgcgaacaa agaattaatt ggtaaactatg 840
ctattcctaa cttggtaaag aatctgccag gaggacagca gaactcctct tggaatttct 900
ctgaggacac tgtcatctct attttgaaca ctatcaacga ggttatcgct gagaacttgg 960
aggctgccaa aaagcttcga gagacacagg gtattgagaa gctgggtgtg atcaacaaat 1020
caggaaccg ctcagaaaaa gaagtccgag cagcagcact tgtattacag acaatctggg 1080
gatataagga actgcggaag ccactggaaa aagaaggatg gaagaaatca gactttcagg 1140
tgaatctaaa caatgcttcc cgaagccaga gcagtcattc atatgatgat agtactctcc 1200
ctctcattga ccggaaccaa aaatcagata agaaacctga tcgggaagaa attcagatga 1260
gcaatattgg atcaaacaca aaatcactag ataacaacta ttccacacca aatgagagag 1320
gagaccacaa tagaacactg gatcgatcgg gggatctagg cgacatggag ccattgaaag 1380
gaacaacacc cttgatgcag gacgaggggc aggaatctct ggaggaagag ttggatgtgt 1440
tggttttggg tgatgagggg ggccaagtgt cttaccctc catgcagaag atttagcacc 1500
actatctccg ttccatctgg gcttatatgt acttttattt ttgggtggtg aaattgactg 1560
atgattttcc tttttcttcg ctggactatt gtgccactg ccaggctgcc tcctgccctt 1620
acagccctaa gtggctgcct tctttccatc aactcccaac ttcttcctgt gaagttaaat 1680
tgtctcaacg cctccccctc cccattccc tccatttttc tccaagaaa cctgactcaa 1740
ttatttgcat attttgagaa actgctgcag attagtctt ttggccagtt ttccctggaa 1800
ctcctggcct tttgtggagg ggagggatgg agagaatagg aatcttcaact agaagccgtg 1860
ggaagaattg gaagttacat gctgtatatg caatgtccag cagtctgata aactgacgat 1920
tcttaatcaa gatttttttc ctgatgggga agggactttt attttctttt agagaggggga 1980
aagtgtgagc tcttccctta ttcctaattg ctatttttga agcaaagaag gccagcaaca 2040
ttggcacatg ccacctggca aaggaccctt gagtaagtga aggtctccta aaactgggat 2100
taagaaacct tgctctctc atctccaagg cagggaccat caagaaccta cagactccat 2160
ctcttctgca agcctcatgc caacctggg ctattgctgc tgccccttaa acacaggctg 2220
tccttaacct acctctcctg ccctgtgata tgtctgctga gttggcctgg ccatttccaa 2280
gaggctgtag aaaggggaga atgtcaagga agacttttgg tagagaagga gcagaaagat 2340
gtgtttttgg gaagaagaag acctctagga ggagctagta ggaatgtaca tgaagcaatt 2400
agtctgaaac tggcttcccc actccccgt ttctcctttt cctatcctta taggcctgtc 2460
ccttgctct gcoctggatt ggttggcaaa ctaaaaggact tgatgtacat aactcctgtc 2520
ccttttccct tacaaggtgg ggattgcccc tggttttgcc tcttctttgt gcctttggcc 2580
tggggtgcat ctctcccgcc ccttccatgt gcctttcttt gcctctgcag tctcatttct 2640
cataattttg caaattatat tttgttgctt tcttacctac tattggccct aaatagcaga 2700
aagaagagaa gtgaccgaga gaacctcaga ttcttcattg aggattggtg tagccatgat 2760
ttcagtcata gcaagctttt gctcaacagc atatgggtgg gattttgcaa aaatcctatt 2820
ctgatgaatc tcaaagtaag gctggtgaaga gaagtgagt gtgtgactct tactccttag 2880
gtgcccagaa tttaccatca tctctgaagg agttacagg aagtggctc cccaattctc 2940
ccctccctcc agtattgccc cctctcactt tagcatatat taattagcag gttgggctag 3000
agaaatcagc tgctatgagg gttgattatt attattattt ctaatccttt tccttatttg 3060
ccttctactc cccttaatct aatctaaaag ctctgttcca tgcaactgga gttccttatt 3120
cctctcttcc ccttccctta tatattgagg ctatggggtg ggagaaaagt gcacaacca 3180
ccacccccct tactcgtgca ttaaaatttc ttatttacc ttttccccct tcccatttct 3240
tcccactttc atctaccttt tctgggcaaa aaggarcctt ttgstctctg tgnaccctaa 3300
gagcacactg cacagggaaa attggccctc ccagacctgg gctccactct tgatctctct 3360
tggtcctctt ctggctcttt tcctgggtgg n 3391

```

<210> 433

<211> 2553

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2510)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2516)
<223> n equals a,t,g, or c

<400> 433
ggcacgaggc atccctgacg ctctggatgt gagagtgtccc caatgcctga cctctgcctc 60
ccccacccct ctcttccctt cctcttctcc agccaaagat ggtgctccct gcctcttcgg 120
tggtacggtg taccgcagcg gagagtcctt ccagagcagc tgcaagtacc agtgcacgtg 180
cctggacggg gcggtgggct gcatgcccct gtgcagcatg gacgttcgtc tgcccagccc 240
tgactgcccc tccccgagga gggcctcaagct gcccgggaaa tgctgcgagg agtgggtgtg 300
tgacgagccc aaggacccaa ccgtgggttg gcctgcccctc gcgggtgagt cgagtccttc 360
tctaagtcag ggtcgtgatt ctctcccagg gagggagtcc taactgtgcc gaccgaacgg 420
gggaaatacc ttatccaggc gttttacatg gtgtttgtgt gctctgcyct cgergcttac 480
cgactggaag acacgttttg cccagaccca actatgatta gagccaaactg cctgggtccag 540
accacagagt ggagcgcctg ttccaagacc tgtgggatgg gcctctccac ccgggttacc 600
aatgacaacg cctcctgcag gctagagaag cagagccgcc tgtgcatggc caggccttgc 660
gaagctgacc tggaagagaa cattaaggta catgtttctg tcctattaac tatttttcac 720
agggaaaaaca gtggatagga cccaacttag ggctcttgcc acgcttggtt gtataagccc 780
gttatctcca aaactatcta accattgagc tgttttgctg gaatgagagc ttgtgtaata 840
gcaaccacca gttttccact acgaaatctt ccacagggtt agttaattca agacattcca 900
agagaggctc tggctatttt kgggacatag caaatgagac tcaaacttcc tcccctcaaa 960
atatwaacag aagtcagaca acagaagact aaaacamagr ggggtgaaga aagscactcc 1020
tcttgtagag tcgstgattt tttttttcct ctctcttttc ccttgkcttc cttagaagg 1080
gcaaaaagtg catccgtact cccaaaatct ccaagcctat caagtttgag ctttctggct 1140
gcaccagcat gaagacatac cgagctaaat tctgtggagt atgtaccgac ggccgatgct 1200
gcacccccca cagaaccacc accctgcccg tggagttcaa gtgccctgac ggcgaggtca 1260
tgaagaagaa catgatgttc atcaagacct gtgcctgcca ttacaactgt cccggagaca 1320
atgacatctt tgaatcgctg tactacagga agatgtacgg agacatggca tgaagccaga 1380
gagtgaagaa cattaactca ttagactgga acttgaactg attcacatct catttttccg 1440
taaaaatgat ttcagtagca caagttatth aaatctgttt ttctaactgg gggaaaagat 1500
tcccacccaa ttcaaaacat tgtgccatgt caaacaataa gtctatcaac cccagacact 1560
ggtttgaaga atgttaagac ttgacagtgg aactacatta gtacacagca ccagaatgta 1620
tattaagggtg tggcttttag agcagtggga gggtagcagc agaaagggtt gtatcatcag 1680
atagcatctt atacgagtaa tatgcctgct atttgaagtg taattgagaa ggaaaatttt 1740
agcgtgctca ctgacctgcc ttagacccca gtgacagcta ggatgtgcat tctccagcca 1800
tcaagagact gagtcaagtt gttccttaag tcagaacagc agactcagct ctgacattct 1860
gattcgaatg aactgttcca ggaatcgga tccgtgtgat tagactggac agcttgtggc 1920
aagtgaattt gcctgtaaca agccagattt tttaaaattt atattgtaaa tattgtgtgt 1980
gtgtgtgtgt gtgtatatat atatatatgt acagttatct aagttaatth aaagttgttt 2040
gtgccttttt atttttgttt ttaatgcttt gatatttcaa tgttagcctc aatttctgaa 2100
caccataggt agaatgtaaa gcttgtctga tcgttcaaag catgaaatgg atacttatat 2160
ggaaattctg ctcatagata atgacagtcc gtcaaacacg attgtttgca aaggggaggc 2220

```

atcagtgtcc ttggcaggct gatttctag taggaaatgt ggtagcctca cttttaatga 2280
acaaatggcc ttatttaaaa actgagtgc tctatatagc tgatcagttt tttcacctgg 2340
aagcatttgt ttctactttg atatgactgt ttttcggaca gtttatttgt tgagagtgtg 2400
accaaagtt acatgtttgc acctttctag ttgaaaataa agtgtatatt ttttctataa 2460
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ccggaattn cgganccgg 2520
tacctgccag gcgtacttgt catcagtgtt cac 2553

```

<210> 434

<211> 2532

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2470)

<223> n equals a,t,g, or c

<400> 434

```

ggcgatttca tcatgctccg agccggggcg cgcgcgcgcg ttccgtcgcc accctctctg 60
gacagcccag ggccgcagct catgccctct ccgcgtccag tgctgcttag aggtgctcgc 120
gccgctctgc tgctgctgct gccgccccgg ctcttagccc gacctcgcct cctgctccgc 180
cggccccca gcgcggcctc ctgcgccccg atctccttgc ccgcgcgcgc ctcccgagc 240
agcatggacg gcgcgggggc tgaggaggtg ctggcacctc tgaggctagc agtgcgccag 300
cagggagatc ttgtgcgaaa actcaaagaa gataaagcac cccaagtaga cgtagacaaa 360
gcagtggctg agctcaaagc ccgcaagagg gttctggaag caaaggagct ggcgttacag 420
cccaaagatg atattgtaga ccgagcaaaa atggaagata ccctgaagag gaggttttct 480
tatgatcaag cttttgctat ttatggaggt gttagtggtc tgtatgactt tgggccagtt 540
ggctgtgctt tgaagaacaa tattattcag acctggaggc agcactttat ccaagaggaa 600
cagatcctgg agatcgattg caccatgctc acccctgagc cagttttaa gacctctggc 660
catgtagaca aatttgctga ctcatgggtg aaagacgtaa aaaatggaga atgtttctgt 720
gctgaccatc tattaaagc tcatttacag aaattgatgt ctgataagaa gtgttctgtc 780
gaaaagaaat cagaaatgga aagtgttttg gccagcttg ataactatgg acagcaagaa 840
cttgcggatc tttttgtgaa ctataatgta aaatctccca ttactggaaa tgatctatcc 900
cctccagtgt cttttaactt aatgttcaag actttcattg ggcctggagg aaacatgcct 960
gggtacttga gaccagaaac tgcacagggg attttcttga atttcaaacg acttttggag 1020
ttcaaccaag gaaagttgcc ttttgctgct gccagattg gaaattcttt tagaaatgag 1080
atctcccctc gatctggact gatcagagtc agagaattca caatggcaga aattgagcac 1140
tttgtagatc ccagtgcgaa agaccacccc aagttccaga atgtggcaga ccttcacctt 1200
tatttgtatt cagcaaaagc ccaggtcagc ggacagtccg ctcgaaaaat gcgcctggga 1260
gatgctgttg aacagggtgt gattaataac acagtattag gctatttcat tggccgcac 1320
tacctctacc tcacgaaggt tggaatatct ccagataaac tccgcttccg gcagcacatg 1380
gagaatgaga tggcccatta tgctgtgac tgttgggatg cagaatccaa aacatcctac 1440
ggttggattg agattgttg atgtgctgat cgttcctgtt atgacctctc ctgtcatgca 1500
cgagccacca aagtccact ttagctgag aaacctctga aagaacccaa aacagtcaat 1560
gttgttcagt ttgaaccag taaggagca attggttaagg catataagaa ggatgcaaaa 1620
ctggtgatgg agtatcttgc catttgtgat gagtgtaca ttacagaaat ggagatgctg 1680
ctgaatgaga aaggggaatt cacaattgaa actgaaggga aaacatttca gttacaaaa 1740
gacatgatca atgtgaagag attccagaaa acatatatg tggagaagat tgttccgaat 1800
gtaattgaac ctcccttcgg cctgggtagg atcatgtata cggattttga acatacatc 1860
catgtacgag aaggagatga acagagaaca ttcttcagtt tccctgctgt agttgctcca 1920
ttcaaatgtt ccgtcctccc actgagccaa aaccaggagt tcatgccatt tgtcaaggaa 1980

```

```

ttatcggaag ccctgaccag gcatggagta tctcacaaag tagacgattc ctctgggtca 2040
atcggaaggc gctatgccag gactgatgag attggcgtgg cttttggtgt caccattgac 2100
tttgacacag tgaacaagac cccccacact gcaactctga gggaccgtga ctcaatgcgg 2160
cagataagag cagagatctc tgagctgccc agcatagtcc aagacctagc caatggcaac 2220
atcacatggg ctgatgtgga ggccaggtat cctctgtttg aagggaaga gactggtaaa 2280
aaagagacaa tcgaggaatg aggacaattt tgacaacttt tgaccacttg cgctaataaa 2340
aaaaaaaaaa actactctta tgtccacttt acaaaagaaa acagcattgt gattactccc 2400
agggaccgta ttttatcttc agtggctgcc tgattttacc cccacaatta aagttgaagg 2460
aatcctgaan aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2520
aaaaaaaaaa aa 2532

```

<210> 435

<211> 1822

<212> DNA

<213> Homo sapiens

<400> 435

```

ggctggcggc ggggtccggt ccgctgcctg gcgctgcggg cggcgggcca tgggtggttg 60
gattgagccg ggcccggccg gggcgccgag tcggaggggg tggcagttag cggcggcaga 120
ggctacgggg ctcgggtttg ctgactgggg agtcggcagg cggcaggaac catgcgaggc 180
cagcggagcc tgctgctggg cccggcccgc ctctgcctcc gcctccttct gctgctgggt 240
tacaggcgcc gctgtccacc tctactccgg ggtctagtac agcgtggtg ctacggcaag 300
gtctgcctgc gctccctgct ctacaactcc tttgggggca gtgacaccgc tgttgatgct 360
gcctttragg ctgtctactg gctggttagac aacgtgatcc gctgggtttg agtgggtgtc 420
gtggctcctg tgatcgtgct gacaggctcc attgtagcta tcgcctacct gtgtgtcctg 480
cctctcatcc tccgaaccta ctcagtgcc aagactctgt ggcattttct ctatagccac 540
tggaatctga tcctgattgt cttccactac taccaggcca tcaccaactc gcctgggtac 600
ccaccccagg gcaggaatga tatcgccacc gtctccatct gtaagaagtg catttaccac 660
aagccagccc gaaacacacca ctgcagcatc tgcaacaggt gtgtgctgaa gatggatcac 720
cactgcccct ggctaaacaa ttgtgtgggc cactataacc atcggtactt cttctctttc 780
tgctttttca tgactctggg ctgtgtctac tgcagctatg gaagtgggga ccttttcogg 840
gaggcttatg ctgccattga gaaaatgaaa cagctcgaca agaacaaact acaggcgggt 900
gccaaaccaga cttatcacca gacccacca cccaccttct cctttcgaga aaggatgact 960
cacaagagtc ttgtctacct ctggttcctg tgcagttctg tggcacttgc cctgggtgcc 1020
ctaactgtat ggcatgctgt tctcatcagt cgaggtgaga ctacgatcga aaggcacatc 1080
aacaagaagg agagacgtcg gctacaggcc aagggcagag tatttaggaa tccttacaac 1140
tacggctgct tggacaactg gaaggtattc ctgggtgtgg atacaggaag gcactggctt 1200
actcgggtgc tcttaccttc tagtcacttg ccccatggga atggaatgag ctgggagccc 1260
cctccctggg tgactgctca ctcagcctct gtgatggcag tgtgagctgg actgtgtcag 1320
ccacgactcg agcactcatt ctgctcccta tgttatttca agggcctcca agggcagctt 1380
ttctcagaat ccttgatcaa aaagagccag tgggcctgcc ttagggtacc atgcaggaca 1440
attcaaggac cagccttttt accactgcag aagaaagaca caatgtggag aaatcttagg 1500
actgacatcc ctttactcag gcaaacagaa gttccaaccc cagactaggg gtcaggcagc 1560
tagctaccta ccttgcccag tgctgacccg gacctcctcc aggatacagc actggagttg 1620
gccaccacct cttctacttg ctgtctgaaa aaacacctga ctagtacagc tgagatcttg 1680
gtttctcaac agggcaaaga taccaggcct gctgctgagg tcaactgccac ttctcacatg 1740
ctgcttaagg gagcacaat aaaggtattc gatttttaaa gawaaaaaaaa aaaaaaaaaa 1800
tttggggggg ggggccccgt ta 1822

```

<210> 436

<211> 1030

<212> DNA

<213> Homo sapiens

<400> 436

```
gttaaggctt ctgctgaaac tccccggccc caaccagtag acaaactgga gaagatcctg 60
gagaagctgc tgacccggtt cccacagtgc aataaggccc agatgaccaa cattcttcag 120
cagatcaaga cagcacgtac caccatggca ggcctgacca tggaggaact tatccagttg 180
gttgctgcac gactggcaga acatgagcgg gtggcagcaa gtactcagcc acttgggtcg 240
atccgggctt tgttccctgc tccactggcc caaatcagta cccaatgtt cttgccttct 300
gccaagtgtt catatcctgg aaggtcttca catgctccag ccacctgtaa gctatgtcta 360
atgtgccaga aactcgtcca gccagtgag ctgcatccaa tggcgtgtac ccatgtattg 420
cacaaggagt gtatcaaatt ctgggcccag accaacacaa atgacacttg tcccttttgt 480
ccaactctta aatgacggac ctgactgggg aggaagaaga agagaaactg atgtgaacag 540
gaagcgcggg ttcaagattt ctaaaactct atatttatac agtgacatat actcatgcca 600
tgtacatttt tattatatag gtaatgtgtg tatagaaagt ctgtattcca atgttcgtaa 660
atgaaactat gtatattatg cagaaacagt ctgttcccc tcattcttgca attcctttgg 720
gggatgcaga ttgtagggaa gatgatgttt agtttggcct tgaaattatg atatccctgc 780
ccagggtgtt tttcaaatac aatataaaaa ccacctagga acctgctgtt gctctaaggc 840
cattctgctt tggtttggct cagcctctag tccatttcct taaggctcat gtatgcagat 900
ttaaagcctg gtgctcacc actgtccaac cagatgcctt gcttaccgaa agcctccaga 960
agcctcagta ttgttttagc cactctactc caaatggata aaatgagact ctgattgagg 1020
aaaaaaaaagt                                     1030
```

<210> 437

<211> 1632

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1602)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1616)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1617)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1628)

<223> n equals a,t,g, or c

<400> 437

```
ggcctgtggc tgtnggccgc gtgcgggtga ccgccgaggg ccgaracatg gttctgcaga 60
cgaccaaggg gctgcggcct ctctttgatg gcgatgccca cctcctcatg tccatcccca 120
gccccttccg tggacggctc tgtggcctct gtgggaactt caatggcaac tggagtgcag 180
actttgtcct gcccaatggc tcagcagcgt ccagtgtgga gaccttcggg gctgcatggc 240
gggygcccgg ctccctccaag ggctgtggcg agggctgcgg gcccgaaggc tgcccagtg 300
gcttggcaga ggagactgca ccctatgaga gcaacgaggc ctgcgggcag ctccggaacc 360
cccagggccc ctccgcgacc tgccaggcgg tgctgagtcc ctctgagtac ttccgccaat 420
gcgtatacga cctgtgcgcg caaaaggggtg acaaagcctt cctgtgccgc agcctggcag 480
cctacacggc ggccgtgtcag gcagctggcg tggccgtgaa gccctggagg acagacagct 540
tctgcccgcct ccattgcccc gccacagcc actactccat ctgcactcgc acctgccagg 600
gatcctgtgc ggctctctcc ggctcacagg gctgcaccac ccgctgtttt gagggtgtgt 660
agtgcgacga ccgyttccctg ctttcccagg gtgtctgcat ccctgtccaa gattgtggct 720
gcacccataa tggccgatac ttgccggtaa actcctccct gctgacctca gactgcagcg 780
agcgtgttcc ctgttccctc agctctggcc tgacatgcca ggcagctggc tgcccaccag 840
gccgtgtatg tgaggtcaag gctgaagccc ggaactgctg ggccaccctg ggtctctgtg 900
tcctgtctgt ggggtgccaac ctcaccacct ttgatggggc ccgtggtgcc accacctctc 960
ctggtgtcta tgagctctct tcccgctgcc caggactaca gaataccatc ccctggtacc 1020
gtgtagtgtc cgaagtccag atctgccatg gcaaaacgga ggctgtgggc cagggtccaca 1080
tcttcttcca ggatgggatg gtgacgttga ctccaaacaa ggggtgtgtg gtgaatggtc 1140
tccgagtggg tctcccagct gagaagttag catctgtgtc cgtgagtcgt acacctgatg 1200
gctccctgct agtccgccag aaggcagggg tccaggtgtg gcttggagcc aatgggaagg 1260
tggctgtgat tgtcagcaat gaccatgctg ggaaactgtg tggggcctgt ggaaactttg 1320
acggggacca gaccaatgat tggcatgact cccaggagaa gccagcgatg gagaaatgga 1380
gagcgcagga cttctcccca tgttatggct gatcagtcac ccaccaggaa cgaagatttc 1440
ctgaagaaga cctgggtccct ctggaggttg crgtggctga aggatgcac atgtgctcct 1500
accctgctct accgcttttc tgggtcacag aggccaaatg tgagagcatt gaataaatat 1560
cttaagctaa aaaaaaaaaa raaaaagggc cgataagggc anagggccct tggcanngag 1620
attcccgnnt cc 1632
```

<210> 438

<211> 1016

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (993)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (994)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (995)

<223> n equals a,t,g, or c

<400> 438

```
actcgtgccg aattcggcac gagcggncac gagcaagccc catctcatcc tggcacgccc 60
tactccactg ccctggcagc agcagggtgtg gccaatggag gggggtgctg gccccagga 120
ttccccagc caaactgtct ttgtcaccac gtggggctca cttttcatcc ttccccaaact 180
tccctagtcc ccgtactagg ttggacagcc cccttcggct acaggaaggc aggaggggtg 240
agtcccctac tccctcttca ctgtggccac agcccccttg ccctccgcct gggatctgag 300
tacatatgtt ggtgatggag atgcagtcac ttattgtcca ggtgaggccc aagagccctg 360
tggccgccac ctgaggtggg ctggggctgc tcccctaacc ctactttgct tccgccactc 420
agccatttcc ccctcctcag atggggcacc aataacaagg agctcaccct gcccgctccc 480
aacccccctc ctgctcctcc ctgcccccca aggttctggt tccatttttc ctctgttcac 540
aaactacctc tggacagtgt tgttggtttt tgttcaatgt tccattcttc gacatccgtc 600
attgctgctg ctaccagcgc caaatgttca tcctcattgc ctctgttct gccacgatac 660
ccctccccca agatactctt tgtggggaag aggggctggg gcatggcagg ctgggtgacc 720
gactacccca gtcccaggga aggtggggcc ctgcccctag gatgctgcag cagagtgcagc 780
aagggggccc gaatcgacca taaaggggtgt aggggccacc tcctccccct gttctgttgg 840
ggaggggtag ccatgatattg tcccagcctg gggctccctc tctggtttcc tatttgcagt 900
tacttgaata aaaaaaatat ccttttctgg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aannnggggg gggccccccc ccccca 1016
```

<210> 439

<211> 594

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (476)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (519)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (530)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (531)

<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (539)
 <223> n equals a,t,g, or c

<400> 439

```

ttgaaaaacg ggtcgactgg cmcgwccsgc cgggagccag cggttctcca agcaccacgc 60
atcctgctag acgcgccgcg caccgacgga ggggacatgg gcagagcaat ggtggccagg 120
ctcgggctgg ggctgctgct gctggcactg ctctaccca cgcagattta ttccagtga 180
acaacaactg gaacttcaag taactcctcc cagagtactt ccaactctgg gttggcccca 240
aatccaacta atgccaccac caaggyggct ggtggtgccc tgcagtcaac agccagtctc 300
ttcgtgggtc cactctctct tctgcatctc tactcttaag agactcaggc caagaaacgt 360
cttctaaatt tccccatctt ctaaacccaa tccaaatggc gtctggaagt ccaatgtggc 420
aaggaaaaac aggtcttcat cgaatctact aattccacac cttttaaaaa ttttnggga 480
acccaaccca aagggtaaaa aaaaaaaaaa atttggggnt tttttgggn naaaggggna 540
aaaaaaattt ttcccccccc ccccaaaaaa aaaaaaaaat tttttttttt tttt 594

```

<210> 440
 <211> 1580
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (873)
 <223> n equals a,t,g, or c

<400> 440

```

gcccacgcgt tgcgaaggct gcccacatctg gcgctgatta tctctgctgct gccgccaccg 60
ctgctgctgc tctgcaaaat tcagctgctg cctctgtctt gaggacccca gcgcctttcc 120
cccggggcca tgctgcctgc agccacagcc tccctcctgg ggccctcct cactgcctgc 180
gccctgctgc cttttgcca gggccagacc cccaactaca ccagaccgt gttcctgtgc 240
ggaggggatg tgaaggggga atcaggttac gtggcaagtg aggggttccc caacctctac 300
ccccctaata aggagtgcac ctggaccata acggtccccg agggccagac tgtgtccctc 360
tcattccgag tcttcgacct ggagctgcac ccgcctgcc gctacgatgc tctggaggtc 420
ttegctgggt ctgggacttc cggccagcgg ctcggacgct tttgtgggac cttccggcct 480
gcgcccctag tcgcccccg caaccagggt accctgagga tgacgacgga tgagggcaca 540
ggaggacgag gcttctctgct ctggtacagc gggcgggcca cctcgggcac tgagcaccaa 600
ttttgcgggg ggcggtgga gaaggccag ggaacctga ccacgccccaa ctggcccag 660
tccgattacc ccccgggcat cagctgttcc tggcacatca tcgcgcccc ggaccaggtc 720
atcgcgctga ctttcgagaa gtttgacctg gagccggaca cctactgccg ctatgactcg 780
gtcagcgtgt tcaacggagc cgtgagcgac gactcccgga ggctggggaa gttctgcggc 840
gacgcaktcc cgggtccat ctctccgaa ggnaatgaac tcctcgtcca gttcgtctca 900
gatctcagtg tcaccgtga tggcttctca gcctcctaca agaccctgcc gcggggcact 960
gccaaagaag ggcaagggcc cggcccaaaa cggggaactg agcctaaagt caagctgccc 1020
cccaagtccc aacctccgga gaaaacagag gaatctcctt cagccccctga tgcaccacc 1080
tgcccaaagc agtgccgccc gacaggcacc ttgcagagca acttctgtgc cagcagcctt 1140
gtgggtgact cgacagtga gtccatggtt cgggagccag gggagggcct tgccgtgact 1200
gtcagtctta ttggtgctta taaaactgga ggactggacc tgccttctcc acccactggt 1260
gcctccctga agttttacgt gccttgcaag cagtgcctccc ccatgaagaa aggagtca 1320
tatctgctga tgggcccagg agaagagaac agaggccccg tccttctctc agagagcttt 1380
gtggttctcc accggcccaa ccaggaccag atcctcacca acctaagcaa gaggaagtgc 1440

```

```

ccctctcaac ctgtgcgggc tgetgcgtcc caggactgag acgcaggcca gccccggccc 1500
ctagccctca ggccttcttt cttatccaaa taaatgtttc ttaatgagga atgggtcaga 1560
tctccatgct tatggtaaaa                                     1580

```

<210> 441

<211> 1082

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (136)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (462)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (465)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1074)

<223> n equals a,t,g, or c

<400> 441

```

ctgccgagcg cctcttgagg ctgggctttc ccccgcggtg cggcgccagg agccgccttt 60
tccgctgggt gtcactcggg ggtggggaag atggccatt caaaagcgcc gcgagggggc 120
ccggccagtg cccttnagtg agcgctcgca agaggacggc agaggcccg cagctcggag 180
ctccgggacc ttgtggcgca tcaggacgcg gctgtccctc tgccgggacc cagagccgcc 240
gccgccgctc tgccctcctgc gtgttagcct cctctgcgcg ctccgggcag gcggccgtgg 300
gagccgctgg ggcgaggacg gcgcgaggct gctgctgctg cccccggccc gcgcggctgg 360
aaacggagag gccgagccaa gcggcgggcc ctcttatgct gggaggatgc tggagagtag 420
cggctgcaaa gcgctgaagg agggcggtgt ggagaagcgc anacngggtt gttgcagctc 480
tggaagaaaa agtgttgcat cctcaccgag gaagggtgct tgcttatccc gccaagcag 540
ctgcaacacc agcagcagca gcaacagcag cagcagcagc agcaacaaca gcccgggcag 600
gggcggggcc agccgtccca acccagtggc cccgctgtcg ccagcctcga gccgcccgtc 660
aagctcaagg aactgcactt ctccaacatg aagaccgtgg actgtgtgga gcgcaagggc 720
aagtacatgt acttcactgt ggtgatggca gagggcaagg agatcgactt tcgggtgccc 780
caagaccagg gctggaacgc cgagatcacg ctgcagatgg tgcagtacaa gaatcgtcag 840
gccatccttg cggtaaaatc cacgcggcag aagcagcagc acctggtcca gcagcagccc 900
ccctcgacgc cgcgacgca gccgcagctc cagccccaac cccagcctca gcctcagccg 960
caaccgccgc cccaatcaca accccagcct cagccccaac ccaagcctca gcccagcag 1020
ctccamccgt atycgcatyc amatcamat ycamaatctt atccttmatt tggnaaccaa 1080
aa

```

<210> 442

<211> 1241

<212> DNA

<213> Homo sapiens

<400> 442

```
agacgagcgt ggcgggccgcg gctgctcggg gccgcgctgg ttgccattg acagcggcgt 60
ctgcagctcg cttcaagatg gccgcttgct cgcattcatt ttctgctgaa cgacttttaa 120
ctttcattgt cttttccgcc cgcttcgacg gcctcgsgcc ggctgctctt tccgggattt 180
tttatcaagc agaaatgcat cgaacaacga gaatcaagat cactgagcta aatccccacc 240
tgatgtgtgt gctttgtgga ggggtacttca ttgatgccac aaccataata gaatgtctac 300
attccttctg taaaacgtgt attgttcgtt acctggagac cagcaagtat tgtcctatatt 360
gtgatgtcca agttcacaag accagaccac tactgaatat aaggtcagat aaaactctcc 420
aagatattgt atacaaatta gttccagggc ttttcaaaaa tgaaatgaag agaagaaggg 480
atttttatgc agctcatcct tctgctgatg ctgccaatgg ctctaataaa gatagaggag 540
aggttgcaga tgaagataag agaattataa ctgatgatga gataataagc ttatccattg 600
aattctttga ccagaacaga ttggatcgga aagtaaacia agacaaagag aaatctaagg 660
aggaggtgaa tgataaaaga tacttacgat gccagcagc aatgactgtg atgcacttaa 720
gaaagtttct cagaagtaaa atggacatac ctaatacttt ccagattgat gtcagtgtat 780
aggaggaacc tttaaaggat tattatacac taatggatat tgcctacatt tatacctgga 840
gaaggaatgg tccacttcca ttgaaataca gagttcgacc tacttgtaaa agaataaga 900
tcagtcacca gagagatgga ctgacaaatg ctggagaact ggaaagtga tctgggagt 960
acaaggccaa cagcccagca ggaggtattc cctccacctc ttcttgtttg cctagcccca 1020
gtactccagt gcagtctcct catccacagt ttccctcacat ttccagtact atgaatggaa 1080
ccagcaacag ccccgagcgg aaccaccaat cttcttttgc caatagacct cgaaaatcat 1140
cagtaaatgg gtcatacagc acttcttctg gttgatacct gagactgtta agggaaaaaa 1200
aaaaaaaaa accccggccg ctcccacttc agatttgtaa c 1241
```

<210> 443

<211> 968

<212> DNA

<213> Homo sapiens

<400> 443

```
cccacgcgtc cgcaggaagc caactatttg aaatgcacga gaaactaagt tgtatggcaa 60
actctgtaat aaaaaatcta cagtcacgtt ggagatcacc atcccatgaa aattctatatt 120
agtattttca gagaaaattg aagggttttt taaacatcac tggattttctt gattgaggaa 180
acaagttctg aaataatagc acaatttcaa agaagagact ctttgcaaag ttgataacat 240
ttcaaaccct gaaggacagt gacttattat gtwagttcaa tkttgtaagt ycattatgtw 300
agatcctttt tttttttcat aatatgtatt cttggctgct atgcgtgggt tttcaggaaa 360
tttaattatc ttactgagat gtgaaagcaa aactagtaac agaacttaca ttttatttca 420
tgctttctta aaccctgca tattctgggt aaacatgtaa aatactttta gtaaaattga 480
acatttttat ttgaattttt gctgaactga taaaggtgtt tataattttt tttgttkgtt 540
tgtttaattc atgtttgttg ggactgaggt ttaggaaagt tggtactgg taaaaacctc 600
aaatgaaatg cgaaagaatt tgaatttttc ctgcataatg caactttgga cagctttcaa 660
gaaaaatgag aaaagtttca acttctggcg gttaaaaatat taatgcagaa tttactaaga 720
ttttattcat ttgcattagc aaatatcat gcagcagcag ttgactgaaa atttattctt 780
atgagacgta tagtattcat ttttaaatgc atgattgtac attatgtata gacgacaatg 840
tttttaattt ataaatttca ttctttgtta attgcatggg tttttctgca gcttattgtg 900
aataccttgg ttctgttcaa tagaaacatt ttgtatatat traatactga aatatcaaaa 960
aaaaaaaaa 968
```

<210> 444
<211> 1360
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (114)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c

<400> 444
cgccggagcg tcattctgcga ctccaatgcc actgcactgg agcttcccgg ccttcctctt 60
tccctgcccc agcccagcat ccccgcggt gtcccgaga gtgctccacc gganccccac 120
cggaagaga cgtgaccgc caccgccact tcccaggtag cccagcagcc tccagccgct 180
gccgcccctg ggaacaggc cgtcgcgggc cctgcccctc gactgtcccc agcagtacca 240
gcaaagaccg cccagtgtcc cagcctagcc ttgtggggag caaagaggag ccgccgccgg 300
angaaagtgg cagcggcggc gcaagcgcmn aaggagccac aggaggaacg gagccagcag 360
caggatgata tcgaagagct ggagaccaag gccgtgggaa tgtctaacga tggccgcttt 420
ctcaagtttg acatcgaaat cggcagaggc tcctttaaga cggctctacaa aggtctggac 480
actgaaacca cgttggaagt cgcctggtgt gaactgcagg atcgaaaatt aacaaagtct 540
gagaggcaga gatttaaaga agaagctgaa atgttaaaag gtcttcagca tcccaatatt 600
gttagatttt atgattcctg ggaatccaca gtaaaaggaa agaagtgcag tgttttggtg 660
actgaactta tgacgtctgg aacacttaaa acgtatctga aaaggtttaa agtgatgaag 720
atcaaagttc taagaagctg gtgcccgcag atccttaaag gtcttcagtt tcttcatact 780
cgaactccac ctatcattca ccgcgatctt aaatgtgaca acatctttat caccggccct 840
actggctcag tcaagrttg agacctcgt ctggcaaccc tgaagcgggc ttcttttgcc 900
aagagtgtga taggtacccc agagttcatg gccctgaga tgtatgagga gaaatatgat 960
gaatccgttg acgtttatgc ttttgggatg tgcagtcttg agatggctac atctgaatat 1020
ccttactcgg agtgccaaaa tgctgcgcag atctaccgtc gcgtgaccag tggggtgaag 1080
ccagccagtt ttgacaaagt agcaattcct gaagtgaagg aaattattga aggatgcata 1140
cgacaaaaca aagatgaaag atattccatc aaagaccttt tgaacctatgc cttcttccaa 1200
gaggaaacag gagtacgggt agaattagca gaagaagatg atggagaaaa aatagccata 1260
aaattatggc tacgtattga agatattaag aaattaaagg gaaaatacaa agataaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaacacc caccgtgccg 1360

<210> 445
<211> 1835
<212> DNA
<213> Homo sapiens

<220>

<221> misc feature
 <222> (326)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1229)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1738)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1747)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1758)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1801)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1806)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1831)
 <223> n equals a,t,g, or c

<400> 445
 tcgacccacg cgtccgggat gaggcccggc ctctcatttc tcctagccct tctgtttcttc 60
 cttggccaag ctgcagggga tttgggggat gtgggaacct caattcccag ccccggttc 120
 agctctttcc caggtgttga ctccagctcc agcttcagct ccagctccag gtcgggctcc 180
 agctccagcc gcagcttagg cagcggaggt tctgtgtccc agttgttttc caatttcacc 240
 ggctccgtgg atgaccgtgg gacctgccag tgctctgttt cctgcccaga caccamcttt 300
 cccgtggaca gagtgaacg yttggnaatt cacagctcat gttctttctc agaagtttga 360
 gaaagaactt tccaaagtga gggaatatgt ccaattaatt agtgtgtatg aaaagaaact 420
 gttaaacctt actgtccgaa ttgacatcat ggagaaggat accatttctt acactgaact 480
 ggacttcgag ctgatcaagg tagaagtga ggagatggaa aaactgggtca tacagctgaa 540
 ggagmstttt ggtggaagct cagaaattgt tgaccagctg gaggtggaga taagaaatat 600
 gactctcttg gtagagaagc ttgagacact agacaaaaac aatgtccttg ccattcgccg 660